(navigation image)
Home American Libraries | Canadian Libraries | Universal Library | Community Texts | Project Gutenberg | Children's Library | Biodiversity Heritage Library | Additional Collections
Search: Advanced Search
Anonymous User (login or join us)
Upload
See other formats

Full text of "Psychopharmacology abstracts"

FHR ROOM UJb.. Ui\i-T 



EfiSffiQM 



UNIVERSITY OF 

ILLINOIS LIBRARY 

AT URB/' A ..-tA.vlPAIGN 



JLtn.-'j-.N w.oct 



NOT TO BE TAKEN F 
£0R ROCvi U: 



JRARY. 



^T' TO Rr > 



'^SSMm;^ 



6r iso^ 

dtf 



ional Institute 
lental Health 




The National Clearinghouse 
for Mental Health Information 



L. 19 CUMULATIVE INDEX June 1982 

1 u^^^^^^i^^^. Abstracts °^°s,tory: 

^^ I LOT AND TICKET NO. 



n 



81418 



CLOTH COLOR 




'^^SSSfi^^^ 



r, 7S0^ 
/? 



ional Institute 
\ental Health 






^OTro 







'^OOM'ust%..H?^'ARK, 



The National Clearinghouse 
for Mental Health Information 



L. 19 CUMULATIVE INDEX June 1982 

ychopharmacology Abstracts 



r 



DEPOS/TORV: 

OCT ^\m 

AT URBANA-CHAMPAIGN 




— /at 



PSYCHOPHARMACOLOGY ABSTRACTS is a publication of the National Clearinghouse 
for Mental Health Information of the National Institute of Mental Health. It is a specialized 
information medium designed to assist the Institute in meeting its obligation to foster and 
support laboratory and clinical research into the nature and causes of mental disorders and 
methods of treatment and prevention. Specifically, this information service is designed to meet 
the needs of investigators in the field of psychopharmacology for rapid and comprehensive 
information about new developments and research results. For information or correspondence 
with the National Institute of Mental Health concerning Psychopharmacology Abstracts, 
changes of address, or removal of names from the mailing list see the inside back cover page. 



The Secretary of Health and Human Services has determined that the 
publication of this periodical is necessary in the transaction of the public 
business required by law of this Department. Use of funds for printing this 
periodical has been approved by the Director of the Office of Management 
and Budget through November 15, 1982. 






JAiZ)7 V 

NATIONAL CLEARINGHOUSE FOR MENTAL HEALTH INFORMATION 
PSYCHOPHARMACOLOGY ABSTRACTS 



Volume 19 



Cumulative Index 



June 1982 



Page 

Cross Reference List 1 

Subject Index S-1 

Author Index A-1 



Carrie Lee Rothgeb, Editor 

Bette L. Shannon, Managing Editor 



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES 
Public Health Service 

Alcohol, Drug Abuse, and Mental Health Administration 

National Institute of Mental Health 

National Clearinghouse for Mental Health Information 

5600 Fishers Lane 

Rockville, Maryland 20857 



DHHS Publication No. (ADM) 83-150 
Printed 1983 



For sale by the Superintendent of Documena, U.S. Government Printing Office, Washington, D.C. :0402. 



CROSS-REFERENCE LIST 

The use of a Key-Word-out-of-Context (KWOC) index, while saving time and 
money, poses a problem to users seeking to locate relevant references on 
a given topic, as all references are not found under one entry. To 
alleviate this problem, we have prepared the following cross-reference 
list. 



Ability 



A 
see also 



Learning ability 
Abuse see also 

Drug abuse 
Access see 

Continuous access 
Accidents see 

Cerebrovascular accidents 
Acetylcholine see also 

ACH 
Acetylsalicylic acid see also 

Aspirin 
ACH see also 

Acetylcholine 
Acid see also 

Names of individual acid; 
Act see 

Controlled substances ac 
ACTH see also 

A drenocortico tropin 
Acting see 

Centrally acting 

CNS acting 

Long-acting 

Short- acting 
Action(s) see 

Anorectic actions 

Behavioural actions 

Biochemical action 

Central action(s) 

Dual action(s) 

Hypotensive action 

Inhibitory actions 

Mechanism -of- action 

Neurotoxic action(s) 

Neurotropic action 

Psychotropic action 

Site-of- action 
Activated see 

Dopamine- activated 

Na - K - ac tivate d 
Active see 

Centrally active 

Highly active 
Activity see 

Alpha- adrenergic activity 



Anorectic activity 

Antiarrhythmic activity 

Anticandidal activity 

Anticholinergic activity 

Anxiolytic activity 

Behavioral activity 

Binding activity 

Bioelectric activity 

Bioelectrical activity 

Biological activity 

Central activity 

Dopaminergic activity 

Electrical activity 

Exploratory activity 

Fast Activity 

General activity 

Hypersynchronous activity 

Locomotor activity 

Motor activity 

Parasympathetic activity 

Social activity 

Structure- activity 

Thyroid activity 
AD-810 see 

Sulfamoylmethylbenzisoxazole 
AD-1308 see 

Ethyl- 2-piperazinyl-4-phenyl- 

quinoline-HCl 
Adenosine monophosphate 

AMP 

C-AMP 

Cyclic AMP 
Adenosine triphosphatase 

ATPASE 
Adenosine triphosphate 

ATP 
Administered see 

Centrally administered 

Self -administered 
Administration see also 

Route-of -administration 

Self -administration 
Adrenaline see also 

Epinephrine 
A drenocortico tropin 

ACTH 



see 



see also 



see 



see also 



ADTN see also 

Aminodihydroxytetrahydro- 
naphthalene 
AEP see also 

Evoked potential 
Affective disorders see also 
Bipolar 
Depression 
Manic-depressive 
Unipolar 
Affinity see also 

High affinity 
Agent(s) see 
Addictive agents 
Anorectic agents 
Antianxiety agents 
Anticonvulsant agents 
Antiepileptic agents 
Blocking agents 
Catecholamine depleting agent 
Convulsant agents 
Depolarizing agent 
Disinhibiting agent 
Dopaminergic agent(s) 
Hallucinogenic agent 
Narcotic agents 
Neuroactive agents 
Neuroleptic agents 
Neuropharmacological agents 
Neuropsychiatric agents 
Oxotremorine-Uke agent 
Pharmaceutic agents 
Pharmacologic agents 
Pharmacological agents 
Psychopharmacologic agents 
Psychopharmacological agents 
Psychotropic agent 
Releasing agents 
Serotonergic agents 
Vasoactive agents 
AHR-mS see 

Pridefine 
Aids see 

Sleeping aids 
Alcohol see also 
Ethanol 
Ethylalcohol 
Alteration see also 
Attentional alteration 
Rate altering 
Amine(s) see also 
Biogenic amine 
Brain amine 
Monoamine(s) 



Names of specific amines 
Sympathomimetic amines 
Aminobutyric acid see also 

GABA 
Aminodihydroxytetrahydronaphthalene 

see also 
ADTN 
Amphetamine see also 
D- Amphetamine 
Dextroamphetamine 
L- Amphetamine 
Methamphetamine 
Methylamphetamine 
Analysis see also 
Behavioral analysis 
Behavioural analysis 
Mass spectral analysis 
Mass spectrometric analysis 
Microanalysis 
Psychometric analysis 
Signal detection analysis 
Symptom profile analysis 
Video analysis 
Analyzed see 

Computer analyzed 
AMPT see 

Methyl-p- tyrosine 
Antidepressant see also 

Names of specific compounds 
Nontricychc antidepressant 
PolycycHc antidepressants 
Tetracyclic antidepressant(s) 
Tricyclic antidepressant(s) 
Antihypertensive effects see also 

Hypotensive effect 
Anxiety see also 
Panic anxiety 
Phobic anxiety 
AOAA see 

Aminooxyacetic acid 
Apnea see 

Sleep apnea 
Application(s) see 

Microiontophoretic applications 
Approach(es) see 

Psychodynamic approach 
Psychotherapeutic approaches 
Area see 

Preoptic area 
Artery(ies) see also 
Cerebral artery (ies) 
Mensenteric arteries 
Pial arteries 
Pulmonary arteries 
Vertebral artery 



^mam^ 



Aspect(s) see 

Associative aspects 

Behavioral aspect 

Biochemical aspects 

CUnical aspects 

Metabolic aspects 

Nonassociative aspects 

Pathophysiological aspects 

Pharmacological aspects 

Psychiatric aspects 

Technical aspect 
Aspirin see also 

Acetylsalicylic-acid 
Assay see also 

Microassay 
Assessment see also 

Electromyographic assessment 
Associations see also 

Verbal associations 
ATPASE see also 

Adenosine- triphosphatase 
Autoreceptor(s) see also 

Alpha2- adrenergic autoreceptor 

Dopamine autoreceptor(s) 

GABA autoreceptors 

Presynaptic autoreceptors 

Serotoninergic autoreceptor 
Availability see also 

Commercially available 
Aversion(s) see also 

Taste aversion(s) 
Avoidance see also 

High avoidance 

Low avoidance 

Passive avoidance 

Shock avoidance 

Sidman avoidance 



B 



Barnetil see 
Sultopride 

Barrier see 

Blood brain barrier 

Based see 

Community based 

Basis; Bases see 
Biochemical basis 
Neurochemical bases 
Neurophysiological basis 
Pathophysiologic basis 
Pharmacokinetic bases 
Pharmacological bases 



Battery see 

Neuropsychological battery 
Behavior(s) see also 

Abnormal behavior 

Abstinence behavior 

Acquisition behavior 

Addictive behavior 

Aggressive behavior 

Ataxic behaviors 

Avoidance behavior 

Bar-pressing behavior 

Conflict behavior 

Defensive behavior 

Drinking behavior 

Eating behavior 

Escape behavior 

Exploratory behavior 

Fighting behavior 

Head- shaking behavior 

Homing behavior 

Hyperactive behavior 

Learned behavior 

Maternal behavior 

Mating behavior 

Maze behavior 

Mothering behavior 

Motor behavior 

Mouse-killing behavior 

Nest-building behavior 

Nonverbal behavior 

Nursing behavior 

Operant behavior 

Pathological behavior 

Pecking behavior 

Punished behavior 

Reaching behavior 

Rotational behavior 

Scent-marking behavior 

Sexual behavior 

Shaking behavior 

Social behavior 

Stereotyped behavior 

Sterotypic behavior 

Violent behavior 

Yawning behavior 
Behaviour see also 

Abstinence behaviour 

Aggressive behaviour 

Agonistic behaviour 

Avoidance behaviour 

Circling behaviour 

Climbing behaviour 

Disturbed behaviour 

Exploratory behaviour 



Rotational behaviour 
Scratching behaviour 
Sexual behaviour 
Social behaviour 
Sociosexual behaviour 
Stereotyped behaviour 
Timid behaviour 
Biochemistry see also 

Brain biochemistry 
Bipolar see also 
Affective disorders 
Depression 
Manic- depressive 
Unipolar 
Biting see 
Self-biting 
Blind see 
Double blind 
Single blind 
Time blind 
Blues see 

Maternity blues 

Bodies see also 

Dense bodies 

Lafora bodies 

Bound see also 

Membrane bound 
Boy(s) see also 
Hyperactive boys 
Hyperkinetic boys 
Schizophrenic boy 
Brain see also 
Anterior forebrain 
Blood brain barrier 
Forebrain 
Midbrain 
Mouse brain 
Rat brain 
Rat forebrain 
Rat midbrain 
Rat whole brain 
Bulb(s) see 
Olfactory bulb 



C-AMP see also 



Cyclic- adenosine monophosphate 

Cyclic- AMP 
C-GMP see 

Cyclic- GMP 

CycUc-guanosine monophosphate 
Ca see also 

Calcium 

45Ca 



Calcium see also 

Ca 

45Ca 
Capacity see also 

Mental capacity 
Care see also 

Sheltered care 
Cardiac see also 

Heart 
CAT-scan see 

Computerized axial tomography 
Catecholamine-O-methyltransf erase 
see 

COMT-A 

COMT-B 
Cation(s) see also 

Divalent cation(s) 
Caused see 

Psychotropic caused 
CCK-8 see 

Cholecystokinin octapeptide 
CEEG see also 

Comp-EEG 

CSEEG 
Cell(s) see also 

Purkinje cell(s) 

Red blood cell(s) 

Schwann cell 
Center see also 

Day treatment center 

Residential center 
Central nervous system see also 

CNS 
Cerebellum see also 

Rat cerebellum 
Cerebral cortex 



see also 



Frontal cerebral cortex 

Rat cerebral cortex 
Cerebrospinal fluid see also 

CSF 
CG-3033 see 

Supidimide 
Chain see 

Branched chain 
Chamber see 

Anterior chamber 
Change(s) see also 

Behavior change 

Behavioral changes 

Behavioural changes 

Biochemical changes 

Developmental change 

Electrocardiographic changes 

Electrocortical changes 

Electrophysiological changes 



ifi^aKss^ 



Electroret±iographic changes 

Mechanical changes 
Channel(s) see 

Calcium channel 

Ion channel(s) 
Characterization see also 

Biochemical characterization 
Check see 

Methodical check 
Child; Children see also 

Borderline children 

Cerebral palsied child 

Depressed child 

Epileptic children 

Hyperactive child(ren) 

Hyperkinetic children 

Special child 
Chlorpromazine see also 

CPZ 
Cholinoceptor see also 

Muscurinic cholinoceptor 
Chorea see also 

Huntingtons chorea 
Chromatography see also 

Gas Chromatography 

Gas liquid chromatography 

Liquid chromatography 

Thin layer chromatography 

TLC 
Circadian see also 

Ultradian 
Circuit see also 

Short circuit 
Classification see also 

Pharmacoclinical classification 
Clinic see also 

Mental hygiene clinic 
CNS see also 

Central nervous system 
Coated see 

Enteric coated 
Colony see 

Social colony 
Comfort see 

Social comfort 
Communication see also 

Preliminary communication 
Comp-EEG see also 

CEEG 

CSEEG 
Comparison see also 

Controlled comparison 
Complaint(s) see 

Psychosomatic complaints 



Complication see also 

Neurological complications 

Ocular complication 
Component see 

Two component 
Compound(s) see 

Hypnotic compounds 

Names of specific compounds 
Computer see also 

Microcomputer 
Concentration(s) see also 

High concentrations 
Conditioning see also 

Appetitive conditioning 

CS 

Pavlovian conditioning 
Conditions see also 

Depressive conditions 

Psychopathological conditions 
Conductance see also 

Ion conductance 
Consequences see 

Behavioral consequences 

Biochemical consequences 

Neurochemical consequences 
Considerations see also 

Behavioral considerations 

Biochemical considerations 

Methodological considerations 

Pharmacological considerations 
Control(Ied) see also 

Autonomic control 

Placebo controlled 

Schedule controlled 

Weight control 
Cord see 

Spinal cord 
Correlates see 

Behavioral correlates 

Biochemical correlates 

Biomedical correlates 

Cortical correlates 

Electrophysiological correlates 

Metabolic correlates 

Neurochemical correlates 

Neuropsychological correlates 

Peripheral correlates 

Pharmacological correlates 

Physiological correlates 
Correlation see also 

Biochemical correlation 

Clinical correlation 

Neuropsychiatric correlations 



Cortex see also 
Cerebellar cortex 
Cerebral cortex 
Frontal cerebral cortex 
Frontal cortex 
Motor cortex 
Occipital cortex 
Olfactory cortex 
Prefrontal cortex 
Rat brain cortex 
Rat cerebral cortex 
Rat cerebral cortical 
Rat cortex 
Rat frontal cortex 
Cortisol see also 

Hydrocortisone 
Course see 

Time course 
Court see 

Federal court 
CP-36584 see 

Flutroline 
C?Z see also 

Chlorpromazine 
CS-386 see 

Mexazolam 
CSD see 

Cysteine sulphinic acid- 
decarboxylase 
CSF see also 

Cerebrospinal fluid 
Culture see also 

Cell culture 
Current see 

Outward current 
Curve see also 
Response curve 
Cycle(s); Cycling see also 
Circadian cycles (cycling) 
Estrous cycle 
Cyclic-adenosine monophosphate 
see also 
C-AMP 
CycUc-AMP 
Cyclic AMP see also 
C-AMP 

Cyclic-adenosine monophosphate 
Cyclic-GMP see also 

Cyclic-guanosine monophosphate 
Cyclic-guanosine monophosphate 
see also 
Cyclic-GMP 
Cylert see 
Pemoline 



D-12524 see 
Lopirazepam 
D- Amphetamine see also 
Amphetamine 
Dextroamphetamine 
L- Amphetamine 
Methamphetamine 
Methylamphetamine 
DA see 

Dopamine 
DAergic see 

Dopaminergic 
Damage(d) see also 

Brain damage(d) 
Dapotum-D see 

Fluphenazine decanoate 
Data see also 

Biochemical data 

Pathophysiological data 
DBH see 

Dopamine-beta-hydroxylase 
Deaza-siba see 

Deoxyisobutylthio-3-deazaadenosine 
Deficiencies see also 

Behavioral deficiencies 
Deficits see also 

Avoidance deficits 

Behavioral deficits 
Delirium see also 

Alcoholic delirium 
Delta sleep see 

DSIP 
Dementia see also 

Senile dementia 
Deoxycorticosterone see also 

DOCA 
Depakene see 

Valproic acid 
Depakine see also 

Dipropylacetate 

Dipropylacetic acid 

Sodium dipropylacetate 

Sodium valproate 

Valproic acid 
Dependent(ence) see also 

Age dependent 

Barbiturate dependence 

Behavior dependent 

Ca++- dependent 

DNA dependent 

Dopamine dependent 



Dose dependent 

Meal dependent 

Morphine dependence(ent) 

Na+- dependent 

Opiate dependent 

Physical dependence 

Prostacyclin dependent 

Rate depencency 

Sodium dependent 

State dependent 

Time dependent 
Depression see also 

Affective disorders 

Behavioral depression 

Bipolar 

Childhood depression 

Manic- depressive 

Motor depression 

Unipolar 
Deprived see also 

Maternally deprived 

Sleep deprivation (ed) 

Water deprived 
Desensitization see also 

Behavioral desensitization 
Desipramine see also 

Desmethylimipramine 

DM1 
Desmethylimipramine see also 

Desipramine 

DM1 
Despair see 

Behavioural despair 
Detection see also 

Electrochemical detection 
Determination see also 

Liquid chromatographic determination 
Deviants ; Deviations see 

Sexual deviants; deviations 
Dextroamphetamine see also 

Amphetamine 

D- Amphetamine 

L- Amphetamine 

Methamphetamine 

Methylamphetamine 
DHT see also 

Dihydroxytryptamine 
Diagnosis see also 

Psychiatric diagnosis 
Difference(s) see 

Sex difference(s) 

Species difference(s) 
Difficulties see 

Sexual difficulties 



Diflunisal see 

Difluorophenylsalicylic acid 
Dihydroxyergotoxine see also 

Hydergine 



Dihydroxyphenylacetic acid see also 

DOPAC 
Dihydroxyphenethylamine see 

Dopamine 
Dihydroxyphenylalanine see also 

DOPA 

L-DOPA 

Levodopa 
Dihydroxytryptamine see also 

DHT 
Diisopropylfluorophosphate see 

DFP 
Dimethoxy-4-methylamphetamine 

see also 

DOM 
Dimethylaminoethanol see 

DEANOL 
Diphenylhydantoin see also 

Phenytoin 
Dipropylacetate ; Dip ropy lace tic acid 

see also 

Depakine 

Sodium dipropylacetate 

Sodium valproate 

Valproic acid 
DIPT see 

Diisopropyltryptamine 
Disability (ies) see 

Learning disabilities 

Reading disabled 
Discharge see also 

Epileptic discharge 
Disease(s) see 

Alzheimers disease 

Cerebrovascular diseases 

Chagas disease 

Gilles de la Tourettes disease 

Heart disease 

Hepatic disease 

Huntington(s) disease 

Mental diseases 

Names of specific diseases 

Parkinson(s) disease 

Psychosomatic diseases 

Renal disease 

Respiratory disease 
Disorder(s)(ed) see also 

Affective disorder(s) 

Anxiety disorders 

Astheno- depressive disorders 



Attention disordered 

Behavior disorders 

Behavioural disorders 

Deficit disorders 

Depressive disorder(s) 

Dystonia disorders 

Extrapyramidal disorders 

Gilles de la Tourettes disorder 

Learning disorders 

Leukopenia disorders 

Manic melancholic disorders 

Mental disorders 

Mood disorders 

Movement disorders 

Obsessive compulsive disorder(s) 

Panic disorder 

Personality disorder 

Psychiatric disorders 

Psychotic disorders 

Schizoaffective disorder 

Sexual disorders 

Sleep disorders 

Sleep wake disorders 
Distalgesic see 

Dextropropoxyphene 
Disturbances see also 

Behavioral disturbances 

Memory disturbances 

Mental disturbances 

Organic brain disturbance 

Psychiatric disturbance 

Sensory disturbances 

Sleep disturbances 
DMI see also 

Desipramine 

Desmethylimipramine 
DN-1417 see 

Butyrolactone-gamma-carbonyl- 

histidyl-prolin amide 
DOC A see also 

Deoxycorticosterone 
Dogs see also 

Beagle dogs 
DOM see also 

Dimethoxy-4-methylamphetamine 
DOPA see also 

Dihydroxy phenylalanine 

L-DOPA 

Levodopa 
DOPAC see also 

Dihydroxyphenylacetic acid 
DOPEG-SO. 



see 



Dihydroxyphenylethylene- glycol- 
sulfate 



Dose(es) (ages) see also 

High dosage(es) 

Hyperthermic dose 

Large doses 

Large single doses 

Log dose 

Low dose(s) (age) 

Minimum doses 

Multiple dose 

Overdose(age) 

Single bedtime dose 

Single daily dose(s) 

Single dosage(e) (es) 

Single nightly dose 

Single oral dosages (e) 

Single therapeutic dose 

Small dose 
Doubt see 

Reasonable doubt 
DPEA see 

Dichloro-6-phenylphenoxyethylamine- 

HBr 
Drugs see also 

Analgesic drugs 

Anorectic drugs 

Antialcoholism drug 

Antianxiety drug(s) 

Anticholinergic drugs 

Anticonvulsant drug(s) 

Antidepressant drug(s) 

Antidepressive drug(s) 

Antiepileptic drugs 

Antihypoxidotic drugs 

Antiinflammatory drugs 

Antiparkinson drugs 

Antiparkinsonian drugs 

Antipsychotic drug(s) 

Antischizophrenic drugs 

Anxiolytic drugs 

Blocking drugs 

Cholinergic drugs 

Hallucinogenic drugs 

Hypnotic drug(s) 

Names of specific drugs 

Narcotic drugs 

Neuroleptic drug(s) 

Neuropharmacological drugs 

Neurotropic drugs 

Nicotinic drugs 

Nootropic drugs 

Opiate-like drugs 

Psychedehc drugs 

Psychiatric drug(s) 

Psychoactive drug(s) 



Psycholeptic drugs 
Psychotherapeutic drug(s) 
Psychotropic drug(s) 
Stimulant drugs 
Tranquilizing drugs 
Two- drug 

Duration see also 
Long duration 

Dysfunction(s) see also 
Attention dysfunction 
Brain dysfunction 
Minimal brain dysfunction 
Sensorimotor dysfunctions 
Sexual dysfunction(s) 

Dyskinesia(s) see also 
Paroxystic dyskinesias 
Tardive dyskinesia (s) 



ECG see 

EKG 

Electrocardiogram 
ECS see 

ECT 

Electroconvulsive shock 

Electroconvulsive therapy 

Electroconvulsive treatment 

Electroshock 
ECT see also 

Electroconvulsive shock 

Electroconvulsive therapy 

Electroconvulsive treatment 

Electroshock 
EEC see also 

CEEG 

Comp-EEG 

Electroencephalography 

PharmacoEEG 
Effect(s) see 

Adverse effects 

Anorectic effect 

Antagonistic effects 

Antianxiety effects 

Anticholinergic effects 

Antidopaminergic effects 

Antiepileptic effect 

Antihypertensive effects 

Antimanic effect 

Antinociceptive effect 

Antinuretic effect 

Antipsychotic effect 

Associative effects 

Autonomic effects 



Aversive effect(s) 
Behavioral effects 
Behavioural effects 
Biochemical effects 
Biological effects 
Biphasic effects 
Cardiovascular effects 
Cataleptic effect(s) 
Choleretic effect 
Clinical effect(s) 
Comparative effect(s) 
Contrasting effects 
Convulsant effect(s) 
Differential effect(s) 
Dipsogenic effect 
Dissociative effects 
Dopaminergic effects 
Dose effects 
Drug effect(s) 
Electrocortical effects 
Electroencephalographic effects 
Electrophysiological effects 
Endocrine effects 
Epileptogenic effect 
Experimental effects 
Extrapyramidal effects 
Hormonal effects 
Hyperthermic effects 
Hypnotic effects 
Hypotensive effect 
Hypothermic effects 
Inhibitory effect(s) 
Interactive effects 
Joint effects 
Laryngeal effects 
Locomotor effects 
Lytic effects 
Metabolic effects 
Motor effects 
Neurochemical effects 
Neuroleptic effect(s) 
Neurophysiological effects 
Neuropsychologic effects 
Opiate effects 
Opposite effects 
Paradoxical effect(s) 
Perceptual effects 
Pharmacologic effects 
Pharmacological effects 
Placebo effect(s) 
Prohypnotic effects 
Psychiatric effects 
Psychic effects 
Psychoactive drug effect 



Psycholeptic effects 

Psychopharmacological effects 

Psychophysiological effects 

Residual effects 

Retinotoxic effects 

Side effect(s) 

Stimulant effect(s) 

Subjective effects 

Thermoregulatory effects 

Transient effect 
Efficacy see also 

Antipsychotic efficacy 

Clinical efficacy 

Therapeutic efficacy 
EKG see also 

Electrocardiogram 
Electrocardiogram see also 

EKG 
Electroconvulsive shock see also 

ECT 

Electroconvulsive therapy 

Electroconvulsive treatment 

Electroshock 
Electroconvulsive therapy see also 

ECT 

Electroconvulsive shock 

Electroconvulsive treatment 

Electroshock 
Electroconvulsive treatment see also 

ECT 

Electroconvulsive shock 

Electroconvulsive therapy 

Electroshock 
Electroencephalography see also 

CEEG 

Comp-EEG 

CSEEG 

EEG 
Electromyographic see also 

EMG 
Elements see 

Mineral elements 

Names of specific elements 
Elicited see 

Amphetamine -eUcited 

Apomorphine-elicited 

Shock-ehcited 
Emergency (ies) see also 

Medical emergencies 
Psychiatric emergencies 
EMG see also 

Electromyographic 
Eminence see 

Median eminence 



Ending see 

Nerve ending(s) 
Enhanced see 

GABA-enhanced 
Enriched see 

K+-enriched 
Entheogenic see 

Hallucinogenic 
Enuresis see also 

Childhood enuresis 
Epilepsy see also 

Childhood epilepsy 

Focal epilepsy 

Petit mal 
Epinephrine see also 

Adrenaline 
Episode see 

Affective episode 

Schizophrenic episodes 
ERG see 

Electroretinography 
Escape see also 

Water escape 
Estimation see 

Microestimation 
ET-495 see 

Piribedil 
Ethanol see also 

Alcohol 

Ethyl alcohol 
Ethyl alcohol see also 

Alcohol 

Ethanol 
Euhypnos-forte see 

Temazepam 
Evaluation see also 

Clinical evaluation 

Preclinical evaluation 

Self- evaluation 
Events see 

Behavioral events 

Biochemical event 

Endocrine events 

Evidence see also 
Behavioral evidence 
Biochemical evidence 

Evoked see also 
Barbiturate-evoked 
Dopamine- evoked 
Flash- evoked 
GABA-evoked 
K+- evoked 
S timulation - evoke d 
Stimulus -evoked 
Striatally - evoked 



10 



:Sm^i 



Evoked Potential see also 

AEP 
Exchange see 

Gas exchange 
Execration see also 

Circadian excretion 
Experiences see also 

Aversive experiences 

Clinical experiences 

Psychedelic experiences 
Exposed see also 

Stress exposed 
Extracts see also 

Coca extracts 



Facilitation see 

Behavioral facilitation 
Factor(s) see also 

Antihemophilic factor 

Bass scale factors 

Growth factor 

Psychopharmacologic factors 

Psychosocial factors 

Risk factors 

Thy rotrophin- releasing factor 
FDA see also 

Food and Drug Administration 
Fear see also 

Learned fear 
Feeding see also 

Freely feeding 
Fiber see also 

Thin fiber 
Field see 

Open field 

Terminal fields 
Fighting see also 

Shock-induced fighting 
Findings see 

Preliminary findings 
Firing see also 

Burst firing 
Fluid see also 

Amniotic fluid 

Crebrospinal fluid 

CSF 

Jejunal fluid 

Spinal fluid 
Flux see also 

Ca++-flux 

Ca-flux 

Calcium flux 



Focus ; Foci see 

Epileptic focus (foci) 

Epileptogenic focus 
Food and Drug Administration 

see also 

FDA 
Forebrain see also 

Anterior forebrain 

Rat forebrain 
Fragmentography see 

Mass fragmentography 
Frequency see also 

High frequency 
FSH see 

Follicle- stimulating hormone 
Function(ing) see also 

Affective functions 

Autonomic functioning 

Mixed functions 

Sexual function(s) 

Thyroid function 



G 



GAB A see also 

Aminobutyric acid 
GAD see also 

Glutamic acid decarboxylase 
Gain see 

Weight gain 
Gas liquid chromatography 

see also 

GLC 
GBL see 

Butyrolactone 
GC see 

Gas chromatography 
Generation see also 

Fl generation 

Second generation 
Gerbil(s) see also 

Mongolian gerbil 
GH see also 

Growth hormone 
Gilles de la Tourette syndrome 

see also 

Tourette syndrome 
Gland see 

Adrenal gland 

Pineal gland 

Pituitary glands 

Salivary gland 

Submarxillary gland 

Thymus gland 

Thyroid gland 



11 



GLC see also 

Gas liquid chromatography 
Glutamic acid decarboxylase see also 

GAD 
Growth Hormone see also 

GH 
GS-385 see 

Chloro-4-phenylsuccinimidobenzene- 

sulfonamide 
Guanosine triphosphate see 

GTP 
Gum see also 

Chewing gum 



H 



H-77-77 see 

Dimethyl-m-tyramine 
Haldol see 

Haloperidol 
Handicapped see also 
Intellectually handicapped 
Mentally handicapped 
Headaches see also 

Cluster headaches 
Health see 

Mental health 
Heart see also 

Cardiac 
Helplessness see 

Learned helplessness 
Hepatic see also 

Liver 
HIAA see also 

Hydroxyindoleacetic acid 
Histamine receptors see also 

HI- receptors 

H2-receptors 
Holidays see 

Drug holidays 
Homes see 

Nursing homes 

Sheltered care homes 
Hormones see also 

Adrenal hormones 

Follicle- stimulating hormone 

GH 

Glucocortical hormones 

Gonadotropin-releasing hormone 

Growth hormone 

LH 

Luteinizing hormone 

Melanocorticotropic hormone 

Melanocyte- stimulating hormone 



Names of specific hormones 
Parathyroid hormones 
Peptide hormones 
Pituitary hormones 
Sex hormone 
Steroid hormones 
STH 

Thyroid hormones 
Thy rotrophin- releasing hormone 
TRH 
TSH 
Hospital see also 
Day hospital 
General hospital 
Lima State Hospital 
Psychiatric hospital 
State hospital 
HT see also 

Hydroxy tryptamine 
Serotonin 
HTP see also 

Hydroxy tryptophan 
Hydergine see also 

Dihydroxyergotoxine 
Hydrocortisone see also 

Cortisol 
Hydroxyindoleautic acid see als 

HIAA 
Hydroxydopamine see also 

OHDA 
Hydroxytryptamine see also 
HT 

Serotonin 
Hydroxy tryptaminergic see also 
Serotonergic 
Serotoninergic 
Hydroxytryptophan see also 

HTP 
Hydroxy vanOlic acid see 

HVA 
Hyperactivity see also 

Hyperkinesis 
Hyperkinesis (ia) see also 
Hyperactivity 
Tardive hyperkinesia 
Hypoactivity see also 

Hypokinesia 
Hypokinesia see also 

Hypoactivity 
Hypotensive effect see also 

Antihypertensive effect 
Hl-receptors see also 

Histamine receptors 

H2-receptors see also 

Histamine receptors 



12 



ICS see 

Intracranial stimulation 
Illness; 111 see also 

Affective illness 

Chronically ill 

Depressive illness 

Lupus like illness 

Manic-depressive illness 

Medically ill 

Mental illness 

Psychosomatic illness 
IMAP see 

Fluspirilene 
IMl see 

Imipramine 
Impact see 

Pathophysiologic impact 
Implication see 

Clinical implications 
Independent see also 

Ca++-independent 

Na+-independent 

Voltage independent 
Induced see also 

ACTH-induced 

Adrenaline-induced 

Agonist-induced 

Ala2-met5- enkephalin amide-induced 

Aminophylline-induced 

Amphetamine-induced 

Analgesic-induced 

Angiotensin-II -induced 

Anticonvulsant-induced 

Apomorphine-induced 

Barbiturate-induced 

Bicuculline-induced 

Caffeine-induced 

Cannabinoid-induced 

Carbachol-induced 

Carbamazepine-induced 

Chemically-induced 

Chloralose-induced 

Chlorophenylalanine-induced 

Chlorpromazine-induced 

Chlorea- toxin-induced 

Cimetidine-induced 

Clonidine-induced 

Cocaine-induced 

Cyclophosphamide-induced 

D- amphetamine-induced 

Denervation-induced 

Depolarization-induced 



Desipramine-induced 

Di-n-propylacetate-induced 

Diazepam-induced 

Dihydroxytryptamine-induced 

Diphenylhydantoin-induced 

Disease-induced 

Dopamine-induced 

Drug-induced 

Electrically-induced 

Electroshock-induced 

Endogenously-induced 

Endorphin-induced 

Endo toxin-induced 

Enkephalin-induced 

Enzyme-inducing 

Ethanol-induced 

Exogenously-induced 

Experimentally-induced 

Flurazepam-induced 

Haloperidol- induced 

Handling-induced 

Harmaline-induced 

Hexobarbital- induced 

Homocysteine-induced 

HTP-induced 

Hydroxy tryptamine-induced 

Insulin-induced 

Iron-induced 

Isolation-induced 

Isoprenaline-induced 

Isoproterenol- induced 

Kainic-acid-induced 

L- dopa-induced 

Lesion-induced 

Lithium-induced 

LSD-induced 

MAOI-induced 

Methadone-induced 

Methamphetamine-induced 

Methylmercury-induced 

Methylphenidate-induced 

Me trazol- induced 

Morphine-induced 

Naloxone-induced 

Narcotic-induced 

Neurolep tic-induced 

Neurotensin-induced 

Opiate-induced 

Organophosphate-induced 

Pemoline-induced 

Penicillin-induced 

Pentobarbital-induced 

Pentylenetetrazol- induced 

Peripherally-induced 






13 



Pethidine-induced 

Phencyclidine-induced 

Potassium-induced 

Psychotropic- drug-induced 

Reflex-induced 

Reserpine-induced 

Schedule-induced 

Scopolamine-induced 

Self-induced 

Shock-induced 

Sound-induced 

Stimulation-induced 

Stimulus-induced 

Stress-induced 

Stretch-induced 

Strychnine-induced 

Sulpiride-induced 

Tetrabenazine-induced 

THC-induced 

Thiazide-induced 

Thyroid-induced 

Tricyclic-antidepressant-induced 

Triethyltin- induced 

Tryptophan-induced 

Tryptophol-induced 
Infarction see 

Myocardial infarction 
Influence(d) see 

Parasympathomimetic influence 

Serotonergially influenced 
Infusion see also 

Microinfusion 
Inhibition(or) see also 

MAOl 

MAO inhibition(or) 

Monoamine-oxidase inhibition (or) 
Injection see also 

Microinjection 

Self-injection 
Injury see also 

Self-injury 
Inpatient(s) see also 

Depressed inpatients 

Insomniac inpatients 

Psychiatric inpatients 

Psychogeriatric inpatients 
Interaction see also 

Behavioral interactions 

Biologic interaction 

Biological interaction 

Drug interactions 

Hypnotic interactions 

Monoaminergic interaction 

Paradoxical interaction 



Pharmacokinetic interaction 

Social interaction(s) 
Interval see also 

Fixed interval 
Intervention see 

Behavioral intervention 

Psychiatric intervention 
Interperitoneal see also 

IP 
Investigation(s) see also 

Psychopharmacological investigation 
lon(s) see 

Calcium ions 

Lithium ion 

Sodi\im ion 
Ionization see also 

Chemical ionization 

Flame ionization 
Iontophoresis see also 

Microiontophoresis 
IP see also 

Intraperitoneal 
Isolation see also 

Social isolation 
Isomers see also 

Cis-isomers 

D-isomers 

L-isomers 

Optical isomers 

Trans-isomers 
Issue(s) see 

Methodological issues 



K 



K 



see also 



Potassium 
Kidney see also 

Renal 
Killing see 

Mouse-killing 

Pup -killing 



L-Amphetamine see also 

Amphetamine 

D- Amphetamine 

Dextroamphetamine 

Methamphetamine 

Methylamphetamine 
L-DOPA see also 

Dihydroxyphenylalanine 

DOPA 

Levodopa 



14 



LAAM see 

Acetylmethadol 
Labeled see also 

Isotope labeled 

Spiroperidol labeled 
Lasting see 

Long-lasting 
Learning see also 

Maze learning 

Motor learning 
Level(s) see 

High levels 
Levodopa see also 

Dihydroxy phenylalanine 

DOPA 

L-DOPA 
LH see also 

Luteinizing hormone 
LHM see 

Lisuride hydrogen maleate 
Li see also 

Lithium 
LiCl see also 

Lithium chloride 
Life see also 

Sex life 
Lilly-110140 see 

Fluoxetine 
Lithium see also 

Li 
Lithium carbonate see also 

Li^CO^ 
Lithium chloride 



see also 



LiCl 
Liver 



see also 



Hepatic 
Li2CO„ see also 

Lithium carbonate 
Localization see also 

Biochemical localization 
Loss see also 

Hair loss 
LSD see also 

Lysergic acid diethylamide 
LU-10-171 see 

Citalopram 
Luteinizing hormone see also 

LH 
Lyorodin see 

Fluphenazine-HCl 
Lysergic acid diethylamide see also 

LSD 

M 
Maladjustments see 



Social maladjustments 
Manic-depressive see also 

Affective- disorders 

Bipolar 

Depression 

Unipolar 
Manifestations see also 

Psychic manifestations 
Manipulation see also 

Behavioural manipulation 
MAO see also 

Monoamine oxidase 
MAOI see also 

MAO inhibition 

Monamine oxidase inhibition 
Maze see also 

T-Maze 

Y-Maze 
MBD see 

Minimal brain dysfunction 
Measurements see also 

Biochemical measurements 
Mechanism(s) see also 

Autonomic mechanisms 

Biochemical mechanism 

Dual mechanism 
Mediated see 

Adrenocep tor-mediated 

Agonist-mediated 

Alpha-adrenocep tor-mediated 

Aminobutyric-acid-mediated 

Dopamine-mediated 

GABA-mediated 

Hl-receptor-mediated 

Receptor-mediated 
Medication ; Medicine see also 

Antipsychotic medications 

Neuroleptic medication; medicine 

Psychoactive medication 

Psychosomatic medicine 

Psychotropic medication 

Self -medication 
Medulla see 

Adrenal medulla 

Pons medulla 
Meeting see 

Psychopharmacological meeting 
Memory see also 

Verbal memory 
MEO-DIPT see 

Methoxydiisopropyltryptamine 
Merital see 

Nomifensine 
Met-enkephalin see also 

Methionine enkephalin 



5 

5 
^ 



15 



-.■■''-r> 



Methamphetamine see also 

Amphetamine 

D- Amphetamine 

Dextroamphetamine 

L- Amphetamine 

Methylamphetamine 
Methionine enkephalin see also 

Met- enkephalin 
Method(s) see also 

Electrochemical method 

Electromyographic method 
Methoxy-4-hydroxyphenylglycol 

see also 

MHPG 
Methylamphetamine see also 

Amphetamine 

D- Amphetamine 

Dextroamphetamine 

L- Amphetamine 

Methamphetamine 
Methylphenidate see also 

Ritalin 
MHPG see also 

Methoxy-4-hydroxyphenylglycol 
Mianserin see also 

ORG-GB-94 
MIF see also 

Pro-leu-gly-NH„ 



Milk 



see also 



Mothers milk 
Minnesota Multiphasic Inventory 

MMPI 
MK-647 see 

Difluorophenylsalicylic acid 
MMH see 

Monomethylhydrazine 
Model see also 

Animal model(s) 

Medical model 
Modification; Modifying; Modified 

see also 

Behavior modification 

Behaviour modifying 

Synthetically modified 
Modulated see 

Stress modulated 
Monitored (ing) see also 

Holtor monitored 

Ion -monitoring 
Monkey (s) see also 

Macaca mulatta 

Pigtail macaque 

Rhesus macaque 

Rhesus monkey(s) 



see 



Squirrel monkey (s) 

Talapoin monkeys 

Vervet monkeys 
Monoamine(s) see also 

Brain monoamine 
Monoamine oxidase see also 

MAO 
Monoamine oxidase inhibitor 

see also 

MAO inhibitor 

MAOI 
MOPEG see 

Methoxy-4-hydroxyphenylethylene- 

glycol 
Motivation see 

Sexual motivation 
Movement(s) see also 

Abnormal movements 

Choreic movements 

Dyskinetic movements 

Eye movements 

Involuntary movements 

Psychiatric movements 

Rapid eye movement 

REM 
MS see 

Mass spectrometry 
MSH see 

Melanocyte- stimulating hormone 
MT see 

Methyl-p- tyrosine 
Muscle see also 

Anococcygeus muscle 

Cardiac muscle 

Intestinal muscle 

Skeletal muscle 

Smooch muscle 

Ventricular muscle 
Mutilation see 

Self -mutilation 

N 

Na see also 

Sodium 
NaCl see also 

Sodium chloride 
Nerve see also 

Hepatic nerve 

Phrenic nerve 

Sciatic nerve 

Sympathetic nerve 
Neuralgia see 

Trigeminal neuralgia 



16 



Neurochemistry see also 

Behavioral neurochemistry 
Neurones see also 

Rat cortical neurones 
Neurosis see also 

Depressive neurosis 

Obsessive-compulsive neurosis 

War neurosis 
Neurotransmission see also 

Transmission 
Neurotransmitter see also 

Transmitter 
NH.-tyr-pro-phe-pro-CONH^ 



see 



Morphiceptin 
Nigrostriatal see also 

Striatonigrsil 
Node see 

Lymph node 
Noradrenaline see also 

Norepinephrine 
Norepinephrine see also 

Noradrenaline 
Noveril; Noveril-240 see 

Dibenzepine 
Nuclear magnetic resonance 

NMR 
Nucleotide(s) see also 

Cyclic nucleotides 

Guanine nucleotides 

Guanyl nucleotides 
Nucleus (Nuclei) see also 

Caudate nucleus 

Preopticus mediaUs nucleus 

Trigeminal nucleus 



O 



Observations see also 

Biochemical observations 
Ocytocin see also 

Oxytocin 
Offenders see also 

Criminally insane offenders 

Sex offenders 

Sexual offenders 
OHDA see also 

Hydroxy dopamine 
Opening see 

Ring opening 
ORAP see 

Pimozide 
Order see 



see 



Higher order 
Randomized order 



Second order 

ORG-GB-94 see also 
Mianserin 

Organ see also 
Pineal organ 

Outpatient(s) see also 
Depressed outpatients 
Psychiatric outpatients 
Psychotic outpatients 
Schizophrenic outpatients 

Oxidase(s) see also 
Amine oxidase 
Cu amine oxidase(s) 
MAO 
Monoamine-oxidase(s) 

Oxytocin see also 
Ocytocin 



Papers see 

Clinical papers 
Parameters see also 

Biochemical parameters 
Parlodel see 

Bromo- alpha- ergocrip tine 
Parnate see 

Tranylcypromine 
Patient(s) see also 

Aggressive patients 

Alcoholic patients 

Autistic patients 

Bipolar- 1 patients 

Bipolar patients 

Borderline patients 

Cancer patients 

Depressed patient(s) 

Depressive patients 

Dysthymic patients 

Elderly patients 

Epileptic patients 

Fibrositis patients 

Geriatric patients 

Gerontopsychiatric patient(s) 

HospitaKzed patients 

Hyperprolactinaemic patients 

Hypertensive patients 

Hypothyroid patients 

Involuntary patients 

Manic patients 

Manic-depressive patient(s) 

Melancholic depressed patients 

Mental patients 

Mentally handicapped patients 

Mentally subnormal patients 



ft 
fie 



17 



Neurotic patients 

Parkinson patients 

Parkinsonian patients 

Physically handicapped patients 

Psychiatric patients 

Psychogeriatric patient(s) 

Psychotic patients 

Schizoaffective patients 

Schizophrenic patients 

Subnormal patients 
Patterns see also 

Drinking patterns 

Mood- swing patterns 
PCP see also 

Phencyclidine 
PCPA see 

Chlorophenylalanine 
PEA see 

Phenethylamine 

Phenylethylamine 
Pemoline see also 

Cylert 
Peptides see also 

Bombesin-like peptides 

Cholecystokinin peptides 

Hexapeptide 

Names of specific peptides 

Neuroleptic peptides 

Neuropeptide( s ) 

Opiate pentapeptide 

Opiod peptide(s) 

Pyrimidine peptide 

Tetrapeptide 
Performance(s) see also 

High performance 

Maze performance 
Periodicity see also 

Circadian periodicity 
Perspective see also 

Biopsychosocial perspective 

Historical perspective 

Neurobiological perspective 

Psychiatric perspective 

Therapeutic perspectives 
Pharmacology see also 

Behavioral pharmacology 

Biochemical pharmacology 
Cardiovascular pharmacology 
Clinical pharmacology 

Neurochemical pharmacology 

Neurovascular pharmacology 
Pharmacotherapy see also 

Behavioral pharmacotherapy 
Phencyclidine see also 
PCP 



Phenethylamine see also 

Phenylethylamine 
Phenylethylamine see also 

Phenethylamine 
Phenytoin see also 

Diphenylhy dan torn 
Picture see 

Clinical picture 
Pills see also 

Sleeping pill(s) 
Placebo see also 

Double placebo 
Platelets see also 

Blood platelets 
Postassium see also 

K 
Potential(s) see also 

Evoked potential(s) 

VEP 

Visually-evoked-potentials 
Practice see 

Clinical practice 

General medical practice 

General practice 

Pediatric practice 

Psychiatric practice 
Practitioner(s) see 

General practitioner(s) 
Predictors see also 

Behavioral predictors 
Preparations see 

Anxiolytic preparations 
Pressure see also 

Blood pressure 

Micropressure 
Primed see 

Estrogen-primed 
Probe(s) see also 

Pharmacologic probes 

Pharmacological probes 
Problem(s) see 

Methodological problem 

Personality problems 
Procedures see also 

Psychopharmacological procedures 
Process see 

Creative process 
Processing see also 

Information processing 
Prone see 

Epilepsy prone 
Properties see 

Anorectic properties 

Antidyskinetic properties 

Antipsychotic properties 



18 



Arrythmogenic properties 

Biochemical properties 

Microproperties 

Pharmacological properties 
Prothieden see 

Dothiepin 
Psychiatry see also 

Biological psychiatry 

Child psychiatry 

Social psychiatry 
Psychopharmacology see also 

Pediatric psychopharmacology 
Psychosis see also 

Affective psychosis 

Epileptic psychosis 

Manic-depressive psychosis 

Manic psychosis 

Schizoaffective psychoses 

Schizophrenic psychoses 
Pulp see 

Tooth pulp 
Pump see 

Lithium- pump 

Na-pump 

Sodium-pump 
Pursuit see 

Smooth pursuit 
Putamen see 

Caudate-putamen 



Q 



Questionnaire see also 

Leeds- Sleep-Evaluation-Questionnaire 



R 



R 33812 see 

Domperidone 
Radiation ; Ray see 

Gamma radiation (ray) 
Radio receptor(s) see also 

Dopamine radioreceptor 
Rapid eye movement see also 

REM 
Rate see also 

Firing rate 

Turnover rate(s) 
Rating see also 

Self-rating 
Ratio see 

Fixed ratio 

Progressive ratio 
RBC see 

Red blood cell 



Reaction(s) see also 

Adverse reactions 

Behavioral reactions 

Hypomanic reaction 
Receptivity see 

Sexual receptivity 
Receptor(s) see also 

Acetylcholine receptor(s) 

ACH receptor 

Adenosine receptors 

Adrenergic receptor(s) 

Alpha-adrenergic receptor(s) 

Alpha-receptors 

Alphal-adrenergic receptors 

Alphal -receptors 

Alpha2-receptors 

Aminobutyric acid receptor(s) 

Apomorphine receptors 

Benzodiazepine receptor(s) 

Beta-adrenergic receptor(s) 

Beta-receptor 

Bradykinesia receptor(s) 

Catecholamine receptors 

Cholinergic receptor(s) 

Delta-receptor(s) 

Diazepam receptor 

Dopamine receptor(s) 

Dopaminergic receptor(s) 

Drug receptors 

Enkepalin receptors 

GABA receptor(s) 

Glucocorticord receptor 

Glutamate receptors 

Histamine receptors 

HT receptor 

HTP receptors 

Hydroxytryptamine receptors 

Hl-receptor(s) 

H2-receptor(s) 

lonophore receptor 

Kappa-receptor ( s ) 

Monamine receptor(s) 

Monoaminergic receptor 

Mu-receptors 

Muscarinic receptor(s) 

Neuroleptic receptor(s) 

Neuropeptide receptor 

Neurotensin receptor 

Neurotransmitter receptor(s) 

Nicotine receptors 

Noradrenaline receptors 

Noradrenergic-alpha2 receptors 

Norepinephrine receptor 

Opiate receptor(s) 

Opiod receptor(s) 



i. 
i 

2 



19 



Postsynaptic receptors 
Presynaptic receptors 
Progestin receptors 
Quisqualate receptors 
Serotonergic receptors 
Serotonin receptor(s) 
Recorded see 
EMG recorded 
Redergine see 
Dihydroergotoxine 

Hydergine 
Reflex(es) see also 

Biting reflex 

Motor reflexes 

Sexual reflexes 
Refusal see 

Drug refusal 
Refuse see also 

Right- to-refuse 
Region see 

Hippocampal CAl-reglon 
Regulation see also 

Central regulation 
Reinforced see 

Cocaine reinforced 

Drug reinforced 

Emotionally reinforced 

Narcotic reinforced 
Related see 

Age related 

Dose related 

Drug related 

Event related 

Sleep related 
Relaxant(s) see 

Muscle relaxant(s) 
Release see also 

Controlled release 

Sustained release 
REM see also 

Rapid eye movement 
Renal see also 

Kidney 
Report(s) see 

Case report 

Preliminary report 

Task force report 
Research see also 

Psychiatric research 

Psychobiological research 

Psychopharmacological research 

Psychoneuropharmacolog^c research 
Resistance see 

Drug resistance 



Galvanic skin resistance 

Skin resistance 

Stress resistance 
Resistant see also 

Atropine resistant 

Drug resistant 

Therapeutically resistant 

Therapy resistant . 

Responding see 

FI responding 

Operant responding 

Punished responding 
Response(s) see 

Behavioral responses 

Behavioural responses 

Biochemical response 

CR 

Clinical response 

Dose response 

Early response 

Evoked response(s) 

Glycemic response 

Hyperthermic response 

Motor response 

Operant response 

Pharmacologic responses 
Results see 

Preliminary results 
Resuscitation see 

Neurosurgical resuscitation 
Retardate(s); Retarded see also 

Mental retardates 

Mentally retarded 
Reversal see also 

Behavioral reversal 
Review see also 

Minireview 
Rhythm(s) see 
Biological rhythm 
Circadian rhythm(s) 
Rhythmicity see 

Biological rhythmicity 
Ribonucleic acid see 

RNA 
Rich see 

Terminal rich 
Risk see also 

High risk 
Ritalin see also 
Methylphenidate 
Roipnol see 

Flunitrazepam 
Rodent see also 
Guinea pig 



20 



Sample see also 

Matching- to -sample 

Psychiatric sample 
Satisfaction see 

Job satisfaction 
Scale(s) see also 

Behavioral rating scales 

Clinical scale 

Hamilton Depression Rating Scale 
Schedule see also 

Automaintenance schedule 

Multiple schedule 
Schizophrenics (ia) see also 

Childhood schizophrenia 

Chronic schizophrenics 
Scores see 

T-scores 
Seizure(s) see also 

Audiogenic seizure(s) 

Cephalgic seizures 

Convulsive seizure . 

Epileptic seizures 

Organic brain seizures 
Selection see also 

Self- selection 
Selective see also 

Behaviorally selective 

Biochemically selective 
Sensitive see also 

Calcium sensitive 

Dopamine sensitive 

HT sensitive 

Opiate sensitive 

Serotonin sensitive 
Sensitivity see also 

Behavioral sensitivity 

High sensitivity 
Sensitization see also 

Behavioral sensitization 
Sequelae see also 

Behavioral sequelae 
Serotonergic see also 

Hydroxytryptaminergic 

Serotoninergic 
Serotonin see also 

HT 

Hydroxy tryptamine 
Serotoninergic see also 

Hydroxytryptaminergic 

Serotonergic 
Serum see also 

Umbilical cord serum 



Service(s) see 

Health care services 

Inpatient service 
Sheet see 

Fact sheet 
Shake(s) see 

Wet dog shake(s) 
Shock(s) see also 

Convulsive shock 

ECS 

Electric shock 

Electroconvulsive shock 

Electroshock 

Footshock 

Stimulus shock 

Tail shock 

Two shock 
SIF see 

Shock-induced fighting 
Site(s) see 

Binding sites 

XQ fragile site 
Situations see 

Aversive situations 

Conflict situation 

Stressful situation 
SKF-525-A see 

Diethylaminoethyldiphenylpropyl- 

acetate 
SKF-69634 see 

Clopipazan 
Sleep see also 

DSIP 

Paradoxical sleep 

REM 
Sleep-walking see also 

Somnambulism 
Sodium see also 

Na 
Sodium chloride see also 

NaCl 
Sodium dipropylacetate see also 

Depakine 

Dipropylacetate 

Dipropylacetic acid 

Sodium valproate 

Valproic acid 
Sodium valproate see also 

Depakine 

Dipropylacetate 

Dipropylacetic acid 

Sodium diproprylacetate 

Valproic acid 
Solvent see also 

Industrial solvent 



i 

I 



21 



-A' "• 






Somnambulism see also 

Sleep-walking 
Specific see 
Age- specific 
Brain specific 
Opiod specific 
Spectrometry see 
Audio-spectrometry 
Mass spectrometry 
Spider see 

Black widow spider 
Stability see also 
Biological stability 
Photochemical stability 
State(s) see 
Behavioral state 
Confusional state 
Depressive states 
Manic state 
Mental state 
Phobic state 
Steady state 
Stay see 

Long- stay 
Stimulation (ed) see also 
Behavioral stimulation 
Brain stimulation 
Electric stimulation 
Electrical stimulation 
GAB A stimulated 
Intracranial stimulation 
Locomotor stimulation 
Pentagastrin stimulated 
Self - stimulation 
Stimulus see also 

Discriminative stimulus 
UCS 

Unconditioned stimulus 
Strategies see also 

Video strategies 
Stress(ed) see also 
Emotional stress 
Ether stressed 
Psychological stress 
Psychosomatic stress 
Striatonigral see also 

Nigrostriatal 
Study see 

Behavioral studies 
Biochemical study (ies) 
Biological studies 
Case study (ies) 
Clinical study (ies) 
Collaborative study 



Comparative study (ies) 
Controlled comparative study 
Controlled study 
Cross-study 
Drug studies 
Early activity studies 
Electrocytochemical study 
Electrophysiological study (ies) 
Empirical study 
Endocrine study 
Experimental study(ies) 
Histochemical study 
Interaction studies 
Metabolic study (ies) 
Microiontophoretic study 
Morphological study 
Multicenter study 
MulticHnical study 
Multiinstitutional study 
Neuroanatomical study 
Neurochemical study (ies) 
Neuroendocrine study(ies) 

Neurological study 

Neuropharmacological study (ies) 

Neurophysiological study 

Neuropsychopharmacological studies 

Neuropsychopharmacology study 

Ontogenetic studies 

Open study 

Pathophysiological studies 

Pharmacokinetic study 

Pharmacologic studies 

Pharmacological study (ies) 

Pharmacomanometric studies 

Physiological studies 

Pilot study 

Placebo controlled study 

Polygraphic study 

Polygraphical studies 

Preliminary study (ies) 

Psychopharmacological studies 

Psychophysiologic studies 

Relapse studies 

Scientific study 
Subject(s) see 

Epileptic subjects 

Phobic subjects 
Substance(s) see also 

Psychoactive substances 

Psychotropic substances 
Supersensitivity see also 

Behavioral supersensitivity 

Cholinergic supersensitivity 

Dopaminergic supersensitivity 



22 



I 



Suppression see also 

Behavioral suppression 
Sustained see 

Self- sustained 
Symposium see 

Mini- symposium 
Symptom(s) see also 

Depressive symptoms 

Manic symptoms 

Mental symptoms 

Obsessive symptoms 

Psychotic symptoms 

Schizophrenic symptoms 
Symptomatology see also 

Depressive symptomatology 

Schizophrenic symptomatology 
Syndrome(s) see also 

Abstinence syndrome 

Anticholinergic syndrome 

Anxious depressive syndromes 

Asthenic depressive syndromes 

Astheno-depressive syndromes 

Behavioral syndrome 

Behavioural syndromes 

Borderline syndromes 

Brain damage syndrome 

Catatonia syndrome 

Chronic brain syndromes 

DeLange syndrome 

Depressive syndrome(s) 

Dissociative syndromes 

Down syndrome 

Downs syndrome 

Episodic dyscontrol syndrome 

Extrapyramidal syndromes 

Forum-fruste-du-syndrome-malin 

Gilles de la Tourette(s) syndrome 

Hyperactive child syndrome 

Hyperactivity syndrome 

Hyperkinetic syndrome 

Hypertension syndrome 

Hyperventilation syndrome 

ICleine Levin syndrome 

Lennox Gastaut syndrome 

Lesch Nyhaus syndrome 

Malignant hyperthermic syndromes 

Malignant syndrome 

Nelsons syndrome 

Neurological syndrome 

Organic brain syndrome 

Organic mental syndrome 

Organic psychosyndromes 

Parkinsonian syndrome 



Phobic anxiety syndrome 

Premenstrual syndrome 

Psychiatric syndromes 

Sleep apnea syndrome 

Stereotypic behavior syndrome 

Stretch yawning syndrome 

Tourette syndrome 

Transient syndromes 

Withdrawal syndrome(s) 
Synthesis see also 

Gas chromatographic synthesis 
System(s) see ♦ 

Cardiovascular system 

Central nervous system 

Dopaminergic system(s) 

HLA system 

Limbic system 

Sympathetic nervous system 



Table see 

Life table 

Techniques 



see also 



Behavioural techniques 
Temperature see also 

Body temperature 
Term see 

Long-term 

Short-term 
Terrors see 

Night terrors 
Test(s) see also 

Behavioral tests 

Clinical tests 

Dexamethasone Suppression Test(s) 

Electroshock test 

Neuroendocrine tests 

Psychometric test 

Psychophysiological tests 

Screening test 

Shock escape test 
Testing see also 

Behavioral testing 

Clinical testing 
Tetrahydrocannabinol see also 

THC 
Tetrahydroisoxazolopyridin-3-ol 

see 

THIP 
THC see also 

Tetrahydrocannabinol 



ft 
i 



23 



Therapy see also 
Behavioral therapy 
Behaviour therapy 
Cognitive therapy 
Drug therapy 
Electroconvulsive therapy 
Maintenance therapy 
Monotherapy 

Psychopharmaceutical therapy 
Thin layer chromatography see also 

TLC 
Thyrotropin- releasing hormone 
see also 
TRH 
Thy rotophin- stimulating hormone 
see 
TSH 
Time see also 
Reaction time 
Sleeping time 
TLC see also 

Thin layer chromatography 
Tolerance(ant) see also 
Behavioral tolerance 
Cross- tolerance 
Morphine tolerance (ant) 
Opiate tolerant 
Opiod tolerance 
Tomography see 

Computed tomography 
Computerized axial tomography 
Positron tomography 
Tourette syndrome see also 

Gilles de la Tourette syndrome 
Tranquilizer (s) see also 
Major tranquilizers 
Minor tranquilizer(s) 
Names of specific tranquilizers 
Transfer see also 

Ion transfer 
Transmission see also 

Neurotransmission 
Transmitter see also 

Neurotransmitter 
Transport see also 
Cellular transport 
Treatment(s) see also 
Behavioral treatments 
Chronic treatment 
Drug treatment 
Convulsive shock treatment 
Electroconvulsive treatment 
Electroshock treatment 



Long-term treatment 

Maintenance treatment 

Pharmacological treatment 

Psychiatric treatment 

Psychologic treatment 

Psychological treatment 

Psychopharmacological treatment 

Subchronic treatment 
TRF see 

Thy rotrophin- releasing factor 
TRH see also 

Thyrotropin- releasing hormone 
Trial(s) see also 

Clinical trial(s) 

Comparative trial 

Controlled trial 

Multicenter trail 

Placebo controlled trial 

Preliminary trial 

Prospective trial 

Randomised trial 
Tumescence see 

Penile tumescence 
Turning see also 

Head turning 
Twitch(es) see 

Head twitches 



U 



U-14-624 see 

Phenyl-2-thiazolyl-2- thiourea 
UCS see also 

Unconditioned stimulus 
Ulcers see 

Gastric ulcers 

Peptic ulcers 

Stress ulcers 
Ultradian see also 

Circadian 
Unconditioned stimulus see also 

UCS 
Unipolar see also 

Affective disorders 

Bipolar 

Depression 

Manic-depressive 



Valproic acid 
Depakine 



see also 



Dipropylacetate 



24 



Dipropylacetic acid 

Sodium dipropylacetate 

Sodium valprovate 
Valve see 

Mitral valve 
Variables see also 

Biochemical variables 

Clinical variables 

Drug variables 

Pharmacokinetic variables 

Psychophysiological variables 
Vasoactive intestinal peptide see 

VIP 
VEP see also 

Visually-evoked potentials 
View(s) see 

Current views 

Modern views 

Psychological view 
Visually- evoked potentials see also 

VEP 

W 

/Wakefulness see also 
Sleep wakefulness 



Walking see 

Sleep-walking 
Wards see 

Outpatients wards 

Psychiatric wards 

Psychogeriatric ward 
Way see 

Two way 
Weight see also 

Body weight 
WHO see 

World Health Organization 
Women see also 

Postmenopausal women 

Premenopausal women 
Word see 

Pure word 
WY-25093 see 

Indol-3-ylmethylpiperid-4-yl-3- 

benzoylurea 






25 



'jV/A 






/. 



SUBJECT INDEX 



[The Subject Index is mochine generoted Keywords in the titles of abstrocts oppeor alphabetically in the the left hand margin; under each keyword is a list 
of titles in which the keyword appeors The spelling of words in the titles of abstracts has not been changed; hence, two spellings of the same word may 
oppeor in this index — for example, BEHAVIOR and BEHAVIOUR ] 



ABANDONMENT 

SELF-AAEDICATION, ABANDONMENT, MANIPULATION, AND DEPENDENCE 
IN DRUG-THERAPY IN PSYCHOSOMATIC-ILLNESS: COMPARATIVE 
POLYCENTRIC RESEARCH ON VARIOUS PSYCHOTROPIC-DRUGS. 

002189 02-11 
ABILITIES 

MOTOR-LEARNING ABILITIES IN SUBJECTS TREATED WITH LITHIUM-SALTS 
AND TRICYCLIC-ANTIDEPRESSANTS. 

002058 02-09 
ABILITY 

A COMPARISON OF HUMAN TACTILE STIMULUS VELOCITY 

DISCRIMINATION WITH THE ABILITY OF S-l CORTICAL NEURONS IN 
AWAKE RHESUS-MONKEYS TO SIGNAL THE SAME VELOCITY 
DIFFERENCES BEFORE AND AFTER NONANESTHETIC DOSES OF 
PENTOBARBITAL. 

000055 01-03 
ABILITY OF AGED RATS TO ALTER BETA-ADRENERGIC-RECEPTORS OF 
BRAIN IN RESPONSE TO REPEATED ADMINISTRATION OF RESERPINE 
AND DESMETHYLIMIPRAMINE. 

000113 01-03 
THE HYPOTHERMIC-EFFECTS OF CLONIDINE AND OTHER IMIDAZOLIDINES 
IN RELATION TO THEIR ABILITY TO ENTER THE CENTRAL-NERVOUS- 
SYSTEM IN MICE. 

003933 04-03 
ABNORMAL 

THE ALBINO LOCUS PRODUCES ABNORMAL RESPONSES TO OPIATES IN 
THE MOUSE. 

001675 02-04 
ABNORMAL REGULATION OF PROLACTIN RELEASE IN IDIOPATHIC 
PARKINSONS-DISEASE. 

002255 02-13 
CORRECTION BY PROPRANOLOL OF THE ABNORMAL ADRENALINE 
DISCHARGE INDUCED BY EMOTIONAL-STRESS IN CEREBRAL 
HEMORRHAGE PATIENTS. 

002295 02-13 
ABNORMAL MATURATION OF CEREBRAL-CORTEX AND BEHAVIORAL- 
DEFICIT IN ADULT RATS AFTER NEONATAL ADMINISTRATION OF 
ANTIBODIES TO GANGLIOSIDE. 

003025 03-04 
ABNORMAL TRANSMETHYLATION REACTION DURING THE METABOLISM 
OF DOPAMINE, TRYPTAMINE, AND SEROTONIN, AND SCHIZOPHRENIC- 
SYMPTOMS: A CRITICAL REVIEW. 

003404 03-13 
PREVALENCE OF PERSISTENT ABNORMAL INVOLUNTARY-MOVEMENTS 
AMONG PATIENTS IN A NIGERIAN LONG-STAY PSYCHIATRIC UNIT. 

004334 04-08 
ABNORMAL MOVEMENTS INDUCED BY PSYCHOTROPIC-DRUGS. 

004652 04-15 
ABNORMAL-BEHAVIOR 

PSYCHONEUROENDOCRINOLOGY AND ABNORMAL-BEHAVIOR. 

002347 02-14 
ABNORAAALITIES 

PROTEIN ABNORMALITIES IN MACROPHAGES BEARING ASBESTOS. 
(UNPUBLISHED PAPER). 

001037 02-01 
VITAMIN RESPONSIVE GENETIC ABNORMALITIES. (UNPUBLISHED PAPER) 

001388 02-03 
HORMONAL ABNORMALITIES IN ANOREXIA-NERVOSA (AN) 

002099 02-11 
ABNORMALITIES OF LITHIUM TRANSPORT IN PATIENTS WITH AFFECTIVE- 
DISORDERS. 

002269 02-13 
DOPAMINERGIC ABNORMALITIES IN POSTMORTEM SCHIZOPHRENIC 
BRAIN. 

002575 02-17 
METABOLIC AND SYMPATHOADRENAL ABNORMALITIES IN THE OBESE 
ZUCKER RAT: EFFECT OF CHRONIC PHENOXYBENZAMINE TREATMENT. 

003905 04-03 
ABNORMALITY 

DEVELOPMENT AND USE OF PHARMACOLOGICAL-PROBES OF THE CNS IN 
MAN: EVIDENCE OF CHOLINERGIC ABNORMALITY IN PRIMARY 
AFFECTIVE-ILLNESS. 

002506 02-16 
ABRUPT 

PANIC-ANXIETY AFTER ABRUPT DISCONTINUATION OF AMITRIPTYLINE 

003223 03-09 
CLINICAL AND BIOCHEMICAL-CORRELATIONS IN ABRUPT 
DISCONTINUATION OF PSYCHOPHARMACOTHERAPY. 

004330 04-08 
ABSCESSES 

ABSCESSES FOLLOWING PROLONGED INTRAMUSCULAR ADMINISTRATION 
OF PERPHENAZINE-ENANTATE. 

000888 01-15 



ABSORPTION 

ABSORPTION OF 14C LABELED METHADONE BY PORTAL AND 

EXTRAPORTAL VENOUS CIRCULATIONS FOLLOWING INTRAPERITONEAL 
AND INTRODUODENAL ADMINISTRATION. 

000094 01-03 
EFFECT OF DOSE ON PHENYTOIN ABSORPTION. 

000773 01-13 
MEAL-DEPENDENT ABSORPTION OF ENTERIC-COATED SODIUM- 
VALPROATE 

000777 01-13 
MICROSCOPIC EVIDENCE OF LYMPHOGENIC ABSORPTION OF OIL IN 
HUMANS RECEIVING NEUROLEPTIC OILY DEPOT PREPARATIONS 
INTRAMUSCULARLY. 

000890 01-15 
PREDICTION OF THE VOLUME OF DISTRIBUTION FROM IN VITRO DATA 
AND USE FOR ESTIMATING THE ABSOLUTE EXTENT OF ABSORPTION. 

000907 01-16 
ABSORPTION OF LEVODOPA AFTER RECTAL ADMINISTRATION. 

003406 03-13 
ORAL AND RECTAL ABSORPTION OF CHLORAL-HYDRATE AND ITS BETAINE 
COMPLEX. 

004554 04-13 
CLINICAL-PHARMACOLOGY: DRUG ABSORPTION. 

004740 04-17 
ABSTINENCE 

ENKEPHALIN LEVELS DECREASE IN RAT STRIATUM DURING MORPHINE 
ABSTINENCE. 

000027 01-03 
AN ELECTROMYOGRAPHIC-METHOD FOR THE ASSESSMENT OF 
NALOXONE-INDUCED ABSTINENCE IN MORPHINE-DEPENDENT RATS. 

000433 01-04 
NARCOTIC ANTAGONIST PRECIPITATED ABSTINENCE: RELATIONSHIP TO 
WITHDRAWAL INDUCING BENZAZOCINES. (PH.D. DISSERTATION) 

001518 02-03 
CYCLIC-AMP-INDUCED CHANGES IN THE ELECTROENCEPHALOGRAM AND 
IN BEHAVIOR DURING MORPHINE-DEPENDENCE AND ABSTINENCE IN 
THE RAT. 

003078 03-04 
EFFECTS OF NARCOTIC ABSTINENCE ON SCHEDULE-CONTROLLED 
BEHAVIOR IN DEPENDENT RATS. 

004230 04-04 
SUPPRESSION OF MORPHINE ABSTINENCE IN HEROIN ADDICTS BY BETA 
ENDORPHIN. 

004489 04-11 
DOPAMINE AND 5 HT SUPERSENSITIVITY IN NONORGANIC CENTRAL PAIN 
AND IN MORPHINE ABSTINENCE: FORTUITOUS OR REAL ANALOGY? 

004553 04-13 
ABSTINENCE-BEHAVIOR 

EFFECTS OF BRANCHED-CHAIN FATTY-ACIDS ON GABA DEGRADATION 
AND BEHAVIOR: FURTHER EVIDENCE FOR A ROLE OF GABA IN QUASI- 
MORPHINE ABSTINENCE-BEHAVIOR 

001809 02-04 
ABSTINENCE-BEHAVIOUR 

DIPROPYLACETATE-INDUCED ABSTINENCE-BEHAVIOUR AS A POSSIBLE 
CORREUTE OF INCREASED GABAERGIC ACTIVITY IN THE RAT. 

001606 02-04 
ABSTINENCE-SYNDROME 

AN ABSTINENCE-SYNDROME FOLLOWING CHRONIC ADMINISTRATION OF 
DELTA9 TETRAHYDROCANNABINOL IN RHESUS-MONKEYS. 

001621 02-04 
THE SHORT-TERM AND LONG-TERM EFFECTS OF BETA ENDORPHIN ON THE 
OPIATE ABSTINENCE-SYNDROME IN RATS. 

001643 02-04 
DOSE-RESPONSE STUDY OF THE PRECIPITATED ABSTINENCE-SYNDROME 
FOR MORPHINE: SYSTEMIC VS PERIAQUEDUCTAL GRAY NALOXONE. 
(PH.D. DISSERTATION). 

002979 03-04 
POSSIBLE INFLUENCE OF OPIOID NORMETABOLITES ON THE ONSET 
MAGNITUDE AND QUALITY OF THE OPIOID ABSTINENCE-SYNDROME 

004610 04-15 
CASE-REPORT OF UNUSUAL DIAZEPAM ABSTINENCE-SYNDROME. 

004643 04-15 
ABSTINENT 

SEXUAL-BEHAVIOUR OF MORPHINE-DEPENDENT AND ABSTINENT MALE 
RATS. 

000438 01-04 
ABSTRACTS 

ABSTRACTS OF THE ANNUAL GENERAL CONFERENCE OF THE EUROPEAN- 
BRAIN-AND-BEHAVIOUR-SOCIETY, HELD AT LOUVAIN-LA-NEUVE, 
BELGIUM, ON NOVEMBER 13-15TH, 1980. 

003617 03-17 






S-1 



Subject Index 



^"" ABUNDANCE AND LOCATION OF 1251 SALMON CALCITONIN BINDING-SITE 
"^•^^•f-B«^'N 001320 02-03 

^""tHE^HIGH-AFFINITY CHOLINE UPTAKE SYSTEM WITH RESPECT TO THE 
MUSCARINIC-RECEPTORS USING A SYNAPTOSOMAL FRACTION 
ABUNDANT IN PRESYNAPTIC MEMBRANES. ^^^^ ^^^^^ 

^""fsSUES FOR INPATIENT TREATMENT OF CHRONIC PCP ABUSE^^^^ ^^^^ 

EPIDEMIOLOGY OF PCP ABUSE. THE MIDWEST PERSPECTIVE^^ 

000740 1 - 1 i! 
PCP ABUSE DIAGNOSTIC AND PSYCHOPHARMACOLOGICAL-TREATMENT 

APPROACHES. 000746 01-12 

USE AND ABUSE OF BENZODIAZEPINES. ^^^^^ ^^^^ 

CHRONIC PHENCYCLIDINE (PCP) ABUSE: A PSYCHIATRIC-PERSPECTIVE.^^^ 
MEDICAL AND PSYCHIATRIC-COMPLICATIONS OF PENTAZOCINE AND 

TRIPELENNAMINE ABUSE. 000955 01-17 

THE BENZODIAZEPINES - USE AND ABUSE ^^^^^ ^ ^ ^ ^ 

ABUSE OF THE ANTIPARKINSON-DRUGS: A REVIEW OF THE UTERATURE^^ 
ABUSE POTENTIAL OF LOPERAMIDE. ^^^^^ ^^.is 

RELAPSE TO NARCOTIC SELF-ADMINISTRATION IN MORPHINE 
POSTADDICT RATS: A POSSIBLE MODEL FOR PREDICTING ABUSE 
LIABILITY OF NARCOTIC-DRUGS. (PH.D. DISSERTATION). 

003097 03-04 

PSYCHOACTIVE-MEDICATION USE AND ABUSE AMONG AN ADULT RURAL 
POPULATION. (PH.D. DISSERTATION). 003627 03-17 

LONG-TERM USE AND ABUSE OF BENZODIAZEPINES ^, ^oo nx i <: 

004598 04- 1 5 
A MULTIVARIATE ANALYSIS OF THE INFRARED SPECTRA OF DRUGS OF 

*^^^^ 004688 04-16 

^""pharmacodynamics AND PHARMACOKINETICS OF DIAZEPAM IN AN 
'^^^^^^ 000867 01-15 

ABUSERS 

OUTPATIENT TREATMENT ISSUES AND STRATEGIES FOR ACUTE AND 
CHRONIC PCP ABUSERS. 000919 01-17 

*^ ACCELERATION OF DESIPRAMINE-INDUCED DECREASE OF RAT 

CORTICOCEREBRAL BETA-ADRENERGIC-RECEPTORS BY YOHIMBINE^ 

000326 01-0 J 
CORTICAL RECOVERY FROM EFFEaS OF MONOCULAR DEPRIVATION: 
ACCELERATION WITH NOREPINEPHRINE AND SUPPRESSION WITH 6 
HYDROXYDOPAMINE. 003024 03-04 

CONDITIONED DRUG-EFFECTS OF D-AMPHETAMINE-INDUCED AND 

MORPHINE-INDUCED MOTOR ACCELERATION IN MICE: EXPERIMENTAL 
APPROACH FOR PLACEBO-EFFEQ. 004128 04-04 

ACCIDENTAL INTRAARTERIAL INJEQION OF DIAZEPAM. 

002d7O Oz- I / 

**^^CO*Rt^™PERATURE CHANGES FOLLOWING ADMINISTRATION OF 

NALOXONE AND NALTREXONE TO RATS EXPOSED TO HOT AND COLD 
AMBIENT TEMPERATURES. EVIDENCE FOR THE PHYSIOLOGICAL ROLE 
OF ENDORPHINS IN HOT AND COLD ACCLIMATIZATION. „,, „, „^ 

004034 04-0J 

ACCUMBENS 

BEHAVIOURAL-RESPONSES TO STEREOTAQICALLY CONTROLLED 
INJECTIONS OF MONOAMINE NEUROTRANSMIHERS INTO THE 
ACCUMBENS AND CAUDATE-PUTAMEN NUCLEI. 

001 70o Oz-04 

INHIBITORY-EFFECTS OF ANTICONVULSANT-DRUGS ON CYCLIC- 
NUCLEOTIOE ACCUMULATION IN BRAIN. ^^^ ^^^^ 

ADENOSINE REGULATES VIA TWO DIFFERENT TYPES OF RECEPTORS, THE 
ACCUMULATION OF CYCLIC-AMP IN CULTURED BRAIN CELLS^ 

000308 1 *0 J 

EFFECT OF DESMETHYLIMIPRAMINE ON THE KINETICS OF 
CHLORPHENTERMINE ACCUMULATION IN ISOLATED PERFUSED RAT 

^^^^ 000524 01-05 

CHANGE IN PYRUVATE-DEHYDROGENASE ACTIVITY INFLUENCE PYRUVATE 
SUPPORTED CALCIUM ACCUMULATION BY BRAIN MITOCHONDRIA. 
(UNPUBLISHED PAPER). 001147 02-03 



Ptychopharmacology Abstracts 

STUDIES ON THE EFFECT OF ALPHA MELANOCYTE-STIMULATING- 
HORMONE AND RELATED PEPTIDES ON THE ACCUMULATION OF P 
AMINOHIPPURIC-ACID IN RENAL CORTICAL SLICES. (UNPUBLISHED 

^'^^^^^ 001372 02-03 

CALCIUM-SENSITIVE ACCUMULATION OF NOREPINEPHRINE IN RAT- 
CEREBRAL-CORTEX. „„„,„r«o,^o 

002685 03-03 
ALPHA2-ADRENERGIC AMINES, ADENOSINE AND PROSTAGLANDINS 
INHIBIT LIPOLYSIS AND CYCLIC-AMP ACCUMULATION IN HAMSTER 
ADIPOCYTES IN THE ABSENCE OF EXTRACELLULAR SODIUM. 

002728 03-03 
EFFEa OF TAURINE ON 45CA2 ACCUMULATION IN RAT BRAIN 
SYNAPTOSOMES. „„^^ „^ „, 

002855 03-03 
EFFECTS OF D AMINOLAEVULINIC-ACID, PORPHOBILINOGEN, AMINO- 
ACIDS AND BARBITURATES ON CALCIUM ACCUMULATION BY 

CULTURED NEURONS. „„„„.„ „o „, 

002859 03-03 

INCREASE OF C-GMP AND ACCUMULATION OF 45CA2 EVOKED BY DRUGS 
ACTING ON SODIUM OR POTASSIUM CHANNELS. 

003709 04-03 
HALOTHANE ACCUMULATION IN RAT-BRAIN AND LIVER. 

003774 04-03 
DOPAMINERGIC MECHANISMS IN THE TELEOST RETINA. II FAQORS 
AFFECTING THE ACCUMULATION OF CYCLIC-AMP IN PIECES OF INTAQ 

^^^'"^^™" 003776 04-03 

ACCUMULATION OF AMANTADINE BY ISOLATED CHROMAFFIN 

^«*^^^^^ 003866 04-03 

THE EFFEaS OF THYROTROPIN-RELEASING-HORMONE ON CYCLIC-AMP 
ACCUMULATION IN RABBIT CEREBROCORTICAL TISSUE IN THE 
PRESENCE AND ABSENCE OF CNS DEPRESSANTS. „ „ „, 

004010 04-03 
PHENYTOIN INHIBITION OF CYCLIC-GUANOSINE-MONOPHOSPHATE (C- 
GMP) ACCUMULATION IN NEUROBLASTOMA CELLS BY CALCIUM- 
CHANNEL BLOCKADE. 004020 04-03 

A MECHANISM FOR THE ACCUMULATION OF CHOLINE IN ERYTHROCYTES 
DURING TREATMENT WITH LITHIUM. 004520 04 13 

EFFECTS OF PIMOZIDE ON ACCURACY OF PERFORMANCE AND 
DISTRIBUTION OF CORREQ RESPONDING ON A SIMULTANEOUS 
DISCRIMINATION TASK IN THE RAT 001806 02-04 

ACCURACY OF PATIENT INTERVIEWS AND ESTIMATES BY CLINICAL STAFF 
IN DETERMINING MEDICATION COMPLIANCE. , o no i -7 

003618 03- 1 / 

MEPROBAMATE REDUCES ACCURACY OF PHYSIOLOGICAL DETEQION OF 

■^^"P™^ 004585 04-14 

SYNTHESIS OF POTENTIAL ANTICONVULSANTS: CONDENSATION OF 
ISATINS WITH ACETONE AND RELATED KETONES. ^^^^ ^^^ 

^"Yo'^RENERGfcTEGULATION OF THE REDUQION IN ACETYL-COENZYME- 
A:ARYLAMINE-N-ACETYLTRANSFERASE IN THE RAT PINEAL 

(X)2654 Oo-Uo 

ACETYL-ETHn-TETRAMETHn-TETRALIN 

THE PATHOGENESIS OF PRIMARY INTERNODAL DEMYELINATION 

PRODUCED BY ACETYL-ETHYL-TETRAMETHYL-TETRALIN: EVIDENCE FOR 
PRESERVED SCHWANN-CELL SOMAL FUNQION ^^^^ ^^^^ 

ACETYLATOR PHENOTYPE AND LUPUS-ERYTHEMATOSUS. 

003545 Uj- 1 5 

^^^THE^C^RYSUL AND MOLECULAR STRUQURE OF THE ACETYLCHOLINE 
ANTAGONIST DIMETHYLAMINOBUTYNYLCYCLOHEXYLHYDROXY 2 

PHENYIACETATEHCL. 000003 01-01 

DOPAMINE ACETYLCHOLINE, AND GABA EFFEQS IN ACUTE DYSTONIA IN 

P'^"^*^^5 000043 01-03 

DIMETHYLAMINOETHANOL (DEANOL) METABOLISM IN RAT-BRAIN AND 
ITS EFFECT ON ACETYLCHOLINE SYNTHESIS. ^^^^ ^^^^ 

THE EFFEQ OF MORPHINE ON PURINE AND ACETYLCHOLINE RELEASE 
FROM RAT-CEREBRAL-CORTEX: EVIDENCE FOR A PURINERGIC 
COMPONENT IN MORPHINES AQION. ^^^^^ ^^_^^ 

(3H)ACETYLCH0LINE AND (3H)5 HYDROXYTRYPTAMINE RELEASE FROM 
RAT-MIDBRAIN SLICES AND THE EFFECTS OF CALCIUM AND 
PHENOBARBITAL. ^^^Sl 01-03 



S-2 



VOLUME 19, SUBJECT INDEX 



Subject Index 



REGULATION OF STRIATAL ACETYLCHOLINE CONCENTRATION BY D2 
DOPAMINE-RECEPTORS, 

000269 01-03 
IN VITRO ACETYLCHOLINE RELEASE FROM RAT CAUDATE-NUCLEUS AS A 
NEW MODEL FOR TESTING DRUGS WITH DOPAMINE-RECEPTOR 
ACTIVITY. 

000289 01-03 
THE EFFECTS OF MUSCARINIC-RECEPTOR BLOCKERS ON THE TURNOVER- 
RATE OF ACETYLCHOLINE IN VARIOUS REGIONS OF THE RAT-BRAIN. 

000328 01-03 
TOLERANCE TO INCREASES IN STRIATAL ACETYLCHOLINE 
CONCENTRATIONS AFTER REPEATED ADMINISTRATION Of 
APOMORPHINE-DIPIVALOYL-ESTER 

000464 01-04 
REGULATION OF ACETYLCHOLINE RELEASE DURING INCREASED NEURONAL 
ACTIVITY. (UNPUBLISHED PAPER). 

001061 02-01 
EFFECT OF THE NEW GAMMA AMINOBUTYRIC-ACID AGONIST SL-76-002 
ON STRIATAL ACETYLCHOLINE: RELATION TO NEUROLEPTIC-INDUCED 
EXTRAPYRAMIDAL ALTERATIONS. 

001119 02-03 
FACTORS INFLUENCING THE RELEASE OF LABELLED GAMMA 
AMINOBUTYRIC-ACID AND ACETYLCHOLINE EVOKED BY ELECTRICAL- 
STIMULATION WITH ALTERNATING POLARITY FROM RAT CORTICAL 
SLICES. 

001130 02-03 
EFFECT OF MOXESTROL ON HALOPERIDOL-INDUCED CHANGES IN 
STRIATAL ACETYLCHOLINE LEVELS AND DOPAMINE TURNOVER. 

001218 02-03 
LONG-TERM ADMINISTRATION OF ATROPINE, IMIPRAMINE, AND 
VILOXAZINE ALTERS RESPONSIVENESS OF RAT-CORTICAL-NEURONES 
TO ACETYLCHOLINE. 

001306 02-03 
ASCORBIC-ACID, AN ENDOGENOUS FACTOR REQUIRED FOR 
ACETYLCHOLINE RELEASE FROM THE SYNAPTIC VESICLES. 

001322 02-03 
DIRECT EVIDENCE AGAINST ACETYLCHOLINE AS THE DILATOR 
TRANSMinER IN THE CAT CEREBRAL-ARTERY. 

001336 02-03 
ACETYLCHOLINE AND AMINO-ACID NEUROTRANSMITTERS IN EPIDURAL 
CUPS OF FREELY-MOVING-RATS: EFFECT OF ACUTE AND CHRONIC- 
TREATMENT WITH ANTISCHIZOPHRENIC-DRUGS. 

001386 02-03 
EFFECTS OF DIAZEPAM ON ADENOSINE AND ACETYLCHOLINE RELEASE 
FROM RAT-CEREBRAL-CORTEX: FURTHER EVIDENCE FOR A PURINERGIC 
MECHANISM IN ACTION OF DIAZEPAM. 

001414 02-03 
EFFECT OF ANTINOCICEPTIVE DOSES OF OXOTREMORINE ON MOUSE- 
BRAIN ACETYLCHOLINE TURNOVER-RATE. 

001513 02-03 
ACTIONS OF ENKEPHALIN, MU AND PARTIAL AGONIST ANALGESICS ON 
ACETYLCHOLINE TURNOVER IN RAT-BRAIN. 

001541 02-03 
GLYCINE, ACETYLCHOLINE, AND SEROTONIN: NEUROTRANSMITTERS OR 
NEUROMODULATORS? 

002271 02-13 
THE EXCITATORY ACTION OF ACETYLCHOLINE ON HIPPOCAMPAL 
NEURONES OF THE GUINEA-PIG AND RAT MAINTAINED IN VITRO 

002704 03-03 
THE PRESYNAPTIC STIMULATING EFFECT OF ACETYLCHOLINE ON 
DOPAMINE RELEASE IS SUPPRESSED DURING ACTIVATION OF 
NIGROSTRIATAL DOPAMINERGIC NEURONS IN THE CAT. 

002733 03-03 
MODULATION BY ENDOGENOUS DOPAMINE OF THE RELEASE OF 
ACETYLCHOLINE IN THE CAUDATE-NUCLEUS OF THE RABBIT. 

PIRACETAM DIMINISHES HIPPOCAMPAL ACETYLCHOLINE LEVELS IN RATS. 

THE EFFECTS OF ACETYLCHOLINE AND GLUTAMATE ON SEPTAL NEURONS 
IN VITRO. 

002941 03-03 
RELEASE OF ACETYLCHOLINE FROM RAT-BRAIN SYNAPTOSOMES 
STIMULATED WITH LEPTINOTARSIN, A NEW NEUROTOXIN. 

MODULATORY EFFECT OF BRAIN ACETYLCHOLINE ON REFLEX-INDUCED 
BRADYCARDIA AND TACHYCARDIA IN CONSCIOUS RATS. 

003744 04-03 

COMPARISON OF THE EFFECTS OF THE STEREOISOMERS OF 
FENFLURAMINE ON THE ACETYLCHOLINE CONTENT OF RAT STRIATUM 
HIPPOCAMPUS AND NUCLEUS-ACCUMBENS 

OXOTREMORINE DOES NOT ENHANCE ACETYLCHOLINE RELEASE FROM ' 
RAT DIAPHRAGM PREPARATIONS. 

ALTERATIONS OF ACETYLCHOLINE AND CHOLINE METABOLISM IN 
MAMMALIAN PREPARATIONS TREATED WITH BETA BUNGAROTOXIN. 

PRESYNAPTIC REGULATION OF THE RELEASE OF ACETYLCHOLINE BY 5 ' 
HYDROXYTRYPTAMINE. 

003843 04-03 



INVESTIGATION OF ACTION OF ENKEPHALIN ON THE SPONTANEOUS AND 
EVOKED RELEASE OF ACETYLCHOLINE FROM RAT CORTICAL AND 
STRIATAL SLICES. 

003862 04-03 
ACTION OF ENKEPHALIN ANALOGUES AND MORPHINE ON BRAIN 

ACETYLCHOLINE RELEASE: DIFFERENTIAL REVERSAL BY NALOXONE AND 
AN OPIATE-PENTAPEPTIDE. 

003863 04-03 
THE EFFECT OF CHRONIC NICOTINE AND WITHDRAWAL ON INTRAAXONAL 

TRANSPORT OF ACETYLCHOLINE AND RELATED ENZYMES IN SCIATIC- 
NERVE OF THE RAT. 

003897 04-03 
THE EFFECT OF ACETYLCHOLINE RELEASE ON CHOLINE FLUXES IN 
ISOLATED SYNAPTIC TERMINALS. 

003924 04-03 
ACETYLCHOLINE AND CHOLINE-ACETYLTRANSFERASE. 

003930 04-03 
CORRELATIONS BETWEEN NA-K-ATPASE ACTIVITY AND ACETYLCHOLINE 
RELEASE IN RAT CORTICAL SYNAPTOSOMES. 

003937 04-03 
EFFECTS OF ETHANOL ON ACETYLCHOLINE AND ADENOSINE EFFLUX FROM 
THE IN VIVO RAT-CEREBRAL-CORTEX. 

003969 04-03 
INHIBITION OF THE SYNTHESIS OF ACETYLCHOLINE IN RAT-BRAIN SLICES 
BY (-) HYDROXYCITRATE AND CITRATE. 

004044 04-03 
5' TRIPHOSPHATE RECYCLES INDEPENDENTLY OF ACETYLCHOLINE IN 
CHOLINERGIC SYNAPTIC VESICLES. 

004063 04-03 
CHOLINE REVERSES NALOXONE-INDUCED DECREASES IN HIPPOCAMPAL 
ACETYLCHOLINE CONTENT AND SUPPRESSES ESCAPE-BEHAVIOR IN 
OPIATE-DEPENDENT RATS. 

004076 04-04 
ANTITREMOR ACTION OF ClODICHOL, A PERIPHERAL ACETYLCHOLINE 
SYNTHESIS INHIBITOR. 

004096 04-04 
ACETYLCHOLINE TURNOVER AND AGGRESSION IN RELATED THREE 
STRAINS OF MICE. 

004151 04-04 
ACETYLCHOLINE-INDUCED 

ACETYLCHOLINE-INDUCED MODULATION OF HIPPOCAMPAL PYRAMIDAL 
NEURONS. 

003728 04-03 
ACETYLCHOLINE-RECEPTOR 

PHOSPHORYLATION OF THE MEMBRANE-BOUND ACETYLCHOLINE- 
RECEPTOR: INHIBITION BY DIPHENYLHYDANTOIN. 

001257 02-03 
ENZYMATIC CARBOXYMETHYLATION OF THE NICOTINIC ACETYLCHOLINE- 
RECEPTOR. (UNPUBLISHED PAPER). 

001318 02-03 
MUSCARINIC ACETYLCHOLINE-RECEPTOR. (UNPUBLISHED PAPER) 

002667 03-03 
ACETYLCHOLINE-RECEPTORS 

LITHIUM REDUCES THE NUMBER OF ACETYLCHOLINE-RECEPTORS IN 
SKELETAL-MUSCLE. 

000232 01-03 
THE BINDING OF SOME ANTIDEPRESSANT-DRUGS TO BRAIN MUSCARINIC 
ACETYLCHOLINE-RECEPTORS. 

001253 02-03 
PSYCHOTHERAPEUTIC-DRUGS, HISTAMINE HI -RECEPTORS AND 
MUSCARINIC ACETYLCHOLINE-RECEPTORS. 

004737 04-17 
ACETYLCHOLINESTERASE 

ACTION OF BARBITURATES ON ACTIVITY OF ACETYLCHOLINESTERASE 
FROM SYNAPTOSOMAL MEMBRANES. 

000224 01-03 
ACETYLCHOLINESTERASE AND CHOLINESTERASE ACTIVITIES IN THE 
MOUSE CEREBELLUM FOLLOWING MISONIDAZOLE TREATMENT 

003123 03-05 
INHIBITION OF AMINOPEPTIDASE AND ACETYLCHOLINESTERASE BY 
PUROMYCIN AND PUROMYCIN ANALOGS. 

003835 04-03 
INSEPARABILITY OF ACETYLCHOLINESTERASE AND NERVE EXCITATION 

003875 04-03 
ACETYLENIC-GABA 

EFFECTS OF GAMMA ACETYLENIC-GABA AND GAMMA VINYL-GABA ON 
ELECTRICALLY-INDUCED SPINAL-CORD CONVULSIONS AND ON SPINAL- 
CORD GABA CONCENTRATION. 

000145 01-03 
MAPPING OF DYSKINETIC-MOVEMENTS INDUCED BY LOCAL APPLICATION 
OF PICROTOXIN OR () GAMMA ACETYLENIC-GABA ON THE RAT 
MOTOR-CORTEX. 

000458 01-04 
GAMMA ACETYLENIC-GABA IN TARDIVE-DYSKINESIA. 

002101 02-11 
MULTIPLE EFFECTS OF REPEATED ADMINISTRATION OF GAMMA 
ACETYLENIC-GABA ON RAT-BRAIN METABOLISM. 

002878 03-03 






I 



S-3 



Subject Index 

TREATMENT OF HUNTINGTON-DISEASE WITH GAMMA ACETYLENIC- 
GABA AN IRREVERSIBLE INHIBITOR OF GABA-TRANSAMINASE: 
INCREASED CSF GABA AND HOMOCARNOSINE WITHOUT CLINICAL 

AMELIORATION. „„o.c„,^o,. 

003458 03-14 

ACETYLENIC-GAMMA-AMINOBUTYRIC-ACID 

CHANGES IN PRIMARY AFFERENT DEPOLARIZATION AFTER 

ADMINISTRATION OF GAMMA ACETYLENIC-GAMMA-AMINOBUTYRIC- 
ACID (GAG) A GAMMA AMINOBUTYRIC-ACID-TRANSAMINASE 
(GABA-TRANSAMINASE) INHIBITOR 

ACETYLESTERS 

GAS-CHROMATOGRAPHY/MASS-SPECTROMETRY STABLE ISOTOPIC 
ANALYSES FOR DEANOL. CHOLINE, AND THEIR ACETYLESTERS. 

004683 04-16 
ACETYLMANNOSAMINE 

INCORPORATION OF N ACETYLMANNOSAMINE INTO RAT-BRAIN 
SUBCELLULAR GANGLIOSIDES: EFFECT OF PENTYLENETETRAZOL- 
INDUCED CONVULSIONS IN BRAIN GANGLIOSIDES. 

002937 03-03 

PHARMACODYNAMIC PROFILES OF L ALPHA ACETYLMETHADOL (LAAM) 
AND ITS N DEMETHYLATED METABOLITES, NORLAAM AND 
DINORLAAM DURING SELF-ADMINISTRATION IN THE DEPENDENT RAT. 

000505 01-04 

OCCURRENCE OF CORNEAL OPACITIES IN RATS AFTER ACUTE 
ADMINISTRATION OF L ALPHA ACETYLMETHADOL. ^^ 

A CHARACTERIZATION OF THE BEHAVIORAL-EFFECTS OF LEVO ALPHA 
ACETYLAAETHADOL IN THE RAT AND IN THE PIGEON. (PH D 

°'5S^'^^^™^^ 003047 03-04 

A CLINICAL CONTROLLED-STUDY OF L ALPHA ACETYLMETHADOL IN THE 

TREATMENT OF NARCOTIC ADDICTION. 003335 03-11 

EFFECTS OF LEVO ALPHA ACETYLMETHADOL (LAAM) ON MORPHINE SELF- 
ADMINISTRATION IN THE RAT. 004170 04-04 
MORPHINE CHALLENGES IN LEVO ALPHA ACETYLMETHADOL (LAAM) 

POSTADDICT RATS „„.^c„„.n. 

004259 04-04 

ACETYLSAIICYIIC-ACID „.^r^...^, 

BEHAVIOURAL-EFFECTS OF ACETYLSALICYLIC-ACID, PARACETAMOL, 
CAFFEINE GUAIPHENESIN AND THEIR COMBINATIONS. 

001805 02-04 

ACH 

INHIBITION OF ACH RELEASE BY PROSTAGLANDIN-El IN THE RABBIT 
SUPERIOR-CERVICAL-GANGLION. 00120502-03 

ACH-RECEPTOR 

IMMUNODETECTION OF ACH-RECEPTOR IN THE CNS (UNPUBLISHED 

''''^' 003670 04-01 

5 HYDROXYTRYPTAMINE CONTROLS ACH-RECEPTOR SENSITIVITY OF 
BULLFROG SYMPATHETIC GANGLION CELLS 

003710 04-03 

ACID 

THE CONTRIBUTION 0" ALPHAl ACID GLYCOPROTEIN, LIPOPROTEINS, 
AND ALBUMIN TO THE PLASMA BINDING OF PERAZINE, 
AMITRIPTYLINE, AND NORTRIPTYLINE IN HEALTHY MAN. 

002214 02-13 
BINDING OF PERAZINE TO ALPHAl ACID GLYCOPROTEIN 

002290 02-13 
PARTIAL PURIFICATION OF ACID SPHINGOMYELINASE FROM NORMAL 
AND PATHOLOGICAL (^.. NIEMANN-PICK TYPE C) HUMAN BRAIN. 

003671 04-01 
THE EFFECTS OF NEFOPAM ON BLOOD ACID BASE STATUS IN THE RABBIT: 
INTERACTIONS WITH MORPHINE IN THE MOUSE AND RABBIT. 

004279 04-05 

ACIDIC 

REVERSIBLE RING-OPENING REACTIONS OF NIMETAZEPAM AND 
NITRAZEPAM IN ACIDIC MEDIA AT BODY-TEMPERATURE. 

004517 04-13 

ACOUSTIC 

5 METHOXYDIMETHYLTRYPTAMINE: SPINAL-CORD AND BRAINSTEM 
MEDIATION OF EXCITATORY EFFECTS ON ACOUSTIC STARTLE. 

001605 02-04 
SPINAL MODULATION OF THE ACOUSTIC STARTLE RESPONSE: THE ROLE 
OF NOREPINEPHRINE, SEROTONIN AND DOPAMINE. 

002950 03-04 

ACQUISITION 

EFFECT OF BETA ENDORPHIN AND NALOXONE ON ACQUISITION, 
MEMORY, AND RETRIEVAL OF SHUTTLE AVOIDANCE AND 
HABITUATION LEARNING IN RATS. ^^^ ,^ „, ^^ 

000410 01-04 

THE EFFECTS OF PIPRADROL ON THE ACQUISITION OF RESPONDING WITH 
CONDITIONED REINFORCEMENT: A ROLE FOR SENSORY 
PRECONDITIONING. 001572 02-04 



Psychopharmacology Abstracts 

EFFEQS OF A LOW-DOSE AND A HIGH-DOSE OF BETA ENDORPHIN ON 
ACQUISITION AND RETENTION IN THE RAT. 

001663 02-04 
L-DOPA ENHANCES ACQUISITION OF AN INHIBITORY AVOIDANCE 

'''''''' 00171102-04 

EFFECTS OF PHENCYCLIDINE, PENTOBARBITAL, AND D-AMPHETAMINE ON 
THE ACQUISITION AND PERFORMANCE OF CONDITIONAL 
DISCRIMINATIONS IN MONKEYS. 

001723 02-04 
CUMULATIVE AFTERDISCHARGE AS THE PRINCIPAL FAQOR IN THE 
ACQUISITION OF KINDLED SEIZURES. 

002862 03-03 
EFFECT OF P CHLOROPHENYLALANINE ON THE ACQUISITION OF 
TOLERANCE TO THE HYPNOTIC-EFFEQS OF PENTOBARBITAL, BARBITAL, 
AND ETHANOL. 

003883 04-03 
RAPID ACQUISITION OF A TWO-DRUG DISCRIMINATION: TIME OF DAY 
EFFECT UPON SALINE STATE 

004214 04-04 

ACQUISITION-BEHAVIOR 

EFFECTS OF METHYLPHENIDATE-HYDROCHLORIDE ON REPEATED 
ACQUISITION-BEHAVIOR IN HYPERKINETIC-CHILDREN. (PH.D. 
DISSERTATION) 

003386 03-11 
EFFEaS OF DEXTROAMPHETAMINE-SULFATE ON REPEATED ACQUISITION- 
BEHAVIOR AND MOOD IN HUMANS: A PRELIMINARY REPORT. 

003459 03-14 

ACRYLAMIDE „ „„^, 

THE ETIOLOGY OF TOXIC PERIPHERAL NEUROPATHIES: IN VITRO EFFEQS 
OF ACRYLAMIDE AND 2,5 HEXANEDIONE ON BRAIN ENOLASE AND 
OTHER GLYCOLYTIC ENZYMES. 

000131 01-03 
NEUROTRANSMIHER-RECEPTORS IN BRAIN REGIONS OF ACRYLAMIDE 
TREATED RATS I: EFFECTS OF A SINGLE EXPOSURE TO ACRYLAMIDE. 

004264 04-05 
NEUROTRANSMinER-RECEPTORS IN BRAIN REGIONS OF ACRYLAMIDE 

TREATED RATS II: EFFECTS OF EXTENDED EXPOSURE TO ACRYLAMIDE. 

004265 04-05 

ACTH 

CHANGES OF AQH, STH, TSH AND PROLAQIN LEVELS IN ENDOTOXIN 

SHOCK IN RATS ^, „, 

000119 01-03 

OPIATE-RECEPTORS MAY MEDIATE THE SUPPRESSIVE BUT NOT THE 
EXCITATORY ACTION OF ACTH ON MOTOR-AQIVITY IN RATS. 

000337 01-04 
ACTH MODULATION OF MEMORY STORAGE PROCESSING. (UNPUBLISHED 

^"^^^^ 001250 02-03 

ACTH MEDIATION OF LEARNED-FEAR: BLOCKADE BY NALOXONE AND 

^*^^^^^°'^^ 001597 02-04 

AQH POTENTIATES MORPHINE-INDUCED CONDITIONED TASTE-AVERSION. 

001781 02-04 
TRIAL OF A PEPTIDE FRACTION OF ACTH (AaH4-10) IN THE ALCOHOLIC 
BRAIN-DAMAGE-SYNDROME ^^^ , „ „o , ^ 

002318 02-14 
EXPLORATION AND MOTOR-ACTIVITY AFTER INTRAVENTRICULAR AQH, 
MORPHINE AND NALOXONE 00299103-04 

*^ ACTH-INDUCED GROOMING INVOLVES HIGH-AFFINITY OPIATE-RECEPTORS. 

002985 03-04 

ACTH LIKE 

ACTH-LIKE PEPTIDES, PITUITARY ADRENOCORTICAL FUNQION AND 
AVOIDANCE-BEHAVIOR. 004109 04-04 

EFf'eCTS OF ACUTE CENTRAL AND PERIPHERAL AQH 1-24 
ADMINISTRATION ON LORDOSIS BEHAVIOR 002975 03-04 

TESTOSTERONE POTENTIATION OF THE EFFEQIVENESS OF ACTH 1-24 ON 
THE INDUCTION OF THE STRETCH-YAWNING-SYNDROME (SYS) IN MALE 

S^"^^*-'''^^ 003074 03-04 

HORMONAL STIMULATION AFTER INJEQION OF THYROTROPHIN- 
RELEASING-FAQOR (TRF) AND AQH 1-24 IN PATIENTS FOLLOWING 
CHRONIC-TREATMENT WITH NEUROLEPTICS: PRELIMINARY-STUDY^ 

004505 04- 1 3 

ACTH4-10 

ACTH4-10 AND MEMORY IN EQ TREATED AND UNTREATED PATIENTS. I. 

EFFEQ ON CONSOLIDATION 001982 02-09 

AaH4-10 AND MEMORY IN EQ TREATED PATIENTS AND UNTREATED 

CONTROLS. II. EFFEQ ON RETRIEVAL. 001983 02-09 

TRIAL OF A PEPTIDE FRACTION OF AQH (AQH4-10) IN THE ALCOHOLIC 

BRAIN-DAMAGE-SYNDROME. 002318 02-14 



S-4 



VOLUME 19, SUBJECT INDEX 



Subject Index 



POSSIBLE MECHANISMS OF EFFECT OF ACTH4-10 AND ITS ANALOG, 
CONTAINING D ISOMER OF PHENYLALANINE, ON BEHAVIOR. 

002949 03-04 
IMITATION, SOCIAL FACILITATION, AND THE EFFECTS OF ACTH4-10 ON 
RATS BAR-PRESSING-BEHAVIOR. 

003009 03-04 
ACTH4-9 

Y-MAZE BEHAVIOR AFTER AN ANALOG OF ACTH4-9, EVIDENCE FOR AN 
AnENTIONAL-ALTERATION . 

001676 02-04 
EFFECTS OF AN ACTH4-9 RELATED PEPTIDE UPON INTRACRANIAL SELF- 
STIMULATION AND GENERAL-ACTIVITY IN THE RAT. 

001679 02-04 
INDUCTION OF ANALGESIA BY CENTRAL ADMINISTRATION OF ORG-2766, 
AN ANALOG OF ACTH4-9. 

003112 03-04 
A SYNTHETIC ACTH4-9 ANALOGUE (ORGANON-2766) AND SLEEP IN 
HEALTHY MAN. 

004574 04-14 
AaiNOMYCIN-0 

INHIBITION OF BEHAVIORAL-EFFECTS OF COCAINE BY ACTINOMYCIN-D IN 
RATS. 

000346 01-04 
ACTIVATION 

ACTIVATION OF CORTICAL CIRCUITS DURING INTERICTAL SPIKES. 

000056 01-03 
THE ROLE OF INTRANEURONAL 5 NT AND OF TRYPTOPHAN- 
HYDROXYLASE ACTIVATION IN THE CONTROL OF 5 HT SYNTHESIS IN 
RAT-BRAIN SLICES INCUBATED IN K-ENRICHED MEDIUM 

000123 01-03 
ANALYSIS OF THE ACTIVATION OF DOPAMINE METABOLISM BY A 
SEROTONIN UPTAKE INHIBITOR. 

000315 01-03 
METERGOLINE ANTAGONISM OF 5 HYDROXYTRYPTAMINE-INDUCED 
ACTIVATION OF RAT-CEREBRAL-CORTICAL NA-K-ATPASE. 

000329 01-03 
BRADYKININ-RECEPTOR STIMULATION OF C-AMP INVOLVES 
PHOSPHOLIPID METHYLATION, CA-FLUX, PH0SPH0LIPASE-A2 
ACTIVATION AND PROSTAGLANDIN FORMATION. (UNPUBLISHED 
PAPER). 

001002 02-01 
CENTRAL LEVELS OF NORADRENALINE, 3 METHOXY-4- 

HYDROXYPHENYLETHYLENEGLYCOL AND CYCLIC-AMP IN THE RAT 
AFTER ACTIVATION OF LOCUS-COERULEUS NEURONS: INFLUENCE OF 
SINGLE AND REPEATED NEUROLEPTIC TREATMENT. 

001095 02-03 
PROSTACYCLIN-DEPENDENT ACTIVATION OF ADENYLATE-CYCLASE IN A 
NEURONAL SOMATIC CELL HYBRID: PROSTANOID STRUCTURE-ACTIVITY 
RELATIONSHIPS. 

001132 02-03 
MIANSERIN: DIRECT ACTIVATION OF BRAIN NOREPINEPHRINE NEURONS 
BY BLOCKING ALPHA2-RECEPT0RS. 

001214 02-03 
ACTIVATION OF PRESYNAPTIC ALPHA NORADRENALINE-RECEPTORS IN 
RAT-BRAIN BY THE POTENT DOPAMINE-MIMETIC N,N DIPROPYL-ADTN 

001390 02-03 
BRAIN STRIATAL TYROSINE-HYDROXYLASE: ACTIVATION OF THE ENZYME 
BY CYCLIC-AMP INDEPENDENT PHOSPHORYLATION. 

001423 02-03 
THE EFFECT OF NALOXONE ON THE ACTIVATION OF EMOTIONALLY 
POSITIVE REACTION PRODUCED BY DRUGS WITH A DEPENDENCE 
LIABILITY. 

001556 02-03 
ACTIVATION AND LATERALIZATION OF SENSORIMOTOR FIELD FOR 
PERIORAL BITING-REFLEX BY INTRANIGRAL GABA AGONIST AND BY 
SYSTEMIC APOMORPHINE IN THE RAT. 

001657 02-04 
VARIATIONS IN PSYCHOPHYSIOLOGICAL ACTIVATION RESPONSES IN 
DEPRESSIVE-STATES. 

001965 02-09 
STRETCH-INDUCED MYOTUBE GROWTH CORRELATES WITH NA-PUMP 
ACTIVATION. (UNPUBLISHED PAPER). 

002087 02-10 
THE PRESYNAPTIC STIMULATING EFFECT OF ACETYLCHOLINE ON 
DOPAMINE RELEASE IS SUPPRESSED DURING ACTIVATION OF 
NIGROSTRIATAL DOPAMINERGIC NEURONS IN THE CAT. 

002733 03-03 
LEVONANTRADOL, A POTENT CANNABINOID RELATED ANALGESIC 
ANTAGONIZES HALOPERIDOL-INDUCED ACTIVATION OF STRIATAL 
DOPAMINE SYNTHESIS. 

002786 03-03 
IDENTICAL RESPONSES OF THE TWO HIPPOCAMPAL THETA GENERATORS 
TO PHYSIOLOGICAL AND PHARMACOLOGICAL ACTIVATION 

002792 03-03 
ACTIVATION OF SOLUBLE STRIATAL TYROSINE-HYDROXYLASE IN THE RAT 
BRAIN AFTER CDP-CHOLINE ADMINISTRATION 

rrrr.T^rr>„ 002816 03-03 

EFFECT OF DOPAMINE ON ACTIVATION OF RAT STRIATAL ADENYLATE- 
CYCLASE BY FREE MG2 AND GUANYL-NUCLEOTIDES. 

002825 03-03 



BARBITURATE ENHANCEMENT OF GABA-MEDIATED INHIBITION AND 
ACTIVATION OF CHLORIDE ION-CONDUCTANCE: CORRELATION WITH 
ANTICONVULSANT AND ANESTHETIC ACTIONS. 

002885 03-03 
EFFECT OF SODIUM-VALPROATE ON MOTOR FUNCTION REGULATED BY 
THE ACTIVATION OF GABA-RECEPTORS. 

003033 03-04 
NEUROLEPTICS: ACTIVATION OR INHIBITION OF THE DOPAMINERGIC- 
SYSTEM? 

003424 03-13 
DOES P CHLOROPHENYLALANINE PRODUCE DISTURBED WAKING 
DISTURBED SLEEP OR ACTIVATION BY PONTO-GENICULO-OCCIPITAL 
WAVES IN CATS? 

003704 04-02 
AN EVALUATION OF THE MECHANISM BY WHICH SEROTONERGIC 
ACTIVATION DEPRESSES RESPIRATION. 

003917 04-03 
BETA PHENYLETHYLAMINE REVERSAL OF CHLORPROMAZINE-INDUCED 
ACTIVATION OF STRIATAL TYROSINE-HYDROXYLASE AND CATALEPSY 

004018 04-03 
INHIBITORY-ACTION OF THE COMBINATION OF AMINOPYRINE AND 
SECOBARBITAL ON EEG ACTIVATION, NEOCORTICAL RECRUITING AND 
AUGMENTING RESPONSES IN RABBITS. 

004022 04-03 
EFFECTS OF PROPRANOLOL ON THE LOCOMOTOR- STIMULATION INDUCED 
BY ACTIVATION OF POSTSYNAPTIC CATECHOLAMINE-RECEPTORS. 

004126 04-04 
REDUCTION IN OPIATE ACTIVATION AFTER CHRONIC 
ELECTROCONVULSIVE-SHOCK - POSSIBLE ROLE FOR ENDORPHINS IN 
THE BEHAVIORAL-EFFECTS OF CONVULSIVE-SHOCK-TREATMENT. 
(UNPUBLISHED PAPER). 

004154 04-04 
CONTRIBUTION OF SOCIAL FACTORS TO OPIATE-INDUCED ACTIVATION IN 
THE MOUSE 

004156 04-04 
A COMPARATIVE EVALUATION OF THE USEFULNESS OF 

PSYCHOPHYSIOLOGICAL-TESTS DURING VARIOUS LEVELS OF 
ACTIVATION OF THE CENTRAL-NERVOUS-SYSTEM. 

004543 04-13 
ACTIVATORS 

PSYCHOMOTOR STIMULANTS AS ACTIVATORS OF NORMAL AND 
PATHOLOGICAL-BEHAVIOR: IMPLICATIONS FOR THE EXCESSES IN 
MANIA. (UNPUBLISHED PAPER). 

002353 02-14 
ACTOMETRIC 

THE ANOREXIC AND ACTOMETRIC EFFECTS OF COCAINE AND TWO COCA- 
EXTRACTS. 

000344 01-04 
ACYLASE 

AN EVALUATION OF THE USEFULNESS OF THE ACYLASE TEST IN 
NEUROLEPTIC TREATMENT. 

004426 04-10 
ACYLCYANAMIOES 

ACYLCYANAMIDES, ACYLUREA, AND VARIOUS SUBSTITUTED 
ARYLALLOPHANATES; EFFECT ON THE CNS. 

003689 04-02 
ACYLUREA 

ACYLCYANAMIDES, ACYLUREA, AND VARIOUS SUBSTITUTED 
ARYLALLOPHANATES; EFFECT ON THE CNS. 

003689 04-02 
ADAPTATION 

NEUROTRANSMITTER RELATED ADAPTATION IN THE CENTRAL-NERVOUS- 
SYSTEM FOLLOWING CHRONIC MONOAMINE-OXIDASE-INHIBITION 

000038 01-03 
CENTRAL NORADRENERGIC ADAPTATION TO LONG-TERM-TREATMENT 
WITH IMIPRAMINE IN RHESUS-MONKEYS. 

000182 01-03 
LONG-TERM-TREATMENT WITH NEUROLEPTIC-AGENTS: ADAPTATION 
PHENOMENA AND THEIR SIGNIFICANCE WITH REGARD TO 
SCHIZOPHRENIC-SYMPTOMATOLOGY AND SIDE-EFFECTS. 

002370 02-15 
IN VITRO CELLULAR ADAPTATION OF SEROTONERGIC PROCESSES AFTER 
CHRONIC CENTRAL PHENOBARBITAL ADMINISTRATION. 

002813 03-03 
THERAPY AND SOCIAL ADAPTATION OF OLIGOPHRENICS (REVIEW OF THE 
LITERATURE). 

004444 04-11 
ADAPTATIONS 

RECEPTOR ADAPTATIONS TO CENTRALLY ACTING DRUGS. 

003585 03-17 
ADAPTIVE 

ADAPTIVE CHANGES OF THE STRIATAL DOPAMINE SYSTEM INDUCED BY 
REPEATED ADMINISTRATION OF NEUROLEPTICS AND ERGOT 
DERIVATIVES. 

001156 02-03 
ADDICTION 

IATROGENIC OPIATE ADDICTION: SUCCESSFUL DETOXIFICATION WITH 
CLONIDINE. 

000666 01-11 



k 
If 



S-5 



Subject Index 

THE TREATMENT OF OPIATE ADDIQION USING METHADONE- 
CHLORHYDRATE. 

002600 02-17 
A CLINICAL, CONTROLLED-STUDY OF L ALPHA ACETYLMETHADOL IN THE 
TREATMENT OF NARCOTIC ADDICTION. 

003335 03-11 
ACTION ON THE EMOTIONALLY-REINFORCED BRAIN SYSTEM AS A MEANS 
OF TREATING ALCOHOLISM AND DRUG ADDICTION 
PATHOGENETICALLY. 

003641 03-17 
ADDICTIVE-AGENTS 

ADDICTIVE-AGENTS AND INTRACRANIAL- STIMULATION (ICS): MORPHINE. 
NALOXONE, AND PRESSING FOR AMYGDALOID ICS. 

000371 01-04 
ADDICTIVE-BEHAVIOR 
ADDICTIVE-BEHAVIOR. 

002114 02-11 

ADDICTS 

A PRELIMINARY OPEN-STUDY OF THE USE OF AMINEPTINE OF THE 
DEFICIENT SYNDROME OF HEBEPHRENICS AND OF ADDICTS DURING 
WITHDRAWAL. 

004445 04-11 
METHADONE TREATMENT OF HEROIN ADDICTS IN SWITZERLAND, 

004452 04-11 
SUPPRESSION OF MORPHINE ABSTINENCE IN HEROIN ADDICTS BY BETA 
ENDORPHIN. 

004489 04-1 1 

ADENINE-NUCLEOTIDES 

ADENINE-NUCLEOTIDES AND SYNAPTIC TRANSMISSION IN THE IN VITRO 
RAT HIPPOCAMPUS. 

000080 01-03 
REACTIVITY OF ISOLATED CANINE CEREBRAL-ARTERIES TO ADENINE- 
NUCLEOTIDES AND ADENOSINE. 

000210 01-03 

ADENOSINE 

REACTIVITY OF ISOLATED CANINE CEREBRAL-ARTERIES TO ADENINE- 
NUCLEOTIDES AND ADENOSINE. 

000210 01-03 
BLOCKADE OF STRIATAL NEURONE RESPONSES TO MORPHINE BY 
AMINOPHYLLINE: EVIDENCE FOR ADENOSINE MEDIATION OF OPIATE 
ACTION. 

000229 01-03 
ADENOSINE REGULATES VIA TWO DIFFERENT TYPES OF RECEPTORS, THE 
ACCUMULATION OF CYCLIC-AMP IN CULTURED BRAIN CELLS. 

000308 01-03 
INHIBITION OF (3H)DIAZEPAM BINDING TO RAT-BRAIN CORTICAL 
SYNAPTOSOMAL MEMBRANES BY ADENOSINE UPTAKE BLOCKERS. 

000330 01-03 
MORPHINE ENHANCES ADENOSINE RELEASE FROM THE IN VIVO RAT- 
CEREBRAL-CORTEX. 

000451 01-04 
ADENOSINE ANALOGS AS SUBSTRATES AND INHIBITORS OF S 
ADENOSYLHOMOCYSTEINE-HYDROLASE. (UNPUBLISHED PAPER). 

001021 02-01 
REGIONAL RELEASE OF (3H)ADEN0SINE DERIVATIVES FROM RAT-BRAIN 
IN VIVO- EFFECT OF EXCITATORY AMINO-ACIDS, OPIATE AGONISTS, 
AND BENZODIAZEPINES. 

001303 02-03 
INHIBITORY ACTION OF ADENOSINE ON SYNAPTIC TRANSMISSION IN THE 
HIPPOCAMPUS OF THE GUINEA-PIG IN VITRO. 

001401 02-03 
AMINOPHYLLINE AND THEOPHYLLINE DERIVATIVES AS ANTAGONISTS OF 
NEURONAL DEPRESSION BY ADENOSINE. A MICROIONTOPHORETIC- 
STUDY. 

001410 02-03 
EFFECTS OF DIAZEPAM ON ADENOSINE AND ACETYLCHOLINE RELEASE 
FROM RAT-CEREBRAL-CORTEX: FURTHER EVIDENCE FOR A PURINERGIC 
MECHANISM IN ACTION OF DIAZEPAM. 

001414 02-03 
ALPHA2-ADRENERGIC AMINES, ADENOSINE AND PROSTAGLANDINS 
INHIBIT LIPOLYSIS AND CYCLIC-AMP ACCUMULATION IN HAMSTER 
ADIPOCYTES IN THE ABSENCE OF EXTRACELLULAR SODIUM 

002728 03-03 
METHYLXANTHINES MODULATE ADENOSINE RELEASE FROM SLICES OF 
CEREBRAL-CORTEX. 

002907 03-03 
DO BENZODIAZEPINES BIND AT ADENOSINE UPTAKE SITES IN CNS? 

002933 03-03 
EFFECTS OF MORPHINE AND CAFFEINE ON ADENOSINE RELEASE FROM 
RAT-CEREBRAL-CORTEX: IS CAFFEINE A MORPHINE ANTAGONIST. 

003864 04-03 
THE EFFECT OF ADENOSINE AND GUANOSINE ON THE CONTENT OF 
SEROTONIN AND CATECHOLAMINES IN THE BRAIN IN THE 
RESTORATION PERIOD FOLLOWING EXPERIMENTAL CLINICAL DEATH. 

003882 04-03 
ADENOSINE AND CYCLIC-AMP IN RAT-CEREBRAL-CORTICAL SLICES: 
EFFECTS OF ADENOSINE UPTAKE INHIBITORS AND ADENOSINE- 
DEAMINASE INHIBITORS. 

003950 04-03 



Psychopharmacology Abstracts 



EFFEaS OF ETHANOL ON ACETYLCHOLINE AND ADENOSINE EFFLUX FROM 
THE IN VIVO RAT-CEREBRAL-CORTEX. 

003969 04-03 
POTENTIATION OF THE EFFECTS OF ADENOSINE ON ISOLATED CARDIAC- 
MUSCLE AND SMOOTH-MUSCLE BY DIAZEPAM. 

004266 04-05 
ADENOSINE-CYCLIC-MONOPHOSPHATE-PHOSPHODIESTERASE 

REGULATION BY A BETA-ADRENERGIC-RECEPTOR OF A CA-INDEPENDENT 
ADENOSINE-CYCLIC-MONOPHOSPHATE-PHOSPHODIESTERASE IN C6- 
GLIOMA CELLS. (UNPUBLISHED PAPER). 

001403 02-03 
ADENOSINE-DEAMINASE 

ADENOSINE AND CYCLIC-AMP IN RAT-CEREBRAL-CORTICAL SLICES: 
EFFECTS OF ADENOSINE UPTAKE INHIBITORS AND ADENOSINE- 
DEAMINASE INHIBITORS. 

003950 04-03 
ADENOSINE-RECEPTORS 

ADENOSINE-RECEPTORS IN RAT TESTES: LABELING WITH 3H 
CYCLOHEXYUVDENOSINE. 

002835 03-03 
ADENOSINE-RECEPTORS IN THE CENTRAL-NERVOUS-SYSTEM: 
RELATIONSHIP TO THE CENTRAL-AQIONS OF METHYLXANTHINES 

003766 04-03 
ADENOSINE-TRIPHOSPHATASE 

ETHANOL SEDATIVE HYPNOTIC-INTERACTIONS: IN VITRO STUDIES ON NA- 
K-ACTIVATED ADENOSINE-TRIPHOSPHATASE . 

004269 04-05 
ADENOSINE-TRIPHOSPHATASES 

INTERACTION STUDIES OF ETHANOL AND PSYCHOTROPIC-DRUGS IN 
RODENTS POSSIBLE INVOLVEMENT OF ADENOSINE-TRIPHOSPHATASES. 

001281 02-03 
ADENOSINE-TRIPHOSPHATE 

4 AMINOPYRIDINE BLOCKADE OF NEURONAL DEPRESSANT RESPONSES TO 
ADENOSINE-TRIPHOSPHATE 

003963 04-03 
ADENOSYL-L-HOMOCYSTEINE 

ANTICONVULSANT PROPERTIES OF S ADENOSYL-L-HOMOCYSTEINE. 

001227 02-03 
ADENOSYL-L-METHIONINE 

DECREASE OF NORADRENALINE METHYUVTION IN RAT-BRAIN INDUCED 
BY L-DOPA. REVERSAL EFFEQ OF S ADENOSYL-L-METHIONINE. 

004019 04-03 
ADENOSYLHOMOCYSTEINE-HYDROLASE 

IRREVERSIBLE INHIBITION OF S ADENOSYLHOMOCYSTEINE-HYDROLASE BY 
NUCLEOSIDE ANALOGS (UNPUBLISHED PAPER). 

001010 02-01 
ADENOSINE ANALOGS AS SUBSTRATES AND INHIBITORS OF S 
ADENOSYLHOMOCYSTEINE-HYDROLASE. (UNPUBLISHED PAPER). 

001021 02-01 
ADENOSYLMETHIONINE 

DECREASED CEREBRAL CATABOLISM OF (3H)HISTAMINE IN VIVO AFTER $■ 
ADENOSYLMETHIONINE ADMINISTRATION. 

002883 03-03 
ADENYLATE-CYCLASE 

(3H)5 HT BINDING-SITES AND 5 HT-SENSITIVE ADENYLATE-CYCLASE IN 
GLIAL CELL MEMBRANE FRAQION. 

000093 01-03 
SUBSENSITIVITY OF THE NOREPINEPHRINE-RECEPTOR COUPLED 
ADENYLATE-CYCUVSE SYSTEM IN BRAIN: EFFEQS OF NISOXETINE 
VERSUS FLUOXETINE. 

000208 01-03 
SEROTONIN-SENSITIVE ADENYLATE-CYCLASE AND (3H)SER0T0NIN 
BINDING-SITES IN THE CNS OF THE RAT - I. KINETIC PARAMETERS 
AND PHARMACOLOGICAL-PROPERTIES. 

000213 01-03 
SEROTONIN-SENSITIVE ADENYLATE-CYCLASE AND (3H)SER0T0NIN 

BINDING-SITES IN THE CNS OF THE RAT - II. RESPEQIVE REGIONAL 
AND SUBCELLULAR DISTRIBUTIONS AND ONTOGENETIC 
DEVELOPMENTS „ „, 

000214 01-03 
OPIOID DEPENDENT DUAL-REGULATION OF ADENYLATE-CYCLASE IN A 

CELL-FREE SYSTEM. (UNPUBLISHED PAPER). 

001033 02-01 
PROSTACYCLIN-DEPENDENT ACTIVATION OF ADENYLATE-CYCLASE IN A 
NEURONAL SOMATIC CELL HYBRID: PROSTANOID STRUQURE-ACTIVITY 
RELATIONSHIPS. 

001132 02-03 

DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND RECEPTOR BINDING- 
AQIVITIES FOLLOWING ACUTE AND CHRONIC NEUROLEPTIC-DRUG 
TREATMENT. (UNPUBLISHED PAPER). 

001172 02-03 
ENDOGENOUS GUANYL-NUCLEOTIDES: COMPONENTS OF THE STRIATUM 
WHICH CONFER DOPAMINE SENSITIVITY TO ADENYLATE-CYCLASE. 

001313 02-03 
DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND DOPAMINE/ 
NEUROLEPTIC-RECEPTOR BINDING: EFFEQ OF NEUROLEPTIC-DRUGS 

001358 02-03 



S-6 



/OLUME T9, SUBJECT INDEX 

OIHYDROXY AND TRIHYOROXY ANALOGS OF CHLORPROMAZINE 
INFLUENCE THE CENTRAL-ACTIVITY OF ADENYLATE-CYCLASE AND 
CYCLIC-AMP-PHOSPHODIESTERASE. 

001405 02-03 
STIMULATION OF ADENYLATE-CYCLASE IN RAT STRIATUM BY 
PERGOLIDE: INFLUENCE OF GTP. 

001448 02-03 
FUNCTIONAL ASPECTS OF THE NOREPINEPHRINE-RECEPTOR COUPLED 
ADENYLATE-CYCUVSE SYSTEM IN THE CENTRAL-NERVOUS-SYSTEM. 

001493 02-03 
STIMULATION OF RETINAL ADENYLATE-CYCUkSE BY VASOACTIVE 
INTESTINAL PEPTIDE (VIP). 

002811 03-03 
EFFECT OF DOPAMINE ON ACTIVATION OF RAT STRIATAL ADENYLATE- 
CYCLASE BY FREE MG2 AND GUANYL-NUCLEOTIDES. 

002825 03-03 
STEREOSPECIFIC INHIBITION OF DOPAMINE-SENSITIVE ADENYLATE- 
CYCLASE IN CARP RETINA BY THE ENANTIOMERS OF (/-) 1 
CYCLOPROPYLMETHYL 
TRIFLUOROMETHYLTHIODIBENZOCYCLOHEPTENYLIDENEPIPERIDINE. 

003706 04-02 
STIMULATORY ACTION OF LISURIDE ON DOPAMINE-SENSITIVE 
ADENYLATE-CYCUSE IN THE RAT STRIATAL HOMOGENATE. 

003718 04-03 
DOPAMINE-ACTIVATED ADENYLATE-CYCLASE OF SPINAL-CORD: 
SUPERSENSITIVITY FOLLOWING TRANSECTION OF THE CORD. 

003800 04-03 
OPIOIDS, NORADRENALINE AND GTP ANALOGS INHIBIT CHOLERA-TOXIN 
ACTIVATED ADENYLATE-CYCLASE IN NEUROBLASTOMA-X GLIOMA 
HYBRID CELLS. 

003975 04-03 
DOPAMINERGIC MECHANISMS IN THE TELEOST RETINA. I. DOPAMINE- 
SENSITIVE ADENYUVTE-CYCLASE IN HOMOGENATES OF CARP RETINA- 
EFFECTS OF AGONISTS, ANTAGONISTS AND ERGOTS. 

004051 04-03 
WHY DOES SULPIRIDE NOT BLOCK THE EFFECT OF DOPAMINE ON THE 
DOPAMINE-SENSITIVE ADENYLATE-CYCLASE? 

004055 04-03 
RECEPTORS, ADENYLATE-CYCLASE, DEPRESSION, AND LITHIUM. 

004353 04-09 
DH 

INAPPROPRIATE ADH SECRETION: THE ROLE OF DRUG RECHALLENGE. 

002629 02-17 
DHERENCE 

ADHERENCE TO LITHIOTHERAPY. 

002507 02-16 
DHESION 

DEVELOPMENTALLY REGULATED LECTINS IN SLIME MOULDS AND CHICK 
TISSUES ~ ARE THEY CELL ADHESION MOLECULES? 

003724 04-03 
JIPOCYTES 

ALPHA2-ADRENERGIC AMINES, ADENOSINE AND PROSTAGLANDINS 
INHIBIT LIPOLYSIS AND CYCLIC-AMP ACCUMULATION IN HAMSTER 
ADIPOCYTES IN THE ABSENCE OF EXTRACELLULAR SODIUM 

002728 03-03 
XPOSE 

EFFECTS OF RATE OF BLOOD FLOW ON FRACTIONAL EXTRACTION AND ON 
UPTAKE OF INFUSED NORADRENALINE BY BROWN ADIPOSE TISSUE IN 
VIVO. 

)JUNCT.VE ""'''' °2-03 

EFFECTS OF PSYCHOTROPIC-DRUGS ON FI-RESPONDING AND ADJUNCTIVE 
DRINKING IN RATS. 

001693 02-04 
>JUSTMENTS 

HEXAMETHONIUM MODIFICATION OF CARDIOVASCULAR ADJUSTMENTS 

DURING COMBINED STATIC DYNAMIC ARM EXERCISE IN MONKEYS 

,JUVANT 001242 02-03 

PSYCHIATRIC MORBIDITY AND PHYSICAL TOXICITY ASSOCIATED WITH 
ADJUVANT CHEMOTHERAPY AFTER MASTECTOMY. 

002433 02-15 
)MINISTRATIONS 

MODIFICATION OF DOPAMINE-RECEPTORS IN BRAIN BY CONTINUOUS 
AMPHETAMINE ADMINISTRATIONS TO RATS. 

001395 02-03 
PHARMACOKINETIC PROFILE OF VALPROIC-ACID IN RHESUS-MONKEYS 
FOLLOWING SINGLE BOLUS AND CONSTANT RATE INTRAVENOUS 
ADMINISTRATIONS. 

002797 03-03 
EFFECTS OF REPEATED ADMINISTRATIONS OF DIHYDROERGOTOXINE 
(REDERGINE) ON THE SLEEP-WAKEFULNESS CYCLE IN THE CAT 

.u.cc.«..e 003703 04-02 

AMISSIONS 

PSYCHOTROPIC-DRUGS AND PSYCHIATRIC-HOSPITAL ADMISSIONS IN 
VERONA, ITALY. 

004717 04-17 
>OLESCENCE " ' u'* i / 

THE USE OF LITHIUM-CARBONATE IN ADOLESCENCE. 

000992 01-17 



Subject Index 

ON THE QUESTION OF PARENCHYMAL DAMAGE CAUSED BY LONG-TERM 
THERAPY WITH PSYCHOTROPICS IN ADOLESCENCE. 

004626 04-15 
ADOLESCENT 

PREDICTORS OF ADOLESCENT HEIGHT AND WEIGHT IN HYPERKINETIC- 
BOYS TREATED WITH METHYLPHENIDATE 

003509 03-15 

PHENYTOIN TOXICITY IN A BRAIN-DAMAGE ADOLESCENT: A CASE- 
REPORT. 

003512 03-15 
MAOI-INOUCED RAPID CYCLING BIPOLAR AFFECTIVE-DISORDER IN AN 
ADOLESCENT. 

004637 04-15 
ADOLESCENTS 

MARIJUANA: A REVIEW OF MEDICAL RESEARCH WITH IMPLICATIONS 
FOR ADOLESCENTS. 

000871 01-15 
INITIAL PRESCRIPTION OF PSYCHOTROPIC-MEDICATIONS FOR 
ADOLESCENTS IN A MEDICAL/ PROFESSIONAL INSTITUTE, AND THE 
ROLE OF THE PSYCHIATRIST IN A MEDICAL/PROFESSIONAL INSTITUTE. 

002621 02-17 
LATE RESULTS OF LITHIUM TREATMENT OF ADOLESCENTS WITH AHACK 
LIKE SCHIZOPHRENIA. 

003177 03-08 
ON THE EFFECTS OF SULTOPRIDE ADMINISTERED IN LOW-DOSAGES TO 
OLDER CHILDREN AND ADOLESCENTS. 

003230 03-09 
TREATMENT OF ANXIETY IN CHILDREN AND ADOLESCENTS. 

003349 03-11 
PHARMACOLOGICAL INFLUENCE OF SEXUAL-FUNCTIONS IN ADOLESCENTS. 

004436 04-11 
DRUG-INDUCED PSYCHOSIS AND SCHIZOPHRENIA IN ADOLESCENTS. 

004596 04-15 
EMOTIONAL-DISORDERS IN CHILDREN AND ADOLESCENTS: MEDICAL AND 
PSYCHOLOGICAL APPROACHES TO TREATMENT. 

004743 04-17 
ADRENAL 

RELEASE OF ARACHIDONIC-ACID FROM ADRENAL CHROMAFFIN CELL- 
CULTURES DURING SECRETION OF EPINEPHRINE. (UNPUBLISHED 
PAPER). 

001027 02-01 

INFLUENCE OF DRUGS AFFECTING THE PITUITARY ADRENAL AXIS ON 
CHROMAFFIN CELLS. 

001183 02-03 
ADRENAL-GLAND 

EFFECT OF OXOTREMORINE ON ORNITHINE-DECARBOXYLASE ACTIVITY OF 
THE ADRENAL-GLAND IN RAT. 

000246 01-03 
IDENTIFICATION AND QUANTIFICATION OF 1,2,3,4 TETRAHYDRO-BETA- 
CARBOLINE, 2 METHYL-TETRAHYDRO-BETA-CARBOLINE, AND 6 
METHOXY-TETRAHYDRO-BETA-CARBOLINE AS IN VIVO CONSTITUENTS 
OF RAT-BRAIN AND ADRENAL-GLAND. 

002636 03-01 
ADRENAL-HORMONES 

ADRENAL-HORMONES AND ETHANOL INGESTION IN C57BL/CRGL AND 
C3H/CRGL/2 MICE. 

002739 03-03 
ADRENAL-MEDULLA 

REGULATION OF CHOLINERGIC TRANSMISSION IN ADRENAL-MEDULLA. 
(UNPUBLISHED PAPER). 

001182 02-03 
BETA ENDORPHIN-INDUCED HYPERGLYCEMIA IS MEDIATED BY INCREASED 
CENTRAL SYMPATHETIC OUTFLOW TO ADRENAL-MEDULLA. 

002924 03-03 
EFFECTS OF TAIPOXIN ON THE ULTRASTRUCTURE OF CHOLINERGIC AXON 
TERMINALS IN THE MOUSE ADRENAL-MEDULLA. 

003916 04-03 
ADRENALECTOMIZED 

CORTICOSTERONE INCREASES THE SYNTHESIS OF A SOLUBLE PROTEIN IN 
PITUITARY-GLANDS FROM ADRENALECTOMIZED MALE RATS WHICH 
PRECIPITATES WITH ANTI-RAT GROWTH-HORMONE ANTISERUM. 
(UNPUBLISHED PAPER). 

001122 02-03 
ADRENALINE 

INCREASED ADRENALINE, BETA-ADRENERGIC-RECEPTOR STIMULATION 
AND PHOSPHOLIPID METHYLATION IN PINEAL-GL^ND OF 
SPONTANEOUSLY HYPERTENSIVE-RATS. (UNPUBLISHED PAPER) 

001458 02-03 

CORRECTION BY PROPRANOLOL OF THE ABNORMAL ADRENALINE 
DISCHARGE INDUCED BY EMOTIONAL- STRESS IN CEREBRAL 
HEMORRHAGE PATIENTS. 

002295 02-13 
ADRENALINE: A SECRET AGENT IN MEMORY. 

002345 02-14 
ADRENALINE-INDUCED 

THE BLOOD-BRAIN-BARRIER IN ADRENALINE-INDUCED HYPERTENSION 

000147 01-03 






S-7 



Subject Index 

ADDENERfilC 

SEIZURES AND RELATED EPILEPTIFORM ACTIVITY IN HIPPOCAMPUS 
TRANSPLANTED TO THE ANTERIOR-CHAMBER OF THE EYE: 
MODULATION BY CHOLINERGIC AND ADRENERGIC INPUT. 

000095 01-03 

THE RELEASE OF CATECHOLAMINES FROM ADRENERGIC NEURONS. 

000974 01-17 

AN EXAMINATION OF FACTORS INFLUENCING ADRENERGIC 
TRANSMISSION IN THE PITHED RAT, WITH SPECIAL REFERENCE TO 
NORADRENALINE UPTAKE MECHANISMS AND POSTJUNCTIONAL 
ALPHA-ADRENOCEPTORS. 001196 02-03 

ADRENERGIC NONSPECIFIC POTENTIATION OF YOHIMBINE TOXICITY IN 
MICE BY ANTIDEPRESSANTS AND RELATED DRUGS AND 
ANTIYOHIMBINE ACTION OF ANTIADRENERGIC AND SEROTONERGIC 

''^^^^ 001330 02-03 

INDIRECT ADRENERGIC EFFECT OF HISTAMINE IN CAT CEREBRAL- 

^•^™IES. 001355 02-03 

RETROGRADE AMNESIA PRODUCED BY ELECTRICAL-STIMULATION OF THE 

AMYGDALA: ATTENUATION WITH ADRENERGIC ANTAGONISTS. 

(UNPUBLISHED PAPER). 001488 02-03 

AMPHETAMINE STEREOTYPIES AND POLYRIBOSOMAL DISAGGREGATION 

IN RATS- EFFECTS OF ADRENERGIC AND SEROTONERGIC BLOCKING- 

^^^^^5 00153102-03 

DORSAL TEGMENTAL BUNDLE DESTRUCTION: EFFECTS ON OPERANT- 
BEHAVIOR BRAIN CATECHOLAMINE LEVELS, AND BEHAVIORAL- 
SUPPRESSION PRODUCED BY ADRENERGIC AGONISTS 

001726 02-04 
ADRENERGIC MODUUVTION OF THE HYPOTHALAMIC CHOLINERGIC 

MECHANISM IN THE CONTROL OF EMOTIONAL DEFENSIVE-BEHAVIOR IN 

T^^^^T 00176102-04 

THE CORRELATION OF CATECHOLAMINE AND ADRENERGIC PARAMETERS 

WITH DRUG-THERAPY OF NEUROTIC AND ENDOGENOUS DEPRESSIONS. 

002047 02-09 
CHANGES IN BODY-TEMPERATURE AFTER ADMINISTRATION OF 

ADRENERGIC AND SEROTONERGIC-AGENTS AND RELATED DRUGS 

INCLUDING ANTIDEPRESSANTS „„...^ „„ ,-, 

002532 02-17 

ADRENERGIC REGULATION OF THE REDUCTION IN ACETYL-COENZYME- 
A ARYLAMINE-N-ACETYLTRANSFERASE IN THE RAT PINEAL. 

002654 03-03 

DIFFERENTIAL-EFFECT OF CHRONIC DESIPRAMINE AND AMITRIPTYLINE 
TREATMENT ON RAT-BRAIN ADRENERGIC AND SEROTONERGIC- 

^'''''''' 002914 03-03 

ROLE OF ADRENERGIC BLOCKING-AGENTS AND GLUCOCORTICOIDS ON 
THE REGULATION OF PITUITARY OPIOID-PEPTIDES LEVELS. 

003801 04-03 
NYSTAGMIC RESPONSES OF HIPPOCAMPAL ORIGIN WITH REFERENCE TO 
EXCITABILITY OF CHOLINERGIC AND ADRENERGIC COMPONENTS 
INVOLVED IN THE HIPPOCAMPUS OF RABBITS 

003842 04-03 
SUBSTANCE-P INCREASES HYPOTHALAMIC BLOOD FLOW VIA AN 
INDIREa ADRENERGIC CHOLINERGIC INTERAQION. 

003887 04-03 
THE IMPORTANCE OF CATECHOLAMINE UPTAKE INHIBITION IN THE 
REVERSAL OF GUANETHIDINE BLOCKADE OF ADRENERGIC NEURONS. 

003900 04-03 
SPINAL-CORD PHARMACOLOGY OF ADRENERGIC AGONIST-MEDIATED 
ANTINOCICEPTION. „„ „^ „^ 

004206 04-04 
RETROGRADE AMNESIA PRODUCED BY ELECTRICAL-STIMULATION OF THE 
AMYGDALA: AHENUATION WITH ADRENERGIC ANTAGONISTS. 

004231 04-04 
PERIPHERAL SEROTONERGIC AND ADRENERGIC RESPONSES IN 

DEPRESSION. „„ ^, „^„„ 

004364 04-09 
THE STATE OF THE ADRENERGIC AND CHOLINERGIC SYSTEMS IN 
SCHIZOPHRENIC-PATIENTS DURING PSYCHPHARMACOTHERAPY. 

004526 04-13 
ADRENERGIC-RECEPTOR 

MORPHINE WITHDRAWAL CAUSES SUBSENSITIVITY OF ADRENERGIC- 
RECEPTOR RESPONSE. 

002838 03-03 

ADRENERGIC-RECEPTORS 

ASSESSMENT OF ADRENERGIC-RECEPTORS IN VIVO IN EXPERIMENTAL 
ANIMALS AND MAN. (UNPUBLISHED PAPER). 

001034 02-01 
ACUTE AND CHRONIC EFFECTS OF PSYCHOACTIVE-DRUGS ON 
ADRENERGIC-RECEPTORS AND CALMODULIN. 

004750 04-17 

ADRENOCEPTOR ^ ,^, 

A NEUROENDOCRINE-STUDY OF ADRENOCEPTOR FUNCTION IN 
ENDOGENOUS DEPRESSION. 004362 04-09 



PtychopharmQCology Abstracts 



ADRENOCEPTORS 

DESENSITIZATION OF ADRENOCEPTORS AFTER IMMOBILIZATION STRESS 
OR REPEATED INJECTION OF ISOPROTERENOL IN RATS. (UNPUBLISHED 
PAPER), 

001546 02-03 

ADRENOCORTICAL 

THE EFFECT OF PROPYLNORANTIFEIN ON BEHAVIORAL-REAaiONS, 
ADRENOCORTICAL ACTIVITY, AND ENERGY METABOLISM IN THE 
ANIMAL BRAIN, 

004075 04-04 
ACTH-LIKE PEPTIDES. PITUITARY ADRENOCORTICAL FUNQION AND 
AVOIDANCE-BEHAVIOR 

004109 04-04 

ADRENOCORTICOTROPIN 

THE EFFECT OF NEUROPEPTIDE FRAGMENTS OF ADRENOCORTICOTROPIN 
AND VASOPRESSIN ON BEHAVIORAL-ACTIVITY IN RATS. 

001812 02-04 

ADRENORECEPTOR 

PLASMA CATECHOLAMINES IN RATS EXPOSED TO COLD: EFFEGS OF 
GANGLIONIC AND ADRENORECEPTOR BLOCKADE. 

002863 03-03 

ADTN 

(3H) 2 AMINODIHYDROXYTETRAHYDRONAPHTHALENE (ADTN): 
REGIONAL DISTRIBUTION AND IN VIVO BINDING AFTER ACUTE AND 
CHRONIC DRUG-TREATMENT 

000052 01-03 
SELECTIVE STORAGE IN VIVO OF 5,6 ADTN IN DOPAMINE RICH AREAS OF 
THE RAT-BRAIN. 

000324 01-03 
HYPERACTIVITY FOLLOWING INJEQION OF A GLUTAMATE AGONIST AND 
6,7 ADTN INTO RAT NUCLEUS-ACCUMBENS AND ITS INHIBITION BY 
THIP. 

004066 04-04 

ADULT 

PLASMA LEVELS OF DIPHENYLHYDANTOIN AND THE CONTROL OF ADULT 
EPILEPTIC-SEIZURES: A CHILEAN EXPERIENCE. 

000102 01-03 
BRAINSTEM AUDITORY EVOKED-POTENTIALS AND MYELIN CHANGES IN 
TRIETHYLTIN-INDUCED EDEMA IN YOUNG ADULT RATS. 

000509 01-05 
DEXTROAMPHETAMINE: COGNITIVE AND BEHAVIORAL-EFFEaS IN 
NORMAL AND HYPERACTIVE-BOYS AND NORMAL ADULT MALES. 

00071601-11 
NEONATAL ADMINISTRATION OF MET-ENKEPHALIN FACILITATES MAZE- 
PERFORMANCE OF ADULT RATS, 

001673 02-04 
NEUROLEPTIC TREATMENT FOR A SUBSTANTIAL PROPORTION OF ADULT 
LIFE: BEHAVIOURAL-SEQUELAE OF 9 MONTHS HALOPERIDOL 
ADMINISTRATION 

001858 02-05 

A COMPARISON OF THE EFFECTS OF PENTOBARBITAL AND 

DIPHENYLHYDANTOIN ON THE GABA SENSITIVITY AND EXCITABILITY 
OF ADULT SENSORY GANGLION CELLS. 

002692 03-03 
EFFECTS OF FETAL TREATMENT WITH METHYLAZOXYMETHANOL-ACETATE 
AT VARIOUS GESTATIONAL DATES ON THE NEUROCHEMISTRY OF THE 
ADULT NEOCORTEX OF THE RAT. „„„,„ „o ,x, 

002770 03-03 
ABNORMAL MATURATION OF CEREBRAL-CORTEX AND BEHAVIORAL- 
DEFICIT IN ADULT RATS AFTER NEONATAL ADMINISTRATION OF 

ANTIBODIES TO GANGLIOSIDE. ^ ^, ^^ 

003025 03-04 
SUPPRESSION OF ACTIVE SLEEP BY CHRONIC-TREATMENT WITH 
CHLORIMIPRAMINE DURING EARLY POSTNATAL DEVELOPMENT: 
EFFECTS UPON ADULT SLEEP AND BEHAVIOR IN THE RAT. 

003056 03-04 
BEHAVIOURAL-CHANGES IN ADULT RATS FOLLOWING ADMINISTRATION 
OF ANTIBODIES AGAINST BRAIN GANGLIOSIDES. 

003071 03-04 

PSYCHOACTIVE-MEDICATION USE AND ABUSE AMONG AN ADULT RURAL 
POPULATION. (PH.D. DISSERTATION) ^^^^^ ^^^^ 

THE EFFECTS OF P CHLOROAMPHETAMINE ADMINISTRATION ON 
LOCOMOTOR-ACTIVITY AND SEROTONIN IN NEONATAL AND ADULT 
RATS. (UNPUBLISHED PAPER). 004169 04-04 

ADULT-ONSET 

ADULT-ONSET STUHERING TREATED WITH ANTICONVULSANTS. 

003290 03-11 

ADULTS 

EFFECTS OF METHYLPHENIDATE ON LEARNING A BEGINNING READING 
VOCABULARY BY NORMAL ADULTS. 000812 01-14 

EFFECT OF OPIATES AND OPIATE ANTAGONISTS ON SOMATOSENSORY 
EVOKED-POTENTIALS IN PATIENTS WITH SCHIZOPHRENIA AND 
NORMAL ADULTS. 002222 02-13 



S-8 



/OLUME 19, SUBJECT INDEX 



Subject Index 



EFFECTS OF THIORIDAZINE (MELLARIL) ON TITRATING DELAYED 
MATCHING-TO-SAMPLE PERFORMANCE IN MENTALLY-RETARDED 
ADULTS 

002471 02-15 

EPILEPSY IN ADULTS. 

003375 03-11 
THE MANAGEMENT OF CHRONIC BEHAVIOR-DISORDERS IN MENTALLY- 
RETARDED ADULTS WITH LITHIUM-CARBONATE 

003376 03-11 
ATTENTION DEFICIT-DISORDER (MINIMAL-BRAIN-DYSFUNCTION) IN 

ADULTS: A REPLICATION STUDY OF DIAGNOSIS AND DRUG- 
TREATMENT. 

003389 03-1 1 
EFFECTS OF THIORIDAZINE (MELLARIL) ON TITRATING DELAYED 
MATCHING-TO-SAMPLE PERFORMANCE OF MENTALLY-RETARDED 
ADULTS, 

003392 03-11 
HYPERACTIVES AS YOUNG ADULTS: PROSPECTIVE TEN-YEAR FOLLOWUP. 

004454 04-11 
lOVANTAGE 

ADVANTAGE OF PHARMACOKINETIC DATA DURING TREATMENT OF 
PSYCHOSES WITH HALOPERIDOL. 

000577 01-08 
STUDY OF MAPROTILINE IN OUTPATIENT TREATMENT OF DEPRESSIVE- 
STATES BY THE GENERAL-PRACTITIONER: ADVANTAGE OF SINGLE- 
NIGHTLY-DOSE. 

001961 02-09 
ADVANTAGE OF MONOTHERAPY WITH CLOBAZAM IN THE TREATMENT 
AND POSHREATMENT OF ALCOHOLIC WITHDRAWAL. 

002140 02-11 
DVANTAGES 

ADVANTAGES AND DISADVANTAGES OF PROLONGED USE OF 
NEUROLEPTICS. 

003470 03-15 
DVERSE 

CLINICAL-PHARMACOLOGY: ADVERSE DRUG INTERACTIONS. 

003399 03-13 
OVERSE-EFFECTS 

PREVENTION OF TARDIVE-DYSKINESIA AND OTHER DRUG RELATED 
ADVERSE-EFFECTS. 

004601 04-15 
ADVERSE-EFFECTS OF ANTIPARKINSON-DRUG WITHDRAWAL. 
(UNPUBLISHED PAPER). 

004623 04-15 
DVERSE-REACTIONS 

PSYCHOTHERAPEUTIC-DRUGS: IMPORTANT ADVERSE-REACTIONS AND 
INTERACTIONS. 

002383 02-15 
ADVERSE-REAQIONS TO MEDICATIONS PRESCRIBED FOR HYPERKINESIS. 
(PH.D. DISSERTATION). 

002411 02-15 
EP 

PSYCHOTROPIC-DRUG-INDUCED CHANGES IN AUDITORY AVERAGED 
EVOKED-POTENTIALS: RESULTS OF A DOUBLE-BLIND TRIAL USING AN 
OBJECTIVE FULLY AUTOMATED AEP ANALYSIS METHOD 

003412 03-13 
FFECTIVE-DISORDER 

INCREASED VULNERABILITY TO CHOLINERGIC STIMULATION IN 
AFFECTIVE-DISORDER PATIENTS. 

002003 02-09 
MAOI-INDUCED RAPID CYCLING BIPOLAR AFFECTIVE-DISORDER IN AN 
ADOLESCENT. 

004637 04-15 
FFECTIVE-DISORDERS 

COGNITIVE AND AFFECTIVE-FUNCTIONS IN PATIENTS WITH AFFECTIVE- 
DISORDERS TREATED WITH LITHIUM: AN ASSESSMENT BY 
QUESTIONNAIRE. 

000604 01-09 

LITHIUM TREATMENT IN AFFECTIVE-DISORDERS: THERAPEUTIC PLASMA 

000635 01-09 
LITHIUM TREATMENT IN AFFECTIVE-DISORDERS FROM VIEWPOINT OF 

TRANSCULTURAL PSYCHOPHARMACOLOGY: THERAPEUTIC PLASMA 

000636 01-09 
AMITRIPTYLINE, NORTRIPTYLINE PLASMA LEVELS AND CLINICAL- 
RESPONSE IN WOMEN WITH AFFECTIVE-DISORDERS. 

000757 01-13 
RENAL FUNCTION IN LITHIUM AND NONLITHIUM TREATED PATIENTS 
WITH AFFECTIVE-DISORDERS. 

DISCUSSION OF CLINICAL-PAPERS ON LITHIUM TRANSPORT IN AFFECTIVE- 
DISORDERS. 

001987 02-09 
LITHIUM TRANSPORT STUDIES IN AFFECTIVE-DISORDERS. 

002024 02-09 
ABNORMALITIES OF LITHIUM TRANSPORT IN PATIENTS WITH AFFECTIVE- 
DISORDERS. 

002269 02-13 
THE ROLE OF NOREPINEPHRINE IN AFFECTIVE-DISORDERS. 

002278 02-13 



A TEST OF A NEUROTRANSMITTER MODEL OF THE AFFECTIVE-DISORDERS. 
(PH.D. DISSERTATION). 

003063 03-04 
THE EFFECT OF SODIUM-VALPROATE ON MANIA: THE GABA HYPOTHESIS 
OF AFFECTIVE-DISORDERS. 

003218 03-09 
PSYCHOTROPIC-DRUGS AND THEIR RELATIONSHIP WITH 
PSYCHOPATHOLOGY OF AFFECTIVE-DISORDERS. 

004361 04-09 
LITHIUM IN THE PROPHYLAXIS OF RECURRENT AFFECTIVE-DISORDERS 
(EFFECTIVENESS OF LOW PLASMA LEVELS AND PREDICTORS TO 
CLINICAL-RESPONSE). 

004365 04-09 
LITHIUM USE IN AFFECTIVE-DISORDERS. 

004367 04-09 
EFFECT OF LITHIUM ON GLYCINE LEVELS IN PATIENTS WITH AFFECTIVE- 
DISORDERS. 

004606 04-15 
KIDNEY FUNCTION IN PATIENTS WITH AFFECTIVE-DISORDERS WITH AND 
WITHOUT LITHIUM THERAPY. 

004664 04-15 
AFFECTIVE-EPISODE 

AFFECTIVE-EPISODE FREQUENCY AND LITHIUM THERAPY. 

000587 01-09 
AFFECTIVE-FUNCTIONS 

COGNITIVE AND AFFECTIVE-FUNCTIONS IN PATIENTS WITH AFFECTIVE- 
DISORDERS TREATED WITH LITHIUM: AN ASSESSMENT BY 
QUESTIONNAIRE. 

000604 01-09 
AFFECTIVE-ILLNESS 

ANTIDEPRESSANT POTENTIATION OF 5 HYDROXYTRYPTOPHAN BY L 
DEPRENIL IN AFFECTIVE-ILLNESS. 

000608 01-09 
AMPHETAMINE AND PIRIBEDIL IN AFFECTIVE-ILLNESS. 

000618 01-09 
SENSITIZATION AND OSCILLATION FOLLOWING REPEATED STIMULATION- 
RELATIONSHIP TO AFFECTIVE-ILLNESS AND ITS TREATMENT WITH 
LITHIUM AND CARBAMAZEPINE. 

002031 02-09 
DEVELOPMENT AND USE OF PHARMACOLOGICAL-PROBES OF THE CNS IN 
MAN: EVIDENCE OF CHOLINERGIC ABNORMALITY IN PRIMARY 
AFFECTIVE-ILLNESS 

002506 02-16 
BIOLOGICAL-RHYTHM DISTURBANCES IN AFFECTIVE-ILLNESS. 

002628 02-17 
THYROTROPHIN RESPONSE TO THYROTROPHIN-RELEASING-HORMONE IN 
UNIPOLAR AND BIPOLAR AFFECTIVE-ILLNESS. 

003237 03-09 
UNWANTED EFFECTS OF LITHIUM-CARBONATE USED IN THE PREVENTION 
OF RELAPSES OF AFFECTIVE-ILLNESS. 

004625 04-15 
AFFECTIVE-PSYCHOSES 

COMPARATIVE CHARACTERISTICS OF THE PROPHYLACTIC PROPERTIES OF 
SHORT-TERM AND LONG-ACTING LITHIUM-CARBONATE PREPARATIONS 
IN ENDOGENOUS AFFECTIVE-PSYCHOSES. 

004390 04-09 
AFFECTIVE-PSYCHOSIS 

BIPOLAR AFFECTIVE-PSYCHOSIS WITH ONSET BEFORE AGE 16 YEARS: 
REPORT OF 10 CASES. 

002001 02-09 
AN ATTEMPT TO ASSESS THE EFFECT OF LITHIUM ON THE NEUTROPHIL 
LEUKOCYTE SYSTEM IN AFFECTIVE-PSYCHOSIS. 

004416 04-09 
AFFERENT 

CHANGES IN PRIMARY AFFERENT DEPOLARIZATION AFTER 
ADMINISTRATION OF GAMMA ACETYLENIC-GAMMA-AMINOBUTYRIC- 
ACID (GAG), A GAMMA AMINOBUTYRIC-ACID-TRANSAMINASE 
(GABA-TRANSAMINASE) INHIBITOR. 

000174 01-03 
DEMONSTRATION OF SUBSTANCE-P IN AORTIC NERVE AFFERENT FIBERS 
BY COMBINED USE OF FLOURESCENT RETROGRADE NEURONAL 
LABELING AND IMMUNOCYTOCHEMISTRY. (UNPUBLISHED PAPER) 

001024 02-01 
AFFERENTS 

SELECTIVE SYNAPTIC ANTAGONISM BY ATROPINE AND ALPHA 
AMINOADIPATE OF PULVINAR AND CORTICAL AFFERENTS TO THE 
SUPRASYLVIAN VISUAL AREA (CLARE-BISHOP AREA). 

002752 03-03 
EVIDENCE THAT THE OPIATE-RECEPTORS OF THE SUBSTANTIA- 
GELATINOSA CONTRIBUTE TO THE DEPRESSION, BY INTRAVENOUS 
MORPHINE, OF THE SPINAL TRANSMISSION OF IMPULSES IN 
UNMYELINATED PRIMARY AFFERENTS. 

002767 03-03 
NALOXONE EFFECTS ON THE BLOOD-PRESSURE RESPONSE INDUCED BY 
THIN-FIBER MUSCULAR AFFERENTS. 

002794 03-03 



i 

f 



S-9 



Subject Index 

SUPRASPINAL INHIBITION OF THE EXCITATION OF DORSAL-HORN 
NEURONES BY IMPULSES IN UNMYELINATED PRIMARY AFFERENTS: 
LACK OF EFFECT BY STRYCHNINE AND BICUCULLINE. 

003778 04-03 
AFFINITIES 

THE AFFINITIES OF ERGOT COMPOUNDS FOR DOPAMINE AGONIST AND 
DOPAMINE ANTAGONIST RECEPTOR SITES. 

001254 02-03 
GABA-RECEPTORS REGULATE THE AFFINITIES OF ANIONS REQUIRED FOR 
BRAIN SPECIFIC BENZODIAZEPINE BINDING. 

002903 03-03 

AFFINITY 

ON THE CAPACITY OF PRESYNAPTIC ALPHA-RECEPTORS TO MODULATE 
NOREPINEPHRINE RELEASE FROM SLICES OF RAT NEOCORTEX AND THE 
AFFINITY OF SOME AGONISTS AND ANTAGONISTS FOR THESE 

^''''''^' 000323 01-03 

AFFINITY CHROMATOGRAPHY OF THE BETA-ADRENERGIC-RECEPTOR AND 
CHARACTERIZATION OF ANTIBODIES RAISED AGAINST PURIFIED 
RECEPTOR PREPARATIONS. 

001009 02-01 
NEGLIGIBLE AFFINITY OF HISTAMINE H2-RECEPT0R ANTAGONISTS FOR 
CENTRAL ALPHA 1 -ADRENOCEPTORS. 

001508 02-03 
MULTIPLE CNS RECEPTOR INTERACTIONS OF ERGOT ALKALOIDS: AFFINITY 
AND INTRINSIC ACTIVITY ANALYSIS IN IN VITRO BINDING SYSTEMS, 

001516 02-03 
MU-RECEPTORS AND DELTA OPIATE-RECEPTORS: CORRELATION WITH 
HIGH-AFFINITY AND LOW AFFINITY OPIATE BINDING-SITES. 

001554 02-03 
RELATIONSHIPS BETWEEN STRUCTURE AND ALPHA-ADRENERGIC- 
RECEPTOR AFFINITY OF CLONIDINE AND AND SOME RELATED CYCLIC- 
AMIDINES. 

002698 03-03 
PENTOBARBITAL: DUAL-ACTIONS TO INCREASE BRAIN BENZODIAZEPINE- 
RECEPTOR AFFINITY. ^^^^^^ ^^ ^, 

002896 03-03 
EFFECT OF THE POSITION OF THE PHENOLIC GROUP IN MORPHINANS ON 
THEIR AFFINITY FOR OPIATE-RECEPTOR BINDING. 

003702 04-02 
AFTERCARE 

DOUBLE-BLIND COMPARISON OF HALOPERIDOL AND THIOTHIXENE WITH 
AFTERCARE TREATMENT EVALUATION IN PSYCHIATRIC-OUTPATIENTS 
WITH SCHIZOPHRENIA. „ „„ 

000574 01-08 
FOLLOWUP TREATMENT AND AFTERCARE OF DISCHARGED 
SCHIZOPHRENIC-PATIENTS. 

000944 01-17 

AFTERDISCHARGE 

FLASH-EVOKED AFTERDISCHARGE IN RAT AS A MODEL OF THE ABSENCE 
SEIZURE: DOSE-RESPONSE STUDIES WITH THERAPEUTIC DRUGS 

000160 01-03 
THE ROLE OF BIOGENIC-AMINES IN AMYGDALAR KINDLING. I. LOCAL 
AMYGDALAR AFTERDISCHARGE. 

000327 01-03 
RELATION OF MONOMETHYLHYDRAZINE (MMH) SEIZURE THRESHOLDS 
TO AFTERDISCHARGE THRESHOLDS WITH AMYGDALOID STIMULATION 
IN CATS. 

000474 01-04 
A STUDY ON EFFECTS OF ANTIEPILEPTIC-DRUGS UPON THE HIPPOCAMPAL 
AFTERDISCHARGE. 

002844 03-03 
CUMULATIVE AFTERDISCHARGE AS THE PRINCIPAL FAQOR IN THE 
ACQUISITION OF KINDLED SEIZURES. 

002862 03-03 
POWER SPECTRAL ANALYSIS OF THE FLASH-EVOKED AFTERDISCHARGE. 

003133 03-06 
AFTERDISCHARGES 

INFLUENCE OF CARBAMAZEPINE ON THALAMOCORTICAL AND 
HIPPOCAMPOCORTICAL SELF-SUSTAINED AFTERDISCHARGES IN RATS. 

001356 02-03 
THE EFFECT OF ELECTRICAL-STIMULATION OF THE LOCUS-COERULEUS AND 
INTRAPERITONEAL INJECTION OF CERTAIN PHARMACOLOGICAL 
SUBSTANCES ON THE THRESHOLD OF HIPPOCAMPAL 
AFTERDISCHARGES. 

003885 04-03 
AFTEREFFECTS 

PERSONALITY AND DRUGS IN VISUAL FIGURAL AFTEREFFECTS. 

004581 04-14 
AG-3-5 

PHARMACOLOGICAL-ASPECTS OF SHAKING-BEHAVIOR PRODUCED BY 
TRH, AG-3-5, AND MORPHINE WITHDRAWAL. 

004248 04-04 



AGE 



AGE, DEMENTIA, DYSKINESIAS, AND LITHIUM RESPONSE. 

000594 01-09 
EFFECTS OF AGE AND OTHER DRUGS ON BENZODIAZEPINE KINETICS. 

000681 01-11 
EFFECT OF AGE AND ROUTE-OF-ADMINISTRATION ON LD50 OF LITHIUAA- 
CHLORIDE IN THE RAT. 

001413 02-03 



Ptychopharmacology Abstracts 

BIPOLAR AFFEaiVE-PSYCHOSIS WITH ONSET BEFORE AGE 16 YEARS: 
REPORT OF 10 CASES. ' 

002001 02-09 
OPEN-STUDY OF L 5 HTP IN MELANCHOLIC-DEPRESSED-PATIENTS OVER 
50 YEARS OF AGE. 

002016 02-09 
SPECIFIC 3H IMIPRAMINE BINDING IN HUMAN PLATELETS: INFLUENCE OF 
AGE AND SEX. 

002254 02-13 
CHANGES IN PREVALENCE, SEVERITY, AND RECOVERY IN TARDIVE- 
DYSKINESIA WITH AGE. 

002455 02-15 
AGE DEPENDENT CHANGES IN THE BETA ENDORPHIN CONTENT OF 
DISCRETE RAT-BRAIN NUCLEI. 

002635 03-01 
MIND/BRAIN IN THE AGE OF PSYCHOPHARMACOLOGY: A CROSSROADS 
FOR MEDICINE AND MINISTRY. 

003624 03-17 
PIRACETAM ACTIVITY MAY DIFFER ACCORDING TO THE AGE OF THE 
RECIPIENT MOUSE. 

003705 04-02 
EFFECTS OF AGE ON DOPAMINERGIC-SUPERSENSITIVITY INDUCED BY 
CHRONIC FLUPHENAZINE. 

003940 04-03 
EFFECTS OF ANIMAL AGE AND PHENOBARBITAL ON RAT LIVER GLUCOSE- 
6-PHOSPHATASE ACTIVITY 

003997 04-03 
EFFECTS OF ANISOMYCIN ON RETENTION OF THE PASSIVE-AVOIDANCE 
HABIT AS A FUNQION OF AGE. 

004097 04-04 
AGE-DEPENDENT 

AGE-DEPENDENT MODIFICATION OF DRUG INTERFERENCE ON THE 
ENZYMATIC ACTIVITIES OF THE RAT-BRAIN. 

003730 04-03 
AGE-RELATED 

AGE-RELATED ELECTROPHYSIOLOGICAL CHANGES IN RAT-CEREBELLUM. 

000197 01-03 
AGE-RELATED CHANGES IN BODY-TEMPERATURE RESPONSES TO 
MORPHINE IN RATS. 

001366 02-03 
AGE-RELATED FAQORS AFFEQING ANTIDEPRESSANT-DRUG METABOLISM 
AND CLINICAL-RESPONSE. 

002035 02-09 
CLINICAL PHARMACOKINETICS IN NEWBORNS AND INFANTS: AGE- 
RELATED DIFFERENCES AND THERAPEUTIC IMPLICATIONS 

003343 03-1 1 
PHARMACOTHERAPY FOR AGE-RELATED BEHAVIORAL-DEFICIENCIES. 

003391 03-11 
AGE-SPECIFIC 

AGE-SPECIFIC DOSES OF LORMETAZEPAM AS A NIGHT SEDATIVE IN 
CASES OF CHRONIC SLEEP-DISTURBANCE 

004309 04-07 

AGED 

ABILITY OF AGED RATS TO ALTER BETA-ADRENERGIC-RECEPTORS OF 
BRAIN IN RESPONSE TO REPEATED ADMINISTRATION OF RESERPINE 
AND DESMETHYLIMIPRAMINE. 

00011301-03 

DRUGS AND THE AGED. 

002593 02-17 

ALTERATIONS IN DIHYDROMORPHINE BINDING IN CEREBRAL 
HEMISPHERES OF AGED MALE RATS. 

003936 04-03 
PSYCHOPHARMACOTHERAPY OF SEXUAL-DISORDERS IN THE AGED. 

004466 04-11 

AN OVERVIEW OF PHARMACOLOGIC-TREATMENT OF COGNITIVE DECLINE 

IN THE AGED. 

004482 04-11 

PSYCHOPHARMACOLOGY FOR THE AGED. 

004701 04-17 

AGENT 

ADRENALINE: A SECRET AGENT IN MEMORY. 

002345 02-14 

AGES 

MORPHINE TREATMENT AT DIFFERENT INFANT AGES: INFLUENCE ON 
LATER MORPHINE EFFECTS IN RATS. (PH.D. DISSERTATION). 

000511 01-05 

AGGRAVATED 

A CASE OF PETIT-MAL EPILEPSY AGGRAVATED BY LITHIUM. 

004641 04-15 

AGGREGATED 

POSSIBLE MECHANISM FOR THE ENHANCED LETHALITY OF MORPHINE IN 
AGGREGATED MICE. 

000437 01-04 

AGGREGATES 

EFFEQS OF ISOPROTERENOL ON THE DEVELOPMENT OF BETA- 
ADRENERGIC-RECEPTORS IN BRAIN CELL AGGREGATES. 

002932 03-03 



S-10 



I 



mssmi^^^Mmm 



VOLUME 19, SUBJECT INDEX 



Subject Index 



AGGREGATION 

PLATELET AGGREGATION, 5 HYDROXYTRYPTAMINE UPTAKE AND 
RELEASE IN HUNTINGTONS-CHOREA. 

002112 02-11 
CANALIZATION OF AROUSAL IN THE PREWEANLING RAT; EFFECTS OF 
AMPHETAMINE ON AGGREGATION WITH SURROGATE STIMULI. 

002965 03-04 
SELECTIVE INHIBITORY-EFFECTS OF CHLORPROMAZINE AND IMIPRAMINE 
ON PLATELET AGGREGATION. 

004518 04-13 
AGGRESSION 

ALCOHOL AND CHLORDIAZEPOXIDE INCREASE SUPPRESSED AGGRESSION 
IN MICE. 

000434 01-04 
PSYCHOPHARMACOLOGY OF AGGRESSION. 

000721 01-11 
PSYCHOPHARMACOLOGY OF AGGRESSION. 

000995 01-17 
COMPARATIVE-STUDY OF AGGRESSIVE-BEHAVIOUR AFTER INJECTION OF 
CHOLINOMIMETICS, ANTICHOLINESTERASES, NICOTINIC, AND 
MUSCARINIC GANGLIONIC STIMULANTS INTO THE CEREBRAL 
VENTRICLES OF CONSCIOUS CATS: FAILURE OF NICOTINIC-DRUGS TO 
EVOKE AGGRESSION. 

001568 02-04 
NALOXONE PRETREATMENT ENHANCES SHOCK-ELICITED AGGRESSION. 

001615 02-04 
AN IMPROVED MODEL OF INTRASPECIFIC AGGRESSION: DOSE-RESPONSE 
ANALYSIS OF APOMORPHINE-INDUCED-FIGHTING AND STEREOTYPY IN 
THE RAT. 

002983 03-04 
DRUG REGIMENS FACILITATING AGGRESSION: BEHAVIOR, AMINE, AND 
RECEPTOR ALTERATIONS. 

002987 03-04 
AGGRESSION ALTERING EFFECTS OF CYCLIC-AMP. 

003021 03-04 
LITHIUM AND PORCINE AGGRESSION. 

003048 03-04 
PHARMACOLOGICAL EVIDENCE FOR CATECHOLAMINE INVOLVEMENT IN 
ANIMAL AGGRESSION. 

003052 03-04 
FACILITATED SHOCK-INDUCED AGGRESSION AFTER CHRONIC-TREATMENT 
WITH ANTIDEPRESSANT-DRUGS IN THE RAT. 

003058 03-04 
FAILURE TO FIND SEX-DIFFERENCES IN TESTOSTERONE ACTIVATED 
AGGRESSION IN TWO STRAINS OF RATS. 

003107 03-04 
PHARMACOLOGICAL EVIDENCE FOR CATECHOLAMINE INVOLVEMENT IN 
ANIMAL AGGRESSION. 

003140 03-06 
ERGOT DRUGS SUPPRESS PLASMA PROLACTIN AND LACTATION BUT NOT 
AGGRESSION IN PARTURIENT MICE. 

003159 03-07 
PRENATAL EXPOSURE TO SYNTHETIC PROGESTINS INCREASES POTENTIAL 
FOR AGGRESSION IN HUMANS. 

003527 03-15 
ACETYLCHOLINE TURNOVER AND AGGRESSION IN RELATED THREE 
STRAINS OF MICE. 

AGGRESSIVE ""'''' ''-'' 

BICUCULLINE ANTAGONIZES EFFECTS OF DIAZEPAM ON AGGRESSIVE AND 
TIMID-BEHAVIOUR IN MICE. 

000485 01-04 
COMPARISON OF SCH-12679 AND THIORIDAZINE IN AGGRESSIVE 
MENTAL-RETARDATES. 

002119 02-11 
LITHIUM THERAPY IN AGGRESSIVE MENTALLY-SUBNORMAL-PATIENTS. 

MOLINDONE-HYDROCHLORIDE IN THE TREATMENT OF AGGRESSIVE 

HOSPITALIZED CHILDREN. 

003321 03-1 1 
EFFECTS OF LITHIUM-CARBONATE AND HALOPERIDOL ON COGNITION IN 

AGGRESSIVE, HOSPITALIZED SCHOOL-AGE CHILDREN. 

EFFECTS OF LITHIUM-CARBONATE AND HALOPERIDOL ON COGNITION IN 
AGGRESSIVE HOSPITALIZED SCHOOL-AGE CHILDREN. 

POSSIBLE MUSCARINIC CHOLINERGIC MEDIATION OF PATTERNED 
AGGRESSIVE REFLEXES IN THE CAT. 

AGGRESSIVE-BEHAVIOR 004153 04-04 

ROLE OF BRAIN DOPAMINERGIC MECHANISMS IN RODENT AGGRESSIVE- 
BEHAVIOR: INFLUENCE OF ( OR -)N N PROPYLNORAPOMORPHINE ON 
THREE EXPERIMENTAL MODELS. 

EFFECTS OF SODIUM-DIPROPYLACETATE, MUSCIMOL-HYDROBROMIDE 
AND (R,S) NIPECOTIC-ACID-AMIDE ON ISOLATION-INDUCED 
AGGRESSIVE-BEHAVIOR IN MICE. 

INHIBITION OF AGGRESSIVE-BEHAVIOR IN RHESUS-MONKEYS BY '°'' 

BUSPIRONE. 

003103 03-04 



AGGRESSIVE-BEHAVIOR INDUCED BY APOMORPHINE IN RATS SUBMinED 
TO FOUR STRESSFUL-SITUATIONS, 

003163 03-07 
LITHIUM AND AGGRESSIVE-BEHAVIOR. 

004409 04-09 
AGGRESSIVE-BEHAVIOUR 

COMPARATIVE-STUDY OF AGGRESSIVE-BEHAVIOUR AFTER INJECTION OF 
CHOLINOMIMETICS, ANTICHOLINESTERASES, NICOTINIC, AND 
MUSCARINIC GANGLIONIC STIMUUNTS INTO THE CEREBRAL 
VENTRICLES OF CONSCIOUS CATS: FAILURE OF NICOTINIC-DRUGS TO 
EVOKE AGGRESSION. 

001568 02-04 
AGGRESSIVE-BEHAVIOURAL-PHENOMENA 

THE PHARMACOLOGY OF AGGRESSIVE-BEHAVIOURAL-PHENOMENA 
ELICITED BY MUSCARINE INJECTED INTO THE CEREBRAL VENTRICLES OF 
CONSCIOUS CATS. 

001569 02-04 
AGGRESSIVE-PATIENT 

ACUTE MANAGEMENT OF THE VIOLENT AGGRESSIVE-PATIENT. 

000586 01-09 
AGING 

SERUM PROLACTIN DURING AGING AND THE EFFECTS OF ERGOTS. 

001171 02-03 
BRAIN CATECHOLAMINES, MENTAL-ILLNESSES, AGING AND SENILE- 
DEMENTIA: BIOCHEMICAL-CONSIDERATIONS AND PHARMACOLOGICAL- 
CONSIDERATIONS. 

001550 02-03 
PSYCHOPHARMACOLOGY OF THE AGING. 

002142 02-11 
NEUROPSYCHIATRIC SIDE-EFFECTS OF DRUGS IN THE ELDERLY. VOL 9 
AGING. 

002573 02-17 
THE PSYCHOBIOLOGY OF AGING. 

003861 04-03 
MEMORY, OPIATE-RECEPTORS, AND AGING. 

004143 04-04 
PSYCHOPHARMACOLOGY OF AGING. 

004710 04-17 
AGITATED 

TREATMENT OF TARDIVE-DYSKINESIA IN AN AGITATED DEPRESSED- 
PATIENT. 

002038 02-09 
AGITATION 

AGITATION, DISORIENTATION, AND HALLUCINATIONS IN PATIENTS ON 
CIMETIDINE: A REPORT OF THREE CASES AND LITERATURE REVIEW. 

000896 01-15 
AGONIST 

CLENBUTEROL, A CENTRAL BETA-ADRENOCEPTOR AGONIST. 

000120 01-03 
DIFFERENTIAL REGULATION OF MUSCARINIC AGONIST BINDING-SITES 
FOLLOWING CHRONIC CHOLINESTERASE INHIBITION. 

000279 01-03 
INTRAVENOUS GABA AGONIST ADMINISTRATION STIMULATES FIRING OF 
AlO DOPAMINERGIC NEURONS. 

000320 01-03 
TRANSIENT ABOLITION OF GENERALIZED PHOTOSENSITIVE EPILEPTIC- 
DISCHARGE IN HUMANS BY APOMORPHINE, A DOPAMINE-RECEPTOR 
AGONIST. 

000714 01-11 
EFFECT OF THE NEW GAMMA AMINOBUTYRIC-ACID AGONIST SL-76-002 
ON STRIATAL ACETYLCHOLINE: RELATION TO NEUROLEPTIC-INDUCED 
EXTRAPYRAMIDAL ALTERATIONS. 

001119 02-03 
EFFECT OF GABA AGONIST AND ANTAGONISTS ON CARDIOVASCULAR 
AND SYMPATHETIC RESPONSES IN SHR AND WKY RATS. 
(UNPUBLISHED PAPER). 

001224 02-03 
THE AFFINITIES OF ERGOT COMPOUNDS FOR DOPAMINE AGONIST AND 
DOPAMINE ANTAGONIST RECEPTOR SITES. 

001254 02-03 
UNITARY DOPAMINERGIC-RECEPTOR COMPOSED OF COOPERATIVELY 
LINKED AGONIST AND ANTAGONIST SUBUNIT BINDING-SITES. 

001342 02-03 
BENZODIAZEPINES MODIFY THE AGONIST RESPONSES AT A PRESYNAPTIC 
GABA-RECEPTOR. 

001377 02-03 
SOME CENTRAL-EFFECTS OF IMPROMIDINE, A POTENT AGONIST OF 
HISTAMINE H2-RECEPT0RS. 

001417 02-03 
ACTIONS OF ENKEPHALIN, MU AND PARTIAL AGONIST ANALGESICS ON 
ACETYLCHOLINE TURNOVER IN RAT-BRAIN. 

001541 02-03 
ACTIVATION AND LATERALIZATION OF SENSORIMOTOR FIELD FOR 
PERIORAL BITING-REFLEX BY INTRANIGRAL GABA AGONIST AND BY 
SYSTEMIC APOMORPHINE IN THE RAT. 

001657 02-04 



1? 

it 



S-11 



Subject Index 

MORPHINE ANALGESIA AFTER INTRATHECAL ADMINISTRATION OF A 
NARCOTIC AGONIST, CHLOROXYMORPHAMINE AND ANTAGONIST, 
CHLORNALTREXAMINE. 001695 02-04 

PHENCYCLIDINE AS AN INDIRECT DOPAMINE AGONIST. 

001719 02-04 
NEUROCHEMICAL EVIDENCE AND BEHAVIORAL-EVIDENCE FOR A 
SELECTIVE PRESYNAPTIC DOPAMINE-RECEPTOR AGONIST. 

002236 02-13 
PERGOLIDE A POTENT LONG-ACTING DOPAMINE-RECEPTOR AGONIST. 

002257 02-13 
DOPAMINE ANTAGONIST AND AGONIST TREATMENT OF TARDIVE- 

■^^^^'^^^'^ 002377 02-15 

PIPERIDINE-4-SULPHONIC-ACID, A NEW SPECIFIC GABA AGONIST. 

002647 03-02 
EFFECT OF KAINIC-ACID LESIONS ON MUSCARINIC AGONIST RECEPTOR 

SUBTYPES IN RAT STRIATUM. 002679 03-03 

DIFFERENTIAL REGULATION BY GUANINE-NUCLEOTIDES OF OPIATE 
AGONIST AND ANTAGONIST RECEPTOR INTERACTIONS. 

002688 03-03 
CHRONOLOGY OF NEUROCHEMICAL ALTERATIONS INDUCED BY GABA 

AGONIST ADMINISTRATION. 002713 03-03 

PROPERTIES OF DOPAMINE AGONIST AND ANTAGONIST BINDING-SITES IN 
MAMMALIAN RETINA. 002814 03-03 

THE NEUROLATHYROGEN, BETA N OXALYL-L-ALPHA-BETA- 

DIAMINOPROPIONIC-ACID, IS A POTENT AGONIST AT GLUTAMATE 
PREFERRING RECEPTORS IN THE FROG SPINAL-CORD. 

002858 03-03 
DOPAMINERGIC AGONIST AND ANTAGONIST EFFECTS ON STRIATAL 
TYROSINE-HYDROXYLASE DISTRIBUTION. „„.„„„ „, „, 

002898 03-03 
EFFECTS OF ACUTE OR CHRONIC ADMINISTRATION OF LOW-DOSES OF A 
DOPAMINE AGONIST ON DRINKING AND LOCOMOTOR-ACTIVITY IN THE 
RAT 

002982 03-04 

CLINICAL-PHARMACOLOGY OF MIXED AGONIST ANTAGONIST DRUGS. 

003329 03-1 1 
MORPHICEPTIN (NH4-TYR-PR0-PHE-PR0-C0NH2). A POTENT AND 
SPECIFIC AGONIST FOR MORPHINE MU-RECEPTORS. 

003746 04-03 
RESPONSE OF STRIATONIGRAL SUBSTANCE-P SYSTEMS TO A DOPAMINE- 
RECEPTOR AGONIST AND ANTAGONIST. 

003826 04-03 
ON THE IMPORTANCE OF AGONIST CONCENTRATION GRADIENTS WITHIN 
ISOLATED TISSUES. INCREASED MAXIMAL RESPONSES OF RAT VASA- 
DEFERENTIA TO (-) NORADRENALINE AFTER BLOCKADE OF NEURONAL 

^^'"^^^- 003879 04-03 

BINDING OF (3H) MUSCIMOL, A POTENT GAMMA AMINOBUTYRIC-ACID- 
RECEPTOR AGONIST, TO MEMBRANES OF THE BOVINE RETINA 

003954 04-03 
AaiONS OF MU KAPPA, SIGMA, DELTA AND AGONIST/ANTAGONIST 
OPIATES ON STRIATAL DOPAMINERGIC FUNCTION 

004053 04-03 
HYPERACTIVITY FOLLOWING INJEQION OF A GLUTAMATE AGONIST AND 
6,7 ADTN INTO RAT NUCLEUS-ACCUMBENS AND ITS INHIBITION BY 
THIP 

004066 04-04 
PHARMACOLOGICAL-STUDIES WITH AN ALKYLATING NARCOTIC 
AGONIST, CHLOROXYMORPHAMINE, AND ANTAGONIST, 

CHLORNALTREXAMINE „„„„.„.„. 

004082 04-04 

AGONIST-INDUCED 

AGONIST-INDUCED CHANGES IN BETA-ADRENERGIC-RECEPTOR DENSITY 
AND RECEPTOR-MEDIATED RESPONSIVENESS IN SLICES OF RAT- 
CEREBRAL-CORTEX. ^„,„ „, „„ 

000072 01-03 

AGONIST-MEDIATED 

SPINAL-CORD PHARMACOLOGY OF ADRENERGIC AGONIST-MEDIATED 

ANTINOCICEPTION. „ „^ „^ 

004206 04-04 

AGONISTIC-BEHAVIOUR 

EFFECTS OF SCOPOLAMINE ON AGONISTIC-BEHAVIOUR IN MICE. 

001690 02-04 

EFFECT OF PIRACETAM ON AGONISTIC-BEHAVIOUR IN MICE. 

001796 02-04 

AGONISTS 

EFFECTS OF DOPAMINERGIC AGONISTS AND ANTAGONISTS ON 

(3H)AP0M0RPHINE BINDING TO STRIATAL MEMBRANES: SULPIRIDE 
LACK OF INTERACTIONS WITH POSITIVE COOPERATIVE 

(3H)AP0M0RPHINE BINDING. „„„„„„ „, „o 

000099 01-03 

COMPARTMENT ATION OF CATECHOLAMINES IN RAT-BRAIN: EFFECTS OF 

AGONISTS AND ANTAGONISTS. 000125 01-03 



Ptychopharmacology Abstracts 



REDUaiON IN THE NUMBER OF SEROTONIN-RECEPTORS IN THE 

BRAINSTEM OF MORPHINE-DEPENDENT RATS: RELATION TO BLOCKADE 
OF NALOXONE PRECIPITATED JUMPING BY SEROTONIN AGONISTS. 

000258 01-03 

EFFECTS OF NORADRENERGIC AGONISTS AND ANTAGONISTS ON 
GROWTH-HORMONE SECRETION UNDER GAMMA HYDROXYBUTYRATE 
NARCOANALGESIA IN THE RAT. 

000262 01-03 

MONOAMINE REPLACEMENT AFTER RESERPINE: CATECHOLAMINERGIC 
AGONISTS RESTORE MOTOR-AQIVITY BUT PHENYLETHYLAMINE 
RESTORES ATROPINE-RESISTANT NEOCORTICAL LOW VOLTAGE FAST- 

'''''"' 000309 01-03 

ON THE CAPACITY OF PRESYNAPTIC ALPHA-RECEPTORS TO MODULATE 
NOREPINEPHRINE RELEASE FROM SLICES OF RAT NEOCORTEX AND THE 
AFFINITY OF SOME AGONISTS AND ANTAGONISTS FOR THESE 

'''''''''' 000323 01-03 

NORADRENERGIC AGONISTS AND ANTAGONISTS: EFFECTS ON 

CONDITIONED FEAR AS MEASURED BY THE POTENTIATED STARTLE 

PARADIGM „„„^,^„, „. 

000372 01-04 

AHEMPTS TO REINSTATE LORDOSIS REFLEX IN ESTROGEN-PRIMED 

SPINAL FEMALE RATS WITH MONOAMINE AGONISTS. 

000421 01-04 
ROTATION INDUCED BY INTRANIGRAL INJECTIONS OF GABA AGONISTS 

AND ANTAGONISTS: ZONE-SPECIFIC EFFEaS. 

000422 01-04 
PSYCHIATRIC MANIFESTATIONS INDUCED BY DOPAMINE PRECURSORS OR 

DOPAMINE AGONISTS. 

000865 01-15 
GUANINE-NUCLEOTIDES INHIBIT BINDING OF AGONISTS AND 
ANTAGONISTS TO SOLUBLE OPIATE-RECEPTORS. (UNPUBLISHED 

^"^^^^ 001035 02-01 

GABA AGONISTS AND UPTAKE INHIBITORS DESIGNED AS AGENTS WITH 

IRREVERSIBLE AQIONS ,„ „o «n 

001079 02-02 
GAMMA AMINOBUTYRIC-ACID AGONISTS: AN IN VITRO COMPARISON 

BETWEEN DEPRESSION OF SPINAL SYNAPTIC AQIVITY AND 

DEPOLARIZATION OF SPINAL ROOT FIBRES IN THE RAT 

001104 02-03 
INTRACELLULAR OBSERVATIONS ON THE EFFEQS OF MUSCARINIC 

AGONISTS ON RAT SYMPATHETIC NEURONES. 

001143 02-03 
EFFEQS OF ALPHA-ADRENOCEPTOR AGONISTS AND ANTAGONISTS AND 

OF ANTIDEPRESSANT-DRUGS ON PRESYNAPTIC AND POSTSYNAPTIC 

ALPHA-ADRENOCEPTORS. 001146 02-03 

A PROPOSED MODE OF AQION FOR NARCOTIC AGONISTS AND 

^^'^^^^^^'^ 001168 02-03' 

DOPAMINERGIC-SUPERSENSITIVITY: INFLUENCE OF DOPAMINE AGONISTS 

AND DRUGS USED FOR THE TREATMENT OF TARDIVE-DYSKINESIA 

001169 02-03 
REGIONAL RELEASE OF (3H)ADEN0SINE DERIVATIVES FROM RAT-BRAIN 

IN VIVO EFFEa OF EXCITATORY AMINO-ACIDS, OPIATE AGONISTS, 

AND BENZODIAZEPINES. 001303 02-03 

AHEMPTS TO DEVELOP SUPERSENSITIVITY OR SUBSENSITIVITY RETINAL 

DOPAMINE-RECEPTORS ARER VARIOUS TREATMENTS WITH 

ANTAGONISTS OR AGONISTS. 001350 02-03 

PRESYNAPTIC AND POSTSYNAPTIC MECHANISMS IN HALOPERIDOL- 
INDUCED SENSITIZATION TO DOPAMINERGIC AGONISTS. 

DECREASE IN (3H) SEROTONIN BINDING IN RAT-BRAIN PRODUCED BY THE 
REPEATED ADMINISTRATION OF EITHER MONOAMINE-OXIDASE- 
INHIBITORS ON CENTRALLY-AQING SEROTONIN AGONISTS^ , , „o n, 

001463 02-03 

GABA AGONISTS DISSOCIATE STRIATAL UNIT AQIVITY FROM DRUG- 
INDUCED STEREOTYPED-BEHAVIOUR. ^^^^^ ^^^ 

DORSAL TEGMENTAL BUNDLE DESTRUCTION: EFFEQS ON OPERANT- 
BEHAVIOR BRAIN CATECHOLAMINE LEVELS, AND BEHAVIORAL- 
SUPPRESSION PRODUCED BY ADRENERGIC AGONISTS. 

CIRCLING PRODUCED BY SEROTONIN AND DOPAMINE AGONISTS IN 
RAPHE LESIONED RATS: A SEROTONIN MODEL. ^^^^^ ^^^ 

EFFEQS OF INTRAPALLIDAL OPIATE-RECEPTOR AGONISTS ON 
STRIATALLY-EVOKED HEAD-TURNING. ^^^^^ ^^^ 

BEHAVIORAL-EFFECTS OF DOPAMINE AGONISTS ACROSS THE ESTROUS- 
CYCLEINRATS. 001792 02^ 

DISCRIMINATIVE-STIMULUS EFFEQS OF PROTOTYPE OPIATE-RECEPTOR 
AGONISTS IN MONKEYS 001803 02-(W 



S-12 



1 



OLUME 19, SUBJECT INDEX 



Subject Index 



COMPARISON OF OPIATE AGONISTS AND THEIR N ALLYL DERIVATIVES IN 
THE PRODUCTION OF PHYSICAL-DEPENDENCE IN THE RAT. 

001841 02-05 
THE ROLE OF DIFFERENTIAL BLOCKADE OF ALPHA-ADRENERGIC AGONISTS 
IN CHLORPROMAZINE-INOUCEO HYPOTENSION. 

001851 02-05 
ANTIPSYCHOTIC-PROPERTIES AND ANTIDYSKINETIC-PROPERTIES OF 
ERGOT DOPAMINE AGONISTS. 

002178 02-11 
DOPA AND DOPAMINE AGONISTS IN DEPRESSION. 

002310 02-13 
TARDIVE-HYPERKINESIA. EFFECTS OF SULPIRIDE AND GABA SYSTEM 
AGONISTS. 

002405 02-15 
AN OBSERVATIONAL METHOD FOR QUANTIFYING THE BEHAVIOURAL- 
EFFEQS OF DOPAMINE AGONISTS: CONTRASTING-EFFECTS OF D- 
AMPHETAMINE AND APOMORPHINE. 

002484 02-16 
HETEROGENEOUS DEPRESSION OF GLUCOSE UTILIZATION IN THE 
CAUDATE-NUCLEUS BY GABA AGONISTS. 

002640 03-01 
EFFECTS OF ELECTROCONVULSIVE-TREATMENT ON GROWTH-HORMONE 
SECRETION INDUCED BY MONOAMINE-RECEPTOR AGONISTS IN 
RESERPINE PRETREATED RATS. 

002664 03-03 
A COMPARISON OF THE CONTRACTILE RESPONSES OF THE RABBIT 
BASILAR AND PULMONARY-ARTERIES TO SYMPATHOMIMETIC 
AGONISTS: CHARACTERISTICS. 

002670 03-03 
GABA-AUTORECEPTORS: STRUCTURE-ACTIVITY RELATIONSHIPS FOR 
AGONISTS. 

002678 03-03 
GABA AGONISTS AS ANTIEPILEPTIC-AGENTS. 

002826 03-03 
ESTROGEN POTENTIATES THE STEREOTYPY INDUCED BY DOPAMINE 
AGONISTS IN THE RAT. 

002968 03-04 
INFLUENCE OF THE DOPAMINERGIC AGONISTS BROMOCRIPTINE, PIRIBEDIL 
AND NOMIFENSINE ON THE SYMPATHETIC NEURAL TRANSMISSION IN 
THE NICTITATING MEMBRANE OF THE CAT. 

003822 04-03 
DOPAMINERGIC MECHANISMS IN THE TELEOST RETINA. I. DOPAMINE- 
SENSITIVE ADENYLATE-CYCLASE IN HOMOGENATES OF CARP RETINA, 
EFFECTS OF AGONISTS, ANTAGONISTS AND ERGOTS. 

004051 04-03 
A COMPARISON OF THE RESPONSES TO SOME DOPAMINE-RECEPTOR 
AGONISTS AND ANTAGONISTS IN THE ISOLATED PERFUSED RAT 
KIDNEY. 

004054 04-03 
GENETIC VARIATIONS IN MIDBRAIN DOPAMINE CELL NUMBER: PARALLEL 
WITH DIFFERENCES IN RESPONSES TO DOPAMINERGIC AGONISTS AND 
IN NATURALISTIC BEHAVIORS MEDIATED BY CENTRAL DOPAMINERGIC- 
SYSTEMS. (UNPUBLISHED PAPER). 

004112 04-04 
INTERAQIONS BETWEEN NARCOTIC AGONISTS, PARTIAL AGONISTS AND 
ANTAGONISTS EVALUATED BY SCHEDULE-CONTROLLED BEHAVIOR. 

004127 04-04 
DOPAMINERGIC AGONISTS DIFFERENTIALLY AFFECT OPEN-FIELD ACTIVITY 
OF RATS WITH AlO LESIONS. 

004135 04-04 
MINI-SYMPOSIUM: III. SIMPLE IN VIVO TESTS THAT DIFFERENTIATE 
PROTOTYPE AGONISTS AT OPIATE-RECEPTORS. 

004289 04-06 
SPECIFIC GABA-RECEPTOR AGONISTS AND UPTAKE INHIBITORS: DESIGN, 
DEVELOPMENT AND STRUCTURE-ACTIVITY STUDIES. 

004725 04-17 
iRANULOCYTOSIS 
MIANSERIN: A POSSIBLE CAUSE OF NEUTROPENIA AND 
AGRANULOCYTOSIS. 

003517 03-15 
A CASE OF ACUTE AGRANULOCYTOSIS DURING TREATMENT WITH 
CLOZAPINE. 

004642 04-15 
MS 

LONG-TERM CHANGES IN AIMS RATINGS AND THEIR RELATION TO 
MEDICATION HISTORY. 

003537 03-15 
RCRAFT 

AIRCRAFT NOISE AND MENTAL-HEALTH: II. USE OF MEDICINES AND 
HEALTH-CARE-SERVtCES. 

003647 03-17 
CINESIA 
IMPORTANCE OF AKINESIA: PLASMA CHLORPROMAZINE AND PROLACTIN 
LEVELS. 

000891 01-15 
PARADOXICAL AKINESIA INDUCED BY ANTIDEPRESSANT-DRUGS 

002378 02-15 



AKINETON 

A COMPARISON OF BIPERIDEN-HYDROCHLORIDE (AKINETON) AND 
BENZHEXOL (ARTANE) IN THE TREATMENT OF DRUG-INDUCED 
PARKINSONISM. 

002146 02-11 
ALANINE 

LOCALIZATION OF SENSITIVE SITES TO TAURINE, GAMMA 
AMINOBUTYRIC-ACID, GLYCINE AND BETA ALANINE IN THE 
MOLECULAR LAYER OF GUINEA-PIG CEREBELLAR SLICES. 

001402 02-03 
MODULATORY INTERACTIONS BETWEEN NOREPINEPHRINE AND TAURINE, 
BETA ALANINE, GAMMA AMINOBUTYRIC-ACID AND MUSCIMOL 
APPLIED lONTOPHORETICALLY TO CEREBELLAR PURKINJE-CELLS. 

004058 04-03 
ALA2-MET-ENKEPHALINAMIDE 

SELF-ADMINISTRATION OF D ALA2-MET-ENKEPHALINAMIDE AT 
HYPOTHALAMIC SELF-STIMULATION SITES. 

001738 02-04 
ALA2-METHIONINE-ENKEPHALIN 

DIFFERENCE IN THE DEVELOPMENT OF TOLERANCE TO MORPHINE AND D 
ALA2-METHI0NINE-ENKEPHALIN IN C57 BL/6J AND DBA/2J MICE. 

003126 03-05 
ALA2-METHIONINE-ENKEPHALINAMIDE 

ELECTROENCEPHALOGRAPHIC AND BEHAVIORAL-TOLERANCE TO AND 
CROSS-TOLERANCE BETWEEN D ALA2-METHI0NINE-ENKEPHALINAMIDE 
AND MORPHINE IN THE RAT. 

004038 04-03 
ALA2-MET5-ENKEPHALINAMIDE-INDUCED 

NALOXONE REVERSIBLE EFFECTS OF D ALA2-MET5-ENKEPHALINAMIDE- 
INDUCED BEHAVIORAL-ACTIVITY IN RATS. 

000402 01-04 
ALBINO 

THE ALBINO LOCUS PRODUCES ABNORMAL RESPONSES TO OPIATES IN 
THE MOUSE. 

001675 02-04 
ALBINO-RATS 

INFERENCES DERIVED FROM ELECTROENCEPHALOGRAPHIC RESPONSES TO 
ACUTE ADMINISTRATION OF CLOMIPHENE-CITRATE IN MALE ALBINO- 
RATS. 

000155 01-03 
ALBUMIN 

EFFECTS OF LEAD ON MOVEMENT OF ALBUMIN INTO BRAIN. 

000076 01-03 
ALBUMIN BINDING INTERACTIONS OF SODIUM-VALPROATE. 

000762 01-13 
THE CONTRIBUTION OF ALPHA 1 ACID GLYCOPROTEIN, LIPOPROTEINS, 
AND ALBUMIN TO THE PLASMA BINDING OF PERAZINE, 
AMITRIPTYLINE, AND NORTRIPTYLINE IN HEALTHY MAN. 

002214 02-13 
EFFECTS OF ALBUMIN, AMINO-ACIDS, AND CLOFIBRATE ON THE UPTAKE 
OF TRYPTOPHAN BY THE RAT-BRAIN. 

002673 03-03 
ALCOHOL 

ALCOHOL AND CHLORDIAZEPOXIDE INCREASE SUPPRESSED AGGRESSION 
IN MICE. 

000434 01-04 
IN UTERO ALCOHOL HEIGHTENS JUVENILE REACTIVITY. 

000510 01-05 
PHARMACOPSYCHOLOGICAL INVESTIGATION OF CHANGES IN MOOD 
INDUCED BY DIPOTASSIUM-CHLORAZEPATE WITH AND WITHOUT 
SIMULTANEOUS ALCOHOL ADMINISTRATION. 

000825 01-14 
INFLUENCE OF CHRONIC ALCOHOL INTOXICATION ON CIRCADIAN-RHYTHM 
OF NEUROSECRETORY CENTERS OF RAT HYPOTHALAMUS. 

001549 02-03 
POSTNATAL ALCOHOL EXPOSURE IN THE RAT: ITS EFFECTS ON 
AVOIDANCE CONDITIONING, HEBB-WILLIAMS MAZE-PERFORMANCE, 
MATERNAL-BEHAVIOR, AND PUP DEVELOPMENT. 

001580 02-04 
ACTION OF TOFISOPAM ON THE ERGONOMIC VIGILANCE LEVEL. ITS 
INTERACTION WITH THE EFFECTS OF ALCOHOL. CLINICAL 
PHARMACOLOGICAL-STUDY . 

001891 02-07 
SODIUM-VALPROATE IN THE TREATMENT OF ALCOHOL WITHDRAWAL- 
SYNDROME. 

002)39 02-11 
USE OF INJECTABLE LORAZEPAM IN ALCOHOL WITHDRAWAL. 

002176 02-11 
THE EFFECTS OF ALCOHOL AND CAFFEINE ON CONCENTRATION TEST 
PERFORMANCE. 

002337 02-14 
ALCOHOL WITHDRAWAL-SYNDROME: TREATMENT WITH TRAZODONE. 

002356 02-14 
EFFECTS OF LITHIUM, AND LITHIUM AND ALCOHOL ADMINISTRATION ON 
NA-K-ATPASE. 

002744 03-03 
COMBINED EFFECTS OF ALCOHOL AND LITHIUM ON BODY COMPOSITION 
IN THE RAT MODEL. 

002928 03-03 



it 



S-13 



Subject Index 



Psychopharmacoiogy Abstracts 



PINEAL-GLAND AND MELATONIN INFLUENCE ON CHRONIC ALCOHOL 
CONSUMPTION BY HAMSTERS. 

003076 03-04 
ALCOHOL WITHDRAWAL USING TIAPRIDE: QUANTITATIVE 
PSYCHOPATHOLOGY. 

003293 03-11 
DOUBLE-BUND COMPARISON OF ALPRAZOLAM AND DIAZEPAM FOR 
SUBCHRONIC WITHDRAWAL FROM ALCOHOL. 

003332 03-11 
SMOOTH-PURSUIT EYE-MOVEMENTS: EFFECTS OF ALCOHOL AND 
CHLORAL-HYDRATE. 

003448 03-14 
INTERACTIONS BETWEEN ALCOHOL AND MEDICATIONS. 

003629 03-17 
SUPPRESSION OF ALCOHOL DRINKING WITH BRAIN ALDEHYDE- 
DEHYDROGENASE INHIBITION. 

004220 04-04 
MEMORY: THE EFFECTS OF ALCOHOL AND OF MARIHUANA. 

004570 04-14 
DRUGS, ALCOHOL AND SEX. 

004706 04-17 
ALCOHOL-DEHYDROGENASE 

INHIBITION OF ALCOHOL-DEHYDROGENASE BY DISULFIRAM, POSSIBLE 
RELATION TO THE DISULFIRAM ETHANOL REACTION. 

000270 01-03 
ALCOHOLIC 

ADVANTAGE OF MONOTHERAPY WITH CLOBAZAM IN THE TREATMENT 
AND POSHREATMENT OF ALCOHOLIC WITHDRAWAL. 

002140 02-11 
TRIAL OF A PEPTIDE FRACTION OF ACTH (ACTH4-10) IN THE ALCOHOLIC 
BRAIN-DAMAGE-SYNDROME. 

002318 02-14 
CLINICAL PHARMACOKINETICS OF CHLORDIAZEPOXIDE IN PATIENTS WITH 
ALCOHOLIC HEPATITIS. 

004473 04-1 1 
DISULFIRAM AND NOCTURNAL PENILE-TUMESCENCE IN THE CHRONIC 
ALCOHOLIC. 

004556 04-13 
TRICYCLIC-ANTIDEPRESSANTS AND ALCOHOLIC BLACKOUTS. 

004617 04-15 
BEHAVIOR AND LEARNING DIFFICULTIES IN CHILDREN OF NORMAL 
INTELLIGENCE BORN TO ALCOHOLIC MOTHERS. 

004658 04-15 
ALCOHOLIC-DELIRIUM 

CHOICE OF TACTICS IN TREATING ALCOHOLIC-DELIRIUM. 

000688 01-11 
ALCOHOLIC-PATIENTS 

SALIVA BENZODIAZEPINE LEVELS AND CLINICAL OUTCOME IN 
DETOXIFYING ALCOHOLIC-PATIENTS. 

004671 04-16 
ALCOHOLICS 

CONCENTRATION OF SEROTONIN METABOLITES IN THE CEREBROSPINAL- 
FLUID FROM ALCOHOLICS BEFORE AND DURING SULFIRAM THERAPY. 

002095 02-1 1 
SEXUAL-DIFFICULTIES AMONG CONVALESCING ALCOHOLICS: INTEREST IN 
PRAZEPAM TREATMENT IN 30 CASES. 

003296 03-11 
ALCOHOLISM 

TOFIZOPAM IN THE TREATMENT OF CHRONIC ALCOHOLISM. 

000706 01-11 
POSSIBILITIES OF INFLUENCE ON THE ORGANIC-PSYCHOSYNDROME WITH 

NOOTROPIC-DRUGS IN CHRONIC ALCOHOLISM. 

000707 01-11 
A POSSIBLE ECOPHARMACOGENETIC MODEL IN 

NEUROPSYCHOPHARMACOLOGY ASPECTS IN ALCOHOLISM AND 
PHARMACODEPENDENCE. 

002596 02-17 
ACTION ON THE EMOTIONALLY-REINFORCED BRAIN SYSTEM AS A MEANS 
OF TREATING ALCOHOLISM AND DRUG ADDiaiON 
PATHOGENETICALLY. 

003641 03-17 
ALDEHYDE-OEHYDROGENASE 

SUPPRESSION OF ALCOHOL DRINKING WITH BRAIN ALDEHYDE- 
DEHYDROGENASE INHIBITION. 

004220 04-04 
ALDOSTERONE 

RENIN AND ALDOSTERONE SECRETIONS DURING HYPOVOLEMIA IN RATS: 
RELATION TO NACL INTAKE. 

000484 01-04 
ALERTING 

CHANGES IN THE HORIZONTAL VESTIBULO-OCULAR REFLEX OF THE 
RHESUS-MONKEY WITH BEHAVIORAL AND PHARMACOLOGICAL 
ALERTING. 

002997 03-04 
ALEXIA 

REVERSIBLE ALEXIA, MITOCHONDRIAL MYOPATHY, AND LACTIC- 
ACIDEMIA. 

000723 01-11 



ALGORITHMS 

PHENCYCLIDINE (PCP) INTOXICATION: DIAGNOSIS IN STAGES AND 
ALGORITHMS OF TREATMENT. 

003525 03-15 
ALIMENTARY 

INTRAHYPOTHALAMIC MICROINJECTIONS OF NORADRENALINE WITH AND 
WITHOUT INDUCTION OF THE ALIMENTARY DRIVE AS A REWARD IN A 
T-MAZE LEARNING IN RATS. 

001604 02-04 
THE EFFEaS OF IMIPRAMINE TREATMENT ON THE UNCONDITIONED 
ALIMENTARY BEHAVIOR AND CLASSICAL CONDITIONED SALIVARY 
REACTIONS IN DOGS. 

003030 03-04 
INHIBITION OF MONOAMINE-OXIDASE BY FURAZOLIDONE IN THE 
CHICKEN AND THE INFLUENCE OF THE ALIMENTARY FLORA THEREON. 

003711 04-03 
ALIVAL 

COOPERATIVE PSYCHIATRIC-STUDY OF ALIVAL: PRELIMINARY RESULTS. 

002045 02-09 
ALIVAL: NEW CLINICAL APPLICATIONS, STUDIES IN PROGRESS, AND NEW 
POSSIBILITIES. 

002530 02-17 
ALIVALS 

ROUNDTABLE DISCUSSION: ALIVALS PLACE IN PSYCHIATRIC-PRAQICE. 

002585 02-17 
ALKALOID 

HYPERTHERMIC-RESPONSE TO (-) CATHINONE, AN ALKALOID OF CATHA- 
EDULIS (KHAT). 

003694 04-02 
SINGLE-CASE STUDY OF CLINICAL-RESPONSE TO HIGH-DOSE ERGOT 
ALKALOID TREATMENT FOR DEMENTIA. PRELIMINARY REPORT. 

004493 04-1 1 
ALKALOIDS 

SELECTIVE INFLUENCE OF ERGOT ALKALOIDS ON CORTICAL AND STRIATAL 
DOPAMINERGIC-RECEPTORS AND SEROTONERGIC-RECEPTORS. 

001447 02-03 
MULTIPLE CNS RECEPTOR INTERACTIONS OF ERGOT ALKALOIDS: AFFINITY 
AND INTRINSIC ACTIVITY ANALYSIS IN IN VITRO BINDING SYSTEMS. 

001516 02-03 
DESIGN ASPEaS OF CLINICAL-TRIALS WITH ERGOT ALKALOIDS: A 
COMPARISON OF TWO GERIATRIC BEHAVIORAL-RATING-SCALES. 

002512 02-16 
ALKOXYALKYL 

N TETRAHYDROFURYLALKYL AND N ALKOXYALKYL DERIVATIVES OF (-) 
NORMETAZOCINE, COMPOUNDS WITH DIFFERENTIATED OPIOID AQION 
PROFILES. 

000013 01-02 
ALKYLATED 

N ALKYLATED 2 AMINOTETRALINS: CENTRAL DOPAMINE-RECEPTOR 
STIMULATING ACTIVITY. 

000399 01-04 
STRUCTURE-ACTIVITY RELATIONSHIPS AMONG SOME D N ALKYLATED 
AMPHETAMINES. 

001542 02-03 
ALKYLATING 

PHARMACOLOGICAL- STUDIES WITH AN ALKYLATING NARCOTIC 
AGONIST CHLOROXYMORPHAMINE, AND ANTAGONIST, 
CHLORNALTREXAMINE 

004082 04-04 
IN VIVO EFFEaS OF TWO NOVEL ALKYLATING BENZODIAZEPINE, 
IRAZEPINE AND KENAZEPINE, 

004251 04-04 
ALL-NIGHT 

THE EFFEa OF BUTOCTAMIDE-HYDROGEN-SUCCINATE ON NOQURNAL 
SLEEP: ALL-NIGHT POLYGRAPHICAL-STUDIES. 

002350 02-14 

ALL-OR-NONE 

A STUDY OF THE QUANTAL (ALL-OR-NONE) CHANGE IN REFLEX LATENCY 
PRODUCED BY OPIATE ANALGESICS. 

000425 01-04 

ALLERGIC-ENCEPHALOMYELITIS 

ENHANCED TRANSFER OF EXPERIMENTAL ALLERGIC-ENCEPHALOMYELITIS 
WITH STRAIN-13 GUINEA-PIG LYMPH-NODE CELLS: REQUIREMENT FOR 
CULTURE WITH SPECIFIC ANTIGEN AND ALLOGENIC PERITONEAL 
EXUDATE CELLS. (UNPUBLISHED PAPER). 

001201 02-03 
ENHANCED TRANSFER OF EXPERIMENTAL ALLERGIC-ENCEPHALOMYELITIS 
WITH LEWIS-RAT LYMPH-NODE CELLS. (UNPUBLISHED PAPER) 

001434 02-03 
CENTRAL SEROTONIN-RECEPTOR SENSITIVITY IN RATS WITH 
EXPERIMENTAL ALLERGIC-ENCEPHALOMYELITIS. 

001821 02-04 

ALLOGENIC 

ENHANCED TRANSFER OF EXPERIMENTAL ALLERGIC-ENCEPHALOMYELITIS 
WITH STRAIN-13 GUINEA-PIG LYMPH-NODE CELLS; REQUIREMENT FOR 
CULTURE WITH SPECIFIC ANTIGEN AND ALLOGENIC PERITONEAL 
EXUDATE CELLS. (UNPUBLISHED PAPER). 

001201 02-03 



S-14 



VOLUME 19, SUBJECT INDEX 



Subject Index 



ALLOXAN 

GLUCOSE OXIDATION IN THE VENTROMEDIAL HYPOTHALAMUS IS NOT 
AFFECTED BY INSULIN OR OUABAIN BUT DEPRESSED BY ALLOXAN 
TREATMENT. 

001145 02-03 
ALLYl 

COMPARISON OF OPIATE AGONISTS AND THEIR N ALLYL DERIVATIVES IN 
THE PRODUCTION OF PHYSICAL-DEPENDENCE IN THE RAT. 

001841 02-05 
ALLYLNORCOCAINE 

DISCRIMINATIVE-STIMULUS PROPERTIES OF COCAINE, NORCOCAINE, AND 
N ALLYLNORCOCAINE. 

002954 03-04 
ALPHA-ADRENERGIC 

MORPHINE ACTS THROUGH ALPHA-ADRENERGIC AND SEROTONINERGIC 
NEURONS TO STIMULATE GROWTH-HORMONE SECRETION IN THE DOG. 

000088 01-03 
CHANGES IN ALPHA-ADRENERGIC-RECEPTORS IN RAT-BRAIN IN VITRO BY 
PREINCUBATION WITH ALPHA-ADRENERGIC LIGANDS. 

001272 02-03 
CENTRAL PHARMACOLOGICAL CONTROL OF CORTICOSTERONE SECRETION 
IN THE INTACT RAT. DEMONSTRATION OF CHOLINERGIC AND 
SEROTONINERGIC FACILITATORY AND ALPHA-ADRENERGIC INHIBITORY 
MECHANISMS. 

001487 02-03 
THE ROLE OF DIFFERENTIAL BLOCKADE OF ALPHA-ADRENERGIC AGONISTS 
IN CHLORPROMAZINE-INDUCED HYPOTENSION. 

001851 02-05 
AMITRIPTYLINE: LONG-TERM-TREATMENT ELEVATES ALPHA-ADRENERGIC 
AND MUSCARINIC-RECEPTOR BINDING IN MOUSE-BRAIN. 

002875 03-03 
FLUORESCENT PROBES OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC 
AND OPIATE-RECEPTORS: BIOCHEMICAL AND HISTOCHEMICAL 
EVALUATION. 

003685 04-02 
EFFECTS OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC BLOCKERS ON 
CHLORPROMAZINE-INDUCED ELEVATION OF PLASMA GLUCOSE AND 
CYCLIC-AMP IN FED MICE. 

003946 04-03 
IkLPHA-ADRENERGIC-ACTIVITY 

CYCLOHEXYLPHENOXYAMIDOXIMES AND IMIDAZOLINES WITH 
ANTIDEPRESSIVE AND ALPHA-ADRENERGIC-ACTIVITY. 

001051 02-01 
MPHA-ADRENERGIC-RECEPTOR 

PERIPHERAL ALPHA-ADRENERGIC-RECEPTOR SUBTYPES. 

000901 01-16 
RELATIONSHIPS BETWEEN STRUCTURE AND ALPHA-ADRENERGIC- 
RECEPTOR AFFINITY OF CLONIDINE AND AND SOME RELATED CYCLIC- 
AMIDINES. 

002698 03-03 
CHARACTERIZATION AND QUANTITATION OF ALPHA-ADRENERGIC- 
RECEPTOR SUBTYPES IN RAT HYPOTHALAMUS. 

002839 03-03 
^LPHA-ADRENERGIC-RECEPTORS 

AMITRIPTYLINE BINDING TO SPECIFIC ALPHA-ADRENERGIC-RECEPTORS IN 
VITRO. 

000181 01-03 
(3H)QUINUCLIDINYL-BENZILATE BINDING TO MUSCARINIC-RECEPTORS 
AND (3H)WB-4101 BINDING TO ALPHA-ADRENERGIC-RECEPTORS IN 
RABBIT IRIS: COMPARISON OF RESULTS IN SLICES AND MICROSOMAL 
FRACTIONS. 

000299 01-03 
TRICYCLIC-ANTIDEPRESSANT DRUG-INTERACTIONS WITH HISTAMINE AND 
ALPHA-ADRENERGIC-RECEPTORS . 

000791 01-13 
CHANGES IN ALPHA-ADRENERGIC-RECEPTORS IN RAT-BRAIN IN VITRO BY 
PREINCUBATION WITH ALPHA-ADRENERGIC LIGANDS. 

001272 02-03 
CHARACTERIZATION BY (3H)DIHYDR0ERG0CRYPTINE BINDING OF ALPHA- 
ADRENERGIC-RECEPTORS IN NEUROBLASTOMA X GLIOMA HYBRID 
CELLS. 

003823 04-03 
MPHA-ADRENOCEPTOR 

SUPPRESSION OF SEROTONERGIC NEURONAL FIRING BY ALPHA- 
ADRENOCEPTOR ANTAGONISTS: EVIDENCE AGAINST GABA 
MEDIATION. 

000024 01-03 
EFFECTS OF ALPHA-ADRENOCEPTOR AGONISTS AND ANTAGONISTS AND 
OF ANTIDEPRESSANT-DRUGS ON PRESYNAPTIC AND POSTSYNAPTIC 
ALPHA-ADRENOCEPTORS. 

001146 02-03 
EFFECTS OF ALPHA-ADRENOCEPTOR STIMULATING DRUGS ON 

BARORECEPTOR REFLEXES IN CONSCIOUS CATS. 
„„,, 001514 02-03 

POSSIBLE ROLE OF AN ENDOGENOUS OPIATE IN THE CARDIOVASCULAR- 
EFFECTS OF CENTRAL ALPHA-ADRENOCEPTOR STIMULATION IN 
SPONTANEOUSLY HYPERTENSIVE-RATS. 

003791 04-03 
PRESYNAPTIC AND POSTSYNAPTIC ALPHA-ADRENOCEPTOR ANTAGONISM 
BY NEUROLEPTICS IN VIVO. 

003966 04-03 



ALPHA-ADRENOCEPTOR-MEDIATED 

ALPHA-ADRENOCEPTOR-MEDIATED MODULATION OF 5 

HYDROXYTRYPTAMINE RELEASE FROM RAT-BRAIN-CORTEX SLICES. 

000111 01-03 
ALPHA-ADRENOCEPTORS 

COMPARISON OF MIANSERIN WITH DESIPRAMINE, MAPROTILINE AND 
PHENTOLAMINE ON CARDIAC PRESYNAPTIC AND VASCULAR 
POSTSYNAPTIC ALPHA-ADRENOCEPTORS AND NORADRENALINE 
REUPTAKE IN PITHED NORMOTENSIVE-RATS. 

000044 01-03 
THE EFFECTS OF BROMOCRIPTINE ON PRESYNAPTIC AND POSTSYNAPTIC 
ALPHA-ADRENOCEPTORS IN THE MOUSE VAS-DEFERENS. 

000108 01-03 
EFFECTS OF ALPHA-ADRENOCEPTOR AGONISTS AND ANTAGONISTS AND 
OF ANTIDEPRESSANT-DRUGS ON PRESYNAPTIC AND POSTSYNAPTIC 
ALPHA-ADRENOCEPTORS. 

001146 02-03 
AN EXAMINATION OF FACTORS INFLUENCING ADRENERGIC 

TRANSMISSION IN THE PITHED RAT, WITH SPECIAL REFERENCE TO 
NORADRENALINE UPTAKE MECHANISMS AND POSTJUNCTIONAL 
ALPHA-ADRENOCEPTORS. 

001196 02-03 
PRESYNAPTIC ALPHA-ADRENOCEPTORS AND THE ACTION OF TRICYCLIC- 
ANTIDEPRESSANT DRUGS IN BEHAVIOURAL-DESPAIR IN RATS. 

001829 02-04 
FUNCTIONAL CHARACTERIZATION OF CENTRAL ALPHA-ADRENOCEPTORS 
BY YOHIMBINE DIASTEREOMERS. 

002748 03-03 
THE TETRACYCLIC-ANTIDEPRESSANT MIANSERIN: EVALUATION OF ITS 
BLOCKADE OF PRESYNAPTIC ALPHA-ADRENOCEPTORS IN A SELF- 
STIMULATION MODEL USING CLONIDINE. 

003016 03-04 
PHARMACOLOGICAL DIFFERENTIATION OF PRESYNAPTIC INHIBITORY 
ALPHA-ADRENOCEPTORS AND OPIATE-RECEPTORS IN THE CAT 
NICTITATING MEMBRANE. 

003777 04-03 
EFFECTS ON THE PINNA-REFLEX OF DRUGS ACTING AT ALPHA- 
ADRENOCEPTORS. 

004078 04-04 
ALPHA-ADRENORECEPTOR 

ALPHA-ADRENORECEPTOR MEDIATED ALTERATION OF ETHANOL EFFECTS 
ON NA-K-ATPASE OF RAT NEURONAL MEMBRANES. 

001425 02-03 
ALPHA-PAHERN 

THE TWO SURVIVAL CASES OF ALPHA-PATTERN COMA CAUSED BY 
LARGE AMOUNTS OF HYPNOTICA AND NEUROLEPTICA. 

004608 04-15 
ALPHA-RECEPTORS 

ON THE CAPACITY OF PRESYNAPTIC ALPHA-RECEPTORS TO MODULATE 
NOREPINEPHRINE RELEASE FROM SLICES OF RAT NEOCORTEX AND THE 
AFFINITY OF SOME AGONISTS AND ANTAGONISTS FOR THESE 
RECEPTORS. 

000323 01-03 
ALPHA METHYLEPINEPHRINE, A METHYLDOPA METABOLITE THAT BINDS 
TO ALPHA-RECEPTORS IN RAT-BRAIN. 

002734 03-03 
ALPHA 1 

THE CONTRIBUTION OF ALPHAl ACID GLYCOPROTEIN, LIPOPROTEINS, 
AND ALBUMIN TO THE PLASMA BINDING OF PERAZINE, 
AMITRIPTYLINE, AND NORTRIPTYLINE IN HEALTHY MAN. 

002214 02-13 
BINDING OF PERAZINE TO ALPHAl ACID GLYCOPROTEIN. 

002290 02-13 
ALPHA 1 -ADRENERGIC-RECEPTORS 

ONTOGENY OF MAMMALIAN CARDIAC ALPHAl -ADRENERGIC- 
RECEPTORS. 

001545 02-03 
ALPHA 1 -ADRENOCEPTOR 

DIFFERENTIAL INHIBITION OF ALPHAl -ADRENOCEPTOR AND ALPHA2- 
ADRENOCEPTOR MEDIATED PRESSOR RESPONSES IN PITHED RATS. 

004057 04-03 
ALPHAl -ADRENOCEPTORS 

3H PRAZOSIN BINDS SPECIFICALLY TO ALPHAl -ADRENOCEPTORS IN RAT- 
BRAIN. 

000205 01-03 
NEGLIGIBLE AFFINITY OF HISTAMINE H2-RECEPT0R ANTAGONISTS FOR 
CENTRAL ALPHAl -ADRENOCEPTORS. 

001508 02-03 
THE DOPAMINE-RECEPTOR ANTAGONIST DOMPERIDONE IS ALSO A 
COMPETITIVE ANTAGONIST AT ALPHA1-ADREN0CEPT0RS. 

003785 04-03 
REGULATION OF ALPHAl -ADRENOCEPTORS IN THE CEREBRAL-CORTEX OF 
THE RAT BY THYROID-HORMONES. 

003816 04-03 
ALPHAl -ADRENOCEPTORS AND ALPHA2-ADREN0CEPT0RS IN RAT- 
CEREBRAL-CORTEX: EFFECT OF FRONTAL LOBOTOMY. 

003944 04-03 






I 



S-15 



Subject Index 



Psychopharmacology Abstracts 



ALPHA1 -RECEPTORS 

AN IN VIVO MODEL FOR INVESTIGATING ALPHA 1 -RECEPTORS AND 
ALPHA2-RECEPT0RS IN THE CNS: STUDIES WITH MIANSERIN. 

000053 01-03 
ALPHA2-ADRENERGIC 

ALPHA2-ADRENERGIC AMINES, ADENOSINE AND PROSTAGLANDINS 
INHIBIT LIPOLYSIS AND CYCLIC-AMP ACCUMULATION IN HAMSTER 
ADIPOCYTES IN THE ABSENCE OF EXTRACELLULAR SODIUM. 

002728 03-03 
ALPHA2-ADRENERGIC-AUTORECEPTOR 

ANTIDEPRESSANTS AND ALPHA2-ADRENERGIC-AUT0RECEPT0R 
DESENSITIZATION. 

004659 04-15 
ALPHA2-ADRENERGIC-RECEPTORS 

HUMAN PLATELET ALPHA2-ADRENERGIC-RECEPT0RS: LABELING WITH 3H 
YOHIMBINE, A SELECTIVE ANTAGONIST LIGAND. 

004676 04-16 
ALPHA2-ADRENOCEPTOR 

EFFECTS OF DESIPRAMINE AND YOHIMBINE ON ALPHA2-ADREN0CEPT0R 
AND BETA-ADRENOCEPTOR SENSITIVITY. 

001305 02-03 
DIFFERENTIAL INHIBITION OF ALPHA 1 -ADRENOCEPTOR AND ALPHA2- 
ADRENOCEPTOR MEDIATED PRESSOR RESPONSES IN PITHED RATS. 

004057 04-03 
ALPHA2-ADRENOCEPTORS 

ALPHA2-ADREN0CEPT0RS IN RAT-BRAIN: THE DIVALENT-CATION SITE. 

001246 02-03 
THE BLOCKADE OF ALPHA2-ADREN0CEPT0RS BY THE PNMT INHIBITOR 
SKF-64139. 

001255 02-03 
THE INABILITY OF CHRONIC MIANSERIN TO BLOCK CENTRAL ALPHA2- 
ADRENOCEPTORS. 

001492 02-03 
ALPHA 1 -ADRENOCEPTORS AND ALPHA2-ADREN0CEPT0RS IN RAT- 
CEREBRAL-CORTEX: EFFECT OF FRONTAL LOBOTOMY 

003944 04-03 
ALPHA2-ADRENORECEPTORS 

TRICYCLIC-ANTIDEPRESSANT DRUG-TREATMENT DECREASES ALPHA2- 
ADRENORECEPTORS ON HUMAN PLATELET MEMBRANES 

003408 03-13 
ALPHA2-ADREN0RECEPT0RS IN RAT-BRAIN ARE DECREASED AFTER 
LONG-TERM TRICYCLIC-ANTIDEPRESSANT DRUG-TREATMENT. 

004008 04-03 
ALPHA2-NORADRENERGIC-RECEPTOR 

MULTIPLE ALPHA2-N0RADRENERGIC-RECEPT0R SITES IN RAT-BRAIN: 
SELECTIVE REGULATION OF HIGH-AFFINITY (3H)CL0NIDINE BINDING BY 
GUANINE-NUCLEOTIDES AND DIVALENT-CATIONS 

003992 04-03 
CLONIDINE-INDUCED HYPERPHAGIA IN MONKEYS: EVIDENCE FOR 
ALPHA2-N0RADRENERGIC-RECEPT0R MEDIATION . 

004215 04-04 
ALPHA2-RECEPTORS 

AN IN VIVO MODEL FOR INVESTIGATING ALPHA 1 -RECEPTORS AND 
ALPHA2-RECEPT0RS IN THE CNS: STUDIES WITH MIANSERIN. 

000053 01-03 
MIANSERIN: DIRECT ACTIVATION OF BRAIN NOREPINEPHRINE NEURONS 
BY BLOCKING ALPHA2-RECEPT0RS. 

001214 02-03 
ALPRAZOLAM 

ANXIOLYTIC EFFICACY OF ALPRAZOLAM COMPARED TO DIAZEPAM AND 
PLACEBO. 

000648 01-10 
DOUBLE-BLIND CLINICAL ASSESSMENT OF ALPRAZOLAM, A NEW 

BENZODIAZEPINE DERIVATIVE, IN THE TREATMENT OF MODERATE TO 
SEVERE ANXIETY. 

002070 02-10 
DOUBLE-BLIND COMPARISON OF ALPRAZOLAM AND DIAZEPAM FOR 
SUBCHRONIC WITHDRAWAL FROM ALCOHOL. 

003332 03-11 
ALPRAZOLAM, A NEW TYPE ANXIOLYTIC IN NEUROTIC-PATIENTS: A 
PILOT-STUDY. 

004422 04-10 
ALTERATION 

ALTERATION OF PHARMACOKINETIC PARAMETERS FOR PENTOBARBITAL 
BY ISCHEMIC STROKE AND REVERSION TO NORMAL BY 
DEXAMETHASONE TREATMENT. 

000321 01-03 
ELECTIVE ALTERATION OF THE STATE OF CONSCIOUSNESS SUBJEQED TO 
THE EFFECTS OF PSYCHOAaiVE-SUBSTANCES. 

000994 01-17 
ALTERATION OF PROLACTIN SECRETION BY CENTRALLY-AQING DRUGS. 

001127 02-03 
ALPHA-ADRENORECEPTOR MEDIATED ALTERATION OF ETHANOL EFFEaS 
ON NA-K-ATPASE OF RAT NEURONAL MEMBRANES. 

001425 02-03 
BENZODIAZEPINE-RECEPTORS: THE EFFECT OF GABA ON THEIR 
CHARACTERISTICS IN HUMAN BRAIN AND THEIR ALTERATION IN 
HUNTINGTONS-DISEASE. 

002163 02-11 



CEEG STUDY ON PATIENTS UNDER THE PSYCHIATRIC-DRUG TREATMENT, 
THE CORRELATION BETWEEN EEG ALTERATION AND CLINICAL 
EVOLUTION. 

002165 02-11 
ENDOCRINE CHANGES AND BEHAVIORAL-CHANGES IN DEPRESSION AFTER 
THYROTROPIN-RELEASING-HORMONE (TRH): ALTERATION BY 
PRETREATMENT WITH THYROID-HORMONES. 

002259 02-13 
HIGH-AFFINITY RENAL (3H)FLUNITRAZEPAM BINDING: 
CHARACTERIZATION, LOCALIZATION, AND ALTERATION IN 
HYPERTENSION. 

002874 03-03 
QUANTITATION AND COMPARISON OF PHENOBARBITAL LEVELS IN THE 
PLASMA, SALIVA, AND CEREBROSPINAL-FLUID OF THE RAT, AND THE 
DEMONSTRATION OF AN ALTERATION OF DRUG PASSAGE BY 
ETHANOL, 

003725 04-03 
STRESS-MODULATED ALTERATION OF BRAIN BIOGENIC-AMINES IN THE 
RAT: EFFECTS OF L TRYPTOPHAN 

003978 04-03 
ALTERATIONS 

LONG-TERM ANTIDEPRESSANT TREATMENT: ALTERATIONS IN CEREBRAL 
CAPILLARY PERMEABILITY. 

000239 01-03 
GABA LEVELS IN HUMAN CEREBROSPINAL-FLUID: ALTERATIONS IN 
PSYCHIATRIC-DISORDERS. (UNPUBLISHED PAPER) 

000764 01-13 
EFFECT OF THE NEW GAMMA AMINOBUTYRIC-ACID AGONIST SL-76-002 
ON STRIATAL ACETYLCHOLINE: RELATION TO NEUROLEPTIC-INDUCED 
EXTRAPYRAMIDAL ALTERATIONS 

001119 02-03 
ALTERATIONS IN BASAL FIRING-RATE AND AUTORECEPTOR SENSITIVITY 
OF DOPAMINE NEURONS IN THE SUBSTANTIA-NIGRA FOLLOWING 
ACUTE AND EXTENDED EXPOSURE TO ESTROGEN 

001167 02-03 
DRUG-INDUCED ALTERATIONS IN NEUROTRANSMIHER-RECEPTOR 
BINDING AND FUNCTION. 

001215 02-03 
CHRONOLOGY OF NEUROCHEMICAL ALTERATIONS INDUCED BY GABA 
AGONIST ADMINISTRATION 

002713 03-03 
DRUG REGIMENS FACILITATING AGGRESSION: BEHAVIOR, AMINE, AND 
RECEPTOR ALTERATIONS. 

002987 03-04 
BEHAVIORAL AND METABOLIC ALTERATIONS IN PROGENY OF 
METHADONE-TREATED RATS. (PHD DISSERTATION) 

003113 03-04 
ALTERATIONS IN CEREBROSPINAL-FLUID DOPAMINE METABOLITES 
FOLLOWING PHYSOSTIGMINE INFUSION. 

003477 03-15 
ALTERATIONS OF ACETYLCHOLINE AND CHOLINE METABOLISM IN 
MAMMALIAN PREPARATIONS TREATED WITH BETA BUNGAROTOXIN. 

003820 04-03 
ALTERATIONS IN DIHYDROMORPHINE BINDING IN CEREBRAL 
HEMISPHERES OF AGED MALE RATS, 

003936 04-03 
ALTERATIONS IN GAMMA AMINOBUTYRIC-ACID-RECEPTOR SENSITIVITY 
FOLLOWING ACUTE AND CHRONIC ETHANOL TREATMENTS 

004037 04-03 
ALTERATIONS OF EVOKED-POTENTIALS LINK RESEARCH IN ATTENTION- 
DYSFUNQION TO PEPTIDE RESPONSE SYMPTOMS OF SCHIZOPHRENIA. 

004316 04-08 
ALTERATIONS IN NORADRENERGIC FUNQION DURING CLORGYLINE 
TREATMENT. 

004393 04-09 
DRUG-INDUCED ALTERATIONS OF THE HYPOTHALAMUS HYPOPHYSIS 

AXIS. 

004535 04-13 

ALTERING 

BEHAVIOURAL-RESPONSES TO DRUGS RELEASING 5 
HYDROXYTRYPTAMINE AND CATECHOLAMINES: EFFECTS OF 
TREATMENTS ALTERING PRECURSOR CONCENTRATIONS IN BRAIN. 

002990 03-04 
AGGRESSION ALTERING EFFECTS OF CYCLIC-AMP. 

003021 03-04 
LITHIUM DRUG INTERAQIONS ALTERING THE INTRACELLULAR LITHIUM 
LEVEL: AN IN VITRO STUDY. 

003142 03-06 
CHLORPROMAZINE EFFECTS ON COCAINE-REINFORCED RESPONDING IN 
RHESUS-MONKEYS: RECIPROCAL MODIFICATION OF RATE ALTERING 
EFFEaS OF THE DRUGS. 

004133 04-04 

MECHANISMS AND PHARMACOLOGICAL IMPLICATIONS OF ALTERING 
CALMODULIN ACTIVITY. 

004751 04-17 

ALTERNATION 

AROUSAL AND SHORT-TERM MEMORY: EFFECTS OF CAFFEINE AND TRIAL 
SPACING ON DELAYED ALTERNATION PERFORMANCE. 

000487 01-04 



S-16 



.23flSS^ 




VOLUME 19, SUBJECT INDEX 



Subject Index 



ALTERNATIVE 

ELECTROLYTIC AAICROINFUSION TRANSDUCER SYSTEM: AN ALTERNATIVE 
METHOD OF INTRACRANIAL DRUG APPLICATION. 

001861 02-06 
ALTHESIN 

EFFECTS OF ALTHESIN IN PSYCHOTHERAPY OF SCHIZOPHRENICS: 
PRELIMINARY REPORT. 

004331 04-08 
ALUMINUM 

ORAL ALUMINUM AND NEUROPSYCHOLOGICAL FUNCTIONING: A STUDY 
OF DIALYSIS PATIENTS RECEIVING ALUMINUM-HYDROXIDE GELS. 

002283 02-13 
ALUMINUM-HYDROXIDE 

ORAL ALUMINUM AND NEUROPSYCHOLOGICAL FUNCTIONING: A STUDY 
OF DIALYSIS PATIENTS RECEIVING ALUMINUM-HYDROXIDE GELS. 

002283 02-13 
ALZHEIMER-LIKE 

USE OF THA IN TREATMENT OF ALZHEIMER-LIKE DEMENTIA: PILOT-STUDY 
IN TWELVE PATIENTS. 

003377 03-11 
ALZHEIMER-TYPE 

CHOLINE-BITARTRATE TREATMENT OF ALZHEIMER-TYPE DEMENTIAS. 

000675 01-11 
ALZHEIMERS-DISEASE 

LECITHIN AND MEMORY TRAINING IN ALZHEIMERS-DISEASE. (PH.D. 
DISSERTATION). 

003299 03-11 
EFFECTS OF CHOLINERGIC-DRUGS ON MEMORY IN ALZHEIMERS-DISEASE. 

003454 03-14 
ALZHEIMERS-TYPE 

THE EFFECTS OF LECITHIN ON MEMORY IN PATIENTS WITH SENILE- 
DEMENTIA OF THE ALZHEIMERS-TYPE. 

003385 03-11 
AMANITIN 

RNA-POLYMERASE-II IN C6-GLI0MA CELLS: ALPHA AMANITIN BLOCKADE 
OF CYCLIC-AMP-PHOSPHODIESTERASE INDUCTION BY BETA- 
ADRENERGIC STIMULATION. (UNPUBLISHED PAPER). 

003998 04-03 
AMANTADINE 

REVIEW OF 38 CASES OF SUBACUTE SCLEROSING PANENCEPHALITIS: 
EFFECT OF AMANTADINE ON THE NATURAL COURSE OF THE DISEASE. 

000718 01-11 
LITHIUM-INDUCED COGWHEEL RIGIDITY: TREATMENT WITH 
AMANTADINE. 

000748 01-13 
CLINICAL-TRIAL WITH AMANTADINE AND HYDERGINE IN ELDERLY- 
PATIENTS. 

002093 02-1 1 
EDEMAS AND MYOCLONIES IN A PATIENT WITH PARKINSONS-DISEASE 
TREATED BY AMANTADINE: PROBLEM WITH ASSOCIATED 
MEDICATIONS. 

002389 02-15 
THE EFFECT OF AMANTADINE ON PROLACTIN LEVELS AND 
GALACTORRHEA ON NEUROLEPTIC TREATED PATIENTS. 

003373 03-1 1 
COMPARATIVE-EFFECTS OF AMANTADINE AND AMFONELIC-ACID ON 
DOPAMINE METABOLISM IN RAT-BRAIN. 

003796 04-03 
ACCUMULATION OF AMANTADINE BY ISOLATED CHROMAFFIN 
GRANULES. 

003866 04-03 
^MBIENT 

THE EFFECTS OF THEOPHYLLINE AND CAFFEINE ON THERMOREGULATORY 
FUNaiONS OF RATS AT DIFFERENT AMBIENT TEMPERATURES 

003907 04-03 
CORE TEMPERATURE CHANGES FOLLOWING ADMINISTRATION OF 
NALOXONE AND NALTREXONE TO RATS EXPOSED TO HOT AND COLD 
AMBIENT TEMPERATURES. EVIDENCE FOR THE PHYSIOLOGICAL ROLE 
OF ENDORPHINS IN HOT AND COLD ACCLIMATIZATION. 

004034 04-03 
\MBLYOPIA 

ROLE OF INTRACORTICAL INHIBITION IN DEPRIVATION AMBLYOPIA 
REVERSAL BY MICROIONTOPHORETIC BICUCULLINE. 

002684 03-03 
AMBULATORY 

COVERT DYSKINESIA IN AMBULATORY SCHIZOPHRENIA. 

000836 01-15 
EVALUATIONS OF LOXAPINE-SUCCINATE IN THE AMBULATORY 
TREATMENT OF ACUTE SCHIZOPHRENIC-EPISODES. 

004345 04-08 
PHARMACOTHERAPY AND PSYCHOTHERAPY FOR AMBULATORY 
DEPRESSION: EFFICACY AND CHOICES. 

004413 04-09 
AMELIORATES 

CLONIDINE AMELIORATES GILLES-DE-LA-TOUREnE-SYNDROME 

002106 02-11 
AMELIORATION 

TREATMENT OF HUNTINGTON-DISEASE WITH GAMMA ACETYLENIC- 
GABA, AN IRREVERSIBLE INHIBITOR OF GABA-TRANSAMINASE- 



INCREASED CSF GABA AND HOMOCARNOSINE WITHOUT CLINICAL 
AMELIORATION. 

003458 03-14 
LITHIUM AMELIORATION OF RESERPINE-INDUCED HYPOACTIVITY IN 
RATS. 

004167 04-04 
AMERICA 

THE TRANQUILIZING OF AMERICA. 

003602 03-17 
AMERICAN-PSYCHIATRIC-ASSOCIATION 

TARDIVE-DYSKINESIA: SUMMARY OF A TASK-FORCE-REPORT OF THE 
AMERICAN-PSYCHIATRIC-ASSOCIATION. 

000875 01-15 
AMFONELIC-ACIO 

DIFFERENT DOPAMINERGIC MECHANISMS FOR AMFONELIC-ACID 
AMPHETAMINE AND APOMORPHINE. 

000465 01-04 
DIVERGENT RESERPINE EFFECTS ON AMFONELIC-ACID AND 
AMPHETAMINE STIMULATION OF SYNAPTOSOMAL DOPAMINE 
FORMATION FROM PHENYLALANINE. 

001113 02-03 
COMPARATIVE-EFFECTS OF AMANTADINE AND AMFONELIC-ACID ON 
DOPAMINE METABOLISM IN RAT-BRAIN. 

003796 04-03 
AMILORiDE 

ATTENUATION OF THE LITHIUM-INDUCED DIABETES-INSIPIDUS-LIKE 
SYNDROME BY AMILORIDE IN RATS. 

002717 03-03 
AMINE 

TRICYCLIC-ANTIDEPRESSANT DRUGS AND INDIVIDUAL DIFFERENCES IN 
THE EXPLORATORY-ACTIVITY OF RATS: CONTRASTING-EFFECTS OF 
TERTIARY AND SECONDARY AMINE COMPOUNDS. 

000401 01-04 
DOPAMINE BIOSYNTHESIS IS REGULATED BY THE AMINE NEWLY 
RECAPTURED BY DOPAMINERGIC NERVE-ENDINGS. 

001163 02-03 
QUINACRINE AND SEROTONIN BINDING BY SYNTHETIC MODELS FOR 
HUMAN PLATELET DENSE-BODIES: EVALUATION OF THE ROLE OF 
BINDING IN AMINE STORAGE. (UNPUBLISHED PAPER). 

002219 02-13 
DRUG REGIMENS FACILITATING AGGRESSION: BEHAVIOR, AMINE, AND 
RECEPTOR ALTERATIONS. 

002987 03-04 
CROSS-OVER STUDY OF ZIMELIDINE AND DESIPRAMINE IN DEPRESSION- 
EVIDENCE FOR AMINE SPECIFICITY. 

003250 03-09 
NONCOMPETITIVE AMINE UPTAKE INHIBITION BY THE NEW 
ANTIDEPRESSANT PRIDEFINE. 

003771 04-03 
AMINE UPTAKE INHIBITORS: CRITERIA OF SELECTIVITY. 

003921 04-03 
THE INTERACTION OF AMINE LOCAL ANESTHETICS WITH MUSCARINIC- 
RECEPTORS. 

004031 04-03 
A SIMPLE HISTOCHEMICAL SCREENING METHOD FOR AMINE UPTAKE. 

004295 04-06 
A RAPID AND SENSITIVE RADIORECEPTOR ASSAY FOR TERTIARY AMINE 
TRICYCLIC-ANTIDEPRESSANTS. 

004689 04-16 
AMINE-OXIDASE 

ESR STUDIES OF BOVINE PLASMA AMINE-OXIDASE: PROBING OF THE 
ENVIRONMENT ABOUT THE SUBSTRATE LIBERATED SULFHYDRYL 
GROUPS IN THE ACTIVE SITE. (UNPUBLISHED PAPER). 

001066 02-01 
CU-AMINE-OXIDASES: STUDIES RELATED TO THE MECHANISM-OF-ACTION 
OF BOVINE PLASMA AMINE-OXIDASE (UNPUBLISHED PAPER). 

003680 04-01 
AMINEPTINE 

AMINEPTINE: CLINICAL REVIEW. 

001896 02-07 
AMINEPTINE, A NEW ANTIDEPRESSANT: PHARMACOLOGICAL REVIEW. 

001898 02-07 
THE IMPORTANCE OF AMINEPTINE IN THE TREATMENT OF NONPSYCHOTIC 
DEPRESSIVE-STATES IN THE ELDERLY. 

001999 02-09 
COMPARATIVE EXPERIMENT OF THE ANTIDEPRESSANT EFFECTS OF 
AMINEPTINE AND CHLORIMIPRAMINE. 

002029 02-09 
ANTIDEPRESSANT ACTION OF AMINEPTINE: CONTROLLED DOUBLE-BLIND 

STUDY. 

002030 02-09 
DOUBLE-BLIND CONTROLLED EXPERIMENT: AMINEPTINE VERSUS 

AMITRIPTYLINE USING THE HAMILTON-DEPRESSION-RATING- SCALE. 

002050 02-09 
DOUBLE-BLIND CONTROLLED-STUDY: AMINEPTINE VERSUS 

TRIMIPRAMINE. 

002051 02-09 



1*1 



S-17 



Subject Index 



Psychopharmacology Abstracts 



COMPARATIVE CROSS-STUDY ON THE EFFECTS OF AMINEPTINE AND 
MAPROTILINE. 

002065 02-10 
DOUBLE-BUND CONTROLLED-STUDY ON THE PSYCHOLEPTIC-EFFECTS OF 
AMINEPTINE IN MENTALLY-HANDICAPPED CHILDREN WITHOUT 
PERSONALITY-PROBLEMS. 

002116 02-n 
A PRELIMINARY OPEN-STUDY OF THE USE OF AMINEPTINE OF THE 
DEFICIENT SYNDROME OF HEBEPHRENICS AND OF ADDIQS DURING 
WITHDRAWAL. 

004445 04-1 1 
AMINERGIC 

CENTRAL AMINERGIC AND PEPTIDERGIC MECHANISMS IN 

SPONTANEOUSLY (GENETIC) HYPERTENSIVE-RATS. (UNPUBLISHED 
PAPER). 

001459 02-03 
SELF-ADMINISTRATION OF D-AMPHET AMINE AND AMINERGIC SYSTEMS 
IN THE RAT. 

001696 02-04 

AMINES 

PHARMACOLOGY OF PHENETHYLAMINE TRACE AMINES IN THE DOG ~ 
DISCUSSION. 

000469 01-04 
ALPHA2-ADRENERGIC AMINES, ADENOSINE AND PROSTAGLANDINS 
INHIBIT LIPOLYSIS AND CYCLIC-AMP ACCUMUUVTION IN HAMSTER 
ADIPOCYTES IN THE ABSENCE OF EXTRACELLULAR SODIUM. 

002728 03-03 
EVIDENCE FOR THE PRESENCE OF TWO TYPES OF MONOAMINE-OXIDASE 
IN RABBIT CHOROID PLEXUS AND THEIR ROLE IN BREAKDOWN OF 
AMINES INFLUENCING CEREBROSPINAL-FLUID FORMATION 

002807 03-03 
REGULATION OF BIOGENESIS OF PSYCHOTOMIMETIC AMINES. 
(UNPUBLISHED PAPER). 

003818 04-03 
EFFECTS OF MOLINDONE AND FLUPHENAZINE ON THE BRAIN 
CONCENTRATION OF SOME PHENOLIC AND CATECHOLIC AMINES IN THE 
MOUSE AND THE RAT. 

003870 04-03 
AMINO-ACID 

INTERACTIONS OF NOREPINEPHRINE WITH PURKINJE-CELL RESPONSES TO 
PUTATIVE AMINO-ACID NEUROTRANSMIHERS APPLIED BY 
MICROIONTOPHORESIS 

000209 01-03 
ACETYLCHOLINE AND AMINO-ACID NEUROTRANSMIHERS IN EPIDURAL 
CUPS OF FREELY-MOVING-RATS: EFFECT OF ACUTE AND CHRONIC- 
TREATMENT WITH ANTISCHIZOPHRENIC-DRUGS. 

001386 02-03 
THE INTERACTION BETWEEN BARBITURATE ANESTHETICS AND 

EXCITATORY AMINO-ACID RESPONSES ON CAT SPINAL NEURONES. 

002799 03-03 
ACTIONS OF BETA BUNGAROTOXIN ON AMINO-ACID TRANSMIHER 
RELEASE. 

002897 03-03 
PHARMACOLOGICAL ANTAGONISTS OF EXCITANT AMINO-ACID ACTION. 

003587 03-17 
EXCITATORY AMINO-ACID TRANSMIHERS. 

003648 03-17 
BACLOFEN: STEREOSELECTIVE INHIBITION OF EXCITANT AMINO-ACID 
RELEASE. 

003867 04-03 
CHANGES IN REGIONAL BRAIN LEVELS OF AMINO-ACID PUTATIVE 
NEUROTRANSMIHERS AFTER PROLONGED TREATMENT WITH THE 
ANTICONVULSANT-DRUGS DIPHENYLHYDANTOIN, PHENOBARBITONE, 
SODIUM-VALPROATE, ETHOSUXIMIDE, AND SULTHIAME IN THE RAT. 

003961 04-03 
DRUG-INDUCED CHANGES IN THE COMPOSITION OF THE CEREBRAL FREE 
AMINO-ACID POOL. 

004039 04-03 
AMINO-ACIDS 

INFLUENCE OF CELLULAR-TRANSPORT ON THE INTERACTION OF AMINO- 
ACIDS WITH GAMMA AMINOBUTYRIC-ACID-RECEPTORS (GABA) IN THE 
ISOLATED OLFACTORY-CORTEX OF THE GUINEA-PIG. 

000034 01-03 
EFFECTS OF L AND D AMINO-ACIDS ON ANALGESIA AND LOCOMOTOR- 
ACTIVITY OF MICE: THEIR INTERACTION WITH MORPHINE. 

000336 01-04 
LITHIUM-INDUCED CHANGES IN THE BRAIN LEVELS OF FREE AMINO-ACIDS 
IN STRESS-EXPOSED RATS. 

001217 02-03 
REGIONAL RELEASE OF (3H)ADEN0SINE DERIVATIVES FROM RAT-BRAIN 
IN VIVO: EFFECT OF EXCITATORY AMINO-ACIDS, OPIATE AGONISTS, 
AND BENZODIAZEPINES. 

001303 02-03 
EFFECTS OF ALBUMIN, AMINO-ACIDS, AND CLOFIBRATE ON THE UPTAKE 
OF TRYPTOPHAN BY THE RAT-BRAIN. 

002673 03-03 
SENSITIVITY OF IDENTIFIED MEDIAL HYPOTHALAMIC NEURONS TO GABA, 

GLYCINE AND RELATED AMINO-ACIDS; INFLUENCE OF BICUCULLINE, 
PICROTOXIN AND STRYCHNINE ON SYNAPTIC INHIBITION. 

002674 03-03 



CELLS. 



TRANSPORT OF NEUTRAL AMINO-ACIDS AT THE BLOOD-BRAIN-BARRIER. 

002764 03-03 
L HISTIDINE: EFFEaS ON SENSITIVITY OF CAT SPINAL NEURONES TO 
AMINO-ACIDS. 

002808 03-03 
LAMINAR DISTRIBUTION OF PUTATIVE NEUROTRANSMIHER AMINO- 
ACIDS AND LIGAND BINDING-SITES IN THE DOG OLFAaORY-BULB 

002836 03-03 
EFFEaS OF D AMINOLAEVULINIC-ACID, PORPHOBILINOGEN, AMINO- 
ACIDS AND BARBITURATES ON CALCIUM ACCUMULATION BY 
CULTURED NEURONS. 

002859 03-03 
AMINO-3-ETHOXYCARBONYL-4-PHENYLTHIOPHENE 

SYNTHESIS AND PHARMACOLOGY OF 2 AMIN0-3-ETH0XYCARB0NYL-4- 
PHENYLTHIOPHENE DERIVATIVES. 

001083 02-02 
AMINO-4-METHYLPYRIDINE 

ON THE MECHANISM-OF-AaiON OF 2 AMINO-4-METHYLPYRIDINE, A 
MORPHINE-LIKE ANALGESIC. 

001574 02-04 
AMINO-4-PHOSPHONOBUTYRIC-ACID 

2 AMINO-4-PHOSPHONOBUTYRIC-ACID: A NEW PHARMACOLOGICAL 
TOOL FOR RETINA RESEARCH. 

003145 03-06 
AMINO-4H-S-TRIAZOLOBENZODIAZEPINES 

6 SUBSTITUTED AMIN0-4H-S-TRIAZ0L0BENZ0DIAZEPINES AND 4 ■ 

SUBSTITUTED AMIN0-6H-S-TRIAZ0L0BENZ0DIAZEPINES WITH ■ 

POTENTIAL ANTIANXIETY ACTIVITY. 

001076 02-02 
AMINO-6H-S-TRIAZOLOBENZODIAZEPINES 

6 SUBSTITUTED AMIN0-4H-S-TRIAZ0L0BENZ0DIAZEPINES AND 4 
SUBSTITUTED AMINO-6H-S-TRIAZOLOBENZO0IAZEPINES WITH 
POTENTIAL ANTIANXIETY ACTIVITY. 

001076 02-02 
AMINOADIPATE 

TOXIC EFFECTS OF ALPHA AMINOADIPATE ON CULTURED CEREBELLAR | 

002729 03-03 

SELEQIVE SYNAPTIC ANTAGONISM BY ATROPINE AND ALPHA 
AMINOADIPATE OF PULVINAR AND CORTICAL AFFERENTS TO THE 
SUPRASYLVIAN VISUAL AREA (CLARE-BISHOP AREA). 

002752 03-03 
DEPRESSION OF VENTRAL ROOT DORSAL ROOT POTENTIAL BY DL ALPHA 
AMINOADIPATE IN FROG SPINAL-CORD 

002755 03-03 
AMINOADIPIC-ACID 

LOCALIZATION OF GABA-RECEPTOR AND DOPAMINE-RECEPTOR SITES IN 
RETINAL GLIAL CELLS USING DL ALPHA AMINOADIPIC-ACID 

002828 03-03 
AMINOALKYL-«-ARYL-4H-S-TRIAZOLOBENZODIAZEPINES 

1 AMIN0ALKYL-6-ARYL-4H-S-TRIAZ0L0BENZ0DIAZEPINES WITH 
ANTIANXIETY AND ANTIDEPRESSANT AQIVITY. 

001074 02-02 
AMINOBUTYRIC-ACID 

DIFFERENTIAL-EFFECTS OF N DIPROPYLACETATE AND AMINOOXYACETIC- 
ACID ON GAMMA AMINOBUTYRIC-ACID LEVELS IN DISCRETE AREAS 
OF RAT-BRAIN. 

000140 01-03 
GAMMA AMINOBUTYRIC-ACID AGONISTS: AN IN VITRO COMPARISON 
BETWEEN DEPRESSION OF SPINAL SYNAPTIC ACTIVITY AND 
DEPOLARIZATION OF SPINAL ROOT FIBRES IN THE RAT. 

001104 02-03 
EFFEQ OF THE NEW GAMMA AMINOBUTYRIC-ACID AGONIST SL-76-002 
ON STRIATAL ACETYLCHOLINE: RELATION TO NEUROLEPTIC-INDUCED 
EXTRAPYRAMIDAL ALTERATIONS. 

001119 02-03 
FACTORS INFLUENCING THE RELEASE OF LABELLED GAMMA 
AMINOBUTYRIC-ACID AND ACETYLCHOLINE EVOKED BY ELEQRICAL- 
STIMULATION WITH ALTERNATING POLARITY FROM RAT CORTICAL 
SLICES. 

001130 02-03 
ROLES OF SEROTONIN AND GAMMA AMINOBUTYRIC-ACID IN OPIOID 
EFFEaS. 

001140 02-03 
PRESYNAPTIC AQIONS OF 4 AMINOPYRIDINE AND GAMMA 
AMINOBUTYRIC-ACID ON RAT SYMPATHETIC GANGLIA IN VITRO. 

001244 02-03 
BENZODIAZEPINE BINDING IN CHICKEN RETINA AND ITS INTERAQION 
WITH GAMMA AMINOBUTYRIC-ACID. 

001287 02-03 
LOCALIZATION OF SENSITIVE SITES TO TAURINE, GAMMA 
AMINOBUTYRIC-ACID, GLYCINE AND BETA ALANINE IN THE 
MOLECULAR LAYER OF GUINEA-PIG CEREBELLAR SLICES. 

001402 02-03 
THE ROLE OF GAMMA AMINOBUTYRIC-ACID IN ACUTE AND CHRONIC 
NEUROLEPTIC AQION. 

001465 02-03 



S-18 



i^OLUME 19, SUBJECT INDEX 



Subject Index 



A STUDY OF A GLIAL GAMMA AMINOBUTYRIC-ACID SYSTEM; ITS 
REGULATION, FUNCTION AND THE EFFECTS OF DIAZEPAM. (PH.D. 
DISSERTATION). 

001524 02-03 
PRELIMINARY-STUDIES ON CSF GAMMA AMINOBUTYRIC-ACID LEVELS IN 
PSYCHIATRIC-PATIENTS BEFORE AND DURING TREATMENT WITH 
DIFFERENT PSYCHOTROPIC-DRUGS. 

001959 02-08 
INCREASED CSF GAMMA AMINOBUTYRIC-ACID AFTER TREATMENT WITH 
GAMMA VINYL-GABA 

002237 02-13 
INHIBITION OF VASOPRESSIN RELEASE TO CAROTID OCCLUSION BY 
GAMMA AMINOBUTYRIC-ACID AND GLYCINE. 

002715 03-03 
DOPAMINE-RECEPTOR SUPERSENSITIVITY IN THE CORPUS-STRIATUM 

FOLLOWING CHRONIC ELEVATION OF BRAIN GAMMA AMINOBUTYRIC- 
ACID. 

002716 03-03 
CENTRAL HYPOTENSIVE-EFFECT OF GAMMA AMINOBUTYRIC-ACID IN 

ANESTHETIZED DOGS. 

003772 04-03 
A STUDY OF GAMMA AMINOBUTYRIC-ACID UPTAKE IN NORMAL AND 
DOWNS-SYNDROME PLATELETS. 

003787 04-03 
THE EFFECT OF SODIUM-DIPROPYLACETATE ON GAMMA AMINOBUTYRIC- 
ACID DEPENDENT INHIBITION IN THE RAT-CORTEX AND SUBSTANTIA- 
NIGRA IN RELATION TO ITS ANTICONVULSANT ACTIVITY. 

003880 04-03 
CHANGES IN GAMMA AMINOBUTYRIC-ACID SHUNT ENZYMES IN 
REGIONS OF RAT-BRAIN WITH KETAMINE ANESTHESIA. 

003891 04-03 
STUDIES ON THE MECHANISM-OF-ACTION OF AVERMECTIN-BIA: 
STIMULATION OF RELEASE OF GAMMA AMINOBUTYRIC-ACID FROM 
BRAIN SYNAPTOSOMES. 

003973 04-03 
STUDIES ON GAMMA AMINOBUTYRIC-ACID TRANSPORT IN COBALT 
EXPERIMENTAL EPILEPSY IN THE RAT. 

003990 04-03 
MODULATORY INTERACTIONS BETWEEN NOREPINEPHRINE AND TAURINE, 
BETA ALANINE, GAMMA AMINOBUTYRIC-ACID AND MUSCIMOL 
APPLIED lONTOPHORETICALLY TO CEREBELLAR PURKINJE-CELLS. 

004058 04-03 
ANTAGONISM OF SOME CENTRAL-EFFECTS OF D TUBOCURARINE BY 
GAMMA AMINOBUTYRIC-ACID. 

004102 04-04 
MINOBUTYRIC-ACID-MEDIATED 

REDUCTION OF GAMMA AMINOBUTYRIC-ACID-MEDIATED (GABA) 
TRANSMISSION BY A CONVULSANT BENZODIAZEPINE. 

000015 01-02 
MINOBUTYRIC-ACID-RECEPTOR 

DIFFERENCES IN GAMMA AMINOBUTYRIC-ACID-RECEPTOR SENSITIVITY IN 
INBRED STRAINS OF MICE. 

000303 01-03 
SUSTAINED GAMMA AMINOBUTYRIC-ACID-RECEPTOR STIMULATION AND 
CHRONIC NEUROLEPTIC-EFFECTS. 

001345 02-03 
BINDING OF (3H) MUSCIMOL, A POTENT GAMMA AMINOBUTYRIC-ACID- 
RECEPTOR AGONIST. TO MEMBRANES OF THE BOVINE RETINA 

003954 04-03 
THE EFFECTS OF ACUTE AND CHRONIC ETHANOL ADMINISTRATION AND 
ITS WITHDRAWAL ON GAMMA AMINOBUTYRIC-ACID-RECEPTOR 
BINDING IN RAT-BRAIN. 

...r„ 004035 04-03 

ALTERATIONS IN GAMMA AMINOBUTYRIC-ACID-RECEPTOR SENSITIVITY 
FOLLOWING ACUTE AND CHRONIC ETHANOL TREATMENTS 

004037 04-03 
MINOBUTYRIC-ACID-RECEPTORS 

INFLUENCE OF CELLULAR-TRANSPORT ON THE INTERACTION OF AMINO- 
ACIDS WITH GAMMA AMINOBUTYRIC-ACID-RECEPTORS (GABA) IN THE 
ISOLATED OLFACTORY-CORTEX OF THE GUINEA-PIG. 

000034 01-03 
MINOBUTYRIC-ACID-TRANSAMINASE 

CHANGES IN PRIMARY AFFERENT DEPOLARIZATION AFTER 
ADMINISTRATION OF GAMMA ACETYLENIC-GAMMA-AMINOBUTYRIC- 
ACID (GAG), A GAMMA AMINOBUTYRIC-ACID-TRANSAMINASE 
(GABA-TRANSAMINASE) INHIBITOR. 

000174 01-03 
INHIBITION OF GAMMA AMINOBUTYRIC-ACID-TRANSAMINASE WITH 6 
AMINONICOTINAMIDE IN REGIONS OF THE RAT-BRAIN. 

002868 03-03 
THE INACTIVATION OF GAMMA AMINOBUTYRIC-ACID-TRANSAMINASE IN 
DISSOCIATED NEURONAL CULTURES FROM SPINAL-CORD. 

003980 04-03 
MINODIHYDROXYTETRAHYDRONAPHTHALENE 

(3H) 2 AMINODIHYDROXYTETRAHYDRONAPHTHALENE (ADTN)- 
REGIONAL DISTRIBUTION AND IN VIVO BINDING AFTER ACUTE AND 
CHRONIC DRUG-TREATMENT. 

000052 01-03 
MINOHIPPURIC-ACID 

STUDIES ON THE EFFECT OF ALPHA MELANOCYTE- STIMULATING- 
HORMONE AND RELATED PEPTIDES ON THE ACCUMULATION OF P 



AMINOHIPPURIC-ACID IN RENAL CORTICAL SLICES. (UNPUBLISHED 
PAPER). 

001372 02-03 
AMINOLAEVULINIC-ACID 

EFFECTS OF D AMINOLAEVULINIC-ACID, PORPHOBILINOGEN, AMINO- 
ACIDS AND BARBITURATES ON CALCIUM ACCUMULATION BY 
CULTURED NEURONS, 

002859 03-03 
AMINOMETHYLCYCLOPROPANECARBOXYLIC-ACID 
THE SYNTHESIS AND ACTIVITY OF CIS AND TRANS 2 
AMINOMETHYLCYCLOPROPANECARBOXYLIC-ACID AS 
CONFORMATIONALLY RESTRICTED ANALOGUES OF GABA. 

002633 03-01 
AMINONICOTINAMIDE 

INHIBITION OF GAMMA AMINOBUTYRIC-ACID-TRANSAMINASE WITH 6 
AMINONICOTINAMIDE IN REGIONS OF THE RAT-BRAIN. 

002868 03-03 
AMINOOXYACETIC-ACIO 

EFFECT OF AMINOOXYACETIC-ACID (AOAA) ON GABA LEVELS IN SOME 
PARTS OF THE RAT-BRAIN. 

000040 01-03 
DIFFERENTIAL-EFFECTS OF N DIPROPYLACETATE AND AMINOOXYACETIC- 
ACID ON GAMMA AMINOBUTYRIC-ACID LEVELS IN DISCRETE AREAS 
OF RAT-BRAIN. 

000140 01-03 
EFFECT OF AMINOOXYACETIC-ACID AND BICUCULLINE ON PROLACTIN 
RELEASE IN CASTRATED MALE RATS. 

001194 02-03 
CONVULSANT-EFFECTS OF AMINOOXYACETIC-ACID DURING ONTOGENESIS 
IN RATS. 

001439 02-03 
AMINOPEPTIDASE 

INHIBITION OF AMINOPEPTIDASE AND ACETYLCHOLINESTERASE BY 
PUROMYCIN AND PUROMYCIN ANALOGS. 

003835 04-03 
AMINOPHYLUNE 

EFFECTS OF RESERPINE, PROPRANOLOL, AND AMINOPHYLLINE ON 
SEIZURE ACTIVITY AND CNS CYCLIC-NUCLEOTIDES. 

000115 01-03 
BLOCKADE OF STRIATAL NEURONE RESPONSES TO MORPHINE BY 
AMINOPHYLLINE: EVIDENCE FOR ADENOSINE MEDIATION OF OPIATE 
ACTION. 

000229 01-03 
AMINOPHYLLINE AND THEOPHYLLINE DERIVATIVES AS ANTAGONISTS OF 
NEURONAL DEPRESSION BY ADENOSINE: A MICROIONTOPHORETIC- 
STUDY. 

001410 02-03 
AMINOPHYLLINE AND IMIDAZOLE AS CONVULSANTS. 

004232 04-04 
AMINOPHYLLINE-INDUCED 

CAFFEINE-INDUCED AND AMINOPHYLLINE-INDUCED SEIZURES 

002689 03-03 
AMINOPYRIDINE 

PRESYNAPTIC ACTIONS OF 4 AMINOPYRIDINE AND GAMMA 
AMINOBUTYRIC-ACID ON RAT SYMPATHETIC GANGLIA IN VITRO. 

001244 02-03 
EFFECTS OF 4 AMINOPYRIDINE ON THE TURNOVER OF MONOAMINES IN 
THE CENTRAL-NERVOUS-SYSTEM OF THE RAT. 

002658 03-03 
AQION OF 4 AMINOPYRIDINE ON THE CEREBRAL CIRCULATION. 

003781 04-03 
4 AMINOPYRIDINE BLOCKADE OF NEURONAL DEPRESSANT RESPONSES TO 
ADENOSINE-TRIPHOSPHATE. 

003963 04-03 
AMINOPYRINE 

INHIBITORY-ACTION OF THE COMBINATION OF AMINOPYRINE AND 
SECOBARBITAL ON EEG ACTIVATION, NEOCORTICAL RECRUITING AND 
AUGMENTING RESPONSES IN RABBITS. 

004022 04-03 
AMINOSULFONIC-ACIDS 

EFFECT OF INTRAVENTRICULAR INJECTIONS OF ALPHA AMINOSULFONIC- 
ACIDS ON THE CENTRAL-NERVOUS-SYSTEM OF CONSCIOUS MICE. 

000009 01-02 
AMINOTETRALINS 

PRODRUGS OF SOME DOPAMINERGIC 2 AMINOTETRALINS: A REVIEW OF 
THEIR SYNTHESES AND NEUROCHEMICAL PROFILES. 

000004 01-01 
N ALKYLATED 2 AMINOTETRALINS: CENTRAL DOPAMINE-RECEPTOR 
STIMULATING ACTIVITY. 

000399 01-04 
AMITRIPTYLINE 

AMITRIPTYLINE BINDING TO SPECIFIC ALPHA-ADRENERGIC-RECEPTORS IN 
VITRO. 

000181 01-03 
A REEXAMINATION OF THE CLINICAL-EFFECTS OF IMIPRAMINE AND 
AMITRIPTYLINE IN DEPRESSIVE-ILLNESS. 

000579 01-09 
STUDY OF INTRAVENOUS AMITRIPTYLINE IN ACUTE DEPRESSIONS 

000581 01-09 



a 

C 

6 



S-19 



Subject Index 



Psychopharmacology Abstracts 



PREDiaiON OF STEADY-STATE PLASMA LEVELS OF AMITRIPTYLINE AND 
NORTRIPTYLINE FROM A SINGLE-DOSE 24-HR. LEVEL IN DEPRESSED- 
PATIENTS. 

000582 01-09 
COMPARATIVE-STUDY OF THE CARDIOTOXICITY OF AMITRIPTYLINE AND 
MAPROTILINE IN DEPRESSIVE-PATIENTS. 

000595 01-09 
ON THE RELATIONSHIP OF NORTRIPTYLINE: AMITRIPTYLINE RATIO TO 
CLINICAL IMPROVEMENT OF AMITRIPTYLINE TREATED DEPRESSIVE- 
PATIENTS. 

000599 01-09 
D-AMPHET AMINE AS A PREDICTOR FOR RESPONSE TO IMIPRAMINE AND 
AMITRIPTYLINE. 

000621 01-09 
URINARY MHPG AND CLINICAL-RESPONSE TO AMITRIPTYLINE IN 
DEPRESSED-PATIENTS. 

000631 01-09 
INTERACTION BETV^EEN AMITRIPTYLINE AND PHENOTHIAZINE IN MAN: 
METABOLITE NORTRIPTYLINE AND THE CORRELATION WITH CLINICAL- 

^'''''''' 000640 01-09 

AMITRIPTYLINE THERAPY OF OBSESSIVE-COMPULSIVE-NEUROSIS. 

000656 01-10 
AMITRIPTYLINE, NORTRIPTYLINE PLASMA LEVELS AND CLINICAL- 
RESPONSE IN WOMEN WITH AFFECTIVE-DISORDERS. 

000757 01-13 
STIMULUS INTENSITY CONTROL IN DEPRESSION: A STUDY OF THE 
COMPARATIVE-EFFECT OF DOXEPIN AND AMITRIPTYLINE ON CORTICAL 
EVOKED-POTENTIALS. 

000763 01-13 
HYPNAGOGIC AND HYPNOPOMPIC HALLUCINATIONS DURING 
AMITRIPTYLINE TREATMENT. 

000850 01-15 
POSSIBLE INVOLVEMENT OF CYCLIC-AMP AND FRONTAL-CORTEX IN 
AMITRIPTYLINE MEDIATED SUPPRESSION OF THE HYPOTENSIVE-EFFEQ 

OFCLONIDINE. „„,o.^^.^o 

001259 02-03 
ANTIARRHYTHMIC-ACTIVITY OF AMITRIPTYLINE ANALOGUES IN 
CONSCIOUS DOGS AFTER MYOCARDIAL-INFARCTION: 
CYPROHEPTADINIUM-METHIODIDE. 

001534 02-03 
EFFECTS OF AMITRIPTYLINE AND CLOMIPRAMINE IN THE ISOLATED, 
PERFUSED RABBIT HEART. „ „^ 

001852 02-05 
EFFECT OF AMITRIPTYLINE ANTIDOTES ON REPETITIVE EXTRASYSTOLE 
THESHOLD. 

001856 02-05 
AMITRIPTYLINE PLASMA CONCENTRATION AND CLINICAL-EFFEQ: A 
WORLD-HEALTH-ORGANIZATION COLLABORATIVE-STUDY. 

001976 02-09 
DOUBLE-BLIND CONTROLLED EXPERIMENT: AMINEPTINE VERSUS 
AMITRIPTYLINE USING THE HAMILTON-DEPRESSION-RATING- SCALE. 

002050 02-09 
BLOOD LEVEL OF AMITRIPTYLINE, NORTRIPTYLINE, NORADRENALINE, 
SEROTONIN AND THERAPEUTIC RESPONSE. 

002057 02-09 
TRICHOTILLOMANIA TREATED WITH AMITRIPTYLINE 

002083 02-10 
THE CONTRIBUTION OF ALPHAl ACID GLYCOPROTEIN, LIPOPROTEINS, 
AND ALBUMIN TO THE PLASMA BINDING OF PERAZINE, 
AMITRIPTYLINE, AND NORTRIPTYLINE IN HEALTHY MAN. 

002214 02-13 
CARDIOVASCULAR-EFFECTS OF AMITRIPTYLINE, MIANSERIN AND 

ZIMELIDINE IN DEPRESSED-PATIENTS. 

002215 02-13 
HIGH-LEVELS OF AMITRIPTYLINE AND CLINICAL-RESPONSE. 

002266 02-13 
INTERINDIVIDUAL DIFFERENCES IN AMITRIPTYLINE DEMETHYLATION. 

002282 02-13 
THE PERIPHERAL ANTICHOLINERGIC-ACTIVITY OF TRICYCLIC- 
ANTIDEPRESSANTS: COMPARISON OF AMITRIPTYLINE AND 
DESIPRAMINE IN HUMAN VOLUNTEERS. 

002298 02-13 
THYMOANALEPTIC TREATMENT CONTROL THROUGH MEASUREMENT OF 
PLASMA CONCENTRATIONS OF AMITRIPTYLINE AND ITS METABOLITE 
NORTRIPTYLINE. 

002304 02-13 
TERATOGENICITY OF IMIPRAMINE AND AMITRIPTYLINE IN FETAL 
HAMSTERS. 

002410 02-15 
HYPOMANIC-REACTION TO AMITRIPTYLINE IN A DEPRESSED-CHILD. 

002418 02-15 
CARDIOVASCULAR-EFFEQS OF MIANSERIN AND AMITRIPTYLINE IN 
HEALTHY VOLUNTEERS. 

002469 02-15 
A METHOD FOR THE DETERMINATION OF AMITRIPTYLINE AND ITS 
METABOLITES NORTRIPTYLINE, 10 HYDROXYAMITRIPTYLINE, AND 10 
HYDROXYNORTRIPTYLINE IN HUMAN PLASMA USING STABLE ISOTOPE 
DILUTION AND GAS-CHROMATOGRAPHY CHEMICAL-IONIZATION 
MASS-SPECTROMETRY. 

002486 02-16 



AMITRIPTYLINE: LONG-TERM-TREATMENT ELEVATES ALPHA-ADRENERGIC 
AND MUSCARINIC-RECEPTOR BINDING IN MOUSE-BRAIN. 

002875 03-03 
DIFFERENTIAL-EFFECT OF CHRONIC DESIPRAMINE AND AMITRIPTYLINE 
TREATMENT ON RAT-BRAIN ADRENERGIC AND SEROTONERGIC- 
RECEPTORS. 

002914 03-03 
AMITRIPTYLINE PROVIDES LONG-LASTING IMMUNIZATION AGAINST 
SUDDEN CARDIAC DEATH FROM COCAINE. 

003122 03-05 
AMOXAPINE AND AMITRIPTYLINE IN THE OUTPATIENT TREATMENT OF 
ENDOGENOUS DEPRESSION. 

003217 03-09 
PANIC-ANXIETY AFTER ABRUPT DISCONTINUATION OF AMITRIPTYLINE 

003223 03-09 
DOUBLE-BUND STUDY OF MIANSERIN AND AMITRIPTYLINE. 

003231 03-09 
A DOUBLE-BLIND COMPARISON BETWEEN AMOXAPINE AND 
AMITRIPTYLINE IN DEPRESSED-INPATIENTS. 

003234 03-09 
DEPRESSION SUBTYPES AFFECT THE STEADY-STATE PLASMA LEVELS AND 
THERAPEUTIC-EFFICACY OF AMITRIPTYLINE AND NORTRIPTYLINE. 

003244 03-09 
PHENEUINE AND AMITRIPTYLINE IN NEUROTIC DEPRESSION. 
(UNPUBLISHED PAPER) 

003248 03-09 
EFFEaS OF PHENELZINE AND AMITRIPTYLINE ON DEPRESSION. 

003249 03-09 
BEHAVIORAL-PREDiaORS OF AMITRIPTYLINE RESPONSE IN DEPRESSION. 

003253 03-09 
PHARMACOKINETICS OF AMITRIPTYLINE, IMIPRAMINE, AND 
MAPROTILINE IN THE ELDERLY. 

003324 03-1 1 
CARDIOVASCULAR-EFFECTS OF MIANSERIN - A COMPARATIVE-STUDY 
WITH AMITRIPTYLINE AND A PLACEBO IN HEALTHY SUBJEQS. 

003503 03-15 
A TARDIVE-DYSKINESIA-LIKE SYNDROME AFTER AMITRIPTYLINE 
TREATMENT 

003552 03-15 
FIRST RESULTS OF AN ORIGINAL METHOD FOR MEASURING BLOOD 
LEVELS OF ANTIDEPRESSANTS (AMITRIPTYLINE AND NORTRIPTYLINE) 

003559 03-16 
INTERAQION OF THE TRICYCLIC-ANTIDEPRESSANT AMITRIPTYLINE WITH 
PREJUNCTIONAL ALPHA AND MUSCARINIC-RECEPTORS IN THE DOG 
SAPHENOUS VEIN 

003756 04-03 
DRUG-INTERACTIONS OF AMITRIPTYLINE AND NORTRIPTYLINE WITH 
WARFARIN IN THE RAT. 

003912 04-03 
REGULATION OF SER0T0NIN2-RECEPT0RS (5 HT2) LABELED WITH 
(3H)SPIR0PERID0L BY CHRONIC-TREATMENT WITH THE 
ANTIDEPRESSANT AMITRIPTYLINE 

003964 04-03 
COMPARATIVE-EFFEQS OF PHENELZINE AND AMITRIPTYLINE: A 
PLACEBO-CONTROLLED-TRIAL. 

004402 04-09 
THE RELATIONSHIPS BETWEEN CLINICAL-RESPONSE, 

PSYCHOPHYSIOLOGICAL-VARIABLES AND PLASMA LEVELS OF 
AMITRIPTYLINE AND DIAZEPAM IN NEUROTIC-OUTPATIENTS. 

004423 04-10 
AMITRIPTYLINE AND NORTRIPTYLINE PLASMA LEVELS MONITORING. 
PERSPECTIVE IN CLINICAL-PRAQICE. 

004675 04-16 
AMITRIPTYLINE-HYDROCHLORIDE 

NMR SPECTRAL STUDY OF PROTON TRANSFER IN AMITRIPTYLINE- 
HYDROCHLORIDE CHLORDIAZEPOXIDE-HYDROCHLORIOE COMBINATIONS 
IN DIPOLAR APROTIC SOLVENTS. 

003654 04-01 
SIMULTANEOUS HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC- 
DETERMINATION OF AMITRIPTYLINE-HYDROCHLORIDE IN TWO- 
COMPONENT TABLET FORMULATIONS. 

004673 04-16 

AMMONIA 

EFFECT OF PYRITINOL AND PIRACETAM ON CHANGES IN FREE AMMONIA 
LEVEL IN CNS TISSUE AFTER PARADOXICAL SLEEP-DEPRIVATION IN 

RATS 

001199 02-03 

AMMONIA AND DISINHIBITION IN CAT MOTOR-CORTEX BY AMMONIUM- 
ACETATE MONOFLUOROACETATE AND INSULIN-INDUCED 
HYPOGLYCEMIA. 

004276 04-05 

AMMONIUM-ACETATE 

AMMONIA AND DISINHIBITION IN CAT MOTOR-CORTEX BY AMMONIUM- 
ACETATE MONOFLUOROACETATE AND INSULIN-INDUCED 
HYPOGLYCEMIA. 

004276 04-05 



S-20 



VOLUME 19, SUBJECT INDEX 



Subject Index 



IkMNESIA 

RETROGRADE AMNESIA PRODUCED BY ELECTRICAL- STIMULATION OF THE 
AMYGDALA: ATTENUATION WITH ADRENERGIC ANTAGONISTS. 
(UNPUBLISHED PAPER). 

001488 02-03 
BETA ENDORPHIN CAUSES RETROGRADE AMNESIA AND IS RELEASED 
FROM THE RAT-BRAIN BY VARIOUS FORMS OF TRAINING AND 
STIMULATION. 

001664 02-04 
TIME-DEPENDENT CHANGES IN ANTEROGRADE SCOPOLAMINE-INDUCED 
AMNESIA IN RATS. 

004182 04-04 
RETROGRADE AMNESIA PRODUCED BY ELECTRICAL-STIMULATION OF THE 
AMYGDALA: AHENUATION WITH ADRENERGIC ANTAGONISTS. 

004231 04-04 
USE OF LYSINE-VASOPRESSIN IN THE TREATMENT OF POSnRAUMATIC 
AMNESIA. 

004583 04-14 
^NIOTIC-FLUID 

CONCENTRATIONS OF CIS(Z) FLUPENTHIXOL IN MATERNAL SERUM, 
AMNIOTIC-FLUID, UMBILICAL-CORD-SERUM, AND MILK. 

002423 02-15 
^MOXAPINE 

AMOXAPINE IN EXPERIMENTAL PSYCHOPHARMACOLOGY: A 
NEUROLEPTIC OR AN ANTIDEPRESSANT? 

001070 02-02 
AMOXAPINE AND AMITRIPTYLINE IN THE OUTPATIENT TREATMENT OF 
ENDOGENOUS DEPRESSION. 

003217 03-09 
A DOUBLE-BUND COMPARISON BETWEEN AMOXAPINE AND 
AMITRIPTYLINE IN DEPRESSED-INPATIENTS. 

003234 03-09 
AMOXAPINE AND IMIPRAMINE IN THE TREATMENT OF DEPRESSED- 
OUTPATIENTS: A CONTROLLED- STUDY. 

003254 03-09 
CLINICAL-RESPONSE AND BLOOD LEVELS IN THE TREATMENT OF 
DEPRESSION WITH A NEW ANTIDEPRESSANT-DRUG, AMOXAPINE. 

004356 04-09 
AMOXAPINE: A REVIEW OF LITERATURE. 

004702 04-17 
KMP 

STUDY ON THE STABILITY OF THE FACTORIAL STRUCTURE OF THE AMP 
SYSTEM DURING TREATMENT. 

004696 04-16 
VMPHET AMINE 

COMPARISON OF THE EFFECTS OF THE ISOMERS OF AMPHETAMINE, 
METHYLPHENIDATE AND DEOXYPIPRADROL ON THE UPTAKE OF L 
(3H)N0REPINEPHRINE AND (3H)D0PAMINE BY SYNAPTIC VESICLES 
FROM RAT-WHOLE-BRAIN, STRIATUM AND HYPOTHALAMUS. 

000091 01-03 
ACUTE AND CHRONIC EFFECTS OF NEUROLEPTICS AND ACUTE EFFECTS OF 
APOMORPHINE AND AMPHETAMINE ON DOPAMINE TURNOVER IN 
CORPUS-STRIATUM AND SUBSTANTIA-NIGRA OF THE RAT-BRAIN. 

000215 01-03 
DECREASED SPIROPERIDOL AND LSD BINDING IN RAT-BRAIN AFTER 

CONTINUOUS AMPHETAMINE. 

000216 01-03 
LONG-TERM EFFECTS OF CONTINUOUS EXPOSURE TO AMPHETAMINE ON 

BRAIN DOPAMINE CONCENTRATION AND SYNAPTOSOMAL UPTAKE IN 
MICE. 

000287 01-03 
INFLUENCE OF AMPHETAMINE AND PHENYLPROPANOLAMINE ON FOOD 
INTAKE, ACTIVITY, AND BODY-TEMPERATURE IN RATS WITH 
VENTROMEDIAL HYPOTHAUMIC OR DORSOLATERAL TEGMENTAL 
DAMAGE. 

000322 01-03 
REWARD SYSTEM DEPRESSION FOLLOWING CHRONIC AMPHETAMINE: 
ANTAGONISM BY HALOPERIDOL. 

000342 01-04 
CONSEQUENT EVENTS AS DETERMINANTS OF DRUG-EFFECTS ON 
SCHEDULE-CONTROLLED BEHAVIOR: MODIFICATION OF EFFECTS OF 
COCAINE AND D-AMPHET AMINE FOLLOWING CHRONIC AMPHETAMINE 
ADMINISTRATION. 

000350 01-04 
DISRUPTION OF SELECTIVE AHENTION BY APOMORPHINE, BUT NOT 
AMPHETAMINE, IN THE MONGOLIAN-GERBIL. 

000358 01-04 
RELATIONSHIPS BETWEEN SELECTIVE DENERVATION OF DOPAMINE 
TERMINAL-FIELDS IN THE ANTERIOR-FOREBRAIN AND BEHAVIORAL- 
RESPONSES TO AMPHETAMINE AND APOMORPHINE. 

000384 01-04 
EFFECTS OF 6 HYDROXYDOPAMINE AND AMPHETAMINE ON RAT 
MOTHERING-BEHAVIOR AND OFFSPRING DEVELOPMENT. 

000452 01-04 
FACILITATION OF SELF-STIMULATION OF THE PREFRONTAL-CORTEX IN 
RATS FOLLOWING CHRONIC ADMINISTRATION OF SPIROPERIDOL OR 
AMPHETAMINE. 

000457 01-04 
DIFFERENT DOPAMINERGIC MECHANISMS FOR AMFONELIC-ACID, 
AMPHETAMINE AND APOMORPHINE. 

000465 01-04 



TEMPORAL PROPERTIES OF THE REWARDING AND AVERSIVE-EFFECTS OF 
AMPHETAMINE IN RATS. 

000471 01-04 
THE INFLUENCE OF GABAERGIC SUBSTANCES ON THE EFFECTS OF 
STIMULATION OF THE CAUDATE-NUCLEUS AND AMPHETAMINE 
STEREOTYPY IN CATS. 

000489 01-04 
CHRONIC AMPHETAMINE ADMINISTRATION TO CATS: BEHAVIORAL- 
EVIDENCE AND NEUROCHEMICAL EVIDENCE FOR DECREASED CENTRAL 
SEROTONERGIC FUNCTION. 

000491 01-04 
ATTENUATION OF AMPHETAMINE ANOREXIA IN RATS FOLLOWING 
SUBCHRONIC-TREATMENT WITH A TRICYCLIC-ANTIDEPRESSANT. 

000501 01-04 
AMPHETAMINE AND PIRIBEDIL IN AFFECTIVE-ILLNESS. 

000618 01-09 
REINFORCING, DISCRIMINATIVE AND ACTIVATING PROPERTIES OF 
AMPHETAMINE. 

000804 01-14 
DIVERGENT RESERPINE EFFECTS ON AMFONELIC-ACID AND 
AMPHETAMINE STIMULATION OF SYNAPTOSOMAL DOPAMINE 
FORMATION FROM PHENYLALANINE. 

001113 02-03 
EPINEPHRINE IS RELEASED FROM HYPOTHALAMUS BY DEPOLARIZING- 
AGENTS AND AMPHETAMINE. 

001155 02-03 
A COMPARISON OF THE EFFECTS OF METHYLPHENIDATE AND 
AMPHETAMINE ON THE SIMULTANEOUS RELEASE OF RADIOLABELLED 
DOPAMINE AND P OR M TYRAMINE FROM RAT STRIATAL SLICES 

001207 02-03 
LONG-TERM DECREASES IN SPONTANEOUS FIRING OF CAUDATE NEURONS 
INDUCED BY AMPHETAMINE IN CATS. 

001340 02-03 
DEVELOPMENT OF AND RECOVERY FROM SUBSENSITIVITY OF THE 
NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN BRAIN: EFFECT 
OF AMPHETAMINE FOLLOWING INHIBITION OF ITS AROMATIC 
HYDROXYLATION BY IPRINDOLE. 

001353 02-03 
MODIFICATION OF DOPAMINE-RECEPTORS IN BRAIN BY CONTINUOUS 
AMPHETAMINE ADMINISTRATIONS TO RATS. 

001395 02-03 
SUPERSENSITIVITY AND THE EFFECTS OF LONG-TERM AMPHETAMINE IN 
THE RAT NIGROSTRIATAL SYSTEM. (PH.D. DISSERTATION). 

001485 02-03 
AMPHETAMINE STEREOTYPIES AND POLYRIBOSOMAL DISAGGREGATION 
IN RATS: EFFECTS OF ADRENERGIC AND SEROTONERGIC BLOCKING- 
AGENTS. 

001531 02-03 
REDUCTION OF DOPAMINERGIC-SUPERSENSITIVITY BY A SINGLE-DOSE OF 
AMPHETAMINE. 

001642 02-04 
BRAIN LOCATIONS CONTROLLING THE BEHAVIORAL-EFFECTS OF CHRONIC 
AMPHETAMINE INTOXICATION. 

001653 02-04 
EFFECTS OF RESERPINE AND AMPHETAMINE ON THE DEVELOPMENT OF 

HYPERACTIVITY IN MATERNALLY-DEPRIVED RAT PUPS. 

001654 02-04 
ENHANCED LATERAL HYPOTHALAMIC SELF- STIMULATION RESPONDING 

AFTER CHRONIC EXPOSURE TO AMPHETAMINE. 

001688 02-04 
EFFECTS OF CHRONIC AMPHETAMINE OR RESERPINE ON SELF- 
STIMULATION RESPONDING: ANIMAL-MODEL OF DEPRESSION? 

001699 02-04 
GENETIC AND EXPERIMENTAL FACTORS AFFECTING THE PARADOXICAL- 
EFFECTS OF AMPHETAMINE IN DOGS. 

001704 02-04 
INTERACTION OF PROSTAGLANDINS AND THE EFFECTS OF MORPHINE AND 
AMPHETAMINE IN RATS. (PH.D. DISSERTATION). 

001732 02-04 
AMPHETAMINE AND MATERNAL-BEHAVIOR: DOSE-RESPONSE 
RELATIONSHIPS. 

001752 02-04 
APPARENT TOLERANCE TO SOME ASPECTS OF AMPHETAMINE 
STEREOTYPY WITH LONG-TERM-TREATMENT. 

001758 02-04 
GO-HERE-GO-THERE PERFORMANCE AFTER AMPHETAMINE: THE 

IMPORTANCE OF THE RESPONSE REQUIREMENT IN SUCCESSIVE 
DISCRIMINATION. 

001759 02-04 
EFFECTS OF AMPHETAMINE AND PHENYLPROPANOLAMINE ON FOOD 

INTAKE IN RATS WITH VENTROMEDIAL HYPOTHALAMIC OR 
DORSOLATERAL TEGMENTAL DAMAGE. 

001818 02-04 
A SILICONE PELLET FOR LONG-TERM CONTINUOUS ADMINISTRATION OF 
AMPHETAMINE. 

001875 02-06 
DIFFERENTIAL-EFFECTS OF AMPHETAMINE AND NEUROLEPTICS ON 
NEGATIVE VS. POSITIVE SYMPTOMS IN SCHIZOPHRENIA. 

001906 02-08 



5 

s 



fe' 



S-21 



Subject Index 



Ptychopharmacology Abstracts 



PARADOXICAL IMPROVEMENT FOLLOWING IV AMPHETAMINE IN 
SCHIZOPHRENIA. (UNPUBLISHED PAPER). 

001951 02-08 
REGIONAL CEREBRAL BLOOD FLOW IN A CASE OF AMPHETAMINE 
INTOXICATION. 

002210 02-13 
EFFECTS OF AMPHETAMINE ON VIGILANCE PERFORMANCE IN NORMAL 
AND HYPERACTIVE-CHILDREN. 

002359 02-14 
SUBJECTIVE DRUG-EFFECTS AND DRUG PREFERENCE IN HEALTHY 
VOLUNTEERS AS A MODEL OF A DRUGS REINFORCING EFFECTS: 
STUDIES ON NOMIFENSINE, AMPHETAMINE AND PLACEBO. 

002362 02-14 
SEX-DIFFERENCES IN THE AMPHETAMINE STIMULATED RELEASE OF 
CATECHOLAMINES FROM RAT STRIATAL TISSUE IN VITRO. 

002668 03-03 
MIDBRAIN DOPAMINE NEURONS: DIFFERENTIAL RESPONSES TO 
AMPHETAMINE ISOMERS. 

002680 03-03 
COCAINE AND AMPHETAMINE ANTAGONIZE THE DECREASE OF 

NORADRENERGIC NEUROTRANSMISSION ELICITED BY OXYMETAZOLINE 
BUT POTENTIATE THE INHIBITION BY ALPHA METHYLNOREPINEPHRINE 
IN THE PERFUSED CAT SPLEEN. 

002801 03-03 
INCREASED AMPHETAMINE STEREOTYPY AND LONGER HALOPERIDOL 
CATALEPSY IN SPONTANEOUSLY HYPERTENSIVE-RATS 

002891 03-03 
CANALIZATION OF AROUSAL IN THE PREWEANLING RAT: EFFECTS OF 
AMPHETAMINE ON AGGREGATION WITH SURROGATE STIMULI. 

002965 03-04 
HYPERACTIVITY IN DEVELOPING RATS: SEX-DIFFERENCES IN 6 
HYDROXYDOPAMINE AND AMPHETAMINE EFFECTS. 

002970 03-04 
ANIMAL-MODEL OF PSYCHOSIS: HALLUCINATORY BEHAVIORS IN 
MONKEYS DURING THE LATE STAGE OF CONTINUOUS AMPHETAMINE 
INTOXICATION. 

002988 03-04 
THE ROLE OF CALCIUM AND DOPAMINE MEMBRANE CARRIER IN 
MEDIATING THE BEHAVIORAL-EFFECTS AND BIOCHEMICAL-EFFECTS OF 
AMPHETAMINE. (PH.D. DISSERTATION). 

002996 03-04 
GONADECTOMY AND SEX-DIFFERENCES IN THE BEHAVIORAL-RESPONSES 
TO AMPHETAMINE AND APOMORPHINE OF RATS 

003084 03-04 
RELATIVE POTENCY OF AMPHETAMINE ISOMERS IN CAUSING THE 
SEROTONIN BEHAVIORAL-SYNDROME IN RATS. 

003094 03-04 
COMPUTER-ANALYZED EEG IN AMPHETAMINE RESPONSIVE 
HYPERACTIVE-CHILDREN. 

003338 03-11 
THE STIMULATING EFFECT OF AMPHETAMINE ON THE VISUAL SYSTEM 

003398 03-13 
EFFECT OF AMPHETAMINE ON THE METABOLISM AND INCORPORATION 
OF (3H) THYMIDINE INTO DNA OF DEVELOPING RAT-BRAIN 

003729 04-03 
UNIT ACTIVITY IN MEDIAL THALAMUS: COMPARATIVE-EFFECTS OF 
CAFFEINE AND AMPHETAMINE. 

003752 04-03 
EFFECTS OF ACUTE AND CHRONIC AMPHETAMINE TREATMENT ON 
PURKINJE NEURON DISCHARGE IN RAT CEREBELLUM. 

003793 04-03 
EFFECT OF AMPHETAMINE ON PLASMA CORTICOSTERONE IN THE 
CONSCIOUS RAT. 

003888 04-03 
EFFECTS OF IN VIVO AMPHETAMINE ADMINISTRATION ON DOPAMINE 
SYNTHESIS REGULATION IN RAT-BRAIN STRIATAL SYNAPTOSOMES. 
(UNPUBLISHED PAPER). 

003960 04-03 
SUSTAINED DECREASE IN FAT CONSUMPTION PRODUCED BY 
AMPHETAMINE IN RATS MAINTAINED ON A DIETARY SELF-SELECTION 
REGIME. 

004150 04-04 
HABITUATION OF THE THE HEAD-POKE RESPONSE: EFFECTS OF AN 
AMPHETAMINE BARBITURATE MIXTURE, PLG AND FENFLURAMINE. 

004159 04-04 
AN ANALYSIS OF VISUAL OBJECT REVERSAL LEARNING IN THE 
MARMOSET AFTER AMPHETAMINE AND HALOPERIDOL. 

004208 04-04 
SELECTIVE EFFECTS OF BARBITURATE AND AMPHETAMINE ON 
INFORMATION-PROCESSING AND RESPONSE EXECUTION. 

004563 04-14 
INTERACTION OF P CHLOROPHENYLALANINE, MIANSERINE AND 
DANITRACEN WITH AMPHETAMINE. 

004599 04-15 
AMPHETAMINE-ELICITED 

SEX-DIFFERENCES IN AMPHETAMINE-ELICITED ROTATIONAL-BEHAVIOR 
AND THE LATERALIZATION OF STRIATAL DOPAMINE IN RATS 

000459 01-04 
AMPHETAMINE-INDUCED 

AMPHETAMINE-INDUCED HYPERSENSITIVITY IN GUINEA-PIGS. 

000498 01-04 



DOSE-DEPENDENT, AMPHETAMINE-INDUCED CHANGES IN PERMEABILITY 
OF THE BLOOD-BRAIN-BARRIER OF NORMOTENSIVE-RATS AND 
SPONTANEOUSLY HYPERTENSIVE-RATS. 

001197 02-03 
5,7 DIHYDROXYTRYPTAMINE LESIONS OF THE AMYGDALA REDUCE 
AMPHETAMINE-INDUCED AND APOMORPHINE-INDUCED STEREOTYPED- 
BEHAVIOUR IN THE RAT. 

001589 02-04 
INFLUENCE OF BENZODIAZEPINE TRANQUILIZERS ON AMPHETAMINE- 
INDUCED LOCOMOTOR-STIMULATION IN MICE. 

001767 02-04 
SUPPRESSION OF AMPHETAMINE-INDUCED EEG AROUSAL IN THE 
HIPPOCAMPUS OF HALOPERIDOL TREATED RABBITS. 

002683 03-03 
AMPHETAMINE-INDUCED ROTATION IN NORMAL CATS. 

003002 03-04 
AMPHETAMINE-INDUCED MOTILITY AND NIGROSTRIATAL IMPULSE FLOW 

003005 03-04 
A PRIMATE ANALOGUE OF AMPHETAMINE-INDUCED BEHAVIORS IN 

HUMANS. 

003006 03-04 
AMPHETAMINE-INDUCED OVEREATING AND OVERWEIGHT IN RATS. 

003015 03-04 
EFFECTS OF DORSOLATERAL TEGMENTAL LESIONS ON AMPHETAMINE- 
INDUCED AND LITHIUM-INDUCED TASTE-AVERSIONS. 

003114 03-04 
NEUROTENSIN BLOCKS CERTAIN AMPHETAMINE-INDUCED BEHAVIOURS. 

004111 04-04 
THE EFFECT OF DOPAMINE UPTAKE BLOCKING-AGENTS ON THE 
AMPHETAMINE-INDUCED CIRCLING-BEHAVIOR IN MICE WITH 
UNILATERAL NIGROSTRIATAL LESIONS. 

004117 04-04 
NALOXONE FAILS TO BLOCK AMPHETAMINE-INDUCED ANOREXIA AND 
CONDITIONED TASTE-AVERSION 

004121 04-04 
CENTRAL AND PERIPHERAL EFFECTS OF LITHIUM ON AMPHETAMINE- 
INDUCED HYPERACTIVITY IN RATS. 

004223 04-04 
AMPHETAMINE-LIKE 

A CONSTITUENT OF KHAT-LEAVES WITH AMPHETAMINE-LIKE RELEASING 
PROPERTIES. 

001307 02-03 
AMPHETAMINE-LIKE REACTIONS TO PHENYLPROPANOLAMINE. 

003480 03-15 
AMPHETAMINES 

STRUCTURE-ACTIVITY RELATIONSHIPS AMONG SOME D N ALKYLATED 
AMPHETAMINES. 

001542 02-03 
AMPHETAMINIL 

AMPHETAMINIL IN THE TREATMENT OF DISTURBED EREQION POTENCY. 

002129 02-11 
AMYGDALA 

EFFECT OF NALOXONE, HALOPERIDOL AND PROPRANOLOL ON CYCLIC- 
ADENOSINE-MONOPHOSPHATE CONTENT OF RAT AMYGDALA. 

000071 01-03 
LOCOMOTOR AND CONVULSIVE RESPONSES TO PICROTOXIN IN 
AMYGDALA KINDLED RATS 

000416 01-04 
EFFECTS OF MORPHINE ON EVOK ED-POTENTIALS RECORDED FROM THE 
AMYGDALA BY TOOTH-PULP STIMULATION IN CATS. 

001379 02-03 
A PHARMACOLOGICAL ANALYSIS OF THE ROLE OF THE AMYGDALA IN 
THE CONTROL OF GONADOTROPIN AND PROLACTIN SECRETION. 

001418 02-03 
RETROGRADE AMNESIA PRODUCED BY ELEQRICAL- STIMULATION OF THE 
AMYGDALA: AHENUATION WITH ADRENERGIC ANTAGONISTS. 
(UNPUBLISHED PAPER). 

001488 02-03 
5,7 DIHYDROXYTRYPTAMINE LESIONS OF THE AMYGDALA REDUCE 
AMPHETAMINE-INDUCED AND APOMORPHINE-INDUCED STEREOTYPED- 
BEHAVIOUR IN THE RAT, 

001589 02-04 
AMYGDALA OPIATE-SENSITIVE MECHANISMS INFLUENCE FEAR 
MOTIVATED RESPONSES AND MEMORY PROCESSES FOR AVERSIVE- 
EXPERIENCES. (UNPUBLISHED PAPER). 

001628 02-04 
MODULATION OF OPIATE-RECEPTOR BINDING IN STRIATUM AND 

AMYGDALA BY SELECTIVE MESENCEPHALIC LESIONS. 

001629 02-04 
INVOLVEMENT OF CAUDATE-NUCLEUS, AMYGDALA OR RETICULAR 

FORMATION IN NEUROLEPTIC AND NARCOTIC CATALEPSY. 

002986 03-04 
EFFECT OF PHENTOLAMINE ADMINISTRATION INTO THE AMYGDALA 
COMPLEX OF RATS ON TIME-DEPENDENT MEMORY PROCESSES. 

002998 03-04 
THE EFFECT OF AMYGDALA KINDLING ON SPONTANEOUS AND COCAINE- 
INDUCED MOTOR-AaiVITY AND LIDOCAINE SEIZURES. 

003067 03-04 



S-22 



4 



VOLUME 19, SUBJECT INDEX 



Subject Index 



OPIATE-EFFECTS IN THE AMYGDALA CENTRAL NUCLEUS ON HEART RATE 
CONDITIONING IN RABBITS. 

003798 04-03 
EFFECTS OF 3 SULFAMOYLMETHYL-BENZISOXAZOLE (AD-810) AND SOME 
ANTIEPILEPTICS ON THE KINDLED SEIZURES IN THE NEOCORTEX, 
HIPPOCAMPUS AND AMYGDALA IN RATS. 

004149 04-04 
SEROTONERGIC MECHANISM IN SEIZURES KINDLED FROM THE RABBIT 
AMYGDALA. 

004227 04-04 
RETROGRADE AMNESIA PRODUCED BY ELECTRICAL-STIMULATION OF THE 
AMYGDALA: ATTENUATION WITH ADRENERGIC ANTAGONISTS. 

004231 04-04 
LESIONS OF AMYGDALA, PYRIFORM CORTEX AND OTHER BRAIN 
STRUCTURES DUE TO DIPIPERIDINOETHANE INTOXICATION. 

004273 04-05 
AMYGDALAR 

THE ROLE OF BIOGENIC-AMINES IN AMYGDALAR KINDLING. I. LOCAL 
AMYGDALAR AFTERDISCHARGE. 

000327 01-03 
AMYGDALOID 

MODIFICATION OF DOPAMINERGIC-RECEPTOR SENSITIVITY IN RAT-BRAIN 
AFTER AMYGDALOID KINDLING. 

000106 01-03 
ADDICTIVE-AGENTS AND INTRACRANIAL- STIMULATION (ICS): MORPHINE, 
NALOXONE, AND PRESSING FOR AMYGDALOID ICS. 

000371 01-04 
RELATION OF MONOMETHYLHYDRAZINE (MMH) SEIZURE THRESHOLDS 
TO AFTERDISCHARGE THRESHOLDS WITH AMYGDALOID STIMULATION 
IN CATS. 

000474 01-04 
BEHAVIORAL-ANALYSIS OF AMYGDALOID KINDLING IN BEAGLE-DOGS 
AND THE EFFECTS OF CLONAZEPAM, DIAZEPAM, PHENOBARBITAL, 
DIPHENYLHYDANTOIN, AND FLUNARIZINE ON SEIZURE 
MANIFESTATION. 

000496 01-04 
ENHANCED SENSITIVITY OF AMYGDALOID NEURONS TO SEROTONIN AND 
NOREPINEPHRINE AFTER CHRONIC ANTIDEPRESSANT TREATMENT. 

001523 02-03 
BARBITURATE SERUM LEVELS AND PROTECTION AGAINST KINDLED 
AMYGDALOID SEIZURES IN THE RAT. 

001559 02-04 
PHARMACOLOGICAL MODIFICATION OF AMYGDALOID KINDLED 
SEIZURES. 

001588 02-04 
NALOXONE FACILITATES AMYGDALOID KINDLING IN RATS. 

001644 02-04 
VALPROIC-ACID SERUM LEVELS AND PROTECTION AGAINST KINDLED 
AMYGDALOID SEIZURES IN THE RAT. 

002946 03-04 
THE EFFECTS OF VARIOUS ANESTHETICS ON AMYGDALOID KINDLED 
SEIZURES. 

002959 03-04 
DIFFERENTIAL ACTIONS OF CLASSICAL AND ATYPICAL ANTIPSYCHOTIC- 
DRUGS ON SPONTANEOUS NEURONAL ACTIVITY IN THE AMYGDALOID 
COMPLEX. 

003131 03-05 
AMYLOBARBITONE 

AMYLOBARBITONE AND FORGEHING. 

001763 02-04 
AMYOTROPHY 

THE USE OF LITHIUM-CARBONATE FOR TREATING KUGELBERG-WELANDER 
SPINAL AMYOTROPHY PATIENTS. 

003326 03-11 
ANAFRANIL 

THE BIOAVAILABILITY OF ORAL AND PARENTERAL CHLORIMIPRAMINE 
(ANAFRANIL). 

002232 02-13 
ANALGESIA 

COMPARATIVE-STUDY OF ANALGESIA INDUCED BY N VAL5-ENKEPHALIN 
AND PR05-ENKEPHALIN ANALOGS. 

000021 01-03 
REVERSIBLE INACTIVATION OF RAPHE-MAGNUS NEURONS: EFFECTS ON 
NOCICEPTIVE THRESHOLD AND MORPHINE-INDUCED ANALGESIA. 

000240 01-03 
THE POSSIBILITY THAT A COMPONENT OF MORPHINE-INDUCED 
ANALGESIA IS CONTRIBUTED INDIRECTLY VIA THE RELEASE OF 
ENDOGENOUS OPIOIDS. 

000263 01-03 
A FURTHER CHARACTERIZATION OF THE DIFFERENTIAL-EFFECTS OF 
LEUCINE-ENKEPHALIN, METHIONINE-ENKEPHALIN AND THEIR ANALOGS 
ON MORPHINE-INDUCED ANALGESIA. 

000311 01-03 
EFFECTS OF L AND D AMINO-ACIDS ON ANALGESIA AND LOCOMOTOR- 
ACTIVITY OF MICE: THEIR INTERACTION WITH MORPHINE. 

000336 01-04 
METHIONINE-ENKEPHALIN ANTAGONISM AND ENDORPHIN POTENTIATION 
OF NARCOTIC-INDUCED ANALGESIA. 

000357 01-04 



PSYCHOPHARMACOLOGY OF ANALGESIA AND PAIN. (UNPUBLISHED 
PAPER), 

001411 02-03 
EFFECTS OF RAPHE-MAGNUS AND RAPHE-PALLIDUS LESIONS ON 
MORPHINE-INDUCED ANALGESIA AND SPINAL-CORD MONOAMINES 

001420 02-03 
MORPHINE ANALGESIA FOLLOWING ITS INFUSION INTO DIFFERENT 
LIQUOR SPACES IN RAT-BRAIN. 

001429 02-03 
DIFFERENTIAL-EFFECTS OF SYSTEMIC VERSUS INTRACRANIAL INJECTION 
OF OPIATES ON CENTRAL, OROFACIAL AND LOWER BODY 
NOCICEPTION: SOMATOTYPY IN BULBAR ANALGESIA SYSTEMS. 

001446 02-03 
INFLUENCE OF THYROTROPIN-RELEASING-HORMONE AND HISTIDYL- 
PROLINE-DIKETOPIPERAZINE ON SPONTANEOUS LOCOMOTOR-ACTIVITY 
AND ANALGESIA INDUCED BY DELTA9 TETRAHYDROCANNABINOL IN 
THE MOUSE. 

001575 02-04 
ANTAGONISTIC-EFFECTS OF PSYCHOLEPTIC-DRUGS ON STRESS-INDUCED 
ANALGESIA. 

001609 02-04 
ETHANOL-INDUCED ANALGESIA IN RATS SELECTIVELY BRED FOR ETHANOL 
SENSITIVITY. 

001625 02-04 
MORPHINE ANALGESIA AFTER INTRATHECAL ADMINISTRATION OF A 
NARCOTIC AGONIST, CHLOROXYMORPHAMINE AND ANTAGONIST, 
CHLORNALTREXAMINE. 

001695 02-04 
OPIATE AND PEPTIDE INTERACTION: EFFECT OF ENKEPHALINS ON 
MORPHINE ANALGESIA. 

001698 02-04 
BRIEF SOCIAL-ISOLATION, PAIN RESPONSIVITY, AND MORPHINE 
ANALGESIA IN YOUNG RATS. 

001744 02-04 
AN INHIBITOR OF OPIOID-PEPTIDE DEGRADATION PRODUCES ANALGESIA 
IN MICE. 

001780 02-04 
ASPIRIN ANALGESIA EVALUATED BY EVENT-RELATED POTENTIALS IN 
MAN: POSSIBLE CENTRAL-ACTION IN BRAIN. 

002195 02-12 
MECHANISMS OF OPIATE ANALGESIA AND THE ROLE OF ENDORPHINS IN 
PAIN SUPPRESSION. (UNPUBLISHED PAPER). 

002275 02-13 
ENKEPHALIN-LIKE CHARACTER AND ANALGESIA. 

002650 03-02 
PHARMACOLOGICAL-STUDIES ON STIMULATION PRODUCED ANALGESIA 
IN MICE. 

002964 03-04 
DYNORPHIN: A POSSIBLE MODULATORY PEPTIDE ON MORPHINE OR BETA 
ENDORPHIN ANALGESIA IN MOUSE. 

002994 03-04 
NALOXONE REVERSIBLE DUPLICATION BY LANTHANUM OF OPIATE 
ANALGESIA EFFECTS ON OROFACIAL, LOWER BODY AND CENTRAL 
NOCICEPTION. 

003028 03-04 
CLONIDINE ANALGESIA AND SUPPRESSION OF OPERANT RESPONDING: 
DISSOCIATION OF MECHANISM. 

003046 03-04 
SUBSTANCE-P, HEXAPEPTIDE-PGLU6(SP6-1 1), ANALGESIA AND 
SEROTONIN DEPLETION. 

003050 03-04 
FOOTSHOCK ANALGESIA: PREVENTION BY BEHAVIOURAL-MANIPULATION 
BUT NOT BY NALOXONE. 

003073 03-04 
EVIDENCE FOR INVOLVEMENT OF SEPARATE MECHANISMS IN THE 
PRODUCTION OF ANALGESIA BY ELECTRICAL- STIMULATION OF THE 
NUCLEUS-RETICULARIS-PARAGIGANTOCELLULARIS AND NUCLEUS- 
RAPHE-MAGNUS IN THE RAT. 

003083 03-04 
EFFECTS OF METHYSERGIDE AND NALOXONE ON ANALGESIA INDUCED BY 
THE PERIPHERAL ELECTRIC-STIMULATION IN MICE. 

003093 03-04 
A NEUROANATOMICAL-STUDY OF ANALGESIA AND CATATONIA INDUCED 
BY ETORPHINE IN THE RAT. (PH.D. DISSERTATION). 

003102 03-04 
INDUCTION OF ANALGESIA BY CENTRAL ADMINISTRATION OF ORG-2766, 
AN ANALOG OF ACTH4-9. 

003112 03-04 
A COMPARISON OF THE EFFECTS OF MORPHINE-SULPHATE AND NITROUS- 
OXIDE ANALGESIA ON CHRONIC PAIN STATES IN MAN. 

003442 03-14 
ANALGESIA FOLLOWING INTRAVENTRICULAR ADMINISTRATION OF 2 
DEOXY-D-GLUCOSE. 

004074 04-04 
NALOXAZONE, A LONG-ACTING OPIATE ANTAGONIST: EFFECTS ON 
ANALGESIA IN INTACT ANIMALS AND ON OPIATE-RECEPTOR BINDING 
IN VITRO. 

004198 04-04 






'IT 
ti- 
ll" 



^ 



S-23 



Subject Index 



Ptychopharmacology Abstracts 



BETA ENDORPHIN: CENTRAL SITES OF ANALGESIA, CATALEPSY AND 
BODY-TEMPERATURE CHANGES IN RATS. 

004238 04-04 
ANALGESIC 

INHIBITION OF (3H)NAL0X0NE BINDING IN HOMOGENATES OF RAT- 
BRAIN BY ESEROLINE, A DRUG, WITH ANALGESIC ACTIVITY, RELATED 
TO PHYSOSTIGMINE. 

000104 01-03 
CHANGES IN BRAIN N DEMETHYLATION AND OPIATE-RECEPTOR CONTENT 
CORREUTE WITH ANALGESIC EFFECTIVENESS OF MORPHINE. 

000400 01-04 
ANALGESIC ACTIVITY OF DIFLUNISAL (MK-647; 5 2,4 

DIFLUOROPHENYLSALICYLIC-ACID) IN RATS WITH HYPERALGESIA 
INDUCED BY FREUNDS-ADJUVANT. 

000502 01-04 
THE ANALGESIC AND RESPIRATORY EFFECTS OF MEPTAZINOL, MORPHINE 
AND PENTAZOCINE IN THE RAT. 

000516 01-05 
MECHANISMS OF PAIN AND ANALGESIC COMPOUNDS. 

000916 01-17 
BETA ENDORPHIN: DISSOCIATION OF RECEPTOR BINDING-ACTIVITY FROM 
ANALGESIC POTENCY. 

001081 02-02 
ON THE MECHANISM-OF-ACTION OF 2 AMINO-4-METHYLPYRIDINE, A 
MORPHINE-LIKE ANALGESIC. 

001574 02-04 
ANALGESIC ACTION OF INTRATHECAL AND INTRACEREBRAL BETA 
ENDORPHIN IN RATS: COMPARISON WITH MORPHINE 

001691 02-04 
OPIATE ANTAGONISTS AND LONG-TERM ANALGESIC REACTION INDUCED 
BY INESCAPABLE SHOCK IN RATS 

001707 02-04 
NEUROCHEMICAL- STUDIES OF AN ANALGESIC, 1,3 DIPHENYL-5-2- 
DIMETHYLAMINOPROPIONAMIDE-PYRAZOLE (DIFENAMIZOLE) , 

002771 03-03 
LEVONANTRADOL, A POTENT CANNABINOID RELATED ANALGESIC, 
ANTAGONIZES HALOPERIDOL-INDUCED ACTIVATION OF STRIATAL 
DOPAMINE SYNTHESIS. 

002786 03-03 
ANALGESIC TOLERANCE PRODUCED BY MORPHINE PELLETS IS 
FACILITATED BY ANALGESIC TESTING 

002943 03-04 
ENVIRONMENTAL MODULATION OF ANALGESIC TOLERANCE INDUCED BY 

MORPHINE PELLETS. 

002944 03-04 
ANALGESIC PROPERTIES OF THE GABAMIMETIC THIP. 

003013 03-04 
COMPARATIVE ANALGESIC, BEHAVIORAL, AND DEPENDENCE PROPERTIES 
OF MORPHINE AND 

METHOXYLPHENYLCARBAMOYLDIETHYLAMINOPROPIOPHENONEOXIME 
HCL. 

003707 04-02 
ANALGESIC AND OTHER PHARMACOLOGICAL ACTIVITIES OF A NEW 
NARCOTIC ANTAGONIST ANALGESIC (-) 1 3 

METHYLBUTENYLHYDROXYPHENYLPHENYLETHYLPIPERAZINE AND ITS 
ENANTIOMORPH IN EXPERIMENTAL ANIMALS, 

004185 04-04 
ANALGESIC-DRUGS 

EFFECTS OF CHANGES IN THE STRUCTURE OF ENKEPHALINS AND OF 
NARCOTIC ANALGESIC-DRUGS ON THEIR INTERACTIONS WITH MU- 
RECEPTORS AND DELTA-RECEPTORS 

000168 01-03 
THE EFFECT OF PSYCHOTROPIC-SUBSTANCES AND NARCOTIC ANALGESIC- 
DRUGS ON 14C NORADRENALINE UPTAKE BY SYNAPTOSOMES OF THE 
CEREBRAL-CORTEX OF RATS. 

001363 02-03 
GUIDELINES FOR THE CLINICAL-EVALUATION OF ANALGESIC-DRUGS. 

002584 02-17 
ANALGESIC-INDUCED 

EFFECT OF QUIPAZINE AND FLUOXETINE ON ANALGESIC-INDUCED 
CATALEPSY AND ANTINOCICEPTION IN THE RAT. 

001709 02-04 
ANALGESICS 

INFLUENCE OF GLUCOSE (IN VIVO OR IN VITRO) ON DURATION OF 
NARCOTIC ANALGESICS AND ON THE KINETICS OF DRUG METABOLISM. 

000292 01-03 
ANTINOCICEPTIVE-EFFECT OF MORPHINE, OPIOID ANALGESICS AND 
HALOPERIDOL INJECTED INTO THE CAUDATE-NUCLEUS OF THE RAT. 

000414 01-04 
A STUDY OF THE QUANTAL (ALL-OR-NONE) CHANGE IN REFLEX LATENCY 
PRODUCED BY OPIATE ANALGESICS. 

000425 01-04 
THE INFLUENCE OF 5 HT-RECEPTOR BLOCKING-AGENTS ON THE 
BEHAVIORAL-EFFECTS OF ANALGESICS IN RATS. 

000429 01-04 
INTERACTION-STUDIES BETWEEN NARCOTIC ANALGESICS, NARCOTIC 
ANTAGONISTS AND ETHANOL: STUDIES DURING ACUTE AND CHRONIC- 
TREATMENT AND WITHDRAWAL STATES IN RATS AND MICE (PH.D. 
DISSERTATION). 

001165 02-03 



AaiONS OF ENKEPHALIN, MU AND PARTIAL AGONIST ANALGESICS ON 
ACETYLCHOLINE TURNOVER IN RAT-BRAIN. 

001541 02-03 
NARCOTIC ANALGESICS AND STEREOTYPED-BEHAVIOUR IN MICE. 

001694 02-04 
CLASSIFICATION OF ANALGESICS. 

002570 02-17 
STRUaURE-ACTIVITY AND RECEPTOR BINDING OF ANTAGONIST 
ANALGESICS. 

003611 03-17 
BLOCKADE BY L LYSINE OF NONNARCOTIC ANALGESICS. 

003857 04-03 
EFFECTS OF ANALGESICS AND CNS-AQING DRUGS ON STRUGGLING 
FOLLOWING REPETITIVE STIMULATION OF THE TAIL, AND FLEXOR 
REFLEX TO A SINGLE STIMULATION OF THE SCIATIC-NERVE IN RATS, 

004148 04-04 
ANALOG 

UNUSUAL DOSE-RELATED EFFECT OF AN ENDORPHIN ANALOG IN A 
COMPLEX MAZE 

001674 02-04 
Y-MAZE BEHAVIOR AFTER AN ANALOG OF ACTH4-9, EVIDENCE FOR AN 
ATTENTIONAL-ALTERATION , 

001676 02-04 
METKEPHAMID, A SYSTEMICALLY ACTIVE ANALOG OF METHIONINE- 
ENKEPHALIN WITH POTENT OPIOID DELTA-RECEPTOR ACTIVITY. 

002720 03-03 
POSSIBLE MECHANISMS OF EFFEa OF AaH4-10 AND ITS ANALOG, 
CONTAINING D ISOMER OF PHENYLALANINE, ON BEHAVIOR 

002949 03-04 
GAMMA BUTYROLACTONE-GAMMA-CARBONYL-HISTIDYL-PROLINAMIDE 
CITRATE (DN-1417): A NOVEL TRH ANALOG WITH POTENT EFFEaS ON 
THE CENTRAL-NERVOUS-SYSTEM. 

003057 03-04 
INDUCTION OF ANALGESIA BY CENTRAL ADMINISTRATION OF ORG-2766, 
AN ANALOG OF AaH4-9. 

003112 03-04 
HIGH-AFFINITY BINDING-SITES FOR A SOMATOSTATIN-28 ANALOG IN 
RAT-BRAIN. 

003985 04-03 
GLC MASS-SPECTROMETRIC-DETERMINATION OF MAPROTILINE AND ITS 
MAJOR METABOLITE USING STABLE ISOTOPE-LABELED ANALOG AS 
INTERNAL STANDARD 

004291 04-06 
ANALOGS 

COMPARATIVE-STUDY OF ANALGESIA INDUCED BY N VAL5-ENKEPHALIN 
AND PR05-ENKEPHALIN ANALOGS. 

000021 01-03 
THE EFFECTS OF TWO ANALOGS OF DOPAMINE ON GANGLIONIC 
TRANSMISSION IN THE SYMPATHETIC-NERVOUS-SYSTEM. 

000162 01-03 
STRUCTURE-ACTIVITY RELATIONSHIPS IN THE EFFEaS OF PHENACEMIDE 
ANALOGS ON SERUM CREATININE AND ANTICONVULSANT ACTIVITY 

000249 01-03 
A FURTHER CHARACTERIZATION OF THE DIFFERENTIAL-EFFEQS OF 
LEUCINE-ENKEPHALIN, METHIONINE-ENKEPHALIN AND THEIR ANALOGS 
ON MORPHINE-INDUCED ANALGESIA. 

000311 01-03 
ROTATIONAL-BEHAVIOR INDUCED BY COCAINE ANALOGS IN RATS WITH 
UNILATERAL 6 HYDROXYDOPAMINE LESIONS OF THE SUBSTANTIA- 
NIGRA: DEPENDENCE UPON DOPAMINE UPTAKE INHIBITION. 

00040401-04 
HISTORY AND PHARMACOLOGY OF PCP AND PCP RELATED ANALOGS 

000737 01-12 
IRREVERSIBLE INHIBITION OF S ADENOSYLHOMOCYSTEINE-HYDROLASE BY 
NUCLEOSIDE ANALOGS. (UNPUBLISHED PAPER). 

001010 02-01 
ADENOSINE ANALOGS AS SUBSTRATES AND INHIBITORS OF S 
ADENOSYLHOMOCYSTEINE-HYDROLASE. (UNPUBLISHED PAPER) 

001021 02-01 
BETA ENDORPHIN AND ANALOGS: 360 MHZ PROTON NMR 
SPEaROSCOPY. 

001028 02-01 
SYNTHESIS OF 180 ANALOGS OF BIOGENIC-AMINES (UNPUBLISHED 
PAPER) 

001044 02-01 
DIHYDROXY AND TRIHYDROXY ANALOGS OF CHLORPROMAZINE 
INFLUENCE THE CENTRAL-AQIVITY OF ADENYLATE-CYCLASE AND 
CYCLIC-AMP-PHOSPHODIESTERASE 

001405 02-03 
MOTOR-AQIVITY AND ROTATIONAL-BEHAVIOR AFTER ANALOGS OF 
COCAINE: CORRELATION WITH DOPAMINE UPTAKE BLOCKADE 

001650 02-04 
ENKEPHALIN ANALOGS AND PHYSICAL-DEPENDENCE 

003572 03-16 
SYNTHESIS AND BIOLOGICAL-AQIVITY OF HUMAN BETA ENDORPHIN 
ANALOGS WITH DISULFIDE BRIDGES. 

003655 04-01 



S-24 



VOLUME 19, SUBJECT INDEX 



Subject Index 



SYNTHESIS AND PHARMACOLOGICAL-STUDY Of SOME ENKEPHALIN 
ANALOGS IN RELATION TO THE PLURALITY Of OPIATE-RECEPTORS. 

003682 04-02 
CENTRALLY ACTIVE N SUBSTITUTED ANALOGS Of 3,4 

METHYLENEDIOXYPHENYLISOPROPYLAMINE (3,4 
METHYLENEDIOXYAMPHETAMINE). 

003683 04-02 
INHIBITION Of AMINOPEPTIDASE AND ACETYLCHOLINESTERASE BY 

PUROMYCIN AND PUROMYCIN ANALOGS. 

003835 04-03 
OPIOIDS, NORADRENALINE AND GTP ANALOGS INHIBIT CHOLERA-TOXIN 
ACTIVATED ADENYLATE-CYCLASE IN NEUROBLASTOMA-X GLIOMA 
HYBRID CELLS. 

003975 04-03 
N,N DIISOPROPYLTRYPT AMINE (DIPT) AND 5 
METHOXYDIISOPROPYLTRYPTAMINE (5 MEO-DIPT). TWO ORALLY 
ACTIVE TRYPTAMINE ANALOGS WITH CNS ACTIVITY. 

004310 04-07 
ANALOGUE 

AN ANALOGUE Of THYROTROPIN-RELEASING-HORMONE WITH IMPROVED 
BIOLOGICAL-STABILITY BOTH IN VITRO AND IN VIVO. 

000032 01-03 
EffECTS Of ENKEPHALIN ANALOGUE AND NALOXONE ON CAT SPINAL- 
CORD DORSAL ROOT POTENTIALS. 

000236 01-03 
APPLICATION Of A SYNTHETIC ENKEPHALIN ANALOGUE DURING HEROIN 
WITHDRAWAL. 

000685 01-11 
CONTRALATERAL CIRCLING-BEHAVIOUR INDUCED BY INTRANIGRAL 
INJECTION Of MORPHINE AND ENKEPHALIN ANALOGUE fK-33-824 IN 
RATS. 

001669 02-04 
BIPHASIC-EffECTS Of A POTENT ENKEPHALIN ANALOGUE D MET2-PR05- 
ENKEPHALINAMIDE AND MORPHINE ON LOCOMOTOR-ACTIVITY IN 
MICE. 

001799 02-04 
A PRIMATE ANALOGUE Of AMPHETAMINE-INDUCED BEHAVIORS IN 
HUMANS. 

003006 03-04 
BIOLOGICAL EVALUATION Of A TRH ANALOGUE WITH A MODIflED 
PROLINE RESIDUE, 

003662 04-01 
INTERACTIONS BETWEEN A MONOfLUORINATED ANALOGUE Of P 
CHLOROAMPHET AMINE AND 5 HYDROXYTRYPTAMINE IN BRAIN. 

003719 04-03 
A SYNTHETIC ACTH4-9 ANALOGUE (ORGANON-2766) AND SLEEP IN 
HEALTHY MAN. 

004574 04-14 
ANALOGUES 

fLUORINATED ANALOGUES Of THE TRICYCLIC NEUROLEPTICS- 2 3 
DIfLUORO DERIVATIVE Of CLOROTEPIN. 

000001 01-01 
EffECT Of GABA ANALOGUES ON BLOOD-PRESSURE AND CENTRAL GABA 
METABOLISM IN THE RAT. 

000231 01-03 
DISPLACEMENT Of (3H)CL0NIDINE BINDING BY CLONIDINE ANALOGUES 
IN MEMBRANES fROM RAT-CEREBRAL-CORTEX. 

000536 01-06 
THE EffECTS Of LSD AND SOME ANALOGUES ON THE RESPONSES Of 
SINGLE CORTICAL NEURONS Of THE CAT TO OPTICAL- STIMULATION 

000738 01-12 
ANTIARRHYTHMIC-ACTIVITY Of AMITRIPTYLINE ANALOGUES IN 
CONSCIOUS DOGS AfTER MYOCARDIAL-INfARCTION: 
CYPROHEPTADINIUM-METHIODIDE. 

001534 02-03 
CONfORMATIONALLY RESTRICTED TRICYCLIC-ANTIDEPRESSANTS 1 
OCTAHYDRODIBENZAZEPINONAPHTHYRIDINES AS RIGID IMIPRAMINE 
ANALOGUES. 

001710 02-04 
THE EffECT Of SOME STRUCTURAL GABA ANALOGUES ON THE 
SEROTONIN AND DOPAMINERGIC MECHANISMS 

001736 02-04 
THE SYNTHESIS AND ACTIVITY Of CIS AND TRANS 2 
AMINOMETHYLCYCLOPROPANECARBOXYLIC-ACID AS 
CONfORMATIONALLY RESTRICTED ANALOGUES Of GABA. 

002633 03-01 
GABA ANALOGUES ACTIVATE CHANNELS Of DIffERENT DURATION ON 
CULTURED MOUSE SPINAL NEURONS. 

002665 03-03 
KINETIC DATA ON THE INHIBITION Of HIGH-AfflNITY CHOLINE 
TRANSPORT INTO RAT-fOREBRAIN SYNAPTOSOMES BY CHOLINE-LIKE 
COMPOUNDS AND NITROGEN-MUSTARD ANALOGUES 

002879 03-03 
DISCRIMINATIVE-STIMULUS PROPERTIES Of PHENCYCLIDINE AND fIVE 
ANALOGUES IN THE SQUIRREL-MONKEY. 

002961 03-04 
SYNTHESIS AND BIOCHEMICAL AND PHARMACOLOGIC PROPERTIES Of 
ANALOGUES AND DERIVATIVES Of P CHLOROPHENYLALANINE 

003691 04-02 



EFfECTS Of CONfORMATIONALLY RESTRAINED ANALOGUES Of 
SEROTONIN ON ITS UPTAKE AND BINDING IN RAT-BRAIN. 

003794 04-03 
IBOTENIC-ACID ANALOGUES AS INHIBITORS Of (3H)GLUTAMIC-ACID 
BINDING TO CEREBELLAR MEMBRANES. 

003848 04-03 
ACTION Of ENKEPHALIN ANALOGUES AND MORPHINE ON BRAIN 
ACETYLCHOLINE RELEASE: DIffERENTIAL REVERSAL BY NALOXONE AND 
AN OPIATE-PENTAPEPTIDE. 

003863 04-03 
ANALYSE 

THE USE Of PSYCHOPHARMACOLOGICAL-PROCEDURES TO ANALYSE THE 
ONTOGENY Of LEARNING AND RETENTION: ISSUES AND CONCERNS. 

000482 01-04 
ANALYSES 

MULTIDIMENSIONAL ANALYSES Of BEHAVIOR IN MICE TREATED WITH 
ALPHA ENDORPHIN. 

003020 03-04 
STATISTICAL ANALYSES Of PHYSIOLOGIC DATA fROM fEMALE PATIENTS 
WITH AN ENDOMORPHOUS DEPRESSIVE COURSE: A TRIAL 
INTERACTIONS BETWEEN PHYSIOLOGIC PARAMETERS, TEST JUNCTURES 
IN THIS PHASE. 

003251 03-09 
CONSISTENCY IN CATECHOLAMINE EXCRETION IN LABORATORY AND 
NATURAL SETTINGS: CORRELATIONAL AND VARIANCE COMPONENTS 
ANALYSES. 

004508 04-13 
GAS-CHROMATOGRAPHY/MASS-SPECTROMETRY STABLE ISOTOPIC 
ANALYSES fOR DEANOL, CHOLINE, AND THEIR ACETYLESTERS. 

004683 04-16 
ANALYSIS 

ANALYSIS fOR DIAZEPAM AND NORDIAZEPAM BY ELECTRON-CAPTURE 
GAS-CHROMATOGRAPHY AND BY LIQUID-CHROMATOGRAPHY 

000006 01-01 
NONLINEAR REGRESSION ANALYSIS Of NOREPINEPHRINE RESPONSE 
KINETICS IN CEREBRAL VASCULATURE. 

000256 01-03 
ANALYSIS Of THE ACTIVATION Of DOPAMINE METABOLISM BY A 
SEROTONIN UPTAKE INHIBITOR. 

000315 01-03 
DRUG-VARIABLES IN THE ETIOLOGY Of TARDIVE-DYSKINESIA: 
APPLICATION Of DISCRIMINANT fUNCTION ANALYSIS 

000844 01-15 
AN HPLC AND RIA ANALYSIS Of THE CHOLECYSTOKININ-PEPTIDES IN 
RAT-BRAIN. (UNPUBLISHED PAPER). 

001004 02-01 
DECOMPOSITION Of PHARMACOLOGICAL ACTIVITY INDICES INTO 
MUTUALLY INDEPENDENT COMPONENTS USING PRINCIPAL 
COMPONENT ANALYSIS. 

001039 02-01 
QUANTITATIVE ANALYSIS Of 6 HYDROXYMELATONIN IN HUMAN URINE 
BY GAS-CHROMATOGRAPHY NEGATIVE CHEMICAL-IONIZATION MASS- 
SPECTROMETRY. (UNPUBLISHED PAPER). 

001058 02-01 
REGIONAL 5 HT ANALYSIS IN ROMAN HIGH-AVOIDANCE AND LOW- 
AVOIDANCE RATS fOLLOWING MAO-INHIBITION. 

001202 02-03 
AUTOCORRELATION ANALYSIS Of SINGLE NEURON ACTIVITY AfTER 
ADMINISTRATION Of PENTOBARBITAL. 

001268 02-03 
ACUTE AND CHRONIC OPIATE-EffECTS ON SINGLE UNITS AND EEG Of 
MEDIAL THALAMUS AND HIPPOCAMPUS: A LATENCY ANALYSIS. 

001344 02-03 
A PHARMACOLOGICAL ANALYSIS Of THE ROLE Of THE AMYGDALA IN 
THE CONTROL Of GONADOTROPIN AND PROLACTIN SECRETION. 

001418 02-03 
MULTIPLE CNS RECEPTOR INTERACTIONS Of ERGOT ALKALOIDS: AfflNITY 
AND INTRINSIC ACTIVITY ANALYSIS IN IN VITRO BINDING SYSTEMS. 

001516 02-03 
AN ANALYSIS Of SOME PERCEPTUAL-EffECTS Of MORPHINE, 
CHLORPROMAZINE, AND LSD. 

001652 02-04 
NEUROPHARMACOLOGICAL ANALYSIS Of HANDLING-INDUCED SEIZURES 
IN GERBILS. 

001876 02-06 
PSYCHOACTIVE-DRUG-EffECTS IN A HYPERACTIVE-CHILD: A CASE-STUDY 
ANALYSIS Of BEHAVIOR-CHANGE AND TEACHER ATTENTION. 

002313 02-14 
VIGILANCE IMPAIRING DRUGS: ANALYSIS Of SUBJECTIVE RESPONSES. 

002332 02-14 
USE Of SURVIVAL CURVES IN ANALYSIS Of ANTIPSYCHOTIC RELAPSE- 
STUDIES. 

002481 02-16 
RESPONDERS AND NONRESPONDERS TO CHLORDIAZEPOXIDE AND 

PLACEBO: A DISCRIMINANT fUNCTION ANALYSIS. 

002482 02-16 
COORDINATING CLINICAL-TRIALS IN PSYCHOPHARMACOLOGY: 

PLANNING, DOCUMENTATION, AND ANALYSIS. 

002574 02-17 



fe 



S-25 



Subject Index 



Psychopharmacology Abstracts 



A QUANTITATIVE REGIONAL ANALYSIS OF PROTEIN SYNTHESIS 

INHIBITION IN THE RAT-BRAIN FOLLOWING LOCALIZED INJECTION OF 
CYCLOHEXIMIDE. 

002780 03-03 
AN IMPROVED MODEL OF INTRASPECIFIC AGGRESSION: DOSE-RESPONSE 
ANALYSIS OF APOMORPHINE-INDUCED-FIGHTING AND STEREOTYPY IN 
THE RAT. 

002983 03-04 
AN ANALYSIS OF SPECIFICITY OF DRUG-INDUCED CHANGES IN DRUG- 
REINFORCED RESPONDING. (PH.D. DISSERTATION). 

003010 03-04 
THE PHARMACOLOGICAL ANALYSIS OF MONOAMINERGIC MECHANISMS 
OF THE MEDIAL HYPOTHALAMUS IN FOOD PROCURING CONDITIONED 
REFLEXES IN RATS. 

003100 03-04 
POWER SPECTRAL ANALYSIS OF THE FLASH-EVOKED AFTERDISCHARGE, 

003133 03-06 
ANALYSIS OF SINGLE-BUND, DOUBLE-BUND PROCEDURES, MAINTENANCE 
OF PLACEBO-EFFECTS, AND DRUG-INDUCED DYSKINESIA WITH 
MENTALLY-RETARDED PERSONS ~ BRIEF REPORT. 

003298 03-11 
PSYCHOTROPIC-DRUG-INDUCED CHANGES IN AUDITORY AVERAGED 
EVOKED-POTENTIALS: RESULTS OF A DOUBLE-BUND TRIAL USING AN 
OBJECTIVE FULLY AUTOMATED AEP ANALYSIS METHOD. 

003412 03-13 
OPERANT ANALYSIS OF HUMAN HEROIN SELF-ADMINISTRATION AND THE 
EFFECTS OF NALTREXONE. 

003449 03-14 
TIME-BLIND ANALYSIS AND OTHER VIDEO-STRATEGIES IN PHASE II 
TRIALS OF PSYCHOTROPIC-DRUGS. 

003568 03-16 
DRUG DEPENDENCE: REFLECTIONS ON AND ANALYSIS OF AN EXPERIENCE 
IN THE PROVINCE OF RIGGIO-EMIUA. 

003591 03-17 
AN ANALYSIS OF DRUG DECISIONS IN A STATE PSYCHIATRIC-HOSPITAL. 

003593 03-17 
FURTHER ANALYSIS OF THE MECHANISMS OF ACTION OF 
BATRACHOTOXIN ON THE MEMBRANE OF MYELINATED NERVE. 

003884 04-03 
RX-336-M, A NEW CHEMICAL TOOL IN THE ANALYSIS OF THE QUASI- 
MORPHINE WITHDRAWAL-SYNDROME, 

004093 04-04 
AN ANALYSIS OF VISUAL OBJECT REVERSAL LEARNING IN THE 
MARMOSET AFTER AMPHETAMINE AND HALOPERIDOL. 

004208 04-04 
PRESENCE OF CONJUGATED CATECHOLAMINES IN RAT-BRAIN: A NEW 
METHOD OF ANALYSIS OF CATECHOLAMINE-SULFATES. 

004286 04-06 
PROPHYLACTIC-EFFECT OF LITHIUM AGAINST DEPRESSION IN 
CYCLOTHYMIC-PATIENTS: A LIFE-TABLE ANALYSIS. 

004391 04-09 
RESPONDERS AND NONRESPONDERS TO CHLORDIAZEPOXIDE AND 
PLACEBO. A DISCRIMINANT FUNCTION ANALYSIS (UNPUBUSHED 
PAPER). 

004420 04-10 
ANALYSIS OF SINGLE-BUND AND DOUBLE-BUND PROCEDURES, 
MAINTENANCE OF PUCEBO-EFFECTS AND DRUG-INDUCED DYSKINESIA 
WITH MENTALLY-RETARDED PERSON. 

004437 04-11 
MECHANISM OF LITHIUM INCLUDED ELEVATION IN RED-BLOOD-CELL 
CHOUNE CONTENT: AN IN VITRO ANALYSIS 

004511 04-13 
COMPUTERIZED ANALYSIS OF SLEEP RECORDINGS APPUED TO DRUG 
EVALUATION: MIDAZOLAM IN NORMAL SUBJECTS. 

004564 04-14 
CHLORPROMAZINE ANALYSIS IN HUMAN PLASMA. (UNPUBUSHED 
PAPER). 

004591 04-15 
MILD, MODERATE, SEVERE - THE STATISTICAL ANALYSIS OF SHORT 
ORDINAL SCALES. 

004677 04-16 
GLC/TLC ANALYSIS OF CODEINE AND MORPHINE IN URINE VIA 
DERIVATIZATION TECHNIQUES. 

004687 04-16 
A MULTIVARIATE ANALYSIS OF THE INFRARED SPEQRA OF DRUGS OF 

ABUSE. 

004688 04-16 
ANALYTICAL 

THE MYTHOLOGEM OF REVERSIBLE DEATH. THE ANALYTICAL 

CONFRONTATION OF ENDOGENOUS DEURIUM WITH DELUSIONS IN 
PSYCHEDELIC-EXPERIENCES. 

002200 02-12 
ANALYZING 

STUDIES ON THE TREATMENT AND DIAGNOSIS OF NEUROTIC VERTIGO 
FROM THE VIEWPOINT OF NEUROOTOLOGY: OBSERVATION OF THE 
BALANCE TEST FOR ANALYZING NEUROTIC VERTIGO. 

004387 04-09 
ANASTOMOSIS 

ORAL BIOAVAILABILITY OF APOMORPHINE IN THE RAT WITH A 
PORTACAVAL VENOUS ANASTOMOSIS. 

001158 02-03 



ANATOMICOPHYSIOLOGICAL 

ANATOMICOPHYSIOLOGICAL AND NEUROCHEMICAL-STUDY OF THE 
UMBIC-SYSTEM: EFFECT OF NOMIFENSINE. 

001160 02-03 
ANATOMOBIOCHEMICAL 

ANATOMOBIOCHEMICAL MAPPING OF THE BRAIN; NEUROPSYCHIATRIC- 
CORRELATIONS. 

002630 02-17 
ANATOMY 

STEREOCHEMICAL ANATOMY OF MORPHINOMIMETICS. 

002197 02-12 
ANESTHESIA 

THE INFLUENCE OF CHLORALOSE ANESTHESIA ON THE AQIVITY OF RED 
NUCLEUS NEURONS IN CATS. 

000245 01-03 
INTRACELLULAR REDOX STATES UNDER HALOTHANE AND BARBITURATE 
ANESTHESIA IN NORMAL, ISCHEMIC, AND ANOXIC MONKEY BRAIN. 

000295 01-03 
ON THE MECHANISM OF A DIFFERENT DRUG DISTRIBUTION DURING 
CONVULSIVE-SEIZURE IN COMPARISON TO ANESTHESIA. 

001151 02-03 
INFLUENCE OF IMIPRAMINE AND PARGYUNE ON THE 
ARRHYTHMOGENICITY OF EPINEPHRINE DURING HALOTHANE, 
ENFLURANE OR METHOXYFLURANE ANESTHESIA IN DOGS. 

001539 02-03 
REDUaiON OF BARBITURATE ANESTHESIA BY NEW GLUTARIMIDE 
COMPOUNDS IN MICE. 

001748 02-04 
ACCELERATED EXTINQION AFTER POSHRIAL HALOTHANE ANESTHESIA IN 
RATS: AN AVERSIVE-EFFECT. 

003001 03-04 
EFFECTS OF ANESTHESIA ON PATIENTS TAKING PSYCHOTROPIC-DRUGS 

003603 03-17 
CHANGES IN GAMMA AMINOBUTYRIC-ACID SHUNT ENZYMES IN 
REGIONS OF RAT-BRAIN WITH KETAMINE ANESTHESIA, 

003891 04-03 
RESPIRATORY DEPRESSION PRODUCED BY DIAZEPAM IN CATS: EFFEQ OF 
ANESTHESIA. 

004272 04-05 
ANESTHETIC 

ANTICONVULSANT AND ANESTHETIC BARBITURATES: DIFFERENT 
POSTSYNAPTIC ACTIONS IN CULTURED MAMMALIAN NEURONS 

000194 01-03 
REGULATION OF THE STATE OF PHOSPHORYLATION OF SPECIFIC 
NEURONAL PROTEINS IN MOUSE-BRAIN BY IN VIVO ADMINISTRATION 
OF ANESTHETIC AND CONVULSANT-AGENTS. 

000291 01-03 
BARBITURATE ENHANCEMENT OF GABA-MEDIATED INHIBITION AND 
AaiVATION OF CHLORIDE ION-CONDUCTANCE: CORRELATION WITH 
ANTICONVULSANT AND ANESTHETIC AQIONS. 

002885 03-03 
ANESTHETICS 

FACTORS INFLUENCING SEIZURE DURATION AND NUMBER OF SEIZURES 
APPLIED IN UNILATERAL ELECTROCONVULSIVE-THERAPY: ANESTHETICS 
AND BENZODIAZEPINES. 

000792 01-13 
INHIBITION BY LOCAL ANESTHETICS, PHENTOLAMINE AND PROPRANOLOL 
OF (3H)QUINUCLYDINYL-BENZYLATE BINDING TO CENTRAL 
MUSCARINIC-RECEPTORS 

001097 02-03 
THE INTERACTION BETWEEN BARBITURATE ANESTHETICS AND 
EXCITATORY AMINO-ACID RESPONSES ON CAT SPINAL NEURONES 

002799 03-03 
THE EFFECTS OF VARIOUS ANESTHETICS ON AMYGDALOID KINDLED 
SEIZURES. 

002959 03-04 
ANESTHETICS AND THE HABENULO-INTERPEDUNCULAR SYSTEM: 
SELEQIVE SPARING OF METABOLIC AQIVITY. 

003833 04-03 
THE INTERAaiON OF AMINE LOCAL ANESTHETICS WITH MUSCARINIC- 
RECEPTORS. 

004031 04-03 
ANESTHETIZED 

MORPHINE AND SUPRASPINAL INHIBITION OF SPINAL NEURONES: 

EVIDENCE THAT MORPHINE DECREASES TONIC DESCENDING INHIBITION 
IN THE ANESTHETIZED CAT. 

001203 02-03 
DIFFERENCES IN CUTANEOUS SENSORY RESPONSE PROPERTIES OF SINGLE 
SOMATOSENSORY CORTICAL NEURONS IN AWAKE AND HALOTHANE 
ANESTHETIZED RATS. 

002687 03-03 
METHYSERGIDE AND SUPRASPINAL INHIBITION OF THE SPINAL 
TRANSMISSION OF NOCICEPTIVE INFORMATION IN THE ANESTHETIZED 
CAT. 

002740 03-03 
SENSITIVE DEPRESSANT EFFECT OF BENZODIAZEPINES ON THE CROSSED 
EXTENSOR REFLEX IN CHLORALOSE ANESTHETIZED RATS. 

003027 03-04 



S-26 



/OLUME 19, SUBJECT INDEX 



Subject Index 



CENTRAL HYPOTENSIVE-EFFECT Of GAMMA AMINOBUTYRIC-ACID IN 
ANESTHETIZED DOGS. 

003772 04-03 
PRESSOR EFFECTS OF ELECTRICAL-STIMULATION OF THE DORSAL AND 
MEDIAN RAPHE NUCLEI IN ANESTHETIZED RATS. 

003892 04-03 
kNOINA 

TREATMENT OF UNSTABLE ANGINA BY DILTIAZEM. 

004307 04-07 
ANGIOTENSIN 

REGULATION OF RECEPTOR BINDING INTERACTIONS OF 1251 
ANGIOTENSIN-II AND )25l SARC0SINE1-LEUCINE8-ANGI0TENSIN-II, AN 
ANGIOTENSIN ANTAGONIST, BY SODIUM-ION. 

001124 02-03 
CAPTOPRIL GIVEN INTRACEREBROVENTRICULARLY, SUBCUTANEOUSLY OR 
BY GAVAGE INHIBITS ANGIOTENSIN CONVERTING ENZYME ACTIVITY 
IN THE RAT-BRAIN 

001614 02-04 
kNGIOTENSIN-ll 

EVIDENCE OF A DIRECT ACTION OF ANGIOTENSIN-II ON NEURONES IN THE 
SEPTUM AND IN THE MEDIAL PREOPTIC-AREA. 

000272 01-03 
REGULATION OF RECEPTOR BINDING INTERACTIONS OF 1251 
ANGIOTENSIN-II AND 1251 SARC0SINE1-LEUCINE8-ANGI0TENSIN-II, AN 
ANGIOTENSIN ANTAGONIST, BY SODIUM-ION. 

001124 02-03 
RECEPTOR BINDING INTERACTIONS OF THE ANGIOTENSIN-II ANTAGONIST, 

1251 SARC0SINE1-LEUCINE8-ANG10TENSIN-II, WITH MAMMALIAN 
BRAIN AND PERIPHERAL TISSUES, 

001125 02-03 
NEURONAL SENSITIVITY OF SOME BRAIN REGIONS TO ANGIOTENSIN-II IN 

RABBITS. 

003716 04-03 
CENTRAL-EFFECTS OF ANGIOTENSIN-II IN WATER AND SALINE LOADED 
RATS. 

003845 04-03 
.NGIOTENSIN-II-INDUCED 

INTRACRANIAL INJECTION PARAMETERS WHICH AFFECT ANGIOTENSIN-II- 
INDUCED DRINKING. 

000534 01-06 
MIMAL 

CHOLINERGIC ASPECTS OF TARDIVE-DYSKINESIA: HUMAN AND ANIMAL 
STUDIES. 

000928 01-17 
ANIMAL ACTIVITY MONITOR FOR CHRONIC DRUG-STUDIES. 
(UNPUBLISHED PAPER). 

001794 02-04 
QUANTITATIVE STUDY OF THE DISTRIBUTION OF LITHIUM IN THE MOUSE- 
BRAIN FOR VARIOUS DOSES OF LITHIUM GIVEN TO THE ANIMAL. 

002299 02-13 
PHARMACOLOGICAL EVIDENCE FOR CATECHOLAMINE INVOLVEMENT IN 
ANIMAL AGGRESSION. 

003052 03-04 
PHARMACOLOGICAL EVIDENCE FOR CATECHOLAMINE INVOLVEMENT IN 
ANIMAL AGGRESSION. 

003140 03-06 
POSITRON-TOMOGRAPHY. A NEW METHOD FOR IN VIVO BRAIN STUDIES 
OF BENZODIAZEPINE, IN ANIMAL AND IN MAN. 

003564 03-16 
EFFECTS OF ANIMAL AGE AND PHENOBARBITAL ON RAT LIVER GLUCOSE- 
6-PHOSPHATASE AQIVITY. 

003997 04-03 
THE EFFECT OF PROPYLNORANTIFEIN ON BEHAVIORAL-REACTIONS 
ADRENOCORTICAL ACTIVITY, AND ENERGY METABOLISM IN THE 
ANIMAL BRAIN. 

004075 04-04 
EFFECTS OF PAIN, MORPHINE AND NALOXONE ON THE DURATION OF 
ANIMAL HYPNOSIS. 

004081 04-04 
LACK OF SPECIFICITY OF AN ANIMAL BEHAVIOR MODEL FOR 
HALLUCINOGENIC DRUG ACTION. 

004250 04-04 
NIMAL-MODEL 

BIOCHEMICAL-STUDY OF THE ANIMAL-MODEL DEPRESSION INDUCED BY 
TETRABENAZINE. 

001506 02-03 
DOPAMINERGIC INVOLVEMENT IN AHENTION A NOVEL ANIMAL-MODEL 

001678 02-04 
EFFECTS OF CHRONIC AMPHETAMINE OR RESERPINE ON SELF- 
STIMULATION RESPONDING: ANIMAL-MODEL OF DEPRESSION? 

001699 02-04 
PRESYNAPTIC AND POSTSYNAPTIC SEROTONERGIC MANIPULATIONS IN 
AN ANIMAL-MODEL OF DEPRESSION. 

001730 02-04 
A PHARMACOLOGICAL INVESTIGATION OF AN ANIMAL-MODEL OF THE 

PETIT-MAL SEIZURE. (PH.D. DISSERTATION). 
,„__^ 001870 02-06 

EFFECTS OF D-AMPHETAMINE AND APOMORPHINE IN A NEW ANIMAL- 
MODEL OF PETIT-MAL EPILEPSY. 

002493 02-16 



ANIMAL-MODEL OF PSYCHOSIS: HALLUCINATORY BEHAVIORS IN 
MONKEYS DURING THE LATE STAGE OF CONTINUOUS AMPHETAMINE 
INTOXICATION. 

002988 03-04 
DOPAMINE AND DEMENTIA. AN ANIMAL-MODEL WITH DESTRUCTION OF 
THE MESOCORTICAL DOPAMINERGIC PATHWAY: A PRELIMINARY 
STUDY. 

00308S 03-04 
ANTAGONISM OF DOPAMINE SUPERSENSITIVITY BY ESTROGEN: 
NEUROCHEMICAL-STUDIES IN AN ANIMAL-MODEL OF TARDIVE- 
DYSKINESIA. 

004268 04-05 
THE SIMULTANEOUS INFUSION OF DRUGS VIA THE LEFT AND RIGHT 
VERTEBRAL-ARTERY OF THE CAT,- A MODIFIED ANIMAL-MODEL FOR 
THE STUDY OF POSSIBLE CENTRAL-ACTIONS OF DRUGS UPON THE 
LOWER BRAINSTEM. 

004297 04-06 
ANIMAL-MODELS 

ANIMAL-MODELS OF ANXIETY AND BENZODIAZEPINE ACTIONS. 

000531 01-06 
INTERACTION OF PSYCHOPHARMALOGIC-FACTORS AND PSYCHOSOCIAL- 
FACTORS IN THE TREATMENT OF ANIMAL-MODELS OF 
HYPOINHIBITORY (HYPERKINETIC) BEHAVIOR. 

001602 02-04 
ANIMAL-MODELS OF PSYCHIATRIC-DISORDERS. 

001871 02-06 
ANIMAL-MODELS OF RELEVANCE TO BIOLOGICAL-PSYCHIATRY. 

002490 02-16 
ANIMAL-MODELS OF TARDIVE-DYSKINESIA. 

003476 03-15 
ANIMALS 

IMIPRAMINE AND REM SLEEP: CHOLINERGIC MEDIATION IN ANIMALS. 

000406 01-04 
ASSESSMENT OF ADRENERGIC-RECEPTORS IN VIVO IN EXPERIMENTAL 
ANIMALS AND MAN. (UNPUBLISHED PAPER). 

001034 02-01 
A CLASSIFICATION OF OPIATE-RECEPTORS THAT MEDIATE 
ANTINOCICEPTION IN ANIMALS. 

001807 02-04 
BEHAVIOURAL-ANALYSIS OF FEEDING: IMPLICATIONS FOR THE 
PHARMACOLOGICAL MANIPULATION OF FOOD INTAKE IN ANIMALS 
AND MAN. 

002527 02-17 
MORPHOLOGICAL CHANGES IN RAT-BRAIN INDUCED BY L CYSTEINE 
INJECTION IN NEWBORN ANIMALS. 

002774 03-03 
PLASMA IMIPRAMINE LEVELS AND DEMETHYLASE ACTIVITY IN THE 
LIVER OF STRESSED ANIMALS. 

002793 03-03 
POTENTIATION OF BARBITURATE HYPNOSIS BY PROBENECID: 
DIFFERENTIAL-EFFECT IN TOLERANT ANIMALS. 

003038 03-04 
SPECIFIC AND NONSPECIFIC MULTIPLE UNIT ACTIVITIES DURING 

PENTYLENETETRAZOL SEIZURES. I. ANIMALS WITH ENCEPHALE ISOLE. 

004046 04-03 
ANALGESIC AND OTHER PHARMACOLOGICAL ACTIVITIES OF A NEW 
NARCOTIC ANTAGONIST ANALGESIC (-) 1 3 

METHYLBUTENYLHYDROXYPHENYLPHENYLETHYLPIPERAZINE AND ITS 
ENANTIOMORPH IN EXPERIMENTAL ANIMALS. 

004185 04-04 
NALOXAZONE, A LONG-ACTING OPIATE ANTAGONIST: EFFECTS ON 
ANALGESIA IN INTACT ANIMALS AND ON OPIATE-RECEPTOR BINDING 
IN VITRO. 

004198 04-04 
LITHIUM AND MOTOR-ACTIVITY OF ANIMALS: EFFECTS AND POSSIBLE 
MECHANISM-OF-ACTION. 

004222 04-04 
THE EFFECT OF MEBICAR ON THE CONDITION OF ANIMALS UNDER 
CERTAIN EXTREME CIRCUMSTANCES. 

004262 04-04 
ANIONS 

GABA-RECEPTORS REGULATE THE AFFINITIES OF ANIONS REQUIRED FOR 
BRAIN SPECIFIC BENZODIAZEPINE BINDING. 

002903 03-03 
ANISAMIDE 

NEUROPHYSIOLOGICAL-STUDY OF TWO ANISAMIDE DERIVATIVES: 
SULPIRIDE AND SULTOPRIDE. 

001170 02-03 
ANISAMIDES 

PHARMACOLOGICAL REFLECTIONS ON ANISAMIDES. 

002292 02-13 
ANISOMYCIN 

EFFECTS OF ANISOMYCIN ON RETENTION OF THE PASSIVE-AVOIDANCE 
HABIT AS A FUNCTION OF AGE. 

004097 04-04 
ANOCOCCYGEUS-MUSCLE 

EFFECT OF MIANSERIN ON NORADRENERGIC TRANSMISSION IN THE RAT 
ANOCOCCYGEUS-MUSCLE. 

000075 01-03 



2 



fe 



I 



S-27 



Subject Index 



Psychopharmacology Abstracts 



ANORECTIC-ACTIONS 

DOUBLE-BUND EVALUATION OF REINFORCING AND ANORECTIC-ACTIONS 
OF WEIGHT-CONTROL MEDICATIONS: INTERACTION OF 
PHARMACOLOGICAL-TREATMENT AND BEHAVIORAL-TREATMENTS. 

002314 02-14 
THE EFFEQ OF THE DOPAMINE-RECEPTOR BLOCKING-DRUG PIMOZIDE ON 
THE STIMULANT AND ANORECTIC-ACTIONS OF DEXTROAMPHETAMINE 
IN MAN. 

004580 04-14 
ANORECTIC-ACTIVITY 

EFFECT OF DESMETHYLIMIPRAMINE ON TISSUE DISTRIBUTION AND 
ANORECTIC-ACTIVITY OF CHLORPHENTERMINE IN RATS. 

004179 04-04 
ANORECTIC-AGENTS 

EFFECTS OF SPIPERONE ALONE AND IN COMBINATION WITH ANOREQIC- 
AGENTS ON FEEDING PARAMETERS IN THE RAT. 

001598 02-04 
INTERACTIONS OF CHLORDIAZEPOXIDE AND ANORECTIC-AGENTS ON RATE 
AND DURATION PARAMETERS OF FEEDING IN THE RAT. 

001600 02-04 
ANORECTIC-DRUGS 

PSYCHOPHARMACOLOGY OF ANORECTIC-DRUGS IN MAN. 

002607 02-17 
ANORECTIC-EFFECT 

ANORECTIC-EFFECT OF LISURIDE AND OTHER ERGOT DERIVATIVES IN THE 
RAT 

000042 01-03 
ANORECTIC-PROPERTIES 

ANORECTIC-PROPERTIES OF A NEW LONG ACTING SEROTONIN UPTAKE 
INHIBITOR. 

004105 04-04 
ANOREXIA 

AnENUATION OF AMPHETAMINE ANOREXIA IN RATS FOLLOWING 
SUBCHRONIC-TREATMENT WITH A TRICYCLIC-ANTIDEPRESSANT 

000501 01-04 
THE EFFECTS OF PARA CHLOROAMPHETAMINE ON FENFLURAMINE 
ANOREXIA IN AD LIBITUM AND STIMULATION-INDUCED FEEDING IN 
THE RAT. 

001823 02-04 
DIFFERENTIAL-EFFECTS OF PHARMACOLOGICAL-AGENTS ACTING ON 
MONOAMINERGIC SYSTEMS ON DRUG-INDUCED ANOREXIA 

002533 02-17 
SUBSTITUTED PHENETHYLAMINES AND ANOREXIA. 

002541 02-17 
EVIDENCE THAT IT IS POSSIBLE TO CAUSE ANOREXIA BY INCREASING 
RELEASE AND/OR DIREQLY STIMULATING POSTSYNAPTIC SEROTONIN- 
RECEPTORS IN THE BRAIN 

002602 02-17 
EFFECTS OF A HIGH-DOSE TREATMENT OF METHAMPHETAMINE ON 
CAUDATE DOPAMINE AND ANOREXIA IN RATS 

004073 04-04 
NALOXONE FAILS TO BLOCK AMPHETAMINE-INDUCED ANOREXIA AND 
CONDITIONED TASTE-AVERSION. 

004121 04-04 
ANOREXIA-NERVOSA 

BODY-WEIGHT AND RESPONSES TO LHRH INFUSION IN ANOREXIA- 
NERVOSA. 

002062 02-10 
HORMONAL ABNORMALITIES IN ANOREXIA-NERVOSA (AN). 

002099 02-11 
NALOXONE IN THE TREATMENT OF ANOREXIA-NERVOSA: EFFECT ON 
WEIGHT-GAIN AND LIPOLYSIS. 

003342 03-11 
TREATMENT OF UNDERNUTRITION AND ELEaROLYTE-DISTURBANCES IN 
ANOREXIA-NERVOSA. 

004531 04-13 
ANOREXIA-NERVOSA. SYMPTOMS, COURSE AND POSSIBILITIES FOR 
TREATMENT. 

004711 04-17 
ANOREXIC 

THE ANOREXIC AND ACTOMETRIC EFFECTS OF COCAINE AND TWO COCA- 
EXTRACTS. 

000344 01-04 
ANOSMIA 

EFFECTS OF OLFACTORY-BULBEaOMY AND PERIPHERALLY-INDUCED 
ANOSMIA ON THERMOREGULATION IN THE RAT: SUSCEPTIBILITY TO 
ANTIDEPRESSANT-DRUGS. 

004113 04-04 
ANOXIC 

INTRACELLULAR REDOX STATES UNDER HALOTHANE AND BARBITURATE 
ANESTHESIA IN NORMAL, ISCHEMIC, AND ANOXIC MONKEY BRAIN. 

000295 01-03 
ANTAGONISE 

CONVULSANTS ANTAGONISE INHIBITION IN THE OLFAQORY-CORTEX 
SLICE. 

001466 02-03 
ANTAGONISES 

ETHYL-BETA-CARBOLINE-3-CARBOXYLATE ANTAGONISES THE EFFECT OF 
DIAZEPAM ON A FUNCTIONAL GABA-RECEPTOR. 

001378 02-03 



ANTAGONISM I 

NALOXONE ANTAGONISM OF GABA-EVOKED MEMBRANE ' 

POLARIZATIONS IN CULTURED MOUSE SPINAL-CORD NEURONS. 

000116 01-03 
ANTAGONISM OF INTRASTRIATAL AND INTRAVENOUS KAINIC-ACID BY 1 
NUCIFERINE: COMPARISON WITH VARIOUS ANTICONVULSANTS AND 
GABAMIMETICS. 

000188 01-03 
METERGOLINE ANTAGONISM OF 5 HYDROXYTRYPTAMINE-INDUCED 
AQIVATION OF RAT-CEREBRAL-CORTICAL NA-K-ATPASE. 

000329 01-03 
MORPHINE EFFECTS UPON DISCRIMINATED APPROACH AND 

DISCRIMINATED AVOIDANCE IN RATS: ANTAGONISM BY NALOXONE. 

000338 01-04 
REWARD SYSTEM DEPRESSION FOLLOWING CHRONIC AMPHETAMINE: 
ANTAGONISM BY HALOPERIDOL. 

000342 01-04 
METHIONINE-ENKEPHALIN ANTAGONISM AND ENDORPHIN POTENTIATION 
OF NARCOTIC-INDUCED ANALGESIA. 

000357 01-04 
STEREOSPECIFIC, DOSE-DEPENDENT ANTAGONISM BY NALOXONE OF 
NONOPIATE BEHAVIOR IN MICE 

000411 01-04 
ANTAGONISM BY CLASSICAL ANTIEPILEPTICS AND SODIUM-VALPROATE 
OF CEFAZOLIN-INDUCED EXPERIMENTAL EPILEPSY IN RATS. 

000442 01-04 
THE NEW ANTIDEPRESSANT PIRLINDOLE: ANTAGONISM OF ACUTE 
OVERDOSAGE IN THE MOUSE. 

001082 02-02 
ANTAGONISM OF THE RENAL VASODILATOR AQIVITY OF DOPAMINE BY 
METOCLOPRAMIDE 

001265 02-03 
ANTAGONISM OF 5 HYDROXYTRYPTAMINE-RECEPTORS BY QUIPAZINE. 

001329 02-03 
ANTAGONISM OF 2 DEOXY-D-GLUCOSE-INDUCED HYPERPHAGIA BY 
NALOXONE: POSSIBLE INVOLVEMENT OF ENDORPHINS. 

001773 02-04 
LITHIUM ANTAGONISM OF ETHANOL-INDUCED DEPLETION OF CEREBELLAR 
GUANOSINE-CYCLIC-MONOPHOSPHATE AND STIMULATION OF 
STRIATAL DOPAMINE RELEASE 

002242 02-13 
APOMORPHINE HALOPERIDOL INTERACTIONS: DIFFERENT TYPES OF 
ANTAGONISM IN CORTICAL AND SUBCORTICAL BRAIN REGIONS. 

002662 03-03 
SELEQIVE SYNAPTIC ANTAGONISM BY ATROPINE AND ALPHA 
AMINOADIPATE OF PULVINAR AND CORTICAL AFFERENTS TO THE 
SUPRASYLVIAN VISUAL AREA (CLARE-BISHOP AREA). 

002752 03-03 
CALCIUM ANTAGONISM OF THE INHIBITORY-EFFEQS OF FENTANYL ON 
THE CONTRAQION OF THE NICTITATING MEMBRANE IN CATS. 

002876 03-03 
ANTAGONISM BY CHLORNALTREXAMINE OF SOME EFFEQS OF DELTA9 
TETRAHYDROCANNABINOL IN RATS. 

003104 03-04 
ANTAGONISM OF INTRAVENOUS COCAINE LETHALITY IN NONHUMAN 
PRIMATES. 

003127 03-05 
CHLORPROMAZINE, HALOPERIDOL, METOCLOPRAMIDE AND 

DOMPERIDONE RELEASE PROLACTIN THROUGH DOPAMINE JL 

ANTAGONISM AT LOW CONCENTRATIONS BUT PARADOXICALLY ■ 

INHIBIT PROLACTIN RELEASE AT HIGH-CONCENTRATIONS. 

003731 04-03 
ANTAGONISM OF ETHANOL-INDUCED DECREASE IN LH BY P 
CHLOROPHENYLALANINE: LACK OF CORRELATION WITH ALTERED 
SEROTONERGIC MECHANISMS 

003748 04-03 
PRESYNAPTIC AND POSTSYNAPTIC ALPHA-AORENOCEPTOR ANTAGONISM 
BY NEUROLEPTICS IN VIVO. 

003966 04-03 
USE OF THE INTRACEREBRAL INJEQION TECHNIQUE TO ELUCIDATE 
MECHANISMS OF APOMORPHINE CLIMBING AND ITS ANTAGONISM IN 
THE MOUSE. 

004092 04-04 
ANTAGONISM OF SOME CENTRAL-EFFEaS OF D TUBOCURARINE BY 
GAMMA AMINOBUTYRIC-ACID. 

004102 04-04 
IS DOPAMINE ANTAGONISM A REQUISITE OF NEUROLEPTIC AQIVITY? 

004122 04-04 
BENZODIAZEPINE ANTAGONISM BY HARMANE AND OTHER BETA 
CARBOLINES IN VITRO AND IN VIVO 

004211 04-04 
ANTAGONISM BY PHENOXYBENZAMINE AND PENTAZOCINE OF THE 
ANTINOCICEPTIVE-EFFECTS OF MORPHINE IN THE SPINAL-CORD. 

004213 04-04 
ANTAGONISM OF DOPAMINE SUPERSENSITIVITY BY ESTROGEN: 
NEUROCHEMICAL-STUDIES IN AN ANIMAL-MODEL OF TARDIVE- 
DYSKINESIA. 

004268 04-05 



S-28 



VOLUME 19, SUBJECT INDEX 



Subject Index 



ANTAGONISMS 

DIFFERENTIATION OF KAINATE AND QUISQUALATE-RECEPTORS IN THE 
CAT SPINAL-CORD BY SELECTIVE ANTAGONISMS WITH GAMMA 
D(AND L) GLUTAMYLGLYCINE. 

002696 03-03 
ANTAGONIST 

THE CRYSTAL AND MOLECULAR STRUCTURE OF THE ACETYLCHOLINE 
ANTAGONIST DIMETHYLAMINOBUTYNYLCYCLOHEXYLHYDROXY 2 
PHENYLACETATE HCL. 

000003 01-01 
ALPHA FLUPENTHIXOL: AN ANTAGONIST OF DOPAMINE-EVOKED FLUID 
SECRETION BY AN INSECT SALIVARY-GLAND PREPARATION. 

000031 01-03 
HYPOALGESIA INDUCED BY MICROINJECTION OF A NOREPINEPHRINE 
ANTAGONIST IN THE RAPHE-MAGNUS: REVERSAL BY INTRATHECAL 
ADMINISTRATION OF A SEROTONIN ANTAGONIST. 

000121 01-03 
CHLOROETHYLNORAPOMORPHINE, A PROPOSED LONG-ACTING 
DOPAMINE ANTAGONIST: INTERACTIONS WITH DOPAMINE-RECEPTORS 
OF MAMMALIAN FOREBRAIN IN VITRO. 

001114 02-03 
REGULATION OF RECEPTOR BINDING INTERACTIONS OF 1251 
ANGIOTENSIN-II AND 1251 SARC0SINE1-LEUCINE8-ANGI0TENSIN-II, AN 
ANGIOTENSIN ANTAGONIST, BY SODIUM-ION. 

001124 02-03 
RECEPTOR BINDING INTERACTIONS OF THE ANGIOTENSIN-II ANTAGONIST 

1251 SARC0SINE1-LEUCINE8-ANGI0TENSIN-II, WITH MAMMALIAN 
BRAIN AND PERIPHERAL TISSUES. 

001125 02-03 
THE AFFINITIES OF ERGOT COMPOUNDS FOR DOPAMINE AGONIST AND 

DOPAMINE ANTAGONIST RECEPTOR SITES. 

001254 02-03 
UNITARY DOPAMINERGIC-RECEPTOR COMPOSED OF COOPERATIVELY 
LINKED AGONIST AND ANTAGONIST SUBUNIT BINDING-SITES. 

001342 02-03 
EFFEaS OF HALOPERIDOL, A DOPAMINE-RECEPTOR ANTAGONIST, ON A 
DELAYED TYPE HYPERSENSITIVITY REACTION TO 1 
CHLORODINITROBENZENE IN MICE. 

001473 02-03 
NARCOTIC ANTAGONIST PRECIPITATED ABSTINENCE: RELATIONSHIP TO 
WITHDRAWAL INDUCING BENZAZOCINES. (PH.D. DISSERTATION) 

001518 02-03 
MORPHINE ANALGESIA AFTER INTRATHECAL ADMINISTRATION OF A 
NARCOTIC AGONIST, CHLOROXYMORPHAMINE AND ANTAGONIST 
CHLORNALTREXAMINE. 

001695 02-04 
DOPAMINE ANTAGONIST AND AGONIST TREATMENT OF TARDIVE- 
DYSKINESIA. 

002377 02-15 
RECEPTOR BINDING PROFILE OF R-41-468, A NOVEL ANTAGONIST AT 5 
HT2-RECEPT0RS. 

002648 03-02 
DIFFERENTIAL REGULATION BY GUANINE-NUCLEOTIDES OF OPIATE 
AGONIST AND ANTAGONIST RECEPTOR INTERACTIONS. 

002688 03-03 
OPIATE ANTAGONIST IMPROVES NEUROLOGIC RECOVERY AFTER SPINAL 
INJURY. 

002714 03-03 
PROPERTIES OF DOPAMINE AGONIST AND ANTAGONIST BINDING-SITES IN 
MAMMALIAN RETINA. 

002814 03-03 
DOPAMINERGIC AGONIST AND ANTAGONIST EFFECTS ON STRIATAL 
TYROSINE-HYDROXYLASE DISTRIBUTION. 

002898 03-03 
A COMPARISON OF HUMAN MUSCARINIC CHOLINERGIC-RECEPTOR 
RESPONSE TO A NUMBER OF PSYCHOTROPICS UTILIZING THE 
RADIOLABELED ANTAGONIST, (3H) QUINUCLIDINYL-BENZILATE (PH D 
DISSERTATION). 

002918 03-03 
ENHANCEMENT OF APOMORPHINE-INDUCED CLIMBING IN MICE BY 
REVERSIBLE AND IRREVERSIBLE NARCOTIC ANTAGONIST DRUGS. 

003068 03-04 
MORPHINE-LIKE STIMULUS EFFEaS IN THE MONKEY: OPIOIDS WITH 
ANTAGONIST PROPERTIES. 

003086 03-04 
GABA AND SCHIZOPHRENIA: STUDY OF THE ACTION OF A GABAERGIC 
ANTAGONIST. PROGABIDE OR SL-76-002. 

003175 03-08 
THE USE OF A MORPHINE ANTAGONIST (NALOXONE) IN THE TREATMENT 
OF DISSOCIATIVE-SYNDROMES. 

003194 03-08 
CLINICAL-PHARMACOLOGY OF MIXED AGONIST ANTAGONIST DRUGS 

003329 03-11 
STRUaURE-ACTIVITY AND RECEPTOR BINDING OF ANTAGONIST 
ANALGESICS. 

T,,r„„„ 00361103-17 

THE DOPAMINE-RECEPTOR ANTAGONIST DOMPERIDONE IS ALSO A 
COMPETITIVE ANTAGONIST AT ALPH A 1 -ADRENOCEPTORS 

003785 04-03 



RESPONSE OF STRIATONIGRAL SUBSTANCE-P SYSTEMS TO A DOPAMINE- 
RECEPTOR AGONIST AND ANTAGONIST. 

003826 04-03 
ISOMERIZATION OF THE MUSCARINIC-RECEPTOR ANTAGONIST COMPLEX. 

003860 04-03 
EFFECTS OF MORPHINE AND CAFFEINE ON ADENOSINE RELEASE FROM 
RAT-CEREBRAL-CORTEX: IS CAFFEINE A MORPHINE ANTAGONIST. 

003864 04-03 
ACTIONS OF MU, KAPPA, SIGMA, DELTA AND AGONIST/ANTAGONIST 
OPIATES ON STRIATAL DOPAMINERGIC FUNCTION. 

004053 04-03 
PHARMACOLOGICAL-STUDIES WITH AN ALKYLATING NARCOTIC 
AGONIST, CHLOROXYMORPHAMINE, AND ANTAGONIST 
CHLORNALTREXAMINE. 

004082 04-04 
ANALGESIC AND OTHER PHARMACOLOGICAL ACTIVITIES OF A NEW 
NARCOTIC ANTAGONIST ANALGESIC (-) 1 3 

METHYLBUTENYLHYDROXYPHENYLPHENYLETHYLPIPERAZINE AND ITS 
ENANTIOMORPH IN EXPERIMENTAL ANIMALS. 

004185 04-04 
NALOXAZONE, A LONG-ACTING OPIATE ANTAGONIST: EFFECTS ON 
ANALGESIA IN INTACT ANIMALS AND ON OPIATE-RECEPTOR BINDING 
IN VITRO. 

004198 04-04 
HUMAN PLATELET ALPHA2-ADRENERGIC-RECEPT0RS: LABELING WITH 3H 
YOHIMBINE, A SELECTIVE ANTAGONIST LIGAND. 

004676 04-16 
ANTAGONISTIC-EFFECTS 

ANTAGONISTIC-EFFECTS OF PROPRANOLOL UPON ETHANOL-INDUCED 
NARCOSIS IN MICE. 

000439 01-04 
ANTAGONISTIC-EFFECTS OF PSYCHOLEPTIC-DRUGS ON STRESS-INDUCED 
ANALGESIA. 

001609 02-04 
ANTAGONISTS 

SUPPRESSION OF SEROTONERGIC NEURONAL FIRING BY ALPHA- 
ADRENOCEPTOR ANTAGONISTS: EVIDENCE AGAINST GABA 
MEDIATION. 

000024 01-03 
EFFECTS OF DOPAMINERGIC AGONISTS AND ANTAGONISTS ON 
(3H)AP0M0RPHINE BINDING TO STRIATAL MEMBRANES: SULPIRIDE 
LACK OF INTERACTIONS WITH POSITIVE COOPERATIVE 
(3H)AP0M0RPHINE BINDING. 

000099 01-03 
HYPOALGESIA FOLLOWING MICROINJECTION OF NORADRENERGIC 
ANTAGONISTS IN THE NUCLEUS-RAPHE-MAGNUS. 

000122 01-03 
COMPARTMENTATION OF CATECHOLAMINES IN RAT-BRAIN: EFFECTS OF 
AGONISTS AND ANTAGONISTS. 

000125 01-03 
EFFECTS OF NORADRENERGIC AGONISTS AND ANTAGONISTS ON 
GROWTH-HORMONE SECRETION UNDER GAMMA HYDROXYBUTYRATE 
NARCOANALGESIA IN THE RAT. 

000262 01-03 
EFFECTS OF ANTICONVULSANTS AND GLUTAMATE ANTAGONISTS ON THE 
CONVULSIVE ACTION OF KAINIC-ACID. 

000288 01-03 
ON THE CAPACITY OF PRESYNAPTIC ALPHA-RECEPTORS TO MODULATE 
NOREPINEPHRINE RELEASE FROM SLICES OF RAT NEOCORTEX AND THE 
AFFINITY OF SOME AGONISTS AND ANTAGONISTS FOR THESE 
RECEPTORS. 

000323 01-03 
POSTSWIM GROOMING IN MICE INHIBITED BY DOPAMINE-RECEPTOR 
ANTAGONISTS AND BY CANNABINOIDS. 

000359 01-04 
NORADRENERGIC AGONISTS AND ANTAGONISTS: EFFECTS ON 
CONDITIONED FEAR AS MEASURED BY THE POTENTIATED STARTLE 
PARADIGM. 

000372 01-04 
ROTATION INDUCED BY INTRANIGRAL INJECTIONS OF GABA AGONISTS 
AND ANTAGONISTS: ZONE-SPECIFIC EFFECTS. 

000422 01-04 
BETA-ADRENOCEPTOR ANTAGONISTS: STUDIES ON BEHAVIOUR (DELAYED 
DIFFERENTIATION) IN THE MONKEY (MACACA-MULAHA). 

000440 01-04 
NOREPINEPHRINE UPTAKE INHIBITORS AS BIOCHEMICALLY-SELECTIVE 
AND BEHAVIORALLY-SELECTIVE ANTAGONISTS OF THE LOCOMOTOR- 
STIMULATION INDUCEn BY INDIRECTLY ACTING SYMPATHOMIMETIC- 
AMINES IN MICE. 

000492 01-04 
GUANINE-NUCLEOTIDES INHIBIT BINDING OF AGONISTS AND 
ANTAGONISTS TO SOLUBLE OPIATE-RECEPTORS. (UNPUBLISHED 
PAPER). 

001035 02-01 
EFFECTS OF ALPHA-ADRENOCEPTOR AGONISTS AND ANTAGONISTS AND 
OF ANTIDEPRESSANT-DRUGS ON PRESYNAPTIC AND POSTSYNAPTIC 
ALPHA-ADRENOCEPTORS. 

001146 02-03 



^ 



S-29 



Subject Index 



INTERACTION-STUDIES BETWEEN NARCOTIC ANALGESICS, NARCOTIC 
ANTAGONISTS AND ETHANOL: STUDIES DURING ACUTE AND CHRONIC- 
TREATMENT AND WITHDRAWAL STATES IN RATS AND MICE. (PH.D. 
■^'SSE^TATION). 001165 02-03 

A PROPOSED MODE OF ACTION FOR NARCOTIC AGONISTS AND 

^^^^^°'^'S^^- 001168 02-03 

EFFECT OF GABA AGONIST AND ANTAGONISTS ON CARDIOVASCULAR 

AND SYMPATHETIC RESPONSES IN SHR AND WKY RATS. 

(UNPUBLISHED PAPER). 001224 02-03 

AHEMPTS TO DEVELOP SUPERSENSITIVITY OR SUBSENSITIVITY RETINAL 

DOPAMINE-RECEPTORS AFTER VARIOUS TREATMENTS WITH 

ANTAGONISTS OR AGONISTS. 001350 02-03 

AMINOPHYLLINE AND THEOPHYLLINE DERIVATIVES AS ANTAGONISTS OF 

NEURONAL DEPRESSION BY ADENOSINE: A MICROIONTOPHORETIC- 

STUDY 

^ 001410 02-03 

RETROGRADE AMNESIA PRODUCED BY ELECTRICAL-STIMULATION OF THE 

AMYGDALA: ATTENUATION WITH ADRENERGIC ANTAGONISTS. 

(UNPUBLISHED PAPER). 001488 02-03 

NEGLIGIBLE AFFINITY OF HISTAMINE H2-RECEPT0R ANTAGONISTS FOR 

CENTRAL ALPHAl-ADRENOCEPTORS. 001508 02-03 

OPIATE ANTAGONISTS AND LONG-TERM ANALGESIC REACTION INDUCED 

BY INESCAPABLE SHOCK IN RATS. 001707 02-04 

OPIATE ANTAGONISTS AND FEMALE FUNCTIONING. (UNPUBLISHED 

^'^^^^'> 001735 02-04 

LACK OF EFFECT OF CHOLINE AND NARCOTIC ANTAGONISTS UPON 

APOMORPHINE DISCRIMINATION. „„,-,-,„ „o /^>. 

001770 02-04 

BIPHASIC-EFFECTS OF DIRECT, BUT NOT INDIRECT, GABAMIMETICS AND 
ANTAGONISTS ON HALOPERIDOL-INDUCED CATALEPSY, 

OUIozO Uz-U4 
DISPOSITION AND ACTIVITY OF BETA-ADRENOCEPTOR ANTAGONISTS IN 
THE RAT USING AN EX VIVO RECEPTOR BINDING ASSAY. 

001878 Oz-Oo 
CHARACTERIZATION OF ERGOT AND NONERGOT SEROTONIN 

ANTAGONISTS BY PROLAQIN AND GROWTH-HORMONE PROFILES 
DURING WAKEFULNESS AND SLEEP. ^^^^^ ^^.is 

EFFECT OF OPIATES AND OPIATE ANTAGONISTS ON SOMATOSENSORY 
EVOKED-POTENTIALS IN PATIENTS WITH SCHIZOPHRENIA AND 
NORMAL ADULTS, 002222 02-13 

SELECTIVE ANTAGONISTS OF BENZODIAZEPINES. 

00z64o Uo-U/ 
GABA ANTAGONISTS ENHANCE DOPAMINE TURNOVER IN THE RAT 

^™^'^^'^° 002772 03-03 

THE EFFECTS OF OPIATE ANTAGONISTS ON THE DISCRIMINATIVE 

STIMULUS PROPERTIES OF ETHANOL, ^^^^^ ^^_^^ 

THE EFFECTS OF OPIATE ANTAGONISTS ON FOOD INTAKE ARE 

^^^^^OSPKmC 003080 03-04 

SUPERSENSITIVITY TO THE BEHAVIORAL-EFFEQS OF OPIATE 

^^^^^°^'^^^ 003096 03-04 

THE RELATIONSHIP BETWEEN THE ACUTE BEHAVIORAL-EFFEQS OF 

NARCOTIC ANTAGONISTS AND THE NARCOTIC DEPENDENT STATE, 

003106 03-04 
INFUSIONS INTO THE OCULOMOTOR NUCLEUS OR NERVE: A METHOD OF 

ESTIMATING THE DOSAGE AT WHICH TRANSMIHER ANTAGONISTS 

INFUSED INTRACRANIALLY PRODUCE NONSPECIFIC BLOCKING OF 

^^^^^^^^^'^'^ 003134 03-06 

PHARMACOLOGICAL ANTAGONISTS OF EXCITANT AMINO-ACID ACTION, 

003587 03-17 
PRESYNAPTIC MODULATION OF SYNAPTIC TRANSMISSION IN HELIX- 

POMATIA: THE EFFECTS OF SEROTONIN AND DOPAMINE 

^^^^^°^'^^^- 003869 04-03 

DOPAMINERGIC MECHANISMS IN THE TELEOST RETINA. I. DOPAMINE- 

SENSITIVE ADENYLATE-CYCLASE IN HOMOGENATES OF CARP RETINA; 

EFFECTS OF AGONISTS, ANTAGONISTS AND ERGOTS. 

004051 04-03 
A COMPARISON OF THE RESPONSES TO SOME DOPAMINE-RECEPTOR 

AGONISTS AND ANTAGONISTS IN THE ISOLATED PERFUSED RAT 

^'°^^^- 004054 04-03 

HISTAMINE AS A PUNISHER IN SQUIRREL-MONKEYS: EFFECTS OF 
PENTOBARBITAL, CHLORDIAZEPOXIDE AND HI -RECEPTOR AND H2- 
RECEPTOR ANTAGONISTS ON BEHAVIOR AND CARDIOVASCULAR 

«^S''0^5^- 004119 04-04 



Ptychopharmacology Abstracts 

INTERAQIONS BETWEEN NARCOTIC AGONISTS, PARTIAL AGONISTS AND 
ANTAGONISTS EVALUATED BY SCHEDULE-CONTROLLED BEHAVIOR, 

004127 04-04 
EFFECTS OF NARCOTIC ANTAGONISTS ON L-DOPA REVERSAL OF 
RESERPINE-INDUCED CATALEPSY AND BLEPHAROPTOSIS IN MICE. 

004186 04-04 
MORPHINE ANTAGONISTS AND CONSUMMATORY-BEHAVIORS. 

004196 04-04 
RETROGRADE AMNESIA PRODUCED BY ELEaRICAL-STIMULATION OF THE 
AMYGDALA: AHENUATION WITH ADRENERGIC ANTAGONISTS. 

004231 04-04 

ANTAGONIZE ^^ ,^ 

ANTICONVULSANTS SPECIFIC FOR PETIT-MAL ANTAGONIZE 
EPILEPTOGENIC-EFFECT OF LEUCINE-ENKEPHALIN. 

000477 01-04 
COCAINE AND AMPHETAMINE ANTAGONIZE THE DECREASE OF 

NORADRENERGIC NEUROTRANSMISSION ELICITED BY OXYMETAZOLINE 
BUT POTENTIATE THE INHIBITION BY ALPHA METHYLNOREPINEPHRINE 
IN THE PERFUSED CAT SPLEEN. _^^^, ^^ ^, 

002801 03-03 
THE BENZODIAZEPINES AND INOSINE ANTAGONIZE CAFFEINE-INDUCED 

'''''''' 004172 04-04 

ANTAGONIZED „_ 

BEHAVIORAL-EFFEaS AND ELEaROCORTICAL-EFFECTS AFTER 

INTRASTRIATAL CEFAZOLIN IN RATS ARE ANTAGONIZED BY DRUGS 
ENHANCING GABAERGIC TRANSMISSION 

000443 01-04 
EFFECTS OF 5 HYDROXYTRYPTAMINE ON CENTRAL NEURONES 
ANTAGONIZED BY BICUCULLINE AND PICROTOXIN. 

003931 04-03 

DIAZEPAM IN COMBINATION WITH TACRINE DERIVATIVES ANTAGONIZES 
BEHAVIOURAL-EFFEaS OF ANTICHOLINERGIC PSYCHOTOMIMETICS IN 

^'^^^ 000420 01-04 

BICUCULLINE ANTAGONIZES EFFEQS OF DIAZEPAM ON AGGRESSIVE AND 
TIMID-BEHAVIOUR IN MICE. 

000485 01-04 

LEVONANTRADOL, A POTENT CANNABINOID RELATED ANALGESIC, 
ANTAGONIZES HALOPERIDOL-INDUCED AQIVATION OF STRIATAL 

DOPAMINE SYNTHESIS. «„o-,n, «o «-, 

002786 03-03 
ETHYL-BETA-CARBOLINE-3-CARBOXYLATE ANTAGONIZES DIAZEPAM 

ACTIVITY. „„o^,r^, „, 

002915 03-03 

ETHYL-BETA-CARBOLINE-CARBOXYLATE LOWERS SEIZURE THRESHOLD 
AND ANTAGONIZES FLURAZEPAM-INDUCED SEDATION IN RATS. 

002971 03-04 

A STEROID DERIVATIVE, R-5135, ANTAGONIZES THE GABA/ 
BENZODIAZEPINE-RECEPTOR INTERAQION. 

3 HYDROXYMETHYL-BETA-CARBOLINE ANTAGONIZES SOME 

PHARMACOLOGIC AQIONS OF DIAZEPAM. ^ 

^'^^Am-^EDE^TS OF SELF-INDUCED WATER INTOXICATION: A PRELIMINARY- 
'^EPO''^ 002414 02-15 

AUTEI CpCIIJ 

TREATMENT OF EPILEPSIES WITH CLONAZEPAM (ANTELEPSIN). 

00448 1 04- 1 I 

^''"nf DEVELOPMENT OF PROGENY IN CASES OF ANTENATAL EXPOSURE TO 
^»^^^^^'^^ 001854 02-Of 

^'^"aILURE of ISOPRENALINE AND BETA-RECEPTOR BLOCKING-DRUGS TO 
MODIFY DEPRESSOR RESPONSE AND BRADYCARDIA INDUCED BY 
ELEQRICAL-STIMULATION OF THE ANTERIOR HYPOTHALAMUS OF 

'-^^^ 000520 01-0; 

THE EFFECTS OF BOMBESIN INJEQED INTO THE ANTERIOR AND ^„^^^, 

POSTERIOR HYPOTHALAMUS ON BODY-TEMPERATURE AND OXYGEN 

CONSUMPTION. 001544 02-0- 

THE INFLUENCE OF ANTERIOR NEOSTRIATAL LESIONS ON THE 

BEHAVIOURAL-EFFECTS OF SPIROPERIDOL IN RATS. ^^^^^ ^^^ 

TEMPORAL PAHERNING OF NEURONAL AQIVITY DURING THERMAL ANC 
NEUROCHEMICAL STIMULATION OF THE PREOPTIC/ANTERIOR 
HYPOTHALAMUS OF THE AWAKE RABBIT. ^^^^^ ^^_^, 

ANTERIOR PITUITARY GABA-RECEPTORS AND THEIR REGULATION OF 
PROLAQIN SECRETION. 002738 03-0: 

THE DIREQ EFFECT OF RESERPINE IN VITRO ON PROLAQIN RELEASE 
FROM RAT ANTERIOR PITUITARY-GLANDS. ^^^^^ ^^^ 



S-30 



I 



/OLUME 19, SUBJECT INDEX 



Subject Index 



CHOLINERGIC, DOPAMINERGIC, NORADRENERGIC, OR GLUTAMINERGIC 
STIMULATION VENTRAL TO THE ANTERIOR SEPTUM DOES NOT 
SPECIFICALLY SUPPRESS DEFENSIVE-BEHAVIOR 

002945 03-04 
ROLE OF THE ANTERIOR PITUITARY GABA-RECEPTOR IN THE CONTROL OF 
PROLACTIN RELEASE. 

003809 04-03 
EFFECTS OF CAFFEINE ON ANTERIOR PITUITARY AND THYROID-FUNCTION 
IN THE RAT. 

004014 04-03 
lNTERIOR-CH AMBER 

SEIZURES AND RELATED EPILEPTIFORM ACTIVITY IN HIPPOCAMPUS 
TRANSPLANTED TO THE ANTERIOR-CHAMBER OF THE EYE: 
MODULATION BY CHOLINERGIC AND ADRENERGIC INPUT. 

000095 01-03 
lNTERIOR-FOREBRAIN 

RELATIONSHIPS BETWEEN SELECTIVE DENERVATION OF DOPAMINE 
TERMINAL-FIELDS IN THE ANTERIOR-FOREBRAIN AND BEHAVIORAL- 
RESPONSES TO AMPHETAMINE AND APOMORPHINE. 

000384 01-04 
kNTEROGRADE 

TIME-DEPENDENT CHANGES IN ANTEROGRADE SCOPOLAMINE-INDUCED 
AMNESIA IN RATS. 

004182 04-04 
iNTI-BETA-ENDORPHIN 

SUPPRESSION OF SERUM PROLACTIN BY NALOXONE BUT NOT BY ANTI- 
BETA-ENDORPHIN ANTISERUM IN STRESSED AND UNSTRESSED RATS. 

002871 03-03 
iNTI-DElTA9-TETRAHYDROCANNABINOL 

IN VIVO AND IN VITRO PROPERTIES OF ANTI-DELTA9- 
TETRAHYDROCANNABINOL ANTIBODY. 

003751 04-03 
iNTI-RAT 

CORTICOSTERONE INCREASES THE SYNTHESIS OF A SOLUBLE PROTEIN IN 
PITUITARY-GLANDS FROM ADRENALECTOMIZED MALE RATS WHICH 
PRECIPITATES WITH ANTI-RAT GROWTH-HORMONE ANTISERUM. 
(UNPUBLISHED PAPER). 

001122 02-03 
lNTI-THY-1-2 

ANTI-THY-1-2 MONOCLONAL ANTIBODY LINKED TO RICIN IS A POTENT 
CELL TYPE SPECIFIC TOXIN. (UNPUBLISHED PAPER). 

001064 02-01 
lNTIADRENERGIC 

ADRENERGIC NONSPECIFIC POTENTIATION OF YOHIMBINE TOXICITY IN 
MICE BY ANTIDEPRESSANTS AND RELATED DRUGS AND 
ANTIYOHIMBINE ACTION OF ANTIADRENERGIC AND SEROTONERGIC 
DRUGS. 

001330 02-03 
iNTIALCOHOLISM-DRUG 

ARCALION-200 PRESCRIBED AS A PSYCHIATRIC-DRUG AND 
ANTIALCOHOLISM-DRUG ON AN OUTPATIENT AND INPATIENT BASIS. 

002103 02-11 
lNTIANOROGENS 

PHARMACOTHERAPY FOR SEXUAL-OFFENDERS: REVIEW OF THE ACTION 
OF ANTIANDROGENS WITH SPECIAL REFERENCE TO THEIR PSYCHIC- 
EFFECTS. 

004455 04-1 1 
CLINICAL APPLICATION OF ANTIANDROGENS IN PSYCHIATRY. 

004457 04-1 1 
ANTIANXIETY 

1 AMIN0ALKYL-6-ARYL-4H-S-TRIAZ0L0BENZ0DIAZEPINES WITH 
ANTIANXIETY AND ANTIDEPRESSANT ACTIVITY. 

001074 02-02 
2,4 DIHYDRO-6-PHENYL-lH-S-TRIAZOLOBENZODIAZEPIN-l-ONES WITH 

ANTIANXIETY AND ANTIDEPRESSANT ACTIVITY. 

001075 02-02 
6 SUBSTITUTED AMIN0-4H-S-TRIAZ0L0BENZ0DIAZEPINES AND 4 

SUBSTITUTED AMIN0-6H-S-TRIAZ0L0BENZ0DIAZEPINES WITH 
POTENTIAL ANTIANXIETY ACTIVITY. 

001076 02-02 
PHARMACOLOGY OF 1 DICHLOROBENZYL-TETRAHYDROPYRIMIDONE, A 

NOVEL ANTIDEPRESSANT COMPOUND WITH ANTIANXIETY ACTIVITY. 

003688 04-02 
THE EFFECTS OF ANTIANXIETY AND ANTIPSYCHOTIC-DRUGS ON SEXUAL- 
BEHAVIOR. 

004657 04-15 
AN EVALUATION OF THE ANTIANXIETY ACTION AND SIDE-EFFECTS OF 
PROPRANOLOL. 

004660 04-15 
lNTIANXIETY-AGENT 

HOSTILITY PRODUCTION AS A COMMON FEATURE OF ANTIANXIETY- 
AGENT ACTION. 

004654 04-15 
kNTIANXIETY-AGENTS 

ANTIANXIETY-AGENTS AND SYNAPTIC TRANSMISSION IN THE BRAIN: 
ELECTROPHYSIOLOGICAL-STUDIES. (PH.D. DISSERTATION). 

002840 03-03 
kNTIANXIETY-DRUG 

PERSONALITY TRAIT AND ANTIANXIETY-DRUG EFFECTS ON 
PSYCHOMOTOR PERFORMANCE. 

002336 02-14 



ANTIANXIETY-DRUGS 

EFFECT OF ANTIANXIETY-DRUGS ON FEAR AND STRESS. 

000801 01-14 
POSSIBLE LIMBIC SITES OF ACTION OF ANTIANXIETY-DRUGS 

002069 02-10 
DISINHIBITION OF BEHAVIOR BY ANTIANXIETY-DRUGS 

002403 02-15 
ANTIANXIETY-EFFECTS 

METHODS AND METHODOLOGICAL-CONSIDERATIONS IN MEASURING 
ANTIANXIETY-EFFECTS OF TRANQUILIZING-DRUGS 

002537 02-17 
ANTIARRHYTHMIC-ACTIVITY 

ANTIARRHYTHMIC-ACTIVITY OF AMITRIPTYLINE ANALOGUES IN 
CONSCIOUS DOGS AFTER MYOCARDIAL-INFARCTION: 
CYPROHEPTADINIUM-METHIODIDE 

001534 02-03 
ANTIAVOIDANCE 

CORRELATION BETWEEN ANTIAVOIDANCE ACTIVITIES OF ANTIPSYCHOTIC- 
DRUGS IN RATS AND DAILY CLINICAL DOSES. 

003032 03-04 
ANTIBIOTICS 

EFFECTS OF THREE ANTIBIOTICS ON THEOPHYLLINE KINETICS. 

000784 01-13 
ANTIBODIES 

AFFINITY CHROMATOGRAPHY OF THE BETA-ADRENERGIC-RECEPTOR AND 
CHARACTERIZATION OF ANTIBODIES RAISED AGAINST PURIFIED 
RECEPTOR PREPARATIONS. 

001009 02-01 
ABNORMAL MATURATION OF CEREBRAL-CORTEX AND BEHAVIORAL- 
DEFICIT IN ADULT RATS AFTER NEONATAL ADMINISTRATION OF 
ANTIBODIES TO GANGLIOSIDE. 

003025 03-04 
BEHAVIOURAL-CHANGES IN ADULT RATS FOLLOWING ADMINISTRATION 
OF ANTIBODIES AGAINST BRAIN GANGLIOSIDES. 

003071 03-04 
ANTIBODY 

PRODUCTION OF A SPECIFIC ANTISERUM TO RAT-BRAIN GLUTAMIC-ACID- 
DECARBOXYLASE (GAD) BY INJECTION OF AN ANTIGEN ANTIBODY 
COMPLEX. (UNPUBLISHED PAPER). 

001047 02-01 
ANTI-THY-1-2 MONOCLONAL ANTIBODY LINKED TO RICIN IS A POTENT 
CELL TYPE SPECIFIC TOXIN. (UNPUBLISHED PAPER). 

001064 02-01 
IN VIVO AND IN VITRO PROPERTIES OF ANTI-DELTA9- 
TETRAHYDROCANNABINOL ANTIBODY. 

003751 04-03 
ANTICANDIDAL-ACTIVITY 

ANTICANDIDAL-ACTIVITY OF PYRIMIDINE-PEPTIDE CONJUGATES. 

001059 02-01 
ANTICHOLINERGIC 

DIAZEPAM IN COMBINATION WITH TACRINE DERIVATIVES ANTAGONIZES 
BEHAVIOURAL-EFFECTS OF ANTICHOLINERGIC PSYCHOTOMIMETICS IN 
RATS. 

000420 01-04 
LONG-TERM APPLICATION OF HALOPERIDOL: EFFECT OF ANTICHOLINERGIC 
TREATMENT ON THE RATE OF DOPAMINE SYNTHESIS. 

001490 02-03 
ANTICHOLINERGIC-ACTIVITY 

THE PERIPHERAL ANTICHOLINERGIC-ACTIVITY OF TRICYCLIC- 
ANTIDEPRESSANTS: COMPARISON OF AMITRIPTYLINE AND 
DESIPRAMINE IN HUMAN VOLUNTEERS. 

002298 02-13 
SELF-STIMULATION AND LOCOMOTOR CHANGES INDICATING LATENT 
ANTICHOLINERGIC-ACTIVITY BY AN ATYPICAL NEUROLEPTIC 
(THIORIDAZINE). 

0035') 03-16 
ANTICHOLINERGIC-DRUGS 

INDIVIDUAL DIFFERENCES IN EFFECTS OF TRICYCLIC-ANTIDEPRESSANTS 
AND ANTICHOLINERGIC-DRUGS ON OPERANT-BEHAVIOR IN THE 
SQUIRREL-MONKEY. 

004176 04-04 
ANTICHOLINERGIC-EFFECTS 

STUDIES ON THE PUTATIVE ANTICHOLINERGIC-EFFECTS OF 
DESMETHYLIMIPRAMINE. 

000228 01-03 
ANTICHOLINERGIC-EFFECTS AND PLASMA DESIPRAMINE LEVELS. 

004550 04-13 
ANTICHOLINERGIC-SYNDROME 

THE INTERACTION OF ANTICHOLINESTERASES AND DIAZEPAM IN THE 
TREATMENT OF ANTICHOLINERGIC-SYNDROME IN DOGS. 

000389 01-04 
ANTICHOLINERGICS 

ANTICHOLINERGICS PROMOTE NEUROLEPTIC-INDUCED TARDIVE- 
DYSKINESIA. 

001834 02-05 
ANTICHOLINESTERASES 

THE INTERACTION OF ANTICHOLINESTERASES AND DIAZEPAM IN THE 
TREATMENT OF ANTICHOLINERGIC-SYNDROME IN DOGS. 

000389 01-04 



^ 



S-31 



Subject Index 



Psychopharmacology Abstracts 



COMPARATIVE-STUDY OF AGGRESSIVE-BEHAVIOUR AFTER INJECTION OF 
CHOLINOMIMETICS, ANTICHOLINESTERASES, NICOTINIC, AND 
MUSCARINIC GANGLIONIC STIMULANTS INTO THE CEREBRAL 
VENTRICLES OF CONSCIOUS CATS: FAILURE OF NICOTINIC-DRUGS TO 
EVOKE AGGRESSION. 

001568 02-04 
ANTICONFLICT 

RELATIONSHIP OF ANTICONFLICT ACTIVITY OF BENZODIAZEPINES TO 
BRAIN RECEPTOR BINDING, SEROTONIN, AND GABA. 

000057 01-03 
MULTIPLE BENZODIAZEPINE-RECEPTORS: EVIDENCE OF A DISSOCIATION 
BETWEEN ANTICONFLICT AND ANTICONVULSANT PROPERTIES BY PK- 
8165 AND PK-9084 (TWO QUINOLINE DERIVATIVES). 

003898 04-03 
ANTICONVULSANT 

EFFECT OF DOPAMINERGIC AND GABAERGIC DRUGS GIVEN ALONE OR IN 
COMBINATION ON THE ANTICONVULSANT ACTION OF PHENOBARBITAL 
AND DIPHENYLHYDANTOIN IN THE ELECTROSHOCK-TEST IN MICE. 

000163 01-03 

single-dose pharmacokinetics and anticonvulsant efficacy of 
pria;\idone in mice. 

000177 01-03 
ANTICONVULSANT AND ANESTHETIC BARBITURATES: DIFFERENT 
POSTSYNAPTIC ACTIONS IN CULTURED MAMMALIAN NEURONS, 

000194 01-03 
STRUCTURE-ACTIVITY RELATIONSHIPS IN THE EFFECTS OF PHENACEMIDE 
ANALOGS ON SERUM CREATININE AND ANTICONVULSANT ACTIVITY. 

000249 01-03 
CORRELATION BETWEEN BENZODIAZEPINE-RECEPTOR OCCUPATION AND 
ANTICONVULSANT EFFECTS OF DIAZEPAM. 

000450 01-04 
PROCONVULSANT AND ANTICONVULSANT ACTION OF MORPHINE IN 

RATS 

000494 01-04 
3 CHLORO-4-PHENYLSUCCINIMIDOBENZENESULFONAMIDE {GS-385), A 
NEW ANTICONVULSANT: ITS QUANTITATIVE DETERMINATION, 
PHARMACOKINETICS AND METABOLISM USING HIGH-PERFORMANCE 
LIQUID-CHROMATOGRAPHY. 

000705 01-11 
EVALUATION OF CLORAZEPATE (TRANXENE) AS AN ANTICONVULSANT - 
A PILOT-STUDY. 

000728 01-11 
ON THE GENETIC SIDE-EFFECTS OF PSYCHOTROPIC-SUBSTANCES: I 
PSYCHOPHARMACEUTICALS, NARCOTICS, AND ANTICONVULSANT. 

000845 01-15 
CONVULSANT AND ANTICONVULSANT BARBITURATES 1 . MOLECULAR 
CONFORMATIONS FROM CLASSICAL POTENTIAL ENERGY 
CALCULATIONS. 

001029 02-01 
EEG AND ANTICONVULSANT EFFECTS OF DIPROPYLACETIC-ACID AND 
DIPROPYLACETAMIDE IN THE BABOON PAPIO-PAPIO. 

001210 02-03 
ANTICONVULSANT PROPERTIES OF S ADENOSYL-L-HOMOCYSTEINE. 

001227 02-03 
DRUG-INDUCED ELEVATION OF GABA AFTER INTRACEREBRAL 
MICROINJECTION: SITE OF ANTICONVULSANT ACTION. 

001627 02-04 
SUBACUTE CANNABINOID TREATMENT: ANTICONVULSANT ACTIVITY AND 
WITHDRAWAL EXCITABILITY IN MICE. 

001671 02-04 
THE ANTICONVULSANT PROPERTIES OF MELATONIN ON KINDLED 
SEIZURES IN RATS. 

002653 03-03 
BARBITURATE ENHANCEMENT OF GABA-MEDIATED INHIBITION AND 
ACTIVATION OF CHLORIDE ION-CONDUCTANCE: CORRELATION WITH 
ANTICONVULSANT AND ANESTHETIC ACTIONS. 

002885 03-03 
CORRELATION OF (14C)MUSCIM0L CONCENTRATION IN RAT-BRAIN WITH 
ANTICONVULSANT ACTIVITY. 

003045 03-04 
KETAMINE: CONVULSANT OR ANTICONVULSANT? 

003060 03-04 
A POSSIBLE ROLE FOR CATECHOLAMINE NEUROTRANSMITTERS IN THE 
ANTICONVULSANT ACTIVITY OF CHLORDIAZEPOXIDE. 

003119 03-04 
ON THE ANTICONVULSANT BLOOD LEVEL IN THERAPY-RESISTANT 
EPILEPTIC-PATIENTS. 

003300 03-1 1 
A PROSPECTIVE RANDOMISED-TRIAL ON THE EFFECT OF MONITORING 
PLASMA ANTICONVULSANT LEVELS IN EPILEPSY. 

003314 03-11 
ANTICONVULSANT PROPERTIES OF SELECTED PYRROLOPYRIMIDINEDIONES 
AND INTERMEDIATES. 

003700 04-02 
THE EFFEQ OF SODIUM-DIPROPYLACETATE ON GAMMA AMINOBUTYRIC- 
ACID DEPENDENT INHIBITION IN THE RAT-CORTEX AND SUBSTANTIA- 
NIGRA IN RELATION TO ITS ANTICONVULSANT ACTIVITY. 

003880 04-03 



MULTIPLE BENZODIAZEPINE-RECEPTORS: EVIDENCE OF A DISSOCIATION I 
BETWEEN ANTICONFLICT AND ANTICONVULSANT PROPERTIES BY PK- ' 
8165 AND PK-9084 (TWO QUINOLINE DERIVATIVES). 

003898 04-03 
ANTICONVULSANT ACTIVITY OF METABOLITES OF VALPROIC-ACID. 

004168 04-04 
BIOCHEMICAL-STUDIES OF HUMAN EPILEPTICS DURING ANTICONVULSANT 
THERAPY 

004490 04-11 
ANTICONVULSANT-AGENTS 

SYNTHESIS OF PHENYLURETHANS OF 1,2 DIALKYL-4-PYRAZOLIDINOLS AS 
ANTICONVULSANT-AGENTS. 

003695 04-02 
ANTICONVULSANT-DRUG 

3 SULFAMOYLMETHYL-l-2-BENZISOXAZOLE, A NEW TYPE OF 
ANTICONVULSANT-DRUG: PHARMACOLOGICAL PROFILE. 

000012 01-02 
3 SULFAMOYLMETHYL-l-2-BENZISOXAZOLE, A NEW TYPE OF 
ANTICONVULSANT-DRUG: ELECTROENCEPHALOGRAPHIC PROFILE 

000142 01-03 
PERINATAL EFFECTS OF PSYCHOTROPIC-DRUGS: THE ANTICONVULSANT- 
DRUG DIPHENYLHYDANTOIN (UNPUBLISHED PAPER). 

001842 02-05 
CONVULSANT AND ANTICONVULSANT-DRUG BINDING-SITES RELATED TO 
GABA REGULATED CHLORIDE ION-CHANNELS. 

002848 03-03 
ANTICONVULSANT-DRUGS 

INHIBITORY-EFFECTS OF ANTICONVULSANT-DRUGS ON CYCLIC- 
NUCLEOTIDE ACCUMULATION IN BRAIN, 

000090 01-03 
COMPARATIVE-STUDY OF THE INHIBITION OF GABA-AMINOTRANSFERASE 
BY DIFFERENT ANTICONVULSANT-DRUGS 

000192 01-03 
PREGNANCY AND EPILEPSY: SHOULD ANTICONVULSANT-DRUGS BE 
CONTINUED? 

000679 01-11 
ANTICONVULSANT-DRUGS AND CANCER. 

000855 01-15 
PSYCHIATRIC IMPLICATIONS OF ANTICONVULSANT-DRUGS 

002463 02-15 
EFFECT OF ANTICONVULSANT-DRUGS ON INHIBITORY AND EXCITATORY 
PATHWAYS 

002724 03-03 
ACCELERATED METABOLISM OF PROBENECID DURING LONG-TERM- 
TREATMENT OF RATS WITH ANTICONVULSANT-DRUGS: EFFEQ ON 
CENTRAL SEROTONIN TURNOVER STUDIES. 

002890 03-03 
CHANGES IN REGIONAL BRAIN LEVELS OF AMINO-ACID PUTATIVE 
NEUROTRANSMinERS AFTER PROLONGED TREATMENT WITH THE 
ANTICONVULSANT-DRUGS DIPHENYLHYDANTOIN, PHENOBARBITONE, 
SODIUM-VALPROATE, ETHOSUXIMIDE, AND SULTHIAME IN THE RAT, 

003961 04-03 
VARIOUS ASPEQS OF THE EFFEQ Of ANTICONVULSANT-DRUGS ON 
MEMORY 

004602 04-15 
PHARMACOKINETICS OF ANTICONVULSANT-DRUGS. 

004738 04-17 
ANTICONVULSANT-INDUCED 

ANTICONVULSANT-INDUCED STATUS-EPILEPTICUS IN LENNOX-GASTAUT- 
SYNDROME. 

003467 03-15 

ANTICONVULSANTS 

CORRELATION BETWEEN MONOAMINE-OXIDASE-INHIBITORS AND 
ANTICONVULSANTS, 

000081 01-03 
ANTAGONISM OF INTRASTRIATAL AND INTRAVENOUS KAINIC-ACID BY 1 
NUCIFERINE: COMPARISON WITH VARIOUS ANTICONVULSANTS AND 
GABAMIMETICS. 

000188 01-03 
EFFEQS OF ANTICONVULSANTS AND GLUTAMATE ANTAGONISTS ON THE 
CONVULSIVE AQION OF KAINIC-ACID. 

000288 01-03 
ANTICONVULSANTS SPECIFIC FOR PETIT-MAL ANTAGONIZE 
EPILEPTOGENIC-EFFECT OF LEUCINE-ENKEPHALIN. 

000477 01-04 
ANTICONVULSANTS AND TREATMENT OF EPILEPSY. 

000661 01-11 
EFFECTS OF ANTICONVULSANTS AND METHOTREXATE ON CALCIUM 
DISPOSITION. „ „ ^„o«c 

001840 02-05 
PLASMA HDL CHOLESTEROL AND GROWTH-HORMONE IN EPILEPTICS 
TREATED WITH ANTICONVULSANTS. 

002260 02-13 
THE QUESTION OF MINIMUM-DOSES OF ANTICONVULSANTS IN THE 
TREATMENT OF EPILEPSY. ^^^ ^^ ,, 

002306 02-13 
CLINICAL-TRIALS OF DEPAKENE (VALPROIC-ACID) COADMINISTERED WITH 
OTHER ANTICONVULSANTS IN EPILEPTIC-PATIENTS. 

002367 02-14 



S-32 



VOLUME 19, SUBJECT INDEX 



THE ROLE OF FOLATE DEFICIENCY IN THE DEVELOPMENT OF PERIPHERAL 
NEUROPATHY CAUSED BY ANTICONVULSANTS 

002402 02-15 
HEPATOTOXICITY OF SODIUM-VALPROATE AND OTHER 
ANTICONVULSANTS IN RAT HEPATOCYTE CULTURES. 

002422 02-15 
A RAPID GAS-LIQUID-CHROMATOGRAPHY METHOD FOR SIMULTANEOUS 
DETERMINATION OF VARIOUS ANTICONVULSANTS. 

002501 02-16 
SAFETY OF ANTICONVULSANTS IN HEPATIC PORPHYRIAS. 

003132 03-05 
ADULT-ONSET STUHERING TREATED WITH ANTICONVULSANTS. 

003290 03-11 
SYNTHESIS OF POTENTIAL ANTICONVULSANTS. CONDENSATION OF 
ISATINS WITH ACETONE AND RELATED KETONES. 

003699 04-02 
GUANYLATE-CYCLASE - CYCLIC-GMP IN MOUSE CEREBRAL-CORTEX AND 
CEREBELLUM: MODIFICATION BY ANTICONVULSANTS. 

003956 04-03 
THERAPEUTIC PLASMA LEVELS OF SOME ANTICONVULSANTS IN FOCAL 
EPILEPSY IN RELATION TO COMPUTERIZED-AXIAL-TOMOGRAPHY. 

004439 04-11 
SERUM CONCENTRATION OF ANTICONVULSANTS. PHARMACOKINETIC 
FINDINGS AND THEIR PRACTICAL APPLICATION. 

004443 04-11 
ANTICONVULSANTS AND MENTAL-SYMPTOMS. 

004649 04-15 
iNTICONVULSIVE 

VALPROIC-ACID IN CHILDHOOD-EPILEPSY: ANTICONVULSIVE EFFICACY IN 
RELATION TO ITS PLASMA LEVELS. 

004525 04-13 
ANTIDEPRESSANT 

A PHARMACOLOGICAL-STUDY OF THE NEW SOVIET ANTIDEPRESSANT 
INKASAN. 

000008 01-02 
HISTAMINE HI -RECEPTORS LABELED IN VIVO: ANTIDEPRESSANT AND 
ANTIHISTAMINE INTERACTIONS. 

000074 01-03 
ANTIDEPRESSANT PROPERTIES OF 2 4 ETHYL-2-PIPERAZINYL-4- 
PHENYLQUINOLINE-HCL (AD- 1308) AND ITS MECHANISM-OF-ACTION 
AS COMPARED WITH TRICYCLIC-ANTIDEPRESSANTS. 

000152 01-03 
LONG-TERM ANTIDEPRESSANT TREATMENT DECREASES SPIROPERIDOL- 
LABELED SEROTONIN-RECEPTOR BINDING. 

000230 01-03 
LONG-TERM ANTIDEPRESSANT TREATMENT: ALTERATIONS IN CEREBRAL 
CAPILLARY PERMEABILITY. 

000239 01-03 
AQION OF THE ANTIDEPRESSANT PRIDEFINE (AHR-1 1 18) ON BIOGENIC- 
AMINES IN THE RAT-BRAIN. 

000312 01-03 
ANTIDEPRESSANT TREATMENT BY INTRAVENOUS ADMINISTRATION 
COMPARED TO PERORAL ADMINISTRATION: A DOUBLE-BUND STUDY 
OF QUINUPRAMINE. 

000552 01-08 
ANTIDEPRESSANT POTENTIATION OF 5 HYDROXYTRYPTOPHAN BY L 
DEPRENIL IN AFFECTIVE-ILLNESS. 

000608 01-09 
THE INFLUENCE OF LITHIUM-SALTS AND ANTIDEPRESSANT MEDICATION 
ON SERUM PROLACTIN LEVEL. 

000780 01-13 
MHPG AS A PREDICTOR OF ANTIDEPRESSANT RESPONSE TO IMIPRAMINE 
AND MAPROTILINE. 

000787 01-13 
EXPERIMENTAL EVALUATION OF ANTIDEPRESSANT ACTIVITY OF 
CLOMIPRAMINE, A NEW TRICYCLIC-ANTIDEPRESSANT DRUG. 

001068 02-02 
AMOXAPINE IN EXPERIMENTAL PSYCHOPHARMACOLOGY- A 
NEUROLEPTIC OR AN ANTIDEPRESSANT? 

001070 02-02 
1 AMIN0ALKYL-6-ARYL-4H-S-TRIAZ0L0BEN20DIAZEPINES WITH 
ANTIANXIETY AND ANTIDEPRESSANT ACTIVITY. 

001074 02-02 
2,4 DIHYDRO-6-PHENYL-lH-S-TRIAZOLOBENZODIAZEPIN-l-ONES WITH 

ANTIANXIETY AND ANTIDEPRESSANT ACTIVITY. 

001075 02-02 
THE NEW ANTIDEPRESSANT PIRLINDOLE: ANTAGONISM OF ACUTE 

OVERDOSAGE IN THE MOUSE. 

001082 02 02 
THE NEUROVASCULAR-PHARMACOLOGY AND CARDIOVASCULAR- 
PHARMACOLOGY OF RS-51324, A POTENTIAL ANTIDEPRESSANT. 

001091 02-02 
THE NEW ANTIDEPRESSANT PIRLINDOLE: A COMPARISON WITH 
IMIPRAMINE AND TRANYLCYPROMINE. 

001360 02-03 
ENHANCED SENSITIVITY OF AMYGDALOID NEURONS TO SEROTONIN AND 
NOREPINEPHRINE AFTER CHRONIC ANTIDEPRESSANT TREATMENT. 

001523 02-03 



Subject Index 

PHARMACOLOGICAL-STUDIES ON A NEW THYMOLEPTIC 
ANTIDEPRESSANT DIMETHYUMINOPROPYL-5-METHYL-3-PHENYL- 1 H- 
INDAZOLE (FS-32). 

001659 02-04 
AMINEPTINE, A NEW ANTIDEPRESSANT: PHARMACOLOGICAL REVIEW. 

001898 02-07 
ANTIDEPRESSANT ACTION OF INJECTABLE 1694 

001960 02-09 
PROFILE OF THE ANTIDEPRESSANT ACTION OF NOMIFENSINE. 

002025 02-09 
COMPARATIVE EXPERIMENT OF THE ANTIDEPRESSANT EFFECTS OF 
AMINEPTINE AND CHLORIMIPRAMINE 

002029 02-09 
ANTIDEPRESSANT ACTION OF AMINEPTINE: CONTROLLED DOUBLE-BLIND 

STUDY. 

002030 02-09 
EFFECT OF PIRIBEDIL (ET-495) ON PLASMA NOREPINEPHRINE: 

RELATIONSHIP TO ANTIDEPRESSANT RESPONSE. 

002034 02-09 
RATING OF ANTIDEPRESSANT ACTIVITY. 

002487 02-16 
NEW DEVELOPMENT IN ANTIDEPRESSANT MEDICATION - A REVIEW. 

002558 02-17 
REPEATED ANTIDEPRESSANT TREATMENTS INDUCE A LONG-USTING 
DOPAMINE-AUTORECEPTOR SUBSENSITIVITY: IS DAILY TREATMENT 
NECESSARY FOR CLINICAL EFFICACY? 

002659 03-03 
INFLUENCE OF A CHRONIC NEW POTENTIAL ANTIDEPRESSANT 
DIMETHYLAMINOPROPYL-5-METHYL-3-PHENYL-1 H-INDAZOLE (FS-32) 
AND ITS N DESMETHYLATED-COMPOUND (FS-97): TREATMENT ON 
MONOAMINERGIC-RECEPTOR SENSITIVITY IN THE RAT-BRAIN. 

002787 03-03 
AN ENHANCED SENSITIVITY OF MUSCARINIC CHOLINERGIC-RECEPTOR 

ASSOCIATED WITH DOPAMINERGIC-RECEPTOR SUBSENSITIVITY AFTER 
CHRONIC ANTIDEPRESSANT TREATMENT 

002788 03-03 
THE ANTIDEPRESSANT ACTION OF SULPHO-ADENOSYL-L-METHIONINE 

(SAME) COMPARED WITH THAT OF CHLORIMIPRAMINE- 
HYPOTHETICAL INTERPRETATIONS OF THE MECHANISM-OF-ACTION 

003150 03-07 
RAPIDITY OF CLINICAL ANTIDEPRESSANT RESPONSE TO IMIPRAMINE 
(UNPUBLISHED PAPER). 

003164 03-07 
THERAPEUTIC TRIAL OF A NEW ANTIDEPRESSANT: MIANSERIN. 

003208 03-09 
CLINICAL-EFFICACY OF THE NEW ANTIDEPRESSANT BUPROPION 
(WELLBUTRIN). 

003227 03-09 
RELATIONSHIP BETWEEN BLOOD CONCENTRATIONS AND CLINICAL- 
EFFECTS OF A NEW ANTIDEPRESSANT MAPROTILINE. 

003271 03-09 
HEPATIC SIDE-EFFECTS OF ANTIDEPRESSANT MEDICATIONS. 

003523 03-15 
SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIP OF A 

PYRIMIDOPYRIMIDINE DERIVATIVE WITH ANTIDEPRESSANT ACTIVITY 

003653 04-01 
PHARMACOLOGY OF 1 DICHLOROBENZYL-TETRAHYDROPYRIMIDONE A 
NOVEL ANTIDEPRESSANT COMPOUND WITH ANTIANXIETY ACTIVITY 

003688 04-02 
SUPERSENSITIVITY OF CENTRAL NORADRENERGIC PRESYNAPTIC- 
AUTORECEPTORS FOLLOWING CHRONIC-TREATMENT WITH THE 
ANTIDEPRESSANT MIANSERIN. 

003745 04-03 
NONCOMPETITIVE AMINE UPTAKE INHIBITION BY THE NEW 
ANTIDEPRESSANT PRIDEFINE. 

003771 04-03 
REGULATION OF SER0T0NIN2-RECEPT0RS (5 '•T2) LABELED WITH 
(3H)SPIR0PERID0L BY CHRONIC-TREATMENT WITH THE 
ANTIDEPRESSANT AMITRIPTYLINE. 

003964 04-03 
PHARMACOLOGICAL-PROPERTIES OF 2,3,3A,4,5,6 HEXAHYDROMETHYL- 
IH-PYRAZINOCARBAZOL-HCL (PIRLINDOLE), A NEW ANTIDEPRESSANT 

004174 04-04 
THE EFFECT OF THE NEW ANTIDEPRESSANT INKAjAN ON THE 
BIOELECTRICAL-ACTIVITY OF THE BRAIN AND ON CONDITIONED 
REFLEXES. 

004212 04-04 
ELECTROCARDIOGRAPHIC-CHANGES IN RATS DURING CHRONIC- 
TREATMENT WITH ANTIDEPRESSANT AND NEUROLEPTIC-DRUGS. 

004284 04-05 
THE ANTIDEPRESSANT EFFECTS OF TRAZODONE AND INHIBITION OF 
PLATELET SEROTONIN REUPTAKE. 

004383 04-09 
TOWARD A BIOCHEMICAL CLASSIFICATION OF DEPRESSIVE-DISORDERS 
IV: PRETREATMENT URINARY MHPG LEVELS AS PREDICTORS OF 
ANTIDEPRESSANT RESPONSE TO IMIPRAMINE. 

004406 04-09 






fe 



S-33 



Subject Index 



MAPROTILINE, NOMIFENSINE, MIANSERIN, ZIMELIDINE: A REVIEW OF 
ANTIDEPRESSANT EFFICACY IN INPATIENTS. 

004731 04-17 
ANTIDEPRESSANT-DRUG 

3H MIANSERIN PINDING IN CALF CAUDATE: POSSIBLE INVOLVEMENT OF 
SEROTONIN-RECEPTORS IN ANTIDEPRESSANT-DRUG AQION. 

000325 01-03 
AGE-RELATED FACTORS AFFECTING ANTIDEPRESSANT-DRUG METABOLISM 

AND CLINICAL-RESPONSE. ^^ „^ „„ 

002035 02-09 
FACTORS WHICH AFFECT ANTIDEPRESSANT-DRUG RESPONSE IN A 

MULTICENTER-TRIAL. „„.^o^ ^o o^ 

003239 03-09 
FLUVOXAMINE AS AN ANTIDEPRESSANT-DRUG. 

003775 04-03 
THE PHARMACOLOGICAL PROFILE OF LOFEPRAMINE, A NEW 

ANTIDEPRESSANT-DRUG. ^ ^ „^ „„ 

004006 04-03 
PHARMACOLOGICAL AND BIOCHEMICAL-PROPERTIES OF BRL- 14342, A 
NOVEL POTENTIAL ANTIDEPRESSANT-DRUG. 

004086 04-04 
CLINICAL-RESPONSE AND BLOOD LEVELS IN THE TREATMENT OF 
DEPRESSION WITH A NEW ANTIDEPRESSANT-DRUG, AMOXAPINE. 

004356 04-09 
ANTIDEPRESSANT-DRUGS „ ^. „„ .,,r 

RELATION BETWEEN THE EFFECTS OF ANTIDEPRESSANT-DRUGS ON THE 
UPTAKE OF MONOAMINES AND ON THE SPONTANEOUS ACTIVITY OF 

CENTRAL NEURONS. „„,.., „, «^ 

000267 01-03 
PROGNOSTIC FACTORS DETERMINING RESPONSE TO ANTIDEPRESSANT- 
DRUGS IN PSYCHIATRIC-OUTPATIENTS AND GENERAL-PRACTICE. 

000638 01-09 
EFFECTS OF ALPHA-ADRENOCEPTOR AGONISTS AND ANTAGONISTS AND 
OF ANTIDEPRESSANT-DRUGS ON PRESYNAPTIC AND POSTSYNAPTIC 

ALPHA-ADRENOCEPTORS. „„ „, 

001146 02-03 
NEW DATA ON THE USE OF ANTIDEPRESSANT-DRUGS. 

001195 02-03 

THE BINDING OF SOME ANTIDEPRESSANT-DRUGS TO BRAIN MUSCARINIC 

ACETYLCHOLINE-RECEPTORS. „„,„,-, „. ^, 

001253 02-03 
ANTIDEPRESSANT-DRUGS SLOW CIRCADIAN-RHYTHMS IN BEHAVIOR AND 
BRAIN NEUROTRANSMITTER-RECEPTORS. 

001536 02-03 
SEROTONINMIMETIC AND ANTIDEPRESSANT-DRUGS ON PASSIVE- 
AVOIDANCE LEARNING BY OLFAQORY BULBECTOMISED RATS 

001585 02-04 
ENHANCEMENT OF 5 HYDROXYTRYPTAMINE-INDUCED BEHAVIORAL- 
EFFECTS FOLLOWING CHRONIC ADMINISTRATION OF ANTIDEPRESSANT- 
DRUGS. 

001667 02-04 

CLASSIFICATION OF THE ANTIDEPRESSANT-DRUGS. 

002015 02-09 
TREATMENT OF CHRONIC PAIN WITH ANTIDEPRESSANT-DRUGS. 

002048 02-09 
OBSESSIVE-SYMPTOM RESPONSE TO BEHAVIOUR-THERAPY AND TO 
ANTIDEPRESSANT-DRUGS. 

002084 02-10 
PARADOXICAL AKINESIA INDUCED BY ANTIDEPRESSANT-DRUGS. 

002378 02-15 
REFLECTIONS ON THE CLASSIFICATION OF ANTIDEPRESSANT-DRUGS. 

002610 02-17 
NEW PER:PECTIVES on the mode of ACTION OF ANTIDEPRESSANT- 
DRUGS. 

002617 02-17 

HOW ANTIDEPRESSANT-DRUGS AQ. 

002694 03-03 
3H SEROTONIN BINDING-SITES IN RAT-BRAIN: EFFECTS OF REPEATED 
ADMINISTRATION OF ANTIDEPRESSANT-DRUGS. (PH.D. 
DISSERTATION). 

002881 03-03 
FACILITATED SHOCK-INDUCED ACGRESSION AFTER CHRONIC-TREATMENT 
WITH ANTIDEPRESSANT-DRUGS IN THE RAT. 

003058 03-04 
SYNAPTIC AND BEHAVIOURAL-ACTIONS OF ANTIDEPRESSANT-DRUGS: 
FURTHER THOUGHTS ON THE IMPLICATIONS FOR THEORIES OF 
DEPRESSION. 

003229 03-09 
EFFECTS OF ANTIDEPRESSANT-DRUGS ON DIFFERENT RECEPTORS IN THE 
BRAIN. 

003824 04-03 
DIFFERENTIAL-EFFEaS OF ELECTROCONVULSIVE-SHOCK AND 
ANTIDEPRESSANT-DRUGS ON SER0T0NIN2-RECEPT0RS IN RAT-BRAIN. 

003878 04-03 
EFFECTS OF OLFACTORY-BULBECTOMY AND PERIPHERALLY-INDUCED 
ANOSMIA ON THERMOREGULATION IN THE RAT: SUSCEPTIBILITY TO 
ANTIDEPRESSANT-DRUGS. 

004113 04-04 

POTENTIATION OF THE EFFECT OF ANTIDEPRESSANT-DRUGS BY 
TRYPTOPHAN. 

004412 04-09 



Ptychopharmacology Abstracts 

CARDIOTOXICITY OF ANTIDEPRESSANT-DRUGS. 

004597 04-15 
NEW ANTIDEPRESSANT-DRUGS AND THE SEIZURE THRESHOLD. 

004662 04-15 
THE USE OF CLINICAL KINETIC DATA IN TREATMENT WITH 
ANTIDEPRESSANT-DRUGS. 

004686 04-16 
RECEPTOR TECHNIQUES IN THE STUDY OF PLASMA LEVELS OF 
NEUROLEPTICS AND ANTIDEPRESSANT-DRUGS. 

004694 04-16 
PHARMACOLOGICAL-PROPERTIES OF SOME SECOND-GENERATION 
ANTIDEPRESSANT-DRUGS. 

004726 04-17 
DOWN REGULATION OF NORADRENERGIC-RECEPTOR FUNCTION BY 
ANTIDEPRESSANT-DRUGS: FUNCTIONAL SIGNIFICANCE AND 
DISTINCTION FROM ANTIPSYCHOTIC-DRUGS. (UNPUBLISHED PAPER). 

004746 04-17 
ANTIDEPRESSANTS j 

EFFECT OF CHRONIC-TREATMENT WITH ANTIDEPRESSANTS ON BETA- | 

ADRENERGIC-RECEPTOR BINDING IN GUINEA-PIG BRAIN. " 

000135 01-03 
THE EFFECT OF ANTIDEPRESSANTS ON L 5 HTP-INDUCED CHANGES IN RAT 
PLASMA CORTICOSTEROIDS. 

000170 01-03 
INTERACTION OF ANTIDEPRESSANTS WITH CLONIDINE ON RAT-BRAIN 
TOTAL 3 METHOXY-4-HYDROXYPHENYLGLYCOL. 

000300 01-03 
PHARMACOLOGY: CURRENT ANTIDEPRESSANTS. 

000793 01-13 
PHARMACOLOGY: NEW ANTIDEPRESSANTS. 

000936 01-17 
ADRENERGIC NONSPECIFIC POTENTIATION OF YOHIMBINE TOXICITY IN 
MICE BY ANTIDEPRESSANTS AND RELATED DRUGS AND 
ANTIYOHIMBINE ACTION OF ANTIADRENERGIC AND SEROTONERGIC 
DRUGS. 

001330 02-03 
ELECTROMYOGRAPHIC-ASSESSMENT OF SPINAL REFLEXES IN 
EXPERIMENTALLY DEPRESSED DOGS TREATED WITH 
ANTIDEPRESSANTS. 

001620 02-04 
NEUROCHEMICAL BASIS OF THE ACTION OF ANTIDEPRESSANTS ON 
LEARNED-HELPLESSNESS. 

001775 02-04 

CARDIOTOXICITY OF ANTIDEPRESSANTS. 

001843 02-05 
OEXAMETHASONE-SUPPRESSION-TEST IDENTIFIES SUBTYPES OF 
DEPRESSION WHICH RESPOND TO DIFFERENT ANTIDEPRESSANTS 

001971 02-09 
CLINICAL-EXPERIENCE WITH SECOND-GENERATION ANTIDEPRESSANTS IN 
ENDOGENOUS DEPRESSIONS. 

001975 02-09 
USE OF ANTIDEPRESSANTS: PHARMACOKINETIC-BASES. 

001981 02-09 
EVALUATION OF THE CLINICAL-EFFICACY OF SINGLE-DAILY-DOSES OF 
ANTIDEPRESSANTS. 

001985 02-09 
EFFECTS OF ANTIDEPRESSANTS ON PITUITARY HORMONAL SECRETIONS IN 
HEALTHY TEST SUBJEQS, NEUROTIC-PATIENTS, AND ENDOGENOUS 
DEPRESSIVE-PATIENTS. „„„,^ „. ~> 

002009 02-09 

INNOVATIONS IN TREATMENT WITH ANTIDEPRESSANTS. 

002019 02-09 
TARDIVE-DYSKINESIA IN DEPRESSED-PATIENTS: SUCCESSFUL THERAPY 
WITH ANTIDEPRESSANTS AND LITHIUM. 

002037 02-09 

SECOND-GENERATION ANTIDEPRESSANTS. ^ 

002042 02-09 
MECHANISMS OF AQION OF THE ANTIDEPRESSANTS. 

002218 02-13 
ON THE PROPOSED MECHANISM-OF-ACTION OF ANTIDEPRESSANTS 

002256 02-13 
PSYCHIATRIC-ASPECTS OF ACUTE POISONING WITH TRiaCLIC AND 
RELATED ANTIDEPRESSANTS - 1980 .„„„,. 

002458 02-15 
CHANGES IN BODY-TEMPERATURE AFTER ADMINISTRATION OF 
ADRENERGIC AND SEROTONERGIC-AGENTS AND RELATED DRUGS 
INCLUDING ANTIDEPRESSANTS. „^„,„„ ^„ ,-, 

002532 02-17 
ANTIPSYCHOTICS AND ANTIDEPRESSANTS: NEW TRENDS AND EXPECTED 

''''''■ 002539 02-17 

THE RESEARCH FOR NEW ANTIDEPRESSANTS: PRESENT ORIENTATIONS. 

002543 02-17 
RESPECTIVE POSITION OF ANTIDEPRESSANTS IN THERAPEUTICS 

002581 02-17 
STUDY OF METABOLISM AND BLOOD LEVELS OF ANTIDEPRESSANTS: 
TOWARDS A RATIONALIZATION OF THEIR THERAPEUTIC USE. 

002625 02-17 



S-34 



VOLUME 19, SUBJECT INDEX 



Subject Index 



EFFECTS OF ACUTELY AND CHRONICALLY ADMINISTERED 
ANTIDEPRESSANTS ON THE CLONIDINE-INDUCED DECREASE IN RAT- 
BRAIN 3 METHOXY-4-HYDROXYPHENYLETHYLENEGLYCOL-SULPHATE 
CONTENT. 

002908 03-03 
THE DEXAMETHASONE-SUPPRESSION-TEST IN THE IDENTIFICATION OF 
SUBTYPES OF DEPRESSION DIFFERENTIALLY RESPONSIVE TO 
ANTIDEPRESSANTS. 

003211 03-09 
LIFE EVENTS AND RESPONSE TO ANTIDEPRESSANTS. 

003238 03-09 
NOVEL ANTIDEPRESSANTS: A CLINICAL-TRIAL OF MIANSERIN. 

003240 03-09 
COMPARISON OF STANDARD AND HOLTOR-MONITORED EKGS IN A 
PATIENT TREATED WITH SEVERAL ANTIDEPRESSANTS. 

003304 03-11 
FIRST RESULTS OF AN ORIGINAL METHOD FOR MEASURING BLOOD 
LEVELS OF ANTIDEPRESSANTS (AMITRIPTYLINE AND NORTRIPTYLINE) 

003559 03-16 
THERAPEUTIC INTEREST OF BLOOD LEVELS DETERMINATION FOR 
ANTIDEPRESSANTS: METHODOLOGICAL APPROACH. 

003571 03-16 
THE USE OF ANTIDEPRESSANTS IN PSYCHIATRY. 

003597 03-17 
SECOND-GENERATION ANTIDEPRESSANTS: A CLINICAL 
PHARMACOTHERAPEUTIC RESEARCH STRATEGY. 

003632 03-17 
THE EFFECTS OF ANTIDEPRESSANTS ON THE RETENTION AND 
METABOLISM OF (3H) NOREPINEPHRINE IN RAT-BRAIN SLICES. 

003763 04-03 
STUDIES ON THE KINETIC PROPERTIES OF TRYPTOPHAN-HYDROXYLASE OF 
RABBIT MESENCEPHALON AND PONS-MEDULLA: EFFECT OF LONG- 
TERM-TREATMENT WITH NEUROLEPTICS AND ANTIDEPRESSANTS 

003852 04-03 
THE EFFECT OF ANTIDEPRESSANTS ON THE HYPOTENSIVE-EFFECT OF 
CLOFELIN IN RATS. 

003934 04-03 
ON THE KINETICS OF IMIPRAMINE AND RELATED ANTIDEPRESSANTS. 

003945 04-03 
INTERACTIONS BETWEEN ANTIDEPRESSANTS AND OTHER DRUGS 

004371 04-09 
CLINICAL NEUROPHYSIOLOGICAL PROPERTIES OF ANTIDEPRESSANTS 

004373 04-09 
CHANGES IN PSYCHOPATHOLOGIC SYMPTOMS DURING 20 DAYS OF 
TREATMENT WITH ANTIDEPRESSANTS AND NEUROLEPTIC-DRUGS 

004415 04-09 
SEXUAL-EFFECTS OF ANTIDEPRESSANTS AND PSYCHOMOTOR STIMULANT- 
DRUGS. 

004646 04-15 
ANTIDEPRESSANTS AND ALPHA2-ADRENERGIC-AUT0RECEPT0R 
DESENSITIZATION. 

004659 04-15 
DO WE NEED ANY MORE ANTIDEPRESSANTS? 

004707 04-17 
ANTIDEPRESSANTS AND THE SEROTONIN UPTAKE IN PLATELETS 

004727 04-17 
iNTIDEPRESSIVE 

ANTIDEPRESSIVE TREATMENT AND MOOD-SWING-PAHERNS IN 
ENDOGENOUS DEPRESSION. 

000633 01-09 
ANTIDEPRESSIVE TREATMENT IN PARKINSONS-DISEASE: A CONTROLLED- 
TRIAL OF THE EFFECT OF NORTRIPTYLINE IN PATIENTS WITH 
PARKINSONS-DISEASE TREATED WITH L-DOPA. 

000659 01-11 
CYCLOHEXYLPHENOXYAMIDOXIMES AND IMIDAZOLINES WITH 
ANTIDEPRESSIVE AND ALPHA-ADRENERGIC-ACTIVITY. 

CAN THE ANTIDEPRESSIVE PROPERTIES OF LITHIUM BE DETERMINED 
EXPERIMENTALLY? 

003089 03-04 
NTIDEPRESSIVE-ORUGS 

EFFECTS OF ANTIDEPRESSIVE-DRUGS UPON THE HEART AND 
CIRCULATION. 

NT.DEPRESS.VES 000863 01-15 

ANTIDEPRESSIVES IN RENAL FAILURE. 
NT.DOPAM.NERG.C 002284 02-13 

DISCRIMINATION OF FUNCTIONALLY HETEROGENEOUS RECEPTOR 
SUBPOPULATIONS: ANTIPSYCHOTIC AND ANTIDOPAMINERGIC 
PROPERTIES OF METOCLOPRAMIDE. 

002877 0*^ 0"? 
ANTIDOPAMINERGIC EFFECT OF ESTROGENS AT THE STRIATAL LEVEL. 

003789 04-03 
ANTIDOPAMINERGIC PROPERTIES OF YOHIMBINE 

NT.DOPAM.NER6.C-EFFECTS 003995 04-03 

BEHAVIORAL-EFFECTS, ANTIDOPAMINERGIC-EFFECTS AND PROHYPNOTIC- 
EFFECTS OF NEUROLEPTICS DURING AND AFTER PROLONGED 
TREATMENT. 

001577 02-04 



ANTIDOTES 

EFFECT OF AMITRIPTYLINE ANTIDOTES ON REPETITIVE EXTRASYSTOLE 
THESHOLD. 

001856 02-05 
ANTIDYSKINETIC-PROPERTIES 

ANTIPSYCHOTIC-PROPERTIES AND ANTIDYSKINETIC-PROPERTIES OF 
ERGOT DOPAMINE AGONISTS. 

002178 02-11 
ANTIENURETIC-EFFECT 

CHILDHOOD-ENURESIS: II PSYCHOPATHOLOGY, TRICYCLIC 
CONCENTRATION IN PLASMA, AND ANTIENURETIC-EFFECT. 

002354 02-14 
ANTIEPILEPTiC 

TRANSFER FROM MULTIPLE TO SINGLE ANTIEPILEPTIC DRUG-THERAPY 

003316 03-11 
ANTIEPILEPTIC THERAPY WITH PHENYTOIN: WHICH IS THE OPTIMUM 
SERUM LEVEL? 

004586 04-14 
THE PROGNOSIS OF EPILEPSY AND THE STRATEGY FOR TERMINATING 
ANTIEPILEPTIC THERAPY. 

004724 04-17 
ANTIEPILEPTIC-AGENTS 

GABA AGONISTS AS ANTIEPILEPTIC-AGENTS. 

002826 03-03 
ANTIEPILEPTIC-DRUGS 

SOCIAL AND CLINICAL SIGNIFICANCE OF DETERMINING THE BARBITURATE 
LEVEL IN THE BLOOD SERUM OF PATIENTS TREATED WITH 
ANTIEPILEPTIC-DRUGS. 

000695 01-11 
INFLUENCE OF DEXTROPROPOXYPHENE ON STEADY-STATE SERUM LEVELS 
AND PROTEIN BINDING OF THREE ANTIEPILEPTIC-DRUGS IN MAN 

000767 01-13 
INTERRELATION AT PLASMATIC LEVEL BETWEEN ANTIEPILEPTIC-DRUGS 
AND LIPIDS. ITS IMPLICATIONS IN THE EFFICIENCY OF TREATMENT IN 
EPILEPSY. I. CHANGES INDUCED BY PHENOBARBITAL OR/AND 
DIPHENYLHYDANTOIN IN SERUM LIPIDS. 

002281 02-13 
CORRELATIONS BETWEEN PLASMA LEVELS OF ANTIEPILEPTIC-DRUGS AND 
EEG INTENSIVE MONITORING. 

002288 02-13 
MULTIINSTITUTIONAL-STUDY ON THE TERATOGENICITY AND FETAL 
TOXICITY OF ANTIEPILEPTIC-DRUGS: A REPORT OF A COLLABORATIVE- 
STUDY GROUP IN JAPAN. 

002442 02-15 
A STUDY ON EFFECTS OF ANTIEPILEPTIC-DRUGS UPON THE HIPPOCAMPAL 
AFTERDISCHARGE. 

002844 03-03 
SIMULTANEOUS ADMINISTRATION OF FIVE ANTIEPILEPTIC-DRUGS IN 
PLASMA THROUGH GAS-LIQUID-CHROMATOGRAPHY. 

003563 03-16 
BEHAVIORAL-INTERACTIONS BETWEEN OPIATE AND ANTIEPILEPTIC-DRUGS 
IN THE MOUSE. 

004155 04-04 
ASPECTS OF PHARMACOLOGICAL-EFFECTS OF ANTIEPILEPTIC-DRUGS 

004462 04-11 
ANTIEPILEPTIC-EFFECT 

ANTIEPILEPTIC-EFFECT OF CLOBAZAM IN LENNOX-GASTAUT-SYNDROME 

004479 04-11 
ANTIEPILEPTICS 

ANTAGONISM BY CLASSICAL ANTIEPILEPTICS AND SODIUM-VALPROATE 
OF CEFAZOLIN-INDUCED EXPERIMENTAL EPILEPSY IN RATS 

000442 01-04 
SERUM CONCENTRATION AND JNICAL-EFFECT OF ANTIEPILEPTICS 

003315 03-11 
EFFECTS OF 3 SULFAMOYLMETHYL-BENZISOXAZOLE (AD-810) AND SOME 
ANTIEPILEPTICS ON THE KINDLED SEIZURES IN THE NEOCORTEX 
HIPPOCAMPUS AND AMYGDALA IN RATS. 

004149 04-04 
ANTIGEN 

PRODUCTION OF A SPECIFIC ANTISERUM TO RAT-BRAIN GLUTAMIC-ACID- 
DECARBOXYLASE (GAD) BY INJECTION OF AN ANTIGEN ANTIBODY 
COMPLEX. (UNPUBLISHED PAPER). 

001047 02-01 
ENHANCED TRANSFER OF EXPERIMENTAL ALLERGIC-ENCEPHALOMYELITIS 
WITH STRAIN-13 GUINEA-PIG LYMPH-NODE CELLS: REQUIREMENT FOR 
CULTURE WITH SPECIFIC ANTIGEN AND ALLOGENIC PERITONEAL 
EXUDATE CELLS. (UNPUBLISHED PAPER). 

001201 02-03 
ANTIHEMOPHILIC-FACTOR 

EFFECT OF PSYCHIATRIC-INTERVENTION ON USE OF ANTIHEMOPHILIC- 
FACTOR CONCENTRATE. 

000945 01-17 
ANTIHISTAMINE 

ANTIHISTAMINE EFFECT ON SYNAPTOSOMAL UPTAKE OF SEROTONIN 
NOREPINEPHRINE AND DOPAMINE. 

000035 01-03 
HISTAMINE HI -RECEPTORS LABELED IN VIVO: ANTIDEPRESSANT AND 
ANTIHISTAMINE INTERACTIONS. 

000074 01-03 



^ 



S-35 



Subfect Index 



Psychopharmacology Abstracts 



AMTIMYPERTENSIVE 

DIETARY PROTEIN INTAKE INFLUENCES THE ANTIHYPERTENSIVE POTENCY 
OF AAETHYLDOPA IN SPONTANEOUSLY HYPERTENSIVE-RATS. 

004025 04-03 
ANTIHYPERTENSIVE-EFFECTS ^ „„.^. „r 

FENFLURAMINE POTENTIATION OF ANTIHYPERTENSIVE-EFFECTS OF 

THIAZIDES. „ „„,, 

002138 02-11 

ANTIHYPOXIDOTIC-DRUGS 

ANTIHYPOXIDOTIC-DRUGS AND NOOTROPIC-DRUGS: PROOF OF THEIR 
ENCEPHALOTROPIC AND PHARMACODYNAMIC PROPERTIES BY 
ENCEPHALOTROPIC AND PHARMACODYNAMIC PROPERTIES BY 
QUANTITATIVE EEC INVESTIGATIONS. 002166 02 

ANTIINFLAMMATORY-DRUGS 

LOWERING OF THE CONVULSIVE THRESHOLD BY NONSTEROIDAL 
ANTIINFLAMMATORY-DRUGS. „„^„„. „o ^o 

002904 03-03 

SPECIES-DIFFERENCES IN CLOBAZAM METABOLISM AND ANTILEPTAZOL 
^^^^''^' 001157 02-03 

*'*TROSPEaS FOR THE TREATMENT OF POSTENCEPHALITIC PARKINSONISM 
WITH ANTILYMPHOCYTIC IMMUNOGLOBULIN. 

004572 04-14 

ANTIMANIC-EFFECT 

ANTIMANIC-EFFECTOFCLONIDINE. 000598 01-09 

ANTINEOPHOBIC 

FOOD PREFERENCE FOLLOWING ACUTE OR CHRONIC CHLORDIAZEPOXIDE 
ADMINISTRATION: TOLERANCE TO AN ANTINEOPHOBIC ACTION 

004090 04-04 

ANTINEOPLASTIC ^ ^„,,^ 

THE IMMUNOSTIMULANT ANTINEOPLASTIC ACTION OF SOME 
PSYCHOTROPIC-DRUGS OF THE SYDNONIMINE SERIES. 

001520 02-03 

ANTINOCICEPTION 

CHLORDIAZEPOXIDE ANTINOCICEPTION: CROSS-TOLERANCE WITH 

OPIATES AND WITH STRESS. ^„„^ „ ^, „^ 

000348 01-04 

STRAIN DEPENDENT EFFECTS OF KET AMINE ON LOCOMOTOR-ACTIVITY 

AND ANTINOCICEPTION IN MICE. ^ ^ ^ 

000382 01-04 

EFFECT OF QUIPAZINE AND FLUOXETINE ON ANALGESIC-INDUCED 
CATALEPSY AND ANTINOCICEPTION IN THE RAT 

001709 02-04 
EFFECT OF SELECTIVE DESTRUCTION OF SEROTONERGIC NEURONS IN 
NUCLEUS-RAPHE-MAGNUS ON MORPHINE-INDUCED ANTINOCICEPTION. 

001724 02-04 
FURTHER STUDIES ON OPIATE-RECEPTORS THAT MEDIATE 
ANTINOCICEPTION: TOOTH-PULP STIMULATION IN THE DOG. 

001782 02-04 
A CLASSIFICATION OF OPIATE-RECEPTORS THAT MEDIATE 
ANTINOCICEPTION IN ANIMALS. 

001807 02-04 
AHENUATION OF PETHIDINE-INDUCED ANTINOCICEPTION BY ZIMELIDINE, 
AN INHIBITOR OF 5 HYDROXYTRYPTAMINE REUPTAKE. 

004118 04-04 
SPINAL-CORD PHARMACOLOGY OF ADRENERGIC AGONIST-MEDIATED 
ANTINOCICEPTION. 

004206 04-04 

ANTINOCICEPTIVE 

ANTINOCICEPTIVE COMPARISON OF QUIPAZINE AND MORPHINE. 

000435 01-04 
EFFECT OF ANTINOCICEPTIVE DOSES OF OXOTREMORINE ON MOUSE- 
BRAIN ACETYLCHOLINE TURNOVER-RATE. 

001513 02-03 
ANTINOCICEPTIVE ACTION OF MORPHINE AND PENTAZOCINE ON UNIT 
ACTIVITY IN THE NUCLEUS-CENTRALIS-LATERALIS, NUCLEUS- 
VENTRALIS-LATERALIS AND NEARBY STRUCTURES OF THE CAT. 

002837 03-03 
ANTINOCICEPTIVE-EFFECT 

ANTINOCICEPTIVE-EFFECT OF MORPHINE, OPIOID ANALGESICS AND 
HALOPERIDOL INJECTED INTO THE CAUDATE-NUCLEUS OF THE RAT 

000414 01-04 
THE ANTINOCICEPTIVE-EFFECT OF INTRACEREBROVENTRICULARLY 
ADMINISTERED PROSTAGLANDIN-El IN THE RAT. 

001769 02-04 

ANTINOCICEPTIVE-EFFECTS 

A REEVALUATION OF THE NEUROCHEMICAL-EFFECTS AND 
ANTINOCICEPTIVE-EFFECTS OF INTRATHECAL CAPSAICIN IN THE RAT. 

004184 04-04 
ANTAGONISM BY PHENOXYBENZAMINE AND PENTAZOCINE OF THE 
ANTINOCICEPTIVE-EFFECTS OF MORPHINE IN THE SPINAL-CORD. 

004213 04-04 
ANTIPARKINSON-DRUG 

ADVERSE-EFFECTS OF ANTIPARKINSON-DRUG WITHDRAWAL. 

(UNPUBLISHED PAPER) „„,„o„.,c 

004623 04-15 



ANTIPARKINSON-DRUGS 

ABUSE OF THE ANTIPARKINSON-DRUGS: A REVIEW OF THE LITERATURE. 

000989 01-17 
ANTIPARKINSONIAN 

THE NEED FOR CONTINUOUS USE OF ANTIPARKINSONIAN MEDICATION 
WITH CHRONIC SCHIZOPHRENIC-PATIENTS RECEIVING LONG-TERM ] 
NEUROLEPTIC THERAPY. ' 

003186 03-08 
ANTIPARKINSONIAN-DRUGS 

ELECTRORETINOGRAPHIC-CHANGES IN PATIENTS WITH PARKINSONISM 
TREATED WITH VARIOUS CLASSES OF ANTIPARKINSONIAN-DRUGS. 

000674 01-11 
PROGRESSIVE SUPRANUCLEAR PALSY, COMPUTED-TOMOGRAPHY, AND 
RESPONSE TO ANTIPARKINSONIAN-DRUGS. 

003322 03-11 
RELEVANCE OF DOPAMINE-RECEPTOR BINDING STUDIES FOR EVALUATION 
OF ANTIPARKINSONIAN-DRUGS 

004120 04-04 
ANTIPEROXIDANT 

ANTIPEROXIDANT PRETREATMENT AND IRON-INDUCED EPILEPTIFORM 
DISCHARGES IN THE RAT: EEG AND HISTOPATHOLOGIC STUDIES. 

002930 03-03 
ANTIPSYCHOTIC 

INHIBITION OF IN VIVO 3H SPIPERONE BINDING BY THE PROPOSED 
ANTIPSYCHOTIC DES-TYR 1 -GAMMA-ENDORPHIN 

000226 01-03 
USE OF SURVIVAL CURVES IN ANALYSIS OF ANTIPSYCHOTIC RELAPSE- 
STUDIES. 

002481 02- 1< 
DISCRIMINATION OF FUNQIONALLY HETEROGENEOUS RECEPTOR 
SUBPOPULATIONS: ANTIPSYCHOTIC AND ANTIDOPAMINERGIC 
PROPERTIES OF METOCLOPRAMIDE. 

002877 03-0: 
REFLECTIONS ON ANTIPSYCHOTIC CHEMOTHERAPY: THE BEGINNING OF 
PHARMACOLOGICAL-TREATMENT. 

003292 03-11 
DYSTONIC REAaiON DURING MAINTENANCE ANTIPSYCHOTIC THERAPY. 

003485 03-1.' 
PROLACTIN RELEASING POTENCIES OF ANTIPSYCHOTIC AND RELATED 
NONANTIPSYCHOTIC COMPOUNDS IN FEMALE RATS: RELATION TO 
CLINICAL POTENCIES. 

003830 04-0: 

ANTIPSYCHOTIC-AGENT 

PRUSSIAN-BLUE: SPECIFIC TREATMENT OF THALLIUM, ARSENIC, 
INDUSTRIAL- SOLVENT INTOXICATION, AND OTHER 
POLYNEUROPATHOLOGIES. A POSSIBLE ANTIPSYCHOTIC-AGENT. 

003348 03-1 
ANTIPSYCHOTIC-DRUG 

PREDICTING OUTCOME OF ANTIPSYCHOTIC-DRUG TREATMENT FROM 

EARLY-RESPONSE „„„.,r^, „. 

000565 01-01 
FOLLOWUP STUDY ON THE INFLUENCE OF AN ANTIPSYCHOTIC-DRUG 
(PROPERICIAZINE) ON LIVER FUNQION, ELEaROCARDIOGRAM AND 
ELEQROENCEPHALOGRAM 

000639 01-0' 
CLINICAL HANDBOOK OF ANTIPSYCHOTIC-DRUG THERAPY. 

000961 01-V 
A STUDY OF ANTIPSYCHOTIC-DRUG USE IN NURSING-HOMES: 
EPIDEMIOLOGIC EVIDENCE SUGGESTING MISUSE. 

000979 01-1 
EEG AND BEHAVIORAL-PROFILE OF FLUTROLINE (CP-36-584), A NOVEL 
ANTIPSYCHOTIC-DRUG ^^^^^ ^^^ 

PROGNOSIS IN SCHIZOPHRENIA: INDIVIDUAL DIFFERENCES IN 

PSYCHOLOGICAL RESPONSE TO A TEST DOSE OF ANTIPSYCHOTIC-DRUG 
AND THEIR RELATIONSHIP TO BLOOD AND SALIVA LEVELS AND 

TREATMENT OUTCOME . „„^ ,„„„-« 

003189 03-0 

A SYMPTOM-PROFILE-ANALYSIS OF ANTIPSYCHOTIC-DRUG TREATMENT: 
NONPARAMETRIC MULTIDIMENSIONAL TECHNIQUE. 

003196 03-0 
DISCONTINUATION OF ANTIPSYCHOTIC-DRUG THERAPY 

003514 03-1 
CLINICAL STRATEGIES FOR ANTIPSYCHOTIC-DRUG TREATMENT, TARDIVE 
DYSKINESIA AND THE TRAINING OF RESEARCH PSYCHIATRISTS 

004603 04-1 

ANTIPSYCHOTIC-DRUGS 

THE ROLE OF CHOLINERGIC-SUPERSENSITIVITY IN THE MEDICAL 
SYMPTOMS ASSOCIATED WITH WITHDRAWAL OF ANTIPSYCHOTIC- 

°^^^^ 000869 01-1 

EFFEaS OF LONG-TERM ADMINISTRATION OF ANTIPSYCHOTIC-DRUGS 01 

ENKEPHAUNERGIC NEURONS. ^^^^^^^ 

DYSKINESIA INDUCED BY LONG-TERM-TREATMENT WITH 
ANTIPSYCHOTIC-DRUGS: INVOLVEMENT OF PRESYNAPTIC AND 
POSTSYNAPTIC DOPAMINERGIC MECHANISMS. 

001839 02-C 



S-36 



OLUME 19, SUBJECT INDEX 



Subject Index 



ANTIPSYCHOTIC-ORUGS IN COMMUNITY-BASED SHELTERED-CARE-HOMES 

002171 02-11 
ANTIPSYCHOTIC-DRUGS: DIFFERENTIAL-EFFECTS ON DOPAMINE NEURONS 
IN BASAL GANGLIA AND MESOCORTEX FOLLOWING CHRONIC 
ADMINISTRATION IN HUMAN AND NONHUMAN PRIMATES 

002285 02-13 
ANTIPSYCHOTIC-DRUGS: MEASUREMENT AND ENDOCRINE-EFFECTS 
(UNPUBLISHED PAPER). 

002287 02-13 
DISTURBED-BEHAVIOUR INDUCED BY HIGH-DOSE ANTIPSYCHOTIC-DRUGS 

002375 02-15 
COMPARATIVE-STUDY OF VARIATIONS IN PROLACTIN LEVELS DURING 
TREATMENT WITH ANTIPSYCHOTIC-DRUGS 

002412 02-15 
LONG-ACTING ANTIPSYCHOTIC-DRUGS. 

002519 02-17 
LONG-ACTING ANTIPSYCHOTIC-DRUGS AND CEREBRAL 5 
HYDROXYTRYPTAMINE. 

002851 03-03 
CORRELATION BETWEEN ANTIAVOIDANCE ACTIVITIES OF ANTIPSYCHOTIC- 
DRUGS IN RATS AND DAILY CLINICAL DOSES. 

003032 03-04 
DIFFERENTIAL ACTIONS OF CLASSICAL AND ATYPICAL ANTIPSYCHOTIC- 
DRUGS ON SPONTANEOUS NEURONAL ACTIVITY IN THE AMYGDALOID 
COMPLEX. 

003131 03-05 
SUBJECTIVE RESPONSE TO ANTIPSYCHOTIC-DRUGS. 

003202 03-08 
THERAPEUTIC (III): GENERAL CHARACTERISTICS OF ANTIPSYCHOTIC- 
DRUGS. 

003644 03-17 
THE EFFECTS OF ANTIANXIETY AND ANTIPSYCHOTIC-DRUGS ON SEXUAL- 
BEHAVIOR. 

004657 04-15 
DOWN REGULATION OF NORADRENERGIC-RECEPTOR FUNCTION BY 
ANTIDEPRESSANT-DRUGS: FUNCTIONAL SIGNIFICANCE AND 
DISTINCTION FROM ANTIPSYCHOTIC-DRUGS. (UNPUBLISHED PAPER) 

004746 04-17 
ITIPSYCHOTIC-EFFECT 
TIME-COURSE OF THE ANTIPSYCHOTIC-EFFECT IN SCHIZOPHRENIA AND 
SOME CHANGES IN POSTMORTEM BRAIN AND THEIR RELATION TO 
NEUROLEPTIC-MEDICATION. 

001911 02-08 
ANTIPSYCHOTIC-EFFECT OF PROPRANOLOL ON CHRONIC 
SCHIZOPHRENICS: STUDY OF A GRADUAL TREATMENT REGIMEN 

001915 02-08 
ANTIPSYCHOTIC-EFFECT OF GAMMA-TYPE ENDORPHINS IN 
SCHIZOPHRENIA. 

001953 02-08 
TIPSYCHOTIC-EFFICACY 

STRIATAL DOPAC LEVELS AS A PREDICTOR OF ANTIPSYCHOTIC-EFFICACY. 

00 1 533 02-03 
METOCLOPRAMIDE: ANTIPSYCHOTIC-EFFICACY OF A DRUG LACKING 
POTENCY IN RECEPTOR MODELS. 

T.PSYCHOT.C-MED.CAT.ONS 001948 02-08 

THE CONSTITUTIONAL RIGHT-TO-REFUSE ANTIPSYCHOTIC-MEDICATIONS 

T.PSYCHOT.CPROPERT,ES 004496 04-12 

ANTIPSYCHOTIC-PROPERTIES AND ANTIDYSKINETIC-PROPERTIES OF 
ERGOT DOPAMINE AGONISTS. 

flPSYCHOTICS 002178 02-11 

HIGH AND VERY HIGH-DOSAGE ANTIPSYCHOTICS: A CRITICAL REVIEW. 
THERAPEUTICS V - THE UNWANTED EFFECTS OF ANTIPSYCHOTICS . ' ^ ' 

PROTOCOLS FOR THE USE OF PSYCHOACTIVE-DRUGS - PARtT^'^ °^"'^ 
PROTOCOL FOR THE TREATMENT OF PSYCHOSIS WITH 
ANTIPSYCHOTICS. 

ANTIPSYCHOTICS AND ANTIDEPRESSANTS: NEW TRENDS AND ExI'ECTED^ 

0025^9 07-17 
CLINICAL USE OF THE ANTIPSYCHOTICS. 

riPYRINE 003607 03-17 

EFFECTS OF UREA ON HEXOBARBITAL AND ANTIPYRINE DISPOSITION IN 
RATS. 

NORTRIPTYLINE AND ANTIPYRINE CLEARANCE IN REIATIOnT^^'' °^"°^ 
DEBRISOQUINE HYDROXYLATION IN MAN 

nSCHIZOPHRENIC-DRUGS 000754 01-13 

REGULATION OF TYROSINE-HYDROXYLASE AFTER CHRONIC-TREATMENT 
WITH CLASSIC AND ATYPICAL ANTISCHIZOPHRENIC-DRUGS. 

ACETYLCHOLINE AND AMINO-ACID NEUROTRANSMITTERS IN EPIDURAL 
CUPS OF FREELY-MOVING-RATS: EFFECT OF ACUTE AND CHRONIC- 
TREATMENT WITH ANTISCHIZOPHRENIC-DRUGS. 

001386 02-03 



ANTISECRETORY 

INHIBITION OF PENTAGASTRIN-STIMULATED AND OVERNIGHT GASTRIC 
SECRETION BY LM24056, A NEW PHENOTHIAZINE DERIVED 
ANTISECRETORY DRUG. 

004306 04-07 
ANTISERUM 

PRODUCTION OF A SPECIFIC ANTISERUM TO RAT-BRAIN GLUTAMIC-ACID- 
DECARBOXYLASE (GAD) BY INJECTION OF AN ANTIGEN ANTIBODY 
COMPLEX. (UNPUBLISHED PAPER). 

001047 02-01 

CORTICOSTERONE INCREASES THE SYNTHESIS OF A SOLUBLE PROTEIN IN 
PITUITARY-GLANDS FROM ADRENALECTOMIZED MALE RATS WHICH 
PRECIPITATES WITH ANTI-RAT GROWTH-HORMONE ANTISERUM 
(UNPUBLISHED PAPER). 

001122 02-03 
SUPPRESSION OF SERUM PROLACTIN BY NALOXONE BUT NOT BY ANTI- 
BETA-ENDORPHIN ANTISERUM IN STRESSED AND UNSTRESSED RATS 

002871 03-03 
ANTISOMATOSTATIN 

ADMINISTRATION OF ANTISOMATOSTATIN SERUM TO RATS REVERSES 
THE INHIBITION OF PULSATILE GROWTH-HORMONE SECRETION 
PRODUCED BY INJECTION OF METERGOLINE BUT NOT YOHIMBINE 
(UNPUBLISHED PAPER). 

000019 01-03 
ANTISTEREOTYPIC 

DIFFERENTIAL REVERSAL BY SCOPOLAMINE AND THIP OF THE 
ANTISTEREOTYPIC AND CATALEPTIC-EFFECTS OF NEUROLEPTICS 

002948 03-04 
ANTITREMOR 

ANTITREMOR ACTION OF C10DICH0L, A PERIPHERAL ACETYLCHOLINE 
SYNTHESIS INHIBITOR. 

004096 04-04 
ANTITUSSIVE 

HIGH-AFFINITY BINDING OF THE ANTITUSSIVE DEXTROMETHORPHAN TO 
GUINEA-PIG BRAIN. 

000061 01-03 
ANTITUSSIVES 

INVESTIGATION OF NARCOTICS AND ANTITUSSIVES USING DRUG 
DISCRIMINATION TECHNIQUES. 

000447 01-04 
ANTIVIRAL 

ANTIVIRAL ACTIVITY OF 3 DEAZAADENOSINE AND 5' 

DEOXYISOBUTYLTHIO-3-DEAZAADENOSINE (3 DEAZA-SIBA) 
(UNPUBLISHED PAPER). 

001006 02-01 
ANTIWITHDRAWAL 

CLONIDINE AND THE PRIMATE LOCUS-COERULEUS: EVIDENCE SUGGESTING 
ANXIOLYTIC AND ANTIWITHDRAWAL EFFECTS. (UNPUBLISHED PAPER) 

003982 04-03 
ANTIYOHIMBINE 

ADRENERGIC NONSPECIFIC POTENTIATION OF YOHIMBINE TOXICITY IN 
MICE BY ANTIDEPRESSANTS AND RELATED DRUGS AND 
ANTIYOHIMBINE ACTION OF ANTIADRENERGIC AND SEROTONERGIC 
DRUGS 

001330 02-03 
ANXIETY 

BENZODIAZEPINES: A TOOL TO EXPLORE THE BIOCHEMICAL-BASIS AND 
NEUROPHYSIOLOGICAL-BASIS OF ANXIETY. 

000397 01-04 
ANIMAL-MODELS OF ANXIETY AND BENZODIAZEPINE ACTIONS 

000531 01-06 
THE EFFECT OF BETADRENOL ON EXAMINATION ANXIETY 

000650 01-10 
KETAZOUM AND DIAZEPAM IN ANXIETY: A CONTROLLED-STUDY 

000655 01-10 
ANXIETY AND THYROID-ACTIVITY IN PSYCHIATRIC-PATIENTS 

000786 01-13 
ANXIETY RECONCEPTUALIZED. 

000951 01-17 
RATIONAL USE OF BENZODIAZEPINES FOR ANXIETY AND INSOMNIA 

002063 02-10 
DOUBLE-BLIND CLINICAL ASSESSMENT OF ALPRAZOLAM A NEW 
BENZODIAZEPINE DERIVATIVE, IN THE TREATMENT OF MODERATE TO 
SEVERE ANXIETY. 

002070 02-10 
KETAZOLAM COMPARED TO DIAZEPAM AND PLACEBO IN THE 
TREATMENT OF ANXIETY. 

^„„^ 002074 02-10 

CORONARY-HEART-DISEASE: TREATING THE ANXIETY COMPONENT 

002088 02-10 
CLINICAL-ASPECTS OF ANXIETY AND ITS THERAPY. 

002089 02-10 
ANXIETY AND SEDATION DURING A STRESSFUL-SITUATION AFTER SINGLE- 
DOSE OF DIAZEPAM VERSUS N DESMETHYLDIAZEPAM - A 
CONTROLLED-TRIAL. 

002329 02-14 
EFFECTS OF ANXIETY REDUCTION BY BEHAVIOURAL-TECHNIQUES AND 
MEPROBAMATE ON CERTAIN PARAMETERS OF INFORMATION THEORY 

003108 03-04 






fe 



S-37 



Subject Index 

CURRENT BIOLOGIC STRATEGIES FOR ANXIETY, ^^^^^^ ^^^^ 

COMPARISON OF ANXIETY REDUCING SUBSTANCES. (PH.D. 
DISSERTATION). 003278 03-10 

BENZODIAZEPINE TREATMENT OF SPECIFIC ANXIETY STATES^ 

00Jzo4 Oj- IU 
TREATMENT OF ANXIETY IN CHILDREN AND ADOLESCENTS.^^^^^^ ^^^ ^ 

A DOUBLE-BUND TRIAL: THE USE OF OXPRENOLOL AND DIAZEPAM IN 

ANXIETY. 004428 04-10 

CLINICAL-REVIEW OF BETA-BLOCKERS IN ANXIETY. 

004464 04- 1 1 

NEW BIOLOGICAL RESEARCH RELEVANT TO ANXIETY. 

004705 04-17 
PSYCHOPHARMACOLOGY AND PSYCHOTHERAPY IN THE TREATMENT OF 

^^^'^^ 004712 04-17 

^'^^pK^NOLOL IN CHRONIC ANXIETY-DISORDERS: A CONTROLLED-|T^U^DY^ 

RECENT ADVANCES IN THE DIAGNOSIS AND TREATMENT OF ANXIETY- 
D'SORDERS. 0Q3275 03.,0 

^"''oTsSmATIVE-STIMULUS PROPERTIES OF COCAINE RELATED TO AN 

ANXIOGENICAaiON. 004219 04-04 

^"''anxiolytic EFFICACY OF ALPRAZOLAM COMPARED TO DIAZEPAM AND 
P^^BO- 000648 01-10 

COMPARATIVE ANXIOLYTIC AND HYPNOTIC-EFFECTS OF 3 

BENZODIAZEPINES ON BABOONS. 00158102-04 

CLONIDINE AND THE PRIMATE LOCUS-COERULEUS: EVIDENCE SUGGESTING 

ANXIOLYTIC AND ANTIWITHDRAWAL EFFEQS (UNPUBLISHED PAPER). 

OOSVoz U4-Uo 
ALPRAZOLAM A NEW TYPE ANXIOLYTIC IN NEUROTIC-PATIENTS: A 
PILOT-STUDY. 004422 04-10 

DOXEPIN PLASMA LEVELS AND ANXIOLYTIC RESPONSE. 

004477 04- 1 1 

SYNTHEsIs AND ANXIOLYTIC-ACTIVITY OF A SERIES OF 

PYRAZINOBENZODIAZEPINE DERIVATIVES. ^^^^^ ^^^^ 

THE USE OF SOCIAL-INTERACTION AS A METHOD FOR DETECTING 
ANXIOLYTIC-ACTIVITY OF CHLORDIAZEPOXIDE-LIKE DRUGS^ 

00 1 000 UZ-Vo 
DIAZEPAM ANXIOLYTIC-AaiVITY IN HIPPOCAMPUS. 

003743 04-03 

^''^'woI'aSS-'sCALE-FACTORS AND RESPONSE TO PLACEBO AND 

ANXIOLYTIC-DRUGS. 000649 01-10 

*''^THEVFFtcT"oF*COMBINEl SEDATIVE AND ANXIOLYTIC-PREPARATIONS 
ON SUBJECTIVE ASPEQS OF SLEEP AND OBJEaiVE MEASURE OF 
AROUSAL AND PERFORMANCE THE MORNING FOLLOWING NOQURNAL 
MEDICATION: II. REPEATED DOSES. 00233102-14 

ANXIOLYTICS 

TO THE CLINICAL-EVALUATION OF ANXIOLYTICS (TOFISOPAM)^ 

002494 02-16 

THERAPEUTICS VI - ANXIOLYTICS (BENZODIAZEPINES). 

003546 Oj-13 
AVOIDANCE ENHANCEMENT AND DISCRIMINATIVE RESPONSE CONTROL 
BY ANXIOLYTICS WITH DRUGS AQING ON THE GABA SYSTEM^ 

004193 04-04 

^'"'tHE*ANXIOMIMETIC properties of PENTYLENETETRAZOL IN THE RAT. 

(PH.D. DISSERTATION). • Q^gQ^j 03-04 

ANXIOUS-DEPRESSED 

TREATMENT OF ANXIOUS-DEPRESSED OUTPATIENTS WITH A FIXED 
COMBINATION (NOMIFENSINE/CLOBAZAM) IN COMPARISON TO A 
MONOSUBSTANCE(DOXEPINE). 002028 02-09 

^''^PRAZEPAm""nEW BENZODIAZEPINE FOR THE TREATMENT OF ANXIOUS- 
DEPRESSIVE STATES. 004419 04-10 

ANXIOUS-DEPRESSIVE-SYNDROME 

ANXIOUS-DEPRESSIVE- SYNDROME. CLINICAL-STUDY OF A NEW 
BENZODIAZEPINE, PRAZEPAM. 004354 04-09 

ANXIOUS-DEPRESSIVE-SYNDROMES 

THE TREATMENT OF ANXIOUS-DEPRESSIVE-SYNDROMES WITH 
^Ofi^OPm. 000615 01-09 



Psychopharmacology Abstracts 

AORTIC 

DEMONSTRATION OF SUBSTANCE-P IN AORTIC NERVE AFFERENT FIBERS 
BY COMBINED USE OF FLOURESCENT RETROGRADE NEURONAL 
LABELING AND IMMUNOCYTOCHEMISTRY. (UNPUBLISHED PAPER). 

001024 02-01 

APATHY 

INHIBITION AND APATHY: TREATMENT WITH SURVEaOR. 

002066 02-10 

APHAGIA 

APHAGIA GASTRIC PATHOLOGY, HYPERTHERMIA, AND SENSORIMOTOR- 
DYSFUNCTIONS FOLLOWING LATERAL HYPOTHALAMIC LESIONS: 
EFFEaS OF INSULIN PRETREATMENTS. 

001638 02-04 

DISTRIBUTION OF MEMBRANE GLYCOPROTEINS AMONG THE ORGANELLES 
OF A SINGLE IDENTIFIED NEURON OF APLYSIA. II. ISOLATION AND 
CHARAQERIZATION OF A GLYCOPROTEIN ASSOCIATED WITH 

'''^'''' 002657 03-03 

TRIMETHADIONE EFFECTS ON CHOLINERGIC RESPONSES IN APLYSIA 

NEURONS. „„„^„^ „„ „o 

002782 03-03 

DIPHENYLHYDANTOIN REDUCES THE OUTWARD-CURRENT OF THE ACTION 
POTENTIAL IN APLYSIA. 

002805 03-03 
EFFECTS OF BARBITURATES ON INHIBITORY AND EXCITATORY RESPONSES 
TO APPLIED NEUROTRANSMIHERS IN APLYSIA. 

003762 04-03 

APLYSIA-CALIFORNICA 

DOPAMINE INHIBITS BURST-FIRING OF NEUROSECRETORY CELL R-15 IN 
APLYSIA-CALIFORNICA: ESTABLISHMENT OF A DOSE-RESPONSE 

RELATIONSHIP. „„^„„, „. „, 

003806 04-03 

APOMORPHINE 

EFFECTS OF DOPAMINERGIC AGONISTS AND ANTAGONISTS ON 

(3H)AP0M0RPH1NE BINDING TO STRIATAL MEMBRANES: SULPIRIDE 
LACK OF INTERACTIONS WITH POSITIVE COOPERATIVE 

(3H)AP0M0RPHINE BINDING ^^^ ^ ^, 

000099 01-0; 
ACUTE AND CHRONIC EFFEaS OF NEUROLEPTICS AND ACUTE EFFECTS OF 
APOMORPHINE AND AMPHETAMINE ON DOPAMINE TURNOVER IN 
CORPUS-STRIATUM AND SUBSTANTIA-NIGRA OF THE RAT-BRAIN 

000215 01-0; 
DISRUPTION OF SELECTIVE AHENTION BY APOMORPHINE, BUT NOT 
AMPHETAMINE, IN THE MONGOLIAN-GERBIL „„„..„ „, „ 

000358 01-0' 
RELATIONSHIPS BETWEEN SELEQIVE DENERVATION OF DOPAMINE 
TERMINAL-FIELDS IN THE ANTERIOR-FOREBRAIN AND BEHAVIORAL- 
RESPONSES TO AMPHETAMINE AND APOMORPHINE 

EFFEaS OF APOMORPHINE ON ESCAPE PERFORMANCE AND AQIVITY IN 
DEVELOPING RAT PUPS TREATED WITH 6 HYDROXYDOPAMINE (6 

°"°^' 000426 01-0 

APOMORPHINE EFFEQS ON THE TIMING AND SEQUENCING OF PECKING- 

BEHAVIOR IN CHICKS. 000428 01^ 

DIFFERENT DOPAMINERGIC MECHANISMS FOR AMFONELIC-ACID, 

AMPHETAMINE AND APOMORPHINE. ^^^^^^^ ^^_^ 

APOMORPHINE REDUCES SCHIZOPHRENIC-SYMPTOMS. ^^^^^ ^^^ 

TRANSIENT ABOLITION OF GENERALIZED PHOTOSENSITIVE EPILEPTIC- 
KaRGE IN HUMANS BY APOMORPHINE, A DOPAMINE-RECEPTOR 

^GO^'S"^ 000714 01-1 

DOPAMINE SYNTHESIS: TOLERANCE TO HALOPERIDOL AND 

SUPERSENSITIVITY TO APOMORPHINE DEPEND ON PRESYNAPTIC- 

RECEPTORS. 001129 02^ 

ORAL BIOAVAILABILITY OF APOMORPHINE IN THE RAT WITH A 

PORTACAVAL VENOUS ANASTOMOSIS. ^^ ^ ^^ ^^^ 

RAPID DEVELOPMENT OF HYPERSENSITIVITY AND HYPOSENSITIVITY TO 
APOMORPHINE AND HALOPERIDOL: ROLE OF NOREPINEPHRINE- 
RECEPTOR MECHANISMS IN CNS ^^^^^ ^^^ 

CHRONIC ADMINISTRATION OF HALOPERIDOL DURING DEVELOPMENT: 
K PSYCHOPHARMACOLOGICAL RESPONSES TO APOMORPHINE 
ANDARECOLINE 001470 02-0 

EFFEQS OF APOMORPHINE ON ELICITED AND OPERANT PECKING IN 
PIGEONS. 001557 02-0 

ACTIVATION AND LATERALIZATION OF SENSORIMOTOR FIELD K)R 
PERIORAL BITING-REFLEX BY INTRANIGRAL GABA AGONIST AND BY 
SYSTEMIC APOMORPHINE IN THE RAT. 



S-38 



)LUME 19, SUBJECT INDEX 

EffECT Of APOMORPHINE ON MORPHINE-INDUCED DECREASE IN 
LOCOMOTOR-ACTIVITY AND INCREASE IN DOPAMINE TURNOVER IN 
RATS. 

001728 02-04 
STEREOTYPED-BEHAVIOUR AND ELECTROCORTICAL-CHANGES AETER 
INTRACEREBRAL MICROINFUSION OF DOPAMINE AND APOMORPHINE 
IN FOWLS. 

001734 02-04 
LACK OF EFFECT OF CHOLINE AND NARCOTIC ANTAGONISTS UPON 
APOMORPHINE DISCRIMINATION. 

001770 02-04 
PSYCHOPHARMACOLOGICAL-EFFECTS OF LOW-DOSES AND HIGH-DOSES 
Of APOMORPHINE DURING ONTOGENY. 

001774 02-04 
SUPERSENSITIVITY TO APOMORPHINE IN EXPERIMENTALLY-INDUCED 
HYPOKINESIA AND DRUG-INDUCED MODIFICATIONS OF THE 
APOMORPHINE RESPONSE. 

001814 02-04 
TOLERANCE TO FLUPHENAZINE AND SUPERSENSITIVITY TO APOMORPHINE 
IN CENTRAL DOPAMINERGIC-SYSTEMS AFTER CHRONIC FLUPHENAZINE- 
DECANOATE TREATMENT. 

001820 02-04 
APOMORPHINE HYPOTHERMIA: AN INDEX OF CENTRAL DOPAMINE- 
RECEPTOR FUNCTION IN MAN. 

002221 02-13 
APOMORPHINE: SELECTIVE INHIBITION OF THE AVERSIVE COMPONENT OF 
LATERAL HYPOTHALAMIC SELF-STIMULATION. 

002476 02-16 
\U OBSERVATIONAL METHOD FOR QUANTIFYING THE BEHAVIOURAL- 
EFFECTS OF DOPAMINE AGONISTS: CONTRASTING-EFFEQS OF D- 
AMPHET AMINE AND APOMORPHINE. 

002484 02-16 
EffECTS OF D-AMPHETAMINE AND APOMORPHINE IN A NEW ANIMAL- 
MODEL OF PETIT-MAL EPILEPSY. 

002493 02-16 
SPONTANEOUS ACTIVITY AND APOMORPHINE STEREOTYPY DURING AND 
AFTER WITHDRAWAL FROM 3 1 /2 MONTHS CONTINUOUS 
ADMINISTRATION OF HALOPERIDOL: SOME METHODOLOGICAL-ISSUES 

002509 02-16 
APOMORPHINE HALOPERIDOL INTERACTIONS: DIFFERENT TYPES OF 
ANTAGONISM IN CORTICAL AND SUBCORTICAL BRAIN REGIONS. 

002662 03-03 
FHREE CLASSES OF DOPAMINE-RECEPTOR (D-2, D-3, D-4) IDENTIFIED BY 
BINDING STUDIES WITH 3H APOMORPHINE AND 3H DOMPERIDONE 

002900 03-03 
ilPHASIC-EFFECTS AND OPPOSITE-EFFECTS OF DOPAMINE AND 
APOMORPHINE ON ENDOGENOUS GABA RELEASE IN THE RAT 
SUBSTANTIA-NIGRA. 

002923 03-03 
'OTENTIATION OF APOMORPHINE AND D-AMPHETAMINE EFFEaS BY 
NALOXONE. 

002942 03-04 
IINGLE OR REPEATED ADMINISTRATION OF SMALL DOSES OF 
APOMORPHINE ON WATER INTAKE AND ACTIVITY IN WATER- 
DEPRIVED RATS. 

002981 03-04 
;ONADECTOMY AND SEX-DIFFERENCES IN THE BEHAVIORAL-RESPONSES 
TO AMPHETAMINE AND APOMORPHINE OF RATS. 

003084 03-04 
AGGRESSIVE-BEHAVIOR INDUCED BY APOMORPHINE IN RATS SUBMIHED 
TO FOUR STRESSFUL-SITUATIONS. 

003163 03-07 
'RESYNAPTIC AND POSTSYNAPTIC STRIATAL DOPAMINE-RECEPTORS- 
DIFFERENTIAL SENSITIVITY TO APOMORPHINE INHIBITION OF 
(3H)D0PAMINE AND (MOGABA RELEASE IN VITRO. 

003741 04-03 
REJUNCTIONAL ACTIONS OF PIRIBEDIL ON THE ISOLATED KIDNEY OF THE 
RABBIT: COMPARISON WITH APOMORPHINE. 

003749 04-03 
HARMACOLOGICAL DIFFERENCE OF L-DOPA, APOMORPHINE AND 
BROMOCRIPTINE AGAINST METOCLOPRAMIDE. 

003790 04-03 
FFECTS OF DOPAMINE, APOMORPHINE, GAMMA HYDROXYBUTYRIC- 
ACID, HALOPERIDOL AND PIMOZIDE ON REFLEX BRADYCARDIA IN 
RATS. 

004085 04-04 
ISE OF THE INTRACEREBRAL INJECTION TECHNIQUE TO ELUCIDATE 
MECHANISMS OF APOMORPHINE CLIMBING AND ITS ANTAGONISM IN 
THE MOUSE. 

004092 04-04 
'JDUCTION OF BEHAVIORAL-SUPERSENSITIVITY TO APOMORPHINE BY 
DFP TREATMENT. 

„„..„ 004099 04-04 

POMORPHINE IN SCHIZOPHRENIA. 

POMORPHINE, HALOPERIDOL AND THE AVERAGE EVOKED-POTENTIALS 
IN NORMAL HUMAN VOLUNTEERS. 

004549 04-13 



Subject Index 

APOMORPHINE-DIPIVALOYL-ESTER 

TOLERANCE TO INCREASES IN STRIATAL ACETYLCHOLINE 
CONCENTRATIONS AFTER REPEATED ADMINISTRATION OF 
APOMORPHINE-DIPIVALOYL-ESTER. 

000464 01-04 
APOMORPHINE-ELICITED 

EFFECTS OF THIORIDAZINE ON APOMORPHINE-ELICITED STEREOTYPIC- 
BEHAVIOR AND MOTOR-ACTIVITY. 

000424 01-04 
APOMORPHINE-INDUCED 

EFFECTS OF THE POTENTIAL NEUROLEPTIC-PEPTIDE DES-TYRl-GAMMA- 
ENOORPHIN AND HALOPERIDOL ON. APOMORPHINE-INDUCED 
BEHAVIOURAL-SYNDROMES IN RATS AND MICE. 

000441 01-04 
5,7 DIHYDROXYTRYPTAMINE LESIONS OF THE AMYGDALA REDUCE 
AMPHETAMINE-INDUCED AND APOMORPHINE-INDUCED STEREOTYPED- 
BEHAVIOUR IN THE RAT. 

001589 02-04 
MODULATION OF APOMORPHINE-INDUCED STEREOTYPY BY ESTROGEN 
TIME-COURSE AND DOSE-RESPONSE. 

001636 02-04 
EMERGENCE OF APOMORPHINE-INDUCED VACUOUS CHEWING DURING 6 
MONTHS CONTINUOUS TREATMENT WITH FLUPHENAZINE-DECANOATE 

001817 02-04 
EFFECT OF L TRYPTOPHAN ON APOMORPHINE-INDUCED GROWTH- 
HORMONE SECRETION IN NORMAL SUBJECTS. 

002253 02-13 
EFFECTS OF CHOLECYSTOKININ-OCTAPEPTIDE ON STRIATAL DOPAMINE 
METABOLISM AND ON APOMORPHINE-INDUCED STEREOTYPED CAGE 
CLIMBING IN MICE. 

003031 03-04 
ENHANCEMENT OF APOMORPHINE-INDUCED CLIMBING IN MICE BY 
REVERSIBLE AND IRREVERSIBLE NARCOTIC ANTAGONIST DRUGS 

003068 03-04 
EFFECT OF L HISTIDINE AND CHLORCYCLIZINE ON APOMORPHINE-INDUCED 
CLIMBING-BEHAVIOUR AND METHAMPHETAMINE STEREOTYPY IN 
MICE. 

004147 04-04 
PHARMACOKINETIC-STUDY OF APOMORPHINE-INDUCED STEREOTYPY IN 
FOOD DEPRIVED RATS. 

004247 04-04 
APOMORPHINE-INDUCED STEREOTYPY IN MATURE AND SENESCENT RATS 
FOLLOWING CESSATION OF CHRONIC HALOPERIDOL TREATMENT 

004651 04-15 
APOMORPHINE-INDUCED-FIGHTING 

AN IMPROVED MODEL OF INTRASPECIFIC AGGRESSION: DOSE-RESPONSE 
ANALYSIS OF APOMORPHINE-INDUCED-FIGHTING AND STEREOTYPY IN 
THE RAT. 

002983 03-04 
APOMORPHINE-RECEPTORS 

3H APOMORPHINE-RECEPTORS IN VARIOUS RAT-BRAIN REGIONS- A 
STUDY OF SPECIFIC AND NONSPECIFIC BINDING AND THE INFLUENCE OF 
CHRONIC NEUROLEPTIC TREATMENT. 

001846 02-05 
APPETITIVE 

INTRAVENTRICULAR CORTICOSTERONE INJECTION FACILITATES MEMORY 
OF AN APPETITIVE DISCRIMINATIVE TASK IN MICE. 

003051 03-04 
APPETITIVE-CONDITIONING 

SENSORY AND ASSOCIATIVE-EFFECTS OF LSD ON CLASSICAL APPETITIVE- 
CONDITIONING OF THE RABBIT JAW MOVEMENT RESPONSE. 

001637 02-04 
APROTIC 

NMR SPECTRAL STUDY OF PROTON TRANSFER IN AMITRIPTYLINE- 
HYDROCHLORIDE CHLORDIAZEPOXIDE-HYDROCHLORIDE COMBINATIONS 
IN DIPOLAR APROTIC SOLVENTS. 

003654 04-01 
ARACHIOONIC-ACID 

RELEASE OF ARACHIDONIC-ACID FROM ADRENAL CHROMAFFIN CELL- 
CULTURES DURING SECRETION OF EPINEPHRINE. (UNPUBLISHED 
PAPER). 

001027 02-01 
IGE MEDIATED HISTAMINE RELEASE IN RAT BASOPHILIC LEUKEMIA 
CELLS: RECEPTOR ACTIVATED PHOSPHOLIPID METHYLATION, CA-FLUX 
AND RELEASE OF ARACHIDONIC-ACID. (UNPUBLISHED PAPER) 

001188 02-03 
ARCALION-200 

ARCALION-200 PRESCRIBED AS A PSYCHIATRIC-DRUG AND 
ANTIALCOHOLISM-DRUG ON AN OUTPATIENT AND INPATIENT BASIS 

002103 02-11 
ARCHITECTURE 

THE MOLECULAR ARCHITECTURE OF ERGOPEPTINES: A BASIS FOR 
BIOLOGICAL-INTERACTION. 

001527 02-03 
AREA-POSTREAAA 

ABSENCE OF LITHIUM-INDUCED TASTE-AVERSION AFTER AREA-POSTREMA 
LESION. 

000456 01-04 






fe 



S-39 



Subject Index 

^"^^HRONIC ADMINISTRATION OF HALOPERIDOL DURING DEVELOPMENT: 
S PSYCHOPHARMACOLOGICAL RESPONSES TO APOMORPHINE 
ANDARECOLINE. 001470 02-03 

^"'*HEXAMETHONIUM MODIFICATION OF CARDIOVASCULAR ADJ^^^^^^ 

DURING COMBINED STATIC DYNAMIC ARM EXERCISE '^ MONKm^ ^^ 

^"^DEVELOPMENT OF AND RECOVERY FROM SUBSENSITIVITY OF THE 

NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN BRA^: EFFECT 
OF AMPHETAMINE FOLLOWING" INHIBITION OF ITS AROMATIC 
HYDROXYLATION BY IPRINDOLE. ^^^^^^ ^^.qs 

^"^I'^E^fR^slt^^rNm^Z-^'^R^^^^^^^ 

BY ALPHA DIFLUOROMETHYL-DOPA AND METABOLISM OF THE 

INHIBITOR. 000248 01-03 

^"°AROUSAL AND SHORT-TERM MEMORY: EFFECTS OF CAFFEINE AND TRIAL 
SPACING ON DELAYED ALTERNATION PERFORMANCE . ^^^_^ ^ ^ ^^ 

THE EFFECT OF SMALL AND MODERATE DOSES OF D-AMPHET AMINE ON 
HUNGER. MOOD, AND AROUSAL IN MAN. ^^^^^ ^^^^ 

THE EFFECTS OF COMBINED SEDATIVE AND ANXIOLYTIC-PREPARATIONS 
ON SUBJECTIVE ASPECTS OF SLEEP AND OBJECTIVE MEASURE OF 
AROUSAL AND PERFORMANCE THE MORNING FOLLOWING NOCTURNAL 
MEDICATION: II. REPEATED DOSES. ^^^331 02-14 

SUPPRESSION OF AMPHETAMINE-INDUCED EEG AROUSAL IN THE 
HIPPOCAMPUS OF HALOPERIDOL TREATED RABBITS. ^^^^^ ^^^^ 

CATECHOIAMINERGIC INVOLVEMENT IN PHASIC VERSUS TONIC 
ELECTROCORTICAL AROUSAL. 002723 03-03 

CANALIZATION OF AROUSAL IN THE PREWEANLING RAT: EFFECTS OF 
AMPHETAMINE ON AGGREGATION WITH SURROGATE STIMULI^ ^^^^ 

EFFECT OF FLURAZEPAM, PENTOBARBITAL, AND CAFFEINE ON AROUSAL 
THRESHOLD. 003439 03-14 

AUDITORY AROUSAL THRESHOLDS OF GOOD SLEEPERS AND POOR 

SLEEPERS WITH AND WITHOUT FLURAZEPAM ^^^^ ^^_^^ 

^** ARRHnHMIA INDUCED BY A TRICYCLIC-ANTIDEPRESSANT IN A PATIENT 
WITH UNDIAGNOSED MITRAL-VALVE PROLAPSE. ^^^^^ ^^^^ 

^""ffluL°CoKL°rN"uRA^ MEDIATED ARRHYTHMOGENIC- 

PROPERTIES OF DESACETYLLANATOSIDE-C. ^^^^4 qS-OS 

INFLUENCE OF IMIPRAMINE AND PARGYLINE ON THE 
ARRHYTHMOGENICITY OF EPINEPHRINE DURING HALOTHANE, 
ENFLURANE OR METHOXYFLURANE ANESTHESIA IN DOGS^^^_^^ ^^_^^ 

ARSENIC 

PRUSSIAN-BLUE: SPECIFIC TREATMENT OF THALLIUM, ARSENIC. 
INDUSTRIAL-SOLVENT INTOXICATION, AND OTHER 
POLYNEUROPATHOLOGIES. A POSSIBLE ANTIPSYCHOTIC-AGENT.^ ^^^ ^ 

^*^ ^COMPARISON OF BIPERIDEN-HYDROCHLORIDE (AKINETON) AND 
BENZHEXOL (ARTANE) IN THE TREATMENT OF DRUG-INDUCED 
PARKINSONISM. 002146 02-11 

^" HIG^-AFFINITY BINDING OF TRICYCLIC-ANTIDEPRESSANTS TO HISTAMINE 
Hl-RECEPTORS: FACT AND ARTIFACT. ^^^^^ ^^-Od 

^*^^y\.CYANAM|"eS. ACYLUREA, and various SUBSTITUTED 

ARYLALLOPHANATES; EFFEQ ON THE CNS. ^^^^^ ^^^^ 

^""^Src'^REG^illtl'^Orre'REDUCTION IN ACETYL-COENZYME- 

A:ARYLAMINE-N-ACETYLTRANSFERASE IN THE RAT PINEAL.^^^^^ ^^^^ 

^"''A^L^SlMS^f^Ss AS SELECTIVE AND VERY POTENT 

INHIBITORS OF DOPAMINE UPTAKE. 000005 01-01 

^*^INHIBITION^b"aRYLSULPHATASE a of NA-INDEPENDENT (3H) gaba 
AND (3H) MUSCIMOL BINDING TO BOVINE CEREBELLAR SYNAPTIC 
MEMBRANES. 001208 02-03 



Psychopharmacology Abstracts 



PROTEIN ABNORMALITIES IN MACROPHAGES BEARING ASBESTOS. 
(UNPUBLISHED PAPER). 001037 02-01 

ASCORBATE DECREASES LIGAND BINDING TO NEUROTRANSMITTER- 

^^«™^^ 002804 03-03 

INHIBITION OF DOPAMINE D-1 AND D-2 BINDING-SITES IN NEURONAL 
TISSUE BY ASCORBATE. 003876 04-03 

ASCORBIC-ACID. AN ENDOGENOUS FAQOR REQUIRED FOR 

ACETYLCHOLINE RELEASE FROM THE SYNAPTIC VESICLES^^_^^^ ^^^^ 

PSYCHOPHARMACOLOGY FOR ASIAN-AMERICANS AND PACIFIC- 
'SL^'^D^'^S. 000734 01-11 

THE RELATIONSHIP BETWEEN MORPHINE, ASPARTIC-ACID AND L 

ASPARAGINASE IN RATS 000169 01-03 

^^'* TOTENTIATION OF L GLUTAMATE AND L ASPARTATE EXCITATION OF CAT 
SPINAL NEURONES BY THE STEREOISOMERS OF THREO-3- 
HYDROXYASPARTATE. 002768 03-03 

L ASPARTATE BINDING-SITES IN RAT-CEREBELLUM: A COMPARISON OF 
THE BINDING OF L (3H)ASPARTATE AND L (3H)GLUTAMATE TO 
SYNAPTIC MEMBRANES 004000 04-03 

ASPARTIC-ACID 

THE RELATIONSHIP BETWEEN MORPHINE, ASPARTIC-ACID AND L 
ASPARAGINASE IN RATS. 000169 01-03 

TWO CONDUCTANCE MECHANISMS AQIVATED BY APPLICATIONS OF L 
GLUTAMIC-ACID L ASPARTIC-ACID, DL HOMOCYSTEIC-ACID, N 
METHYL-D-ASPARTIC-ACID, AND DL KAINIC-ACID TO CULTURED 
MAMMALIAN CENTRAL NEURONES . ^ ^ ^^^ ^^^ 

**'''mED1CATI0N use AND DEATHS AHRIBUTED TO ASPHYXIA AMONG 

PSYCHIATRIC-PATIENTS 000838 Ol-li 

^^•"'ji^ EFFECT OF ASPIRIN AND PARACETAMOL ON THE INCREASED 

NALOXONE POTENCY INDUCED BY MORPHINE P^ETREATMENT^^ ^^^ 

ASPIRIN ANALGESIA EVALUATED BY EVENT-RELATED POTENTIALS IN 
MAN: POSSIBLE CENTRAL-AQION IN BRAIN. ^^^^^ ^^^^^ 

ASPIRIN AND HUMAN SLEEP. ^^241 02-1 

^"^HE DOPAMINE-RADIORECEPTOR ASSAY - A CLINICAL APP^TION^^^^ 
AN IMPROVED ASSAY OF CYCLIC-NUCLEOTIDE-PHOSPHODIESTERASES 

WITH QAE-SEPHADEX COLUMNS 001860 02-0 

DISPOSITION AND AQIVITY OF BETA-ADRENOCEPTOR ANTAGONISTS IN 

THE RAT USING AN EX VIVO RECEPTOR BINDING ASSAY.^^^_^^ ^^^ 

DETERMINATION OF GABA LEVELS BY A (3H)MUSaM0L RADIORECEPTO 
ASSAY 003135 03-0 

A rOMPARISON OF DOPAMINE-RECEPTOR BLOCKING ASSAY WITH 
* PLASMA DRUG LEVELS OF HALOPERIDOL IN SCHIZOPHRENIGPATIE^NTS 

NEUROLEPTIC SERUM LEVELS MEASURED BY RADIORECEPTOR ASSAY 
AND CLINICAL-RESPONSE IN SCHIZOPHRENIC-PATIENTS. ^^^^^ ^^ 

A SELEQED ION-MONITORING ASSAY FOR BIOGENIC-AMINE 
METABOLITES AND PROBENECID, IN HUMAN LUMBAR 
CEREBROSPINAL-FLUID. ^^^^^ ^ 

TISSUE CHOLINE STUDIED USING A SIMPLE CHEMICAL ASSAYV _^^^^ ^ 

MEASUREMENT OF NEUROLEPTIC CONCENTRATIONS BY GLC AND 

RADIORECEPTOR ASSAY 004682 04- 

A RAPID AND SENSITIVE RADIORECEPTOR ASSAY FOR TERTIARY AMINI 

TRICYCLIC-ANTIDEPRESSANTS. ^^^^g^ ^ 

*"irSAYlNG GABA-MODULIN ACTIVITY IN BRAIN EXTRAQS: RESOLUTIOI 
OF INHERENT DIFFICULTIES (UNPUBLISHED PAPER) ^^^^ ^^^ 



S-40 



rOLUME 19, SUBJECT INDEX 



Subject Index 



SSAYS 

PSYCHOTROPIC-DRUGS DO NOT INTERFERE WITH RADIOLIGAND ASSAYS 
FOR PROLACTIN, CORTISOL, AND GROWTH-HORMONE. 

002511 02-16 
SSERTIVENESS 

THE EFFECT OF ASSERTIVENESS TRAINING, PROVERA AND SEX OF 
THERAPIST IN THE TREATMENT OF GENITAL EXHIBITIONISM. 

000697 01-11 
SSESSMENT 

ASSESSMENT OF TOLERANCE TO AND PHYSICAL-DEPENDENCE ON 
PENTOBARBITAL, INDUCED BY MULTIPLE PELLET IMPLANTATION 

000385 01-04 
AN ELECTROMYOGRAPHIC-METHOD FOR THE ASSESSMENT OF 
NALOXONE-INDUCED ABSTINENCE IN MORPHINE-DEPENDENT RATS. 

000433 01-04 
CLINICAL ASSESSMENT OF ONCE A DAY PHENOTHIAZINE 
ADMINISTRATION. 

000573 01-08 
COGNITIVE AND AFFECTIVE-FUNCTIONS IN PATIENTS WITH AFFECTIVE- 
DISORDERS TREATED WITH LITHIUM: AN ASSESSMENT BY 
QUESTIONNAIRE. 

000604 01-09 
CLASSIFICATION AND ASSESSMENT OF CEREBRAL BIOAVAILABILITY OF 
LOPIRAZEPAM (D- 12524) BY QUANTITATIVE EEG AND 
PSYCHOMETRIC-ANALYSIS. 

000720 01-11 
ASSESSMENT OF MULTIVARIATE RELATIONSHIPS IN REACTIVITY OF 
PATIENTS RECEIVING LITHIUM THERAPY. 

000819 01-14 
A NEW APPROACH TO THE ASSESSMENT OF THE POTENCY OF 
REVERSIBLE MONOAMINE-OXIDASE-INHIBITORS IN VIVO, AND ITS 
APPLICATION TO D-AMPHET AMINE, P METHOXYAMPHETAMINE AND 
HARMALINE. 

000900 01-16 
AN ASSESSMENT PROGRAM TO REDUCE DRUG USE WITH THE 
MENTALLY-RETARDED. 

000937 01-17 
ASSESSMENT OF ADRENERGIC-RECEPTORS IN VIVO IN EXPERIMENTAL 
ANIMALS AND MAN. (UNPUBLISHED PAPER). 

001034 02-01 
DOUBLE-BLIND CLINICAL ASSESSMENT OF ALPRAZOLAM, A NEW 
BENZODIAZEPINE DERIVATIVE, IN THE TREATMENT OF MODERATE TO 
SEVERE ANXIETY. 

002070 02-10 
TOLERANCE TO DEXTROAMPHETAMINE-SULFATE IN HYPERACTIVE- 
CHILDREN: ASSESSMENT USING AN EMPIRICAL NEUROPSYCHOLOGICAL 
PARADIGM - A PILOT-STUDY. 

002126 02-11 
QUANTITATIVE ASSESSMENT OF SMOOTH-PURSUIT EYE-MOVEMENTS IN 
HEALTHY AND EPILEPTIC-SUBJECTS. 

002376 02-15 
CASE 3: ASSESSMENT AND TREATMENT OF DRUG-INDUCED TREMOR 

002407 02-15 
SUBJECTIVE ASSESSMENT OF SEXUAL-DYSFUNCTION OF PATIENTS ON 

LONG-TERM ADMINISTRATION OF DIGOXIN. 
,,,„ 002443 02-15 

ELEQROPHYSIOLOGIC ASSESSMENT OF RECEPTOR CHANGES FOLLOWING 

CHRONIC DRUG-TREATMENT. 
^„,,^ 003136 03-06 

DRUG PREFERENCE AND MOOD IN HUMANS: REPEATED ASSESSMENT OF 
D-AMPHETAMINE. 

003445 03-14 
EVALUATION OF DRUG EFFICACY IN DEMENTIA: A COMPUTERIZED 
COGNITIVE ASSESSMENT SYSTEM. 

003557 03-16 
PHARMACOLOGICAL-BASES OF PSYCHONEUROENDOCRINOLOGY- 
PRECLINICAL ASSESSMENT OF CLINICAL FACTS. 

003735 04-03 
OPIATE-DEPENDENCE FOLLOWING ACUTE INJECTIONS OF MORPHINE AND 
NALOXONE: THE ASSESSMENT OF VARIOUS WITHDRAWAL SIGNS 

004209 04-04 
SESSMENTS 
EEG ASSESSMENTS OF DOSAGE AND SLEEP PROFILES FOR A HYPNOTIC- 
DRUG OF THE TRIAZOLOTHIENODIACEPINE SERIES. 

002338 02-14 
SIMILATION 

LITHIUM, ASSIMILATION OF NUTRIENTS AND REPRODUCTION 
(UNPUBLISHED PAPER), 

002777 03-03 
SOCIATION 

HUMAN PLATELET 5 HT-RECEPTORS: CHARACTERISATION AND 
FUNCTIONAL ASSOCIATION. 

001412 02-03 
THE ASSOCIATION OF RETARD NEUROLEPTICS TO OTHER NEUROLEPTICS 
IN THE REHABILITATION OF PSYCHOTIC-PATIENTS. 

002108 02-11 
HYPERPARATHYROIDISM IN ASSOCIATION WITH LITHIUM THERAPY 

003489 03-15 



ASSOCIATIVE-ASPECTS 

INTERFERENCE WITH INGESTIONAL AVERSION LEARNING PRODUCED BY 
PREEXPOSURE TO THE UNCONDITIONED-STIMULUS: ASSOCIATIVE- 
ASPECTS AND NONASSOCIATIVE-ASPECTS. 

001610 02-04 
ASSOCIATIVE-EFFECTS 

SENSORY AND ASSOCIATIVE-EFFECTS OF LSD ON CLy\SSICAL APPETITIVE- 
CONDITIONING OF THE RABBIT JAW MOVEMENT RESPONSE 

001637 02-04 
ASTERIXIS 

ASTERIXIS ASSOCIATED WITH SODIUM-VALPROATE. 

003468 03-15 
ASTHENIA 

ATTEMPT AT PSYCHOLOGICAL UNDERSTANDING AND TREATMENT OF 
PSYCHOLOGICAL ASTHENIA AND ASTHENO-DEPRESSIVE-SYNDROMES 
USING ERGADYL. 

001974 02-09 
DOSE-EFFECT OF DEAE ON SUBJECTIVE PROBLEMS, VERTIGO 
DEPRESSION, ASTHENIA, CEPHALALGIA, AND TONIC POSTURAL 
ACTIVITY PROBLEMS RECORDED WITH STATOKINESIMETER IN 
POSTCONCUSSIONAL-SYNDROME. 

004472 04-1 1 
ASTHENIC-DEPRESSIVE-SYNDROMES 

CLINICAL-TESTING OF MINAPRINE ON ELDERLY SUBJECTS WITH THE 
ASTHENIC-DEPRESSIVE-SYNDROMES. 

002123 02-11 
ASTHENO-DEPRESSIVE-DISORDERS 

TREATMENT OF ASTHENO-DEPRESSIVE-DISORDERS WITH MINAPRINE 
(CANTOR). MULTICENTER-STUDY OF 248 CASES EVALUATED WITH THE 
FATIGUE STUDY GROUPS NO. 4 CLINICAL- SCALE. 

001980 02-09 
ASTHENO-DEPRESSIVE-SYNDROMES 

ATTEMPT AT PSYCHOLOGICAL UNDERSTANDING AND TREATMENT OF 
PSYCHOLOGICAL ASTHENIA AND ASTHENO-DEPRESSIVE-SYNDROMES 
USING ERGADYL. 

001974 02-09 
ASTHMA 

NEUROPSYCHOLOGICAL-CORRELATES OF ASTHMA: EFFECT OF HYPOXIA 
OR DRUGS? 

003482 03-15 
NEUROPSYCHOLOGICAL-CORRELATES OF ASTHMA: BRAIN-DAMAGE OR 
DRUG-EFFECTS? 

003538 03-15 
ASTHMA THERAPY MAY UNDERCUT KIDS AT SCHOOL. 

004475 04-11 
ASTROCYTES 

BENZODIAZEPINE-RECEPTORS ON PRIMARY CULTURES OF MOUSE 
ASTROCYTES. 

004029 04-03 
ASTROGLIAL 

DOXEPIN, A TRICYCLIC-ANTIDEPRESSANT, BINDS TO NORMAL, INTACT 
ASTROGLIAL CELLS IN CULTURES AND INHIBITS THE ISOPROTERENOL- 
INDUCED INCREASE IN CYCLIC-AMP PRODUCTION. 

003836 04-03 
ASYMMETRY 

POSTURAL ASYMMETRY AND DIRECTIONALITY OF ROTATION IN RATS 

001729 02-04 
DOES POSTURAL ASYMMETRY INDICATE DIRECTIONALITY OF ROTATION 
IN RATS: ROLE OF SEX AND HANDLING. 

003061 03-04 
ATARACTIC-DRUG 

PHARMACOLOGICAL PECULIARITIES OF A BENZODIAZEPINE/ATARACTIC- 
DRUG AND ITS THERAPEUTIC RELEVANCE: THE SPECIAL STATUS OF 
CLORAZEPATE-DIPOTASSIUM (TRANXILIUM) . 

004527 04-13 
ATAXIA 

ORAL CHOLINE IN CEREBELLAR ATAXIA. 

000722 01-11 
DIAZEPAM-INDUCED ATAXIA IN TROHING SQUIRREL-MONKEYS. 

004138 04-04 
ATAXIC-BEHAVIORS 

EFFECTS OF CHRONIC ADMINISTRATION OF PHENCYCLIDINE ON 
STEREOTYPED-BEHAVIORS AND ATAXIC-BEHAVIORS IN THE RAT 

003095 03-04 
ATENOLOL 

EFFECTS OF ATENOLOL AND PROPRANOLOL ON HUMAN PERFORMANCE 
AND SUBJECTIVE FEELINGS. 

002340 02-14 
ATMOSPHERE 

CORRELATED STUDY OF THE EFFECTS OF SE-5023 IN AN HYPOXIC 
ATMOSPHERE ON QUANTIFIED EEG, VIGILANCE, MEMORY, AND 
MOOD. 

003440 03-14 



ATP 



.t 

i. 
& 
•r 



fe 



ATP COMPLEXES WITH THE ATPASE INHIBITOR QUERCETIN. 

ATPASE 

ATP COMPLEXES WITH THE ATPASE INHIBITOR QUERCETIN. 



000045 01-03 



000045 01-03 



S-41 



Subject Index 



Psychopharmacology Abstracts 



THE INFLUENCE OF PENTIFYLLINE AND THEOPHYLLINE ON REAQION 
KINETICS OF CATECHOLAMINE STIMULATED ATPASE FROM RAT-BRAIN. 

001052 02-01 
EFFECTS OF MALNUTRITION AND QUIPAZINE ON RAT-CEREBRAL-CORTEX 
ATPASE ACTIVITY DURING DEVELOPMENT. 

001276 02-uJ 

ATPASES 

CERTAIN MECHANISMS OF THE ACTION OF PSYCHOTROPIC-DRUGS ON 
TRANSPORT ATPASES. 00133102-03 

IMIPRAMINE AFFECTS AUTONOMIC-CONTROL OF SINOATRIAL RATE IN 
ISOLATED RIGHT ATRIAL PREPARATIONS. 000195 01-03 

^^*?N*VIVO EFFECT OF PROTEASE INHIBITORS IN DENERVATION ATROPHY. 

^^" THe'?FFECT of DIAZEPAM ON EEG CHANGES FOLLOWING INTRASEPTAL 

ADMINISTRATION OF ATROPINE. 000127 01-03 

BEHAVIOR-DEPENDENT EVOKED-POTENTIALS IN THE HIPPOCAMPAL-CAl 
REGION OF THE RAT. II. EFFECTS OF ESERINE, ATROPINE, ETHER AND 

P^'^™^'^'^^'^^^ 000184 01-03 

THE EFFEQ OF CLONAZEPAM ON ATROPINE SPIKES IN THE LIMBIC- 

S^S™. 001274 02-03 

LONG-TERM ADMINISTRATION OF ATROPINE, IMIPRAMINE, AND 

VILOXAZINE ALTERS RESPONSIVENESS OF RAT-CORTICAL-NEURONES 

TO ACETYLCHOLINE. 001306 02-03 

ATROPINE AND NATURAL SLEEP: ACTIVITY DATA OF THE STRIATUM IN 

RATS 

001551 02-03 
SELECTIVE SYNAPTIC ANTAGONISM BY ATROPINE AND ALPHA 
AMINOADIPATE OF PULVINAR AND CORTICAL AFFERENTS TO THE 
SUPRASYLVIAN VISUAL AREA (CLARE-BISHOP AREA) 

SLEEP ELICITED BY OLFACTORY TUBERCLE STIMULATION AND THE EFFEQ 
Of^^^OPm. 002955 03-04 

THE EXCITATORY EFFECT OF ATROPINE ON THE NEURONS OF THE FROG 
SYMPATHETIC GANGLIA. 00404104-03 

DEVELOPMENTAL-CHANGE IN REARING RESPONSE TO ATROPINE IN RATS 

TREATED WITH 6 HYDROXYDOPA. 

004191 04-04 

ATROPINE-RESISTANT 

MONOAMINE REPLACEMENT AFTER RESERPINE: CATECHOLAMINERGIC 
AGONISTS RESTORE MOTOR-ACTIVITY BUT PHENYLETHYLAMINE 
RESTORES ATROPINE-RESISTANT NEOCORTICAL LOW VOLTAGE FAST- 

*^^'^'^ 000309 01-03 

RESERPINE ABOLISHES MOVEMENT CORRELATED ATROPINE-RESISTANT 

NEOCORTICAL LOW VOLTAGE FAST-ACTIVITY. 

000310 01-03 

ATTACK 

LATE RESULTS OF LITHIUM TREATMENT OF ADOLESCENTS WITH AHACK 
LIKE SCHIZOPHRENIA. 

003177 03-08 

AHACKS , „.,„, ...r« 

DIFFERENTIAL DIAGNOSIS AND TREATMENT OF PANIC AHACKS AND 

PHOBIC-STATES. „„ „.„.,« 

004424 04-10 

A MODIFIED VERSION OF THE SIMULTANEOUS DISCONTINUATION OF 

PSYCHOTROPIC-DRUGS (COMBINED WITH THE ADMINISTRATION OF 

DIURETICS) AS A METHOD OF HALTING PROLONGED AHACKS OF 

SCHIZOPHRENIA. „„.co.«>,,. 

004584 04-14 

ATTEMPTS 

AHEMPTS TO REINSTATE LORDOSIS REFLEX IN ESTROGEN-PRIMED 
SPINAL FEMALE RATS WITH MONOAMINE AGONISTS. 

000421 01-04 

AHEMPTS TO DEVELOP SUPERSENSITIVITY OR SUBSENSITIVITY RETINAL 

DOPAMINE-RECEPTORS AFTER VARIOUS TREATMENTS WITH 

ANTAGONISTS OR AGONISTS. „„,..„ „o no 

001350 02-03 

PRESENT AHEMPTS AT TREATING TARDIVE-DYSKINESIA. 

004629 04-15 

BEHAVIORAL-INTERVENTION FOR SELF- STIMULATORY, AHENDING AND 
SEIZURE BEHAVIOR IN A CEREBRAL-PALSIED-CHILD. 

002104 02-11 

DISRUPTION OF SELECTIVE AHENTION BY APOMORPHINE, BUT NOT 
AMPHETAMINE, IN THE MONGOLIAN-GERBIL. „ „, „. 

000358 01-04 

THE EFFECTS OF NOREPINEPHRINE PERFUSION OF THE MESENCEPHALIC 
RETICULAR FORMATION ON BEHAVIOR IN THE RAT: INTERACTION 



WITH SEVERAL NEUROLEPTIC-DRUGS ON A MEASURE OF SUSTAINED 
AHENTION. (PH.D. DISSERTATION). 

001563 02-04 
DOPAMINERGIC INVOLVEMENT IN AHENTION A NOVEL ANIMAL-MODEL. 

001678 02-04 
EFFECTS OF METHYLPHENIDATE ON SELEQIVE AND SUSTAINED 
AHENTION IN HYPERACTIVE, READING-DISABLED, AND PRESUMABLY 
AHENTION-DISORDERED BOYS. 

002118 02-11 
PSYCHOACTIVE-DRUG-EFFEaS IN A HYPERACTIVE-CHILD: A CASE-STUDY 
ANALYSIS OF BEHAVIOR-CHANGE AND TEACHER AHENTION. 

002313 02-14 
EFFEaS OF LITHIUM ON EVOKED-POTENTIALS AND PERFORMANCE 
DURING SUSTAINED AHENTION. 

002419 02-15 
PREDICTING OUTCOME FROM MEASURES OF AHENTION AND 
AUTONOMIC-FUNQIONING. 

003205 03-08 
AHENTION DEFICIT-DISORDER (MINIMAL-BRAIN-DYSFUNQION) IN 
ADULTS: A REPLICATION STUDY OF DIAGNOSIS AND DRUG- 
TREATMENT. 

003389 03-11 
CAPACITIES OF AHENTION, STRESS-RESISTANCE, AND SLOW CEREBRAL 
POTENTIALS EFFEaS OF CARPIPRAMINE ON CONTINGENT NEGATIVE 
VARIATION WAVES AND P-300. 

003451 03-14 

AHENTION-DISORDERED 

EFFECTS OF METHYLPHENIDATE ON SELECTIVE AND SUSTAINED 
AUENTION IN HYPERACTIVE, READING-DISABLED, AND PRESUMABLY 
ATTENTION-DISORDERED BOYS. 

002118 02-11 

AHENTION-DYSFUNCTION 

ALTERATIONS OF EVOKED-POTENTIALS LINK RESEARCH IN AHENTION- 
DYSFUNCTION TO PEPTIDE RESPONSE SYMPTOMS OF SCHIZOPHRENIA. 

004316 04-08 
AnENTIONAL-ALTERATION 

Y-MAZE BEHAVIOR AFTER AN ANALOG OF AaH4-9, EVIDENCE FOR AN 
ATTENTION AL-ALTERATION. 

001676 02-04 

AUENTUATION 

POSTINGESTION INTERFERENCE WITH BRAIN FUNQION PREVENTS 
AHENTUATION OF NEOPHOBIA IN RATS. 

000352 01-04 

MORPHINE INJECTIONS INTO THE PERIAQUEDUQAL PERIVENTRICULAR 
GRAY AHENUATE SEPTAL HYPERREAQIVITY 

000390 01-04 
PHENOXYBENZAMINE AND BROMOCRIPTINE AHENUATE NEED FOR REM 

SLEEP IN RATS. ^.o„o «. n. 

004203 04-04 

LOCOMOTOR-AQIVITY ELICITED BY INJEQIONS OF PICROTOXIN INTO THE 
VENTRAL TEGMENTAL AREA IS AHENUATED BY INJECTIONS OF GABA 
INTO THE GLOBUS-PALLIDUS _^^^^ „, „^ 

000436 01-04 

PATIENT CHARACTERISTICS AND CLINICIAN AHITUDES INFLUENCING THE 
PRESCRIBING OF BENZODIAZEPINES. ^^^^^„ ^^ ,, 

003598 03-17 

ATTRIBUTED 

MEDICATION USE AND DEATHS AHRIBUTED TO ASPHYXIA AMONG 
PSYCHIATRIC-PATIENTS. 000838 01-15 

ATTRIBUTION 

CASE-REPORT USING AHRIBUTION THEORY TO LIMIT NEED FOR 
NEUROLEPTIC-MEDICINE. 000559 01-08 

REGULATION OF TYROSINE-HYDROXYLASE AFTER CHRONIC-TREATMENT 
WITH CLASSIC AND ATYPICAL ANTISCHIZOPHRENIC-DRUGS. 

DIFFERENTIAL ACTIONS OF CLASSICAL AND ATYPICAL ANTI PSYCHOTIC- 
DRUGS ON SPONTANEOUS NEURONAL AQIVITY IN THE AMYGDALOID 

C°^''^^^ 003131 03^5 

SELF-STIMULATION AND LOCOMOTOR CHANGES INDICATING LATENT 

ANTICHOLINERGIC-AQIVITY BY AN ATYPICAL NEUROLEPTIC 

^^»^ORmzm. 003560 03-16 

THE EFFECT OF TYPICAL AND ATYPICAL NEUROLEPTICS ON BINDING OF 

(3H)SPIR0PERID0L IN CALF CAUDATE. ^^^^ ^_^j 

DRUG AND SEIZURE IDENTIFICATION BY AUDIO-SPEaROMETRY. (PH.D. 
D'SSERTATION). 000532 01^ 



S-42 



VOLUME 19, SUBJECT INDEX 

AUOIOGENIC-SEIZURE 

DIFFERENCES IN ACTIVITY IN CEREBRAL METHYLTRANSFERASES AND 
MONOAMINE-OXIDASES BETWEEN AUDIOGENIC-SEIZURE SUSCEPTIBLE 
AND RESISTANT MICE AND DEERMICE. 

000377 01-04 
EFFECT OF RO-4-1284 ON AUDIOGENIC-SEIZURE SUSCEPTIBILITY AND 
INTENSITY IN EPILEPSY-PRONE RATS, 

003865 04-03 
IkUDIOOENIC-SEIZURES 

AUDIOGENIC-SEIZURES; INCREASED BENZODIAZEPINE-RECEPTOR BINDING 
IN A SUSCEPTIBLE STRAIN OF MICE. 

000252 01-03 
THE EFFECTS OF NOOTROPIC-DRUGS ON THE SUSCEPTIBILITY TO 
AUDIOGENIC-SEIZURES IN RATS. 

001571 02-04 
EFFEQS OF WITHDRAWAL FROM LONG-TERM DIPHENYLHYDANTOIN 
TREATMENT ON AUDIOGENIC-SEIZURES AND MAXIMAL 
ELECTROSHOCK-INDUCED SEIZURES IN RATS. 

004101 04-04 
kUDITORY 

BRAINSTEM AUDITORY EVOKEO-POTENTIALS AND MYELIN CHANGES IN 
TRIETHYLTIN-INDUCED EDEMA IN YOUNG ADULT RATS. 

000509 01-05 
EFFECTS OF HIPPOCAMPAL BRAIN-DAMAGE ON AUDITORY AND VISUAL 
RECENT MEMORY: COMPARISON WITH MARIJUANA INTOXICATED 
SUBJECTS. 

002320 02-14 
PHASIC ACTIVITY INDUCED BY P CHLOROPHENYLALANINE IN THE 
AUDITORY PATHWAY. 

002661 03-03 
PSYCHOTROPIC-DRUG-INDUCED CHANGES IN AUDITORY AVERAGED 
EVOKED-POTENTIALS: RESULTS OF A DOUBLE-BLIND TRIAL USING AN 
OBJECTIVE FULLY AUTOMATED AEP ANALYSIS METHOD. 

003412 03-13 
AUDITORY BRAINSTEM EVOKED-RESPONSES IN HOSPITALIZED-PATIENTS 
UNDERGOING DRUG-TREATMENT OR ECT. 

003430 03-13 
AUDITORY AROUSAL THRESHOLDS OF GOOD SLEEPERS AND POOR 
SLEEPERS WITH AND WITHOUT FLURAZEPAM. 

003446 03-14 
THE BRAINSTEM AUDITORY EVOKED-RESPONSE AS A TOOL IN 
NEUROBEHAVIORAL TOXICOLOGY AND MEDICINE. 

004277 04-05 
kUGMENTER 

CHANGES IN THE AUGMENTER REDUCER TENDENCY AND IN PAIN 
MEASURES AS A RESULT OF TREATMENT WITH A SEROTONIN 
REUPTAKE INHIBITOR ZIMELIDINE. 

002305 02-13 
AUGMENTING 

INHIBITORY-AQION OF THE COMBINATION OF AMINOPYRINE AND 
SECOBARBITAL ON EEG ACTIVATION, NEOCORTICAL RECRUITING AND 
AUGMENTING RESPONSES IN RABBITS. 

004022 04-03 
lUTHORITIES 

QUALITY OF REPORTS OF CLINICAL-TRIALS SUBMIHED BY THE DRUG 
INDUSTRY TO THE FINNISH AND SWEDISH CONTROL AUTHORITIES 

003599 03-17 
lUTISM 

THE BIOLOGICAL-EFFECTS AND CLINICAL-EFFECTS OF ORAL MAGNESIUM 
AND ASSOCIATED MAGNESIUM VITAMIN-B6 ADMINISTRATION ON 
CERTAIN DISORDERS OBSERVED IN INFANTILE AUTISM. 

003291 03-11 
lUTISTIC-PATIENT 

TARDIVE TOUREHE-SYNDROME IN AN AUTISTIC-PATIENT AFTER LONG- 
TERM NEUROLEPTIC ADMINISTRATION. 

000887 01-15 
AUTOCORRELATION 

AUTOCORRELATION ANALYSIS OF SINGLE NEURON ACTIVITY AFTER 
ADMINISTRATION OF PENTOBARBITAL. 

001268 02-03 
UTOINDUCTION 

THE AUTOINDUCTION OF CARBAMAZEPINE DURING LONG-TERM 
THERAPY. 

000785 01-13 
UTOMAINTENANCE-SCHEDULE 

DRUG-EFFEQS ON THE PERFORMANCE OF PIGEONS UNDER A NEGATIVE 
AUTOMAINTENANCE-SCHEDULE . 
UTOMATED 001754 02-04 

AN AUTOMATED ELECTROCHEMICAL-METHOD FOR IN VIVO MONITORING 
OF CATECHOLAMINE RELEASE. 

001873 02-06 
AN AUTOMATED METHOD FOR STUDYING STEREOTYPED GNAWING. 

002500 02-16 
PSYCHOTROPIC-DRUG-INDUCED CHANGES IN AUDITORY AVERAGED 
EVOKED-POTENTIALS: RESULTS OF A DOUBLE-BUND TRIAL USING AN 
OBJECTIVE FULLY AUTOMATED AEP ANALYSIS METHOD. 

003412 03-13 



Subject Index 



AUTONOMIC 

THE EFFECTS OF ALPHA AND BETA NEUROTOXINS FROM THE VENOMS OF 
VARIOUS SNAKES ON TRANSMISSION IN AUTONOMIC GANGLIA. 

003750 04-03 
AUTONOMIC-ACTIVITY 

THE INFLUENCE OF METHYLPHENIOATE ON SPONTANEOUS AUTONOMIC- 
ACTIVITY AND BEHAVIOR IN CHILDREN DIAGNOSED AS HYPERACTIVE. 

003363 03-11 
AUTONOMIC-CONTROL 

IMIPRAMINE AFFECTS AUTONOMIC-CONTROL OF SINOATRIAL RATE IN 
ISOLATED RIGHT ATRIAL PREPARATIONS. 

000195 01-03 
AUTONOMIC-EFFECTS 

AUTONOMIC-EFFEaS OF DEXTROAMPHETAMINE IN NORMAL MEN: 
IMPLICATIONS FOR HYPERACTIVITY AND SCHIZOPHRENIA. 

003437 03-13 
AUTONOMIC-FUNCTIONING 

PREDICTING OUTCOME FROM MEASURES OF ATTENTION AND 
AUTONOMIC-FUNCTIONING. 

003205 03-08 
AUTONOMIC-MECHANISMS 

PERIPHERAL AUTONOMIC-MECHANISMS AND PAVLOVIAN-CONDITIONING 
IN THE RABBIT (ORYCTOLAGUS-CUNICULUS). 

001560 02-04 
AUTORADIOGRAPHIC 

AUTORADIOGRAPHIC STUDIES ON DISTRIBUTION OF L-3 4 
DIHYDROXYPHENYLALANINE (L-DOPA) 14C AND L 5 
HYDROXYTRYPTOPHAN (L 5 HTP) 14C IN THE CAT BRAIN. 

003941 04-03 
AUTORADIOGRAPHIC LOCALIZATION OF DRUG AND NEUROTRANSMIHER- 
RECEPTORS IN THE BRAIN. 

004292 04-06 
AUTORAOIOGRAPHICAL 

BENZODIAZEPINE-RECEPTORS: AUTORAOIOGRAPHICAL AND 
IMMUNOCYTOCHEMICAL EVIDENCE FOR THEIR LOCALIZATION IN 
REGIONS OF GABAERGIC SYNAPTIC CONTACTS. 

002643 03-01 
AUTORADIOGRAPHY 

IN VITRO AUTORADIOGRAPHY OF OPIATE-RECEPTORS IN RAT-BRAIN 
SUGGESTS LOCI OF OPIATE-ERGIC PATHWAYS. (UNPUBLISHED PAPER) 

001025 02-01 
NEUROTENSIN-RECEPTOR LOCALIZATION BY LIGHT MICROSCOPIC 
AUTORADIOGRAPHY IN RAT-BRAIN. 

002938 03-03 
AUTORECEPTOR 

REPEATED TRICYCLIC-ANTIDEPRESSANTS INDUCE A PROGRESSIVE SWITCH 

IN THE ELEaROPHYSIOLOGICAL RESPONSE OF DOPAMINE NEURONS TO 

AUTORECEPTOR STIMULATION. 

000046 01-03 
ALTERATIONS IN BASAL FIRING-RATE AND AUTORECEPTOR SENSITIVITY 

OF DOPAMINE NEURONS IN THE SUBSTANTIA-NIGRA FOLLOWING 

ACUTE AND EXTENDED EXPOSURE TO ESTROGEN. 

001167 02-03 
AUTOSHAPED 

DISRUPTION OF AUTOSHAPED RESPONDING TO A SIGNAL OF BRAIN- 
STIMULATION REWARD BY NEUROLEPTIC-DRUGS. 

004199 04-04 
AVAILABILITY 

SWIMMING CAPACITY OF MICE AFTER PROLONGED TREATMENT WITH 
PSYCHOSTIMULANTS: II. EFFECT OF METHAMPHETAMINE ON 
SWIMMING PERFORMANCE AND AVAILABILITY OF METABOLIC 
SUBSTRATES. 

001613 02-04 
AVAILABILITY OF ISOSORBIDE-DINITRATE, DIAZEPAM AND 
CHLORMETHIAZOLE, FROM I.V. DELIVERY SYSTEMS. 

003558 03-16 
AVERAGE 

APOMORPHINE, HALOPERIDOL AND THE AVERAGE EVOKED-POTENTIALS 
IN NORMAL HUMAN VOLUNTEERS. 

004549 04-13 
AVERAGED 

PSYCHOTROPIC-DRUG-INDUCED CHANGES IN AUDITORY AVERAGED 
EVOKED-POTENTIALS: RESULTS OF A DOUBLE-BLIND TRIAL USING AN 
OBJECTIVE FULLY AUTOMATED AEP ANALYSIS METHOD 

003412 03-13 
AVERMECTIN-B1A 

STUDIES ON THE MECHANISM-OF-ACTION OF AVERMECTIN-BIA- 
STIMULATION OF RELEASE OF GAMMA AMINOBUTYRIC-ACID FROM 
BRAIN SYNAPTOSOMES. 

003973 04-03 
IN VITRO MODULATION BY AVERMECTIN-BIA OF THE GABA/ 
BENZODIAZEPINE-RECEPTOR COMPLEX OF RAT-CEREBELLUM. 

004023 04-03 
AVERSION 

INTERFERENCE WITH INGESTIONAL AVERSION LEARNING PRODUCED BY 
PREEXPOSURE TO THE UNCONDITIONED- STIMULUS: ASSOCIATIVE- 
ASPECTS AND NONASSOCIATIVE-ASPECTS. 

001610 02-04 






fe: 



S-43 



Subject Index 



Psychopharmacology Abttrocft 



ETHANOL AVERSION INDUCED BY PARENTERALLY ADMINISTERED 
ETHANOL ACTING BOTH AS CS AND UCS. 

001721 02-04 
AVERSIONS 

LITHIUM-CHLORIDE AND DELTA9 THC LEAD TO CONDITIONED AVERSIONS 
IN THE PIGEON. 

003003 03-04 
AVERSIVE 

APOMORPHINE: SELECTIVE INHIBITION OF THE AVERSIVE COMPONENT OF 
LATERAL HYPOTHALAMIC SELF-STIMULATION. 

002476 02-16 
PHARMACOLOGICAL EVIDENCE ON THE SPECIALIZATION OF CNS 
MECHANISMS RESPONSIBLE FOR MOTOR ACT INHIBITION BY AVERSIVE 
EVENTS. 

002671 03-03 
AVERSIVE-EFFECT 

ACCELERATED EXTINCTION AFTER POSHRIAL HALOTHANE ANESTHESIA IN 
RATS; AN AVERSIVE-EFFECT. 

003001 03-04 
AVERSIVE-EFFECTS 

REWARDING AND AVERSIVE-EFFECTS OF MORPHINE: TEMPORAL AND 
PHARMACOLOGICAL-PROPERTIES. 

000470 01-04 
TEMPORAL PROPERTIES OF THE REWARDING AND AVERSIVE-EFFECTS OF 

AMPHETAMINE IN RATS. 

000471 01-04 
CALCITONIN: AVERSIVE-EFFECTS IN RATS? 

002977 03-04 
CALCITONIN: AVERSIVE-EFFECTS IN RATS? 

002992 03-04 
AVERSIVE-EXPERIENCES 

AMYGDALA OPIATE-SENSITIVE MECHANISMS INFLUENCE FEAR 
MOTIVATED RESPONSES AND MEMORY PROCESSES FOR AVERSIVE- 
EXPERIENCES. (UNPUBLISHED PAPER). 

001628 02-04 
AVERSIVE-PROPERTIES 

A COMPARISON BETWEEN THE EFFECTS OF MORPHINE ON THE 

REWARDING AND AVERSIVE-PROPERTIES OF LATERAL HYPOTHALAMIC 
AND CENTRAL GRAY STIMULATION. 

001771 02-04 
AVERSIVE-SITUATIONS 

DIFFERENTIAL-EFFECTS OF NALOXONE AGAINST THE DIAZEPAM-INDUCED 
RELEASE OF BEHAVIOR IN RATS IN THREE AVERSIVE-SITUATIONS 

000480 01-04 
AVERSIVENESS 

SOCIAL CROWDING ENHANCES AVERSIVENESS OF NALOXONE IN RATS. 

004201 04-04 
AVFAIL 

DEPENDENCE OF THE AVFAIL EFFECT ON THE SEQUENCE OF TRAINING 
OPERATIONS. 

001086 02-02 
AVOIDANCE 

ENHANCED SUPPRESSION OF CONDITIONED AVOIDANCE RESPONSE BY 
HALOPERIDOL BUT NOT PHENOXYBENZAMINE IN RATS WITH 
BILATERAL PARAFASCICULAR LESIONS. 

000334 01-04 
MORPHINE EFFECTS UPON DISCRIMINATED APPROACH AND 

DISCRIMINATED AVOIDANCE IN RATS: ANTAGONISM BY NALOXONE 

000338 01-04 
EFFEQ OF BETA ENDORPHIN AND NALOXONE ON ACQUISITION, 
MEMORY, AND RETRIEVAL OF SHUTTLE AVOIDANCE AND 
HABITUATION LEARNING IN RATS. 

000410 01-04 
POSTNATAL ALCOHOL EXPOSURE IN THE RAT: ITS EFFECTS ON 
AVOIDANCE CONDITIONING, HEBB-WILLIAMS MAZE-PERFORMANCE, 
MATERNAL-BEHAVIOR, AND PUP DEVELOPMENT. 

001580 02-04 
TWO-WAY AVOIDANCE LEARNING UNDER THE INFLUENCE OF NOOTROPIC- 
DRUGS. 

001647 02-04 
L-DOPA ENHANCES ACQUISITION OF AN INHIBITORY AVOIDANCE 
RESPONSE. 

001711 02-04 
AVOIDANCE ENHANCEMENT AND DISCRIMINATIVE RESPONSE CONTROL 
BY ANXIOLYTICS WITH DRUGS ACTING ON THE GABA SYSTEM. 

004193 04-04 
EFFEaS OF CHLORPROMAZINE ON ESCAPE AND AVOIDANCE RESPONSES: 
A CLOSER LOOK. 

004226 04-04 
AVOIDANCE RESPONSE IN RATS AFTER INJEQION OF DOPAMINE INTO 
THE NEOSTRIATUM. 

004255 04-04 
AVOIDANCE-BEHAVIOR 

IMPAIRMENT OF AVOIDANCE-BEHAVIOR FOLLOWING SHORT-TERM 
INGESTION OF ETHANOL, TERTIARY BUTANOL, OR PENTOBARBITAL IN 
MICE. 

000479 01-04 
INTERACTION AMONG D-AMPHETAMINE, SCOPOLAMINE AND GENOTYPE 
IN AVOIDANCE-BEHAVIOR OF RATS. 

003082 03-04 



ACTH-LIKE PEPTIDES, PITUITARY ADRENOCORTICAL FUNQION AND 
AVOIDANCE-BEHAVIOR. 

004109 04-04 
AVOIDANCE-BEHAVIOUR 

EFFECTS OF MORPHINE AND CHLORDIAZEPOXIDE ON AVOIDANCE- 
BEHAVIOUR IN TWO INBRED STRAINS OF MICE. 

002973 03-04 
AVOIDANCE-DEFICITS 

THE USE OF EXTINCTION TO INVESTIGATE THE NATURE OF NEUROLEPTIC- 
INDUCED AVOIDANCE-DEFICITS. 

000345 01-04 
THE USE OF CONDITIONED SUPPRESSION TO EVALUATE THE NATURE OF 
NEUROLEPTIC-INDUCED AVOIDANCE-DEFICITS. 

004070 04-04 
AVOIDING 

APPROACHES TO THE PROBLEM OF PREVENTING HAZARDS OF LONG- 
TERM NEUROLEPTIC TREATMENT AND OF AVOIDING UNNECESSARY 
DRUGS. 

002426 02-15 
AVP 

DIFFERENTIAL-EFFECTS OF VARIOUS STIMULI ON AVP LEVELS IN BLOOD 
AND CEREBROSPINAL-FLUID. 

001370 02-03 
AWAKE 

A COMPARISON OF HUMAN TAQILE STIMULUS VELOCITY 

DISCRIMINATION WITH THE ABILITY OF S-l CORTICAL NEURONS IN 
AWAKE RHESUS-MONKEYS TO SIGNAL THE SAME VELOCITY 
DIFFERENCES BEFORE AND AFTER NONANESTHETIC DOSES OF 
PENTOBARBITAL. 

000055 01-03 
DIFFERENCES IN CUTANEOUS SENSORY RESPONSE PROPERTIES OF SINGLE 
SOMATOSENSORY CORTICAL NEURONS IN AWAKE AND HALOTHANE 
ANESTHETIZED RATS. 

002687 03-03 
TEMPORAL PAHERNING OF NEURONAL AQIVITY DURING THERMAL AND 
NEUROCHEMICAL STIMULATION OF THE PREOPTIC/ANTERIOR 
HYPOTHALAMUS OF THE AWAKE RABBIT. 

002737 03-03 
AWAKENING 

COMPARATIVE-STUDY OF SLEEP AND STATE ON AWAKENING WITH TWO 
HYPNOTIC DIAZEPINES. 

000817 01-14 
AXIS 

INFLUENCE OF DRUGS AFFEQING THE PITUITARY ADRENAL AXIS ON 
CHROMAFFIN CELLS. 

001183 02-03 
DEVELOPMENT OF ACUTE TOLERANCE TO THE EFFEaS OF NALOXONE ON 
THE HYPOTHALAMIC PITUITARY LUTEINIZING-HORMONE AXIS IN THE 
MALE RAT 

002853 03-03 
DRUG-INDUCED ALTERATIONS OF THE HYPOTHALAMUS HYPOPHYSIS 
AXIS. 

004535 04-13 
AXON 

EFFECTS OF TAIPOXIN ON THE ULTRASTRUQURE OF CHOLINERGIC AXON 
TERMINALS IN THE MOUSE ADRENAL-MEDULLA. 

003916 04-03 
AXONAL 

BIOSYNTHESIS, AXONAL TRANSPORT AND RELEASE OF POSTERIOR 
PITUITARY-HORMONES. (UNPUBLISHED PAPER). 

001148 02-03 
PAPAIN-DERIVED FRAGMENT IIC TETANUS-TOXIN: ITS BINDING TO 
ISOLATED SYNAPTIC MEMBRANES AND RETROGRADE AXONAL 
TRANSPORT. 

003734 04-03 
STUDIES ON AXONAL TRANSPORT IN DOPAMINERGIC NEURONS: EFFEQ 
OF NEUROPHARMACOLOGIC LESIONS. 

003858 04-03 
RESERPINE EFFECT ON THE AXONAL TRANSPORT OF DOPAMINE-BETA- 
HYDROXYLASE AND TYROSINE-HYDROXYLASE IN RAT-BRAIN. 

003904 04-03 
AXONS 

ABSENCE OF POTASSIUM CONDUQANCE IN CENTRAL MYELINATED 
AXONS. 

000166 01-03 
AZETIDINYIBUTYNYL 

SYNTHESIS AND PHARMACOLOGICAL PROPERTIES OF N-4 1 
AZETIDINYLBUTYNYL 2 PYRROLIDONE, A HIGHLY POTENT 
OXOTREMORINE-LIKE-AGENT. 

003701 04-02 
A10 

INTRAVENOUS GABA AGONIST ADMINISTRATION STIMULATES FIRING OF 
AlO DOPAMINERGIC NEURONS. 

000320 01-03 
DOPAMINERGIC AGONISTS DIFFERENTIALLY AFFEQ OPEN-FIELD AQIVITY 
OF RATS WITH AlO LESIONS. 

004135 04-04 



S-44 



VOLUME 19, SUBJECT INDEX 



Subject Index 



BABOON 

EEG AND ANTICONVULSANT EFFECTS OF DIPROPYLACETIC-ACID AND 
DIPROPYLACETAMIDE IN THE BABOON PAPIO-PAPIO. 

001210 02-03 
BABOONS 

PROGRESSIVE-RATIO AND FIXED-RATIO SCHEDULES OF COCAINE 
MAINTAINED RESPONDING IN BABOONS. 

000395 01-04 
COMPARATIVE ANXIOLYTIC AND HYPNOTIC-EFFECTS OF 3 
BENZODIAZEPINES ON BABOONS. 

001581 02-04 
BACKGROUND 

THE BIOCHEMICAL BACKGROUND TO TARDIVE-DYSKINESIA 

004588 04- 1 5 
BACKWARD 

THE ROLE OF CENTRAL SEROTONERGIC MECHANISMS ON HEAD-TWITCH 
AND BACKWARD LOCOMOTION INDUCED BY HALLUCINOGENIC-DRUGS. 

003397 03-12 
BACLOFEN 

CIRCLING-BEHAVIOUR INDUCED BY INTRANIGRAL INJECTION OF 
BACLOFEN IN RATS. 

000415 01-04 
MANIC-PSYCHOSIS FOLLOWING RAPID WITHDRAWAL FROM BACLOFEN. 

000832 01-15 
THE EFFECTS OF ETHANOL, PHENOBARBITAL, AND BACLOFEN ON 
ETHANOL WITHDRAWAL IN THE RHESUS-MONKEY. 

001802 02-04 
BACLOFEN IN TRIGEMINAL-NEURALGIA: ITS EFFECT ON THE SPINAL 
TRIGEMINAL-NUCLEUS: A PILOT-STUDY. 

002122 02-11 
EFFECT OF SODIUM-VALPROATE AND BACLOFEN IN TARDIVE-DYSKINESIA: 
CLINICAL-STUDIES AND NEUROENDOCRINE-STUDIES. 

002441 02-15 
CROSS-TOLERANCE OF DOPAMINE METABOLISM TO BACLOFEN, GAMMA 
BUTYROLACTONE AND HA-966 IN THE STRIATUM AND OLFACTORY 
TUBERCLE OF THE RAT. 

002681 03-03 
GABA AND BACLOFEN POTENTIATE THE K-EVOKED RELEASE OF 
METHIONINE-ENKEPHALIN FROM RAT STRIATAL SLICES. 

002882 03-03 
BACLOFEN: BROADER ASPECTS OF ACTIVITY. 

003429 03-13 
3H BACLOFEN AND 3H GABA BIND TO BICUCULLINE INSENSITIVE GABAB 
SITES IN RAT-BRAIN. 

003839 04-03 
BACLOFEN: STEREOSELECTIVE INHIBITION OF EXCITANT AMINO-ACID 
RELEASE. 

003867 04-03 
CENTRAL CARDIOVASCULAR-EFFEQS AND BIOCHEMICAL-EFFECTS OF 
BACLOFEN IN THE CONSCIOUS RAT. 

003965 04-03 
BACLOFEN IN THE TREATMENT OF TARDIVE-DYSKINESIA: OPEN LABEL 
STUDY. 

004619 04-15 
BACTERIAL 

SYNTHETIC IMMUNOSTIMULANTS DERIVED FROM THE BACTERIAL CELL 
WALL. 

001080 02-02 
BAR-PRESSING-BEHAVIOR 

FIRST DOSE BEHAVIORAL-TOLERANCE TO PHENCYCLIDINE ON FOOD 
REWARDED BAR-PRESSING-BEHAVIOR IN THE RAT. 

000462 01-04 
IMITATION, SOCIAL FACILITATION, AND THE EFFECTS OF ACTH4-10 ON 
RATS BAR-PRESSING-BEHAVIOR. 

003009 03-04 
BARBITAL 

EFFECT OF P CHLOROPHENYLALANINE ON THE ACQUISITION OF 
TOLERANCE TO THE HYPNOTIC-EFFEQS OF PENTOBARBITAL, BARBITAL, 
AND ETHANOL. 

003883 04-03 
BARBITURATE 

INTRACELLULAR REDOX STATES UNDER HALOTHANE AND BARBITURATE 
ANESTHESIA IN NORMAL, ISCHEMIC, AND ANOXIC MONKEY BRAIN. 

000295 01-03 
SOCIAL AND CLINICAL SIGNIFICANCE OF DETERMINING THE BARBITURATE 
LEVEL IN THE BLOOD SERUM OF PATIENTS TREATED WITH 
ANTIEPILEPTIC-DRUGS. 

000695 01-11 
INTRAVENOUS PHENOBARBITAL THERAPY IN BARBITURATE AND OTHER 
HYPNOSEDATIVE WITHDRAWAL REACTIONS: A KINETIC APPROACH. 

000703 01-11 
BARBITURATE SERUM LEVELS AND PROTECTION AGAINST KINDLED 
AMYGDALOID SEIZURES IN THE RAT. 

001559 02-04 
REDUCTION OF BARBITURATE ANESTHESIA BY NEW GLUTARIMIDE 
COMPOUNDS IN MICE. 

001748 02-04 
THE INTERACTION BETWEEN BARBITURATE ANESTHETICS AND 

EXCITATORY AMINO-ACID RESPONSES ON CAT SPINAL NEURONES. 

002799 03-03 



BARBITURATE ENHANCEMENT OF GABA-MEDIATED INHIBITION AND 
ACTIVATION OF CHLORIDE ION-CONDUCTANCE: CORRELATION WITH 
ANTICONVULSANT AND ANESTHETIC ACTIONS. 

002885 03-03 
POTENTIATION OF BARBITURATE HYPNOSIS BY PROBENECID: 
DIFFERENTIAL-EFFECT IN TOLERANT ANIMALS. 

003038 03-04 
NEUTRALIZATION OF THE EFFECT OF DELTA9 TETRAHYDROCANNABINOL 
ON BARBITURATE SLEEPING-TIME BY SPECIFIC ACTIVE IMMUNIZATION 

003803 04-03 
HABITUATION OF THE THE HEAD-POKE RESPONSE: EFFECTS OF AN 
AMPHETAMINE BARBITURATE MIXTURE, PLG AND FENFLURAMINE. 

004159 04-04 
SELECTIVE EFFECTS OF BARBITURATE AND AMPHETAMINE ON 
INFORMATION-PROCESSING AND RESPONSE EXECUTION. 

004563 04-14 
BARBITURATE-DEPENDENCE 

BARBITURATE-DEPENDENCE IN MICE: EFFECTS OF PROPRANOLOL ON THE 
WITHDRAWAL-SYNDROME (40798). 

000313 01-03 
BARBITURATE-DEPENDENCE AND DRUG PREFERENCE. 

004235 04-04 
BARBITURATE-EVOKED 

A BARBITURATE-EVOKED INTENSIFICATION OF POSTSYNAPTIC INHIBITION 
IN THE PREOPTIC OVULATORY TRIGGER REGION OF THE 
HYPOTHALAMUS. 

002818 03-03 
BARBITURATE-INDUCED 

TOLERANCE TO BARBITURATE-INDUCED CENTRAL-NERVOUS-SYSTEM 
DEPRESSION: INVOLVEMENT OF STIMULUS SECRETION COUPLING IN 
DISCRETE BRAIN AREAS. (PH.D. DISSERTATION). 

001213 02-03 
BARBITURATES 

ANTICONVULSANT AND ANESTHETIC BARBITURATES: DIFFERENT 
POSTSYNAPTIC ACTIONS IN CULTURED MAMMALIAN NEURONS. 

000194 01-03 
ACTION OF BARBITURATES ON ACTIVITY OF ACETYLCHOLINESTERASE 
FROM SYNAPTOSOMAL MEMBRANES. 

000224 01-03 
CONVULSANT AND ANTICONVULSANT BARBITURATES. 1. MOLECULAR 
CONFORMATIONS FROM CLASSICAL POTENTIAL ENERGY 
CALCULATIONS. 

001029 02-01 
LACK OF INFLUENCE OF BRAIN CATECHOLAMINES ON ACUTE EFFECTS OF 
BARBITURATES. 

001138 02-03 
EXPERIMENTAL DEPENDENCE ON BARBITURATES: II. RELATIONSHIP 
BETWEEN DRUG LEVELS IN SERUM AND BRAIN AND THE 
DEVELOPMENT OF DEPENDENCE IN RATS. 

001800 02-04 
THE EFFECT OF BARBITURATES ON THE DEGRADATION OF ENKEPHALIN BY 
BRAIN ENZYMES. 

002656 03-03 
BARBITURATES AND GABA-RECEPTORS. 

002769 03-03 
EFFECTS OF D AMINOLAEVULINIC-ACID, PORPHOBILINOGEN, AMINO- 
ACIDS AND BARBITURATES ON CALCIUM ACCUMULATION BY 
CULTURED NEURONS. 

002859 03-03 
MECHANISM-OF-ACTION OF BARBITURATES. 

003600 03-17 
EFFEQS OF BARBITURATES ON INHIBITORY AND EXCITATORY RESPONSES 
TO APPLIED NEUROTRANSMIHERS IN APLYSIA. 

003762 04-03 
SOME BARBITURATES ENHANCE THE EFFECT OF MUSCIMOL ON 
DOPAMINE TURNOVER IN THE RAT RETINA. 

003873 04-03 
INTERACTION OF STEREOISOMERS OF BARBITURATES WITH (3H)ALPHA 
DIHYDROPICROTOXININ BINDING-SITES. 

004036 04-03 
SEPARATION OF BARBITURATES USING REVERSE PHASE THIN-LAYER- 
CHROMATOGRAPHY. 

004670 04-16 
BARORECEPTOR 

EVIDENCE SUGGESTING A TRANSMITTER OR NEUROMODULATORY ROLE 
FOR SUBSTANCE-P AT THE FIRST SYNAPSE OF THE BARORECEPTOR 
REFLEX. 

001264 02-03 
EFFECTS OF ALPHA-ADRENOCEPTOR STIMULATING DRUGS ON 
BARORECEPTOR REFLEXES IN CONSCIOUS CATS. 

001514 02-03 
BASAL 

PROSTAGLANDIN-E RELEASE BY RAT MEDIAL BASAL HYPOTHALAMUS IN 
VITRO. INHIBITION BY MELATONIN AT SUBMICROMOLAR 
CONCENTRATIONS. 

001159 02-03 



i1 



is- 



S-45 



Subject Index 



Psychopharmacology Abstracts 



ALTERATIONS IN BASAL FIRING-RATE AND AUTORECEPTOR SENSITIVITY 

OF DOPAMINE NEURONS IN THE SUBSTANTIA-NIGRA FOLLOWING 

ACUTE AND EXTENDED EXPOSURE TO ESTROGEN. 

001167 02-03 
DENERVATION IN THE DOPAMINERGIC MESOLIMBIC SYSTEM: 

FUNCTIONAL CHANGES FOLLOWED USING (-)N N 

PROPYLNORAPOMORPHINE DEPEND ON THE BASAL AQIVITY LEVELS 

OF RATS. 

001603 02-04 
BASAL AND STIMULATED LEVELS OF PROLAQIN, TSH AND LH IN SERUM 

OF CHRONIC SCHIZOPHRENIC-PATIENTS, LONG-TERM TREATED WITH 

NEUROLEPTICS. 

001935 02-08 
BASAL AND STIMULATED LEVELS OF PROLACTIN, TSH, AND LH IN SERUM 

OF CHRONIC SCHIZOPHRENIC-PATIENTS LONG-TERM TREATED WITH 
NEUROLEPTICS: RELATIONS TO PSYCHOPATHOLOGY. 

001936 02-08 
ANTIPSYCHOTIC-DRUGS: DIFFERENTIAL-EFFECTS ON DOPAMINE NEURONS 

IN BASAL GANGLIA AND MESOCORTEX FOLLOWING CHRONIC 
ADMINISTRATION IN HUMAN AND NONHUMAN PRIMATES. 

002285 02-13 
BASAL GANGLIA DOPAMINERGIC CONTROL OF SENSORIMOTOR 
FUNaiONS RELATED TO MOTIVATED BEHAVIOR. 

002815 03-03 
KAINIC-ACID AND NEUROTRANSMinER INTERAQIONS IN THE BASAL 
GANGLIA. 

002824 03-03 
GLUCOSE SUPPRESSES BASAL FIRING AND HALOPERIDOL-INDUCED 
INCREASES IN THE FIRING-RATE OF CENTRAL DOPAMINERGIC 
NEURONS. 

002880 03-03 
SELECTIVE MODIFICATION BY OPIATES OF NEURONAL AQIVITY OF THE 
MEDIAL BASAL HYPOTHALAMUS. 

003773 04-03 
BASAL PROLACTINAEMIA AND RESPONSES TO TRH AND SULPIRIDE IN 
DIFFERENT CATEGORIES OF MALE SEXUAL-DYSFUNCTIONS. 

004503 04-13 
BASELINE 

EFFEaS OF SINGLE-ORAL-DOSAGES OF STEROIDS ON HUMAN EEG 
BASELINE CROSSING T-SCORES SHOWN BY MULTIVARIATE STATISTICS 
AND STANDARD PROFILES. 

002239 02-13 
BASILAR 

A COMPARISON OF THE CONTRAQILE RESPONSES OF THE RABBIT 
BASILAR AND PULMONARY-ARTERIES TO SYMPATHOMIMETIC 
AGONISTS: CHARACTERISTICS. 

002670 03-03 
BASOPHILIC 

IGE MEDIATED HISTAMINE RELEASE IN RAT BASOPHILIC LEUKEMIA 
CELLS: RECEPTOR ACTIVATED PHOSPHOLIPID METHYLATION, CA-FLUX 
AND RELEASE OF ARACHIDONIC-ACID. (UNPUBLISHED PAPER). 

001188 02-03 
BASS-SCALE-FACTORS 

TWO BASS-SCALE-FAaORS AND RESPONSE TO PLACEBO AND 
ANXIOLYTIC-DRUGS. 

000649 01-10 
BATRACHOTOXIN 

FURTHER ANALYSIS OF THE MECHANISMS OF AQION OF 
BATRACHOTOXIN ON THE MEMBRANE OF MYELINATED NERVE. 

003884 04-03 
BEAGLE-DOGS 

BEHAVIORAL-ANALYSIS OF AMYGDALOID KINDLING IN BEAGLE-DOGS 
AND THE EFFECTS OF CLONAZEPAM, DIAZEPAM, PHENOBARBITAL, 
DIPHENYLHYOANTOIN, AND FLUNARIZINE ON SEIZURE 
MANIFESTATION. 

000496 01-04 
BEARING 

PROTEIN ABNORMALITIES IN MACROPHAGES BEARING ASBESTOS. 
(UNPUBLISHED PAPER). 

001037 02-01 
BED 

CONSISTENT UNMASKING OF DOPAMINE-INDUCED DILATION OF THE 
CANINE FEMORAL VASCULAR BED. 

00391 1 04-03 
BEHAVIOR 

TRANYLCYPROMINE STEREOISOMERS, MONOAMINERGIC 
NEUROTRANSMISSION AND BEHAVIOR. A MINIREVIEW. 

000016 01-02 
SCHEDULE-CONTROLLED BEHAVIOR IN THE MORPHINE-DEPENDENT AND 
POSTDEPENDENT RAT. 

000349 01-04 
CONSEQUENT EVENTS AS DETERMINANTS OF DRUG-EFFECTS ON 

SCHEDULE-CONTROLLED BEHAVIOR: MODIFICATION OF EFFEQS OF 
COCAINE AND D-AMPHET AMINE FOLLOWING CHRONIC AMPHETAMINE 
ADMINISTRATION. 

000350 01-04 
BEHAVIORAL-PHARMACOLOGY AND THE STIMULUS CONTROL OF 

BEHAVIOR. 

000381 01-04 



STEREOSPECIFIC, DOSE-DEPENDENT ANTAGONISM BY NALOXONE OF 
NONOPIATE BEHAVIOR IN MICE. 

000411 01-04 
DIFFERENTIAL-EFFEaS OF NALOXONE AGAINST THE DIAZEPAM-INDUCED 
RELEASE OF BEHAVIOR IN RATS IN THREE AVERSIVE-SITUATIONS. 

000480 01-04 
CONFIRMATION BEHAVIOR OF PHENCYCLIDINES AND BIOLOGICAL- 
ACTIVITY. 

001031 02-01 
ANTIDEPRESSANT-DRUGS SLOW CIRCADIAN-RHYTHMS IN BEHAVIOR AND 
BRAIN NEUROTRANSMITTER-RECEPTORS. 

001536 02-03 
THE EFFECTS OF NOREPINEPHRINE PERFUSION OF THE MESENCEPHALIC 
RETICULAR FORMATION ON BEHAVIOR IN THE RAT: INTERACTION 
WITH SEVERAL NEUROLEPTIC-DRUGS ON A MEASURE OF SUSTAINED 
AHENTION. (PH.D. DISSERTATION). 

001563 02-04 
ACUTE AND CHRONIC EFFEaS OF DELTA9 TETRAHYDROCANNABINOL ON 
COMPLEX BEHAVIOR OF SQUIRREL-MONKEYS. 

001583 02-04 
EFFECTS OF LILLY-1 10140 (FLUOXETINE) ON SELF-STIMULATION 
BEHAVIOR IN THE DORSAL AND VENTRAL REGIONS OF THE LATERAL 
HYPOTHALAMUS IN THE MOUSE. 

001590 02-04 
INTERAQION OF PSYCHOPHARMALOGIC-FAaORS AND PSYCHOSOCIAL- 
FACTORS IN THE TREATMENT OF ANIMAL-MODELS OF 
HYPOINHIBITORY (HYPERKINETIC) BEHAVIOR. 

001602 02-04 
THE BEHAVIOR OF RATS IN THE OPEN-FIELD WITHOUT STRESS, UNDER 
ACUTE AND PERSISTING INFLUENCE OF IMIPRAMINE AND 
TRANYLCYPROMINE AS WELL AS ON THE INDIVIDUAL REAQION TYPE 
(EMOTIVE AND NONEMOTIVE) 

001624 02-04 
INTERACTIONS BETWEEN NALTREXONE AND NONOPIATE DRUGS 
EVALUATED BY SCHEDULE-CONTROLLED BEHAVIOR. 

001645 02-04 
Y-MAZE BEHAVIOR AFTER AN ANALOG OF AaH4-9, EVIDENCE FOR AN 
AnENTIONAL-ALTERATION . 

001676 02-04 
THE EFFEaS OF D-AMPHETAMINE, CHLORDIAZEPOXIDE, AND 
PENTOBARBITAL ON BEHAVIOR MAINTAINED BY ESCAPE FROM 
PUNISHMENT IN PIGEONS (PHD DISSERTATION). 

001713 02-04 
INTERRELATIONS AMONG PRIOR EXPERIENCE AND CURRENT CONDITIONS 
IN THE DETERMINATION OF BEHAVIOR AND THE EFFECTS OF DRUGS. 

001715 02-04 
EFFEaS OF NEONATAL 6 HYDROXYDOPA ON BEHAVIOR IN FEMALE 
RATS. 

001717 02-04 
EFFECTS OF ACUTE VS. CHRONIC PHENCYCLIDINE ON BRAIN- 
BIOCHEMISTRY AND BEHAVIOR. 

001789 02-04 
EFFECTS OF BRANCHED-CHAIN FATTY-ACIDS ON GABA DEGRADATION 
AND BEHAVIOR: FURTHER EVIDENCE FOR A ROLE OF GABA IN QUASI- 
MORPHINE ABSTINENCE-BEHAVIOR 

001809 02-04 
BEHAVIOR MAINTAINED BY INTRAVENOUS INJEQION OF CODEINE, 
COCAINE, AND ETORPHINE IN THE RHESUS-MACAQUE AND THE 
PIGTAIL-MACAQUE 

001828 02-04 
BEHAVIORAL-INTERVENTION FOR SELF- STIMULATORY, AHENDING AND 
SEIZURE BEHAVIOR IN A CEREBRAL-PALSIED-CHILO. 

002104 02-1 1 
DISINHIBITION OF BEHAVIOR BY ANTIANXIETY-DRUGS. 

002403 02-15 
THE EFFEa OF ALTERED DOPAMINERGlC-AaiVITY ON FOOD INTAKE IN 
THE RAT: EVIDENCE FOR AN OPTIMAL LEVEL OF DOPAMINERGIC- 
AaiVITY FOR BEHAVIOR. 

002632 02-17 
FUNDAMENTAL MECHANISMS UNDERLYING ALTERED BEHAVIOR 
FOLLOWING CHRONIC ADMINISTRATION OF PSYCHOMOTOR 
STIMULANTS. 

002711 03-03 
BASAL GANGLIA DOPAMINERGIC CONTROL OF SENSORIMOTOR 
FUNQIONS RELATED TO MOTIVATED BEHAVIOR. 

002815 03-03 
POSSIBLE MECHANISMS OF EFFEQ OF AaH4-10 AND ITS ANALOG, 
CONTAINING D ISOMER OF PHENYLALANINE, ON BEHAVIOR. 

002949 03-04 
FACILITATION OF LORDOSIS BEHAVIOR IN THE OVARIEaOMIZED 
ESTROGEN-PRIMED RAT BY DIBUTYRYL-C-AMP. 

002957 03-04 
EFFECTS OF ACUTE CENTRAL AND PERIPHERAL AaHl-24 
ADMINISTRATION ON LORDOSIS BEHAVIOR. 

002975 03-04 
VASOTOCIN, PROSTAGLANDIN, AND FEMALE REPRODUaiVE BEHAVIOR 
IN THE FROG, RANA-PIPIENS. 

002978 03-04 



S-46 



VOLUME 19, SUBJECT INDEX 



Subject Index 



DRUG REGIMENS FACILITATING AGGRESSION; BEHAVIOR, AMINE, AND 
RECEPTOR ALTERATIONS 

002987 03-04 
CONFLICT-SITUATION BASED ON INTRACRANIAL SELF-STIMULATION 
BEHAVIOR AND THE EFFECT OF BENZODIAZEPINES. 

003004 03-04 
MULTIDIMENSIONAL ANALYSES OF BEHAVIOR IN MICE TREATED WITH 
ALPHA ENDORPHIN. 

003020 03-04 
THE EFFECTS OF IMIPRAMINE TREATMENT ON THE UNCONDITIONED 
ALIMENTARY BEHAVIOR AND CLASSICAL CONDITIONED SALIVARY 
REACTIONS IN DOGS. 

003030 03-04 
SUPPRESSION OF ACTIVE SLEEP BY CHRONIC-TREATMENT WITH 
CHLORIMIPRAMINE DURING EARLY POSTNATAL DEVELOPMENT: 
EFFECTS UPON ADULT SLEEP AND BEHAVIOR IN THE RAT. 

003056 03-04 
CYCLIC-AMP-INDUCED CHANGES IN THE ELECTROENCEPHALOGRAM AND 
IN BEHAVIOR DURING MORPHINE-DEPENDENCE AND ABSTINENCE IN 
THE RAT. 

003078 03-04 
RESEARCH STRATEGIES FOR ASSESSING THE EFFECTS OF 
METHYLMERCURY ON BEHAVIOR. 

003128 03-05 
THE INFLUENCE OF METHYLPHENIDATE ON SPONTANEOUS AUTONOMIC- 
ACTIVITY AND BEHAVIOR IN CHILDREN DIAGNOSED AS HYPERACTIVE. 

003363 03-11 
SENSORY PROCESSING, CARDIOVASCULAR REACTIVITY, AND THE TYPE A 
CORONARY-PRONE BEHAVIOR PAHERN. 

003405 03-13 
COMPARISON OF THE EFFECTS OF FOUR BENZODIAZEPINES ON FRAME OF 
MIND AND BEHAVIOR IN HEALTHY SUBJECTS. 

003441 03-14 
EFFECTS OF NORCOCAINE AND SOME NORCOCAINE DERIVATIVES ON 
SCHEDULE-CONTROLLED BEHAVIOR OF PIGEONS AND SQUIRREL- 
MONKEYS. 

004012 04-03 
EFFECTS OF DOPAMINERGIC DRUGS ON PHENCYCLIDINE-INDUCED 
BEHAVIOR IN THE RAT. 

004083 04-04 
HISTAMINE AS A PUNISHER IN SQUIRREL-MONKEYS; EFFECTS OF 
PENTOBARBITAL, CHLORDIAZEPOXIDE AND HI -RECEPTOR AND H2- 
RECEPTOR ANTAGONISTS ON BEHAVIOR AND CARDIOVASCULAR 
RESPONSE. 

004119 04-04 
INTERAaiONS BETWEEN NARCOTIC AGONISTS, PARTIAL AGONISTS AND 
ANTAGONISTS EVALUATED BY SCHEDULE-CONTROLLED BEHAVIOR. 

004127 04-04 
EFFEaS OF NARCOTIC ABSTINENCE ON SCHEDULE-CONTROLLED 
BEHAVIOR IN DEPENDENT RATS. 

004230 04-04 
STUDIES OF CARBACHOL-INDUCED WET-DOG-SHAKE BEHAVIOR IN RATS. 

004241 04-04 
LACK OF SPECIFICITY OF AN ANIMAL BEHAVIOR MODEL FOR 
HALLUCINOGENIC DRUG AQION. 

004250 04-04 
BEHAVIOR OF RATS AND MICE ADMINISTERED ACTIVE METABOLITES OF 
FLUPHENAZINE, 7 HYDROXYFLUPHENAZINE AND FLUPHENAZINE- 
SULFOXIDE. 

004256 04-04 
DOSAGE FORM DESIGN FOR IMPROVEMENT OF BIOAVAILABILITY OF 
LEVODOPA III: INFLUENCE OF DOSE ON PHARMACOKINETIC BEHAVIOR 
OF LEVODOPA IN DOGS AND PARKINSONIAN-PATIENTS. 

004551 04-13 
SEROTONERGIC APPROACHES TO THE MODIFICATION OF BEHAVIOR IN 
THE LESCH-NYHANS-SYNDROME. 

004576 04-14 
BEHAVIOR AND LEARNING DIFFICULTIES IN CHILDREN OF NORMAL 
INTELLIGENCE BORN TO ALCOHOLIC MOTHERS. 

004658 04-15 
BEHAVIOR-CHANGE 

PSYCHOACTIVE-ORUG-EFFECTS IN A HYPERACTIVE-CHILD: A CASE-STUDY 
ANALYSIS OF BEHAVIOR-CHANGE AND TEACHER AHENTION. 

002313 02-14 
BEHAVIOR-DEPENDENT 

BEHAVIOR-DEPENDENT EVOKED-POTENTIALS IN THE HIPPOCAMPAL-CAl 
REGION OF THE RAT. II. EFFECTS Of ESERINE, ATROPINE, ETHER AND 
PENTOBARBITAL. 

000184 01-03 
BEHAVIOR-DISORDERS 

UNDERSTANDING AND USE OF CHEMOTHERAPY BY LEARNING- 
DISABILITIES AND BEHAVIOR-DISORDERS TEACHERS. 

000965 01-17 
THE MANAGEMENT OF CHRONIC BEHAVIOR-DISORDERS IN MENTALLY- 
RETARDED ADULTS WITH LITHIUM-CARBONATE. 

003376 03-11 
PREVALENCE OF DRUG-TREATMENT FOR HYPERACTIVITY AND OTHER 
CHILDHOOD BEHAVIOR-DISORDERS. 

004713 04-17 



BEHAVIOR-MODIFICATION 

A CONTROLLED-TRIAL Of BEHAVIOR-MODIFICATION AND 
METHYLPHENIDATE IN HYPERACTIVE-CHILDREN. 

000678 01-11 
EVALUATION Of THE RELATIVE EfFECTIVENESS OF METHYLPHENIDATE 
AND COGNITIVE BEHAVIOR-MODIFICATION IN THE TREATMENT OF 
KINDERGARTEN-AGED HYPERACTIVE-CHILDREN 

003306 03-11 
BEHAVIORAL 

BEHAVIORAL CONFIRMATION Of DIffUSE NOXIOUS INHIBITORY 
CONTROLS (DNIC) AND EVIDENCE fOR A ROLE OF ENDOGENOUS 
OPIATES. 

002791 03-03 
THE EFFECTS OF INJECTIONS OF BOMBESIN INTO THE CEREBRAL 
VENTRICLES ON BEHAVIORAL THERMOREGULATION. 

002952 03-04 
BRIEF COMMUNICATION: BEHAVIORAL RECOVERY AFTER TOLUENE 
EXPOSURE IN RATS. 

002969 03-04 
CHANGES IN THE HORIZONTAL VESTIBULO-OCULAR REFLEX OF THE 
RHESUS-MONKEY WITH BEHAVIORAL AND PHARMACOLOGICAL 
ALERTING. 

002997 03-04 
BOMBESIN ALTERS BEHAVIORAL THERMOREGULATION IN FISH. 

003026 03-04 
BEHAVIORAL AND METABOLIC ALTERATIONS IN PROGENY Of 
METHADONE-TREATED RATS. (PH.D. DISSERTATION). 

003113 03-04 
A RADIOIMMUNOASSAY fOR EPENDYMINS BETA AND GAMMA: TWO 
GOLDFISH BRAIN PROTEINS INVOLVED IN BEHAVIORAL PLASTICITY. 

003677 04-01 
DOM AND RELATED 2,5 DIMETHOXY-4-ALKYLPHENYLISOPROPYLAMINES: 
BEHAVIORAL AND SEROTONIN-RECEPTOR PROPERTIES. 

003690 04-02 
COMPARATIVE ANALGESIC, BEHAVIORAL. AND DEPENDENCE PROPERTIES 
Of MORPHINE AND 

METHOXYLPHENYLCARBAMOYLDIETHYLAMINOPROPIOPHENONEOXIME 
HCL. 

003707 04-02 
BEHAVIORAL AND REGIONAL NEUROCHEMICAL SEQUELAE Of 
HIPPOCAMPAL DESTRUCTION IN THE RAT. 

003721 04-03 
THE EffECT Of SMALL DOSES Of HALOPERIDOL AND CLOZAPINE ON 
BEHAVIORAL SHIfTS IN CATS, ARISING AfTER CESSATION Of 
ELECTRICAL-STIMULATION Of THE CAUDATE-NUCLEUS. 

004067 04-04 
BEHAVIORAL AND BIOCHEMICAL- STUDIES Of THE SCOPOLAMINE-INDUCED 
REVERSAL Of NEUROLEPTIC ACTIVITY. 

004195 04-04 
PHYSIOLOGICAL AND BEHAVIORAL APPROACHES TO THE STUDY Of THE 
QUASI-MORPHINE WITHDRAWAL- SYNDROME. 

004242 04-04 
A MICROCOMPUTER SYSTEM fOR THE CONTROL Of BEHAVIORAL 
EXPERIMENTS. 

004287 04-06 
BEHAVIORAL-ACTIVITY 

NALOXONE REVERSIBLE EffECTS Of D ALA2-MET5-ENKEPHAL1NAMIDE- 
INDUCED BEHAVIORAL-ACTIVITY IN RATS. 

000402 01-04 
COMPARISON Of BIOLOGICAL-ACTIVITY AND BEHAVIORAL-ACTIVITY Of 
ALPHA AND GAMMA MELANOCYTE-STIMUIATING-HORMONES. 
(UNPUBLISHED PAPER). 

001398 02-03 
THE EffECT Of NEUROPEPTIDE fRAGMENTS Of ADRENOCORTICOTROPIN 
AND VASOPRESSIN ON BEHAVIORAL-ACTIVITY IN RATS. 

001812 02-04 
BEHAVIORAL-ANALYSIS 

MORPHINE VERSUS HALOPERIDOL CATALEPSY IN THE RAT: A 
BEHAVIORAL-ANALYSIS Of POSTURAL SUPPORT MECHANISMS. 

000376 01-04 
BEHAVIORAL-ANALYSIS Of AMYGDALOID KINDLING IN BEAGLE-DOGS 
AND THE EffECTS Of CLONAZEPAM, DIAZEPAM, PHENOBARBITAL, 
DIPHENYLHYDANTOIN, AND FLUNARIZINE ON SEIZURE 
MANIFESTATION. 

000496 01-04 
BEHAVIORAL-ASPECT 

MECHANISM-OF-ACTION OF THE BENZODIAZEPINES: BEHAVIORAL- 
ASPECT. 

000468 01-04 
BEHAVIORAL-ASPECTS 

THE ROLE OF NICOTINE IN THE BEHAVIORAL-ASPECTS Of CIGAREHE 
SMOKING. 

004575 04-14 
BEHAVIORAL-CHANGES 

ENDOCRINE CHANGES AND BEHAVIORAL-CHANGES IN DEPRESSION AfTER 
THYROTROPIN-RELEASING-HORMONE (TRH): ALTERATION BY 
PRETREATMENT WITH THYROID-HORMONES. 

002259 02-13 



IT 



fe 



S-47 



Subject Index 



Psychopharmacology Abstracts 



BEHAVIORAL-CHANGES AND BIOCHEMICAL-CHANGES AFTER 
HIPPOCAMPAL DAMAGE. (PH.D. DISSERTATION). 

003069 03-04 
BEHAVrORAL-CONSEQUENCES 

LARGE-DOSES OF VITAMINS AND BEHAVIORAL-CONSEQUENCES. (PH.D. 
DISSERTATION). 

001633 02-04 
BEHAVIORAL-CONSEQUENCES OF LONG-TERM-TREATMENT WITH 
NEUROLEPTIC-DRUGS. 

001661 02-04 
BEHAVIORAL-CONSIDERATIONS 

RAPID TREATMENT OF ACUTE PSYCHOTIC-SYMPTOMS WITH HIGH-DOSE 
AND LOW-DOSE HALOPERIDOL: BEHAVIORAL-CONSIDERATIONS. 

003346 03-1 1 
BEHAVIORAL-CORRELATES 

BEHAVIORAL-CORRELATES AND BIOCHEMICAL-CORRELATES AFTER 
HALOPERIDOL AND CLOZAPINE LONG-TERM-TREATMENT. 

001422 02-03 
BEHAVIORAL-DEFICIENCIES 

PHARMACOTHERAPY FOR AGE-RELATED BEHAVIORAL-DEFICIENCIES. 

003391 03-11 
BEHAVIORAL-DEFICIT 

PHENYLACETATE AND THE ENDURING BEHAVIORAL-DEFICIT IN 
EXPERIMENTAL PHENYLKETONURIA. 

000388 01-04 
ABNORMAL MATURATION OF CEREBRAL-CORTEX AND BEHAVIORAL- 
DEFICIT IN ADULT RATS AFTER NEONATAL ADMINISTRATION OF 
ANTIBODIES TO GANGLIOSIDE. 

003025 03-04 
BEHAVIORAL-DEPRESSION 

BEHAVIORAL-DEPRESSION AND ITS NEUROCHEMICAL-CORRELATES AT 
HIGH-DOSES OF D-AMPHETAMINE IN RATS 

001601 02-04 
BEHAVIORAL-DESENSITIZATION 

BEHAVIORAL-DESENSITIZATION OF PHOBIC-ANXIETY USING THIOPENTAL- 
SODIUM. 

002352 02-14 
BEHAVIORAL-DISORDERS 

PLASMA CHLORPROMAZINE CONCENTRATIONS IN CHILDREN WITH 
BEHAVIORAL-DISORDERS AND MENTAL-ILLNESS. 

000717 01-11 
INVESTIGATION INTO THE EFFECT OF FLUPHENAZINE-HCL (LYORODIN) IN 
CHILDREN WITH BEHAVIORAL-DISORDERS BY MEANS OF 
PSYCHOPHYSIOLOGICAL PARAMETERS 

003344 03-11 
POLYPHARMACY REGIMEN AS AN EXACERBATING RISK IN THERAPY- 
RESISTANT EPILEPTIC-SEIZURES AND BEHAVIORAL-DISORDERS. 

004720 04-17 
BEHAVIORAL-DISTURBANCES 

BEHAVIORAL-DISTURBANCES IN PSYCHIATRY: A THERAPEUTIC 
APPROACH. 

002321 02-14 
BEHAVIORAL-EFFECTS 

INHIBITION OF BEHAVIORAL-EFFEQS OF COCAINE BY AQINOMYCIN-D IN 
RATS. 

000346 01-04 
ENHANCEMENT OF THE BEHAVIORAL-EFFEQS OF 2,5 DIMETHOXY-4- 
METHYLAMPHETAMINE (DOM) BY PRETREATMENT WITH P 
CHLOROPHENYLALANINE. 

000364 01-04 
THE INFLUENCE OF 5 HT-RECEPTOR BLOCKING-AGENTS ON THE 
BEHAVIORAL-EFFECTS OF ANALGESICS IN RATS. 

000429 01-04 
BEHAVIORAL-EFFEaS AND ELECTROCORTICAL-EFFECTS AFTER 
INTRASTRIATAL CEFAZOLIN IN RATS ARE ANTAGONIZED BY DRUGS 
ENHANCING GABAERGIC TRANSMISSION. 

000443 01-04 
NALOXONE OVERCOMES THE DOPAMINERGIC, EEG, AND BEHAVIORAL- 
EFFECTS OF GAMMA HYDROXYBUTYRATE. 

000478 01-04 
CHRONIC ADMINISTRATION OF HALOPERIDOL DURING DEVELOPMENT: 
BEHAVIORAL-EFFECTS AND PSYCHOPHARMACOLOGICAL-EFFECTS. 

000481 01-04 
BEHAVIORAL-EFFECTS OF ETHYNYL ESTROGENS IN THE FEMALE RAT. 

000483 01-04 
DEXTROAMPHETAMINE: COGNITIVE AND BEHAVIORAL-EFFEaS IN 
NORMAL AND HYPERACTIVE-BOYS AND NORMAL ADULT MALES. 

00071601-11 
BEHAVIORAL-EFFEQS OF DRUGS: THE ROLE OF THE STIMULUS 
REINFORCER CONTINGENCY. (PH.D. DISSERTATION). 

001537 02-03 
BEHAVIORAL-EFFECTS, ANTIDOPAMINERGIC-EFFECTS, AND PROHYPNOTIC- 
EFFECTS OF NEUROLEPTICS DURING AND AFTER PROLONGED 
TREATMENT. 

001577 02-04 
BEHAVrORAL-EFFECTS AND ELEQROPHYSIOLOGICAL-EFFEQS OF OPIOID- 
PEPTIDES IN CATS. 

001612 02-04 
BEHAVIORAL-EFFECTS OF HASHISH IN MICE: II. NURSING-BEHAVIOR AND 
DEVELOPMENT OF THE SUCKLINGS. 

001626 02-04 



BRAIN LOCATIONS CONTROLLING THE BEHAVIORAL-EFFECTS OF CHRONIC 
AMPHETAMINE INTOXICATION. 

001653 02-04 
DIFFERENT BEHAVIORAL-EFFECTS FOLLOWING INTRACEREBRAL, 
INTRACEREBROVENTRICULAR OR INTRAPERITONEAL INJEQION OF 
NALOXONE IN THE RAT. 

001665 02-04 
ENHANCEMENT OF 5 HYDROXYTRYPTAMINE-INDUCED BEHAVIORAL- 
EFFECTS FOLLOWING CHRONIC ADMINISTRATION OF ANTIDEPRESSANT- 
DRUGS. 

001667 02-04 
NEUROCHEMICAL-EFFECTS AND BEHAVIORAL-EFFECTS OF CHRONIC D- 
AMPHETAMINE TREATMENT IN GENETICALLY OBESE (OBOB) MICE 
(PH.D. DISSERTATION). 

001739 02-04 
BEHAVIORAL-EFFECTS OF HASHISH IN MICE: III. SOCIAL-INTERAQIONS 
BETWEEN TWO RESIDENTS AND AN INTRUDER MALE. 

001776 02-04 
BEHAVIORAL-EFFECTS OF HASHISH IN MICE: I. SOCIAL-INTERAQIONS 

AND NEST-BUILDING-BEHAVIOR OF MALES. 

001777 02-04 
BEHAVIORAL-EFFECTS OF DOPAMINE AGONISTS ACROSS THE ESTROUS- 

CYCLE IN RATS 

001792 02-04 
BEHAVIORAL-EFFECTS AND SUBJEQIVE-EFFEQS OF BETA-ADRENERGIC 
BLOCKADE IN PHOBIC-SUBJEQS. 

002060 02-10 
MOOD AND BEHAVIORAL-EFFEQS OF PHYSOSTIGMINE ON HUMANS ARE 
ACCOMPANIED BY ELEVATIONS IN PLASMA BETA ENDORPHIN AND 
CORTISOL 

002280 02-13 
BIOCHEMICAL-EFFECTS AND BEHAVIORAL-EFFECTS OF ACUTE ETHANOL IN 
RATS AT DIFFERENT ENVIRONMENTAL TEMPERATURES. 

002864 03-03 
THE ROLE OF CALCIUM AND DOPAMINE MEMBRANE CARRIER IN 

MEDIATING THE BEHAVIORAL-EFFECTS AND BIOCHEMICAL-EFFECTS OF 
AMPHETAMINE. (PH.D. DISSERTATION). 

002996 03-04 
A CHARACTERIZATION OF THE BEHAVIORAL-EFFEQS OF LEVO ALPHA 
ACETYLMETHADOL IN THE RAT AND IN THE PIGEON. (PH.D. 
DISSERTATION) i 

003047 03-04 
2,4,5 TRICHLOROPHENOXYACETIC-ACID CAUSES BEHAVIORAL-EFFEQS IN 
CHICKENS AT ENVIRONMENTALLY RELEVANT DOSES. I 

003079 03-04 I 
SUPERSENSITIVITY TO THE BEHAVIORAL-EFFEQS OF OPIATE 
ANTAGONISTS 

003096 03-04 '\ 
THE RELATIONSHIP BETWEEN THE ACUTE BEHAVIORAL-EFFEQS OF 
NARCOTIC ANTAGONISTS AND THE NARCOTIC DEPENDENT STATE. 

003106 03-04 , 
BEHAVIORAL-EFFECTS OF METHADONE IN SCHIZOPHRENIC-PATIENTS. ' 

(X)3178 03-08 
BEHAVIORAL-EFFEQS AND BIOLOGICAL-EFFEQS OF ACUTE BETA 
ENDORPHIN INJEQION IN SCHIZOPHRENIC-PATIENTS AND DEPRESSED- 
PATIENTS 

003357 03-11 
THE BEHAVIORAL-EFFECTS OF D-AMPHETAMINE ALONE AND IN 
COMBINATION WITH ACUTE AND CHRONIC MORPHINE TREATMENTS IN | 
RATS. 

003915 04-03 
A COMMON MECHANISM FOR LYSERGIC-ACID, INDOLEALKYLAMINE AND 
PHENETHYLAMINE HALLUCINOGENS: SEROTONERGIC MEDIATION OF 
BEHAVIORAL-EFFECTS IN RATS. 

004007 04-03 
REDUQION IN OPIATE AQIVATION AFTER CHRONIC 

ELEQROCONVULSIVE-SHOCK - POSSIBLE ROLE FOR ENDORPHINS IN 
THE BEHAVIORAL-EFFEQS OF CONVULSIVE-SHOCK-TREATMENT. 
(UNPUBLISHED PAPER). 

004154 04-04 
SAME OR DIFFERENT? AN EXPLORATION OF THE BEHAVIORAL-EFFEQS OF 
BENZAMIDES. 

004207 04-04 
INTRACEREBRAL SUBSTANCE-P IN MICE; BEHAVIORAL-EFFEQS AND 
NARCOTIC-AGENTS. 

004218 04-04 
BEHAVIORAL-EFFEQS OF SELF-ADMINISTERED COCAINE: RESPONDING 
MAINTAINED ALTERNATELY BY COCAINE AND ELECTRIC-SHOCK IN 
SQUIRREL-MONKEYS. 

004225 04-04 
CANNABINOIDS. I. BEHAVIORAL-EFFEQS. 

004228 04-04 
BEHAVIORAL-EVENTS 

BRAIN GLUCOCORTICOID-RECEPTOR: CORRELTVTIOn OF IN VIVO UPTAKE 
OF CORTICOSTERONE WITH BEHAVIORAL-EVENTS, ENDOCRINE-EVENTS, 
AND NEUROPHARMACOLOGICAL EVENTS. 

002515 02-17 



S-48 



VOLUME 19, SUBJECT INDEX 



Subject Index 



BEHAVIORAL-EVIDENCE 

CHRONIC AMPHETAMINE ADMINISTRATION TO CATS: BEHAVIORAL- 
EVIDENCE AND NEUROCHEMICAL EVIDENCE FOR DECREASED CENTRAL 
SEROTONERGIC FUNCTION. 

00049) 01-04 
NEUROCHEMICAL EVIDENCE AND BEHAVIORAL-EVIDENCE FOR A 
SELECTIVE PRESYNAPTIC DOPAMINE-RECEPTOR AGONIST, 

002236 02-) 3 
BEHAVIORAL-EVIDENCE THAT SUBSTANCE-P MAY BE A SPINAL-CORD 
SENSORY NEUROTRANSMITTER. 

004200 04-04 
BEHAVIORAL-FACILITATION 

BEHAVIORAL-FACILITATION FOLLOWING CHRONIC ADMINISTRATION OF N 
N PROPYLNORAPOMORPHINE. 

001822 02-04 
BEHAVIORAL-INTERACTIONS 

BEHAVIORAL-INTERACTIONS BETV\/EEN OPIATE AND ANTIEPILEPTIC-DRUGS 
IN THE MOUSE. 

004155 04-04 
BEHAVIORAL-INTERVENTION 

BEHAVIORAL-INTERVENTION FOR SELF-STIMULATORY, AHENDING AND 
SEIZURE BEHAVIOR IN A CEREBRAL-PALSIED-CHILD. 

002104 02-11 
BEHAVIORAL-NEUROCHEMISTRY 

BEHAVIORAL-NEUROCHEMISTRY OF BENZODIAZEPINES. 

000991 01-17 
BEHAVIORAL-PHARMACOLOGY 

BEHAVIORAL-PHARMACOLOGY AND THE STIMULUS CONTROL OF 
BEHAVIOR. 

00038) 0)-04 
CUMULATIVE DOSE RESPONSE-CURVES IN BEHAVIORAL- 
PHARMACOLOGY. 

001883 02-06 
ADVANCES IN BEHAVIORAL-PHARMACOLOGY. VOL. 2. 

002364 02-14 
BEHAVIORAL-PHARMACOLOGY OF TETRAHYDROCANNABINOL 
CONVULSIONS IN RABBITS. 

004288 04-06 
BEHAVIORAL-PHARMACOTHERAPY 

A COMBINED BEHAVIORAL-PHARMACOTHERAPY APPROACH TO 
OBSESSIVE-COMPULSIVE-DISORDERS. 

002082 02-10 
BEHAVIORAL-PREDICTORS 

BEHAVIORAL-PREDICTORS OF AMITRIPTYLINE RESPONSE IN DEPRESSION. 

003253 03-09 
BEHAVIORAL-PROFILE 

EEG AND BEHAVIORAL-PROFILE OF FLUTROLINE (CP-36-584), A NOVEL 
ANTIPSYCHOTIC-DRUG. 

001071 02-02 
BEHAVIORAL-RATING-SCALES 

DESIGN ASPECTS OF CLINICAL-TRIALS WITH ERGOT ALKALOIDS: A 
COMPARISON OF TWO GERIATRIC BEHAVIORAL-RATING-SCALES. 

002512 02-16 
BEHAVIORAL-REACTIONS 

ON CORRELATION OF BEHAVIORAL-REACTIONS AND NEURONAL ACTIVITY 
IN THE HYPOTHALAMUS UNDER SUBCUTANEOUS GASTRIN INJECTION. 

002892 03-03 
THE EFFECT OF PROPYLNORANTIFEIN ON BEHAVIORAL-REACTIONS, 
ADRENOCORTICAL ACTIVITY, AND ENERGY METABOLISM IN THE 
ANIMAL BRAIN. 

004075 04-04 
BEHAVIORAL-RESPONSES 

RELATIONSHIPS BETWEEN SELECTIVE DENERVATION OF DOPAMINE 
TERMINAL-FIELDS IN THE ANTERIOR-FOREBRAIN AND BEHAVIORAL- 
RESPONSES TO AMPHETAMINE AND APOMORPHINE. 

000384 01-04 
EFFECTS OF CHRONIC ADMINISTRATION OF DELTA9 
TETRAHYDROCANNABINOL ON THE CARDIOVASCULAR SYSTEM, AND 
PRESSOR AND BEHAVIORAL-RESPONSES TO BRAIN-STIMULATION IN 
FREELY-MOVING-RATS. 

000417 01-04 
EFFECTS OF DELTA9 TETRAHYDROCANNABINOL ON THE 
CARDIOVASCULAR-SYSTEM, AND PRESSOR AND BEHAVIORAL- 
RESPONSES TO BRAIN-STIMULATION IN RATS. 

001681 02-04 
GONADECTOMY AND SEX-DIFFERENCES IN THE BEHAVIORAL-RESPONSES 
TO AMPHETAMINE AND APOMORPHINE OF RATS. 

003084 03-04 
BEHAVIORAL-REVERSAL 

5,7 DIHYDROXYTRYPTAMINE-INDUCED MOUSE-KILLING AND 
BEHAVIORAL-REVERSAL WITH VENTRICULAR ADMINISTRATION OF 
SEROTONIN IN RATS. 

001562 02-04 
BEHAVIORAL-SENSITIVITY 

THE INFLUENCE OF GENOTYPE AND SEX ON BEHAVIORAL-SENSITIVITY TO 
NICOTINE IN MICE 

001648 02-04 
BEHAVIORAL-SENSITIZATION 

DRUG ENVIRONMENT INTERACTION: CONTEXT DEPENDENCY OF COCAINE- 
INDUCED BEHAVIORAL-SENSITIZATION. 

002866 03-03 



BEHAVIORAL-STIMULATION 

NEUROPHARMACOLOGICAL-STUDIES OF PHENCYCLIDINE-INDUCED 
BEHAVIORAL STIMULATION IN MICE. 

001622 02-04 
BEHAVIORAL-STUDIES 

BEHAVIORAL-STUDIES AND NEUROCHEMICAL-STUDIES OF LESCH-NYHANS- 
SYNDROME, 

001743 02-04 
PHYSIOLOGICAL- STUDIES AND BEHAVIORAL-STUDIES WITH MUSCIMOL. 

002538 02-17 
BEHAVIORAL-SUPERSENSITIVITY 

SELECTIVE INHIBITION OF MESOLIMBIC BEHAVIORAL-SUPERSENSITIVITY 
BY NALOXONE. 

000467 01-04 
INDUCTION OF BEHAVIORAL-SUPERSENSITIVITY TO APOMORPHINE BY 
DFP TREATMENT. 

004099 04-04 
THE EFFECT OF CHRONIC LEVODOPA ON HALOPERIDOL-INDUCED 
BEHAVIORAL-SUPERSENSITIVITY IN THE GUINEA-PIG. 

004249 04-04 
BEHAVIORAL-SUPPRESSION 

DORSAL TEGMENTAL BUNDLE DESTRUCTION: EFFECTS ON OPERANT- 
BEHAVIOR, BRAIN CATECHOLAMINE LEVELS, AND BEHAVIORAL- 
SUPPRESSION PRODUCED BY ADRENERGIC AGONISTS. 

001726 02-04 
BEHAVIORAL-SYNDROME 

RELATIVE POTENCY OF AMPHETAMINE ISOMERS IN CAUSING THE 
SEROTONIN BEHAVIORAL-SYNDROME IN RATS. 

003094 03-04 
BEHAVIORAL-TEST 

BEHAVIORAL-TEST FOR DETECTION OF SUBCLINICAL BRAIN-DAMAGE: AN 
EXPERIMENTAL MODEL. 

003120 03-04 
BEHAVIORAL-TESTING 

CYCLOPHOSPHAMIDE-INDUCED SPERMATOGENIC EFFECTS DETEQED IN 
THE Fl -GENERATION BY BEHAVIORAL-TESTING. 

003121 03-05 
BEHAVIORAL-TESTS 

EFFECT OF DRUGS ON LEARNING AND MEMORY PROCESSES IN SIMPLE 
BEHAVIORAL-TESTS. 

000809 01-14 
BEHAVIORAL-THERAPY 

PSYCHOPHARMACOLOGY AND BEHAVIORAL-THERAPY. 

003584 03-17 
BEHAVIORAL-TOLERANCE 

FIRST DOSE BEHAVIORAL-TOLERANCE TO PHENCYCLIDINE ON FOOD 
REWARDED BAR-PRESSING-BEHAVIOR IN THE RAT. 

000462 01-04 
ELECTROENCEPHALOGRAPHIC AND BEHAVIORAL-TOLERANCE TO AND 
CROSS-TOLERANCE BETWEEN D ALA2-METHI0NINE-ENKEPHALINAMIDE 
AND MORPHINE IN THE RAT. 

004038 04-03 
BEHAVIORAL-TREATMENT 

BEHAVIORAL-TREATMENT AND PHARMACOLOGICAL-TREATMENT OF 
OBSESSIVE-COMPULSIVE-DISORDERS. 

000657 01-10 
BEHAVIORAL-TREATMENTS 

DOUBLE-BLIND EVALUATION OF REINFORCING AND ANORECTIC-ACTIONS 
OF WEIGHT-CONTROL MEDICATIONS: INTERACTION OF 
PHARMACOLOGICAL-TREATMENT AND BEHAVIORAL-TREATMENTS. 

002314 02-14 
BEHAVIORALLY-SELECTIVE 

NOREPINEPHRINE UPTAKE INHIBITORS AS BIOCHEMICALLY-SELECTIVE 
AND BEHAVIORALLY-SELECTIVE ANTAGONISTS OF THE LOCOMOTOR- 
STIMULATION INDUCED BY INDIRECTLY ACTING SYMPATHOMIMETIC- 
AMINES IN MICE. 

000492 01-04 
BEHAVIORS 

EFFECTS OF PHENCYCLIDINE AND METHYLPHENIDATE ON D- 
AMPHETAMINE-INDUCED BEHAVIORS IN RESERPINE PRETREATED RATS. 

001616 02-04 
DIFFERENTIAL DOPAMINERGIC FUNCTION IN YOUNG AND OLD FEMALE 
RATS AS MEASURED BY THREE BEHAVIORS. 

001683 02-04 
DRUG-EFFECTS ON SCHEDULE-INDUCED BEHAVIORS. (PH.D. 
DISSERTATION). 

001786 02-04 
ANIMAL-MODEL OF PSYCHOSIS: HALLUCINATORY BEHAVIORS IN 
MONKEYS DURING THE LATE STAGE OF CONTINUOUS AMPHETAMINE 
INTOXICATION. 

002988 03-04 
A PRIMATE ANALOGL" OF AMPHETAMINE-INDUCED BEHAVIORS IN 
HUMANS. 

003006 03-04 
GENETIC VARIATIONS IN MIDBRAIN DOPAMINE CELL NUMBER: PARALLEL 
WITH DIFFERENCES IN RESPONSES TO DOPAMINERGIC AGONISTS AND 
IN NATURALISTIC BEHAVIORS MEDIATED BY CENTRAL DOPAMINERGIC- 
SYSTEMS. (UNPUBLISHED PAPER). 

004112 04-04 



i'5 






I 
I 



S-49 



Subject Index 



Ptychopharmocology Abttractt 



HIPPOCAMPAL INVOLVEMENT IN THE PHARMACOLOGIC INDUQION OF 
WITHDRAWAL-LIKE BEHAVIORS. 

004140 04-04 
PERIPHERAL-CORRELATES OF SEROTONERGICALLY-INFLUENCED 
BEHAVIORS IN VERVET-MONKEYS (CERCOPITHECUS-AETHIOPS- 
SABAEUS). 

004204 04-04 
BEHAVIOUR 

BETA-ADRENOCEPTOR ANTAGONISTS: STUDIES ON BEHAVIOUR (DELAYED 
DIFFERENTIATION) IN THE MONKEY (MACACA-MULAHA). 

000440 01-04 
EPILEPSY: NEUROTRANSMIHER, BEHAVIOUR AND PREGNANCY. 

002466 02-15 
EFFECTS OF NEONATAL TESTOSTERONE AND ESTROGEN ON OPEN-FIELD 
BEHAVIOUR IN RATS. 

003098 03-04 
EFFECTS OF LITHIUM ON BEHAVIOUR AND CENTRAL MONOAMINES. 

004110 04-04 
ATTENUATION OF DELTA9 TETRAHYDROCANNABINOL-INDUCED 
WITHDRAWAL-LIKE BEHAVIOUR BY DELTA9 
TETRAHYDROCANNABINOL. 

004243 04-04 
ON MONOAMINERGIC-INTERACTION WITH BEHAVIOUR MODIFYING 
PEPTIDE-HORMONES. 

004700 04-17 
BEHAVIOUR-THERAPY 

CONTROLLED-TRIAL OF BEHAVIOUR-THERAPY, PHARMACOTHERAPY. AND 
THEIR COMBINATION IN THE TREATMENT OF OBESITY. 

000725 01-11 
OBSESSIVE-SYMPTOM RESPONSE TO BEHAVIOUR-THERAPY AND TO 
ANTIDEPRESSANT-DRUGS. 

002084 02-10 
BEHAVIOURAL 

BEHAVIOURAL AND NEUROCHEMICAL PROPERTIES OF 1 1 INDOL-3- 
YLMETHYLPIPERID-4-YL-3-BENZ0YLUREA (WY-25093) IN RODENTS. 

003686 04-02 
BEHAVIOURAL-ACTIONS 

SYNAPTIC AND BEHAVIOURAL-ACTIONS OF ANTIDEPRESSANT-DRUGS: 
FURTHER THOUGHTS ON THE IMPLICATIONS FOR THEORIES OF 
DEPRESSION. 

003229 03-09 
BEHAVIOURAL-ANALYSIS 

BEHAVIOURAL-ANALYSIS OF FEEDING: IMPLICATIONS FOR THE 
PHARMACOLOGICAL MANIPULATION OF FOOD INTAKE IN ANIMALS 
AND MAN. 

002527 02-17 
BEHAVIOURAL-CHANGES 

GABA DEPLETION AND BEHAVIOURAL-CHANGES PRODUCED BY 
INTRAVENTRICULAR PUTRESCINE IN CHICKS. 

000218 01-03 
BEHAVIOURAL-CHANGES INDUCED BY N,N DIMETHYLTRYPTAMINE IN 
RODENTS. 

000413 01-04 
BEHAVIOURAL-CHANGES IN ADULT RATS FOLLOWING ADMINISTRATION 
OF ANTIBODIES AGAINST BRAIN GANGLIOSIDES. 

003071 03-04 
BEHAVIOURAL-DESPAIR 

PRESYNAPTIC ALPHA-ADRENOCEPTORS AND THE AQION OF TRICYCLIC- 
ANTIDEPRESSANT DRUGS IN BEHAVIOURAL-DESPAIR IN RATS. 

001829 02-04 
BEHAVIOURAL-EFFECTS 

DIAZEPAM IN COMBINATION WITH TACRINE DERIVATIVES ANTAGONIZES 
BEHAVIOURAL-EFFECTS OF ANTICHOLINERGIC PSYCHOTOMIMETICS IN 
RATS. 

000420 01-04 
OXOTREMORINE BEHAVIOURAL-EFFEaS AS A SCREENING-TEST IN MICE. 

001072 02-02 
STUDIES ON THE BIOCHEMICAL-EFFECTS AND BEHAVIOURAL-EFFEQS OF 
ORAL NICOTINE. 

001115 02-03 
THE INFLUENCE OF ANTERIOR NEOSTRIATAL LESIONS ON THE 
BEHAVIOURAL-EFFECTS OF SPIROPERIDOL IN RATS. 

001702 02-04 
BEHAVIOURAL-EFFECTS AND ENDOCRINE-EFFEaS OF NALTREXONE IN 
MALE TALAPOIN-MONKEYS. 

001718 02-04 
ENHANCED BEHAVIOURAL-EFFECTS, ELECTROCORTICAL-EFFEaS AND 
HYPERTHERMIC-EFFECTS OF SEROTONIN-LIKE AGENTS AFTER 
IMPAIRMENT OF SEROTONIN TRANSMISSION IN FOWL BRAIN. 

001733 02-04 
BEHAVIOURAL-EFFECTS OF ACETYLSALICYLIC-ACID, PARACETAMOL, 
CAFFEINE, GUAIPHENESIN AND THEIR COMBINATIONS. 

001805 02-04 
ELECTROENCEPHALOGRAPHIC-EFFECTS AND BEHAVIOURAL-EFFEQS OF 
SODIUM-VALPROATE IN PATIENTS WITH PHOTOSENSITIVE EPILEPSY. A 
SINGLE-DOSE TRIAL. 

002154 02-11 
AN OBSERVATIONAL METHOD FOR QUANTIFYING THE BEHAVIOURAL- 
EFFEaS OF DOPAMINE AGONISTS: CONTRASTING-EFFEQS OF D- 
AMPHETAMINE AND APOMORPHINE. 

002484 02-16 



A COMPARISON BETWEEN SOME BIOCHEMICAL-EFFEaS AND 
BEHAVIOURAL-EFFECTS PRODUCED BY NEUROLEPTICS. 

004116 04-04 
BEHAVIOURAL-MANIPULATION 

FOOTSHOCK ANALGESIA: PREVENTION BY BEHAVIOURAL-MANIPULATION 
BUT NOT BY NALOXONE. 

003073 03-04 
BEHAVIOURAL-RESPONSES 

BEHAVIOURAL-RESPONSES TO STEREOTACTICALLY CONTROLLED 
INJECTIONS OF MONOAMINE NEUROTRANSMIHERS INTO THE 
ACCUMBENS AND CAUDATE-PUTAMEN NUCLEI. 

001708 02-04 
EFFECT OF ACUTE AND CHRONIC TRIIODOTHYRONINE (T3) 
ADMINISTRATION TO RATS ON CENTRAL 5 HT AND DOPAMINE- 
MEDIATED BEHAVIOURAL-RESPONSES AND RELATED BRAIN- 
BIOCHEMISTRY. 

002951 03-04 
BEHAVIOURAL-RESPONSES TO DRUGS RELEASING 5 
HYDROXYTRYPTAMINE AND CATECHOLAMINES: EFFECTS OF 
TREATMENTS ALTERING PRECURSOR CONCENTRATIONS IN BRAIN. 

002990 03-04 
BEHAVIOURAL-SEQUELAE 

NEUROLEPTIC TREATMENT FOR A SUBSTANTIAL PROPORTION OF ADULT 
LIFE: BEHAVIOURAL-SEQUELAE OF 9 MONTHS HALOPERIDOL 
ADMINISTRATION. 

001858 02-05 
BEHAVIOURAL-STATE 

THE BEHAVIOURAL-STATE DURING CLIMAX (HATCHING) IN THE 
DOMESTIC-FOWL (GALLUS-DOMESTICUS) . 

001564 02-04 
BEHAVIOURAL-STRATEGIES 

ROLE OF THE NEOSTRIATAL DOPAMINERGIC-AQIVITY IN SEQUENCING 
AND SELECTING BEHAVIOURAL- STRATEGIES: FACILITATION OF 
PROCESSES INVOLVED IN SELECTING THE BEST STRATEGY IN A 
STRESSFUL-SITUATION. 

000366 01-04 
BEHAVIOURAL-STUDIES 

EVIDENCE FOR A GABAERGIC NIGROTHALAMIC PATHWAY IN THE RAT: I 
BEHAVIOURAL-STUDIES AND BIOCHEMICAL-STUDIES. 

000158 01-03 
EFFECT OF SINGLE AND REPEATED ELECTROCONVULSIVE-SHOCK ON 
SEROTONERGIC SYSTEM IN RAT-BRAIN - II. BEHAVIOURAL-STUDIES. 

001697 02-04 
BEHAVIOURAL-SYNDROMES 

EFFECTS OF THE POTENTIAL NEUROLEPTIC-PEPTIDE DES-TYRl-GAMMA- 
ENDORPHIN AND HALOPERIDOL ON APOMORPHINE-INDUCED 
BEHAVIOURAL-SYNDROMES IN RATS AND MICE. 

000441 01-04 
BEHAVIOURAL-TECHNIQUES 

EFFEaS OF ANXIETY REDUCTION BY BEHAVIOURAL-TECHNIQUES AND 
MEPROBAMATE ON CERTAIN PARAMETERS OF INFORMATION THEORY. 

003108 03-04 
BEHAVIOURS 

THE DIFFERENTIAL NEUROCHEMICAL-BASES OF THE BEHAVIOURS ELICITED 
BY SEROTONERGIC-AGENTS AND BY THE COMBINATION OF A 
MONOAMINE-OXIDASE-INHIBITOR AND L-DOPA. 

002976 03-04 
NEUROTENSIN BLOCKS CERTAIN AMPHETAMINE-INDUCED BEHAVIOURS. 

004111 04-04 
BELGIUM 

ABSTRACTS OF THE ANNUAL GENERAL CONFERENCE OF THE EUROPEAN- 
BRAIN-AND-BEHAVIOUR-SOCIETY, HELD AT LOUVAIN-LA-NEUVE, 
BELGIUM, ON NOVEMBER 13-15TH, 1980. 

003617 03-17 
BELIEFS 

THE INFLUENCE OF PATIENT BELIEFS ON COMPLIANCE TO THERAPY FOR 
DIABETES-MELLITUS. (PH.D. DISSERTATION) 

003631 03-17 
BENSERASIDE 

THE TREATMENT OF PARKINSONS-DISEASE USING A COMBINATION OF L- 
DOPA AND DECARBOXYLASE INHIBITORS (CARBIDOPA, BENSERASIDE). 
A CLINICAL AND BIOCHEMICAL COMPARATIVE INVESTIGATION. 

000712 01-11 
BENSERAZIDE 

EFFEQS OF BENSERAZIDE AND CARBIDOPA ON THE METABOLISM OF L 
TRYPTOPHAN BY ISOLATED RAT LIVER CELLS. 

002899 03-03 
BENSERAZIDE-HCL 

COMPARATIVE-STUDIES OF L-DOPA ALONE AND COMBINATION WITH A 
PERIPHERAL DOPA-DECARBOXYLASE INHIBITOR, BENSERAZIDE-HCL, ON 
PARKINSONS-DISEASE - PART II: PHARMACOKINETIC-STUDY. 

002309 02-13 
BENZAMIDE 

STEREOSELEaiVE AQIONS OF SUBSTITUTED BENZAMIDE DRUGS ON 
CEREBRAL DOPAMINE MECHANISMS. 

001301 02-03 
NEUROPSYCHOPHARMACOLOGICAL-STUDIES ON SOME BENZAMIDE 
DERIVATIVES. 

002220 02-13 



S-50 



VOLUME 19, SUBJECT INDEX 



Subject Index 



COMPARISON OF THE POTENCIES OF CLEBOPRIDE AND OTHER 

SUBSTITUTED BENZAMIDE DRUGS ON ISOLATED GASTROINTESTINAL 
TRACT OF THE GUINEA-PIG AND RAT. 

003928 04-03 
BENZAMIDES 

SODIUM-DEPENDENT INTERACTION OF BENZAMIDES WITH DOPAMINE- 
RECEPTORS. 

000285 01-03 
THE EFFECTS OF SUBSTITUTED BENZAMIDES ON FROG RECTUS- 
ABDOMINIS. 

001228 02-03 
CLINICAL-EXPERIENCE WITH SUBSTITUTED BENZAMIDES IN FRENCH- 
SPEAKING COUNTRIES. 

002036 02-09 
SAME OR DIFFERENT? AN EXPLORATION OF THE BEHAVIORAL-EFFECTS OF 
BENZAMIDES. 

004207 04-04 
BENZAZOCINES 

NARCOTIC ANTAGONIST PRECIPITATED ABSTINENCE: RELATIONSHIP TO 
WITHDRAWAL INDUCING BENZAZOCINES. (PH.D. DISSERTATION). 

001518 02-03 
BENZHEXOL 

A COMPARISON OF BIPERIDEN-HYDROCHLORIDE (AKINETON) AND 
BENZHEXOL (ARTANE) IN THE TREATMENT OF DRUG-INDUCED 
PARKINSONISM. 

002146 02-11 
BENZILATE 

QUINUCLIDINYL BENZILATE BINDING IN HOUSEFLY HEADS AND RAT- 
BRAIN. 

003868 04-03 
BENZOCTAMINE 

THE INFLUENCE OF BENZOCTAMINE ON DOPAMINE AND NOREPINEPHRINE 
CONTENTS OF THE SUBSTANTIA-NIGRA AND ON THE MUSCLE STRETCH 
REFLEX OF THE CAT. 

000054 01-03 
ACUTE EFFECT OF BENZOCTAMINE (10 MG). SODIUM- 
HYDROXYBUTYRATE (2 G) AND FENCAMFAMINE (10 MG) ON VERBAL- 
ASSOCIATIONS. 

000806 01-14 
BENZODIAZEPINE 

REDUCTION OF GAMMA AMINOBUTYRIC-ACID-MEDIATED (GABA) 
TRANSMISSION BY A CONVULSANT BENZODIAZEPINE. 

000015 01-02 
GABA BENZODIAZEPINE INTERACTIONS: PHYSIOLOGICAL, 
PHARMACOLOGICAL AND DEVELOPMENTAL ASPECTS. 

000103 01-03 
ANIMAL-MODELS OF ANXIETY AND BENZODIAZEPINE ACTIONS. 

000531 01-06 
EFFECTS OF AGE AND OTHER DRUGS ON BENZODIAZEPINE KINETICS. 

000681 01-11 
DIFFERENTIAL-EFFECTS ON BENZODIAZEPINE DISPOSITION BY DISULFIRAM 
AND ETHANOL. 

000789 01-13 
INTROVERSION AND SEVERITY OF THE BENZODIAZEPINE WITHDRAWAL. 

000923 01-17 
THE REGULATION OF GABA-RECEPTORS AS A POSSIBLE MECHANISM FOR 
GABA 1,4 BENZODIAZEPINE INTERACTIONS. (UNPUBLISHED PAPER). 

001012 02-01 
ETHANOL ENHANCES (3H)DIAZEPAM BINDING AT THE BENZODIAZEPINE 
GABA-RECEPTOR lONOPHORE COMPLEX. 

001154 02-03 
PHARMACOLOGICAL EVIDENCE AND BIOCHEMICAL-EVIDENCE FOR AN 
INTERACTION BETWEEN THE BENZODIAZEPINE AND GABA-RECEPTORS. 

001261 02-03 
GABA-MODULIN REGULATES SOLUBILIZED BENZODIAZEPINE AND GABA 
RECOGNITION SITES. (UNPUBLISHED PAPER). 

001263 02-03 
BENZODIAZEPINE BINDING IN CHICKEN RETINA AND ITS INTERACTION 
WITH GAMMA AMINOBUTYRIC-ACID. 

001287 02-03 
RENAL BENZODIAZEPINE BINDING INCREASES DURING 
DEOXYCORTICOSTERONE/SALT HYPERTENSION IN RATS. 

001430 02-03 
MULTIPLE BENZODIAZEPINE-RECEPTOR COMPLEXES: SOME 
BENZODIAZEPINE RECOGNITION SITES ARE COUPLED TO GABA- 
RECEPTORS AND lONOPHORES. 

001484 02-03 
CHARACTERIZATION OF BENZODIAZEPINE BINDING-SITES. (UNPUBLISHED 
PAPER). 

001503 02-03 
BENZODIAZEPINE BINDING-SITES: PROPERTIES AND MODULATION. 

(UNPUBLISHED PAPER). 

001504 02-03 
INFLUENCE OF BENZODIAZEPINE TRANQUILIZERS ON AMPHETAMINE- 
INDUCED LOCOMOTOR- STIMULATION IN MICE. 

001767 02-04 
INFLUENCE OF BENZODIAZEPINE TRANQUILIZERS ON SCOPOLAMINE- 

INDUCED LOCOMOTOR-STIMULATION IN MICE. 

001768 02-04 
CLINICAL AQIVITY OF A NEW BENZODIAZEPINE: CLOXAZOLAM. 

001904 02-07 



DOUBLE-BLIND CLINICAL ASSESSMENT OF ALPRAZOLAM, A NEW 
BENZODIAZEPINE DERIVATIVE, IN THE TREATMENT OF MODERATE TO 
SEVERE ANXIETY. 

002070 02-10 
THE REGULATION OF BENZODIAZEPINE RECOGNITION SITES BY 
ENDOGENOUS MODULATORS. 

002642 03-01 
RADIOHISTOCHEMICAL STUDIES OF BENZODIAZEPINE AND GABA- 
RECEPTORS AND THEIR INTERACTIONS. 

002644 03-01 
BENZODIAZEPINE RECOGNITION SITES ON GABA-RECEPTORS. 

002730 03-03 
THE EFFECTS OF A BENZODIAZEPINE ON THE HYPERPOLARIZING AND THE 
DEPOLARIZING RESPONSES OF HIPPOCAMPAL CELLS TO GABA 

002763 03-03 
IDENTIFICATION OF TWO BENZODIAZEPINE BINDING-SITES ON CELLS 
CULTURED FROM RAT-CEREBRAL-CORTEX. 

002820 03-03 
THE BENZODIAZEPINE GABA-CHLORIDE lONOPHORE-RECEPTOR COMPLEX: 
COMMON SITE OF MINOR-TRANQUILIZER ACTION. 

002857 03-03 
GABA-RECEPTORS REGULATE THE AFFINITIES OF ANIONS REQUIRED FOR 
BRAIN SPECIFIC BENZODIAZEPINE BINDING. 

002903 03-03 
BENZODIAZEPINE BINDING-SITES: PROPERTIES AND MODULATION. 

002912 03-03 
INTERACTION BETWEEN PURINE AND BENZODIAZEPINE: INOSINE 
REVERSES DIAZEPAM-INDUCED STIMULATION OF MOUSE 
EXPLORATORY-BEHAVIOR. 

002972 03-04 
BENZODIAZEPINE TREATMENT OF SPECIFIC ANXIETY STATES. 

003284 03-10 
SEVERE WITHDRAWAL-SYNDROME AFTER CESSATION OF 
BENZODIAZEPINE TREATMENT: SIX CLINICAL CASES. 

003505 03-15 
BENZODIAZEPINE WITHDRAWAL SYMPTOMS AND PROPRANOLOL. 

003543 03-15 
POSITRON-TOMOGRAPHY. A NEW METHOD FOR IN VIVO BRAIN STUDIES 
OF BENZODIAZEPINE, IN ANIMAL AND IN MAN. 

003564 03-16 
BENZODIAZEPINE ANTAGONISM BY HARMANE AND OTHER BETA 
CARBOLINES IN VITRO AND IN VIVO. 

004211 04-04 
IN VIVO EFFECTS OF TWO NOVEL ALKYLATING BENZODIAZEPINE, 
IRAZEPINE AND KENAZEPINE, 

004251 04-04 
ANXIOUS-DEPRESSIVE-SYNDROME. CLINICAL-STUDY OF A NEW 
BENZODIAZEPINE, PRAZEPAM. 

004354 04-09 
PRAZEPAM: A NEW BENZODIAZEPINE FOR THE TREATMENT OF ANXIOUS- 
DEPRESSIVE STATES. 

004419 04-10 
CLINICAL USE OF A NEW BENZODIAZEPINE, PRAZEPAM. 

004421 04-10 
PHARMACOLOGICAL PECULIARITIES OF A BENZODIAZEPINE/ATARACTIC- 
DRUG AND ITS THERAPEUTIC RELEVANCE: THE SPECIAL STATUS OF 
CLORAZEPATE-DIPOTASSIUM (TRANXILIUM) . 

004527 04-13 
EFFECTS OF A SHORT-ACTING BENZODIAZEPINE ON BRAIN ELECTRICAL- 
ACTIVITY DURING SLEEP. 

004568 04-14 
PROLONGED BENZODIAZEPINE COMA. 

004653 04-15 
SALIVA BENZODIAZEPINE LEVELS AND CLINICAL OUTCOME IN 
DETOXIFYING ALCOHOLIC-PATIENTS. 

004671 04-16 
A SENSITIVE BENZODIAZEPINE RADIOIMMUNOASSAY OF BROAD 
SPECIFICITY. 

004693 04-16 
BENZODIAZEPINE-LIKE 

BRAIN-SPECIFIC BENZODIAZEPINE-RECEPTORS AND PUTATIVE 
ENDOGENOUS BENZODIAZEPINE-LIKE COMPOUNDS. 

000225 01-03 
PHARMACOLOGY OF 2 CHLOROBENZOYL-CHLORO-METHYL-NA- 
GLYCYLGLYCINANILIDE HYDRATE (45-0088-S), A COMPOUND WITH 
BENZODIAZEPINE-LIKE PROPERTIES. 

003692 04-02 
BENZODIAZEPINE-RECEPTOR 

AUDIOGENIC-SEIZURES: INCREASED BENZODIAZEPINE-RECEPTOR BINDING 
IN A SUSCEPTIBLE STRAIN OF MICE. 

000252 01-03 
PURINES AS ENDOGENOUS LIGANDS OF THE BENZODIAZEPINE-RECEPTOR. 

000276 01-03 
CORRELATION BETWEEN BENZODIAZEPINE-RECEPTOR OCCUPATION AND 
ANTICONVULSANT EFFECTS OF DIAZEPAM. 

000450 01-04 
CHARACTERIZATION OF GABA-STIMULATED BENZODIAZEPINE-RECEPTOR 
BINDING. 

001309 02-03 












S-51 



Subject Index 



Psychopharmacology Abstracts 



DECREASED BENZODIAZEPINE-RECEPTOR DENSITY IN RAT-CEREBELLUM 
FOLLOWING NEUROTOXIC DOSES OF PHENYTOIN. 

001373 02-03 
BENZODIAZEPINE-RECEPTOR: LOCALIZATION BY PHOTOAFFINITY 
LABELING AND ISOLATION OF A POSSIBLE ENDOGENOUS LIGAND. 

001381 02-03 
HARMALINE-INDUCED TREMOR: THE BENZODIAZEPINE-RECEPTOR AS A 
SITE-OF-ACTION. 

001436 02-03 
1 METHYL-BETA-CARBOLINE (HARMANE), A POTENT ENDOGENOUS 
INHIBITOR OF BENZODIAZEPINE-RECEPTOR BINDING. 

001440 02-03 
INCREASED BENZODIAZEPINE-RECEPTOR NUMBER ELICITED IN VITRO BY A 
NOVEL PURINE, EMD-28422. 

001475 02-03 
MULTIPLE BENZODIAZEPINE-RECEPTOR COMPLEXES: SOME 
BENZODIAZEPINE RECOGNITION SITES ARE COUPLED TO GABA- 
RECEPTORS AND lONOPHORES. 

001484 02-03 
MODULATION BY PICROTOXIN AND IPTBO OF 3H FLUNITRAZEPAM 

BINDING TO THE GABA/ BENZODIAZEPINE-RECEPTOR COMPLEX OF RAT- 
CEREBELLUM. 

002775 03-03 
THE BENZODIAZEPINE-RECEPTOR: AN UPDATE. 

002833 03-03 
PENTOBARBITAL: DUAL-ACTIONS TO INCREASE BRAIN BENZODIAZEPINE- 
RECEPTOR AFFINITY. 

002896 03-03 
ACTION OF PYRAZOLOPYRIDINES AS MODULATORS OF 

(3H)FLUNITRAZEPAM BINDING TO THE GABA/BENZODIAZEPINE- 
RECEPTOR COMPLEX OF THE CEREBELLUM. 

002909 03-03 
A STEROID DERIVATIVE, R-5135, ANTAGONIZES THE GABA/ 
BENZODIAZEPINE-RECEPTOR INTERACTION . 

003851 04-03 
IN VITRO MODULATION BY AVERMECTIN-BIA OF THE GABA/ 
BENZODIAZEPINE-RECEPTOR COMPLEX OF RAT-CEREBELLUM. 

004023 04-03 
BENZODIAZEPINE-RECEPTOR: HETEROGENEITY IN RABBIT BRAIN. 

004060 04-03 
BENZODIAZEPINE-RECEPTORS 

DISSIMILAR EFFECTS OF NICOTINAMIDE AND INOSINE, PUTATIVE 
ENDOGENOUS LIGANDS OF THE BENZODIAZEPINE-RECEPTORS, ON 
PENTYLENETETRAZOL SEIZURES IN FOUR STRAINS OF MICE 

000173 01-03 
BRAIN-SPECIFIC BENZODIAZEPINE-RECEPTORS AND PUTATIVE 
ENDOGENOUS BENZODIAZEPINE-LIKE COMPOUNDS. 

000225 01-03 
PENTOBARBITAL POTENTIATES GABA-ENHANCED (3H) DIAZEPAM 
BINDING TO BENZODIAZEPINE-RECEPTORS. 

000275 01-03 
BRAIN-SPECIFIC BENZODIAZEPINE-RECEPTORS ARE LOCALIZED IN THE 
INNER PLEXIFORM LAYER OF RAT RETINA. 

000277 01-03 
BENZODIAZEPINE-RECEPTORS. 

000918 01-17 
TWO OR MORE CONFORMATIONS OF BENZODIAZEPINE-RECEPTORS 
DEPENDING ON GABA-RECEPTORS AND OTHER VARIABLES. 

001139 02-03 
STUDIES ON BENZODIAZEPINE-RECEPTORS. 

001502 02-03 
GABA-RECEPTORS AND BENZODIAZEPINE-RECEPTORS IN THE OFFSPRING 
OF DAMS RECEIVING DIAZEPAM: ONTOGENETIC-STUDIES. 

001849 02-05 
BENZODIAZEPINE-RECEPTORS: THE EFFECT OF GABA ON THEIR 
CHARACTERISTICS IN HUMAN BRAIN AND THEIR ALTERATION IN 
HUNTINGTONS-DISEASE. 

002163 02-11 

DIFFERENTIAL-EFFECTS OF KAINIC-ACID ON BENZODIAZEPINE-RECEPTORS, 

GABA-RECEPTORS, AND GABA-MODULIN IN THE CEREBELLAR-CORTEX. 

002477 02-16 
BENZODIAZEPINE-RECEPTORS: AUTORADIOGRAPHICAL AND 

IMMUNOCYTOCHEMICAL EVIDENCE FOR THEIR LOCALIZATION IN 
REGIONS OF GABAERGIC SYNAPTIC CONTACTS. 

002643 03-01 
BENZODIAZEPINE-RECEPTORS IN CHICK RETINA: DEVELOPMENT AND 
CELLULAR LOCALIZATION. 

002655 03-03 
BETA CARBOLINE-3-CARBOXYLATES AND BENZODIAZEPINE-RECEPTORS. 

002676 03-03 
EFFEQ OF PICROTOXIN ON BENZODIAZEPINE-RECEPTORS AND GABA- 
RECEPTORS WITH REFERENCE TO THE EFFECT OF CHLORIDE ION. 

002725 03-03 
GABA-RECEPTORS AND BENZODIAZEPINE-RECEPTORS. STUDIES ON THEIR 
LOCALIZATION IN THE HIPPOCAMPUS AND THEIR INTERACTION WITH 
CENTRAL DOPAMINE NEURONS IN THE RAT-BRAIN. 

002727 03-03 
KAINIC-ACID INDUCED LESION OF RAT RETINA: DIFFERENTIAL-EFFECT ON 
CYCLIC-GMP AND BENZODIAZEPINE-RECEPTORS AND GABA- 
RECEPTORS. 

002743 03-03 



NEURONAL LOCALIZATION OF BENZODIAZEPINE-RECEPTORS IN THE 
MURINE CEREBELLUM. 

002902 03-03 
MULTIPLE BENZODIAZEPINE-RECEPTORS. 

003579 03-17 
ENDOGENOUS LIGANDS FOR BENZODIAZEPINE-RECEPTORS. 

003615 03-17 
BRAIN BENZODIAZEPINE-RECEPTORS AND THEIR RAPID CHANGES ARER 
SEIZURES IN THE MONGOLIAN-GERBIL. 

003717 04-03 
NEURONAL LOCALISATION OF BENZODIAZEPINE-RECEPTORS IN 
CEREBELLUM. 

003739 04-03 
MULTIPLE BENZODIAZEPINE-RECEPTORS: EVIDENCE OF A DISSOCIATION 
BETWEEN ANTICONFLICT AND ANTICONVULSANT PROPERTIES BY PK- 
8165 AND PK-9084 (TWO QUINOUNE DERIVATIVES). 

003898 04-03 
THE INSENSITIVITY OF DEVELOPING BENZODIAZEPINE-RECEPTORS TO 
CHRONIC-TREATMENT WITH DIAZEPAM, GABA AND MUSCIMOL IN 
BRAIN CELL-CULTURES. 

004002 04-03 
BENZODIAZEPINE-RECEPTORS: EFFECT OF TISSUE PREINCUBATION AT 37 
DEGREES C. 

004013 04-03 
BENZODIAZEPINE-RECEPTORS ON PRIMARY CULTURES OF MOUSE 
ASTROCYTES. 

004029 04-03 
BENZODIAZEPINES 

RELATIONSHIP OF ANTICONFLIQ ACTIVITY OF BENZODIAZEPINES TO 
BRAIN RECEPTOR BINDING, SEROTONIN, AND GABA 

000057 01-03 
ELEaROPHYSIOLOGICAL ACTIONS OF BENZODIAZEPINES. 

000107 01-03 
RELATIONSHIPS BETWEEN PLASMA CORTICOSTEROIDS AND 
BENZODIAZEPINES IN STRESS 

000176 01-03 
CARDIOVASCULAR RESPONSE TO THE INTERAaiON OF ETHANOL AND 
SOME BENZODIAZEPINES IN RATS. 

000332 01-03 
BENZODIAZEPINES: A TOOL TO EXPLORE THE BIOCHEMICAL-BASIS AND 
NEUROPHYSIOLOGICAL-BASIS OF ANXIETY. 

000397 01-04 
MECHANISM-OF-AaiON OF THE BENZODIAZEPINES: BEHAVIORAL- 
ASPECT 

000468 01-04 
FACTORS INFLUENCING SEIZURE DURATION AND NUMBER OF SEIZURES 
APPLIED IN UNILATERAL ELECTROCONVULSIVE-THERAPY: ANESTHETICS 
AND BENZODIAZEPINES. 

000792 01-13 
THE DIFFERENTIAL-EFFEQS OF SHORT-ACTING AND LONG-AQING 
BENZODIAZEPINES UPON NOQURNAL SLEEP AND DAYTIME 
PERFORMANCE. 

000822 01-14 
USE AND ABUSE OF BENZODIAZEPINES. 

000877 01-15 
USE OF BENZODIAZEPINES IN PSYCHIATRIC-INPATIENTS. 

00091001-17 
PHARMACOKINETICS OF BENZODIAZEPINES: SHORT-AQING VERSUS 
LONG-AQING. 

000920 01-17 
BENZODIAZEPINES AND NEUROTRANSMIHERS. 

000925 01-17 
THE PRESENT STATUS OF BENZODIAZEPINES IN PSYCHOPHARMACOLOGY. 

000948 01-17 
THE PRESENT STATUS OF THE BENZODIAZEPINES IN PSYCHIATRY AND 
MEDICINE. 

000954 01-17 
THE BENZODIAZEPINES - USE AND ABUSE. 

000960 01-17 
THE SHORT-TERM USE OF BENZODIAZEPINES. 

000962 01-17 
BEHAVIORAL-NEUROCHEMISTRY OF BENZODIAZEPINES. 

000991 01-17 
REGIONAL RELEASE OF (3H)ADEN0SINE DERIVATIVES FROM RAT-BRAIN 
IN VIVO: EFFECT OF EXCITATORY AMINO-ACIDS, OPIATE AGONISTS, 
AND BENZODIAZEPINES. 

001303 02-03 
BENZODIAZEPINES MODIFY THE AGONIST RESPONSES AT A PRESYNAPTIC 
GABA-RECEPTOR 

001377 02-03 
COMPARATIVE ANXIOLYTIC AND HYPNOTIC-EFFEQS OF 3 
BENZODIAZEPINES ON BABOONS. 

001581 02-04 
RATIONAL USE OF BENZODIAZEPINES FOR ANXIETY AND INSOMNIA. 

002063 02-10 
THE LONG-TERM TREATMENT WITH BENZODIAZEPINES: SUGGESTIONS 
FOR FURTHER RESEARCH. 

002085 02-10 



S-52 



VOLUME 19, SUBJECT INDEX 

MECHANISM-OF-ACTION OF BENZODIAZEPINES, 

002302 02-13 
BENZODIAZEPINES CAUSE SMALL LOSS Of BODY-WEIGHT 

002446 02-15 
DEPENDENCE ON BENZODIAZEPINES. 

002464 02-15 
BENZODIAZEPINES: CLINICAL-PHARMACOLOGY AND THERAPEUTIC USE. 

002521 02-17 
SELECTIVE ANTAGONISTS OF BENZODIAZEPINES. 

002646 03-02 
THE ACTION OF BENZODIAZEPINES ON THE LIMBIC-SYSTEM COMPARED 
TO OTHER TRANQUILIZERS 

002731 03-03 
DO BENZODIAZEPINES BIND AT ADENOSINE UPTAKE SITES IN CNS? 

002933 03-03 
CONFLICT-SITUATION BASED ON INTRACRANIAL SELF-STIMULATION 
BEHAVIOR AND THE EFFECT OF BENZODIAZEPINES. 

003004 03-04 
SENSITIVE DEPRESSANT EFFECT OF BENZODIAZEPINES ON THE CROSSED 
EXTENSOR REFLEX IN CHLORALOSE ANESTHETIZED RATS. 

003027 03-04 
BENZODIAZEPINES, STRESS AND RAT PLASMA CORTICOSTEROIDS: THE 
ROLE OF INDOLEAMINES. 

003034 03-04 
COMPARISON OF THE EFFECTS OF FOUR BENZODIAZEPINES ON FRAME OF 
MIND AND BEHAVIOR IN HEALTHY SUBJECTS. 

003441 03-14 
THERAPEUTICS VI - ANXIOLYTICS (BENZODIAZEPINES). 

003546 03-15 
PATIENT CHARACTERISTICS AND CLINICIAN ATTITUDES INFLUENCING THE 
PRESCRIBING OF BENZODIAZEPINES. 

003598 03-17 
NEW TRENDS CONCERNING THE BIOCHEMICAL-MECHANISM OF ACTION 
OF BENZODIAZEPINES. 

003642 03-17 
THE BENZODIAZEPINES AND INOSINE ANTAGONIZE CAFFEINE-INDUCED 
SEIZURES. 

004172 04-04 
CLINICAL PHARMACOKINETICS OF BENZODIAZEPINES. 

004524 04-13 
LONG-TERM USE AND ABUSE OF BENZODIAZEPINES. 

004598 04-15 
BENZODIAZEPINES IN SCHIZOPHRENIA: A NEED FOR REASSESSMENT. 

004733 04-17 
BENZTROPINE-MESYLATE 

THE EFFECT OF BENZTROPINE-MESYLATE ON THE PROLACTIN RESPONSE 
TO HALOPERIDOL. 

002238 02-13 
BENZYL 

ON-COLUMN GAS-CHROMATOGRAPHIC- SYNTHESIS OF 1,3 DIALYKYL 
(C=l-10), BENZYL, AND CYCLOHEXYLBARBITURATE DERIVATIVES. 

003656 04-01 
BENZYLTETRAHYDROPYRIMIDONES 

1 SUBSTITUTED BENZYLTETRAHYDROPYRIMIDONES: A SERIES WITH 
STIMULANT AND DEPRESSANT ACTIVITIES. 

003687 04-02 
BETA-ADRENERGIC 

ISOLATION INCREASES THE RESPONSES TO BETA-ADRENERGIC 
STIMULATION IN MICE. 

001232 02-03 
BEHAVIORAL-EFFECTS AND SUBJECTIVE-EFFECTS OF BETA-ADRENERGIC 
BLOCKADE IN PHOBIC-SUBJECTS. 

002060 02-10 
SIDE-EFFECTS OF BETA-ADRENERGIC BLOCKING-DRUGS: A 
METHODOLOGICAL-PROBLEM . 

002395 02-15 
PROPRANOLOL (INDERAL) FOR TARDIVE-DYSKINESIA AND 
EXTRAPYRAMIDAL SIDE-EFFECTS FROM NEUROLEPTICS: POSSIBLE 
INVOLVEMENT OF BETA-ADRENERGIC MECHANISMS. 

002470 02-15 
FLUORESCENT PROBES OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC 
AND OPIATE-RECEPTORS: BIOCHEMICAL AND HISTOCHEMICAL 
EVALUATION. 

003685 04-02 
BETA-ADRENERGIC INFLUENCE ON CARDIAC DYNAMICS DURING SHOCK- 
AVOIDANCE IN DOGS. 

003813 04-03 
EFFECTS OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC BLOCKERS ON 
CHLORPROMAZINE-INDUCED ELEVATION OF PLASMA GLUCOSE AND 
CYCLIC-AMP IN FED MICE. 

003946 04-03 
RNA-POLYMERASE-II IN C6-GLI0MA CELLS: ALPHA AMANITIN BLOCKADE 
OF CYCLIC-AMP-PHOSPHODIESTERASE INDUCTION BY BETA- 
ADRENERGIC STIMULATION. (UNPUBLISHED PAPER). 

003998 04-03 
BETA-ADRENERGIC-RECEPTOR 

AGONIST-INDUCED CHANGES IN BETA-ADRENERGIC-RECEPTOR DENSITY 
AND RECEPTOR-MEDIATED RESPONSIVENESS IN SLICES OF RAT- 
CEREBRAL-CORTEX. 

000072 01-03 



Subject Index 



EFFECT OF CHRONIC-TREATMENT WITH ANTIDEPRESSANTS ON BETA- 
ADRENERGIC-RECEPTOR BINDING IN GUINEA-PIG BRAIN 

000135 01-03 
COMPARISON OF BETA-ADRENERGIC-RECEPTOR SUBTYPES IN 
MAMMALIAN TISSUES. 

000207 01-03 
DOPAMINE-BETA-HYDROXYLASE: A MODULATOR OF BETA-ADRENERGIC- 
RECEPTOR ACTIVITY. 

000302 01-03 
AFFINITY CHROMATOGRAPHY OF THE BETA-ADRENERGIC-RECEPTOR AND 
CHARACTERIZATION OF ANTIBODIES RAISED AGAINST PURIFIED 
RECEPTOR PREPARATIONS 

001009 02-01 
LONG-TERM HALOPERIDOL TREATMENT OF MICE: A CHANGE IN BETA- 
ADRENERGIC-RECEPTOR RESPONSIVENESS 

001206 02-03 
REGULATION BY A BETA-ADRENERGIC-RECEPTOR OF A CA-INDEPENDENT 
ADENOSINE-CYCLIC-MONOPHOSPHATE-PHOSPHODIESTERASE IN C6- 
GLIOMA CELLS. (UNPUBLISHED PAPER). 

001403 02-03 
INCREASED ADRENALINE, BETA-ADRENERGIC-RECEPTOR STIMULATION 
AND PHOSPHOLIPID METHYLATION IN PINEAL-GLAND OF 
SPONTANEOUSLY HYPERTENSIVE-RATS. (UNPUBLISHED PAPER). 

001458 02-03 
THE EFFECT OF BETA-ADRENERGIC-RECEPTOR BLOCKING-DRUGS ON 
CEREBRAL BLOOD FLOW IN HYPERTENSIVE-PATIENTS. 

002071 02-10 
BETA-ADRENERGIC-RECEPTOR SUBTYPES: PROPERTIES, DISTRIBUTION, 
AND REGULATION. 

002829 03-03 
BETA-ADRENERGIC-RECEPTORS 

ABILITY OF AGED RATS TO ALTER BETA-ADRENERGIC-RECEPTORS OF 
BRAIN IN RESPONSE TO REPEATED ADMINISTRATION OF RESERPINE 
AND DESMETHYLIMIPRAMINE. 

000113 01-03 
ACCELERATION OF DESIPRAMINE-INDUCED DECREASE OF RAT 
CORTICOCEREBRAL BETA-ADRENERGIC-RECEPTORS BY YOHIMBINE 

000326 01-03 
MODULATION OF BETA-ADRENERGIC-RECEPTORS AND CALMODULIN 
FOLLOWING ACUTE AND CHRONIC-TREATMENT WITH NEUROLEPTICS. 

001529 02-03 
MEPACRINE TREATMENT PREVENTS IMMOBILIZATION-INDUCED 
DESENSITIZATION OF BETA-ADRENERGIC-RECEPTORS IN RAT 
HYPOTHALAMUS AND BRAINSTEM. 

002919 03-03 
EFFECTS OF ISOPROTERENOL ON THE DEVELOPMENT OF BETA- 
ADRENERGIC-RECEPTORS IN BRAIN CELL AGGREGATES. 

002932 03-03 
DEVELOPMENTAL-CHANGE OF BETA-ADRENERGIC-RECEPTORS IN RAT- 
BRAIN. 

004050 04-03 
BETA-ADRENOCEPTOR 

CLENBUTEROL, A CENTRAL BETA-ADRENOCEPTOR AGONIST. 

000120 01-03 
BETA-ADRENOCEPTOR ANTAGONISTS: STUDIES ON BEHAVIOUR (DELAYED 
DIFFERENTIATION) IN THE MONKEY (MACACA-MULATTA). 

000440 01-04 
EFFECTS OF DESIPRAMINE AND YOHIMBINE ON ALPHA2-ADREN0CEPT0R 
AND BETA-ADRENOCEPTOR SENSITIVITY. 

001305 02-03 
EFFECTS OF THE BETA-ADRENOCEPTOR BLOCKING-AGENT SOTALOL ON 
CNS: SLEEP, EEG, AND PSYCHOPHYSIOLOGICAL PARAMETERS. 

001570 02-04 
DISPOSITION AND ACTIVITY OF BETA-ADRENOCEPTOR ANTAGONISTS IN 
THE RAT USING AN EX VIVO RECEPTOR BINDING ASSAY. 

001878 02-06 
BETA-ADRENORECEPTOR 

REVERSAL OF NORADRENALINE DENERVATION-INDUCED INCREASE OF 
BETA-ADRENORECEPTOR BINDING IN RAT NEOCORTEX BY 
NORADRENALINE INFUSION. 



002672 03-03 



BETA-BLOCKERS 

BETA-BLOCKERS IN PSYCHIATRY. 

CLINICAL-REVIEW OF BETA-BLOCKERS IN ANXIETY. 
PSYCHIATRIC USES OF BETA-BLOCKERS. 



002109 02-11 

004464 04-11 

004709 04-17 
BETA-RECEPTOR 

FAILURE OF ISOPRENALINE AND BETA-RECEPTOR BLOCKING-DRUGS TO 
MODIFY DEPRESSOR RESPONSE AND BRADYCARDIA INDUCED BY 
ELECTRICAL- STIMULATION OF THE ANTERIOR HYPOTHALAMUS OF 
CATS. 

000520 01-05 
EFFECTS OF PROLONGED TREATMENT WITH LITHIUM AND TRICYCLIC- 
ANTIDEPRESSANTS ON DISCHARGE FREQUENCY, NOREPINEPHRINE 
RESPONSES AND BETA-RECEPTOR BINDING IN RAT-CEREBELLUM: 
ELECTROPHYSIOLOGICAL AND BIOCHEMICAL COMPARISON. 

002884 03-03 



a. 









fe 



I 



S-53 



Subject Index 



Ptychopharmacology Abstracts 



HYPERVENTILATION-SYNDROME AND BETA-RECEPTOR FUNCTION - 
CLINICAL-EFFECT OF BETA BLOCKER UPON THE SYNDROME. 

004459 04-11 
BETA-SYMPATHOMIMETICS 

SPONTANEOUS MOTOR-ACTIVITY IN RATS GIVEN REPEATEDLY BETA- 
SYMPATHOMIMETICS - ISOPRENALIN AND SALBUTAMOL. 

001804 02-04 
BETAORENOL 

THE EFFECT OF BETADRENOL ON EXAMINATION ANXIETY. 

000650 01-10 
BETAINE 

ORAL AND RECTAL ABSORPTION OF CHLORAL-HYDRATE AND ITS BETAINE 
COMPLEX. 

004554 04-13 
BEHA-SPLENDENS 

BETTA-SPLENDENS MAZE-BEHAVIOR UNDER THE INFLUENCE OF THE BETA 
FENIL-ISOPROPIL-AMINA-SULFATE. 

001558 02-04 
BIBLIOGRAPHY 

BIBLIOGRAPHY ON THE BIOLOGY AND PHARMACOLOGY OF LITHIUM. 

003630 03-17 
BICUCULLINE 

BICUCULLINE ANTAGONIZES EFFECTS OF DIAZEPAM ON AGGRESSIVE AND 
TIMID-BEHAVIOUR IN MICE. 

000485 01-04 
EFFECT OF AMINOOXYACETIC-ACID AND BICUCULLINE ON PROLACTIN 
RELEASE IN CASTRATED MALE RATS. 

001194 02-03 
SENSITIVITY OF IDENTIFIED MEDIAL HYPOTHALAMIC NEURONS TO GABA, 
GLYCINE AND RELATED AMINO-ACIDS; INFLUENCE OF BICUCULLINE, 
PICROTOXIN AND STRYCHNINE ON SYNAPTIC INHIBITION. 

002674 03-03 
ROLE OF INTRACORTICAL INHIBITION IN DEPRIVATION AMBLYOPIA: 
REVERSAL BY MICROIONTOPHORETIC BICUCULLINE. 

002684 03-03 
SUPRASPINAL INHIBITION OF THE EXCITATION OF DORSAL-HORN 
NEURONES BY IMPULSES IN UNMYELINATED PRIMARY AFFERENTS: 
LACK OF EFFECT BY STRYCHNINE AND BICUCULLINE. 

003778 04-03 
3H BACLOFEN AND 3H GABA BIND TO BICUCULLINE INSENSITIVE GABAB 
SITES IN RAT-BRAIN. 

003839 04-03 
EFFECTS OF 5 HYDROXYTRYPTAMINE ON CENTRAL NEURONES 
ANTAGONIZED BY BICUCULLINE AND PICROTOXIN. 

003931 04-03 
BICUCULUNE-iNDUCED 

EFFECTS OF BICUCULUNE-INDUCED SEIZURES ON CEREBRAL METABOLISM 
AND CIRCULATION OF RATS RENDERED HYPOGLYCEMIC BY 
STARVATION. 

001134 02-03 
BRAIN AND SERUM CALCIUM CONCENTRATIONS FOLLOWING 
ELECTROCONVULSIVE-SHOCK OR BICUCULUNE-INDUCED CONVULSIONS 
IN RATS. 

003736 04-03 
EFFECT OF GAMMA VINYL-GABA ON BICUCULUNE-INDUCED SEIZURES. 

004157 04-04 
BICYCLIC 

CLINICAL-TRIALS WITH NEW BICYCUC AND TETRACYCLIC COMPOUNDS: 
ZIMEUDINE AND MAPROTIUNE. 

003213 03-09 
BILE 

COMPARISON OF BLOOD AND BILE LEVELS OF OXYPROTHEPIN AND 
DOCLOXYTHEPIN IN RATS. 

000242 01-03 
BIND 

DO BENZODIAZEPINES BIND AT ADENOSINE UPTAKE SITES IN CNS? 

002933 03-03 
3H BACLOFEN AND 3H GABA BIND TO BICUCULUNE INSENSITIVE GABAB 
SITES IN RAT-BRAIN. 

003839 04-03 
BINDING 

OXAZEPAM-ESTERS. 2. CORRELATION OF HYDROPHOBICITY WITH SERUM 
BINDING, BRAIN PENETRATION, AND EXCRETION. 

000011 01-02 
3H IMIPRAMINE BINDING IN NEURONAL AND GUAL FRACTIONS OF 
HORSE STRIATUM. 

000033 01-03 
(3H) 2 AMINODIHYDROXYTETRAHYDRt JAPHTHALENE (ADTN): 
REGIONAL DISTRIBUTION AND IN Vi /O BINDING AFTER ACUTE AND 
CHRONIC DRUG-TREATMENT. 

000052 01-03 
RELATIONSHIP OF ANTICONFLICT ACTIVITY OF BENZODIAZEPINES TO 
BRAIN RECEPTOR BINDING, SEROTONIN, AND GABA 

000057 01-03 
HIGH-AFFINITY BINDING OF THE ANTITUSSIVE DEXTROMETHORPHAN TO 
GUINEA-PIG BRAIN. 

000061 01-03 
CHARACTERISTICS OF 3H CIS FLUPENTHIXOL BINDING TO CALF BRAIN 

MEMBRANES. 

000062 01-03 



REDUCTION OF OPIATE BINDING TO BRAINSTEM SLICES ASSOCIATED 
WITH THE DEVELOPMENT OF TOLERANCE TO MORPHINE IN RATS. 

000066 01-03 
STEREOSPECIFIC BINDING OF 3H HALOPERIDOL IN RAT DORSAL SPINAL- 
CORD. 

000070 01-03 
INCREASED MESOUMBIC 3H SPIROPERIDOL BINDING IN 4 WEEK OLD 
OFFSPRING OF NURSING RAT MOTHERS TREATED WITH PENFLURIDOL. 

000087 01-03 
EFFECTS OF DOPAMINERGIC AGONISTS AND ANTAGONISTS ON 
(3H)AP0M0RPHINE BINDING TO STRIATAL MEMBRANES: SULPIRIDE 
LACK OF INTERACTIONS WITH POSITIVE COOPERATIVE 
(3H)AP0M0RPHINE BINDING. 

000099 01-03 
INHIBITION OF (3H)NAL0X0NE BINDING IN H0M06ENATES OF RAT- 
BRAIN BY ESEROLINE, A DRUG, WITH ANALGESIC AQIVITY, RELATED 
TO PHYSOSTIGMINE. 

000104 01-03 
HIGH-AFFINITY BINDING OF 3H ETHYLKETOCYCLAZOCINE TO RAT-BRAIN 
HOMOGENATE. 

000124 01-03 
3H ETHYLKETOCYCLAZOCINE BINDING: LACK OF EVIDENCE FOR A 
SEPARATE KAPPA-RECEPTOR IN RAT CNS. 

000128 01-03 
EFFECT OF CHRONIC-TREATMENT WITH ANTIDEPRESSANTS ON BETA- 
ADRENERGIC-RECEPTOR BINDING IN GUINEA-PIG BRAIN. 

000135 01-03 
CHARACTERIZATION OF 3H GABA-RECEPTOR BINDING TO RAT-BRAIN 
SYNAPTOSOMAL MEMBRANES: EFFEQ OF NONGABAERGIC 
COMPOUNDS. 

000139 01-03 
AMITRIPTYLINE BINDING TO SPECIFIC ALPHA-ADRENERGIC-RECEPTORS IN 
VITRO. 

000181 01-03 
DECREASED SPIROPERIDOL AND LSD BINDING IN RAT-BRAIN AFTER 
CONTINUOUS AMPHETAMINE. 

000216 01-03 
INHIBITION OF IN VIVO 3H SPIPERONE BINDING BY THE PROPOSED 
ANTIPSYCHOTIC DES-TYRl-GAMMA-ENDORPHIN. 

000226 01-03 
LONG-TERM ANTIDEPRESSANT TREATMENT DECREASES SPIROPERIDOL- 
LABELED SEROTONIN-RECEPTOR BINDING 

000230 01-03 
CHRONIC SYMPATHETIC DENERVATION INCREASES MUSCARINIC- 
CHOLINOCEPTOR BINDING IN THE RAT SUBMAXILLARY-GLAND. 

000235 01-03 
AUDIOGENIC-SEIZURES: INCREASED BENZODIAZEPINE-RECEPTOR BINDING 
IN A SUSCEPTIBLE STRAIN OF MICE. 

000252 01-03 
EFFEQS OF CHRONIC HALOPERIDOL ON CAUDATE 3H SPIROPERIDOL 
BINDING IN LESIONED RATS 

000255 01-03 
PENTOBARBITAL POTENTIATES GABA-ENHANCED (3H) DIAZEPAM 
BINDING TO BENZODIAZEPINE-RECEPTORS. 

000275 01-03 
CHANGES IN MOUSE-BRAIN DIAZEPAM-RECEPTOR BINDING AFTER 
PHENOBARBITAL ADMINISTRATION. 

000281 01-03 
BIOCHEMICAL-PROPERTIES OF SPIPERONE BINDING TO RAT-BRAIN 
MEMBRANES. 

000294 01-03 
(3H)QUINUCUDINYL-BENZIUTE BINDING TO MUSCARINIC-RECEPTORS 
AND (3H)WB-4101 BINDING TO ALPHA-ADRENERGIC-RECEPTORS IN 
RABBIT IRIS: COMPARISON OF RESULTS IN SLICES AND MICROSOMAL 
FRAQIONS. 

000299 01-03 
3H MIANSERIN BINDING IN CALF CAUDATE: POSSIBLE INVOLVEMENT OF 
SEROTONIN-RECEPTORS IN ANTIDEPRESSANT-DRUG AQION. 

000325 01-03 
INHIBITION OF (3H)DIAZEPAM BINDING TO RAT-BRAIN CORTICAL 
SYNAPTOSOMAL MEMBRANES BY ADENOSINE UPTAKE BLOCKERS. 

000330 01-03 
INCREASED DOPAMINE-RECEPTOR BINDING IN THE STRIATUM OF RATS 
AFTER LONG-TERM ISOLATION. 

000398 01-04 
DISPLACEMENT OF (3H)CL0NIDINE BINDING BY CLONIDINE ANALOGUES 
IN MEMBRANES FROM RAT-CEREBRAL-CORTEX. 

000536 01-06 
VALPROIC-ACID DOSAGE AND PLASMA PROTEIN BINDING AND 
CLEARANCE. 

000755 01-13 
ALBUMIN BINDING INTERAQIONS OF SODIUM-VALPROATE. 

000762 01-13 
INFLUENCE OF DEXTROPROPOXYPHENE ON STEADY- STATE SERUM LEVELS 
AND PROTEIN BINDING OF THREE ANTIEPILEPTIC-DRUGS IN MAN. 

000767 01-13 
SPECIFIC BINDING FOR OPIATE-LIKE-DRUGS IN THE PLACENTA. 

000797 01-13 



S-54 



VOLUME 19, SUBJECT INDEX 



Subject Index 



TECHNIQUES FOR PLASMA PROTEIN BINDING OF 
DEMETHYLCHLORIMIPRAMINE , 

000897 01-16 
DISEASE-INDUCED CHANGES IN THE PLASMA BINDING OF BASIC DRUGS. 

000975 01-17 
GUANINE-NUCLEOTIDES INHIBIT BINDING OF AGONISTS AND 
ANTAGONISTS TO SOLUBLE OPIATE-RECEPTORS (UNPUBLISHED 
PAPER). 

001035 02-01 
HISTAMINE-RECEPTORS IN THE BRAIN: CHARACTERIZATION BY BINDING 
STUDIES AND BIOCHEMICAL-EFFECTS. 

001054 02-01 
INHIBITION BY LOCAL ANESTHETICS, PHENTOLAMINE AND PROPRANOLOL 
OF (3H)QUINUCLYDINYL-BENZYLATE BINDING TO CENTRAL 
MUSCARINIC-RECEPTORS. 

001097 02-03 
REGULATION OF RECEPTOR BINDING INTERACTIONS OF 1251 
ANGIOTENSIN-II AND 1251 SARC0SINE1-LEUCINE8-ANGI0TENSIN-II, AN 
ANGIOTENSIN ANTAGONIST, BY SODIUM-ION. 

001124 02-03 
RECEPTOR BINDING INTERACTIONS OF THE ANGIOTENSIN-II ANTAGONIST, 

1251 SARC0SINE1-LEUCINE8-ANGI0TENSIN-II. WITH MAMMALIAN 
BRAIN AND PERIPHERAL TISSUES. 

001125 02-03 
IN VIVO (3H)SPIPER0NE BINDING TO THE RAT HIPPOCAMPAL 

FORMATION: INVOLVEMENT OF DOPAMINE-RECEPTORS. 

001131 02-03 
ETHANOL ENHANCES (3H)DIAZEPAM BINDING AT THE BENZODIAZEPINE 
GABA-RECEPTOR lONOPHORE COMPLEX. 

001154 02-03 
RADIOLIGAND BINDING STUDIES: EVIDENCE FOR MULTIPLE DOPAMINE- 
RECEPTORS. 

001186 02-03 
HIGH-AFFINITY BINDING OF (3H)MIANSERIN TO RAT-CEREBRAL-CORTEX. 

001204 02-03 
INHIBITION BY ARYLSULPHATASE A OF NA-INDEPENDENT (3H) GABA 
AND (3H) MUSCIMOL BINDING TO BOVINE CEREBELLAR SYNAPTIC 
MEMBRANES. 

001208 02-03 
DRUG-INDUCED ALTERATIONS IN NEUROTRANSMITTER-RECEPTOR 
BINDING AND FUNCTION. 

001215 02-03 
THE EFFECT OF GABAMIMETICS ON NEUROTRANSMITTER-RECEPTOR 
BINDING AND FUNCTION IN RAT-BRAIN. (PH.D. DISSERTATION). 

001221 02-03 
THE BINDING OF SOME ANTIDEPRESSANT-DRUGS TO BRAIN MUSCARINIC 
ACETYLCHOLINE-RECEPTORS . 

001253 02-03 
OPIATES AND SPECIFIC RECEPTOR BINDING OF (3H)CL0NIDINE. 

001256 02-03 
PERSISTENT EFFECTS OF HIGH-CONCENTRATIONS OF CHLORPROMAZINE 
ON 3H PROPYLBENZILYLCHOLINE-MUSTARD BINDING TO MUSCARINIC- 
RECEPTORS IN GUINEA-PIG INTESTINAL-MUSCLE STRIPS. 

001266 02-03 
BENZODIAZEPINE BINDING IN CHICKEN RETINA AND ITS INTERACTION 
WITH GAMMA AMINOBUTYRIC-ACID. 

001287 02-03 
NO EVIDENCE FOR INCREASED DOPAMINE-RECEPTOR BINDING IN 
SUPERRESPONSIVE MICE AFTER A SINGLE-DOSE OF NEUROLEPTICS. 

001292 02-03 
EVIDENCE FOR AN ENDOGENOUS COMPOUND INTERFERING WITH 3H 
DIAZEPAM BINDING TO RAT-BRAIN MEMBRANES. 

001308 02-03 
CHARACTERIZATION OF GABA-STIMULATED BENZODIAZEPINE-RECEPTOR 

BINDING. 

001309 02-03 
INCREASED MUSCARINIC-RECEPTOR BINDING IN RAT-FOREBRAIN AFTER 

SCOPOLAMINE. 

001351 02-03 
DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND DOPAMINE/ 
NEUROLEPTIC-RECEPTOR BINDING: EFFECT OF NEUROLEPTIC-DRUGS. 

001358 02-03 
CHARACTERIZATION AND RADIOAUTOGRAPHY OF (3H)LSD BINDING BY 
RAT-BRAIN SLICES IN VITRO: THE EFFECT OF 5 HYDROXYTRYPT AMINE. 

001369 02-03 
FURTHER CHARACTERIZATION OF THE BINDING OF SUBSTANCE-P TO A 
FRAaiON FROM RABBIT BRAIN ENRICHED IN SYNAPTIC MEMBRANES. 

001394 02-03 
RENAL BENZODIAZEPINE BINDING INCREASES DURING 
DEOXYCORTICOSTERONE/SALT HYPERTENSION IN RATS. 

001430 02-03 
1 METHYL-BETA-CARBOLINE (HARMANE), A POTENT ENDOGENOUS 
INHIBITOR OF BENZODIAZEPINE-RECEPTOR BINDING. 

001440 02-03 
CHRONIC LITHIUM REDUCES (3H)SPIR0PERID0L BINDING IN RAT 
STRIATUM. 

001443 02-03 
INCREASED RENAL NEUROLEPTIC BINDING IN SPONTANEOUSLY 

HYPERTENSIVE-RATS. 

001444 02-03 



EFFECTS OF HALOPERIDOL AND D-AMPHETAMINE ON IN VIVO 3H 
SPIROPERIDOL BINDING IN THE RAT-FOREBRAIN 

001461 02-03 
DECREASE IN (3H) SEROTONIN BINDING IN RAT-BRAIN PRODUCED BY THE 
REPEATED ADMINISTRATION OF EITHER MONOAMINE-OXIDASE- 
INHIBITORS ON CENTRALLY-ACTING SEROTONIN AGONISTS. 

001463 02-03 
MULTIPLE CNS RECEPTOR INTERACTIONS OF ERGOT ALKALOIDS: AFFINITY 
AND INTRINSIC ACTIVITY ANALYSIS IN IN VITRO BINDING SYSTEMS 

001516 02-03 
BINDING OF (3H)PERG0LIDE-MESYLATE TO DOPAMINE-RECEPTORS OF 
MAMMALIAN BRAINS. 

001538 02-03 
(3H) PHENCYCLIDINE BINDING TO SPECIFIC BRAIN RECEPTOR SITES 

001555 02-03 
MODULATION OF OPIATE-RECEPTOR BINDING IN STRIATUM AND 
AMYGDALA BY SELECTIVE MESENCEPHALIC LESIONS. 

001629 02-04 
3H APOMORPHINE-RECEPTORS IN VARIOUS RAT-BRAIN REGIONS: A 
STUDY OF SPECIFIC AND NONSPECIFIC BINDING AND THE INFLUENCE OF 
CHRONIC NEUROLEPTIC TREATMENT. 

001846 02-05 
STUDIES ON THIORIDAZINE AND MESORIDAZINE METABOLISM. I. 
PROTEIN BINDING. 

001867 02-06 
DISPOSITION AND ACTIVITY OF BETA-ADRENOCEPTOR ANTAGONISTS IN 
THE RAT USING AN EX VIVO RECEPTOR BINDING ASSAY. 

001878 02-06 
HIGH-AFFINITY BINDING OF TRICYCLIC-ANTIDEPRESSANTS TO HISTAMINE 
HI -RECEPTORS: FACT AND ARTIFACT. 

001880 02-06 
BINDING OF PHENCYCLIDINE TO RAT-BRAIN MEMBRANES: TECHNICAL- 
ASPECT. 

001882 02-06 
COMPARATIVE PROTEIN BINDING OF DIAZEPAM AND 
DESMETHYLDIAZEPAM. 

002206 02-13 
THE CONTRIBUTION OF ALPHAl ACID GLYCOPROTEIN, LIPOPROTEINS, 
AND ALBUMIN TO THE PLASMA BINDING OF PERAZINE, 
AMITRIPTYLINE, AND NORTRIPTYLINE IN HEALTHY MAN. 

002214 02-13 
QUINACRINE AND SEROTONIN BINDING BY SYNTHETIC MODELS FOR 
HUMAN PLATELET DENSE-BODIES: EVALUATION OF THE ROLE OF 
BINDING IN AMINE STORAGE. (UNPUBLISHED PAPER). 

002219 02-13 
SPECIFIC 3H IMIPRAMINE BINDING IN HUMAN PLATELETS: INFLUENCE OF 
AGE AND SEX. 

002254 02-13 
EFFECTS OF CAFFEINE ON PLASMA FREE FATTY-ACIDS, URINARY 
CATECHOLAMINES, AND DRUG BINDING. 

002272 02-13 
INTERACTION BETWEEN PHENYTOIN AND VALPROIC-ACID: PLASMA 
PROTEIN BINDING AND METABOLIC-EFFECTS. 

002276 02-13 
BINDING OF PERAZINE TO ALPHAl ACID GLYCOPROTEIN. 

002290 02-13 
THE EFFECTS OF ACUTE AND CHRONIC MORPHINE ADMINISTRATION ON 
GABA-RECEPTOR BINDING. 

002301 02-13 
DEMONSTRATION AND CHARACTERIZATION OF AN ENDOGENOUS 
INHIBITOR OF GABA-ENHANCED (3H) DIAZEPAM BINDING FROM 
BOVINE CEREBRAL-CORTEX. 

002645 03-01 
RECEPTOR BINDING PROFILE OF R-41-468, A NOVEL ANTAGONIST AT 5 
HT2-RECEPT0RS. 

002648 03-02 
REVERSAL OF NORADRENALINE DENERVATION-INDUCED INCREASE OF 
BETA-ADRENORECEPTOR BINDING IN RAT NEOCORTEX BY 
NORADRENALINE INFUSION. 

002672 03-03 
NA-INDEPENDENT BINDING OF (3H)GABA AND (3H)MUSCIM0L TO 
SUBCELLULAR PARTICLES OF NEURAL PRIMARY CULTURES AND WHOLE 
BRAIN. 

002699 03-03 
THE EFFECT OF GUANOSINE-NUCLEOTIDES ON (3H)SULPIRIDE BINDING TO 
RAT STRIATAL MEMBRANES. 

002722 03-03 
SIMILARITIES BETWEEN THE BINDING OF 3H PIFLUTIXOL AND 3H 
FLUPENTIXOL TO RAT STRIATAL DOPAMINE-RECEPTORS IN VITRO. 

002760 03-03 
MODULATION BY PICROTOXIN AND IPTBO OF 3H FLUNITRAZEPAM 

BINDING TO THE GABA/BENZODIAZEPINE-RECEPTOR COMPLEX OF RAT- 
CEREBELLUM. 

002775 03-03 
IMIPRAMINE: EFFECT OF OVARIAN STEROIDS ON MODIFICATIONS IN 
SEROTONIN-RECEPTOR BINDING. 

002778 03-03 



I 



5 

■> 



fi: 



S-55 



Subject Index 



Psychopharmacology Abstracts 



THE EFFECT OF SPECIFIC BRAIN LESIONS ON THE HIGH-AFFINITY BINDING 
OF GABA IN THE SUBSTANTIA-NIGRA. 

002795 03-03 
ASCORBATE DECREASES LIGAND BINDING TO NEUROTRANSAAinER- 
RECEPTORS. 

002804 03-03 
BRAIN MUSCARINIC CHOLINERGIC-RECEPTOR BINDING IN ROMAN HIGH- 
AVOIDANCE AND LOW-AVOIDANCE RATS. 

002852 03-03 
TWO DISTINCT SEROTONIN-RECEPTORS: REGIONAL VARIATIONS IN 
RECEPTOR BINDING IN MAMMALIAN BRAIN. 

002861 03-03 
HIGH-AFFINITY RENAL (3H)FLUNITRAZEPAM BINDING: 
CHARACTERIZATION, LOCALIZATION, AND ALTERATION IN 
HYPERTENSION. 

002874 03-03 
AMITRIPTYLINE: LONG-TERM-TREATMENT ELEVATES ALPHA-ADRENERGIC 

AND MUSCARINIC-RECEPTOR BINDING IN MOUSE-BRAIN. 

002875 03-03 
EFFECTS OF PROLONGED TREATMENT WITH LITHIUM AND TRICYCLIC- 
ANTIDEPRESSANTS ON DISCHARGE FREQUENCY, NOREPINEPHRINE 
RESPONSES AND BETA-RECEPTOR BINDING IN RAT-CEREBELLUM: 
ELECTROPHYSIOLOGICAL AND BIOCHEMICAL COMPARISON. 

002884 03-03 
EFFECTS OF PROTEIN AND MEMBRANE MODIFYING AGENTS ON THE 
BINDING OF L (3H)GLUTAMATE TO CEREBELLAR SYNAPTIC 
MEMBRANES. 

002888 03-03 
THREE CLASSES OF OOPAMINE-RECEPTOR (D-2, D-3, D-4) IDENTIFIED BY 
BINDING STUDIES WITH 3H APOMORPHINE AND 3H DOMPERIDONE. 

002900 03-03 
GABA-RECEPTORS REGULATE THE AFFINITIES OF ANIONS REQUIRED FOR 
BRAIN SPECIFIC BENZODIAZEPINE BINDING 

002903 03-03 
ACTION OF PYRAZOLOPYRIDINES AS MODULATORS OF 

(3H)FLUNITRAZEPAM BINDING TO THE GABA/BENZODIAZEPINE- 
RECEPTOR COMPLEX OF THE CEREBELLUM. 

002909 03-03 
REGULATION BY CATIONS OF (3H)SPIR0PERID0L BINDING ASSOCIATED 
WITH DOPAMINE-RECEPTORS OF RAT-BRAIN. 

002922 03-03 
3H IMIPRAMINE BINDING IN HUMAN PLATELETS: DIMINUTION OF 
BINDING-SITES IN DEPRESSED-PATIENTS. 

003427 03-13 
DIFFERENTIAL BINDING OF CHLORPROMAZINE TO HUMAN BLOOD CELLS: 
APPLICATION OF THE HYGROSCOPIC DESORPTION METHOD. 

003556 03-16 
HIGH-AFFINITY 3H IMIPRAMINE BINDING: A NEW BIOLOGICAL TOOL FOR 
STUDIES IN DEPRESSION. 

003610 03-17 
STRUCTURE-ACTIVITY AND RECEPTOR BINDING OF ANTAGONIST 

ANALGESICS 

003611 03-17 
EFFECT OF THE POSITION OF THE PHENOLIC GROUP IN MORPHINANS ON 

THEIR AFFINITY FOR OPIATE-RECEPTOR BINDING. 

003702 04-02 
EFFECT OF CHRONIC SULPIRIDE ON STRIATAL SPIPERONE BINDING. 

003720 04-03 
PAPAIN-DERIVED FRAGMENT IIC TETANUS-TOXIN: ITS BINDING TO 
ISOLATED SYNAPTIC MEMBRANES AND RETROGRADE AXONAL 
TRANSPORT. 

003734 04-03 
INHIBITION OF (3H)DIAZEPAM BINDING BY AN ENDOGENOUS FRACTION 
FROM RAT-BRAIN SYNAPTOSOMES. 

003768 04-03 
EFFECTS OF CONFORMATIONALLY RESTRAINED ANALOGUES OF 
SEROTONIN ON ITS UPTAKE AND BINDING IN RAT-BRAIN. 

003794 04-03 
COMPARISON OF THE BINDING CHARACTERISTICS OF TRITIATED OPIATES 
AND OPIOID-PEPTIDES. 

003802 04-03 
CHARACTERIZATION BY (3H)DIHYDR0ERG0CRYPTINE BINDING OF ALPHA- 
ADRENERGIC-RECEPTORS IN NEUROBLASTOMA X GLIOMA HYBRID 
CELLS. 

003823 04-03 
SPECIFIC, HIGH-AFFINITY (3H)ETHYLKET0CYCLAZ0CINE BINDING IN RAT 
CENTRAL-NERVOUS-SYSTEM: LACK OF EVIDENCE FOR KAPPA- 
RECEPTORS. 

003840 04-03 
REGIONAL CHANGES IN {3H)DIAZEPAM BINDING IN THE BRAINS OF MICE 
AFTER REMOVAL OF THE OLFACTORY-BULBS. 

003844 04-03 
IBOTENIC-ACID ANALOGUES AS INHIBITORS OF (3H)GLUTAMIC-ACID 
BINDING TO CEREBELLAR MEMBRANES. 

003848 04-03 
QUINUCLIDINYL BENZILATE BINDING IN HOUSEFLY HEADS AND RAT- 
BRAIN. 

003868 04-03 
INCREASED MESOLIMBIC DOPAMINE BINDING FOLLOWING CHRONIC 
HALOPERIDOL TREATMENT. 

003872 04-03 



OPIOID BINDING PROPERTIES OF BRAIN AND PERIPHERAL TISSUES: 
EVIDENCE FOR HETEROGENEITY IN OPIOID LIGAND BINDING SITES. 

003902 04-03 
THE EFFECT OF TYPICAL AND ATYPICAL NEUROLEPTICS ON BINDING OF 
(3H)SPIR0PERID0L IN CALF CAUDATE. 

003906 04-03 
EFFECTS OF HALOPEMIDE ON GABA-RECEPTOR BINDING, UPTAKE AND 
RELEASE. 

003913 04-03 
ALTERATIONS IN DIHYDROMORPHINE BINDING IN CEREBRAL 
HEMISPHERES OF AGED MALE RATS. 

003936 04-03 
DOPAMINE-RECEPTORS IN SUBCELLULAR FRACTIONS FROM BOVINE 
CAUDATE: ENRICHMENT OF (3H)SPIPER0NE BINDING IN A 
POSTSYNAPTIC MEMBRANE FRACTION 

003948 04-03 
BINDING OF (3H) MUSCIMOL, A POTENT GAMMA AMINOBUTYRIC-ACID- 
RECEPTOR AGONIST, TO MEMBRANES OF THE BOVINE RETINA 

003954 04-03 
REGIONAL DISTRIBUTION OF (3H)IMIPRAMINE BINDING IN RAT-BRAIN 

003955 04-03 
DOES HIGH-AFFINITY (3H) IMIPRAMINE BINDING LABEL SEROTONIN 

REUPTAKE SITES IN BRAIN AND PLATELET? 

003962 04-03 
MULTIPLE ALPHA2-N0RADRENERGIC-RECEPT0R SITES IN RAT-BRAIN: 
SELECTIVE REGULATION OF HIGH-AFFINITY (3H)CL0NIDINE BINDING BY 
GUANINE-NUCLEOTIDES AND DIVALENT-CATIONS. 

003992 04-03 
L ASPARTATE BINDING-SITES IN RAT-CEREBELLUM: A COMPARISON OF 
THE BINDING OF L (3H)ASPARTATE AND L (3H)GLUTAMATE TO 
SYNAPTIC MEMBRANES 

004000 04-03 
DOPAMINE-RECEPTOR BINDING IN BOVINE INTERMEDIATE LOBE 
PITUITARY MEMBRANES 

004003 04-03 
CATION REGULATION DIFFERENTIATES SPECIFIC BINDING OF 

(3H)SULPIRIDE AND (3H)SPIPER0NE TO RAT STRIATAL PREPARATIONS. 

004032 04-03 
THE EFFECTS OF ACUTE AND CHRONIC ETHANOL ADMINISTRATION AND 
ITS WITHDRAWAL ON GAMMA AMINOBUTYRIC-ACID-RECEPTOR 
BINDING IN RAT-BRAIN 

004035 04-03 
RELEVANCE OF DOPAMINE-RECEPTOR BINDING STUDIES FOR EVALUATION 
OF ANTIPARKINSONIAN-DRUGS 

004120 04-04 
THE RELATIONSHIP BETWEEN LOSS OF DOPAMINE NERVE TERMINALS, 
STRIATAL (3H)SPIR0PERID0L BINDING AND ROTATIONAL-BEHAVIOR IN 
UNILATERALLY 6 HYDROXYDOPAMINE LESIONED RATS 

004129 04-04 
NALOXAZONE, A LONG-ACTING OPIATE ANTAGONIST: EFFEaS ON 
ANALGESIA IN INTACT ANIMALS AND ON OPIATE-RECEPTOR BINDING 
IN VITRO. 

004198 04-04 
SPECIFIC IN VIVO BINDING OF 77BR P BROMOSPIROPERIDOL IN RAT- 
BRAIN: A POTENTIAL TOOL FOR GAMMA-RAY IMAGING. 

004293 04-06 
PROTEIN BINDING OF CHLORPROMAZINE IN CEREBROSPINAL-FLUID AND 
SERUM 

004311 04-08 
DECREASED 3H IMIPRAMINE BINDING IN DEPRESSED MALES AND 
FEMALES. 

004349 04-09 
(3H) IMIPRAMINE BINDING IN HUMAN PLATELETS: A NEW 
BIOCHEMICAL-PARAMETER IN DEPRESSION. 

004358 04-09 
BINDING-ACTIVITIES 

DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND RECEPTOR BINDING- 
AQIVITIES FOLLOWING ACUTE AND CHRONIC NEUROLEPTIC-DRUG 
TREATMENT. (UNPUBLISHED PAPER). 

001172 02-03 

BINDING-ACTIVITY 

IDENTIFICATION AND PARTIAL PURIFICATION OF A HYDROPHOBIC 

PROTEIN COMPONENT ASSOCIATED WITH (3H)SPIR0PERID0L BINDING- 
AQIVITY. (UNPUBLISHED PAPER). 

001007 02-01 
BETA ENDORPHIN: DISSOCIATION OF RECEPTOR BINDING-AQIVITY FROM 
ANALGESIC POTENCY. 

001081 02-02 
SYNTHESIS AND GABA-RECEPTOR BINDING-AQIVITY OF TWO 
FLUOROAMINOMETHYLPHENOLS. 

003693 04-02 

BINDING-SITE ^ , ,^ 

ABUNDANCE AND LOCATION OF 1251 SALMON CALCITONIN BINDING-SITE 
IN RAT-BRAIN. 

001320 02-03 
A HIGH-AFFINITY GTP BINDING-SITE IN RAT-BRAIN. (UNPUBLISHED 

''^''^'^' 001442 02-03 



S-56 



VOLUME 19, SUBJECT INDEX 



Subject Index 



THE PHARMACOLOGICAL RELEVANCE OF THE COCAINE BINDING-SITE IN 
MOUSE-BRAIN. 

001772 02-04 
BINDINO-SITES 

LOCALIZATION OF ALPHA BUNGAROTOXIN BINDING-SITES IN SYNAPSES 
Of THE DEVELOPING CHICK RETINA. 

000065 01-03 
(3H)5 HT BINDING-SITES AND 5 HT-SENSITIVE ADENYLATE-CYCLASE IN 
GLIAL CELL MEMBRANE FRACTION. 

000093 01-03 
EVIDENCE FOR, AND LOCALIZATION OF, A UNITARY DOPAMINE- 
RECEPTOR COMPOSED OF COOPERATIVELY LINKED SUBUNIT BINDING- 
SITES IN RAT STRIATUM. 

000186 01-03 
SEROTONIN-SENSITIVE ADENYLATE-CYCLASE AND (3H)SER0T0NIN 
BINDING-SITES IN THE CNS OF THE RAT ~ I. KINETIC PARAMETERS 
AND PHARMACOLOGICAL-PROPERTIES. 

000213 01-03 
SEROTONIN-SENSITIVE ADENYLATE-CYCLASE AND (3H)SER0T0NIN 

BINDING-SITES IN THE CNS OF THE RAT - II. RESPECTIVE REGIONAL 
AND SUBCELLULAR DISTRIBUTIONS AND ONTOGENETIC 
DEVELOPMENTS. 

000214 01-03 
REGIONAL DISTRIBUTION AND BIOCHEMICAL-PROPERTIES OF 1251 TYR8- 

SUBSTANCE-P BINDING-SITES IN SYNAPTIC VESICLES. 

000259 01-03 
DIFFERENTIAL REGULATION OF MUSCARINIC AGONIST BINDING-SITES 
FOLLOWING CHRONIC CHOLINESTERASE INHIBITION. 

000279 01-03 
PROPERTIES OF (3H)DIAZEPAM BINDING-SITES ON RAT BLOOD- 
PLATELETS. 

000317 01-03 
SOLUBILIZATION OF THE DIHYDROPICROTOXININ BINDING-SITES. 

001192 02-03 
DOWN REGULATION OF DIHYDROALPRENOLOL AND IMIPRAMINE 
BINDING-SITES IN BRAIN OF RATS REPEATEDLY TREATED WITH 
IMIPRAMINE. 

001317 02-03 
UNITARY DOPAMINERGIC-RECEPTOR COMPOSED OF COOPERATIVELY 
LINKED AGONIST AND ANTAGONIST SUBUNIT BINDING-SITES. 

001342 02-03 
LOCALIZATION OF NALOXONE SENSITIVE (3H)DIHYDR0M0RPHINE 
BINDING-SITES WITHIN THE HIPPOCAMPUS OF THE RAT. 

001368 02-03 
CHARACTERIZATION OF BENZODIAZEPINE BINDING-SITES. (UNPUBLISHED 
PAPER). 

001503 02-03 
BENZODIAZEPINE BINDING-SITES: PROPERTIES AND MODULATION. 

(UNPUBLISHED PAPER). 

001504 02-03 
COMPARED PROPERTIES OF CENTRAL AND PERIPHERAL BINDING-SITES 

FOR PHENCYCLIDINE. 

001521 02-03 
MU-RECEPTORS AND DELTA OPIATE-RECEPTORS: CORRELATION WITH 
HIGH-AFFINITY AND LOW AFFINITY OPIATE BINDING-SITES. 

001554 02-03 
KAINATE LESION DISSOCIATES STRIATAL DOPAMINE-RECEPTOR 
RADIOLIGAND BINDING-SITES. 

002803 03-03 
PROPERTIES OF DOPAMINE AGONIST AND ANTAGONIST BINDING-SITES IN 
MAMMALIAN RETINA. 

002814 03-03 
IDENTIFICATION OF TWO BENZODIAZEPINE BINDING-SITES ON CELLS 
CULTURED FROM RAT-CEREBRAL-CORTEX. 

002820 03-03 
LAMINAR DISTRIBUTION OF PUTATIVE NEUROTRANSMITTER AMINO- 
ACIDS AND LIGAND BINDING-SITES IN THE DOG OLFACTORY-BULB. 

002836 03-03 
CONVULSANT AND ANTICONVULSANT-DRUG BINDING-SITES RELATED TO 
GABA REGULATED CHLORIDE ION-CHANNELS. 

002848 03-03 
3H SEROTONIN BINDING-SITES IN RAT-BRAIN: EFFECTS OF REPEATED 
ADMINISTRATION OF ANTIDEPRESSANT-DRUGS. (PH.D. 
DISSERTATION). 

002881 03-03 
BENZODIAZEPINE BINDING-SITES: PROPERTIES AND MODULATION. 

002912 03-03 
3H IMIPRAMINE BINDING IN HUMAN PLATELETS: DIMINUTION OF 
BINDING-SITES IN DEPRESSED-PATIENTS. 

003427 03-13 
CHARACTERIZATION OF TWO (3H)GLUTAMATE BINDING-SITES IN RAT 
HIPPOCAMPAL MEMBRANES. 

003726 04-03 
INHIBITION OF DOPAMINE D-1 AND D-2 BINDING-SITES IN NEURONAL 
TISSUE BY ASCORBATE. 

003876 04-03 
HIGH-AFFINITY BINDING-SITES FOR A SOMATOSTATIN-28 ANALOG IN 
RAT-BRAIN. 

003985 04-03 



L ASPARTATE BINDING-SITES IN RAT-CEREBELLUM: A COMPARISON Of 
THE BINDING OF L (3H)ASPARTATE AND L (3H)GLUTAMATE TO 
SYNAPTIC MEMBRANES. 

004000 04-03 
INTERACTION OF STEREOISOMERS OF BARBITURATES WITH (3H)ALPHA 
DIHYDROPICROTOXININ BINDING-SITES. 

004036 04-03 
BIOAVAILABILITY 

BIOAVAILABILITY OF 14C SULPIRIDE IN DOGS. 

000017 01-03 
CLASSIFICATION AND ASSESSMENT OF CEREBRAL BIOAVAILABILITY OF 
LOPIRAZEPAM (D-1 2524) BY QUANTITATIVE EEG AND 
PSYCHOMETRIC-ANALYSIS. 

000720 01-11 
BIOAVAILABILITY OF SULPIRIDE TABLET AND ''APSULE IN DOGS. 

001101 02-03 
ORAL BIOAVAILABILITY OF APOMORPHINE IN THE RAT WITH A 
PORTACAVAL VENOUS ANASTOMOSIS, 

001158 02-03 
LOW ORAL CPZ BIOAVAILABILITY IN CHRONIC SCHIZOPHRENIA. 
(UNPUBLISHED PAPER). 

001938 02-08 
BIOAVAILABILITY AND KINETICS OF MAPROTILINE. 

002204 02-13 
THE BIOAVAILABILITY OF ORAL AND PARENTERAL CHLORIMIPRAMINE 
(ANAFRANIL). 

002232 02-13 
BIOAVAILABILITY AND RELATED PHARMACOKINETICS IN MAN OF 
ORALLY ADMINISTERED L 5 HYDROXYTRYPTOPHAN IN STEADY- ST ATE. 

002261 02-13 
PHARMACOKINETICS AND BIOAVAILABILITY OF CHLORDIAZEPOXIDE IN 
HUMANS. 

002564 02-17 
EFFECT OF DOSE ON BIOAVAILABILITY OF ORAL DIGOXIN. 

003161 03-07 
DOSAGE FORM DESIGN FOR IMPROVEMENT OF BIOAVAILABILITY OF 
LEVODOPA III: INFLUENCE OF DOSE ON PHARMACOKINETIC BEHAVIOR 
OF LEVODOPA IN DOGS AND PARKINSONIAN-PATIENTS. 

004551 04-13 
BIOCHEMICAL 

THE TREATMENT OF PARKINSONS-DISEASE USING A COMBINATION OF L- 
DOPA AND DECARBOXYLASE INHIBITORS (CARBIDOPA, BENSERASIDE). 
A CLINICAL AND BIOCHEMICAL COMPARATIVE INVESTIGATION. 

000712 01-11 
EFFECTS OF PROLONGED TREATMENT WITH LITHIUM AND TRICYCLIC- 
ANTIDEPRESSANTS ON DISCHARGE FREQUENCY, NOREPINEPHRINE 
RESPONSES AND BETA-RECEPTOR BINDING IN RAT-CEREBELLUM: 
ELECTROPHYSIOLOGICAL AND BIOCHEMICAL COMPARISON. 

002884 03-03 
RECENT REVIEWS OF BIOCHEMICAL, NEUROCHEMICAL, AND 
PHARMACOLOGICAL TOPICS. 

003649 03-17 
BIOCHEMICAL AND IMMUNOLOGICAL PROPERTIES OF THE MOUSE BRAIN 
ENOLASES PURIFIED BY A SIMPLE METHOD. 

003668 04-01 
FLUORESCENT PROBES OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC 
AND OPIATE-RECEPTORS: BIOCHEMICAL AND HISTOCHEMICAL 
EVALUATION. 

003685 04-02 
SYNTHESIS AND BIOCHEMICAL AND PHARMACOLOGIC PROPERTIES OF 
ANALOGUES AND DERIVATIVES OF P CHLOROPHENYLALANINE. 

003691 04-02 
BIOCHEMICAL INVESTIGATIONS INTO THE MODE Of ACTION OF 
TRAZODONE. 

003753 04-03 
TOWARD A BIOCHEMICAL CLASSIFICATION OF DEPRESSIVE-DISORDERS 
IV: PRETREATMENT URINARY MHPG LEVELS AS PREDICTORS OF 
ANTIDEPRESSANT RESPONSE TO IMIPRAMINE. 

004406 04-09 
PROLACTIN AND NEUROLEPTIC-DRUGS: A BIOCHEMICAL INDEX OF 
CLINICAL-RESPONSE? 

004539 04-13 
THE BIOCHEMICAL BACKGROUND TO TARDIVE-DYSKINESIA. 

004588 04-15 
BIOCHEMICAL AND NEUROENDOCRINE APPROACHES TO A MALIGNANT- 
SYNDROME OF NEUROLEPTIC. 

004589 04-15 
BIOCHEMICAL-ACTION 

CLINICAL AND BIOCHEMICAL-ACTION OF PIRACETAM (NOOTROPIL) IN 
DRUG-RESISTANT DEPRESSION. 

000600 01-09 
BIOCHEMICAL-ASPECTS 

SOME PHARMACOLOGICAL-ASPECTS AND BIOCHEMICAL-ASPECTS OF 
TRH: EXPERIMENTAL AND CLINICAL DATA. 

001189 02-03 
CLOMIPRAMINE TREATMENT OF OBSESSIVE-COMPULSIVE-DISORDER: II. 
BIOCHEMICAL-ASPECTS. 

002300 02-13 



d.. 



•T 
■t 



"lit 









S-57 



Subject Index 



Psychopharmacology Abstracit 



BIOCHEMICAL-BASIS 

BENZODIAZEPINES: A TOOL TO EXPLORE THE BIOCHEMICAL-BASIS AND 
NEUROPHYSIOLOGICAL-BASIS OF ANXIETY. 

000397 01-04 
BIOCHEMICAL-CHANGES 

BEHAVIORAL-CHANGES AND BIOCHEMICAL-CHANGES AFTER 
HIPPOCAMPAL DAMAGE. (PH.D. DISSERTATION). 

003069 03-04 
BIOCHEMICAL-CHARACTERIZATION 

BIOCHEMICAL-CHARACTERIZATION OF THE RAT SYMPATHETIC 
GANGLION; PHARMACOLOGICAL-EFFECTS OF RESERPINE ON 
GANGLIONIC CATECHOLAMINES. 

000153 01-03 
BIOCHEMICAL-CHARACTERIZATION AND PHARMACOLOGICAL 
CHARACTERIZATION OF A PEPTIDE FROM THE HEMODIALYSATE OF 
PSYCHOTIC-PATIENTS. 

001049 02-01 
BIOCHEMICAL-CONSEQUENCES 

THE DOPAMINE-RECEPTOR COMPLEX: BIOCHEMICAL-CONSEQUENCES OF 
SUPERSENSITIVITY INDUCED BY TREATMENT WITH 6 
HYDROXYDOPAMINE OR MORPHINE. 

003958 04-03 
BIOCHEMICAL-CONSIDERATIONS 

BRAIN CATECHOLAMINES, MENTAL-ILLNESSES, AGING AND SENILE- 
DEMENTIA: BIOCHEMICAL-CONSIDERATIONS AND PHARMACOLOGICAL- 
CONSIDERATIONS. 

001550 02-03 
BIOCHEMICAL-CORRELATES 

SODIUM-VALPROATE IN SCHIZOPHRENIA: SOME BIOCHEMICAL- 
CORRELATES. 

000561 01-08 
RECEPTOR PLASTICITY: BIOCHEMICAL-CORRELATES AND 
PHARMACOLOGICAL SIGNIFICANCE. 

001181 02-03 
BEHAVIORAL-CORRELATES AND BIOCHEMICAL-CORRELATES AFTER 
HALOPERIDOL AND CLOZAPINE LONG-TERM-TREATMENT 

001422 02-03 
BIOCHEMICAL-CORRELATION 

CLINICAL-CORRELATION, BIOCHEMICAL-CORRELATION, AND 
PSYCHOPHARMACOLOGICAL-CORRELATION IN PATIENTS WITH 
DEPRESSIVE-SYMPTOMATOLOGY. 

002018 02-09 
BIOCHEMICAL-CORRELATIONS 

CLINICAL AND BIOCHEMICAL-CORRELATIONS IN ABRUPT 
DISCONTINUATION OF PSYCHOPHARMACOTHERAPY. 

004330 04-08 
BIOCHEMICAL-DATA 

CLINICAL AND BIOCHEMICAL-DATA ON THE ACTION OF MAPROTILINE 
AND CLOMIPRAMINE IN DEPRESSIVE-STATES (PRELIMINARY 
OBSERVATION). 

002032 02-09 
BIOCHEMICAL-EFFECTS 

HISTAMINE-RECEPTORS IN THE BRAIN: CHARACTERIZATION BY BINDING 
STUDIES AND BIOCHEMICAL-EFFECTS. 

001054 02-01 
STUDIES ON THE BIOCHEMICAL-EFFECTS AND BEHAVIOURAL-EFFECTS OF 
ORAL NICOTINE. 

001115 02-03 
BIOCHEMICAL-EFFECTS OF ZIMELIDINE IN MAN. 

001967 02-09 
BIOCHEMICAL-EFFECTS AND BEHAVIORAL-EFFECTS OF ACUTE ETHANOL IN 
RATS AT DIFFERENT ENVIRONMENTAL TEMPERATURES. 

002864 03-03 
THE ROLE OF CALCIUM AND DOPAMINE MEMBRANE CARRIER IN 

MEDIATING THE BEHAVIORAL-EFFECTS AND BIOCHEMICAL-EFFECTS OF 
AMPHETAMINE (PH.D. DISSERTATION). 

002996 03-04 
CENTRAL CARDIOVASCULAR-EFFECTS AND BIOCHEMICAL-EFFECTS OF 
BACLOFEN IN THE CONSCIOUS RAT. 

003965 04-03 
A COMPARISON BETWEEN SOME BIOCHEMICAL-EFFECTS AND 
BEHAVIOURAL-EFFECTS PRODUCED BY NEUROLEPTICS. 

004116 04-04 
LONG-TERM NEUROLEPTIC TREATMENT OF CHRONIC SCHIZOPHRENIC- 
PATIENTS: CLINICAL AND BIOCHEMICAL-EFFECTS OF WITHDRAWAL. 

004344 04-08 
BIOCHEMICAL-EVENT 

PHOSPHOLIPID METHYLATION: A BIOCHEMICAL-EVENT OF SIGNAL 
TRANSDUCTION. (UNPUBLISHED PAPER). 

001279 02-03 
BIOCHEMICAL-EVIDENCE 

BIOCHEMICAL-EVIDENCE FOR TYPE-1 AND TYPE-2 OPIATE-RECEPTORS. 
(UNPUBLISHED PAPER). 

001050 02-01 
PHARMACOLOGICAL EVIDENCE AND BIOCHEMICAL-EVIDENCE FOR AN 

INTERACTION BETWEEN THE BENZODIAZEPINE AND GABA-RECEPTORS. 

001261 02-03 
BIOCHEMICAL-EVIDENCE FOR OSTEOMALACIA WITH CARBAMAZEPINE 
THERAPY. 

002445 02-15 



BIOCHEMICAL-LOCALIZATION 

BIOCHEMICAL-LOCALIZATION AND CHARACTERIZATION OF BOMBESIN- 
UKE-PEPTIDES IN DISCRETE REGIONS OF RAT-BRAIN. (UNPUBLISHED 
PAPER). 

001046 02-01 
BIOCHEMICAL-MEASUREMENTS 

BIOCHEMICAL-MEASUREMENTS DURING (-)DEPRENYL TREATMENT OF 
PARKINSONISM. 

000673 01-11 
BIOCHEMICAL-MECHANISM 

BIOCHEMICAL-MECHANISM OF SIGNAL TRANSDUCTION ACROSS 
BIOMEMBRANES. (UNPUBLISHED PAPER). 

001026 02-01 
NEW TRENDS CONCERNING THE BIOCHEMICAL-MECHANISM OF ACTION 
OF BENZODIAZEPINES. 

003642 03-17 
BIOCHEMICAL-OBSERVATIONS 

TREATMENT OF MYOCLONUS WITH L 5 HYDROXYTRYPTOPHAN AND 
CARBIDOPA: CLINICAL, ELECTROPHYSIOLOGICAL, AND BIOCHEMICAL- 
OBSERVATIONS. 

002180 02-11 
BIOCHEMICAL-PARAMETER 

(3H) IMIPRAMINE BINDING IN HUMAN PLATELETS: A NEW 
BIOCHEMICAL-PARAMETER IN DEPRESSION. 

004358 04-09 
BIOCHEMICAL-PARAMETERS 

DRUG INTERFERENCE ON SOME BIOCHEMICAL-PARAMETERS OF RAT- 
CEREBRAL-CORTEX DURING POSTISCHEMIC RECOVERY. 

001126 02-03 
BIOCHEMICAL-PHARMACOLOGY 

NEUROCHEMICAL-PHARMACOLOGY AND BIOCHEMICAL-PHARMACOLOGY. 

003639 03-17 
BIOCHEMICAL-PROPERTIES 

REGIONAL DISTRIBUTION AND BIOCHEMICAL-PROPERTIES OF 1251 TYR8- 
SUBSTANCE-P BINDING-SITES IN SYNAPTIC VESICLES. 

000259 01-03 
BIOCHEMICAL-PROPERTIES OF SPIPERONE BINDING TO RAT-BRAIN 
MEMBRANES 

000294 01-03 
PHARMACOLOGICAL AND BIOCHEMICAL-PROPERTIES OF BRL- 14342, A 
NOVEL POTENTIAL ANTIDEPRESSANT-DRUG. 

004086 04-04 
BIOCHEMICAL-RESPONSE 

RELATIONSHIPS BETWEEN CHLORPROMAZINE CONCENTRATIONS IN 
PLASMA AND CEREBROSPINAL-FLUIO AND CLINICAL-RESPONSE AND 
BIOCHEMICAL-RESPONSE IN PSYCHOTIC-PATIENTS. 

001905 02-08 
BIOCHEMICAL-STUDIES 

EVIDENCE FOR A GABAERGIC NIGROTHALAMIC PATHWAY IN THE RAT: I. 
BEHAVIOURAL-STUDIES AND BIOCHEMICAL-STUDIES 

000158 01-03 
BIOCHEMICAL- STUDIES AFTER CHRONIC ADMINISTRATION OF 
NEUROLEPTICS TO MONKEYS. 

000523 01-05 
TARDIVE-DYSKINESIA: BIOCHEMICAL-STUDIES. (UNPUBLISHED PAPER). 

002245 02-13 
BEHAVIORAL AND BIOCHEMICAL- STUDIES OF THE SCOPOLAMINE-INDUCEO 
REVERSAL OF NEUROLEPTIC AQIVITY. 

004 1 95 04-04 
BIOCHEMICAL-STUDIES OF HUMAN EPILEPTICS DURING ANTICONVULSANT 
THERAPY 

004490 04-11 
BIOCHEMICAL-STUDY 

EFFECT OF CHLORPROMAZINE ON CELL PROLIFERATION IN THE 
DEVELOPING RAT-BRAIN. A COMBINED BIOCHEMICAL-STUDY AND 
MORPHOLOGICAL-STUDY. 

001407 02-03 
BIOCHEMICAL-STUDY OF THE ANIMAL-MODEL DEPRESSION INDUCED BY 
TETRABENAZINE. 

001506 02-03 
A BIOCHEMICAL-STUDY OF LUMBAR CEREBROSPINAL-FLUID IN 
EXTRAPYRAMIDAL-DISORDERS. 

002186 02-11 
BIOCHEMICAL-VARIABLES 

RELATIONSHIPS AMONG BIOCHEMICAL-VARIABLES, CLINICAL- 
VARIABLES, AND PHARMACOKINETIC-VARIABLES IN NEUROLEPTIC 
TREATED SCHIZOPHRENIC-PATIENTS. 

001946 02-08 
BIOCHEMICALLY-SELECTIVE 

NOREPINEPHRINE UPTAKE INHIBITORS AS BIOCHEMICALLY-SELEQIVE 
AND BEHAVIORALLY-SELEaiVE ANTAGONISTS OF THE LOCOMOTOR- 
STIMULATION INDUCED BY INDIRECTLY ACTING SYMPATHOMIMETIC- 
AMINES IN MICE. 

000492 01-04 
BIOCHEMISTRY 

INFLUENCE OF CANNABIS AND DELTA9 TETRAHYDROCANNABINOL ON 
THE BIOCHEMISTRY OF THE MALE REPRODUCTIVE ORGANS. 

002686 03-03 



S-58 



VOLUME 19, SUBJECT INDEX 



Subject Index 



BIOELECTRIC-ACTIVITY 

THE EFFECT OF CLOFELIN ON THE BIOELECTRIC-ACTIVITY OF THE BRAIN. 

001449 02-03 
BIOELECTRICAUACTIVITY 

BIOELECTRICAL-ACTIVITY OF THE RAT BRAIN AFTER PREMATURE 
WEANING AND AFTER RNA ADMINISTRATION. 

002865 03-03 
THE EFFECT OF LITHIUM-HYDROXYBUTYRATE ON THE BIOELECTRICAL- 
ACTIVITY OF THE CORTEX AND SOME SUBCORTICAL STRUCTURES OF 
THE RABBIT BRAIN. 

003994 04-03 
THE EFFECT OF THE NEW ANTIDEPRESSANT INKASAN ON THE 
BIOELEQRICAL-ACTIVITY OF THE BRAIN AND ON CONDITIONED 
REFLEXES. 

004212 04-04 
BIOGENESIS 

REGULATION OF BIOGENESIS OF PSYCHOTOMIMETIC AMINES. 
(UNPUBLISHED PAPER). 

003818 04-03 
BIOGENIC- AMINE 

INTERACTION OF BIOGENIC-AMINE SYSTEMS IN BRAIN. (UNPUBLISHED 
PAPER). 

001141 02-03 
SHORT-TERM AND LONG-TERM EFFECTS OF METHAMPHETAMINE ON 
BIOGENIC-AMINE METABOLISM IN EXTRASTRIATAL DOPAMINERGIC 
NUCLEI. 

001384 02-03 
A SELECTED ION-MONITORING ASSAY FOR BIOGENIC-AMINE 
METABOLITES AND PROBENECID, IN HUMAN LUMBAR 
CEREBROSPINAL-FLUID. 

003663 04-01 
BIOGENIC-AMINES 

REUPTAKE OF BIOGENIC-AMINES BY BRAIN SLICES: EFFECT OF 
HYDROCORTISONE. 

000187 01-03 
ACTION OF THE ANTIDEPRESSANT PRIDEFINE (AHR-1 1 18) ON BIOGENIC- 
AMINES IN THE RAT-BRAIN. 

000312 01-03 
THE ROLE OF BIOGENIC-AMINES IN AMYGDALAR KINDLING. I. LOCAL 
AMYGDALAR AFTERDISCHARGE. 

000327 01-03 
HIGH-SENSITIVITY NEGATIVE CHEMICAL-IONIZATION MASS-SPECTRAL- 
ANALYSIS OF BIOGENIC-AMINES AND METABOLITES. (UNPUBLISHED 
PAPER). 

001042 02-01 
SYNTHESIS OF 180 ANALOGS OF BIOGENIC-AMINES. (UNPUBLISHED 
PAPER). 

001044 02-01 
BIOGENIC-AMINES AND NEUROPEPTIDES PLAY A ROLE IN THE CENTRAL- 
REGULATION OF GENETIC HYPERTENSION. (UNPUBLISHED PAPER). 

001455 02-03 
CENTRAL BIOGENIC-AMINES AND NEUROPEPTIDES IN GENETIC 

HYPERTENSION. (UNPUBLISHED PAPER). 

001456 02-03 
EFFEa OF LOW-DOSE LITHIUM ADMINISTRATION AND SUBSEQUENT 

WITHDRAWAL ON BIOGENIC-AMINES IN RAT-BRAIN. 

003708 04-03 
STRESS-MODULATED ALTERATION OF BRAIN BIOGENIC-AMINES IN THE 
RAT: EFFEaS OF L TRYPTOPHAN. 

003978 04-03 
THE EFFEQ OF P CHLOROPHENYLALANINE ON THE DISTRIBUTION OF 
BIOGENIC-AMINES IN THE BRAIN, AND ON MEMORY IN RATS. 

004068 04-04 
BIOLOGIC 

CURRENT BIOLOGIC STRATEGIES FOR ANXIETY. 

003276 03-10 
BIOLOGIC-INTERACTION 

BIOLOGIC-INTERACTION OF GAMMA-RADIATION WITH 
PHENYLBUTAZONE, PHENYTOIN, OR HYDRALAZINE. 

000518 01-05 
BIOLOGICAL 

INFLUENCE OF NICERGOLINE ON MOLECULAR BIOLOGICAL PROCESSES IN 
THE BRAIN AND LEARNING-ABILITY OF THE RAT. 

000449 01-04 
LITHIUM LEVEL IN SOME BIOLOGICAL FLUIDS AT ITS PROPHYLAQIC 
THERAPEUTIC APPLICATION. 

000605 01-09 
DETERMINATION OF TRICYCLIC-ANTIDEPRESSANTS AND TETRACYCLIC- 
ANTIDEPRESSANTS AND OF THEIR METABOLIC PRODUCTS IN 
BIOLOGICAL FLUIDS. 

002498 02-16 
HIGH-AFFINITY 3H IMIPRAMINE BINDING: A NEW BIOLOGICAL TOOL FOR 
STUDIES IN DEPRESSION. 

003610 03-17 
BIOLOGICAL EVALUATION OF A TRH ANALOGUE WITH A MODIFIED 
PROLINE RESIDUE. 

003662 04-01 
PREPARATION AND BIOLOGICAL ACTIONS OF N 2,2,2 TRIFLUOROETHYL- 
DIHYDROXYPHENYLETHYLAMINE . 

003697 04-02 



NEW BIOLOGICAL RESEARCH RELEVANT TO ANXIETY. 

004705 04-17 
BIOLOGICAL AND PHYSIOLOGICAL PREDICTORS OF DRUG RESPONSE. 
(UNPUBLISHED PAPER). 

004708 04-17 
BIOLOGICAL-ACTIVITY 

MODIFICATION OF THE PROLINE RESIDUE OF TRH ENHANCES BIOLOGICAL- 
ACTIVITY AND INHIBITS DEGRADATION. 

000351 01-04 
CONFIRMATION BEHAVIOR OF PHENCYCLIDINES AND BIOLOGICAL- 
ACTIVITY. 

001031 02-01 
COMPARISON OF BIOLOGICAL-ACTIVITY AND BEHAVIORAL-ACTIVITY OF 
ALPHA AND GAMMA MELANOCYTE-STIMULATING-HORMONES. 
(UNPUBLISHED PAPER). 

001398 02-03 
BIOLOGICAL-ACTIVITY OF THE TETRAHYDROCANNABINOLS. 

002556 02-17 
DIFFERENTIAL LOSS OF BIOLOGICAL-ACTIVITY OF THE ENKEPHALINS 
INDUCED BY CURRENT. 

002783 03-03 
SYNTHESIS AND BIOLOGICAL-ACTIVITY OF HUMAN BETA ENDORPHIN 
ANALOGS WITH DISULFIDE BRIDGES. 

003655 04-01 
BIOLOGICAL-EFFECTS 

BIOLOGICAL-EFFECTS OF CHLORPROMAZINE IN CHRONIC 
SCHIZOPHRENICS. III. THE MUTUAL RELATION OF EACH INDEX. 

003179 03-08 
THE BIOLOGICAL-EFFECTS AND CLINICAL-EFFECTS OF ORAL MAGNESIUM 
AND ASSOCIATED MAGNESIUM VITAMIN-B6 ADMINISTRATION ON 
CERTAIN DISORDERS OBSERVED IN INFANTILE AUTISM. 

003291 03-11 
BEHAVIORAL-EFFECTS AND BIOLOGICAL-EFFECTS OF ACUTE BETA 
ENDORPHIN INJECTION IN SCHIZOPHRENIC-PATIENTS AND DEPRESSED- 
PATIENTS. 

003357 03-11 
BIOLOGICAL-EFFECTS OF CHLORPROMAZINE IN CHRONIC 
SCHIZOPHRENICS. I. WITH REFERENCE TO PITUITARY-HORMONES. 

003415 03-13 
BIOLOGICAL-EFFECTS OF CHLORPROMAZINE IN CHRONIC 

SCHIZOPHRENICS. II. WITH REFERENCE TO SYMPATHETIC NEURONAL 
FUNCTION. 

003416 03-13 
BIOLOGICAL-INTERACTION 

THE MOLECULAR ARCHITECTURE OF ERGOPEPTINES: A BASIS FOR 
BIOLOGICAL-INTERACTION. 

001527 02-03 
BIOLOGICAL-MATERIAL 

A SPECIFIC AND SENSITIVE MICROASSAY FOR HYDROXYINDOLES IN 
BIOLOGICAL-MATERIAL - APPLICATION FOR CEREBRAL MICROVESSELS, 
BRAIN, AND PINEAL-ORGAN OF THE RAT. 

002503 02-16 
BIOLOGICAL-PSYCHIATRY 

ANIMAL-MODELS OF RELEVANCE TO BIOLOGICAL-PSYCHIATRY. 

002490 02-16 
DISCUSSION OF WHO ACTIVITY IN BIOLOGICAL-PSYCHIATRY WITH 
SPECIAL REFERENCE TO TRAINING. 

002520 02-17 
CONVERGENCES AND DIVERGENCES BETWEEN BIOLOGICAL-PSYCHIATRY 
AND PSYCHOTHERAPY. 

002536 02-17 
BIOLOGICAL-PSYCHIATRY TODAY ~ VOL. B. 

002588 02-17 
BIOLOGICAL-PSYCHIATRY TODAY ~ VOL. A. 

002589 02-17 
A QUANTITATIVE PROBE F.OR BIOLOGICAL-PSYCHIATRY: SELECTED ION- 
MONITORING. 

004685 04-16 
THE PROMISE OF BIOLOGICAL-PSYCHIATRY. 

004752 04-17 
BIOLOGICAL-RHYTHM 

BIOLOGICAL-RHYTHM DISTURBANCES IN AFFECTIVE-ILLNESS. 

002628 02-17 
BIOLOGICAL-RHYTHMICITY 

THE INFLUENCE OF DAILY BIOLOGICAL-RHYTHMICITY ON THE HOMING- 
BEHAVIOR, PSYCHOPHARMACOLOGICAL RESPONSIVENESS, LEARNING 
AND RETENTION OF SUCKLING RATS. (PH.D. DISSERTATION). 

001660 02-04 
BIOLOGICAL-STABILITY 

AN ANALOGUE OF THYROTROPIN-RELEASING-HORMONE WITH IMPROVED 
BIOLOGICAL- STABILITY BOTH IN VITRO AND IN VIVO. 

000032 01-03 
BIOLOGICAL-STUDIES 

CLINICAL-STUDIES AND BIOLOGICAL-STUDIES OF L TRYPTOPHAN IN 
DEPRESSION. 

001977 02-09 
BIOLOGY 

BIOLOGY OF MANIC-MELANCHOLIC-DISORDERS. 

000978 01-17 



I 

(3; 






'1* 



5 



5T 



S-59 



Subject Index 



Psychopharmacology Abstracts 



BIOLOGY AND THERAPY OF VIOLENT-BEHAVIOUR IN CHILDREN. 

002608 02-17 
BIBLIOGRAPHY ON THE BIOLOGY AND PHARMACOLOGY OF LITHIUM. 

003630 03-17 
BIOMEDICAL-CORRELATES 

LECITHIN ADMINISTRATION IN TARDIVE-DYSKINESIA: CLINICAL AND 
BIOMEDICAL-CORRELATES. 

003496 03-15 
BrOMEMBRANES 

BIOCHEMICAL-MECHANISM OF SIGNAL TRANSDUCTION ACROSS 
BIOMEMBRANES. (UNPUBLISHED PAPER). 

001026 02-01 
BIOPSY 

RENAL FUNCTION AND BIOPSY IN PATIENTS ON LITHIUM THERAPY. 

000830 01-15 
BIOPSYCHOSOCIAL-PERSPECTIVE 

LITHIUM: A BIOPSYCHOSOCIAL-PERSPECTIVE. 

003247 03-09 
BIOPTERIN 

THE INFLUENCE OF D-AMPHETAMINE ON RAT-BRAIN STRIATAL REDUCED 
BIOPTERIN CONCENTRATION. 

003922 04-03 
BIOSYNTHESIS 

HYPOTHALAMIC CATECHOLAMINE BIOSYNTHESIS IN VITRO AS 
MEASURED BY LIQUID-CHROMATOGRAPHY AND ELECTROCHEMICAL- 
DETECTION. 

000537 01-06 
BIOSYNTHESIS OF POSTERIOR PITUITARY-HORMONES (UNPUBLISHED 
PAPER). 

001053 02-01 
INHIBITORS OF PHENYLETHANOLAMINE-N-METHYLTRANSFERASE AND 
EPINEPHRINE BIOSYNTHESIS 2 1 ,2,3,4 TETRAHYDROISOQUlNOLINE-7- 
SULFONANILIDES. 

001069 02-02 
BIOSYNTHESIS, AXONAL TRANSPORT AND RELEASE OF POSTERIOR 
PITUITARY-HORMONES (UNPUBLISHED PAPER). 

001148 02-03 
DOPAMINE BIOSYNTHESIS IS REGULATED BY THE AMINE NEWLY 
RECAPTURED BY DOPAMINERGIC NERVE-ENDINGS. 

001163 02-03 
EFFECT OF OPIATES ON MACROMOLECULE BIOSYNTHESIS. 

001335 02-03 
EFFECT OF MELANOSTATIN AND THYROLIBERIN ON THE BIOSYNTHESIS 
AND RELEASE OF DOPAMINE BY RAT-BRAIN STRIATAL P2-FRACTI0NS 

001472 02-03 
EFFECT OF PROSTAGLANDIN-El AND ITS BIOSYNTHESIS INHIBITOR 
INDOMETHACIN ON DRINKING IN THE RAT. 

001749 02-04 
INFLUENCE OF PSYCHOACTIVE AND NONPSYCHOACTIVE CANNABINOIDS 
ON CELL PROLIFERATION AND MACROMOLECULAR BIOSYNTHESIS IN 
HUMAN CELLS. 

002830 03-03 
LONG-TERM-TREATMENT OF RATS WITH MORPHINE DECREASES IN VITRO 
BIOSYNTHESIS IN AND RELEASE OF BETA ENDORPHIN FROM 
INTERMEDIATE/POSTERIOR LOBES OF PITUITARY. 

003846 04-03 
BIOTRANSFORMATION 

EFFECTS OF LISURIDE ON BODY-TEMPERATURE OF RATS AND RABBITS: 
RELATION TO MICROSOMAL BIOTRANSFORMATION AND 
DOPAMINERGIC-RECEPTOR STIMULATION . 

001161 02-03 
KINETICS AND BIOTRANSFORMATION OF LORMETAZEPAM: II. 

RADIOIMMUNOLOGIC DETERMINATIONS IN PLASMA AND URINE OF 
YOUNG AND ELDERLY SUBJECTS: FIRST-PASS EFFECT. 

004516 04-13 
BIPERIDEN-HYDROCHIORIDE 

A COMPARISON OF BIPERIDEN-HYDROCHLORIDE (AKINETON) AND 
BENZHEXOL (ARTANE) IN THE TREATMENT OF DRUG-INDUCED 
PARKINSONISM. 

002146 02-11 
BIPHASIC 

BIPHASIC RESPONSIVENESS OF RAT PIAL-ARTERIOLES TO DOPAMINE: 
DIRECT OBSERVATIONS ON THE MICROCIRCULATION. 

001105 02-03 
BIPHASIC ACTIVITY OF MEMBRANE-BOUND ENZYMES IN BRAIN 
MITOCHONDRIA AND SYNAPTOSOMES DURING THE DEVELOPMENT OF 
TOLERANCE TO AND PHYSICAL-DEPENDENCE ON CHRONIC MORPHINE 
ADMINISTRATION TO RATS. 

001285 C2-03 
APPARENT SEROTONERGIC MODULATION OF THE DOSE-DEPENDENT 
BIPHASIC RESPONSE OF NEOSTRIATAL NEURONS PRODUCED BY D- 
AMPHETAMINE. 

003981 04-03 
BIPHASIC-EFFECTS 

BIPHASIC-EFFECTS OF PIMOZIDE ON SLEEP-WAKEFULNESS IN DOGS. 

000495 01-04 
BIPHASIC-EFFECTS OF A POTENT ENKEPHALIN ANALOGUE D MET2-PR05- 
ENKEPHALINAMIDE AND MORPHINE ON LOCOMOTOR-ACTIVITY IN 
MICE. 

001799 02-04 



BIPHASIC-EFFECTS OF THYROTROPIN-RELEASING-HORMONE ON 
EXPLORATORY-BEHAVIOR IN MICE. 

001808 02-04 
BIPHASIC-EFFECTS OF DIRECT, BUT NOT INDIREQ, GABAMIMETICS AND 
ANTAGONISTS ON HALOPERIDOL-INDUCED CATALEPSY. 

001826 02-04 
BIPHASIC-EFFECTS AND OPPOSITE-EFFECTS OF DOPAMINE AND 
APOMORPHINE ON ENDOGENOUS GABA RELEASE IN THE RAT 
SUBSTANTIA-NIGRA. 

002923 03-03 
BIPOLAR 

BIPOLAR AFFECTIVE-PSYCHOSIS WITH ONSET BEFORE AGE 16 YEARS: 
REPORT OF 10 CASES. 

002001 02-09 
THYROTROPHIN RESPONSE TO THYROTROPHIN-RELEASING-HORMONE IN 
UNIPOLAR AND BIPOLAR AFFECTIVE-ILLNESS. 

003237 03-09 
MAOI-INDUCED RAPID CYCLING BIPOLAR AFFEQIVE-DISORDER IN AN 
ADOLESCENT, 

004637 04-15 
BIPOLAR-I-PATIENTS 

PROPHYLACTIC LITHIUM WITH AND WITHOUT IMIPRAMINE FOR BIPOLAR- 
I-PATIENTS: A DOUBLE-BUND STUDY. 

003233 03-09 
BIPOLAR-M 

LITHIUM AND IMIPRAMINE IN THE PROPHYLAXIS OF UNIPOLAR AND 
BIPOLAR-II DEPRESSION: A PROSPECTIVE, PLACEBO-CONTROLLED 
COMPARISON. 

003252 03-09 
BIPOLAR-PATIENTS 

THE RELATIVE PROPHYLACTIC EFFICACY OF LITHIUM AGAINST MANIC 
AND DEPRESSIVE RECURRENCES IN BIPOLAR-PATIENTS. 

002040 02-09 
BIS-TETRAHYDRO-2-FURANYL-5-FLUOROPYRIMIDINEDIONE 
EFFECTS OF 1,3 BIS-TETRAHYDRO-2-FURANYL-5- 
FLUOROPYRIMIDINEDIONE (FD-1) ON THE CENTRAL-NERVOUS-SYSTEM: 
1. EFFECTS OF MONOAMINES IN THE BRAIN 

001857 02-05 
BISFLUOROPHENYL-BUTYLPIPERIDYLBENZIMIDAZOLINONE-HCL 
THE CRYSTAL AND MOLECULAR STRUCTURE OF THE NEUROLEPTIC 
PIMOZIDE-HYDROCHLORIDE, BISFLUOROPHENYL- 
BUTYLPIPERIDYLBENZIMIDAZOLINONE-HCL. 

001015 02-01 
BITING-REFLEX 

ACTIVATION AND LATERALIZATION OF SENSORIMOTOR FIELD FOR 
PERIORAL BITING-REFLEX BY INTRANIGRAL GABA AGONIST AND BY 
SYSTEMIC APOMORPHINE IN THE RAT 

001657 02-04 
BLACK-WIDOW-SPIDER 

METABOLISM OF 3H NORADRENALINE RELEASED FROM ISOLATED RAT 
HYPOTHALAMUS BY EXTRACTS OF BLACK-WIDOW-SPIDER GLANDS. 

000223 01-03 
BLACKOUTS 

TRICYCLIC-ANTIDEPRESSANTS AND ALCOHOLIC BLACKOUTS. 

004617 04-15 
BLEPHAROPTOSIS 

EFFECTS OF NARCOTIC ANTAGONISTS ON L-DOPA REVERSAL OF 
RESERPINE-INDUCED CATALEPSY AND BLEPHAROPTOSIS IN MICE. 

004186 04-04 

BLINK 

BLINK RATES AND RECEPTOR SUPERSENSITIVITY. 

003022 03-04 
DRUG-EFFEa ON BLINK RATES IN RHESUS-MONKEYS: PRELIMINARY 

STUDIES 

003023 03-04 
EARLY DETECTION OF HUNTINGTONS-DISEASE. BLINK REFLEX AND 

LEVODOPA LOAD IN PRESYMPTOMATIC AND INCIPIENT SUBJEQS. 

003311 03-11 
BLINKS 

EYE BLINKS. (UNPUBLISHED PAPER). 

001672 02-04 

BLOCK 

THE INABILITY OF CHRONIC MIANSERIN TO BLOCK CENTRAL ALPHA2- 
ADRENOCEPTORS. 

001492 02-03 
DIPHENYLHYDANTOIN-INDUCED BLOCK OF THE RAT PHRENIC-NERVE 
DIAPHRAGM PREPARATION PRETREATED WITH P 
HYDROXYMERCURIBENZOATE. 

002749 03-03 
A CRITICAL EVALUATION OF THE USE OF TOXINS FROM DENDROASPIS 
VIRIDIS TO BLOCK NICOTINIC RESPONSES AT CENTRAL AND 
GANGLIONIC SYNAPSES. 

002870 03-03 
WHY DOES SULPIRIDE NOT BLOCK THE EFFECT OF DOPAMINE ON THE 
DOPAMINE-SENSITIVE ADENYLATE-CYCLASE? 

004055 04-03 
NALOXONE FAILS TO BLOCK AMPHETAMINE-INDUCED ANOREXIA AND 
CONDITIONED TASTE-AVERSION. 

004121 04-04 



S-60 



VOLUME 19, SUBJECT INDEX 



Subject Index 



KLOCKADE 

BLOCKADE OF METHAMPHETAMINE-INDUCED DEPRESSION OF TYROSINE- 
HYDROXYLASE BY GABA-TRANSAMINASE INHIBITORS. 

000130 01-03 
BLOCKADE OF STRIATAL NEURONE RESPONSES TO MORPHINE BY 
AMINOPHYLLINE: EVIDENCE FOR ADENOSINE MEDIATION OF OPIATE 
ACTION. 

000229 01-03 
REDUCTION IN THE NUMBER OF SEROTONIN-RECEPTORS IN THE 
BRAINSTEM OF MORPHINE-DEPENDENT RATS: REUTION TO BLOCKADE 
OF NALOXONE PRECIPITATED JUMPING BY SEROTONIN AGONISTS. 

000258 01-03 
5 HT BLOCKADE AND THE STIMULANT-EFFECTS OF D-AMPHETAMINE AND 
L-AMPHETAMINE: NO INTERACTION IN SELF-STIMULATION OF 
PREFRONTAL-CORTEX, HYPOTHALAMUS, OR DORSAL TEGMENTUM. 
UNEXPECTED LETHALITY IN HIPPOCAMPAL SITES. 

000387 01-04 
EXTINCTION AND DOPAMINE-RECEPTOR BLOCKADE AFTER INTERMITTENT 
REINFORCEMENT TRAINING: FAILURE TO OBSERVE FUNCTIONAL 
EQUIVALENCE. 

000490 01-04 
THE BLOCKADE OF ALPHA2-ADREN0CEPT0RS BY THE PNMT INHIBITOR 
SKF-64139 

001255 02-03 
DOPAMINE-RECEPTOR BLOCKADE IN RAT-BRAIN AFTER ACUTE AND 
SUBCHRONIC-TREATMENT WITH TRICYCLIC-ANTIDEPRESSANTS. 

001314 02-03 
PSYCHOTROPIC-DRUG BLOCKADE OF HISTAMINE Hl-RECEPTORS. 

001432 02-03 
ACTH MEDIATION OF LEARNED-FEAR: BLOCKADE BY NALOXONE AND 
NALTREXONE. 

001597 02-04 
MOTOR-AQIVITY AND ROTATIONAL-BEHAVIOR AFTER ANALOGS OF 
COCAINE: CORRELATION WITH DOPAMINE UPTAKE BLOCKADE. 

001650 02-04 
DOPAMINE-RECEPTOR BLOCKADE BY IMIDOLINE AND ITS PROPOSED 
ACTIVE CONFORMATION. 

001687 02-04 
OPIOID BLOCKADE AND SOCIAL-COMFORT IN CHICKS. 

001745 02-04 
HANDEDNESS IN RATS: BLOCKADE OF REACHING-BEHAVIOR BY 
UNILATERAL 6 OHDA INJECTIONS INTO SUBSTANTIA-NIGRA AND 
CAUDATE-NUCLEUS. 

001778 02-04 
THE ROLE OF DIFFERENTIAL BLOCKADE OF ALPHA-ADRENERGIC AGONISTS 
IN CHLORPROMAZINE-INDUCED HYPOTENSION. 

001851 02-05 
BEHAVIORAL-EFFEaS AND SUBJECTIVE-EFFECTS OF BETA-ADRENERGIC 
BLOCKADE IN PHOBIC-SUBJEaS. 

002060 02-10 
DURING ONE YEARS NEUROLEPTIC TREATMENT IN RATS STRIATAL 
DOPAMINE-RECEPTOR BLOCKADE DECREASES BUT SERUM PROLACTIN 
LEVELS REMAIN ELEVATED. 

002707 03-03 
NALOXONE REVERSAL OF THE PENTOBARBITAL-INDUCED BLOCKADE OF 
OVULATION IN THE RAT. 

002817 03-03 
PLASMA CATECHOLAMINES IN RATS EXPOSED TO COLD: EFFECTS OF 
GANGLIONIC AND ADRENORECEPTOR BLOCKADE. 

002863 03-03 
THE TETRACYCLIC-ANTIDEPRESSANT MIANSERIN: EVALUATION OF ITS 
BLOCKADE OF PRESYNAPTIC ALPHA-ADRENOCEPTORS IN A SELF- 
STIMULATION MODEL USING CLONIDINE. 

003016 03-04 
BLOCKADE OF ENDOGENOUS OPIATES REDUCES ACTIVITY IN THE RAT. 

003111 03-04 
NEUROLEPTIC MALIGNANT-SYNDROME: A PATHOGENETIC ROLE FOR 
DOPAMINE-RECEPTOR BLOCKADE? 

003492 03-15 
BLOCKADE BY L LYSINE OF NONNARCOTIC ANALGESICS. 

003857 04-03 
ON THE IMPORTANCE OF AGONIST CONCENTRATION GRADIENTS WITHIN 
ISOLATED TISSUES. INCREASED MAXIMAL RESPONSES OF RAT VASA- 
DEFERENTIA TO (-) NORADRENALINE AFTER BLOCKADE OF NEURONAL 
UPTAKE. 

003879 04-03 
THE IMPORTANCE OF CATECHOLAMINE UPTAKE INHIBITION IN THE 
REVERSAL OF GUANETHIDINE BLOCKADE OF ADRENERGIC NEURONS. 

003900 04-03 
4 AMINOPYRIDINE BLOCKADE OF NEURONAL DEPRESSANT RESPONSES TO 
ADENOSINE-TRIPHOSPHATE. 

003963 04-03 
RNA-POLYMERASE-II IN C6-GLI0MA CELLS: ALPHA AMANITIN BLOCKADE 
OF CYCLIC-AMP-PHOSPHODIESTERASE INDUCTION BY BETA- 
ADRENERGIC STIMULATION. (UNPUBLISHED PAPER). 

003998 04-03 
PHENYTOIN INHIBITION OF CYCLIC-GUANOSINE-MONOPHOSPHATE (C- 
GMP) ACCUMULATION IN NEUROBL^STOMA CELLS BY CALCIUM- 
CHANNEL BLOCKADE. 

004020 04-03 



PHYSIOLOGICAL SIGNIFICANCE OF DOPAMINEAUTORECtPIORS AS 
STUDIED FOLLOWING THEIR SELECTIVE BLOCKADE BY MOLINDONE 

004065 0404 
BLOCKADE BY IMIPRAMINE OR DESIPRAMINE OF PANIC-INDUCED BY 
SODIUM-LACTATE. 

004427 04-10 
IN NORMAL YOUNG MEN ACUTE DOPAMINERGIC BLOCKADE DOES NOT 
IMPAIR FREE WATER EXCRETION FOLLOWING A STANDARD WATER 
LOAD. 

004600 04-15 
BLOCKER 

HYPERVENTILATION-SYNDROME AND BETA-RECEPTOR FUNCTION - 
CLINICAL-EFFECT OF BETA BLOCKER UPON THE SYNDROME. 

004459 04-11 
BLOCKERS 

ACUTE VERSUS CHRONIC EFFECTS OF SEROTONIN UPTAKE BLOCKERS ON 
POTENTIATION OF THE SEROTONIN SYNDROME. 

000050 01-03 
CGP-6085-A, A NEW, SPECIFIC, INHIBITOR OF SEROTONIN UPTAKE: 
NEUROCHEMICAL CHARACTERIZATION AND COMPARISON WITH OTHER 
SEROTONIN UPTAKE BLOCKERS. 

000316 01-03 
THE EFFECTS OF MUSCARINIC-RECEPTOR BLOCKERS ON THE TURNOVER- 
RATE OF ACETYLCHOLINE IN VARIOUS REGIONS OF THE RAT-BRAIN. 

000328 01-03 
INHIBITION OF i3H)DIAZEPAM BINDING TO RAT-BRAIN CORTICAL 
SYNAPTOSOMAL MEMBRANES BY ADENOSINE UPTAKE BLOCKERS. 

000330 01-03 
EFFECTS OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC BLOCKERS ON 
CHLORPROMAZINE-INDUCED ELEVATION OF PLASMA GLUCOSE AND 
CYCLIC-AMP IN FED MICE. 

003946 04-03 
EFFECT OF NOREPINEPHRINE UPTAKE BLOCKERS ON NOREPINEPHRINE 
KINETICS. 

004506 04-13 
BLOCKING 

MIANSERIN: DIRECT ACTIVATION OF BRAIN NOREPINEPHRINE NEURONS 
BY BLOCKING ALPHA2-RECEPT0RS 

001214 02-03 
INFUSIONS INTO THE OCULOMOTOR NUCLEUS OR NERVE: A METHOD OF 
ESTIMATING THE DOSAGE AT WHICH TRANSMITTER ANTAGONISTS 
INFUSED INTRACRANIALLY PRODUCE NONSPECIFIC BLOCKING OF 
NEURAL ACTIVITY. 

003134 03-06 
A COMPARISON OF DOPAMINE-RECEPTOR BLOCKING ASSAY WITH 
PLASMA DRUG LEVELS OF HALOPERIDOL IN SCHIZOPHRENIC-PATIENTS. 

003182 03-08 
BLOCKING-AGENT 

EFFECTS OF THE BETA-ADRENOCEPTOR BLOCKING-AGENT SOTALOL ON 
CNS: SLEEP, EEG, AND PSYCHOPHYSIOLOGICAL PARAMETERS. 

001570 02-04 
BLOCKING-AGENTS 

THE INFLUENCE OF 5 HT-RECEPTOR BLOCKING-AGENTS ON THE 
BEHAVIORAL-EFFECTS OF ANALGESICS IN RATS. 

000429 01-04 
METOCLOPRAMIDE AND SULPIRIDE AS SELECTIVE BLOCKING-AGENTS 
PRESYNAPTIC AND POSTSYNAPTIC DOPAMINE-RECEPTORS. 

001102 02-03 
AMPHETAMINE STEREOTYPIES AND POLYRIBOSOMAL DISAGGREGATION 
IN RATS: EFFECTS OF ADRENERGIC AND SEROTONERGIC BLOCKING- 
AGENTS. 

001531 02-03 
ROLE OF ADRENERGIC BLOCKING-AGENTS AND GLUCOCORTICOIDS ON 
THE REGULATION OF PITUITARY OPIOID-PEPTIDES LEVELS. 

003801 04-03 
THE EFFECT OF DOPAMINE UPTAKE BLOCKING-AGENTS ON THE 
AMPHETAMINE-INDUCED CIRCLING-BEHAVIOR IN MICE WITH 
UNILATERAL NIGROSTRIATAL LESIONS. 

004117 04-04 
BLOCKING-DRUG 

THE EFFECT OF THE DOPAMINE-RECEPTOR BLOCKING-DRUG PIMOZIDE ON 
THE STIMULANT AND ANORECTIC-ACTIONS OF DEXTROAMPHETAMINE 
IN MAN. 

004580 04-14 
BLOCKING-DRUGS 

FAILURE OF ISOPRENALINE AND BETA-RECEPTOR BLOCKING-DRUGS TO 
MODIFY DEPRESSOR RESPONSE AND BRADYCARDIA INDUCED BY 
ELECTRICAL-STIMULATION OF THE ANTERIOR HYPOTHALAMUS OF 
CATS. 

000520 01-05 
INTERACTION OF HISTAMINE H2-RECEPT0R BLOCKING-DRUGS WITH THE 
NORADRENERGIC SYSTEM IN RAT-BRAIN AND HEART. 

001397 02-03 
THE EFFECT OF BETA-ADRENERGIC-RECEPTOR BLOCKING-DRUGS ON 
CEREBRAL BLOOD FLOW IN HYPERTENSIVE-PATIENTS. 

002071 02-10 
SIDE-EFFECTS OF BETA-ADRENERGIC BLOCKING-DRUGS: A 
METHODOLOGICAL-PROBLEM. 

002395 02-15 












u. 






S-61 



Subject Index 



Psychopharmacology Abstracts 



BLOCKS 

PREEXPOSURE TO DELTA9 THC BLOCKS THC-INDUCEO CONDITIONED 
TASTE-AVERSION IN RATS. 

001618 02-04 
DISRUPTION OF 5 HYDROXYTRYPTAMINERGIC NEURONAL FUNCTION 
BLOCKS THE ACTION OF MORPHINE ON TUBEROINFUNDIBULAR 
DOPAMINERGIC NEURONS. 

002700 03-03 
CAFFEINE BLOCKS THE DELAYED K OUTWARD-CURRENT OF MOLLUSCAN 
NEURONS. 

003834 04-03 
NEUROTENSIN BLOCKS CERTAIN AMPHETAMINE-INDUCED BEHAVIOURS. 

004111 04-04 

BLOOD 

COMPARISON OF BLOOD AND BILE LEVELS OF OXYPROTHEPIN AND 
DOCLOXYTHEPIN IN RATS. 

000242 01-03 
SOCIAL AND CLINICAL SIGNIFICANCE OF DETERMINING THE BARBITURATE 
LEVEL IN THE BLOOD SERUM OF PATIENTS TREATED WITH 
ANTIEPILEPTIC-DRUGS. „„„,„.„,,, 

000695 01-11 
PARASYMPATHOMIMETIC-INFLUENCE OF CARBACHOL ON LOCAL 
CEREBRAL BLOOD FLOW IN THE RABBIT BY A DIRECT VASODILATOR 
ACTION AND AN INHIBITION OF THE SYMPATHETIC MEDIATED 

VASOCONSTRICTION . ^ „^ „^ 

001109 02-03 
EFFECT OF PAPAVERINE ON REGIONAL CEREBRAL BLOOD FLOW AND 

SMALL VESSEL BLOOD CONTENT . 

001177 02-03 
EFFECTS OF RATE OF BLOOD FLOW ON FRACTIONAL EXTRACTION AND ON 
UPTAKE OF INFUSED NORADRENALINE BY BROWN ADIPOSE TISSUE IN 
VIVO. 

001231 02-03 
DIFFERENTIAL-EFFECTS OF VARIOUS STIMULI ON AVP LEVELS IN BLOOD 

AND CEREBROSPINAL-FLUID. ^ 

001370 02-03 
THE EFFECT OF SODIUM-SALICYLATE ON CEREBRAL BLOOD FLOW AND 

METABOLISM. „„,.,, ^o«o 

001416 02-03 

SUBCUTANEOUS SILASTIC IMPLANTS: MAINTENANCE OF HIGH BLOOD 
ETHANOL LEVELS IN RATS' DRINKING A LIQUID DIET. 

001865 02-06 
ENDOGENOUS DEPRESSION AND IMIPRAMINE LEVELS IN THE BLOOD. 

001979 02-09 
BLOOD LEVEL OF AMITRIPTYLINE, NORTRIPTYLINE, NORADRENALINE, 
SEROTONIN AND THERAPEUTIC RESPONSE 

002057 02-09 
THE EFFECT OF BETA-ADRENERGIC-RECEPTOR BLOCKING-DRUGS ON 
CEREBRAL BLOOD FLOW IN HYPERTENSIVE-PATIENTS. 

002071 02-10 
REGIONAL CEREBRAL BLOOD FLOW IN A CASE OF AMPHETAMINE 

INTOXICATION. 

002210 02-13 
CARDIOVASCULAR-EFFECTS OF THERAPEUTIC DOSES OF TRICYCLIC- 
ANTIDEPRESSANTS: IMPORTANCE OF BLOOD LEVEL MONITORING. 

002456 02-15 
NEUROLEPTIC BLOOD LEVELS AND THERAPEUTIC EFFEQ. 

002480 02-16 
HALOPERIDOL STIMULATION OF PROLACTIN SECRETION: HOW MANY 
BLOOD SAMPLES ARE NEEDED TO DEFINE THE HORMONE RESPONSE? 

002505 02-16 
THE CHANGE OF BLOOD PROLACTIN LEVEL DUE TO THE WITHDRAWAL OF 
MAINTENANCE NEUROLEPTICS. 

002559 02-17 
STUDY OF METABOLISM AND BLOOD LEVELS OF ANTIDEPRESSANTS: 
TOWARDS A RATIONALIZATION OF THEIR THERAPEUTIC USE. 

002625 02-17 
STEADY- STATE LITHIUM BLOOD LEVEL FLUCTUATIONS IN MAN 
FOLLOWING ADMINISTRATION OF A LITHIUM-CARBONATE 
CONVENTIONAL AND CONTROLLED-RELEASE DOSAGE FORM. 

003151 03-07 
PROGNOSIS IN SCHIZOPHRENIA: INDIVIDUAL DIFFERENCES IN 
PSYCHOLOGICAL RESPONSE TO A TEST DOSE OF ANTIPSYCHOTIC-DRUG 
AND THEIR RELATIONSHIP TO BLOOD AND SALIVA LEVELS AND 
TREATMENT OUTCOME. 

003189 03-08 
CORRELATIONS BETWEEN LITHIUM LEVELS IN CEREBROSPINAL-FLUID AND 
LITHIUM LEVELS IN BLOOD PLASMA AND ERYTHROCYTES. 

003210 03-09 
RELATIONSHIP BETWEEN BLOOD CONCENTRATIONS AND CLINICAL- 
EFFEaS OF A NEW ANTIDEPRESSANT MAPROTILINE. 

003271 03-09 
ON THE ANTICONVULSANT BLOOD LEVEL IN THERAPY-RESISTANT 

EPILEPTIC-PATIENTS. „„„^„„ „„ , , 

003300 03-11 
PLASMA FREE AND TOTAL TRYPTOPHAN, BLOOD SEROTONIN, AND THE 
HYPERAQIVITY-SYNDROME: NO EVIDENCE FOR THE SEROTONIN 

DEFICIENCY HYPOTHESIS . _ „ , , 

003312 03-11 



PHENYTOIN CONCENTRATIONS IN VENOUS VERSUS CAPILLARY BLOOD OF 
GERIATRIC-PATIENTS. 

003381 03-1 1 
LEVELS OF 5 HYDROXYINDOLEACETIC-ACID AND TRYPTOPHAN IN 
LUMBAR CEREBROSPINAL-FLUID AND BLOOD OF PATIENTS WITH 
DEMENTIA AND NORMAL PRESSURE HYDROCEPHALUS AFTER 
TRYPTOPHAN ADMINISTRATION. 

003419 03-13 
DIFFERENTIAL BINDING OF CHLORPROMAZINE TO HUMAN BLOOD CELLS: 
APPLICATION OF THE HYGROSCOPIC DESORPTION METHOD. 

003556 03-16 
FIRST RESULTS OF AN ORIGINAL METHOD FOR MEASURING BLOOD 
LEVELS OF ANTIDEPRESSANTS (AMITRIPTYLINE AND NORTRIPTYLINE). 

003559 03-16 
THERAPEUTIC INTEREST OF BLOOD LEVELS DETERMINATION FOR 
ANTIDEPRESSANTS: METHODOLOGICAL APPROACH. 

003571 03-16 
SUBSTANCE-P INCREASES HYPOTHALAMIC BLOOD FLOW VIA AN 
INDIRECT ADRENERGIC CHOLINERGIC INTERACTION. 

003887 04-03 
EFFECTS OF METHAMPHETAMINE ON BLOOD FLOW IN THE CAUDATE- 
PUTAMEN AFTER LESIONS OF THE NIGROSTRIATAL DOPAMINERGIC 
BUNDLE IN THE RAT. 

003910 04^3 
THE EFFEQS OF NEFOPAM ON BLOOD ACID BASE STATUS IN THE RABBIT: 
INTERACTIONS WITH MORPHINE IN THE MOUSE AND RABBIT. 

004279 04-05 
CHANGES IN BLOOD PLASMA OSMOLALITY AND STATES OF MANIA. 

004352 04-09 
CLINICAL-RESPONSE AND BLOOD LEVELS IN THE TREATMENT OF 
DEPRESSION WITH A NEW ANTIDEPRESSANT-DRUG, AMOXAPINE. 

004356 04-09 ; 
BLOOD LEVEL MEASUREMENTS OF TRICYCLIC DRUGS AS A DIAGNOSTIC 1 
TOOL. 

004368 04-09 , 
CORREQION OF THE EXTRAPYRAMIDAL NEUROLEPTIC-SYNDROME BY 
TRYPTOPHAN AND THE TIME-COURSE OF ITS CONTENT IN THE BLOOD 
OF PATIENTS. 

004434 04-11 : 

THE EFFECT OF CHLORPROMAZINE AND MAGEPTIL ON THE 

PROLIFERATION OF PERIPHERAL BLOOD LYMPHOCYTES IN CULTIVATION 
WITH PHYTOHEMAGGLUTININ. 

004541 04-13 
SIMULTANEOUS DETERMINATION OF MORPHINE AND CODEINE IN BLOOD : 
BY USE OF SELEa ION-MONITORING AND DEUTERATED INTERNAL 
STANDARDS 

004690 04-16 

COMPARISON OF SPEaROFLUOROMETRIC AND GAS- 
CHROMATOGRAPHY/MASS-SPEaROMETRY PROCEDURES FOR THE 
QUANTITATION OF MORPHINE IN BLOOD AND BRAIN. 

004692 04-16 
BLOOD-BRAIN-BARRIER 

THE BLOOD-BRAIN-BARRIER IN ADRENALINE-INDUCED HYPERTENSION. 

000147 01-03 
DOSE-DEPENDENT, AMPHETAMINE-INDUCED CHANGES IN PERMEABILITY 
OF THE BLOOD-BRAIN-BARRIER OF NORMOTENSIVE-RATS AND 
SPONTANEOUSLY HYPERTENSIVE-RATS. 

001197 02-03 
INFLUENCE OF RESPIRATORY STRESS AND HYPERTENSION UPON THE , 

BLOOD-BRAIN-BARRIER. ^ „ ^^ „, 

001437 02-03 
TRANSPORT OF NEUTRAL AMINO-ACIDS AT THE BLOOD-BRAIN-BARRIER 

002764 03-03 
INDICATIONS FOR A BRAIN UPTAKE OF LABELLED VASOPRESSIN AND 
OCYTOCIN AND THE PROBLEM OF THE BLOOD-BRAIN-BARRIER 

003669 04-01 
H2-RECEPT0RS MEDIATE INCREASES IN PERMEABIUTY OF THE BLOOD- 
BRAIN-BARRIER DURING ARTERIAL HISTAMINE INFUSION. 

003817 04-03 
PASSAGE THROUGH THE BLOOD-BRAIN-BARRIER OF THYROTROPIN- 
RELEASING-HORMONE ENCAPSULATED IN LIPOSOMES. 

004298 04-06 

BLOOD-PLATELET 

THE AQIVITY OF BLOOD-PLATELET MONOAMINE-OXIDASE IN 
ENDOGENOUS DEPRESSION. ^..-,„. ,, 

004547 04-13 

BLOOD-PLATELETS , „ 

LITHIUM LEVELS IN BLOOD-PIATELETS, SERUM, RED-BLOOD-CELLS AND 
BRAIN REGIONS IN RATS GIVEN ACUTE OR CHRONIC UTHIUM-SALT 

TREATMENTS. „„^„„ „, no 

000082 01-03 

PROPERTIES OF (3H)DIAZEPAM BINDING-SITES ON RAT BLOOD- 

P^^^^^^- 000317 01^3 

DECREASED UPTAKE OF 5 HYDROXYTRYPTAMINE IN BLOOD-PLATELETS 
FROM PATIENTS WITH ENDOGENOUS DEPRESSION. 

000637 01-09 



S-62 



y^OLUME 19, SUBJECT INDEX 



Subject Index 



TETRAHYDRO-BETA-CARBOLINES AND CORRESPONDING TRYPT AMINES: 
IN VITRO INHIBITION OF SEROTONIN AND DOPAMINE UPTAKE BY 
HUMAN BLOOD-PLATELETS. 

001067 02-02 
EFFECT OF DOXEPIN ON SEROTONIN METABOLISM IN RAT-BRAIN AND 
SEROTONIN UPTAKE BY HUMAN BLOOD-PLATELETS. 

002243 02-13 
LIBERATION OF CATECHOLAMINES AND 5 HYDROXYTRYPTAMINE FROM 
HUMAN BLOOD-PLATELETS. 

003967 04-03 
ILOOD-PRESSURE 

EFFECT OF GABA ANALOGUES ON BLOOD-PRESSURE AND CENTRAL GABA 
METABOLISM IN THE RAT. 

000231 01-03 
CENTRAL BLOOD-PRESSURE EFFECTS OF GUANYLYLIMIDODIPHOSPHATE 
ANDCYCLIC-GUANOSINE-MONOPHOSPHATE. 

000266 01-03 
TYROSINE ADMINISTRATION REDUCES BLOOD-PRESSURE AND ENHANCES 
BRAIN NOREPINEPHRINE RELEASE IN SPONTANEOUSLY HYPERTENSIVE- 
RATS. 

000296 01-03 
HALLUCINATORY AND DELUSIONAL-STATES IN CONNECTION WITH BLOOD- 
PRESSURE AND EEG. 

000814 01-14 
EFFECT OF PROSTAGLANDINS ON PLASMA CATECHOLAMINES, HEART 
AND BLOOD-PRESSURE RESPONSES TO HEMORRHAGE. (UNPUBLISHED 
PAPER). 

001223 02-03 
NALOXONE EFFECTS ON THE BLOOD-PRESSURE RESPONSE INDUCED BY 
THIN-FIBER MUSCULAR AFFERENTS. 

002794 03-03 
COVARIANCE OF PLASMA FREE 3 METHOXY-4- 
HYDROXYPHENETHYLENEGLYCOL AND DIASTOLIC BLOOD-PRESSURE. 

003418 03-13 
BLOOD-PRESSURE AND COGNITIVE FUNCTIONING. 

004492 04-11 
^LOOD-PRESSURES 

NICOTINE INGESTION REDUCES ELEVATED BLOOD-PRESSURES IN RATS 
AND SQUIRREL-MONKEYS. 

002759 03-03 
lOOIES 

EFFECT OF REPEATED TREATMENT WITH NEUROLEPTICS ON DOPAMINE 
METABOLISM IN CELL BODIES AND TERMINALS OF DOPAMINERGIC- 
SYSTEMS IN THE RAT-BRAIN. 

001464 02-03 
lODY 

EFFECTS OF CHRONIC-TREATMENT WITH L SULPIRIDE AND HALOPERIDOL 
ON CENTRAL DOPAMINE TURNOVER EVALUATED IN DOPAMINE CELL 
BODY AND NERVE TERMINAL-RICH AREAS, 

001096 02-03 
DIFFERENTIAL-EFFECTS OF SYSTEMIC VERSUS INTRACRANIAL INJECTION 
OF OPIATES ON CENTRAL, OROFACIAL AND LOWER BODY 
NOCICEPTION: SOMATOTYPY IN BULBAR ANALGESIA SYSTEMS. 

001446 02-03 
COMBINED EFFECTS OF ALCOHOL AND LITHIUM ON BODY COMPOSITION 
IN THE RAT MODEL. 

002928 03-03 
NALOXONE REVERSIBLE DUPLICATION BY LANTHANUM OF OPIATE 
ANALGESIA EFFECTS ON OROFACIAL, LOWER BODY AND CENTRAL 
NOCICEPTION. 

003028 03-04 
iODY-TEMPERATURE 

EFFECTS OF GAMMA HYDROXYBUTYRIC-ACID ON METABOLIC 
RESPIRATORY AND VASOMOTOR ACTIVITIES AND BODY- 
TEMPERATURE IN RATS. 

000189 01-03 
INFLUENCE OF AMPHETAMINE AND PHENYLPROPANOLAMINE ON FOOD 
INTAKE, ACTIVITY, AND BODY-TEMPERATURE IN RATS WITH 
VENTROMEDIAL HYPOTHALAMIC OR DORSOLATERAL TEGMENTAL 
DAMAGE. 

000322 01-03 
EFFECTS OF LISURIDE ON BODY-TEMPERATURE OF RATS AND RABBITS: 
RELATION TO MICROSOMAL BIOTRANSFORMATION AND 
DOPAMINERGIC-RECEPTOR STIMULATION. 

001161 02-03 
THE MECHANISM-OF-ACTION OF DELTA9 TETRAHYDROCANNABINOL ON 
BODY-TEMPERATURE IN MICE. 

001190 02-03 
COMPARISON OF THE EFFECTS OF CENTRAL ADMINISTRATION OF SERINE 
AND GLYCINE ON BODY-TEMPERATURE OF THE RABBIT. 

001248 02-03 
AGE-RELATED CHANGES IN BODY-TEMPERATURE RESPONSES TO 
MORPHINE IN RATS. 

001366 02-03 
PHENOBARBITAL EFFECTS ON WEIGHT-GAIN AND CIRCADIAN-CYCLING OF 
FOOD INTAKE AND BODY-TEMPERATURE. 

001409 02-03 
EFFECTS OF KAINIC-ACID ON BODY-TEMPERATURE OF RATS: ROLE OF 
CATECHOLAMINERGIC AND SEROTONERGIC SYSTEMS 

001515 02-03 



THE EFFECTS OF BOMBESIN INJECTED INTO THE ANTERIOR AND 

POSTERIOR HYPOTHALAMUS ON BODY-TEMPERATURE AND OXYGEN 
CONSUMPTION. 

001544 02-03 
CHRONIC DELTA9 TETRAHYDROCANNABINOL IN RATS: EFFECT ON 
SOCIAL-INTERACTIONS, MOUSE-KILLING, MOTOR-ACTIVITY, 
CONSUMMATORY-BEHAVIOR, AND BODY-TEMPERATURE 

001722 02-04 
CHANGES IN BODY-TEMPERATURE AFTER ADMINISTRATION OF 
ADRENERGIC AND SEROTONERGIC-AGENTS AND RELATED DRUGS 
INCLUDING ANTIDEPRESSANTS. 

002532 02-17 
INTERACTION BETWEEN THE EFFECTS OF STRESS AND MORPHINE ON 
BODY-TEMPERATURE IN RATS. 

002906 03-03 
THE EFFECT OF PHARMACOLOGICAL DESTRUCTION OF HYPOTHALAMIC 
MONOAMINERGIC STRUCTURES ON BODY-TEMPERATURE AND GAS- 
EXCHANGE DURING EXTREME COOLING. 

004016 04-03 
BETA ENDORPHIN: CENTRAL SITES OF ANALGESIA, CATALEPSY AND 
BODY-TEMPERATURE CHANGES IN RATS. 

004238 04-04 
REVERSIBLE RING-OPENING REACTIONS OF NIMETAZEPAM AND 
NITRAZEPAM IN ACIDIC MEDIA AT BODY-TEMPERATURE. 

004517 04-13 
BODY-WEIGHT 

BODY-WEIGHT, FEEDING, AND DRINKING-BEHAVIORS IN RATS WITH 
KAINIC-ACID-INDUCED LESIONS OF STRIATAL NEURONS - WITH A 
NOTE ON BODY-WEIGHT SYMPTOMATOLOGY IN HUNTINGTONS- 
DISEASE. 

000463 01-04 
EFFECTS OF BODY-WEIGHT LEVELS ON CANNABIS SELF-INJECTION. 

001801 02-04 
BODY-WEIGHT AND RESPONSES TO LHRH INFUSION IN ANOREXIA- 
NERVOSA, 

002062 02-10 
BENZODIAZEPINES CAUSE SMALL LOSS OF BODY-WEIGHT. 

002446 02-15 
SUSTAINED INTRACEREBROVENTRICULAR INFUSION OF BRAIN FUELS 
REDUCES BODY-WEIGHT AND FOOD INTAKE IN RATS. 

004098 04-04 
BOLUS 

PHARMACOKINETIC PROFILE OF VALPROIC-ACID IN RHESUS-MONKEYS 
FOLLOWING SINGLE BOLUS AND CONSTANT RATE INTRAVENOUS 
ADMINISTRATIONS. 

002797 03-03 

BOMBESIN 

THE EFFECTS OF BOMBESIN INJECTED INTO THE ANTERIOR AND 

POSTERIOR HYPOTHALAMUS ON BODY-TEMPERATURE AND OXYGEN 
CONSUMPTION. 

001544 02-03 
BOMBESIN PRODUCES TASTE-AVERSION IN RATS. 

002702 03-03 
THE EFFECTS OF INJECTIONS OF BOMBESIN INTO THE CEREBRAL 
VENTRICLES ON BEHAVIORAL THERMOREGULATION. 

002952 03-04 
BOMBESIN ALTERS BEHAVIORAL THERMOREGULATION IN FISH. 

003026 03-04 
ENHANCEMENT OF ETHANOL-INDUCED SEDATION AND HYPOTHERMIA BY 
CENTRALLY ADMINISTERED NEUROTENSIN, BETA ENDORPHIN AND 
BOMBESIN. 

003037 03-04 
BOMBESIN INHIBITS STRESS-INDUCED EATING. 

003059 03-04 
BOMBESIN-LIKE-PEPTIDES 

BIOCHEMICAL-LOCALIZATION AND CHARACTE'^'ZATION OF BOMBESIN- 
LIKE-PEPTIDES IN DISCRETE REGIONS OF RAl -BRAIN. (UNPUBLISHED 
PAPER). 

001046 02-01 
BONDS 

COMT-A AND COMT-B: CATALYTIC DIFFERENCES AND ROLE OF DISULFIDE 
BONDS. 

003927 04-03 
BORDERLINE-CHILDREN 

IMIPRAMINE TREATMENT OF BORDERLINE-CHILDREN: CASE-REPORTS 
WITH A CONTROLLED-STUDY. 

003356 03-11 
BORDERLINE-PATIENT 

THE INTERACTION OF PSYCHOPHARMACOLOGY AND PSYCHOANALYSIS IN 
THE BORDERLINE-PATIENT. 

004430 04-10 
BORDERLINE-SYNDROMES 

EXTRAPYRAMIDAL-DISORDERS AND BORDERLINE-SYNDROMES: 
EREDOATAXIAS AND DEMENTIA. 

003518 03-15 
BORN 

BEHAVIOR AND LEARNING DIFFICULTIES IN CHILDREN OF NORMAL 
INTELLIGENCE BORN TO ALCOHOLIC MOTHERS. 

004658 04-15 



■t: 



5?;: 






« 

«<». 



S-63 



Subject Index 



Psychopharmacology Abstracts 



BOUND 

ISOLATION OF SELECTIVE 3H CHLORNALTREXAMINE BOUND COMPLEXES, 
POSSIBLE OPIOID-RECEPTOR COMPONENTS IN BRAINS OF MICE. 

001162 02-03 
DISSOCIATION BETWEEN FREE AND BOUND PHENYTOIN LEVELS IN 
PRESENCE OF SODIUM-VALPROATE. 

003367 03-11 
BOVINE 

ESR STUDIES OF SPIN LABELLED BOVINE LIVER MONOAMINE-OXIDASE-B. 
(UNPUBLISHED PAPER). 

001065 02-01 
ESR STUDIES OF BOVINE PLASMA AMINE-OXIDASE: PROBING OF THE 

ENVIRONMENT ABOUT THE SUBSTRATE LIBERATED SULFHYDRYL 
GROUPS IN THE ACTIVE SITE (UNPUBLISHED PAPER). 

001066 02-01 
INHIBITION BY ARYLSULPHATASE A OF NA-INDEPENDENT (3H) GABA 

AND (3H) MUSCIMOL BINDING TO BOVINE CEREBELLAR SYNAPTIC 
MEMBRANES. 

001208 02-03 
DEMONSTRATION AND CHARACTERIZATION OF AN ENDOGENOUS 
INHIBITOR OF GABA-ENHANCED (3H) DIAZEPAM BINDING FROM 
BOVINE CEREBRAL-CORTEX. 

002645 03-01 
PHYSICAL AND KINETIC PROPERTIES OF CHOLINE-ACETYL-TRANSFERASE 
FROM RAT AND BOVINE BRAIN. 

003676 04-01 
CU-AMINE-OXIDASES: STUDIES RELATED TO THE MECHANISM-OF-ACTION 
OF BOVINE PLASMA AMINE-OXIDASE (UNPUBLISHED PAPER). 

003680 04-01 
DOPAMINE-RECEPTORS IN SUBCELLULAR FRACTIONS FROM BOVINE 
CAUDATE; ENRICHMENT OF (3H)SPIPER0NE BINDING IN A 
POSTSYNAPTIC MEMBRANE FRACTION. 

003948 04-03 
BINDING OF (3H) MUSCIMOL, A POTENT GAMMA AMINOBUTYRIC-ACID- 
RECEPTOR AGONIST, TO MEMBRANES OF THE BOVINE RETINA 

003954 04-03 
ELECTROPHYSIOLOGICAL-EFFECTS OF IMIPRAMINE ON BOVINE 
VENTRICULAR-MUSCLE AND PURKINJE-FIBRES. 

003988 04-03 
DOPAMINE-RECEPTOR BINDING IN BOVINE INTERMEDIATE LOBE 
PITUITARY MEMBRANES. 

004003 04-03 
BOYS 

EFFECTS OF METHYLPHENIDATE ON SELECTIVE AND SUSTAINED 
ATTENTION IN HYPERACTIVE, READING-DISABLED, AND PRESUMABLY 
ATTENTION-DISORDERED BOYS. 

002118 02-11 
ACUTE EFFECTS OF CAFFEINE IN NORMAL PREPUBERTAL BOYS. 

003310 03-11 
EFFECT OF PIRACETAM ON EEG SPECTRA OF BOYS WITH LEARNING- 
DISORDERS. 

003383 03-1 1 
BRADYCARDIA 

FAILURE OF ISOPRENALINE AND BETA-RECEPTOR BLOCKING-DRUGS TO 
MODIFY DEPRESSOR RESPONSE AND BRADYCARDIA INDUCED BY 
ELECTRICAL-STIMULATION OF THE ANTERIOR HYPOTHALAMUS OF 
CATS. 

000520 01-05 
BRADYCARDIA, PERSISTENT DIABETES-INSIPIDUS, AND TARDIVE- 
DYSKINESIA WITH LITHIUM INTOXICATION 

002427 02-15 
MODULATORY EFFECT OF BRAIN ACETYLCHOLINE ON REFLEX-INDUCED 
BRADYCARDIA AND TACHYCARDIA IN CONSCIOUS RATS. 

003744 04-03 
EFFECTS OF DOPAMINE, APOMORPHINE, GAMMA HYDROXYBUTYRIC- 
ACID, HALOPERIDOL AND PIMOZIDE ON REFLEX BRADYCARDIA IN 
RATS. 

004085 04-04 
BRADYKININ 

CENTRALLY INDUCED CARDIOVASCULAR AND SYMPATHETIC-NERVE 
RESPONSES TO BRADYKININ IN RATS. 

003099 03-04 
BRADYKININ-LIKE 

INHIBITORY ACTION OF MORPHINE ON THE RELEASE OF A BRADYKININ- 
LIKE SUBSTANCE AFTER SCIATIC-NERVE STIMULATION. 

001293 02-03 
BRADYKININ-RECEPTOR 

BRADYKININ-RECEPTOR STIMULATION OF C-AMP INVOLVES 
PHOSPHOLIPID METHYLATION, CA-FLUX, PH0SPH0LIPASE-A2 
ACTIVATION AND PROSTAGLANDIN FORMATION. (UNPUBLISHED 
PAPER). 

001002 02-01 
BRAIN 

OXAZEPAM-ESTERS. 1. CORRELATION BETWEEN HYDROLYSIS RATES AND 
BRAIN APPEARANCE OF OXAZEPAM. 

000010 01-02 
OXAZEPAM-ESTERS. 2. CORRELATION OF HYDROPHOBICITY WITH SERUM 

BINDING, BRAIN PENETRATION, AND EXCRETION. 

000011 01-02 



PHARMACOLOGICAL ACTIVITIES OF CLOBAZAM AND DIAZEPAM IN THE 
RAT: RELATION TO DRUG BRAIN LEVELS. 

000036 01-03 
RELATIONSHIP OF ANTICONFLICT ACTIVITY OF BENZODIAZEPINES TO 
BRAIN RECEPTOR BINDING, SEROTONIN, AND GABA. 

000057 01-03 
ACUTE CHANGES IN BRAIN TRYPTOPHAN AND SEROTONIN FOLLOWING 
CARBOHYDRATE OR PROTEIN INGESTION BY DIABETIC RATS. 
(UNPUBLISHED PAPER). 

000060 01-03 
HIGH-AFFINITY BINDING OF THE ANTITUSSIVE DEXTROMETHORPHAN TO 

GUINEA-PIG BRAIN. 

000061 01-03 
CHARACTERISTICS OF 3H CIS FLUPENTHIXOL BINDING TO CALF BRAIN 

MEMBRANES. 

000062 01-03 
EFFECTS OF LEAD ON MOVEMENT OF ALBUMIN INTO BRAIN. 

000076 01-03 
LITHIUM LEVELS IN BLOOD-PLATELETS, SERUM. RED-BLOOD-CELLS AND 
BRAIN REGIONS IN RATS GIVEN ACUTE OR CHRONIC LITHIUM-SALT 
TREATMENTS. 

000082 01-03 
INHIBITION OF BRAIN SYNAPTOSOMAL UPTAKE OF CHOLINE BY SOME 2 
CARBOXAMIDOSTRYCHNINE DERIVATIVES WITH MUSCLE-RELAXANT 
PROPERTIES. 

000084 01-03 
RELATIONSHIPS BETWEEN SEIZURE ACTIVITY AND CYCLIC-NUCLEOTIDE 
LEVELS IN BRAIN. 

000089 01-03 
INHIBITORY-EFFECTS OF ANTICONVULSANT-DRUGS ON CYCLIC- 
NUCLEOTIDE ACCUMULATION IN BRAIN. 

000090 01-03 
ABILITY OF AGED RATS TO ALTER BETA-ADRENERGIC-RECEPTORS OF 

BRAIN IN RESPONSE TO REPEATED ADMINISTRATION OF RESERPINE 
AND DESMETHYLIMIPRAMINE 1 

00011301-03 1 
ACTIONS OF CHLORPROMAZINE, HALOPERIDOL AND PIMOZIDE ON LIPID : 
METABOLISM IN GUINEA-PIG BRAIN SLICES 

000129 01-03 
THE ETIOLOGY OF TOXIC PERIPHERAL NEUROPATHIES: IN VITRO EFFEQS 
OF ACRYLAMIDE AND 2,5 HEXANEDIONE ON BRAIN ENOLASE AND 
OTHER GLYCOLYTIC ENZYMES 

000131 01-03 
EFFECT OF CHRONIC-TREATMENT WITH ANTIDEPRESSANTS ON BETA- 
ADRENERGIC-RECEPTOR BINDING IN GUINEA-PIG BRAIN. 

000135 01-03 
REUPTAKE OF BIOGENIC-AMINES BY BRAIN SLICES: EFFEQ OF 
HYDROCORTISONE. 

000187 01-03 
SUBSENSITIVITY OF THE NOREPINEPHRINE-RECEPTOR COUPLED 
ADENYLATE-CYCLASE SYSTEM IN BRAIN: EFFECTS OF NISOXETINE 
VERSUS FLUOXETINE. 

000208 01-03 
THE MECHANISM OF EFFECT OF NEUROPHARMACOLOGICAL-DRUGS VI: , 
EFFECT OF NORADRENALINE AND 5 HYDROXYTRYPTAMINE ON BRAIN 
FREE FATTY-ACIDS 

000274 01-03 
LONG-TERM EFFEQS OF CONTINUOUS EXPOSURE TO AMPHETAMINE ON 
BRAIN DOPAMINE CONCENTRATION AND SYNAPTOSOMAL UPTAKE IN 
MICE. 

000287 01-03 
INTRACELLULAR REDOX STATES UNDER HALOTHANE AND BARBITURATE 
ANESTHESIA IN NORMAL, ISCHEMIC, AND ANOXIC MONKEY BRAIN. 

000295 01-03 
TYROSINE ADMINISTRATION REDUCES BLOOD-PRESSURE AND ENHANCES 

BRAIN NOREPINEPHRINE RELEASE IN SPONTANEOUSLY HYPERTENSIVE- 
RATS. 

000296 01-03 
ADENOSINE REGULATES VIA TWO DIFFERENT TYPES OF RECEPTORS, THE 

ACCUMULATION OF CYCLIC-AMP IN CULTURED BRAIN CELLS. 

000308 01-03 
ROLE OF BRAIN DOPAMINERGIC MECHANISMS IN RODENT AGGRESSIVE- 
BEHAVIOR: INFLUENCE OF ( OR -)N N PROPYLNORAPOMORPHINE ON 
THREE EXPERIMENTAL MODELS. 

000340 01-04 

POSTINGESTION INTERFERENCE WITH BRAIN FUNCTION PREVENTS 
AHENTUATION OF NEOPHOBIA IN RATS. 

000352 01-04 
HANDLING IN INFANCY, TASTE-AVERSION, AND BRAIN LATERALITY IN 

RATS. 

000375 01-04 

CHANGES IN BRAIN N DEMETHYLATION AND OPIATE-RECEPTOR CONTENT 
CORRELATE WITH ANALGESIC EFFECTIVENESS OF MORPHINE 

000400 01-04 
INFLUENCE OF NICERGOLINE ON MOLECULAR BIOLOGICAL PROCESSES IN 
THE BRAIN AND LEARNING-ABILITY OF THE RAT. 

000449 01-04 



S-64 



VOLUME 19, SUBJECT INDEX 



Subject Index 



RELATIONSHIP BETWEEN DELTA9 TETRAHYDROCANNABINOL-INDUCED 
MOUSE-KILLING-BEHAVIOR ON THE RAT AND THE METABOLISM OF 
MONOAMINES IN THE BRAIN, PARTICULARLY THE OLFACTORY-BULB. 

000472 01-04 
BRAIN FUNCTION IN OLD-AGE: EVALUATION OF CHANGES AND 
DISORDERS 

000684 01-11 
INFLUENCING BRAIN CONCUSSION BY NOOTROPIL. 

000724 01-11 
ELECTRON MICROSCOPIC STUDIES OF BRAIN SLICES: THE EFFECTS OF 
HIGH-FREQUENCY STIMULATION ON DENDRITIC ULTRASTRUCTURE. 
(UNPUBLISHED PAPER). 

001036 02-01 
ASSAYING GABA-MODULIN ACTIVITY IN BRAIN EXTRACTS: RESOLUTION 
OF INHERENT DIFFICULTIES. (UNPUBLISHED PAPER). 

001045 02-01 
COMPARISON OF CYSTEINE-SULPHINIC-ACID-DECARBOXYLASE (CSD) 
ISOENZYMES AND GLUTAMIC-ACID-DECARBOXYLASE (GAD) IN RAT: IS 
BRAIN CSD-I IDENTICAL WITH LIVER CSD AND BRAIN CSD-II WITH 
GAD? (UNPUBLISHED PAPER). 

001048 02-01 
HISTAMINE-RECEPTORS IN THE BRAIN: CHARACTERIZATION BY BINDING 
STUDIES AND BIOCHEMICAL-EFFECTS. 

001054 02-01 
THE EFFECT OF PHENELZINE AND SOME OF ITS PARA HALOGENATED 
DERIVATIVES ON THE LEVELS OF BRAIN TYRAMINE AND OCTOPAMINE 
IN THE MOUSE. 

001077 02-02 
DYNAMICS OF ENDOGENOUS CATECHOLAMINE RELEASE FROM BRAIN 
FRAGMENTS OF MALE AND FEMALE RATS. 

001121 02-03 
RECEPTOR BINDING INTERACTIONS OF THE ANGIOTENSIN-II ANTAGONIST, 
1251 SARC0SINE1-LEUCINE8-ANGI0TENSIN-II, WITH MAMMALIAN 
BRAIN AND PERIPHERAL TISSUES. 

001125 02-03 
LACK OF INFLUENCE OF BRAIN CATECHOLAMINES ON ACUTE EFFECTS OF 
BARBITURATES. 

001138 02-03 
INTERACTION OF BIOGENIC-AMINE SYSTEMS IN BRAIN. (UNPUBLISHED 
PAPER). 

001141 02-03 
CHANGE IN PYRUVATE-DEHYDROGENASE ACTIVITY INFLUENCE PYRUVATE 
SUPPORTED CALCIUM ACCUMULATION BY BRAIN MITOCHONDRIA. 
(UNPUBLISHED PAPER). 

001147 02-03 
BRAIN SEROTONIN AND 5 HYDROXYINDOLEACETIC-ACID 
CONCENTRATIONS AND SEROTONIN SYNTHESIS FOLLOWING 
TETRAHYDRO-BETA-CARBOLINE ADMINISTRATION IN MICE. 

001152 02-03 
ROLE OF PROTEIN-KINASES IN OPIATE ACTIONS IN BRAIN. 

001173 02-03 
EFFECT OF TABERNANTHINE ON THE TURNOVER TIME OF BRAIN 
CATECHOLAMINES IN NORMAL AND HYPOBARIC HYPOXIC RATS. 

001187 02-03 
TOLERANCE TO BARBITURATE-INDUCED CENTRAL-NERVOUS-SYSTEM 
DEPRESSION: INVOLVEMENT OF STIMULUS SECRETION COUPLING IN 
DISCRETE BRAIN AREAS. (PH.D. DISSERTATION). 

001213 02-03 
MIANSERIN: DIRECT ACTIVATION OF BRAIN NOREPINEPHRINE NEURONS 

BY BLOCKING ALPHA2-RECEPT0RS. 

001214 02-03 
EFFECT OF LITHIUM ON STRESS-INDUCED CHANGES IN THE BRAIN LEVELS 

OF MONOAMINES IN RATS. 

601216 02-03 
LITHIUM-INDUCED CHANGES IN THE BRAIN LEVELS OF FREE AMINO-ACIOS 
IN STRESS-EXPOSED RATS. 

001217 02-03 
TRYPTOPHOL-INDUCED CHANGE IN BRAIN 5 HYDROXYTRYPTAMINE 
METABOLISM. 

001236 02-03 
EFFECTS OF CHRONIC NEUROLEPTIC TREATMENT ON TYROSINE- 
HYDROXYLASE IN DOPAMINERGIC TERMINALS: COMPARISONS 
BETWEEN DRUGS AND BRAIN REGIONS REVEALS DIFFERENT 
MECHANISMS OF TOLERANCE. 

001243 02-03 
THE BINDING OF SOME ANTIDEPRESSANT-DRUGS TO BRAIN MUSCARINIC 
ACETYLCHOLINE-RECEPTORS . 

001253 02-03 
SEX-DIFFERENCE IN BRAIN IRON. (UNPUBLISHED PAPER). 

001278 02-03 
BIPHASIC ACTIVITY OF MEMBRANE-BOUND ENZYMES IN BRAIN 
MITOCHONDRIA AND SYNAPTOSOMES DURING THE DEVELOPMENT OF 
TOLERANCE TO AND PHYSICAL-DEPENDENCE ON CHRONIC MORPHINE 
ADMINISTRATION TO RATS. 

001285 02-03 
THE INFLUENCE OF EXTERNAL SODIUM AND POTASSIUM ON LITHIUM 
UPTAKE BY PRIMARY BRAIN CELL CULTURES AT THERAPEUTIC LITHIUM 
CONCENTRATION. 

001300 02-03 



DOWN REGULATION OF DIHYDROALPRENOLOL AND IMIPRAMINE 

BINDING-SITES IN BRAIN OF RATS REPEATEDLY TREATED WITH 

IMIPRAMINE 

001317 02-03 
INTERACTION OF TRIAZOLAM WITH DESIPRAMINE: EFFECTS OF SINGLE 

AND REPEATED TREATMENT ON CERTAIN PHARMACOLOGIC- 

RESPONSES AND BRAIN CATECHOLAMINE LEVELS. 

001323 02-03 
DEVELOPMENT OF AND RECOVERY FROM SUBSENSITIVITY OF THE 

NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN BRAIN: EFFECT 

OF AMPHETAMINE FOLLOWING INHIBITION OF ITS AROMATIC 

HYDROXYLATION BY IPRINDOLE 

001353 02-03 
SUBCELLULAR REACTION OF THE BRAIN TO HYPOXIA. 

001354 02-03 
FURTHER CHARACTERIZATION OF THE BINDING OF SUBSTANCE-P TO A 

FRACTION FROM RABBIT BRAIN ENRICHED IN SYNAPTIC MEMBRANES. 

001394 02-03 
MODIFICATION OF DOPAMINE-RECEPTORS IN BRAIN BY CONTINUOUS 

AMPHETAMINE ADMINISTRATIONS TO RATS. 

001395 02-03 
BRAIN STRIATAL TYROSINE-HYDROXYLASE: ACTIVATION OF THE ENZYME 

BY CYCLIC-AMP INDEPENDENT PHOSPHORYLATION. 

001423 02-03 
THYROTROPIN-RELEASING-HORMONE: NEUROCHEMICAL EVIDENCE FOR 
THE POTENTIATION OF IMIPRAMINE EFFECTS ON THE METABOLISM 
AND UPTAKE OF BRAIN CATECHOLAMINES. 

001427 02-03 
EVIDENCE FOR INVOLVEMENT OF DOPAMINE IN THE ACTION OF 

DIAZEPAM: POTENTIATION OF HALOPERIDOL AND CHLORPROMAZINE 
ACTION IN THE BRAIN 

001428 02-03 
THE EFFECT OF CLOFELIN ON THE BIOELECTRIC-ACTIVITY OF THE BRAIN. 

001449 02-03 
PROSTAGLANDINS IN THE BRAIN OF RATS GIVEN, ACUTELY, AND 
CHRONICALLY, A HYPERTHERMIC-DOSE OF MET-ENKEPHALIN. 

001468 02-03 
THE EFFECTS OF PIRACETAM ON FREE FAHY-ACIDS IN THE BRAIN. 

001474 02-03 
ROLE OF BRAIN CATECHOLAMINES AND 5 HYDROXYTRYPTAMINE IN 
MORPHINE-INDUCED TEMPERATURE CHANGES IN NORMAL AND 
TOLERANT RATS AND MICE. 

001476 02-03 
GLUCOCORTICOIDS AS A REGULATORY FACTOR FOR BRAIN TRYPTOPHAN- 
HYDROXYLASE DURING DEVELOPMENT. 

001500 02-03 
ANTIDEPRESSANT-DRUGS SLOW CIRCADIAN-RHYTHMS IN BEHAVIOR AND 
BRAIN NEUROTRANSMITTER-RECEPTORS. 

001536 02-03 
BRAIN CATECHOLAMINES, MENTAL-ILLNESSES, AGING AND SENILE- 
DEMENTIA: BIOCHEMICAL-CONSIDERATIONS AND PHARMACOLOGICAL- 
CONSIDERATIONS. 

001550 02-03 
(3H) PHENCYCLIDINE BINDING TO SPECIFIC BRAIN RECEPTOR SITES. 

001555 02-03 
BRAIN LOCATIONS CONTROLLING THE BEHAVIORAL-EFFECTS OF CHRONIC 
AMPHETAMINE INTOXICATION. 

001653 02-04 
BRAIN CATECHOLAMINES MODIFICATIONS. THE EFFECTS ON MEMORY 
FACILITATION INDUCED BY OXOTREMORINE IN MICE. 

001658 02-04 
DORSAL TEGMENTAL BUNDLE DESTRUCTION: EFFECTS ON OPERANT- 
BEHAVIOR, BRAIN CATECHOLAMINE LEVELS, AND BEHAVIORAL- 
SUPPRESSION PRODUCED BY ADRENERGIC AGONISTS. 

001726 02-04 
ENHANCED BEHAVIOURAL-EFFECTS, ELECTROCORTICAL-EFFECTS AND 
HYPERTHERMIC-EFFECTS OF SEROTONIN-LIKE AGENTS AFTER 
IMPAIRMENT OF SEROTONIN TRANSMISSION IN FOWL BRAIN. 

001733 02-04 
PLASMA AND BRAIN LEVELS OF DELTA6 THC AND SEVEN 
MONOOXYGENATED METABOLITES CORRELATED TO THE CATALEPTIC- 
EFFECT IN THE MOUSE. 

001737 02-04 
CHANGES OF PHYSICAL MORPHINE-DEPENDENCE IN RATS CHRONICALLY 
TREATED WITH DRUGS ACTING ON BRAIN 5 HYDROXYTRYPTAMINE. 

001764 02-04 
P CHLOROAMPHETAMINE: EVALUATION OF A BRAIN METABOLITE. 

001779 02-04 
EXPERIMENTAL DEPENDENCE ON BARBITURATES: II. RELATIONSHIP 
BETWEEN DRUG LEVELS IN SERUM AND BRAIN AND THE 
DEVELOPMENT OF DEPENDENCE IN RATS. 

001800 02-04 
EFFECT OF L FUCOSE ON BRAIN PROTEIN METABOLISM AND RETENTION 
OF A LEARNED-BEHAVIOR IN RATS. 

001819 02-04 
REGIONAL CHANGES IN BRAIN GLUCOSE UTILIZATION IN RATS GIVEN A 
PYRETHROID INSECTICIDE. 

001838 02-05 



I 



a. 

J 



is 



"I* 
it: 



S-65 



Subject Index 

EFFECTS OF 1,3 BIS-TETRAHYDRO-2-FURANYL-5- 
FLUOROPYRIMIDINEDIONE (FD-1) ON THE CENTRAL-NERVOUS- SYSTEM: 
1 EFFECTS OF MONOAMINES IN THE BRAIN. 

001857 02-05 
THE IN VITRO BRAIN SLICE AS A USEFUL NEUROPHYSIOLOGICAL 
PREPARATION FOR INTRACELLULAR RECORDING. 

001864 02-06 
ESTIMATING IN VIVO THE TURNOVER-RATE OF BRAIN ENKEPHALINS. 

001884 02-06 
TIME-COURSE OF THE ANTIPSYCHOTIC-EFFECT IN SCHIZOPHRENIA AND 
SOME CHANGES IN POSTMORTEM BRAIN AND THEIR RELATION TO 
NEUROLEPTIC-MEDICATION. ^ ^ , „^ „„ 

001911 02-08 
BENZODIAZEPINE-RECEPTORS: THE EFFECT OF GABA ON THEIR 
CHARACTERISTICS IN HUMAN BRAIN AND THEIR ALTERATION IN 
HUNTINGTONS-DISEASE. „^^, ,. „o , , 

002163 02-11 
ASPIRIN ANALGESIA EVALUATED BY EVENT-RELATED POTENTIALS IN 
MAN: POSSIBLE CENTRAL-ACTION IN BRAIN. 

002195 02-12 
SPECIES-DIFFERENCES IN THE DEAMINATION OF DOPAMINE AND OTHER 
SUBSTRATES FOR MONOAMINE-OXIDASE IN BRAIN. 

002233 02-13 
CLASSIFICATION OF ENDORPHINS/ENKEPHALINS IN BRAIN PHYSIOLOGY 
AND PATHOLOGY (BASED ON EEG AND CLINICAL-STUDY OF 
SYNTHETICALLY-MODIFIED METHIONINE-ENKEPHALIN) 

002286 02-13 
POSSIBLE INVOLVEMENT OF BRAIN DOPAMINERGIC-SYSTEMS IN THE 
EXPRESSION OF EMOTIONS IN DREAMS. 

002325 02-14 
NOOTROPIC-DRUGS AND RELATED DRUGS INTERACTING WITH THE 
INTEGRATIVE ACTIVITY OF THE BRAIN. 

002327 02-14 
A SPECIFIC AND SENSITIVE MICROASSAY FOR HYDROXYINDOLES IN 
BIOLOGICAL-MATERIAL - APPLICATION FOR CEREBRAL MICROVESSELS, 
BRAIN, AND PINEAL-ORGAN OF THE RAT. 

002503 02-16 
BRAIN GLUCOCORTICOID-RECEPTOR: CORRELATION OF IN VIVO UPTAKE 
OF CORTICOSTERONE WITH BEHAVIORAL-EVENTS, ENDOCRINE-EVENTS, 
AND NEUROPHARMACOLOGICAL EVENTS. 

002515 02-17 
DOPAMINERGIC ABNORMALITIES IN POSTMORTEM SCHIZOPHRENIC 

^'""^ 002575 02-17 

EVIDENCE THAT IT IS POSSIBLE TO CAUSE ANOREXIA BY INCREASING 
RELEASE AND/OR DIRECTLY STIMULATING POSTSYNAPTIC SEROTONIN- 
RECEPTORS IN THE BRAIN. 

002602 02-17 

ANATOMOBIOCHEMICAL MAPPING OF THE BRAIN: NEUROPSYCHIATRIC- 
CORRELATIONS. 

002630 02-17 
THE EFFECT OF BARBITURATES ON THE DEGRADATION OF ENKEPHALIN BY 
BRAIN ENZYMES. 

002656 03-03 
APOMORPHINE HALOPERIDOL INTERACTIONS: DIFFERENT TYPES OF 
ANTAGONISM IN CORTICAL AND SUBCORTICAL BRAIN REGIONS. 

002662 03-03 
NA-INDEPENDENT BINDING OF (3H)GABA AND (3H)MUSCIM0L TO 
SUBCELLULAR PARTICLES OF NEURAL PRIMARY CULTURES AND WHOLE 
BRAIN. 

002699 03-03 
DOPAMINE-RECEPTOR SUPERSENSITIVITY IN THE CORPUS-STRIATUM 
FOLLOWING CHRONIC ELEVATION OF BRAIN GAMMA AMINOBUTYRIC- 

^^'°' 002716 03-03 

EFFECT OF MAZINDOL ON BRAIN DOPAMINE TURNOVER IN SPIPERONE 
TREATED RATS. 

002726 03-03 
EFFECT OF NEUROLEPTICS ON INDOLEAMINE-N-METHYLTRANSFERASE 
ACTIVITY AND BRAIN METABOLISM OF BUFOTENIN. 

002735 03-03 
CANNABIS-SATIVA: EFFECTS ON BRAIN FUNCTION AND ULTRASTRUQURE 
IN RHESUS-MONKEYS. 

002747 03-03 
EFFECTS OF LITHIUM ON MORPHOLOGICAL CHARACTERISTICS OF 
DISSOCIATED BRAIN CELLS IN CULTURE. 

002765 03-03 
THE FUNCTIONAL IMPORTANCE OF INCREASED BRAIN TRYPTOPHAN IN 
THE SEROTONERGIC RESPONSE TO RESTRAINT STRESS. 

002779 03-03 
THE EFFECT OF SPECIFIC BRAIN LESIONS ON THE HIGH-AFFINITY BINDING 
OF GABA IN THE SUBSTANTIA-NIGRA. 

002795 03-03 
ENHANCEMENT OF ETORPHINE BRAIN CONCENTRATIONS AND CHANGES 
IN ETORPHINE NALOXONE PA2 VALUES IN MORPHINE PRETREATED 

'^'^^' 002800 03-03 

ACTIVATION OF SOLUBLE STRIATAL TYROSINE-HYDROXYLASE IN THE RAT 
BRAIN AFTER CDP-CHOLINE ADMINISTRATION. 

002816 03-03 



Psychopharmacology Abstracts 

ANTIANXIETY-AGENTS AND SYNAPTIC TRANSMISSION IN THE BRAIN: 
ELECTROPHYSIOLOGICAL- STUDIES. (PHD DISSERTATION). 

002840 03-03 
BRAIN MUSCARINIC CHOLINERGIC-RECEPTOR BINDING IN ROMAN HIGH- 
AVOIDANCE AND LOW-AVOIDANCE RATS. 

002852 03-03 
EFFECT OF TAURINE ON 45CA2 ACCUMULATION IN RAT BRAIN 
SYNAPTOSOMES. 

002855 03-03 
TWO DISTINCT SEROTONIN-RECEPTORS: REGIONAL VARIATIONS IN 
RECEPTOR BINDING IN MAMMALIAN BRAIN. 

002861 03-03 
BIOELECTRICAL-ACTIVITY OF THE RAT BRAIN AFTER PREMATURE 
WEANING AND AFTER RNA ADMINISTRATION. 

002865 03-03 
PENTOBARBITAL; DUAL-ACTIONS TO INCREASE BRAIN BENZODIAZEPINE- 
RECEPTOR AFFINITY. 

002896 03-03 
GABA-RECEPTORS REGULATE THE AFFINITIES OF ANIONS REQUIRED FOR 
BRAIN SPECIFIC BENZODIAZEPINE BINDING 

002903 03-03 
DIFFERENTIAL-EFFECTS OF SHORT-TERM AND LONG-TERM LITHIUM ON 
TRYPTOPHAN UPTAKE AND SEROTONERGIC FUNQION IN CAT BRAIN 

00291 1 03-03 
BRAIN MECHANISMS OF LEARNING. 

002916 03-03 
EFFECTS OF ISOPROTERENOL ON THE DEVELOPMENT OF BETA- 
ADRENERGIC-RECEPTORS IN BRAIN CELL AGGREGATES. 

002932 03-03 
INCORPORATION OF N ACETYLMANNOSAMINE INTO RAT-BRAIN 
SUBCELLULAR GANGLIOSIDES: EFFECT OF PENTYLENETETRAZOL- 
INDUCED CONVULSIONS IN BRAIN GANGLIOSIDES. 

002937 03-03 
BEHAVIOURAL-RESPONSES TO DRUGS RELEASING 5 
HYDROXYTRYPTAMINE AND CATECHOLAMINES; EFFEaS OF 
TREATMENTS ALTERING PRECURSOR CONCENTRATIONS IN BRAIN. 

002990 03-04 
INDUCTION OF HYPERSENSITIVITY OF BRAIN BY HYDRALAZINE 
TREATMENT IN RATS. 

003008 03-04 
BEHAVIOURAL-CHANGES IN ADULT RATS FOLLOWING ADMINISTRATION 
OF ANTIBODIES AGAINST BRAIN GANGLIOSIDES. 

003071 03-04 
DIFFERENTIATION OF OPIATE-RECEPTORS IN THE BRAIN BY THE SELEQIVE 
DEVELOPMENT OF TOLERANCE. 

003088 03-04 
SIMULTANEOUS DETERMINATION OF FEMTOMOLE QUANTITIES OF 5 
HYDROXYTRYPTOPHAN, SEROTONIN AND 5 HYDROXYINDOLEACETIC- 
ACID IN BRAIN USING HPLC WITH ELEaROCHEMICAL-OETECTION. 

003139 03-06 
A NEW METHOD FOR APPLICATION OF HORSERADISH-PEROXIDASE INTO 
A RESTRICTED AREA OF THE BRAIN 

003141 03-06 
MODIFIED CUP TECHNIQUE FOR MICROESTIMATION OF THE RELEASE AND 
UPTAKE OF NEUROTRANSMinERS IN BRAIN SLICES. 

003147 03-06 
HUMAN BRAIN, PLASMA, AND CEREBROSPINAL-FLUID CONCENTRATION 
OF SODIUM-VALPROATE AFTER 72 HOURS OF THERAPY. 

003433 03-13 
POSITRON-TOMOGRAPHY. A NEW METHOD FOR IN VIVO BRAIN STUDIES 
OF BENZODIAZEPINE, IN ANIMAL AND IN MAN. 

003564 03-16 
MIND/BRAIN IN THE AGE OF PSYCHOPHARMACOLOGY: A CROSSROADS 
FOR MEDICINE AND MINISTRY. 

003624 03-17 

AaiON ON THE EMOTIONALLY-REINFORCED BRAIN SYSTEM AS A MEANS 

OF TREATING ALCOHOLISM AND DRUG ADDIQION 

PATHOGENETICALLY. ^^^ , „^ ,, 

003641 03-17 
BIOCHEMICAL AND IMMUNOLOGICAL PROPERTIES OF THE MOUSE BRAIN 

ENOLASES PURIFIED BY A SIMPLE METHOD. 

003668 04-01 
INDICATIONS FOR A BRAIN UPTAKE OF LABELLED VASOPRESSIN AND 

OCYTOCIN AND THE PROBLEM OF THE BLOOD-BRAIN-BARRIER. 

003669 04-01 
PARTIAL PURIFICATION OF ACID SPHINGOMYELINASE FROM NORMAL 

AND PATHOLOGICAL (M. NIEMANN-PICK TYPE C) HUMAN BRAIN. 

003671 04-01 
A RAPID AND SIMPLE METHOD FOR THE DETERMINATION OF PICOGRAM 
LEVELS OF 3 METHOXYTYRAMINE IN BRAIN TISSUE USING LIQUID- 
CHROMATOGRAPHY WITH ELEaROCHEMICAL DETEQION. 

003674 04-01 
PHYSICAL AND KINETIC PROPERTIES OF CHOLINE-ACETYL-TRANSFERASE 

FROM RAT AND BOVINE BRAIN. 003676 04-01 

A RADIOIMMUNOASSAY FOR EPENDYMINS BETA AND GAMMA: TWO 
GOLDFISH BRAIN PROTEINS INVOLVED IN BEHAVIORAL PLASTICITY. 

003677 04-01 



S-66 



VOLUME 19, SUBJECT INDEX 



Subject Index 



NEURONAL SENSITIVITY OF SOME BRAIN REGIONS TO ANGIOTENSIN-II IN 
RABBITS. 

003716 04-03 
BRAIN BENZODIAZEPINE-RECEPTORS AND THEIR RAPID CHANGES AFTER 

SEIZURES IN THE MONGOLIAN-GERBIL. 

003717 04-03 
INTERACTIONS BETWEEN A MONOFLUORINATED ANALOGUE OF P 

CHLOROAMPHETAMINE AND 5 HYDROXYTRYPTAMINE IN BRAIN. 

003719 04-03 
EFFECT OF ALPHA METHYLPHENYLALANINE AND PHENYLALANINE ON 
BRAIN POLYRIBOSOMES AND PROTEIN SYNTHESIS. 

003733 04-03 
BRAIN AND SERUM CALCIUM CONCENTRATIONS FOLLOWING 
ELECTROCONVULSIVE-SHOCK OR BICUCULLINE-INOUCED CONVULSIONS 
IN RATS. 

003736 04-03 
MODULATORY EFFECT OF BRAIN ACETYLCHOLINE ON REFLEX-INDUCED 
BRADYCARDIA AND TACHYCARDIA IN CONSCIOUS RATS. 

003744 04-03 
EFFECT OF INTRAVENOUS ADMINISTRATION OF D LYSERGIC-ACID- 
DIETHYLAMIDE ON SUBSEQUENT PROTEIN SYNTHESIS IN A CELL-FREE 
SYSTEM DERIVED FROM BRAIN. 

003761 04-03 
SOLUBILIZATION OF NEUROLEPTIC/DOPAMINE-RECEPTORS OF HUMAN 
BRAIN STRIATUM. 

003767 04-03 
DOPAMINE, NORADRENALINE AND 3,4 DIHYDROXYPHENYLACETIC-ACID 
(DOPAC) LEVELS OF INDIVIDUAL BRAIN NUCLEI, EFFECTS OF 
HALOPERIDOL AND PARGYLINE. 

003792 04-03 
OPPOSITE EFFECTS OF NALOXONE ON SUBSTANCE-P-INDUCED IN BRAIN 
DOPA SYNTHESIS AND IN LOCOMOTOR-ACTIVITY IN RATS. 

003799 04-03 
EFFECTS OF ANTIDEPRESSANT-DRUGS ON DIFFERENT RECEPTORS IN THE 
BRAIN. 

003824 04-03 
COMPARISON OF THE EFFEQ OF INTRAVENOUS ADMINISTRATION OF D 
LYSERGIC-ACID-DIETHYLAMIDE ON FREE AND MEMBRANE-BOUND 
POLYSOMES IN THE RABBIT BRAIN. 

003831 04-03 
CELL-FREE TRANSLATION OF FREE AND MEMBRANE-BOUND POLYSOMES 

AND POLYADENYLATED MRNA FROM RABBIT BRAIN FOLLOWING 
ADMINISTRATION OF D LYSERGIC-ACID-DIETHYLAMIDE IN VIVO. 

003832 04-03 
PHARMACOLOGIC MANIPULATION OF BRAIN AND PITUITARY ENDORPHIN 

CONTENT AND RELEASE. 

003837 04-03 
COMPARATIVE-EFFECTS OF SUBSTITUTED PHENYLETHYLAMINES ON BRAIN 
SEROTONERGIC MECHANISMS. 

003854 04-03 
AQION OF ENKEPHALIN ANALOGUES AND MORPHINE ON BRAIN 
ACETYLCHOLINE RELEASE: DIFFERENTIAL REVERSAL BY NALOXONE AND 
AN OPIATE-PENTAPEPTIDE. 

003863 04-03 
EFFECTS OF MOLINDONE AND FLUPHENAZINE ON THE BRAIN 
CONCENTRATION OF SOME PHENOLIC AND CATECHOLIC AMINES IN THE 
MOUSE AND THE RAT. 

003870 04-03 
THE EFFECT OF ADENOSINE AND GUANOSINE ON THE CONTENT OF 
SEROTONIN AND CATECHOLAMINES IN THE BRAIN IN THE 
RESTORATION PERIOD FOLLOWING EXPERIMENTAL CLINICAL DEATH. 

003882 04-03 
OPIOID BINDING PROPERTIES OF BRAIN AND PERIPHERAL TISSUES: 
EVIDENCE FOR HETEROGENEITY IN OPIOID LIGAND BINDING SITES. 

003902 04-03 
EFFEQ OF INHIBITORS OF GABA-AMINOTRANSFERASE ON THE 
METABOLISM OF GABA IN BRAIN TISSUE AND SYNAPTOSOMAL 
FRAQIONS. 

003914 04-03 
EFFEQ OF DIAZEPAM ON STRESS-INDUCED CHANGES IN BRAIN 
HISTAMINE. 

003932 04-03 
THE EFFEQ OF PRENATAL EXPOSURE TO ETHANOL OR OPIATES ON BRAIN 
CATECHOLAMINE AQIVITY. 

003939 04-03 
AUTORADIOGRAPHIC STUDIES ON DISTRIBUTION OF L-3,4 
DIHYDROXYPHENYLALANINE (L-DOPA) 14C AND L 5 
HYDROXYTRYPTOPHAN (L 5 HTP) 14C IN THE CAT BRAIN. 

003941 04-03 
EVIDENCE TO SUGGEST THAT DOPAMINE-INDUCED INCREASE IN GABA 
CONCENTRATIONS IN CHICK BRAIN IS MEDIATED THROUGH CYCLIC- 
AMP. 

003952 04-03 
CHANGES IN REGIONAL BRAIN LEVELS OF AMINO-ACID PUTATIVE 
NEUROTRANSMinERS AFTER PROLONGED TREATMENT WITH THE 
ANTICONVULSANT-DRUGS DIPHENYLHYDANTOIN, PHENOBARBITONE 
SODIUM-VALPROATE, ETHOSUXIMIDE, AND SULTHIAME IN THE RAT. 

003961 04-03 
DOES HIGH-AFFINITY (3H) IMIPRAMINE BINDING LABEL SEROTONIN 

REUPTAKE SITES IN BRAIN AND PLATELET? 

003962 04-03 



STUDIES ON THE MECHANISM-OF-ACTION OF AVERMECTIN-BIA: 
STIMULATION OF RELEASE OF GAMMA AMINOBUTYRIC-ACID FROM 
BRAIN SYNAPTOSOMES. 

003973 04-03 
STRESS-MODULATED ALTERATION OF BRAIN BIOGENIC-AMINES IN THE 
RAT: EFFECTS OF L TRYPTOPHAN 

003978 04-03 
EFFECT OF PR0STAGLANDIN-D2, PR0STAGLANDIN-E2 AND 
PR0STAGLANDIN-F2ALPHA ON CATECHOLAMINE RELEASE FROM SLICES 
OF RAT AND RABBIT BRAIN. 

003983 04-03 
PROPERTIES OF A CDP-DIGLYCERIDE-HYDROLASE FROM GUINEA-PIG 
BRAIN. 

003987 04-03 
EFFECT OF PRENATAL NEUROLEPTIC TREATMENT ON MEMBRANE 
RECEPTOR DEVELOPMENT IN THE BRAIN, 

003989 04-03 
THE EFFECT OF LITHIUM-HYDROXYBUTYRATE ON THE BIOELECTRICAL- 
ACTIVITY OF THE CORTEX AND SOME SUBCORTICAL STRUCTURES OF 
THE RABBIT BRAIN. 

003994 04-03 
THE INSENSITIVITY OF DEVELOPING BENZODIAZEPINE-RECEPTORS TO 
CHRONIC-TREATMENT WITH DIAZEPAM, GABA AND MUSCIMOL IN 
BRAIN CELL-CULTURES. 

004002 04-03 
THE ROLE OF OPIATE-RECEPTORS OF DIFFERENT BRAIN REGIONS IN 
DETERMINING THE EMOTIONAL REACTIONS OF RATS. 

004017 04-03 
OXIDATION OF BETA PHENYLETHYLAMINE BY BOTH TYPES OF 
MONOAMINE-OXIDASE: EXAMINATION OF ENZYMES IN BRAIN AND 
LIVER MITOCHONDRIA OF EIGHT SPECIES. 

004024 04-03 
EFFECT OF CHRONIC-TREATMENT WITH TRICYCLIC-ANTIDEPRESSANT 
DRUGS ON IDENTIFIED BRAIN NORADRENERGIC AND SEROTONERGIC 
NEURONS. 

004026 04-03 
INHIBITION BY CAFFEINE OF CALCIUM UPTAKE BY BRAIN MICROSOMAL 
VESICLES. 

004042 04-03 
POSTMORTEM STABILITY OF BRAIN 3 METHOXY-4- 
HYDROXYPHENYLETHYLENEGLYCOL AND 3,4 
DIHYDROXYPHENYLETHYLENEGLYCOL IN THE RAT AND MOUSE. 

004048 04-03 
BENZODIAZEPINE-RECEPTOR: HETEROGENEITY IN RABBIT BRAIN. 

004060 04-03 
RELATIONSHIP BETWEEN PENTYLENETETRAZOL-INDUCED SEIZURES AND 

BRAIN PENTYLENETETRAZOL LEVELS IN MICE. 

004061 04-03 
EFFECTS OF TRICYCLIC-ANTIDEPRESSANTS ON TETRABENAZINE-INDUCED 

DEPLETION OF BRAIN MONOAMINES IN RATS. 1. NOREPINEPHRINE. 

004062 04-03 
THE EFFECT OF P CHLOROPHENYLALANINE ON THE DISTRIBUTION OF 

BIOGENIC-AMINES IN THE BRAIN, AND ON MEMORY IN RATS. 

004068 04-04 
THE EFFECT OF PROPYLNORANTIFEIN ON BEHAVIORAL-REACTIONS, 
ADRENOCORTICAL ACTIVITY, AND ENERGY METABOLISM IN THE 
ANIMAL BRAIN. 

004075 04-04 
DOES RAPID-EYE-MOVEMENT SLEEP PLAY A ROLE IN BRAIN 
DEVELOPMENT? 

004091 04-04 
SUSTAINED INTRACEREBROVENTRICULAR INFUSION OF BRAIN FUELS 
REDUCES BODY-WEIGHT AND FOOD INTAKE IN RATS. 

004098 04-04 
COCAINE AND SEIZURE PROTECTION IN MICE OF VARYING BRAIN 
WEIGHTS. 

004103 04-04 
EFFECT OF PRENATAL PHENYTOIN ADMINISTRATION ON BRAIN 
TRYPTOPHAN METABOLISM OF RAT OFFSPRING DURING THE 
PREWEANING PERIOD. 

004108 04-04 
RELATION BETWEEN BRAIN CATECHOLAMINE-RECEPTORS AND 
DOPAMINERGIC STEREOTYPY IN RAT STRAINS. 

004131 04-04 
MORPHINE DIFFERENTIALLY AFFECTS VENTRAL TEGMENTAL AND 
SUBSTANTIA-NIGRA BRAIN REWARD THRESHOLDS. 

004187 04-04 
THE EFFECT OF THE NEW ANTIDEPRESSANT INKASAN ON THE 
BIOELECTRICAL-ACTIVITY OF THE BRAIN AND ON CONDITIONED 
REFLEXES. 

004212 04-04 
SUPPRESSION OF ALCOHOL DRINKING WITH BRAIN ALDEHYDE- 
DEHYDROGENASE INHIBITION. 

004220 04-04 
NEUROTRANSMITTER-RECEPTORS IN BRAIN REGIONS OF ACRYLAMIDE 
TREATED RATS. I: EFFECTS OF A SINGLE EXPOSURE TO ACRYLAMIDE. 

004264 04-05 



."if 









^ 



X 

ft, 
it: 



S-67 



Subject Index 



Psychopharmacology Abstracts 



NEUROTRANSMITTER-RECEPTORS IN BRAIN REGIONS OF ACRYLAMIDE 
TREATED RATS. Ih EFFECTS OF EXTENDED EXPOSURE TO ACRYLAMIDE. 

004265 04-05 
LESIONS OF AMYGDALA, PYRIFORM CORTEX AND OTHER BRAIN 
STRUCTURES DUE TO DIPIPERIDINOETHANE INTOXICATION. 

004273 04-05 
EFFECTS OF A SINGLE-THERAPEUTIC-DOSE OF GLYCEROL ON CEREBRAL 
METABOLISM IN THE BRAINS OF YOUNG MICE: POSSIBLE INCREASE IN 
BRAIN GLUCOSE TRANSPORT AND GLUCOSE UTILIZATION. 

004281 04-05 
AUTORADIOGRAPHIC LOCALIZATION OF DRUG AND NEUROTRANSMITTER- 
RECEPTORS IN THE BRAIN. 

004292 04-06 
LSD PSYCHOTOGENIC PROCEDURES AND BRAIN NEUROHUMORS. 
(UNPUBLISHED PAPER). 

004448 04-11 
EFFECTS OF A SHORT-ACTING BENZODIAZEPINE ON BRAIN ELECTRICAL- 
ACTIVITY DURING SLEEP. 

004568 04-14 
THE USE OF EVENT-RELATED SLOW POTENTIALS OF THE BRAIN AS AN 
OBJECTIVE METHOD TO STUDY THE EFFECTS OF CENTRALLY ACTING 
DRUGS. 

004669 04-16 
COMPARISON OF SPECTROFLUOROMETRIC AND GAS- 
CHROMATOGRAPHY/MASS-SPECTROMETRY PROCEDURES FOR THE 
QUANTITATION OF MORPHINE IN BLOOD AND BRAIN. 

004692 04-16 
BRAIN DOPAMINE-RECEPTORS. 

004741 04-17 
BRAIN-AMINE 

MONOAMINE-OXIDASE-INHIBITION AND BRAIN-AMINE METABOLISM 
AFTER ORAL TREATMENT WITH TOLOXATONE IN THE RAT 

000156 01-03 
BRAIN-BIOCHEMISTRY 

EFFECTS OF ACUTE VS CHRONIC PHENCYCLIDINE ON BRAIN- 
BIOCHEMISTRY AND BEHAVIOR. 

001789 02-04 
CHANGES IN CEREBRAL DOPAMINE METABOLISM AND RECEPTORS 
DURING ONE-YEAR NEUROLEPTIC ADMINISTRATION AND SUBSEQUENT 
WITHDRAWAL: RELEVANCE TO BRAIN-BIOCHEMISTRY IN 
SCHIZOPHRENIA 

002390 02-15 
EFFECT OF ACUTE AND CHRONIC TRIIODOTHYRONINE {T3) 
ADMINISTRATION TO RATS ON CENTRAL 5 HT AND DOPAMINE- 
MEDIATED BEHAVIOURAL-RESPONSES AND RELATED BRAIN- 
BIOCHEMISTRY. 

002951 03-04 
BRAIN-DAMAGE 

EFFECTS OF HIPPOCAMPAL BRAIN-DAMAGE ON AUDITORY AND VISUAL 
RECENT MEMORY: COMPARISON WITH MARIJUANA INTOXICATED 
SUBJECTS. 

002320 02-14 
BEHAVIORAL-TEST FOR DETECTION OF SUBCLINICAL BRAIN-DAMAGE: AN 
EXPERIMENTAL MODEL. 

003120 03-04 
PHENYTOIN TOXICITY IN A BRAIN-DAMAGE ADOLESCENT: A CASE- 
REPORT. 

003512 03-15 
NEUROPSYCHOLOGICAL-CORRELATES OF ASTHMA: BRAIN-DAMAGE OR 
DRUG-EFFECTS? 

003538 03-15 
BRAIN-DAMAGE-SYNDROME 

TRIAL OF A PEPTIDE FRACTION OF AQH (AaH4-10) IN THE ALCOHOLIC 
BRAIN-DAMAGE-SYNDROME . 

002318 02-14 
BRAIN-DAMAGED 

ORAL DYSKINESIA IN BRAIN-DAMAGED RATS WITHDRAWN FROM A 
NEUROLEPTIC: IMPLICATION FOR MODELS OF TARDIVE-DYSKINESIA 

000393 01-04 
BRAIN-DYSFUNCTION 

PHENYLACETATE AND BRAIN-DYSFUNCTION IN EXPERIMENTAL 
PHENYLKETONURIA: SYNAPTIC DEVELOPMENT. 

000191 01-03 
BRAIN-MONOAMINE 

EFFECTS OF BRAIN-MONOAMINE DEPLETION ON THERMOREGULATORY 
RESPONSES OF RABBITS TO DIFFERENT HYPOTHALAMIC 
TEMPERATURES. 

000190 01-03 
BRAIN-MONOAMINES 

BRAIN-MONOAMINES IN THE RHESUS-MONKEY DURING LONG-TERM 
NEUROLEPTIC ADMINISTRATION. 

001471 02-03 
EFFECT OF BROMOCRIPTINE ON EXPLORATORY-ACTIVITY, BRAIN- 
MONOAMINES AND PLASMA CORTICOSTERONE IN THE 
NORMOTENSIVE-RATS, GENETICALLY HYPERTENSIVE-RATS AND/OR 
HYPERTENSIVE OBESE RATS. 

001635 02-04 
BRAIN-MONOAMINES AND THE HIGH PRESSURE NEUROLOGICAL- 
SYNDROME. 

001686 02-04 



EFFECT OF NEONATAL HYDROCORTISONE TREATMENT ON BRAIN- 
MONOAMINES IN DEVELOPING RATS 

003893 04-03 
BRAIN-SPECIFIC 

BRAIN-SPECIFIC BENZODIAZEPINE-RECEPTORS AND PUTATIVE 
ENDOGENOUS BENZODIAZEPINE-LIKE COMPOUNDS. 

000225 01-03 
BRAIN-SPECIFIC BENZODIAZEPINE-RECEPTORS ARE LOCALIZED IN THE 
INNER PLEXIFORM LAYER OF RAT RETINA. 

000277 01-03 
BRAIN-STIMULATION 

EFFECTS OF KINDLING OR BRAIN-STIMULATION ON PENTYLENETETRAZOL- 
INDUCED CONVULSION SUSCEPTIBILITY. 

000037 01-03 
EFFECTS OF CHRONIC ADMINISTRATION OF DELTA9 
TETRAHYDROCANNABINOL ON THE CARDIOVASCULAR SYSTEM, AND 
PRESSOR AND BEHAVIORAL-RESPONSES TO BRAIN-STIMULATION IN 
FREELY-MOVING-RATS. 

000417 01-04 
EFFECTS OF DELTA9 TETRAHYDROCANNABINOL ON THE 
CARDIOVASCULAR-SYSTEM, AND PRESSOR AND BEHAVIORAL- 
RESPONSES TO BRAIN-STIMULATION IN RATS. 

001681 02-04 
EFFECTS OF CHRONIC NALOXONE TREATMENT ON BRAIN-STIMULATION 
REWARD 

003066 03-04 
REWARD AND DETECTION THRESHOLDS FOR BRAIN-STIMULATION: 
DISSOCIATIVE-EFFECTS OF COCAINE. 

004160 04-04 
DISRUPTION OF AUTOSHAPED RESPONDING TO A SIGNAL OF BRAIN- 
STIMULATION REWARD BY NEUROLEPTIC-DRUGS. 

004199 04-04 
BRAINS 

ISOLATION OF SELECTIVE 3H CHLORNALTREXAMINE BOUND COMPLEXES, 
POSSIBLE OPIOID-RECEPTOR COMPONENTS IN BRAINS OF MICE. 

001162 02-03 
THE EFFECT OF CARBIDINE ON DOPAMINE TURNOVER IN THE CORPUS- 
STRIATUM OF THE BRAINS OF RATS. 

001352 02-031 
BINDING OF (3H)PERG0LIDE-MESYLATE TO DOPAMINE-RECEPTORS OF | 
MAMMALIAN BRAINS. 

001538 02-03 
REGIONAL CHANGES IN (3H)DIAZEPAM BINDING IN THE BRAINS OF MICE ' 
AFTER REMOVAL OF THE OLFAQORY-BULBS. 

003844 04-03 
EFFECTS OF A SINGLE-THERAPEUTIC-DOSE OF GLYCEROL ON CEREBRAL 
METABOLISM IN THE BRAINS OF YOUNG MICE: POSSIBLE INCREASE IN 
BRAIN GLUCOSE TRANSPORT AND GLUCOSE UTILIZATION. 

004281 04-05 
BRAINSTEM 

REDUCTION OF OPIATE BINDING TO BRAINSTEM SLICES ASSOCIATED 
WITH THE DEVELOPMENT OF TOLERANCE TO MORPHINE IN RATS. 

000066 01-03 
REDUCTION IN THE NUMBER OF SEROTONIN-RECEPTORS IN THE 
BRAINSTEM OF MORPHINE-DEPENDENT RATS: RELATION TO BLOCKADE 
OF NALOXONE PRECIPITATED JUMPING BY SEROTONIN AGONISTS 

000258 01-03 
BRAINSTEM AUDITORY EVOKED-POTENTIALS AND MYELIN CHANGES IN 
TRIETHYLTIN-INDUCED EDEMA IN YOUNG ADULT RATS. 

000509 01-05 
EFFECT OF QUIPAZINE ON BRAINSTEM MONOAMINE NEURONS 
HISTOFLUORESCENCE STUDIES. 

001477 02-03 
5 METHOXYDIMETHYLTRYPTAMINE: SPINAL-CORD AND BRAINSTEM 
MEDIATION OF EXCITATORY EFFEaS ON ACOUSTIC STARTLE. 

001605 02-04 
GABA DEPLETION IN CHICK BRAINSTEM AFTER INTRAVENTRICULAR 
INJECTION OF CEFAZOLIN. 

002762 03-03 
MEPACRINE TREATMENT PREVENTS IMMOBILIZATION-INDUCED 
DESENSITIZATION OF BETA-ADRENERGIC-RECEPTORS IN RAT 
HYPOTHALAMUS AND BRAINSTEM. 

002919 03-03 
EFFICACY OF LITHIUM IN TREATING MOOD-DISORDER OCCURRING AFTER 
BRAINSTEM INJURY. 

003354 03-11 
AUDITORY BRAINSTEM EVOKED-RESPONSES IN HOSPITALIZED-PATIENTS 
UNDERGOING DRUG-TREATMENT OR EQ. 

003430 03-13 
DIFFERENTIAL-EFFECTS OF ALPHA METHYLDOPAMINE, CLONIDINE AND 
HYDRALAZINE ON NOREPINEPHRINE AND EPINEPHRINE SYNTHESIZING 
ENZYMES IN THE BRAINSTEM NUCLEI OF SPONTANEOUSLY 
HYPERTENSIVE-RATS. 

003947 04-03 
THE BRAINSTEM AUDITORY EVOKED-RESPONSE AS A TOOL IN 
NEUROBEHAVIORAL TOXICOLOGY AND MEDICINE. 

004277 04-05 
THE SIMULTANEOUS INFUSION OF DRUGS VIA THE LEFT AND RIGHT 
VERTEBRAL-ARTERY OF THE CAT; A MODIFIED ANIMAL-MODEL FOR 



S-68 



VOLUME 19, SUBJECT INDEX 

»THE STUDY OF POSSIBLE CENTRAL-ACTIONS OF DRUGS UPON THE 
LOWER BRAINSTEM. 

004297 04-06 
BRANCHED-CHAIN 

EFFECTS OF BRANCHED-CHAIN FATTY-ACIDS ON GABA DEGRADATION 
AND BEHAVIOR: FURTHER EVIDENCE FOR A ROLE OF GABA IN QUASI- 
MORPHINE ABSTINENCE-BEHAVIOR. 

001809 02-04 
MEAKDOWN 

EVIDENCE FOR THE PRESENCE OF TWO TYPES OF MONOAMINE-OXIDASE 
IN RABBIT CHOROID PLEXUS AND THEIR ROLE IN BREAKDOWN OF 
AMINES INFLUENCING CEREBROSPINAL-FLUID FORMATION. 

002807 03-03 
MEAKING-POINT 

DRUG-INDUCED STIMULUS CONTROL AND THE CONCEPT OF BREAKING- 
POINT: LSD AND QUIPAZINE. 

003116 03-04 
BRED 

TOLERANCE TO ETHANOL-INDUCED IMPAIRMENT OF WATER-ESCAPE IN 
RATS BRED FOR ETHANOL SENSITIVITY 

001567 02-04 
ETHANOL-INDUCED ANALGESIA IN RATS SELECTIVELY BRED FOR ETHANOL 
SENSITIVITY. 

001625 02-04 
MIDGES 

SYNTHESIS AND BIOLOGICAL-ACTIVITY OF HUMAN BETA ENDORPHIN 
ANALOGS WITH DISULFIDE BRIDGES. 

003655 04-01 
IRITISH-PHARMACOLOGICAL-SOCIETY 

PROCEEDINGS OF THE BRITISH-PHARMACOLOGICAL-SOCIETY, 12TH-14TH 
SEPTEMBER, 1979, UNIVERSITY-OF-LEEDS. 

000966 01-17 
IRL- 14342 

PHARMACOLOGICAL AND BIOCHEMICAL-PROPERTIES OF BRL- 14342 A 
NOVEL POTENTIAL ANTIDEPRESSANT-DRUG. 

004086 04-04 
iROMAZEPAM 

CONTROLLED-STUDY WITH BROMAZEPAM AND CLOROTEPIN IN CHILD 
INSTABILITY, 

002190 02-11 
ACTIVITY OF BROMAZEPAM AND LORAZEPAM IN NEUROTIC 
DEPRESSIONS. 

004384 04-09 
IROMISM 

BROMISM, HYSTERIA AND NARCOLEPSY. 

002472 02-15 
tROMO-ALPHA-ERGOCRIPTINE 

PLASMA DOPAMINE-BETA-HYDROXYLASE ACTIVITY IN CHRONIC 
SCHIZOPHRENIC-PATIENTS TESTED WITH SINGLE-DOSE OF 2 BROMO- 
ALPHA-ERGOCRIPTINE (PARLODEL). 

004343 04-08 
BROMOCRIPTINE 

THE EFFECTS OF BROMOCRIPTINE ON PRESYNAPTIC AND POSTSYNAPTIC 
ALPHA-ADRENOCEPTORS IN THE MOUSE VAS-DEFERENS. 

000108 01-03 

DISTRIBUTION AND EXCRETION IN THE RAT AND MONKEY OF (82BR) 
BROMOCRIPTINE. 

000196 01-03 
LONG-TERM EFFICACY OF BROMOCRIPTINE IN PARKINSONS-DISEASE. 

000698 01-11 
BROMOCRIPTINE AND DOPAMINERGIC FUNCTION IN HUNTINGTON- 
DISEASE. 

IMPROVEMENT OF L-DOPA-INDUCED DYSKINESIA AND OF ON-OFF- 
PHENOMENON BY BROMOCRIPTINE. 

NEUROPHARMACOLOGY OF BROMOCRIPTINE AND DIHYDROERGOTOXINE 
(HYDERGINE). 

EFFECT OF BROMOCRIPTINE ON EXPLORATORY-ACTIVITY BRAIN- 
MONOAMINES AND PLASMA CORTICOSTERONE IN THE 
NORMOTENSIVE-RATS. GENETICALLY HYPERTENSIVE-RATS AND/OR 
HYPERTENSIVE OBESE RATS. 

USE OF LARGE-SINGLE-DOSES OF BROMOCRIPTINE IN SCHIZOPHRENIC- 
PATIENTS WITH ELEVATED SERUM PROLACTIN LEVELS AND 
EXTRAPYRAMIDAL SIDE-EFFEQS ASSOCIATED WITH NEUROLEPTIC 
TREATMENT. 

00 1 944 02-08 
AN AnEMPT TO TREAT THE SIDE-EFFECTS OF PSYCHOTROPIC THERAPY 
WITH BROMOCRIPTINE. 

A COMPARATIVE-STUDY OF BROMOCRIPTINE AND LEVODOPA IN 
PARKINSONS-DISEASE. 

BROMOCRIPTINE AND PARKINSONS-DISEASE: A 16-HOUR CLINICAL- 
EVALUATION. 

THE ROLE OF BROMOCRIPTINE IN THE TREATMENT OF PARKINSONS- 
DISEASE. 

002177 02-11 



Subject Index 



THE USE OF BROMOCRIPTINE FOR TESTING CENTRAL DOPAMINERGIC 
REACTIVITY. 

002205 02-13 
THE PHARMACOKINETICS OF BROMOCRIPTINE IN MAN. 

002291 02-13 
BROMOCRIPTINE IN PARKINSONS-DISEASE: REPORT ON 106 PATIENTS 
TREATED FOR UP TO 5 YEARS. 

002342 02-14 
FURTHER EXPERIENCES WITH LOW-DOSES OF BROMOCRIPTINE IN 
PARKINSONS-DISEASE. 

002401 02-15 
LEVODOPA COMPARED WITH BROMOCRIPTINE IN THE TREATMENT OF 
PARKINSONS-DISEASE. 

002406 02-15 
PSYCHIATRIC-EFFECTS OF BROMOCRIPTINE AND LERGOTRILE IN 
PARKINSONIAN-PATIENTS. 

002453 02-15 
PHARMACOLOGICAL DIFFERENCE OF L-DOPA, APOMORPHINE AND 
BROMOCRIPTINE AGAINST METOCLOPRAMIDE, 

003790 04-03 
INFLUENCE OF THE DOPAMINERGIC AGONISTS BROMOCRIPTINE PIRIBEDIL 
AND NOMIFENSINE ON THE SYMPATHETIC NEURAL TRANSMISSION IN 
THE NICTITATING MEMBRANE OF THE CAT. 

003822 04-03 
PHENOXYBENZAMINE AND BROMOCRIPTINE AHENUATE NEED FOR REM 
SLEEP IN RATS. 

004203 04-04 
BROMOCRYPTINE 

EVIDENCE FOR AN IRREVERSIBLE INTERACTION OF BROMOCRYPTINE 
WITH CENTRAL DOPAMINE-RECEPTORS. 

000023 01-03 
BROMOSPIROPERIDOL 

SPECIFIC IN VIVO BINDING OF 77BR P BROMOSPIROPERIDOL IN RAT- 
BRAIN: A POTENTIAL TOOL FOR GAMMA-RAY IMAGING. 

004293 04-06 
BROMPERIDOL 

CLINICAL-EVALUATION OF BROMPERIDOL VERSUS HALOPERIDOL IN 
PSYCHOTIC-PATIENTS. 

004562 04-14 
BUCCOLINGUOFACIAL 

THE TREATMENT OF BUCCOLINGUOFACIAL DYSKINESIA IN THE ELDERLY- 
THE CHOICE OF A NEUROLEPTIC-AGENT. 

002223 02-13 
BUFFERS 

EFFECT OF STRUCTURE ON PHEN0THIA2INE CATION RADICAL REACTIONS 
IN AQUEOUS BUFFERS. 

000014 01-02 
BUFOTENIN 

EFFECT OF NEUROLEPTICS ON INDOLEAMINE-N-METHYLTRANSFERASE 
ACTIVITY AND BRAIN METABOLISM OF BUFOTENIN. 

002735 03-03 
BULBECTOMISED 

SEROTONINMIMETIC AND ANTIDEPRESSANT-DRUGS ON PASSIVE- 
AVOIDANCE LEARNING BY OLFACTORY BULBECTOMISED RATS 

001585 02-04 
BULLFROG 

CALCIUM LOCALIZATION IN THE SYMPATHETIC GANGLION OF THE 

BULLFROG AND EFFECTS OF CAFFEINE. 

000098 01-03 
5 HYDROXYTRYPTAMINE CONTROLS ACH-RECEPTOR SENSITIVITY OF 

BULLFROG SYMPATHETIC GANGLION CELLS. 

003710 04-03 
BUMETANIDE 

THE EFFECT OF FRUSEMIDE PIRETANIDE AND BUMETANIDE ON COCHLEAR 
SUCCINIC-DEHYDROGENASE. 

003757 04-03 
BUNDLE 

MALE RAT SEXUAL-BEHAVIOR COMPARED AFTER 6 OHDA AND 
ELECTROLYTIC LESIONS IN THE DORSAL NA BUNDLE REGION OF THE 
MIDBRAIN. 

001593 02-04 
DORSAL TEGMENTAL BUNDLE DESTRUCTION: EFFECTS ON OPERANT- 
BEHAVIOR, BRAIN CATECHOLAMINE LEVELS, AND BEHAVIORAL- 
SUPPRESSION PRODUCED BY ADRENERGIC AGONISTS 

001726 02-04 
EFFECTS OF METHAMPHETAMINE ON BLOOD FLOW IN THE CAUDATE- 
PUTAMEN AFTER LESIONS OF THE NIGROSTRIATAL DOPAMINERGIC 
BUNDLE IN THE RAT. 

003910 04-03 
BUNGAROTOXIN 

LOCALIZATION OF ALPHA BUNGAROTOXIN BINDING-SITES IN SYNAPSES 
OF THE DEVELOPING CHICK RETINA. 

000065 01-03 
ACTIONS OF BETA BUNGAROTOXIN ON AMINO-ACID TRANSMITTER 
RELEASE. 

002897 03-03 
ALTERATIONS OF ACETYLCHOLINE AND CHOLINE METABOLISM IN 
MAMMALIAN PREPARATIONS TREATED WITH BETA BUNGAROTOXIN 

003820 04-03 



K 
13. 

■1 



1'5 



<5; 



S-69 



Subject Index 



Psychopharmacology Abstracts 



BUPRENORPHINE 

A COMPARISON OF THE NEUROCHEMICAL-EFFECTS OF BUPRENORPHINE 
WITH THOSE OF MORPHINE AND HALOPERIDOL IN RATS. 

002701 03-03 
BUPRENORPHINE: DEMONSTRATION OF PHYSICAL-DEPENDENCE LIABILITY. 

004104 04-04 
BUPROPION 

CLINICAL-EFFICACY OF THE NEW ANTIDEPRESSANT BUPROPION 
(WELLBUTRIN). 

003227 03-09 
BURST-FIRING 

DOPAMINE INHIBITS BURST-FIRING OF NEUROSECRETORY CELL R-15 IN 
APLYSIA-CALIFORNICA: ESTABLISHMENT OF A DOSE-RESPONSE 
RELATIONSHIP. 

003806 04-03 
BURYING _ 

CONDITIONING AND RETENTION OF DEFENSIVE BURYING AS A FUNaiON 
OF ELAVIL AND THORAZINE INJECTION. 

002974 03-04 
BUSPIRONE 

INHIBITION OF AGGRESSIVE-BEHAVIOR IN RHESUS-MONKEYS BY 
BUSPIRONE. 

003103 03-04 
BUTACLAMOL 

CALMODULIN RELEASE FROM STRIATAL MEMBRANES AFTER ACUTE AND 
CHRONIC TREATMENT WITH BUTACLAMOL. 

001249 02-03 
BUTANOL 

IMPAIRMENT OF AVOIDANCE-BEHAVIOR FOLLOWING SHORT-TERM 
INGESTION OF ETHANOL, TERTIARY BUTANOL, OR PENTOBARBITAL IN 
MICE. 

000479 01-04 
BUTOCTAMIDE-HYDROGEN-SUCCINATE 

THE EFFECT OF BUTOaAMIDE-HYDROGEN-SUCCINATE ON NOCTURNAL 
SLEEP: ALL-NIGHT POLYGRAPHICAL-STUDIES. 

002350 02-14 
BUTORPHANOL 

SERUM LEVELS OF BUTORPHANOL BY RADIOIMMUNOASSAY. 

004691 04-16 
BUTRIPTYLINE-HYDROCHLORIDE 

ACTION OF BUTRIPTYLINE-HYDROCHLORIDE IN THE 
GERONTOPSYCHIATRIC-PATIENT. 

003358 03-11 
BUTYROLAaONE 

CROSS-TOLERANCE OF DOPAMINE METABOLISM TO BACLOFEN, GAMMA 
BUTYROLACTONE AND HA-966 IN THE STRIATUM AND OLFACTORY 
TUBERCLE OF THE RAT. 

002681 03-03 
BUTYROLACTONE-GAMMA-CARBONYL-HISTIDYL-PROLINAMIDE 

GAMMA BUTYROLAaONE-GAMMA-CARBONYL-HISTIDYL-PROLINAMIDE 
CITRATE (DN-1417): A NOVEL TRH ANALOG WITH POTENT EFFEaS ON 
THE CENTRAL-NERVOUS-SYSTEM. 

003057 03-04 
BUTYROPHENONE 

SLEEP PROFILE AND ULTRADIAN SLEEP PERIODICITY IN HUMANS UNDER 
THE INFLUENCE OF A BUTYROPHENONE DERIVATIVE: I. SLEEP 
CORREaiON IN SUBJECTS WITH OLIGOSYMPTOMATIC SLEEP- 
DISORDERS. 

001869 02-06 
INCREASED SERUM PROLAQIN LEVELS DURING PHENOTHIAZINE AND 
BUTYROPHENONE TREATMENT OF SIX POSTPARTUM WOMEN. 

003318 03-11 
C-AMP 

HALOTHANE EFFEQ ON C-\MP GENERATION AND HYDROLYSIS IN RAT- 
BRAIN. 

000305 01-03 
BRADYKININ-RECEPTOR STIMULATION OF C-AMP INVOLVES 
PHOSPHOLIPID METHYLATION, CA-FLUX, PH0SPH0LIPASE-A2 
ACTIVATION AND PROSTAGLANDIN FORMATION. (UNPUBLISHED 
PAPER). 

001002 02-01 
C-GMP 

INCREASE OF C-GMP AND ACCUMULATION OF 45CA2 EVOKED BY DRUGS 
AaiNG ON SODIUM OR POTASSIUM CHANNELS. 

003709 04-03 
PHENYTOIN INHIBITION OF CYCLIC-GUANOSINE-MONOPHOSPHATE (C- 
GMP) ACCUMULATION IN NEUROBLASTOMA CELLS BY CALCIUM- 
CHANNEL BLOCKADE. 

004020 04-03 
C-TYPE 

SELECTIVE NEUROTOXIC-AaiON OF CAPSAICIN ON GLOMERULAR C-TYPE 
TERMINALS IN RAT SUBSTANTIA-GELATINOSA. 

003143 03-06 
CA 

CA DIAZEPAM LINK? NO SCIENTIFIC TAKERS SO FAR. 

003519 03-15 
CA -DEPENDENT 

SEROTONIN-RECEPTOR MEDIATED MODULATION OF CA-DEPENDENT 5 
HYDROXYTRYPTAMINE RELEASE FROM NEURONES OF THE RAT-BRAIN- 
CORTEX. 

001258 02-03 



CA-FLUX 

IGE MEDIATED HISTAMINE RELEASE IN RAT BASOPHILIC LEUKEMIA 
CELLS: RECEPTOR ACTIVATED PHOSPHOLIPID METHYLATION, CA-FLUX 
AND RELEASE OF ARACHIDONIC-ACID. (UNPUBLISHED PAPER). 

001188 02-03 
CA -INDEPENDENT 

REGULATION BY A BETA-ADRENERGIC-RECEPTOR OF A CA -INDEPENDENT 
ADENOSINE-CYCLIC-MONOPHOSPHATE-PHOSPHODIESTERASE IN C6- 
GLIOMA CELLS (UNPUBLISHED PAPER) 

001403 02-03 
CA-FLUX 

BRADYKININ-RECEPTOR STIMULATION OF C-AMP INVOLVES 
PHOSPHOLIPID METHYLATION, CA-FLUX, PH0SPH0LIPASE-A2 
AQIVATION AND PROSTAGLANDIN FORMATION. (UNPUBLISHED 
PAPER). 

001002 02-01 
CACTUS 

CATECHOLAMINE METABOLISM IN A PSYCHOAQIVE CAQUS. 

004722 04-17 
CAERULEIN 

CENTRAL DEPRESSANT EFFEaS OF CAERULEIN AND CHOLECYSTOKININ- 
OaAPEPTIDE (CCK-8) DIFFER FROM THOSE OF DIAZEPAM AND 
HALOPERIDOL 

002652 03-02 
CAFFEINE 

CALCIUM LOCALIZATION IN THE SYMPATHETIC GANGLION OF THE 
BULLFROG AND EFFEaS OF CAFFEINE. 

000098 01-03 
CAFFEINE PRODUCES REM SLEEP REBOUND IN RATS. 

000244 01-03 
AROUSAL AND SHORT-TERM MEMORY: EFFEaS OF CAFFEINE AND TRIAL 
SPACING ON DELAYED ALTERNATION PERFORMANCE. 

000487 01-04 
BEHAVIOURAL-EFFEaS OF ACETYLSALICYLIC-ACID, PARACETAMOL, 
CAFFEINE, GUAIPHENESIN AND THEIR COMBINATIONS. 

001805 02-04 
EFFEQS OF CAFFEINE ON PLASMA FREE FATTY-ACIDS, URINARY 
CATECHOLAMINES, AND DRUG BINDING. 

002272 02-13 
THE EFFECTS OF ALCOHOL AND CAFFEINE ON CONCENTRATION TEST 
PERFORMANCE. 

002337 02-14 
EFFECTS OF CAFFEINE ADMINISTRATION ON FOOD AND WATER 
CONSUMPTION UNDER VARIOUS EXPERIMENTAL CONDITIONS. 

003049 03-04 
ACUTE EFFEQS OF CAFFEINE IN NORMAL PREPUBERTAL BOYS. 

003310 03-11 
EFFECT OF FLURAZEPAM, PENTOBARBITAL, AND CAFFEINE ON AROUSAL 
THRESHOLD. 

003439 03-14 
UNIT AaiVITY IN MEDIAL THALAMUS: COMPARATIVE-EFFEaS OF 
CAFFEINE AND AMPHETAMINE. 

003752 04-03 
CAFFEINE BLOCKS THE DELAYED K OUTWARD-CURRENT OF MOaUSCAN 
NEURONS. 

003834 04-03 
EFFEQS OF MORPHINE AND CAFFEINE ON ADENOSINE RELEASE FROM 
RAT-CEREBRAL-CORTEX: IS CAFFEINE A MORPHINE ANTAGONIST. 

003864 04-03 
THE EFFEQS OF THEOPHYLLINE AND CAFFEINE ON THERMOREGULATORY 
FUNQIONS OF RATS AT DIFFERENT AMBIENT TEMPERATURES. 

003907 04-03 
EFFECTS OF CAFFEINE ON ANTERIOR PITUITARY AND THYROID-FUNCTION 
IN THE RAT. 

004014 04-03 
INHIBITION BY CAFFEINE OF CALCIUM UPTAKE BY BRAIN MICROSOMAL 
VESICLES. 

004042 04-03 

CAFFEINE-INDUCED 

CAFFEINE-INDUCED AND AMINOPHYLLINE-INDUCED SEIZURES. 

002689 03-03 
THE BENZODIAZEPINES AND INOSINE ANTAGONIZE CAFFEINE-INDUCED 

SEIZURES. 

004172 04-04 

CAGE 

REPEATED ELECTROCONVULSIVE-SHOCK DOES NOT INCREASE THE 
SUSCEPTIBILITY OF RATS TO A CAGE CONVULSANT 
(ISOPROPYLBICYCLOPHOSPHATE) . 

001184 02-03 
EFFECTS OF CHOLECYSTOKININ-OCTAPEPTIDE ON STRIATAL DOPAMINE 
METABOLISM AND ON APOMORPHINE-INDUCED STEREOTYPED CAGE 
CLIMBING IN MICE. 

003031 03-04 

CAIMAN-SCLEROPS 

INFLUENCE OF MONOAMINE DEPLETING PHARMACOLOGIC-AGENTS ON 
LEVELS OF ACTIVITY IN CAIMAN-SCLEROPS. 

001810 02-04 



S-70 



VOLUME 19, SUBJECT INDEX 



Subject Index 



CALCITONIN 

ABUNDANCE AND LOCATION OF 1251 SALMON CALCITONIN BINDING-SITE 
IN RAT-BRAIN. 

001320 02-03 
IMMUNOREACTIVE CALCITONIN IN CEREBROSPINAL-FLUID OF MAN. 

002637 03-01 
EVOKED-POTENTIAL STUDIES OF PORCINE CALCITONIN IN RABBITS. 

002936 03-03 
CALCITONIN: AVERSIVE-EFFECTS IN RATS? 

002977 03-04 
CALCITONIN: AVERSIVE-EFFECTS IN RATS? 

002992 03-04 
CALOUM 

CALCIUM LOCALIZATION IN THE SYMPATHETIC GANGLION OF THE 
BULLFROG AND EFFECTS OF CAFFEINE. 

000098 01-03 
EFFECT OF MORPHINE ON CALCIUM UPTAKE BY LYSED SYNAPTOSOMES. 

000117 01-03 
EFFEQS OF CHLORDIAZEPOXIDE ON DEPOLARIZATION-INDUCED CALCIUM 
INFLUX INTO SYNAPTOSOMES. 

000183 01-03 
(3H)ACETYLCH0LINE AND (3H)5 HYDROXYTRYPTAMINE RELEASE FROM 
RAT-MIDBRAIN SLICES AND THE EFFECTS OF CALCIUM AND 
PHENOBARBITAL. 

000251 01-03 
TWENTY YEARS CLINICAL THERAPEUTIC EXPERIENCE WITH CALCIUM 
GLUTAMATES EFFICACY. 

000963 01-17 
ELECTRON PROBE MICROANALYSIS OF CALCIUM AND PHOSPHORUS IN 
DENSE-BODIES ISOLATED FROM HUMAN PLATELETS. (UNPUBLISHED 
PAPER). 

001014 02-01 
CHANGE IN PYRUVATE-DEHYDROGENASE ACTIVITY INFLUENCE PYRUVATE 
SUPPORTED CALCIUM ACCUMULATION BY BRAIN MITOCHONDRIA. 
(UNPUBLISHED PAPER). 

001147 02-03 
NERVE CELL CALCIUM AS A MESSENGER FOR OPIATE AND ENDORPHIN 
ACTONS. 

001450 02-03 
EFFEQS OF ANTICONVULSANTS AND METHOTREXATE ON CALCIUM 
DISPOSITION. 

001840 02-05 
EFFECT OF LITHIUM ON POTASSIUM AND CALCIUM IN SERUM, 
ERYTHOCYTES AND IN URINE. 

002054 02-09 
INTERACTIONS OF NARCOTICS WITH SYNAPTOSOMAL CALCIUM 
TRANSPORT. 

002712 03-03 
EFFECTS OF NEOMYCIN ON CALCIUM AND POLYPHOSPHOINOSITIDE 
METABOLISM OF GUINEA-PIG SYNAPTOSOMES. 

002741 03-03 
EFFEQS OF D AMINOLAEVULINIC-ACID, PORPHOBILINOGEN, AMINO- 
ACIDS AND BARBITURATES ON CALCIUM ACCUMULATION BY 
CULTURED NEURONS. 

002859 03-03 
CALCIUM ANTAGONISM OF THE INHIBITORY-EFFEQS OF FENTANYL ON 
THE CONTRACTION OF THE NICTITATING MEMBRANE IN CATS. 

002876 03-03 
THE ROLE OF CALCIUM AND DOPAMINE MEMBRANE CARRIER IN 
MEDIATING THE BEHAVIORAL-EFFECTS AND BIOCHEMICAL-EFFECTS OF 
AMPHETAMINE. (PH.D. DISSERTATION). 

002996 03-04 
GLOMERULAR FILTRATION RATE AND CALCIUM METABOLISM IN LONG- 
TERM LITHIUM TREATMENT. 

003542 03-15 
BRAIN AND SERUM CALCIUM CONCENTRATIONS FOLLOWING 
ELECTROCONVULSIVE-SHOCK OR BICUCULLINE-INDUCED CONVULSIONS 
IN RATS. 

003736 04-03 
INVOLVEMENT OF CALCIUM CHANNELS IN SHORT-TERM 
DESENSITIZATION OF MUSCARINIC-RECEPTOR MEDIATED CYCLIC-GMP 
FORMATION IN MOUSE NEUROBLASTOMA CELLS. 

003783 04-03 
INHIBITION OF SYNAPTOSOMAL CALCIUM UPTAKE BY ETHANOL 

003827 04-03 
INFLUENCE OF CALCIUM ON NORADRENALINE RELEASE EVOKED BY 5 
HYDROXYTRYPTAMINE, TYRAMINE AND POTASSIUM FROM GOAT 
PIAL-ARTERIES. 

003925 04-03 
INHIBITION BY CAFFEINE OF CALCIUM UPTAKE BY BRAIN MICROSOMAL 
VESICLES. 

004042 04-03 
^LCIUM-ACTIVATED 

REGULATION OF HIPPOCAMPAL GLUTAMATE-RECEPTORS: EVIDENCE FOR 
THE INVOLVEMENT OF A CALCIUM-ACTIVATED PROTEASE. 
.^,,. 001120 02-03 

:alcium-carbimide 

a comparative review of the pharmacological and 

TOXICOLOGICAL PROPERTIES OF DISULFIRAM AND CALCIUM- 
CARBIMIDE, 

003522 03-15 



calcium-channel 

phenytoin inhibition of cyclic-guanosine-monophosphate (c- 
gmp) accumulation in neuroblastoma cells by calcium- 
channel blockade. 

004020 04-03 
CALCIUM-FLUX 

PHOSPHOLIPID METABOLISM, CALCIUM-FLUX AND THE RECEPTOR- 
MEDIATED INDUCTION OF CHEMOTAXIS IN RABBIT NEUTROPHILS. 
(UNPUBLISHED PAPER). 

001118 02-03 
CALCIUM-IONS 

RELATIONSHIP BETWEEN THE ACTIONS OF CALCIUM-IONS, OPIOIDS, AND 
PROSTAGLANDIN-El ON THE LEVEL OF CYCLIC-AMP IN 
NEUROBLASTOMA-X GLIOMA HYBRID CELLS. 

002677 03-03 
CALCIUM-SENSITIVE 

CALCIUM-SENSITIVE ACCUMULATION OF NOREPINEPHRINE IN RAT- 
CEREBRAL-CORTEX. 

002685 03-03 
CALCULATIONS 

CONVULSANT AND ANTICONVULSANT BARBITURATES. 1. MOLECULAR 
CONFORMATIONS FROM CLASSICAL POTENTIAL ENERGY 
CALCULATIONS. 

001029 02-01 
CALF 

CHARACTERISTICS OF 3H CIS FLUPENTHIXOL BINDING TO CALF BRAIN 
MEMBRANES. 

000062 01-03 
3H MIANSERIN BINDING IN CALF CAUDATE: POSSIBLE INVOLVEMENT OF 
SEROTONIN-RECEPTORS IN ANTIDEPRESSANT-DRUG ACTION. 

000325 01-03 
THE EFFECT OF TYPICAL AND ATYPICAL NEUROLEPTICS ON BINDING OF 
(3H)SPIR0PERID0L IN CALF CAUDATE. 

003906 04-03 
CALM 

PSYCHOPHARMACEUTICAL-THERAPY TO CALM DRIVE, AQIVITY AND 
RESTLESSNESS IN CHILDHOOD. 

002604 02-17 
CALMODULIN 

CALMODULIN RELEASE FROM STRIATAL MEMBRANES AFTER ACUTE AND 
CHRONIC TREATMENT WITH BUTACLAMOL. 

001249 02-03 
ROLE OF CALMODULIN IN DOPAMINERGIC TRANSMISSION. 
(UNPUBLISHED PAPER). 

001270 02-03 
MODULATION OF BETA-ADRENERGIC-RECEPTORS AND CALMODULIN 
FOLLOWING ACUTE AND CHRONIC-TREATMENT WITH NEUROLEPTICS. 

001529 02-03 
CALMODULIN: ITS ROLE IN SYNAPTIC TRANSMISSION. 

003162 03-07 
PHARMACOLOGICAL REGULATION OF CALMODULIN. 

004052 04-03 
ACUTE AND CHRONIC EFFECTS OF PSYCHOACTIVE-DRUGS ON 
ADRENERGIC-RECEPTORS AND CALMODULIN. 

004750 04-17 
MECHANISMS AND PHARMACOLOGICAL IMPLICATIONS OF ALTERING 

CALMODULIN ACTIVITY. 

004751 04-17 
CANALIZATION 

CANALIZATION OF AROUSAL IN THE PREWEANLING RAT: EFFECTS OF 
AMPHETAMINE ON AGGREGATION WITH SURROGATE STIMULI. 

002965 03-04 
CANCER 

ANTICONVULSANT-DRUGS AND CANCER. 

000855 01-15 
INTRAVENOUS LORAZEPAM TO PREVENT NAUSEA AND VOMITING 
ASSOCIATED WITH CANCER CHEMOTHERAPY. 

003614 03-17 
TREATMENT OF CANCER PAIN. 

003619 03-17 
CANCER-PATIENTS 

SERIAL COGNITIVE TESTING IN CANCER-PATIENTS RECEIVING 
CHEMOTHERAPY. 

000876 01-15 
CANINE 

REACTIVITY OF ISOLATED CANINE CEREBRAL-ARTERIES TO ADENINE- 
NUCLEOTIDES AND ADENOSINE. 

000210 01-03 
PROTEQIVE EFFECT OF PRENYLAMINE AGAINST VULNERABILITY TO 
VENTRICULAR FIBRILLATION IN THE NORMAL AND ISCHEMIC CANINE 
MYOCARDIUM. 

000265 01-03 
CONSISTENT UNMASKING OF DOPAMINE-INDUCED DILATION OF THE 
CANINE FEMORAL VASCULAR BED. 

003911 04-03 
CANNABIDIOL 

CHRONIC ADMINISTRATION OF CANNABIDIOL TO HEALTHY VOLUNTEERS 
AND EPILEPTIC-PATIENTS. 

000669 01-11 



I 












S-71 



Subject Index 



Psychopharmacoiogy Abstracts 



THE EFFEaS OF 0ELTA9 TETRAHYDROCANNABINOL ALONE AND IN 
COMBINATION WITH CANNABIDIOL ON FIXED-INTERVAL 
PERFORMANCE IN RHESUS-MONKEYS. 

001582 02-04 
METABOLIC- STUDIES AND PSYCHOPHYSIOLOGIC- STUDIES OF 
CANNABIDIOL HEXOBARBITAL INTERACTION. 

002209 02-13 
EFFECT OF CANNABIDIOL ON CYTOCHROME-P-450 AND HEXOBARBITAL 
SLEEP-TIME. 

002675 03-03 
EFFECTS OF DELTA9 TETRAHYDROCANNABINOL AND CANNABIDIOL ON 
SODIUM-DEPENDENT HIGH-AFFINITY CHOLINE UPTAKE IN THE RAT 
HIPPOCAMPUS. 

003908 04-03 
CHARACTERISTICS OF THE STIMULUS PRODUCED BY THE MIXTURE OF 
CANNABIDIOL WITH DELTA9 TETRAHYDROCANNABINOL. 

004263 04-04 
CANNABINOID 

ISOLATION OF PSYCHOACTIVE CANNABINOID PRECURSORS FROM 
CANNABIS OF SOVIET PROVENIENCE GROWN IN MISSISSIPPI. 

001023 02-01 
SUBACUTE CANNABINOID TREATMENT: ANTICONVULSANT ACTIVITY AND 
WITHDRAWAL EXCITABILITY IN MICE. 

001671 02-04 
INTERCANNABINOID AND CANNABINOID ETHANOL INTERACTIONS AND 
THEIR EFFECTS ON HUMAN PERFORMANCE. 

002193 02-12 
A SINGLE-DOSE STUDY OF NABILONE, A SYNTHETIC CANNABINOID 

002328 02-14 
DIFFERENTIAL-EFFECTS OF CANNABINOID EXPOSURE AND STRESS ON 
PLASMA PROLACTIN, GROWTH-HORMONE AND CORTICOSTERONE 
LEVELS IN MALE MICE. 

002695 03-03 
LEVONANTRADOL, A POTENT CANNABINOID RELATED ANALGESIC, 
ANTAGONIZES HALOPERIDOL-INDUCED ACTIVATION OF STRIATAL 
DOPAMINE SYNTHESIS. 

002786 03-03 
CANNABINOID-INDUCED 

CANNABINOID-INDUCED ENHANCEMENT AND DEPRESSION OF CAT 
MONOSYNAPTIC REFLEXES. 

004040 04-03 
CANNABINOIDS 

EFFECTS OF SYSTEMIC AND INTRAVENTRICULAR ADMINISTRATION OF 
CANNABINOIDS ON SCHEDULE-CONTROLLED RESPONDING IN THE 
SQUIRREL-MONKEY. 

000354 01-04 
POSTSWIM GROOMING IN MICE INHIBITED BY DOPAMINE-RECEPTOR 
ANTAGONISTS AND BY CANNABINOIDS. 

000359 01-04 
INFLUENCE OF PSYCHOACTIVE AND NONPSYCHOAQIVE CANNABINOIDS 
ON CELL PROLIFERATION AND MACROMOLECULAR BIOSYNTHESIS IN 
HUMAN CELLS. 

002830 03-03 
INFLUENCE OF PSYCHOACTIVE AND NONPSYCHOAQIVE CANNABINOIDS 

ON CHROMATIN STRUCTURE AND FUNCTION IN HUMAN CELLS 

002831 03-03 
EFFECTS OF CANNABINOIDS ON CATECHOLAMINE UPTAKE AND RELEASE 

IN HYPOTHALAMIC AND STRIATAL SYNAPTOSOMES. 

003970 04-03 
CANNABINOIDS. I. BEHAVIORAL-EFFECTS. 

004228 04-04 
CANNABINOIDS. II. CARDIOVASCULAR-EFFEaS. 

004280 04-05 
CANNABIS 

INTERACTIVE-EFFECTS OF NUTRITION AND CANNABIS UPON RAT 
PERINATAL DEVELOPMENT. 

000513 01-05 
ISOLATION OF PSYCHOACTIVE CANNABINOID PRECURSORS FROM 
CANNABIS OF SOVIET PROVENIENCE GROWN IN MISSISSIPPI. 

001023 02-01 
EFFECTS OF BODY-WEIGHT LEVELS ON CANNABIS SELF-INJECTION. 

001801 02-04 
SIMILARITIES BETWEEN CANNABIS AND OPIUM. 

002554 02-17 
INFLUENCE OF CANNABIS AND DELTA9 TETRAHYDROCANNABINOL ON 
THE BIOCHEMISTRY OF THE MALE REPRODUCTIVE ORGANS. 

002686 03-03 
CANNABIS-SATIVA 

CANNABIS-SATIVA: EFFECTS ON BRAIN FUNQION AND ULTRASTRUCTURE 
IN RHESUS-MONKEYS. 

002747 03-03 
CANNED 

TYRAMINE CONTENT OF CANNED AND PACKET SOUPS. 

002394 02-15 
CANNULA 

QUICKLY-MADE CANNULA FOR REPEATED CEREBROSPINAL-FLUID 
SAMPLING IN RATS. 

001879 02-06 



CANTOR 

TREATMENT OF ASTHENO-DEPRESSIVE-DISORDERS WITH MINAPRINE 
(CANTOR). MULTICENTER-STUDY OF 248 CASES EVALUATED WITH THE 
FATIGUE STUDY GROUPS NO. 4 CLINICAL- SCALE. 

001980 02-09 
CAPACITIES 

CAPACITIES OF AHENTION, STRESS-RESISTANCE, AND SLOW CEREBRAL 
POTENTIALS; EFFECTS OF CARPIPRAMINE ON CONTINGENT NEGATIVE 
VARIATION WAVES AND P-300. 

003451 03-14 
CAPACITY 

ON THE CAPACITY OF PRESYNAPTIC ALPHA-RECEPTORS TO MODULATE 
NOREPINEPHRINE RELEASE FROM SLICES OF RAT NEOCORTEX AND THE 
AFFINITY OF SOME AGONISTS AND ANTAGONISTS FOR THESE 
RECEPTORS. 

000323 01-03 
SWIMMING CAPACITY OF MICE AFTER PROLONGED TREATMENT WITH 
PSYCHOSTIMULANTS: II. EFFEQ OF METHAMPHETAMINE ON 
SWIMMING PERFORMANCE AND AVAILABILITY OF METABOLIC 
SUBSTRATES. 

001613 02-04 
EFFECTS OF PSYCHOPHARMACEUTICALS ON DRIVING CAPACITY 

003453 03-14 
CAPILLARIES 

DECARBOXYLATION OF EXOGENOUS L-DOPA IN RAT STRIATUM AFTER 
LESIONS OF THE DOPAMINERGIC NIGROSTRIATAL NEURONS: THE ROLE 
OF STRIATAL CAPILLARIES 

000202 01-03 
CAPILLARY 

LONG-TERM ANTIDEPRESSANT TREATMENT: ALTERATIONS IN CEREBRAL 
CAPILLARY PERMEABILITY. 

000239 01-03 
PHENYTOIN CONCENTRATIONS IN VENOUS VERSUS CAPILLARY BLOOD OF 
GERIATRIC-PATIENTS. 

003381 03-1 1 
THE EFFECT OF DIBENZAZEPINES (TRICYCLIC-ANTIDEPRESSANTS) ON 
CEREBRAL CAPILLARY PERMEABILITY IN THE RAT IN VIVO. 

003974 04-03 
CAPSAICIN 

NEUROPHYSIOLOGICAL-EFFEaS AND THERMOREGULATORY-EFFEaS OF 
CAPSAICIN. 

001421 02-03 
SELECTIVE NEUROTOXIC-ACTION OF CAPSAICIN ON GLOMERULAR C-TYPE 
TERMINALS IN RAT SUBSTANTIA-GELATINOSA. 

003143 03-06 
INTRANIGRAL INJECTION OF CAPSAICIN ENHANCES MOTOR-AQIVITY ; 
AND DEPLETES NIGRAL 5 HYDROXYTRYPTAMINE BUT NOT SUBSTANCE- ' 
P. 

004100 04-04 
A REEVALUATION OF THE NEUROCHEMICAL-EFFEaS AND 
ANTINOCICEPTIVE-EFFEaS OF INTRATHECAL CAPSAICIN IN THE RAT. 

004184 04-04 
CAPSULE 

BIOAVAILABILITY OF SULPIRIDE TABLET AND CAPSULE IN DOGS. 

001101 02-03 
CAPTOPRIL 

CAPTOPRIL GIVEN INTRACEREBROVENTRICULARLY, SUBCUTANEOUSLY OR 
BY GAVAGE INHIBITS ANGIOTENSIN CONVERTING ENZYME AQIVITY 
IN THE RAT-BRAIN. 

001614 02-04' 
POTENTIATION OF THE MORPHINE-INDUCED RESPIRATORY RATE 

DEPRESSION BY CAPTOPRIL. 

004275 04-05 
CAPTURE 

A METHOD FOR MEASUREMENT OF TRANYLCYPROMINE IN RAT-BRAIN 
REGIONS USING GAS-CHROMATOGRAPHY WITH ELEaRON CAPTURE 
DETEQION. 

003137 03-06 
CARBACHOL 

PARASYMPATHOMIMETIC-INFLUENCE OF CARBACHOL ON LOCAL 
CEREBRAL BLOOD FLOW IN THE RABBIT BY A DIREQ VASODILATOR 
ACTION AND AN INHIBITION OF THE SYMPATHETIC MEDIATED 
VASOCONSTRiaiON. 

001109 02-03 
FUNQIONAL ORGANIZATION OF THE CAUDATE-NUCLEUS AFTER 
ADMINISTRATION OF CARBACHOL. 

001495 02-03 
EFFECT OF MEDIAN RAPHE STIMULATION ON HIPPOCAMPAL SEIZURE 
DISCHARGE INDUCED BY CARBACHOL IN Th£ RABBIT. 

003951 04-03 
CARBACHOL-INDUCED 

STUDIES OF CARBACHOL-INDUCED WET-DOG-SHAKE BEHAVIOR IN RATS. 

004241 04-04 
CARBAMAZEPINE 

PHARMACOKINETICS OF CARBAMAZEPINE IN THE DOG. 

000096 01-03 
CARBAMAZEPINE-EPOXIDE DETERMINED BY EMIT CARBAMAZEPINE 
REAGENT. 

000533 01-06 



S-72 



VOLUME 19, SUBJECT INDEX 



Subject Index 



THE AUTOINDUCTION OF CARBAMAZEPINE DURING LONG-TERM 
THERAPY. 

000785 01-13 
CORRELATION BETWEEN DAILY FLUCTUATIONS OF CARBAMAZEPINE 
SERUM LEVELS AND INTERMITTENT SIDE-EFFECTS. 

000851 01-15 
CARBAMAZEPINE INTOXICATION DUE TO TRIACETYLOLEANDOMYCIN 
ADMINISTRATION IN EPILEPTIC-PATIENTS. 

000873 01-15 
VALUE OF SALIVA SAMPLES IN MONITORING CARBAMAZEPINE 
CONCENTRATIONS IN EPILEPTIC-PATIENTS. 

000903 01-16 
INFLUENCE OF CARBAMAZEPINE ON THALAMOCORTICAL AND 
HIPPOCAMPOCORTICAL SELF-SUSTAINED AFTERDISCHARGES IN RATS. 

001356 02-03 
SENSITIZATION AND OSCILLATION FOLLOWING REPEATED STIMULATION: 
RELATIONSHIP TO AFFECTIVE-ILLNESS AND ITS TREATMENT WITH 
LITHIUM AND CARBAMAZEPINE 

002031 02-09 
CARBAMAZEPINE THERAPY IN TRIGEMINAL-NEURALGIA: CLINICAL- 
EFFECTS IN RELATION TO PLASMA CONCENTRATION. 

002181 02-11 
SALIVARY IMMUNOGLOBULIN CONCENTRATIONS IN PATIENTS WITH 

EPILEPSY TREATED WITH CARBAMAZEPINE. 

002234 02-13 
BIOCHEMICAL-EVIDENCE FOR OSTEOMALACIA WITH CARBAMAZEPINE 
THERAPY. 

002445 02-15 
A DOUBLE-BUND, PLACEBO-CONTROLLED, CROSS-OVER TRIAL OF 
CARBAMAZEPINE IN OVERACTIVE, SEVERELY MENTALLY- 
HANDICAPPED PATIENTS. 

003365 03-11 
A PRELIMINARY DOUBLE-BUND STUDY ON THE EFFICACY OF 
CARBAMAZEPINE IN PROPHYLAXIS OF MANIC-DEPRESSIVE-ILLNESS. 

004388 04-09 
MEASUREMENTS OF NERVE CONDUCTION VELOCITY DURING DECREASING 
TOXIC DIPHENYLHYDANTOIN LEVELS AND THE BEGINNING OF 
CARBAMAZEPINE MEDICATION: A CLINICAL NEUROPHYSIOLOGICAL 
REPORT. 

004441 04-11 
INFLUENCE OF CARBAMAZEPINE ON SERUM THYROXINE AND 
TRIIODOTHYRONINE IN PATIENTS WITH EPILEPSY. 

004488 04-11 
CONCENTRATIONS AND KINETICS OF CARBAMAZEPINE IN WHOLE 
SAUVA, PAROTID SALIVA, SERUM ULTRAFILTRATE, AND SERUM. 

004545 04-13 
CARBAMAZEPINE-EPOXIDE 

CARBAMAZEPINE-EPOXIDE DETERMINED BY EMIT CARBAMAZEPINE 
REAGENT. 

000533 01-06 
CARBAMAZEPINE-ETHOSUXIMIDE 

KINETICS OF A CARBAMAZEPINE-ETHOSUXIMIDE INTERACTION. 

004558 04-13 
CARBAAAAZEPINE-INDUCED 

REVERSAL BY PHENYTOIN OF CARBAMAZEPINE-INDUCED WATER 
INTOXICATION: A PHARMACOKINETIC-INTERACTION. 

000783 01-13 
CARBAMAZEPINE-INDUCED OROFACIAL DYSKINESIA. 

002415 02-15 
CARBIDINE 

THE EFFECT OF CARBIDINE ON DOPAMINE TURNOVER IN THE CORPUS- 
STRIATUM OF THE BRAINS OF RATS. 

001352 02-03 
CARBIDOPA 

THE TREATMENT OF PARKINSONS-DISEASE USING A COMBINATION OF L- 
DOPA AND DECARBOXYLASE INHIBITORS (CARBIDOPA, BENSERASIDE) 
A CLINICAL AND BIOCHEMICAL COMPARATIVE INVESTIGATION. 

000712 01-11 
TREATMENT OF MYOCLONUS WITH L 5 HYDROXYTRYPTOPHAN AND 
CARBIDOPA: CLINICAL, ELECTROPHYSIOLOGICAL, AND BIOCHEMICAL- 
OBSERVATIONS. 

002180 02-11 
INCREASED RATIO OF CARBIDOPA TO LEVODOPA IN TREATMENT OF 
PARKINSONS-DISEASE. 

002182 02-11 
EFFECTS OF BENSERAZIDE AND CARBIDOPA ON THE METABOLISM OF L 

TRYPTOPHAN BY ISOLATED RAT LIVER CELLS. 

002899 03-03 
ELECTRORETINOGRAPHY (ERG) AS A TOOL OF INVESTIGATION IN HUMAN 
PSYCHOPHARMACOLOGY. ELECTRORETINOGRAPHIC-CHANGES INDUCED 
BY A COMBINATION OF CARBIDOPA AND LEVODOPA. 

004507 04-13 
ELECTROENCEPHALOGRAPHIC CHANGE IN PARKINSONIAN-PATIENTS 
TREATED WITH LEVODOPA CARBIDOPA. 

004557 04-13 
CARBOHYDRATE 

ACUTE CHANGES IN BRAIN TRYPTOPHAN AND SEROTONIN FOLLOWING 
CARBOHYDRATE OR PROTEIN INGESTION BY DIABETIC RATS. 
(UNPUBUSHED PAPER). 

000060 01-03 



CARBOLINE-3-CARBOXYLATES 

BETA CARBOUNE-3-CARBOXYLATES AND BENZODIAZEPINE-RECEPTORS. 

002676 03-03 
CARBOLINES 

BENZODIAZEPINE ANTAGONISM BY HARMANE AND OTHER BETA 
CARBOUNES IN VITRO AND IN VIVO. 

004211 04-04 
CARBOXAMIDOSTRYCHNINE 

INHIBITION OF BRAIN SYNAPTOSOMAL UPTAKE OF CHOLINE BY SOME 2 
CARBOXAMIDOSTRYCHNINE DERIVATIVES WITH MUSCLE-RELAXANT 
PROPERTIES. 

000084 01-03 
CARBOXYMETHYLATION 

ENZYMATIC CARBOXYMETHYLATION OF THE NICOTINIC ACETYLCHOLINE- 
RECEPTOR. (UNPUBLISHED PAPER). 

001318 02-03 
CARDIAC 

COMPARISON OF MIANSERIN WITH DESIPRAMINE, MAPROTIUNE AND 
PHENTOLAMINE ON CARDIAC PRESYNAPTIC AND VASCULAR 
POSTSYNAPTIC ALPHA-ADRENOCEPTORS AND NORADRENALINE 
REUPTAKE IN PITHED NORMOTENSIVE-RATS. 

000044 01-03 
THE REGULATION OF CARDIAC MUSCARINIC CHOLINERGIC-RECEPTORS BY 
ISOPROTERENOL. 

001441 02-03 
ONTOGENY OF MAMMALIAN CARDIAC ALPHA 1-ADRENERGIC- 
RECEPTORS. 

001545 02-03 
AMITRIPTYLINE PROVIDES LONG-LASTING IMMUNIZATION AGAINST 
SUDDEN CARDIAC DEATH FROM COCAINE. 

003122 03-05 
BETA-ADRENERGIC INFLUENCE ON CARDIAC DYNAMICS DURING SHOCK- 
AVOIDANCE IN DOGS. 

003813 04-03 
CARDIAC-MUSCLE 

POTENTIATION OF THE EFFECTS OF ADENOSINE ON ISOLATED CARDIAC- 
MUSCLE AND SMOOTH-MUSCLE BY DIAZEPAM. 

004266 04-05 
CARDIOLOGICAL 

PLASMA NOMIFENSINE CONCENTRATION: CARDIOLOGICAL EFFECTS AND 
CLINICAL-RESPONSE. 

004639 04-15 
CARDIOLOGY 

INTERFACES OF PSYCHOPHARMACOLOGY AND CARDIOLOGY - PART 
TWO. 

003529 03-15 
INTERFACES OF PSYCHOPHARMACOLOGY AND CARDIOLOGY - PART 

ONE. 

003530 03-15 
CARDIOMYOPATHY 

INTRAVENOUS QUINIDINE IN CONGESTIVE CARDIOMYOPATHY. 

003352 03-11 
CARDIOTOXICITY 

COMPARATIVE-STUDY OF THE CARDIOTOXICITY OF AMITRIPTYLINE AND 
MAPROTIUNE IN DEPRESSIVE-PATIENTS. 

000595 01-09 
CARDIOTOXICITY OF ANTIDEPRESSANTS. 

001843 02-05 
CARDIOTOXICITY OF ANTIDEPRESSANT-DRUGS. 

004597 04-15 
CARDIOVASCULAR 

CARDIOVASCULAR RESPONSE TO THE INTERAQION OF ETHANOL AND 
SOME BENZODIAZEPINES IN RATS. 

000332 01-03 
EFFECTS OF CHRONIC ADMINISTRATION OF DELTA9 
TETRAHYDROCANNABINOL ON THE CARDIOVASCULAR SYSTEM, AND 
PRESSOR AND BEHAVIORAL-RESPONSES TO BRAIN-STIMULATION IN 
FREELY-MOVING-RATS. 

000417 01-04 
A COMPARISON OF THE CARDIOVASCULAR EFFECTS OF HALOPERIDOL, 
THIORIDAZINE AND CHLORPROMAZINE-HCL. 

000512 01-05 
A CASE OF CARDIOVASCULAR COLLAPSE DURING UTHIUM-CARBONATE 
THERAPY. 

000860 01-15 
CARDIOVASCULAR EFFECTS OF NORTRIPTYLINE IN GERIATRIC-PATIENTS. 

000882 01-15 
DESIPRAMINE: CARDIOVASCULAR EFFECTS AND PLASMA LEVELS. 

000884 01-15 
EFFECT OF GABA AGONIST AND ANTAGONISTS ON CARDIOVASCULAR 
AND SYMPATHETIC RESPONSES IN SHR AND WKY RATS. 
(UNPUBUSHED PAPER). 

001224 02-03 
HEXAMETHONIUM MODIFICATION OF CARDIOVASCULAR ADJUSTMENTS 
DURING COMBINED STATIC DYNAMIC ARM EXERCISE IN MONKEYS. 

001242 02-03 
CENTRALLY INDUCED CARDIOVASCULAR AND SYMPATHETIC-NERVE 
RESPONSES TO BRADYKININ IN RATS. 

003099 03-04 



I 















S-73 



Subject Index 



Ptychopharmacology Abstracts 



SENSORY PROCESSING, CARDIOVASCULAR REACTIVITY, AND THE TYPE A 
CORONARY-PRONE BEHAVIOR PATTERN, 

003405 03-13 

HISTAMINE AS A PUNISHER IN SQUIRREL-MONKEYS: EFFECTS OF 
PENTOBARBITAL, CHLORDIAZEPOXIDE AND HI -RECEPTOR AND H2- 
RECEPTOR ANTAGONISTS ON BEHAVIOR AND CARDIOVASCULAR 

RESPONSE. „„,,,„«.«„ 

004119 04-04 

CARDIOVASCULAR-EFFECTS 

CARDIOVASCULAR-EFFECTS OF AMITRIPTYLINE, MIANSERIN AND 

ZIMELIDINE IN DEPRESSED-PATIENTS. 

002215 02-13 
CARDIOVASCULAR-EFFECTS OF THERAPEUTIC DOSES OF TRICYCLIC- 
ANTIDEPRESSANTS: IMPORTANCE OF BLOOD LEVEL MONITORING. 

002456 02-15 
CARDIOVASCULAR-EFFECTS OF MIANSERIN AND AMITRIPTYLINE IN 

HEALTHY VOLUNTEERS. 002469 02-15 

TYRAMINE PRESSOR TEST AND CARDIOVASCULAR-EFFECTS OF 

CHLORIMIPRAMINE AND NORTRIPTYLINE IN HEALTHY VOLUNTEERS. 

003428 03-13 
CARDIOVASCULAR-EFFECTS OF MIANSERIN - A COMPARATIVE-STUDY 
WITH AMITRIPTYLINE AND A PLACEBO IN HEALTHY SUBJEQS. 

003503 03-15 
POSSIBLE ROLE OF AN ENDOGENOUS OPIATE IN THE CARDIOVASCULAR- 
EFFECTS OF CENTRAL ALPHA-ADRENOCEPTOR STIMULATION IN 
SPONTANEOUSLY HYPERTENSIVE-RATS. ^^^^^ ^^^^ 

CENTRAL CARDIOVASCULAR-EFFECTS AND BIOCHEMICAL-EFFECTS OF 

BACLOFEN IN THE CONSCIOUS RAT. 003965 04-03 

CANNABINOIDS. II. CARDIOVASCULAR-EFFECTS. ^^ 

CARDIOVASCULAR-PHARMACOLOGY 

THE NEUROVASCUIAR-PHARMACOLOGY AND CARDIOVASCULAR- 
PHARMACOLOGY OF RS-51324, A POTENTIAL ANTIDEPRESSANT. 

001091 02-02 
CARDIOVASCULAR-SYSTEM 

EFFECTS OF DELTA9 TETRAHYDROCANNABINOL ON THE 
CARDIOVASCULAR- SYSTEM, AND PRESSOR AND BEHAVIORAL- 
RESPONSES TO BRAIN-STIMULATION IN RATS. 

001681 02-04 

CARE 

HOSPITAL AND OUTPATIENT CARE FOR PSYCHOTIC-PATIENTS DURING THE 
LAST THREE DECADES: SUBSEQUENT HOSPITAL AND OUTPATIENT 
TREATMENT OF PSYCHOTIC-PATIENTS HOSPITALIZED FOR THE FIRST 
TIME IN 1949-50, 1959-60 OR 1969-70. „,„,„„ 

000571 01-08 
OUTPATIENT CARE OF DEPRESSIVE-PATIENTS WITH MIANSERIN. 

002041 02-09 
PSYCHOPHARMACOLOGY - AN AREA OF RESEARCH TO IMPROVE 

MENTAL-HEALTH CARE. „„„.„, „o ,-, 

002586 02-17 

THE MEDICATION SEMINAR AND PRIMARY CARE EDUCATION. 

003592 03-17 

CARNITINE „ ^ 

THE UPTAKE OF CARNITINE BY SLICES OF RAT-CEREBRAL-CORTEX. 

. 003853 04-03 

CAROTID 

INHIBITION OF VASOPRESSIN RELEASE TO CAROTID OCCLUSION BY 
GAMMA AMINOBUTYRIC-ACID AND GLYCINE. 

002715 03-03 

CARP 

STEREOSPECIFIC INHIBITION OF DOPAMINE-SENSITIVE ADENYLATE- 
CYCLASE IN CARP RETINA BY THE ENANTIOMERS OF (/-) 1 
CYCLOPROPYLMETHYL 
TRIFLUOROMETHYLTHIODIBENZOCYCLOHEPTENYLIDENEPIPERIDINE. 

003706 04-02 
DOPAMINERGIC MECHANISMS IN THE TELEOST RETINA. II. FACTORS 
AFFECTING THE ACCUMULATION OF CYCLIC-AMP IN PIECES OF INTAQ 
CARP RETINA. 

003776 04-03 
DOPAMINERGIC MECHANISMS IN THE TELEOST RETINA. I. DOPAMINE- 
SENSITIVE ADENYLATE-CYCLASE IN HOMOGENATES OF CARP RETINA, 
EFFECTS OF AGONISTS, ANTAGONISTS AND ERGOTS 

004051 04-03 
CARPIPRAMINE 

THE INTEREST OF THE STIMULATING EFFECT OF CARPIPRAMINE IN 
PSYCHOSOMATIC-MEDICINE. 

002061 02-10 
PERSPECTIVES ON PRAZINIL (CARPIPRAMINE): A DISINHIBITING-AGENT 
WITH NO NEUROLEPTIC ACTIVITY. A REVIEW OF 38 CASES. 

003149 03-07 
CARPIPRAMINE: A DISINHIBITORY DRUG COMPOUND IN CHRONIC 

SCHIZOPHRENIA. ^ „, „o 

003192 03-08 
CAPACITIES OF AHENTION, STRESS-RESISTANCE, AND SLOW CEREBRAL 
POTENTIALS- EFFECTS OF CARPIPRAMINE ON CONTINGENT NEGATIVE 
VARIATION WAVES AND P-300. , „. , . 

003451 03-14 



CARRIER 

THE ROLE OF CALCIUM AND DOPAMINE MEMBRANE CARRIER IN 

MEDIATING THE BEHAVIORAL-EFFECTS AND BIOCHEMICAL-EFFEQS OF 
AMPHETAMINE. (PH.D. DISSERTATION). 

002996 03-04 

CASE 

A CASE OF TRIGEMINAL-NEURALGIA TREATED WITH LITHIUM- 
CARBONATE. 

000690 01-11 
A CASE OF CARDIOVASCULAR COLLAPSE DURING LITHIUM-CARBONATE 
THERAPY. 

000860 01-15 
METHODOLOGICAL-ISSUES IN SPINAL-FLUID STUDIES OF SCHIZOPHRENIA: 
THE CASE OF NOREPINEPHRINE AND DOPAMINE-BETA-HYDROXYLASE. 
(UNPUBLISHED PAPER). 

001952 02-08 
REGIONAL CEREBRAL BLOOD FLOW IN A CASE OF AMPHETAMINE 
INTOXICATION. 

002210 02-13 
CASE 3 ASSESSMENT AND TREATMENT OF DRUG-INDUCED TREMOR. 

002407 02-15 
ON A CASE OF MEMORY-DISTURBANCES TREATED WITH VASOPRESSIN. 

003301 03-11 
A CASE OF REVERSIBLE PURE-WORD DEAFNESS DURING LITHIUM 
TOXICITY. 

003481 03-15 
AN UNUSUAL CASE OF THIORIDAZINE AND LEVOMEPROMAZINE 
DEPENDENCE. 

004634 04-15 
TRANSIENT HYPERKINESIA AFTER A SINGLE INTRAVENOUS PERFUSION OF 
DIPHENYLHYDANTOIN: REPORT OF A CASE ASSOCIATED WITH 
NONTOXIC PLASMA LEVELS OF DIPHENYLHYDANTOIN. 

004638 04-15 
A CASE OF PETIT-MAL EPILEPSY AGGRAVATED BY LITHIUM 

004641 04-15 
A CASE OF ACUTE AGRANULOCYTOSIS DURING TREATMENT WITH 

CLOZAPINE. 

004642 04-15 

CASE-HISTORY 

THE ROLE OF LITHIUM IN THE PRODUQION OF INTERSTITIAL NEPHRITIS: 
A CASE-HISTORY ^ ,, 

004655 04-15 

CASE-REPORT „ ,^„ I 

CASE-REPORT: USING AHRIBUTION THEORY TO LIMIT NEED FOR 

NEUROLEPTIC-MEDICINE. „„„„„ „, „„ 

000559 01-08 
FAILURE OF NALOXONE TO REVERSE CATALEPSY ASSOCIATED WITH 

SCHIZOPHRENIA: A CASE-REPORT 

000560 01-08 
A CASE-REPORT OF CIMETIDINE-INDUCED DEPRESSIVE-SYNDROME. 

000839 01-15 
CUTANEOUS REACTION TO LITHIUM-CARBONATE: A CASE-REPORT. 

000872 01-15 
A CASE-REPORT OF LORAZEPAM WITHDRAWAL. 

000889 01-15 
PHENYTOIN TOXICITY IN A BRAIN-DAMAGE ADOLESCENT: A CASE- 

^^''^^^ 003512 03-15 

LITHIUM NEUROTOXICITY AT THERAPEUTIC LEVELS: A CASE-REPORT^ 

003533 03-15 
CASE-REPORT OF UNUSUAL DIAZEPAM ABSTINENCE-SYNDROME 

004643 04- 1 - 

CASE-REPORTS 

IMIPRAMINE TREATMENT OF BORDERLINE-CHILDREN: CASE-REPORTS 
WITHACONTROLLED-STUDY. 003356 03-11 

d'ePENDENCE on TRANQUILIZERS (AN OVERVIEW WITH (CASE-STUDIES) _ 

003580 03-1/ 

CASE-STUDY 

SATYRIASIS: A CASE-STUDY. 000709 01-11 

PSYCHOAaiVE-DRUG-EFFEaS IN A HYPERACTIVE-CHILD: A CASE-STUDY 
ANALYSIS OF BEHAVIOR-CHANGE AND TEACHER AHENTION. 

002313 02-1' 

SYNERGISM OF COMBINED LITHIUM NEUROLEPTIC THERAPY: A DOUBLE- 
BUND, PLACEBO-CONTROLLED CASE-STUDY. 

003 loj Oo-Oc 

CORTICAL EVOKED-POTENTIALS IN GILLES-DE-IA-TOUREHES-SYNDROME 
-A SINGLE CASE-STUDY. 00343103-1: 

TREATMENT OF NARCOLEPSY AND SLEEP-APNEA WITH GAMMA 
HYDROXYBUTYRATE: A CLINICAL AND POLYSOMNOGRAPHIC CASE- 

5™°^ 004571 04-1. 

^"^RUG-THERAPY IN ENDOGENOUS DEPRESSION WITH POSSIBLE PRIMARY 
GABA DEFICIENCY CLINICALLY DETEQED: 38 NEW CASES ^^^ 



S-74 



^;; 



VOLUME 19, SUBJECT INDEX 

THREE CASES OF UNIPOLAR DELUSIONAL DEPRESSION RESPONSIVE TO L- 
DOPA 

000628 01-09 
REVIEW OF 38 CASES OF SUBACUTE SCLEROSING PANENCEPHALITIS: 
EFFECT OF AMANTADINE ON THE NATURAL COURSE OF THE DISEASE 

000718 01-11 
TARDIVE-DYSKINESIAS (OBSERVATIONS CONCERNING THREE CASES). 

000861 01-15 
AGITATION DISORIENTATION, AND HALLUCINATIONS IN PATIENTS ON 
CIMETIDINE: A REPORT OF THREE CASES AND LITERATURE REVIEW. 

000896 01-15 
THE DEVELOPMENT OF PROGENY IN CASES OF ANTENATAL EXPOSURE TO 

PHENAZEPAM „„,„.. „^„c 

001854 02-05 
TREATMENT OF ASTHENO-DEPRESSIVE-DISOROERS WITH MINAPRINE 
(CANTOR). MULTICENTER-STUDY OF 248 CASES EVALUATED WITH THE 
FATIGUE STUDY GROUPS NO. 4 CLINICAL-SCALE. 

001980 02-09 
BIPOLAR AFFECTIVE-PSYCHOSIS WITH ONSET BEFORE AGE 16 YEARS: 

REPORT OF 10 CASES. „„„„„, „o «o 

002001 02-09 
MINAPRINE IN SEVERE PSYCHOPATHOLOGY: STUDY OF 20 CASES. 

002135 02-11 
MEDICAL PSYCHOLOGICAL AND COMBINED THERAPY IN THE CASES OF 
ENURESIS: A COMPARATIVE-STUDY. 

002175 02-11 
PERSPECTIVES ON PRAZINIL (CARPIPRAMINE): A DISINHIBITING-AGENT 
WITH NO NEUROLEPTIC ACTIVITY. A REVIEW OF 38 CASES. 

003149 03-07 
THE TREATMENT OF DEPRESSION USING CLOMIPRAMINE IN GENERAL- 
MEDICAL-PRACTICE: 48 CASES TREATED ON AN OUTPATIENT BASIS. 

003268 03-09 
SEXUAL-DIFFICULTIES AMONG CONVALESCING ALCOHOLICS: INTEREST IN 
PRAZEPAM TREATMENT IN 30 CASES. 

003296 03-11 
EXCESSIVE PLASMA CONCENTRATIONS OF TRICYCLIC-ANTIDEPRESSANTS 
RESULTING FROM USUAL DOSES: A REPORT OF SIX CASES. 

003479 03-15 
EXCEPTIONAL CASES OF DEATH CAUSED BY TRICYCLIC-ANTIDEPRESSANT 
AGENTS. 

003490 03-15 
SEVERE WITHDRAWAL-SYNDROME AFTER CESSATION OF 
BENZODIAZEPINE TREATMENT: SIX CLINICAL CASES. 

003505 03-15 
AGE-SPECIFIC DOSES OF LORMETAZEPAM AS A NIGHT SEDATIVE IN 
CASES OF CHRONIC SLEEP-DISTURBANCE. 

004309 04-07 
NEUROLOGICAL TOLERANCE OF LITHIUM AND PSYCHOTROPIC-DRUGS IN 
COMBINATION: 265 CASES. 

004594 04-15 
THE TWO SURVIVAL CASES OF ALPHA-PATTERN COMA CAUSED BY 
LARGE AMOUNTS OF HYPNOTICA AND NEUROLEPTICA. 

004608 04-15 
TWO CASES OF FORM-FRUSTE-DU-SYNDROME-MALIN WITH HIGH-LEVELS 
OF SERUM CPK. 

004636 04-15 
CASQMQRPHINS 

OPIOID ACTIVITIES OF BETA CASOMORPHINS. 

003740 04-03 
CASTRATED 

MORPHINE EXERTS TESTOSTERONE-LIKE EFFEQS IN THE HYPOTHALAMUS 
OF THE CASTRATED MALE RAT. 

000051 01-03 
EFFECT OF AMINOOXY ACETIC-ACID AND BICUCULLINE ON PROLACTIN 
RELEASE IN CASTRATED MALE RATS. 

001194 02-03 
SUPPRESSIVE EFFECT OF MORPHINE ON SERUM GONADOTROPIN LEVELS 
IN CASTRATED RATS. 

001393 02-03 



CAT 



THE INFLUENCE OF BENZOCTAMINE ON DOPAMINE AND NOREPINEPHRINE 
CONTENTS OF THE SUBSTANTIA-NIGRA AND ON THE MUSCLE STRETCH 
REFLEX OF THE CAT. 

000054 01-03 
EFFEQS OF ALPHA CHLORALOSE ON THE ACTIVITY OF THE 
NIGROSTRIATAL DOPAMINERGIC SYSTEM IN THE CAT. 

000217 01-03 
EFFECTS OF ENKEPHALIN ANALOGUE AND NALOXONE ON CAT SPINAL- 
CORD DORSAL ROOT POTENTIALS. 

000236 01-03 
EFFECTS OF CENTRALLY-ADMINISTERED PENTAZOCINE AND 
ETHYLKETOCYCLAZOCINE ON THERMOREGULATION IN THE CAT. 

000361 01-04 
THE EFFECTS OF LSD AND SOME ANALOGUES ON THE RESPONSES OF 
SINGLE CORTICAL NEURONS OF THE CAT TO OPTICAL-STIMULATION. 

000738 01-12 
EVOKED-POTENTIAL CHANGES IN THE SUPERIOR-COLLICULUS PARALLEL 
THE LESION-INDUCED DEVELOPMENT OF GROOMING REFLEXES IN THE 
CAT. (PH.D. DISSERTATION). 

001179 02-03 



Subject Index 

DEPRESSION AND FACILITATION OF SYNAPTIC RESPONSES IN CAT 
DORSAL-HORN BY SUBSTANCE-P ADMINISTERED INTO SUBSTANTIA- 
GELATINOSA. 

001191 02-03 
MORPHINE AND SUPRASPINAL INHIBITION OF SPINAL NEURONES: 

EVIDENCE THAT MORPHINE DECREASES TONIC DESCENDING INHIBITION 
IN THE ANESTHETIZED CAT. 

001203 02-03 
THE QUANTITATIVE MEASUREMENT OF CHANGES IN EEG FREQUENCY 
SPECTRA PRODUCED IN THE CAT BY SEDATIVE HYPNOTICS AND 
NEUROLEPTICS. 

001220 02-03 
METHYLDOPA PRODUCES CENTRAL INHIBITION OF PARASYMPATHETIC- 
ACTIVITY IN THE CAT. 

001321 02-03 
DIRECT EVIDENCE AGAINST ACETYLCHOLINE AS THE DILATOR 
TRANSMinER IN THE CAT CEREBRAL-ARTERY. 

001336 02-03 
INDIRECT ADRENERGIC EFFECT OF HISTAMINE IN CAT CEREBRAL- 
ARTERIES. 

001355 02-03 
DOPAMINE-BETA-HYDROXYLASE ACTIVITY AND NORADRENALINE 
CONTENT IN PIAL-ARTERIES OF CAT AND GOAT. 

001357 02-03 
ADRENERGIC MODULATION OF THE HYPOTHALAMIC CHOLINERGIC 

MECHANISM IN THE CONTROL OF EMOTIONAL DEFENSIVE-BEHAVIOR IN 
THE CAT. 

001761 02-04 
IMMUNOHISTOCHEMICAL LOCALIZATION OF LEUCINE-ENKEPHALIN IN THE 
SPINAL-CORD OF THE CAT: ENKEPHALIN-CONTAINING MARGINAL 
NEURONS AND PAIN MODULATION. 

002638 03-01 
DIFFERENTIATION OF KAINATE AND QUISQUALATE-RECEPTORS IN THE 
CAT SPINAL-CORD BY SELECTIVE ANTAGONISMS WITH GAMMA 
D(AND L) GLUTAMYLGLYCINE. 

002696 03-03 
PRESYNAPTIC REGULATION OF THE RELEASE OF CATECHOLAMINES IN THE 
CAT HYPOTHALAMUS. 

002703 03-03 
THE PRESYNAPTIC STIMULATING EFFECT OF ACETYLCHOLINE ON 
DOPAMINE RELEASE IS SUPPRESSED DURING ACTIVATION OF 
NIGROSTRIATAL DOPAMINERGIC NEURONS IN THE CAT. 

002733 03-03 
METHYSERGIDE AND SUPRASPINAL INHIBITION OF THE SPINAL 
TRANSMISSION OF NOCICEPTIVE INFORMATION IN THE ANESTHETIZED 
CAT. 

002740 03-03 
POTENTIATION OF L GLUTAMATE AND L ASPARTATE EXCITATION OF CAT 
SPINAL NEURONES BY THE STEREOISOMERS OF THREO-3- 
HYDROXYASPARTATE. 

002768 03-03 
THE INTERACTION BETWEEN BARBITURATE ANESTHETICS AND 

EXCITATORY AMINO-ACID RESPONSES ON CAT SPINAL NEURONES. 

002799 03-03 
COCAINE AND AMPHETAMINE ANTAGONIZE THE DECREASE OF 

NORADRENERGIC NEUROTRANSMISSION ELICITED BY OXYMETAZOLINE 
BUT POTENTIATE THE INHIBITION BY ALPHA METHYLNOREPINEPHRINE 
IN THE PERFUSED CAT SPLEEN. 

002801 03-03 
L HISTIDINE: EFFECTS ON SENSITIVITY OF CAT SPINAL NEURONES TO 
AMINO-ACIDS. 

002808 03-03 
ANTINOCICEPTIVE ACTION OF MORPHINE AND PENTAZOCINE ON UNIT 
ACTIVITY IN THE NUCLEUS-CENTRALIS-LATERALIS, NUCLEUS- 
VENTRALIS-LATERALIS AND NEARBY STRUCTURES OF THE CAT. 

002837 03-03 
VOLTAGE CLAMP STUDY OF CAT SPINAL MOTONEURONS DURING 
STRYCHNINE-INDUCED SEIZURES. 

002886 03-03 
DIFFERENTIAL-EFFECTS OF SHORT-TERM AND LONG-TERM LITHIUM ON 
TRYPTOPHAN UPTAKE AND SEROTONERGIC FUNCTION IN CAT BRAIN. 

00291 1 03-03 
EFFECTS OF REPEATED ADMINISTRATIONS OF DIHYDROERGOTOXINE 
(REDERGINE) ON THE SLEEP-WAKEFULNESS CYCLE IN THE CAT. 

003703 04-02 
PHARMACOLOGICAL DIFFERENTIATION OF PRESYNAPTIC INHIBITORY 
ALPHA-ADRENOCEPTORS AND OPIATE-RECEPTORS IN THE CAT 
NICTITATING MEMBRANE. 

003777 04-03 
THE EFFECT OF NOOTROPIL ON THE TRANSCALLOSAL AND PRIMARY 
EVOKED-RESPONSES OF THE CAT CEREBRAL-CORTEX. 

003780 04-03 
INFLUENCE OF THE DOPAMINERGIC AGONISTS BROMOCRIPTINE, PIRIBEDIL 
AND NOMIFENSINE ON THE SYMPATHETIC NEURAL TRANSMISSION IN 
THE NICTITATING MEMBRANE OF THE CAT. 

003822 04-03 



A. 






U 






S-75 



Subject Index 



Psychopharmacology Abstracts 



AUTORADIOGRAPHIC STUDIES ON DISTRIBUTION OF L-3,4 
DIHYDROXYPHENYLALANINE (L-DOPA) 14C AND L 5 
HYDROXYTRYPTOPHAN (L 5 HTP) 14C IN THE CAT BRAIN. 

003941 04-03 
IN VIVO EVIDENCE FOR GABAERGIC CONTROL OF SEROTONIN RELEASE IN 
THE CAT SUBSTANTIA-NIGRA. 

00401 1 04-03 
CANNABINOID-INDUCED ENHANCEMENT AND DEPRESSION OF CAT 
MONOSYNAPTIC REFLEXES. 

004040 04-03 
NALOXONE SUPPRESSES FOOD/WATER CONSUMPTION IN THE DEPRIVED 
CAT. 

004114 04-04 
SELECTIVE EFFECT OF ETHANOL ON THE VESTIBULAR NUCLEUS NEURONS 
IN THE CAT. 

004139 04-04 
POSSIBLE MUSCARINIC CHOLINERGIC MEDIATION OF PAHERNED 
AGGRESSIVE REFLEXES IN THE CAT. 

004153 04-04 
AMMONIA AND DISINHIBITION IN CAT MOTOR-CORTEX BY AMMONIUM- 
ACETATE, MONOFLUOROACETATE AND INSULIN-INDUCED 
HYPOGLYCEMIA. 

004276 04-05 
THE SIMULTANEOUS INFUSION OF DRUGS VIA THE LEFT AND RIGHT 
VERTEBRAL-ARTERY OF THE CAT, A MODIFIED ANIMAL-MODEL FOR 
THE STUDY OF POSSIBLE CENTRAL-ACTIONS OF DRUGS UPON THE 
LOWER BRAINSTEM. 

004297 04-06 
CATABOLISM 

DECREASED CEREBRAL CATABOLISM OF (3H)HISTAMINE IN VIVO AFTER S 
ADENOSYLMETHIONINE ADMINISTRATION. 

002883 03-03 
PROPERTIES OF THE OPTICAL-ISOMERS AND METABOLITES OF KETAMINE 
ON THE HIGH-AFFINITY TRANSPORT AND CATABOLISM OF 
MONOAMINES. 

004009 04-03 
CATALEPSY 

EFFECTS OF DOPAMINERGIC AND CHOLINERGIC-DRUGS, NALOXONE AND 
L PROLYL-LEUCYL-GLYCINAMIDE ON LSD-INDUCED CATALEPSY 

000360 01-04 
MORPHINE VERSUS HALOPERIDOL CATALEPSY IN THE RAT: A 
BEHAVIORAL-ANALYSIS OF POSTURAL SUPPORT MECHANISMS. 

000376 01-04 
FAILURE OF NALOXONE TO REVERSE CATALEPSY ASSOCIATED WITH 
SCHIZOPHRENIA: A CASE-REPORT 

000560 01-08 
STRESS-INDUCED FACILITATION OF OPIATE CATALEPSY IN THE RAT 

001680 02-04 
EFFECT OF QUIPAZINE AND FLUOXETINE ON ANALGESIC-INDUCED 
CATALEPSY AND ANTINOCICEPTION IN THE RAT 

001709 02-04 
BIPHASIC-EFFECTS OF DIRECT, BUT NOT INDIRECT, GABAMIMETICS AND 
ANTAGONISTS ON HALOPERIDOL-INDUCED CATALEPSY. 

001826 02-04 
INCREASED AMPHETAMINE STEREOTYPY AND LONGER HALOPERIDOL 
CATALEPSY IN SPONTANEOUSLY HYPERTENSIVE-RATS. 

002891 03-03 
INVOLVEMENT OF CAUDATE-NUCLEUS, AMYGDALA OR RETICULAR 
FORMATION IN NEUROLEPTIC AND NARCOTIC CATALEPSY. 

002986 03-04 
BETA PHENYLETHYLAMINE REVERSAL OF CHLORPROMAZINE-INDUCED 
ACTIVATION OF STRIATAL TYROSINE-HYDROXYLASE AND CATALEPSY. 

004018 04-03 
EFFECTS OF NARCOTIC ANTAGONISTS ON L-OOPA REVERSAL OF 
RESERPINE-INDUCED CATALEPSY AND BLEPHAROPTOSIS IN MICE. 

004186 04-04 
BETA ENDORPHIN: CENTRAL SITES OF ANALGESIA, CATALEPSY AND 
BODY-TEMPERATURE CHANGES IN RATS 

004238 04-04 
CATALEPTIC-EFFECT 

PLASMA AND BRAIN LEVELS OF DELTA6 THC AND SEVEN 
MONOOXYGENATED METABOLITES CORRELATED TO THE CATALEPTIC- 
EFFECT IN THE MOUSE. 

001737 02-04 
CATALEPTIC-EFFECTS 

DIFFERENTIAL REVERSAL BY SCOPOLAMINE AND THIP OF THE 
ANTISTEREOTYPIC AND CATALEPTIC-EFFECTS OF NEUROLEPTICS. 

002948 03-04 
THE EFFECTS OF PEPTIDES ON TOLERANCE TO THE CATALEPTIC-EFFECTS 
AND HYPOTHERMIC-EFFECTS OF MORPHINE IN THE RAT. 

004072 04-04 
CATALYTIC 

COMT-A AND COMT-B: CATALYTIC DIFFERENCES AND ROLE OF DISULFIDE 
BONDS. 

003927 04-03 
CATAPLEXY 

CHOLINERGIC MECHANISMS AND CATAPLEXY IN DOGS. 

000374 01-04 
CATATONIA 

EPIDURAL MORPHINE-INDUCED CATATONIA. 

002400 02-15 



A NEUROANATOMICAL-STUDY OF ANALGESIA AND CATATONIA INDUCED 
BY ETORPHINE IN THE RAT. (PH.D. DISSERTATION) 

003102 03-04 
MODIFICATION OF DRUG-INDUCED CATATONIA AND TREMORS BY 
QUIPAZINE IN RATS AND MICE. 

004164 04-04 
CATATONIA-SYNDROME 

DISULFIRAM ENCEPHALOPATHY AS A CAUSE OF THE CATATONIA- 
SYNDROME. 

000894 01-15 
CATCH-UP 

ACTIVITY AND CATCH-UP GROWTH IN HYPOTHYROID RATS. 

004190 04-04 
CATECHOl-O-METHYLTRANSFERASE 

THE ACTIVITY OF ERYTHROCYTE CATECHOL-O-METHYLTRANSFERASE IN 
ENDOGENOUS DEPRESSIVE-SYNDROMES. 

004546 04-13 
CATECHOLAMINE 

EFFECTS OF MORPHINE, BETA ENDORPHIN AND NALOXONE ON 
CATECHOLAMINE LEVELS AND SEXUAL-BEHAVIOR IN THE MALE RAT. 

000430 01-04 
EFFECTS OF L-DOPA AND L 5 HYDROXYTRYPTOPHAN ON LOCOMOTOR- 
ACTIVITY OF THE RAT AFTER SELECTIVE OR COMBINED DESTRUCTION 
OF CENTRAL CATECHOLAMINE AND SEROTONIN NEURONS 

000466 01-04 
HYPOTHALAMIC CATECHOLAMINE BIOSYNTHESIS IN VITRO AS 
MEASURED BY LIQUID-CHROMATOGRAPHY AND ELECTROCHEMICAL- 
DETECTION 

000537 01-06 
CATECHOLAMINE TRANSMIHER SYSTEMS. 

000580 01-09 
THE INFLUENCE OF PENTIFYLLINE AND THEOPHYLLINE ON REAQION 
KINETICS OF CATECHOLAMINE STIMULATED ATPASE FROM RAT-BRAIN. 

001052 02-01 
DYNAMICS OF ENDOGENOUS CATECHOLAMINE RELEASE FROM BRAIN 
FRAGMENTS OF MALE AND FEMALE RATS 

001121 02-03 
INTERACTION OF TRIAZOLAM WITH DESIPRAMINE EFFECTS OF SINGLE 
AND REPEATED TREATMENT ON CERTAIN PHARMACOLOGIC- 
RESPONSES AND BRAIN CATECHOLAMINE LEVELS. 

001323 02-03 
ERGOT AND CATECHOLAMINE POTENCIES AT CATECHOLAMINE- 
RECEPTORS 

001510 02-03 
THE PHARMACOLOGY OF CATECHOLAMINE INVOLVEMENT IN THE 
NEURAL MECHANISMS OF REWARD 

001526 02-03 
DOSE-DEPENDENT PHARMACOKINETICS OF ALPHA METHYL-P-TYROSINE 
(ALPHA MT) AND COMPARISON OF CATECHOLAMINE TURNOVER- 
RATES AFTER TWO DOSES OF ALPHA MT. 

001532 02-03 
DORSAL TEGMENTAL BUNDLE DESTRUCTION EFFEaS ON OPERANT- 
BEHAVIOR, BRAIN CATECHOLAMINE LEVELS, AND BEHAVIORAL- 
SUPPRESSION PRODUCED BY ADRENERGIC AGONISTS. 

001726 02-04 
AN AUTOMATED ELECTROCHEMICAL-METHOD FOR IN VIVO MONITORING 
OF CATECHOLAMINE RELEASE 

001873 02-06 
THE CORRELATION OF CATECHOLAMINE AND ADRENERGIC PARAMETERS 
WITH DRUG-THERAPY OF NEUROTIC AND ENDOGENOUS DEPRESSIONS. 

002047 02-09 
IMMUNOCYTOCHEMICAL LOCALIZATION OF CATECHOLAMINE 
SYNTHESIZING ENZYMES AND NEUROPEPTIDES IN AREA POSTREMA 
AND MEDIAL NUCLEUS-TRACTUS-SOLITARIUS OF RAT-BRAIN. 

002634 03-01 
CENTRAL AND PERIPHERAL CATECHOLAMINE FUNQION IN LEARNING 
AND MEMORY PROCESSES. 

002823 03-03 
PHARMACOLOGICAL EVIDENCE FOR CATECHOLAMINE INVOLVEMENT IN 
ANIMAL AGGRESSION. 

003052 03-04 
A POSSIBLE ROLE FOR CATECHOLAMINE NEUROTRANSMIHERS IN THE 
ANTICONVULSANT ACTIVITY OF CHLORDIAZEPOXIDE. 

003119 03-04 
PHARMACOLOGICAL EVIDENCE FOR CATECHOLAMINE INVOLVEMENT IN 
ANIMAL AGGRESSION. 

003140 03-06 
CATECHOLAMINE TURNOVER IN RAT-CEREBRAL-CORTEX AND CAUDATE 
FOLLOWING REPEATED TREATMENT WITH DIHYDROERGOTOXINE 

003765 04-03 
CATECHOLAMINE AND 5 HYDROXYTRYPTAMINE SYNTHESIS AND 
METABOLISM FOLLOWING INTRACEREBROVENTRICULAR INJECTION OF 
DIBUTYRYL-CYCLIC-AMP. 

003769 04-03 
CATECHOLAMINE SYNTHESIS REGULATION IN HYPOTHALAMIC 
SYNAPTOSOMES. (UNPUBLISHED PAPER). 

003829 04-03 



S-76 



VOLUME 19, SUBJECT INDEX 



Subject Index 



CHANGE IN CATECHOLAMINE SENSITIVE NA-K-ATPASE ACTIVITY IN THE 
RAT STRIATUM MICROSOMES FOLLOWING ELECTROLYTIC OR 6 
HYDROXYDOPAMINE-INDUCED LESIONS OF DOPAMINERGIC NEURONS 

003871 04-03 
THE IMPORTANCE OF CATECHOLAMINE UPTAKE INHIBITION IN THE 
REVERSAL OF GUANETHIOINE BLOCKADE OF ADRENERGIC NEURONS. 

003900 04-03 
THE EFFECT OF PRENATAL EXPOSURE TO ETHANOL OR OPIATES ON BRAIN 
CATECHOLAMINE ACTIVITY 

003939 04-03 
CATECHOLAMINE MODULATION OF ENKEPHALIN-INDUCED 
ELECTROPHYSIOLOGICAL RESPONSES IN CEREBRAL-CORTEX. 

003957 04-03 
EFFECTS OF CANNABINOIDS ON CATECHOLAMINE UPTAKE AND RELEASE 
IN HYPOTHALAMIC AND STRIATAL SYNAPTOSOMES. 

003970 04-03 
EFFECT OF PR0STAGLANDIN-D2, PR0STAGLANDIN-E2 AND 
PR0STAGLANDIN-F2ALPHA ON CATECHOLAMINE RELEASE FROM SLICES 
OF RAT AND RABBIT BRAIN. 

003983 04-03 
CATECHOLAMINE SEROTONIN INTERACTION EFFECTS ON ACTIVITY IN 
RATS NEONATALLY TREATED WITH 6 HYDROXYDOPAMINE. 

004194 04-04 
CONSISTENCY IN CATECHOLAMINE EXCRETION IN LABORATORY AND 
NATURAL SEniNGS. CORRELATIONAL AND VARIANCE COMPONENTS 
ANALYSES. 

004508 04-13 
CATECHOLAMINE METABOLISM IN A PSYCHOACTIVE CACTUS. 

004722 04-17 
CATECHOLAMINE-DEPLETING-AGENT 

EFFECT OF THE CATECHOLAMINE-DEPLETING-AGENT 1 PHENYL-2- 
THIAZOLYL-2-THIOUREA (U-14-624) ON DRUG METABOLISM IN THE 
RAT 

000280 01-03 
CATECHOLAMINE-RECEPTORS 

ERGOT AND CATECHOLAMINE POTENCIES AT CATECHOLAMINE- 
RECEPTORS. 

001510 02-03 
EFFECTS OF PROPRANOLOL ON THE LOCOMOTOR- STIMULATION INDUCED 
BY ACTIVATION OF POSTSYNAPTIC CATECHOLAMINE-RECEPTORS. 

004126 04-04 
RELATION BETWEEN BRAIN CATECHOLAMINE-RECEPTORS AND 
DOPAMINERGIC STEREOTYPY IN RAT STRAINS. 

004131 04-04 
CATECHOLAMINE-SULFATES 

PRESENCE OF CONJUGATED CATECHOLAMINES IN RAT-BRAIN: A NEW 
METHOD OF ANALYSIS OF CATECHOLAMINE-SULFATES. 

004286 04-06 
CATECHOLAMINERGIC 

MONOAMINE REPLACEMENT AFTER RESERPINE: CATECHOLAMINERGIC 
AGONISTS RESTORE MOTOR-ACTIVITY BUT PHENYLETHYLAMINE 
RESTORES ATROPINE-RESISTANT NEOCORTICAL LOW VOLTAGE FAST- 
ACTIVITY. 

000309 01-03 
SEROTONERGIC AND CATECHOLAMINERGIC INFLUENCE ON THYROID- 
FUNCTION IN THE VERVET-MONKEY 

001385 02-03 
EFFEQS OF KAINIC-ACID ON BODY-TEMPERATURE OF RATS: ROLE OF 
CATECHOLAMINERGIC AND SEROTONERGIC SYSTEMS. 

001515 02-03 
PATHOPHYSIOLOGIC-IMPACT OF CENTRAL CATECHOLAMINERGIC 
FUNCTION IN SCHIZOPHRENIA AND SCHIZOPHRENIA-LIKE PSYCHOSES. 

002174 02-11 
CATECHOLAMINERGIC INVOLVEMENT IN PHASIC VERSUS TONIC 
ELECTROCORTICAL AROUSAL. 

002723 03-03 
CATECHOLAMINES 

COMPARTMENTATION OF CATECHOLAMINES IN RAT-BRAIN: EFFECTS OF 
AGONISTS AND ANTAGONISTS. 

000125 01-03 
BIOCHEMICAL-CHARACTERIZATION OF THE RAT SYMPATHETIC 
GANGLION: PHARMACOLOGICAL-EFFECTS OF RESERPINE ON 
GANGLIONIC CATECHOLAMINES. 

000153 01-03 
INCREASED URINARY EXCRETION OF CATECHOLAMINES AND THEIR 

METABOLITES IN STREPTOZOTOCIN DIABETIC RAT. 

000154 01-03 
FALSE LABELLING OF COMMERCIALLY-AVAILABLE 3H CATECHOLAMINES? 

000535 01-06 
THE RELEASE OF CATECHOLAMINES FROM ADRENERGIC NEURONS. 

000974 01-17 
LACK OF INFLUENCE OF BRAIN CATECHOLAMINES ON ACUTE EFFECTS OF 
BARBITURATES. 

001138 02-03 
EFFECT OF TABERNANTHINE ON THE TURNOVER TIME OF BRAIN 
CATECHOLAMINES IN NORMAL AND HYPOBARIC HYPOXIC RATS. 

001187 02-03 
EFFECT OF PROSTAGLANDINS ON PLASMA CATECHOLAMINES, HEART 
AND BLOOD-PRESSURE RESPONSES TO HEMORRHAGE. (UNPUBLISHED 
PAPER). 

001223 02-03 



PERIPHERAL CATECHOLAMINES AND MEMORY MODULATION 
(UNPUBLISHED PAPER) 
f 001251 02-03 

EFFECTS OF PRENATAL METHADONE ON RAT-BRAIN CATECHOLAMINES. 

001367 02-03 
THYROTROPIN-RELEASING-HORMONE: NEUROCHEMICAL EVIDENCE FOR 
THE POTENTIATION OF IMIPRAMINE EFFECTS ON THE METABOLISM 
AND UPTAKE OF BRAIN CATECHOLAMINES. 

001427 02-03 
ROLE OF BRAIN CATECHOLAMINES AND 5 HYDROXYTRYPTAMINE IN 
MORPHINE-INDUCED TEMPERATURE CHANGES IN NORMAL AND 
TOLERANT RATS AND MICE 

001476 02-03 
BRAIN CATECHOLAMINES, MENTAL-ILLNESSES, AGING AND SENILE- 
DEMENTIA: BIOCHEMICAL-CONSIDERATIONS AND PHARMACOLOGICAL- 
CONSIDERATIONS. 

001550 02-03 
BRAIN CATECHOLAMINES MODIFICATIONS. THE EFFECTS ON MEMORY 
FACILITATION INDUCED BY OXOTREMORINE IN MICE. 

001658 02-04 
OPIATE ACTIONS AND CATECHOLAMINES. 

001662 02-04 
EFFECTS OF CAFFEINE ON PLASMA FREE FATTY-ACIDS, URINARY 
CATECHOLAMINES, AND DRUG BINDING. 

002272 02-13 
SEX-DIFFERENCES IN THE AMPHETAMINE STIMULATED RELEASE OF 
CATECHOLAMINES FROM RAT STRIATAL TISSUE IN VITRO 

002668 03-03 
PRESYNAPTIC REGULATION OF THE RELEASE OF CATECHOLAMINES IN THE 
CAT HYPOTHALAMUS. 

002703 03-03 
PLASMA CATECHOLAMINES IN RATS EXPOSED TO COLD: EFFECTS OF 
GANGLIONIC AND ADRENORECEPTOR BLOCKADE. 

002863 03-03 
BEHAVIOURAL-RESPONSES TO DRUGS RELEASING 5 

HYDROXYTRYPTAMINE AND CATECHOLAMINES: EFFECTS OF 
TREATMENTS ALTERING PRECURSOR CONCENTRATIONS IN BRAIN. 

002990 03-04 
THE EFFECT OF ADENOSINE AND GUANOSINE ON THE CONTENT OF 
SEROTONIN AND CATECHOLAMINES IN THE BRAIN IN THE 
RESTORATION PERIOD FOLLOWING EXPERIMENTAL CLINICAL DEATH. 

003882 04-03 
LIBERATION OF CATECHOLAMINES AND 5 HYDROXYTRYPTAMINE FROM 
HUMAN BLOOD-PLATELETS. 

003967 04-03 
HYPOTENSION ALTERS THE RELEASE OF CATECHOLAMINES IN THE 

HYPOTHALAMUS OF THE CONSCIOUS RABBIT. 

003968 04-03 
PRESENCE OF CONJUGATED CATECHOLAMINES IN RAT-BRAIN: A NEW 

METHOD OF ANALYSIS OF CATECHOLAMINE-SULFATES. 

004286 04-06 
CATECHOLESTROGEN 

DEVELOPMENTAL ASPECTS OF CATECHOLESTROGEN SYNTHESIS. 
(UNPUBLISHED PAPER). 

001282 02-03 
CATECHOLIC 

EFFECTS OF MOLINDONE AND FLUPHENAZINE ON THE BRAIN 
CONCENTRATION OF SOME PHENOLIC AND CATECHOLIC AMINES IN THE 
MOUSE AND THE RAT. 

003870 04-03 
CATEGORIES 

ON THE USE OF CERTAIN PHARMACOLOGICAL CATEGORIES IN HYSTERIA. 

004347 04-09 
BASAL PROLACTINAEMIA AND RESPONSES TO TRH AND SULPIRIDE IN 
DIFFERENT CATEGORIES OF MALE SEXUAL-DYSFUNCTIONS. 

004503 04-13 
CATHA-EDULIS 

RELATIVE POTENCIES OF TWO PHENYLALKYLAMINES FOUND IN THE 
ABUSED PLANT CATHA-EDULIS, KHAT. 

001084 02-02 
HYPERTHERMIC-RESPONSE TO (-) CATHINONE, AN ALKALOID OF CATHA- 
EDULIS (KHAT). 

003694 04-02 
CATHINONE 

HYPERTHERMIC-RESPONSE TO (-) CATHINONE, AN ALKALOID OF CATHA- 
EDULIS (KHAT). 

003694 04-02 
CATION 

EFFECT OF STRUCTURE ON PHENOTHIAZINE CATION RADICAL REACTIONS 
IN AQUEOUS BUFFERS. 

000014 01-02 
MEASUREMENT OF THE MEMBRANE POTENTIAL OF ISOLATED NERVE 
TERMINALS BY THE LIPOPHILIC CATION 
(3H)TRIPHENYLMETHYLPH0SPH0NIUM-BR0MIDE. 

002746 03-03 
CATION REGULATION DIFFERENTIATES SPECIFIC BINDING OF 

(3H)SULPIRIDE AND (3H)SPIPER0NE TO RAT STRIATAL PREPARATIONS. 

004032 04-03 






tic 












S-77 



Subject Index 

CATIONS 

REGULATION BY CATIONS OF (3H)SPIR0PERID0L BINDING ASSOCIATED 
WITH DOPAMINE-RECEPTORS OF RAT-BRAIN. 

002922 03-03 
SPECTRA OF RADICAL CATIONS OF PHENOTHIAZINE DERIVATIVES IN 
SOLUTION AND SOLID STATE. 

003673 04-01 

CATS 

NEURONAL ACTIVITY IN CHRONIC FERRIC-CHLORIDE EPILEPTIC-FOCI IN 
CATS AND MONKEY. 

000172 01-03 
THE INFLUENCE OF CHLORALOSE ANESTHESIA ON THE ACTIVITY OF RED 
NUCLEUS NEURONS IN CATS. 

000245 01-03 
RELATION OF AAONOMETHYLHYDRAZINE (MMH) SEIZURE THRESHOLDS 
TO AFTERDISCHARGE THRESHOLDS WITH AMYGDALOID STIMULATION 

IN CATS. 

000474 01-04 

THE INFLUENCE OF GABAERGIC SUBSTANCES ON THE EFFECTS OF 
STIMULATION OF THE CAUDATE-NUCLEUS AND AMPHETAMINE 
STEREOTYPY IN CATS. 

000489 01-04 
CHRONIC AMPHETAMINE ADMINISTRATION TO CATS: BEHAVIORAL- 
EVIDENCE AND NEUROCHEMICAL EVIDENCE FOR DECREASED CENTRAL 
SEROTONERGIC FUNCTION. 

000491 01-04 
FAILURE OF ISOPRENALINE AND BETA-RECEPTOR BLOCKING-DRUGS TO 
MODIFY DEPRESSOR RESPONSE AND BRADYCARDIA INDUCED BY 
ELECTRICAL-STIMULATION OF THE ANTERIOR HYPOTHALAMUS OF 
CATS 

000520 01-05 
THE EFFECT OF EMOTIONAL- STRESS AND DIAZEPAM ON MONOAMINE 
METABOLITES IN THE CEREBROSPINAL-FLUID OF CATS. (PH.D. 
DISSERTATION). „^,„,„„. „, 

001260 02-03 
LONG-TERM DECREASES IN SPONTANEOUS FIRING OF CAUDATE NEURONS 
INDUCED BY AMPHETAMINE IN CATS. 

001340 02-03 
EFFECTS OF MORPHINE ON EVOKED-POTENTIALS RECORDED FROM THE 
AMYGDALA BY TOOTH-PULP STIMULATION IN CATS. 

001379 02-03 
INHIBITION OF NEUROSYMPATHETIC CEREBROARTERIAL CONSTRICTION 
BY CLONIDINE IN CATS. 

001431 02-03 
EFFECTS OF ALPHA-ADRENOCEPTOR STIMULATING DRUGS ON 
BARORECEPTOR REFLEXES IN CONSCIOUS CATS 

001514 02-03 
COMPARATIVE-STUDY OF AGGRESSIVE-BEHAVIOUR AFTER INJECTION OF 
CHOLINOMIMETICS, ANTICHOLINESTERASES, NICOTINIC, AND 
MUSCARINIC GANGLIONIC STIMULANTS INTO THE CEREBRAL 
VENTRICLES OF CONSCIOUS CATS: FAILURE OF NICOTINIC-DRUGS TO 
EVOKE AGGRESSION. 

001568 02-04 
THE PHARMACOLOGY OF AGGRESSIVE-BEHAVIOURAL-PHENOMENA 

ELICITED BY MUSCARINE INJEQED INTO THE CEREBRAL VENTRICLES OF 

CONSCIOUS CATS. 

001569 02-04 

BEHAVIORAL-EFFECTS AND ELECTROPHYSIOLOGICAL-EFFECTS OF OPIOID- 
PEPTIDES IN CATS. 

001612 02-04 

EFFECT OF CHOLINE ON CONDITIONED FOOD MOTOR-REFLEXES IN CATS 

001731 02-04 
CALCIUM ANTAGONISM OF THE INHIBITORY-EFFECTS OF FENTANYL ON 
THE CONTRACTION OF THE NICTITATING MEMBRANE IN CATS. 

002876 03-03 
AMPHETAMINE-INDUCED ROTATION IN NORMAL CATS. 

003002 03-04 
CATS DEVELOP TOLERANCE TO D-AMPHETAMINES EFFECTS UPON 
LOCOMOTION AND STEREOTYPED-BEHAVIORS. 

003018 03-04 
MODIFICATION OF MOTOR-ACTIVITY, PASSIVE-AVOIDANCE 
CONDITIONING AND EVOKED-POTENTIALS BY MICROINJECTIONS OF 
STRYCHNINE IN BOTH CAUDATE-NUCLEI IN CATS 

003101 03-04 
DOES P CHLOROPHENYLALANINE PRODUCE DISTURBED WAKING, 
DISTURBED SLEEP OR ACTIVATION BY PONTO-GENICULO-OCCIPITAL 
WAVES IN CATS? 

003704 04-02 
THE EFFECT OF SMALL DOSES OF HALOPERIDOL AND CLOZAPINE ON 
BEHAVIORAL SHIFTS IN CATS, ARISING AFTER CESSATION OF 
ELECTRICAL-STIMULATION OF THE CAUDATE-NUCLEUS. 

004067 04-04 
RESPIRATORY DEPRESSION PRODUCED BY DIAZEPAM IN CATS: EFFEQ OF 
ANESTHESIA. 

004272 04-05 

CAUDATE 

EFFECTS OF CHRONIC HALOPERIDOL ON CAUDATE 3H SPIROPERIDOL 
BINDING IN LESIONED RATS. 

000255 01-03 



Psychopharmacology Abstracts 



3H MIANSERIN BINDING IN CALF CAUDATE: POSSIBLE INVOLVEMENT OF 
SEROTONIN-RECEPTORS IN ANTIDEPRESSANT-DRUG AQION. 

000325 01-03 
GLYCINE ENHANCEMENT OF CAUDATE NEURONAL ACTIVITIES: 

RELATIONSHIP WITH THE DOPAMINERGIC NIGROSTRIATAL PATHWAY. 

001225 02-03 
LONG-TERM DECREASES IN SPONTANEOUS FIRING OF CAUDATE NEURONS 
INDUCED BY AMPHETAMINE IN CATS. 

001340 02-03 
THE PARTICIPATION OF SUBSTANTIA-NIGRA ZONA-COMPACTA AND 
ZONA-RETICULATA NEURONS IN MORPHINE SUPPRESSION OF CAUDATE 
SPONTANEOUS NEURONAL ACTIVITIES IN THE RAT. 

002718 03-03 
DOPAMINE METABOLITES IN CAUDATE AND CORTEX AFTER LITHIUM AND 
HALOPERIDOL. (UNPUBLISHED PAPER). 

003738 04-03 
CATECHOLAMINE TURNOVER IN RAT-CEREBRAL-CORTEX AND CAUDATE 
FOLLOWING REPEATED TREATMENT WITH DIHYDROERGOTOXINE. 

003765 04-03 
THE EFFECT OF TYPICAL AND ATYPICAL NEUROLEPTICS ON BINDING OF 
(3H)SPIR0PERID0L IN CALF CAUDATE. 

003906 04-03 
DOPAMINE-RECEPTORS IN SUBCELLULAR FRACTIONS FROM BOVINE 
CAUDATE: ENRICHMENT OF (3H)SPIPER0NE BINDING IN A 
POSTSYNAPTIC MEMBRANE FRACTION. 

003948 04-03 
EFFECTS OF A HIGH-DOSE TREATMENT OF METHAMPHETAMINE ON 
CAUDATE DOPAMINE AND ANOREXIA IN RATS. 

004073 04-04 
CAUDATE-NUCLEI 

MODIFICATION OF MOTOR-ACTIVITY, PASSIVE-AVOIDANCE 

CONDITIONING AND EVOKED-POTENTIALS BY MICROINJEQIONS OF 
STRYCHNINE IN BOTH CAUDATE-NUCLEI IN CATS. 

003)01 03-04 
CAUDATE-NUCLEUS 

IN VITRO ACETYLCHOLINE RELEASE FROM RAT CAUDATE-NUCLEUS AS A 
NEW MODEL FOR TESTING DRUGS WITH DOPAMINE-RECEPTOR 
ACTIVITY 

000289 01-03 
ANTINOCICEPTIVE-EFFEQ OF MORPHINE, OPIOID ANALGESICS AND 
HALOPERIDOL INJECTED INTO THE CAUDATE-NUCLEUS OF THE RAT. 

000414 01-04 
THE INFLUENCE OF GABAERGIC SUBSTANCES ON THE EFFECTS OF 
STIMULATION OF THE CAUDATE-NUCLEUS AND AMPHETAMINE 
STEREOTYPY IN CATS. 

000489 01-04 
INTERNEURONES ARE PROBABLY NOT INVOLVED IN THE PRESYNAPTIC 
DOPAMINERGIC CONTROL OF DOPAMINE RELEASE IN RABBIT 
CAUDATE-NUCLEUS. 

001298 02-03 
FUNCTIONAL ORGANIZATION OF THE CAUDATE-NUCLEUS AFTER 
ADMINISTRATION OF CARBACHOL. 

001495 02-03 
OPIOID-RECEPTORS IN THE CAUDATE-NUCLEUS CAN MEDIATE EMG- 
RECOROED RIGIDITY IN RATS. 

001649 02-04 

HANDEDNESS IN RATS: BLOCKADE OF REACHING-BEHAVIOR BY 
UNILATERAL 6 OHDA INJECTIONS INTO SUBSTANTIA-NIGRA AND 
CAUDATE-NUCLEUS. 

001778 02-04 

HETEROGENEOUS DEPRESSION OF GLUCOSE UTILIZATION IN THE 
CAUDATE-NUCLEUS BY GABA AGONISTS. 

002640 03-01 
MODULATION BY ENDOGENOUS DOPAMINE OF THE RELEASE OF 
ACETYLCHOLINE IN THE CAUDATE-NUCLEUS OF THE RABBIT. 

002751 03-03 
INVOLVEMENT OF CAUDATE-NUCLEUS, AMYGDALA OR RETICULAR 
FORMATION IN NEUROLEPTIC AND NARCOTIC CATALEPSY. 

002986 03-04 
THE EFFECT OF SMALL DOSES OF HALOPERIDOL AND CLOZAPINE ON 
BEHAVIORAL SHIFTS IN CATS, ARISING ARER CESSATION OF 
ELEQRICAL- STIMULATION OF THE CAUDATE-NUCLEUS. 

004067 04-04 

CAUDATE-PUT AMEN 

BEHAVIOURAL-RESPONSES TO STEREOTAQICALLY CONTROLLED 
INJEQIONS OF MONOAMINE NEUROTRANSMIHERS INTO THE 
ACCUMBENS AND CAUDATE-PUTAMEN NUCLEI. 

001708 02-04 

EFFEaS OF METHAMPHETAMINE ON BLOOD FLOW IN THE CAUDATE- . 

PUTAMEN AFTER LESIONS OF THE NIGROSTRIATAL DOPAMINERGIC | 

BUNDLE IN THE RAT. ^ I 

003910 04-03 

CDP-CHOLINE 

ACTIVATION OF SOLUBLE STRIATAL TYROSINE-HYDROXYLASE IN THE RAT 
BRAIN AFTER CDP-CHOLINE ADMINISTRATION. 

002816 03-03 



S-78 



VOLUME 19, SUBJECT INDEX 



Subject Index 



CDP-DIGLYCERIDE-HYDROLASE 

PROPERTIES OF A CDPDIGLYCERIDE-HYOROLASE FROM GUINEA-PIG 
BRAIN. 

003987 04-03 
CEEO 

CEEG STUDY ON PATIENTS UNDER THE PSYCHIATRIC-DRUG TREATMENT; 
THE CORRELATION BETWEEN EEG ALTERATION AND CLINICAL 
EVOLUTION. 

002165 02-11 
CEFAZOLIN 

BEHAVIORAL-EFFECTS AND ELECTROCORTICAL-EFFECTS AFTER 
INTRASTRIATAL CEFAZOLIN IN RATS ARE ANTAGONIZED BY DRUGS 
ENHANCING GABAERGIC TRANSMISSION. 

000443 01-04 
GABA DEPLETION IN CHICK BRAINSTEM AFTER INTRAVENTRICULAR 
INJECTION OF CEFAZOLIN. 

002762 03-03 
CEFAZOLIN-INDUCED 

ANTAGONISM BY CLASSICAL ANTIEPILEPTICS AND SODIUM-VALPROATE 
OF CEFAZOLIN-INDUCED EXPERIMENTAL EPILEPSY IN RATS. 

000442 01-04 
CELL 

CEREBELLAR GRANULE CELL GENESIS IN THE HYDROCORTISONE TREATED 
RAT. 

000030 01-03 
(3H)5 NT BINDING-SITES AND 5 HT-SENSITIVE ADENYLATE-CYCLASE IN 
GLIAL CELL MEMBRANE FRACTION. 

000093 01-03 
GLIAL CELL EFFECTS OF SUBACUTE FORMIC-ACID VAPOUR EXPOSURE. 

000527 01-05 
ANTI-THY-1-2 MONOCLONAL ANTIBODY LINKED TO RICIN IS A POTENT 
CELL TYPE SPECIFIC TOXIN. (UNPUBLISHED PAPER). 

001064 02-01 
SYNTHETIC IMMUNOSTIMULANTS DERIVED FROM THE BACTERIAL CELL 
WALL. 

001080 02-02 
EFFECTS OF CHRONIC-TREATMENT WITH L SULPIRIDE AND HALOPERIDOL 
ON CENTRAL DOPAMINE TURNOVER EVALUATED IN DOPAMINE CELL 
BODY AND NERVE TERMINAL-RICH AREAS. 

001096 02-03 
CHEMOTAXIS BY MOUSE MACROPHAGE CELL LINES. (UNPUBLISHED 
PAPER). 

001099 02-03 
INHIBITION OF CHEMOTAXIS BY S 3 DEAZAADENOSYLHOMOCYSTEINE IN 

A MOUSE MACROPHAGE CELL LINE. (UNPUBLISHED PAPER). 

001100 02-03 
PROSTACYCLIN-DEPENDENT ACTIVATION OF ADENYLATE-CYCLASE IN A 

NEURONAL SOMATIC CELL HYBRID: PROSTANOID STRUCTURE-ACTIVITY 
RELATIONSHIPS. 

001132 02-03 
THE INFLUENCE OF EXTERNAL SODIUM AND POTASSIUM ON LITHIUM 
UPTAKE BY PRIMARY BRAIN CELL CULTURES AT THERAPEUTIC LITHIUM 
CONCENTRATION. 

001300 02-03 
EFFECT OF CHLORPROMAZINE ON CELL PROLIFERATION IN THE 
DEVELOPING RAT-BRAIN. A COMBINED BIOCHEMICAL-STUDY AND 
MORPHOLOGICAL-STUDY. 

001407 02-03 
NERVE CELL CALCIUM AS A MESSENGER FOR OPIATE AND ENDORPHIN 
ACTIONS. 

001450 02-03 
EFFECT OF REPEATED TREATMENT WITH NEUROLEPTICS ON DOPAMINE 
METABOLISM IN CELL BODIES AND TERMINALS OF DOPAMINERGIC- 
SYSTEMS IN THE RAT-BRAIN. 

001464 02-03 
INFLUENCE OF PSYCHOACTIVE AND NONPSYCHOACTIVE CANNABINOIDS 
ON CELL PROLIFERATION AND MACROMOLECULAR BIOSYNTHESIS IN 
HUMAN CELLS. 

002830 03-03 
A REEVALUATION OF THE MECHANISMS UNDERLYING SIMPLE CELL 
ORIENTATION SELECTIVITY. 

002894 03-03 
EFFECTS OF ISOPROTERENOL ON THE DEVELOPMENT OF BETA- 
AORENERGIC-RECEPTORS IN BRAIN CELL AGGREGATES. 

002932 03-03 
DEVELOPMENTALLY REGULATED LECTINS IN SLIME MOULDS AND CHICK 
TISSUES - ARE THEY CELL ADHESION MOLECULES? 

003724 04-03 
DOPAMINE INHIBITS BURST-FIRING OF NEUROSECRETORY CELL R-15 IN 
APLYSIA-CALIFORNICA: ESTABLISHMENT OF A DOSE-RESPONSE 
RELATIONSHIP. 

003806 04-03 
GENETIC VARIATIONS IN MIDBRAIN DOPAMINE CELL NUMBER: PARALLEL 
WITH DIFFERENCES IN RESPONSES TO DOPAMINERGIC AGONISTS AND 
IN NATURALISTIC BEHAVIORS MEDIATED BY CENTRAL DOPAMINERGIC- 
SYSTEMS. (UNPUBLISHED PAPER). 

004112 04-04 
CELL-CULTURE 

NEURONAL MATURATION IN MAMMALIAN CELL-CULTURE IS DEPENDENT 
ON SPONTANEOUS ELECTRICAL-ACTIVITY. 

002669 03-03 



CELL-CULTURES 

RELEASE OF ARACHIDONIC-ACID FROM ADRENAL CHROMAFFIN CELL- 
CULTURES DURING SECRETION OF EPINEPHRINE. (UNPUBLISHED 
PAPER). 

001027 02-01 
THE INSENSITIVITY OF DEVELOPING BENZODIAZEPINE-RECEPTORS TO 
CHRONIC-TREATMENT WITH DIAZEPAM, GABA AND MUSCIMOL IN 
BRAIN CELL-CULTURES. 

004002 04-03 
CELL-FREE 

OPIOID DEPENDENT DUAL-REGULATION OF ADENYLATE-CYCLASE IN A 
CELL-FREE SYSTEM. (UNPUBLISHED PAPER). 

001033 02-01 
EFFECT OF INTRAVENOUS ADMINISTRATION OF D LYSERGIC-ACID- 
DIETHYLAMIDE ON SUBSEQUENT PROTEIN SYNTHESIS IN A CELL-FREE 
SYSTEM DERIVED FROM BRAIN. 

003761 04-03 
CELL-FREE TRANSLATION OF FREE AND MEMBRANE-BOUND POLYSOMES 
AND POLYADENYLATED MRNA FROM RABBIT BRAIN FOLLOWING 
ADMINISTRATION OF D LYSERGIC-ACID-DIETHYLAMIDE IN VIVO. 

003832 04-03 
CELLS 

PSYCHOTROPIC-DRUGS AND HISTAMINE HI -RECEPTORS OF CULTURED 
MOUSE NEUROBLASTOMA CELLS. 

000250 01-03 
ADENOSINE REGULATES VIA TWO DIFFERENT TYPES OF RECEPTORS, THE 
ACCUMULATION OF CYCLIC-AMP IN CULTURED BRAIN CELLS. 

000308 01-03 
HYBRID PROTEINS USED TO STUDY THE MECHANISM OF TOXIN 
ENTRANCE INTO CELLS. (UNPUBLISHED PAPER). 

001063 02-01 
INFLUENCE OF DRUGS AFFECTING THE PITUITARY ADRENAL AXIS ON 
CHROMAFFIN CELLS. 

001183 02-03 
IGE MEDIATED HISTAMINE RELEASE IN RAT BASOPHILIC LEUKEMIA 
CELLS: RECEPTOR ACTIVATED PHOSPHOLIPID METHYLATION, CA-FLUX 
AND RELEASE OF ARACHIDONIC-ACID. (UNPUBLISHED PAPER). 

001188 02-03 
ENHANCED TRANSFER OF EXPERIMENTAL ALLERGIC-ENCEPHALOMYELITIS 
WITH STRAIN- 13 GUINEA-PIG LYMPH-NODE CELLS: REQUIREMENT FOR 
CULTURE WITH SPECIFIC ANTIGEN AND ALLOGENIC PERITONEAL 
EXUDATE CELLS. (UNPUBLISHED PAPER). 

001201 02-03 
EXCITATORY ACTION OF OPIOID-PEPTIDES AND OPIATES ON CULTURED 
HIPPOCAMPAL PYRAMIDAL CELLS. 

001241 02-03 
REGULATION BY A BETA-ADRENERGIC-RECEPTOR OF A CA -INDEPENDENT 
ADENOSINE-CYCLIC-MONOPHOSPHATE-PHOSPHODIESTERASE IN C6- 
GLIOMA CELLS. (UNPUBLISHED PAPER). 

001403 02-03 
LITHIUM-ION ENTRY INTO CULTURED CELLS OF NEURAL ORIGIN. 

001433 02-03 
ENHANCED TRANSFER OF EXPERIMENTAL ALLERGIC-ENCEPHALOMYELITIS 

WITH LEWIS-RAT LYMPH-NODE CELLS. (UNPUBLISHED PAPER). 

001434 02-03 
STIMULATION OF THE PLASMA MEMBRANE ENZYME, 5' NUCLEOTIDASE, 

BY ETHANOL EXPOSURE TO NEURAL CELLS IN CULTURE. 

001499 02-03 
RELATIONSHIP BETWEEN THE ACTIONS OF CALCIUM-IONS, OPIOIDS, AND 
PROSTAGLANDIN-El ON THE LEVEL OF CYCLIC-AMP IN 
NEUROBLASTOMA-X GLIOMA HYBRID CELLS. 

002677 03-03 
A COMPARISON OF THE EFFECTS OF PENTOBARBITAL AND 

DIPHENYLHYDANTOIN ON THE GABA SENSITIVITY AND EXCITABILITY 
Of ADULT SENSORY GANGLION CELLS. 

002692 03-03 
TOXIC EFFECTS OF ALPHA AMINOADIPATE ON CULTURED CEREBELLAR 
CELLS. 

002729 03-03 
THE EFFECTS OF A BENZODIAZEPINE ON THE HYPERPOLARIZING AND THE 
DEPOLARIZING RESPONSES OF HIPPOCAMPAL CELLS TO GABA. 

002763 03-03 
EFFECTS OF LITHIUM ON MORPHOLOGICAL CHARACTERISTICS OF 
DISSOCIATED BRAIN CELLS IN CULTURE. 

002765 03-03 
IDENTIFICATION OF TWO BENZODIAZEPINE BINDING-SITES ON CELLS 
CULTURED FROM RAT-CEREBRAL-CORTEX. 

002820 03-03 
LOCALIZATION OF GABA-RECEPTOR AND DOPAMINE-RECEPTOR SITES IN 
RETINAL GLIAL CELLS USING DL ALPHA AMINOADIPIC-ACID. 

002828 03-03 
INFLUENCE OF PSYCHOACTIVE AND NONPSYCHOACTIVE CANNABINOIDS 
ON CELL PROLIFERATION AND MACROMOLECULAR BIOSYNTHESIS IN 
HUMAN CELLS. 

002830 03-03 
INFLUENCE OF PSYCHOACTIVE AND NONPSYCHOACTIVE CANNABINOIDS 

ON CHROMATIN STRUCTURE AND FUNCTION IN HUMAN CELLS. 

002831 03-03 



'•i 









S 






S-79 



Subject Index 



Psychopharmacology Abstracts 



k.','.'' -V' 



EFFECTS OF BENSERAZIDE AND CARBIDOPA ON THE METABOLISM OF L 
TRYPTOPHAN BY ISOLATED RAT LIVER CELLS. 

002899 03-03 
LITHIUM UPTAKE IN RED CELLS OF CYCLOID AND UNIPOUVR DYSTHYMIC- 
PATIENTS. 

003258 03-09 
DIFFERENTIAL BINDING OF CHLORPROMAZINE TO HUMAN BLOOD CELLS: 
APPLICATION OF THE HYGROSCOPIC DESORPTION METHOD. 

003556 03-16 
5 HYDROXYTRYPTAMINE CONTROLS ACH-RECEPTOR SENSITIVITY OF 
BULLFROG SYMPATHETIC GANGLION CELLS. 

003710 04-03 
INVOLVEMENT OF CALCIUM CHANNELS IN SHORT-TERM 
DESENSITIZATION OF MUSCARINIC-RECEPTOR MEDIATED CYCLIC-GMP 
FORMATION IN MOUSE NEUROBL^STOMA CELLS. 

003783 04-03 
CHARACTERIZATION BY (3H)DIHYDR0ERG0CRYPTINE BINDING OF 
ALPHA-ADRENERGIC-RECEPTORS IN NEUROBLASTOMA X GLIOMA 
HYBRID CELLS. 

003823 04-03 
DOXEPIN A TRICYCLIC-ANTIDEPRESSANT, BINDS TO NORMAL, INTACT 
ASTROGLIAL CELLS IN CULTURES AND INHIBITS THE ISOPROTERENOL- 
INDUCED INCREASE IN CYCLIC-AMP PRODUCTION. 

003836 04-03 
OPIOIDS NORADRENALINE AND GTP ANALOGS INHIBIT CHOLERA-TOXIN 
ACTIVATED ADENYLATE-CYCLASE IN NEUROBLASTOMA-X GLIOMA 
HYBRID CELLS. 

003975 04-03 
RNA-POLYMERASE-II IN C6-GLI0MA CELLS: ALPHA AMANITIN BLOCKADE 
OF CYCLIC-AMP-PHOSPHODIESTERASE INDUCTION BY BETA- 
ADRENERGIC STIMULATION. (UNPUBLISHED PAPER) 

003998 04-03 
PHENYTOIN INHIBITION OF CYCLIC-GUANOSINE-MONOPHOSPHATE (C- 
GMP) ACCUMULATION IN NEUROBLASTOMA CELLS BY CALCIUM- 
CHANNEL BLOCKADE. 

004020 04-03 
DESENSITIZATION OF HISTAMINE HI -RECEPTOR-MEDIATED CYCLIC-GMP 
FORMATION IN MOUSE NEUROBLASTOMA CELLS. 

004030 04-03 
RELATIVE ACTIVITIES OF SUBSTANCES RELATED TO 5 

HYDROXYTRYPTAMINE AS DEPOLARIZING-AGENTS OF SUPERIOR 
CERVICAL GANGLION CELLS. 

004047 04-03 
DEMONSTRATION OF A MUSCARINIC-RECEPTOR-MEDIATED CYCLIC-GMP- 
DEPENDENT HYPERPOLARIZATION OF THE MEMBRANE POTENTIAL OF 
MOUSE NEUROBLASTOMA CELLS USING 
(3H)TETRAPHENYLPH0SPH0NIUM. 

004049 04-03 
CELLULAR 

BENZODIAZEPINE-RECEPTORS IN CHICK RETINA: DEVELOPMENT AND 
CELLULAR LOCALIZATION. 

002655 03-03 
IN VITRO CELLULAR ADAPTATION OF SEROTONERGIC PROCESSES AFTER 
CHRONIC CENTRAL PHENOBARBITAL ADMINISTRATION. 

002813 03-03 
CELLULAR-TRANSPORT 

INFLUENCE OF CELLULAR-TRANSPORT ON THE INTERACTION OF AMINO- 
ACIDS WITH GAMMA AMINOBUTYRIC-ACID-RECEPTORS (GABA) IN THE 
ISOLATED OLFACTORY-CORTEX OF THE GUINEA-PIG. 

000034 01-03 
CENTER 

SATIETY CENTER NEUROANATOMY. (UNPUBLISHED PAPER). 

003678 04-01 
CENTERS 

INFLUENCE OF CHRONIC ALCOHOL INTOXICATION ON CIRCADIAN-RHYTHM 
OF NEUROSECRETORY CENTERS OF RAT HYPOTHALAMUS. 

001549 02-03 
CENTRAL 

EVIDENCE FOR AN IRREVERSIBLE INTERACTION OF BROMOCRYPTINE 
WITH CENTRAL DOPAMINE-RECEPTORS. 

000023 01-03 
EVIDENCE FOR A RECEPTOR SUPERSENSITIVITY FOLLOWING IMPAIRMENT 
OF CENTRAL SEROTONERGIC ACTIVITY IN THE RABBIT. 

000041 01-03 
NUCIFERINE AND CENTRAL GLUTAMATE-RECEPTORS. 

000063 01-03 
CLENBUTEROL, A CENTRAL BETA-ADRENOCEPTOR AGONIST. 

000120 01-03 
ABSENCE OF POTASSIUM CONDUCTANCE IN CENTRAL MYELINATED 
AXONS. 

000166 01-03 
CENTRAL NORADRENERGIC ADAPTATION TO LONG-TERM-TREATMENT 
WITH IMIPRAMINE IN RHESUS-MONKEYS. 

000182 01-03 
EFFECT OF GABA ANALOGUES ON BLOOD-PRESSURE AND CENTRAL GABA 
METABOLISM IN THE RAT. 

000231 01-03 
DIAZEPAM POTENTIATION OF PURINERGIC DEPRESSION OF CENTRAL 
NEURONS. 

000233 01-03 



INVOLVEMENT OF CENTRAL CHOLINOCEPTORS IN METRAZOL-INDUCED 

CONVULSIONS. 

000247 01-03 
CENTRAL BLOOD-PRESSURE EFFEaS OF GUANYLYLIMIDODIPHOSPHATE 

AND CYCLIC-GUANOSINE-MONOPHOSPHATE. 

000266 01-03 
RELATION BETWEEN THE EFFEQS OF ANTIDEPRESSANT-DRUGS ON THE 

UPTAKE OF MONOAMINES AND ON THE SPONTANEOUS AQIVITY OF 
CENTRAL NEURONS. 

000267 01-03 
A COMPARISON OF RATES OF DEPLETION AND RECOVERY OF 

NORADRENALINE STORES OF PERIPHERAL AND CENTRAL 
NORADRENERGIC NEURONES AFTER RESERPINE ADMINISTRATION: 
IMPORTANCE OF NEURONAL ACTIVITY. 

000314 01-03 
N ALKYLATED 2 AMINOTETRAUNS: CENTRAL DOPAMINE-RECEPTOR 
STIMULATING ACTIVITY. 

000399 01-04 
EFFECTS OF L-DOPA AND L 5 HYDROXYTRYPTOPHAN ON LOCOMOTOR- 
ACTIVITY OF THE RAT AFTER SELECTIVE OR COMBINED DESTRUCTION 
OF CENTRAL CATECHOLAMINE AND SEROTONIN NEURONS 

000466 01-04 
CHRONIC AMPHETAMINE ADMINISTRATION TO CATS: BEHAVIORAL- 
EVIDENCE AND NEUROCHEMICAL EVIDENCE FOR DECREASED CENTRAL 
SEROTONERGIC FUNCTION. 

000491 01-04 
CENTRAL EXCITATORY ACTIONS OF FLURAZEPAM. 

000526 01-05 
CENTRAL LEVELS OF NORADRENALINE, 3 METHOXY-4- 

HYDROXYPHENYLETHYLENEGLYCOL AND CYCLIC-AMP IN THE RAT 
AFTER ACTIVATION OF LOCUS-COERULEUS NEURONS: INFLUENCE OF 
SINGLE AND REPEATED NEUROLEPTIC TREATMENT. 

001095 02-03 
EFFECTS OF CHRONIC-TREATMENT WITH L SULPIRIDE AND HALOPERIDOL 

ON CENTRAL DOPAMINE TURNOVER EVALUATED IN DOPAMINE CELL 
BODY AND NERVE TERMINAL-RICH AREAS. 

001096 02-03 
INHIBITION BY LOCAL ANESTHETICS. PHENTOLAMINE AND PROPRANOLOL 

OF (3H)QUINUCLYDINYL-BENZYLATE BINDING TO CENTRAL 
MUSCARINIC-RECEPTORS. 

001097 02-03 
CENTRAL SYMPATHETIC REAQIVITY INHIBITED BY INDORAMIN 

001193 02-03 
CENTRAL MONOAMINE SYNAPSES AS SITES OF ACTION FOR ERGOT I 

DRUGS. 

001238 02-03 
EFFECTS OF CHRONIC-TREATMENT WITH L SULPIRIDE AND HALOPERIDOL I 
ON CENTRAL MONOAMINERGIC MECHANISMS. 

001240 02-03 
CENTRAL ADMINISTRATION OF SERINE CAUSES HYPOTHERMIA AND 
INHIBITS FEVER IN RABBITS 

001247 02-03 
COMPARISON OF THE EFFECTS OF CENTRAL ADMINISTRATION OF SERINE 

AND GLYCINE ON BODY-TEMPERATURE OF THE RABBIT. 

001248 02-03 
METHYLDOPA PRODUCES CENTRAL INHIBITION OF PARASYMPATHETIC- 

AQIVITY IN THE CAT. 

001321 02-03 
TWO CONDUCTANCE MECHANISMS AQIVATED BY APPLICATIONS OF L 
GLUTAMIC-ACID, L ASPARTIC-ACID, DL HOMOCYSTEIC-ACID, N 
METHYL-D-ASPARTIC-ACID, AND DL KAINIC-ACID TO CULTURED 
MAMMALIAN CENTRAL NEURONES 

001349 02-03 
EFFECTS OF DIFFERENT MONOAMINE-OXIDASE-INHIBITORS ON 
RESPIRATORY ACTIVITY IN RATS WITH CHRONICALLY IMPAIRED 
CENTRAL SEROTONERGIC FUNCTION 

001389 02-03 
DIFFERENTIAL-EFFEQS OF SYSTEMIC VERSUS INTRACRANIAL INJEQION 
OF OPIATES ON CENTRAL, OROFACIAL AND LOWER BODY 
NOCICEPTION: SOMATOTYPY IN BULBAR ANALGESIA SYSTEMS 

001446 02-03 
CENTRAL BIOGENIC-AMINES AND NEUROPEPTIDES IN GENETIC 
HYPERTENSION. (UNPUBLISHED PAPER). 

001456 02-03 
CENTRAL AMINERGIC AND PEPTIDERGIC MECHANISMS IN 

SPONTANEOUSLY (GENETIC) HYPERTENSIVE-RATS. (UNPUBLISHED 
PAPER). 

001459 02-03 
CENTRAL PHARMACOLOGICAL CONTROL OF CORTICOSTERONE SECRETION 
IN THE INTAQ RAT. DEMONSTRATION OF CHOLINERGIC AND 
SEROTONINERGIC FACILITATORY AND ALPHA-ADRENERGIC INHIBITORY 
MECHANISMS. 

001487 02-03 
THE INABILITY OF CHRONIC MIANSERIN TO BLOCK CENTRAL ALPHA2- 
ADRENOCEPTORS. 

001492 02-03 
NEGLIGIBLE AFFINITY OF HISTAMINE H2-RECEPT0R ANTAGONISTS FOR 
CENTRAL ALPHAl -ADRENOCEPTORS. 

001508 02-03 



S-80 



VOLUME 19, SUBJECT INDEX 



Subject Index 



COMPARED PROPERTIES OF CENTRAL AND PERIPHERAL BINDING-SITES 
FOR PHENCYCLIDINE. 

001521 02-03 
KAINIC-ACID-INDUCED WET-DOG-SHAKES IN RATS: THE RELATION TO 
CENTRAL NEUROTRANSMITTERS 

001685 02-04 
INVESTIGATIONS ON THE INTERACTION OF THYROTROPIN-RELEASING- 
HORMONE (TRH) AND MK-771 WITH CENTRAL NORADRENERGIC 
MECHANISMS 

001701 02-04 
A COMPARISON BETWEEN THE EFFECTS OF MORPHINE ON THE 
REWARDING AND AVERSIVE-PROPERTIES OF LATERAL HYPOTHALAMIC 
AND CENTRAL GRAY STIMULATION. 

001771 02-04 
TOLERANCE TO FLUPHENAZINE AND SUPERSENSITIVITY TO APOMORPHINE 
IN CENTRAL DOPAMINERGIC-SYSTEMS AFTER CHRONIC FLUPHENAZINE- 
DECANOATE TREATMENT 

001820 02-04 
CENTRAL SEROTONIN-RECEPTOR SENSITIVITY IN RATS WITH 

EXPERIMENTAL ALLERGIC-ENCEPHALOMYELITIS, 

001821 02-04 
ELECTROPHYSIOLOGICAL-CHANGES AT A CENTRAL NORADRENERGIC 

SYNAPSE DURING THALLIUM TOXICOSIS. 

001848 02-05 
CLINICAL PROCESSES AND CENTRAL DOPAMINERGIC-ACTIVITY IN 
PSYCHOTIC-DISORDERS. 

002098 02-11 
PATHOPHYSIOLOGIC-IMPACT OF CENTRAL CATECHOLAMINERGIC 
FUNCTION IN SCHIZOPHRENIA AND SCHIZOPHRENIA-LIKE PSYCHOSES. 

002174 02-11 
THE USE OF BROMOCRIPTINE FOR TESTING CENTRAL DOPAMINERGIC 
REACTIVITY, 

002205 02-13 
APOMORPHINE HYPOTHERMIA; AN INDEX OF CENTRAL DOPAMINE- 
RECEPTOR FUNCTION IN MAN. 

002221 02-13 
CENTRAL DOPAMINERGIC-EFFECTS OF ERGOLINE DERIVATIVES. 

002540 02-17 
CENTRAL NEUROPHARMACOLOGY OF ENDORPHINS. 

002599 02-17 
CENTRAL DEPRESSANT EFFECTS OF CAERULEIN AND CHOLECYSTOKININ- 
OCTAPEPTIDE (CCK-8) DIFFER FROM THOSE OF DIAZEPAM AND 
HALOPERIDOL. 

002652 03-02 
GABA-RECEPTORS AND BENZODIAZEPINE-RECEPTORS. STUDIES ON THEIR 
LOCALIZATION IN THE HIPPOCAMPUS AND THEIR INTERACTION WITH 
CENTRAL DOPAMINE NEURONS IN THE RAT-BRAIN. 

002727 03-03 
FUNCTIONAL CHARACTERIZATION OF CENTRAL ALPHA-ADRENOCEPTORS 
BY YOHIMBINE DIASTEREOMERS. 

002748 03-03 
IN VITRO CELLULAR ADAPTATION OF SEROTONERGIC PROCESSES AFTER 
CHRONIC CENTRAL PHENOBARBITAL ADMINISTRATION. 

002813 03-03 
CENTRAL AND PERIPHERAL CATECHOLAMINE FUNCTION IN LEARNING 
AND MEMORY PROCESSES. 

002823 03-03 
IN VIVO VOLTAMMETRIC INVESTIGATIONS INTO THE ACTION OF HA-966 
ON CENTRAL DOPAMINERGIC NEURONS. 

002832 03-03 
A CRITICAL EVALUATION OF THE USE OF TOXINS FROM DENDROASPIS 
VIRIDIS TO BLOCK NICOTINIC RESPONSES AT CENTRAL AND 
GANGLIONIC SYNAPSES. 

002870 03-03 
GLUCOSE SUPPRESSES BASAL FIRING AND HALOPERIDOL-INDUCED 
INCREASES IN THE FIRING-RATE OF CENTRAL DOPAMINERGIC 
NEURONS. 

002880 03-03 
ACCELERATED METABOLISM OF PROBENECID DURING LONG-TERM- 
TREATMENT OF RATS WITH ANTICONVULSANT-DRUGS: EFFECT ON 
CENTRAL SEROTONIN TURNOVER STUDIES. 

002890 03-03 
BETA ENDORPHIN-INDUCED HYPERGLYCEMIA IS MEDIATED BY INCREASED 
CENTRAL SYMPATHETIC OUTFLOW TO ADRENAL-MEDULLA. 

002924 03-03 
ACTION OF CYCLIC-ADENOSINE-MONOPHOSPHATE ON CENTRAL 
NEURONS. 

002940 03-03 
EFFECT OF ACUTE AND CHRONIC TRIIODOTHYRONINE (T3) 
ADMINISTRATION TO RATS ON CENTRAL 5 HT AND DOPAMINE- 
MEDIATED BEHAVIOURAL-RESPONSES AND RELATED BRAIN- 
BIOCHEMISTRY. 

002951 03-04 
EFFECTS OF ACUTE CENTRAL AND PERIPHERAL ACTHl-24 
ADMINISTRATION ON LORDOSIS BEHAVIOR. 

002975 03-04 
NALOXONE REVERSIBLE DUPLICATION BY LANTHANUM OF OPIATE 
ANALGESIA EFFECTS ON OROFACIAL, LOWER BODY AND CENTRAL 
NOCICEPTION. 

003028 03-04 



INDUCTION OF ANALGESIA BY CENTRAL ADMINISTRATION OF ORG-2766, 
AN ANALOG OF ACTH4-9 

003112 03-04 
THE ROLE OF CENTRAL SEROTONERGIC MECHANISMS ON HEAD-TWITCH 
AND BACKWARD LOCOMOTION INDUCED BY HALLUCINOGENIC-DRUGS 

003397 03-12 
SUPERSENSITIVITY OF CENTRAL NORADRENERGIC PRESYNAPTIC- 
AUTORECEPTORS FOLLOWING CHRONIC-TREATMENT WITH THE 
ANTIDEPRESSANT MIANSERIN. 

003745 04-03 
CENTRAL HYPOTENSIVE-EFFECT OF GAMMA AMINOBUTYRIC-ACID IN 
ANESTHETIZED DOGS. 

003772 04-03 
POSSIBLE ROLE OF AN ENDOGENOUS OPIATE IN THE CARDIOVASCULAR- 
EFFECTS OF CENTRAL ALPHA-ADRENOCEPTOR STIMULATION IN 
SPONTANEOUSLY HYPERTENSIVE-RATS. 

003791 04-03 
OPIATE-EFFECTS IN THE AMYGDALA CENTRAL NUCLEUS ON HEART RATE 
CONDITIONING IN RABBITS. 

003798 04-03 
CENTRAL DOPAMINERGIC NEURONS DURING DEVELOPMENT OF GENETIC 
AND DOCA-SALT HYPERTENSION IN THE RAT. 

003899 04-03 
EFFECTS OF 5 HYDROXYTRYPTAMINE ON CENTRAL NEURONES 
ANTAGONIZED BY BICUCULLINE AND PICROTOXIN. 

003931 04-03 
CENTRAL CARDIOVASCULAR-EFFECTS AND BIOCHEMICAL-EFFECTS OF 
BACLOFEN IN THE CONSCIOUS RAT. 

003965 04-03 
OPIATE SYSTEM INFLUENCES CENTRAL RESPIRATORY CHEMOSENSORS. 

003971 04-03 
EFFECT OF IMIPRAMINE ON CENTRAL 5 HYDROXYTRYPTAMINE 
TURNOVER AND METABOLISM IN RATS. 

003999 04-03 
EFFECTS OF LITHIUM ON BEHAVIOUR AND CENTRAL MONOAMINES. 

004110 04-04 
GENETIC VARIATIONS IN MIDBRAIN DOPAMINE CELL NUMBER: PARALLEL 
WITH DIFFERENCES IN RESPONSES TO DOPAMINERGIC AGONISTS AND 
IN NATURALISTIC BEHAVIORS MEDIATED BY CENTRAL DOPAMINERGIC- 
SYSTEMS. (UNPUBLISHED PAPER). 

004112 04-04 
CENTRAL AND PERIPHERAL EFFECTS OF LITHIUM ON AMPHETAMINE- 
INDUCED HYPERACTIVITY IN RATS. 

004223 04-04 
BETA ENDORPHIN: CENTRAL SITES OF ANALGESIA, CATALEPSY AND 
BODY-TEMPERATURE CHANGES IN RATS. 

004238 04-04 
A POSSIBLE NEUROCHEMICAL BASIS OF THE CENTRAL STIMULATORY 
EFFECTS OF PP'DDT. 

004274 04-05 
THE EFFICACY OF PIRACETAM IN VERTIGO: A DOUBLE-BUND STUDY IN 
PATIENTS WITH VERTIGO OF CENTRAL ORIGIN. 

004478 04-11 
DOPAMINE AND 5 HT SUPERSENSITIVITY IN NONORGANIC CENTRAL PAIN 
AND IN MORPHINE ABSTINENCE: FORTUITOUS OR REAL ANALOGY? 

004553 04-13 
CENTRAL-ACTION 

CENTRAL-ACTION OF INTRAVENTRICULARLY INJECTED MIDODRINE IN 
RATS. 

001684 02-04 
ASPIRIN ANALGESIA EVALUATED BY EVENT-RELATED POTENTIALS IN 
MAN: POSSIBLE CENTRAL-ACTION IN BRAIN. 

002195 02-12 
CENTRAL-ACTIONS 

CENTRAL-ACTIONS OF NOREPINEPHRINE, PHENTOLAMINE AND 6 
HYDROXYDOPAMINE IN SPONTANEOUSLY HYPERTENSIVE-RATS. 

001553 02-03 
KINETICS OF CENTRAL-ACTIONS OF ISOFLOXYTHEPIN, AN ORAL 
NEUROLEPTIC-DRUG WITH PROLONGED ACTION IN RODENTS. 

001720 02-04 
ADENOSINE-RECEPTORS IN THE CENTRAL-NERVOUS-SYSTEM: 

RELATIONSHIP TO THE CENTRAL-ACTIONS OF METHYLXANTHINES. 

003766 04-03 
THE SIMULTANEOUS INFUSION OF DRUGS VIA THE LEFT AND RIGHT 
VERTEBRAL-ARTERY OF THE CAT, A MODIFIED ANIMAL-MODEL FOR 
THE STUDY OF POSSIBLE CENTRAL-ACTIONS OF DRUGS UPON THE 
LOWER BRAINSTEM. 

004297 04-06 
CENTRAL-ACTIVITY 

DIHYDROXY AND TRIHYDROXY ANALOGS OF CHLORPROMAZINE 
INFLUENCE THE CENTRAL-ACTIVITY OF ADENYLATE-CYCLASE AND 
CYCLIC-AMP-PHOSPHODIESTERASE . 

001405 02-03 
CENTRAL-EFFECTS 

MECHANISMS INVOLVED IN CENTRAL-EFFECTS OF PROSTAGLANDIN- 
F2ALPHA. (UNPUBLISHED PAPER). 

001222 02-03 















ill;' 



S-81 



Subject Index 



Psychopharmacology Abstracts 



SOME CENTRAL-EFFECTS OF IMPROMIDINE, A POTENT AGONIST OF 
HISTAMINE H2-RECEPT0RS. 

001417 02-03 
CYCLIC-NUCLEOTIDES AND THE CENTRAL-EFFECTS OF OPIATES: AN 
OVERVIEW OF CURRENT RESEARCH. 

001445 02-03 
CENTRAL-EFFECTS OF SUBSTANCE-P IN FOWLS. 

003075 03-04 
CENTRAL-EFFECTS OF ANGIOTENSIN-II IN WATER AND SALINE LOADED 
RATS. 

003845 04-03 
ANTAGONISM OF SOME CENTRAL-EFFECTS OF D TUBOCURARINE BY 
GAMMA AMINOBUTYRIC-ACID. 

004102 04-04 
CENTRAL-NERVOUS-SYSTEM 

EFFECT OF INTRAVENTRICULAR INJECTIONS OF ALPHA AMINOSULFONIC- 
ACIDS ON THE CENTRAL-NERVOUS-SYSTEM OF CONSCIOUS MICE. 

000009 01-02 
NEUROTRANSMITTER RELATED ADAPTATION IN THE CENTRAL-NERVOUS- 
SYSTEM FOLLOWING CHRONIC MONOAMINE-OXIDASE-INHIBITION. 

000038 01-03 
THE EFFECTS OF OPIATES ON THE LEVELS OF CYCLIC-GUANOSINE- 
MONOPHOSPHATE IN DISCRETE AREAS OF THE RAT CENTRAL- 
NERVOUS-SYSTEM. 

000220 01-03 
THE INVOLVEMENT OF SEROTONERGIC NEURONS IN THE CENTRAL- 
NERVOUS-SYSTEM AS THE POSSIBLE MECHANISM FOR SLOW HEAD- 
SHAKING-BEHAVIOR INDUCED BY METHAMPHET AMINE IN RATS. 

000408 01-04 
MOTOR-EFFECTS OF SEROTONIN IN THE CENTRAL-NERVOUS-SYSTEM. 

000941 01-17 
DERIVATIVES OF 1 1 1 PIPERAZINYL-5H-PYRR0L0BENZ0DIAZEPINE AS 
CENTRAL-NERVOUS-SYSTEM AGENTS. 

001093 02-02 
CENTRAL-NERVOUS-SYSTEM DOPAMINE-RECEPTORS . 

001185 02-03 
TOLERANCE TO BARBITURATE-INDUCED CENTRAL-NERVOUS-SYSTEM 
DEPRESSION: INVOLVEMENT OF STIMULUS SECRETION COUPLING IN 
DISCRETE BRAIN AREAS. (PH.D. DISSERTATION) 

001213 02-03 
PERIPHERAL PRESYNAPTIC AND POSTSYNAPTIC DOPAMINE-RECEPTORS: 
ARE THEY DIFFERENT FROM DOPAMINE-RECEPTORS IN THE CENTRAL- 
NERVOUS-SYSTEM. 

001252 02-03 
FURTHER EVIDENCE FOR THE EXISTENCE OF MULTIPLE RECEPTORS FOR 
DOPAMINE IN THE CENTRAL-NERVOUS-SYSTEM 

001296 02-03 
PINEAL INTERACTIONS WITH THE CENTRAL-NERVOUS-SYSTEM: 
NEUROENDOCRINE IMPLICATIONS. (PH D. DISSERTATION). 

001341 02-03 
THE ELECTROPHYSIOLOGICAL-EFFECTS OF ENKEPHALIN AND 

PHENCYCLIDINE IN THE RAT CENTRAL-NERVOUS-SYSTEM. (PH.D. 
DISSERTATION). 

001406 02-03 
FUNCTIONAL ASPECTS OF THE NOREPINEPHRINE-RECEPTOR COUPLED 
ADENYLATE-CYCLASE SYSTEM IN THE CENTRAL-NERVOUS-SYSTEM. 

001493 02-03 
ON THE USE OF OPERANT-BEHAVIOR TO STUDY THE 

NEUROPSYCHOPHARMACOLOGY OF OPIATES WITH SPECIAL REFERENCE 
TO MORPHINE AND ITS RELATIONSHIP TO DOPAMINE IN THE CENTRAL- 
NERVOUS-SYSTEM. 

001790 02-04 
EFFECTS OF 1,3 BIS-TETRAHYDRO-2-FURANYL-5- 
FLUOROPYRIMIDINEDIONE (FD-1) ON THE CENTRAL-NERVOUS-SYSTEM: 
1 . EFFECTS OF MONOAMINES IN THE BRAIN. 

001857 02-05 
THEORY, PROCEDURE, AND APPLICATIONS OF THE RADIOACTIVE 

DEOXYGLUCOSE METHOD FOR THE MEASUREMENT OF LOCAL GLUCOSE 
UTILIZATION IN THE CENTRAL-NERVOUS-SYSTEM. (UNPUBLISHED 
PAPER). 

001877 02-06 
NEUROLEPTIC-INDUCED REINNERVATION SPROUTING IN THE CENTRAL- 
NERVOUS-SYSTEM (A MODEL FOR THE DEVELOPMENT OF TARDIVE- 
DYSKINESIA AND SUPERSENSITIVITY PSYCHOSIS). 

002459 02-15 
EFFECTS OF 4 AMINOPYRIDINE ON THE TURNOVER OF MONOAMINES IN 
THE CENTRAL-NERVOUS-SYSTEM OF THE RAT. 

002658 03-03 
GAMMA BUTYROLACTONE-GAMMA-CARBONYL-HISTIDYL-PROLINAMIDE 
CITRATE (DN-1417): A NOVEL TRH ANALOG WITH POTENT EFFECTS ON 
THE CENTRAL-NERVOUS-SYSTEM. 

003057 03-04 
ADENOSINE-RECEPTORS IN THE CENTRAL-NERVOUS-SYSTEM: 

RELATIONSHIP TO THE CENTRAL-ACTIONS OF METHYLXANTHINES. 

003766 04-03 
SPECIFIC, HIGH-AFFINITY (3H)ETHYLKET0CYCLAZ0CINE BINDING IN RAT 
CENTRAL-NERVOUS- SYSTEM: LACK OF EVIDENCE FOR KAPPA- 
RECEPTORS. 

003840 04-03 



THE HYPOTHERMIC-EFFECTS OF CLONIDINE AND OTHER IMIDAZOLIDINES 
IN RELATION TO THEIR ABILITY TO ENTER THE CENTRAL-NERVOUS- 
SYSTEM IN MICE. 

003933 04-03 
KINETIC STUDIES ON THE ENTRY OF D-AMPHETAMINE INTO THE 
CENTRAL-NERVOUS-SYSTEM: I. CEREBROSPINAL-FLUID 

004005 04-03 
A COMPARATIVE EVALUATION OF THE USEFULNESS OF 

PSYCHOPHYSIOLOGICAL-TESTS DURING VARIOUS LEVELS OF 
ACTIVATION OF THE CENTRAL-NERVOUS-SYSTEM 

004543 04-13 
CENTRAL-REGULATION 

BIOGENIC-AMINES AND NEUROPEPTIDES PLAY A ROLE IN THE CENTRAL- 
REGULATION OF GENETIC HYPERTENSION. (UNPUBLISHED PAPER). 

001455 02-03 
CENTRALLY-ACTING 

EFFECTS OF MORPHINE AND OTHER CENTRALLY-ACTING DRUGS ON 3,4 
DIHYDROXYPHENYLETHYLENE-GLYCOL-SULFATE (D0PEG-S04) IN RAT- I 
BRAIN. J 

000136 01-03 1 
ALTERATION OF PROLACTIN SECRETION BY CENTRALLY-AQING DRUGS. 

001127 02-03 
DECREASE IN (3H) SEROTONIN BINDING IN RAT-BRAIN PRODUCED BY THE 
REPEATED ADMINISTRATION OF EITHER MONOAMINE-OXIDASE- 
INHIBITORS ON CENTRALLY-ACTING SEROTONIN AGONISTS. 

001463 02-03 I 
THE EFFECT OF REPEATED ELECTROCONVULSIVE-SHOCK ON 1 

CORTICOSTERONE RESPONSES TO CENTRALLY-ACTING 
PHARMACOLOGICAL STIMULI IN THE MALE RAT 

001486 02-03 
CENTRALLY-ACTIVE 

A SIGNAL-DETECTION-ANALYSIS OF CENTRALLY-ACTIVE DRUGS IN MICE. 

001631 02-04 
CENTRALLY-ADMINISTERED 

EFFECTS OF CENTRALLY-ADMINISTERED PENTAZOCINE AND 
ETHYLKETOCYCLAZOCINE ON THERMOREGULATION IN THE CAT 

000361 01-04 
EFFECTS OF CENTRALLY-ADMINISTERED AND SYSTEMICALLY 
ADMINISTERED L TYROSINE AND L LEUCINE ON OVARIAN FUNQION IN 
THE OLD RAT 

001180 02-03 
THE HYPOTENSIVE-EFFEa OF CENTRALLY-ADMINISTERED TYROSINE 

001548 02-03 
CENTURIES 

THE OPIATES: TWO CENTURIES OF SCIENTIFIC-STUDY. 

000952 01-17 
CEPHALALGIA 

DOSE-EFFECT OF DEAE ON SUBJECTIVE PROBLEMS, VERTIGO, 
DEPRESSION, ASTHENIA, CEPHALALGIA, AND TONIC POSTURAL 
ACTIVITY PROBLEMS RECORDED WITH STATOKINESIMETER IN 
POSTCONCUSSIONAL- SYNDROME 

004472 04-11 
CEPHALGIC-SEIZURES 
CEPHALGIC-SEIZURES. 

002172 02-11 
CERCOPITHECUS-AETHIOPS-SABAEUS 

PERIPHERAL-CORRELATES OF SEROTONERGICALLY-INFLUENCED 
BEHAVIORS IN VERVET-MONKEYS (CERCOPITHECUS-AETHIOPS- 
SABAEUS). 

004204 04-04 
CEREBELLAR 

CEREBELLAR GRANULE CELL GENESIS IN THE HYDROCORTISONE TREATED 
RAT 

000030 01-03 
A PROBABLE SITE-OF-ACTION OF DIAZEPAM IN RAT CEREBELLAR GABA 
SYSTEM 

000151 01-03 
DISTRIBUTION OF 14C PHENYTOIN IN RAT PURKINJE-CELLS, CEREBELLAR 
AND CEREBRAL NEURONAL TISSUE AFTER A SINGLE INTRAPERITONEAL 
INJECTION. 

000261 01-03 
ORAL CHOLINE IN CEREBELLAR ATAXIA 

000722 01-11 
INHIBITION BY ARYLSULPHATASE A OF NA-INDEPENDENT (3H) GABA 
AND (3H) MUSCIMOL BINDING TO BOVINE CEREBELLAR SYNAPTIC 
MEMBRANES. 

001208 02-03 
LOCALIZATION OF SENSITIVE SITES TO TAURINE, GAMMA 
AMINOBUTYRIC-ACID, GLYCINE AND BETA ALANINE IN THE 
MOLECULAR LAYER OF GUINEA-PIG CEREBELLAR SLICES. 

001402 02-03 
LITHIUM ANTAGONISM OF ETHANOL-INDUCED DEPLETION OF CEREBELLAR 
GUANOSINE-CYCLIC-MONOPHOSPHATE AND STIMULATION OF 
STRIATAL DOPAMINE RELEASE. 

002242 02-13 
TOXIC EFFECTS OF ALPHA AMINOADIPATE ON CULTURED CEREBELLAR 
CELLS. 

002729 03-03 



S-82 



VOLUME 19, SUBJECT INDEX 



Subject Index 



INHIBITORY ACTIONS OF TAUROCYAMINE, HYPOTAURINE, 
HOMOTAURINE, TAURINE AND GABA ON SPIKE DISCHARGES OF 
PURKINJE-CELLS, AND LOCALIZATION OF SENSITIVE SITES, IN GUINEA- 
PIG CEREBELLAR SLICES. 

002846 03-03 
EFFECTS OF PROTEIN AND MEMBRANE MODIFYING AGENTS ON THE 
BINDING OF L (3H)GLUTAMATE TO CEREBELLAR SYNAPTIC 
MEMBRANES. 

002888 03-03 
EFFECTS OF PHENYTOIN ON MOUSE CEREBELLAR 5 HYDROXYTRYPTAMINE 
AND NOREPINEPHRINE. 

003795 04-03 
ACTION OF DRUGS ON THE CEREBELLAR ELECTRICAL-ACTIVITIES. 

003804 04-03 
IBOTENIC-ACID ANALOGUES AS INHIBITORS OF (3H)GLUTAMIC-ACID 
BINDING TO CEREBELLAR MEMBRANES. 

003848 04-03 
MODULATORY INTERACTIONS BETWEEN NOREPINEPHRINE AND TAURINE, 
BETA ALANINE, GAMMA AMINOBUTYRIC-ACID AND MUSCIMOL 
APPLIED lONTOPHORETICALLY TO CEREBELLAR PURKINJE-CELLS, 

004058 04-03 
CEREBEILAR-CORTEX 

DIFFERENTIAL-EFFECTS OF KAINIC-ACID ON BENZODIAZEPINE-RECEPTORS, 
GABA-RECEPTORS, AND GABA-MODULIN IN THE CEREBELLAR-CORTEX. 

002477 02-16 
CEREBELLUM 

GABA FACILITATION BY NORADRENALINE SHOWED SUPERSENSITIVITY IN 
CEREBELLUM AFTER 6 HYDROXYDOPAMINE. 

001382 02-03 
NEURONAL LOCALIZATION OF BENZODIAZEPINE-RECEPTORS IN THE 
MURINE CEREBELLUM. 

002902 03-03 
ACTION OF PYRAZOLOPYRIDINES AS MODULATORS OF 

(3H)FLUNITRAZEPAM BINDING TO THE GABA/BENZODIAZEPINE- 
RECEPTOR COMPLEX OF THE CEREBELLUM. 

002909 03-03 
ACETYLCHOLINESTERASE AND CHOLINESTERASE ACTIVITIES IN THE 
MOUSE CEREBELLUM FOLLOWING MISONIDAZOLE TREATMENT. 

003123 03-05 
THE EFFECTS OF LITHIUM ON MYOINOSITOL LEVELS IN LAYERS OF 
FRONTAL-CEREBRAL-CORTEX, IN CEREBELLUM, AND IN CORPUS- 
CALLOSUM OF THE RAT. 

003712 04-03 
NEURONAL LOCALISATION OF BENZODIAZEPINE-RECEPTORS IN 
CEREBELLUM. 

003739 04-03 
EFFECTS OF ACUTE AND CHRONIC AMPHETAMINE TREATMENT ON 
PURKINJE NEURON DISCHARGE IN RAT CEREBELLUM 

003793 04-03 
ELECTROPHYSIOLOGICAL EVIDENCE FOR PRESYNAPTIC ACTIONS OF 
PHENCYCLIDINE ON NORADRENERGIC TRANSMISSION IN RAT 
CEREBELLUM. 

003926 04-03 
GUANYLATE-CYCLASE - CYCLIC-GMP IN MOUSE CEREBRAL-CORTEX AND 
CEREBELLUM: MODIFICATION BY ANTICONVULSANTS. 

003956 04-03 
THE EFFECT OF PROPRANOLOL AND ITS ISOMERS ON PURKINJE 
NEURONES IN RAT CEREBELLUM. 

004059 04-03 
CEREBRAL 

EFFECT OF ISOPROTERENOL ON CEREBRAL CIRCULATION IN DOGS. 

000199 01-03 
CEREBRAL CIRCULATORY AND METABOLIC-EFFECTS OF PIRIBEDIL. 

000200 01-03 
LONG-TERM ANTIDEPRESSANT TREATMENT: ALTERATIONS IN CEREBRAL 

CAPILLARY PERMEABILITY. 

000239 01-03 
IN VIVO OCCUPATION OF CEREBRAL HISTAMINE HI -RECEPTORS 
EVALUATED WITH 3H MEPYRAMINE MAY PREDICT SEDATIVE 
PROPERTIES OF PSYCHOTROPIC-DRUGS. 

000241 01-03 
NONLINEAR REGRESSION ANALYSIS OF NOREPINEPHRINE RESPONSE 
KINETICS IN CEREBRAL VASCULATURE. 

000256 01-03 
DISTRIBUTION OF 14C PHENYTOIN IN RAT PURKINJE-CELLS, CEREBELLAR 
AND CEREBRAL NEURONAL TISSUE AFTER A SINGLE INTRAPERITONEAL 
INJECTION. 

000261 01-03 
DIFFERENCES IN ACTIVITY IN CEREBRAL METHYLTRANSFERASES AND 
MONOAMINE-OXIDASES BETWEEN AUDIOGENIC-SEIZURE SUSCEPTIBLE 
AND RESISTANT MICE AND DEERMICE. 

000377 01-04 
IMPROVEMENT OF RESTITUTION FROM CEREBRAL ISCHEMIA IN 
HYPERGLYCEMIC RATS BY PENTOBARBITAL OR DIAZEPAM. 

000475 01-04 
CONTRIBUTION TO THE CLINICAL-STUDY OF CEREBRAL DOPAMINERGIC 
MECHANISMS: THE ACTION OF PIRIBEDIL IN PSYCHIATRY. FIRST 
RESULTS. 

000616 01-09 



CLASSIFICATION AND ASSESSMENT OF CEREBRAL BIOAVAILABILITY OF 
LOPIRAZEPAM (D- 12524) BY QUANTITATIVE EEG AND 
PSYCHOMETRIC-ANALYSIS. 

000720 01-11 
CONTRIBUTION TO STUDY OF CEREBRAL DOPAMINERGIC MECHANISMS: 
REALITY OF THE PROBLEM. 

000782 01-13 
OPIOID MECHANISMS IN REGULATION OF CEREBRAL MONOAMINES IN 
VIVO. 

001098 02-03 
PARASYMPATHOMIMETIC-INFLUENCE OF CARBACHOL ON LOCAL 
CEREBRAL BLOOD FLOW IN THE RABBIT BY A DIRECT VASODILATOR 
ACTION AND AN INHIBITION OF THE SYMPATHETIC MEDIATED 
VASOCONSTRICTION. 

001109 02-03 
EFFECTS OF BICUCULLINE-INDUCED SEIZURES ON CEREBRAL METABOLISM 
AND CIRCULATION OF RATS RENDERED HYPOGLYCEMIC BY 
STARVATION. 

001134 02-03 
CHANGES IN CEREBRAL DOPAMINE FUNCTION INDUCED BY A YEARS 
ADMINISTRATION OF TRIFLUOPERAZINE OR THIORIDAZINE AND THEIR 
SUBSEQUENT WITHDRAWAL. 

001175 02-03 
EFFECT OF PAPAVERINE ON REGIONAL CEREBRAL BLOOD FLOW AND 
SMALL VESSEL BLOOD CONTENT, 

001177 02-03 
STEREOSELECTIVE ACTIONS OF SUBSTITUTED BENZAMIDE DRUGS ON 
CEREBRAL DOPAMINE MECHANISMS. 

001301 02-03 
LOCAL CEREBRAL GLUCOSE UTILIZATION (LCGU) IN RAT-BRAIN DURING 
HYPOXEMIA. (UNPUBLISHED PAPER). 

001380 02-03 
THE EFFECT OF SODIUM-SALICYLATE ON CEREBRAL BLOOD FLOW AND 
METABOLISM. 

001416 02-03 
COMPARATIVE-STUDY OF AGGRESSIVE-BEHAVIOUR AFTER INJECTION OF 
CHOLINOMIMETICS, ANTICHOLINESTERASES, NICOTINIC, AND 
MUSCARINIC GANGLIONIC STIMULANTS INTO THE CEREBRAL 
VENTRICLES OF CONSCIOUS CATS: FAILURE OF NICOTINIC-DRUGS TO 
EVOKE AGGRESSION 

001568 02-04 
THE PHARMACOLOGY OF AGGRESSIVE-BEHAVIOURAL-PHENOMENA 

ELICITED BY MUSCARINE INJECTED INTO THE CEREBRAL VENTRICLES OF 
CONSCIOUS CATS. 

001569 02-04 
CEREBRAL VENTRICLES AND DOPAMINE IN SCHIZOPHRENIA. 

(UNPUBLISHED PAPER). 

001928 02-08 
THE EFFECT OF BETA-ADRENERGIC-RECEPTOR BLOCKING-DRUGS ON 
CEREBRAL BLOOD FLOW IN HYPERTENSIVE-PATIENTS. 

002071 02-10 
CEREBRAL SENESCENCE AND ITS PSYCHIC-MANIFESTATIONS. THE 
EFFECTIVENESS OF DEBRUMYL. 

002105 02-11 
LSD-INDUCED ULTRASTRUCTURAL MODIFICATIONS OF LIMBIC-SYSTEM 
NUCLEI AND OTHER CEREBRAL ZONES. 

002198 02-12 
REGIONAL CEREBRAL BLOOD FLOW IN A CASE OF AMPHETAMINE 
INTOXICATION. 

002210 02-13 
HEMODYNAMIC AND CEREBRAL METABOLIC-STUDY OF DIAZEPAM IN 
NEUROSURGICAL-RESUSCITATION. 

002231 02-13 
CORRECTION BY PROPRANOLOL OF THE ABNORMAL ADRENALINE 
DISCHARGE INDUCED BY EMOTIONAL-STRESS IN CEREBRAL 
HEMORRHAGE PATIENTS. 

002295 02-13 
CHANGES IN CEREBRAL DOPAMINE METABOLISM AND RECEPTORS 
DURING ONE- YEAR NEUROLEPTIC ADMINISTRATION AND SUBSEQUENT 
WITHDRAWAL: RELEVANCE TO BRAIN-BIOCHEMISTRY IN 
SCHIZOPHRENIA. 

002390 02-15 
A SPECIFIC AND SENSITIVE MICROASSAY FOR HYDROXYINDOLES IN 
BIOLOGICAL-MATERIAL - APPLICATION FOR CEREBRAL MICROVESSELS, 
BRAIN, AND PINEAL-ORGAN OF THE RAT. 

002503 02-16 
PURSUING THE ACTIONS OF PSYCHOTROPIC-DRUGS: RECEPTOR SITES 
AND ENDOGENOUS CEREBRAL PROGRAMMES. 

002578 02-17 
NOREPINEPHRINE DEPLETION ALTERS CEREBRAL OXIDATIVE METABOLISM 
IN THE ACTIVE STATE. 

002798 03-03 
PHENOTHIAZINE ACTION ON CEREBRAL 5 HYDROXYTRYPTAMINE. 

002850 03-03 
LONG-ACTING ANTIPSYCHOTIC-DRUGS AND CEREBRAL 5 

HYDROXYTRYPTAMINE. 

002851 03-03 



Hi 



51:: 









S-83 



'<■:<■•.:■ 



Subject Index 

NOREPINEPHRINE AND DOPAMINE CEREBRAL LEVELS AFTER CHRONIC- 
TREATMENT WITH NOMIFENSINE. 

002872 03-03 
DECREASED CEREBRAL CATABOLISM OF (3H)HISTAMINE IN VIVO AFTER S 
ADENOSYLMETHIONINE ADMINISTRATION . 

002883 03-03 
THE EFFECTS OF INJECTIONS OF BOMBESIN INTO THE CEREBRAL 
VENTRICLES ON BEHAVIORAL THERMOREGULATION. 

002952 03-04 
DOSAGE OF INTRATUMORAL LITHIUM (CEREBRAL GLIOBLASTOMA): ON A 
FAILURE OF TREATMENT OF MANIC-DEPRESSIVE-PSYCHOSIS. 

003226 03-09 
CEREBRAL EVOKED-POTENTIAL CHANGES PRODUCED BY TREATMENT 
WITH LITHIUM-CARBONATE. 

003263 03-09 
CAPACITIES OF ATTENTION, STRESS-RESISTANCE, AND SLOW CEREBRAL 
POTENTIALS: EFFECTS OF CARPIPRAMINE ON CONTINGENT NEGATIVE 
VARIATION WAVES AND P-300. 

003451 03-14 
ACUTE PHARMACOTOXIC PSYCHOSES IN CHRONIC CEREBRAL 
CONDITIONS. 

003475 03-15 

ACTION OF 4 AMINOPYRIDINE ON THE CEREBRAL CIRCULATION. 

003781 04-03 
NA-GAMMA-HYDROXYBUTYRATE IN CEREBRAL PROTECTION DURING 
SEVERE HYPOXEMIA IN THE RAT. 

003895 04-03 
ALTERATIONS IN DIHYDROMORPHINE BINDING IN CEREBRAL 
HEMISPHERES OF AGED MALE RATS. 

003936 04-03 
THE EFFECT OF DIBENZAZEPINES (TRICYCLIC-ANTIDEPRESSANTS) ON 
CEREBRAL CAPILLARY PERMEABILITY IN THE RAT IN VIVO. 

003974 04-03 
DRUG-INDUCED CHANGES IN THE COMPOSITION OF THE CEREBRAL FREE 
AMINO-ACID POOL. 

004039 04-03 
CLASSICAL NEUROLEPTICS AND DECONDITIONING ACTIVITY AFTER SINGLE 
OR REPEATED TREATMENTS: ROLE OF DIFFERENT CEREBRAL 
NEUROTRANSMITTERS. 

004115 04-04 
EFFECTS OF A SINGLE-THERAPEUTIC-DOSE OF GLYCEROL ON CEREBRAL 
METABOLISM IN THE BRAINS OF YOUNG MICE: POSSIBLE INCREASE IN 
BRAIN GLUCOSE TRANSPORT AND GLUCOSE UTILIZATION 

004281 04-05 
PECULIARITIES OF THE CEREBRAL PATHOMORPHOLOGY OF PATIENTS 
WITH SCHIZOPHRENIA TREATED WITH PSYCHOTROPIC-DRUGS 
(PHARMACOLOGICAL PATHOMORPHOSIS) 

004528 04-13 
CEREBRAL FLUORIDE IN MAHiA AND THE EFFECT OF LITHIUM: A 
HYPOTHESIS. 

004715 04-17 

CEREBRAL-ARTERIES 

REACTIVITY OF ISOLATED CANINE CEREBRAL-ARTERIES TO ADENINE- 
NUCLEOTIDES AND ADENOSINE. 

000210 01-03 
RESPONSIVENESS TO VASOACTIVE-AGENTS OF CEREBRAL-ARTERIES AND 
MESENTERIC-ARTERIES ISOLATED FROM CONTROL AND RESERPINE 
TREATED DOGS. 

001273 02-03 
INDIRECT ADRENERGIC EFFECT OF HISTAMINE IN CAT CEREBRAL- 
ARTERIES. 

001355 02-03 

CEREBRAL-ARTERY 

RELEASE OF ENDOGENOUS NOREPINEPHRINE FROM A RABBIT CEREBRAL- 
ARTERY. 

000079 01-03 
DIRECT EVIDENCE AGAINST ACETYLCHOLINE AS THE DILATOR 
TRANSMIHER IN THE CAT CEREBRAL-ARTERY. 

001336 02-03 
CEREBRAL-CORTEX 

FUNCTIONAL HYPERINNERVATION OF CEREBRAL-CORTEX BY 

NORADRENERGIC NEURONS RESULTS FROM FETAL LESIONS: PARALLELS 
WITH SCHIZOPHRENIA. 

000059 01-03 
THE EFFECT OF PSYCHOTROPIC-SUBSTANCES AND NARCOTIC ANALGESIC- 
DRUGS ON 14C NORADRENALINE UPTAKE BY SYNAPTOSOMES OF THE 
CEREBRAL-CORTEX OF RATS. 

001363 02-03 
OPIATE-RECEPTOR GRADIENTS IN MONKEY CEREBRAL-CORTEX: 
CORRESPONDENCE WITH SENSORY PROCESSING HIERARCHIES. 

002641 03-01 
DEMONSTRATION AND CHARAQERIZATION OF AN ENDOGENOUS 
INHIBITOR OF GABA-ENHANCED (3H) DIAZEPAM BINDING FROM 
BOVINE CEREBRAL-CORTEX. 

002645 03-01 
METHYLXANTHINES MODULATE ADENOSINE RELEASE FROM SLICES OF 
CEREBRAL-CORTEX. 

002907 03-03 



Psychopharmacology Abstracts 

ABNORMAL MATURATION OF CEREBRAL-CORTEX AND BEHAVIORAL- 
DEFICIT IN ADULT RATS AFTER NEONATAL ADMINISTRATION OF 
ANTIBODIES TO GANGLIOSIDE. 

003025 03-04 
THE EFFECT OF NOOTROPIL ON THE TRANSCALLOSAL AND PRIMARY 
EVOKED-RESPONSES OF THE CAT CEREBRAL-CORTEX. 

003780 04-03 
REGULATION OF ALPHAl -ADRENOCEPTORS IN THE CEREBRAL-CORTEX OF 
THE RAT BY THYROID-HORMONES 

003816 04-03 
STIMULATION OF FRUCTOSEBIPHOSPHATASE AQIVITY AND SYNTHESIS 
IN THE CEREBRAL-CORTEX OF RATS SUBMIHED TO THE CONVULSANT 
METHIONINE-SULFOXIMINE. 

003838 04-03 
THE EFFECT OF PSYCHOSTIMULANTS ON CHANGES IN THE EXCITABILITY 
OF THE VISUAL CEREBRAL-CORTEX. 

003919 04-03 
GUANYLATE-CYCLASE ~ CYCLIC-GMP IN MOUSE CEREBRAL-CORTEX AND 
CEREBELLUM: MODIFICATION BY ANTICONVULSANTS. 

003956 04-03 
CATECHOLAMINE MODULATION OF ENKEPHALIN-INDUCED 

ELECTROPHYSIOLOGICAL RESPONSES IN CEREBRAL-CORTEX 

003957 04-03 
CEREBRAL-PALSIED-CHILD 

BEHAVIORAL-INTERVENTION FOR SELF- STIMULATORY, AHENDING AND 
SEIZURE BEHAVIOR IN A CEREBRAL-PALSIED-CHILD. 

002104 02-11 
CEREBROARTERIAL 

INHIBITION OF NEUROSYMPATHETIC CEREBROARTERIAL CONSTRIQION 
BY CLONIDINE IN CATS. 

001431 02-03 
CEREBROCORTICAL 

EFFEQS OF HALOPEMIDE ON POTASSIUM-INDUCED RELEASE OF 

RADIOLABELED NEUROTRANSMIHERS FROM RAT CEREBROCORTICAL 
SLICES IN VITRO. 

001347 02-03 
THE EFFECTS OF THYROTROPIN-RELEASING-HORMONE ON CYCLIC-AMP 
ACCUMULATION IN RABBIT CEREBROCORTICAL TISSUE IN THE 
PRESENCE AND ABSENCE OF CNS DEPRESSANTS. 

004010 04-03 
CEREBROSPINAL-FLUID 

ENTRY OF DIAZEPAM AND ITS MAJOR METABOLITE INTO 
CEREBROSPINAL-FLUID. 

000114 01-03 
PATHOPHYSIOLOGICAL- STUDIES ON SCHIZOPHRENIA WITH SPECIAL 
REFERENCE TO HOMOVANILLIC-ACID CONCENTRATION IN 
CEREBROSPINAL-FLUID 

000271 01-03 
GABA LEVELS IN HUMAN CEREBROSPINAL-FLUID: ALTERATIONS IN 
PSYCHIATRIC-DISORDERS (UNPUBLISHED PAPER). 

000764 01-13 
THE EFFECT OF EMOTIONAL-STRESS AND DIAZEPAM ON MONOAMINE 
METABOLITES IN THE CEREBROSPINAL-FLUID OF CATS. (PH.D. 
DISSERTATION). 

001260 02-03 
DIFFERENTIAL-EFFECTS OF VARIOUS STIMULI ON AVP LEVELS IN BLOOD 
AND CEREBROSPINAL-FLUID 

001370 02-03 
EFFECTS OF TIAPRIOE ON HOMOVANILLIC-ACID LEVELS IN HUMAN 
CEREBROSPINAL-FLUID DRAWN AT PNEUMOENCEPHALOGRAPHY. 

001483 02-03 
QUICKLY-MADE CANNULA FOR REPEATED CEREBROSPINAL-FLUID 
SAMPLING IN RATS 

001879 02-06 

REL^TIONSHIPS BETWEEN CHLORPROMAZINE CONCENTRATIONS IN 
PUVSMA AND CEREBROSPINAL-FLUID AND CLINICAL-RESPONSE AND 
BIOCHEMICAL-RESPONSE IN PSYCHOTIC-PATIENTS. 

001905 02-08 
CONCENTRATION OF SEROTONIN METABOLITES IN THE CEREBROSPINAL- 
FLUID FROM ALCOHOLICS BEFORE AND DURING SULFIRAM THERAPY. 

002095 02-11 
CEREBROSPINAL-FLUID GABA IN PSYCHOTIC-DISORDERS. 

002097 02-11 
A BIOCHEMICAL- STUDY OF LUMBAR CEREBROSPINAL-FLUID IN 
EXTRAPYRAMIDAL-DISORDERS. 

002186 02-11 
METHOD FOR THE DETERMINATION OF TRYPTOPHAN IN SERUM AND 

CEREBROSPINAL-FLUID. ^ „ ^^ ,, 

002208 02-13 
IMMUNOREAQIVE CALCITONIN IN CEREBROSPINAL-FLUID OF MAN. 

002637 03-01 
EVIDENCE FOR THE PRESENCE OF TWO TYPES OF MONOAMINE-OXIDASE 
IN RABBIT CHOROID PLEXUS AND THEIR ROLE IN BREAKDOWN OF 
AMINES INFLUENCING CEREBROSPINAL-FLUID FORMATION. 

002807 03-03 
BETA ENDORPHIN LEVELS IN THE CEREBROSPINAL-FLUID OF 

SCHIZOPHRENICS. „„„,,, „o«t 

003176 03-OE 



S-84 



VOLUME 19, SUBJECT INDEX 



Subject Index 



CORRELATIONS BETWEEN LITHIUM LEVELS IN CEREBROSPINAL-FLUID AND 
LITHIUM LEVELS IN BLOOD PLASMA AND ERYTHROCYTES 

003210 03-09 
LEVELS OF 5 HYDROXYINDOLEACETIC-ACID AND TRYPTOPHAN IN 
LUMBAR CEREBROSPINAL-FLUID AND BLOOD OF PATIENTS WITH 
DEMENTIA AND NORMAL PRESSURE HYDROCEPHALUS AFTER 
TRYPTOPHAN ADMINISTRATION. 

003419 03-13 
DOPAMINE CONJUGATE IN CEREBROSPINAL-FLUID. 

003432 03-13 
HUMAN BRAIN, PLASMA, AND CEREBROSPINAL-FLUID CONCENTRATION 

OF SODIUM-VALPROATE AFTER 72 HOURS OF THERAPY. 

003433 03-13 
ALTERATIONS IN CEREBROSPINAL-FLUID DOPAMINE METABOLITES 

FOLLOWING PHYSOSTIGMINE INFUSION 

003477 03-15 
CEREBROSPINAL-FLUID CONCENTRATIONS OF THIORIDAZINE AND ITS 
MAIN METABOLITES IN PSYCHIATRIC-PATIENTS. 

003569 03-16 
A SELECTED ION-MONITORING ASSAY FOR BIOGENIC-AMINE 
METABOLITES AND PROBENECID, IN HUMAN LUMBAR 
CEREBROSPINAL-FLUID. 

003663 04-01 
QUANTITATION AND COMPARISON OF PHENOBARBITAL LEVELS IN THE 
PLASMA, SALIVA, AND CEREBROSPINAL-FLUID OF THE RAT, AND THE 
DEMONSTRATION OF AN ALTERATION OF DRUG PASSAGE BY 
ETHANOL. 

003725 04-03 
KINETIC STUDIES ON THE ENTRY OF D-AMPHETAMINE INTO THE 
CENTRAL-NERVOUS-SYSTEM: I. CEREBROSPINAL-FLUID. 

004005 04-03 
THE DYNAMICS OF SYSTEMIC VENOUS, ARTERIAL, AND CEREBROSPINAL- 
FLUID PRESSURE UNDER I.V. ADMINISTRATION OF POLYETHYLENE- 
GLYCOL. 

004045 04-03 
PROTEIN BINDING OF CHLORPROMAZINE IN CEREBROSPINAL-FLUID AND 
SERUM. 

004311 04-08 
CEREBROSPINAL-FLUID VALUES OF HVA AND 5 HIAA IN PATIENTS WITH 
ENDOGENOUS DEPRESSION DURING THE COURSE OF TREATMENT. 

004382 04-09 
CEREBROSPINAL-FLUID HOMOVANILLIC-ACID PATTERNS DURING 
NEUROLEPTIC TREATMENT. (UNPUBLISHED PAPER). 

004502 04-13 
CONCENTRATIONS OF CHLORPROMAZINE AND TWO OF ITS ACTIVE 
METABOLITES IN PLASMA AND CEREBROSPINAL-FLUID OF PSYCHOTIC- 
PATIENTS TREATED WITH FIXED DRUG DOSES. 

004559 04-13 
CEREBROVASCULAR-ACCIDENTS 

EFFECTS OF CYCLOSPASMOL UPON SENSORY PARAMETERS IN PATIENTS 
RECOVERING FROM CEREBROVASCULAR-ACCIDENTS. 

002360 02-14 
CEREBROVASCULAR-DISEASES 

THERAPEUTIC TREATMENT OF INSUFFICIENT PERFORMANCE IN 
CEREBROVASCULAR-DISEASES . 

004718 04-17 
CESIUM 
CESIUM. 

001090 02-02 
DISTRIBUTION OF CESIUM IN THE ORGANISM AND ITS EFFECT ON THE 
NUCLEOTIDE METABOLISM ENZYMES. 

003696 04-02 
CESSATION 

SEVERE WITHDRAWAL-SYNDROME AFTER CESSATION OF 
BENZODIAZEPINE TREATMENT. SIX CLINICAL CASES. 

003505 03-15 
THE EFFECT OF SMALL DOSES OF HALOPERIDOL AND CLOZAPINE ON 
BEHAVIORAL SHIFTS IN CATS, ARISING AFTER CESSATION OF 
ELECTRICAL- STIMULATION OF THE CAUDATE-NUCLEUS. 

004067 04-04 
THE EFFECT OF AN INTENSIVE COURSE OF NEUROLEPTIC-DRUGS ON 
SCHIZOPHRENIC-PATIENTS AND THEIR SUBSEQUENT COURSE 
FOLLOWING THE CESSATION OF ALL NEUROLEPTIC-MEDICATION. 

004341 04-08 
WITHDRAWAL SYMPTOMS AFTER GRADUATED CESSATION OF 
IMIPRAMINE IN CHILDREN. 

004630 04-15 
APOMORPHINE-INDUCED STEREOTYPY IN MATURE AND SENESCENT RATS 
FOLLOWING CESSATION OF CHRONIC HALOPERIDOL TREATMENT. 

004651 04-15 
CF-25-397 

TREATMENT OF DYSKINETIC AND DYSTONIC-DISORDERS WITH CF-25- 
397: CLINICAL-ASPECTS AND PHARMACOLOGICAL ASPECTS. 

002121 02-11 



CFF 



SMOKING AND VIGILANCE: THE EFFECTS OF TOBACCO SMOKING ON CFF 
AS RELATED TO PERSONALITY AND SMOKING HABITS. 

002368 02-14 



C6P-6085-A 

CGP-6085-A, A NEW, SPECIFIC, INHIBITOR OF SEROTONIN UPTAKE: 
NEUROCHEMICAL CHARACTERIZATION AND COMPARISON WITH OTHER 
SEROTONIN UPTAKE BLOCKERS 

000316 01-03 
CH-757 

PHARMACOKINETIC-STUDY IN MAN OF THE CH-757 PREPARATION. 

004440 04-11 
CHAGAS-DISEASE 

EPILEPSY AND CHRONIC CHAGAS-DISEASE. 

003328 03-11 
CHALLENGE 

PHENCYCLIDINE-HCL: A CHALLENGE TO MEDICINE. 

003395 03-12 
NEUROENDOCRINE-TESTS DURING TREATMENT WITH NEUROLEPTIC- 
DRUGS: I. PLASMA PROLACTIN RESPONSE TO CHLORPROMAZINE 
CHALLENGE 

004329 04-08 
CHALLENGE-DOSE 

THE EFFECT OF THIORIDAZINE ON PROLACTIN LEVELS IN ACUTELY 
SCHIZOPHRENIC-PATIENTS: CHALLENGE-DOSE AND STEADY-STATE 
LEVELS. 

000558 01-08 
CHALLENGES 

MORPHINE CHALLENGES IN LEVO ALPHA ACETYLMETHADOL (LAAM) 
POSTADDICT RATS. 

004259 04-04 
CLINICAL DEPRESSIONS: DIAGNOSTIC AND THERAPEUTIC CHALLENGES. 

004350 04-09 
CHANCES 

SOME WAYS TO INCREASE CHANCES TO DISCOVER THE CNS DRUGS OF 
THE FUTURE. 

002528 02-17 
CHANGE 

A STUDY OF THE QUANTAL (ALL-OR-NONE) CHANGE IN REFLEX LATENCY 
PRODUCED BY OPIATE ANALGESICS. 

000425 01-04 
HOW TO SUCCESSFULLY CHANGE A PATIENT FROM ONE DRUG TO 
ANOTHER. 

000913 01-17 
CHANGE IN PYRUVATE-DEHYDROGENASE ACTIVITY INFLUENCE PYRUVATE 
SUPPORTED CALCIUM ACCUMULATION BY BRAIN MITOCHONDRIA. 
(UNPUBLISHED PAPER). 

001147 02-03 
LONG-TERM HALOPERIDOL TREATMENT OF MICE: A CHANGE IN BETA- 
ADRENERGIC-RECEPTOR RESPONSIVENESS. 

001206 02-03 
TRYPTOPHOL-INDUCED CHANGE IN BRAIN 5 HYDROXYTRYPTAMINE 
METABOLISM. 

001236 02-03 
EEG CHANGE IN THE CONSCIOUS RAT DURING IMMOBILITY INDUCED BY 
PSYCHOLOGICAL-STRESS. 

001297 02-03 
CHANGE IN OVERINCLUSIVE THINKING OF SCHIZOPHRENIC-PATIENTS IS 
RELATED TO PLASMA PHENOTHIAZINE CONCENTRATION. 

001941 02-08 
THERAPEUTIC RESULTS IN A PSYCHOGERIATRIC-WARD AFTER CHANGE OF 
MEDICATION. 

002136 02-11 
THE CHANGE OF BLOOD PROLACTIN LEVEL DUE TO THE WITHDRAWAL OF 
MAINTENANCE NEUROLEPTICS. 

002559 02-17 
CHANGE IN CATECHOLAMINE SENSITIVE NA-K-ATPASE ACTIVITY IN THE 
RAT STRIATUM MICROSOMES FOLLOWING ELECTROLYTIC OR 6 
HYDROXYDOPAMINE-INDUCED LESIONS OF DOPAMINERGIC NEURONS. 

003871 04-03 
SCHEDULE DEPENDENT CHANGE OF PUNISHED-RESPONDING AFTER 
DIAZEPAM IN RATS. 

004165 04-04 
ELECTROENCEPHALOGRAPHIC CHANGE IN PARKINSONIAN-PATIENTS 
TREATED WITH LEVODOPA CARBIDOPA. 

004557 04-13 
CHANGES 

ACUTE CHANGES IN BRAIN TRYPTOPHAN AND SEROTONIN FOLLOWING 
CARBOHYDRATE OR PROTEIN INGESTION BY DIABETIC RATS. 
(UNPUBLISHED PAPER). 

000060 01-03 
AGONIST-INDUCED CHANGES IN BETA-ADRENERGIC-RECEPTOR DENSITY 
AND RECEPTOR-MEDIATED RESPONSIVENESS IN SLICES OF RAT- 
CEREBRAL-CORTEX. 

000072 01-03 
CHANGES IN PLASMA CORTICOSTERONE LEVELS AS A MEASURE OF 
ACUTE DEPENDENCE UPON LEVORPHANOL IN RATS. 

000085 01-03 
CHANGES OF ACTH, STH, TSH AND PROLACTIN LEVELS IN ENDOTOXIN 
SHOCK IN RATS. 

000119 01-03 



I 

a. 



Si: 









S-85 



Subject Index 



Psychopharmacology Abstracts 



THE EFFECT OF DIAZEPAM ON EEG CHANGES FOLLOWING INTRASEPTAL 
ADMINISTRATION OF ATROPINE. 

000127 01-03 
CORTICAL NEUROCHEMICAL CHANGES AFTER INTRASTRIATAL INJECTION 
OF KAINIC-ACID. 

000133 01-03 
EFFECTS OF CHANGES IN THE STRUCTURE OF ENKEPHALINS AND OF 
NARCOTIC ANALGESIC-DRUGS ON THEIR INTERAQIONS WITH MU- 
RECEPTORS AND DELTA-RECEPTORS 

000168 01-03 
THE EFFECT OF ANTIDEPRESSANTS ON L 5 HTP-INDUCED CHANGES IN RAT 
PLASMA CORTICOSTEROIDS. 

000170 01-03 
CHANGES IN PRIMARY AFFERENT DEPOLARIZATION AFTER 
ADMINISTRATION OF GAMMA ACETYLENIC-GAMMA-AMINOBUTYRIC- 
ACID (GAG), A GAMMA AMINOBUTYRIC-ACID-TRANSAMINASE 
(GABA-TRANSAMINASE) INHIBITOR. 

000174 01-03 
AGE-RELATED ELECTROPHYSIOLOGICAL CHANGES IN RAT-CEREBELLUM 

000197 01-03 
CHANGES IN MOUSE-BRAIN DIAZEPAM-RECEPTOR BINDING AFTER 
PHENOBARBITAL ADMINISTRATION. 

000281 01-03 
CHANGES IN OPIATE ACTIVITY OF RAT PITUITARY FOLLOWING ACUTE 

ADMINISTRATION OF NEUROLEPTICS. 

000282 01-03 
CHANGES IN BRAIN N DEMETHYLATION AND OPIATE-RECEPTOR CONTENT 

CORRELATE WITH ANALGESIC EFFECTIVENESS OF MORPHINE. 

000400 01-04 
BRAINSTEM AUDITORY EVOKED-POTENTIALS AND MYELIN CHANGES IN 
TRIETHYLTIN-INDUCED EDEMA IN YOUNG ADULT RATS. 

000509 01-05 
BRAIN FUNCTION IN OLD-AGE: EVALUATION OF CHANGES AND 
DISORDERS. 

000684 01-11 
PROLACTIN CHANGES IN MAJOR DEPRESSIVE-DISORDERS 

000752 01-13 
THE ULTRASTRUCTURAL CHANGES OF SYNAPSES IN RAT FOLLOWING 
LONG-TERM ADMINISTRATION OF THE NEUROLEPTICS RESERPINE AND 
HALOPERIDOL 

000795 01-13 
PHARMACOPSYCHOLOGICAL INVESTIGATION OF CHANGES IN MOOD 
INDUCED BY DIPOTASSIUM-CHLORAZEPATE WITH AND WITHOUT 
SIMULTANEOUS ALCOHOL ADMINISTRATION 

000825 01-14 
NEUROLOGICAL SIDE-EFFECTS OF LITHIUM: ORGANIC-BRAIN-SYNDROME, 
SEIZURES, EXTRAPYRAMIDAL SIDE-EFFECTS, AND EEG CHANGES 

000847 01-15 
ENDOCRINOLOGICAL CHANGES IN PATIENTS WITH SEXUAL-DYSFUNCTION 
UNDER LONG-TERM NEUROLEPTIC TREATMENT 

000912 01-17 
DISEASE-INDUCED CHANGES IN THE PLASMA BINDING OF BASIC DRUGS. 

000975 01-17 
INFERENTIAL CHANGES AFTER CHRONIC-TREATMENTS WITH LI, DMI, OR 
ETHANOL DETECTED BY ELECTROPHYSIOLOGICAL-CORRELATES. 

001136 02-03 
ADAPTIVE CHANGES OF THE STRIATAL DOPAMINE SYSTEM INDUCED BY 
REPEATED ADMINISTRATION OF NEUROLEPTICS AND ERGOT 
DERIVATIVES. 

001156 02-03 
CHANGES IN CEREBRAL DOPAMINE FUNCTION INDUCED BY A YEARS 
ADMINISTRATION OF TRIFLUOPERAZINE OR THIORIDAZINE AND THEIR 
SUBSEQUENT WITHDRAWAL. 

001175 02-03 
EVOKED-POTENTIAL CHANGES IN THE SUPERIOR-COLLICULUS PARALLEL 
THE LESION-INDUCED DEVELOPMENT OF GROOMING REFLEXES IN THE 
CAT. (PH.D. DISSERTATION) 

001179 02-03 
DOSE-DEPENDENT, AMPHETAMINE-INDUCED CHANGES IN PERMEABILITY 
OF THE BLOOD-BRAIN-BARRIER OF NORMOTENSIVE-RATS AND 
SPONTANEOUSLY HYPERTENSIVE-RATS. 

001197 02-03 
EFFECT OF PYRITINOL AND PIRACETAM ON CHANGES IN FREE AMMONIA 
LEVEL IN CNS TISSUE AFTER PARADOXICAL SLEEP-DEPRIVATION IN 
RATS. 

001199 02-03 
EFFECT OF LITHIUM ON STRESS-INDUCED CHANGES IN THE BRAIN LEVELS 
OF MONOAMINES IN RATS. 

001216 02-03 
LITHIUM-INDUCED CHANGES IN THE BRAIN LEVELS OF FREE AMINO-ACIDS 

IN STRESS-EXPOSED RATS 

001217 02-03 
EFFECT OF MOXESTROL ON HALOPERIDOL-INDUCED CHANGES IN 

STRIATAL ACETYLCHOLINE LEVELS AND DOPAMINE TURNOVER 

001218 02-03 
THE QUANTITATIVE MEASUREMENT OF CHANGES IN EEG FREQUENCY 

SPECTRA PRODUCED IN THE CAT BY SEDATIVE HYPNOTICS AND 
NEUROLEPTICS. 

001220 02-03 



CHANGES IN ALPHA-ADRENERGIC-RECEPTORS IN RAT-BRAIN IN VITRO BY 
PREINCUBATION WITH ALPHA-ADRENERGIC LIGANDS. 

001272 02-03 
AGE-RELATED CHANGES IN BODY-TEMPERATURE RESPONSES TO 
MORPHINE IN RATS. 

001366 02-03 
ROLE OF BRAIN CATECHOLAMINES AND 5 HYDROXYTRYPTAMINE IN 
MORPHINE-INDUCED TEMPERATURE CHANGES IN NORMAL AND 
TOLERANT RATS AND MICE. 

001476 02-03 
IN VIVO CHANGES IN THE GABA CONTENT OF NERVE-ENDINGS 
(SYNAPTOSOMES) INDUCED BY INHIBITORS OF GABA UPTAKE. 

001540 02-03 
NEUROPHARMACOLOGICAL-AGENTS MODIFYING ENDOTOXIN-INDUCED 
CHANGES IN MICE. 

001543 02-03 
DENERVATION IN THE DOPAMINERGIC MESOLIMBIC SYSTEM: 
FUNCTIONAL CHANGES FOLLOWED USING (-)N N 
PROPYLNORAPOMORPHINE DEPEND ON THE BASAL AQIVITY LEVELS 
OF RATS. 

001603 02-04 
CHANGES OF PHYSICAL MORPHINE-DEPENDENCE IN RATS CHRONICALLY 
TREATED WITH DRUGS ACTING ON BRAIN 5 HYDROXYTRYPTAMINE. 

001764 02-04 
REGIONAL CHANGES IN BRAIN GLUCOSE UTILIZATION IN RATS GIVEN A 
PYRETHROID INSEQICIDE. 

001838 02-05 
LONG-TERM CHLORPROMAZINE IN RHESUS-MONKEYS: PRODUQION OF 
DYSKINESIAS AND CHANGES IN SOCIAL-BEHAVIOR. 

001850 02-05 
TIME-COURSE OF THE ANTIPSYCHOTIC-EFFECT IN SCHIZOPHRENIA AND 
SOME CHANGES IN POSTMORTEM BRAIN AND THEIR RELATION TO 
NEUROLEPTIC-MEDICATION. 

001911 02-08 
CLINICAL AND EEG CHANGES IN DEPRESSIVE-PATIENTS AFTER A SINGLE 
INJECTION OF BETA ENDORPHIN 

001962 02-09 
EEG CHANGES IN CHILDREN WITH TREATED PHENYLKETONURIA AFTER 
PHENYLALANINE LOAD. 

002115 02-11 
ENDOCRINE CHANGES AND BEHAVIORAL-CHANGES IN DEPRESSION AFTER 
THYROTROPIN-RELEASING-HORMONE (TRH): ALTERATION BY 
PRETREATMENT WITH THYROID-HORMONES. 

002259 02-13 
INTERRELATION AT PLASMATIC LEVEL BETWEEN ANTIEPILEPTIC-DRUGS 
AND LIPIDS ITS IMPLICATIONS IN THE EFFICIENCY OF TREATMENT IN 
EPILEPSY I. CHANGES INDUCED BY PHENOBARBITAL OR/AND 
DIPHENYLHYDANTOIN IN SERUM LIPIDS 

002281 02-13 
CHANGES IN THE AUGMENTER REDUCER TENDENCY AND IN PAIN 
MEASURES AS A RESULT OF TREATMENT WITH A SEROTONIN 
REUPTAKE INHIBITOR ZIMELIDINE. 

002305 02-13 
CHANGES IN CEREBRAL DOPAMINE METABOLISM AND RECEPTORS 
DURING ONE-YEAR NEUROLEPTIC ADMINISTRATION AND SUBSEQUENT 
WITHDRAWAL: RELEVANCE TO BRAIN-BIOCHEMISTRY IN 
SCHIZOPHRENIA. 

002390 02-15 
ON THE MEASUREMENT IN RATS OF THE CONVULSANT-EFFEQ OF DRUGS 
AND THE CHANGES WHICH FOLLOW ELECTROCONVULSIVE-SHOCK 

002444 02-15 
CHANGES IN PREVALENCE, SEVERITY, AND RECOVERY IN TARDIVE- 
DYSKINESIA WITH AGE 

002455 02-15 
CHANGES IN BODY-TEMPERATURE AFTER ADMINISTRATION OF 
ADRENERGIC AND SEROTONERGIC-AGENTS AND RELATED DRUGS 
INCLUDING ANTIDEPRESSANTS. 

002532 02-17 

AGE DEPENDENT CHANGES IN THE BETA ENDORPHIN CONTENT OF 
DISCRETE RAT-BRAIN NUCLEI 

002635 03-01 
MORPHOLOGICAL CHANGES IN RAT-BRAIN INDUCED BY L CYSTEINE 
INJECTION IN NEWBORN ANIMALS. 

002774 03-03 
CHANGES IN THE CORTICAL AQIVITY OF SUCCINATE-DEHYDROGENASE 
UNDER THE INFLUENCE OF CHLORPROMAZINE (A HISTOCHEMICAL- 
STUDY AND ELECTROCYTOCHEMICAL- STUDY). 

002784 03-03 
ENHANCEMENT OF ETORPHINE BRAIN CONCENTRATIONS AND CHANGES 
IN ETORPHINE NALOXONE PA2 VALUES IN MORPHINE PRETREATED 

'^""^ 002800 03-03 

LACK OF CORRELATION BETWEEN NALOXONE-INDUCED CHANGES IN 
SEXUAL-BEHAVIOR AND SERUM LH IN MALE RATS 

002821 03-03 
CHANGES IN NORADRENERGIC TRANSMISSION ALTER THE 
CONCENTRATION OF CYTOPLASMIC PROGESTIN-RECEPTORS IN 
HYPOTHALAMUS. 

002842 03-03 



S-86 



VOLUME 19, SUBJECT INDEX 



Subject Index 



CHANGES IN THE HORIZONTAL VESTIBULO-OCULAR REFLEX OF THE 
RHESUS-MONKEY WITH BEHAVIORAL AND PHARMACOLOGICAL 
ALERTING 

002997 03-04 
AN ANALYSIS OF SPECIFICITY OF DRUG-INDUCED CHANGES IN DRUG- 
REINFORCED RESPONDING. (PHD, DISSERTATION). 

003010 03-04 
CYCLIC-AMP-INDUCED CHANGES IN THE ELECTROENCEPHALOGRAM AND 
IN BEHAVIOR DURING MORPHINE-DEPENDENCE AND ABSTINENCE IN 
THE RAT 

003078 03-04 
ELECTROPHYSIOLOGIC ASSESSMENT OF RECEPTOR CHANGES FOLLOWING 
CHRONIC DRUG-TREATMENT, 

003136 03-06 
CEREBRAL EVOKED-POTENTIAL CHANGES PRODUCED BY TREATMENT 
WITH LITHIUM-CARBONATE 

003263 03-09 
CHANGES IN THE PSYCHOPATHOLOGY OF PSYCHOSIS DUE TO 
NEUROLEPTIC TREATMENT. 

003281 03-10 
PSYCHOTROPIC-DRUG-INDUCED CHANGES IN AUDITORY AVERAGED 
EVOKED-POTENTIALS: RESULTS OF A DOUBLE-BLIND TRIAL USING AN 
OBJECTIVE FULLY AUTOMATED AEP ANALYSIS METHOD. 

003412 03-13 
INTRAOCULAR PRESSURE CHANGES FOLLOWING MODIFIED ECT. 

003536 03-15 
LONG-TERM CHANGES IN AIMS RATINGS AND THEIR RELATION TO 

MEDICATION HISTORY. 

003537 03-15 
CHANGES IN AND CURRENT PROGRESS OF NEUROLOGY AND 

PSYCHIATRY. 

003550 03-15 
SELF-STIMULATION AND LOCOMOTOR CHANGES INDICATING LATENT 
ANTICHOLINERGIC-ACTIVITY BY AN ATYPICAL NEUROLEPTIC 
(THIORIDAZINE). 

003560 03-16 
BRAIN BENZODIAZEPINE-RECEPTORS AND THEIR RAPID CHANGES AFTER 
SEIZURES IN THE MONGOLIAN-GERBIL. 

003717 04-03 
ETHANOL-INDUCED CHANGES IN CYCLIC-GUANOSINE-PHOSPHATE 
METABOLISM IN MOUSE VESTIBULAR REGION. 

003784 04-03 
CHANGES OF ELECTRORETINOGRAM AND NEUROCHEMICAL ASPECTS OF 
GABAERGIC NEURONS OF RETINA AFTER INTRAOCULAR INJECTION OF 
KAINIC-ACID IN RATS. 

003807 04-03 
REGIONAL CHANGES IN (3H)DIAZEPAM BINDING IN THE BRAINS OF MICE 
AFTER REMOVAL OF THE OLFACTORY-BULBS. 

003844 04-03 
CHANGES IN GAMMA AMINOBUTYRIC-ACID SHUNT ENZYMES IN 
REGIONS OF RAT-BRAIN WITH KETAMINE ANESTHESIA. 

003891 04-03 
THE EFFECT OF PSYCHOSTIMULANTS ON CHANGES IN THE EXCITABILITY 
OF THE VISUAL CEREBRAL-CORTEX. 

003919 04-03 
EFFECT OF DIAZEPAM ON STRESS-INDUCED CHANGES IN BRAIN 
HISTAMINE. 

003932 04-03 
CHANGES IN REGIONAL BRAIN LEVELS OF AMINO-ACID PUTATIVE 
NEUROTRANSMIHERS AFTER PROLONGED TREATMENT WITH THE 
ANTICONVULSANT-DRUGS DIPHENYLHYDANTOIN, PHENOBARBITONE 
SODIUM-VALPROATE, ETHOSUXIMIDE, AND SULTHIAME IN THE RAT. 

003961 04-03 
THE EFFECT OF DIAZEPAM ON CYCLIC EXCITABILITY CHANGES IN AN 
EPILEPTIC-FOCUS IN THE CORTEX OF THE MAJOR HEMISPHERES. 

003984 04-03 
CORE TEMPERATURE CHANGES FOLLOWING ADMINISTRATION OF 
NALOXONE AND NALTREXONE TO RATS EXPOSED TO HOT AND COLD 
AMBIENT TEMPERATURES. EVIDENCE FOR THE PHYSIOLOGICAL ROLE 
OF ENDORPHINS IN HOT AND COLD ACCLIMATIZATION. 

004034 04-03 
DRUG-INDUCED CHANGES IN THE COMPOSITION OF THE CEREBRAL FREE 
AMINO-ACID POOL. 

004039 04-03 
TIME-DEPENDENT CHANGES IN ANTEROGRADE SCOPOLAMINE-INDUCED 
AMNESIA IN RATS. 

004182 04-04 
DOPAMINE-RECEPTOR CHANGES FOLLOWING DESTRUCTION OF THE 
NIGROSTRIATAL PATHWAY: LACK OF A RELATIONSHIP TO 
ROTATIONAL-BEHAVIOR. 

004229 04-04 
BETA ENDORPHIN: CENTRAL SITES OF ANALGESIA, CATALEPSY AND 
BODY-TEMPERATURE CHANGES IN RATS. 

004238 04-04 
CHANGES OF RESPONSE TO DOPAMINERGIC DRUGS IN RATS SUBMIHED 

TO REM SLEEP DEPRIVATION. 

004239 04-04 
METHYLMERCURY-INDUCED CHANGES IN OPERANT DISCRIMINATION BY 

THE PIGEON. 

004271 04-05 



CHANGES IN BLOOD PLASMA OSMOLALITY AND STATES OF MANIA 

004352 04-09 
CHANGES IN PSYCHOPATHOLOGIC SYMPTOMS DURING 20 DAYS OF 
TREATMENT WITH ANTIDEPRESSANTS AND NEUROLEPTIC-DRUGS. 

004415 04-09 
ELECTROPHYSIOLOGICAL AND PSYCHOLOGICAL CHANGES INDUCED BY 
STEROID-HORMONES IN MEN AND WOMEN. 

004500 04-13 
EVENT-RELATED POTENTIAL CHANGES WITH MORPHINE IN NONADDICTED 
HUMANS. 

004512 04-13 
PATHOPHYSIOLOGICAL AND MORPHOLOGICAL CHANGES IN THE CNS 
DURING LONG-TERM ADMINISTRATION OF HALOPERIDOL. 

004633 04-15 
DEPOT FLUPHENAZINE MAINTENANCE-TREATMENT AND ASSOCIATED 
WEIGHT CHANGES. 

004635 04-15 
CHANGES IN THE CLINICAL-PICTURE AND THE COURSE OF PSYCHOSES 
DURING MASSIVE PSYCHOPHARMACOTHERAPY AND THE 
SIGNIFICANCE OF THESE CHANGES FOR IMPROVEMENTS IN 
PSYCHIATRIC-TREATMENT. 

004699 04-17 
FLURAZEPAM-INDUCED SLEEP-APNEA- SYNDROME IN A PATIENT WITH 
INSOMNIA AND MILD SLEEP-RELATED RESPIRATORY CHANGES. 

004729 04-17 
CHARACTER 

ENKEPHALIN-LIKE CHARACTER AND ANALGESIA. 

002650 03-02 
EFFECTS OF PENTAZOCINE AND NALORPHINE ON MOTILITY IN 
CHRONICALLY MORPHINE TREATED RATS: A POTENTIAL SUBSTITUTION 
TEST TO DETECT THE NARCOTIC CHARACTER OF A DRUG. 

003555 03-16 
CHARACTER AND MEANING OF QUASI-MORPHINE WITHDRAWAL 
PHENOMENA ELICITED BY METHYLXANTHINES. 

004087 04-04 
CHARACTERISATION 

HUMAN PLATELET 5 HT-RECEPTORS: CHARACTERISATION AND 
FUNCTIONAL ASSOCIATION. 

001412 02-03 
CHARACTERISTIC 

CHARACTERISTIC HYPERPYREXIA INDUCED BY LICL AND 
TRANYLCYPROMINE IN RATS. 

004278 04-05 
CHARACTERISTICS 

CHARACTERISTICS OF 3H CIS FLUPENTHIXOL BINDING TO CALF BRAIN 
MEMBRANES. 

000062 01-03 
CHARACTERISTICS OF OSCILLATORY CONTRACTIONS ELICITED BY 
NALOXONE IN ILEUM PREPARATION FROM MORPHINE-DEPENDENT 
GUINEA-PIGS. 

001491 02-03 
THE STRIATONIGRAL GABA PATHWAY: FUNCTIONAL AND 

NEUROCHEMICAL CHARACTERISTICS IN RATS WITH UNILATERAL 
STRIATAL KAINIC-ACID LESIONS. 

001816 02-04 
BENZODIAZEPINE-RECEPTORS: THE EFFECT OF GABA ON THEIR 
CHARACTERISTICS IN HUMAN BRAIN AND THEIR ALTERATION IN 
HUNTINGTONS-DISEASE. 

002163 02-11 
PHYSICAL AND PHYSIOLOGICAL CHARACTERISTICS OF MICROPRESSURE 
EJECTION OF DRUGS FROM MULTIBARRELED PIPETTES. 

002502 02-16 
A COMPARISON OF THE CONTRACTILE RESPONSES OF THE RABBIT 
BASILAR AND PULMONARY-ARTERIES TO SYMPATHOMIMETIC 
AGONISTS: CHARACTERISTICS. 

002670 03-03 
EFFECTS OF LITHIUM ON MORPHOLOGICAL CHARACTERISTICS OF 
DISSOCIATED BRAIN CELLS IN CULTURE. 

002765 03-03 
PATIENT CHARACTERISTICS AND CLINICIAN ATTITUDES INFLUENCING THE 
PRESCRIBING OF BENZODIAZEPINES. 

003598 03-17 
THERAPEUTIC (III): GENERAL CHARACTERISTICS OF ANTIPSYCHOTIC- 
DRUGS. 

003644 03-17 
COMPARISON OF THE BINDING CHARACTERISTICS OF TRITIATED OPIATES 
AND OPIOID-PEPTIDES. 

003802 04-03 
CHARACTERISTICS OF THE INHIBITION OF RAT-BRAIN MONOAMINE- 
OXIDASE IN VITRO BY MD780515. 

003874 04-03 
THE PHARMACOLOGICAL CHARACTERISTICS OF THE TRANQUILIZING 
EFFECT OF HYDIPHEN. 

004261 04-04 
CHARACTERISTICS OF THE STIMULUS PRODUCED BY THE MIXTURE OF 
CANNABIDIOL WITH DELTA9 TETRAHYDROCANNABINOL. 

004263 04-04 



a. 



i'5 



<5: 



>. 



At 



S-87 



Subject Index 



Psychopharmacology Abstracts 



COMPARATIVE CHARACTERISTICS OF THE PROPHYLACTIC PROPERTIES OF 
SHORT-TERM AND LONG-ACTING LITHIUM-CARBONATE PREPARATIONS 
IN ENDOGENOUS AFFECTIVE-PSYCHOSES, 

004390 04-09 
CHARACTERIZATION 

ENDORPHIN-INDUCED HYPERTHERMIA: CHARACTERIZATION OF THE 
EXOGENOUSLY-INDUCED AND ENDOGENOUSLY-INDUCED EFFECTS. 

000029 01-03 
CHARACTERIZATION OF 3H GABA-RECEPTOR BINDING TO RAT-BRAIN 
SYNAPTOSOMAL MEMBRANES. EFFECT OF NONGABAERGIC 
COMPOUNDS. 

000139 01-03 
A FURTHER CHARACTERIZATION OF THE DIFFERENTIAL-EFFECTS OF 
LEUCINE-ENKEPHALIN, METHIONINE-ENKEPHALIN AND THEIR ANALOGS 
ON MORPHINE-INDUCED ANALGESIA. 

000311 01-03 
CGP-6085-A, A NEW, SPECIFIC, INHIBITOR OF SEROTONIN UPTAKE: 
NEUROCHEMICAL CHARACTERIZATION AND COMPARISON WITH OTHER 
SEROTONIN UPTAKE BLOCKERS. 

000316 01-03 
AFFINITY CHROMATOGRAPHY OF THE BETA-ADRENERGIC-RECEPTOR AND 
CHARACTERIZATION OF ANTIBODIES RAISED AGAINST PURIFIED 
RECEPTOR PREPARATIONS. 

001009 02-01 
PREPARATION AND CHARACTERIZATION OF SYNTHETIC MODELS FOR THE 
DENSE-BODIES OF HUMAN PLATELETS (UNPUBLISHED PAPER). 

001013 02-01 
CHARACTERIZATION OF LRF-LIKE IMMUNOREACTIVITY IN THE FROG 
SYMPATHETIC GANGLIA: NONIDENTITY WITH LRF-DECAPEPTIDE. 
(UNPUBLISHED PAPER). 

001018 02-01 
BIOCHEMICAL-LOCALIZATION AND CHARACTERIZATION OF BOMBESIN- 
LIKE-PEPTIDES IN DISCRETE REGIONS OF RAT-BRAIN. (UNPUBLISHED 
PAPER). 

001046 02-01 
BIOCHEMICAL-CHARACTERIZATION AND PHARMACOLOGICAL 
CHARACTERIZATION OF A PEPTIDE FROM THE HEMODIALYSATE OF 
PSYCHOTIC-PATIENTS. 

001049 02-01 
HISTAMINE-RECEPTORS IN THE BRAIN: CHARACTERIZATION BY BINDING 
STUDIES AND BIOCHEMICAL-EFFECTS. 

001054 02-01 
CHARACTERIZATION OF GABA-STIMULATED BENZODIAZEPINE-RECEPTOR 
BINDING. 

001309 02-03 
CHARACTERIZATION AND RADIOAUTOGRAPHY OF (3H)LSD BINDING BY 
RAT-BRAIN SLICES IN VITRO: THE EFFECT OF 5 HYDROXYTRYPTAMINE 

001369 02-03 
FURTHER CHARACTERIZATION OF THE BINDING OF SUBSTANCE-P TO A 
FRACTION FROM RABBIT BRAIN ENRICHED IN SYNAPTIC MEMBRANES. 

001394 02-03 
CHARACTERIZATION OF BENZODIAZEPINE BINDING-SITES. (UNPUBLISHED 
PAPER). 

001503 02-03 
CHARACTERIZATION OF ERGOT AND NONERGOT SEROTONIN 
ANTAGONISTS BY PROLACTIN AND GROWTH-HORMONE PROFILES 
DURING WAKEFULNESS AND SLEEP. 

002217 02-13 
OPIATE-RECEPTORS: PROBLEMS OF DEFINITION AND CHARAQERIZATION. 

002620 02-17 
DEMONSTRATION AND CHARACTERIZATION OF AN ENDOGENOUS 
INHIBITOR OF GABA-ENHANCED (3H) DIAZEPAM BINDING FROM 
BOVINE CEREBRAL-CORTEX. 

002645 03-01 
DISTRIBUTION OF MEMBRANE GLYCOPROTEINS AMONG THE ORGANELLES 
OF A SINGLE IDENTIFIED NEURON OF APLYSIA. II. ISOLATION AND 
CHARACTERIZATION OF A GLYCOPROTEIN ASSOCIATED WITH 
VESICLES. 

002657 03-03 
FUNCTIONAL CHARACTERIZATION OF CENTRAL ALPHA-ADRENOCEPTORS 
BY YOHIMBINE DIASTEREOMERS. 

002748 03-03 
CHARACTERIZATION AND QUANTITATION OF ALPHA-ADRENERGIC- 
RECEPTOR SUBTYPES IN RAT HYPOTHALAMUS. 

002839 03-03 
CHARACTERIZATION OF HALOPERIDOL MEDIATED EFFECTS ON RAT 
STRIATAL TYROSINE-HYDROXYLASE. 

002867 03-03 
HIGH-AFFINITY RENAL (3H)FLUNITRAZEPAM BINDING: 
CHARACTERIZATION, LOCALIZATION, AND ALTERATION IN 
HYPERTENSION. 

002874 03-03 
SUPPRESSION OF DRINKING BY NALOXONE IN THE RAT: A FURTHER 
CHARACTERIZATION. 

002963 03-04 
PHARMACOLOGICAL CHARACTERIZATION OF SCRATCHING-BEHAVIOUR 
INDUCED BY INTRACRANIAL INJECTION OF SUBSTANCE-P AND 
SOMATOSTATIN. 

002980 03-04 



A CHARACTERIZATION OF THE BEHAVIORAL-EFFECTS OF LEVO ALPHA 
ACETYLMETHADOL IN THE RAT AND IN THE PIGEON. (PHD 
DISSERTATION). 

003047 03-04 
CHARACTERIZATION OF THE ISOLATED PERFUSED MOUSE-BRAIN AS A 
SYSTEM FOR NEUROCHEMICAL-STUDIES. 

003146 03-06 
PHARMACOLOGIC CHARACTERIZATION AND LECITHIN TREATMENT OF A 
PATIENT WITH SPONTANEOUS ORAL FACIAL DYSKINESIA AND 
DEMENTIA. 

003347 03-11 
DOPAMINE-RECEPTOR PURIFICATION AND CHARAQERIZATION. 
(UNPUBLISHED PAPER). 

003661 04-01 
PURIFICATION AND CHARACTERIZATION OF RAT PHEOCHROMOCYTOMA 
DOPAMINE-BETA-HYDROXYLASE. 

003664 04-01 
CHARACTERIZATION OF THE BASIC PROTEINS FROM RODENT 

PERIPHERAL-NERVOUS-SYSTEM MYELIN. 

003665 04-01 
CHARACTERIZATION OF TWO (3H)GLUTAMATE BINDING-SITES IN RAT 

HIPPOCAMPAL MEMBRANES. 

003726 04-03 
CHARACTERIZATION BY (3H)DIHYDR0ERG0CRYPTINE BINDING OF ALPHA- 
ADRENERGIC-RECEPTORS IN NEUROBLASTOMA X GLIOMA HYBRID 
CELLS 

003823 04-03 
CHARACTERIZATION OF ENKEPHALIN RELEASE FROM RAT STRIATUM 

003909 04-03 
CHARGED 

VOLUNTARY INTOXICATION FROM PHENCYCLIDINE WILL IT RAISE A 
REASONABLE-DOUBT OF THE MENTAL-CAPACITY OF A PERSON 
CHARGED WITH A CRIME REQUIRING SPECIFIC INTENT OR MENTAL- 
STATE''. 

000914 01-17 
CHECKLIST 

A REVISED CHECKLIST TO OBTAIN CONSENT TO TREATMENT WITH 
MEDICATION. 

000984 01-17 
CHEESE 

IS THE FAILURE OF (-)DEPRENYL, A SELECTIVE MONOAMINE-OXIDASE-B- 
INHIBITOR, TO ALLEVIATE DEPRESSION RELATED TO FREEDOM FROM 
THE CHEESE EFFEQ? 

004640 04-15 
CHEMICAL 

GASTRIC AND PYLORIC MOTOR-RESPONSE TO SYMPATHETIC-NERVE 
STIMULATION AFTER CHEMICAL SYMPATHECTOMY. (UNPUBLISHED 
PAPER). 

001337 02-03 
THE EFFECT OF CYCLO-LEU-GLY ON CHEMICAL DENERVATION 
SUPERSENSITIVITY OF DOPAMINE-RECEPTORS INDUCED BY 
INTRACEREBROVENTRICULAR INJECTION OF 6 HYDROXYDOPAMINE IN 
MICE. 

001435 02-03 
A MODEL FOR PSYCHONEUROENDOCRINE INVESTIGATION: SPECIFIC 
CHEMICAL LESIONING OF THE MEDIAN-EMINENCE 

001478 02-03 
CHEMICAL STRUCTURE OF SURVEQOR STRUaURE-AQIVITY 
RELATIONSHIP 

002262 02-13 
TIME-COURSE OF CLINICAL CHEMICAL PARAMETERS UNDER LONG-TERM 
LITHIUM TREATMENT 

003515 03-15 
NEUROLEPTICS: INTERACTIONS WITH FOOD ~ CHEMICAL AND 
PHARMACODYNAMIC STUDIES ON THE INTERAQIONS OF COFFEE AND 
TEA 

003612 03-17 
TISSUE CHOLINE STUDIED USING A SIMPLE CHEMICAL ASSAY. 

003828 04-03 
CONVERGENT PROPERTIES AND CHEMICAL SENSITIVITY OF MIDBRAIN 
RETICULAR FORMATION NEURONS OF UNANESTHETIZED RABBITS 

003972 04-03 
RX-336-M A NEW CHEMICAL TOOL IN THE ANALYSIS OF THE OUASI- 
MORPHINE WITHDRAWAL-SYNDROME. 

004093 04-04 
CHEMICAL-IONIZATION 

HIGH-SENSITIVITY NEGATIVE CHEMICAL-IONIZATION MASS-SPEQRAL- 
ANALYSIS OF BIOGENIC-AMINES AND METABOLITES. (UNPUBLISHED 
PAPER). 

001042 02-01 
QUANTITATIVE ANALYSIS OF 6 HYDROXYMELATONIN IN HUMAN URINE 
BY GAS-CHROMATOGRAPHY NEGATIVE CHEMICAL-IONIZATION MASS- 
SPEQROMETRY. (UNPUBLISHED PAPER). 

001058 02-01 
A METHOD FOR THE DETERMINATION OF AMITRIPTYLINE AND ITS 
METABOLITES NORTRIPTYLINE, 10 HYDROXYAMITRIPTYLINE, AND 10 
HYDROXYNORTRIPTYLINE IN HUMAN PLASMA USING STABLE ISOTOPE 



S-88 



VOLUME 19, SUBJECT INDEX 



Subject Index 



DILUTION AND GAS-CHROMATOGRAPHY CHEMICAL-IONIZATION 
MASS-SPECTROMETRY. 

002486 02-16 
CHEMICALLY-INDUCED 

SENSORY NEUROTOXINS: CHEMICALLY-INDUCED SELECTIVE DESTRUCTION 
OF PRIMARY SENSORY NEURONS, 

003859 04-03 
CHEMISTRY 

CHEMISTRY OF BETA ENDORPHIN. 

001038 02-01 
CHEMOSENSORS 

OPIATE SYSTEM INFLUENCES CENTRAL RESPIRATORY CHEMOSENSORS. 

003971 04-03 
CHEMOTAXIS 

CHEMOTAXIS BY MOUSE MACROPHAGE CELL LINES. (UNPUBLISHED 
PAPER). 

001099 02-03 
INHIBITION OF CHEMOTAXIS BY S 3 DEAZAADENOSYLHOMOCYSTEINE IN 

A MOUSE MACROPHAGE CELL LINE. (UNPUBLISHED PAPER). 

001100 02-03 
PHOSPHOLIPID METABOLISM, CALCIUM-FLUX AND THE RECEPTOR- 
MEDIATED INDUCTION OF CHEMOTAXIS IN RABBIT NEUTROPHILS. 
(UNPUBLISHED PAPER). 

001118 02-03 
PHAGOCYTIC FUNCTION IN DOWN-SYNDROME - I. CHEMOTAXIS. 

003401 03-13 
CHEMOTHERAPY 

SERIAL COGNITIVE TESTING IN CANCER-PATIENTS RECEIVING 
CHEMOTHERAPY. 

000876 01-15 
UNDERSTANDING AND USE OF CHEMOTHERAPY BY LEARNING- 
DISABILITIES AND BEHAVIOR-DISORDERS TEACHERS 

000965 01-17 
PHARMACOMANOMETRIC-STUDIES OF COLONIC MOTILITY AS A GUIDE 
TO THE CHEMOTHERAPY OF SCHIZOPHRENIA. 

001930 02-08 
THE RELATIVE EFFICACY OF COGNITIVE-THERAPY AND CHEMOTHERAPY 
FOR THE TREATMENT OF DEPRESSION AMONG THE RETIRED ELDERLY. 
(PH.D. DISSERTATION). 

002148 02-11 
PSYCHIATRIC MORBIDITY AND PHYSICAL TOXICITY ASSOCIATED WITH 
ADJUVANT CHEMOTHERAPY AFTER MASTECTOMY. 

002433 02-15 
ADVANCES IN PHARMACOLOGY AND CHEMOTHERAPY. 

002546 02-17 
CONSIDERATIONS ON LONG-ACTING CHEMOTHERAPY: AN EXPERIENCE 
WITH FLUPHENAZINE-DECANOATE. 

003173 03-08 
REFLECTIONS ON ANTIPSYCHOTIC CHEMOTHERAPY: THE BEGINNING OF 
PHARMACOLOGICAL-TREATMENT . 

003292 03-11 
INTRAVENOUS LORAZEPAM TO PREVENT NAUSEA AND VOMITING 
ASSOCIATED WITH CANCER CHEMOTHERAPY. 

003614 03-17 
CHEWING 

EMERGENCE OF APOMORPHINE-INDUCED VACUOUS CHEWING DURING 6 
MONTHS CONTINUOUS TREATMENT WITH FLUPHENAZINE-DECANOATE. 

001817 02-04 
CHEWING-GUM 

THE USE OF NICOTINE CHEWING-GUM AS AN AID TO STOPPING 
SMOKING. 

002343 02-14 
CHICK 

LOCALIZATION OF ALPHA BUNGAROTOXIN BINDING-SITES IN SYNAPSES 
OF THE DEVELOPING CHICK RETINA. 

000065 01-03 
THE EFFECT OF FLA-63 ON PENTOBARBITONE-INDUCED SLEEP IN THE 
CHICK. 

001741 02-04 
BENZODIAZEPINE-RECEPTORS IN CHICK RETINA: DEVELOPMENT AND 
CELLULAR LOCALIZATION. 

002655 03-03 
GABA DEPLETION IN CHICK BRAINSTEM AFTER INTRAVENTRICULAR 
INJEQIONOFCEFAZOLIN. 

002762 03-03 
THE EFFECT OF COLCHICINE AND CYTOCHALASIN B ON THE RELEASE OF 
TAURINE FROM THE CHICK RETINA. 

002856 03-03 
DEVELOPMENTALLY REGULATED LECTINS IN SLIME MOULDS AND CHICK 
TISSUES - ARE THEY CELL ADHESION MOLECULES? 

003724 04-03 
EVIDENCE TO SUGGEST THAT DOPAMINE-INDUCED INCREASE IN GABA 
CONCENTRATIONS IN CHICK BRAIN IS MEDIATED THROUGH CYCLIC- 
AMP. 

003952 04-03 
CHICKEN 

BENZODIAZEPINE BINDING IN CHICKEN RETINA AND ITS INTERACTION 
WITH GAMMA AMINOBUTYRIC-ACID. 

001287 02-03 



INHIBITION OF MONOAMINE-OXIDASE BY FURAZOLIDONE IN THE 
CHICKEN AND THE INFLUENCE OF THE ALIMENTARY FLORA THEREON. 

003711 04-03 
CHICKENS 

2,4,5 TRICHLOROPHENOXYACETIC-ACID CAUSES BEHAVIORAL-EFFECTS IN 
CHICKENS AT ENVIRONMENTALLY RELEVANT DOSES. 

003079 03-04 
THE EFFECTS OF TRYPTOPHAN AND MANIPULATIONS OF SEROTONERGIC- 
RECEPTORS ON TONIC IMMOBILITY IN CHICKENS 

004245 04-04 
CHICKS 

GABA DEPLETION AND BEHAVIOURAL-CHANGES PRODUCED BY 
INTRAVENTRICULAR PUTRESCINE IN CHICKS. 

000218 01-03 
APOMORPHINE: EFFECTS ON THE TIMING AN'^ SEQUENCING OF PECKING- 
BEHAVIOR IN CHICKS. 

000428 01-04 
OPIOID BLOCKADE AND SOCIAL-COMFORT IN CHICKS. 

001745 02-04 
THE EFFECTS OF COLCHICINE AND VINBLASTINE ON MEMORY IN CHICKS, 

004069 04-04 
CHILD 

THE PARENT CHILD INTERACTIONS OF HYPERACTIVE-CHILDREN AND THEIR 
MODIFICATION BY STIMULANT-DRUGS. 

002092 02-11 
CONTROLLED-STUDY WITH BROMAZEPAM AND CLOROTEPIN IN CHILD 
INSTABILITY. 

002190 02-11 
HALOPERIDOL-INDUCED TARDIVE-DYSKINESIA IN A CHILD WITH GILLES- 
DE-LA-TOURETTES-DISEASE. 

002437 02-15 

004470 04-11 

004497 04-12 



CHILD PSYCHOPHARMACOLOGY. 
LSD: MY PROBLEM CHILD. 



CHILD-PSYCHIATRY 

USE OF PIMOZIDE (ORAP) 1N CHILD-PSYCHIATRY. 

002100 02-11 
THE USE OF MINAPRINE IN CHILD-PSYCHIATRY IN HOSPITALS AND 
OUTPATIENT CLINICS. 

002169 02-11 
EXPERIMENTATION WITH MINAPRINE IN CHILD-PSYCHIATRY. 

002344 02-14 
CHILD-PSYCHIATRY AND PSYCHOPHARMACOTHERAPY IN GENERAL 
PRACTICE, IN PEDIATRICS, AND IN NEUROLOGY. 

003288 03-1 1 
CHILDHOOD 

PSYCHOPHARMACOLOGY IN CHILDHOOD: CURRENT STATUS AND FUTURE 
PROSPECTIVES. 

002192 02-11 
PSYCHOPHARMACEUTICAL-THERAPY TO CALM DRIVE, ACTIVITY, AND 
RESTLESSNESS IN CHILDHOOD. 

002604 02-17 
ON THE EVALUATION OF A PROVOCATIVE EEG METHOD USING 
MEDICATION IN THE DIAGNOSIS OF ORGANIC-BRAIN-SEIZURES IN 
CHILDHOOD, WITH SPECIAL EMPHASIS ON SLEEP INDUCTION THROUGH 
MEDICATION. 

003387 03-1 1 
PREVALENCE OF DRUG-TREATMENT FOR HYPERACTIVITY AND OTHER 
CHILDHOOD BEHAVIOR-DISORDERS. 

004713 04-17 
CHILDHOOD-DEPRESSION 
CHILDHOOD-DEPRESSION. 

000680 01-11 
CHILDHOOD-ENURESIS 

CHILDHOOD-ENURESIS: II. PSYCHOPATHOLOGY, TRICYCLIC 
CONCENTRATION IN PLASMA, AND ANTIENURETIC-EFFECT. 

002354 02-14 
CHILDHOOD-EPILEPSY 

VALPROIC-ACID IN CHILDHOOD-EPILEPSY: ANTICONVULSIVE EFFICACY IN 
RELATION TO ITS PLASMA LEVELS. 

004525 04-13 
CHILDHOOD-SCHIZOPHRENIA 

CLINICAL-RESPONSE AND SERUM NEUROLEPTIC LEVELS IN CHILDHOOD- 
SCHIZOPHRENIA. (UNPUBLISHED PAPER). 

000566 01-08 
CHILDREN 

OUR EXPERIENCE WITH PIRACETAM (NOOTROPIL-UCB) TREATMENT IN 
CHILDREN FROM HIGH-RISK PREGNANCIES WITH SUBSEQUENT 
MINIMAL-BRAIN-DYSFUNCTION . 

000544 01-07 
PYRITINOL ADMINISTRATION AS PART OF EPILEPSY TREATMENT IN 
CHILDREN. 

000671 01-11 
CHILDREN ON MEDICATION: A PRIMER FOR SCHOOL PERSONNEL. 

000676 01-11 
PLASMA CHLORPROMAZINE CONCENTRATIONS IN CHILDREN WITH 
BEHAVIORAL-DISORDERS AND MENTAL-ILLNESS. 

000717 01-11 



I 



15 



A, 
"I* 



S-89 



Subject Index 



Psychopharmacology Abstracts 



TARDIVE-DYSKINESIA AND OTHER MOVEMENT-DISORDERS IN CHILDREN 
TREATED WITH PSYCHOTROPIC-DRUGS. 

000849 01-15 
DYSKINETIC AND NEUROLOGICAL-COMPLICATIONS IN CHILDREN TREATED 
WITH PSYCHOTROPIC-MEDICATIONS, 

000880 01-15 
PHENYTOIN KINETICS IN CHILDREN. 

002113 02-11 
EEG CHANGES IN CHILDREN WITH TREATED PHENYLKETONURIA AFTER 
PHENYLALANINE LOAD 

002115 02-11 
DOUBLE-BLIND CONTROLLED- STUDY ON THE PSYCHOLEPTIC-EFFECTS OF 

AMINEPTINE IN MENTALLY-HANDICAPPED CHILDREN WITHOUT 
PERSONALITY-PROBLEMS. 

002116 02-11 
5 HYDROXYTRYPTOPHAN AND PYRIDOXINE: THEIR EFFECTS IN YOUNG 

CHILDREN WITH DOWNS-SYNDROME. 

002161 02-11 
IMIPRAMINE AND EEG SLEEP IN CHILDREN WITH DEPRESSIVE- 
SYMPTOMS. 

002339 02-14 
EFFECTS OF IMIPRAMINE ON LEFT VENTRICULAR PERFORMANCE IN 
CHILDREN. 

002385 02-15 
THE INFLUENCE OF NEUROLEPTIC-DRUGS ON PROLACTIN SECRETION IN 
CHILDREN. 

002409 02-15 
BIOLOGY AND THERAPY OF VIOLENT-BEHAVIOUR IN CHILDREN. 

002608 02-17 
ON THE EFFECTS OF SULTOPRIDE ADMINISTERED IN LOW-DOSAGES TO 
OLDER CHILDREN AND ADOLESCENTS. 

003230 03-09 
LITHIUM IN CHILDREN OF LITHIUM RESPONDING PARENTS. 

003242 03-09 
MOLINDONE-HYDROCHLORIDE IN THE TREATMENT OF AGGRESSIVE, 
HOSPITALIZED CHILDREN. 

003321 03-11 
A COMPARATIVE-STUDY ON THE CLINICALEFFECTS OF RECTAL 

DIAZEPAM AND PENTOBARBITAL ON SMALL CHILDREN. RELATIONSHIP 
BETWEEN PLASMA LEVEL AND EFFECT. 

003330 03-11 
INVESTIGATION INTO THE EFFECT OF FLUPHENAZINE-HCL (LYORODIN) IN 
CHILDREN WITH BEHAVIORAL-DISORDERS BY MEANS OF 
PSYCHOPHYSIOLOGICAL PARAMETERS. 

003344 03-11 
TREATMENT OF ANXIETY IN CHILDREN AND ADOLESCENTS. 

003349 03-11 
EFFECTS OF LITHIUM-CARBONATE AND HALOPERIDOL ON COGNITION IN 
AGGRESSIVE, HOSPITALIZED SCHOOL-AGE CHILDREN 

003360 03-11 
EFFECTS OF LITHIUM-CARBONATE AND HALOPERIDOL ON COGNITION IN 

AGGRESSIVE HOSPITALIZED SCHOOL-AGE CHILDREN. 

003361 03-11 
THE INFLUENCE OF METHYLPHENIDATE ON SPONTANEOUS AUTONOMIC- 

ACTIVITY AND BEHAVIOR IN CHILDREN DIAGNOSED AS HYPERACTIVE. 

003363 03-11 
HALOPERIDOL - ITS USE IN CHILDREN. 

003370 03-1 1 
STOPPING MEDICATION IN CHILDREN WITH EPILEPSY. 

004447 04-11 
PREVALENCE OF HYPERACTIVITY AND RELATED TREATMENTS AMONG 
ELEMENTARY SCHOOL CHILDREN. 

004469 04-1 1 
TARDIVE-DYSKINESIA AND OTHER DRUG-INDUCED MOVEMENT- 
DISORDERS AMONG HANDICAPPED CHILDREN AND YOUTH. 

004614 04-15 
WITHDRAWAL SYMPTOMS AFTER GRADUATED CESSATION OF 
IMIPRAMINE IN CHILDREN. 

004630 04-15 
BEHAVIOR AND LEARNING DIFFICULTIES IN CHILDREN OF NORMAL 
INTELLIGENCE BORN TO ALCOHOLIC MOTHERS. 

004658 04-15 
EMOTIONAL-DISORDERS IN CHILDREN AND ADOLESCENTS: MEDICAL AND 
PSYCHOLOGICAL APPROACHES TO TREATMENT. 

004743 04-17 
CHILEAN 

PU\SMA LEVELS OF DIPHENYLHYDANTOIN AND THE CONTROL OF ADULT 
EPILEPTIC-SEIZURES: A CHILEAN EXPERIENCE. 

000102 01-03 
CHLORAL-HYDRATE 

EFFICACY AND SIDE-EFFECTS OF CHLORAL-HYDRATE AND TRYPTOPHAN 
AS SLEEPING-AIDS IN PSYCHOGERIATRIC-PATIENTS. 

002077 02-10 
THE EFFICACY OF TRIAZOLAM AND CHLORAL-HYDRATE IN GERIATRIC 
INSOMNIACS. 

002160 02-11 
SMOOTH-PURSUIT EYE-MOVEMENTS: EFFECTS OF ALCOHOL AND 
CHLORAL-HYDRATE. 

003448 03-14 



ORAL AND RECTAL ABSORPTION OF CHLORAL-HYDRATE AND ITS BETAINE 
COMPLEX. 

004554 04-13 
CHLORALOSE 

EFFECTS OF ALPHA CHLORALOSE ON THE ACTIVITY OF THE 
NIGROSTRIATAL DOPAMINERGIC SYSTEM IN THE CAT. 

000217 01-03 
THE INFLUENCE OF CHLORALOSE ANESTHESIA ON THE AQIVITY OF RED 
NUCLEUS NEURONS IN CATS. 

000245 01-03 
SENSITIVE DEPRESSANT EFFECT OF BENZODIAZEPINES ON THE CROSSED 
EXTENSOR REFLEX IN CHLORALOSE ANESTHETIZED RATS. 

003027 03-04 
CHLORALOSE-INDUCEO 

OBSERVATIONS ON CHLORALOSE-INDUCED MYOCLONUS IN GUINEA-PIGS. 

001164 02-03 
CHLORCYCLIZINE 

EFFECT OF L HISTIDINE AND CHLORCYCLIZINE ON APOMORPHINE-INOUCED 
CLIMBING-BEHAVIOUR AND METHAMPHETAMINE STEREOTYPY IN 
MICE 

004147 04-04 
CHLORDIAZEPOXIDE 

THE SENSITIVITY OF THE RAT CORTICOSTERONE RESPONSE TO 
ENVIRONMENTAL MANIPULATIONS AND TO CHRONIC 
CHLORDIAZEPOXIDE TREATMENT. 

000092 01-03 
EFFECTS OF CHLORDIAZEPOXIDE ON DEPOLARIZATION-INDUCED CALCIUM 
INFLUX INTO SYNAPTOSOMES. 

000 18301 -03 
CHLORDIAZEPOXIDE ANTINOCICEPTION: CROSS-TOLERANCE WITH 
OPIATES AND WITH STRESS 

000348 01-04 
RATS REACTIONS TO A PREDATOR: MODIFICATION BY 
CHLORDIAZEPOXIDE. 

000353 01-04 
TOLERANCE TO SUPPRESSIVE EFFECTS OF CHLORDIAZEPOXIDE ON 
OPERANT-BEHAVIOR: LACK OF CROSS-TOLERANCE TO PENTOBARBITAL. 

000356 01-04 
EFFECTS OF CHLORDIAZEPOXIDE AND DIAZEPAM ON FEEDING 
PERFORMANCE IN A FOOD PREFERENCE TEST 

000367 01-04 
EFFECTS OF ACUTE OR CHRONIC ADMINISTRATION OF 

CHLORDIAZEPOXIDE ON FEEDING PARAMETERS USING TWO FOOD 
TEXTURES IN THE RAT. 

000368 01-04 
WATER INTAKE AND TIME-COURSE OF DRINKING AFTER SINGLE OR 

REPEATED CHLORDIAZEPOXIDE INJECTIONS 

000369 01-04 
ALCOHOL AND CHLORDIAZEPOXIDE INCREASE SUPPRESSED AGGRESSION 

IN MICE. 

000434 01-04 
CHLORDIAZEPOXIDE AND OXAZEPAM DISPOSITION IN CIRRHOSIS. 

000790 01-13 
INTERACTIONS OF CHLORDIAZEPOXIDE AND ANOREQIC-AGENTS ON RATE 
AND DURATION PARAMETERS OF FEEDING IN THE RAT 

001600 02-04 
THE EFFECTS OF D-AMPHETAMINE, CHLORDIAZEPOXIDE, AND 
PENTOBARBITAL ON BEHAVIOR MAINTAINED BY ESCAPE FROM 
PUNISHMENT IN PIGEONS. (PH.D. DISSERTATION). 

001713 02-04 
EFFEQS OF CHLORDIAZEPOXIDE MORPHINE COMBINATIONS ON 
SPONTANEOUS LOCOMOTOR-ACTIVITY IN THREE INBRED STRAINS OF 
MICE. 

001766 02-04 
AnENUATION OF THE EFFEQS OF PUNISHMENT BY ETHANOL: 
COMPARISONS WITH CHLORDIAZEPOXIDE. 

001813 02-04 
SHORT-TERM ETHANOL ADMINISTRATION IMPAIRS THE ELIMINATION OF 
CHLORDIAZEPOXIDE (LIBR"'M) IN MAN 

002224 02-13 
RESPONDERS AND NONRESHONDERS TO CHLORDIAZEPOXIDE AND 
PLACEBO: A DISCRIMINANT FUNQION ANALYSIS. 

002482 02-16 
PHARMACOKINETICS AND BIOAVAILABILITY OF CHLORDIAZEPOXIDE IN 
HUMANS. 

002564 02-17 
INTERACTION OF CHLORDIAZEPOXIDE AND SODIUM-VALPROATE IN THE 
NUCLEUS-ACCUMBENS OF THE RAT. 

002796 03-03 
EFFEaS OF MORPHINE AND CHLORDIAZEPOXIDE ON AVOIDANCE- 
BEHAVIOUR IN TWO INBRED STRAINS OF MICE. 

002973 03-04 
EFFECTS OF CHLORDIAZEPOXIDE AND D-AMPHETAMINE ON RESPONDING 
SUPPRESSED BY CONDITIONED PUNISHMENT. 

003105 03-04 
A POSSIBLE ROLE FOR CATECHOLAMINE NEUROTRANSMIHERS IN THE 
ANTICONVULSANT AQIVITY OF CHLORDIAZEPOXIDE. 

003119 03-04 



S-90 



VOLUME 19, SUBJECT INDEX 



Subject Index 



FOOD PREFERENCE FOLLOWING ACUTE OR CHRONIC CHLORDIAZEPOXIDE 
ADMINISTRATION: TOLERANCE TO AN ANTINEOPHOBIC ACTION. 

004090 04-04 
HISTAMINE AS A PUNISHER IN SQUIRREL-MONKEYS: EFFECTS OF 
PENTOBARBITAL, CHLORDIAZEPOXIDE AND HI -RECEPTOR AND H2- 
RECEPTOR ANTAGONISTS ON BEHAVIOR AND CARDIOVASCULAR 
RESPONSE 

0041)9 04-04 
RESPONDERS AND NONRESPONDERS TO CHLORDIAZEPOXIDE AND 
PLACEBO. A DISCRIMINANT FUNCTION ANALYSIS. (UNPUBLISHED 
PAPER). 

004420 04-10 
CLINICAL PHARMACOKINETICS OF CHLORDIAZEPOXIDE IN PATIENTS WITH 
ALCOHOLIC HEPATITIS. 

004473 04-11 
CHLORDIAZEPOXIDE-HCL 

THE EFFECTS OF CHLORDIAZEPOXIDE-HCL ADMINISTRATION UPON 
PUNISHMENT AND CONDITIONED SUPPRESSION IN THE RAT. 

001757 02-04 
CHLORDIAZEPOXIDE-HYDROCHLORIDE 

NMR SPECTRAL STUDY OF PROTON TRANSFER IN AMITRIPTYLINE- 
HYDROCHLORIDE CHLORDIAZEPOXIDE-HYDROCHLORIDE COMBINATIONS 
IN DIPOLAR APROTIC SOLVENTS. 

003654 04-01 
CHLORDIAZEPOXIDE-LIKE 

THE USE OF SOCIAL-INTERACTION AS A METHOD FOR DETECTING 
ANXIOLYTIC-ACTIVITY OF CHLORDIAZEPOXIDE-LIKE DRUGS. 

001866 02-06 
CHLORIDE 

EFFECT OF PICROTOXIN ON BENZODIAZEPINE-RECEPTORS AND GABA- 
RECEPTORS WITH REFERENCE TO THE EFFECT OF CHLORIDE ION. 

002725 03-03 
CONVULSANT AND ANTICONVULSANT-DRUG BINDING-SITES RELATED TO 
GABA REGULATED CHLORIDE ION-CHANNELS. 

002848 03-03 
BARBITURATE ENHANCEMENT OF GABA-MEDIATED INHIBITION AND 
ACTIVATION OF CHLORIDE ION-CONDUCTANCE: CORRELATION WITH 
ANTICONVULSANT AND ANESTHETIC ACTIONS. 

002885 03-03 
CHLORIMIPRAMINE 

PROLONGATION OF THE EJACULATION LATENCY IN THE MALE RAT BY 
THIORIDAZINE AND CHLORIMIPRAMINE. 

000335 01-04 
COMPARATIVE EXPERIMENT OF THE ANTIDEPRESSANT EFFECTS OF 
AMINEPTINE AND CHLORIMIPRAMINE. 

002029 02-09 
THE BIOAVAILABILITY OF ORAL AND PARENTERAL CHLORIMIPRAMINE 
(ANAFRANIL). 

002232 02-13 
INTRAVENOUS CHLORIMIPRAMINE AFFECTS REM CYCLE IN PATIENTS 
WITH EXCESSIVE DAYTIME SLEEPINESS AND CONTROL SUBJECTS. 

002341 02-14 
SUPPRESSION OF ACTIVE SLEEP BY CHRONIC-TREATMENT WITH 
CHLORIMIPRAMINE DURING EARLY POSTNATAL DEVELOPMENT: 
EFFECTS UPON ADULT SLEEP AND BEHAVIOR IN THE RAT. 

003056 03-04 
THE ANTIDEPRESSANT ACTION OF SULPHO-ADENOSYL-L-METHIONINE 
(SAME) COMPARED WITH THAT OF CHLORIMIPRAMINE: 
HYPOTHETICAL INTERPRETATIONS OF THE MECHANISM-OF-ACTION. 

003150 03-07 
TYRAMINE PRESSOR TEST AND CARDIOVASCULAR-EFFEaS OF 

CHLORIMIPRAMINE AND NORTRIPTYLINE IN HEALTHY VOLUNTEERS. 

003428 03-13 
A DOUBLE-BUND MULTICENTRE-TRIAL COMPARING THE EFFICACY AND 
SIDE-EFFEQS OF MIANSERIN AND CHLORIMIPRAMINE IN DEPRESSED- 
INPATIENTS AND DEPRESSED-OUTPATIENTS. 

004395 04-09 
CHLORMETHIAZOLE 

SORPTION OF CHLORMETHIAZOLE BY INTRAVENOUS INFUSION GIVING 
SETS. 

002508 02-16 
AVAILABILITY OF ISOSORBIDE-DINITRATE, DIAZEPAM AND 
CHLORMETHIAZOLE, FROM I.V. DELIVERY SYSTEMS. 

003558 03-16 
CHLORNALTREXAMINE 

ISOLATION OF SELECTIVE 3H CHLORNALTREXAMINE BOUND COMPLEXES, 
POSSIBLE OPIOID-RECEPTOR COMPONENTS IN BRAINS OF MICE. 

001162 02-03 
MORPHINE ANALGESIA AFTER INTRATHECAL ADMINISTRATION OF A 
NARCOTIC AGONIST, CHLOROXYMORPHAMINE AND ANTAGONIST, 
CHLORNALTREXAMINE. 

001695 02-r ■ 
ANTAGONISM BY CHLORNALTREXAMINE OF SOME EFFECTS OF DELTA9 
TETRAHYDROCANNABINOL IN RATS. 

003104 03-04 
PHARMACOLOGICAL- STUDIES WITH AN ALKYLATING NARCOTIC 
AGONIST, CHLOROXYMORPHAMINE, AND ANTAGONIST, 
CHLORNALTREXAMINE. 

004082 04-04 



CHLORO-4-PHENYLSUCCINIMIDOBENZENESULFONAMIDE 

3 CHLORO-4-PHENYLSUCCINIMIOOBENZENESULFONAMIDE (GS-385), A 
NEW ANTICONVULSANT: ITS QUANTITATIVE DETERMINATION, 
PHARMACOKINETICS AND METABOLISM USING HIGH-PERFORMANCE 
LIQUID-CHROMATOGRAPHY. 

000705 01-11 
CHLOROAMPHET AMINE 

COMPARATIVE-EFFECTS OF P CHLOROAMPHETAMINE AND L P 
CHLOROPHENYLPIPERAZINE ON 5 HYDROXYINDOLE CONCENTRATION IN 
RAT-BRAIN. 

000101 01-03 
P CHLOROAMPHETAMINE: EVALUATION OF A BRAIN METABOLITE. 

001779 02-04 
THE EFFECTS OF PARA CHLOROAMPHETAMINE ON FENFLURAMINE 
ANOREXIA IN AD LIBITUM AND STIMULATION-INDUCED FEEDING IN 
THE RAT. 

001823 02-04 
INTERACTIONS BETWEEN A MONOFLUORINATED ANALOGUE OF P 
CHLOROAMPHETAMINE AND 5 HYDROXYTRYPT AMINE IN BRAIN 

003719 04-03 
THE EFFECTS OF P CHLOROAMPHETAMINE ADMINISTRATION ON 
LOCOMOTOR-ACTIVITY AND SEROTONIN IN NEONATAL AND ADULT 
RATS. (UNPUBLISHED PAPER). 

004169 04-04 
CHLOROBENZOYL-CHLORO-METHYL-NA-GLYCYLGLYCINANIIIDE 
PHARMACOLOGY OF 2 CHLOROBENZOYL-CHLORO-METHYL-NA- 
GLYCYLGLYCINANILIDE HYDRATE (45-0088-S), A COMPOUND WITH 
BENZODIAZEPINE-LIKE PROPERTIES. 

003692 04-02 
CHLORODIMETHYLAMINOETHOXYDIBENZOTHIEPINE 
PHARMACOKINETICS AND METABOLISM OF 
CHLORODIMETHYLAMINOETHOXYDIBENZOTHIEPINE (ZOTEPINE) IN RAT, 
MOUSE, DOG AND MAN. 

000219 01-03 
PHARMACOLOGICAL-STUDY OF 
CHLORODIMETHYLAMINOETHOXYDIBENZOTHIEPINE (ZOTEPINE), A NEW 
NEUROLEPTIC-DRUG. 

000493 01-04 
TOXICOLOGICAL AND TERATOLOGICAL STUDIES OF 

CHLORODIMETHYLAMINOETHOXYDIBENZOTHIEPINE (ZOTEPINE), A NEW 
NEUROLEPTIC-DRUG. 

000515 01-05 
CHLORODINITROBENZENE 

EFFECTS OF HALOPERIDOL, A DOPAMINE-RECEPTOR ANTAGONIST, ON A 
DELAYED TYPE HYPERSENSITIVITY REACTION TO 1 
CHLORODINITROBENZENE IN MICE. 

001473 02-03 
CHLOROETHYLNORAPOMORPHINE 

CHLOROETHYLNORAPOMORPHINE, A PROPOSED LONG-ACTING 

DOPAMINE ANTAGONIST: INTERACTIONS WITH DOPAMINE-RECEPTORS 
OF MAMMALIAN FOREBRAIN IN VITRO. 

001114 02-03 
CHLOROPHENYL-CYCLOPROPYLAMINE 

EFFECT OF 2 P CHLOROPHENYL-CYCLOPROPYLAMINE ON 5 
HYDROXYINDOLE CONCENTRATION AND MONOAMINE-OXIDASE 
ACTIVITY IN RAT-BRAIN. 

001237 02-03 
CHLOROPHENYL-4-HYDROXYPIPERIDINE-4-FLUOROBUTYROPHENONE 
THE STRUCTURE OF HALOPERIDOL-HYDROBROMIDE (CHLOROPHENYL-4- 
HYDROXYPIPERIDINE-4-FLUOROBUTYROPHENONE HBR) . 

000002 01-01 
CHLOROPHENYLALANINE 

ENHANCEMENT OF THE BEHAVIORAL-EFFECTS OF 2,5 DIMETHOXY-4- 
METHYLAMPHETAMINE (DOM) BY PRETREATMENT WITH P 
CHLOROPHENYLALANINE. 

000364 01-04 
EFFECT OF P CHLOROPHENYLALANINE ON DIAZEPAM WITHDRAWAL 
SIGNS IN RATS. 

001797 02-04 
PHASIC ACTIVITY INDUCED BY P CHLOROPHENYLALANINE IN THE 
AUDITORY PATHWAY. 

002661 03-03 
EFFECT OF P CHLOROPHENYLALANINE AND TRYPTOPHAN ON SLEEP, EEG 
AND MOTOR-ACTIVITY IN THE RAT. 

002958 03-04 
SYNTHESIS AND BIOCHEMICAL AND PHARMACOLOGIC PROPERTIES OF 
ANALOGUES AND DERIVATIVES OF P CHLOROPHENYLALANINE. 

003691 04-02 
DOES P CHLOROPHENYLALANINE PRODUCE DISTURBED WAKING, 
DISTURBED SLEEP OR ACTIVATION BY PONTO-GENICULO-OCCIPITAL 
WAVES IN CATS? 

003704 04-02 
ANTAGONISM OF ETHANOL-INDUCED DECREASE IN LH BY P 
CHLOROPHENYLALANINE: LACK OF CORRELATION WITH ALTERED 
SEROTONERGIC MECHANISMS. 

003748 04-03 



I 



■■T 



St: 









S-91 



Subject Index 



Psychopharmacology Abstracts 



EFFECT OF P CHLOROPHENYLALANINE ON THE ACQUISITION OF 
TOLERANCE TO THE HYPNOTIC-EFFECTS OF PENTOBARBITAL, BARBITAL, 
AND ETHANOL. 

003883 04-03 
THE EFFECT OF P CHLOROPHENYLALANINE ON THE DISTRIBUTION OF 
BIOGENIC-AMINES IN THE BRAIN, AND ON MEMORY IN RATS. 

004068 04-04 
INTERACTION OF P CHLOROPHENYLALANINE, MIANSERINE AND 
DANITRACEN WITH AMPHETAMINE. 

004599 04-15 
CHLOROPHENYLALANINE-INDUCED 

REVERSAL OF PARA CHLOROPHENYLALANINE-INDUCED INSOMNIA BY 5 
HYDROXYTRYPTOPHAN IN THE RAT. 

000423 01-04 
CHLOROPHENYLPIPERAZINE 

COMPARATIVE-EFFECTS OF P CHLOROAMPHETAMINE AND L P 
CHLOROPHENYLPIPERAZINE ON 5 HYDROXYINDOLE CONCENTRATION IN 
RAT-BRAIN. 

000101 01-03 
1-M CHLOROPHENYLPIPERAZINE: A METABOLITE OF TRAZODONE 
ISOLATED FROM RAT URINE. 

000204 01-03 
DISPOSITION AND PHARMACOLOGICAL-EFFECTS OF M 
CHLOROPHENYLPIPERAZINE IN RATS. 

002995 03-04 
5 HYDROXYTRYPTAMINE-LIKE PROPERTIES OF M 
CHLOROPHENYLPIPERAZINE: COMPARISON WITH QUIPAZINE. 

004210 04-04 
CHLOROXYMORPHAMINE 

MORPHINE ANALGESIA AFTER INTRATHECAL ADMINISTRATION OF A 
NARCOTIC AGONIST, CHLOROXYMORPHAMINE AND ANTAGONIST, 
CHLORNALTREXAMINE. 

001695 02-04 
PHARMACOLOGICAL-STUDIES WITH AN ALKYLATING NARCOTIC 
AGONIST, CHLOROXYMORPHAMINE, AND ANTAGONIST, 
CHLORNALTREXAMINE. 

004082 04-04 
CHLORPHENTERMINE 

EFFECT OF DESMETHYLIMIPRAMINE ON THE KINETICS OF 
CHLORPHENTERMINE ACCUMULATION IN ISOLATED PERFUSED RAT 
LUNG. 

000524 01-05 
EFFECT OF DESMETHYLIMIPRAMINE ON TISSUE DISTRIBUTION AND 
ANORECTIC-ACTIVITY OF CHLORPHENTERMINE IN RATS. 

004179 04-04 
CHLORPROMAZINE 

ACTIONS OF CHLORPROMAZINE, HALOPERIDOL AND PIMOZIDE ON LIPID 
METABOLISM IN GUINEA-PIG BRAIN SLICES. 

000129 01-03 
MECHANISM OF CHLORPROMAZINE ACTION ON PLASMA GLUCOSE AND 
CYCLIC-AMP LEVELS. 

000211 01-03 
PRIOR AND ONGOING EXPERIENCE AS DETERMINANTS OF THE EFFECTS OF 
D-AMPHETAMINE AND CHLORPROMAZINE ON PUNISHED-BEHAVIOR 

000339 01-04 
EXPERIMENTAL DYSTONIA INDUCED BY QUATERNARY 
CHLORPROMAZINE. 

000461 01-04 
EFFECT OF MORPHINE IN COMBINATION WITH CHLORPROMAZINE AND 
HALOPERIDOL ON OPERANT-BEHAVIOR. 

000486 01-04 
EFFECTS OF TRIFLUOPERAZINE, CHLORPROMAZINE, AND HALOPERIDOL 
UPON TEMPORAL INFORMATION-PROCESSING BY SCHIZOPHRENIC- 
PATIENTS. 

000554 01-08 
COMPARATIVE ENZYME-INDUCING EFFECTS OF CHLORPROMAZINE AND 
FLUPHENAZINE THERAPIES IN PSYCHOTIC-PATIENTS. 

000682 01-11 
PLASMA CHLORPROMAZINE CONCENTRATIONS IN CHILDREN WITH 
BEHAVIORAL-DISORDERS AND MENTAL-ILLNESS. 

000717 01-11 
PLASMA CHLORPROMAZINE SERUM PROLACTIN RELATIONSHIP IN A 
SINGLE-DOSE EXPERIMENT. 

000761 01-13 
PHARMACOKINETICS OF CHLORPROMAZINE IN NORMAL VOLUNTEERS. 

000778 01-13 
PLASMA AND SALIVA LEVELS OF CHLORPROMAZINE AND SUBJECTIVE 
RESPONSE. 

000826 01-14 
IMPORTANCE OF AKINESIA: PLASMA CHLORPROMAZINE AND PROLACTIN 
LEVELS. 

000891 01-15 
PERSISTENT EFFECTS OF HIGH-CONCENTRATIONS OF CHLORPROMAZINE 
ON 3H PROPYLBENZILYLCHOLINE-MUSTARD BINDING TO MUSCARINIC- 
RECEPTORS IN GUINEA-PIG INTESTINAL-MUSCLE STRIPS. 

001266 02-03 
DIHYDROXY AND TRIHYDROXY ANALOGS OF CHLORPROMAZINE 
INFLUENCE THE CENTRAL-ACTIVITY OF ADENYLATE-CYCLASE AND 
CYCLIC-AMP-PHOSPHODIESTERASE . 

001405 02-03 



EFFECT OF CHLORPROMAZINE ON CELL PROLIFERATION IN THE 
DEVELOPING RAT-BRAIN. A COMBINED BIOCHEMICAL-STUDY AND 
MORPHOLOGICAL-STUDY. 

001407 02-03 
EVIDENCE FOR INVOLVEMENT OF DOPAMINE IN THE AQION OF 
DIAZEPAM: POTENTIATION OF HALOPERIDOL AND CHLORPROMAZINE 
ACTION IN THE BRAIN. 

001428 02-03 
MECHANISMS OF CHLORPROMAZINE AND CHLORPROMAZINE ISOSTERES 
ON THE GLYCEMIC-RESPONSE IN MICE. (PH.D. DISSERTATION). 

001525 02-03 
AN ANALYSIS OF SOME PERCEPTUAL-EFFEaS OF MORPHINE, 
CHLORPROMAZINE, AND LSD. 

001652 02-04 
CORRELATION BETWEEN DAILY DOSAGE OF CHLORPROMAZINE AND 
SUBSEQUENT SUPERSENSITIVITY. 

001845 02-05 
LONG-TERM CHLORPROMAZINE IN RHESUS-MONKEYS: PRODUQION OF 
DYSKINESIAS AND CHANGES IN SOCIAL-BEHAVIOR. 

001850 02-05 
RELATIONSHIPS BETWEEN CHLORPROMAZINE CONCENTRATIONS IN 
PLASMA AND CEREBROSPINAL-FLUID AND CLINICAL-RESPONSE AND 
BIOCHEMICAL-RESPONSE IN PSYCHOTIC-PATIENTS. 

001905 02-08 
PHARMACOKINETIC INTERACTION BETWEEN PROPRANOLOL AND 
CHLORPROMAZINE IN SCHIZOPHRENIC-PATIENTS. 

001940 02-08 
THE RELATIONSHIP OF ALPHA AND DELTA EEG FREQUENCIES TO PAIN 
AND MOOD IN FIBROSITIS-PATIENTS TREATED WITH CHLORPROMAZINE 
AND L TRYPTOPHAN. 

002152 02-n 
LUPUS-LIKE-ILLNESS ASSOCIATED WITH CHLORPROMAZINE. 

002408 02-15 
THE DISTRIBUTION OF CHLORPROMAZINE BETWEEN PLASMA AND 
ERYTHROCYTES. 

002496 02-16 
EFFECTS OF CHLORPROMAZINE ON DOPAMINERGIC-RECEPTOR FUNQIONS 
IN RAT-BRAIN - DIFFERENCE OF THE RESPONSE OF SEVERAL 
DOPAMINERGIC-SYSTEMS AFTER CHRONIC ADMINISTRATION. 

002773 03-03 
CHANGES IN THE CORTICAL ACTIVITY OF SUCCINATE-DEHYDROGENASE 
UNDER THE INFLUENCE OF CHLORPROMAZINE (A HISTOCHEMICAL- 
STUDY AND ELECTROCYTOCHEMICAL- STUDY). 

002784 03-03 
BIOLOGICAL-EFFECTS OF CHLORPROMAZINE IN CHRONIC 
SCHIZOPHRENICS III THE MUTUAL RELATION OF EACH INDEX. 

003179 03-08 
CHLORPROMAZINE LEVELS AND THE OUTCOME OF TREATMENT IN 
SCHIZOPHRENIC-PATIENTS. 

003188 03-08 ' 
PLASMA LEVELS OF CHLORPROMAZINE AND CLINICAL-RESPONSE. 

003201 03-08 , 

BIOLOGICAL-EFFECTS OF CHLORPROMAZINE IN CHRONIC J 

SCHIZOPHRENICS. I WITH REFERENCE TO PITUITARY-HORMONES. 1 

003415 03-131 
BIOLOGICAL-EFFEaS OF CHLORPROMAZINE IN CHRONIC 

SCHIZOPHRENICS. II. WITH REFERENCE TO SYMPATHETIC NEURONAL 
FUNCTION. 

003416 03-13 j 
DIFFERENTIAL BINDING OF CHLORPROMAZINE TO HUMAN BLOOD CEUS: 

APPLICATION OF THE HYGROSCOPIC DESORPTION METHOD. 

003556 03-16 
CHLORPROMAZINE, HALOPERIDOL, METOCLOPRAMIDE AND 
DOMPERIDONE RELEASE PROLACTIN THROUGH DOPAMINE 
ANTAGONISM AT LOW CONCENTRATIONS BUT PARADOXICALLY 
INHIBIT PROLACTIN RELEASE AT HIGH-CONCENTRATIONS. 

003731 04-03 
THE EFFEQ OF LONG-TERM CONCURRENT ADMINISTRATION OF 
CHLORPROMAZINE AND LITHIUM ON THE STRIATAL AND FRONTAL 
CORTICAL DOPAMINE METABOLISM IN RATS. 

003788 04-03 
INHIBITION OF LYSOSOMAL LIPASES BY CHLORPROMAZINE: A POSSIBLE 
MECHANISMS OF STABILIZATION ' 

003993 04-03 
INTERACTIONS BETWEEN CHLORPROMAZINE AND SOME OF ITS 
METABOLITES. 

004001 04-03 
CHLORPROMAZINE EFFEQS ON COCAINE-REINFORCED RESPONDING IN 
RHESUS-MONKEYS: RECIPROCAL MODIFICATION OF RATE ALTERING 
EFFEaS OF THE DRUGS. 

004133 04-04 
EFFEQS OF CHLORPROMAZINE ON ESCAPE AND AVOIDANCE RESPONSES: 
A CLOSER LOOK. 

004226 04-04 
PROTEIN BINDING OF CHLORPROMAZINE IN CEREBROSPINAL-FLUID AND 
SERUM. 

004311 04-08 



S-92 



VOLUME 19, SUBJECT INDEX 



Subject Index 



A TWELVE-YEAR FOLLOWUP OF THE NIMH-PRB HIGH-DOSE 
CHL0RPR0MA2INE STUDY OF CHRONIC SCHIZOPHRENICS - 
IMPLICATIONS FOR DEINSTITUTIONALIZATION. (UNPUBLISHED PAPER). 

004323 04-08 
NEUROENDOCRINE-TESTS DURING TREATMENT WITH NEUROLEPTIC- 
DRUGS: I. PLASMA PROLACTIN RESPONSE TO CHLORPROMAZINE 
CHALLENGE. 

004329 04-08 
SELECTIVE INHIBITORY-EFFECTS OF CHLORPROMAZINE AND IMIPRAMINE 
ON PLATELET AGGREGATION 

004518 04-13 
INTERACTION OF CHLORPROMAZINE WITH THE TRANSPORT SYSTEM OF 
GLUCOSE IN HUMAN ERYTHROCYTES 

004529 04-13 
THE EFFECT OF CHLORPROMAZINE AND MAGEPTIL ON THE 

PROLIFERATION OF PERIPHERAL BLOOD LYMPHOCYTES IN CULTIVATION 
WITH PHYTOHEMAGGLUTININ. 

004541 04-13 
BILATERAL SKIN CONDUCTANCE AND THE PUPILLARY LIGHT DARK 
REFLEX: MANIPULATION BY CHLORPROMAZINE, HALOPERIDOL, 
SCOPOLAMINE, AND PLACEBO. 

004544 04-13 
CONCENTRATIONS OF CHLORPROMAZINE AND TWO OF ITS ACTIVE 
METABOLITES IN PLASMA AND CEREBROSPINAL-FLUID OF PSYCHOTIC- 
PATIENTS TREATED WITH FIXED DRUG DOSES. 

004559 04-13 
HUMAN SOCIAL CONVERSATION: EFFEQS OF ETHANOL, SECOBARBITAL 
AND CHLORPROMAZINE. 

004582 04-14 
CHLORPROMAZINE ANALYSIS IN HUMAN PLASMA. (UNPUBLISHED 
PAPER). 

004591 04-15 

:hlorpromazine-hcl 

a comparison of the cardiovascular effects of haloperidol, 
thioridazine and chlorpromazine-hcl. 

000512 01-05 
ORIENTATIONAL TESTING OF CHLORPROMAZINE-HCL ON HOSPITALIZED 
MENTAL-PATIENTS. 

002131 02-11 
RAPID DETERMINATION OF CHLORPROMAZINE-HCL AND TWO OXIDATION 
PRODUaS IN VARIOUS PHARMACEUTICAL SAMPLES USING HIGH- 
PERFORMANCE LIQUID-CHROMATOGRAPHY AND FLUORESCENCE 
DETECTION. 

004302 04-06 

:hlorpromazine-induced 

the role of differential blockade of alpha-adrenergic agonists 
in chlorpromazine-induced hypotension. 

001851 02-05 
EFFECTS OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC BLOCKERS ON 
CHLORPROMAZINE-INDUCED ELEVATION OF PLASMA GLUCOSE AND 
CYCLIC-AMP IN FED MICE. 

003946 04-03 
BETA PHENYLETHYLAMINE REVERSAL OF CHLORPROMAZINE-INDUCED 
ACTIVATION OF STRIATAL TYROSINE-HYDROXYLASE AND CATALEPSY 

004018 04-03 
IHOICE 

HYPOMANIA AND TRICYCLIC-ANTIDEPRESSANT CHOICE. 

000545 01-07 
CHOICE OF TACTICS IN TREATING ALCOHOLIC-DELIRIUM. 

000688 01-11 
THE EFFECTS OF LITHIUM ON CHOICE BETWEEN COCAINE AND FOOD IN 
THE RHESUS-MONKEY. 

001825 02-04 
THE TREATMENT OF BUCCOLINGUOFACIAL DYSKINESIA IN THE ELDERLY 
THE CHOICE OF A NEUROLEPTIC-AGENT. 

002223 02-13 
AN INVOLVEMENT OF DOPAMINE IN HIGHER-ORDER CHOICE 
MECHANISMS IN THE MONKEY. 

003072 03-04 
CHOICE BETWEEN FOOD AND HEROIN: EFFECTS OF MORPHINE 
NALOXONE, AND SECOBARBITAL. 

004123 04-04 
DRUG PREFERENCE IN HUMANS: DOUBLE-BLIND CHOICE COMPARISON OF 
PENTOBARBITAL, DIAZEPAM AND PLACEBO. 

004566 04-14 
HOICES 

PHARMACOTHERAPY AND PSYCHOTHERAPY FOR AMBULATORY 
DEPRESSION: EFFICACY AND CHOICES. 

004413 04-09 
HOLECYSTOKININ 

THE IDENTITY AND HYPOTHALAMIC ORIGIN OF CHOLECYSTOKININ IN 
RAT-BRAIN AND POSTERIOR PITUITARY AND ITS POSSIBLE ROLE IN 
REGULATION OF NEUROSECRETION. (UNPUBLISHED PAPER) 

001003 02-01 
RIA AND HPLC EVIDENCE FOR THE PRESENCE OF METHIONINE- 
ENKEPHALIN AND CHOLECYSTOKININ IN THE NEURAL RETINA OF 
SEVERAL VERTEBRATE SPECIES. (UNPUBLISHED PAPER). 

001017 02-01 
NEWLY SYNTHESIZED CHOLECYSTOKININ IN SUBCELLULAR FRACTIONS OF 
THE RAT-BRAIN. 

003805 04-03 



CHOLECYSTOKININ-LIKE 

EFFECTS OF CHOLECYSTOKININ-LIKE PEPTIDES ON REARING ACTIVITY AND 
HEXOBARBITAL-INDUCED SLEEP 

000507 01-04 
CHOLECYSTOKININ-OCTAPEPTIDE 

INHIBITION OF THE ACTION OF CHOLECYSTOKININ-OCTAPEPTIDE ON THE 
GUINEA-PIG ILEUM MYENTERIC PLEXUS BY DIBUTYRYL-CYCLIC- 
GUANOSINE-MONOPHOSPHATE , 

001291 02-03 
CENTRAL DEPRESSANT EFFECTS OF CAERULEIN AND CHOLECYSTOKININ- 
OCTAPEPTIDE (CCK-8) DIFFER FROM THOSE OF DIAZEPAM AND 
HALOPERIDOL. 

002652 03-02 
EFFECTS OF CHOLECYSTOKININ-OCTAPEPTIDE ON STRIATAL DOPAMINE 
METABOLISM AND ON APOMORPHINE-INDUCED STEREOTYPED CAGE 
CLIMBING IN MICE. 

003031 03-04 
OPERANT FEEDING AND DRINKING IN PIGS FOLLOWING 
INTRACEREBROVENTRICULAR INJECTION OF SYNTHETIC 
CHOLECYSTOKININ-OCTAPEPTIDE, 

003064 03-04 
INTRAVENTRICULAR CHOLECYSTOKININ-OCTAPEPTIDE PRODUCES 
HYPERGLYCEMIA IN RATS. 

003943 04-03 
CHOLECYSTOKININ-PEPTIDES 

AN HPLC AND RIA ANALYSIS OF THE CHOLECYSTOKININ-PEPTIDES IN 
RAT-BRAIN. (UNPUBLISHED PAPER). 

001004 02-01 
HPLC SEPARATION OF CHOLECYSTOKININ-PEPTIDES - TWO SYSTEMS. 

(UNPUBLISHED PAPER). 

001005 02-01 
CHOLECYSTOKININ-PEPTIDES PRODUCE MARKED REDUCTION OF 

DOPAMINE TURNOVER IN DISCRETE AREAS IN THE RAT-BRAIN 
FOLLOWING INTERAVENTRICULAR INJECTION. 

001239 02-03 
CHOLERA-TOXIN 

OPIOIDS, NORADRENALINE AND GTP ANALOGS INHIBIT CHOLERA-TOXIN 
ACTIVATED ADENYLATE-CYCLASE IN NEUROBLASTOMA-X GLIOMA 
HYBRID CELLS. 

003975 04-03 
CHOLERA-TOXIN-INDUCED 

CHOLERA-TOXIN-INDUCED EPILEPTOGENIC-FOCUS - SPECIAL REFERENCE 
TO CYCLIC-AMP METABOLISM AND EPILEPTOGENIC-FOCUS. 

000522 01-05 
CHOLERETIC-EFFECT 

DISPOSITION OF VALPROIC-ACID IN THE RAT: DOSE-DEPENDENT 
METABOLISM, DISTRIBUTION, ENTEROHEPATIC RECIRCULATION AND 
CHOLERETIC-EFFECT. 

000073 01-03 
CHOLESTEROL 

PLASMA HDL CHOLESTEROL AND GROWTH-HORMONE IN EPILEPTICS 
TREATED WITH ANTICONVULSANTS. 

002260 02-13 
CHOLINE 

INHIBITION OF HIGH-AFFINITY CHOLINE UPTAKE: STRUCTURE-ACTIVITY 
STUDIES. 

000026 01-03 
INHIBITION OF BRAIN SYNAPTOSOMAL UPTAKE OF CHOLINE BY SOME 2 
CARBOXAMIDOSTRYCHNINE DERIVATIVES WITH MUSCLE-RELAXANT 
PROPERTIES. 

000084 01-03 
ORAL CHOLINE IN CEREBELLAR ATAXIA. 

000722 01-11 
EFFECTS OF CHOLINE CONTAINING COMPOUNDS ON TARDIVE-DYSKINESIA 
AND OTHER MOVEMENT-DISORDERS. 

000942 01-17 
EFFECTS OF HEMICHOLINIUM-3 AND CHOLINE ON HIPPOCAMPAL 
ELECTRICAL-ACTIVITY DURING IMMOBILITY VS. MOVEMENT 

001438 02-03 
EFFECT OF CHOLINE ON CONDITIONED FOOD MOTOR-REFLEXES IN CATS. 

001731 02-04 
UCK OF EFFECT OF CHOLINE AND NARCOTIC ANTAGONISTS UPON 
APOMORPHINE DISCRIMINATION. 

001770 02-04 
EFFECTS OF ORAL CHOLINE ON HUMAN COMPLEX PARTIAL SEIZURES. 

002149 02-11 
USE OF CHOLINE AND LECITHIN IN THE TREATMENT OF TARDIVE- 
DYSKINESIA. 

002473 02-15 
KINETIC DATA ON THE INHIBITION OF HIGH-AFFINITY CHOLINE 
TRANSPORT INTO RAT-FOREBRAIN SYNAPTOSOMES BY CHOLINE-LIKE 
COMPOUNDS AND NITROGEN-MUSTARD ANALOGUES. 

002879 03-03 
ALTERATIONS OF ACETYLCHOLINE AND CHOLINE METABOLISM IN 
MAMMALIAN PREPARATIONS TREATED WITH BETA BUNGAROTOXIN. 

003820 04-03 
TISSUE CHOLINE STUDIED USING A SIMPLE CHEMICAL ASSAY 

003828 04-03 



I 

9 



it* 

ii- 
S5 



fe: 



K 



S-93 



Subject Index 



Psychopharmacology Abstracts 



■•:-':'i 



M 



EFFECTS OF DELTA9 TETRAHYDROCANNABINOL AND CANNABIDIOL ON 
SODIUM-DEPENDENT HIGH-AFFINITY CHOLINE UPTAKE IN THE RAT 
HIPPOCAMPUS 

003908 04-03 
THE EFFECT OF ACETYLCHOLINE RELEASE ON CHOLINE FLUXES IN 
ISOLATED SYNAPTIC TERMINALS. 

003924 04-03 
CNS EFFECTS OF CHOLINE ADMINISTRATION: EVIDENCE FOR TEMPORAL 
DEPENDENCE. 

003996 04-03 
THE HIGH-AFFINITY CHOLINE UPTAKE SYSTEM WITH RESPECT TO THE 
MUSCARINIC-RECEPTORS USING A SYNAPTOSOMAL FRACTION 
ABUNDANT IN PRESYNAPTIC MEMBRANES. 

004028 04-03 
CHOLINE REVERSES NALOXONE-INDUCED DECREASES IN HIPPOCAMPAL 
ACETYLCHOLINE CONTENT AND SUPPRESSES ESCAPE-BEHAVIOR IN 
OPIATE-DEPENDENT RATS. 

004076 04-04 
MECHANISM OF LITHIUM INCLUDED ELEVATION IN RED-BLOOD-CELL 
CHOLINE CONTENT; AN IN VITRO ANALYSIS. 

004511 04-13 
A MECHANISM FOR THE ACCUMULATION OF CHOLINE IN ERYTHROCYTES 
DURING TREATMENT WITH LITHIUM. 

004520 04-13 
ERYTHROCYTE CHOLINE CONCENTRATIONS ARE ELEVATED IN MANIC- 

"^^'^^^^ 004521 04-13 

GAS-CHROMATOGRAPHY/MASS-SPECTROMETRY STABLE ISOTOPIC 
ANALYSES FOR OEANOL, CHOLINE, AND THEIR ACETYLESTERS. 

004683 04-16 
CHOLINE-ACETYL-TRANSFERASE 

PHYSICAL AND KINETIC PROPERTIES OF CHOLINE-ACETYL-TRANSFERASE 
FROM RAT AND BOVINE BRAIN. 

003676 04-01 
CHOLINE-ACETYLTRANSFERASE 

ACETYLCHOLINE AND CHOLINE-ACETYLTRANSFERASE 

003930 04-03 
CHOLINE-BITARTRATE 

CHOLINE-BITARTRATE TREATMENT OF ALZHEIMER-TYPE DEMENTIAS. 

000675 01-11 
CHOLINE-CHLORIDE „ „^ 

HUMAN MEMORY AND THE EFFECTS OF PHYSOSTIGMINE AND CHOLINE- 

'''''''' 002317 02-14 

PHARMACOKINETIC-STUDIES WITH CHOLINE-CHLORIDE: A PRELIMINARY 
REPORT. 

004514 04-13 
CLINICAL AND PRECLINICAL EXPERIENCE WITH CHOLINE-CHLORIDE IN 
HUNTINGTONS-DISEASE AND TARDIVE-DYSKINESIA: UNANSWERED 
QUESTIONS. 

004604 04-15 

CHOLINE-LIKE 

KINETIC DATA ON THE INHIBITION OF HIGH-AFFINITY CHOLINE 
TRANSPORT INTO RAT-FOREBRAIN SYNAPTOSOMES BY CHOLINE-LIKE 
COMPOUNDS AND NITROGEN-MUSTARD ANALOGUES. 

002879 03-03 
CHOLINERGIC 

SEIZURES AND RELATED EPILEPTIFORM ACTIVITY IN HIPPOCAMPUS 
TRANSPLANTED TO THE ANTERIOR-CHAMBER OF THE EYE: 
MODULATION BY CHOLINERGIC AND ADRENERGIC INPUT. 

000095 01-03 
ENKEPHALINS PRESYNAPTICALLY INHIBIT CHOLINERGIC TRANSMISSION 
IN SYMPATHETIC GANGLIA. 

000167 01-03 
CHOLINERGIC MECHANISMS AND CATAPLEXY IN DOGS. 

000374 01-04 
IMIPRAMINE AND REM SLEEP: CHOLINERGIC MEDIATION IN ANIMALS. 

000406 01-04 
CHOLINERGIC MECHANISMS IN SCENT-MARKING-BEHAVIOR BY 
MONGOLIAN-GERBILS (MERIONES-UNGUICULATUS) . 

000504 01-04 
CHOLINERGIC ASPECTS OF TARDIVE-DYSKINESIA: HUMAN AND ANIMAL 
STUDIES. 

000928 01-17 
INTERACTIONS OF NEUROPEPTIDES WITH CHOLINERGIC 

SEPTOHIPPOCAMPAL PATHWAY: INDICATION FOR A POSSIBLE 
TRANSSYNAPTIC REGULATION. (UNPUBLISHED PAPER). 

001062 02-01 
MARIJUANA AND CHOLINERGIC DYNAMICS. (UNPUBLISHED PAPER). 

001166 02-03 
REGULATION OF CHOLINERGIC TRANSMISSION IN ADRENAL-MEDULLA. 
(UNPUBLISHED PAPER). 

001182 02-03 
OPIATE INTERACTIONS WITH CHOLINERGIC NEURONS. 

001198 02-03 
LONG-TERM EFFECTS OF HALOPERIDOL, CLOZAPINE, AND METHADONE 
ON RAT STRIATAL CHOLINERGIC AND DOPAMINERGIC DYNAMICS. 

001325 02-03 
INTRINSIC CHOLINERGIC EXCITATION IN THE RAT NEOSTRIATUM: 
NICOTINIC AND MUSCARINIC-RECEPTORS. 

001374 02-03 



CENTRAL PHARMACOLOGICAL CONTROL OF CORTICOSTERONE SECRETION 
IN THE INTACT RAT. DEMONSTRATION OF CHOLINERGIC AND 
SEROTONINERGIC FACILITATORY AND ALPHA-ADRENERGIC INHIBITORY 
MECHANISMS. 

001487 02-03 
INTERACTION OF CHOLINERGIC AND DOPAMINERGIC INFLUENCES ON 
YAWNING-BEHAVIOR. 

001656 02-04 
ADRENERGIC MODULATION OF THE HYPOTHALAMIC CHOLINERGIC 
MECHANISM IN THE CONTROL OF EMOTIONAL DEFENSIVE-BEHAVIOR IN 
THE CAT. 

001761 02-04 
INVOLVEMENT OF CHOLINERGIC AND GABAERGiC SYSTEMS IN 
SCHIZOPHRENIA. 

001907 02-08 
INCREASED VULNERABILITY TO CHOLINERGIC STIMULATION IN 
AFFECTIVE-DISORDER PATIENTS 

002003 02-09 
CHOLINERGIC ASPEQS OF TARDIVE-DYSKINESIA. 

002102 02-11 
DEVELOPMENT AND USE OF PHARMACOLOGICAL-PROBES OF THE CNS IN 
MAN: EVIDENCE OF CHOLINERGIC ABNORMALITY IN PRIMARY 
AFFEQIVE-ILLNESS. 

002506 02-16 
DYSFUNCTIONS OF CHOLINERGIC PROCESSES IN SCHIZOPHRENIA. 

002611 02-17 
TRIMETHADIONE EFFECTS ON CHOLINERGIC RESPONSES IN APLYSIA 
NEURONS 

002782 03-03 
CHOLINERGIC, DOPAMINERGIC, NORADRENERGIC, OR GLUTAMINERGIC 
STIMULATION VENTRAL TO THE ANTERIOR SEPTUM DOES NOT 
SPECIFICALLY SUPPRESS DEFENSIVE-BEHAVIOR. 

002945 03-04 
INJECTIONS OF DOPAMINERGIC, CHOLINERGIC, SEROTONINERGIC AND 
GABAERGIC DRUGS INTO THE NUCLEUS-ACCUMBENS EFFECTS ON 
LOCOMOTOR-ACTIVITY IN THE RAT. 

003019 03-04 
PHYSOSTIGMINE IN TOUREHE-SYNDROME: EVIDENCE FOR CHOLINERGIC 
UNDERAQIVITY. 

003286 03-10 
CHOLINERGIC REBOUND IN NEUROLEPTIC WITHDRAWAL-SYNDROMES. 

003506 03-15 
THE EFFECT OF CHOLINERGIC SUBSTANCES ON NOCICEPTIVE EVOKED- 
RESPONSES IN SPECIFIC NUCLEI OF THE THALAMUS. 

003770 04-03 
NYSTAGMIC RESPONSES OF HIPPOCAMPAL ORIGIN WITH REFERENCE TO 
EXCITABILITY OF CHOLINERGIC AND ADRENERGIC COMPONENTS 
INVOLVED IN THE HIPPOCAMPUS OF RABBITS. 

003842 04^3 
SUBSTANCE-P INCREASES HYPOTHALAMIC BLOOD FLOW VIA AN 
INDIRECT ADRENERGIC CHOLINERGIC INTERAQION. 

003887 04-03 j 
EFFECTS OF TAIPOXIN ON THE ULTRASTRUQURE OF CHOLINERGIC AXON 
TERMINALS IN THE MOUSE ADRENAL-MEDULLA. 

003916 04-03 
5' TRIPHOSPHATE RECYCLES INDEPENDENTLY OF ACETYLCHOLINE IN 
CHOLINERGIC SYNAPTIC VESICLES 

004063 04-03 
POSSIBLE MUSCARINIC CHOLINERGIC MEDIATION OF PAHERNEO 
AGGRESSIVE REFLEXES IN THE CAT. 

004153 04-04 

CHOLINERGIC MECHANISMS IN MANIA AND DEPRESSION: QUESTIONS OF 

SPECIFICITY. „ ^ 

004374 04-09 

THE STATE OF THE ADRENERGIC AND CHOLINERGIC SYSTEMS IN 
SCHIZOPHRENIC-PATIENTS DURING PSYCHPHARMACOTHERAPY. 

004526 04-13 
CHOLINERGIC-DRUGS 

EFFECTS OF DOPAMINERGIC AND CHOLINERGIC-DRUGS, NALOXONE AND 
L PROLYL-LEUCYL-GLYCINAMIDE ON LSD-INDUCED CATALEPSY. 

000360 01-04 
THE EFFECS OF CHOLINERGIC-DRUGS ON THE INVOLUNTARY- 
MOVEMENTS OF TARDIVE-DYSKINESIA. 

000726 01-11 
EFFEaS OF CHOLINERGIC-DRUGS ON MEMORY IN ALZHEIMERS-DISEASE. 

003454 03-14 

CHOLINERGIC-RECEPTOR 

AN ENHANCED SENSITIVITY OF MUSCARINIC CHOLINERGIC-RECEPTOR 
ASSOCIATED WITH DOPAMINERGIC-RECEPTOR SUBSENSITIVITY AFTER 
CHRONIC ANTIDEPRESSANT TREATMENT. 

002788 03-03 

BRAIN MUSCARINIC CHOLINERGIC-RECEPTOR BINDING IN ROMAN HIGH- 
AVOIDANCE AND LOW-AVOIDANCE RATS. ^^^^ „^ „, 

002852 03-03 

A COMPARISON OF HUMAN MUSCARINIC CHOLINERGIC-RECEPTOR 
RESPONSE TO A NUMBER OF PSYCHOTROPICS UTILIZING THE 
RADIOLABELED ANTAGONIST, (3H) QUINUCLIDINYL-BENZILATE. (PH.D. 

DISSERTATION). „„^,o „, „, 

002918 03-03 



S-94 



VOLUME 19, SUBJECT INDEX 



Subject Index 



CHOLINEROIC-RECEPTORS 

THE REGULATION OF CARDIAC MUSCARINIC CHOLINERGIC-RECEPTORS BY 
ISOPROTERENOL 

001441 02-03 
CHOllNERGIC-SUPERSENSmVITY 

THE ROLE Of CHOLINERGIC-SUPERSENSITIVITY IN THE MEDICAL 
SYMPTOMS ASSOCIATED WITH WITHDRAWAL OF ANTIPSYCHOTIC- 
DRUGS. 

000869 01-15 
CHOLINESTERASE 

DIFFERENTIAL REGUL*TION OF MUSCARINIC AGONIST BINDING-SITES 
FOLLOWING CHRONIC CHOLINESTERASE INHIBITION. 

000279 01-03 
ACETYLCHOLINESTERASE AND CHOLINESTERASE ACTIVITIES IN THE 
MOUSE CEREBELLUM FOLLOWING MISONIDAZOLE TREATMENT. 

003123 03-05 
CHOLINOCEPTORS 

INVOLVEMENT OF CENTRAL CHOLINOCEPTORS IN METRAZOL-INOUCED 
CONVULSIONS. 

000247 01-03 
CHOLINOLYTIC 

SCOPOLAMINE IN CHOLINOLYTIC TREATMENT, 

004468 04-1 1 
CHOLINOMIMETICS 

COMPARATIVE-STUDY OF AGGRESSIVE-BEHAVIOUR AFTER INJECTION OF 
CHOLINOMIMETICS, ANTICHOLINESTERASES, NICOTINIC, AND 
MUSCARINIC GANGLIONIC STIMULANTS INTO THE CEREBRAL 
VENTRICLES OF CONSCIOUS CATSr FAILURE Of NICOTINIC-DRUGS TO 
EVOKE AGGRESSION. 

001568 02-04 
CHOLINOMIMETICS IN HUNTINGTONS-DISEASE. 

004442 04-11 
CHOLINOMIMETICS IN MANIA, SCHIZOPHRENIA, AND MEMORY- 
DISORDERS. 

004703 04-17 
CHOREA 

PEMOLINE-INDUCED CHOREA. 

003516 03-15 
CHOREIC-MOVEMENTS 

CHOREIC-MOVEMENTS INDUCED BY THE USE OF METHADONE. 

002467 02-15 
CHORIONIC 

INCREASES IN TESTOSTERONE LEVELS AND IN COPULATORY-BEHAVIOR OF 
MALE RHESUS-MONKEYS FOLLOWING TREATMENT WITH HUMAN 
CHORIONIC GONADOTROPHIN. 

003012 03-04 
CHOROID 

EVIDENCE FOR THE PRESENCE OF TWO TYPES Of MONOAMINE-OXIDASE 
IN RABBIT CHOROID PLEXUS AND THEIR ROLE IN BREAKDOWN OF 
AMINES INFLUENCING CEREBROSPINAL-fLUID fORMATION 

002807 03-03 
CHROMAFFIN 

RELEASE Of ARACHIDONIC-ACID fROM ADRENAL CHROMAffIN CELL- 
CULTURES DURING SECRETION OF EPINEPHRINE. (UNPUBLISHED 
PAPER). 

001027 02-01 
INFLUENCE OF DRUGS AFfECTING THE PITUITARY ADRENAL AXIS ON 
CHROMAFFIN CELLS. 

001183 02-03 
ACCUMULATION OF AMANTADINE BY ISOLATED CHROMAFFIN 
GRANULES. 

003866 04-03 
CHROMATIN 

INFLUENCE Of PSYCHOACTIVE AND NONPSYCHOACTIVE CANNABINOIDS 
ON CHROMATIN STRUCTURE AND FUNCTION IN HUMAN CELLS 

002831 03-03 
CHROMATOGRAPHY 

AfflNITY CHROMATOGRAPHY Of THE BETA-ADRENERGIC-RECEPTOR AND 
CHARACTERIZATION Of ANTIBODIES RAISED AGAINST PURIflED 
RECEPTOR PREPARATIONS. 

001009 02-01 
GAS-CHROMATOGRAPHY, MASS-SPECTROMETRY, AND COMBINED 
CHROMATOGRAPHY MASS-SPECTROMETRY. 

^„_^ 004290 04-06 

CHROMOSOMES 

fRAGILE SITES IN HUMAN CHROMOSOMES I THE EfFECT OF METHIONINE 
ON THE XQ-FRAGILE-SITE. 

^„.^ 004515 04-13 

CHRONIC-BRAIN-SYNOROMES 

PROPRANOLOL IN THE TREATMENT OF RAGE AND VIOLENT-BEHAVIOR IN 
PATIENTS WITH CHRONIC-BRAIN-SYNDROMES. 
,„„^ 003394 03-1 1 

CHRONIC-OUTPATIENTS 

USING DRUG-HOLIDAYS FOR CHRONIC-OUTPATIENTS. 
^—^ 004742 04-17 

CHRONIC-SCHIZOPHRENICS 

THE EFFECTS OF A DRUG-HOLIDAY ON RELAPSE AND TARDIVE- 
DYSKINESIA IN CHRONIC-SCHIZOPHRENICS. 

003487 03-15 



CHRONIC-TREATMENT 

EFFECT OF CHRONIC-TREATMENT WITH ANTIDEPRESSANTS ON BETA- 
ADRENERGIC-RECEPTOR BINDING IN GUINEA-PIG BRAIN 

000135 01-03 
EFFECTS OF CHRONIC-TREATMENT WITH L SULPIRIDE AND HALOPERIDOL 
ON CENTRAL DOPAMINE TURNOVER EVALUATED IN DOPAMINE CELL 
BODY AND NERVE TERMINAL-RICH AREAS. 

001096 02-03 
INTERACTION-STUDIES BETWEEN NARCOTIC ANALGESICS, NARCOTIC 
ANTAGONISTS AND ETHANOL: STUDIES DURING ACUTE AND CHRONIC- 
TREATMENT AND WITHDRAWAL STATES IN RATS AND MICE. (PHD 
DISSERTATION). 

001165 02-03 
EFFECTS OF CHRONIC-TREATMENT WITH L SULPIRIDE AND HALOPERIDOL 
ON CENTRAL MONOAMINERGIC MECHANISMS. 

001240 02-03 
REGUL^TION OF TYROSINE-HYDROXYLASE AFTER CHRONIC-TREATMENT 
WITH CLASSIC AND ATYPICAL ANTISCHIZOPHRENIC-DRUGS. 

001262 02-03 
ACETYLCHOLINE AND AMINO-ACID NEUROTRANSMITTERS IN EPIDURAL 
CUPS OF FREELY-MOVING-RATS: EFFECT OF ACUTE AND CHRONIC- 
TREATMENT WITH ANTISCHIZOPHRENIC-DRUGS. 

001386 02-03 
MODULATION OF BETA-ADRENERGIC-RECEPTORS AND CALMODULIN 
FOLLOWING ACUTE AND CHRONIC-TREATMENT WITH NEUROLEPTICS 

001529 02-03 
CHRONIC-TREATMENT WITH VALIUM (DIAZEPAM) FAILS TO AFFECT THE 
REPRODUCTIVE SYSTEM OF THE MALE RAT. 

001535 02-03 
DIFFERENTIAL-EFFECTS OF CLOMIPRAMINE AND CLORGYLINE ON THE 
SENSITIVITY OF CORTICAL NEURONS TO SEROTONIN: EFFECT OF 
CHRONIC-TREATMENT. 

002847 03-03 
NOREPINEPHRINE AND DOPAMINE CEREBRAL LEVELS AFTER CHRONIC- 
TREATMENT WITH NOMIFENSINE. 

002872 03-03 
SUPPRESSION OF ACTIVE SLEEP BY CHRONIC-TREATMENT WITH 
CHLORIMIPRAMINE DURING EARLY POSTNATAL DEVELOPMENT 
EFFECTS UPON ADULT SLEEP AND BEHAVIOR IN THE RAT. 

003056 03-04 
FACILITATED SHOCK-INDUCED AGGRESSION AFTER CHRONIC-TREATMENT 
WITH ANTIDEPRESSANT-DRUGS IN THE RAT. 

003058 03-04 
SUPERSENSITIVITY OF CENTRAL NORADRENERGIC PRESYNAPTIC- 
AUTORECEPTORS FOLLOWING CHRONIC-TREATMENT WITH THE 
ANTIDEPRESSANT MIANSERIN. 

003745 04-03 
REGULATION OF SER0T0NIN2-RECEPT0RS (5 HT2) LABELED WITH 
(3H)SPIR0PERID0L BY CHRONIC-TREATMENT WITH THE 
ANTIDEPRESSANT AMITRIPTYLINE. 

003964 04-03 
THE INSENSITIVITY OF DEVELOPING BENZODIAZEPINE-RECEPTORS TO 
CHRONIC-TREATMENT WITH DIAZEPAM, GABA AND MUSCIMOL IN 
BRAIN CELL-CULTURES. 

004002 04-03 
EffECT OF CHRONIC-TREATMENT WITH TRICYCLIC-ANTIDEPRESSANT 
DRUGS ON IDENTIFIED BRAIN NORADRENERGIC AND SEROTONERGIC 
NEURONS. 

004026 04-03 
ELECTROCARDIOGRAPHIC-CHANGES IN RATS DURING CHRONIC- 
TREATMENT WITH ANTIDEPRESSANT AND NEUROLEPTIC-DRUGS. 

004284 04-05 
HORMONAL STIMULATION AFTER INJECTION OF THYROTROPHIN- 
RELEASING-FACTOR (TRF) AND ACTH1-24 IN PATIENTS FOLLOWING 
CHRONIC-TREATMENT WITH NEUROLEPTICS: PRELIMINARY-STUDY. 

004505 04-13 
CHRONIC-TREATMENTS 

INFERENTIAL CHANGES AFTER CHRONIC-TREATMENTS WITH LI, DMI OR 
ETHANOL DETECTED BY ELECTROPHYSIOLOGICAL-CORRELATES. 

001136 02-03 
CHRONICALLY-ILL 

CHRONIC DRUG-TREATMENT OF THE CHRONICALLY-ILL: BENEFITS AND 
RISKS. 

003625 03-17 
CHRONOLOGICAL 

CHRONOLOGICAL ELECTROENCEPHALOGRAPHIC AND 

NEUROPHARMACOLOGICAL- STUDY IN CORTICAL KINDLING RABBITS. 

002761 03-03 
CHRONOLOGY 

CHRONOLOGY Of EXTRAPYRAMIDAL-EfFECTS OF NEUROLEPTIC-DRUGS 
AND THE NIGROSTRIATAL DOPAMINERGIC-SYSTEM 

002449 02-15 
CHRONOLOGY OF NEUROCHEMICAL ALTERATIONS INDUCED BY GABA 
AGONIST ADMINISTRATION. 

002713 03-03 
CICLAZINDOL 

INFLUENCE Of CICLAZINDOL ON MONOAMINE UPTAKE AND CNS 
FUNCTION IN NORMAL SUBJECTS. 

002268 02-13 



J 

S 



.■.•i«' 



5?5 









S-95 



Subject Index 



Psychopharmacology Abstracto 



CIGAREHE 

NALOXONE REDUCES CIGARETTE SMOKING. 

000808 01-14 
THE ROLE OF NICOTINE IN THE BEHAVIORAL-ASPECTS OF CIGAREHE 
SMOKING. 

004575 04-14 
CIMETIDINE 

SYNERGISTIC ACTIONS OF PROPANTHELINE-BROMIDE WITH CIMETIDINE 
AND THIOPROPAZATE-HYDROCHLORIDE IN THE PREVENTION OF 
STRESS-ULCER FORMATION IN RATS 

000064 01-03 
DELAYED CLEARANCE OF DIAZEPAM DUE TO CIMETIDINE. 

000164 01-03 
CIMETIDINE TOXICITY MANIFESTED AS PARANOIA AND 
HALLUCINATIONS. 

000829 01-15 
AGITATION, DISORIENTATION, AND HALLUCINATIONS IN PATIENTS ON 
CIMETIDINE: A REPORT OF THREE CASES AND LITERATURE REVIEW. 

000896 01-15 
INFLUENCE OF CIMETIDINE ON THE PHARMACOKINETICS OF 
DESMETHYLDIAZEPAM AND OXAZEPAM. 

002249 02-13 
CIMETIDINE-INDUCED 

A CASE-REPORT OF CIMETIDINE-INDUCED DEPRESSIVE-SYNDROME. 

000839 01-15 
DIFFERENTIAL DIAGNOSIS OF CIMETIDINE-INDUCED DELIRIUM. 

003488 03-15 
CIRCADIAN-CYCLES 

THE EFFECTS OF PROGESTERONE ON THE CIRCADIAN-CYCLES AND 
ESTROUS-CYCLES IN THE RAT. (PH D. DISSERTATION). 

001 1 1 1 02-03 
ORCADIAN-CYCLING 

PHENOBARBITAL EFFECTS ON WEIGHT-GAIN AND CIRCADIAN-CYCLING OF 
FOOD INTAKE AND BODY-TEMPERATURE. 

001409 02-03 
CIRCADIAN-EXCRETION 

EFFECT OF FLUPHENAZINE ON THE CIRCADIAN-EXCRETION OF CYCLIC- 
NUCLEOTIDES AND ELECTROLYTES IN THE URINE OF CHRONIC 
SCHIZOPHRENICS. 

001927 02-08 
CIRCADIAN-PERIODICITY 

EFFECT OF LITHIUM-CARBONATE ON CIRCADIAN-PERIODICITY IN 
HUMANS, 

000772 01-13 
CIRCADIAN-RHYTHM 

CIRCADIAN-RHYTHM OF CYCLIC-NUCLEOTIDE AND GABA LEVELS IN THE 
RAT-BRAIN. 

000049 01-03 
INFLUENCE OF CHRONIC ALCOHOL INTOXICATION ON CIRCADIAN-RHYTHM 
OF NEUROSECRETORY CENTERS OF RAT HYPOTHALAMUS 

001549 02-03 
CIRCADIAN-RHYTHMc 

antidepressant-lRugs slow circadian-rhythms in behavior and 

BRAIN NEUROTRANSMITTER-RECEPTORS. 

001536 02-03 
circadian-variation 

circadian-variation of cyclic-amp in the rat pineal-gland. 

003938 04-03 
CIRCLING 

MORPHINE-DEPENDENCE AND DOPAMINERGIC-ACTIVITY: TESTS OF 
CIRCLING RESPONSES IN RATS WITH UNILATERAL NIGRAL LESIONS. 

001641 02-04 
CIRCLING PRODUCED BY SEROTONIN AND DOPAMINE AGONISTS IN 
RAPHE LESIONED RATS. A SEROTONIN MODEL. 

001783 02-04 
INVOLVEMENT OF DOPAMINE IN CIRCLING RESPONSES TO MUSCIMOL 
DEPENDS ON INTRANIGRAL SITE OF INJEQION. 

004158 04-04 
CIRCLING-BEHAVIOR 

THE EFFECT OF DOPAMINE UPTAKE BLOCKING-AGENTS ON THE 
AMPHETAMINE-INDUCED CIRCLING-BEHAVIOR IN MICE WITH 
UNILATERAL NIGROSTRIATAL LESIONS. 

004117 04-04 
CIRCLING-BEHAVIOUR 

CIRCLING-BEHAVIOUR INDUCED BY INTRANIGRAL INJECTION OF 
BACLOFEN IN RATS. 

000415 01-04 
CONTRALATERAL CIRCLING-BEHAVIOUR INDUCED BY INTRANIGRAL 
INJECTION OF MORPHINE AND ENKEPHALIN ANALOGUE FK-33-824 IN 
RATS. 

001669 02-04 
CONTRALATERAL CIRCLING-BEHAVIOUR INDUCED BY INTRANIGRAL 

INJECTION OF TAURINE IN RATS. 

001670 02-04 
THE ROLE OF NIGRAL PROJECTIONS TO THE THALAMUS IN DRUG- 
INDUCED CIRCLING-BEHAVIOUR IN THE RAT. 

004205 04-04 
CIRCUITS 

ACTIVATION OF CORTICAL CIRCUITS DURING INTERIQAL SPIKES. 

000056 01-03 



CIRCULATION 

EFFECT OF ISOPROTERENOL ON CEREBRAL CIRCULATION IN DOGS. 

000199 01-03 
EFFECTS OF ANTIDEPRESSIVE-DRUGS UPON THE HEART AND 

CIRCULATION. 

000863 01-15 
EFFECTS OF BICUCULLINE-INDUCED SEIZURES ON CEREBRAL METABOLISM 
AND CIRCULATION OF RATS RENDERED HYPOGLYCEMIC BY 
STARVATION. 

001134 02-03 
ACTION OF 4 AMINOPYRIDINE ON THE CEREBRAL CIRCULATION. 

003781 04-03 
CIRCULATIONS 

ABSORPTION OF 14C LABELED METHADONE BY PORTAL AND 

EXTRAPORTAL VENOUS CIRCULATIONS FOLLOWING INTRAPERITONEAL 
AND INTRODUODENAL ADMINISTRATION 

000094 01-03 
CIRCULATORY 

CEREBRAL CIRCUUTORY AND METABOLIC-EFFEaS OF PIRIBEDIL. 

000200 01-03 
CIRCUMSTANCES 

THE EFFECT OF MEBICAR ON THE CONDITION OF ANIMALS UNDER 
CERTAIN EXTREME CIRCUMSTANCES. 

004262 04-04 
CIRCUMVENTRICULAR 

INHIBITION OF MONOAMINE-OXIDASE BY CLORGYLINE AND DEPRENYL IN 
CIRCUMVENTRICULAR STRUCTURES OF RAT-BRAIN. 

000159 01-03 
MONOAMINE-OXIDASE-B ACTIVITIES TOWARD BETA PHENYLETHYLAMINE 
IN DISCRETE HYPOTHALAMIC AND CIRCUMVENTRICULAR NUCLEI OF 
THE RAT. 

002781 03-03 
CIRRHOSIS 

CHLORDIAZEPOXIDE AND OXAZEPAM DISPOSITION IN CIRRHOSIS 

000790 01-13 
CIS-ISOMERS 

THE PHOTOCHEMICAL-STABILITY OF CIS-ISOMERS AND TRANS-ISOMERS 
OF TRICYCLIC NEUROLEPTIC-DRUGS 

001872 02-06 
PLASMA LEVELS OF THE CIS-ISOMERS AND TRANS-ISOMERS OF DOXEPIN 
AND DESMETHYLDOXEPIN AFTER ADMINISTRATION OF DOXEPIN TO 
PATIENTS. 

004355 04-09 
CISMETHRIN 

THE EFFECT OF CISMETHRIN ON THE RAT DORSAL ROOT POTENTIALS. 

000528 01-05 
CITALOPRAM 

INITIAL, CLINICAL-TRIAL OF A NEW, SPECIFIC 5 HT REUPTAKE INHIBITOR, I 
CITALOPRAM (LU-10-171). i 

000591 01-09 
EFFECT OF CITALOPRAM (LU-10-171) ON TRANYLCYPROMINE AND 
TRYPTOPHAN-INDUCED WET-DOG-SHAKES IN RATS. 

001682 02-04 
CITICOLINE ^ 

OBSERVATIONS ON THE USE OF CITICOLINE IN DYSTHYMIC-PATIENTS. 

003207 03-09 , 
CITRATE 

GAMMA BUTYROLACTONE-GAMMA-CARBONYL-HISTIDYL-PROLINAMIDE 
CITRATE (DN-1417): A NOVEL TRH ANALOG WITH POTENT EFFECTS ON , 
THE CENTRAL-NERVOUS-SYSTEM. 

003057 03-04 
INHIBITION OF THE SYNTHESIS OF ACETYLCHOLINE IN RAT-BRAIN SLICES 
BY (-) HYDROXYCITRATE AND CITRATE. 

004044 04-03 
LITHIUM EFFEQS ON CITRATE METABOLISM IN HUMANS AND RATS. 

004537 04-13 
CLAMP 

VOLTAGE CLAMP STUDY OF CAT SPINAL MOTONEURONS DURING 
STRYCHNINE-INDUCED SEIZURES. 

002886 03-03 
CLARE-BISHOP 

SELECTIVE SYNAPTIC ANTAGONISM BY ATROPINE AND ALPHA 
AMINOADIPATE OF PULVINAR AND CORTICAL AFFERENTS TO THE 
SUPRASYLVIAN VISUAL AREA (CLARE-BISHOP AREA). 

002752 03-03 
CLASSIC 

REGULATION OF TYROSINE-HYDROXYLASE AFTER CHRONIC-TREATMENT 
WITH CLASSIC AND ATYPICAL ANTISCHIZOPHRENIC-DRUGS. 

001262 02-03 
CLASSICALLY 

EFFECTS OF SUBCHRONIC DESMETHYLIMIPRAMINE (DMI) TREATMENT OF 
THE CLASSICALLY CONDITIONED EYEBLINK RESPONSE IN RABBITS. 

004180 04-04 
CLASSIFICATION 

CLASSIFICATION AND ASSESSMENT OF CEREBRAL BIOAVAILABILITY OF 
LOPIRAZEPAM (D-12524) BY QUANTITATIVE EEG AND 
PSYCHOMETRIC-ANALYSIS. 

000720 01-11 



S-96 



'i*3**' 



:1fSf 



VOLUME 19, SUBJECT rNDEX 



Subject Index 



CRITERIA FOR CLINICAL DEVELOPMENT AND CLASSIFICATION OF 
NOOTROPIC-DRUGS. AN EXAMPLE: PIRACETAM. 

000988 0)-l 7 
A CLASSIFICATION OF OPIATE-RECEPTORS THAT MEDIATE 
ANTINOCICEPTION IN ANIMALS. 

001807 02-04 
AN OBJECTIVE CLASSIFICATION OF PSYCHOACTIVE-DRUGS. 

001894 02-07 
CLASSIFICATION OF PSYCHOTROPIC-DRUGS IN PEDIATRIC- 
PSYCHOPHARMACOLOGY. 

001903 02-07 
DIAGNOSTIC CLASSIFICATION AND THE ENDORPHIN HYPOTHESIS OF 
SCHIZOPHRENIA; INDIVIDUAL DIFFERENCES AND 
PSYCHOPHARMACOLOGICAL STRATEGIES. (UNPUBLISHED PAPER) 

001910 02-08 
CLASSIFICATION OF THE ANTIDEPRESSANT-DRUGS. 

002015 02-09 
CLASSIFICATION OF ENDORPHINS/ENKEPHALINS IN BRAIN PHYSIOLOGY 
AND PATHOLOGY (BASED ON EEG AND CLINICAL- STUDY OF 
SYNTHETICALLY-MODIFIED METHIONINE-ENKEPHALIN). 

002286 02-13 
CLASSIFICATION OF DRUGS AND PATIENTS TO ACHIEVE MAXIMUM 
THERAPEUTIC RESPONSE. 

002560 02-17 
CLASSIFICATION OF ANALGESICS. 

002570 02-17 
CLASSIFICATION AND PSYCHOTROPIC-DRUGS. 

002605 02-17 
REFLECTIONS ON THE CLASSIFICATION OF ANTIDEPRESSANT-DRUGS. 

002610 02-17 
DIAGNOSTIC CLASSIFICATION AND THE ENDORPHIN HYPOTHESIS OF 
SCHIZOPHRENIA: INDIVIDUAL DIFFERENCES AND 
PSYCHOPHARMACOLOGICAL STRATEGIES. 

003167 03-08 
TOWARD A BIOCHEMICAL CLASSIFICATION OF DEPRESSIVE-DISORDERS 
IV: PRETREATMENT URINARY MHPG LEVELS AS PREDICTORS OF 
ANTIDEPRESSANT RESPONSE TO IMIPRAMINE. 

004406 04-09 
THE CLASSIFICATION OF SLEEP-DISORDERS AND THE TREATMENT OF 
VARIOUS FORMS OF SOMNAMBULISM. 

004461 04-11 
CLEARANCE 

DELAYED CLEARANCE OF DIAZEPAM DUE TO CIMETIDINE. 

000164 01-03 
NORTRIPTYLINE AND ANTIPYRINE CLEARANCE IN RELATION TO 
DEBRISOQUINE HYOROXYLATION IN MAN. 

000754 01-13 
VALPROIC-ACID DOSAGE AND PLASMA PROTEIN BINDING AND 

CLEARANCE. 

000755 01-13 
CLEBOPRIDE 

COMPARISON OF THE POTENCIES OF CLEBOPRIDE AND OTHER 
SUBSTITUTED BENZAMIDE DRUGS ON ISOLATED GASTROINTESTINAL 
TRACT OF THE GUINEA-PIG AND RAT. 

003928 04-03 
CLEFTS 

FACIAL CLEFTS AMONG EPILEPTIC-PATIENTS. 

003484 03-15 
CLENBUTEROL 

CLENBUTEROL, A CENTRAL BETA-ADRENOCEPTOR AGONIST. 

000120 01-03 
CLIMAX 

THE BEHAVIOURAL-STATE DURING CLIMAX (HATCHING) IN THE 
DOMESTIC-FOWL (GALLUS-DOMESTICUS) . 

001564 02-04 
CLIMBING 

THE MESOLIMBIC SYSTEM, DENERVATION AND THE CLIMBING RESPONSE 
IN THE MOUSE. 

000370 01-04 
EFFECTS OF CHOLECYSTOKININ-OCTAPEPTIDE ON STRIATAL DOPAMINE 
METABOLISM AND ON APOMORPHINE-INDUCED STEREOTYPED CAGE 
CLIMBING IN MICE. 

003031 03-04 
ENHANCEMENT OF APOMORPHINE-INDUCED CLIMBING IN MICE BY 
REVERSIBLE AND IRREVERSIBLE NARCOTIC ANTAGONIST DRUGS. 

003068 03-04 
USE OF THE INTRACEREBRAL INJECTION TECHNIQUE TO ELUCIDATE 
MECHANISMS OF APOMORPHINE CLIMBING AND ITS ANTAGONISM IN 
THE MOUSE. 

004092 04-04 
CLIMBING-BEHAVIOUR 

EFFECT OF L HISTIDINE AND CHLORCYCLIZINE ON APOMORPHINE-INDUCED 
CLIMBING-BEHAVIOUR AND METHAMPHETAMINE STEREOTYPY IN 
MICE. 

004147 04-04 
CLINIC 

NONCOOPERATION: AN EXAMINATION OF FACTORS LEADING TO 
NONCOMPLIANCE IN A HYPERTENSION CLINIC. 

002557 02-17 
THE TREATMENT OF INSOMNIA THROUGH HOMEOPATHY IN A CLINIC. 

004484 04-11 



CLINICAL 

CLINICAL COMPARISON OF OXYPROTHEPIN AND CLOTEPINE IN 
SCHIZOPHRENIC-PATIENTS (CONTROLLED-STUDY) 

000568 01-08 
CLINICAL ASSESSMENT OF ONCE A DAY PHENOTHIAZINE 
ADMINISTRATION. 

000573 01-08 
CLINICAL AND LABORATORY DIAGNOSTICS APPLICATIONS IN 
DEPRESSION. (UNPUBLISHED PAPER) 

000588 01-09 
ON THE RELATIONSHIP OF NORTRIPTYLINE: AMITRIPTYLINE RATIO TO 
CLINICAL IMPROVEMENT OF AMITRIPTYLINE TREATED DEPRESSIVE- 
PATIENTS 

000599 01-09 
CLINICAL AND BIOCHEMICAL-ACTION OF PIRACETAM (NOOTROPIL) IN 

DRUG-RESISTANT DEPRESSION. 

000600 01-09 
PSYCHIATRIC-DISTURBANCE IN MENTALLY-HANDICAPPED-PATIENTS: A 

PROSPECTIVE STUDY OF CURRENT CLINICAL USAGE OF DEPOT 
FLUPHENAZINE IN HOSPITALS FOR THE MENTALLY-HANDICAPPED. 

000668 01-11 
SOCIAL AND CLINICAL SIGNIFICANCE OF DETERMINING THE BARBITURATE 
LEVEL IN THE BLOOD SERUM OF PATIENTS TREATED WITH 
ANTIEPILEPTIC-DRUGS. 

000695 01-11 
THE TREATMENT OF PARKINSONS-DISEASE USING A COMBINATION OF L- 
DOPA AND DECARBOXYLASE INHIBITORS (CARBIOOPA, BENSERASIDE). 
A CLINICAL AND BIOCHEMICAL COMPARATIVE INVESTIGATION 

000712 01-11 
THE DOPAMINE-RADIORECEPTOR ASSAY - A CLINICAL APPLICATION. 

000904 01-16 
ROTTING WITH THEIR RIGHTS ON: CONSTITUTIONAL THEORY AND 
CLINICAL REALITY IN DRUG-REFUSAL BY PSYCHIATRIC-PATIENTS. 

000911 01-17 
TEXTBQOK OF CLINICAL PSYCHOPHARMACOLOGY. 

000929 01-17 
CLINICAL HANDBOOK OF ANTIPSYCHOTIC-DRUG THERAPY. 

000961 01-17 
TWENTY YEARS CLINICAL THERAPEUTIC EXPERIENCE WITH CALCIUM 
GLUTAMATES EFFICACY. 

000963 01-17 
MONOAMINE-OXIDASE AND ITS INHIBITION: SOME CLINICAL 
IMPLICATIONS. 

000983 01-17 
CRITERIA FOR CLINICAL DEVELOPMENT AND CLASSIFICATION OF 
NOOTROPIC-DRUGS. AN EXAMPLE: PIRACETAM. 

000988 01-17 
BASIC AND CLINICAL NEUROBIOLOGICAL APPLICATIONS OF NEURONAL 
(NSE) AND NONNEURONAL (NNE) ENOLASE. (UNPUBLISHED PAPER). 

001041 02-01 
SOME PHARMACOLOGICAL-ASPECTS AND BIOCHEMICAL-ASPECTS OF 
TRH: EXPERIMENTAL AND CLINICAL DATA. 

001189 02-03 
POSSIBLE CLINICAL APPLICATIONS OF NOOTROPICS. 

001890 02-07 
ACTION OF TOFISOPAM ON THE ERGONOMIC VIGILANCE LEVEL. ITS 

INTERACTION WITH THE EFFECTS OF ALCOHOL. CLINICAL 
PHARMACOLOGICAL-STUDY. 

001891 02-07 
AMINEPTINE: CLINICAL REVIEW. 

001896 02-07 
CLINICAL ACTIVITY OF A NEW BENZODIAZEPINE: CLOXAZOLAM. 

001904 02-07 
CLINICAL STATE, PLASMA LEVELS OF HALOPERIDOL AND PROLACTIN: 

001943 02-08 
CLINICAL AND EEG CHANGES IN DEPRESSIVE-PATIENTS AFTER A SINGLE 
INJECTION OF BETA ENDORPHIN. 

001962 02-09 
CLINICAL AND BIOCHEMICAL-DATA ON THE ACTION OF MAPROTILINE 
AND CLOMIPRAMINE IN DEPRESSIVE-STATES (PRELIMINARY 
OBSERVATION). 

002032 02-09 
FIRST CLINICAL IMPRESSIONS IN DAILY PRACTICE. 

002046 02-09 
DOUBLE-BLIND CLINICAL ASSESSMENT OF ALPRAZOLAM, A NEW 
BENZODIAZEPINE DERIVATIVE, IN THE TREATMENT OF MODERATE TO 
SEVERE ANXIETY. 

002070 02-10 
CLINICAL PROCESSES AND CENTRAL DOPAMINERGIC-ACTIVITY IN 
PSYCHOTIC-DISORDERS. 

002098 02-11 
THE USE AND MISUSE OF SLEEPING-PILLS: A CLINICAL GUIDE. 

002150 02-11 
CEEG STUDY ON PATIENTS UNDER THE PSYCHIATRIC-DRUG TREATMENT; 
THE CORRELATION BETWEEN EEG ALTERATION AND CLINICAL 
EVOLUTION. 

002165 02-11 



I 
5 

&. 






in 

ttl;- 






to;. 



S-97 



Subject Index 



Psychopharmacology Abstracts 



TREATMENT OF MYOCLONUS WITH L 5 HYDROXYTRYPTOPHAN AND 
CARBIDOPA: CLINICAL, ELECTROPHYSIOLOGICAL, AND BIOCHEMICAL- 
OBSERVATIONS. 

002180 02-11 
CLINICAL USE OF SULPIRIDE IN ITALY. 

002187 02-11 
ON THE CLINICAL PHARMACOKINETICS OF THIORIDAZINE AND ITS 
METABOLITES. 

002207 02-13 
CLINICAL EVIDENCE FOR MULTIPLE DOPAMINE-RECEPTORS IN MAN. 

002264 02-13 
CLINICAL NEUROPHYSIOLOGICAL ASPECTS OF PSYCHOPATHOLOGICAL- 
CONDITIONS. 

002274 02-13 
CLINICAL COMPARABILITY OF PSYCHOTROPIC-DRUGS. 

002526 02-17 
ALIVAL: NEW CLINICAL APPLICATIONS, STUDIES IN PROGRESS, AND NEW 
POSSIBILITIES. 

002530 02-17 
CLINICAL NEUROPHARMACOLOGY. 

002567 02-17 
REGULATION OF NEUROTRANSMISSION THROUGH PRESYNAPTIC- 

RECEPTORS AND OTHER MECHANISMS: POSSIBLE CLINICAL RELEVANCE 
AND THERAPEUTIC POTENTIAL. 

002569 02-16 
LIMITS, VALUE AND PERSPECTIVES OF THE PSYCHIATRIC-DIAGNOSIS IN 
CLINICAL PSYCHOPHARMACOLOGY. 

002631 02-17 
REPEATED ANTIDEPRESSANT TREATMENTS INDUCE A LONG-LASTING 
DOPAMINE-AUTORECEPTOR SUBSENSITIVITY: IS DAILY TREATMENT 
NECESSARY FOR CLINICAL EFFICACY? 

002659 03-03 
CORRELATION BETWEEN ANTIAVOIDANCE ACTIVITIES OF ANTIPSYCHOTIC- 
DRUGS IN RATS AND DAILY CLINICAL DOSES. 

003032 03-04 
RAPIDITY OF CLINICAL ANTIDEPRESSANT RESPONSE TO IMIPRAMINE. 
(UNPUBLISHED PAPER). 

003164 03-07 
DIFFERENCES IN THE CLINICAL ACTION OF SOME NEUROLEPTIC-DRUGS. 

003204 03-08 
TREATMENT OF ORGANIC-BRAIN-DISTURBANCES IN ELDERLY-PATIENTS. A 
CLINICAL DOUBLE-BUND STUDY WITH MACROMOLECULAR ORGAN 
LYSATES (CYTOPLASMATIC THERAPY ACCORDING TO THEURER). 

003327 03-11 
A CLINICAL, CONTROLLED-STUDY OF L ALPHA ACETYLMETHADOL IN THE 
TREATMENT OF NARCOTIC ADDICTION. 

003335 03-11 
CLINICAL PHARMACOKINETICS IN NEWBORNS AND INFANTS: AGE- 
RELATED DIFFERENCES AND THERAPEUTIC IMPLICATIONS. 

003343 03-11 
CLINICAL SIGNIFICANCE OF PYRIDOXINE ADMINISTRATION IN L-DOPA 
THERAPY OF PARKINSONISM. 

003345 03-11 
PHENYTOIN: PHARMACOKINETICS AND CLINICAL THERAPEUTICS. 

003353 03-1 1 
CLINICAL PHARMACOKINETICS OF OXAZEPAM AND LORAZEPAM. 

003410 03-13 
SPINOCEREBELLAR DEGENERATION WITH PARKINSONIAN FEATURES: A 
CLINICAL AND PATHOLOGICAL REPORT. 

003436 03-13 
TREATMENT OF HUNTINGTON-DISEASE WITH GAMMA ACETYLENIC- 
GABA, AN IRREVERSIBLE INHIBITOR OF GABA-TRANSAMINASE: 
INCREASED CSF GABA AND HOMOCARNOSINE WITHOUT CLINICAL 
AMELIORATION. 

003458 03-14 
EFFECTS OF GRADUAL DECREASE AND DISCONTINUATION OF 
NEUROLEPTICS ON CLINICAL CONJITION AND TARDIVE-DYSKINESIA. 

003469 03-15 
LECITHIN ADMINISTRATION IN TARDIVE-DYSKINESIA: CLINICAL AND 
BIOMEDICAL-CORRELATES. 

003496 03-15 
THE CLINICAL DYNAMICS OF TETRAETHYL-LEAD POISONING. 

003500 03-15 
SEVERE WITHDRAWAL-SYNDROME AFTER CESSATION OF 
BENZODIAZEPINE TREATMENT: SIX CLINICAL CASES. 

003505 03-15 
TIME-COURSE OF CLINICAL CHEMICAL PARAMETERS UNDER LONG-TERM 
LITHIUM TREATMENT. 

003515 03-15 
CLINICAL USE OF THE ANTIPSYCHOTICS. 

003607 03-17 
ACCURACY OF PATIENT INTERVIEWS AND ESTIMATES BY CLINICAL STAFF 
IN DETERMINING MEDICATION COMPLIANCE. 

003618 03-17 
SECOND-GENERATION ANTIDEPRESSANTS: A CLINICAL 
PHARMACOTHERAPEUTIC RESEARCH STRATEGY. 

003632 03-17 
PHARMACOLOGICAL-BASES OF PSYCHONEUROENDOCRINOLOGY: 
PRECLINICAL ASSESSMENT OF CLINICAL FACTS. 

003735 04-03 



PROLACTIN RELEASING POTENCIES OF ANTIPSYCHOTIC AND RELATED 
NONANTIPSYCHOTIC COMPOUNDS IN FEMALE RATS: RELATION TO 
CLINICAL POTENCIES. 

003830 04-03 
THE EFFECT OF ADENOSINE AND GUANOSINE ON THE CONTENT OF 
SEROTONIN AND CATECHOLAMINES IN THE BRAIN IN THE 
RESTORATION PERIOD FOLLOWING EXPERIMENTAL CLINICAL DEATH. 

003882 04-03 
CLINICAL AND BIOCHEMICAL-CORRELATIONS IN ABRUPT 
DISCONTINUATION OF PSYCHOPHARMACOTHERAPY. 

004330 04-08 
HALOPERIDOL AND DROPERIDOL TREATMENT IN SCHIZOPHRENICS: 
CLINICAL APPLICATION OF THE PROLAQIN MODEL. 

004332 04-08 
THE USE OF CLINICAL AND PHARMACOKINETIC CRITERIA IN FORECASTING 
THE EFFICACY OF THERAPY IN SCHIZOPHRENIA. 

004335 04-08 
A CLINICAL AND PHARMACODYNAMIC EVALUATION OF SULPIRIDE. 

004338 04-08 
LONG-TERM NEUROLEPTIC TREATMENT OF CHRONIC SCHIZOPHRENIC- 
PATIENTS: CLINICAL AND BIOCHEMICAL-EFFECTS OF WITHDRAWAL. 

004344 04-08 
CLINICAL DEPRESSIONS: DIAGNOSTIC AND THERAPEUTIC CHALLENGES 

004350 04-09 
CLINICAL SIGNIFICANCE OF THE ERYTHROPLASMATIC RATIO OF LITHIUM. 

004357 04-09 
CLINICAL NEUROPHYSIOLOGICAL PROPERTIES OF ANTIDEPRESSANTS 

004373 04-09 
CLINICAL RESULTS OBTAINED WITH THE USE OF LYSONEURO IN 
DEPRESSIVE-SYNDROMES 

004397 04-09 
CLINICAL USE OF A NEW BENZODIAZEPINE, PRAZEPAM. 

004421 04-10 
ARE THE ENKEPHALINS INVOLVED IN PARKINSONS-DISEASE? CLINICAL 
AND NEUROENDOCRINE RESPONSES TO NALOXONE ADMINISTRATION. 

004431 04-11 
MEASUREMENTS OF NERVE CONDUCTION VELOCITY DURING DECREASING 
TOXIC DIPHENYLHYDANTOIN LEVELS AND THE BEGINNING OF 
CARBAMAZiPINE MEDICATION: A CLINICAL NEUROPHYSIOLOGICAL 
REPORT. 

004441 04-11 
CLINICAL APPLICATION OF ANTIANOROGENS IN PSYCHIATRY. 

004457 04-11 
CLINICAL PHARMACOKINETICS OF CHLORDIAZEPOXIDE IN PATIENTS WITH 
ALCOHOLIC HEPATITIS. 

004473 04-11 
CLINICAL PHARMACOKINETICS OF BENZODIAZEPINES. 

004524 04-13 
TREATMENT OF NARCOLEPSY AND SLEEP-APNEA WITH GAMMA 
HYDROXYBUTYRATE: A CLINICAL AND POLYSOMNOGRAPHIC CASE- 
STUDY. 

004571 04-14 
EFFECTS OF NEUROLEPTIC ADJUSTMENT ON CLINICAL CONDITION AND 
TARDIVE-DYSKINESIA IN SCHIZOPHRENIC-PATIENTS. 

004595 04-15 
CLINICAL STRATEGIES FOR ANTIPSYCHOTIC-DRUG TREATMENT, TARDIVE- 
DYSKINESIA, AND THE TRAINING OF RESEARCH PSYCHIATRISTS. 

004603 04-15 
CLINICAL AND PRECLINICAL EXPERIENCE WITH CHOLINE-CHLORIDE IN 

HUNTINGTONS-DISEASE AND TARDIVE-DYSKINESIA: UNANSWERED 
QUESTIONS. 

004604 04-15 
EPILEPTOGENIC PROPERTIES OF ENFLURANE AND THEIR CLINICAL 

INTERPRETATION. 

004609 04-15 
ACUTE PHENCYCLIDINE (PCP) INTOXICATION: QUANTITATIVE URINE 
LEVELS AND CLINICAL MANAGEMENT. 

004665 04-15 
SALIVA BENZODIAZEPINE LEVELS AND CLINICAL OUTCOME IN 
DETOXIFYING ALCOHOLIC-PATIENTS. 

004671 04-16 
THERAPEUTIC MONITORING OF PLASMA CONCENTRATIONS OF TRICYCLIC- 
ANTIDEPRESSANTS: PERSPEQIVE OF THE CLINICAL LABORATORY. 

004681 04-16 
THE USE OF CLINICAL KINETIC DATA IN TREATMENT WITH 
ANTIDEPRESSANT-DRUGS. 

004686 04-16 
CLINICAL-ASPECTS 

SOME CLINICAL-ASPECTS AND METABOLIC-ASPEaS OF PROPRANOLOL IN 
CHRONIC SCHIZOPHRENIA. 

001926 02-08 
CLINICAL-ASPECTS OF ANXIETY AND ITS THERAPY 

002089 02-10 
TREATMENT OF DYSKINETIC AND DYSTONIC-DISORDERS WITH CF-25- 
397: CLINICAL-ASPECTS AND PHARMACOLOGICAL ASPEQS. 

002121 02-11 
CLINICAL-ASPECTS OF LITHIUM EFFLUX FROM ERYTHROCYTES. 

002228 02-13 



S-98 



VOLUME 19, SUBJECT INDEX 



Subject Index 



CLINICAL-ASPECTS ON PROLACTIN RESPONSE TO NEUROLEPTIC-DRUGS 

002590 02-17 
THE NEUROPHYSIOLOGICAL AND CLINICAL-ASPECTS OF PAIN. 

003457 03-14 
CLINICAL-ASPECTS OF DYSKINESIA 

003461 03-15 
CLINICAL-CORRELATION 

CLINICAL-CORRELATION, BIOCHEMICAL-CORRELATION, AND 
PSYCHOPHARMACOLOGICAL-CORRELATION IN PATIENTS WITH 
DEPRESSIVE-SYMPTOMATOLOGY. 

002018 02-09 
CLINICAL-EFFECT 

AMITRIPTYLINE PLASMA CONCENTRATION AND CLINICAL-EFFECT: A 
WORLD-HEALTH-ORGANIZATION COLLABORATIVE-STUDY. 

001976 02-09 
SERUM CONCENTRATION AND CLINICAL-EFFECT OF ANTIEPILEPTICS. 

003315 03-11 
HYPERVENTILATION-SYNDROME AND BETA-RECEPTOR FUNCTION - 
CLINICAL-EFFECT OF BETA BLOCKER UPON THE SYNDROME, 

004459 04-11 
CLINICAL-EFFECTIVENESS 

TWENTY YEARS HALOPERIOOL; CLINICAL-EFFECTIVENESS AND 
THEORETICAL IMPLICATIONS. 

000938 01-17 
CLINICAL-EFFECTS 

A REEXAMINATION OF THE CLINICAL-EFFECTS OF IMIPRAMINE AND 
AMITRIPTYLINE IN DEPRESSIVE-ILLNESS. 

000579 01-09 
A COMPARATIVE-STUDY ON THE CLINICAL-EFFECTS OF FLUNITRAZEPAM 
AND LORAZEPAM. 

000702 01-11 
CLOMIPRAMINE: PLASMA LEVELS AND CLINICAL-EFFECTS. 

002033 02-09 
HUNTINGTONS-DISEASE: CLINICAL-EFFECTS OF A SHORT-TERM 
TREATMENT WITH PIMOZIDE. 

002091 02-11 
CARBAMAZEPINE THERAPY IN TRIGEMINAL-NEURALGIA: CLINICAL- 
EFFECTS IN RELATION TO PLASMA CONCENTRATION. 

, 00218102-11 
A CONTROLLED DOUBLE-BLIND STUDY OF HALOPERIDOE VERSUS 
THIORIDAZINE IN THE TREATMENT OF RESTLESS MENTALLY- 
SUBNORMAL-PATIENTS: SERUM LEVELS AND CLINICAL-EFFECTS. 

002185 02-11 
PLASMA DELTA9 TETRAHYDROCANNABINOL CONCENTRATIONS AND 
CLINICAL-EFFECTS AFTER ORAL AND INTRAVENOUS ADMINISTRATION 
AND SMOKING. 

002201 02-12 
RELATIONSHIP BETWEEN BLOOD CONCENTRATIONS AND CLINICAL- 
EFFECTS OF A NEW ANTIDEPRESSANT MAPROTILINE. 

003271 03-09 
THE BIOLOGICAL-EFFECTS AND CLINICAL-EFFECTS OF ORAL MAGNESIUM 
AND ASSOCIATED MAGNESIUM VITAMIN-B6 ADMINISTRATION ON 
CERTAIN DISORDERS OBSERVED IN INFANTILE AUTISM. 

003291 03-11 
A COMPARATIVE- STUDY ON THE CLINICAL-EFFECTS OF RECTAL 
DIAZEPAM AND PENTOBARBITAL ON SMALL CHILDREN. RELATIONSHIP 
BETWEEN PLASMA LEVEL AND EFFECT. 

003330 03-11 
CLINICAL-EFFECTS OF BETA ENDORPHIN INFUSIONS. 

004360 04-09 
CLINICAL-EFFICACY 

THE CLINICAL-EFFICACY OF CLOZAPINE AS COMPARED TO LABORATORY 
PARAMETERS. 

001955 02-08 
EVALUATION OF THE CLINICAL-EFFICACY OF SINGLE-DAILY-DOSES OF 
ANTIDEPRESSANTS. 

001985 02-09 
PHENOTHIAZINE PLASMA AND RED-BLOOD-CELL CONCENTRATIONS THEIR 
RELATIONSHIP TO SIDE-EFFECTS AND CLINICAL-EFFICACY. 

002386 02-15 
CLINICAL-EFFICACY OF THE NEW ANTIDEPRESSANT BUPROPION 
(WELLBUTRIN). 

„„..^ 003227 03-09 

CLINICAL-EVALUATION 

CLINICAL-EVALUATION OF THE EFFECTS OF MINAPRINE. 

001899 02-07 
AN AnEMPT AT A CLINICAL-EVALUATION OF MINAPRINE. 
... „ 001900 02-07 

AN AHEMPT TO MAKE A CLINICAL-EVALUATION OF MINAPRINE 
(CONTINUATION OF THE STUDY). 

001901 02-07 
BROMOCRIPTINE AND PARKINSONS-DISEASE: A 16-HOUR CLINICAL- 
EVALUATION. 

002127 02-11 
TO THE CLINICAL-EVALUATION OF ANXIOLYTICS (TOFISOPAM) 

002494 02-16 
GUIDELINES FOR THE CLINICAL-EVALUATION OF ANALGESIC-DRUGS 

002584 02-17 



CLINICAL-EVALUATION OF THE PROPHYLACTIC EFFECTIVENESS OF 
PROLONGED LITHIUM-CARBONATE THERAPY IN ENDOGENOUS 
DEPRESSIVE-SYNDROMES. 

004404 04-09 
A CLINICAL-EVALUATION OF THE EFFECTS OF A NEW PSYCHOTROPIC- 
AGENT, MEXAZOLAM (CS-386) ON PSYCHOSOMATIC-DISEASES AND 
NEUROSIS: A COMPARATIVE-STUDY WITH OXAZOLAM, USING THE 
DOUBLE-BLIND METHOD. 

004491 04-11 
CLINICAL-EVALUATION OF BROMPERIDOL VERSUS HALOPERIOOL IN 
PSYCHOTIC-PATIENTS, 

004562 04-14 
CLINICAL-EXPERIENCE 

NOMIFENSIN IN THE TREATMENT OF ENDOGENOUS DEPRESSIONS 
CLINICAL-EXPERIENCE AND EEG FINDINGS. 

000613 01-09 
CLINICAL-EXPERIENCE WITH NOMIFENSINE. 

000642 01-09 
CLINICAL-EXPERIENCE WITH LOW-DOSES OF HALOPERIOOL IN THE 
TREATMENT OF NEUROSES. 

000654 01-10 
CLINICAL-EXPERIENCE WITH PIRACETAM THERAPY IN GERONTOLOGY. 

000686 01-11 
TREATMENT OF TARDIVE-DYSKINESIA WITH OXYPERTINE - PRELIMINARY 
CLINICAL-EXPERIENCE AND A BRIEF REVIEW OF THE LITERATURE. 

000692 01-11 
TRIMIPRAMINE: TWENTY YEARS WORLDWIDE CLINICAL-EXPERIENCE. 

000985 01-17 
CLINICAL-EXPERIENCE WITH SECOND-GENERATION ANTIDEPRESSANTS IN 
ENDOGENOUS DEPRESSIONS. 

001975 02-09 
CLINICAL-EXPERIENCE WITH LITHIUM-CARBONICUM-RETARD IN 
PSYCHIATRY. 

002000 02-09 
CLINICAL-EXPERIENCE WITH SUBSTITUTED BENZAMIDES IN FRENCH- 
SPEAKING COUNTRIES. 

002036 02-09 
CLINICAL-EXPERIENCE WITH PSYCHIATRIC-TREATMENT OF THE ELDERLY 
INVOLVING THE USE OF PIRACETAM. 

002188 02-11 
CLINICAL-EXPERIENCE WITH RETARD DIBENZEPINE (NOVERIL-240) IN 
ENDOGENOUS DEPRESSIONS ACCOMPANIED BY SYMPTOMS OF DRUG- 
RESISTANCE. 

003245 03-09 
CLINICAL-IMPLICATIONS 

STRESS AND HYPERTENSION: CLINICAL-IMPLICATIONS. 

002307 02-13 
PSYCHOTROPIC-DRUGS AND THE HEART: CLINICAL-IMPLICATIONS. 

002425 02-15 
CLINICAL-IMPLICATIONS OF ENZYME INDUCTION AND ENZYME 
INHIBITION. 

003621 03-17 
CLINICAL-PAPERS 

DISCUSSION OF CLINICAL-PAPERS ON LITHIUM TRANSPORT IN AFFECTIVE- 
DISORDERS. 

001987 02-09 
CLINICAL-PHARMACOLOGY 

OBSERVATIONS ON CLINICAL-PHARMACOLOGY. 

000970 01-17 
CLINICAL-PHARMACOLOGY. 

002247 02-13 
BENZODIAZEPINES: CLINICAL-PHARMACOLOGY AND THERAPEUTIC USE 

002521 02-17 
DRUGS AND THE ELDERLY: PERSPECTIVES IN GERIATRIC CLINICAL- 
PHARMACOLOGY 

002534 02-17 
CLINICAL-PHARMACOLOGY: DRUG DEVELOPMENT. 

002547 02-17 
CLINICAL-PHARMACOLOGY OF MIXED AGONIST ANTAGONIST DRUGS. 

003329 03-11 
CLINICAL-PHARMACOLOGY: ADVERSE DRUG INTERACTIONS, 

003399 03-13 
CLINICAL-PHARMACOLOGY: ELIMINATION OF DRUGS. 

003400 03-13 
CLINICAL-PHARMACOLOGY: DRUG ABSORPTION. 

004740 04-17 
CLINICAL-PICTURE 

GERIATRIC ASPECTS OF PARKINSONISM (CLINICAL-PICTURE 
PATHOLOGICAL MECHANISMS, AND MULTIPLE TREATMENT). 

003643 03-17 
CHANGES IN THE CLINICAL-PICTURE AND THE COURSE OF PSYCHOSES 
DURING MASSIVE PSYCHOPHARMACOTHERAPY AND THE 
SIGNIFICANCE OF THESE CHANGES FOR IMPROVEMENTS IN 
PSYCHIATRIC-TREATMENT. 

004699 04-17 



I 

(Si, 



■■?•' 






ft*,. 



ft;. 



S-99 



Subject Index 



Ptychopharmacology Abstracts 



CLINICAL-PRACTICE 

THE REAL AND IDEAL MANAGEMENT OF STIMULANT DRUG-TREATMENT 
FOR HYPERACTIVE-CHILDREN: RECENT FINDINGS AND A REPORT FROM 

CLINICAL-PRACTICE. „„„^,.„, ,, 

000715 01-11 
NOOTROPIC-DRUGS IN CLINICAL-PRACTICE. 

000811 01-14 

RELIEF OF PAIN IN CLINICAL-PRACTICE. 

003613 03-17 
AMITRIPTYLINE AND NORTRIPTYLINE PLASMA LEVELS MONITORING. 
PERSPECTIVE IN CLINICAL-PRACTICE. 

004675 04-16 

CLINICAL-RESPONSE 

CLINICAL-RESPONSE AND SERUM NEUROLEPTIC LEVELS IN CHILDHOOD- 
SCHIZOPHRENIA. (UNPUBLISHED PAPER). 

000566 01-08 
VILOXAZINE PLASMA CONCENTRATIONS AND CLINICAL-RESPONSE. 

000614 01-09 
PLASMA LEVELS OF IMIPRAMINE (IMI) AND DESMETHYLIMIPRAMINE 
(DMI) AND CLINICAL-RESPONSE IN PREPUBERTAL MAJOR DEPRESSIVE- 
DISORDER: A PRELIMINARY REPORT 

000619 01-09 
IMIPRAMINE TREATMENT OF PREPUBERTAL MAJOR DEPRESSIVE- 
DISORDERS: PLASMA LEVELS AND CLINICAL-RESPONSE - 
PRELIMINARY REPORT. 

000620 01-09 
URINARY MHPG AND CLINICAL-RESPONSE TO AMITRIPTYLINE IN 

DEPRESSED-PATIENTS. ^, ^, „„ 

000631 01-09 
INTERACTION BETWEEN AMITRIPTYLINE AND PHENOTHIAZINE IN MAN: 
METABOLITE NORTRIPTYLINE AND THE CORREUVTION WITH CLINICAL- 
RESPONSE. „„„, ,„ „, „„ 

000640 01-09 

AMITRIPTYLINE, NORTRIPTYLINE PLASMA LEVELS AND CLINICAL- 
RESPONSE IN WOMEN WITH AFFECTIVE-DISORDERS. 

000757 01-13 
INTERINDIVIDUAL VARIATION OF CLINICAL-RESPONSE TO HALOPERIDOL. 

001230 02-03 
RELATIONSHIPS BETWEEN CHLORPROMAZINE CONCENTRATIONS IN 
PLASMA AND CEREBROSPINAL-FLUID AND CLINICAL-RESPONSE AND 
BIOCHEMICAL-RESPONSE IN PSYCHOTIC-PATIENTS 

001905 02-08 
CLINICAL-RESPONSE, PLASMA LEVELS AND PHARMACOKINETICS OF 
DESIPRAMINE IN DEPRESSED-INPATIENTS. 

002002 02-09 
AGE-RELATED FACTORS AFFECTING ANTIDEPRESSANT-DRUG METABOLISM 
AND CLINICAL-RESPONSE. 

002035 02-09 
HIGH-LEVELS OF AMITRIPTYLINE AND CLINICAL-RESPONSE. 

002266 02-13 
NEUROLEPTIC SERUM LEVELS MEASURED BY RADIORECEPTOR ASSAY 
AND CLINICAL-RESPONSE IN SCHIZOPHRENIC-PATIENTS. 

003199 03-08 
PLASMA LEVELS OF CHLORPROMAZINE AND CLINICAL-RESPONSE. 

003201 03-08 
CLINICAL-RESPONSE AND BLOOD LEVELS IN THE TREATMENT OF 
DEPRESSION WITH A NEW ANTIDEPRESSANT-DRUG, AMOXAPINE. 

004356 04-09 
LITHIUM IN THE PROPHYLAXIS OF RECURRENT AFFECTIVE-DISORDERS 
(EFFECTIVENESS OF LOW PLASMA LEVELS AND PREDICTORS TO 
CLINICAL-RESPONSE). 

004365 04-09 
PHARMACOKINETICS AND CLINICAL-RESPONSE TO TRICYCLIC- 
ANTIDEPRESSANTS. 

004370 04-09 
THE RELATIONSHIPS BETWEEN CLINICAL-RESPONSE, 

PSYCHOPHYSIOLOGICAL-VARIABLES AND PLASMA LEVELS OF 
AMITRIPTYLINE AND DIAZEPAM IN NEUROTIC-OUTPATIENTS. 

004423 04-10 
SINGLE-CASE STUDY OF CLINICAL-RESPONSE TO HIGH-DOSE ERGOT 
ALKALOID TREATMENT FOR DEMENTIA. PRELIMINARY REPORT. 

004493 04-1 1 
PROLACTIN AND NEUROLEPTIC-DRUGS: A BIOCHEMICAL INDEX OF 
CLINICAL-RESPONSE? 

004539 04-13 
PLASMA NOMIFENSINE CONCENTRATION: CARDIOLOGICAL EFFECTS AND 
CLINICAL-RESPONSE. 

004639 04-15 

CLINICAL-REVIEW 

CLINICAL-REVIEW OF BETA-BLOCKERS IN ANXIETY. 

004464 04-11 

CLINICAL-SCALE 

TREATMENT OF ASTHENO-DEPRESSIVE-DISORDERS WITH MINAPRINE 
(CANTOR). MULTICENTER- STUDY OF 248 CASES EVALUATED WITH THE 
FATIGUE STUDY GROUPS NO. 4 CLINICAL-SCALE. 

001980 02-09 

CLINICAL-STUDIES 

HYDERGINE: A REVIEW OF 26 CLINICAL-STUDIES. 

000704 01-11 



MINAPRINE-CHLOROHYDRATE: SURVEY OF THE FIRST CLINICAL-STUDIES 
OF THE FOURTH STAGE. 

001902 02-07 
CLINICAL-STUDIES AND BIOLOGICAL-STUDIES OF L TRYPTOPHAN IN 
DEPRESSION. 

001977 02-09 
EFFECT OF SODIUM-VALPROATE AND BACLOFEN IN TARDIVE-DYSKINESIA: 
CLINICAL-STUDIES AND NEUROENDOCRINE-STUDIES. 

002441 02-15 
REVIEW OF CLINICAL- STUDIES WITH ERGOTS IN GERONTOLOGY. 

002624 02-17 
MANAGEMENT OF SCHIZOPHRENIA: LONG-TERM CLINICAL- STUDIES WITH 
SPECIAL REFERENCE TO THE COMBINATION OF PSYCHOTHERAPY AND 
DEPOT NEUROLEPTICS. 

003183 03-08 

CLINICAL-STUDY 

CONTRIBUTION TO THE CLINICAL-STUDY OF CEREBRAL DOPAMINERGIC 
MECHANISMS: THE ACTION OF PIRIBEDIL IN PSYCHIATRY. FIRST 
RESULTS. 

00061601-09 
TRANSIENT-EFFECT OF L TRYPTOPHAN IN PROGRESSIVE MYOCLONUS 
EPILEPSY WITHOUT UkFORA-BODIES: CLINICAL-STUDY AND 
ELECTROPHYSIOLOGICAL-STUDY. 

000694 01-11 
CLINICAL-STUDY OF VILOXAZINE 

001972 02-09 
VILOXAZINE IN THE TREATMENT OF DEPRESSIVE-NEUROSIS: A 
CONTROLLED CLINICAL-STUDY WITH DOXEPIN AND PLACEBO 

002080 02-10 
CLASSIFICATION OF ENDORPHINS/ENKEPHALINS IN BRAIN PHYSIOLOGY 
AND PATHOLOGY (BASED ON EEG AND CLINICAL- STUDY OF 
SYNTHETICALLY-MODIFIED METHIONINE-ENKEPHALIN) . 

002286 02-13 
A CLINICAL- STUDY AND ENDOCRINE-STUDY OF MESTEROLONE IN 
SECONDARY IMPOTENCE 

002315 02-14 

A DOUBLE-BLIND CROSSED CLINICAL- STUDY WITH A NEW 

PSYCHOPHARMACEUTICAL: TIADIPONE (QM-6008). DIAZEPAM, AND 
A PLACEBO 

003153 03-07 
CLINICAL-STUDY OF MAPROTILINE IN THE TREATMENT OF DEPRESSIVE- 
STATES: COMPILATION OF 1520 OBSERVATIONS 

003206 03-09 
ANXIOUS-DEPRESSIVE-SYNDROME CLINICAL-STUDY OF A NEW 
BENZODIAZEPINE, PRAZEPAM. 

004354 04-09 
VILOXAZINE IN THE TREATMENT OF DEPRESSIVE-NEUROSIS: A PLACEBO 
AND STANDARD (IMIPRAMINE) CONTROLLED CLINICAL-STUDY. 

004392 04-09 
CLINICAL-TESTING 

CLINICAL-TESTING OF MINAPRINE ON ELDERLY SUBJECTS WITH THE 
ASTHENIC-DEPRESSIVE-SYNDROMES. 

002123 02-11 

RESULTS OF CLINICAL-TESTS OF VILOXAZINE (VIVALAN ICI): PART OF A 
MULTICLINICAL-STUDY. ^^^^^ „^ ^„ 

002006 02-09 

CLINICAL-TRIAL 

CLINICAL-TRIAL OF OXYPROTHEPIN-DECANOATE. 000540 01^7 

CLINICAL-TRIAL OF VILOXAZINE IN DEPRESSIVE-CONDITIONS. 

000589 01-09 

INITIAL CLINICAL-TRIAL OF A NEW. SPECIFIC 5 HT REUPTAKE INHIBITOR, 

CITAL0PRAM(LU-10-171). 00059101-09 

A CLINICAL-TRIAL OF ZIMELIDINE IN DEPRESSION. 001992 02-09 

CLINICAL-TRIAL OF PYRAZIDOL IN ENDOGENOUS DEPRESSIVE-STATES. 

002021 02-09 
CLOMIPRAMINE TREATMENT OF OBSESSIVE-COMPULSIVE-DISORDER: I A 
CONTROLLED CLINICAL-TRIAL. 

002086 02-10 

CLINICAL-TRIAL WITH AMANTADINE AND HYDERGINE IN ELDERLY- 
PATIENTS. „„„„^oo«,, 

002093 02-11 
FREE DESCRIPTION OF DRUG-EFFECTS AS A METHOD OF CLINICAL-TRIAL, 
PRESENTED BY THE EXAMPLE OF PENTOBARBITONE, PROMAZINE AND 
THEIR COMBINATION 00256102-17 

NOVEL ANTIDEPRESSANTS: A CLINICAL-TRIAL OF '^'^^SERIKL 
AN OPEN CLINICAL-TRIAL OF MIANSERIN. ^^^^^ ^^^ 

DO PSYCHOTHERAPY AND PHARMACOTHERAPY FOR DEPRESSION 
CONFLICT? EMPIRICAL EVIDENCE FROM A CLINICAL-TRIAL 

003256 03-Ot 

CLINICAL-TRIAL OF HALAZEPAM AND CLORAZEPATE: CONSIDERATIONS 
OF A SINGLE-BEDTIME-DOSE. 003277 03-10 



S-100 



(VOLUME 19, SUBJECT INDEX 



Subject Index 



CLINICAL-TRIAL Of PSYCHOTHERAPIES IS UNDER WAY 

004378 04-09 
A COMPARATIVE CLINICAL-TRIAL WITH THE TRANQUILIZER TRAZODONE 
AND THE TRICYCLIC-ANTIDEPRESSANT CLOMIPRAMINE. 

004380 04-09 
DO PSYCHOTHERAPY AND PHARMACOTHERAPY FOR DEPRESSION 
CONFLICT? EMPIRICAL EVIDENCE FROM A CLINICAL-TRIAL. 
(UNPUBLISHED PAPER). 

004401 04-09 
CONTROLLED CLINICAL-TRIAL OF NOMIFENSINE IN THE TREATMENT OF 
DEPRESSION. 

004417 04-09 
CLOPIPAZAN (SKF-69634), A NEW NEUROLEPTIC ESSENTIALLY FREE OF 
EXTRAPYRAMIDAL LIABILITY: QUANTITATIVE PHARMACOEEG AND 
OPEN LABEL CLINICAL-TRIAL. 

004620 04-15 

:linical-trials 

clonidine for opiate detoxification: outpatient clinical-trials. 

000731 01-11 
CLINICAL-TRIALS WITH RUBIDIUM-CHLORIDE IN DEPRESSED-PATIENTS. 

001893 02-07 
CLINICAL-TRIALS OF DEPAKENE (VALPROIC-ACID) COADMINISTERED WITH 
OTHER ANTICONVULSANTS IN EPILEPTIC-PATIENTS. 

002367 02-14 
DESIGN ASPECTS OF CLINICAL-TRIALS WITH ERGOT ALKALOIDS: A 
COMPARISON OF TWO GERIATRIC BEHAVIORAL-RATING-SCALES. 

002512 02-16 
PSYCHOTROPIC-DRUG REGISTRATION IN THE SCANDINAVIAN-COUNTRIES: 
THE ROLE OF CLINICAL-TRIALS. 

002550 02-17 
COORDINATING CLINICAL-TRIALS IN PSYCHOPHARMACOLOGY: 
PL^NNING, DOCUMENTATION, AND ANALYSIS. 

002574 02-17 
PREDICTION AND PROGNOSTIC FACTORS IN CLINICAL-TRIALS OF 
PSYCHOTROPIC-DRUGS. 

002615 02-17 
CLINICAL-TRIALS WITH NEW BICYCLIC AND TETRACYCLIC COMPOUNDS: 
ZIMELIDINE AND MAPROTILINE. 

003213 03-09 
CLINICAL-TRIALS WITH CLOBAZAM IN GERIATRICS. 

003279 03-10 
QUALITY OF REPORTS OF CLINICAL-TRIALS SUBMIHED BY THE DRUG 
INDUSTRY TO THE FINNISH AND SWEDISH CONTROL AUTHORITIES. 

003599 03-17 

:linical-variables 

relationships among biochemical-variables, clinical- 
variables, and pharmacokinetic-variables in neuroleptic 
treated schizophrenic-patients. 

001946 02-08 
:UNICALLY 

DRUG-THERAPY IN ENDOGENOUS DEPRESSION WITH POSSIBLE PRIMARY 
GABA DEFICIENCY CLINICALLY DETECTED: 38 NEW CASES. 

000584 01-09 
CLINICALLY SIGNIFICANT SIDE-EFFECTS OF LITHIUM TREATMENT. 

000893 01-15 
:UNICIAN 

PATIENT CHARACTERISTICS AND CLINICIAN AHITUDES INFLUENCING THE 
PRESCRIBING OF BENZODIAZEPINES. 

003598 03-17 
:UNICIANS 

PREDICTABILITY OF PHENYTOIN SERUM LEVELS BY NOMOGRAMS AND 
CLINICIANS. 

000909 01-16 
THE CLINICIANS ROLE IN PSYCHOPHARMACOLOGICAL-RESEARCH. 

002563 02-17 
aiNICOEPIDEMIOLOGICAL 

TARDIVE-DYSKINESIA: CLINICOEPIDEMIOLOGICAL REVISION AND 
CONTRIBUTION. 

003466 03-15 

:linics 

the use of minaprine in child-psychiatry in hospitals and 
outpatient clinics. 

002169 02-11 

:lobazam 

pharmacological activities of clobazam and diazepam in the 
rat: relation to drug brain levels. 

000036 01-03 
SPECIES-DIFFERENCES IN CLOBAZAM METABOLISM AND ANTILEPTAZOL 
EFFECT. 

001157 02-03 
TREATMENT OF ANXIOUS-DEPRESSED OUTPATIENTS WITH A FIXED 
COMBINATION (NOMIFENSINE/CLOBAZAM) IN COMPARISON TO A 
MONOSUBSTANCE (DOXEPINE). 

002028 02-09 
ADVANTAGE OF MONOTHERAPY WITH CLOBAZAM IN THE TREATMENT 

AND POSHREATMENT OF ALCOHOLIC WITHDRAWAL. 
,-,,... 002140 02-11 

CLINICAL-TRIALS WITH CLOBAZAM IN GERIATRICS. 

■003279 03-10 
ANTIEPILEPTIC-EFFECT OF CLOBAZAM IN LENNOX-GASTAUT-SYNDROME. 

004479 04-1 1 



CLOCK 

THE CLOCK AND THE BLUE GUITAR: STUDIES OF HUMAN GROWTH- 
HORMONE SECRETION IN SLEEP AND WAKING (UNPUBLISHED PAPER) 

002346 02-14 
CLOFELIN 

THE EFFECT OF CLOFELIN ON THE BIOELECTRIC-ACTIVITY OF THE BRAIN. 

001449 02-03 
THE EFFECT OF ANTIDEPRESSANTS ON THE HYPOTENSIVE-EFFECT OF 
CLOFELIN IN RATS. 

003934 04-03 
CLOFIBRATE 

EFFECTS OF ALBUMIN, AMINO-ACIDS, AND CLOFIBRATE ON THE UPTAKE 
OF TRYPTOPHAN BY THE RAT-BRAIN. 

002673 03-03 
CLOMIPHENE-CITRATE 

INFERENCES DERIVED FROM ELECTROENCEPHALOGRAPHIC RESPONSES TO 
ACUTE ADMINISTRATION OF CLOMIPHENE-CITRATE IN MALE ALBINO- 
RATS. 

000155 01-03 
CLOMIPRAMIN 

INFUSION OF MAPROTILIN AND CLOMIPRAMIN AND THEIR COMBINATION 
IN THE TREATMENT OF DEPRESSION. 

002056 02-09 
CLOMIPRAMINE 

EXPERIMENTAL EVALUATION OF ANTIDEPRESSANT ACTIVITY OF 
CLOMIPRAMINE, A NEW TRICYCLIC-ANTIDEPRESSANT DRUG. 

001068 02-02 
EFFECTS OF AMITRIPTYLINE AND CLOMIPRAMINE IN THE ISOLATED, 
PERFUSED RABBIT HEART. 

001852 02-05 
OUR FIRST EXPERIENCE WITH CLOMIPRAMINE. 

002008 02-09 
CLINICAL AND BIOCHEMICAL-DATA ON THE ACTION OF MAPROTILINE 
AND CLOMIPRAMINE IN DEPRESSIVE- STATES (PRELIMINARY 
OBSERVATION). 

002032 02-09 
CLOMIPRAMINE: PLASMA LEVELS AND CLINICAL-EFFECTS. 

002033 02-09 
CLOMIPRAMINE TREATMENT OF OBSESSIVE-COMPULSIVE-DISORDER: I. A 

CONTROLLED CLINICAL-TRIAL. 

002086 02-10 
CLOMIPRAMINE AND DOXEPIN IN DEPRESSIVE-NEUROSIS: PLASMA 
LEVELS AND THERAPEUTIC RESPONSE. 

002258 02-13 
CLOMIPRAMINE TREATMENT OF OBSESSIVE-COMPULSIVE-DISORDER: II. 
BIOCHEMICAL-ASPECTS. 

002300 02-13 
DIFFERENTIAL-EFFECTS OF CLOMIPRAMINE AND CLORGYLINE ON THE 
SENSITIVITY OF CORTICAL NEURONS TO SEROTONIN: EFFECT OF 
CHRONIC-TREATMENT. 

002847 03-03 
PHARMACOKINETICS OF CLOMIPRAMINE IN DEPRESSIVE-PATIENTS. 

003216 03-09 
THE TREATMENT OF DEPRESSION USING CLOMIPRAMINE IN GENERAL- 
MEDICAL-PRACTICE: 48 CASES TREATED ON AN OUTPATIENT BASIS. 

003268 03-09 
A COMPARATIVE CLINICAL-TRIAL WITH THE TRANQUILIZER TRAZODONE 
AND THE TRICYCLIC-ANTIDEPRESSANT CLOMIPRAMINE. 

004380 04-09 
CLONAZEPAM 

BEHAVIORAL-ANALYSIS OF AMYGDALOID KINDLING IN BEAGLE-DOGS 
AND THE EFFECTS OF CLONAZEPAM, DIAZEPAM, PHENOBARBITAL, 
DIPHENYLHYDANTOIN, AND FLUNARIZINE ON SEIZURE 
MANIFESTATION. 

000496 01-04 
CLONAZEPAM AND DITHIADEN IN HYPERKINETIC-CHILDREN. 

000729 01-11 
THE EFFECT OF CLONAZEPAM ON ATROPINE SPIKES IN THE LIMBIC- 
SYSTEM. 

001274 02-03 
COMPARISON OF CLONAZEPAM AND DIAZEPAM IN EXPERIMENTAL- 
STUDIES. 

001815 02-04 
INFLUENCE OF PHENYTOIN AND PHENOBARBITAL ON THE DISPOSITION OF 
A SINGLE-ORAL-DOSE OF CLONAZEPAM. 

002248 02-13 
CLONAZEPAM AND PHENOBARBITAL IN TARDIVE-DYSKINESIA. 

003294 03-11 
TREATMENT OF EPILEPSIES WITH CLONAZEPAM (ANTELEPSIN). 

004481 04-11 
A COMPARATIVE-STUDY OF INTRAVENOUS LORAZEPAM AND 
CLONAZEPAM IN STATUS-EPILEPTICUS. 

004487 04-11 
CLONIDINE 

INHIBITION OF NEURONAL UPTAKE REDUCES THE PRESYNAPTIC EFFECTS 
OF CLONIDINE BUT NOT OF ALPHA METHYLNORADRENALINE ON THE 
STIMULATION-EVOKED RELEASE OF 3H NORADRENALINE FROM RAT 
OCCIPITAL-CORTEX SLICES. 

000227 01-03 



9 

liL 

1 

a 
5 

Ml 



4ir 



S-101 



Subject Index 

INTERACTION OF ANTIDEPRESSANTS WITH CLONIDINE ON RAT-BRAIN 
TOTAL 3 METHOXY-4-HYDROXYPHENYLGLYCOL. ^^^ ^ ^ ^^ 

THE LOCOMOTOR-EFFECT OF CLONIDINE AND ITS INTERACTION WITH 
ALPHA FLUPENTHIXOL OR HALOPERIDOL IN THE DEVELOPING^AT^^^^ 

DISPLACEMENT OF (3H)CL0NIDINE BINDING BY CLONIDINE ANALOGUES 
IN MEMBRANES FROM RAT-CEREBRAL-CORTEX ^^^^^ ^ ^ ^^ 

ANTIMANIC-EFFECT OF CLONIDINE. ^^^^^ ^^^^ 

IATROGENIC OPIATE ADDICTION: SUCCESSFUL DETOXIFICATION WITH 

CLONIDINE. 000666 01-11 

CLONIDINE IN TOUREHE-SYNDROME. ^^^^^ ^^^ ^ 

CLONIDINE FOR OPIATE DETOXIFICATION: OUTPATIENT CI-INIO^L^-TRIALS. ^ 
RAPID OPIATE DETOXIFICATION WITH CLONIDINE AND NALOXONE^ ^^^^ 
■ CLONIDINE FOR OUTPATIENT OPIATE DETOXIFICATION. qoo827 01-14 
OPIATES AND SPECIFIC RECEPTOR BINDING OF (3H)CL0NIDINE.^^^^ ^^^^ 

POSSIBLE INVOLVEMENT OF CYCLIC-AMP AND FRONTAL-CORTEX IN 
AMrrRIPTYLINE MEDIATED SUPPRESSION OF THE HYPOTENSIVE-EFFECT 
OF CLONIDINE. 001259 02-03 

CLONIDINE ON THE PRESSOR RESPONSE TO RAISED INTRACRANIAL 
''■'^^^^''^ 001316 02-03 

INHIBITION OF NEUROSYMPATHETIC CEREBROARTERIAL CONSTRICTION 
BY CLONIDINE IN CATS. 00143102-03 

CLONIDINE AMELIORATES GILLES-DE-LA-TOUREHE-SYNDROME^ ^ ^^ ^^^ ^ 

CLONIDINE AND PSYCHOPHYSICAL PAIN . ^^^^^ ^^ ^ ^ 

RELATIONSHIPS BETWEEN STRUCTURE AND ALPHA-ADRENERGIC- 
RECEPTOR AFFINITY OF CLONIDINE AND AND SOME RELATED CYCLIC- 

A'^'°'^^5 002698 03-03 

THE TETRACYCLIC-ANTIDEPRESSANT MIANSERIN: EVALUATION OF ITS 
BLOCKADE OF PRESYNAPTIC ALPHA-ADRENOCEPTORS IN A SELF- 
STIMULATION MODEL USING CLONIDINE. ^^^^^ ^^^ 

PROSTAGLANDINS, CLONIDINE AND SEXUAL-RECEPTIVITY IN THE GUINEA- 
^'^ 003017 03-04 

CLONIDINE ANALGESIA AND SUPPRESSION OF OPERANT RESPONDING: 
DISSOCIATION OF MECHANISM. 003046 03-04 

EFFICACY OF CLONIDINE IN OPIATE WITHDRAWAL: A STUDY OF THIRTY 
PATIENTS. 003317 03-11 

CLONIDINE IN TOURETTE-SYNDROME . ^^^^^ ^^ ^ ^ 

DELIRIUM SECONDARY TO CLONIDINE THERAPY ^^^^^ ^^ ^ ^ 

THE HYPOTHERMIC-EFFECTS OF CLONIDINE AND OTHER IMIDAZOLIDINES 
IN RELATION TO THEIR ABILITY TO ENTER THE CENTRAL-NERVOUS- 
SYSTEM IN MICE. 003933 04-03 

DIFFERENTIAL-EFFECTS OF ALPHA METHYLDOPAMINE, CLONIDINE AND 
HYDRALAZINE ON NOREPINEPHRINE AND EPINEPHRINE SYNTHESIZING 
ENZYMES IN THE BRAINSTEM NUCLEI OF SPONTANEOUSLY 
HYPERTENSIVE-RATS. 003947 04-03 

CLONIDINE AND THE PRIMATE LOCUS-COERULEUS: EVIDENCE SUGGESTING 
ANXIOLYTIC AND ANTIWITHDRAWAL EFFEaS. (UNPUBLISHED PAPER). 

0039oz u4-Uj 

MULTIPLE ALPHA2-N0RADRENERGIC-RECEPT0R SITES IN RAT-BRAIN: 
SELECTIVE REGULATION OF HIGH-AFFINITY (3H)CLONI0INE BINDING BY 
GUANINE-NUCLEOTIDES AND DIVALENT-CATIONS. 

003992 04-Oj 

PRELIMINARY TRIAL OF CLONIDINE TREATMENT IN TWO PATIENTS 

SUFFERING FROM CHRONIC SCHIZOPHRENIA. ^^^^^ ^^^^ 

"° SERotSKeCHANISMS of CLONIDINE-INDUCEO HYPOTHERMIA IN 

■^AT^- 002806 03-03 

EFFEQS OF ACUTELY AND CHRONICALLY ADMINISTERED 
ANTIDEPRESSANTS ON THE CLONIDINE-INDUCED DECREASE IN RAT- 
BRAIN 3 METHOXY-4-HYDROXYPHENYLETHYLENEGLYCOL-SULPHATE 

CO'^T^^T 002908 03-03 

CLONIDINE-INDUCED HYPERPHAGIA IN MONKEYS: EVIDENCE FOR 

ALPHA2-N0RADRENERGIC-RECEPT0R MEDIATION „„,„,. n^ n>, 

0042 1 5 04-04 



Psychopharmacology Abstracts 



^""^CLOPIPAZAN (SKF-69634), A NEW NEUROLEPTIC ESSENTIALLY FREE OF 
EXTRAPYRAMIDAL LIABILITY: QUANTITATIVE PHARMACOEEG AND 
OPEN LABEL CLINICAL-TRIAL. 004620 04-15 

FAILURE OF CLORAZEPATE TO CAUSE MALFORMATIONS OR FETAL 

WASTAGE IN THE RAT. 000514 01-05 

DELAYED MAZE-LEARNING IN RATS AFTER PRENATAL EXPOSURE TO 

CLO^A^^'"^^^ 000521 01-05 

EVALUATION OF CLORAZEPATE (TRANXENE) AS AN ANTICONVULSANT ~ 

^^^^OVmO^. 000728 01-11 

INDIVIDUAL VARIATIONS IN THE EFFECTS OF FLURAZEPAM, 

CLORAZEPATE L-DOPA AND THYROTROPIN-RELEASING-HORMONE ON 

REM SLEEP IN MAN. 002349 02-14 

CLINICAL-TRIAL OF HfKlMlPm AND CLORAZEPATE: CONSIDERATIONS 

OF A SINGLE-BEDTIME-DOSE. 003277 03-10 

^^'■^PHARAfAODLOGICAL PECULIARITIES OF A BENZODIAZEPINE /ATARACTIC- 
DRUG AND ITS THERAPEUTIC RELEVANCE: THE SPECIAL STATUS OF 
CLORAZEPATE-DIPOTASSIUM (TRANXILIUM). 

004527 04-13 

^"■^^NHIBITION OF MONOAMINE-OXIDASE BY CLORGYLINE AND DEPRENYL IN 
CIRCUMVENTRICULAR STRUQURES OF RAT-BRAIN. 

(XX) I jV \) I *UJ 
THE MONOAMINE-OXIDASE-INHIBITORS CLORGYLINE AND L DEPRENYL 
ALSO AFFECT THE UPTAKE OF DOPAMINE, NORADRENALINE AND 
SEROTONIN BY RAT-BRAIN SYNAPTOSOMAL PREPARATIONS 

tX/U I / I U I "UJ 
DIFFERENTIAL-EFFECTS OF CLOMIPRAMINE AND CLORGYLINE ON THE 
SENSITIVITY OF CORTICAL NEURONS TO SEROTONIN: EFFEQ OF 
CHRONIC-TREATMENT 002847 03-03 

ALTERATIONS IN NORADRENERGIC FUNQION DURING CLORGYLINE 
^^^^'^'^' 004393 04^ 

*^''°"u[oRINATED ANALOGUES OF THE TRICYCLIC NEUROLEPTICS: 2,3 

DIFLUORO DERIVATIVE OF CLOROTEPIN. • ^^^^^^^ ^^^^ 

CONTROLLED-COMPARISON OF MEDIUM AND HIGH CLOROTEPIN DOSES j 
IN CHRONIC SCHIZOPHRENIA. 000548 01-08 

LONG-TERM APPLICATION OF HIGH-DOSES OF CLOROTEPIN TO CHRONIC 
SCHIZOPHRENIC-PATIENTS. 001908 02-08 

THE USE OF CLOROTEPIN AND DIAZEPAM IN A COMPLEX THERAPY OF 
NEUROSES (CONTROLLED-COMPARISON) ^^^^ ^^^^ 

CONTROLLED-STUDY WITH BROMAZEPAM AND CLOROTEPIN IN CHILD 
INSTABILITY. 002190 02-11 

ACUTE EFFECT OF CLOROTEPIN (0.5MG AND 1 OMG) AND 

METHAQUALONE (300MG) ON VERBAL-ASSOCIATIONS. ^^^^^ ^^^^ 

^^''^O.In'iCAL comparison OF OXYPROTHEPIN AND CLOTEPINE IN 

SCHIZOPHRENIC-PATIENTS (CONTROLLED-STUDY) ^^^^ ^ ^ _^ 

^^°CLINICAL^CTIVITY OF A NEW BENZODIAZEPINE: CLOXAZOUM^ ^^_^^ 
PHARMACOKINETICS OF CLOXAZOLAM IN MAN AFTER SINGLE AND 
MULTIPLE ORAL DOSES. 004530 04-1: 

"° Hx'd^RATIO SCHEDULES OF FOOD PRESENTATION AND STIMULUS-SHOCK 
TERMINATION EFFEaS OF D-AMPHETAMINE, MORPHINE, AND 
CLOZAPINE. 000^3, g,^ 

CLOZAPINE IN THE TREATMENT OF TARDIVE-DYSKINESIA: AN INTERIM 
^^^^^'^ 000677 01 -r 

LONG-TERM EFFEaS OF HALOPERIDOL, CLOZAPINE, AND METHADONE 
ON RAT STRIATAL CHOLINERGIC AND DOPAMINERGIC DYNA^«^2-0: 

BEHAVIORAL-CORRELATES AND BIOCHEMICAL-CORREIATES AFTER 
HALOPERIDOL AND CLOZAPINE LONG-TERM-TREATMENT ^^^^^ ^^^ 

THE CLINICAL-EFFICACY OF CLOZAPINE AS COMPARED TO LABORATORY 
PARAMETERS. 001955 02-0! 



S-102 



I/OLUME 19, SUBJECT INDEX 



Subject Index 



AN INVESTIGATION OF SOME SIDE-EFfECTS IN 47 PSYCHOTIC-PATIENTS 
DURING TREATMENT WITH CLOZAPINE AND DISCONTINUING OF THE 
TREATMENT. 

002424 02-) 5 
TIME-COURSE OF CHRONIC HALOPERIDOL AND CLOZAPINE UPON 
OPERANT RATE AND DURATION 

002989 03-04 
TREATMENT OF THERAPEUTICALLY-RESISTANT PARANOID 
SCHIZOPHRENIC-PATIENTS WITH FLUPHENAZINE DEPOT COMBINED 
WITH OTHER PSYCHOTROPIC-DRUGS AND CLOZAPINE. 

003172 03-08 
THE EFFECT OF SMALL DOSES OF HALOPERIDOL AND CLOZAPINE ON 
BEHAVIORAL SHIFTS IN CATS, ARISING AFTER CESSATION OF 
ELECTRICAL-STIMUUVTION OF THE CAUDATE-NUCLEUS. 

004067 04-04 
SOME EFFECTS Of CLOZAPINE ON PUNISHED-RESPONDING BY MICE AND 
SQUIRREL-MONKEYS. 

004224 04-04 
A CASE OF ACUTE AGRANULOCYTOSIS DURING TREATMENT WITH 
CLOZAPINE. 

004642 04-15 

:lues 

family-tree gives clues to treating psychoses. 

002363 02-14 

:luster-headaches 

lithium-carbonate in the treatment of cluster-headaches. 

000670 01-11 

:ns 

an in vivo model for investigating alpha 1 -receptors and 
alpha2-recept0rs in the cns: studies with mianserin. 

000053 01-03 
EFFECTS OF RESERPINE, PROPRANOLOL, AND AMINOPHYLLINE ON 
SEIZURE ACTIVITY AND CNS CYCLIC-NUCLEOTIDES. 

000115 01-03 
3H ETHYLKETOCYCLAZOCINE BINDING: LACK OF EVIDENCE FOR A 
SEPARATE KAPPA-RECEPTOR IN RAT CNS. 

000128 01-03 
SEROTONIN-SENSITIVE ADENYLATE-CYCLASE AND (3H)SER0T0NIN 
BINDING-SITES IN THE CNS OF THE RAT - I. KINETIC PARAMETERS 
AND PHARMACOLOGICAL-PROPERTIES. 

000213 01-03 
SEROTONIN-SENSITIVE ADENYLATE-CYCLASE AND (3H)SER0T0NIN 

BINDING-SITES IN THE CNS OF THE RAT - II. RESPECTIVE REGIONAL 
AND SUBCELLULAR DISTRIBUTIONS AND ONTOGENETIC 
DEVELOPMENTS. 

000214 01-03 
STEROID-HORMONES AND CNS AQIVITY. 

000794 01-13 
RAPID DEVELOPMENT OF HYPERSENSITIVITY AND HYPOSENSITIVITY TO 
APOMORPHINE AND HALOPERIDOL: ROLE OF NOREPINEPHRINE- 
RECEPTOR MECHANISMS IN CNS. 

001178 02-03 
EFFECT OF PYRITINOL AND PIRACETAM ON CHANGES IN FREE AMMONIA 
LEVEL IN CNS TISSUE AFTER PARADOXICAL SLEEP-DEPRIVATION IN 
RATS. 

001199 02-03 
EFFEQ OF REPEATED ELECTROCONVULSIVE-SHOCKS (ECS) ON 
SUBTHRESHOLD DOSES OF SOME CNS STIMULANTS. 

001361 02-03 
EFFEQS OF GUANINE-NUCLEOTIDES ON CNS NEUROPEPTIDE-RECEPTORS. 
(UNPUBLISHED PAPER). 

001383 02-03 
NEW EXPERIMENTAL TECHNIQUES IN THE PHARMACOLOGICAL 
EVALUATION OF CNS ACTING DRUGS. 

001479 02-03 
SIMILARITIES AND DISSIMILARITIES BETWEEN DOPAMINE AND 

NEUROLEPTIC-RECEPTORS: FURTHER EVIDENCE FOR TYPE-1 AND TYPE-2 
DOPAMINE-RECEPTORS IN THE CNS. 

001480 02-03 
MULTIPLE CNS RECEPTOR INTERACTIONS OF ERGOT ALKALOIDS: AFFINITY 

AND INTRINSIC ACTIVITY ANALYSIS IN IN VITRO BINDING SYSTEMS. 

001516 02-03 
EFFECTS OF THE BETA-ADRENOCEPTOR BLOCKING-AGENT SOTALOL ON 
CNS: SLEEP, EEG, AND PSYCHOPHYSIOLOGICAL PARAMETERS. 

001570 02-04 
HEMODYNAMIC FAILURE INDUCED BY NARCOTIC AND TOXIC DOSES OF 
12 CNS DEPRESSANTS IN INTAQ AND PITHED RATS. 

001855 02-05 
INFLUENCE OF CICLAZINDOL ON MONOAMINE UPTAKE AND CNS 
FUNCTION IN NORMAL SUBJECTS. 

002268 02-13 
DEVELOPMENT AND USE OF PHARMACOLOGICAL-PROBES OF THE CNS IN 
MAN: EVIDENCE OF CHOLINERGIC ABNORMALITY IN PRIMARY 
AFFECTIVE-ILLNESS. 

002506 02-16 
SOME WAYS TO INCREASE CHANCES TO DISCOVER THE CNS DRUGS OF 
THE FUTURE. 

002528 02-17 



PHARMACOLOGICAL EVIDENCE ON THE SPECIALIZATION OF CNS 
MECHANISMS RESPONSIBLE FOR MOTOR ACT INHIBITION BY AVERSIVE 
EVENTS. 

002671 03-03 
NEUROCHEMICAL-CONSEQUENCES FOLLOWING ADMINISTRATION OF CNS 
STIMULANTS TO THE NEONATAL RAT. 

002926 03-03 
DO BENZODIAZEPINES BIND AT ADENOSINE UPTAKE SITES IN CNS? 

002933 03-03 
IMMUNODETECTION OF ACH-RECEPTOR IN THE CNS. (UNPUBLISHED 
PAPER). 

003670 04-01 
ACYLCYANAMIDES, ACYLUREA, AND VARIOUS SUBSTITUTED 
ARYLALLOPHANATES; EFFECT ON THE CNS. 

003689 04-02 
CNS EFFECTS OF CHOLINE ADMINISTRATION: EVIDENCE FOR TEMPORAL 
DEPENDENCE. 

003996 04-03 
THE EFFECTS OF THYROTROPIN-RELEASING-HORMONE ON CYCLIC-AMP 
ACCUMULATION IN RABBIT CEREBROCORTICAL TISSUE IN THE 
PRESENCE AND ABSENCE OF CNS DEPRESSANTS. 

004010 04-03 
N,N DIISOPROPYLTRYPTAMINE (DIPT) AND 5 
METHOXYDIISOPROPYLTRYPTAMINE (5 MEO-DIPT). TWO ORALLY 
ACTIVE TRYPTAMINE ANALOGS WITH CNS ACTIVITY. 

004310 04-07 
CNS EFFECTS OF ISF-2522, A NEW NOOTROPIC (A PHASE I SAFETY AND 
CNS EFFICACY STUDY WITH QUANTITATIVE PHARMACOEEG AND 
PHARMACOPSYCHOLOGY) . 

004519 04-13 
PATHOPHYSIOLOGICAL AND MORPHOLOGICAL CHANGES IN THE CNS 
DURING LONG-TERM ADMINISTRATION OF HALOPERIDOL. 

004633 04-15 
CNS-ACTIN6 

EFFECTS OF ANALGESICS AND CNS-ACTING DRUGS ON STRUGGLING 
FOLLOWING REPETITIVE STIMULATION OF THE TAIL, AND FLEXOR 
REFLEX TO A SINGLE STIMULATION OF THE SCIATIC-NERVE IN RATS. 

004148 04-04 
CNV 

CNV VARIATIONS INDUCED BY THE ADMINISTRATION OF DIAZEPAM, 
HALOPERIDOL, PHENELZINE AND D-AMPHETAMINE. 

002355 02-14 
COADMINISTERED 

CLINICAL-TRIALS OF DEPAKENE (VALPROIC-ACID) COADMINISTERED WITH 
OTHER ANTICONVULSANTS IN EPILEPTIC-PATIENTS. 

002367 02-14 
COBALT 

STUDIES ON GAMMA AMINOBUTYRIC-ACID TRANSPORT IN COBALT 
EXPERIMENTAL EPILEPSY IN THE RAT. 

003990 04-03 
COCA-EXTRACTS 

THE ANOREXIC AND ACTOMETRIC EFFEaS OF COCAINE AND TWO COCA- 
EXTRACTS. 

000344 01-04 
COCA-LEAF 

A CONTRIBUTION TO OUR KNOWLEDGE OF COCA-LEAF CONTENT 
SUBSTANCES. 

001022 02-01 
COCAINE 

THE ANOREXIC AND ACTOMETRIC EFFECTS OF COCAINE AND TWO COCA- 
EXTRACTS. 

000344 01-04 
INHIBITION OF BEHAVIORAL-EFFECTS OF COCAINE BY ACTINOMYCIN-D IN 
RATS. 

000346 01-04 
CONSEQUENT EVENTS AS DETERMINANTS OF DRUG-EFFECTS ON 
SCHEDULE-CONTROLLED BEHAVIOR: MODIFICATION OF EFFECTS OF 
COCAINE AND D-AMPHETAMINE FOLLOWING CHRONIC AMPHETAMINE 
ADMINISTRATION. 

000350 01-04 
EVIDENCE THAT A PREFERRED SUBSTRATE FOR MONOAMINE-OXIDASE-B 
MEDIATES STIMULUS PROPERTIES OF MAO-INHIBITORS: A POSSIBLE 
ROLE FOR BETA PHENYLETHYLAMINE IN THE COCAINE CUE. 

000363 01-04 
PROGRESSIVE-RATIO AND FIXED-RATIO SCHEDULES OF COCAINE 
MAINTAINED RESPONDING IN BABOONS. 

000395 01-04 
ROTATIONAL-BEHAVIOR INDUCED BY COCAINE ANALOGS IN RATS WITH 
UNILATERAL 6 HYDROXYDOPAMINE LESIONS OF THE SUBSTANTIA- 
NIGRA: DEPENDENCE UPON DOPAMINE UPTAKE INHIBITION. 

000404 01-04 
A COMPARISON OF THE EFFECTS OF D-AMPHETAMINE, COCAINE, 

IMIPRAMINE AND PENTOBARBITAL ON LOCAL AND OVERALL RATES OF 
RESPONDING MAINTAINED UNDER A FOUR-COMPONENT MULTIPLE 
FIXED-INTERVAL SCHEDULE. 

000508 01-04 
PROLONGED EFFECTS OF COCAINE ON HIPPOCAMPAL ACTIVITY. 

001338 02-03 



5 



5 
'lit' 

tic 



(fir 



rliM 



S-103 



Subject Index 



Ptychopharmacology Abstract! 



DIFFERENTIAL-EFFECTS OF COCAINE ON LIMBIC EXCITABILITY^^ ^^^ ^^^^ 

MOTOR-ACTIVITY AND ROTATIONAL-BEHAVIOR AFTER ANALOGS OF 
cocaine! CORRELATION WITH DOPAMINE UPTAKE BLOCKADE^^ ^^^^ 

INTRAVENOUS SELF-ADMINISTRATION OF COCAINE AND NORCOCAINE BY 
DOGS. 001760 02-04 

THE PHARMACOLOGICAL RELEVANCE OF THE COCAINE BINDING-SITE IN 
MOUSE-BRAIN. 001772 02-04 

THE EFFECTS OF LITHIUM ON CHOICE BETV/EEN COCAINE AND FOOD IN 
THE RHESUS-MONKEY. 001825 02-04 

BEHAVIOR MAINTAINED BY INTRAVENOUS INJECTION OF CODEINE, 
COCAINE AND ETORPHINE IN THE RHESUS-MACAQUE AND THE 
PIGTAIL-MACAQUE. 001828 02-04 

COCAINE EFFECTS IN SLEEP-DEPRIVED HUMANS. ^^^^3 02-14 

rnfAINE AND AMPHETAMINE ANTAGONIZE THE DECREASE OF ^^,^,,,,^ 
SdrENERQC NEUROTRANSMISSION ELICITED BY OXYMETAZOLINE 
SSt POTENtIX^E THeTnHIBITION by ALPHA METHYLNOREPINEPHRINE 
IN THE PERFUSED CAT SPLEEN. ^^^801 03-03 

DISCRIMINATIVE-STIMULUS PROPERTIES OF COCAINE, NORCOCAINE, AND 
N ALLYLNORCOCAINE. ^^2954 03-04 

INTERACTIONS OF DIAZEPAM AND COCAINE IN THE MORPHINE TREATED 
RAT. (PH.D. DISSERTATION). ^q^i 15 03-04 

AMITRIPTYLINE PROVIDES LONG-LASTING IMMUNIZATION AGAINST 
SUDDEN CARDIAC DEATH FROM COCAINE ^^ ^ ^2 03-05 

ANTAGONISM OF INTRAVENOUS COCAINE LETHALITY IN NONHUMAN 
PRIMATES. 003127 03-05 

THE EFFECTS OF ELECTRIC-SHOCK ON RESPONDING MAINTAINED BY 
COCAINE IN RHESUS-MONKEYS. ^^^^^ q^ q^ 

COCAINE AND SEIZURE PROTECTION IN MICE OF VARYING BRAIN 
WEIGHTS. 004103 04-04 

SECOND-ORDER SCHEDULES OF INTRAMUSCULAR COCAINE INJECTION IN 
THE SQUIRREL^ONKEY: COMPARISONS WITH FOOD PRESENTATION 
AND EFFECTS OF D-AMPHETAMINE AND PROMAZINE. ^^^ ^^ ^^ ^^ 

REWARD AND DETECTION THRESHOLDS FOR BRAIN-STIMULATION: 

DISSOCIATIVE-EFFECTS OF COCAINE. ^^^^^ ^^^^ 

DISCRIMINATIVE-STIMULUS PROPERTIES OF COCAINE RELATED TO AN 
ANXIOGENIC ACTION. ^^^219 04-04 

BEHAVIORAL-EFFECTS OF SELF-ADMINISTERED COCAINE: RESPONDING 
MA^TAINED ALTERNATELY BY COCAINE AND ELECTRIC-SHOCK IN 
SQUIRREL-MONKEYS. ^^^225 04-04 

EFFECT OF COCAINE AND LIDOCAINE ON THE EXPRESSION OF KINDLED 
SEIZURES IN THE RAT. ^^^233 04-04 

^°*^RUgS"nMENT INTERAaiON: CONTEXT DEPENDENCY OF COCAINE- 
INDUCED BEHAVIORAL-SENSITIZATION . ^^866 03-03 
THE EFFECT OF AMYGDALA KINDLING ON SPONTANEOUS AND COCAINE- 
INDUCED MOTOR-ACTIVITY AND LIDOCAINE SEIZURES. ^^^^^ ^^^^ 

^°^HLORPROMAZIn"eFFECTS on COCAINE-REINFORCED RESPONDING IN 
RHESuSkEYS RECIPROCAL MODIFICATION OF RATE ALTERING 
EFFECTS OF THE DRUGS. 004133 04-04 

^^^theIffect of frusemide piretanide and bumetanide on cochlear 

SUCCINIC-DEHYDROGENASE. ^^^^^ ^^ qj 

*^°°IeHAVIOR maintained by intravenous injection of CODEINE, 
COCAINE AND ETORPHINE IN THE RHESUS-MACAQUE AND THE 
PIGTAIL-MACAQUE. 001828 02-04 

COMPARATIVE-STUDIES OF THE PHARMACOLOGICAL-EFFECTS OF THE D- 
ISOMERS AND L-ISOMERS OF CODEINE. ^^^ ^^^ 

GLC/TLC ANALYSIS OF CODEINE AND MORPHINE IN URINE VIA 

DERIVATIZATION TECHNIQUES. ^^^^^ q^,^^ 

SIMULTANEOUS DETERMINATION OF MORPHINE AND CODEINE IN BLOOD 
^Y USE OF SELECTION -MONITORING AND DEUTERATED INTERNAL 
STANDARDS. 004690 04-16 



MCiipni PPTir>;. INTERACTIONS WITH FOOD - CHEMICAL AND 

KmACOdZKuDIES ON THE INTERAQIONS OF COFFEE AND 

^E* 003612 03-17 

COGNITION 

COGNITION AND PSYCHOSOMATICS 002312 02-14 

EFFECTS OF LITHIUM-CARBONATE AND HALOPERIDOL ON COGNITION IN 
AGGRESSIVE, HOSPITALIZED SCHOOL-AGE CHILDREN. ^^^^^ ^^^ ^ 

EFFECTS OF LITHIUM-CARBONATE AND HALOPERIDOL ON COGNITION IN 
AGGRESSIVE HOSPITALIZED SCHOOL-AGE CHILDREN. ^^^^^ ^^_^ ^ 

COONITIVl ^^ THIORIDAZINE ON THE COGNITIVE FUNQIONING OF A 

HYPOTONIC SCHIZOPHRENIC-BOY. ^^^^^ ^^^^ 

COGNITIVE AND AFFECTIVE-FUNaiONS IN PATIENTS WITH AFFEQIVE- 
DISORDERS TREATED WITH LITHIUM: AN ASSESSMENT BY 
QUESTIONNAIRE 000604 01-09 

DEXTROAMPHETAMINE : COGNITIVE AND BEHAVlORAL-EFFEm 

NORMAL AND HYPERACTIVE-BOYS AND NORMAL ADULT^ALES.^^^^ ^ 

MEMORY AND COGNITIVE FUNQION IN THE ELDERLY: A PRELIMINARY- 
TRIAL OF PHYSOSTIGMINE 000802 01-14 

EFFECTS OF LITHIUM-CARBONATE ON MEMORY AND OTHER COGNITIVE 
FUNaiONS. 000824 01-14 

SERIAL COGNITIVE TESTING IN CANCER-PATIENTS RECEIVING 
CHEMOTHERAPY. 000876 01-15 

RESIDUAL-EFFECTS OF TEMAZEPAM AND OTHER HYPNOTIC-COMPOUNDS 
ON COGNITIVE FUNCTION. 000879 01-15 

EVALUATION OF THE RELATIVE EFFECTIVENESS OF METHYLPHENIDATE 
AND COGNITIVE BEHAVIOR-MODIFICATION IN THE TREATMENT OF 
KINDERGARTEN-AGED HYPERACTIVE-CHILDREN ^^^^^ ^^^ ^ 

EVALUATION OF DRUG EFFICACY IN DEMENTIA: A COMPUTERIZED 
COGNITIVE ASSESSMENT SYSTEM. ^^^^^ ^^.ift 

AN OVERVIEW OF PHARMACOLOGIC-TREATMENT OF COGNITIVE DECLINE 
IN THE AGED. 004482 04-11 

BLOOD-PRESSURE AND COGNITIVE FUNCTIONING ^^^^^^ ^^^ ^ 

THE EFFECTS OF PSYCHOTROPIC-MEDICATION ON COGNITIVE CONTROL 
MEASURES. (PH D. DISSERTATION) ^^^^3 04-1 • 

*^°°THE'RELATIVE*EFnCACY OF COGNITIVE-THERAPY AND CHEMOTHERAPY 
FOR T>1E TREATMENT OF DEPRESSION AMONG THE RETIRED ELDERLY. 
(PH . D . DISSERTATION) 002 1 48 02- 1 

DEPRESSED-OUTPATIENTS TREATED WITH COGNITIVE-THERAPY OR 
PHARMACOTHERAPY: A ONE-YEAR FOLLOWUP ^^^35 OS-C 

GROUP VERSUS INDIVIDUAL COGNITIVE-THERAPY: A PILOT-^TUD^ ^^^ 

^°°UTHIUM-INDUCED COGWHEEL RIGIDITY: TREATMENT WITH 

AMANTADINE. 000748 01-1 

^°"rELEa1e'0F*G0NAD0TR0PIN-RELEASING-H0RM0NE BY VERATRINE IN A 
HYPOTHALAMIC PITUITARY COINCUBATION ^^^^^ ^^^ 

^°^THE^EF'FEa OF COLCHICINE AND CYTOCHALASIN B ON THE RELEASE OF 
TAURINE FROM THE CHICK RETINA. ^2356 03-0 

THE EFFEQS OF COLCHICINE AND VINBLASTINE ON ^EMORYm^HlCKS^ 

^°''°PLASMA CATECHOLAMINES IN RATS EXPOSED TO COLD: EFFEaS OF 

GANGLIONIC AND ADRENORECEPTOR BLOCKADE. ^^^^^ ^^_^ 

rnPF TFMPFRATURE CHANGES FOLLOWING ADMINISTRATION OF 
nLoS AND NALTREXONE TO RATS EXPOSED TO HOT AND COLD 

amb°enTtempermures. ^^^J^^Vr^^'^^Zm'"''''^^ 

OF ENDORPHINS IN HOT AND COLD ACCLIMATIZATION. ^^^^^ ^^ 

•"""fMSffNE^Py^lMA CONCENTRATION AND CLINICAL-EFFEa: A 

WORLD-HEALTH-ORGANIZATION COLLABORATIVE-STUDY^ ^_^^^ ^^_^ 



S-104 



VOLUME 19, SUBJECT INDEX 



Subject Index 



MULTIINSTITUTIONAL-STUDY ON THE TERATOGENICITY AND FETAL 
TOXICITY OF ANTIEPILEPTIC-DRUGS: A REPORT OF A COLLABORATIVE- 
STUDY GROUP IN JAPAN. 

002442 02-15 
COLLAPSE 

A CASE OF CARDIOVASCULAR COLLAPSE DURING LITHIUM-CARBONATE 
THERAPY. 

000860 01-15 
COLLECTION 

A NOVEL PSYCHOMETRIC-TEST MODEL APPLYING TAILORED TESTING FOR 
ECONOMIC AND EFFICIENT COLLECTION OF 
PSYCHOPHARMACOLOGICAL-EFFECTS. 

002479 02-16 
COLONIC 

PHARMACOMANOMETRIC-STUDIES OF COLONIC MOTILITY AS A GUIDE 
TO THE CHEMOTHERAPY OF SCHIZOPHRENIA. 

001930 02-08 
COLONIES 

A DRUG DISPENSER TO MEASURE INDIVIDUAL DRINKING IN RAT 
COLONIES. 

000530 01-06 
COLUMNS 

AN IMPROVED ASSAY OF CYCLIC-NUCLEOTIDE-PHOSPHODIESTERASES 
WITH QAE-SEPHAOEX COLUMNS. 

001860 02-06 
COMA 

THE TWO SURVIVAL CASES OF ALPHA-PAHERN COMA CAUSED BY 
LARGE AMOUNTS OF HYPNOTICA AND NEUROLEPTICA. 

004608 04-15 
PROLONGED BENZODIAZEPINE COMA. 

004653 04-15 
COMBINATION 

EFFECT OF DOPAMINERGIC AND GABAERGIC DRUGS GIVEN ALONE OR IN 
COMBINATION ON THE ANTICONVULSANT ACTION OF PHENOBARBITAL 
AND DIPHENYLHYDANTOIN IN THE ELECTROSHOCK-TEST IN MICE. 

000163 01-03 
DIAZEPAM IN COMBINATION WITH TACRINE DERIVATIVES ANTAGONIZES 
BEHAVIOURAL-EFFECTS OF ANTICHOLINERGIC PSYCHOTOMIMETICS IN 
RATS. 

000420 01-04 
EFFECT OF MORPHINE IN COMBINATION WITH CHLORPROMAZINE AND 
HALOPERIDOL ON OPERANT-BEHAVIOR. 

000486 01-04 
THE TREATMENT OF PARKINSONS-DISEASE USING A COMBINATION OF L- 
DOPA AND DECARBOXYLASE INHIBITORS (CARBIDOPA, BENSERASIDE). 
A CLINICAL AND BIOCHEMICAL COMPARATIVE INVESTIGATION. 

000712 01-11 
CONTROLLED-TRIAL OF BEHAVIOUR-THERAPY, PHARMACOTHERAPY, AND 
THEIR COMBINATION IN THE TREATMENT OF OBESITY. 

000725 01-11 
PROBLEMS INVOLVED IN THE COMBINATION OF PHARMACEUTIC-AGENTS 
WITH PSYCHOTHERAPY OR PSYCHOANALYSIS. 

000971 01-17 
PRODUCTION OF CONVULSIONS IN MICE BY THE COMBINATION OF 
METHIONINE AND HOMOCYSTEINE. 

001233 02-03 
THE EFFECTS OF DELTA9 TETRAHYDROCANNABINOL ALONE AND IN 
COMBINATION WITH CANNABIDIOL ON FIXED-INTERVAL 
PERFORMANCE IN RHESUS-MONKEYS 

001582 02-04 
EFFECTS OF SPIPERONE ALONE AND IN COMBINATION WITH ANORECTIC- 
AGENTS ON FEEDING PARAMETERS IN THE RAT. 

001598 02-04 
EFFECTS OF MORPHINE, PENTAZOCINE AND CYCLAZOCINE ALONE AND IN 
COMBINATION WITH NALOXONE ON ELECTRIC-SHOCK TITRATION IN 
THE SQUIRREL-MONKEY. 

001611 02-04 
A COMPARISON OF HALOPERIDOL, LITHIUM-CARBONATE AND THEIR 
COMBINATION IN THE TREATMENT OF MANIA. 

001990 02-09 
TREATMENT OF ANXIOUS-DEPRESSED OUTPATIENTS WITH A FIXED 
COMBINATION (NOMIFENSINE/CLOBAZAM) IN COMPARISON TO A 
MONOSUBSTANCE (DOXEPINE). 

002028 02-09 
INFUSION OF MAPROTILIN AND CLOMIPRAMIN AND THEIR COMBINATION 
IN THE TREATMENT OF DEPRESSION. 

002056 02-09 
COMPARATIVE-STUDIES OF L-DOPA ALONE AND COMBINATION WITH A 
PERIPHERAL DOPA-DECARBOXYLASE INHIBITOR, BENSERAZIDE-HCL ON 
PARKINSONS-DISEASE - PART II: PHARMACOKINETIC-STUDY. 

002309 02-13 
FREE DESCRIPTION OF DRUG-EFFECTS AS A METHOD OF CLINICAL-TRIAL 
PRESENTED BY THE EXAMPLE OF PENTOBARBITONE, PROMAZINE AND 
THEIR COMBINATION. 

002561 02-17 
THE DIFFERENTIAL NEUROCHEMICAL-BASES OF THE BEHAVIOURS ELICITED 
BY SEROTONERGIC-AGENTS AND BY THE COMBINATION OF A 
MONOAMINE-OXIDASE-INHIBITOR AND L-DOPA. 

002976 03-04 



MANAGEMENT OF SCHIZOPHRENIA: LONG-TERM CLINICAL-STUDIES WITH 
SPECIAL REFERENCE TO THE COMBINATION OF PSYCHOTHERAPY AND 
DEPOT NEUROLEPTICS. 

003183 03-08 
THE BEHAVIORAL-EFFECTS OF D-AMPHETAMINE ALONE AND IN 
COMBINATION WITH ACUTE AND CHRONIC MORPHINE TREATMENTS IN 
RATS, 

003915 04-03 
INHIBITORY-ACTION OF THE COMBINATION OF AMINOPYRINE AND 
SECOBARBITAL ON EEG ACTIVATION, NEOCORTICAL RECRUITING AND 
AUGMENTING RESPONSES IN RABBITS, 

004022 04-03 
NEUROLEPTIC TRICYCLIC-ANTIDEPRESSANT COMBINATION: 
PHARMACOLOGICAL-ASPECTS AND THERAPEUTIC INTEREST. 

004501 04-13 
ELECTRORETINOGRAPHY (ERG) AS A TOOL OF INVESTIGATION IN HUMAN 
PSYCHOPHARMACOLOGY. ELECTRORETINOGRAPHIC-CHANGES INDUCED 
BY A COMBINATION OF CARBIDOPA AND LEVODOPA. 

004507 04-13 
NEUROLOGICAL TOLERANCE OF LITHIUM AND PSYCHOTROPIC-DRUGS IN 
COMBINATION: 265 CASES. 

004594 04-15 
COMBINATIONS 

POTENTIATION OF LETHALITY IN MICE BY COMBINATIONS OF 
PENTAZOCINE AND TRIPELENNAMINE. 

000529 01-05 
EFFECTS OF CHLORDIAZEPOXIDE MORPHINE COMBINATIONS ON 
SPONTANEOUS LOCOMOTOR-ACTIVITY IN THREE INBRED STRAINS OF 
MICE. 

001766 02-04 
BEHAVIOURAL-EFFECTS OF ACETYLSALICYLIC-ACID, PARACETAMOL, 
CAFFEINE, GUAIPHENESIN AND THEIR COMBINATIONS. 

001805 02-04 
NMR SPECTRAL STUDY OF PROTON TRANSFER IN AMITRIPTYLINE- 
HYDROCHLORIDE CHLORDIAZEPOXIDE-HYDROCHLORIDE COMBINATIONS 
IN DIPOLAR APROTIC SOLVENTS. 

003654 04-01 
SIDE-EFFECTS AND UNDESIRABLE COMBINATIONS OF PSYCHOTROPIC- 
MEDICATIONS. 

004663 04-15 
COMBINED 

EFFECTS OF L-DOPA AND L 5 HYDROXYTRYPTOPHAN ON LOCOMOTOR- 
ACTIVITY OF THE RAT AFTER SELECTIVE OR COMBINED DESTRUCTION 
OF CENTRAL CATECHOLAMINE AND SEROTONIN NEURONS. 

000466 01-04 
COMBINED MONOAMINE-OXIDASE-INHIBITOR TRICYCLIC- 
ANTIDEPRESSANT TREATMENT: A PILOT- STUDY. 

000644 01-09 
DEMONSTRATION OF SUBSTANCE-P IN AORTIC NERVE AFFERENT FIBERS 
BY COMBINED USE OF FLOURESCENT RETROGRADE NEURONAL 
LABELING AND IMMUNOCYTOCHEMISTRY. (UNPUBLISHED PAPER). 

001024 02-01 
HEXAMETHONIUM MODIFICATION OF CARDIOVASCULAR ADJUSTMENTS 
DURING COMBINED STATIC DYNAMIC ARM EXERCISE IN MONKEYS. 

001242 02-03 
EFFECT OF CHLORPROMAZINE ON CELL PROLIFERATION IN THE 
DEVELOPING RAT-BRAIN. A COMBINED BIOCHEMICAL-STUDY AND 
MORPHOLOGICAL-STUDY. 

001407 02-03 
A COMBINED BEHAVIORAL-PHARMACOTHERAPY APPROACH TO 
OBSESSIVE-COMPULSIVE-DISORDERS. 

002082 02-10 
MEDICAL PSYCHOLOGICAL AND COMBINED THERAPY IN THE CASES OF 
ENURESIS: A COMPARATIVE-STUDY. 

002175 02-11 
THE EFFECTS OF COMBINED SEDATIVE AND ANXIOLYTIC-PREPARATIONS 
ON SUBJECTIVE ASPECTS OF SLEEP AND OBJECTIVE MEASURE OF 
AROUSAL AND PERFORMANCE THE MORNING FOLLOWING NOCTURNAL 
MEDICATION: II. REPEATED DOSES. 

002331 02-14 
A TOPOGRAPHIC LOCALIZATION OF ENKEPHALIN ON THE DOPAMINE 
NEURONS OF THE RAT SUBSTANTIA-NIGRA AND VENTRAL TEGMENTAL 
AREA DEMONSTRATED BY COMBINED HISTOFLUORESCENCE 
IMMUNOCYTOCHEMISTRY. 

002639 03-01 
COMBINED EFFECTS OF ALCOHOL AND LITHIUM ON BODY COMPOSITION 
IN THE RAT MODEL. 

002928 03-03 
SYNERGISM OF COMBINED LITHIUM NEUROLEPTIC THERAPY: A DOUBLE- 
BLIND, PLACEBO-CONTROLLED CASE-STUDY. 

003165 03-08 
LITHIUM COMBINED WITH NEUROLEPTICS IN CHRONIC SCHIZOPHRENIC- 
PATIENTS AND SCHIZOAFFECTIVE-PATIENTS. 

003168 03-08 
TREATMENT OF THERAPEUTICALLY-RESISTANT PARANOID 

SCHIZOPHRENIC-PATIENTS WITH FLUPHENAZINE DEPOT COMBINED 
WITH OTHER PSYCHOTROPIC-DRUGS AND CLOZAPINE. 

003172 03-08 



I 



ii'iit 






a 



S-105 



Subject Index 



COMBINED ADMINISTRATION OF NIALAMIDE AND VILOXAZINE TO 
DEPRESSIVE-PATIENTS. 003232 03-09 

SENILE-DEMENTIA: COMBINED PHARMACOLOGIC-TREATMENT AND 
PSYCHOLOGIC-TREATMENT. ^^^^^ ^^_^ ^ 

PHARMACOPSYCHOLOGICAL INVESTIGATIONS CONCERNING THE 
COMBINED EFFECTS OF DIPOTASSIUM-CLORAZEPATE AND ETHANOL^ 

003456 03-14 
GAS-CHROMATOGRAPHY, MASS-SPECTROMETRY, AND COMBINED 
CHROMATOGRAPHY MASS-SPECTROMETRY. 

004290 04-06 
NEUROTROPIC-DRUGS AS COMEDICATION TO PSYCHOTROPICS: 
COMBINED ADMINISTRATION OF A NEUROTROPIC-DRUG AND A 
TETRACYCLIC-ANTIDEPRESSANT. 004396 04-09 

A MODIFIED VERSION OF THE SIMULTANEOUS DISCONTINUATION OF 
PSYCHOTROPIC-DRUGS (COMBINED WITH THE ADMINISTRATION OF 
DIURETICS) AS A METHOD OF HALTING PROLONGED AHACKS OF 
SCHIZOPHRENIA. 004584 04-14 

^°*?He"b1nEFITS and risks of COMBINING AN MAO-INHIBITOR AND A 

TRICYCLIC-ANTIDEPRESSANT. 003273 03-09 

^°**NEUR0TR0PIC-DRUGS as COMEDICATION TO PSYCHOTROPICS: 

COMBINED ADMINISTRATION OF A NEUROTROPIC-DRUG AND A 
TETRACYCLIC-ANTIDEPRESSANT. 004396 04-09 

^°**FS'llBEl[l^rO^Co'LERCIALLY-AVAILABLE 3H CATECHOl^^^ 

COMMUNAL 

COMMUNAL MEDICATION . ^^595 02- 1 7 

^°%*is"cUS*SIOrCOMMUNlCATION AND POLYPHARMACY: DRUGS AND THE 

^'-'^^'^'■^ 000957 01-17 

BRIEF COMMUNICATION: BEHAVIORAL RECOVERY AFTER TOLUENE 
EXPOSURE IN RATS. 002969 03-04 

^°TNTrPsVcHOTIGDRUGS IN COMMUNITY-BASED SHELTERED-CARE-HOMES. 

002 \ I I Oz" 1 I 

^°Te""cOMP-EEG, REO-EG AND PHARMACOLOGICAL-CORRELATES OF 

GERIATRICS. 002162 02-11 

COMPARABILITY ^ „„..^. 

CLINICAL COMPARABILITY OF PSYCHOTROPIC-DRUGS . ^^^^^ ^^ ^ ^ 

COMPARATIVE 

A COMPARATIVE EVALUATION OF DOTHIEPIN (PROTHIEDEN) AND 

"^"'^^'^'^E- 000583 01-09 

COMPARATIVE ENZYME-INDUCING EFFECTS OF CHLORPROMAZINE AND 

FLUPHENAZINE THERAPIES IN PSYCHOTIC-PATIENTS. 

OOOooz 01-11 
THE TREATMENT OF PARKINSONS-DISEASE USING A COMBINATION OF L- 

DOPA AND DECARBOXYLASE INHIBITORS (CARBIDOPA, BENSERASIDE). 

A CLINICAL AND BIOCHEMICAL COMPARATIVE INVESTIGATION 

000/ \ i. 01"! I 
THE COMPARATIVE DISPOSITION OF NOMIFENSINE (MERITAL) IN THE 

PREGNANT AND NONPREGNANT RAT. 000853 01-15 

COMPARATIVE ANXIOLYTIC AND HYPNOTIC-EFFEQS OF 3 

BENZODIAZEPINES ON BABOONS. 00158102-04 

COMPARATIVE EXPERIMENT OF THE ANTIDEPRESSANT EFFEaS OF 

AMINEPTINE AND CHLORIMIPRAMINE. ^^^^^ ^^_^ 

COMPARATIVE CROSS-STUDY ON THE EFFEaS OF AMINEPTINE AND 
^APROTILINE. 002065 02-10 

SELF-MEDICATION ABANDONMENT, MANIPULATION, AND DEPENDENCE 
IN DRUG-THERAPY IN PSYCHOSOMATIC-ILLNESS: COMPARATIVE 
POLYCENTRIC RESEARCH ON VARIOUS PSYCHOTROPIC-DRUGS. 

0021 89 02- 1 I 

COMPARATIVE PROTEIN BINDING OF DIAZEPAM AND 
DESMETHYLDIAZEPAM. 002206 02-13 

A COMPARATIVE REVIEW OF THE PHARMACOLOGICAL AND 
TOXICOLOGICAL PROPERTIES OF DISULFIRAM AND CALCIUM- 
CARBIMIDE. 003522 03-15 

COMPARATIVE ANALGESIC, BEHAVIORAL, AND DEPENDENCE PROPERTIES 
OF MORPHINE AND 



Psychopharmacology Abstracts 

METHOXYLPHENYLCARBAMOYLDIETHYLAMINOPROPIOPHENONEOXIME 
Hfl 

003707 04-02 
A COMPARATIVE CLINICAL-TRIAL WITH THE TRANQUILIZER TRAZODONE 
AND THE TRICYCLIC-ANTIDEPRESSANT CLOMIPRAMINE. 

004380 04-09 
COMPARATIVE CHARAQERISTICS OF THE PROPHYLAQIC PROPERTIES OF 
SHORT-TERM AND LONG-ACTING LITHIUM-CARBONATE PREPARATIONS 
IN ENDOGENOUS AFFECTIVE-PSYCHOSES. 

004390 04-09 
A COMPARATIVE EVALUATION OF THE EFFICACY OF SOME THERAPEUTIC 
METHODS USED IN DELIRIUM-TREMENS. 

004486 04-11 

A COMPARATIVE EVALUATION OF THE USEFULNESS OF 

PSYCHOPHYSIOLOGICAL-TESTS DURING VARIOUS LEVELS OF 
ACTIVATION OF THE CENTRAL-NERVOUS-SYSTEM. 

004543 04-13 

COMPARATIVE-EFFECT 

STIMULUS INTENSITY CONTROL IN DEPRESSION: A STUDY OF THE 
COMPARATIVE-EFFECT OF DOXEPIN AND AMITRIPTYLINE ON CORTICAL 
EVOKED-POTENTIALS. 000763 01-13 

COMPARATIVE-EFFECTS ^ ^,„ , „ 

COMPARATIVE-EFFECTS OF P CHLOROAMPHETAMINE AND L P 
CHLOROPHENYLPIPERAZINE ON 5 HYDROXYINDOLE CONCENTRATION IN 

^^^-^"^^'^ 000101 01-03 

COMPARATIVE-EFFEaS OF SOMATOSTATIN AND ENKEPHALINS ON THE 
GUINEA-PIG ILEUM AND THE RAT VAS-DEFERENS. 

UNIT AaiVITY IN MEDIAL THALAMUS: COMPARATIVE-EFFEQS OF 

CAFFEINE AND AMPHETAMINE. 003752 04-03 

COMPARATIVE-EFFECTS OF AMANTADINE AND AMFONELIC-ACID ON 

DOPAMINE METABOLISM IN RAT-BRAIN. 003796 04-03 

COMPARATIVE-EFFEaS OF SUBSTITUTED PHENYLETHYLAMINES ON BRAIN 

SEROTONERGIC MECHANISMS 003854 04-03 

COMPARATIVE-EFFECTS OF PHENELZINE AND AMITRIPTYLINE: A 

PLACEBO-CONTROLLED-TRIAL. 004402 04-09 

COMPARATIVE-STUDIES 

COMPARATIVE-STUDIES OF MAO-A AND MAO-B INHIBITORSIN MAN. • 

0006 1 2 1 -OV 

COMPARATIVE-STUDIES ON THE METABOLISM AND THE DISTRIBUTION OF 

SULPIRIDE AND SULTOPRIDE 002240 02-13 

COMPARATIVE-STUDIES OF L-DOPA ALONE AND COMBINATION WITH A 
PERIPHERAL DOPA-DECARBOXYL*SE INHIBITOR, BENSERAZIDE-HCL, ON 
PARKINSONS-DISEASE - PART II: PHARMACOKINETIC-STUDY^^^ ^^^^ 

COMPARATIVE-STUDIES OF THE PHARMACOLOGICAL-EFFEQS OF THE D- 
ISOMERS AND L-ISOMERS OF CODEINE ^^^ ^^ 

COMPABATiVE-STUDY 

COMPARATIVE-STUDY OF ANALGESIA INDUCED BY N VAL5-ENKEPHALIN 
AND PR05-ENKEPHALIN ANALOGS. 00002101-03 

COMPARATIVE- STUDY OF THE INHIBITION OF GABA-AMINOTRANSFERASE 
BY DIFFERENT ANTICONVULSANT-DRUGS. ^^^^^ ^^^^ 

COMPARATIVE-STUDY OF THE CARDIOTOXICITY OF AMITRIPTYLINE AND 
MAPROTILINE IN DEPRESSIVE-PATIENTS ^^^^^ ^^_^ 

COMPARATIVE-STUDY OF PROPHYLAQIC LITHIUM AND 

DIETHYLSTILBESTROL IN SEXUAL-DEVIANTS. ^^^^^ ^^ ^ ^ 

A COMPARATIVE-STUDY ON THE CLINICAL-EFFEaS OF FLUNITRAZEPAM 
ANDLORAZEPAM 000702 01-11 

COMPARATIVE-STUDY OF SLEEP AND STATE ON AWAKENING WITH TWO 
HYPNOTIC DIAZEPINES 000817 01-14 

COMPARATIVE-STUDY OF AGGRESSIVE-BEHAVIOUR AFTER INJEQION OF 
CHOLINOMIMETICS, ANTICHOLINESTERASES, NICOTINIC AND 
MUSCARINIC GANGLIONIC STIMULANTS INTO THE CEREBRAL 
VENTRICLES OF CONSCIOUS CATS: FAILURE OF NICOTINIC-DRUGS TO 
EVOKE AGGRESSION. 001568 02-04 

COMPARATIVE-STUDY OF THE INDUQIVE EFFEQ OF TWO 

PSYCHOMODERATORS - TETRABAMATE AND COMPLEXE-1656 - AND 
OF PHENOBARBITAL ON LIVER MICROSOMAL ENZYMES IN RATS- 

0018/4 Kil-Kjo 

MAINTENANCE-THERAPY WITH f LUPHENAZINE-pECANOATE AND 
OXYPROTHEPINE-DECANOATE IN SCHIZOPHRENIC-PATIENTS - A 
DOUBLE-BUND CROSS-OVER COMPARATIVE-STUDY. 



S-106 



VOLUME 19, SUBJECT INDEX 



Subject Index 



A COMPARATIVE-STUDY OF BROMOCRIPTINE AND LEVODOPA IN 
PARKINSONS-DISEASE. 

002117 02-11 
MEDICAL PSYCHOLOGICAL AND COMBINED THERAPY IN THE CASES OF 
ENURESIS: A COMPARATIVE-STUDY. 

002175 02-11 
COMPARATIVE-STUDY OF VARIATIONS IN PROLACTIN LEVELS DURING 
TREATMENT WITH ANTIPSYCHOTIC-DRUGS. 

002412 02-15 
COMPARATIVE-STUDY ON THE EFFECT OF MORPHINE AND THE OPIOID- 
LIKE PEPTIDES IN THE VAS-DEFERENS OF RODENTS: STRAIN AND 
SPECIES-DIFFERENCES, EVIDENCE FOR MULTIPLE OPIATE-RECEPTORS. 

002757 03-03 
A COMPARATIVE-STUDY OF THE PHARMACOLOGY OF INHIBITORS OF 
GABA METABOLISM. 

003036 03-04 
A COMPARATIVE-STUDY ON THE CLINICAL-EFFECTS OF RECTAL 

DIAZEPAM AND PENTOBARBITAL ON SMALL CHILDREN. RELATIONSHIP 
BETWEEN PLASMA LEVEL AND EFFECT. 

003330 03-1 1 
CARDIOVASCULAR-EFFECTS OF MIANSERIN - A COMPARATIVE-STUDY 
WITH AMITRIPTYLINE AND A PLACEBO IN HEALTHY SUBJECTS. 

003503 03-15 
A COMPARATIVE-STUDY OF THE PHARMACOLOGICAL-PROPERTIES OF THE 
POSITIVE POTENTIAL RECORDED FROM THE SUPERIOR CERVICAL 
GANGLIA OF SEVERAL SPECIES. 

003779 04-03 
A COMPARATIVE-STUDY OF INTRAVENOUS LORAZEPAM AND 
CLONAZEPAM IN STATUS-EPILEPTICUS. 

004487 04-11 
A CLINICAL-EVALUATION OF THE EFFECTS OF A NEW PSYCHOTROPIC- 
AGENT, MEXAZOLAM (CS-386) ON PSYCHOSOMATIC-DISEASES AND 
NEUROSIS: A COMPARATIVE-STUDY WITH OXAZOLAM, USING THE 
DOUBLE-BLIND METHOD. 

004491 04-11 
COMPARATIVE-TRIAL 

A DOUBLE-BLIND GROUP COMPARATIVE-TRIAL OF MIANSERIN AND 
DIAZEPAM IN DEPRESSED-OUTPATIENTS. 

000592 01-09 
SINGLE-DOSE VERSUS MULTIPLE-DOSE COMPARATIVE-TRIAL OF 
DESIPRAMINE-HYDROCHLORIDE: A DOUBLE-PLACEBO METHOD. 

002059 02-10 
COMPARED 

ANTIDEPRESSANT PROPERTIES OF 2 4 ETHYL-2-PIPERAZINYL-4- 

PHENYLQUINOLINE-HCL (AD-1308) AND ITS MECHANISM-OF-ACTION 
AS COMPARED WITH TRICYCLIC-ANTIDEPRESSANTS. 

000152 01-03 
ANTIDEPRESSANT TREATMENT BY INTRAVENOUS ADMINISTRATION 
COMPARED TO PERORAL ADMINISTRATION: A DOUBLE-BLIND STUDY 
OF QUINUPRAMINE. 

000552 01-08 
ANXIOLYTIC EFFICACY OF ALPRAZOLAM COMPARED TO DIAZEPAM AND 
PLACEBO. 

000648 01-10 
COMPARED PROPERTIES OF CENTRAL AND PERIPHERAL BINDING-SITES 
FOR PHENCYCLIDINE. 

001521 02-03 
MALE RAT SEXUAL-BEHAVIOR COMPARED AFTER 6 OHDA AND 
ELECTROLYTIC LESIONS IN THE DORSAL NA BUNDLE REGION OF THE 
MIDBRAIN. 

001593 02-04 
OXYPROTHEPINE-DECANOATE COMPARED WITH FLUPHENAZINE- 

DECANOATE IN THE TREATMENT OF SCHIZOPHRENIA: PRELIMINARY- 
COMMUNICATION. 

001934 02-08 
THE CLINICAL-EFFICACY OF CLOZAPINE AS COMPARED TO LABORATORY 
PARAMETERS. 

001955 02-08 
KETAZOLAM COMPARED TO DIAZEPAM AND PLACEBO IN THE 
TREATMENT OF ANXIETY. 

002074 02-10 
LEVODOPA COMPARED WITH BROMOCRIPTINE IN THE TREATMENT OF 
PARKINSONS-DISEASE. 

002406 02-15 
THE ACTION OF BENZODIAZEPINES ON THE LIMBIC-SYSTEM COMPARED 
TO OTHER TRANQUILIZERS. 

002731 03-03 
THE ANTIDEPRESSANT ACTION OF SULPHO-ADENOSYL-L-METHIONINE 
(SAME) COMPARED WITH THAT OF CHLORIMIPRAMINE: 
HYPOTHETICAL INTERPRETATIONS OF THE MECHANISM-OF-ACTION. 

003150 03-07 
COMPARING 

EFFICACY AND PAHERN VALENCE OF PSYCHOACTIVE-DRUGS: A NEW 
METHOD OF COMPARING DRUGS APPLIED TO IDENTICAL PATIENTS IN 
RANDOMIZED-ORDER. 

000699 01-11 
A DOUBLE-BUND MULTICENTRE-TRIAL COMPARING THE EFFICACY AND 
SIDE-EFFECTS OF MIANSERIN AND CHLORIMIPRAMINE IN DEPRESSED- 
INPATIENTS AND DEPRESSED-OUTPATIENTS. 

004395 04-09 



COMPARISON 

COMPARISON OF MIANSERIN WITH DESIPRAMINE, MAPROTILINE AND 
PHENTOLAMINE ON CARDIAC PRESYNAPTIC AND VASCULAR 
POSTSYNAPTIC ALPHA-ADRENOCEPTORS AND NORADRENALINE 
REUPTAKE IN PITHED NORMOTENSIVE-RATS. 

000044 01-03 
A COMPARISON OF HUMAN TACTILE STIMULUS VELOCITY 

DISCRIMINATION WITH THE ABILITY OF S-l CORTICAL NEURONS IN 
AWAKE RHESUS-MONKEYS TO SIGNAL THE SAME VELOCITY 
DIFFERENCES BEFORE AND AFTER NONANESTHETIC DOSES OF 
PENTOBARBITAL. 

000055 01-03 
COMPARISON OF THE EFFECTS OF THE ISOMERS OF AMPHETAMINE, 
METHYLPHENIDATE AND DEOXYPIPRADROL ON THE UPTAKE OF L 
(3H)N0REPINEPHRINE AND (3H)D0PAMINE BY SYNAPTIC VESICLES 
FROM RAT-WHOLE-BRAIN, STRIATUM AND HYPOTHALAMUS. 

000091 01-03 
ANTAGONISM OF INTRASTRIATAL AND INTRAVENOUS KAINIC-ACID BY 1 
NUCIFERINE: COMPARISON WITH VARIOUS ANTICONVULSANTS AND 
GABAMIMETICS. 

000188 01-03 
COMPARISON OF BETA-ADRENERGIC-RECEPTOR SUBTYPES IN 
MAMMALIAN TISSUES. 

000207 01-03 
COMPARISON OF BLOOD AND BILE LEVELS OF OXYPROTHEPIN AND 
DOCLOXYTHEPIN IN RATS. 

000242 01-03 
(3H)QUINUCLIDINYL-BENZILATE BINDING TO MUSCARINIC-RECEPTORS 
AND (3H)WB-4101 BINDING TO ALPHA-ADRENERGIC-RECEPTORS IN 
RABBIT IRIS: COMPARISON OF RESULTS IN SLICES AND MICROSOMAL 
FRACTIONS. 

000299 01-03 
A COMPARISON OF RATES OF DEPLETION AND RECOVERY OF 
NORADRENALINE STORES OF PERIPHERAL AND CENTRAL 
NORADRENERGIC NEURONES AFTER RESERPINE ADMINISTRATION: 
IMPORTANCE OF NEURONAL ACTIVITY. 

000314 01-03 
CGP-6085-A, A NEW, SPECIFIC, INHIBITOR OF SEROTONIN UPTAKE: 
NEUROCHEMICAL CHARACTERIZATION AND COMPARISON WITH OTHER 
SEROTONIN UPTAKE BLOCKERS. 

000316 01-03 
GABAERGIC ACTIONS OF THIP IN VIVO AND IN VITRO: A COMPARISON 
WITH MUSCIMOL AND GABA. 

000319 01-03 
ANTINOCICEPTIVE COMPARISON OF QUIPAZINE AND MORPHINE. 

000435 01-04 
A COMPARISON OF THE EFFECTS OF D-AMPHETAMINE, COCAINE, 

IMIPRAMINE AND PENTOBARBITAL ON LOCAL AND OVERALL RATES OF 
RESPONDING MAINTAINED UNDER A FOUR-COMPONENT MULTIPLE 
FIXED-INTERVAL SCHEDULE. 

000508 01-04 
A COMPARISON OF THE CARDIOVASCULAR EFFECTS OF HALOPERIDOL, 
THIORIDAZINE AND CHLORPROMAZINE-HCL. 

000512 01-05 
STUDY OF VIGILANCE AFTER INGESTION OF ZOPICLONE IN COMPARISON 
WITH NITRAZEPAM AND PLACEBO. METHODOLOGY OF THE STUDY: 
SELF-EVALUATION QUESTIONNAIRE AND PSYCHOMETRIC-TESTS. 

000543 01-07 
COMPUTERIZED EEG IN THE COMPARISON OF OXYPROTHEPIN AND 
FLUPHENAZINE-DECANOATE. 

000567 01-08 
CLINICAL COMPARISON OF OXYPROTHEPIN AND CLOTEPINE IN 

SCHIZOPHRENIC-PATIENTS (CONTROLLED-STUDY) . 

000568 01-08 
DOUBLE-BUND COMPARISON OF HALOPERIDOL AND THIOTHIXENE WITH 

AFTERCARE TREATMENT EVALUATION IN PSYCHIATRIC-OUTPATIENTS 
WITH SCHIZOPHRENIA. 

000574 01-08 
COMPARISON OF SINGLE-DOSE PHARMACOKINETICS OF IMIPRAMINE 
AND MAPROTILINE IN THE ELDERLY. 

000596 01-09 
SINTAMIL IN THE TREATMENT OF DEPRESSION: A COMPARISON OF 
SINGLE VS. DIVIDED DOSE ADMINISTRATION. 

000629 01-09 
DOUBLE-BLIND COMPARISON OF KETAZOLAM, DIAZEPAM AND PLACEBO 
IN ONCE-A-DAY VS T.I.D. DOSING. 

000660 01-11 
COMPARISON OF SUSTAINED-RELEASE AND STANDARD 
METHYLPHENIDATE IN THE TREATMENT OF MINIMAL-BRAIN- 
DYSFUNCTION. 

000732 01-11 
COMPARISON OF CYSTEINE-SULPHINIC-ACID-DECARBOXYLASE (CSD) 
ISOENZYMES AND GLUTAMIC-ACID-OECARBOXYLASE (GAD) IN RAT: IS 
BRAIN CSD-I IDENTICAL WITH LIVER CSD AND BRAIN CSD-II WITH 
GAD? (UNPUBLISHED PAPER). 

001048 02-01 
COMPARISON OF HIGHLY-ACTIVE AND ACTIVITY DEPLETED HEPARIN BY 
CIRCULAR DICHROISM SPECTROSCOPY. (UNPUBLISHED PAPER). 

001057 02-01 



til. 

■•■It; 



'•til: 
tic, 









S-l 07 



Subject index 

GAMMA AMINOBUTYRIC-ACID AGONISTS: AN IN VITRO COMPARISON 
BETWEEN DEPRESSION OF SPINAL SYNAPTIC ACTIVITY AND 
DEPOLARIZATION OF SPINAL ROOT FIBRES IN THE RAT. 

001104 02-03 
ON THE MECHANISM OF A DIFFERENT DRUG DISTRIBUTION DURING 
CONVULSIVE-SEIZURE IN COMPARISON TO ANESTHESIA. 

001151 02-03 
A COMPARISON OF STRIATAL AND MESOLIMBIC DOPAMINE FUNCTION IN 
THE RAT DURING 6-MONTH TRIFLUOPERAZINE ADMINISTRATION. 

001174 02-03 
A COMPARISON OF THE EFFECTS OF METHYLPHENIDATE AND 

AMPHETAMINE ON THE SIMULTANEOUS RELEASE OF RADIOLABELLED 
DOPAMINE AND P OR M TYRAMINE FROM RAT STRIATAL SLICES. 

001207 02-03 
COMPARISON OF THE EFFECTS OF CENTRAL ADMINISTRATION OF SERINE 
AND GLYCINE ON BODY-TEMPERATURE OF THE RABBIT. 

001248 02-03 
MORPHINE AND ELEaROACUPUNCTURE: COMPARISON OF THE EFFECTS 
ON THE CORTICAL EVOKED-RESPONSES AFTER TOOTH-PULP 
STIMULATION IN RATS. 001294 02-03 

THE NEW ANTIDEPRESSANT PIRLINDOLE; A COMPARISON WITH 
IMIPRAMINE AND TRANYLCYPROMINE. 

001360 02-03 
COMPARISON OF BIOLOGICAL-ACTIVITY AND BEHAVIORAL-ACTIVITY OF 
ALPHA AND GAMMA MELANOCYTE-STIMULATING-HORMONES. 
(UNPUBLISHED PAPER). 001398 02-03 

DOPAMINE-AUTORECEPTORS: PHARMACOLOGY, FUNCTION AND 
COMPARISON WITH POSTSYNAPTIC DOPAMINE-RECEPTORS 

001453 02-03 
DOSE-DEPENDENT PHARMACOKINETICS OF ALPHA METHYL-P-TYROSINE 
(ALPHA MT) AND COMPARISON OF CATECHOLAMINE TURNOVER- 
RATES AFTER TWO DOSES OF ALPHA MT. ^^ ^^^ ^^^^ 

ANALGESIC ACTION OF INTRATHECAL AND INTRACEREBRAL BETA 

ENDORPHIN IN RATS: COMPARISON WITH MORPHINE. 

001691 02-04 

A COMPARISON BETWEEN THE EFFECTS OF MORPHINE ON THE 

REWARDING AND AVERSIVE-PROPERTIES OF LATERAL HYPOTHALAMIC 
AND CENTRAL GRAY STIMULATION 00 1 77 1 02 04 

COMPARISON OF CLONAZEPAM AND DIAZEPAM IN EXPERIMENTAL- 

^™°'^5 001815 02-04 

COMPARISON OF OPIATE AGONISTS AND THEIR N ALLYL DERIVATIVES IN 
THE PRODUCTION OF PHYSICAL-DEPENDENCE IN THE RAT. 

001841 02-05 
COMPARISON OF THE CLASSICAL AND RETARDED FORM OF LITHIUM- 
CARBONATE. „„,„„„ „^„-, 

001888 02-07 

A COMPARISON OF HALOPERIDOL, LITHIUM-CARBONATE AND THEIR 
COMBINATION IN THE TREATMENT OF MANIA. 

001990 02-09 
COMPARISON OF THE EFFECTS OF LOFEPRAMINE AND MIANSERIN IN 
DEPRESSED-PATIENTS IN A DOUBLE-BLIND TRIAL. 

001996 02-09 
THE USE OF VILOXAZINE IN HOSPITALIZED DEPRESSED-PATIENTS: 

RANDOM COMPARISON WITH IMIPRAMINE IN A DOUBLE-BLIND TRIAL 

001998 02-09 
TREATMENT OF ANXIOUS-DEPRESSED OUTPATIENTS WITH A FIXED 
COMBINATION (NOMIFENSINE/CLOBAZAM) IN COMPARISON TO A 
MONOSUBSTANCE (DOXEPINE). ^^^^^^ ^^ ^^ 

002028 02-09 
DOUBLE-BUND COMPARISON OF KETAZOLAM AND PLACEBO USING 

ONCE-A-DAY DOSING. „„„„,^ „^ ,„ 

002067 02-10 
NOMIFENSINE IN THE TREATMENT OF OBSESSIVE-COMPULSIVE-NEUROSIS. 
THERAPEUTIC-EFFICACY AND TOLERABILITY IN COMPARISON TO 

IMIPRAMINE. „„,„„^,„ 

002078 02-10 
A DOUBLE-BUND PARALLEL GROUP COMPARISON OF SINGLE-BEDTIME- 
DOSES OF HALAZEPAM AND PLACEBO. 

002079 02-10 
COMPARISON OF NITRAZEPAM 5 MG WITH TRIAZOLAM 0.5 MG IN 

YOUNG PSYCHIATRIC INSOMNIAC-INPATIENTS. 

002096 02-1 1 
COMPARISON OF SCH- 12679 AND THIORIDAZINE IN AGGRESSIVE 

MENTAL-RETARDATES. „„o, ,^ /,o , , 

002119 02-11 

A COMPARISON OF BIPERIDEN-HYDROCHLORIDE (AKINETON) AND 

BENZHEXOL (ARTANE) IN THE TREATMENT OF DRUG-INDUCED 

PARKINSONISM. „„„,., „o,, 

002146 02-11 

THE PERIPHERAL ANTICHOUNERGIC-ACTIVITY OF TRICYCUC- 
ANTIDEPRESSANTS: COMPARISON OF AMITRIPTYLINE AND 
DESIPRAMINE IN HUMAN VOLUNTEERS. „ „„ ,. 

002298 02-13 



Psychopharmacology Abstracts 



EFFEaS OF HIPPOCAMPAL BRAIN-DAMAGE ON AUDITORY AND VISUAL 
RECENT MEMORY: COMPARISON WITH MARIJUANA INTOXICATED 
SUBJEaS. 

002320 02-14 

AN EVALUATION OF MAPROTILINE INTRAVENOUS KINETICS AND 
COMPARISON OF TWO ORAL DOSES. 

002497 02-16 
DESIGN ASPECTS OF CUNICAL-TRIALS WITH ERGOT ALKALOIDS: A 
COMPARISON OF TWO GERIATRIC BEHAVIORAL-RATING- SCALES. 

002512 02-16 
COMPARISON OF DRUG PRESCRIPTIONS FOR PSYCHIATRIC-PATIENTS 
AFTER HOSPITAL DISCHARGE IN THE DISTRIQS TEPLICE AND UHERSKE- 
HRADISTE. 

002518 02-17 

UTIUZATION OF PSYCHOTROPIC-DRUGS. AN INTERNATIONAL 
COMPARISON. 

002616 02-16 
A COMPARISON OF THE CONTRACTILE RESPONSES OF THE RABBIT 
BASILAR AND PULMONARY-ARTERIES TO SYMPATHOMIMETIC 
AGONISTS: CHARACTERISTICS. 

002670 03-03 
A COMPARISON OF THE EFFEQS OF PENTOBARBITAL AND 

DIPHENYLHYDANTOIN ON THE GABA SENSITIVITY AND EXCITABILITY 
OF ADULT SENSORY GANGLION CELLS. 

002692 03-03 
A COMPARISON OF THE NEUROCHEMICAL-EFFECTS OF BUPRENORPHINE 
WITH THOSE OF MORPHINE AND HALOPERIDOL IN RATS. 

002701 03-03 
PULMONARY METABOLISM OF IMIPRAMINE IN THE RAT AND RABBIT: 
COMPARISON WITH HEPATIC METABOLISM. 

002845 03-03 
EFFECTS OF PROLONGED TREATMENT WITH LITHIUM AND TRICYCUC- 
ANTIDEPRESSANTS ON DISCHARGE FREQUENCY, NOREPINEPHRINE 
RESPONSES AND BETA-RECEPTOR BINDING IN RAT-CEREBELLUM: 
ELECTROPHYSIOLOGICAL AND BIOCHEMICAL COMPARISON. 

002884 03-03 
A COMPARISON OF HUMAN MUSCARINIC CHOUNERGIC-RECEPTOR 
RESPONSE TO A NUMBER OF PSYCHOTROPICS UTILIZING THE 
RADIOLABELED ANTAGONIST, (3H) QUINUCUDINYL-BENZILATE. (PHD 

DISSERTATION). „ „. ,xo 

002918 03-03 

A COMPARISON OF DOPAMINE-RECEPTOR BLOCKING ASSAY WITH 
PLASMA DRUG LEVELS OF HALOPERIDOL IN SCHIZOPHRENIC-PATIENTS. 

003182 03-08 
A DOUBLE-BLIND COMPARISON BETWEEN AMOXAPINE AND 

AMITRIPTYUNE IN DEPRESSED-INPATIENTS. ^ _ 

003234 03-09 
UTHIUM AND IMIPRAMINE IN THE PROPHYLAXIS OF UNIPOLAR AND 
BIPOLAR-II DEPRESSION: A PROSPEaiVE, PLACEBO-CONTROLLED 

COMPARISON. „„ „^^ 

003252 03-09 

COMPARISON OF ANXIETY REDUCING SUBSTANCES. (PH.D. 

'^'^^^•^^^^'^'^^ 003278 03-10 

COMPARISON OF STANDARD AND HOLTOR-MONITORED EKGS IN A 

PATIENT TREATED WITH SEVERAL ANTIDEPRESSANTS. 

003304 03-11 
DOUBLE-BLIND COMPARISON OF ALPRAZOLAM AND DIAZEPAM FOR 

SUBCHRONIC WITHDRAWAL FROM ALCOHOL. „„,--- „-» 

COMPARISON OF SODIUM-VALPROATE AND PHENYTOIN AS SINGLE 
DRUG-TREATMENT IN EPILEPSY. 00337103-11 

COMPARISON OF THE EFFEQS OF FOUR BENZODIAZEPINES ON FRAME OF 
MIND AND BEHAVIOR IN HEALTHY SUBJEQS „„..., „o ,. 

003441 0o-14 

A COMPARISON OF THE EFFECTS OF MORPHINE-SULPHATE AND NITROUS- 
OXIDE ANALGESIA ON CHRONIC PAIN STATES IN MAN. 

(X)3442 Oj-14 

QUANTITATION AND COMPARISON OF PHENOBARBITAL LEVELS IN THE 
PLASMA SAUVA, AND CEREBROSPINAL-FLUID OF THE RAT, AND THE 
DEMONSTRATION OF AN ALTERATION OF DRUG PASSAGE BY 

E™^^OL 003725 04-03 

PREJUNQIONAL AQIONS OF PIRIBEDIL ON THE ISOLATED KIDNEY OF THE 

RABBIT: COMPARISON WITH APOMORPHINE. 

003/4y 04-UJ 
COMPARISON OF THE EFFEaS OF THE STEREOISOMERS OF 

FENFLURAMINE ON THE ACETYLCHOUNE CONTENT OF RAT STRIATUM. 

HIPPOCAMPUS AND NUCLEUS-ACCUMBENS. ^^^^^ ^^^ 

COMPARISON OF THE BINDING CHARACTERISTICS OF TRITIATED OPIATES 
AND OPIOID-PEPTIDES. 003802 04-03 

COMPARISON OF THE EFFEQ OF INTRAVENOUS ADMINISTRATION OF D 
LYSERGIC-ACID-DIETHYLAMIDE ON FREE AND MEMBRANE-BOUND 
POLYSOMES IN THE RABBIT BRAIN. 00383104-03 



S-108 



VOLUME 19, SUBJECT INDEX 



Subject Index 



COMPARISON Of THE POTENCIES OF CLEBOPRIOE AND OTHER 

SUBSTITUTED BENZAMIDE DRUGS ON ISOLATED GASTROINTESTINAL 
TRACT OF THE GUINEA-PIG AND RAT 

003928 04-03 
IN VIVO INTRANEURONAL MAO-INHIBITION IN RAT-BRAIN SKF-64139, 
COMPARISON TO OTHER POTENT PNMT INHIBITORS 

003935 04-03 
L ASPARTATE BINDING-SITES IN RAT-CEREBELLUM: A COMPARISON OF 
THE BINDING OF L (3H)ASPARTATE AND L (3H)GLUTAMATE TO 
SYNAPTIC MEMBRANES. 

004000 04-03 
A COMPARISON OF THE RESPONSES TO SOME DOPAMINE-RECEPTOR 
AGONISTS AND ANTAGONISTS IN THE ISOLATED PERFUSED RAT 
KIDNEY. 

004054 04-03 
A COMPARISON BETW/EEN SOME BIOCHEMICAL-EFFECTS AND 
BEHAVIOURAL-EFFECTS PRODUCED BY NEUROLEPTICS. 

004)16 04-04 
COMPARISON OF THE EFFECTS OF BETA ENDORPHIN AND MORPHINE ON 
EXPLORATORY-BEHAVIOUR AND SOCIOSEXUAL-BEHAVIOUR IN THE 
MALE RAT. 

004178 04-04 
5 HYDROXYTRYPTAMINE-LIKE PROPERTIES OF M 
CHLOROPHENYLPIPERAZINE: COMPARISON WITH QUIPAZINE. 

004210 04-04 
A DOUBLE-BLIND COMPARISON OF THREE DOSAGES OF FLUTROLINE (CP- 
36584) IN THE TREATMENT OF SCHIZOPHRENIA. 

004333 04-08 
TRAZODONE EFFICACY AND SAFETY IN ENDOGENOUS DEPRESSION: A 
DOUBLE-BLIND COMPARISON WITH IMIPRAMINE. 

004346 04-09 
VALUE OF PROPANIDID IN ELECTROCONVULSIVE-THERAPY (COMPARISON 
WITH THIOPENTONE). 

004379 04-09 
A COMPARISON OF TRAZODONE AND DOTHIEPIN IN DEPRESSION. 

004394 04-09 
COMPARISON OF PSYCHOTROPIC-DRUG, RESPONSE COST, AND 
PSYCHOTROPIC-DRUG PLUS RESPONSE COST PROCEDURES FOR 
CONTROLLING INSTITUTIONALIZED MENTALLY-RETARDED PERSONS. 

004438 04-1 1 
DRUG PREFERENCE IN HUMANS: DOUBLE-BLIND CHOICE COMPARISON OF 
PENTOBARBITAL, DIAZEPAM AND PLACEBO. 

004566 04-14 
A COMPARISON OF RADIOIMMUNOASSAY WITH SPECTROPHOTOMETRY 
FOR THE DETERMINATION OF PLASMA DIPHENYLHYDANTOIN 
CONCENTRATIONS. 

004684 04-16 
COMPARISON OF SPECTROFLUOROMETRIC AND GAS- 
CHROMATOGRAPHY/MASS-SPECTROMETRY PROCEDURES FOR THE 
QUANTITATION OF MORPHINE IN BLOOD AND BRAIN. 

004692 04-16 
COMPARISONS 

EFFEQS OF CHRONIC NEUROLEPTIC TREATMENT ON TYROSINE- 
HYDROXYLASE IN DOPAMINERGIC TERMINALS: COMPARISONS 
BETWEEN DRUGS AND BRAIN REGIONS REVEALS DIFFERENT 
MECHANISMS OF TOLERANCE. 

001243 02-03 
COMPARISONS OF THE EFFECTS OF GUANETHIDINE, 6 

HYDROXYDOPAMINE AND DIETHYLDITHIOCARBAMATE ON RETENTION 
OF PASSIVE-AVOIDANCE. 

001742 02-04 
AHENUATION OF THE EFFECTS OF PUNISHMENT BY ETHANOL: 
COMPARISONS WITH CHLORDIAZEPOXIDE. 

001813 02-04 
SECOND-ORDER SCHEDULES OF INTRAMUSCULAR COCAINE INJECTION IN 
THE SQUIRREL-MONKEY: COMPARISONS WITH FOOD PRESENTATION 
AND EFFEQS OF D-AMPHETAMINE AND PROMAZINE. 

004152 04-04 
COMPARTMENT ALIZAION 

HA-966 EFFEQS ON STRIATAL DOPAMINE METABOLISM: IMPLICATIONS 
FOR DOPAMINE COMPARTMENTALIZAION. 

001150 02-03 
COMPARTMENTATION 

COMPARTMENTATION OF CATECHOLAMINES IN RAT-BRAIN: EFFECTS OF 
AGONISTS AND ANTAGONISTS. 

000125 01-03 
COMPARTMENTS 

EFFECTS OF PSYCHOTROPIC-DRUGS ON THE DISTRIBUTION OF 3H 
DOPAMINE INTO COMPARTMENTS OF RAT STRIATAL SYNAPTOSOMES 
AND ON SUBSEQUENT DEPOLARIZATION-INDUCED 3H DOPAMINE 
RELEASE. 

000067 01-03 
COMPETITION 

EFFECTS OF MORPHINE WITHDRAWAL ON FOOD COMPETITION 
HIERARCHIES AND FIGHTING-BEHAVIOR IN RATS. 

001632 02-04 
COMPETITIVE 

THE DOPAMINE-RECEPTOR ANTAGONIST DOMPERIDONE IS ALSO A 
COMPETITIVE ANTAGONIST AT ALPHA 1 -ADRENOCEPTORS. 

003785 04-03 



COMPILATION 

CLINICAL-STUDY OF MAPROTILINE IN THE TREATMENT OF DEPRESSIVE- 
STATES: COMPILATION OF 1520 OBSERVATIONS. 

003206 03-09 
COMPLEXE-I6S6 

COMPARATIVE-STUDY OF THE INDUCTIVE EFFECT OF TWO 

PSYCHOMODERATORS - TETRABAMATE AND COMPLEXE-1656 - AND 
OF PHENOBARBITAL ON LIVER MICROSOMAL ENZYMES IN RATS. 

001874 02-06 
COMPLEXES 

ATP COMPLEXES WITH THE ATPASE INHIBITOR QUERCETIN. 

000045 01-03 
ISOLATION OF SELECTIVE 3H CHLORNALTREXAMINE BOUND COMPLEXES, 
POSSIBLE OPIOID-RECEPTOR COMPONENTS IN BRAINS OF MICE. 

001162 02-03 
MULTIPLE BENZODIAZEPINE-RECEPTOR COMPLEXES: SOME 
BENZODIAZEPINE RECOGNITION SITES ARE COUPLED TO GABA- 
RECEPTORS AND lONOPHORES, 

001484 02-03 
COMPLIANCE 

THE LITHIUM RATIO AS A GUIDE TO PATIENT COMPLIANCE. 

000940 01-17 
ACCURACY OF PATIENT INTERVIEWS AND ESTIMATES BY CLINICAL STAFF 
IN DETERMINING MEDICATION COMPLIANCE. 

003618 03-17 
THE INFLUENCE OF PATIENT BELIEFS ON COMPLIANCE TO THERAPY FOR 
DIABETES-MELLITUS. (PH.D. DISSERTATION). 

003631 03-17 
PHENYTOIN THERAPY FOR EPILEPTIC-CHILDREN: EVALUATION OF 
SALIVARY AND PLASMA CONCENTRATIONS AND OF METHODS OF 
ASSESSING COMPLIANCE. 

004495 04-11 
THE NEGATIVE INFLUENCE OF FAMILIES ON COMPLIANCE. 

004745 04-17 
COMPLICATING 

ILEUS COMPLICATING HALOPERIDOL THERAPY. 

003511 03-15 
COMPLICATIONS 

COMPLICATIONS OF CHRONIC LEVODOPA THERAPY: LONG-TERM 
EFFICACY OF DRUG-HOLIDAY. 

003502 03-15 
COMPOSED 

EVIDENCE FOR, AND LOCALIZATION OF, A UNITARY DOPAMINE- 
RECEPTOR COMPOSED OF COOPERATIVELY LINKED SUBUNIT BINDING- 
SITES IN RAT STRIATUM. 

000186 01-03 
UNITARY DOPAMINERGIC-RECEPTOR COMPOSED OF COOPERATIVELY 
LINKED AGONIST AND ANTAGONIST SUBUNIT BINDING-SITES. 

001342 02-03 
COMPOSITION 

COMBINED EFFECTS OF ALCOHOL AND LITHIUM ON BODY COMPOSITION 
IN THE RAT MODEL. 

002928 03-03 
DRUG-INDUCED CHANGES IN THE COMPOSITION OF THE CEREBRAL FREE 
AMINO-ACID POOL. 

004039 04-03 
COMPOUND-48-80 

COMPOUND-48-80 INHIBITS NEUROTENSIN-INDUCED HYPOTENSION IN 
RATS. 

000243 01-03 
COMPREHENSIVE 

STUDIES ON THE COMPREHENSIVE MEDICAL TREATMENT OF PEPTIC- 
ULCERS (3) ~ UTILIZATION OF TRANQUILIZERS IN THE TREATMENT OF 
GASTRIC-ULCERS. 

000653 01-10 
IS IT POSSIBLE TO SET UP ANY RULES FOR A COMPREHENSIVE 
TREATMENT OF DEPRESSIVE-STATES? 

001997 02-09 
SOME PRINCIPLES OF DIFFERENTIATED METABOLIC DRUG-TREATMENT IN 
COMPREHENSIVE THERAPY OF MENTAL-DISORDERS. 

004433 04-1 1 
CORRECTION OF HORMONAL ACTIVITY OF THE THYROID-GLAND AS A 
METHOD OF PATHOGENIC THERAPY IN A COMPREHENSIVE TREATMENT 
OF PATIENTS WITH TEMPORAL EPILEPSY. 

004579 04-14 
COMPRESSED 

TOLERANCE IN A COMPRESSED GASTRORESISTANT FORM IN 
PSYCHIATRIC-PATIENTS. 

003157 03-07 
COMPUTED-TOMOGRAPHY 

PROGRESSIVE SUPRANUCLEAR PALSY, COMPUTED-TOMOGRAPHY, AND 
RESPONSE TO ANTIPARKINSONIAN-DRUGS. 

003322 03-1 1 
COMPUTER 

A COMPUTER OCULOGRAPHIC AND EEG DOUBLE-BLIND STUDY INCLUDING 
WELL-BEING FOR DETERMINING CHANGED VIGILANCE UNDER THERAPY 
WITH TIAPRIDE. 

000751 01-13 



iil. 












S-109 



Subject Index 



Psychopharmacology Abstracts 



^°**DISCOVERY OF PSYCHOTROPIC-DRUGS BY MEANS OF COMPUTER- 

^N^^Y^^'^"'^- 002203 02-13 

COMPUTER-ANALYZED EEC IN AMPHETAMINE RESPONSIVE 

HYPERACTIVE-CHILDREN. - 003338 03-11 

COMPUTER-ANALYZED ELECTROENCEPHALOGRAM TO PREDIQ THE 

THERAPEUTIC OUTCOME IN SCHIZOPHRENIA. 

004680 04-16 

COMPUTERIZED 

COMPUTERIZED EEC IN THE COMPARISON OF OXYPROTHEPIN AND 

FLUPHENAZINE-DECANOATE. 000567 01-08 

COMPUTERIZED SLEEP EEC (CSEEG) IN PSYCHIATRY AND 

PSYCHOPHARMACOLOGY. 002614 02-17 

EVALUATION OF DRUG EFFICACY IN DEMENTIA: A COMPUTERIZED 

COGNITIVE ASSESSMENT SYSTEM. 003557 03-16 

COMPUTERIZED MONITORING OF PSYCHOTROPIC-DRUG ORDERS: SOME 

TRENDS AND REVELATIONS. 003566 03-16 

COMPUTERIZED ANALYSIS OF SLEEP RECORDINGS APPLIED TO DRUG 

EVALUATION: MIDAZOLAM IN NORMAL SUBJECTS. 

004564 04- 1 4 

COMPUTERIZED-AXIAl-TOMOGRAPHY ^^ ., .„^., 

THERAPEUTIC PLASMA LEVELS OF SOME ANTICONVULSANTS IN FOCAL 
EPILEPSY IN RELATION TO COMPUTERIZED-AXIAL-TOMOGRAPHY. 

004439 04- 1 I 

^°ToMPUT^ERIZING THE MMPI IN THE STUDY OF A NEW PSYCHOTROPIC- 

^GmJ^^?mi. 000585 01-09 

COMT-A 

COMT-A AND COMT-B: CATALYTIC DIFFERENCES AND ROLE OF DISULFIDE 

^O'^'^S 003927 04-03 

COMT-B 

COMT-A AND COMT-B: CATALYTIC DIFFERENCES AND ROLE OF DISULFIDE 

^°^°5 003927 04-03 

^°'*E?FEaOpPSYCHIATRIC-INTERVENTION ON USE OF ANTIHEMOPHILIC- 

FACTOR CONCENTRATE. 000945 01-17 

CONCENTRATION 

COMPARATIVE-EFFECTS OF P CHLOROAMPHETAMINE AND L P 
CHLOROPHENYLPIPERAZINE ON 5 HYDROXYINDOLE CONCENTRATION IN 

■^^^-^^^"^ 000101 01-03 

EFFEaS OF GAMMA ACETYLENIC-GABA AND GAMMA VINYL-GABA ON 
ELECTRICALLY-INDUCED SPINAL-CORD CONVULSIONS AND ON SPINAL- 
CORD GABA CONCENTRATION. 000145 01-03 
REGULATION OF STRIATAL ACETYLCHOLINE CONCENTRATION BY 02 

DOPAMINE-RECEPTORS. 000269 01-03 

PATHOPHYSIOLOGICAL-STUDIES ON SCHIZOPHRENIA WITH SPECIAL 
REFERENCE TO HOMOVANILLIC-ACID CONCENTRATION IN 
CEREBROSPINAL-FLUID. ^^^^ ^, ^3 

LONG-TERM EFFECTS OF CONTINUOUS EXPOSURE TO AMPHETAMINE ON 
BRAIN DOPAMINE CONCENTRATION AND SYNAPTOSOMAL UPTAKE IN 

'^'"' 000287 01-03 

INTRA AND EXTRA ERYTHROCYTE LITHIUM-ION CONCENTRATION RATIOS 

IN MANIC-PATIENTS. 000627 01-09 

PRAQICAL AND THEORETICAL ASPEQS OF PHENYTOIN 

ADMINISTRATION. I. RELATIONSHIP BETWEEN DOSE AND PLASMA 

^O^^^^^^^™"^- 000760 01-13 

TRANSCULTURAL PHARMACOKINETIC STUDY ON LI CONCENTRATION IN 

PLASMA AND SALIVA. 000769 01-13 

LEVORPHANOL: RADIOIMMUNOASSAY AND PLASMA CONCENTRATION 

PROFILES IN DOG AND MAN. 000898 01-16 

DETERMINATION OF DOSE PLASMA CONCENTRATION RELATIONSHIP OF 

PHENOBARBITAL IN EPILEPTIC-PATIENTS BY A NEW SPECIFIC 

RADIOIMMUNOASSAY. „„„„„„«, ,^ 

000902 01-16 

EFFECT OF 2 P CHLOROPHENYL-CYCLOPROPYLAMINE ON 5 

HYDROXYINDOLE CONCENTRATION AND MONOAMINE-OXIDASE 
ACTIVITY IN RAT-BRAIN. 001237 02-03 

THE INFLUENCE OF EXTERNAL SODIUM AND POTASSIUM ON LITHIUM 
UPTAKE BY PRIMARY BRAIN CELL CULTURES AT THERAPEUTIC LITHIUM 
CONCENTRATION. 001300 02-03 



CHANGE IN OVERINCLUSIVE THINKING OF SCHIZOPHRENIC-PATIENTS IS 
RELATED TO PLASMA PHENOTHIAZINE CONCENTRATION. 

001941 02-08 
AMITRIPTYLINE PLASMA CONCENTRATION AND CLINICAL-EFFEQ: A 
WORLD-HEALTH-ORGANIZATION COLLABORATIVE-STUDY. 

001976 02-09 
CONCENTRATION OF SEROTONIN METABOLITES IN THE CEREBROSPINAL- 
FLUID FROM ALCOHOLICS BEFORE AND DURING SULFIRAM THERAPY. 

002095 02-11 
CARBAMAZEPINE THERAPY IN TRIGEMINAL-NEURALGIA: CLINICAL- 
EFFEaS IN RELATION TO PLASMA CONCENTRATION. 

002181 02-11 
THE EFFECTS OF ALCOHOL AND CAFFEINE ON CONCENTRATION TEST 
PERFORMANCE. 

002337 02-14 

CHILDHOOD-ENURESIS: II PSYCHOPATHOLOGY, TRICYCLIC 
CONCENTRATION IN PLASMA, AND ANTIENURETIC-EFFEQ. 

002354 02-14 
CHANGES IN NORADRENERGIC TRANSMISSION ALTER THE 
CONCENTRATION OF CYTOPLASMIC PROGESTIN-RECEPTORS IN 
HYPOTHALAMUS. 

002842 03-03 
CORRELATION OF (14C)MUSCIM0L CONCENTRATION IN RAT-BRAIN WITH 
ANTICONVULSANT AQIVITY. 

003045 03-04 
SERUM CONCENTRATION AND CLINICAL-EFFEQ OF ANTIEPILEPTICS. 

003315 03-11 
HUMAN BRAIN, PLASMA, AND CEREBROSPINAL-FLUID CONCENTRATION 
OF SODIUM-VALPROATE AFTER 72 HOURS OF THERAPY. 

003433 03-13 
EFFECTS OF MOLINDONE AND FLUPHENAZINE ON THE BRAIN 
CONCENTRATION OF SOME PHENOLIC AND CATECHOLIC AMINES IN THE 
MOUSE AND THE RAT. 

003870 04-03 
ON THE IMPORTANCE OF AGONIST CONCENTRATION GRADIENTS WITHIN 
ISOLATED TISSUES INCREASED MAXIMAL RESPONSES OF RAT VASA- 
DEFERENTIA TO (-) NORADRENALINE AFTER BLOCKADE OF NEURONAL 
UPTAKE. 

003879 04-03 
THE INFLUENCE OF D-AMPHET AMINE ON RAT-BRAIN STRIATAL REDUCED 
BIOPTERIN CONCENTRATION. 

003922 04-03 
SERUM CONCENTRATION OF ANTICONVULSANTS. PHARMACOKINETIC 
FINDINGS AND THEIR PRACTICAL APPLICATION. 

004443 04-11 
USE OF PLASMA CONCENTRATION DETERMINATIONS. 

004498 04-13 
PLASMA NOMIFENSINE CONCENTRATION: CARDIOLOGICAL EFFEaS AND 
CLINICAL-RESPONSE. _ ^^^^^ ,^ 

004639 04-15 

CONCENTRATIONS 

TOLERANCE TO INCREASES IN STRIATAL ACETYLCHOLINE 
CONCENTRATIONS AFTER REPEATED ADMINISTRATION OF 
APOMORPHINE-DIPIVALOYL-ESTER 

000464 01-04 

VILOXAZINE PLASMA CONCENTRATIONS AND CLINICAL-RESPONSE. 

000614 01-09 

EFFEQ OF DIAZEPAM AND DESMETHYLDIAZEPAM IN SPASTICITY AND 
RIGIDITY A QUANTITATIVE STUDY OF REFLEXES AND PLASMA 
CONCENTRATIONS. 00070101-11 

PLASMA CHLORPROMAZINE CONCENTRATIONS IN CHILDREN WITH 

BEHAVIORAL-DISORDERS AND MENTAL-ILLNESS. 000717 01 11 

CONVERSION SCALES FOR COMMONLY REQUESTED SERUM 
CONCENTRATIONS OF DRUGS AND OTHER SUBSTANCES OF 
THERAPEUTIC AND TOXICOLOGICAL IMPORTANCE. AND OF 

"0'^^°'^^^ 000759 01-13 

NEUROLEPTIC-EFFEQ ON DESIPRAMINE STEADY-STATE PLASMA 
CONCENTRATIONS. 00078101-13 

SERUM CONCENTRATIONS OF PHENOBARBITAL AND „_^ .„„ 
DIPHENYLHYDANTOIN IN SEVERE MENTAUY-HANDICAPPED AND 
PHYSICALLY-HANDICAPPED-PATIENTS. ,^„c. n, ,c 

000856 01-15 

VALUE OF SALIVA SAMPLES IN MONITORING CARBAMAZEPINE 

CONCENTRATIONS IN EPILEPTIC-PATIENTS. „„,^, „, ,, 

000903 01-16 

BRAIN SEROTONIN AND 5 HYDROXYINDOLEACETIC-ACID 
CONCENTRATIONS AND SEROTONIN SYNTHESIS FOLLOWING 
TETRAHYDRO-BETA-CARBOLINE ADMINISTRATION IN MICE. 

CXJ I I jz Uz"Uo 

PROSTAGLANDIN-E RELEASE BY RAT MEDIAL BASAL HYPOTHALAMUS IN 
VITRO INHIBITION BY MELATONIN AT SUBMICROMOLAR 
CONCENTRATIONS. 001159 02-03 



s-no 



VOLUME 19, SUBJECT INDEX 



Subject Indsx 



RELATIONSHIPS BETWEEN CHLORPROMAZINE CONCENTRATIONS IN 
PLASMA AND CEREBROSPINAL-f LUID AND CLINICAL-RESPONSE AND 
BIOCHEMICAL-RESPONSE IN PSYCHOTIC-PATIENTS. 

001905 02-08 
SERUM NEUROLEPTIC CONCENTRATIONS IN SCHIZOPHRENIA. 
(UNPUBLISHED PAPER). 

001945 02-08 
LONG-TERM MONITORING OF TRICYCLIC-ANTIDEPRESSANT PLASMA 
CONCENTRATIONS. 

002014 02-09 
PLASMA DELTA9 TETRAHYDROCANNABINOL CONCENTRATIONS AND 
CLINICAL-EFFECTS AFTER ORAL AND INTRAVENOUS ADMINISTRATION 
AND SMOKING. 

002201 02-12 
PHARMACOKINETIC BASIS FOR PREDICTING STEADY-STATE SERUM DRUG 
CONCENTRATIONS OF IMIPRAMINE FROM SINGLE-DOSE DATA. 

002225 02-13 
SALIVARY IMMUNOGLOBULIN CONCENTRATIONS IN PATIENTS WITH 
EPILEPSY TREATED WITH CARBAMAZEPINE. 

002234 02-13 
THYMOANALEPTIC TREATMENT CONTROL THROUGH MEASUREMENT OF 
PLASMA CONCENTRATIONS OF AMITRIPTYLINE AND ITS METABOLITE 
NORTRIPTYLINE. 

002304 02-13 
PHENOTHIAZINE PLASMA AND RED-BLOOD-CELL CONCENTRATIONS, THEIR 
RELATIONSHIP TO SIDE-EFFECTS AND CLINICAL-EFFICACY. 

002386 02-15 
CONCENTRATIONS OF CIS(Z) FLUPENTHIXOL IN MATERNAL SERUM, 
AMNIOTIC-FLUID, UMBILICAL-CORD-SERUM, AND MILK. 

002423 02-15 
MEASUREMENT OF PLASMA CONCENTRATIONS OF DRUGS AS A 
FEEDBACK CONTROL MECHANISM DURING DRUG-THERAPY. 

002525 02-17 
ENHANCEMENT OF ETORPHINE BRAIN CONCENTRATIONS AND CHANGES 
IN ETORPHINE NALOXONE PA2 VALUES IN MORPHINE PRETREATED 
MICE. 

002800 03-03 
BEHAVIOURAL-RESPONSES TO DRUGS RELEASING 5 
HYDROXYTRYPTAMINE AND CATECHOLAMINES: EFFECTS OF 
TREATMENTS ALTERING PRECURSOR CONCENTRATIONS IN BRAIN. 

002990 03-04 
RELATIONSHIP BETWEEN BLOOD CONCENTRATIONS AND CLINICAL- 
EFFECTS OF A NEW ANTIDEPRESSANT MAPROTILINE. 

003271 03-09 
PHENYTOIN CONCENTRATIONS IN VENOUS VERSUS CAPILLARY BLOOD OF 
GERIATRIC-PATIENTS. 

003381 03-11 
EXCESSIVE PLASMA CONCENTRATIONS OF TRICYCLIC-ANTIDEPRESSANTS 
RESULTING FROM USUAL DOSES: A REPORT OF SIX CASES. 

003479 03-15 
RESPIRATORY-DISEASE AND NASAL IMMUNOGLOBULIN 
CONCENTRATIONS IN PHENYTOIN TREATED EPILEPTIC-PATIENTS. 

003486 03-15 
CEREBROSPINAL-FLUID CONCENTRATIONS OF THIORIDAZINE AND ITS 
MAIN METABOLITES IN PSYCHIATRIC-PATIENTS. 

003569 03-16 
CHLORPROMAZINE, HALOPERIDOL, METOCLOPRAMIDE AND 
DOMPERIDONE RELEASE PROLACTIN THROUGH DOPAMINE 
ANTAGONISM AT LOW CONCENTRATIONS BUT PARADOXICALLY 
INHIBIT PROLACTIN RELEASE AT HIGH-CONCENTRATIONS. 

003731 04-03 
BRAIN AND SERUM CALCIUM CONCENTRATIONS FOLLOWING 
ELECTROCONVULSIVE-SHOCK OR BICUCULLINE-INDUCED CONVULSIONS 
IN RATS. 

003736 04-03 
EVIDENCE TO SUGGEST THAT DOPAMINE-INDUCED INCREASE IN GABA 
CONCENTRATIONS IN CHICK BRAIN IS MEDIATED THROUGH CYCLIC- 
AMP. 

003952 04-03 
PHENYTOIN THERAPY FOR EPILEPTIC-CHILDREN: EVALUATION OF 
SALIVARY AND PLASMA CONCENTRATIONS AND OF METHODS OF 
ASSESSING COMPLIANCE. 

004495 04-11 
ERYTHROCYTE CHOLINE CONCENTRATIONS ARE ELEVATED IN MANIC- 
PATIENTS. 

004521 04-13 
CONCENTRATIONS AND KINETICS OF CARBAMAZEPINE IN WHOLE 
SALIVA, PAROTID SALIVA, SERUM ULTRAFILTRATE, AND SERUM. 

004545 04-13 
CONCENTRATIONS OF CHLORPROMAZINE AND TWO OF ITS ACTIVE 
METABOLITES IN PLASMA AND CEREBROSPINAL-FLUID OF PSYCHOTIC- 
PATIENTS TREATED WITH FIXED DRUG DOSES. 

004559 04-13 
THERAPEUTIC MONITORING OF PLASMA CONCENTRATIONS OF TRICYCLIC- 
ANTIDEPRESSANTS: PERSPECTIVE OF THE CLINICAL LABORATORY. 

004681 04-16 
MEASUREMENT OF NEUROLEPTIC CONCENTRATIONS BY GLC AND 

RADIORECEPTOR ASSAY. 

004682 04-16 



A COMPARISON OF RADIOIMMUNOASSAY WITH SPECTROPHOTOMETRY 
FOR THE DETERMINATION OF PLASMA DIPHENYLHYDANTOIN 
CONCENTRATIONS, 

004684 04-16 
DRUG CONCENTRATIONS IN NEUROPSYCHIATRY. 

004735 04-17 
CONCERNS 

THE USE OF PSYCHOPHARMACOLOGICAL-PROCEDURES TO ANALYSE THE 
ONTOGENY OF LEARNING AND RETENTION: ISSUES AND CONCERNS. 

000482 01-04 
CONCUSSION 

INFLUENCING BRAIN CONCUSSION BY NOOTROPIL. 

000724 01-11 
CONDENSATION 

SYNTHESIS OF POTENTIAL ANTICONVULSANTS: CONDENSATION OF 
ISATINS WITH ACETONE AND RELATED KETONES. 

003699 04-02 
CONDITIONAL 

EFFECTS OF PHENCYCLIDINE, PENTOBARBITAL, AND D-AMPHET AMINE ON 
THE ACQUISITION AND PERFORMANCE OF CONDITIONAL 
DISCRIMINATIONS IN MONKEYS. 

001723 02-04 
CONDITIONED 

ENHANCED SUPPRESSION OF CONDITIONED AVOIDANCE RESPONSE BY 
HALOPERIDOL BUT NOT PHENOXYBENZAMINE IN RATS WITH 
BILATERAL PARAFASCICULAR LESIONS. 

000334 01-04 
NORADRENERGIC AGONISTS AND ANTAGONISTS: EFFECTS ON 
CONDITIONED FEAR AS MEASURED BY THE POTENTIATED STARTLE 
PARADIGM. 

000372 01-04 
THE EFFECTS OF PIPRADROL ON THE ACQUISITION OF RESPONDING WITH 
CONDITIONED REINFORCEMENT: A ROLE FOR SENSORY 
PRECONDITIONING. 

001572 02-04 
MODULATION OF CONDITIONED TASTE-AVERSION BY SODIUM- 
PENTOBARBITAL. 

001596 02-04 
EFFECTS OF DRUGS ON THE EFFECTIVENESS OF CONDITIONED STIMULI. 

001608 02-04 
PREEXPOSURE TO DELTA9 THC BLOCKS THC-INDUCED CONDITIONED 
TASTE-AVERSION IN RATS. 

001618 02-04 
EFFECT OF CHOLINE ON CONDITIONED FOOD MOTOR-REFLEXES IN CATS. 

001731 02-04 
CONDITIONED SUPPRESSION OF DRINKING: A MEASURE OF THE CR 
ELICITED BY A LITHIUM CONDITIONED FLAVOR. 

001747 02-04 
THE EFFECTS OF CHLORDIAZEPOXIDE-HCL ADMINISTRATION UPON 
PUNISHMENT AND CONDITIONED SUPPRESSION IN THE RAT. 

001757 02-04 
ACTH POTENTIATES MORPHINE-INDUCED CONDITIONED TASTE-AVERSION. 

001781 02-04 
THE RELATIONSHIP BETWEEN POSITIVE REINFORCEMENT AND 
CONDITIONED TASTE-AVERSION PRODUCED BY SELF-ADMINISTERED 
DRUGS. (PH.D. DISSERTATION). 

001798 02-04 
EFFECTS OF DESGLYCINAMIDE-LYSINE-VASOPRESSIN ON A CONDITIONED 
TASTE-AVERSION IN RATS. 

001811 02-04 
TEMPORAL AND ENVIRONMENTAL CUES IN CONDITIONED HYPOTHERMIA 
AND HYPERTHERMIA ASSOCIATED WITH MORPHINE. 

002709 03-03 
LITHIUM-CHLORIDE AND DELTA9 THC LEAD TO CONDITIONED AVERSIONS 
IN THE PIGEON. 

003003 03-04 
THE EFFECTS OF IMIPRAMINE TREATMENT ON THE UNCONDITIONED 
ALIMENTARY BEHAVIOR AND CLASSICAL CONDITIONED SALIVARY 
REACTIONS IN DOGS. 

003030 03-04 
THE PHARMACOLOGICAL ANALYSIS OF MONOAMINERGIC MECHANISMS 
OF THE MEDIAL HYPOTHALAMUS IN FOOD PROCURING CONDITIONED 
REFLEXES IN RATS. 

003100 03-04 
EFFECTS OF CHLORDIAZEPOXIDE AND D-AMPHETAMINE ON RESPONDING 
SUPPRESSED BY CONDITIONED PUNISHMENT. 

003105 03-04 
DOPAMINE DEPLETION BY 6 HYDROXYDOPAMINE PREVENTS 
CONDITIONED TASTE-AVERSION INDUCED BY METHYLAMPHETAMINE 
BUT NOT LITHIUM-CHLORIDE. 

003110 03-04 
THE USE OF CONDITIONED SUPPRESSION TO EVALUATE THE NATURE OF 
NEUROLEPTIC-INDUCED AVOIDANCE-DEFICITS. 

004070 04-04 
NALOXONE FAILS TO BLOCK AMPHETAMINE-INDUCED ANOREXIA AND 
CONDITIONED TASTE-AVERSION. 

004121 04-04 



lii, 

I 

5 









S-111 



Subject Index 



Psychopharmacology Abstracts 



CONDITIONED DRUG-EFFECTS OF D-AMPHETAMINE-INDUCED AND 

MORPHINE-INDUCED MOTOR ACCELERATION IN MICE. EXPERIMENTAL 
APPROACH FOR PLACEBO-EFFECT. 004128 04-04 

EFFECTS OF SUBCHRONIC DESMETHYLIMIPRAMINE (DMI) TREATMENT OF 
THE CLASSICALLY CONDITIONED EYEBLINK RESPONSE IN RABBITS. 

004180 04-04 

THE EFFECT OF THE NEW ANTIDEPRESSANT INKASAN ON THE 
BIOELECTRICAL-ACTIVITY OF THE BRAIN AND ON CONDITIONED 

'^^'''-^^"- 004212 04-04 

CONDITIONING 

POSTNATAL ALCOHOL EXPOSURE IN THE RAT: ITS EFFECTS ON 
AVOIDANCE CONDITIONING, HEBB-WILLIAMS MAZE-PERFORMANCE, 
MATERNAL-BEHAVIOR, AND PUP DEVELOPMENT. 

00 1 DoO Uz-U4 

THE EFFECTS OF PIMOZIDE DURING PAIRING ON THE TRANSFER OF 

CLASSICAL CONDITIONING TO AN OPERANT DISCRIMINATION^ ^^ 

CONDITIONING AND RETENTION OF DEFENSIVE BURYING AS A FUNCTION 
OF ELAVIL AND THORAZINE INJECTION. ^^^^^ ^^^^ 

MODIFICATION OF MOTOR-ACTIVITY, PASSIVE-AVOIDANCE 
CONDITIONING AND EVOKED-POTENTIALS BY MICROINJECTIONS OF 
STRYCHNINE IN BOTH CAUDATE-NUCLEI IN CATS. 

003101 03-04 

PHOSPHODIESTERASE INHIBITORS FACILITATE MEMORY FOR PASSIVE- 
AVOIDANCE CONDITIONING. 003109 03-04 

OPIATE-EFFECTS IN THE AMYGDALA CENTRAL NUCLEUS ON HEART RATE 
CONDITIONING IN RABBITS. 003798 04-03 

CONDITIONING OF AN INTEROCEPTIVE DRUG STIMULUS TO DIFFERENT 
EXTEROCEPTIVE CONTEXTS. 004142 04-04 

*^°'^INTERRELATIONS AMONG PRIOR EXPERIENCE AND CURRENT CONDITIONS 
IN THE DETERMINATION OF BEHAVIOR AND THE EFFEaS OF DRUGS. 

00 1 7 1 5 02-04 
THE EFFECT OF CONDITIONS INFLUENCING ENDOGENOUS 
PROSTAGLANDINS ON THE ACTIVITY OF DELTA' 
TETRAHYDROCANNABINOL. 002196 02-12 

EFFECTS OF CAFFEINE ADMINISTRATION ON FOOD AND WATER 
CONSUMPTION UNDER VARIOUS EXPERIMENTAL CONDITIONS^ „ „, „, 

003049 03-04 
ACUTE PHARMACOTOXIC PSYCHOSES IN CHRONIC CEREBRAL 

^O^-^'^'^^^ 003475 03-15 

CONDUCTANCE 

ABSENCE OF POTASSIUM CONDUCTANCE IN CENTRAL MYELINATED 

^'^^^^ 000166 01-03 

TWO CONDUCTANCE MECHANISMS ACTIVATED BY APPLICATIONS OF L 
GLUTAMIC-ACID, L ASPARTIC-ACID, DL HOMOCYSTEIC-ACID, N 
METHYL-D-ASPARTIC-ACID, AND DL KAINIC-ACID TO CULTURED 
MAMMALIAN CENTRAL NEURONES. ^^^^^ ^^^^ 

BILATERAL SKIN CONDUCTANCE AND THE PUPILLARY LIGHT DARK 
REFLEX MANIPULATION BY CHLORPROMAZINE, HALOPERIDOL, 

SCOPOLAMINE, AND PLACEBO. „„.c „. ,, 

004544 04-13 

CONDUCTION 

MEASUREMENTS OF NERVE CONDUCTION VELOCITY DURING DECREASING 
TOXIC DIPHENYLHYDANTOIN LEVELS AND THE BEGINNING OF 
CARBAMAZEPINE MEDICATION. A CLINICAL NEUROPHYSIOLOGICAL 

^^'°'^ 00444104-11 

CONFERENCE 

ABSTRACTS OF THE ANNUAL GENERAL CONFERENCE OF THE EUROPEAN- 
BRAIN-AND-BEHAVIOUR-SOCIETY, HELD AT LOUVAIN-LA-NEUVE, 
BELGIUM, ON NOVEMBER 13-15TH, 1980. 003617 

CONFERENCES 

PSYCHOPHARMACOLOGY AFTER 20 YEARS OF CONFERENCES IN JESENIK^ 

003646 03-17 

CONFIRMATION „^^.. 

CONFIRMATION BEHAVIOR OF PHENCYCLIDINES AND BIOLOGICAL- 
ACTIVITY. „„,„o, ««n, 

001031 02-01 
BEHAVIORAL CONFIRMATION OF DIFFUSE NOXIOUS INHIBITORY 
CONTROLS (DNIC) AND EVIDENCE FOR A ROLE OF ENDOGENOUS 

^'''^^^ 002791 03-03 

MASS SCREENING AND CONFIRMATION OF DIAZEPAM IN URINE BY EMIT 
THIN-LAYER-CHROMATOGRAPHY. 

004672 04-16 

^^^^HOSTILITY CONFLICT AND REPORTING OF SIDE-EFFECTS BY PSYCHIATRIC- 
O^^''^^'^'^^^ 000840 01-15 



DO PSYCHOTHERAPY AND PHARMACOTHERAPY FOR DEPRESSION 
CONFLia? EMPIRICAL EVIDENCE FROM A CLINICAL-TRIAL. 

003256 03-09 
DO PSYCHOTHERAPY AND PHARMACOTHERAPY FOR DEPRESSION 
CONFLICT? EMPIRICAL EVIDENCE FROM A CLINICAL-TRIAL. 
(UNPUBLISHED PAPER). 

004401 04-09 

CONFLICT-BEHAVIOR 

AN INTERFERENCE REDUCTION THEORY OF THE EFFEQS OF ETHANOL ON 
CONFLICT-BEHAVIOR. 

001586 02-04 

EFFECT OF SODIUM-DIPROPYLACETATE ON CONFLia-BEHAVIOR IN RATS 

004192 04-04 
CONFLICT-SITUATION 

CONFLICT-SITUATION BASED ON INTRACRANIAL SELF- STIMULATION 
BEHAVIOR AND THE EFFECT OF BENZODIAZEPINES. 

003004 03-04 

CONFORMATION 

DOPAMINE-RECEPTOR BLOCKADE BY IMIDOLINE AND ITS PROPOSED 
ACTIVE CONFORMATION 

001687 02-04 

CONFORMATIONALLY 

CONFORMATIONALLY RESTRICTED PHENOTHIAZINE NEUROLEPTICS. 1. 3 
DIMETHYLAMINO-TETRAHYDROAZEPINOPHENOTHIAZINE 

001359 02-03 

CONFORMATIONALLY RESTRICTED TRICYCLIC-ANTIDEPRESSANTS. 1 
OCTAHYDRODIBENZAZEPINONAPHTHYRIDINES AS RIGID IMIPRAMINE 

ANALOGUES. 

001710 02-04 

THE SYNTHESIS AND AQIVITY OF CIS AND TRANS 2 
AMINOMETHYLCYCLOPROPANECARBOXYLIC-ACID AS 
CONFORMATIONALLY RESTRICTED ANALOGUES OF GABA. 

002633 03-01 
EFFEaS OF CONFORMATIONALLY RESTRAINED ANALOGUES OF 
SEROTONIN ON ITS UPTAKE AND BINDING IN RAT-BRAIN. 

003794 04-03 

CONFORMATIONS 

CONVULSANT AND ANTICONVULSANT BARBITURATES. 1 . MOLECULAR 
CONFORMATIONS FROM CLASSICAL POTENTIAL ENERGY 
CALCULATIONS. 

001029 02-01 
TV/O OR MORE CONFORMATIONS OF BENZODIAZEPINE-RECEPTORS 
DEPENDING ON GABA-RECEPTORS ANDOTHER VARIABLES. 

001139 02-03 

CONFRONTATION 

THE MYTHOLOGEM OF REVERSIBLE DEATH. THE ANALYTICAL 

CONFRONTATION OF ENDOGENOUS DELIRIUM WITH DELUSIONS IN 

PSYCHEDELIC-EXPERIENCES. „ „^ ,^ 

002200 02-12 

CONFUSIONAL-STATE 

PROLONGED CONFUSIONAL-STATE AND EEG SEIZURE AQIVITY 
FOLLOWING CONCURRENT EQ AND LITHIUM USE. 

000895 01-15 

CONGESTIVE 

INTRAVENOUS QUINIDINE IN CONGESTIVE CARDIOMYOPATHY. 

003352 03-11 

TRANSFER OF LORAZEPAM AND ITS CONJUGATE ACROSS THE HUMAN 

^^"^^* 000774 01-13 

DOPAMINE CONJUGATE IN CEREBROSPINAL-FLUID. 003439 

' CONJUGATED 

PRESENCE OF CONJUGATED CATECHOLAMINES IN RAT-BRAIN: A NEW 

METHOD OF ANALYSIS OF CATECHOLAMINE-SULFATES. 

004286 04-06 

CONJUGATES 

ANTICANDIDAL-AQIVITY OF PYRIMIDINE-PEPTIDE CONJUGATES. 

001059 02-01 

BETA DIETHYLAMINOETHYLDIPHENYLPROPYLACETATE (SKF-525-A) AND ; 
2 4 DICHLORO-6-PHENYLPHENOXYETHYLAMINE-HBR (DPEA) INHIBITION 
OF FAHY-ACID CONJUGATION TO 11 HY0R0XY-DELTA9- 
TETRAHYDROCANNABINOL BY THE RAT LIVER MICROSOMAL SYSTEM. 

000179 01-03 ; 

^°'*EF"FE'aS°?CYCLOHEXIMIDE ADMINISTERED IN CONJUNQION WITH 

NICOTINE ON RETENTION OF A PASSIVE-AVOIDANCE TASK IN MICE^ 

001791 02-04 

CONNECTION 

HALLUCINATORY AND DELUSIONAL-STATES IN CONNEQION WITH BLOOD- 
PRESSURE AND EEG. 000814 01-14 

VARIOUS FAQORS IN THE PATHOGENESIS OF PATHOLOGICAL REAQIONS 
OBSERVED IN CONNEQION WITH THE ADMINISTRATION OF 
PSYCHOTROPIC-DRUGS. 003532 03-15 



S-112 



VOLUME 19, SUBJECT INDEX 



Subject Index 



CONSCIOUS 

EFFECT OF INTRAVENTRICULAR INJECTIONS OF ALPHA AMINOSULFONIC- 
ACIDS ON THE CENTRAL-NERVOUS-SYSTEM OF CONSCIOUS MICE 

000009 01-02 
EEC CHANGE IN THE CONSCIOUS RAT DURING IMMOBILITY INDUCED BY 
PSYCHOLOGICAL-STRESS 

001297 02-03 
EFFECTS OF ALPHA-ADRENOCEPTOR STIMULATING DRUGS ON 
BARORECEPTOR REFLEXES IN CONSCIOUS CATS. 

00)514 02-03 
ANTIARRHYTHMIC-ACTIVITY OF AMITRIPTYLINE ANALOGUES IN 
CONSCIOUS DOGS AFTER MYOCARDIAL-INFARCTION: 
CYPROHEPTADINIUM-METHIODIDE. 

001534 02-03 
COMPARATIVE-STUDY OF AGGRESSIVE-BEHAVIOUR AFTER INJECTION OF 
CHOLINOMIMETICS, ANTICHOLINESTERASES, NICOTINIC, AND 
MUSCARINIC GANGLIONIC STIMULANTS INTO THE CEREBRAL 
VENTRICLES OF CONSCIOUS CATS: FAILURE OF NICOTINIC-DRUGS TO 
EVOKE AGGRESSION. 

001568 02-04 
THE PHARMACOLOGY OF AGGRESSIVE-BEHAVIOURAL-PHENOMENA 

ELICITED BY MUSCARINE INJECTED INTO THE CEREBRAL VENTRICLES OF 
CONSCIOUS CATS. 

001569 02-04 
VASOPRESSIN STIMULATES RELEASE OF BETA LIPOTROPIN AND BETA 

ENDORPHIN IN CONSCIOUS RATS AS MEASURED BY 
RADIOIMMUNOASSAY OF UNEXTRACTED PLASMA. 

003715 04-03 
MODULATORY EFFECT OF BRAIN ACETYLCHOLINE ON REFLEX-INDUCED 
BRADYCARDIA AND TACHYCARDIA IN CONSCIOUS RATS. 

003744 04-03 
EFFECT OF AMPHETAMINE ON PLASMA CORTICOSTERONE IN THE 
CONSCIOUS RAT. 

003888 04-03 
CENTRAL CARDIOVASCULAR-EFFECTS AND BIOCHEMICAL-EFFECTS OF 
BACLOFEN IN THE CONSCIOUS RAT. 

003965 04-03 
HYPOTENSION ALTERS THE RELEASE OF CATECHOLAMINES IN THE 
HYPOTHALAMUS OF THE CONSCIOUS RABBIT. 

003968 04-03 
CONSCIOUSNESS 

ELECTIVE ALTERATION OF THE STATE OF CONSCIOUSNESS SUBJECTED TO 
THE EFFECTS OF PSYCHOACTIVE-SUBSTANCES. 

000994 01-17 
CONSENT 

A REVISED CHECKLIST TO OBTAIN CONSENT TO TREATMENT WITH 
MEDICATION. 

000984 01-17 
MISINFORMED CONSENT. 

004326 04-08 
CONSIDERATIONS 

CONSIDERATIONS ON PSYCHOACTIVE-DRUGS. 

002622 02-17 
CONSIDERATIONS ON LONG-ACTING CHEMOTHERAPY: AN EXPERIENCE 
WITH FLUPHENAZINE-DECANOATE. 

003173 03-08 
NOMIFENSINE: CONSIDERATIONS ON A NEW NONTRICYCLIC- 
ANTIDEPRESSANT. 

003222 03-09 
CLINICAL-TRIAL OF HALAZEPAM AND CLORAZEPATE: CONSIDERATIONS 
OF A SINGLE-BEDTIME-DOSE. 

003277 03-10 
CONSTITUENT 

A CONSTITUENT OF KHAT-LEAVES WITH AMPHETAMINE-LIKE RELEASING 
PROPERTIES. 

001307 02-03 
CONSTITUTIONAL 

ROniNG WITH THEIR RIGHTS ON: CONSTITUTIONAL THEORY AND 
CLINICAL REALITY IN DRUG-REFUSAL BY PSYCHIATRIC-PATIENTS. 

000911 01-17 
THE CONSTITUTIONAL RIGHT-TO-REFUSE ANTIPSYCHOTIC-MEDICATIONS. 

004496 04-12 
CONSTRICTION 

INHIBITION OF NEUROSYMPATHETIC CEREBROARTERIAL CONSTRICTION 
BY CLONIDINE IN CATS. 

001431 02-03 
CONSUMMATORY-BEHAVIOR 

CHRONIC DELTA9 TETRAHYDROCANNABINOL IN RATS: EFFECT ON 
SOCIAL-INTERACTIONS, MOUSE-KILLING, MOTOR-ACTIVITY, 
CONSUMMATORY-BEHAVIOR, AND BODY-TEMPERATURE. 

001722 02-04 
CONSUMMATORY-BEHAVIORS 

MORPHINE ANTAGONISTS AND CONSUMMATORY-BEHAVIORS. 

004196 04-04 
CONTAaS 

BENZODIAZEPINE-RECEPTORS: AUTORADIOGRAPHICAL AND 
IMMUNOCYTOCHEMICAL EVIDENCE FOR THEIR LOCALIZATION IN 
REGIONS OF GABAERGIC SYNAPTIC CONTACTS. 

002643 03-01 



CONTAMINATION 

STREET PCP SCENE: ISSUES ON SYNTHESIS AND CONTAMINATION. 

000744 01-12 
CONTEMPORARY 

CONTEMPORARY PROBLEMS IN THE PHARMACOLOGICAL-TREATMENT OF 
PARKINSONISM. 

004628 04-15 
CONTEXT 

DRUG ENVIRONMENT INTERACTION: CONTEXT DEPENDENCY Of COCAINE- 
INDUCED BEHAVIORAL-SENSITIZATION 

002866 03-03 
CONTEXTS 

CONDITIONING OF AN INTEROCEPTIVE DRUG STIMULUS TO DIFFERENT 
EXTEROCEPTIVE CONTEXTS. 

004142 04-04 
CONTINGENCY 

BEHAVIORAL-EFFECTS OF DRUGS: THE ROLE OF THE STIMULUS 
REINFORCER CONTINGENCY. (PH.D. DISSERTATION). 

001537 02-03 
CONTINGENT 

CAPACITIES OF ATTENTION, STRESS-RESISTANCE, AND SLOW CEREBRAL 
POTENTIALS: EFFECTS OF CARPIPRAMINE ON CONTINGENT NEGATIVE 
VARIATION WAVES AND P-300. 

003451 03-14 
CONTINUOUS-ACCESS 

CONTINUOUS-ACCESS PHENCYCLIDINE SELF-ADMINISTRATION BY RHESUS- 
MONKEYS LEADING TO PHYSICAL-DEPENDENCE. 

000341 01-04 
CONTRACEPTIVE 

PHENOBARBITONE INTERACTION WITH ORAL CONTRACEPTIVE STEROIDS 
IN THE RABBIT AND RAT. 

001832 02-05 
CONTRACEPTIVES 

EFFECT OF IMIPRAMINE ON HEPATIC GAMMA GLUTAMYLTRANSFERASE 
IN FEMALE RATS. INTERACTION WITH CONTRACEPTIVES. 

001507 02-03 
CONTRACTILE 

A COMPARISON OF THE CONTRACTILE RESPONSES OF THE RABBIT 
BASILAR AND PULMONARY-ARTERIES TO SYMPATHOMIMETIC 
AGONISTS: CHARACTERISTICS. 

002670 03-03 
CONTRACTION 

CALCIUM ANTAGONISM OF THE INHIBITORY-EFFECTS OF FENTANYL ON 
THE CONTRACTION OF THE NICTITATING MEMBRANE IN CATS. 

002876 03-03 
CONTRACTIONS 

CHARACTERISTICS OF OSCILLATORY CONTRACTIONS ELICITED BY 
NALOXONE IN ILEUM PREPARATION FROM MORPHINE-DEPENDENT 
GUINEA-PIGS. 

001491 02-03 
CONTRALATERAL 

CONTRALATERAL CIRCLING-BEHAVIOUR INDUCED BY INTRANIGRAL 
INJECTION OF MORPHINE AND ENKEPHALIN ANALOGUE FK-33-824 IN 
RATS. 

001669 02-04 
CONTRALATERAL CIRCLING-BEHAVIOUR INDUCED BY INTRANIGRAL 

INJECTION OF TAURINE IN RATS. 

001670 02-04 
CONTRASTING-EFFECTS 

TRICYCLIC-ANTIDEPRESSANT DRUGS AND INDIVIDUAL DIFFERENCES IN 
THE EXPLORATORY-ACTIVITY OF RATS: CONTRASTING-EFFECTS OF 
TERTIARY AND SECONDARY AMINE COMPOUNDS. 

000401 01-04 
AN OBSERVATIONAL METHOD FOR QUANTIFYING THE BEHAVIOURAL- 
EFFECTS OF DOPAMINE AGONISTS: CONTRASTING-EFFECTS OF D- 
AMPHET AMINE AND APOMORPHINE. 

002484 02-16 
CONTRIBUTE 

EVIDENCE THAT THE OPIATE-RECEPTORS OF THE SUBSTANTIA- 
GELATINOSA CONTRIBUTE TO THE DEPRESSION, BY INTRAVENOUS 
MORPHINE, OF THE SPINAL TRANSMISSION OF IMPULSES IN 
UNMYELINATED PRIMARY AFFERENTS. 

002767 03-03 
CONTRIBUTED 

THE POSSIBILITY THAT A COMPONENT OF MORPHINE-INDUCED 
ANALGESIA IS CONTRIBUTED INDIRECTLY VIA THE RELEASE OF 
ENDOGENOUS OPIOIDS. 

000263 01-03 
CONTRIBUTION 

CONTRIBUTION TO THE CLINICAL- STUDY OF CEREBRAL DOPAMINERGIC 
MECHANISMS: THE ACTION OF PIRIBEDIL IN PSYCHIATRY. FIRST 
RESULTS. 

000616 01-09 
CONTRIBUTION TO STUDY OF CEREBRAL DOPAMINERGIC MECHANISMS: 
REALITY OF THE PROBLEM. 

000782 01-13 
A CONTRIBUTION TO OUR KNOWLEDGE OF COCA-LEAF CONTENT 
SUBSTANCES. 

001022 02-01 



9 



-■fc 

a 

m 

tic 






f ll >M> 



S-113 



Subject Index 

THE CONTRIBUTION OF ALPHAl ACID GLYCOPROTEIN, LIPOPROTEINS, 
AND ALBUMIN TO THE PLASMA BINDING OF PERAZINE, 
AMITRIPTYLINE, AND NORTRIPTYLINE IN HEALTHY MAN. 

002214 02-13 
CONTRIBUTION TO THE PHARMACOKINETICS AND METABOLISM OF 

OXYPROTHEPIN. ,„„.,, 

002279 02-13 
CONFESSION OF A MELANCHOLIAC: CONTRIBUTION TO THE PROBLEM OF 
PROPHYLAXIS OF MANIC-DEPRESSIVE-PSYCHOSIS USING LITHIUM. 

003267 03-09 
TARDIVE-DYSKINESIA: CLINICOEPIDEMIOLOGICAL REVISION AND 

CONTRIBUTION. „„..., „-,,c 

003466 03-15 

CONTRIBUTION OF SOCIAL FACTORS TO OPIATE-INDUCED ACTIVATION IN 
THE MOUSE. „ „ 

004156 04-04 

CONTRIBUTIONS 

CONTRIBUTIONS OF INDIVIDUAL DIFFERENCES TO SUBJECTIVE 

INTOXICATION. „„„o«. «oio 

002202 02-12 

CONTRIBUTORS 

CONTRIBUTORS TO FEMALE USE OF PSYCHOPHARMACOLOGICAL-AGENTS: 
DISSERTATION). 

000956 01-17 

CONTROL 

PLASMA LEVELS OF DIPHENYLHYDANTOIN AND THE CONTROL OF ADULT 
EPILEPTIC-SEIZURES: A CHILEAN EXPERIENCE. 

000102 01-03 
THE ROLE OF INTRANEURONAL 5 HT AND OF TRYPTOPHAN- 
HYDROXYLASE ACTIVATION IN THE CONTROL OF 5 HT SYNTHESIS IN 
RAT-BRAIN SLICES INCUBATED IN K-ENRICHED MEDIUM. 

000123 01-03 
ROLE OF DOPAMINE STORAGE FUNCTION IN THE CONTROL OF RAT 
STRIATAL TYROSINE-HYDROXYLASE ACTIVITY. 

000201 01-03 
THE EFFECT OF DELTA9 TETRAHYDROCANNABINOL ON THE POSITIVE AND 
NEGATIVE FEEDBACK CONTROL OF LUTEINIZING-HORMONE RELEASE. 

000286 01-03 
BEHAVIORAL-PHARMACOLOGY AND THE STIMULUS CONTROL OF 
BEHAVIOR. 

000381 01-04 
STIMULUS INTENSITY CONTROL IN DEPRESSION: A STUDY OF THE 
COMPARATIVE-EFFECT OF DOXEPIN AND AMITRIPTYLINE ON CORTICAL 
EVOKED-POTENTIALS. 

000763 01-13 
RAPID CONTROL OF ACUTE PATIENTS THROUGH THE ADMINISTRATION OF 
HALOPERIDOL. 

000818 01-14 
RESPONSIVENESS TO VASOACTIVE-AGENTS OF CEREBRAL-ARTERIES AND 
MESENTERIC-ARTERIES ISOLATED FROM CONTROL AND RESERPINE 
TREATED DOGS. 

001273 02-03 
INTERNEURONES ARE PROBABLY NOT INVOLVED IN THE PRESYNAPTIC 
DOPAMINERGIC CONTROL OF DOPAMINE RELEASE IN RABBIT 
CAUDATE-NUCLEUS. 

001298 02-03 
A PHARMACOLOGICAL ANALYSIS OF THE ROLE OF THE AMYGDALA IN 
THE CONTROL OF GONADOTROPIN AND PROLACTIN SECRETION. 

001418 02-03 
CENTRAL PHARMACOLOGICAL CONTROL OF CORTICOSTERONE SECRETION 
IN THE INTACT RAT. DEMONSTRATION OF CHOLINERGIC AND 
SEROTONINERGIC FACILITATORY AND ALPHA-ADRENERGIC INHIBITORY 
MECHANISMS. 

001487 02-03 
THE EFFECTS OF D LYSERGIC-ACID-DIETHYLAMIDE (LSD), 2,5 

DIMETHOXY-4-METHYLAMPHETAMINE (DOM) AND D-AMPHETAMINE 
ON OPERANT-RESPONDING IN CONTROL AND 6 HYDROXYDOPAMINE 
TREATED RATS. 

001595 02-04 

ADRENERGIC MODULATION OF THE HYPOTHALAMIC CHOLINERGIC 

MECHANISM IN THE CONTROL OF EMOTIONAL DEFENSIVE-BEHAVIOR IN 
THE CAT. 

001761 02-04 
A TRIPEPTIDE FOR CONTROL OF SCHIZOPHRENIC-SYMPTOMS. 

001919 02-08 
THYMOANALEPTIC TREATMENT CONTROL THROUGH MEASUREMENT OF 
PLASMA CONCENTRATIONS OF AMITRIPTYLINE AND ITS METABOLITE 
NORTRIPTYLINE. 

002304 02-13 
INTRAVENOUS CHLORIMIPRAMINE AFFECTS REM CYCLE IN PATIENTS 
WITH EXCESSIVE DAYTIME SLEEPINESS AND CONTROL SUBJEQS. 

002341 02-14 
A SIMPLE SYSTEM FOR CONTROL OF THE CONTINUOUS PERFORMANCE 
TEST IN PSYCHOPHARMACOLOGICAL-RESEARCH. 

002474 02-16 
MEASUREMENT OF PLASMA CONCENTRATIONS OF DRUGS AS A 
FEEDBACK CONTROL MECHANISM DURING DRUG-THERAPY. 

002525 02-17 
GABAERGIC MECHANISMS IN THE CONTROL OF PRL AND GH RELEASE. 

002690 03-03 



Psychopharmacology Abstracts 



EVIDENCE FOR A TONIC GABAERGIC CONTROL OF SEROTONIN NEURONS 
IN THE MEDIAN RAPHE NUCLEUS. 

002719 03-03 
BASAL GANGLIA DOPAMINERGIC CONTROL OF SENSORIMOTOR 
FUNCTIONS RELATED TO MOTIVATED BEHAVIOR. 

002815 03-03 
DISCRIMINATIVE RESPONSE CONTROL BY NALOXONE IN MORPHINE 
PRETREATED RATS. 

003053 03-04 
DRUG-INDUCED STIMULUS CONTROL AND THE CONCEPT OF BREAKING- 
POINT: LSDANDQUIPAZINE. 

003116 03-04 
CORTICAL CONTROL OF NEURALLY MEDIATED ARRHYTHMOGENIC- 
PROPERTIES OF DESACETYLLANATOSIDE-C. 

003124 03-05 
PLACEBO-EFFEQ: FROM CONTROL TO EXPERIMENTAL CONDITION 

003195 03-08 
QUALITY OF REPORTS OF CLINICAL-TRIALS SUBMIHED BY THE DRUG 
INDUSTRY TO THE FINNISH AND SWEDISH CONTROL AUTHORITIES 

003599 03-17 
ROLE OF THE ANTERIOR PITUITARY GABA-RECEPTOR IN THE CONTROL OF 
PROLACTIN RELEASE. 

003809 04-03 
NEUROTRANSMITTER CONTROL OF HYPOTHALAMIC PITUITARY THYROID- 
FUNCTION IN RATS. 

003942 04-03 
IN VIVO EVIDENCE FOR GABAERGIC CONTROL OF SEROTONIN RELEASE IN 
THE CAT SUBSTANTIA-NIGRA 

004011 04-03 
AVOIDANCE ENHANCEMENT AND DISCRIMINATIVE RESPONSE CONTROL 
BY ANXIOLYTICS WITH DRUGS ACTING ON THE GABA SYSTEM 

004193 04-04 
A MICROCOMPUTER SYSTEM FOR THE CONTROL OF BEHAVIORAL 
EXPERIMENTS 

004287 04-06 
THE EFFEQS OF PSYCHOTROPIC-MEDICATION ON COGNITIVE CONTROL 
MEASURES. (PH D DISSERTATION) 

004523 04-13 
CONTROLLED 

BEHAVIOURAL-RESPONSES TO STEREOTAQICALLY CONTROLLED 
INJECTIONS OF MONOAMINE NEUROTRANSMIHERS INTO THE 
ACCUMBENS AND CAUDATE-PUTAMEN NUCLEI. 

001708 02-04 
TREATMENT OF THERAPY-RESISTANT DEPRESSED-PATIENTS WITH IV. 
INFUSIONS OF NOMIFENSINE CONTROLLED BY GALVANIC-SKIN- 
RESISTANCE. 

002012 02-09 
ANTIDEPRESSANT AQION OF AMINEPTINE: CONTROLLED DOUBLE-BUND 
STUDY. 

002030 02-09 
DOUBLE-BUND CONTROLLED EXPERIMENT: AMINEPTINE VERSUS 
AMITRIPTYUNE USING THE HAMILTON-DEPRESSION-RATING-SCALE 

002050 02-09 
VILOXAZINE IN THE TREATMENT OF DEPRESSIVE-NEUROSIS: A 
CONTROLLED CLINICAL-STUDY WITH DOXEPIN AND PLACEBO. 

002080 02-10 
CLOMIPRAMINE TREATMENT OF OBSESSIVE-COMPULSIVE-DISORDER: I A 
CONTROLLED CLINICAL-TRIAL. 

002086 02-10 
A CONTROLLED DOUBLE-BLIND STUDY OF HALOPERIDOL VERSUS 
THIORIDAZINE IN THE TREATMENT OF RESTLESS MENTALLY- 
SUBNORMAL-PATIENTS: SERUM LEVELS AND CUNICAL-EFFEaS. 

002185 02-11 
DIFFICULTIES ENCOUNTERED DURING A CONTROLLED STUDY OF A NEW 
HYPNOTIC-DRUG (TRIAZOLAM) BY A GROUP OF GENERAL- . 

PRACTITIONERS. 

003155 03-071 

PIPERIDONE IN CHRONIC SCHIZOPHRENIC-PATIENTS: A CONTROLLED 
DOUBLE-BUND STUDY. 

003184 03-08 

MORPHINE DEPRESSES DORSAL-HORN NEURON RESPONSES TO 
CONTROLLED NOXIOUS AND NONNOXIOUS CUTANEOUS STIMULATION. 

003782 04-03 
VILOXAZINE IN THE TREATMENT OF DEPRESSIVE-NEUROSIS: A PLACEBO 
AND STANDARD (IMIPRAMINE) CONTROU.ED CUNICAL-STUDY 

004392 04-09 
CONTROLLED CLINICAL-TRIAL OF NOMIFENSINE IN THE TREATMENT OF 
DEPRESSION. „ ^ 

004417 04-09 

CONTROLLED-COMPARATIVE-STUDY 

TREATMENT OF DRUG-INDUCED DRYNESS OF MOUTH IN PSYCHIATRIC- 
PATIENTS - A CONTROLLED-COMPARATIVE-STUDY. 

000799 01-13 
CONTROLLED-COMPARISON ^^^^ ( 

CONTROLLED-COMPARISON OF MEDIUM AND HIGH CLOROTEPIN DOSES 
IN CHRONIC SCHIZOPHRENIA. 

000548 01-08. 



S-114 



( 



VOLUME 19, SUBJECT INDEX 



Subject Index 



CONTROLLED-COMPARISON OF MIANSERINE WITH IMIPRAMINE IN 

ENDOGENOUS DEPRESSIONS 

000634 01-09 
CONTROLLED-COMPARISON OF THE THERAPEUTIC EFFECTS OF NATRIUM- 

OXYBUTYRATE AND OXAZEPAM. 

000658 01-10 
CONTROLLED-COMPARISON OF PERPHENAZINE WITH PERPHENAZINE IN 

SCHIZOPHRENIA: A METHODICAL-CHECK OF A DOUBLE-BUND CROSS- 
OVER DESIGN. 

001937 02-08 
LONG-TERM CONTROLLED-COMPARISON OF INJECTION OXYPROTHEPIN 
AND FLUPHENAZINE-DECANOATES IN PSYCHOTICS IN REMISSION. 

001949 02-08 
THE USE OF CLOROTEPIN AND DIAZEPAM IN A COMPLEX THERAPY OF 
NEUROSES (CONTROLLED-COMPARISON) 

002064 02-10 
THERAPEUTIC EFFECT OF MIANSERINE AND IMIPRAMINE IN ENDOGENOUS 
DEPRESSIONS (CONTROLLED-COMPARISON) . 

003264 03-09 
CONTROLLED-RELEASE 

STEADY-STATE LITHIUM BLOOD LEVEL FLUCTUATIONS IN MAN 
FOLLOWING ADMINISTRATION OF A LITHIUM-CARBONATE 
CONVENTIONAL AND CONTROLLED-RELEASE DOSAGE FORM. 

003151 03-07 
CONTROLLED-STUDY 

CLINICAL COMPARISON OF OXYPROTHEPIN AND CLOTEPINE IN 
SCHIZOPHRENIC-PATIENTS (CONTROLLED-STUDY) . 

000568 01-08 
KETAZOLAM AND DIAZEPAM IN ANXIETY; A CONTROLLED-STUDY. 

000655 01-10 
DISCONTINUATION OF ORAL AND DEPOT FLUPHENAZINE IN 
SCHIZOPHRENIC-PATIENTS AFTER ONE YEAR OF CONTINUOUS 
MEDICATION: A CONTROLLED-STUDY. 

001931 02-08 
NOMIFENSINE IN THE TREATMENT OF ENDOGENOUS DEPRESSION. A 
CONTROLLED-STUDY VS. NORTRIPTYLINE. 

001978 02-09 
DOUBLE-BLIND CONTROLLED-STUDY: AMINEPTINE VERSUS 
TRIMIPRAMINE. 

002051 02-09 
PROPRANOLOL IN CHRONIC ANXIETY-DISORDERS: A CONTROLLED-STUDY. 

002073 02-10 
DOUBLE-BLIND CONTROLLED-STUDY ON THE PSYCHOLEPTIC-EFFECTS OF 
AMINEPTINE IN MENTALLY-HANDICAPPED CHILDREN WITHOUT 
PERSONALITY-PROBLEMS. 

002116 02-11 
CONTROLLED-STUDY WITH BROMAZEPAM AND CLOROTEPIN IN CHILD 
INSTABILITY. 

002190 02-11 
AMOXAPINE AND IMIPRAMINE IN THE TREATMENT OF DEPRESSED- 
OUTPATIENTS: A CONTROLLED-STUDY. 

003254 03-09 
A CLINICAL, CONTROLLED-STUDY OF L ALPHA ACETYLMETHADOL IN THE 
TREATMENT OF NARCOTIC ADDICTION. 

003335 03-11 
IMIPRAMINE TREATMENT OF BORDERLINE-CHILDREN: CASE-REPORTS 
WITH A CONTROLLED-STUDY. 

003356 03-11 
A CONTROLLED-STUDY OF L-DOPA IN SCHIZOPHRENIA WITH REFERENCE 
TO THE THEORY OF DOPAMINERGIC-RECEPTOR HYPERSENSITIVITY. 

004312 04-08 
CONTROLLEO-SUBSTANCES-ACT 

GUIDELINES FOR SCHEDULING DRUGS UNDER THE CONTROLLED- 
SUBSTANCES-ACT. 

003606 03-17 
CONTROLLED-TRIAL 

ANTIDEPRESSIVE TREATMENT IN PARKINSONS-DISEASE: A CONTROLLED- 
TRIAL OF THE EFFECT OF NORTRIPTYLINE IN PATIENTS WITH 
PARKINSONS-DISEASE TREATED WITH L-DOPA. 

000659 01-11 
A CONTROLLED-TRIAL OF BEHAVIOR-MODIFICATION AND 

METHYLPHENIDATE IN HYPERACTIVE-CHILDREN. 

000678 01-11 
CONTROLLED-TRIAL OF BEHAVIOUR-THERAPY, PHARMACOTHERAPY, AND 
THEIR COMBINATION IN THE TREATMENT OF OBESITY. 

000725 01-11 
CONTROLLED-TRIAL OF SULPIRIDE IN CHRONIC SCHIZOPHRENIC-PATIENTS. 

001914 02-08 
ANXIETY AND SEDATION DURING A STRESSFUL-SITUATION AFTER SINGLE- 
DOSE OF DIAZEPAM VERSUS N DESMETHYLDIAZEPAM - A 
CONTROLLED-TRIAL. 

002329 02-14 
A CONTROLLED-TRIAL OF OXYPERTINE IN TARDIVE-DYSKINESIA, 

004611 04-15 
CONTROLLING 

BRAIN LOCATIONS CONTROLLING THE BEHAVIORAL-EFFECTS OF CHRONIC 
AMPHETAMINE INTOXICATION. 

001653 02-04 



COMPARISON OF PSYCHOTROPIC-DRUG, RESPONSE COST, AND 
PSYCHOTROPIC-DRUG PLUS RESPONSE COST PROCEDURES FOR 
CONTROLLING INSTITUTIONALIZED MENTALLY-RETARDED PERSONS. 

004438 04-11 
CONTROLS 

DOES SYSTEMIC MORPHINE INCREASE DESCENDING INHIBITORY 
CONTROLS OF DORSAL-HORN NEURONES INVOLVED IN NOCICEPTION? 

000175 01-03 
ACTH4-10 AND MEMORY IN ECT TREATED PATIENTS AND UNTREATED 
CONTROLS. II. EFFECT ON RETRIEVAL. 

001983 02-09 
EVALUATION OF NOMIFENSINE IN THE TREATMENT OF GERIATRIC 
DEPRESSION USING PSYCHOMETRIC-TESTS AND PLASMA LEVEL 
CONTROLS. 

002004 02-09 
BEHAVIORAL CONFIRMATION OF DIFFUSE NOXIOUS INHIBITORY 
CONTROLS (DNIC) AND EVIDENCE FOR A ROLE OF ENDOGENOUS 
OPIATES. 

002791 03-03 
5 HYDROXYTRYPTAMINE CONTROLS ACH-RECEPTOR SENSITIVITY OF 
BULLFROG SYMPATHETIC GANGLION CELLS. 

003710 04-03 
PROLACTIN AND GROWTH-HORMONE STUDIES IN SCHIZOPHRENIC- 
PATIENTS AND NORMAL CONTROLS. 

004538 04-13 
CONVALESCING 

SEXUAL-DIFFICULTIES AMONG CONVALESCING ALCOHOLICS: INTEREST IN 
PRAZEPAM TREATMENT IN 30 CASES, 

003296 03-11 
CONVERGENCES 

CONVERGENCES AND DIVERGENCES BETWEEN BIOLOGICAL-PSYCHIATRY 
AND PSYCHOTHERAPY. 

002536 02-17 
CONVERGENT 

CONVERGENT PROPERTIES AND CHEMICAL SENSITIVITY OF MIDBRAIN 
RETICULAR FORMATION NEURONS OF UNANESTHETIZED RABBITS. 

003972 04-03 
CONVERSATION 

HUMAN SOCIAL CONVERSATION: EFFECTS OF ETHANOL, SECOBARBITAL 
AND CHLORPROMAZINE. 

004582 04-14 
CONVERSION 

THE CONVERSION OF (3H)TRYPT0PHAN TO 5 (3H)HYDR0XYTRYPTAMINE 
IN MOUSE-BRAIN FOLLOWING DEPLETION OF PHENYLALANINE AND 
TYROSINE. 

000148 01-03 
CONVERSION SCALES FOR COMMONLY REQUESTED SERUM 
CONCENTRATIONS OF DRUGS AND OTHER SUBSTANCES OF 
THERAPEUTIC AND TOXICOLOGICAL IMPORTANCE, AND OF 
HORMONES. 

000759 01-13 
CONVERTING 

CAPTOPRIL GIVEN INTRACEREBROVENTRICULARLY, SUBCUTANEOUSLY OR 
BY GAVAGE INHIBITS ANGIOTENSIN CONVERTING ENZYME ACTIVITY 
IN THE RAT-BRAIN. 

001614 02-04 
CONVULSANT 

REDUCTION OF GAMMA AMINOBUTYRIC-ACID-MEDIATED (GABA) 
TRANSMISSION BY A CONVULSANT BENZODIAZEPINE. 

000015 01-02 
SYSTEMIC DIPIPERIDINOETHANE MIMICS THE CONVULSANT AND 
NEUROTOXIC-ACTIONS OF KAINIC-ACID. 

000222 01-03 
CONVULSANT AND ANTICONVULSANT BARBITURATES. 1. MOLECULAR 
CONFORMATIONS FROM CLASSICAL POTENTIAL ENERGY 
CALCULATIONS. 

001029 02-01 
REPEATED ELECTROCONVULSIVE-SHOCK DOES NOT INCREASE THE 
SUSCEPTIBILITY OF RATS TO A CAGE CONVULSANT 
(ISOPROPYLBICYCLOPHOSPHATE) . 

001184 02-03 
CONVULSANT AND ANTICONVULSANT-DRUG BINDING-SITES RELATED TO 
GABA REGULATED CHLORIDE ION-CHANNELS. 

002848 03-03 
KET AMINE: CONVULSANT OR ANTICONVULSANT? 

003060 03-04 
STIMULATION OF FRUCTOSEBIPHOSPHATASE ACTIVITY AND SYNTHESIS 
IN THE CEREBRAL-CORTEX OF RATS SUBMITTED TO THE CONVULSANT 
METHIONINE-SULFOXIMINE. 

003838 04-03 
CONVULSANT-AGENTS 

REGULATION OF THE STATE OF PHOSPHORYLATION OF SPECIFIC 

NEURONAL PROTEINS IN MOUSE-BRAIN BY IN VIVO ADMINISTRATION 
OF ANESTHETIC AND CONVULSANT-AGENTS. 

000291 01-03 
CONVULSANT-EFFECT 

ON THE MEASUREMENT IN RATS OF THE CONVULSANT-EFFECT OF DRUGS 
AND THE CHANGES WHICH FOLLOW ELECTROCONVULSIVE-SHOCK. 

002444 02-15 



I 

a, 



I 

't,f 



It- 



m.. 
iiii'iji" 



S-115 



Subject Index 



Psychopharmacology Abstracts 



CONVULSANT-EFFECTS 

CONVULSANT-EFFECTS OF AMINOOXY ACETIC-ACID DURING ONTOGENESIS 
IN RATS. 

001439 02-03 
CONVULSANTS 

CONVULSANTS ANTAGONISE INHIBITION IN THE OLFACTORY-CORTEX 
SLICE, 

001466 02-03 
AMINOPHYLLINE AND IMIDAZOLE AS CONVULSANTS. 

004232 04-04 
CONVULSION 

EFFECTS OF KINDLING OR BRAIN-STIMULATION ON PENTYLENETETRAZOL- 
INDUCED CONVULSION SUSCEPTIBILITY. 

000037 01-03 
CONVULSIONS 

EFFECTS OF GAMMA ACETYLENIC-GABA AND GAMMA VINYL-GABA ON 
ELECTRICALLY-INDUCED SPINAL-CORD CONVULSIONS AND ON SPINAL- 
CORD GABA CONCENTRATION. 

000145 01-03 
INVOLVEMENT OF CENTRAL CHOLINOCEPTORS IN METRAZOL-INDUCED 
CONVULSIONS. 

000247 01-03 
PRODUCTION OF CONVULSIONS IN MICE BY THE COMBINATION OF 
METHIONINE AND HOMOCYSTEINE. 

001233 02-03 
EFFECT OF ERGOT DERIVATIVES ON POSTDECAPITATION CONVULSIONS. 

001288 02-03 
HOMOCYSTEINE-INDUCED CONVULSIONS: ENHANCEMENT BY VITAMIN-B6 
AND INHIBITION BY HYDRAZINE. 

002758 03-03 
INCORPORATION OF N ACETYLMANNOSAMINE INTO RAT-BRAIN 
SUBCELLULAR GANGLIOSIDES: EFFECT OF PENTYLENETETRAZOL- 
INDUCED CONVULSIONS IN BRAIN GANGLIOSIDES 

002937 03-03 
BRAIN AND SERUM CALCIUM CONCENTRATIONS FOLLOWING 
ELECTROCONVULSIVE-SHOCK OR BICUCULLINE-INDUCED CONVULSIONS 
IN RATS. 

003736 04-03 
PYRAZOLE EXACERBATES HANDLING-INDUCED CONVULSIONS IN MICE. 

004094 04-04 
BEHAVIORAL-PHARMACOLOGY OF TETRAHYDROCANNABINOL 
CONVULSIONS IN RABBITS. 

004288 04-06 
CONVULSIVE 

EFFECTS OF ANTICONVULSANTS AND GLUTAMATE ANTAGONISTS ON THE 
CONVULSIVE ACTION OF KAINIC-ACID. 

000288 01-03 
LOCOMOTOR AND CONVULSIVE RESPONSES TO PICROTOXIN IN 
AMYGDALA KINDLED RATS. 

000416 01-04 
LOWERING OF THE CONVULSIVE THRESHOLD BY NONSTEROIDAL 
ANTIINFLAMMATORY-DRUGS. 

002904 03-03 
THE ROLE OF GABA-MEDIATED NEUROTRANSMISSION IN CONVULSIVE 
STATES. 

003334 03-11 
CONVULSIVE AND DRUG-THERAPIES OF DEPRESSION. 

004366 04-09 
CONVULSIVE-SEIZURE 

ON THE MECHANISM OF A DIFFERENT DRUG DISTRIBUTION DURING 
CONVULSIVE-SEIZURE IN COMPARISON TO ANESTHESIA. 

001151 02-03 
ON SOME RELATIONSHIPS BETWEEN GABAERGIC AND 5 HT-ERGIC 
MECHANISMS IN PENTYLENETETRAZOL CONVULSIVE-SEIZURE 
REACTIONS. 

004166 04-04 
CONVULSIVE-SHOCK-TREATMENT 

REDUCTION IN OPIATE ACTIVATION AFTER CHRONIC 

ELECTROCONVULSIVE-SHOCK - POSSIBLE ROLE FOR ENDORPHINS IN 
THE BEHAVIORAL-EFFECTS OF CONVULSIVE-SHOCK-TREATMENT. 
(UNPUBLISHED PAPER). 

004154 04-04 
COOLING 

THE EFFECT OF PHARMACOLOGICAL DESTRUCTION OF HYPOTHALAMIC 
MONOAMINERGIC STRUCTURES ON BODY-TEMPERATURE AND GAS- 
EXCHANGE DURING EXTREME COOLING. 

004016 04-03 
COOPERATIVE 

EFFECTS OF DOPAMINERGIC AGONISTS AND ANTAGONISTS ON 

(3H)AP0M0RPHINE BINDING TO STRIATAL MEMBRANES: SULPIRIDE 
LACK OF INTERACTIONS WITH POSITIVE COOPERATIVE 
(3H)AP0M0RPHINE BINDING. 

000099 01-03 
COOPERATIVE PSYCHIATRIC- STUDY OF ALIVAL: PRELIMINARY RESULTS. 

002045 02-09 
COOPERATIVELY 

EVIDENCE FOR, AND LOCALIZATION OF, A UNITARY DOPAMINE- 
RECEPTOR COMPOSED OF COOPERATIVELY LINKED SUBUNIT BINDING- 
SITES IN RAT STRIATUM. 

000186 01-03 



UNITARY DOPAMINERGIC-RECEPTOR COMPOSED OF COOPERATIVELY 
LINKED AGONIST AND ANTAGONIST SUBUNIT BINDING-SITES. 

001342 02-03 
COORDINATING 

COORDINATING CLINICAL-TRIALS IN PSYCHOPHARMACOLOGY: 
PLANNING, DOCUMENTATION, AND ANALYSIS 

002574 02-17 
COPULATORY-BEHAVIOR 

INCREASES IN TESTOSTERONE LEVELS AND IN COPULATORY-BEHAVIOR OF 
MALE RHESUS-MONKEYS FOLLOWING TREATMENT WITH HUMAN 
CHORIONIC GONADOTROPHIN 

003012 03-04 
COPULATORY-BEHAVIOR AND SEXUAL-REFLEXES OF MALE RATS TREATED 
WITH NALOXONE. 

003077 03-04 
CORNEAL 

OCCURRENCE OF CORNEAL OPACITIES IN RATS AFTER ACUTE 
ADMINISTRATION OF L ALPHA ACETYLMETHADOL. 

001853 02-05 
CORONARY-HEART-DISEASE 

CORONARY-HEART-DISEASE: TREATING THE ANXIETY COMPONENT 

002088 02-10 
CORONARY-PRONE 

SENSORY PROCESSING, CARDIOVASCULAR REACTIVITY, AND THE TYPE A 
CORONARY-PRONE BEHAVIOR PAHERN. 

003405 03-13 
CORPUS-CALLOSUM 

THE EFFECTS OF LITHIUM ON MYOINOSITOL LEVELS IN LAYERS OF 
FRONTAL-CEREBRAL-CORTEX, IN CEREBELLUM, AND IN CORPUS- 
CALLOSUM OF THE RAT. 

003712 04-03 
CORPUS-STRIATUM 

ACUTE AND CHRONIC EFFECTS OF NEUROLEPTICS AND ACUTE EFFECTS OF 
APOMORPHINE AND AMPHETAMINE ON DOPAMINE TURNOVER IN 
CORPUS-STRIATUM AND SUBSTANTIA-NIGRA OF THE RAT-BRAIN. 

000215 01-03 
DRUG-INDUCED RELEASE OF DOPAMINE FROM CORPUS-STRIATUM. 
(PH.D. DISSERTATION). 

001343 02-03 
THE EFFECT OF CARBIDINE ON DOPAMINE TURNOVER IN THE CORPUS- 
STRIATUM OF THE BRAINS OF RATS. 

001352 02-03 
DOPAMINE-RECEPTOR SUPERSENSITIVITY IN THE CORPUS-STRIATUM 

FOLLOWING CHRONIC ELEVATION OF BRAIN GAMMA AMINOBUTYRIC- : 
ACID 

002716 03-03 
ROTATIONAL-BEHAVIOUR ELICITED BY 5 HT IN THE RAT: EVIDENCE FOR 
AN INHIBITORY ROLE OF 5 HT IN THE SUBSTANTIA-NIGRA AND 
CORPUS-STRIATUM 

004141 04-04 
CORRECT 

EFFECTS OF PIMOZIDE ON ACCURACY OF PERFORMANCE AND 
DISTRIBUTION OF CORRECT RESPONDING ON A SIMULTANEOUS 
DISCRIMINATION TASK IN THE RAT 

001806 02-04' 
CORRECTION 

SLEEP PROFILE AND ULTRADIAN SLEEP PERIODICITY IN HUMANS UNDER 
THE INFLUENCE OF A BUTYROPHENONE DERIVATIVE: I SLEEP 
CORRECTION IN SUBJECTS WITH OLIGOSYMPTOMATIC SLEEP- 
DISORDERS 

001869 02-06 
CORRECTION BY PROPRANOLOL OF THE ABNORMAL ADRENALINE 
DISCHARGE INDUCED BY EMOTIONAL-STRESS IN CEREBRAL 
HEMORRHAGE PATIENTS. 

002295 02-13 
CORRECTION OF THE EXTRAPYRAMIDAL NEUROLEPTIC-SYNDROME BY 
TRYPTOPHAN AND THE TIME-COURSE OF ITS CONTENT IN THE BLOOD 
OF PATIENTS. 

004434 04-11 
CORRECTION OF HORMONAL ACTIVITY OF THE THYROID-GLAND AS A 
METHOD OF PATHOGENIC THERAPY IN A COMPREHENSIVE TREATMENT 
OF PATIENTS WITH TEMPORAL EPILEPSY. 

004579 04-14 
CORRELATION 

OXAZEPAM-ESTERS 1 CORRELATION BETWEEN HYDROLYSIS RATES AND 
BRAIN APPEARANCE OF OXAZEPAM. 

000010 01-02 
OXAZEPAM-ESTERS. 2 CORRELATION OF HYDROPHOBICITY WITH SERUM 

BINDING, BRAIN PENETRATION, AND EXCRETION. 

000011 01-02 
CORRELATION BETWEEN MONOAMINE-OXIDASE-INHIBITORS AND 

ANTICONVULSANTS. 

000081 01-03 
CORRELATION BETWEEN BENZODIAZEPINE-RECEPTOR OCCUPATION AND 
ANTICONVULSANT EFFEQS OF DIAZEPAM. 

000450 01-04 



S-116 



VOLUME 19, SUBJECT INDEX 

INTERACTION BETWEEN AMITRIPTYLINE AND PHENOTHIAZINE IN MAN: 
METABOLITE NORTRIPTYLINE AND THE CORRELATION WITH CLINICAL- 
RESPONSE. 

000640 01-09 
CORRELATION BETWEEN DAILY FLUCTUATIONS OF CARBAMAZEPINE 
SERUM LEVELS AND INTERMITTENT SIDE-EFFECTS. 

000851 01-15 
MU-RECEPTORS AND DELTA OPIATE-RECEPTORS: CORRELATION WITH 
HIGH-AFFINITY AND LOW AFFINITY OPIATE BINDING-SITES. 

001554 02-03 
MOTOR-ACTIVITY AND ROTATIONAL-BEHAVIOR AFTER ANALOGS OF 
COCAINE: CORRELATION WITH DOPAMINE UPTAKE BLOCKADE. 

001650 02-04 
CORRELATION BETWEEN DAILY DOSAGE OF CHLORPROMAZINE AND 
SUBSEQUENT SUPERSENSITIVITY. 

001845 02-05 
THE CORRELATION OF CATECHOLAMINE AND ADRENERGIC PARAMETERS 
WITH DRUG-THERAPY OF NEUROTIC AND ENDOGENOUS DEPRESSIONS. 

002047 02-09 
CEEG STUDY ON PATIENTS UNDER THE PSYCHIATRIC-DRUG TREATMENT; 
THE CORRELATION BETWEEN EEG ALTERATION AND CLINICAL 
EVOLUTION. 

002165 02-11 
BRAIN GLUCOCORTICOID-RECEPTOR: CORRELATION OF IN VIVO UPTAKE 
OF CORTICOSTERONE WITH BEHAVIORAL-EVENTS, ENDOCRINE-EVENTS, 
AND NEUROPHARMACOLOGICAL EVENTS. 

002515 02-17 
STRUCTURE OF VARIABILITY AND CORRELATION IN LEARNING AFTER 
DRUG ADMINISTRATION. 

002562 02-17 
LACK OF CORRELATION BETWEEN NALOXONE-INDUCED CHANGES IN 
SEXUAL-BEHAVIOR AND SERUM LH IN MALE RATS. 

002821 03-03 
BARBITURATE ENHANCEMENT OF GABA-MEDIATED INHIBITION AND 
ACTIVATION OF CHLORIDE ION-CONDUCTANCE: CORREL^TION WITH 
ANTICONVULSANT AND ANESTHETIC ACTIONS. 

002885 03-03 
ON CORRELATION OF BEHAVIORAL-REACTIONS AND NEURONAL ACTIVITY 
IN THE HYPOTHALAMUS UNDER SUBCUTANEOUS GASTRIN INJECTION. 

002892 03-03 
CORRELATION BETVi^EEN ANTIAVOIDANCE ACTIVITIES OF ANTIPSYCHOTIC- 
DRUGS IN RATS AND DAILY CLINICAL DOSES. 

003032 03-04 
CORRELATION OF (14C)MUSCIM0L CONCENTRATION IN RAT-BRAIN WITH 
ANTICONVULSANT ACTIVITY. 

003045 03-04 
AN INVERSE CORRELATION BETWEEN SERUM LEVELS OF 

DESMETHYLIMIPRAMINE AND MELATONIN-LIKE IMMUNOREACTIVITY 
IN DMI RESPONSIVE DEPRESSIVES. 

003228 03-09 
ANTAGONISM OF ETHANOL-INDUCED DECREASE IN LH BY P 
CHLOROPHENYLALANINE: LACK OF CORRELATION WITH ALTERED 
SEROTONERGIC MECHANISMS. 

003748 04-03 
A SIMPLE DETERMINATION OF SEROTONIN, 5 HYDROXYINDOLEACETIC- 
ACID AND 5 HYDROXYTRYPTOPHAN-DECARBOXYLASE ACTIVITY IN 
RAT-BRAIN AREAS AND PARALLEL CORRELATION AMONG THE LEVELS. 

004301 04-06 
CORRELATIONAL 

CONSISTENCY IN CATECHOLAMINE EXCRETION IN LABORATORY AND 
NATURAL SEHINGS: CORRELATIONAL AND VARIANCE COMPONENTS 
ANALYSES. 

004508 04-13 
CORRELATIONS 

CORRELATIONS BETWEEN HEMODYNAMIC PARAMETERS OF THE LIVER 
AND NOREPINEPHRINE RELEASE UPON HEPATIC-NERVE STIMULATION IN 
THE DOG. 

001547 02-03 
CORRELATIONS BETWEEN PUVSMA LEVELS OF ANTIEPILEPTIC-DRUGS AND 
EEG INTENSIVE MONITORING. 

002288 02-13 
CORRELATIONS BETWEEN LITHIUM LEVELS IN CEREBROSPINAL-FLUID AND 
LITHIUM LEVELS IN BLOOD PLASMA AND ERYTHROCYTES. 

003210 03-09 
CORRELATIONS BETWEEN NA-K-ATPASE ACTIVITY AND ACETYLCHOLINE 
RELEASE IN RAT CORTICAL SYNAPTOSOMES. 

003937 04-03 
CORRELATIONS BETWEEN VISUAL-EVOKED-POTENTIALS AND 

PSYCHOPATHOLOGICAL-FINDINGS IN SCHIZOPHRENIC-PATIENTS UNDER 
TREATMENT WITH VARIOUS PSYCHOPHARMACOLOGICAL-DRUGS 

004315 04-08 
CORRESPONDENCE 

OPIATE-RECEPTOR GRADIENTS IN MONKEY CEREBRAL-CORTEX: 
CORRESPONDENCE WITH SENSORY PROCESSING HIERARCHIES. 

002641 03-01 
CORRESPONDING 

TETRAHYDRO-BETA-CARBOLINES AND CORRESPONDING TRYPTAMINES: 
IN VITRO INHIBITION OF SEROTONIN AND DOPAMINE UPTAKE BY 
HUMAN BLOOD-PLATELETS. 

001067 02-02 



Subject Index 



TETRAHYDRO-BETA-CARBOLINES AND CORRESPONDING TRYPTAMINES: 
IN VITRO INHIBITION OF SEROTONIN, DOPAMINE AND 
NORADRENALINE UPTAKE IN RAT-BRAIN SYNAPTOSOMES 

001078 02-02 
CORTEX 

DOPAMINE METABOLITES IN CAUDATE AND CORTEX AFTER LITHIUM AND 
HALOPERIDOL, (UNPUBLISHED PAPER) 

003738 04-03 
EFFECTS OF PENTOBARBITAL AND ETHANOL UPON SINGLE NEURON 
ACTIVITY IN THE PRIMARY SOMATOSENSORY CORTEX OF THE RHESUS- 
MONKEY, 

003755 04-03 
THE EFFECT OF DIAZEPAM ON CYCLIC EXCITABILITY CHANGES IN AN 
EPILEPTIC-FOCUS IN THE CORTEX OF THE MAJOR HEMISPHERES. 

003984 04-03 
THE EFFECT OF LITHIUM-HYDROXYBUTYRATE ON THE BIOELECTRICAL- 
ACTIVITY OF THE CORTEX AND SOME SUBCORTICAL STRUCTURES OF 
THE RABBIT BRAIN. 

003994 04-03 
LESIONS OF AMYGDALA, PYRIFORM CORTEX AND OTHER BRAIN 
STRUCTURES DUE TO DIPIPERIDINOETHANE INTOXICATION. 

004273 04-05 
CORTICAL 

A COMPARISON OF HUMAN TACTILE STIMULUS VELOCITY 

DISCRIMINATION WITH THE ABILITY OF S-l CORTICAL NEURONS IN 
AWAKE RHESUS-MONKEYS TO SIGNAL THE SAME VELOCITY 
DIFFERENCES BEFORE AND AFTER NONANESTHETIC DOSES OF 
PENTOBARBITAL. 

000055 01-03 
ACTIVATION OF CORTICAL CIRCUITS DURING INTERICTAL SPIKES. 

000056 01-03 
CORTICAL NEUROCHEMICAL CHANGES AFTER INTRASTRIATAL INJECTION 

OF KAINIC-ACID. 

000133 01-03 
INHIBITION OF (3H)DIAZEPAM BINDING TO RAT-BRAIN CORTICAL 
SYNAPTOSOMAL MEMBRANES BY ADENOSINE UPTAKE BLOCKERS. 

000330 01-03 
THE EFFECTS OF LSD AND SOME ANALOGUES ON THE RESPONSES OF 
SINGLE CORTICAL NEURONS OF THE CAT TO OPTICAL- STIMULATION. 

000738 01-12 
STIMULUS INTENSITY CONTROL IN DEPRESSION: A STUDY OF THE 
COMPARATIVE-EFFECT OF DOXEPIN AND AMITRIPTYLINE ON CORTICAL 
EVOKED-POTENTIALS. 

000763 01-13 
PRESSURE REVERSAL OF THE EFFECT OF URETHANE ON THE EVOKED 
SOMATOSENSORY CORTICAL RESPONSE IN THE RAT 

001106 02-03 
FACTORS INFLUENCING THE RELEASE OF LABELLED GAMMA 
AMINOBUTYRIC-ACID AND ACETYLCHOLINE EVOKED BY ELECTRICAL- 
STIMULATION WITH ALTERNATING POLARITY FROM RAT CORTICAL 
SLICES. 

001130 02-03 
MORPHINE AND ELECTROACUPUNCTURE: COMPARISON OF THE EFFECTS 
ON THE CORTICAL EVOKED-RESPONSES AFTER TOOTH-PULP 
STIMULATION IN RATS. 

001294 02-03 
STUDIES ON THE EFFECT OF ALPHA MELANOCYTE-STIMULATING- 
HORMONE AND RELATED PEPTIDES ON THE ACCUMULATION OF P 
AMINOHIPPURIC-ACID IN RENAL CORTICAL SLICES. (UNPUBLISHED 
PAPER). 

001372 02-03 
SELECTIVE INFLUENCE OF ERGOT ALKALOIDS ON CORTICAL AND STRIATAL 
DOPAMINERGIC-RECEPTORS AND SEROTONERGIC-RECEPTORS. 

001447 02-03 
APOMORPHINE HALOPERIDOL INTERACTIONS: DIFFERENT TYPES OF 
ANTAGONISM IN CORTICAL AND SUBCORTICAL BRAIN REGIONS. 

002662 03-03 
DIFFERENCES IN CUTANEOUS SENSORY RESPONSE PROPERTIES OF SINGLE 
SOMATOSENSORY CORTICAL NEURONS IN AWAKE AND HALOTHANE 
ANESTHETIZED RATS. 

002687 03-03 
SELECTIVE SYNAPTIC ANTAGONISM BY ATROPINE AND ALPHA 
AMINOADIPATE OF PULVINAR AND CORTICAL AFFERENTS TO THE 
SUPRASYLVIAN VISUAL AREA (CLARE-BISHOP AREA). 

002752 03-03 
CHRONOLOGICAL ELECTROENCEPHALOGRAPHIC AND 

NEUROPHARMACOLOGICAL-STUDY IN CORTICAL KINDLING RABBITS. 

002761 03-03 
CHANGES IN THE CORTICAL ACTIVITY OF SUCCINATE-DEHYDROGENASE 
UNDER THE INFLUENCE OF CHLORPROMAZINE (A HISTOCHEMICAL- 
STUDY AND ELECTROCYTOCHEMICAL- STUDY). 

002784 03-03 
DIFFERENTIAL-EFFECTS OF CLOMIPRAMINE AND CLORGYLINE ON THE 
SENSITIVITY OF CORTICAL NEURONS TO SEROTONIN: EFFECT OF 
CHRONIC-TREATMENT. 

002847 03-03 



I 
9 






'Jit; 
a- 






Ji., 

m 

'll'HI* 



s-nz 



Subject Index 



Ptychopharmacology Abstracts 



CORTICAL RECOVERY FROM EFFECTS OF MONOCULAR DEPRIVATION: 
ACCELERATION WITH NOREPINEPHRINE AND SUPPRESSION WITH 6 
HYDROXYDOPAMINE. 

003024 03-04 
CORTICAL CONTROL OF NEURALLY MEDIATED ARRHYTHMOGENIC- 
PROPERTIES OF DESACETYLLANATOSIDE-C. 

003124 03-05 
CORTICAL EVOKED-POTENTIALS IN GILLES-DE-LA-TOURETTES-SYNDROME 
- A SINGLE CASE-STUDY. 

003431 03-13 
THYROXIN SENSITIVITY OF SENSORIMOTOR CORTICAL NEURONS AND THE 
HYPOTHALAMIC VENTROMEDIAL NUCLEUS. 

003713 04-03 
THE EFFECT OF LONG-TERM CONCURRENT ADMINISTRATION OF 
CHLORPROMAZINE AND LITHIUM ON THE STRIATAL AND FRONTAL 
CORTICAL DOPAMINE METABOLISM IN RATS. 

003788 04-03 
INVESTIGATION OF ACTION OF ENKEPHALIN ON THE SPONTANEOUS AND 
EVOKED RELEASE OF ACETYLCHOLINE FROM RAT CORTICAL AND 
STRIATAL SLICES. 

003862 04-03 
CORRELATIONS BETWEEN NA-K-ATPASE ACTIVITY AND ACETYLCHOLINE 
RELEASE IN RAT CORTICAL SYNAPTOSOMES 

003937 04-03 
CORTICAL-CORRELATES 

CORTICAL-CORRELATES OF VIGILANCE REGUUTION AND THEIR USE IN 
EVALUATING THE EFFECTS OF TREATMENT 

002147 02-11 
CORTICOCEREBRAL 

ACCELERATION OF DESIPRAMINE-INDUCED DECREASE OF RAT 
CORTICOCEREBRAL BETA-ADRENERGIC-RECEPTORS BY YOHIMBINE 

000326 01-03 
CORTICOSTERIODS 

PLASMA CORTICOSTERIODS IN MANIA: THE EFFECTS OF PIMOZIDE 

004363 04-09 
CORTICOSTEROID 

SIDE-EFFECTS OF CORTICOSTEROID THERAPY: PSYCHIATRIC-ASPECTS. 

003508 03-15 
CORTICOSTEROIDS 

THE EFFECT OF ANTIDEPRESSANTS ON L 5 HTP-INDUCED CHANGES IN RAT 
PLASMA CORTICOSTEROIDS. 

000170 01-03 
RELATIONSHIPS BETWEEN PLASMA CORTICOSTEROIDS AND 
BENZODIAZEPINES IN STRESS. 

000176 01-03 
BENZODIAZEPINES, STRESS AND RAT PLASMA CORTICOSTEROIDS: THE 
ROLE OF INDOLEAMINES. 

003034 03-04 
CORTICOSTERONE 

CHANGES IN PLASMA CORTICOSTERONE LEVELS AS A MEASURE OF 
ACUTE DEPENDENCE UPON LEVORPHANOL IN RATS. 

000085 01-03 
THE SENSITIVITY OF THE RAT CORTICOSTERONE RESPONSE TO 
ENVIRONMENTAL MANIPULATIONS AND TO CHRONIC 
CHLORDIAZEPOXIDE TREATMENT. 

000092 01-03 
EFFECTS OF PERINATAL THYROXINE AND/OR CORTICOSTERONE 
TREATMENT ON THE ONTOGENESIS OF HYPOTHALAMIC AND 
MESENCEPHALIC NOREPINEPHRINE AND DOPAMINE CONTENT. 

000180 01-03 
LONG-TERM EFFECT OF NEUROLEPTICS ON CORTICOSTERONE 
SEPTOHIPPOCAMPAL UPTAKE IN RATS. 

001107 02-03 
CORTICOSTERONE INCREASES THE SYNTHESIS OF A SOLUBLE PROTEIN IN 
PITUITARY-GLANDS FROM ADRENALECTOMIZED MALE RATS WHICH 
PRECIPITATES WITH ANTI-RAT GROWTH-HORMONE ANTISERUM. 
(UNPUBLISHED PAPER). 

001122 02-03 
LEUCINE-ENKEPHALIN AND METHIONINE-ENKEPHALIN PRODUCE OPPOSING 
EFFEQS ON PLASMA CORTICOSTERONE LEVELS IN ETHER-STRESSED 
MICE. 

001245 02-03 
THE EFFECT OF REPEATED ELECTROCONVULSIVE-SHOCK ON 
CORTICOSTERONE RESPONSES TO CENTRALLY-ACTING 
PHARMACOLOGICAL STIMULI IN THE MALE RAT. 

001486 02-03 
CENTRAL PHARMACOLOGICAL CONTROL OF CORTICOSTERONE SECRETION 

IN THE INTACT RAT. DEMONSTRATION OF CHOLINERGIC AND 
SEROTONINERGIC FACILITATORY AND ALPHA-ADRENERGIC INHIBITORY 
MECHANISMS. 

001487 02-03 
EFFECT OF BROMOCRIPTINE ON EXPLORATORY-ACTIVITY, BRAIN- 

MONOAMINES AND PLASMA CORTICOSTERONE IN THE 
NORMOTENSIVE-RATS, GENETICALLY HYPERTENSIVE-RATS AND/OR 
HYPERTENSIVE OBESE RATS 

001635 02-04 
BRAIN GLUCOCORTICOID-RECEPTOR: CORRELATION OF IN VIVO UPTAKE 
OF CORTICOSTERONE WITH BEHAVIORAL-EVENTS, ENDOCRINE-EVENTS, 
AND NEUROPHARMACOLOGICAL EVENTS. 

002515 02-17 



DIFFERENTIAL-EFFEaS OF CANNABINOID EXPOSURE AND STRESS ON 
PLASMA PROL^aiN, GROWTH-HORMONE AND CORTICOSTERONE 
LEVELS IN MALE MICE 

002695 03-03 
INTRAVENTRICULAR CORTICOSTERONE INJEQION FACILITATES MEMORY 
OF AN APPETITIVE DISCRIMINATIVE TASK IN MICE. 

003051 03-04 
EFFECT OF AMPHETAMINE ON PLASMA CORTICOSTERONE IN THE 
CONSCIOUS RAT. 

003888 04-03 
CORTICOSTRIATAL 

A NOVEL GABA-RECEPTOR MODULATES STIMULUS-INDUCED GLUTAMATE 
RELEASE FROM CORTICOSTRIATAL TERMINALS. 

001376 02-03 
CORTICOTROPIN 

EFFECT OF TREATMENT WITH SODIUM-VALPROATE AND DIAZEPAM ON 
PLASMA CORTICOTROPIN IN NELSONS- SYNDROME. 

004463 04-1 1 
CORTISOL 

THE EFFEQ OF CORTISOL MICROIONOPHORETIC-APPLICATIONS ON THE 
ACTIVITY OF HIPPOCAMPAL NEURONS IN UNRESTRAINED RABBITS 

001123 02-03 
EFFECTS OF NALOXONE UPON PROLACTIN AND CORTISOL IN NORMAL 
WOMEN 

002213 02-13 
MOOD AND BEHAVIORAL-EFFECTS OF PHYSOSTIGMINE ON HUMANS ARE 
ACCOMPANIED BY ELEVATIONS IN PLASMA BETA ENDORPHIN AND 
CORTISOL. 

002280 02-13 
PSYCHOTROPIC-DRUGS DO NOT INTERFERE WITH RADIOLIGAND ASSAYS 
FOR PROLACTIN, CORTISOL, AND GROWTH-HORMONE 

002511 02-16 
TSH, HGH, HPR, AND CORTISOL RESPONSE TO TRH IN DEPRESSED- 
PATIENTS. 

004399 04-09 
CORTISOL DYNAMICS AND DEXAMETHASONE PHARMACOKINETICS IN 
PRIMARY ENDOGENOUS DEPRESSION: PRELIMINARY FINDINGS 

004403 04-09 
COST 

COMPARISON OF PSYCHOTROPIC-DRUG, RESPONSE COST, AND 
PSYCHOTROPIC-DRUG PLUS RESPONSE COST PROCEDURES FOR 
CONTROLLING INSTITUTIONALIZED MENTALLY-RETARDED PERSONS 

004438 04-11 
COTARDS-SYNDROME 

BETA ENDORPHIN IN COTARDS-SYNDROME. 

003187 03-08 
COUNT 

THE SPECIFIC ACTIVITY OF PLATELET MONOAMINE-OXIDASE VARIES 
WITH PLATELET COUNT DURING SEVERE EXERCISE AND 
NORADRENALINE INFUSION. 

004509 04-13 
COUNTERAa 

PLASMA LEVELS OF BETA ENDORPHIN UNDER CHRONIC NEUROLEPTIC 
TREATMENT IN SCHIZOPHRENIC-PATIENTS: FAILURE OF NALOXONE TO 
COUNTERACT CURATIVE EFFECTS Of NEUROLEPTIC-DRUGS 

004321 04-08 
COUNTERTRANSPORT 

NA-DEPENDENT LI COUNTERTRANSPORT AND THE LITHIUM DISTRIBUTION 
ACROSS THE HUMAN ERYTHROCYTE MEMBRANE: INTRODUQION. 

002227 02-13 
COUNTRIES 

CLINICAL-EXPERIENCE WITH SUBSTITUTED BENZAMIDES IN FRENCH- 
SPEAKING COUNTRIES. 

002036 02-09 
COUPLED 

SUBSENSITIVITY OF THE NOREPINEPHRINE-RECEPTOR COUPLED 
ADENYLATE-CYCLASE SYSTEM IN BRAIN: EFFEQS OF NISOXETINE 
VERSUS FLUOXETINE. 

000208 01-03 
MULTIPLE BENZODIAZEPINE-RECEPTOR COMPLEXES: SOME 
BENZODIAZEPINE RECOGNITION jITES ARE COUPLED TO GABA- 
RECEPTORS AND lONOPHORES 

001484 02-03 
FUNCTIONAL ASPECTS OF THE NOREPINEPHRINE-RECEPTOR COUPLED 
ADENYIATE-CYCIASE SYSTEM IN THE CENTRAL-NERVOUS- SYSTEM 

001493 02-03 
COUPLING 

TOLERANCE TO BARBITURATE-INDUCED CENTRAL-NERVOUS-SYSTEM 
DEPRESSION: INVOLVEMENT OF STIMULUS SECRETION COUPLING IN 
DISCRETE BRAIN AREAS. (PH.D. DISSERTATION). 

001213 02-03 
COVALENTLY-BONDED 

THIOLS LIBERATE COVALENTLY-BONDED FLAVIN FROM MONOAMINE- 
OXIDASE (UNPUBLISHED PAPER). 

001060 02-01 
COVARIANCE 

COVARIANCE OF PLASMA FREE 3 METHOXY-4- 

HYDROXYPHENETHYLENEGLYCOL AND DIASTOLIC BLOOD-PRESSURE. 

003418 03-13 



S-118 



VOLUME 19, SUBJECT INDEX 



Subject Index 



COVERT 

COVERT DYSKINESIA IN AMBULATORY SCHIZOPHRENIA. 



COYOTE 

EFFECT OF LITHIUM-CHLORIDE IN COYOTE PUP DIET. 



000836 0)-15 



001835 02-05 



CPK 



CPZ 



CR 



TWO CASES OF FORM-FRUSTE-DU-SYNDROME-MALIN WITH HIGH-LEVELS 
OF SERUM CPK 

004636 04-15 

LOW ORAL CPZ BIOAVAILABILITY IN CHRONIC SCHIZOPHRENIA. 
(UNPUBLISHED PAPER) 

001938 02-08 



CONDITIONED SUPPRESSION OF DRINKING: A MEASURE OF THE CR 
ELICITED BY A LITHIUM CONDITIONED FLAVOR. 

001747 02-04 
CRAB 

MECHANICAL-CHANGES IN CRAB NERVE FIBERS DURING ACTION 
POTENTIALS. (UNPUBLISHED PAPER). 

001505 02-03 
CREATININE 

STRUCTURE-ACTIVITY RELATIONSHIPS IN THE EFFECTS OF PHENACEMIDE 
ANALOGS ON SERUM CREATININE AND ANTICONVULSANT ACTIVITY. 

000249 01-03 
CREATIVE-PROCESS 

PSYCHEDELIC-DRUGS AND THE CREATIVE-PROCESS. 

002199 02-12 
CRIME 

VOLUNTARY INTOXICATION FROM PHENCYCLIDINE. WILL IT RAISE A 
REASONABLE-DOUBT OF THE MENTAL-CAPACITY OF A PERSON 
CHARGED WITH A CRIME REQUIRING SPECIFIC INTENT OR MENTAL- 
STATE?. 

000914 01-17 
PCP AND VIOLENT CRIME: THE PEOPLE VS. PEACE. 

000986 01-17 
CRIMINAL 

CYCLICAL CRIMINAL ACTS IN PREMENSTRUAL-SYNDROME. 

000927 01-17 
CRIMINALLY-INSANE-OFFENDERS 

RECIDIVISM AND REHABILITATION RATES FOR 135 CRIMINALLY-INSANE- 
OFFENDERS. (D.ED. DISSERTATION). 

002514 02-17 
CRITERIA 

CRITERIA FOR CLINICAL DEVELOPMENT AND CLASSIFICATION OF 
NOOTROPIC-DRUGS. AN EXAMPLE: PIRACETAM. 

000988 01-17 
PREDiaiVE CRITERIA FOR LITHIUM-SALTS ACTIVITY. 

002619 02-17 
AMINE UPTAKE INHIBITORS: CRITERIA OF SELECTIVITY. 

003921 04-03 
THE USE OF CLINICAL AND PHARMACOKINETIC CRITERIA IN FORECASTING 
THE EFFICACY OF THERAPY IN SCHIZOPHRENIA. 

004335 04-08 
CROSS-OVER 

MAINTENANCE-THERAPY WITH FLUPHENAZINE-DECANOATE AND 
OXYPROTHEPINE-DECANOATE IN SCHIZOPHRENIC-PATIENTS - A 
DOUBLE-BLIND CROSS-OVER COMPARATIVE-STUDY. 

001924 02-08 
CONTROLLED-COMPARISON OF PERPHENAZINE WITH PERPHENAZINE IN 
SCHIZOPHRENIA: A METHODICAL-CHECK OF A DOUBLE-BLIND CROSS- 
OVER DESIGN. 

001937 02-08 
CROSS-OVER STUDY OF ZIMELIDINE AND DESIPRAMINE IN DEPRESSION: 
EVIDENCE FOR AMINE SPECIFICITY. 

003250 03-09 
A DOUBLE-BLIND, PLACEBO-CONTROLLED, CROSS-OVER TRIAL OF 
CARBAMAZEPINE IN OVERACTIVE, SEVERELY MENTALLY- 
HANDICAPPED PATIENTS. 

003365 03-1 1 
CROSS-STUDY 

COMPARATIVE CROSS- STUDY ON THE EFFECTS OF AMINEPTINE AND 
MAPROTILINE. 

002065 02-10 
CROSS-TOLERANCE 

CHLORDIAZEPOXIDE ANTINOCICEPTION: CROSS-TOLERANCE WITH 
OPIATES AND WITH STRESS. 

000348 01-04 
TOLERANCE TO SUPPRESSIVE EFFECTS OF CHLORDIAZEPOXIDE ON 

OPERANT-BEHAVIOR: LACK OF CROSS-TOLERANCE TO PENTOBARBITAL. 

000356 01-04 
CROSS-TOLERANCE OF DOPAMINE METABOLISM TO BACLOFEN, GAMMA 
BUTYROLACTONE AND HA-966 IN THE STRIATUM AND OLFACTORY 
TUBERCLE OF THE RAT. 

002681 03-03 
DEVELOPMENT OF TOLERANCE TO THE EXCITATORY EFFECT OF MORPHINE 
AND CROSS-TOLERANCE TO THE INHIBITORY ACTION OF BETA 
ENDORPHIN IN THE ISOLATED RAT VAS-DEFERENS. 

002756 03-03 



ELECTROENCEPHALOGRAPHIC AND BEHAVIORAL-TOLERANCE TO AND 
CROSS-TOLERANCE BETWEEN D ALA2-METHI0NINE-ENKEPHALINAMIDE 
AND MORPHINE IN THE RAT. 

004038 04-03 
CROSSED 

SENSITIVE DEPRESSANT EFFECT OF BENZODIAZEPINES ON THE CROSSED 
EXTENSOR REFLEX IN CHLORALOSE ANESTHETIZED RATS. 

003027 03-04 
A DOUBLE-BLIND CROSSED CLINICAL-STUDY WITH A NEW 

PSYCHOPHARMACEUTICAL: TIADIPONE (QM-6008), DIAZEPAM, AND 
A PLACEBO. 

003153 03-07 
CROSSING 

EFFECTS OF SINGLE-ORAL-DOSAGES OF STEROIDS ON HUMAN EEG 
BASELINE CROSSING T-SCORES SHOWN BY MULTIVARIATE STATISTICS 
AND STANDARD PROFILES. 

002239 02-13 
CROSSROADS 

MIND/BRAIN IN THE AGE OF PSYCHOPHARMACOLOGY: A CROSSROADS 
FOR MEDICINE AND MINISTRY. 

003624 03-17 
CROWDING 

SOCIAL CROWDING ENHANCES AVERSIVENESS OF NALOXONE IN RATS. 

004201 04-04 
CRYSTAL 

THE CRYSTAL AND MOLECULAR STRUCTURE OF THE ACETYLCHOLINE 
ANTAGONIST DIMETHYLAMINOBUTYNYLCYCLOHEXYLHYDROXY 2 
PHENYLACETATE HCL. 

000003 01-01 
THE CRYSTAL AND MOLECULAR STRUCTURE OF THE NEUROLEPTIC 
PIMOZIDE-HYDROCHLORIDE, BISFLUOROPHENYL- 
BUTYLPIPERIDYLBENZIMIDAZOLINONE-HCL. 

001015 02-01 
CS 

ETHANOL AVERSION INDUCED BY PARENTERALLY ADMINISTERED 
ETHANOL ACTING BOTH AS CS AND UCS. 

001721 02-04 
CSEEG 

COMPUTERIZED SLEEP EEG (CSEEG) IN PSYCHIATRY AND 
PSYCHOPHARMACOLOGY. 

002614 02-17 
CSF 

PRELIMINARY-STUDIES ON CSF GAMMA AMINOBUTYRIC-ACID LEVELS IN 
PSYCHIATRIC-PATIENTS BEFORE AND DURING TREATMENT WITH 
DIFFERENT PSYCHOTROPIC-DRUGS 

001959 02-08 
INCREASED CSF GAMMA AMINOBUTYRIC-ACID AFTER TREATMENT WITH 
GAMMA VINYL-GABA. 

002237 02-13 
TREATMENT OF HUNTINGTON-DISEASE WITH GAMMA ACETYLENIC- 
GABA, AN IRREVERSIBLE INHIBITOR OF GABA-TRANSAMINASE: 
INCREASED CSF GABA AND HOMOCARNOSINE WITHOUT CLINICAL 
AMELIORATION. 

003458 03-14 
CU-AMINE-OXIDASES 

CU-AMINE-OXIDASES: STUDIES RELATED TO THE MECHANISM-OF-ACTION 
OF BOVINE PLASMA AMINE-OXIDASE (UNPUBLISHED PAPER). 

003680 04-01 
CUE 

EVIDENCE THAT A PREFERRED SUBSTRATE FOR MONOAMINE-OXIDASE-B 
MEDIATES STIMULUS PROPERTIES OF MAO-INHIBITORS: A POSSIBLE 
ROLE FOR BETA PHENYLETHYIAMINE IN THE COCAINE CUE. 

000363 01-04 
FACTORS REGULATING DRUG CUE SENSITIVITY: LIMITS OF 
DISCRIMINABILITY AND THE ROLE OF A PROGRESSIVELY DECREASING 
TRAINING DOSE IN FENTANYL SALINE DISCRIMINATION. 

004088 04-04 
CUES 

TEMPORAL AND ENVIRONMENTAL CUES IN CONDITIONED HYPOTHERMIA 
AND HYPERTHERMIA ASSOCIATED WITH MORPHINE. 

002709 03-03 
CULTIVATION 

THE EFFECT OF CHLORPROMAZINE AND MAGEPTIL ON THE 

PROLIFERATION OF PERIPHERAL BLOOD LYMPHOCYTES IN CULTIVATION 
WITH PHYTOHEMAGGLUTININ. 

004541 04-13 
CULTURE 

ENHANCED TRANSFER OF EXPERIMENTAL ALLERGIC-ENCEPHALOMYELITIS 
WITH STRAIN-13 GUINEA-PIG LYMPH-NODE CELLS: REQUIREMENT FOR 
CULTURE WITH SPECIFIC ANTIGEN AND ALLOGENIC PERITONEAL 
EXUDATE CELLS. (UNPUBLISHED PAPER). 

001201 02-03 
STIMULATION OF THE PLASMA MEMBRANE ENZYME, 5' NUCLEOTIDASE, 
BY ETHANOL EXPOSURE TO NEURAL CELLS IN CULTURE. 

001499 02-03 
EFFEQS OF LITHIUM ON MORPHOLOGICAL CHARACTERISTICS OF 
DISSOCIATED BRAIN CELLS IN CULTURE. 

002765 03-03 



I 

lai, 












5 

fft:ii'. 



S-119 



Subject Index 



Psychopharmacology Abstracts 



CULTURED 

NALOXONE ANTAGONISM OF GABA-EVOKED MEMBRANE 

POLARIZATIONS IN CULTURED MOUSE SPINAL-CORD NEURONS. 

000116 01-03 
ANTICONVULSANT AND ANESTHETIC BARBITURATES: DIFFERENT 
POSTSYNAPTIC ACTIONS IN CULTURED MAMMALIAN NEURONS. 

000194 01-03 
(-)PENTOBARBITAL OPENS ION-CHANNELS OF LONG-DURATION IN 
CULTURED MOUSE SPINAL NEURONS. 

000198 01-03 
PSYCHOTROPiC-DRUGS AND HISTAMINE HI -RECEPTORS OF CULTURED 
MOUSE NEUROBLASTOMA CELLS. 

000250 01-03 
ADENOSINE REGULATES VIA TWO DIFFERENT TYPES OF RECEPTORS, THE 
ACCUMULATION OF CYCLIC-AMP IN CULTURED BRAIN CELLS. 

000308 01-03 
GABA SYNTHESIS BY CULTURED FIBROBLASTS OBTAINED FROM PERSONS 
WITH HUNTINGTONS-DISEASE. 

000765 01-13 
EXCITATORY ACTION OF OPIOID-PEPTIDES AND OPIATES ON CULTURED 
HIPPOCAMPAL PYRAMIDAL CELLS. 

001241 02-03 
TWO CONDUCTANCE MECHANISMS ACTIVATED BY APPLICATIONS OF L 
GLUTAMIC-ACID, L ASPARTIC-ACID, DL HOMOCYSTEIC-ACID, N 
METHYL-D-ASPARTIC-ACID, AND DL KAINIC-ACID TO CULTURED 
MAMMALIAN CENTRAL NEURONES. 

001349 02-03 
LITHIUM-ION ENTRY INTO CULTURED CELLS OF NEURAL ORIGIN. 

001433 02-03 
GABA ANALOGUES ACTIVATE CHANNELS OF DIFFERENT DURATION ON 
CULTURED MOUSE SPINAL NEURONS. 

002665 03-03 
TOXIC EFFECTS OF ALPHA AMINOADIPATE ON CULTURED CEREBELLAR 
CELLS. 

002729 03-03 
HISTAMINE ACTIONS ON ACTIVITY OF CULTURED HYPOTHALAMIC 
NEURONS: EVIDENCE FOR MEDIATION BY HISTAMINE Hl-RECEPTORS 
AND H2-RECEPT0RS. 

002732 03-03 
IDENTIFICATION OF TWO BENZODIAZEPINE BINDING-SITES ON CELLS 
CULTURED FROM RAT-CEREBRAL-CORTEX. 

002820 03-03 
EFFECTS OF D AMINOLAEVULINIC-ACID, PORPHOBILINOGEN, AMINO- 
ACIDS AND BARBITURATES ON CALCIUM ACCUMULATION BY 
CULTURED NEURONS. 

002859 03-03 

CULTURES 

THE INFLUENCE OF EXTERNAL SODIUM AND POTASSIUM ON LITHIUM 
UPTAKE BY PRIMARY BRAIN CELL CULTURES AT THERAPEUTIC LITHIUM 
CONCENTRATION. 

001300 02-03 
HEPATOTOXICITY OF SODIUM-VALPROATE AND OTHER 
ANTICONVULSANTS IN RAT HEPATOCYTE CULTURES 

002422 02-15 
NA-INDEPENDENT BINDING OF (3H)GABA AND (3H)MUSCIM0L TO 

SUBCELLULAR PARTICLES OF NEURAL PRIMARY CULTURES AND WHOLE 
BRAIN. 

002699 03-03 
DOXEPIN, A TRICYCLIC-ANTIDEPRESSANT, BINDS TO NORMAL, INTAQ 
ASTROGLIAL CELLS IN CULTURES AND INHIBITS THE ISOPROTERENOL- 
INDUCED INCREASE IN CYCLIC-AMP PRODUCTION 

003836 04-03 
THE INACTIVATION OF GAMMA AMINOBUTYRIC-ACID-TRANSAMINASE IN 
DISSOCIATED NEURONAL CULTURES FROM SPINAL-CORD 

003980 04-03 
BENZODIAZEPINE-RECEPTORS ON PRIMARY CULTURES OF MOUSE 
ASTROCYTES. 

004029 04-03 
CUMULATIVE 

CUMULATIVE DOSE RESPONSE-CURVES IN BEHAVIORAL- 
PHARMACOLOGY. 

001883 02-06 
CUMULATIVE AFTERDISCHARGE AS THE PRINCIPAL FACTOR IN THE 
ACQUISITION OF KINDLED SEIZURES. 

002862 03-03 
CUP 

MODIFIED CUP TECHNIQUE FOR MICROESTIMATION OF THE RELEASE AND 
UPTAKE OF NEUROTRANSMIHERS IN BRAIN SLICES. 

003147 03-06 
CUPS 

ACETYLCHOLINE AND AMINO-ACID NEUROTRANSMIHERS IN EPIDURAL 
CUPS OF FREELY-MOVING-RATS: EFFECT OF ACUTE AND CHRONIC- 
TREATMENT WITH ANTISCHIZOPHRENIC-DRUGS. 

001386 02-03 
CURATIVE 

PLASMA LEVELS OF BETA ENDORPHIN UNDER CHRONIC NEUROLEPTIC 
TREATMENT IN SCHIZOPHRENIC-PATIEN"^S: FAILURE OF NALOXONE TO 
COUNTERACT CURATIVE EFFECTS OF NcUROLEPTIC-DRUGS. 

004321 04-08 



CURRENT-VIEWS 

ACTION MECHANISMS OF INSULIN THERAPY IN PSYCHIATRY, AND 
CURRENT-VIEWS ON THESE MECHANISMS. 

002553 02-17 
CURVES 

USE OF SURVIVAL CURVES IN ANALYSIS OF ANTIPSYCHOTIC RELAPSE- 
STUDIES. 

002481 02-16 
THE EFFECT OF DIPHENYLHYDANTOIN ON EEG CURVES IN EPILEPTICS. 

004494 04-11 
CUTANEOUS 

CUTANEOUS REAQION TO LITHIUM-CARBONATE: A CASE-REPORT. 

000872 01-15 
DIFFERENCES IN CUTANEOUS SENSORY RESPONSE PROPERTIES OF SINGLE 
SOMATOSENSORY CORTICAL NEURONS IN AWAKE AND HALOTHANE 
ANESTHETIZED RATS. 

002687 03-03 
MORPHINE DEPRESSES DORSAL-HORN NEURON RESPONSES TO 
CONTROLLED NOXIOUS AND NONNOXIOUS CUTANEOUS STIMULATION. 

003782 04-03 
CYCLAZOCINE 

EFFECTS OF MORPHINE, PENTAZOCINE AND CYCLAZOCINE ALONE AND IN 
COMBINATION WITH NALOXONE ON ELEaRIC-SHOCK TITRATION IN 
THE SQUIRREL-MONKEY 

001611 02-04 
DISCRIMINATIVE-STIMULUS EFFEaS OF CYCLAZOCINE IN THE RAT. 

004236 04-04 
CYCLE 

INTRAVENOUS CHLORIMIPRAMINE AFFECTS REM CYCLE IN PATIENTS 
WITH EXCESSIVE DAYTIME SLEEPINESS AND CONTROL SUBJECTS. 

002341 02-14 
EFFECTS OF REPEATED ADMINISTRATIONS OF DIHYDROERGOTOXINE 
(REDERGINE) ON THE SLEEP-WAKEFULNESS CYCLE IN THE CAT. 

003703 04-02 
CYCLIC 

THE LONG-TERM-TREATMENT OF PERIODICAL AND CYCLIC DEPRESSIONS 
WITH FLUPENTHIXOL-DECANOATE. 

000603 01-09 
THE EFFECT OF DIAZEPAM ON CYCLIC EXCITABILITY CHANGES IN AN 
EPILEPTIC-FOCUS IN THE CORTEX OF THE MAJOR HEMISPHERES. 

003984 04-03 
CYCLIC-ADENOSINE-MONOPHOSPHATE 

EFFECT OF NALOXONE, HALOPERIDOL AND PROPRANOLOL ON CYCLIC- 
ADENOSINE-MONOPHOSPHATE CONTENT OF RAT AMYGDALA. 

000071 01-03 
ACTION OF CYCLIC-ADENOSINE-MONOPHOSPHATE ON CENTRAL 
NEURONS 

002940 03-03 
CYCLIC- AMIDINES 

RELATIONSHIPS BETWEEN STRUQURE AND ALPHA-ADRENERGIC- 
RECEPTOR AFFINITY OF CLONIDINE AND AND SOME RELATED CYCLIC- 
AMIDINES. 

002698 03-03 

CYCLIC- AMP 

MECHANISM OF CHLORPROMAZINE AQION ON PLASMA GLUCOSE AND 
CYCLIC-AMP LEVELS. 

000211 01-03 
ADENOSINE REGULATES VIA TWO DIFFERENT TYPES OF RECEPTORS, THE 
ACCUMULATION OF CYCLIC-AMP IN CULTURED BRAIN CELLS. 

000308 01-03 
CHOLERA-TOXIN-INDUCED EPILEPTOGENIC-FOCUS - SPECIAL REFERENCE 
TO CYCLIC-AMP METABOLISM AND EPILEPTOGENIC-FOCUS. 

000522 01-05 
CENTRAL LEVELS OF NORADRENALINE, 3 METHOXY-4- 

HYDROXYPHENYLETHYLENEGLYCOL AND CYCLIC-AMP IN THE RAT 
AFTER AaiVATION OF LOCUS-COERULEUS NEURONS: INFLUENCE OF 
SINGLE AND REPEATED NEUROLEPTIC TREATMENT. 

001095 02-03 
POSSIBLE INVOLVEMENT OF CYCLIC-AMP AND FRONTAL-CORTEX IN 
AMITRIPTYLINE MEDIATED SUPPRESSION OF THE HYPOTENSIVE-EFFEa 
OF CLONIDINE. 

001259 02-03 
DEVELOPMENT OF AND RECOVERY FROM SUBSENSITIVITY OF THE 
NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN BRAIN: EFFEQ 
OF AMPHETAMINE FOLLOWING INHIBITION OF ITS AROMATIC 
HYDROXYLATION BY IPRINDOLE. 

001353 02-03 
BRAIN STRIATAL TYROSINE-HYDROXYLASE: AQIVATION OF THE ENZYME 
BY CYCLIC-AMP INDEPENDENT PHOSPHORYLATION. 

001423 02-03 

CYCLIC-AMP IN PSYCHOSES AND THE EFFEQ OF DRUGS 

002294 02-13 
RELATIONSHIP BETWEEN THE AQIONS OF CALCIUM-IONS, OPIOIDS, AND 
PROSTAGLANDIN-El ON THE LEVEL OF CYCLIC-AMP IN 
NEUROBLASTOMA-X GLIOMA HYBRID CELLS. 

002677 03-03 



S-120 



VOLUME 19, SUBJECT INDEX 



Subject Index 



ALPHA2-ADRENERGIC AMINES, ADENOSINE AND PROSTAGLANDINS 
INHIBIT LIPOLYSIS AND CYCLIC-AMP ACCUMULATION IN HAMSTER 
ADIPOCYTES IN THE ABSENCE OF EXTRACELLULAR SODIUM 

002728 03-03 
INCREASE IN PLASMA CYCLIC-AMP LEVELS ELICITED BY NALOXONE IN 
MORPHINE-DEPENDENT MALE MICE. 

002834 03-03 



AGGRESSION ALTERING EFFECTS OF CYCLIC-AMP 
PLASMA LEVEL OF CYCLIC-AMP AND MENTAL-DISEASES. 



003021 03-04 

003170 03-08 

DOPAMINERGIC MECHANISMS IN THE TELEOST RETINA. II FACTORS 
AFFECTING THE ACCUMULATION OF CYCLIC-AMP IN PIECES OF INTACT 
CARP RETINA, 

003776 04-03 
DOXEPIN, A TRICYCLIC-ANTIDEPRESSANT, BINDS TO NORMAL, INTACT 
ASTROGLIAL CELLS IN CULTURES AND INHIBITS THE ISOPROTERENOL- 
INDUCED INCREASE IN CYCLIC-AMP PRODUCTION. 

003836 04-03 
CIRCADIAN-VARIATION OF CYCLIC-AMP IN THE RAT PINEAL-GLAND. 

003938 04-03 
EFFECTS OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC BLOCKERS ON 
CHLORPROMAZINE-INDUCEO ELEVATION OF PLASMA GLUCOSE AND 
CYCLIC-AMP IN FED MICE. 

003946 04-03 
ADENOSINE AND CYCLIC-AMP IN RAT-CEREBRAL-CORTICAL SLICES: 
EFFECTS OF ADENOSINE UPTAKE INHIBITORS AND ADENOSINE- 
DEAMINASE INHIBITORS. 

003950 04-03 
EVIDENCE TO SUGGEST THAT DOPAMINE-INOUCED INCREASE IN GABA 
CONCENTRATIONS IN CHICK BRAIN IS MEDIATED THROUGH CYCLIC- 
AMP. 

003952 04-03 
THE EFFECTS OF THYROTROPIN-RELEASING-HORMONE ON CYCLIC-AMP 
ACCUMULATION IN RABBIT CEREBROCORTICAL TISSUE IN THE 
PRESENCE AND ABSENCE OF CNS DEPRESSANTS. 

004010 04-03 
CYCLIC- AMP-INDUCED 

CYCLIC-AMP-INDUCED CHANGES IN THE ELECTROENCEPHALOGRAM AND 
IN BEHAVIOR DURING MORPHINE-DEPENDENCE AND ABSTINENCE IN 
THE RAT. 

003078 03-04 
CYCLIC- AMP-PHOSPHODIESTERASE 

DIHYDROXY AND TRIHYDROXY ANALOGS OF CHLORPROMAZINE 
INFLUENCE THE CENTRAL-ACTIVITY OF ADENYLATE-CYCLASE AND 
CYCLIC-AMP-PHOSPHODIESTERASE. 

001405 02-03 
RNA-POLYMERASE-II IN C6-GLI0MA CELLS: ALPHA AMANITIN BLOCKADE 
OF CYCLIC-AMP-PHOSPHODIESTERASE INDUCTION BY BETA- 
ADRENERGIC STIMULATION. (UNPUBLISHED PAPER). 

003998 04-03 
CYCLIC-GMP 

KAINIC-ACID INDUCED LESION OF RAT RETINA: DIFFERENTIAL-EFFECT ON 
CYCLIC-GMP AND BENZODIAZEPINE-RECEPTORS AND GABA- 
RECEPTORS. 

002743 03-03 
INVOLVEMENT OF CALCIUM CHANNELS IN SHORT-TERM 
DESENSITIZATION OF MUSCARINIC-RECEPTOR MEDIATED CYCLIC-GMP 
FORMATION IN MOUSE NEUROBLASTOMA CELLS. 

003783 04-03 
GUANYLATE-CYCLASE - CYCLIC-GMP IN MOUSE CEREBRAL-CORTEX AND 

CEREBELLUM: MODIFICATION BY ANTICONVULSANTS. 

003956 04-03 
DESENSITIZATION OF HISTAMINE HI -RECEPTOR-MEDIATED CYCLIC-GMP 
FORMATION IN MOUSE NEUROBLASTOMA CELLS. 

004030 04-03 
CYCIIC-GMP-DEPENDENT 

DEMONSTRATION OF A MUSCARINIC-RECEPTOR-MEDIATED CYCLIC-GMP- 
DEPENDENT HYPERPOLARIZATION OF THE MEMBRANE POTENTIAL OF 
MOUSE NEUROBLASTOMA CELLS USING 
(3H)TETRAPHENYLPH0SPH0NIUM . 

004049 04-03 
CYCLIC-GUANOSINE-MONOPHOSPHATE 

THE EFFECTS OF OPIATES ON THE LEVELS OF CYCLIC-GUANOSINE- 
MONOPHOSPHATE IN DISCRETE AREAS OF THE RAT CENTRAL- 
NERVOUS-SYSTEM. 

000220 01-03 
CENTRAL BLOOD-PRESSURE EFFECTS OF GUANYLYLIMIDODIPHOSPHATE 
AND CYCLIC-GUANOSINE-MONOPHOSPHATE . 

000266 01-03 
PHENYTOIN INHIBITION OF CYCLIC-GUANOSINE-MONOPHOSPHATE (C- 
GMP) ACCUMULATION IN NEUROBLASTOMA CELLS BY CALCIUM- 
CHANNEL BLOCKADE. 

004020 04-03 
CYCLIC-GUANOSINE-PHOSPHATE 

ETHANOL-INDUCED CHANGES IN CYCLIC-GUANOSINE-PHOSPHATE 
METABOLISM IN MOUSE VESTIBULAR REGION. 

003784 04-03 



CYCIIC-NUCIEOTIDE 

CIRCADIAN-RHYTHM OF CYCLIC-NUCLEOTIDE AND GABA LEVELS IN THE 

RAT-BRAIN, 

000049 01-03 
RELATIONSHIPS BETWEEN SEIZURE ACTIVITY AND CYCLIC-NUCLEOTIDE 

LEVELS IN BRAIN. 

000089 01-03 
INHIBITORY-EFFECTS OF ANTICONVULSANT-DRUGS ON CYCLIC- 
NUCLEOTIDE ACCUMULATION IN BRAIN. 

000090 01-03 
INTERACTION OF DOPAMINERGIC ERGOT DERIVATIVES WITH CYCLIC- 
NUCLEOTIDE SYSTEM, 

001482 02-03 
CYCLIC-NUCLEOTIDE-PHOSPHODIESTERASES 

AN IMPROVED ASSAY OF CYCLIC-NUCLEOTirCPHOSPHODIESTERASES 
WITH QAE-SEPHADEX COLUMNS, 

001860 02-06 
CYCLIC-NUCLEOTIDES 

EFFECTS OF RESERPINE, PROPRANOLOL, AND AMINOPHYLLINE ON 
SEIZURE ACTIVITY AND CNS CYCLIC-NUCLEOTIDES. 

000115 01-03 
RAT-BRAIN STEADY-STATE LEVELS OF CYCLIC-NUCLEOTIDES AS AN 
ENDPOINT OF LSD-LIKE HALLUCINOGEN EFFECTS. (PH D 
DISSERTATION). 

001426 02-03 
CYCLIC-NUCLEOTIDES AND THE CENTRAL-EFFECTS OF OPIATES: AN 
OVERVIEW OF CURRENT RESEARCH. 

001445 02-03 
EFFECT OF FLUPHENAZINE ON THE CIRCADIAN-EXCRETION OF CYCLIC- 
NUCLEOTIDES AND ELECTROLYTES IN THE URINE OF CHRONIC 
SCHIZOPHRENICS. 

001927 02-08 
CYCLIC-NUCLEOTIDES AND THE NERVOUS-SYSTEM 

004542 04-13 
CYCLICAL 

CYCLICAL CRIMINAL ACTS IN PREMENSTRUAL- SYNDROME. 

000927 01-17 
CYCLING 

MAOI-INDUCED RAPID CYCLING BIPOLAR AFFECTIVE-DISORDER IN AN 
ADOLESCENT. 

004637 04-15 
CYCLO-LEU-GLY 

THE EFFEQ OF CYCLO-LEU-GLY ON CHEMICAL DENERVATION 
SUPERSENSITIVITY OF DOPAMINE-RECEPTORS INDUCED BY 
INTRACEREBROVENTRICULAR INJECTION OF 6 HYDROXYDOPAMINE IN 
MICE. 

001435 02-03 
INHIBITION OF NEUROLEPTIC-INDUCED DOPAMINE-RECEPTOR 
SUPERSENSITIVITY BY CYCLO-LEU-GLY. 

001576 02-04 
CYCLOHEXIMIDE 

EFFECTS OF CYCLOHEXIMIDE ADMINISTERED IN CONJUNCTION WITH 
NICOTINE ON RETENTION OF A PASSIVE-AVOIDANCE TASK IN MICE. 

001791 02-04 
A QUANTITATIVE REGIONAL ANALYSIS OF PROTEIN SYNTHESIS 

INHIBITION IN THE RAT-BRAIN FOLLOWING LOCALIZED INJECTION OF 
CYCLOHEXIMIDE. 

002780 03-03 
CYCLOHEXYLADENOSINE 

ADENOSINE-RECEPTORS IN RAT TESTES: LABELING WITH 3H 
CYCLOHEXYLADENOSINE. 

002835 03-03 
CYCLOHEXYLBARBITURATE 

ON-COLUMN GAS-CHROMATOGRAPHIC-SYNTHESIS OF 1,3 DIALYKYL 
(C=l-10), BENZYL, AND CYCLOHEXYLBARBITURATE DERIVATIVES. 

003656 04-01 
CYCLOHEXYLPHENOXYAMIDOXIMES 

CYCLOHEXYLPHENOXYAMIDOXIMES AND IMIDAZOLINES WITH 
ANTIDEPRESSIVE AND ALPHA-ADRENERGIC-ACTIVITY. 

001051 02-01 
CYCLOID 

LITHIUM UPTAKE IN RED CELLS OF CYCLOID AND UNIPOLAR DYSTHYMIC- 
PATIENTS. 

003258 03-09 
CYCLOPHOSPHAMIDE-INDUCED 

CYCLOPHOSPHAMIDE-INDUCED SPERMATOGENIC EFFECTS DETECTED IN 
THE Fl -GENERATION BY BEHAVIORAL-TESTING. 

003121 03-05 
CYCLOPROPYL-N-ARYLALKYLAMINES 

MECHANISM OF INACTIVATION OF MITOCHONDRIAL MONOAMINE- 
OXIDASE BY N CYCLOPROPYL-N-ARYLALKYLAMINES. 

001055 02-01 
MECHANISM OF INACTIVATION OF MITOCHONDRIAL MONOAMINE- 
OXIDASE BY N CYCLOPROPYL-N-ARYLALKYLAMINES. 

001088 02-02 
CYCLOPROPYLMETHYL 

STEREOSPECIFIC INHIBITION OF DOPAMINE-SENSITIVE ADENYLATE- 
CYCLASE IN CARP RETINA BY THE ENANTIOMERS OF (/-) 1 



tai. 
M 

•ST 

:-t 



fe: 



Ifc, 



S-121 



Subject index 



Psychopharmacology Abstracts 



CYCLOPROPYLMETHYL 
TRIFLUOROMETHYLTHIODIBENZOCYCLOHEPTENYLIDENEPIPERIDINE. 

003706 04-02 
CYCLOSPASMOl 

EFFECTS OF CYCLOSPASMOL UPON SENSORY PARAMETERS IN PATIENTS 
RECOVERING FROM CEREBROVASCULAR-ACCIDENTS. 

002360 02-14 
CYCIOTHYMIC-PATIENTS 

PROPHYLACTIC-EFFECT OF LITHIUM AGAINST DEPRESSION IN 
CYCLOTHYMIC-PATIENTS: A LIFE-TABLE ANALYSIS. 

004391 04-09 
CYPROHEPTADINE 

METERGOLINE AND CYPROHEPTADINE SUPPRESS PROLACTIN RELEASE BY 
A NON-5-HYDROXYTRYPTAMINERGIC, NONDOPAMINERGIC 
MECHANISM. 

003732 04-03 
CYPROHEPTADiNIUM-METHIODIDE 

ANTIARRHYTHMIC-ACTIVITY OF AMITRIPTYLINE ANALOGUES IN 
CONSCIOUS DOGS AFTER MYOCARDIAL-INFARCTION: 
CYPROHEPTADINIUM-METHIODIDE. 

001534 02-03 
CYPROTERONACETATE 

CYPROTERONACETATE IN THE THERAPY OF SEXUAL-DEVIATIONS. 

000735 01-11 
CYSTEINE 

MORPHOLOGICAL CHANGES IN RAT-BRAIN INDUCED BY L CYSTEINE 
INJECTION IN NEWBORN ANIMALS. 

002774 03-03 
CYSTEINE-SULPHINIC-ACID-DECARBOXYLASE 

COMPARISON OF CYSTEINE-SUlPHINIC-ACID-DECARBOXYUkSE (CSD) 
ISOENZYMES AND GLUTAMIC-ACID-DECARBOXYLASE (GAD) IN RAT: IS 
BRAIN CSD-I IDENTICAL WITH LIVER CSD AND BRAIN CSD-II WITH 
GAD? (UNPUBLISHED PAPER). 

001048 02-01 
CYTOCHALASIN 

THE EFFECT OF COLCHICINE AND CYTOCHALASIN B ON THE RELEASE OF 
TAURINE FROM THE CHICK RETINA. 

002856 03-03 
CYTOCHROME-P-450 

EFFECT OF CANNABIDIOL ON CYTOCHROME-P-450 AND HEXOBARBITAL 
SLEEP-TIME. 

002675 03-03 

CYTOPLASMATIC 

TREATMENT OF ORGANIC-BRAIN-DISTURBANCES IN ELDERLY-PATIENTS. A 
CLINICAL DOUBLE-BLIND STUDY WITH MACROMOLECULAR ORGAN 
LYSATES (CYTOPLASMATIC THERAPY ACCORDING TO THEURER). 

003327 03-11 
CYTOPLASMIC 

CHANGES IN NORADRENERGIC TRANSMISSION ALTER THE 
CONCENTRATION OF CYTOPLASMIC PROGESTIN-RECEPTORS IN 
HYPOTHALAMUS. 

002842 03-03 
THE NA-K-ATPASE: A PLAUSIBLE TRIGGER FOR VOLTAGE-INDEPENDENT 
RELEASE OF CYTOPLASMIC NEUROTRANSMITTERS. 

003953 04-03 
CYTOSKELETAL 

SYNTHESIS OF CYTOSKELETAL PROTEINS IN BULK ISOLATED NEURONAL 
PERIKARYA 

003672 04-01 
CZECHOSLOVAK 

21 ANNUAL CZECHOSLOVAK PSYCHOPHARMACOLOGICAL-MEETING. 

000917 01-17 
CZECHOSLOVAKIA 

CONSUMPTION OF PSYCHOTROPIC-DRUGS IN CZECHOSLOVAKIA. 

002542 02-17 
C10DICHOL 

ANTITREMOR ACTION OF ClODICHOL, A PERIPHERAL ACETYLCHOLINE 
SYNTHESIS INHIBITOR. 

004096 04-04 
C6-GLIOMA 

REGULATION BY A BETA-ADRENERGIC-RECEPTOR OF A CA-INDEPENDENT 
ADENOSINE-CYCLIC-MONOPHOSPHATE-PHOSPHODIESTERASE IN C6- 
GLIOMA CELLS. (UNPUBLISHED PAPER). 

001403 02-03 
RNA-POLYMERASE-II IN C6-GLI0MA CELLS: ALPHA AMANITIN BLOCKADE 
OF CYCLIC-AMP-PHOSPHODIESTERASE INDUCTION BY BETA- 
ADRENERGIC STIMULATION. (UNPUBLISHED PAPER). 

003998 04-03 
D-AMPHET AMINE 

PRIOR AND ONGOING EXPERIENCE AS DETERMINANTS OF THE EFFEQS OF 
D-AMPHETAMINE AND CHLORPROMAZINE ON PUNISHED-BEHAVIOR. 

000339 01-04 
CONSEQUENT EVENTS AS DETERMINANTS OF DRUG-EFFECTS ON 
SCHEDULE-CONTROLLED BEHAVIOR: MODIFICATION OF EFFEQS OF 
COCAINE AND D-AMPHETAMINE FOLLOWING CHRONIC AMPHETAMINE 
ADMINISTRATION. 

000350 01-04 
EFFECTS OF ACUTE AND CHRONIC INTERAQIONS OF DIAZEPAM AND D- 
AMPHETAMINE ON PUNISHED-BEHAVIOR OF RATS. 

000386 01-04 



5 HT BLOCKADE AND THE STIMULANT-EFFECTS OF D-AMPHETAMINE AND 
L-AMPHETAMINE: NO INTERAQION IN SELF-STIMULATION OF 
PREFRONTAL-CORTEX, HYPOTHALAMUS, OR DORSAL TEGMENTUM. 
UNEXPECTED LETHALITY IN HIPPOCAMPAL SITES. 

000387 01-04 
JOINT-EFFECTS OF D-AMPHETAMINE AND ETHANOL OR PENTOBARBITAL 
IN PIGEONS 

000403 01-04 
FIXED-RATIO SCHEDULES OF FOOD PRESENTATION AND STIMULUS-SHOCK 
TERMINATION: EFFECTS OF D-AMPHETAMINE, MORPHINE, AND 
CLOZAPINE. 

000431 01-04 
OPPOSITE EFFECTS OF D-AMPHETAMINE ON SPONTANEOUS NEURONAL 
ACTIVITY IN THE NEOSTRIATUM AND NUCLEUS-ACCUMBENS. 

000454 01-04 
THE EFFECTS OF THE METHYLPHENIDATE AND D-AMPHETAMINE RELATED 
TO ROUTE-OF-ADMINISTRATION. 

000476 01-04 
A COMPARISON OF THE EFFEQS OF D-AMPHETAMINE, COCAINE, 

IMIPRAMINE AND PENTOBARBITAL ON LOCAL AND OVERALL RATES OF 
RESPONDING MAINTAINED UNDER A FOUR-COMPONENT MULTIPLE 
FIXED-INTERVAL SCHEDULE. 

000508 01-04 
D-AMPHETAMINE AS A PREDICTOR FOR RESPONSE TO IMIPRAMINE AND 
AMITRIPTYLINE 

000621 01-09 
THE EFFECT OF SMALL AND MODERATE DOSES OF D-AMPHETAMINE ON 
HUNGER, MOOD, AND AROUSAL IN MAN. 

000807 01-14 
A NEW APPROACH TO THE ASSESSMENT OF THE POTENCY OF 
REVERSIBLE MONOAMINE-OXIDASE-INHIBITORS IN VIVO, AND ITS 
APPLICATION TO D-AMPHETAMINE, P METHOXYAMPHETAMINE AND 
HARMALINE. 

000900 01-16 
EFFECTS OF HALOPERIDOL AND D-AMPHETAMINE ON IN VIVO 3H 
SPIROPERIDOL BINDING IN THE RAT-FOREBRAIN. 

001461 02-03 
THE EFFECTS OF D LYSERGIC-ACID-DIETHYLAMIDE (LSD), 2,5 

DIMETHOXY-4-METHYLAMPHETAMINE (DOM) AND D-AMPHETAMINE 
ON OPERANT-RESPONDING IN CONTROL AND 6 HYDROXYDOPAMINE 
TREATED RATS 

001595 02-04 
BEHAVIORAL-DEPRESSION AND ITS NEUROCHEMICAL-CORRELATES AT 
HIGH-DOSES OF D-AMPHETAMINE IN RATS. 

001601 02-04 
EFFECTS OF MORPHINE, D-AMPHETAMINE, AND PENTOBARBITAL ON 
SHOCK AND LIGHT DISCRIMINATION PERFORMANCE IN RATS. 

001639 02-04 
EFFECTS OF REPEATED ADMINISTRATION OF D-AMPHETAMINE ON 
SIDMAN-AVOIDANCE RESPONDING IN RATS. 

001692 02-04 
SELF-ADMINISTRATION OF D-AMPHETAMINE AND AMINERGIC SYSTEMS 
IN THE RAT i 

001696 02-04 
THE EFFECTS OF D-AMPHETAMINE, CHLORDIAZEPOXIDE, AND J 

PENTOBARBITAL ON BEHAVIOR MAINTAINED BY ESCAPE FROM 
PUNISHMENT IN PIGEONS. (PH D. DISSERTATION). 

001713 02-04 
EFFECTS OF PHENCYCLIDINE, PENTOBARBITAL, AND D-AMPHETAMINE ON , 
THE ACQUISITION AND PERFORMANCE OF CONDITIONAL 
DISCRIMINATIONS IN MONKEYS. 

001723 02-04 
NEUROCHEMICAL-EFFECTS AND BEHAVIORAL-EFFECTS OF CHRONIC D- | 
AMPHETAMINE TREATMENT IN GENETICALLY OBESE (OBOB) MICE. 
(PH.D. DISSERTATION). 

001739 02-04 

THERMOREGULATORY AND LOCOMOTOR-EFFECTS OF DSIP: 
PARADOXICAL-INTERACTION WITH D-AMPHETAMINE. 

001827 02-04 
DRUG PREFERENCE AND MOOD IN HUMANS: D-AMPHETAMINE. I 

002335 02-14; 
CNV VARIATIONS INDUCED BY THE ADMINISTRATION OF DIAZEPAM, 
HALOPERIDOL, PHENELZINE AND D-AMPHETAMINE. 

002355 02-141 
AN OBSERVATIONAL METHOD FOR QUANTIFYING THE BEHAVIOURAL- 
EFFECTS OF DOPAMINE AGONISTS: CONTRASTING-EFFECTS OF D- 
AMPHETAMINE AND APOMORPHINE. 

002484 02-16 
EFFECTS OF D-AMPHETAMINE AND APOMORPHINE IN A NEW ANIMAL- 
MODEL OF PETIT-MAL EPILEPSY 

002493 02-16 
THE EFFECTS OF D-AMPHETAMINE AND POTASSIUM ON SEROTONIN 
RELEASE AND METABOLISM IN RAT-CEREBRAL-CORTEX TISSUE 

002754 03-03 
POTENTIATION OF APOMORPHINE AND D-AMPHETAMINE EFFECTS BY 

NALOXONE. ^ ^, 

002942 03-041 



S-122 



VOLUME 19, SUBJECT INDEX 



Subject Index 



TOLERANCE TO THE DISCRIMINATIVE- STIMULUS PROPERTIES OF D- 
AMPHETAMINE. 

002953 03-04 
INTERACTION AMONG D-AMPHETAMINE, SCOPOLAMINE AND GENOTYPE 
IN AVOIDANCE-BEHAVIOR OF RATS. 

003082 03-04 
EFFECTS OF CHLORDIAZEPOXIDE AND D-AMPHETAMINE ON RESPONDING 
SUPPRESSED BY CONDITIONED PUNISHMENT. 

003105 03-04 
THE HYPERACTIVE-CHILD-SYNDROME: PERIPHERAL SYMPATHETIC- 
NERVOUS-SYSTEM FUNCTION AND THE EFFECT OF D-AMPHETAMINE. 

003340 03-1 1 
DRUG PREFERENCE AND MOOD IN HUMANS; REPEATED ASSESSMENT OF 
D-AMPHETAMINE. 

003445 03-14 
MYOINOSITOL TURNOVER IN THE INTACT RAT-BRAIN: INCREASED 
PRODUCTION AFTER D-AMPHETAMINE. 

003723 04-03 
THE BEHAVIORAL-EFFECTS OF D-AMPHETAMINE ALONE AND IN 
COMBINATION WITH ACUTE AND CHRONIC MORPHINE TREATMENTS IN 
RATS. 

003915 04-03 
THE INFLUENCE OF D-AMPHETAMINE ON RAT-BRAIN STRIATAL REDUCED 
BIOPTERIN CONCENTRATION. 

003922 04-03 
APPARENT SEROTONERGIC MODULATION OF THE DOSE-DEPENDENT 
BIPHASIC RESPONSE OF NEOSTRIATAL NEURONS PRODUCED BY D- 
AMPHET AMINE. 

003981 04-03 
KINETIC STUDIES ON THE ENTRY OF D-AMPHETAMINE INTO THE 
CENTRAL-NERVOUS-SYSTEM: I. CEREBROSPINAL-FLUID. 

004005 04-03 
SECOND-ORDER SCHEDULES OF INTRAMUSCULAR COCAINE INJECTION IN 
THE SQUIRREL-MONKEY: COMPARISONS WITH FOOD PRESENTATION 
AND EFFECTS OF D-AMPHETAMINE AND PROMAZINE. 

004152 04-04 
SEX, PLASMA PROLACTIN AND PLASMA 3 METHOXY-4- 
HYDROXYPHENYLGLYCOL (MHPG) PREDICT HERITABLE D- 
AMPHETAMINE EXCITATION IN MAN. (UNPUBLISHED PAPER). 

004565 04-14 
D-AMPHETAMINE-INDUCED 

EFFECTS OF PHENCYCLIDINE AND METHYLPHENIDATE ON D- 
AMPHETAMINE-INDUCED BRHAVIORS IN RESERPINE PRETREATED RATS. 

001616 02-04 
DISSOCIATION OF D-AMPHETAMINE-INDUCED LOCOMOTOR-ACTIVITY AND 
STEREOTYPED-BEHAVIOUR BY LESIONS OF THE SUPERIOR-COLLICULUS. 

001755 02-04 
CONDITIONED DRUG-EFFECTS OF D-AMPHETAMINE-INDUCED AND 
MORPHINE-INDUCED MOTOR ACCELERATION IN MICE: EXPERIMENTAL 
APPROACH FOR PLACEBO-EFFEQ. 

004128 04-04 
0- AMPHETAMINES 

CATS DEVELOP TOLERANCE TO D-AMPHET AMINES EFFECTS UPON 
LOCOMOTION AND STEREOTYPED-BEHAVIORS. 

003018 03-04 
D-ISOMERS 

COMPARATIVE-STUDIES OF THE PHARMACOLOGICAL-EFFEaS OF THE D- 
ISOMERS AND L-ISOMERS OF CODEINE. 

004084 04-04 
D-1 

INHIBITION OF DOPAMINE D-1 AND D-2 BINDING-SITES IN NEURONAL 
TISSUE BY ASCORBATE. 

003876 04-03 
D-2 

THREE CLASSES OF DOPAMINE-RECEPTOR (D-2, D-3, D-4) IDENTIFIED BY 
BINDING STUDIES WITH 3H APOMORPHINE AND 3H DOMPERIDONE. 

002900 03-03 
INHIBITION OF DOPAMINE D-1 AND D-2 BINDING-SITES IN NEURONAL 
TISSUE BY ASCORBATE. 

003876 04-03 

THREE CLASSES OF DOPAMINE-RECEPTOR (D-2, D-3, D-4) IDENTIFIED BY 
BINDING STUDIES WITH 3H APOMORPHINE AND 3H DOMPERIDONE. 

002900 03-03 
D-4 

THREE CLASSES OF DOPAMINE-RECEPTOR (D-2, D-3, D-4) IDENTIFIED BY 
BINDING STUDIES WITH 3H APOMORPHINE AND 3H DOMPERIDONE. 

002900 03-03 
DAILY 

REPEATED TRICYCLICS INDUCE A PROGRESSIVE DOPAMINE- 
AUTORECEPTOR SUBSENSITIVITY INDEPENDENT OF DAILY DRUG- 
TREATMENT. 

000047 01-03 
CORRELATION BETWEEN DAILY FLUCTUATIONS OF CARBAMAZEPINE 
SERUM LEVELS AND INTERMIHENT SIDE-EFFECTS. 

000851 01-15 
LOG-DOSE/RESPONSE-CURVE FLAHENING IN RATS AFTER DAILY 
INJECTION OF OPIATES. 

001387 02-03 



D-3 



THE INFLUENCE OF DAILY BIOLOGICAL-RHYTHMICITY ON THE HOMING- 
BEHAVIOR, PSYCHOPHARMACOLOGICAL RESPONSIVENESS, LEARNING 
AND RETENTION OF SUCKLING RATS (PH D DISSERTATION) 

001660 02-04 
THE INFLUENCE OF SINGLE DAILY HEROIN INJECTIONS ON DRINKING- 
PATTERNS IN THE RAT. 

001746 02-04 
CORRELATION BETWEEN DAILY DOSAGE OF CHLORPROMAZINE AND 
SUBSEQUENT SUPERSENSITIVITY. 

001845 02-05 
FIRST CLINICAL IMPRESSIONS IN DAILY PRACTICE. 

002046 02-09 
REPEATED ANTIDEPRESSANT TREATMENTS INDUCE A LONG-LASTING 
DOPAMINE-AUTORECEPTOR SUBSENSITIVITY: IS DAILY TREATMENT 
NECESSARY FOR CLINICAL EFFICACY? 

002659 03-03 
CORRELATION BETWEEN ANTIAVOIDANCE ACTIVITIES OF ANTIPSYCHOTIC- 
DRUGS IN RATS AND DAILY CLINICAL DOSES. 

003032 03-04 
DAMAGE 

INFLUENCE OF AMPHETAMINE AND PHENYLPROPANOLAMINE ON FOOD 
INTAKE, ACTIVITY, AND BODY-TEMPERATURE IN RATS WITH 
VENTROMEDIAL HYPOTHALAMIC OR DORSOLATERAL TEGMENTAL 
DAMAGE. 

000322 01-03 
FACILITATION OF RECOVERY BY PROPANTHELINE-BROMIDE AFTER 
LATERAL HYPOTHALAMIC DAMAGE, 

000396 01-04 
EFFECTS OF AMPHETAMINE AND PHENYLPROPANOLAMINE ON FOOD 
INTAKE IN RATS WITH VENTROMEDIAL HYPOTHALAMIC OR 
DORSOLATERAL TEGMENTAL DAMAGE. 

001818 02-04 
FLUORESCENCE HISTOCHEMISTRY INDICATES DAMAGE OF STRIATAL 
DOPAMINE NERVE TERMINALS IN RATS AFTER MULTIPLE DOSES OF 
METHAMPHET AMINE. 

002812 03-03 
BEHAVIORAL-CHANGES AND BIOCHEMICAL-CHANGES AFTER 
HIPPOCAMPAL DAMAGE. (PH.D. DISSERTATION). 

003069 03-04 
ON THE QUESTION OF PARENCHYMAL DAMAGE CAUSED BY LONG-TERM 
THERAPY WITH PSYCHOTROPICS IN ADOLESCENCE. 

004626 04-15 
DAMS 

GABA-RECEPTORS AND BENZODIAZEPINE-RECEPTORS IN THE OFFSPRING 
OF DAMS RECEIVING DIAZEPAM: ONTOGENETIC- STUDIES. 

001849 02-05 
DANGER 

ON THE DANGER OF USING PSYCHOPHARMACEUTICALS DURING 
PREGNANCY: CRITICAL REVIEW OF THE LITERATURE. 

000833 01-15 
DANGEROUS 

DIURETICS ARE DANGEROUS WITH LITHIUM. 

002420 02-15 
RECENT DEVELOPMENTS IN LITHIUM TREATMENT: IS IT DANGEROUS FOR 
THE KIDNEY? 

002465 02-15 
DANITRACEN 

INTERACTION OF P CHLOROPHENYLALANINE, MIANSERINE AND 
DANITRACEN WITH AMPHETAMINE. 

004599 04-15 
DARK 

BILATERAL SKIN CONDUCTANCE AND THE PUPILLARY LIGHT DARK 
REFLEX: MANIPULATION BY CHLORPROMAZINE, HALOPERIDOL, 
SCOPOLAMINE, AND PLACEBO. 

004544 04-13 
DATA 

PRELIMINARY DATA ON ETHOSUXIMIDE AND THE EPISODIC-DYSCONTROL- 
SYNDROME. 

000539 01-07 
ADVANTAGE OF PHARMACOKINETIC DATA DURING TREATMENT OF 
PSYCHOSES WITH HALOPERIDOL. 

000577 01-08 
PREDICTION OF THE VOLUME OF DISTRIBUTION FROM IN VITRO DATA 
AND USE FOR ESTIMATING THE ABSOLUTE EXTENT OF ABSORPTION. 

000907 01-16 
SOME PHARMACOLOGICAL-ASPECTS AND BIOCHEMICAL-ASPECTS OF 
TRH: EXPERIMENTAL AND CLINICAL DATA. 

001189 02-03 
NEW DATA ON THE USE OF ANTIDEPRESSANT-DRUGS. 

001195 02-03 
ATROPINE AND NATURAL SLEEP: ACTIVITY DATA OF THE STRIATUM IN 
RATS. 

001551 02-03 
ACUTE AND CHRONIC LSD EFFECTS ON RAT STARTLE: DATA SUPPORTING 
AN LSD RAT MODEL OF SCHIZOPHRENIA. 

002194 02-12 
PHARMACOKINETIC BASIS FOR PREDICTING STEADY-STATE SERUM DRUG 
CONCENTRATIONS OF IMIPRAMINE FROM SINGLE-DOSE DATA. 

002225 02-13 



I 

lai. 












S-123 



Subject Index 

KINETIC DATA ON THE INHIBITION OF HIGH-AFFINITY CHOLINE 
TRANSPORT INTO RAT-FOREBRAIN SYNAPTOSOMES BY CHOLINE-LIKE 
COMPOUNDS AND NITROGEN-MUSTARD ANALOGUES. 

002879 03-03 
STATISTICAL ANALYSES OF PHYSIOLOGIC DATA FROM FEMALE PATIENTS 
WITH AN ENDOMORPHOUS DEPRESSIVE COURSE: A TRIAL, 
INTERACTIONS BETWEEN PHYSIOLOGIC PARAMETERS, TEST JUNCTURES 
IN THIS PHASE. 

003251 03-09 
USE OF CURRENTLY AVAILABLE DATA SOURCES TO ASSESS DRUG 
SCHEDULING. 

003594 03-17 
PRACTICAL IMPLICATIONS OF MODERN PSYCHOPHARMACOLOGICAL 
DATA 

003596 03-17 
SINGLE-DOSE PHARMACOKINETIC DATA ON ZIMELIDINE IN DEPRESSED- 
PATIENTS. 

004385 04-09 
THE USE OF CLINICAL KINETIC DATA IN TREATMENT WITH 
ANTIDEPRESSANT-DRUGS. 

004686 04-16 

DATES 

EFFECTS OF FETAL TREATMENT WITH METHYUVZOXYMETHANOL-ACETATE 
AT VARIOUS GESTATIONAL DATES ON THE NEUROCHEMISTRY OF THE 
ADULT NEOCORTEX OF THE RAT 

002770 03-03 
DAY-HOSPITAL 

PSYCHIATRIC-DRUG-STUDY. PART II. MENTAL-HYGIENE-CLINIC SURVEY, 
DAY-TREATMENT-CENTER SURVEY, DAY-HOSPITAL SURVEY. 

004716 04-17 
DAY-TREATMENT-CENTER 

PSYCHIATRIC-DRUG-STUDY. PART II. MENTAL-HYGIENE-CLINIC SURVEY, 
DAY-TREATMENT-CENTER SURVEY, DAY-HOSPITAL SURVEY 

004716 04-17 

DAYTIME 

THE DIFFERENTIAL-EFFECTS OF SHORT-ACTING AND LONG-ACTING 
BENZODIAZEPINES UPON NOCTURNAL SLEEP AND DAYTIME 
PERFORMANCE. 

000822 01-14 

INTRAVENOUS CHLORIMIPRAMINE AFFECTS REM CYCLE IN PATIENTS 
WITH EXCESSIVE DAYTIME SLEEPINESS AND CONTROL SUBJECTS. 

002341 02-14 
DAYTIME EFFECTS OF L TRYPTOPHAN. 

003455 03-14 

DDT 

A POSSIBLE NEUROCHEMICAL BASIS OF THE CENTRAL STIMULATORY 
EFFECTS OF PP'DDT 

004274 04-05 

DEACYLATION 

PHYSIOLOGIC AND PHARMACOLOGIC IMPLICATIONS IN THE 
DEACYLATION OF PHOSPHATIDYLSERINE IN MICE. 

002682 03-03 
DEAE 

DOSE-EFFECT OF DEAE ON SUBJECTIVE PROBLEMS, VERTIGO, 
DEPRESSION, ASTHENIA, CEPHALALGIA, AND TONIC POSTURAL 
ACTIVITY PROBLEMS RECORDED WITH STATOKINESIMETER IN 
POSTCONCUSSIONAL- SYNDROME. 

004472 04-1 1 
DEAFNESS 

A CASE OF REVERSIBLE PURE-WORD DEAFNESS DURING LITHIUM 
TOXICITY. 

003481 03-15 
DEALING 

EXPERIMENTATION WITH MINAPRINE IN DEALING WITH CERTAIN 
SEXUAL-DISORDERS: IMPOTENCE OR FRIGIDITY. 

002153 02-11 
DEAMINATION 

SPECIES-DIFFERENCES IN THE DEAMINATION OF DOPAMINE AND OTHER 
SUBSTRATES FOR MONOAMINE-OXIDASE IN BRAIN. 

002233 02-13 
DEANOL 

DIMETHYLAMINOETHANOL (DEANOL) METABOLISM IN RAT-BRAIN AND 
ITS EFFECT ON ACETYLCHOLINE SYNTHESIS. 

000150 01-03 
ON THE THERAPY OF NEUROLEPTIC-INDUCED TARDIVE-DYSKINESIA WITH 
DIMETHYLAMINOETHANOL (DEANOL). 

004627 04-15 
GAS-CHROMATOGRAPHY/MASS-SPECTROMETRY STABLE ISOTOPIC 
ANALYSES FOR DEANOL, CHOLINE. AND THEIR ACETYLESTERS. 

004683 04-16 
DEATH 

THE MYTHOLOGEM OF REVERSIBLE DEATH. THE ANALYTICAL 

CONFRONTATION OF ENDOGENOUS DELIRIUM WITH DELUSIONS IN 
PSYCHEDELIC-EXPERIENCES. 

002200 02-12 
AMITRIPTYLINE PROVIDES LONG-LASTING IMMUNIZATION AGAINST 
SUDDEN CARDIAC DEATH FROM COCAINE. 

003122 03-05 
EXCEPTIONAL CASES OF DEATH CAUSED BY TRICYCLIC-ANTIDEPRESSANT 
AGENTS. 

003490 03-15 



Ptychopharmacology Abstracts 



THE EFFEQ OF ADENOSINE AND GUANOSINE ON THE CONTENT OF 
SEROTONIN AND CATECHOLAMINES IN THE BRAIN IN THE 
RESTORATION PERIOD FOLLOWING EXPERIMENTAL CLINICAL DEATH. 

003882 04-03 
DEATHS 

MEDICATION USE AND DEATHS AHRIBUTED TO ASPHYXIA AMONG 
PSYCHIATRIC-PATIENTS. 

000838 01-15 
DEAZAADENOSINE 

ANTIVIRAL ACTIVITY OF 3 DEAZAADENOSINE AND 5' 

DEOXYISOBUTYLTHIO-3-DEAZAADENOSINE (3 DEAZA-SIBA). 
(UNPUBLISHED PAPER). 

001006 02-01 
THE HYPOTENSIVE-ACTION OF 3 DEAZAADENOSINE. 

001415 02-03 
DEAZAADENOSYLHOMOCYSTEINE 

INHIBITION OF CHEMOTAXIS BY S 3 DEAZAADENOSYLHOMOCYSTEINE IN 
A MOUSE MACROPHAGE CELL LINE. (UNPUBLISHED PAPER). 

001100 02-03 
DEBATE 

DEBATE: THERAPEUTIC TRIALS IN A NATURAL ENVIRONMENT. 

003635 03-17 
DEBRISOQUINE 

NORTRIPTYLINE AND ANTIPYRINE CLEARANCE IN RELATION TO 
DEBRISOQUINE HYDROXYLATION IN MAN. 

000754 01-13 
DEBRUMYL 

CEREBRAL SENESCENCE AND ITS PSYCHIC-MANIFESTATIONS. THE 
EFFECTIVENESS OF DEBRUMYL. 

002105 02-11 
DECARBOXYLASE 

THE TREATMENT OF PARKINSONS-DISEASE USING A COMBINATION OF L- 
DOPA AND DECARBOXYLASE INHIBITORS (CARBIDOPA, BENSERASIDE). 
A CLINICAL AND BIOCHEMICAL COMPARATIVE INVESTIGATION. 

000712 01-11 
DECARBOXYLATION 

DECARBOXYLATION OF EXOGENOUS L-DOPA IN RAT STRIATUM AFTER 
LESIONS OF THE DOPAMINERGIC NIGROSTRIATAL NEURONS: THE ROLE 
OF STRIATAL CAPILLARIES 

000202 01-03 
DECEPTION 

MEPROBAMATE REDUCES ACCURACY OF PHYSIOLOGICAL DETEQION OF 
DECEPTION. 

004585 04-14, 
DECISIONS 

AN ANALYSIS OF DRUG DECISIONS IN A STATE PSYCHIATRIC-HOSPITAL. 

003593 03-17 
DECOMPOSITION 

DECOMPOSITION OF PHARMACOLOGICAL AQIVITY INDICES INTO 
MUTUALLY INDEPENDENT COMPONENTS USING PRINCIPAL 
COMPONENT ANALYSIS. 

001039 02-01 ■ 
DECONDITIONING 

CLASSICAL NEUROLEPTICS AND DECONDITIONING AQIVITY AFTER SINGLE. 
OR REPEATED TREATMENTS: ROLE OF DIFFERENT CEREBRAL 
NEUROTRANSMIHERS 

004115 04-04 

DECORTICATION 

INTERMIHENT DECORTICATION AND PROGRESSIVE HYPERTHERMIA, 
HYPERTENSION AND TACHYCARDIA FOLLOWING METHYLGLUCAMINE 
lOTHALAMATE VENTRICULOGRAM. 

003520 03-15 
DECREASING 

FACTORS REGULATING DRUG CUE SENSITIVITY: LIMITS OF 
DISCRIMINABILITY AND THE ROLE OF A PROGRESSIVELY DECREASING 
TRAINING DOSE IN FENTANYL SALINE DISCRIMINATION. 

004088 04-04 
MEASUREMENTS OF NERVE CONDUQION VELOCITY DURING DECREASING 
TOXIC DIPHENYLHYDANTOIN LEVELS AND THE BEGINNING OF | 

CARBAMAZEPINE MEDICATION: A CLINICAL NEUROPHYSIOLOGICAL 
REPORT. 

004441 04-11 

DEEPER * 

THE STEREOSPECIFIC EFFEQ OF NALOXONE ON RAT DORSAL-HORN 
NEURONES, INHIBITION IN SUPERFICIAL LAMINAE AND EXCITATION IN 
DEEPER LAMINAE 

001226 02-03 

DEERMICE 

DIFFERENCES IN AQIVITY IN CEREBRAL METHYLTRANSFERASES AND 
MONOAMINE-OXIDASES BETWEEN AUDIOGENIC-SEIZURE SUSCEPTIBLE 
AND RESISTANT MICE AND DEERMICE 

000377 01-04 

DEFENSE 

THE INFLUENCE OF NOOTROPIC-DRUGS ON LEARNING AND MEMORY OF 
DEFENSE REAQIONS. 

00081501-14 



S-124 



\ 



::^y. 



VOLUME 19, SUBJECT INDEX 



Subject Index 



DEFENSIVE 

CONDITIONING AND RETENTION OF DEFENSIVE BURYING AS A FUNCTION 
OF ELAVIL AND THORAZINE INJECTION 

002974 03-04 
DEFENSIVE-BEHAVIOR 

ADRENERGIC MODULATION OF THE HYPOTHALAMIC CHOLINERGIC 
MECHANISM IN THE CONTROL OF EMOTIONAL DEFENSIVE-BEHAVIOR IN 
THE CAT. 

001761 02-04 
CHOLINERGIC, DOPAMINERGIC, NORADRENERGIC, OR GLUTAMINERGIC 
STIMULATION VENTRAL TO THE ANTERIOR SEPTUM DOES NOT 
SPECIFICALLY SUPPRESS DEFENSIVE-BEHAVIOR. 

002945 03-04 
DEFICIENCY 

DRUG-THERAPY IN ENDOGENOUS DEPRESSION WITH POSSIBLE PRIMARY 
GABA DEFICIENCY CLINICALLY DETECTED: 38 NEW CASES. 

000584 01-09 
THE ROLE OF FOLATE DEFICIENCY IN THE DEVELOPMENT OF PERIPHERAL 
NEUROPATHY CAUSED BY ANTICONVULSANTS. 

002402 02-15 
PLASMA FREE AND TOTAL TRYPTOPHAN, BLOOD SEROTONIN, AND THE 
HYPERACTIVITY-SYNDROME: NO EVIDENCE FOR THE SEROTONIN 
DEFICIENCY HYPOTHESIS. 

003312 03-11 
DEFICIENT 

A PRELIMINARY OPEN-STUDY OF THE USE OF AMINEPTINE OF THE 
DEFICIENT SYNDROME OF HEBEPHRENICS AND OF ADDICTS DURING 
WITHDRAWAL. 

004445 04-1 1 
DEFICIT-DISORDER 

AHENTION DEFICIT-DISORDER (MINIMAL-BRAIN-DYSFUNCTION) IN 
ADULTS: A REPLICATION STUDY OF DIAGNOSIS AND DRUG- 
TREATMENT. 

003389 03-1 1 
DEFICITS 

LATERALIZED DEFICITS AND DRUG INFLUENCES ON THE DICHOTIC 
LISTENING OF SCHIZOPHRENIC-PATIENTS. 

003443 03-14 
DEFINITION 

OPIATE-RECEPTORS: PROBLEMS OF DEFINITION AND CHARACTERIZATION. 

002620 02-17 
DEFORMING 

PROBLEMS OF TREATING DEFORMING MYODYSTONIA WITH L-DOPA, 
AND PREDICTION OF ITS THERAPEUTIC EFFECT. 

004536 04-13 
DEGENERATION 

LOCAL AND DISTANT NEURONAL DEGENERATION FOLLOWING 
INTRASTRIATAL INJEQION OF KAINIC-ACID. 

001885 02-06 
SPINOCEREBELLAR DEGENERATION WITH PARKINSONIAN FEATURES: A 
CLINICAL AND PATHOLOGICAL REPORT. 

003436 03-13 
DEGRADATION 

MODIFICATION OF THE PROLINE RESIDUE OF TRH ENHANCES BIOLOGICAL- 
AQIVITY AND INHIBITS DEGRADATION. 

000351 01-04 
AN INHIBITOR OF OPIOID-PEPTIDE DEGRADATION PRODUCES ANALGESIA 
IN MICE. 

001780 02-04 
EFFEaS OF BRANCHED-CHAIN FAHY-ACIOS ON GABA DEGRADATION 
AND BEHAVIOR: FURTHER EVIDENCE FOR A ROLE OF GABA IN QUASI- 
MORPHINE ABSTINENCE-BEHAVIOR. 

001809 02-04 
THE EFFECT OF BARBITURATES ON THE DEGRADATION OF ENKEPHALIN BY 
BRAIN ENZYMES. 

002656 03-03 
DEINSTITUTIONALIZATION 

A TWELVE-YEAR FOLLOWUP OF THE NIMH-PRB HIGH-DOSE 
CHLORPROMAZINE STUDY OF CHRONIC SCHIZOPHRENICS - 
IMPLICATIONS FOR DEINSTITUTIONALIZATION. (UNPUBLISHED PAPER) 

004323 04-08 
DELANGE-SYNDROME 

PEMOLINE-INDUCED SELF-BITING IN RATS AND SELF-MUTILATION IN THE 
DELANGE-SYNDROME. 

001727 02-04 
DELAYED 

DELAYED CLEARANCE OF DIAZEPAM DUE TO CIMETIDINE. 

000164 01-03 
BETA-ADRENOCEPTOR ANTAGONISTS: STUDIES ON BEHAVIOUR (DELAYED 
DIFFERENTIATION) IN THE MONKEY (MACACA-MULAHA). 

000440 01-04 
AROUSAL AND SHORT-TERM MEMORY: EFFECTS OF CAFFEINE AND TRIAL 
SPACING ON DELAYED ALTERNATION PERFORMANCE. 

000487 01-04 
DELAYED MAZE-LEARNING IN RATS AFTER PRENATAL EXPOSURE TO 
CLORAZEPATE. 

000521 01-05 
EFFECTS OF HALOPERIDOL, A DOPAMINE-RECEPTOR ANTAGONIST, ON A 
DELAYED TYPE HYPERSENSITIVITY REACTION TO 1 
CHLORODINITROBENZENE IN MICE. 

001473 02-03 



THE EFFECT OF PHRENOLON ON DELAYED REACTIONS IN LOWER 
MONKEYS. 

001640 02-04 
EFFECTS OF THIORIDAZINE (MELLARIL) ON TITRATING DELAYED 
MATCHING-TO-SAMPLE PERFORMANCE IN MENTALLY-RETARDED 
ADULTS, 

002471 02-15 
EFFECTS OF THIORIDAZINE (MELLARIL) ON TITRATING DEUYED 
MATCHING-TO-SAMPLE PERFORMANCE OF MENTALLY-RETARDED 
ADULTS. 

003392 03-1 1 
CAFFEINE BLOCKS THE DELAYED K OUTWARD-CURRENT OF MOLLUSCAN 
NEURONS. 

003834 04-03 
THE EFFECT OF THIOPROPERAZINE ON DELAYED REACTIONS IN LOWER 
MONKEYS. 

004125 04-04 
DELIMITED 

PSYCHIATRIC-ILLNESS AND USE OF PSYCHOTROPIC-DRUGS IN THE 
GEOGRAPHICALLY DELIMITED POPULATION OF SAMSO, DENMARK. 

004734 04-17 
DELIRIUM 

DELIRIUM: TREATMENT POSSIBILITIES. 

002141 02-11 
DELIRIUM OR PSYCHOSIS? DIAGNOSTIC USE OF THE SODIUM- 
AMOBARBITAL INTERVIEW. 

002167 02-11 
THE MYTHOLOGEM OF REVERSIBLE DEATH. THE ANALYTICAL 

CONFRONTATION OF ENDOGENOUS DELIRIUM WITH DELUSIONS IN 
PSYCHEDELIC-EXPERIENCES. 

002200 02-12 
DIFFERENTIAL DIAGNOSIS OF CIMETIDINE-INDUCED DELIRIUM. 

003488 03-15 
DELIRIUM SECONDARY TO CLONIDINE THERAPY. 

003494 03-15 
DELIRIUM-TREMENS 

FLUNITRAZEPAM IN THE TREATMENT OF DELIRIUM-TREMENS - 
PRELIMINARY REPORT. 

000719 01-11 
PHYSOSTIGMINE FOR TREATMENT OF DELIRIUM-TREMENS. 

003364 03-11 
A COMPARATIVE EVALUATION OF THE EFFICACY OF SOME THERAPEUTIC 
METHODS USED IN DELIRIUM-TREMENS. 

004486 04-11 
DELIVERY 

AVAILABILITY OF ISOSORBIDE-DINITRATE, DIAZEPAM AND 
CHLORMETHIAZOLE, FROM I.V. DELIVERY SYSTEMS. 

003558 03-16 
DELTA-FORMS 

INTERCONVERTING MU AND DELTA-FORMS OF TYPE-1 OPIATE-RECEPTORS 
IN THE RAT STRIATAL PATCHES. 

003737 04-03 
DELTA-RECEPTOR 

METKEPHAMID, A SYSTEMICALLY ACTIVE ANALOG OF METHIONINE- 
ENKEPHALIN WITH POTENT OPIOID DELTA-RECEPTOR ACTIVITY. 

002720 03-03 
DELTA-RECEPTORS 

EFFECTS OF CHANGES IN THE STRUCTURE OF ENKEPHALINS AND OF 
NARCOTIC ANALGESIC-DRUGS ON THEIR INTERACTIONS WITH MU- 
RECEPTORS AND DELTA-RECEPTORS. 

000168 01-03 
DELUSIONAL 

THREE CASES OF UNIPOLAR DELUSIONAL DEPRESSION RESPONSIVE TO L- 
DOPA. 

000628 01-09 
DELUSIONAL-STATES 

HALLUCINATORY AND DELUSIONAL-STATES IN CONNECTION WITH BLOOD- 
PRESSURE AND EEG. 

000814 01-14 
DELUSIONS 

THE MYTHOLOGEM OF REVERSIBLE DEATH. THE ANALYTICAL 
CONFRONTATION OF ENDOGENOUS DELIRIUM WITH DELUSIONS IN 
PSYCHEDELIC-EXPERIENCES. 

002200 02-12 
DEMENTIA 

AGE, DEMENTIA, DYSKINESIAS, AND LITHIUM RESPONSE. 

000594 01-09 
NEUROLOGICAL-STUDY AND NEUROPSYCHOPHARMACOLOGY-STUDY ON 
DEMENTIA. 

001090 02-11 
DRUG-INDUCED DEMENTIA. 

002431 02-15 
PHARMACOLOGIC AND THERAPEUTIC-PERSPECTIVES ON DEMENTIA: AN 
EXPERIMENTAL APPROACH 

003065 03-04 
DOPAMINE AND DEMENTIA. AN ANIMAL-MODEL WITH DESTRUCTION OF 
THE MESOCORTICAL DOPAMINERGIC PATHWAY: A PRELIMINARY 
STUDY. 

003085 03-04 



I 



•at 
Hi- 



*t!lMi>i 



A 
tin-., 

IL'Li" 



S-125 



Subiect Index 



PHARMACOLOGIC CHARACTERIZATION AND LECITHIN TREATMENT OF A 
PATIENT WITH SPONTANEOUS ORAL FACIAL DYSKINESIA AND 

DEMENTIA. „„^o.-,^o,, 

003347 03-11 

USE OF THA IN TREATMENT OF ALZHEIMER-LIKE DEMENTIA: PILOT-STUDY 

IN TWELVE PATIENTS. „„oo-,-, «o , , 

003377 03-11 

LEVELS OF 5 HYDROXYINDOLEACETIC-ACID AND TRYPTOPHAN IN 
LUMBAR CEREBROSPINAL-FLUID AND BLOOD OF PATIENTS WITH 
DEMENTIA AND NORMAL PRESSURE HYDROCEPHALUS AFTER 
TRYPTOPHAN ADMINISTRATION. ^ ^ 

003419 03-13 

EXTRAPYRAMIDAL-DISORDERS AND BORDERLINE-SYNDROMES. 

EREDOATAXIAS AND DEMENTIA. 003518 03-15 

EVALUATION OF DRUG EFFICACY IN DEMENTIA: A COMPUTERIZED 
COGNITIVE ASSESSMENT SYSTEM. 003557 03-16 

SINGLE-CASE STUDY OF CLINICAL-RESPONSE TO HIGH-DOSE ERGOT 
ALKALOID TREATMENT FOR DEMENTIA. PRELIMINARY REPORT. 

004493 04-11 

CHOLINE-BITARTRATE TREATMENT OF ALZHEIMER-TYPE DEMENTIAS. 

000675 01-11 

PLASMA IMIPRAMINE LEVELS AND DEMETHYLASE ACTIVITY IN THE 
LIVER OF STRESSED ANIMALS. „„„,„, „„ „, 

002793 03-03 

PHARMACODYNAMIC PROFILES OF L ALPHA ACETYLMETHADOL (LAAM) 
AND ITS N DEMETHYLATED METABOLITES, NORLAAM AND 
DINORLAAM DURING SELF-ADMINISTRATION IN THE DEPENDENT RAT. 

000505 01-04 

CHANGES IN BRAIN N DEMETHYUVTION AND OPIATE-RECEPTOR CONTENT 
CORRELATE WITH ANALGESIC EFFECTIVENESS OF MORPHINE 

000400 01-04 
INTERINDIVIDUAL DIFFERENCES IN AMITRIPTYLINE DEMETHYLATION. 

002282 02-13 
DEMETHYLCHLORIMIPRAMINE 

TECHNIQUES FOR PLASMA PROTEIN BINDING OF 

DEMETHYLCHLORIMIPRAMINE. ^„„, „, ,, 

000897 01-16 

DEMETRIN 

THE TRANQUILIZER DEMETRIN (PRAZEPAM). 

003331 03-11 

DEMONSTRATION 

DEMONSTRATION OF SUBSTANCE-P IN AORTIC NERVE AFFERENT FIBERS 
BY COMBINED USE OF FLOURESCENT RETROGRADE NEURONAL 
LABELING AND IMMUNOCYTOCHEMISTRY. (UNPUBLISHED PAPER). 

001024 02-01 

A DEMONSTRATION OF NALOXONE PRECIPITATED OPIATE WITHDRAWAL 
ON SINGLE NEURONES IN THE MORPHINE-TOLERANT/DEPENDENT RAT- 

^'^^'^- 001234 02-03 

CENTRAL PHARMACOLOGICAL CONTROL OF CORTICOSTERONE SECRETION 
IN THE INTACT RAT. DEMONSTRATION OF CHOLINERGIC AND 
SEROTONINERGIC FACILITATORY AND ALPHA-ADRENERGIC INHIBITORY 

MECHANISMS. 

001487 02-03 

DEMONSTRATION AND CHARACTERIZATION OF AN ENDOGENOUS 
INHIBITOR OF GABA-ENHANCED (3H) DIAZEPAM BINDING FROM 
BOVINE CEREBRAL-CORTEX. 

002645 03-01 

QUANTITATION AND COMPARISON OF PHENOBARBITAL LEVELS IN THE 
PLASMA SALIVA, AND CEREBROSPINAL-FLUID OF THE RAT, AND THE 
DEMONSTRATION OF AN ALTERATION OF DRUG PASSAGE BY 

^™^^°^ 003725 04-03 

DEMONSTRATION OF A MUSCARINIC-RECEPTOR-MEDIATED CYCLIC-GMP- 
DEPENDENT HYPERPOLARIZATION OF THE MEMBRANE POTENTIAL OF 
MOUSE NEUROBLASTOMA CELLS USING 
(3H)TETRAPHENYLPH0SPH0NIUM. 

004049 04-03 
BUPRENORPHINE: DEMONSTRATION OF PHYSICAL-DEPENDENCE LIABILITY. 

004104 04-04 

DEMYELINATION 

THE PATHOGENESIS OF PRIMARY INTERNODAL DEMYELINATION 

PRODUCED BY ACETYL-ETHYL-TETRAMETHYL-TETRALIN: EVIDENCE FOR 
PRESERVED SCHWANN-CELL SOMAL FUNCTION. 

002905 03-03 

DENDRITIC 

EFFECTS OF LEAD EXPOSURE DURING DEVELOPMENT ON NEOCORTICAL 

DENDRITIC AND SYNAPTIC STRUCTURE. 

000525 01-05 
ELECTRON MICROSCOPIC STUDIES OF BRAIN SLICES: THE EFFECTS OF 

HIGH-FREQUENCY STIMULATION ON DENDRITIC ULTRASTRUCTURE. 

(UNPUBLISHED PAPER). „„,„^, „o ^, 

001036 02-01 



Psychopharmacology Abstracts 

DENDROASPIS 

A CRITICAL EVALUATION OF THE USE OF TOXINS FROM DENDROASPIS 
VIRIDIS TO BLOCK NICOTINIC RESPONSES AT CENTRAL AND 
GANGLIONIC SYNAPSES 

002870 03-03 

DENERVATED 

REINNERVATION OF THE DENERVATED STRIATUM BY SUBSTANTIA-NIGRA 
TRANSPLANTS: FUNCTIONAL CONSEQUENCES AS REVEALED BY 
PHARMACOLOGICAL AND SENSORIMOTOR TESTING. 

000347 01-04 

DENERVATION 

MONOAMINERGIC DENERVATION OF THE RAT HIPPOCAMPUS: 

MICROIONTOPHORETIC STUDIES OF PRESYNAPTIC AND POSTSYNAPTIC 
SUPERSENSITIVITY TO NOREPINEPHRINE AND SEROTONIN 

000068 01-03 
CHRONIC SYMPATHETIC DENERVATION INCREASES MUSCARINIC- 
CHOLINOCEPTOR BINDING IN THE RAT SUBMAXILLARY-GLAND. 

000235 01-03 
IN VIVO EFFEQ OF PROTEASE INHIBITORS IN DENERVATION ATROPHY. 

000290 01-03 
THE MESOLIMBIC SYSTEM, DENERVATION AND THE CLIMBING RESPONSE 
IN THE MOUSE 

000370 01-04 
RELATIONSHIPS BETWEEN SELEQIVE DENERVATION OF DOPAMINE 
TERMINAL-FIELDS IN THE ANTERIOR-FOREBRAIN AND BEHAVIORAL- 
RESPONSES TO AMPHETAMINE AND APOMORPHINE. 

000384 01-04 
DENERVATION SUPERSENSITIVITY TO SEROTONIN IN THE FACIAL 
NUCLEUS. 

001364 02-03 
THE EFFECT OF CYCLO-LEU-GLY ON CHEMICAL DENERVATION 
SUPERSENSITIVITY OF DOPAMINE-RECEPTORS INDUCED BY 
INTRACEREBROVENTRICULAR INJECTION OF 6 HYDROXYDOPAMINE IN 

'^'" 001435 02-03 

DENERVATION IN THE DOPAMINERGIC MESOLIMBIC SYSTEM: 
FUNCTIONAL CHANGES FOLLOWED USING (-)N N 
PROPYLNORAPOMORPHINE DEPEND ON THE BASAL AQIVITY LEVELS 

OF RATS. „„, 

001603 02-04 

DENERVATION SUPERSENSITIVITY TO 5 HYDROXYTRYPTOPHAN IN RATS 
FOLLOWING SPINAL TRANSECTION AND 5,7 DIHYDROXYTRYPTAMINE 

"^^^™ 003722 04-03 

DENERVATION-INDUCED 

REVERSAL OF NORADRENALINE DENERVATION-INDUCED INCREASE OF 
BETA-ADRENORECEPTOR BINDING IN RAT NEOCORTEX BY 
NORADRENALINE INFUSION. 

002672 03-03 i 

DENMARK , , ,^ 

PSYCHIATRIC-ILLNESS AND USE OF PSYCHOTROPIC-DRUGS IN THE 
GEOGRAPHICALLY DELIMITED POPULATION OF SAMSO, DENMARK. 

004734 04-17 

DENSE-BODIES 

PREPARATION AND CHARACTERIZATION OF SYNTHETIC MODELS FOR THE 
DENSE-BODIES OF HUMAN PLATELETS (UNPUBLISHED PAPER) j 

001013 02-01 I 

ELECTRON PROBE MICROANALYSIS OF CALCIUM AND PHOSPHORUS IN 
DENSE-BODIES ISOLATED FROM HUMAN PLATELETS. (UNPUBLISHED 

''^''^'^' 001014 02-01. 

QUINACRINE AND SEROTONIN BINDING BY SYNTHETIC MODELS FOR 
HUMAN PLATELET DENSE-BODIES: EVALUATION OF THE ROLE OF 
BINDING IN AMINE STORAGE. (UNPUBLISHED PAPER). 

AGONIST-INDUCED CHANGES IN BETA-ADRENERGIC-RECEPTOR DENSITY 
AND RECEPTOR-MEDIATED RESPONSIVENESS IN SLICES OF RAT- 
CEREBRAL-CORTEX. 000072 01^ 

DECREASED BENZODIAZEPINE-RECEPTOR DENSITY IN RAT-CEREBELLUM 
FOLLOWING NEUROTOXIC DOSES OF PHENYTOIN qq, 373 02-03 

DEOXY-D-GLUCOSE 

METABOLIC-CORRELATES OF THE EFFEQS OF 2 DEOXY-D-GLUCOSE ON 
MEAL SIZE AND POST MEAL SATIETY IN RATS. ^^^^^ ^^^ 

ANALGESIA FOLLOWING INTRAVENTRICULAR ADMINISTRATION OF 2 
DEOXY-D-GLUCOSE. 004074 04-04 

DEOXY-D-GLUCOSE-INDUCED 

ANTAGONISM OF 2 DEOXY-D-GLUCOSE-INDUCED HYPERPHAGIA BY 
NALOXONE: POSSIBLE INVOLVEMENT OF ENDORPHINS. ^^^^ ^^^ 



DEOXYCORTICOSTERONE 

RENAL BENZODIAZEPINE BINDING INCREASES DURING 
DEOXYCORTICOSTERONE /SALT HYPERTENSION IN RATS. 



001430 02-03 



S-126 




VOLUME 19, SUBJECT INDEX 



Subject Index 



lEOXYOLUCOSE 

THEORY, PROCEDURE, AND APPLICATIONS OF THE RADIOACTIVE 

DEOXYGLUCOSE METHOD FOR THE MEASUREMENT Of LOCAL GLUCOSE 
UTILIZATION IN THE CENTRAL-NERVOUS-SYSTEM. (UNPUBLISHED 
PAPER). 

001877 02-06 
)EOXYISOBUTYLTHIO-3-DEAZAADENOSINE 

ANTIVIRAL ACTIVITY OF 3 DEAZAADENOSINE AND 5' 
OEOXYISOBUTYLTHIO-3-DEAZAADENOSINE (3 DEAZA-SIBA). 
(UNPUBLISHED PAPER). 

001006 02-01 
>EOXYPIPRA0ROL 

COMPARISON OF THE EFFECTS OF THE ISOMERS OF AMPHETAMINE, 
METHYLPHENIDATE AND DEOXYPIPRADROL ON THE UPTAKE OF L 
(3H)N0REPINEPHRINE AND (3H)D0PAMINE BY SYNAPTIC VESICLES 
FROM RAT-WHOLE-BRAIN, STRIATUM AND HYPOTHALAMUS. 

000091 01-03 
>EPAKINE 

PRELIMINARY EVALUATION OF THE EFFECTS OF DEPAKINE IN EPILEPSY. 

000664 01-11 
lEPENDENCE 

CHANGES IN PLASMA CORTICOSTERONE LEVELS AS A MEASURE OF 
ACUTE DEPENDENCE UPON LEVORPHANOL IN RATS. 

000085 01-03 
ROTATIONAL-BEHAVIOR INDUCED BY COCAINE ANALOGS IN RATS WITH 
UNILATERAL 6 HYDROXYDOPAMINE LESIONS OF THE SUBSTANTIA- 
NIGRA: DEPENDENCE UPON DOPAMINE UPTAKE INHIBITION. 

000404 01-04 
DEPENDENCE OF THE AVFAIL EFFECT ON THE SEQUENCE OF TRAINING 
OPERATIONS. 

001086 02-02 
DEVELOPMENT OF ACUTE OPIOID-TOLERANCE AND DEPENDENCE IN RAT 
STRIATAL NEURONES. 

001235 02-03 
THE EFFECT OF NALOXONE ON THE ACTIVATION OF EMOTIONALLY 
POSITIVE REACTION PRODUCED BY DRUGS WITH A DEPENDENCE 
LIABILITY. 

001556 02-03 
PENTYLENETETRAZOL SEIZURE THRESHOLD: A QUANTITATIVE MEASURE 
OF ETHANOL DEPENDENCE IN RATS. 

001750 02-04 
EXPERIMENTAL DEPENDENCE ON BARBITURATES: II. RELATIONSHIP 
BETWEEN DRUG LEVELS IN SERUM AND BRAIN AND THE 
DEVELOPMENT OF DEPENDENCE IN RATS. 

001800 02-04 
SELF-MEDICATION, ABANDONMENT, MANIPULATION, AND DEPENDENCE 
IN DRUG-THERAPY IN PSYCHOSOMATIC-ILLNESS: COMPARATIVE 
POLYCENTRIC RESEARCH ON VARIOUS PSYCHOTROPIC-DRUGS. 

002189 02-11 
TREATMENT OF IATROGENIC DRUG DEPENDENCE IN THE GENERAL- 
HOSPITAL. 

002460 02-15 
DEPENDENCE ON BENZODIAZEPINES. 

002464 02-15 
DEPENDENCE ON TRANQUILIZERS (AN OVERVIEW WITH (CASE-STUDIES). 

003580 03-17 
DRUG DEPENDENCE: REFLECTIONS ON AND ANALYSIS OF AN EXPERIENCE 
IN THE PROVINCE OF RIGGIO-EMILIA. 

003591 03-17 
A REFORMULATION OF THE DUAL-ACTION MODEL OF OPIOID 
DEPENDENCE: OPIOID-SPECIFIC NEURONAL KINDLING. 

003645 03-17 
COMPARATIVE ANALGESIC, BEHAVIORAL, AND DEPENDENCE PROPERTIES 
OF MORPHINE AND 

METHOXYLPHENYLCARBAMOYLDIETHYLAMINOPROPIOPHENONEOXIME 
HCL. 

003707 04-02 
GABA-ENHANCEMENT OF (3H)D0PAMINE RELEASE FROM SLICES OF RAT 
STRIATUM: DEPENDENCE ON SLICE SIZE. 

003786 04-03 
CNS EFFECTS OF CHOLINE ADMINISTRATION: EVIDENCE FOR TEMPORAL 
DEPENDENCE. 

003996 04-03 
OPIOID DEPENDENCE: MECHANISMS AND TREATMENT. 

004587 04-14 
AN UNUSUAL CASE OF THIORIDAZINE AND LEVOMEPROMAZINE 
DEPENDENCE. 

004634 04-15 
lEPENDENCY 

DRUG ENVIRONMENT INTERACTION: CONTEXT DEPENDENCY OF COCAINE- 
INDUCED BEHAVIORAL-SENSITIZATION . 

002866 03-03 

A NOTE ON THE PARADOXICAL-EFFECT OF STIMULANTS ON 

HYPERACTIVITY WITH REFERENCE TO THE RATE DEPENDENCY EFFECT 
OF DRUGS. 

003320 03-11 
lEPENDENT 

THE EFFECT OF PROPRANOLOL ON THE ELEaROENCEPHALOGRAM IN 
NORMAL AND ETHANOL DEPENDENT RATS. 

000126 01-03 



STRAIN DEPENDENT EFFECTS OF KETAMINE ON LOCOMOTOR-ACTIVITY 
AND ANTINOCICEPTION IN MICE. 

000382 01-04 
PHARMACODYNAMIC PROFILES OF L ALPHA ACETYLMETHADOL (LAAM) 
AND ITS N DEMETHYUVTED METABOLITES, NORLAAM AND 
DINORLAAM, DURING SELF-ADMINISTRATION IN THE DEPENDENT RAT. 

000505 01-04 
OPIOID DEPENDENT DUAL-REGULATION OF ADENYLATE-CYCLASE IN A 
CELL-FREE SYSTEM (UNPUBLISHED PAPER). 

001033 02-01 
A DEMONSTRATION OF NALOXONE PRECIPITATED OPIATE WITHDRAWAL 
ON SINGLE NEURONES IN THE MORPHINE-TOLERANT/DEPENDENT RAT- 
BRAIN. 

001234 02-03 
AGE DEPENDENT CHANGES IN THE BETA ENDORPHIN CONTENT OF 
DISCRETE RAT-BRAIN NUCLEI. 

002635 03-01 
NEURONAL MATURATION IN MAMMALIAN CELL-CULTURE IS DEPENDENT 
ON SPONTANEOUS ELECTRICAL-ACTIVITY. 

002669 03-03 
THE RELATIONSHIP BETWEEN THE ACUTE BEHAVIORAL-EFFECTS OF 
NARCOTIC ANTAGONISTS AND THE NARCOTIC DEPENDENT STATE. 

003106 03-04 
THE EFFECT OF SODIUM-DIPROPYLACETATE ON GAMMA AMINOBUTYRIC- 
ACID DEPENDENT INHIBITION IN THE RAT-CORTEX AND SUBSTANTIA- 
NIGRA IN RELATION TO ITS ANTICONVULSANT ACTIVITY. 

003880 04-03 
SCHEDULE DEPENDENT CHANGE OF PUNISHED-RESPONDING AFTER 
DIAZEPAM IN RATS. 

004165 04-04 
EFFECTS OF NARCOTIC ABSTINENCE ON SCHEDULE-CONTROLLED 
BEHAVIOR IN DEPENDENT RATS. 

004230 04-04 
DEPENDING 

TWO OR MORE CONFORMATIONS OF BENZODIAZEPINE-RECEPTORS 
DEPENDING ON GABA-RECEPTORS AND OTHER VARIABLES. 

001139 02-03 
DEPENDS 

INVOLVEMENT OF DOPAMINE IN CIRCLING RESPONSES TO MUSCIMOL 
DEPENDS ON INTRANIGRAL SITE OF INJECTION. 

004158 04-04 
DEPLETED 

COMPARISON OF HIGHLY-ACTIVE AND ACTIVITY DEPLETED HEPARIN BY 
CIRCULAR DICHROISM SPECTROSCOPY. (UNPUBLISHED PAPER). 

001057 02-01 
DEPLETES 

INTRANIGRAL INJECTION OF CAPSAICIN ENHANCES MOTOR-ACTIVITY 
AND DEPLETES NIGRAL 5 HYDROXYTRYPTAMINE BUT NOT SUBSTANCE- 
P. 

004100 04-04 
DEPLETING 

INFLUENCE OF MONOAMINE DEPLETING PHARMACOLOGIC-AGENTS ON 
LEVELS OF ACTIVITY IN CAIMAN-SCLEROPS. 

001810 02-04 
DEPLETION 

DEPLETION OF EPINEPHRINE IN RAT HYPOTHALAMUS BY RO-4-1284: 
INFLUENCE OF PARGYLINE AND HARMALINE. 

000100 01-03 
THE CONVERSION OF (3H)TRYPT0PHAN TO 5 (3H)HYDR0XYTRYPTAMINE 
IN MOUSE-BRAIN FOLLOWING DEPLETION OF PHENYLALANINE AND 
TYROSINE. 

000148 01-03 
EFFECTS OF BRAIN-MONOAMINE DEPLETION ON THERMOREGULATORY 
RESPONSES OF RABBITS TO DIFFERENT HYPOTHALAMIC 
TEMPERATURES. 

000190 01-03 
GABA DEPLETION AND BEHAVIOURAL-CHANGES PRODUCED BY 
INTRAVENTRICULAR PUTRESCINE IN CHICKS. 

000218 01-03 
A COMPARISON OF RATES OF DEPLETION AND RECOVERY OF 
NORADRENALINE STORES OF PERIPHERAL AND CENTRAL 
NORADRENERGIC NEURONES AFTER RESERPINE ADMINISTRATION: 
IMPORTANCE OF NEURONAL ACTIVITY. 

000314 01-03 
INTRAVENTRICULAR 6 HYDROXYDOPAMINE IN THE NEWBORN RAT AND 
LOCOMOTOR RESPONSES TO DRUGS IN INFANCY: NO SUPPORT FOR 
THE DOPAMINE DEPLETION MODEL OF MINIMAL-BRAIN-DYSFUNCTION. 

000448 01-04 
THE EFFECT OF SEROTONIN DEPLETION ON THE DISCRIMINABILITY OF LSD. 

000499 01-04 
LITHIUM ANTAGONISM OF ETHANOL-INDUCED DEPLETION OF CEREBELLAR 
GUANOSINE-CYCLIC-MONOPHOSPHATE AND STIMULATION OF 
STRIATAL DOPAMINE RELEASE. 

002242 02-13 
DOPAMINE DEPLETION SLOWS RETINAL TRANSMISSION. 

002708 03-03 
GABA DEPLETION IN CHICK BRAINSTEM AFTER INTRAVENTRICULAR 
INJECTION OF CEFAZOLIN. 

002762 03-03 



.11 



•IS' 

iic 






«B;. 

Ac 



S-127 



Subject Index 

NOREPINEPHRINE DEPLETION ALTERS CEREBRAL OXIDATIVE METABOLISM 
IN THE ACTIVE STATE. 

002798 03-03 
SUBSTANCE-P, HEXAPEPTIDE-PGLU6(SP6-1 1), ANALGESIA AND 

SEROTONIN DEPLETION . ^^^^^^ ^^ „ _ 

003050 03-04 
DOPAMINE DEPLETION BY 6 HYDROXYDOPAMINE PREVENTS 
CONDITIONED TASTE-AVERSION INDUCED BY METHYLAMPHETAMINE 
BUT NOT LITHIUM-CHLORIDE. 

003110 03-04 
EFFECTS OF TRICYCLIC-ANTIDEPRESSANTS ON TETRABENAZINE-INDUCED 
DEPLETION OF BRAIN MONOAMINES IN RATS. 1. NOREPINEPHRINE. 

004062 04-03 
DEPOLARIZATION 

CHANGES IN PRIMARY AFFERENT DEPOLARIZATION AFTER 
ADMINISTRATION OF GAMMA ACETYLENIC-GAMMA-AMINOBUTYRIC- 
ACID (GAG), A GAMMA AMINOBUTYRIC-ACID-TRANSAMINASE 
(GABA-TRANSAMINASE) INHIBITOR. 

000174 01-03 
GAMMA AMINOBUTYRIC-ACID AGONISTS: AN IN VITRO COMPARISON 
BETWEEN DEPRESSION OF SPINAL SYNAPTIC ACTIVITY AND 
DEPOLARIZATION OF SPINAL ROOT FIBRES IN THE RAT. 

001104 02-03 
DEPOLARIZATION-INDUCED 

EFFECTS OF PSYCHOTROPIC-DRUGS ON THE DISTRIBUTION OF 3H 
DOPAMINE INTO COMPARTMENTS OF RAT STRIATAL SYNAPTOSOMES 
AND ON SUBSEQUENT DEPOLARIZATION-INDUCED 3H DOPAMINE 

RELEASE. „„„„,-, „, „o 

000067 01-03 

EFFECTS OF CHLORDIAZEPOXIDE ON DEPOLARIZATION-INDUCED CALCIUM 
INFLUX INTO SYNAPTOSOMES. 

000183 01-03 

THE EFFECTS OF A BENZODIAZEPINE ON THE HYPERPOLARIZING AND THE 
DEPOLARIZING RESPONSES OF HIPPOCAMPAL CELLS TO GABA. 

002763 03-03 
DEPOLARiZING-AGENTS 

EPINEPHRINE IS RELEASED FROM HYPOTHALAMUS BY DEPOLARIZING- 
AGENTS AND AMPHETAMINE. 

001155 02-03 

RELATIVE ACTIVITIES OF SUBSTANCES RELATED TO 5 

HYOROXYTRYPTAMINE AS DEPOLARIZING-AGENTS OF SUPERIOR 
CERVICAL GANGLION CELLS. 

004047 04-03 

DEPOT 

PSYCHIATRIC-DISTURBANCE IN MENTALLY-HANDICAPPED-PATIENTS: A 
PROSPECTIVE STUDY OF CURRENT CLINICAL USAGE OF DEPOT 
FLUPHENAZINE IN HOSPITALS FOR THE MENTALLY-HANDICAPPED. 

000668 01-11 
MICROSCOPIC EVIDENCE OF LYMPHOGENIC ABSORPTION OF OIL IN 
HUMANS RECEIVING NEUROLEPTIC OILY DEPOT PREPARATIONS 
INTRAMUSCULARLY. 

000890 01-15 
DISCONTINUATION OF ORAL AND DEPOT FLUPHENAZINE IN 
SCHIZOPHRENIC-PATIENTS AFTER ONE YEAR OF CONTINUOUS 
MEDICATION: A CONTROLLED-STUDY. 

001931 02-08 
PLASMA FLUPHENAZINE LEVELS BY RADIOIMMUNOASSAY IN 
SCHIZOPHRENIC-PATIENTS TREATED WITH DEPOT INJECTIONS OF 
FLUPHENAZINE-DECANOATE. 

002510 02-16 
TWELVE YEARS EXPERIENCE WITH THE TOTAL USE OF DEPOT 
NEUROLEPTICS IN A DEFINED POPULATION. 

002544 02-17 
TREATMENT OF THERAPEUTICALLY-RESISTANT PARANOID 

SCHIZOPHRENIC-PATIENTS WITH FLUPHENAZINE DEPOT COMBINED 
WITH OTHER PSYCHOTROPIC-DRUGS AND CLOZAPINE. 

003172 03-08 
MANAGEMENT OF SCHIZOPHRENIA: LONG-TERM CLINICAL- STUDIES WITH 
SPECIAL REFERENCE TO THE COMBINATION OF PSYCHOTHERAPY AND 
DEPOT NEUROLEPTICS. 

003183 03-08 
A FOLLOWUP STUDY OF SCHIZOPHRENIC-OUTPATIENTS TREATED WITH 
DEPOT NEUROLEPTICS. 

004342 04-08 
DEPOT FLUPHENAZINE MAINTENANCE-TREATMENT AND ASSOCIATED 
WEIGHT CHANGES 

004635 04-15 
RESULTS OF TREATMENT BY MODITEN DEPOT IN OUTPATIENTS-WARDS IN 
THE SOUTH MORAVIAN REGION. 

004648 04-15 

DEPRENIL 

ANTIDEPRESSANT POTENTIATION OF 5 HYDROXYTRYPTOPHAN BY L 
DEPRENIL IN AFFECTIVE-ILLNESS. 

000608 01-09 

DEPRENYL 

INHIBITION OF MONOAMINE-OXIDASE BY CLORGYLINE AND DEPRENYL IN 
CIRCUMVENTRICULAR STRUCTURES OF RAT-BRAIN. 

000159 01-03 



Psychopharmacology Abstracts 



THE MONOAMINE-OXIDASE-INHIBITORS CLORGYLINE AND L DEPRENYL 
ALSO AFFECT THE UPTAKE OF DOPAMINE, NORADRENALINE AND 
SEROTONIN BY RAT-BRAIN SYNAPTOSOMAL PREPARATIONS. 

000171 01-03 
BIOCHEMICAL-MEASUREMENTS DURING (-)DEPRENYL TREATMENT OF 
PARKINSONISM. 

000673 01-11 
DEPRENYL IN THE MANAGEMENT OF RESPONSE FLUCTUATIONS IN 
PATIENTS WITH PARKINSONS-DISEASE ON LEVODOPA. 

002358 02-14 
THE EFFECT OF DEPRENYL, A SELECTIVE MONOAMINE-OXIDASE-B- 
INHIBITOR, ON SLEEP AND MOOD IN MAN. 

002365 02-14 
DEPRENYL IN PARKINSON-DISEASE 

003309 03-1 1 
DEPRENYL DOES NOT CAUSE INSOMNIA IN PARKINSONIAN-PATIENTS. 

004569 04-14 
IS THE FAILURE OF (-)DEPRENYL, A SELECTIVE MONOAMINE-OXIDASE-B- 
INHIBITOR TO ALLEVIATE DEPRESSION RELATED TO FREEDOM FROM 
THE CHEESE EFFECT? 

004640 04-15 

DEPRESSANT 

CENTRAL DEPRESSANT EFFECTS OF CAERULEIN AND CHOLECYSTOKININ- 
OCTAPEPTIDE (CCK-8) DIFFER FROM THOSE OF DIAZEPAM AND 
HALOPERIDOL. 

002652 03-02 
GABA-RECEPTORS AND THE DEPRESSANT ACTION OF PENTOBARBITAL. 

002666 03-03 
SENSITIVE DEPRESSANT EFFECT OF BENZODIAZEPINES ON THE CROSSED 
EXTENSOR REFLEX IN CHLORALOSE ANESTHETIZED RATS. 

003027 03-04 
1 SUBSTITUTED BENZYLTETRAHYDROPYRIMIDONES: A SERIES WITH 
STIMULANT AND DEPRESSANT ACTIVITIES. 

003687 04-02 
4 AMINOPYRIDINE BLOCKADE OF NEURONAL DEPRESSANT RESPONSES TO 
ADENOSINE-TRIPHOSPHATE. 

003963 04-03 
DEPRESSANTS 

HEMODYNAMIC FAILURE INDUCED BY NARCOTIC AND TOXIC DOSES OF 
12 CNS DEPRESSANTS IN INTAQ AND PITHED RATS. 

001855 02-05 
THE EFFECTS C' THYROTROPIN-RELEASING-HORMONE ON CYCLtC-AMP 
ACCUMULATION IN RABBIT CEREBROCORTICAL TISSUE IN THE 
PRESENCE AND ABSENCE OF CNS DEPRESSANTS. 

004010 04-03 

DEPRESSED 

GLUCOSE OXIDATION IN THE VENTROMEDIAL HYPOTHALAMUS IS NOT 
AFFECTED BY INSULIN OR OUABAIN BUT DEPRESSED BY ALLOXAN 

TREATMENT 

001145 02-03 
ELECTROMYOGRAPHIC-ASSESSMENT OF SPINAL REFLEXES IN 
EXPERIMENTALLY DEPRESSED DOGS TREATED WITH 
ANTIDEPRESSANTS. 

001620 02-04 

VILOXAZINE AND THE DEPRESSED SCHIZOPHRENIC - METHODOLOGICAL- 

'^^"^^^ 003181 03-08 

THE PHARMACOLOGICAL-TREATMENT OF SCHIZOAFFEaiVE-DISORDER 

DEPRESSED, A REVIEW OF THE LITERATURE. 

003634 03-17 
DECREASED 3H IMIPRAMINE BINDING IN DEPRESSED MALES AND 

fEMALES. „„ „.„„.«, 

004349 04-09 

DEPRESSED-CHILD 

HYPOMANIC-REACTION TO AMITRIPTYLINE IN A DEPRESSED-CHILD. 

002418 02-15 

DEPRESSED-INPATIENTS 

CLINICAL-RESPONSE, PLASMA LEVELS AND PHARMACOKINETICS OF 
DESIPRAMINE IN DEPRESSED-INPATIENTS. ^^ ^ 

002002 02-09 
A DOUBLE-BLIND COMPARISON BETWEEN AMOXAPINE AND 
AMITRIPTYLINE IN DEPRESSED-INPATIENTS. 

003234 03-09 
A DOUBLE-BUND MULTICENTRE-TRIAL COMPARING THE EFFICACY AND 
SIDE-EFFEQS OF MIANSERIN AND CHLORIMIPRAMINE IN DEPRESSED- 
INPATIENTS AND DEPRESSED-OUTPATIENTS. .„. „,^ 

004395 04-09 

DEPRESSED-OUTPATIENTS 

A DOUBLE-BUND GROUP COMPARATIVE-TRIAL OF MIANSERIN AND 
DIAZEPAM IN DEPRESSED-OUTPATIENTS. „„„.„„ „, ^ 

000592 01-09 

CHRONIC MOOD-DISORDERS IN DEPRESSED-OUTPATIENTS: DIAGNOSIS 

AND RESPONSE TO PHARMACOTHERAPY. 

000624 1 -Or 
DEPRESSED-OUTPATIENTS TREATED WITH COGNITIVE-THERAPY OR 

PHARMACOTHERAPY: A ONE-YEAR FOLLOWUP. 



S-128 



VOLUME 19, SUBJECT INDEX 



Subject Index 



AMOXAPINE AND IMIPRAMINE IN THE TREATMENT OF DEPRESSED- 
OUTPATIENTS: A CONTROLLED-STUOY. 

003254 03-09 
DEPRESSED-OUTPATIENTS; RESULTS ONE YEAR AFTER TREATMENT WITH 
DRUGS AND/OR INTERPERSONAL PSYCHOTHERAPY. 

003272 03-09 
A DOUBLE-BLIND MULTICENTRETRIAL COMPARING THE EFFICACY AND 
SIDE-EFFECTS OF MIANSERIN AND CHLORIMIPRAMINE IN DEPRESSED- 
INPATIENTS AND DEPRESSED-OUTPATIENTS. 

004395 04-09 
PERSONALITY AS A PREDICTOR OF PSYCHOTHERAPY AND 
PHARMACOTHERAPY-OUTCOME FOR DEPRESSED-OUTPATIENTS. 
(UNPUBLISHED PAPER). 

004418 04-09 
DEPRESSED-PATIENT 

TREATMENT OF TARDIVE-DYSKINESIA IN AN AGITATED, DEPRESSED- 
PATIENT. 

002038 02-09 
DEPRESSED-PATIENTS 

PREDICTION OF STEADY-STATE PLASMA LEVELS OF AMITRIPTYLINE AND 
NORTRIPTYLINE FROM A SINGLE-DOSE 24-HR. LEVEL IN DEPRESSED- 
PATIENTS. 

000582 01-09 
URINARY MHPG AND CLINICAL-RESPONSE TO AMITRIPTYLINE IN 
DEPRESSED-PATIENTS. 

000631 01-09 
EFFICACY OF DESIPRAMINE IN ENDOGENOMORPHICALLY DEPRESSED- 
PATIENTS. 

000632 01-09 
CLINICAL-TRIALS WITH RUBIDIUM-CHLORIDE IN DEPRESSED-PATIENTS. 

001893 02-07 
COMPARISON OF THE EFFECTS OF LOFEPRAMINE AND MIANSERIN IN 
DEPRESSED-PATIENTS IN A DOUBLE-BLIND TRIAL. 

001996 02-09 
THE USE OF VILOXAZINE IN HOSPITALIZED DEPRESSED-PATIENTS: 

RANDOM COMPARISON WITH IMIPRAMINE IN A DOUBLE-BLIND TRIAL. 

001998 02-09 
TREATMENT OF THERAPY-RESISTANT DEPRESSED-PATIENTS WITH IV. 
INFUSIONS OF NOMIFENSINE CONTROLLED BY GALVANIC-SKIN- 
RESISTANCE. 

002012 02-09 
TARDIVE-DYSKINESIA IN DEPRESSED-PATIENTS: SUCCESSFUL THERAPY 
WITH ANTIDEPRESSANTS AND LITHIUM. 

002037 02-09 
CARDIOVASCULAR-EFFECTS OF AMITRIPTYLINE, MIANSERIN AND 
ZIMELIDINE IN DEPRESSED-PATIENTS. 

002215 02-13 
EFFICACY OF DESIPRAMINE IN MILDLY DEPRESSED-PATIENTS: A DOUBLE- 
BUND, PLACEBO-CONTROLLED-TRIAL. 

003262 03-09 
BEHAVIORAL-EFFECTS AND BIOLOGICAL-EFFECTS OF ACUTE BETA 
ENDORPHIN INJECTION IN SCHIZOPHRENIC-PATIENTS AND DEPRESSED- 
PATIENTS. 

003357 03-11 
3H IMIPRAMINE BINDING IN HUMAN PLATELETS: DIMINUTION OF 
BINDING-SITES IN DEPRESSED-PATIENTS. 

003427 03-13 
MULTICENTRE- STUDY WITH VILOXAZINE (VIVALAN) IN DEPRESSED- 
PATIENTS. 

004375 04-09 
SINGLE-DOSE PHARMACOKINETIC DATA ON ZIMELIDINE IN DEPRESSED- 
PATIENTS. 

004385 04-09 
TSH, HGH, HPR, AND CORTISOL RESPONSE TO TRH IN DEPRESSED- 
PATIENTS. 

004399 04-09 
DEPRESSION 

BLOCKADE OF METHAMPHETAMINE-INDUCED DEPRESSION OF TYROSINE- 
HYDROXYLASE BY GABA-TRANSAMINASE INHIBITORS. 

000130 01-03 
DIAZEPAM POTENTIATION OF PURINERGIC DEPRESSION OF CENTRAL 
NEURONS. 

000233 01-03 
REWARD SYSTEM DEPRESSION FOLLOWING CHRONIC AMPHETAMINE: 
ANTAGONISM BY HALOPERIDOL. 

000342 01-04 
POSTAMPHET AMINE DEPRESSION OF SELF-STIMULATION RESPONDING 
FROM THE SUBSTANTIA-NIGRA: REVERSAL BY TRICYCLIC- 
ANTIDEPRESSANTS. 

000419 01-04 
LITHIUM TREATMENT IN POSTPSYCHOTIC DEPRESSION. 

000575 01-08 
DRUG-THERAPY IN ENDOGENOUS DEPRESSION WITH POSSIBLE PRIMARY 
GABA DEFICIENCY CLINICALLY DETECTED: 38 NEW CASES. 

000584 01-09 
CLINICAL AND LABORATORY DIAGNOSTICS APPLICATIONS IN 
DEPRESSION. (UNPUBLISHED PAPER). 

000588 01-09 
CLINICAL AND BIOCHEMICAL-ACTION OF PIRACETAM (NOOTROPIL) IN 
DRUG-RESISTANT DEPRESSION. 

000600 01-09 



TREATMENT OF DEPRESSION IN THE MEDICALLY-ILL ELDERLY WITH 
METHYLPHENIDATE 

000602 01-09 
PREDICTION OF LOFEPRAMINE RESPONSE IN DEPRESSION BASED ON 
RESPONSE TO PARTIAL SLEEP-DEPRIVATION 

000617 01-09 
THREE CASES OF UNIPOLAR DELUSIONAL DEPRESSION RESPONSIVE TO L- 
DOPA. 

000628 01-09 
SINTAMIL IN THE TREATMENT OF DEPRESSION: A COMPARISON OF 

SINGLE VS. DIVIDED DOSE ADMINISTRATION. 

000629 01-09 
ANTIDEPRESSIVE TREATMENT AND MOOD-SWING-PATTERNS IN 

ENDOGENOUS DEPRESSION. 

000633 01-09 
DECREASED UPTAKE OF 5 HYDROXYTRYPTAMINE IN BLOOD-PLATELETS 
FROM PATIENTS WITH ENDOGENOUS DEPRESSION. 

000637 01-09 
STIMULUS INTENSITY CONTROL IN DEPRESSION: A STUDY OF THE 
COMPARATIVE-EFFECT OF DOXEPIN AND AMITRIPTYLINE ON CORTICAL 
EVOKED-POTENTIALS. 

000763 01-13 
DEXAMETHASONE-SUPPRESSION-TESTS IN DEPRESSION AND RESPONSE 
TO TREATMENT. 

000899 01-16 
MONOAMINES AND DEPRESSION: AN INTERIM REPORT. I. SEROTONIN 
AND SEROTONIN PRECURSORS. 

000996 01-17 
DEPRESSION IN THE ELDERLY: RESEARCH DIRECTIONS IN 
PSYCHOPATHOLOGY, EPIDEMIOLOGY, AND TREATMENT. 

000998 01-17 
GAMMA AMINOBUTYRIC-ACID AGONISTS: AN IN VITRO COMPARISON 
BETV\/EEN DEPRESSION OF SPINAL SYNAPTIC ACTIVITY AND 
DEPOLARIZATION OF SPINAL ROOT FIBRES IN THE RAT. 

001104 02-03 
DEPRESSION AND FACILITATION OF SYNAPTIC RESPONSES IN CAT 
DORSAL-HORN BY SUBSTANCE-P ADMINISTERED INTO SUBSTANTIA- 
GELATINOSA. 

001191 02-03 
TOLERANCE TO BARBITURATE-INDUCED CENTRAL-NERVOUS- SYSTEM 
DEPRESSION: INVOLVEMENT OF STIMULUS SECRETION COUPLING IN 
DISCRETE BRAIN AREAS. (PH.D. DISSERTATION). 

001213 02-03 
AMINOPHYILINE AND THEOPHYLLINE DERIVATIVES AS ANTAGONISTS OF 
NEURONAL DEPRESSION BY ADENOSINE: A MICROIONTOPHORETIC- 
STUDY. 

001410 02-03 
BIOCHEMICAL-STUDY OF THE ANIMAL-MODEL DEPRESSION INDUCED BY 
TETRABENAZINE. 

001506 02-03 
EFFECTS OF CHRONIC AMPHETAMINE OR RESERPINE ON SELF- 
STIMULATION RESPONDING: ANIMAL-MODEL OF DEPRESSION? 

001699 02-04 
PRESYNAPTIC AND POSTSYNAPTIC SEROTONERGIC MANIPULATIONS IN 
AN ANIMAL-MODEL OF DEPRESSION. 

001730 02-04 
RESULTS OF A SURVEY ON THE PRESENT TREATMENT OF DEPRESSION IN 
SPAIN. 

001963 02-09 
NOMIFENSINE IN THE TREATMENT OF VARIOUS TYPES OF DEPRESSION. 

001968 02-09 
DEXAMETHASONE-SUPPRESSION-TEST IDENTIFIES SUBTYPES OF 
DEPRESSION WHICH RESPOND TO DIFFERENT ANTIDEPRESSANTS 

001971 02-09 
CLINICAL-STUDIES AND BIOLOGICAL-STUDIES OF L TRYPTOPHAN IN 
DEPRESSION 

001977 02-09 
NOMIFENSINE IN THE TREATMENT OF ENDOGENOUS DEPRESSION. A 

CONTROLLED-STUDY VS. NORTRIPTYLINE. 

001978 02-09 
ENDOGENOUS DEPRESSION AND IMIPRAMINE LEVELS IN THE BLOOD. 

001979 02-09 
DEPRESSION: HOW TO RATIONALISE DRUG-THERAPY. 

001988 02-09 
A CLINICAL-TRIAL OF ZIMELIDINE IN DEPRESSION. 

001992 02-09 
TRAZODONE IN THE TREATMENT OF NEUROTIC DEPRESSION. 

001994 02-09 
AN OVERVIEW OF SEVENTEEN YEARS OF EXPERIENCE WITH DOTHIEPIN IN 

THE TREATMENT OF DEPRESSION IN EUROPE. 

001995 02-09 
EVALUATION OF NOMIFENSINE IN THE TREATMENT OF GERIATRIC 

DEPRESSION USING PSYCHOMETRIC-TESTS AND PLASMA LEVEL 
CONTROLS. 

002004 02-09 
INFUSION THERAPY IN THERAPY-RESISTANT DEPRESSION. 

002007 02-09 
LONG-TERM-TREATMENT OF DEPRESSION WITH ISOCARBOXAZIDE, 

002011 02-09 



I 






in;!,' 






to;, 



S-129 



Subject Index 

D PHENYLALANINE IN ENDOGENOUS DEPRESSION. 

002017 02-09 
THE PHARMACOTHERAPY OF MAJOR DEPRESSIVE- SYNDROME. PART 1: 
TREATMENT OF ACUTE DEPRESSION. 

002044 02-09 
INFUSION OF MAPROTILIN AND CLOMIPRAMIN AND THEIR COMBINATION 
IN THE TREATMENT OF DEPRESSION. 

002056 02-09 
PHARMACOTHERAPY OF DEPRESSION IN THE ELDERLY. 

002144 02-11 
THE RELATIVE EFFICACY OF COGNITIVE-THERAPY AND CHEMOTHERAPY 
FOR THE TREATMENT OF DEPRESSION AMONG THE RETIRED ELDERLY. 

(PH.D. DISSERTATION). 

002148 02-11 
ENDOCRINE CHANGES AND BEHAVIORAL-CHANGES IN DEPRESSION AFTER 
THYROTROPIN-RELEASING-HORMONE (TRH): ALTERATION BY 
PRETREATMENT WITH THYROID-HORMONES. 

002259 02-13 
DORA AND DOPAMINE AGONISTS IN DEPRESSION. 

002310 02-13 
L HTP AND THE SEROTONIN HYPOTHESIS: THEIR MEANING FOR 
TREATMENT OF DEPRESSION. 

002326 02-14 
THEOPHYLLINE AND DEPRESSION. 

002439 02-15 
SUBTYPES OF DEPRESSION BASED ON EXCRETION OF MHPG AND 
RESPONSE TO NORTRIPTYLINE. 

002488 02-16 
HETEROGENEOUS DEPRESSION OF GLUCOSE UTILIZATION IN THE 
CAUDATE-NUCLEUS BY GABA AGONISTS. 

002640 03-01 
NONSEROTONERGIC DEPRESSION OF SPINAL MONOSYNAPTIC REFLEX 
TRANSMISSION BY 5 HYDROXYTRYPTOPHAN. 

002745 03-03 
DEPRESSION OF VENTRAL ROOT DORSAL ROOT POTENTIAL BY DL ALPHA 
AMINOADIPATE IN FROG SPINAL-CORD. 

002755 03-03 
EVIDENCE THAT THE OPIATE-RECEPTORS OF THE SUBSTANTIA- 
GEU^TINOSA CONTRIBUTE TO THE DEPRESSION, BY INTRAVENOUS 
MORPHINE, OF THE SPINAL TRANSMISSION OF IMPULSES IN 
UNMYELINATED PRIMARY AFFERENTS. 

002767 03-03 
ROLE OF MONOAMINERGIC SYSTEMS IN MORPHINE-INDUCED 
RESPIRATORY DEPRESSION. 

002827 03-03 
NEUROTRANSMIHERS AND DEPRESSION: TOO MUCH, TOO LIHLE, TOO 
UNSTABLE - OR NOT UNSTABLE ENOUGH? 

002931 03-03 
DEPRESSION OF RESERPINE-INDUCED MUSCULAR RIGIDITY IN RATS AFTER 
ADMINISTRATION OF LISURIDE INTO THE SPINAL SUBARACHNOID 
SPACE. 

002962 03-04 
THE DEXAMETHASONE-SUPPRESSION-TEST IN THE IDENTIFICATION OF 
SUBTYPES OF DEPRESSION DIFFERENTIALLY RESPONSIVE TO 
ANTIDEPRESSANTS. 

003211 03-09 
PROTOCOLS FOR THE USE OF PSYCHOACTIVE-DRUGS ~ PART II: 
PROTOCOL FOR THE TREATMENT OF DEPRESSION WITH TRICYCLIC- 
ANTIDEPRESSANTS. 

003214 03-09 
AMOXAPINE AND AMITRIPTYLINE IN THE OUTPATIENT TREATMENT OF 
ENDOGENOUS DEPRESSION. 

003217 03-09 
METHADONE AND MORPHINE IN DEPRESSION. 

003220 03-09 
SYNAPTIC AND BEHAVIOURAL-ACTIONS OF ANTIDEPRESSANT-DRUGS: 
FURTHER THOUGHTS ON THE IMPLICATIONS FOR THEORIES OF 
DEPRESSION. 

003229 03-09 
SLEEP AND TREATMENT PREDICTION IN ENDOGENOUS DEPRESSION. 

003236 03-09 
DEPRESSION SUBTYPES AFFECT THE STEADY-STATE PLASMA LEVELS AND 
THERAPEUTIC-EFFICACY OF AMITRIPTYLINE AND NORTRIPTYLINE. 

003244 03-09 
PHENELZINE AND AMITRIPTYLINE IN NEUROTIC DEPRESSION. 
(UNPUBLISHED PAPER). 

003248 03-09 
EFFECTS OF PHENELZINE AND AMITRIPTYLINE ON DEPRESSION. 

003249 03-09 
CROSS-OVER STUDY OF ZIMELIDINE AND DESIPRAMINE IN DEPRESSION: 

EVIDENCE FOR AMINE SPECIFICITY. 

003250 03-09 
LITHIUM AND IMIPRAMINE IN THE PROPHYLAXIS OF UNIPOLAR AND 

BIPOLAR-II DEPRESSION: A PROSPECTIVE, PLACEBO-CONTROLLED 
COMPARISON. 

003252 03-09 
BEHAVIORAL-PREDICTORS OF AMITRIPTYLINE RESPONSE IN DEPRESSION. 

003253 03-09 
DO PSYCHOTHERAPY AND PHARMACOTHERAPY FOR DEPRESSION 

CONFLICT? EMPIRICAL EVIDENCE FROM A CLINICAL-TRIAL. 

003256 03-09 



Ptychopharmacology Abstracts 



THE TREATMENT OF DEPRESSION USING CLOMIPRAMINE IN GENERAL- 
MEDICAL-PRACTICE: 48 CASES TREATED ON AN OUTPATIENT BASIS. 

003268 03-09 
MANAGEMENT OF DEPRESSION WITH SEROTONIN PRECURSORS. 

003269 03-09 
MAPROTILINE VERSUS IMIPRAMINE AND PLACEBO IN NEUROTIC 

DEPRESSION. 

003287 03-10 
NEUROENDOCRINOLOGY OF DEPRESSION - A DISCUSSION. 

003402 03-13 
HIGH-AFFINITY 3H IMIPRAMINE BINDING: A NEW BIOLOGICAL TOOL FOR 
STUDIES IN DEPRESSION. 

003610 03-17 
SPREADING DEPRESSION INDUCED BY MICROINJEQION OF ENKEPHALINS 
INTO THE HIPPOCAMPUS AND NEOCORTEX 

004015 04-03 
CANNABINOID-INDUCED ENHANCEMENT AND DEPRESSION OF CAT 
MONOSYNAPTIC REFLEXES. 

004040 04-03 
RESPIRATORY DEPRESSION PRODUCED BY DIAZEPAM IN CATS: EFFEQ OF 
ANESTHESIA 

004272 04-05 
POTENTIATION OF THE MORPHINE-INDUCED RESPIRATORY RATE 
DEPRESSION BY CAPTOPRIL. 

004275 04-05 
TRAZODONE EFFICACY AND SAFETY IN ENDOGENOUS DEPRESSION: A 
DOUBLE-BLIND COMPARISON WITH IMIPRAMINE. 

004346 04-09 
PHARMACOTHERAPY FOR DEPRESSION. 

004351 04-09 
RECEPTORS, ADENYLATE-CYCLASE, DEPRESSION, AND LITHIUM. 

004353 04-09 
CLINICAL-RESPONSE AND BLOOD LEVELS IN THE TREATMENT OF 
DEPRESSION WITH A NEW ANTIDEPRESSANT-DRUG, AMOXAPINE. 

004356 04-09 
(3H) IMIPRAMINE BINDING IN HUMAN PLATELETS: A NEW 
BIOCHEMICAL-PARAMETER IN DEPRESSION. 

004358 04-09 
A NEUROENDOCRINE-STUDY OF ADRENOCEPTOR FUNQION IN 
ENDOGENOUS DEPRESSION. 

004362 04-09 
PERIPHERAL SEROTONERGIC AND ADRENERGIC RESPONSES IN 
DEPRESSION. 

004364 04-09 
CONVULSIVE AND DRUG-THERAPIES OF DEPRESSION. 

004366 04-09 
LONG-TERM-TREATMENT FOR DEPRESSION. 

004372 04-09 
CHOLINERGIC MECHANISMS IN MANIA AND DEPRESSION: QUESTIONS OF 
SPECIFICITY 

004374 04-09 
GUIDELINES ON THE DIAGNOSIS AND TREATMENT OF DEPRESSION 

004376 04-09 
TREATMENT OF DEPRESSION WITH AN MAO-INHIBITOR FOLLOWED BY 5 

HTP - AN UNFINISHED RESEARCH PROJECT. 

004377 04-09 
CEREBROSPINAL-FLUID VALUES OF HVA AND 5 HIAA IN PATIENTS WITH 

ENDOGENOUS DEPRESSION DURING THE COURSE OF TREATMENT 

004382 04-09 
AN EVALUATION OF TRAZODONE IN THE TREATMENT OF DEPRESSION. 

004386 04-09 
THE NOSOLOGICAL INDEPENDENCE OF INVOLUTIONAL DEPRESSION AND 
ITS DYNAMICS DURING PSYCHOPHARMACOTHERAPY. 

004389 04-09 
PROPHYLACTIC-EFFEQ OF LITHIUM AGAINST DEPRESSION IN 
CYCLOTHYMIC-PATIENTS: A LIFE-TABLE ANALYSIS. 

004391 04-09 
A COMPARISON OF TRAZODONE AND DOTHIEPIN IN DEPRESSION 

004394 04-09 
DO PSYCHOTHERAPY AND PHARMACOTHERAPY FOR DEPRESSION 
CONFLICT? EMPIRICAL EVIDENCE FROM A CLINICAL-TRIAL. 
(UNPUBLISHED PAPER). „,„.„„ 

004401 04-09 
CORTISOL DYNAMICS AND DEXAMETHASONE PHARMACOKINETICS IN 
PRIMARY ENDOGENOUS DEPRESSION: PRELIMINARY FINDINGS. 

004403 04-09 

NEUROENDOCRINE DISTURBANCE IN DEPRESSION. 

004405 04-09 
ELECTROCARDIOGRAM-CHANGES AND PLASMA DESIPRAMINE LEVELS 
DURING TREATMENT OF DEPRESSION. 

004411 04-09 
PHARMACOTHERAPY AND PSYCHOTHERAPY FOR AMBULATORY 
DEPRESSION: EFFICACY AND CHOICES. ^^^^ ^^ 

TRAZODONE IN DEPRESSION. CX)44 14 04-09 

CONTROLLED CLINICAL-TRIAL OF NOMIFENSINE IN THE TREATMENT OF 
'''^'''^'''- 004417 04-09 



S-130 



VOLUME 19, SUBJECT INDEX 

DOSE-EFFECT OF OtAE ON SUBJECTIVE PROBLEMS, VERTIGO, 
DEPRESSION, ASTHENIA, CEPHALALGIA, AND TONIC POSTURAL 
ACTIVITY PROBLEMS RECORDED WITH STATOKINESIMETER IN 
POSTCONCUSSIONAL-SYNDROME . 

004472 04-11 
THE ACTIVITY OF BLOOD-PLATELET MONOAMINE-OXIDASE IN 
ENDOGENOUS DEPRESSION 

004547 04-13 
IS THE FAILURE OF (-)DEPRENYL, A SELECTIVE MONOAMINE-OXIDASE-B- 
INHIBITOR, TO ALLEVIATE DEPRESSION RELATED TO FREEDOM FROM 
THE CHEESE EFFECT? 

004640 04-15 
DEPRESSIONS 

STUDY OF INTRAVENOUS AMITRIPTYLINE IN ACUTE DEPRESSIONS. 

000581 01-09 
THE LONG-TERM-TREATMENT OF PERIODICAL AND CYCLIC DEPRESSIONS 
WITH FLUPENTHIXOL-DECANOATE. 

000603 01-09 
NOMIFENSIN IN THE TREATMENT OF ENDOGENOUS DEPRESSIONS. 
CLINICAL-EXPERIENCE AND EEG FINDINGS. 

000613 01-09 
CONTROLLED-COMPARISON OF MIANSERINE WITH IMIPRAMINE IN 
ENDOGENOUS DEPRESSIONS. 

000634 01-09 
TRAZODONE IN DEPRESSIONS. 

000643 01-09 
CLINICAL-EXPERIENCE WITH SECOND-GENERATION ANTIDEPRESSANTS IN 
ENDOGENOUS DEPRESSIONS. 

001975 02-09 
THE CORRELATION OF CATECHOLAMINE AND ADRENERGIC PARAMETERS 
WITH DRUG-THERAPY OF NEUROTIC AND ENDOGENOUS DEPRESSIONS. 

002047 02-09 
PYRAZIDOL IN THE TREATMENT OF DEPRESSIONS. 

002055 02-09 
IATROGENIC DEPRESSIONS. 

002388 02-15 
CLINICAL-EXPERIENCE WITH RETARD DIBENZEPINE (NOVERIL-240) IN 
ENDOGENOUS DEPRESSIONS ACCOMPANIED BY SYMPTOMS OF DRUG- 
RESISTANCE. 

003245 03-09 
THERAPEUTIC EFFECT OF MIANSERINE AND IMIPRAMINE IN ENDOGENOUS 
DEPRESSIONS (CONTROLLED-COMPARISON) . 

003264 03-09 
THERAPEUTICS (I) - PHARMACOLOGICAL-TREATMENT OF DEPRESSIONS. 

003270 03-09 
CLINICAL DEPRESSIONS: DIAGNOSTIC AND THERAPEUTIC CHALLENGES 

004350 04-09 
ACTIVITY OF BROMAZEPAM AND LORAZEPAM IN NEUROTIC 
DEPRESSIONS. 

004384 04-09 
DEPRESSIVE 

THE RELATIVE PROPHYLAQIC EFFICACY OF LITHIUM AGAINST MANIC 
AND DEPRESSIVE RECURRENCES IN BIPOLAR-PATIENTS. 

002040 02-09 
STATISTICAL ANALYSES OF PHYSIOLOGIC DATA FROM FEMALE PATIENTS 
WITH AN ENDOMORPHOUS DEPRESSIVE COURSE: A TRIAL, 
INTERACTIONS BETWEEN PHYSIOLOGIC PARAMETERS, TEST JUNCTURES 
IN THIS PHASE. 

003251 03-09 
DEPRESSIVE-CONDITIONS 

CLINICAL-TRIAL OF VILOXAZINE IN DEPRESSIVE-CONDITIONS 

000589 01-09 
THE TREATMENT OF DEPRESSIVE-CONDITIONS WITH NOMIFENSINE 

000609 01-09 
VARIATIONS IN URINARY EXCRETION OF 3 METHOXY-4- 
HYDROXYPHENYLGLYCOL-SULFATE IN DEPRESSIVE-CONDITIONS 

002013 02-09 
TREATMENT OF DEPRESSIVE-CONDITIONS IN THE ELDERLY. 

003578 03-17 
DEPRESSIVE-DISORDER 

PLASMA LEVELS OF IMIPRAMINE (IMI) AND DESMETHYLIMIPRAMINE 
(DMI) AND CLINICAL-RESPONSE IN PREPUBERTAL MAJOR DEPRESSIVE- 
DISORDER: A PRELIMINARY REPORT. 

000619 01-09 
DEPRESSIVE-DISORDERS 

IMIPRAMINE TREATMENT OF PREPUBERTAL MAJOR DEPRESSIVE- 
DISORDERS: PLASMA LEVELS AND CLINICAL-RESPONSE ~ 
PRELIMINARY REPORT. 

000620 01-09 
PROLACTIN CHANGES IN MAJOR DEPRESSIVE-DISORDERS. 

000752 01-13 
TOWARD A BIOCHEMICAL CLASSIFICATION OF DEPRESSIVE-DISORDERS 
IV: PRETREATMENT URINARY MHPG LEVELS AS PREDICTORS OF 
ANTIDEPRESSANT RESPONSE TO IMIPRAMINE. 

004406 04-09 
DEPRESSIVE-ILLNESS 

A REEXAMINATION OF THE CLINICAL-EFFECTS OF IMIPRAMINE AND 
AMITRIPTYLINE IN DEPRESSIVE-ILLNESS. 

000579 01-09 
GROWTH-HORMONE AFTER TRH IN WOMEN WITH DEPRESSIVE-ILLNESS 

000606 01-09 



Subject Index 



THE PHARMACOTHERAPY OF MAJOR DEPRESSIVE-SYNDROME PART 2: 
PROPHYLAXIS OF RECURRENT DEPRESSIVE-ILLNESS 

002043 02-09 
DEPRESSIVE-NEUROSIS 

VILOXAZINE IN THE TREATMENT OF DEPRESSIVE-NEUROSIS: A 
CONTROLLED CLINICAL-STUDY WITH DOXEPIN AND PLACEBO. 

002080 02-10 
CLOMIPRAMINE AND DOXEPIN IN DEPRESSIVE-NEUROSIS: PLASMA 
LEVELS AND THERAPEUTIC RESPONSE, 

002258 02-13 
VILOXAZINE IN THE TREATMENT OF DEPRESSIVE-NEUROSIS: A PLACEBO 
AND STANDARD (IMIPRAMINE) CONTROLLED CLINICAL-STUDY. 

004392 04-09 
DEPRESSIVE-PATIENTS 

COMPARATIVE-STUDY OF THE CARDIOTOXICITY OF AMITRIPTYLINE AND 
MAPROTILINE IN DEPRESSIVE-PATIENTS. 

000595 01-09 
ON THE RELATIONSHIP OF NORTRIPTYLINE: AMITRIPTYLINE RATIO TO 
CLINICAL IMPROVEMENT OF AMITRIPTYLINE TREATED DEPRESSIVE- 
PATIENTS. 

000599 01-09 
A PRELIMINARY STUDY ON DETERMINATION OF THE OPTIMUM 
OPIPRAMOL DOSAGE IN DEPRESSIVE-PATIENTS. 

000601 01-09 
CLINICAL AND EEG CHANGES IN DEPRESSIVE-PATIENTS AFTER A SINGLE 
INJECTION OF BETA ENDORPHIN. 

001962 02-09 
EFFECTS OF ANTIDEPRESSANTS ON PITUITARY HORMONAL SECRETIONS IN 
HEALTHY TEST SUBJECTS, NEUROTIC-PATIENTS, AND ENDOGENOUS 
DEPRESSIVE-PATIENTS. 

002009 02-09 
OUTPATIENT CARE OF DEPRESSIVE-PATIENTS WITH MIANSERIN. 

002041 02-09 
PHARMACOKINETICS OF CLOMIPRAMINE IN DEPRESSIVE-PATIENTS. 

003216 03-09 
COMBINED ADMINISTRATION OF NIALAMIDE AND VILOXAZINE TO 
DEPRESSIVE-PATIENTS. 

003232 03-09 
DEPRESSIVE-STATES 

OUR EXPERIENCE WITH MAPROTILIN TREATMENT OF DEPRESSIVE-STATES. 

000623 01-09 
VILOXAZINE IN THE TREATMENT OF DEPRESSIVE-STATES. 

000626 01-09 
STUDY OF MAPROTILINE IN OUTPATIENT TREATMENT OF DEPRESSIVE- 
STATES BY THE GENERAL-PRACTITIONER: ADVANTAGE OF SINGLE- 
NIGHTLY-DOSE. 

001961 02-09 
VARIATIONS IN PSYCHOPHYSIOLOGICAL ACTIVATION RESPONSES IN 
DEPRESSIVE-STATES. 

001965 02-09 
IS IT POSSIBLE TO SET UP ANY RULES FOR A COMPREHENSIVE 
TREATMENT OF DEPRESSIVE-STATES? 

001997 02-09 
THE IMPORTANCE OF AMINEPTINE IN THE TREATMENT OF NONPSYCHOTIC 
DEPRESSIVE-STATES IN THE ELDERLY. 

001999 02-09 
LARGE-DOSES OF DIBENZEPINE NOVERIL IN THE TREATMENT OF 
DEPRESSIVE-STATES. 

002020 02-09 
CLINICAL-TRIAL OF PYRAZIDOL IN ENDOGENOUS DEPRESSIVE-STATES. 

002021 02-09 
CLINICAL AND BIOCHEMICAL-DATA ON THE ACTION OF MAPROTILINE 

AND CLOMIPRAMINE IN DEPRESSIVE-STATES (PRELIMINARY 
OBSERVATION). 

002032 02-09 
AN OPEN-STUDY OF MAPROTILINE 75MG IN THE TREATMENT OF 
DEPRESSIVE-STATES. 

003152 03-07 
CLINICAL-STUDY OF MAPROTILINE IN THE TREATMENT OF DEPRESSIVE- 
STATES: COMPILATION OF 1520 OBSERVATIONS. 

003206 03-09 
DEPRESSIVE-SYMPTOMATOLOGY 

CLINICAL-CORRELATION, BIOCHEMICAL-CORRELATION, AND 
PSYCHOPHARMACOLOGICAL-CORRELATION IN PATIENTS WITH 
DEPRESSIVE-SYMPTOMATOLOGY . 

002018 02-09 
PHYSOSTIGMINE INDUCTION OF DEPRESSIVE-SYMPTOMATOLOGY IN 
■ NORMAL HUMAN SUBJECTS. 

003255 03-09 
DEPRESSIVE-SYMPTOMS 

IMIPRAMINE AND EEG SLEEP IN CHILDREN WITH DEPRESSIVE- 
SYMPTOMS. 

002339 02-14 
DEPRESSIVE-SYNDROME 

PSYCHOTROPIC-DRUGS AND DEPRESSIVE-SYNDROME IN SCHIZOPHRENIA. 

000569 01-08 
A CASE-REPORT OF CIMETIDINE-INDUCED DEPRESSIVE-SYNDROME. 

000839 01-15 



5 

IS;, 









p.. 



S-131 



Subject Index 



THE PHARMACOTHERAPY OF MAJOR DEPRESSIVE-SYNDROME. PART 1. 
PROPHYLAXIS OF RECURRENT DEPRESSIVE-ILLNESS. 

002043 02-09 
THE PHARMACOTHERAPY OF MAJOR DEPRESSIVE-SYNDROME. PART 1: 

TREATMENT OF ACUTE DEPRESSION. 

002044 02-09 

DEPRESSIVE-SYNDROMES 

THE USEFULNESS OF THE ERYTHROCYTE LITHIUM INDEX IN THE 
EVALUATION OF DISORDERS OF ION-TRANSFER IN PATIENTS WITH 
DEPRESSIVE-SYNDROMES. 000625 01-09 

CLINICAL RESULTS OBTAINED WITH THE USE OF LYSONEURO IN 

DEPRESSIVE-SYNDROMES. „„.oo-, «. «n 

004397 04-09 
CLINICAL-EVALUATION OF THE PROPHYLACTIC EFFECTIVENESS OF 
PROLONGED LITHIUM-CARBONATE THERAPY IN ENDOGENOUS 

DEPRESSIVE-SYNDROMES. „„..„. «. „„ 

004404 04-09 

VARIATIONS IN URINARY LEVELS OF 3 METHOXY-4- 

HYDROXYPHENYLGLYCOL-SULFATE IN PATIENTS WITH DEPRESSIVE- 

^^^■^^^^^^ 004533 04-13 

THE ACTIVITY OF ERYTHROCYTE CATECHOL-0-METHYLTRANSFERASE IN 
ENDOGENOUS DEPRESSIVE-SYNDROMES 

004546 04-13 
THE ACTIVITY OF DOPAMINE-BETA-HYDROXYLASE IN THE PLASMA OF 
PATIENTS WITH ENDOGENOUS DEPRESSIVE-SYNDROMES 

004548 04-13 

DEPRESSIVES 

AN INVERSE CORRELATION BETWEEN SERUM LEVELS OF 

DESMETHYLIMIPRAMINE AND MELATONIN-LIKE IMMUNOREACTIVITY 

IN DMI RESPONSIVE DEPRESSIVES. „„..on «o nn 

003228 03-09 
THE THERAPEUTIC PROFILE OF MIANSERIN IN MILD ELDERLY 

■^^^^^^^'^^^ 003297 03-11 

DEPRESSOR 

FAILURE OF ISOPRENALINE AND BETA-RECEPTOR BLOCKING-DRUGS TO 
MODIFY DEPRESSOR RESPONSE AND BRADYCARDIA INDUCED BY 
ELECTRICAL-STIMULATION OF THE ANTERIOR HYPOTHALAMUS OF 
CATS 

000520 01-05 

DEPRIVATION 

ROLE OF INTRACORTICAL INHIBITION IN DEPRIVATION AMBLYOPIA: 

REVERSAL BY MICROIONTOPHORETIC BICUCULLINE. 

002684 03-03 
CORTICAL RECOVERY FROM EFFECTS OF MONOCULAR DEPRIVATION: 

ACCELERATION WITH NOREPINEPHRINE AND SUPPRESSION WITH 6 

HYDROXYDOPAMINE „„o^^. „^ „^ 

003024 03-04 
CHANGES OF RESPONSE TO DOPAMINERGIC DRUGS IN RATS SUBMIHED 

TO REM SLEEP DEPRIVATION. „„.„.„ „. „. 

004239 04-04 

DEPRIVED 

NALOXONE: EFFECTS ON FOOD AND WATER CONSUMPTION IN THE 
NONDEPRIVED AND DEPRIVED RAT. „„„„„. 

001599 02-04 
DIFFERENTIAL-EFFECTS OF MORPHINE ON FOOD AND WATER INTAKE IN 
FOOD DEPRIVED AND FREELY-FEEDING RATS. 

001765 02-04 
NALOXONE SUPPRESSES FOOD/WATER CONSUMPTION IN THE DEPRIVED 
CAT 

004114 04-04 

PHARMACOKINETIC- STUDY OF APOMORPHINE-INDUCED STEREOTYPY IN 
FOOD DEPRIVED RATS. 

004247 04-04 

DERIVATIVE ^. ^ n 

FLUORINATED ANALOGUES OF THE TRICYCLIC NEUROLEPTICS: 2,3 
DIFLUORO DERIVATIVE OF CLOROTEPIN. 

000001 01-01 
THE USE OF THIOPROPERAZINE, A PHENOTHIAZINE DERIVATIVE, AS A 
LIGAND FOR NEUROLEPTIC-RECEPTORS - I. IN VITRO STUDIES. 

001133 02-03 
THE USE OF THIOPROPERAZINE, A PHENOTHIAZINE DERIVATIVE, AS A 
LIGAND FOR NEUROLEPTIC-RECEPTORS - II. IN VIVO STUDIES. 

001137 02-03 
SLEEP PROFILE AND ULTRADIAN SLEEP PERIODICITY IN HUMANS UNDER 
THE INFLUENCE OF A BUTYROPHENONE DERIVATIVE: I. SLEEP 
CORRECTION IN SUBJECTS WITH OLIGOSYMPTOMATIC SLEEP- 
DISORDERS. 

001869 02-06 

DOUBLE-BUND CLINICAL ASSESSMENT OF ALPRAZOLAM, A NEW 
BENZODIAZEPINE DERIVATIVE, IN THE TREATMENT OF MODERATE TO 
SEVERE ANXIETY. 

002070 02-10 
DU-24565, A QUIPAZINE DERIVATIVE, A POTENT SELECTIVE SEROTONIN 
UPTAKE INHIBITOR. 

002651 03-02 
SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIP OF A 

PYRIMIDOPYRIMIDINE DERIVATIVE WITH ANTIDEPRESSANT ACTIVITY. 

003653 04-01 



Psychopharmacology Abstracts 

A STEROID DERIVATIVE, R-5135, ANTAGONIZES THE GABA/ 
BENZODIAZEPINE-RECEPTORINTERAaiON. 

003851 04-03 
DERIVATIVES 

N TETRAHYDROFURYLALKYL AND N ALKOXYALKYL DERIVATIVES OF (-) 
NORMETAZOCINE, COMPOUNDS WITH DIFFERENTIATED OPIOID AQION 
PROFILES. 

000013 01-02 
EFFECTS OF PHENOTHIAZINE DERIVATIVES AND RELATED COMPOUNDS ON 
TYROSINE-AMINOTRANSFERASE AQIVITY. 

000018 01-03 
ANORECTIC-EFFECT OF LISURIDE AND OTHER ERGOT DERIVATIVES IN THE 
RAT 

000042 01-03 
INHIBITION OF BRAIN SYNAPTOSOMAL UPTAKE OF CHOLINE BY SOME 2 
CARBOXAMIDOSTRYCHNINE DERIVATIVES WITH MUSCLE-RELAXANT 
PROPERTIES. 

000084 01-03 
DIAZEPAM IN COMBINATION WITH TACRINE DERIVATIVES ANTAGONIZES 
BEHAVIOURAL-EFFEQS OF ANTICHOLINERGIC PSYCHOTOMIMETICS IN 

RATS. 

000420 01-04 

STRUCTURE-AQIVITY RELATIONSHIP OF PHENCYCLIDINE DERIVATIVES. 

001030 02-01 , 
THE EFFECT OF PHENELZINE AND SOME OF ITS PARA HALOGENATED " 

DERIVATIVES ON THE LEVELS OF BRAIN TYRAMINE AND OQOPAMINE 
IN THE MOUSE 

001077 02-02 . 
SYNTHESIS AND PHARMACOLOGY OF 2 AMIN0-3-ETHOXYCARB0NYL-4- ' 
PHENYLTHIOPHENE DERIVATIVES. 

001083 02-02 
SYNTHESIS AND ANXIOLYTIC-ACTIVITY OF A SERIES OF 
PYRAZINOBENZODIAZEPINE DERIVATIVES. 

001089 02-02 
DERIVATIVES OF 1 1 1 PIPERAZINYL-5H-PYRR0L0BENZ0DIAZEPINE AS 
CENTRAL-NERVOUS-SYSTEM AGENTS. 

001093 02-02 
ADAPTIVE CHANGES OF THE STRIATAL DOPAMINE SYSTEM INDUCED BY 
REPEATED ADMINISTRATION OF NEUROLEPTICS AND ERGOT 

DERIVATIVES. 

001156 02-03 
NEUROPHYSIOLOGICAL-STUDY OF TWO ANISAMIDE DERIVATIVES: 
SULPIRIDE AND SUlTOPRIDE. 

001170 02-03 
EFFECT OF ERGOT DERIVATIVES ON POSTDECAPITATION CONVULSIONS. 

001288 02-03 
REGIONAL RELEASE OF (3H)ADEN0SINE DERIVATIVES FROM RAT-BRAIN 
IN VIVO EFFECT OF EXCITATORY AMINO-ACIDS, OPIATE AGONISTS, 
AND BENZODIAZEPINES. 

001303 02-03 
AMINOPHYLLINE AND THEOPHYLLINE DERIVATIVES AS ANTAGONISTS OF 
NEURONAL DEPRESSION BY ADENOSINE: A MICROIONTOPHORETIC- 

^™^^ 001410 02-03 

INTERACTION OF DOPAMINERGIC ERGOT DERIVATIVES WITH CYCLIC- 

NUCLEOTIDE SYSTEM. 

001482 02-03 
PHENCYCLIDINE (PCP) AND DERIVATIVES: PHARMACOLOGY AND 

STRUCTURE-ACTIVITY RELATIONSHIPS. 001706 02^ 

COMPARISON OF OPIATE AGONISTS AND THEIR N ALLYL DERIVATIVES IN 
THE PRODUCTION OF PHYSICAL-DEPENDENCE IN THE RAT. 

001841 02-05 
NEUROPSYCHOPHARMACOLOGICAL-STUDIES ON SOME BENZAMIDE 

DERIVATIVES. ^ „ „^ ,, 

002220 02-13 

NEUROPHARMACOLOGY OF SYNTHETIC ERGOT DERIVATIVES IN MAN^ 

002429 02-15 

CENTRAL DOPAMINERGIC-EFFEaS OF ERGOLINE DERIVATIVES. 

002540 02-17 
ON-COLUMN GAS-CHROMATOGRAPHIC-SYNTHESIS OF 1,3 DIALYKYL 
{C=l-10) BENZYL, AND CYCLOHEXYLBARBITURATE DERIVATIVES. 

003656 04-01 
GAS-CHROMATOGRAPHIC-PROPERTIES OF 1,3 DIALKYLBARBITURATE 

^^^'^*^'^^^ 003658 04-01 

SPECTRA OF RADICAL CATIONS OF PHENOTHIAZINE DERIVATIVES IN 

SOLUTION AND SOLID STATE 003673 04-01 

SYNTHESIS AND BIOCHEMICAL AND PHARMACOLOGIC PROPERTIES OF 

ANALOGUES AND DERIVATIVES OF P CHLOROPHENYLALANINE. 

003691 04-02 
SYNTHESIS AND PHARMACOLOGICAL AQIVITY OF SOME 2 IMINO-3- 

ALKYLTHIAZOLINE DERIVATIVES. 003698 04-02 

MULTIPLE BENZODIAZEPINE-RECEPTORS: EVIDENCE OF A DISSOCIATION 

BETWEEN ANTICONFLICT AND ANTICONVULSANT PROPERTIES BY PK- 

8 1 65 AND PK-9084 (TWO QUINOLINE DERIVATIVES) 

003898 04-UJ 



S-132 



VOLUME 19, SUBJECT INDEX 



Subject Index 



EFFECTS OF NORCOCAINE AND SOME NORCOCAINE DERIVATIVES ON 
SCHEDULE-CONTROLLED BEHAVIOR OF PIGEONS AND SQUIRREL- 
MONKEYS. 

004012 04-03 
CRIVATIZATION 

GLC/TLC ANALYSIS OF CODEINE AND MORPHINE IN URINE VIA 
DERIVATIZATION TECHNIQUES 

004687 04-16 
ERMATOLOGIC 

DERMATOLOGIC MANIFESTATIONS OF LITHIUM: A REVIEW. 

003462 03-15 
CS-TYR-GAMMA-ENDORPHIN 

EFFECTS OF DES-TYR-GAMMA-ENDORPHIN ON DOPAMINE RELEASE FROM 
VARIOUS RAT-BRAIN REGIONS IN VITRO. 

000264 01-03 
DES-TYR-GAMMA-ENDORPHIN ADMINISTRATION IN CHRONIC 
SCHIZOPHRENICS: A PRELIMINARY REPORT. 

003198 03-08 
EFFECT OF DES-TYR-GAMMA-ENDORPHIN IN TARDIVE-DYSKINESIA. 

003472 03-15 
ES-TYROSINE-GAMMA-ENDORPHIN 

DES-TYROSINE-GAMMA-ENDORPHIN: H-REFLEX RESPONSE SIMILAR TO 
NEUROLEPTICS. 

004540 04-13 
ES-TYROSYL-GAMMA-ENDORPHIN 

DES-TYROSYL-GAMMA-ENDORPHIN IN SCHIZOPHRENIA: A DOUBLE-BLIND 
TRIAL IN 13 PATIENTS. 

004322 04-08 
ES-TYR 1 -GAMMA-ENDORPHIN 

INHIBITION OF IN VIVO 3H SPIPERONE BINDING BY THE PROPOSED 
ANTIPSYCHOTIC DES-TYR 1 -GAMMA-ENDORPHIN . 

000226 01-03 
EFFEQS OF THE POTENTIAL NEUROLEPTIC-PEPTIDE DES-TYR 1 -GAMMA- 
ENDORPHIN AND HALOPERIDOL ON APOMORPHINE-INDUCED 
BEHAVIOURAL-SYNDROMES IN RATS AND MICE. 

000441 01-04 
DES-TYR 1 -GAMMA-ENDORPHIN IN SCHIZOPHRENIA. 

001918 02-08 
ESACETYLLANATOSIDE-C 

CORTICAL CONTROL OF NEURALLY MEDIATED ARRHYTHMOGENIC- 
PROPERTIES OF DESACETYLLANATOSIDE-C. 

003124 03-05 
ESCRIPTION 

FREE DESCRIPTION OF DRUG-EFFECTS AS A METHOD OF CLINICAL-TRIAL 
PRESENTED BY THE EXAMPLE OF PENTOBARBITONE, PROMAZINE AND 
THEIR COMBINATION. 

002561 02-17 
ESENSITIZATION 

DESENSITIZATION OF ADRENOCEPTORS AFTER IMMOBILIZATION STRESS 
OR REPEATED INJECTION OF ISOPROTERENOL IN RATS. (UNPUBLISHED 
PAPER). 

001546 02-03 
MEPACRINE TREATMENT PREVENTS IMMOBILIZATION-INDUCED 
DESENSITIZATION OF BETA-ADRENERGIC-RECEPTORS IN RAT 
HYPOTHALAMUS AND BRAINSTEM. 

002919 03-03 
INVOLVEMENT OF CALCIUM CHANNELS IN SHORT-TERM 
DESENSITIZATION OF MUSCARINIC-RECEPTOR MEDIATED CYCLIC-GMP 
FORMATION IN MOUSE NEUROBLASTOMA CELLS. 

003783 04-03 
DESENSITIZATION OF HISTAMINE HI -RECEPTOR-MEDIATED CYCLIC-GMP 
FORMATION IN MOUSE NEUROBLASTOMA CELLS. 

004030 04-03 
ANTIDEPRESSANTS AND ALPHA2-ADRENERGIC-AUT0RECEPT0R 
DESENSITIZATION. 

004659 04-15 
:S6LYCINAMIDE-LYSINE-VASOPRESSIN 

EFFECTS OF DESGLYCINAMIDE-LYSINE-VASOPRESSIN ON A CONDITIONED 
TASTE-AVERSION IN RATS. 

■SIGN 00181102-04 

CONTROLLED-COMPARISON OF PERPHENAZINE WITH PERPHENAZINE IN 
SCHIZOPHRENIA: A METHODICAL-CHECK OF A DOUBLE-BUND CROSS- 
OVER DESIGN. 

„..,^ 001937 02-08 

DESIGN ASPECTS OF CLINICAL-TRIALS WITH ERGOT ALKALOIDS A 
COMPARISON OF TWO GERIATRIC BEHAVIORAL-RATING-SCALES 
^„,.^ 002512 02-16 

DOSAGE FORM DESIGN FOR IMPROVEMENT OF BIOAVAILABILITY OF 
LEVODOPA III: INFLUENCE OF DOSE ON PHARMACOKINETIC BEHAVIOR 
OF LEVODOPA IN DOGS AND PARKINSONIAN-PATIENTS. 

SPECIFIC GABA-RECEPTOR AGONISTS AND UPTAKE INHIBITORS: DESIGN 
DEVELOPMENT AND STRUCTURE-ACTIVITY STUDIES 
•SIGNS 004725 04-17 

ON THE USE OF REPEATED MEASURES DESIGNS IN 
PSYCHOPHARMACOLOGY. 

004695 04-16 



DESIPRAMINE 

COMPARISON OF MIANSERIN WITH DESIPRAMINE, MAPROIILINE AND 
PHENTOLAMINE ON CARDIAC PRESYNAPTIC AND VASCULAR 
POSTSYNAPTIC ALPHA-ADRENOCEPTORS AND NORADRENALINE 
REUPTAKE IN PITHED NORMOTENSIVE-RATS 

000044 01-03 
FUNCTIONAL EVIDENCE FOR SUBSENSITIVITY OF NORADRENERGIC- 
ALPHA2-RECEPT0RS AFTER CHRONIC DESIPRAMINE TREATMENT. 

000283 01-03 
EFFICACY OF DESIPRAMINE IN ENDOGENOMORPHICALLY DEPRESSED- 
PATIENTS. 

000632 01-09 
NEUROLEPTIC-EFFECT ON DESIPRAMINE STEADY-STATE PLASMA 
CONCENTRATIONS, 

000781 01-13 
DESIPRAMINE: CARDIOVASCULAR EFFECTS AND PLASMA LEVELS. 

000884 01-15 
THE TIME-COURSE OF NORADRENERGIC PRESYNAPTIC AND 
POSTSYNAPTIC ACTIVITY DURING CHRONIC DESIPRAMINE 
TREATMENT. 

001289 02-03 
EFFECTS OF DESIPRAMINE AND YOHIMBINE ON ALPHA2-ADREN0CEPT0R 
AND BETA-ADRENOCEPTOR SENSITIVITY 

001305 02-03 
INTERACTION OF TRIAZOLAM WITH DESIPRAMINE: EFFECTS OF SINGLE 
AND REPEATED TREATMENT ON CERTAIN PHARMACOLOGIC- 
RESPONSES AND BRAIN CATECHOLAMINE LEVELS. 

001323 02-03 
EFFECTS OF NOMIFENSINE AND DESIPRAMINE ON THE SEQUELAE OF 
INTRACEREBRALLY INJECTED 6 OHDA AND 5 6 DHT 

001522 02-03 
CLINICAL-RESPONSE, PLASMA LEVELS AND PHARMACOKINETICS OF 
DESIPRAMINE IN DEPRESSED-INPATIENTS. 

002002 02-09 
PLASMA DESIPRAMINE LEVELS AFTER SINGLE-DOSAGE AND AT STEADY- 
STATE IN OUTPATIENTS. 

002039 02-09 
THE PERIPHERAL ANTICHOLINERGIC-ACTIVITY OF TRICYCLIC- 
ANTIDEPRESSANTS: COMPARISON OF AMITRIPTYLINE AND 
DESIPRAMINE IN HUMAN VOLUNTEERS. 

002298 02-13 
DIFFERENTIAL-EFFECT OF CHRONIC DESIPRAMINE AND AMITRIPTYLINE 
TREATMENT ON RAT-BRAIN ADRENERGIC AND SEROTONERGIC- 
RECEPTORS. 

002914 03-03 
DESIPRAMINE AND 2 HYDROXYDESIPRAMINE PHARMACOKINETICS IN 
NORMAL VOLUNTEERS. 

003154 03-07 
CROSS-OVER STUDY OF ZIMELIDINE AND DESIPRAMINE IN DEPRESSION: 
EVIDENCE FOR AMINE SPECIFICITY. 

003250 03-09 
EFFICACY OF DESIPRAMINE IN MILDLY DEPRESSED-PATIENTS: A DOUBLE- 
BLIND, PLACEBO-CONTROLLED-TRIAL. 

003262 03-09 
ELECTROCARDIOGRAM-CHANGES AND PLASMA DESIPRAMINE LEVELS 
DURING TREATMENT OF DEPRESSION. 

004411 04-09 
BLOCKADE BY IMIPRAMINE OR DESIPRAMINE OF PANIC-INDUCED BY 
SODIUM-LACTATE. 

004427 04-10 
ANTICHOLINERGIC-EFFECTS AND PLASMA DESIPRAMINE LEVELS. 

004550 04-13 
DESIPRAMINE-HYDROCHLORIDE 

SINGLE-DOSE VERSUS MULTIPLE-DOSE COMPARATIVE-TRIAL OF 
DESIPRAMINE-HYDROCHLORIDE: A DOUBLE-PLACEBO METHOD 

002059 02-10 
DESIPRAMINE-INDUCED 

ACCELERATION OF DESIPRAMINE-INDUCED DECREASE OF RAT 
CORTICOCEREBRAL BETA-ADRENERGIC-RECEPTORS BY YOHIMBINE. 

000326 01-03 
DESMETHYL 

KINETICS AND NEUROPSYCHOLOGIC-EFFECTS OF IV DIAZEPAM IN THE 
PRESENCE AND ABSENCE OF ITS ACTIVE N DESMETHYL METABOLITE IN 
HUMANS. 

002229 02-13 
OESMETHYLATED-COMPOUND 

INFLUENCE OF A CHRONIC NEW POTENTIAL ANTIDEPRESSANT 
DIMETHYLAMINOPROPYL-5-METHYL-3-PHENYL-1 H-INDAZOLE (FS-32) 
AND ITS N DESMETHYLATED-COMPOUND (FS-97): TREATMENT ON 
MONOAMINERGIC-RECEPTOR SENSITIVITY IN THE RAT-BRAIN. 

002787 03-03 
DESMETHYLDIAZEPAM 

EFFECT OF DIAZEPAM AND DESMETHYLDIAZEPAM IN SPASTICITY AND 
RIGIDITY: A QUANTITATIVE STUDY OF REFLEXES AND PLASMA 
CONCENTRATIONS. 

000701 01-11 
COMPARATIVE PROTEIN BINDING OF DIAZEPAM AND 
DESMETHYLDIAZEPAM. 

002206 02-13 









««.: 
t'." 

£'!' 



"IrW' 



S-133 



Subject Index 

INFLUENCE OF CIMETIDINE ON THE PHARMACOKINETICS OF 
DESMETHYLDIAZEPAM AND OXAZEPAM. 

002249 02-13 
ANXIETY AND SEDATION DURING A STRESSFUL-SITUATION AFTER SINGLE- 
DOSE OF DIAZEPAM VERSUS N DESMETHYLDIAZEPAM - A 
CONTROLLED-TRIAL. 

002329 02-14 
DESMETHYLDIAZEPAM KINETICS IN THE ELDERLY AFTER ORAL 

PRAZEPAM. „„..o„^. ,, 

004432 04-11 

RADIOIMMUNOASSAY FOR TOTAL DOXEPIN AND N DESMETHYLDOXEPIN 

IN PLASMA. „„^.„„„ow 

002499 02-16 
PLASMA LEVELS OF THE CIS-ISOMERS AND TRANS-ISOMERS OF DOXEPIN 
AND DESMETHYLDOXEPIN AFTER ADMINISTRATION OF DOXEPIN TO 

"^^'^^^^ 004355 04-09 

DESMETHYLIMIPRAMINE 

ABILITY OF AGED RATS TO ALTER BETA-ADRENERGIC-RECEPTORS OF 
BRAIN IN RESPONSE TO REPEATED ADMINISTRATION OF RESERPINE 
AND DESMETHYLIMIPRAMINE. „„„, , o «, „o 

000113 01-03 
STUDIES ON THE PUTATIVE ANTICHOLINERGIC-EFFEaS OF 
DESMETHYLIMIPRAMINE. „„„..„ „, „. 

000228 01-03 
EFFECT OF DESMETHYLIMIPRAMINE ON THE KINETICS OF 
CHLORPHENTERMINE ACCUMULATION IN ISOLATED PERFUSED RAT 

LUNG. 

000524 01-05 
PLASMA LEVELS OF IMIPRAMINE (IMI) AND DESMETHYLIMIPRAMINE 
(DMI) AND CLINICAL-RESPONSE IN PREPUBERTAL MAJOR DEPRESSIVE- 
DISORDER: A PRELIMINARY REPORT. 

000619 01-09 
AN INVERSE CORRELATION BETV/EEN SERUM LEVELS OF 

DESMETHYLIMIPRAMINE AND MELATONIN-LIKE IMMUNOREAQIVITY 
IN DMI RESPONSIVE DEPRESSIVES. „„..„„ „. „„ 

003228 03-09 
EFFECT OF DESMETHYLIMIPRAMINE ON TISSUE DISTRIBUTION AND 
ANORECTIC-AQIVITY OF CHLORPHENTERMINE IN RATS. 

004179 04-04 
EFFECTS OF SUBCHRONIC DESMETHYLIMIPRAMINE (DMI) TREATMENT OF 

THE CLASSICALLY CONDITIONED EYEBLINK RESPONSE IN RABBITS. 

004180 04-04 

DESMETHYLMETHSUXIMIDE 

ELECTRON-CAPTURE GAS-LIQUID-CHROMATOGRAPHIC-DETERMINATION 
OF ETHOSUXIMIDE AND DESMETHYLMETHSUXIMIDE IN PLASMA OR 

^^■^^^ 000538 01-06 

DESORPTION 

DIFFERENTIAL BINDING OF CHLORPROMAZINE TO HUMAN BLOOD CELLS: 
APPLICATION OF THE HYGROSCOPIC DESORPTION METHOD 

003556 03-16 
DESTROYS 

EXPOSURE OF MITOCHONDRIAL OUTER MEMBRANES TO NEURAMINIDASE 
SELECTIVELY DESTROYS MONOAMINE-OXIDASE-A ACTIVITY. 

001286 02-03 
DESTRUCTION 

EFFEaS OF L-DOPA AND L 5 HYDROXYTRYPTOPHAN ON LOCOMOTOR- 
ACTIVITY OF THE RAT AFTER SELECTIVE OR COMBINED DESTRUCTION 
OF CENTRAL CATECHOLAMINE AND SEROTONIN NEURONS. 

000466 01-04 
EFFECT OF SELECTIVE DESTRUQION OF SEROTONERGIC NEURONS IN 
NUCLEUS-RAPHE-MAGNUS ON MORPHINE-INDUCED ANTINOCICEPTION 

001724 02-04 
DORSAL TEGMENTAL BUNDLE DESTRUQION: EFFECTS ON OPERANT- 
BEHAVIOR, BRAIN CATECHOLAMINE LEVELS, AND BEHAVIORAL- 
SUPPRESSION PRODUCED BY ADRENERGIC AGONISTS. 

001726 02-04 
DOPAMINE AND DEMENTIA. AN ANIMAL-MODEL WITH DESTRUCTION OF 
THE MESOCORTICAL DOPAMINERGIC PATHWAY: A PRELIMINARY 
STUDY. 

003085 03-04 
BEHAVIORAL AND REGIONAL NEUROCHEMICAL SEQUELAE OF 
HIPPOCAMPAL DESTRUCTION IN THE RAT. 

003721 04-03 
SENSORY NEUROTOXINS: CHEMICALLY-INDUCED SELEQIVE DESTRUCTION 
OF PRIMARY SENSORY NEURONS. 

003859 04-03 
THE EFFEQ OF PHARMACOLOGICAL DESTRUQION OF HYPOTHALAMIC 
MONOAMINERGIC STRUCTURES ON BODY-TEMPERATURE AND GAS- 
EXCHANGE DURING EXTREME COOLING. 

004016 04-03 
DESTRUCTION OF 5 HYDROXYTRYPTAMINERGIC NEURONS AND THE 
DYNAMICS OF DOPAMINE IN NUCLEUS-ACCUMBENS SEPTI AND OTHER 
FOREBRAIN REGIONS OF THE RAT. 

004171 04-04 
DOPAMINE-RECEPTOR CHANGES FOLLOWING DESTRUCTION OF THE 
NIGROSTRIATAL PATHWAY: LACK OF A RELATIONSHIP TO 
ROTATIONAL-BEHAVIOR. 

004229 04-04 



Psychopharmacology Abstracts k 

DETECT 

USING PROFILES OF SACCHARIN AND WATER DRINKING TO DETEQ AND 
DISCRIMINATE ACTIONS OF DRUGS AND TOXICANTS. 

000503 01-04 
EFFECTS OF PENTAZOCINE AND NALORPHINE ON MOTILITY IN 
CHRONICALLY MORPHINE TREATED RATS: A POTENTIAL SUBSTITUTION 
TEST TO DETECT THE NARCOTIC CHARACTER OF A DRUG. 

003555 03-16 
DETECTED 

DRUG-THERAPY IN ENDOGENOUS DEPRESSION WITH POSSIBLE PRIMARY 
GABA DEFICIENCY CLINICALLY DETECTED: 38 NEW CASES. 

000584 01-09 
INFERENTIAL CHANGES AFTER CHRONIC-TREATMENTS WITH LI. DMI, OR 
ETHANOL DETECTED BY ELECTROPHYSIOLOGICAL-CORRELATES 

001136 02-03 
CYCLOPHOSPHAMIDE-INDUCED SPERMATOGENIC EFFECTS DETECTED IN 
THE Fl-GENERATION BY BEHAVIORAL-TESTING. 

003121 03-05 
DETECTING 

THE USE OF SOCIAL-INTERACTION AS A METHOD FOR DETECTING 
ANXIOLYTIC-ACTIVITY OF CHLORDIAZEPOXIDE-LIKE DRUGS. 

001866 02-06 
DETECTION 

APPLICATION OF A RADIOIMMUNOASSAY SCREENING-TEST FOR 
DETECTION AND MANAGEMENT OF PHENCYCLIDINE INTOXICATION. 

000859 01-15 
LEVODOPA AND PRESYMPTOMATIC DETECTION OF HUNTINGTONS- 
DISEASE - EIGHT-YEAR FOLLOWUP. 

000950 01-17 
DETECTION OF MULTIPLE RECEPTORS FOR DOPAMINE. 

001481 02-03 
BEHAVIORAL-TEST FOR DETECTION OF SUBCLINICAL BRAIN-DAMAGE: AN 
EXPERIMENTAL MODEL. 

003120 03-04 
A METHOD FOR MEASUREMENT OF TRANYLCYPROMINE IN RAT-BRAIN 
REGIONS USING GAS-CHROMATOGRAPHY WITH ELECTRON CAPTURE 
DETECTION. 

003137 03-06 
EARLY DETECTION OF HUNTINGTONS-DISEASE. BLINK REFLEX AND 
LEVODOPA LOAD IN PRESYMPTOMATIC AND INCIPIENT SUBJECTS. 

003311 03-11 
A RAPID AND SIMPLE METHOD FOR THE DETERMINATION OF PICOGRAM 
LEVELS OF 3 METHOXYTYRAMINE IN BRAIN TISSUE USING LIQUID- 
CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION. 

003674 04-01 
REWARD AND DETECTION THRESHOLDS FOR BRAIN-STIMULATION: 
DISSOCIATIVE-EFFECTS OF COCAINE. 

004160 04-04 
RAPID DETERMINATION OF CHLORPROMAZINE-HCL AND TWO OXIDATION 
PRODUCTS IN VARIOUS PHARMACEUTICAL SAMPLES USING HIGH- 
PERFORMANCE LIQUID-CHROMATOGRAPHY AND FLUORESCENCE 
DETECTION 

004302 04-06 
MEPROBAMATE REDUCES ACCURACY OF PHYSIOLOGICAL DETECTION OF 

DECEPTION. „. „ ,. 

004585 04-14 , 

DETERMINANTS ,_, „, 

PRIOR AND ONGOING EXPERIENCE AS DETERMINANTS OF THE EFFECTS OF 
D-AMPHETAMINE AND CHLORPROMAZINE ON PUNISHED-BEHAVIOR. 

000339 01-04 

CONSEQUENT EVENTS AS DETERMINANTS OF DRUG-EFFECTS ON 
SCHEDULE-CONTROLLED BEHAVIOR: MODIFICATION OF EFFECTS OF 
COCAINE AND D-AMPHETAMINE FOLLOWING CHRONIC AMPHETAMINE 

ADMINISTRATION. ,,^„,„ „, „. ' 

000350 01-04 

DETERMINATION 

A PRELIMINARY STUDY ON DETERMINATION OF THE OPTIMUM 
OPIPRAMOL DOSAGE IN DEPRESSIVE-PATIENTS 

000601 01-09 

3 CHLORO-4-PHENYLSUCCINIMIDOBENZENESULFONAMIDE (GS-385), A 
NEW ANTICONVULSANT: ITS QUANTITATIVE DETERMINATION. , 

PHARMACOKINETICS AND METABOLISM USING HIGH-PERFORMANCE 
LIQUID-CHROMATOGRAPHY. 000705 01-11 

DETERMINATION OF THE ENCEPHALOTROPIC, PSYCHOTROPIC AND 
PHARMACODYNAMIC PROPERTIES OF NICERGOLINE BY MEANS OF 
QUANTITATIVE PHARMACOELECTROENCEPHALOGRAPHY AND 
PSYCHOMETRIC-ANALYSES. 000788 01-13 

DETERMINATION OF DOSE PLASMA CONCENTRATION RELATIONSHIP OF 

PHENOBARBITAL IN EPILEPTIC-PATIENTS BY A NEW SPECIFIC 

RADIOIMMUNOASSAY. „„„„„^ „, ,^ 

000902 01-16 

DETERMINATION OF VALPROIC-ACID BY FLAME-IONIZATION GAS-LIQUID- 
CHROMATOGRAPHY 000906 01-16 

INTERRELATIONS AMONG PRIOR EXPERIENCE AND CURRENT CONDITIONS 
IN THE DETERMINATION OF BEHAVIOR AND THE EFFECTS OF DRUGS. 

0017)5 02-04 



S-134 



fOLUME 19, SUBJECT INDEX 



Subject Index 



DETERMINATION OF PHARMACODYNAMICS OF PSYCHOTROPIC-DRUGS BY 
PSYCHOMETRIC-ANALYSIS, 

001895 02-07 
MIANSERIN: DETERMINATION OF THERAPEUTIC DOSE RANGE. 

002026 02-09 
METHOD FOR THE DETERMINATION OF TRYPTOPHAN IN SERUM AND 
CEREBROSPINAL-FLUID. 

002208 02-13 
A METHOD FOR THE DETERMINATION OF AMITRIPTYLINE AND ITS 
METABOLITES NORTRIPTYLINE, 10 HYDROXYAMITRIPTYLINE, AND 10 
HYDROXYNORTRIPTYLINE IN HUMAN PLASMA USING STABLE ISOTOPE 
DILUTION AND GAS-CHROMATOGRAPHY CHEMICAL-IONIZATION 
MASS-SPECTROMETRY. 

002486 02-16 
DETERMINATION OF TRICYCLIC-ANTIDEPRESSANTS AND TETRACYCLIC- 
ANTIDEPRESSANTS AND OF THEIR METABOLIC PRODUCTS IN 
BIOLOGICAL FLUIDS. 

002498 02-16 
A RAPID GAS-LIQUID-CHROMATOGRAPHY METHOD FOR SIMULTANEOUS 
DETERMINATION OF VARIOUS ANTICONVULSANTS. 

002501 02-16 
DETERMINATION OF GABA LEVELS BY A (3H)MUSCIM0L RADIORECEPTOR 
ASSAY. 

003135 03-06 
SIMULTANEOUS DETERMINATION OF FEMTOMOLE QUANTITIES OF 5 
HYDROXYTRYPTOPHAN, SEROTONIN AND 5 HYDROXYINDOLEACETIC- 
ACID IN BRAIN USING HPLC WITH ELECTROCHEMICAL-DETECTION. 

003139 03-06 
THERAPEUTIC INTEREST OF BLOOD LEVELS DETERMINATION FOR 
ANTIDEPRESSANTS: METHODOLOGICAL APPROACH. 

003571 03-16 
A RAPID AND SIMPLE METHOD FOR THE DETERMINATION OF PICOGRAM 
LEVELS OF 3 METHOXYTYRAMINE IN BRAIN TISSUE USING LIQUID- 
CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION. 

003674 04-01 
A SIMPLE DETERMINATION OF SEROTONIN, 5 HYDROXYINDOLEACETIC- 
ACID AND 5 HYDROXYTRYPTOPHAN-DECARBOXYLASE ACTIVITY IN 
RAT-BRAIN AREAS AND PARALLEL CORRELATION AMONG THE LEVELS. 

004301 04-06 
RAPID DETERMINATION OF CHLORPROMAZINE-HCL AND TWO OXIDATION 

PRODUCTS IN VARIOUS PHARMACEUTICAL SAMPLES USING HIGH- 
PERFORMANCE LIQUID-CHROMATOGRAPHY AND FLUORESCENCE 
DETEQION. 

004302 04-06 
DETERMINATION OF PICOMOLE AMOUNTS OF DOPAMINE, 

NORADRENALINE, 3,4 DIHYDROXYPHENYLALANINE, 3,4 
DIHYDROXYPHENYLACETIC-ACID, HOMOVANILLIC-ACID, AND 5 
HYDROXYINDOLEACETIC-ACID IN NERVOUS-TISSUE AFTER ONE-STEP 
PURIFICATION ON SEPHADEX-G-10, USING HIGH. 

004305 04-06 
bFFECTS OF RO-1 1-2465, A NEW PSYCHOTROPIC-AGENT ON THE UPTAKE 
OF SEROTONIN BY HUMAN PLATELETS - IN VITRO DETERMINATION OF 
THE IC50. 

004532 04-13 
A COMPARISON OF RADIOIMMUNOASSAY WITH SPEQROPHOTOMETRY 
FOR THE DETERMINATION OF PLASMA DIPHENYLHYDANTOIN 
CONCENTRATIONS. 

004684 04-16 
SIMULTANEOUS DETERMINATION OF MORPHINE AND CODEINE IN BLOOD 
BY USE OF SELECT ION-MONITORING AND DEUTERATED INTERNAL 
STANDARDS. 

004690 04-16 
ETERMINATIONS 

USE OF PLASMA CONCENTRATION DETERMINATIONS. 

004498 04-13 
KINETICS AND BIOTRANSFORMATION OF LORMETAZEPAM: II. 
RADIOIMMUNOLOGIC DETERMINATIONS IN PLASMA AND URINE OF 
YOUNG AND ELDERLY SUBJECTS: FIRST-PASS EFFECT. 

004516 04-13 
ETOXIFICATION 

IATROGENIC OPIATE ADDICTION: SUCCESSFUL DETOXIFICATION WITH 
CLONIDINE. 

000666 01-11 
CLONIDINE FOR OPIATE DETOXIFICATION: OUTPATIENT CLINICAL-TRIALS. 

000731 01-11 
RAPID OPIATE DETOXIFICATION WITH CLONIDINE AND NALOXONE. 

000820 01-14 
CLONIDINE FOR OUTPATIENT OPIATE DETOXIFICATION. 

000827 01-14 
ETOXIFYIN6 

SALIVA BENZODIAZEPINE LEVELS AND CLINICAL OUTCOME IN 
DETOXIFYING ALCOHOLIC-PATIENTS. 

004671 04-16 
EUTERATED 

SIMULTANEOUS DETERMINATION OF MORPHINE AND CODEINE IN BLOOD 
BY USE OF SELECT ION-MONITORING AND DEUTERATED INTERNAL 
STANDARDS. 

004690 04-16 



DEUTERIUM 

NOREPINEPHRINE METABOLISM IN MAN USING DEUTERIUM LABELLING: 4 
HYDROXY-3-METHOXYMANDELIC-ACID 

004534 04-13 
DEVELOPED 

A STUDY ON MENTAL-SYMPTOMS DEVELOPED DURING THE TREATMENT 
OF PARKINSONS-DISEASE. 

004618 04-15 
DEVELOPING 

LOCALIZATION OF ALPHA BUNGAROTOXIN BINDING-SITES IN SYNAPSES 
OF THE DEVELOPING CHICK RETINA. 

000065 01-03 
EFFECTS OF APOMORPHINE ON ESCAPE PERFORMANCE AND ACTIVITY IN 

DEVELOPING RAT PUPS TREATED WITH 6 HYDROXYDOPAMINE (6 
OHDA). 

000426 01-04 
THE LOCOMOTOR-EFFECT OF CLONIDINE AND ITS INTERACTION WITH 
ALPHA FLUPENTHIXOL OR HALOPERIDOL IN THE DEVELOPING RAT. 

000445 01-04 
EFFECT OF CHLORPROMAZINE ON CELL PROLIFERATION IN THE 
DEVELOPING RAT-BRAIN. A COMBINED BIOCHEMICAL- STUDY AND 
MORPHOLOGICAL-STUDY. 

001407 02-03 
HYPERACTIVITY IN DEVELOPING RATS: SEX-DIFFERENCES IN 6 
HYDROXYDOPAMINE AND AMPHETAMINE EFFECTS. 

002970 03-04 
EFFECT OF AMPHETAMINE ON THE METABOLISM AND INCORPORATION 
OF (3H) THYMIDINE INTO DNA OF DEVELOPING RAT-BRAIN. 

003729 04-03 
THE EFFECTS OF CHRONIC METHYLPHENIDATE TREATMENT ON GROWTH 
AND ENDOCRINE FUNCTION IN THE DEVELOPING RAT. 

003811 04-03 
EFFECT OF NEONATAL HYDROCORTISONE TREATMENT ON BRAIN- 
MONOAMINES IN DEVELOPING RATS. 

003893 04-03 
THE INSENSITIVITY OF DEVELOPING BENZODIAZEPINE-RECEPTORS TO 
CHRONIC-TREATMENT WITH DIAZEPAM, GABA AND MUSCIMOL IN 
BRAIN CELL-CULTURES. 

004002 04-03 
DEVELOPMENT 

REDUCTION OF OPIATE BINDING TO BRAINSTEM SLICES ASSOCIATED 
WITH THE DEVELOPMENT OF TOLERANCE TO MORPHINE IN RATS. 

000066 01-03 
PHENYLACETATE AND BRAIN-DYSFUNCTION IN EXPERIMENTAL 

PHENYLKETONURIA: SYNAPTIC DEVELOPMENT. 

000191 01-03 
EFFECTS OF 6 HYDROXYDOPAMINE AND AMPHETAMINE ON RAT 
MOTHERING-BEHAVIOR AND OFFSPRING DEVELOPMENT. 

000452 01-04 
CHRONIC ADMINISTRATION OF HALOPERIDOL DURING DEVELOPMENT: 
BEHAVIORAL-EFFECTS AND PSYCHOPHARMACOLOGICAL-EFFECTS. 

000481 01-04 
INTERACTIVE-EFFECTS OF NUTRITION AND CANNABIS UPON RAT 
PERINATAL DEVELOPMENT. 

000513 01-05 
EFFECTS OF LEAD EXPOSURE DURING DEVELOPMENT ON NEOCORTICAL 
DENDRITIC AND SYNAPTIC STRUCTURE. 

000525 01-05 
CRITERIA FOR CLINICAL DEVELOPMENT AND CLASSIFICATION OF 
NOOTROPIC-DRUGS. AN EXAMPLE: PIRACETAM. 

000988 01-17 
PRESYNAPTIC DOPAMINE-RECEPTORS: INSENSITIVITY TO KAINIC-ACID 
AND THE DEVELOPMENT OF SUPERSENSITIVITY FOLLOWING CHRONIC 
HALOPERIDOL. 

001117 02-03 
RAPID DEVELOPMENT OF HYPERSENSITIVITY AND HYPOSENSITIVITY TO 
APOMORPHINE AND HALOPERIDOL: ROLE OF NOREPINEPHRINE- 
RECEPTOR MECHANISMS IN CNS. 

001178 02-03 
EVOKED-POTENTIAL CHANGES IN THE SUPERIOR-COLLICULUS PARALLEL 

THE LESION-INDUCED DEVELOPMENT OF GROOMING REFLEXES IN THE 
CAT. (PH.D. DISSERTATION). 

001179 02-03 
DEVELOPMENT OF ACUTE OPIOID-TOLERANCE AND DEPENDENCE IN RAT 

STRIATAL NEURONES. 

001235 02-03 
EFFECTS OF MALNUTRITION AND QUIPAZINE ON RAT-CEREBRAL-CORTEX 
ATPASE ACTIVITY DURING DEVELOPMENT. 

001276 02-03 
BIPHASIC ACTIVITY OF MEMBRANE-BOUND ENZYMES IN BRAIN 
MITOCHONDRIA AND SYNAPTOSOMES DURING THE DEVELOPMENT OF 
TOLERANCE TO AND PHYSICAL-DEPENDENCE ON CHRONIC MORPHINE 
ADMINISTRATION TO RATS. 

001285 02-03 
EFFECTS OF PAVLOVIAN-CONDITIONING AND MIF-1 ON THE 
DEVELOPMENT OF MORPHINE-TOLERANCE IN RATS. 

001327 02-03 
DEVELOPMENT OF AND RECOVERY FROM SUBSENSITIVITY OF THE 
NORADRENERGIC CYCLIC-AMP GENERATING SYSTEM IN BRAIN: EFFECT 



I 

if 






•lit 

iic 



liktn 



S-135 



Subject Index 

OF AMPHETAMINE FOLLOWING INHIBITION OF ITS AROMATIC 
HYDROXYLATION BY IPRINDOLE. 

001353 02-03 
CHRONIC ADMINISTRATION OF HALOPERIDOL DURING DEVELOPMENT: 
LATER PSYCHOPHARMACOLOGICAL RESPONSES TO APOMORPHINE 
AND ARECOLINE. 

001470 02-03 
GLUCOCORTICOIDS AS A REGULATORY FACTOR FOR BRAIN TRYPTOPHAN- 
HYDROXYLASE DURING DEVELOPMENT. 

001500 02-03 
POSTNATAL ALCOHOL EXPOSURE IN THE RAT. ITS EFFECTS ON 
AVOIDANCE CONDITIONING, HEBB-WILLIAMS MAZE-PERFORMANCE, 
MATERNAL-BEHAVIOR, AND PUP DEVELOPMENT. 

001580 02-04 
TOLERANCE DEVELOPMENT TO PHENCYCLIDINE BY CHRONIC 
ADMINISTRATION. 

001619 02-04 
BEHAVIORAL-EFFECTS OF HASHISH IN MICE: II. NURSING-BEHAVIOR AND 
DEVELOPMENT OF THE SUCKLINGS. 

001626 02-04 
EFFECTS OF RESERPINE AND AMPHETAMINE ON THE DEVELOPMENT OF 
HYPERACTIVITY IN MATERNALLY-DEPRIVED RAT PUPS. 

001654 02-04 
EXPERIMENTAL DEPENDENCE ON BARBITURATES: II. RELATIONSHIP 
BETWEEN DRUG LEVELS IN SERUM AND BRAIN AND THE 
DEVELOPMENT OF DEPENDENCE IN RATS. 

001800 02-04 
THE DEVELOPMENT OF PROGENY IN CASES OF ANTENATAL EXPOSURE TO 
PHENAZEPAM. 

001854 02-05 
THE ROLE OF FOLATE DEFICIENCY IN THE DEVELOPMENT OF PERIPHERAL 
NEUROPATHY CAUSED BY ANTICONVULSANTS. 

002402 02-15 
NEUROLEPTIC-INDUCED REINNERVATION SPROUTING IN THE CENTRAL- 
NERVOUS- SYSTEM (A MODEL FOR THE DEVELOPMENT OF TARDIVE- 
DYSKINESIA AND SUPERSENSITIVITY PSYCHOSIS). 

002459 02-15 
DEVELOPMENT AND USE OF PHARMACOLOGICAL-PROBES OF THE CNS IN 
MAN- EVIDENCE OF CHOLINERGIC ABNORMALITY IN PRIMARY 
AFFECTIVE-ILLNESS 

002506 02-16 
CLINICAL-PHARMACOLOGY: DRUG DEVELOPMENT. 

002547 02-17 
NEW DEVELOPMENT IN ANTIDEPRESSANT MEDICATION - A REVIEW. 

002558 02-17 
BENZODIAZEPINE-RECEPTORS IN CHICK RETINA: DEVELOPMENT AND 
CELLULAR LOCALIZATION 

002655 03-03 
DEVELOPMENT OF TOLERANCE TO THE EXCITATORY EFFECT OF MORPHINE 
AND CROSS-TOLERANCE TO THE INHIBITORY ACTION OF BETA 
ENDORPHIN IN THE ISOLATED RAT VAS-DEFERENS. 

002756 03-03 
DEVELOPMENT OF ACUTE TOLERANCE TO THE EFFECTS OF NALOXONE ON 
THE HYPOTHALAMIC PITUITARY LUTEINIZING-HORMONE AXIS IN THE 
MALE RAT. 

002853 03-03 
EFFECTS OF ISOPROTERENOL ON THE DEVELOPMENT OF BETA- 
ADRENERGIC-RECEPTORS IN BRAIN CELL AGGREGATES. 

002932 03-03 
SUPPRESSION OF AQIVE SLEEP BY CHRONIC-TREATMENT WITH 
CHLORIMIPRAMINE DURING EARLY POSTNATAL DEVELOPMENT: 
EFFEaS UPON ADULT SLEEP AND BEHAVIOR IN THE RAT. 

003056 03-04 
DIFFERENTIATION OF OPIATE-RECEPTORS IN THE BRAIN BY THE SELECTIVE 
DEVELOPMENT OF TOLERANCE. 

003088 03-04 
DIFFERENCE IN THE DEVELOPMENT OF TOLERANCE TO MORPHINE AND D 
ALA2-METHI0NINE-ENKEPHALIN IN C57 BL/6J AND DBA/2J MICE. 

003126 03-05 
PRELIMINARY-FINDINGS WITH REGARD TO RISK-FACTORS IN THE 
DEVELOPMENT OF TARDIVE-DYSKINESIA. 

003501 03-15 
THE NECESSITY OF PSYCHOPHARMACOLOGY IN THE DEVELOPMENT OF 
PSYCHIATRY. 

003575 03-17 
NERVE GROWTH-FACTOR STIMULATES DEVELOPMENT OF SUBSTANCE-P 
IN THE EMBRYONIC SPINAL-CORD. 

003881 04-03 
CENTRAL DOPAMINERGIC NEURONS DURING DEVELOPMENT OF GENETIC 
AND DOCA-SALT HYPERTENSION IN THE RAT. 

003899 04-03 
EFFECT OF PRENATAL NEUROLEPTIC TREATMENT ON MEMBRANE 
RECEPTOR DEVELOPMENT IN THE BRAIN. 

003989 04-03 
ONTOGENY OF HISTAMINERGIC NEUROTRANSMISSION IN THE RAT- 
BRAIN- CONCOMITANT DEVELOPMENT OF NEURONAL HISTAMINE, Hl- 
RECEPTORS, AND HI -RECEPTOR-MEDIATED STIMULATION OF 
PHOSPHOLIPID TURNOVER. 

004021 04-03 



Psychopharmacology Abstracts 



DOES RAPID-EYE-MOVEMENT SLEEP PLAY A ROLE IN BRAIN 
DEVELOPMENT? 

004091 04^ 
DEVELOPMENT OF PSYCHOPHARMACOLOGY. 

004667 04-15 
PSYCHOPHARMACOTHERAPY: THE PRESENT STATE AND THE 
DEVELOPMENT OF TRENDS. 

004723 04-17 
SPECIFIC GABA-RECEPTOR AGONISTS AND UPTAKE INHIBITORS: DESIGN, 
DEVELOPMENT AND STRUCTURE-ACTIVITY STUDIES. 

004725 04-17 
DEVELOPMENTAL 

GABA BENZODIAZEPINE INTERACTIONS: PHYSIOLOGICAL, 
PHARMACOLOGICAL AND DEVELOPMENTAL ASPEQS. 

000103 01-03 
PERINATAL NEUROLEPTIC ACTIONS - DEVELOPMENTAL RESULTS. 
(UNPUBLISHED PAPER) 

001277 02-03 
DEVELOPMENTAL ASPECTS OF CATECHOLESTROGEN SYNTHESIS. 
(UNPUBLISHED PAPER). 

001282 02-03 
DEVELOPMENTAL-CHANGE 

DEVELOPMENTAL-CHANGE OF BETA-ADRENERGIC-RECEPTORS IN RAT- 
BRAIN 

004050 04-03 
DEVELOPMENTAL-CHANGE IN REARING RESPONSE TO ATROPINE IN RATS 
TREATED WITH 6 HYDROXYDOPA. 

004191 04-04 - 
DEVELOPMENTAL-CHANGES 

MATURATION OF SYMPATHETIC NEUROTRANSMISSION IN THE RAT 
HEART III DEVELOPMENTAL-CHANGES IN RESERPINE INHIBITION OF 
NOREPINEPHRINE UPTAKE INTO ISOLATED SYNAPTIC VESICLES. 

000025 01-03 
DEVELOPMENTALLY 

RETINAL TOXICITY OF MAM-ACETATE IS DEVELOPMENTALLY SPECIFIC. i 
(UNPUBLISHED PAPER). 

001212 02-03 
DEVELOPMENTALLY REGULATED LECTINS IN SLIME MOULDS AND CHICK 
TISSUES - ARE THEY CELL ADHESION MOLECULES' i 

003724 04-03 
DEXAMETHASONE 

ALTERATION OF PHARMACOKINETIC PARAMETERS FOR PENTOBARBITAL 
BY ISCHEMIC STROKE AND REVERSION TO NORMAL BY 
DEXAMETHASONE TREATMENT. 

000321 01-03 
SELEaiVE REDUCTION BY DEXAMETHASONE OF STRESS RELATED 
HYPERPHAGIAS. 

001703 02-04 
MATURATION OF SYMPATHETIC NEUROTRANSMISSION IN THE RAT 
HEART VII SUPPRESSION OF SYMPATHETIC RESPONSES BY 
DEXAMETHASONE. 

002802 03-03 
CORTISOL DYNAMICS AND DEXAMETHASONE PHARMACOKINETICS IN 
PRIMARY ENDOGENOUS DEPRESSION: PRELIMINARY FINDINGS , 

004403 04-09 
DEXAMETHASONE-SUPPRESSION-TEST 

DEXAMETHASONE-SUPPRESSION-TEST IDENTIFIES SUBTYPES OF 
DEPRESSION WHICH RESPOND TO DIFFERENT ANTIDEPRESSANTS. 

001971 02-09 
THE DEXAMETHASONE-SUPPRESSION-TEST IN THE IDENTIFICATION OF 
SUBTYPES OF DEPRESSION DIFFERENTIALLY RESPONSIVE TO 
ANTIDEPRESSANTS. ^ 

003211 03-09 
STANDARDIZATION OF THE DEXAMETHASONE-SUPPRESSION-TEST FOR 
THE DIAGNOSIS OF MELANCHOLIA. (UNPUBLISHED PAPER). 

004359 04-09 

DEXAMETHASONE-SUPPRESSION-TESTS 

DEXAMETHASONE-SUPPRESSION-TESTS IN DEPRESSION AND RESPONSE 
TO TREATMENT. 

000899 01-16 

DEXETIMIDE 

TREATMENT OF PARKINSONIAN-SYNDROME WITH DEXETIMIDE. 

002111 02-11 
DEXTROAMPHETAMINE 

DEXTROAMPHETAMINE: COGNITIVE AND BEHAVIORAL-EFFEaS IN 
NORMAL AND HYPERAQIVE-BOYS AND NORMAL ADULT MALES. 

000716 01-11 
DIURNAL GROWTH-HORMONE RESPONSES TO DEXTROAMPHETAMINE IN 
NORMAL YOUNG MEN AND POSTMENOPAUSAL-WOMEN. 

00341 1 03-13 
AUTONOMIC-EFFEaS OF DEXTROAMPHETAMINE IN NORMAL MEN: 
IMPLICATIONS FOR HYPERACTIVITY AND SCHIZOPHRENIA. 

003437 03-13 
THE EFFECT OF THE DOPAMINE-RECEPTOR BLOCKING-DRUG PIMOZIDE ON 
THE STIMULANT AND ANOREQIC-AQIONS OF DEXTROAMPHETAMINE 

IN MAN. „ ,, 

004580 04-14 



S-136 



I/OLUME 19, SUBJECT INDEX 



Subject Index 



>EXTROAMPHET AMINE-SULFATE 

TOLERANCE TO DEXTROAMPHETAMINE-SULFATE IN HYPERACTIVE- 
CHILDREN: ASSESSMENT USING AN EMPIRICAL NEUROPSYCHOLOGICAL 
PARADIGM - A PILOT-STUDY 

002126 02-11 
EFFECTS OF DEXTROAMPHETAMINE-SULFATE ON REPEATED ACQUISITION- 
BEHAVIOR AND MOOD IN HUMANS: A PRELIMINARY REPORT. 

003459 03-14 
)EXTROMETHORPHAN 

HIGH-AFFINITY BINDING OF THE ANTITUSSIVE DEXTROMETHORPHAN TO 
GUINEA-PIG BRAIN 

000061 01-03 
>EXTROPROPOXYPHENE 

INFLUENCE OF DEXTROPROPOXYPHENE ON STEADY-STATE SERUM LEVELS 
AND PROTEIN BINDING OF THREE ANTIEPILEPTIC-DRUGS IN MAN. 

000767 01-13 



)FP 



INDUCTION OF BEHAVIORAL-SUPERSENSITIVITY TO APOMORPHINE BY 
DFP TREATMENT. 

004099 04-04 
>HT 

EFFECTS OF NOMIFENSINE AND DESIPRAMINE ON THE SEQUELAE OF 
INTRACEREBRALLY INJECTED 6 OHDA AND 5,6 DHT. 

001522 02-03 
HIPPOCAMPAL SEROTONIN REUPTAKE AND NOCTURNAL LOCOMOTOR- 
ACTIVITY AFTER MICROINJECTIONS OF 5,7 DHT IN THE FORNIX- 
FIMBRIA. 

002929 03-03 
MABETES-INSIPIDUS 

BRADYCARDIA, PERSISTENT DIABETES-INSIPIDUS, AND TARDIVE- 
DYSKINESIA WITH LITHIUM INTOXICATION. 

002427 02-15 
)IABETES-INSIPIDUS-LIKE 

AnENUATION OF THE LITHIUM-INDUCED DIABETES-INSIPIDUS-LIKE 
SYNDROME BY AMILORIDE IN RATS. 

002717 03-03 
IIABETES-MELIITUS 

THE INFLUENCE OF PATIENT BELIEFS ON COMPLIANCE TO THERAPY FOR 
DIABETES-MELLITUS. (PH.D. DISSERTATION). 

003631 03-17 
IIABETIC 

ACUTE CHANGES IN BRAIN TRYPTOPHAN AND SEROTONIN FOLLOWING 
CARBOHYDRATE OR PROTEIN INGESTION BY DIABETIC RATS. 
(UNPUBLISHED PAPER). 

000060 01-03 
INCREASED URINARY EXCRETION OF CATECHOLAMINES AND THEIR 
METABOLITES IN STREPTOZOTOCIN DIABETIC RAT, 

000154 01-03 
tIAGNOSED 

THE INFLUENCE OF METHYLPHENIDATE ON SPONTANEOUS AUTONOMIC- 
ACTIVITY AND BEHAVIOR IN CHILDREN DIAGNOSED AS HYPERACTIVE. 

003363 03-1 1 
IIAGNOSING 

IS MANIA OVERDIAGNOSED?: THE THREE COMMON PITFALLS IN 
DIAGNOSING MANIC-DEPRESSIVE-ILLNESS. 

003260 03-09 
IIAGNOSIS 

CHRONIC MOOD-DISORDERS IN DEPRESSED-OUTPATIENTS: DIAGNOSIS 
AND RESPONSE TO PHARMACOTHERAPY. 

000624 01-09 
DIAGNOSIS AND TREATMENT OF ACUTE SCHIZOPHRENIC-PSYCHOSES. 

003191 03-08 
RECENT ADVANCES IN THE DIAGNOSIS AND TREATMENT OF ANXIETY- 
DISORDERS. 

003275 03-10 
ON THE EVALUATION OF A PROVOCATIVE EEG METHOD USING 
MEDICATION IN THE DIAGNOSIS OF ORGANIC-BRAIN-SEIZURES IN 
CHILDHOOD, WITH SPECIAL EMPHASIS ON SLEEP INDUCTION THROUGH 
MEDICATION. 

003387 03-1 1 
ATTENTION DEFICIT-DISORDER (MINIMAL-BRAIN-DYSFUNCTION) IN 
ADULTS: A REPLICATION STUDY OF DIAGNOSIS AND DRUG- 
TREATMENT. 

003389 03-11 
DIFFERENTIAL DIAGNOSIS OF CIMETIDINE-INDUCED DELIRIUM 

003488 03-15 
THE DIAGNOSIS AND TREATMENT OF NEUROLEPTIC-INDUCED 
PARKINSONISM. 

003493 03-15 
PHENCYCLIDINE (PCP) INTOXICATION: DIAGNOSIS IN STAGES AND 
ALGORITHMS OF TREATMENT. 

003525 03-15 
STANDARDIZATION OF THE DEXAMETHASONE-SUPPRESSION-TEST FOR 
THE DIAGNOSIS OF MELANCHOLIA. (UNPUBLISHED PAPER). 

004359 04-09 
GUIDELINES ON THE DIAGNOSIS AND TREATMENT OF DEPRESSION 

004376 04-09 
STUDIES ON THE TREATMENT AND DIAGNOSIS OF NEUROTIC VERTIGO 
FROM THE VIEWPOINT OF NEUROOTOLOGY: OBSERVATION OF THE 
BALANCE TEST FOR ANALYZING NEUROTIC VERTIGO. 

004387 04-09 



DIFFERENTIAL DIAGNOSIS AND TREATMENT OF PANIC AHACKS AND 
PHOBIC-STATES. 

004424 04-10 
DIAGNOSTIC 

DIAGNOSTIC AND PROGNOSTIC SIGNIFICANCE OF 
ELECTROENCEPHALOGRAPHY WITH INTRAVENOUS DIAZEPAM IN 
EPILEPSY. 

000696 01-11 
PCP ABUSE: DIAGNOSTIC AND PSYCHOPHARMACOLOGICAL-TREATMENT 
APPROACHES. 

000746 01-12 
DIAGNOSTIC CLASSIFICATION AND THE ENDORPHIN HYPOTHESIS OF 
SCHIZOPHRENIA: INDIVIDUAL DIFFERENCES AND 
PSYCHOPHARMACOLOGICAL STRATEGIES. (UNPUBLISHED PAPER) 

001910 02-08 
DELIRIUM OR PSYCHOSIS? DIAGNOSTIC USE OF THE SODIUM- 
AMOBARBITAL INTERVIEW. 

002167 02-11 
DIAGNOSTIC CLASSIFICATION AND THE ENDORPHIN HYPOTHESIS OF 
SCHIZOPHRENIA: INDIVIDUAL DIFFERENCES AND 
PSYCHOPHARMACOLOGICAL STRATEGIES. 

003167 03-08 
CLINICAL DEPRESSIONS: DIAGNOSTIC AND THERAPEUTIC CHALLENGES. 

004350 04-09 
BLOOD LEVEL MEASUREMENTS OF TRICYCLIC DRUGS AS A DIAGNOSTIC 
TOOL. 

004368 04-09 
DIAGNOSTICS 

CLINICAL AND LABORATORY DIAGNOSTICS APPLICATIONS IN 
DEPRESSION. (UNPUBLISHED PAPER). 

000588 01-09 
THE USE OF SENSORY INTEGRATIVE DIAGNOSTICS TO PREDICT 
HYPERACTIVE-CHILDRENS RESPONSIVENESS TO METHYLPHENIDATE 
(RITALIN) AND PEMOLINE (CYLERT). (PH.D. DISSERTATION). 

002133 02-11 
DIALKYL-4-PYRAZOLIDINOLS 

SYNTHESIS OF PHENYLURETHANS OF 1,2 DIALKYL-4-PYRAZOLIDINOLS AS 
ANTICONVULSANT-AGENTS. 

003695 04-02 
DIALKYLBARBITURATE 

GAS-CHROMATOGRAPHIC-PROPERTIES OF 1,3 DIALKYLBARBITURATE 
DERIVATIVES. 

003658 04-01 
DIALYKYl 

ON-COLUMN GAS-CHROMATOGRAPHIC-SYNTHESIS OF 1,3 DIALYKYL 
(C=l-10), BENZYL, AND CYCLOHEXYLBARBITURATE DERIVATIVES. 

003656 04-01 
DIALYSIS 

ORAL ALUMINUM AND NEUROPSYCHOLOGICAL FUNCTIONING: A STUDY 
OF DIALYSIS PATIENTS RECEIVING ALUMINUM-HYDROXIDE GELS. 

002283 02-13 
DIAMINODIPHENOXYBUTANE 

RETINOTOXIC-EFFECTS OF DIAMINODIPHENOXYBUTANE IN RATS. 

000444 01-04 
DIAPHRAGM 

DIPHENYLHYDANTOIN-INDUCED BLOCK OF THE RAT PHRENIC-NERVE 
DIAPHRAGM PREPARATION PRETREATED WITH P 
HYDROXYMERCURIBENZOATE. 

002749 03-03 
OXOTREMORINE DOES NOT ENHANCE ACETYLCHOLINE RELEASE FROM 
RAT DIAPHRAGM PREPARATIONS. 

003819 04-03 
DIASTEREOMERS 

FUNCTIONAL CHARACTERIZATION OF CENTRAL ALPHA-ADRENOCEPTORS 
BY YOHIMBINE DIASTEREOMERS. 

002748 03-03 
DIASTOLIC 

COVARIANCE OF PLASMA FREE 3 METHOXY-4- 

HYDROXYPHENETHYLENEGLYCOL AND DIASTOLIC BLOOD-PRESSURE 

003418 03-13 
DIAZEPAM 

ANALYSIS FOR DIAZEPAM AND NORDIAZEPAM BY ELECTRON-CAPTURE 
GAS-CHROMATOGRAPHY AND BY LIQUID-CHROMATOGRAPHY. 

000006 01-01 
PHARMACOLOGICAL ACTIVITIES OF CLOBAZAM AND DIAZEPAM IN THE 
RAT: RELATION TO DRUG BRAIN LEVELS. 

000036 01-03 
THE EFFECT OF DIAZEPAM ON TENSION AND ELECTROLYTE DISTRIBUTION 
IN FROG MUSCLE. 

000069 01-03 
ENTRY OF DIAZEPAM AND ITS MAJOR METABOLITE INTO 
CEREBROSPINAL-FLUID. 

000114 01-03 
THE EFFECT OF DIAZEPAM ON EEG CHANGES FOLLOWING INTRASEPTAL 
ADMINISTRATION OF ATROPINE. 

000127 01-03 
A PROBABLE SITE-OF-ACTION OF DIAZEPAM IN RAT CEREBELLAR GABA 
SYSTEM. 

000151 01-03 



a, 

■if 






fe: 






S-137 



Subject Index 

DELAYED CLEARANCE OF DIAZEPAM DUE TO CIMETIDINE. 

000164 01-03 
INTERACTION OF DIAZEPAM WITH SYNAPTIC TRANSMISSION IN THE IN 
VITRO RAT HIPPOCAMPUS. 

000178 01-03 
DIAZEPAM POTENTIATION OF PURINERGIC DEPRESSION OF CENTRAL 
NEURONS. 

000233 01-03 

PENTOBARBITAL POTENTIATES GABA-ENHANCED (3H) DIAZEPAM 
BINDING TO BENZODIAZEPINE-RECEPTORS. 

000275 01-03 
PROPERTIES OF (3H)DIAZEPAM BINDING-SITES ON RAT BLOOD- 

''^''''''- 000317 01-03 

INHIBITION OF (3H)DIAZEPAM BINDING TO RAT-BRAIN CORTICAL 
SYNAPTOSOMAL MEMBRANES BY ADENOSINE UPTAKE BLOCKERS. 

000330 01-03 
EFFEaS OF CHLORDIAZEPOXIDE AND DIAZEPAM ON FEEDING 
PERFORMANCE IN A FOOD PREFERENCE TEST. 

000367 01-04 
EFFECTS OF ACUTE AND CHRONIC INTERACTIONS OF DIAZEPAM AND D- 
AMPHETAMINE ON PUNISHED-BEHAVIOR OF RATS. 

000386 01-04 
THE INTERACTION OF ANTICHOLINESTERASES AND DIAZEPAM IN THE 
TREATMENT OF ANTICHOLINERGIC-SYNDROME IN DOGS. 

000389 01-04 
DIAZEPAM IN COMBINATION WITH TACRINE DERIVATIVES ANTAGONIZES 
BEHAVIOURAL-EFFECTS OF ANTICHOLINERGIC PSYCHOTOMIMETICS IN 
RATS 

000420 01-04 

CORRELATION BETWEEN BENZODIAZEPINE-RECEPTOR OCCUPATION AND 
ANTICONVULSANT EFFECTS OF DIAZEPAM. 

000450 01-04 
IMPROVEMENT OF RESTITUTION FROM CEREBRAL ISCHEMIA IN 
HYPERGLYCEMIC RATS BY PENTOBARBITAL OR DIAZEPAM. 

000475 01-04 
BICUCULLINE ANTAGONIZES EFFECTS OF DIAZEPAM ON AGGRESSIVE AND 
TIMID-BEHAVIOUR IN MICE. 

000485 01-04 

BEHAVIORAL-ANALYSIS OF AMYGDALOID KINDLING IN BEAGLE-DOGS 
AND THE EFFECTS OF CLONAZEPAM, DIAZEPAM, PHENOBARBITAL, 
DIPHENYLHYDANTOIN, AND FLUNARIZINE ON SEIZURE 
MANIFESTATION. 

000496 01-04 
A DOUBLE-BUND GROUP COMPARATIVE-TRIAL OF MIANSERIN AND 
DIAZEPAM IN DEPRESSED-OUTPATIENTS. 

000592 01-09 
ANXIOLYTIC EFFICACY OF ALPRAZOLAM COMPARED TO DIAZEPAM AND 
PLACEBO. „„ ,„ 

000648 01-10 
KETAZOLAM AND DIAZEPAM IN ANXIETY: A CONTROLLED-STUDY. 

000655 01-10 
DOUBLE-BUND COMPARISON OF KETAZOLAM, DIAZEPAM AND PLACEBO 
IN ONCE-A-DAY VS T.I.D. DOSING. 

000660 01-11 
DIAGNOSTIC AND PROGNOSTIC SIGNIFICANCE OF 

ELECTROENCEPHALOGRAPHY WITH INTRAVENOUS DIAZEPAM IN 
EPILEPSY. 

000696 01-11 
EFFECT OF DIAZEPAM AND DESMETHYLDIAZEPAM IN SPASTICITY AND 
RIGIDITY: A QUANTITATIVE STUDY OF REFLEXES AND PLASMA 
CONCENTRATIONS. 

000701 01-11 
INTERSUBJECT AND INTRASUBJEQ VARIATION IN DIAZEPAM FREE 
FRACTION. 

000747 01-13 
PHARMACODYNAMICS AND PHARMACOKINETICS OF DIAZEPAM IN AN 
ABUSER. 

000867 01-15 
EFFEaS OF GABA AND DIAZEPAM ON 3H SEROTONIN RELEASE FROM 
HIPPOCAMPAL SYNAPTOSOMES. 

001116 02-03 
ETHANOL ENHANCES (3H)DIAZEPAM BINDING AT THE BENZODIAZEPINE 
GABA-RECEPTOR lONOPHORE COMPLEX. 

001154 02-03 
THE EFFECT OF EMOTIONAL- STRESS AND DIAZEPAM ON MONOAMINE 
METABOLITES IN THE CEREBROSPINAL-FLUID OF CATS. (PH.D. 

DISSERTATION). 

001260 02-03 
EVIDENCE FOR AN ENDOGENOUS COMPOUND INTERFERING WITH 3H 
DIAZEPAM BINDING TO RAT-BRAIN MEMBRANES. 

001308 02-03 
ETHYL-BETA-CARBOLINE-3-CARBOXYLATE ANTAGONISES THE EFFEQ OF 
DIAZEPAM ON A FUNCTIONAL GABA-RECEPTOR. 

001378 02-03 
THE PROCONVULSANT AND DIAZEPAM REVERSING EFFEaS OF ETHYL- 
BET A-CARBOLINE-3-CARBOXYLATE. 

001399 02-03 



Psychopharmacology Abstracts 



EFFEaS OF DIAZEPAM ON ADENOSINE AND ACETYLCHOLINE RELEASE 
FROM RAT-CEREBRAL-CORTEX: FURTHER EVIDENCE FOR A PURINERGIC 
MECHANISM IN ACTION OF DIAZEPAM. 

001414 02-03 
EVIDENCE FOR INVOLVEMENT OF DOPAMINE IN THE AQION OF 

DIAZEPAM: POTENTIATION OF HALOPERIDOL AND CHLORPROMAZINE 
AQION IN THE BRAIN. 

001428 02-03 
A STUDY OF A GLIAL GAMMA AMINOBUTYRIC-ACID SYSTEM: ITS 
REGULATION, FUNCTION AND THE EFFECTS OF DIAZEPAM. (PH.D. 
DISSERTATION). 

001524 02-03 
CHRONIC-TREATMENT WITH VALIUM (DIAZEPAM) FAILS TO AFFEQ THE 
REPRODUatVE SYSTEM OF THE MALE RAT. 

001535 02-03 
VESTIBULO-OCULAR REFLEXES IN RABBITS: REDUQION BY INTRAVENOUS 
INJEQION OF DIAZEPAM. 

001566 02-04 
EFFECT OF P CHLOROPHENYLALANINE ON DIAZEPAM WITHDRAWAL 
SIGNS IN RATS. 

001797 02-04 
COMPARISON OF CLONAZEPAM AND DIAZEPAM IN EXPERIMENTAL- 
STUDIES. 

001815 02-04 
GABA-RECEPTORS AND BENZODIAZEPINE-RECEPTORS IN THE OFFSPRING 
OF DAMS RECEIVING DIAZEPAM: ONTOGENETIC-STUDIES. 

001849 02-05 
HIGH-DOSE DIAZEPAM IN SCHIZOPHRENIA 

001909 02-08 
THE USE OF CLOROTEPIN AND DIAZEPAM IN A COMPLEX THERAPY OF 
NEUROSES (CONTROLLED-COMPARISON) . 

002064 02-10 
KETAZOLAM COMPARED TO DIAZEPAM AND PLACEBO IN THE 
TREATMENT OF ANXIETY 

002074 02-10 
COMPARATIVE PROTEIN BINDING OF DIAZEPAM AND 
DESMETHYLDIAZEPAM. 

002206 02-13 
KINETICS AND NEUROPSYCHOLOGIC-EFFECTS OF IV DIAZEPAM IN THE 
PRESENCE AND ABSENCE OF ITS AQIVE N DESMETHYL METABOLITE IN 
HUMANS 

002229 02-13 
HEMODYNAMIC AND CEREBRAL METABOLIC-STUDY OF DIAZEPAM IN 
NEUROSURGICAL-RESUSCITATION 

002231 02-13 
ANXIETY AND SEDATION DURING A STRESSFUL-SITUATION AFTER SINGLE- 
DOSE OF DIAZEPAM VERSUS N DESMETHYLDIAZEPAM - A 
CONTROLLED-TRIAL. 

002329 02-14 
DRUG PREFERENCE AND MOOD IN HUMANS: DIAZEPAM. 

002334 02-14 
CNV VARIATIONS INDUCED BY THE ADMINISTRATION OF DIAZEPAM, 
HALOPERIDOL, PHENELZINE AND D-AMPHET AMINE. 

002355 02-14 
ACCIDENTAL INTRAARTERIAL INJEQION OF DIAZEPAM. 

002598 02-17 
DEMONSTRATION AND CHARAQERIZATION OF AN ENDOGENOUS 
INHIBITOR OF GABA-ENHANCED (3H) DIAZEPAM BINDING FROM 
BOVINE CEREBRAL-CORTEX. 

002645 03-01 
CENTRAL DEPRESSANT EFFECTS OF CAERULEIN AND CHOLECYSTOKININ- 
OQAPEPTIDE (CCK-8) DIFFER FROM THOSE OF DIAZEPAM AND 
HALOPERIDOL. 

002652 03-02 

ETHYL-BETA-CARBOLINE-3-CARBOXYLATE ANTAGONIZES DIAZEPAM 

*^'^'^ 002915 03-03 

ELECTRICAL-ACTIVITY AND NA-K-ATPASE LEVEL IN THE PENICILLIN- 

INDUCED EPILEPTOGENIC-FOCUS OF THE RAT-BRAIN-CORTEX, AND THE 

EFFEQ OF DIAZEPAM. 003070 03-04 

INTERAQIONS OF DIAZEPAM AND COCAINE IN THE MORPHINE TREATED 

RAT. (PH.D. DISSERTATION,. 003115 03-04 

A DOUBLE-BLIND CROSSED CLINICAL- STUDY WITH A NEW 

PSYCHOPHARMACEUTICAL: TIADIPONE (QM-6008), DIAZEPAM, AND 

^"^"^^ 003153 03-07 

A COMPARATIVE-STUDY ON THE CLINICAL-EFFEQS OF REQAL 

DIAZEPAM AND PENTOBARBITAL ON SMALL CHILDREN. RELATIONSHIP 
BETWEEN PLASMA LEVEL AND EFFECT. „„.o.„ ^, , , 

003330 03-11 

DOUBLE-BUND COMPARISON OF ALPRAZOLAM AND DIAZEPAM FOR 
SUBCHRONIC WITHDRAWAL FROM ALCOHOL 

003332 03-11 

THE REPLICABILITY OF THE PSYCHOPHYSIOLOGICAL-EFFEQS OF 
°'^^^f^^ 003413 03-13 



S-138 



/OLUME 19, SUBJECT INDEX 

DIAZEPAM AS TUMOUR PROMOTER. 

ABSENCE OF EFFECT OF DIAZEPAM ON TUMOURS. 

CA DIAZEPAM LINK? NO SCIENTIFIC TAKERS SO FAR. 



Subject Index 



003495 03-15 
003497 03-15 
003519 03-15 



AVAILABILITY OF ISOSORBIDE-DINITRATE, DIAZEPAM AND 
CHLORMETHIAZOLE, FROM I.V. DELIVERY SYSTEMS. 

003558 03-16 
DIAZEPAM ANXIOLYTIC-ACTIVITY IN HIPPOCAMPUS. 

003743 04-03 
INHIBITION OF (3H)DIAZEPAM BINDING BY AN ENDOGENOUS FRACTION 
FROM RAT-BRAIN SYNAPTOSOMES. 

003768 04-03 
REGIONAL CHANGES IN (3H)DIAZEPAM BINDING IN THE BRAINS OF MICE 
AFTER REMOVAL OF THE OLfACTORY-BULBS. 

003844 04-03 
EFFECT OF DIAZEPAM ON STRESS-INDUCED CHANGES IN BRAIN 
HISTAMINE. 

003932 04-03 
THE EFFECT OF DIAZEPAM ON CYCLIC EXCITABILITY CHANGES IN AN 
EPILEPTIC-FOCUS IN THE CORTEX OF THE MAJOR HEMISPHERES. 

003984 04-03 
THE INSENSITIVITY OF DEVELOPING BENZODIAZEPINE-RECEPTORS TO 
CHRONIC-TREATMENT WITH DIAZEPAM, GABA AND MUSCIMOL IN 
BRAIN CELL-CULTURES. 

004002 04-03 
SCHEDULE DEPENDENT CHANGE OF PUNISHED-RESPONDING AFTER 
DIAZEPAM IN RATS. 

004165 04-04 
3 HYDROXYMETHYL-BETA-CARBOLINE ANTAGONIZES SOME 
PHARMACOLOGIC ACTIONS OF DIAZEPAM. 

004221 04-04 
POTENTIATION OF THE EFFECTS OF ADENOSINE ON ISOLATED CARDIAC- 
MUSCLE AND SMOOTH-MUSCLE BY DIAZEPAM. 

004266 04-05 
RESPIRATORY DEPRESSION PRODUCED BY DIAZEPAM IN CATS: EFFECT OF 
ANESTHESIA. 

004272 04-05 
THE RELATIONSHIPS BETWEEN CLINICAL-RESPONSE, 

PSYCHOPHYSIOLOGICAL-VARIABLES AND PU^SMA LEVELS OF 
AMITRIPTYLINE AND DIAZEPAM IN NEUROTIC-OUTPATIENTS. 

004423 04-10 
A DOUBLE-BUND TRIAL: THE USE OF OXPRENOLOL AND DIAZEPAM IN 
ANXIETY. 

004428 04-10 
EFFECT OF TREATMENT WITH SODIUM-VALPROATE AND DIAZEPAM ON 
PLASMA CORTICOTROPIN IN NELSONS-SYNDROME. 

004463 04-1 1 
PROMETHAZINE AND DIAZEPAM POTENTIATE THE HALOPERIDOL-INDUCED 
PROLACTIN RESPONSES. 

004499 04-13 
INTRAVENOUS DIAZEPAM AND ORAL ETHANOL INTERACTION. 

004552 04-13 
DRUG PREFERENCE IN HUMANS: DOUBLE-BUND CHOICE COMPARISON OF 
PENTOBARBITAL, DIAZEPAM AND PLACEBO. 

004566 04-14 
CASE-REPORT OF UNUSUAL DIAZEPAM ABSTINENCE-SYNDROME. 

004643 04-15 
MASS SCREENING AND CONFIRMATION OF DIAZEPAM IN URINE BY EMIT 
THIN-LAYER-CHROMATOGRAPHY. 

004672 04-16 
lAZEPAM-INDUCED 

DIFFERENTIAL-EFFECTS OF NALOXONE AGAINST THE DIAZEPAM-INDUCED 
RELEASE OF BEHAVIOR IN RATS IN THREE AVERSIVE-SITUATIONS. 

000480 01-04 
INTERAQION BETWEEN PURINE AND BENZODIAZEPINE: INOSINE 
REVERSES DIAZEPAM-INDUCED STIMULATION OF MOUSE 
EXPLORATORY-BEHAVIOR. 

002972 03-04 
DIAZEPAM-INDUCED ATAXIA IN TROTTING SQUIRREL-MONKEYS 

004138 04-04 
lAZEPAM-RECEPTOR 

CHANGES IN MOUSE-BRAIN DIAZEPAM-RECEPTOR BINDING AFTER 
PHENOBARBITAL ADMINISTRATION. 

000281 01-03 
lAZEPINES 

COMPARATIVE-STUDY OF SLEEP AND STATE ON AWAKENING WITH TWO 
HYPNOTIC DIAZEPINES. 

000817 01-14 
IBENZAZEPINES 

THE EFFECT OF DIBENZAZEPINES (TRICYCUC-ANTIDEPRESSANTS) ON 
CEREBRAL CAPILLARY PERMEABIUTY IN THE RAT IN VIVO. 

003974 04-03 
IBENZEPINE 

LARGE-DOSES OF DIBENZEPINE NOVERIL IN THE TREATMENT OF 
DEPRESSIVE-STATES. 

002020 02-09 



CUNICAL-EXPERIENCE WITH RETARD DIBENZEPINE (NOVERIL-240) IN 
ENDOGENOUS DEPRESSIONS ACCOMPANIED BY SYMPTOMS OF DRUG- 
RESISTANCE. 

003245 03-09 
DIBUTYRYL-C-AMP 

FACILITATION OF LORDOSIS BEHAVIOR IN THE OVARIECTOMIZED 
ESTROGEN-PRIMED RAT BY DIBUTYRYL-C-AMP 

002957 03-04 
DIBUTYRYL-CYCLIC-AMP 

CATECHOLAMINE AND 5 HYDROXYTRYPTAMINE SYNTHESIS AND 
METABOLISM FOLLOWING INTRACEREBROVENTRICULAR INJECTION OF 
DIBUTYRYL-CYCLIC-AMP. 

003769 04-03 
OIBUTYRYL-CYCLIC-GUANOSINE-MONOPHOSPHATE 

INHIBITION OF THE ACTION OF CHOLECYSTOKININ-OCTAPEPTIDE ON THE 
GUINEA-PIG ILEUM MYENTERIC PLEXUS BY DIBUTYRYL-CYCLIC- 
GUANOSINE-MONOPHOSPHATE. 

001291 02-03 
DICHLORO-6-PHENYLPHENOXYETHYLAMINE-HBR 

BETA DIETHYLAMINOETHYLDIPHENYLPROPYLACETATE (SKF-525-A) AND 
2,4 DICHLORO-6-PHENYLPHENOXYETHYLAMrNE-HBR (DPEA) INHIBITION 
OF FAHY-ACID CONJUGATION TO 1 1 HYDR0XY-DELTA9- 
TETRAHYDROCANNABINOL BY THE RAT LIVER MICROSOMAL SYSTEM. 

000179 01-03 
DICHLOROBENZYL-TETRAHYDROPYRIMIOONE 

PHARMACOLOGY OF 1 DICHLOROBENZYL-TETRAHYDROPYRIMIDONE, A 
NOVEL ANTIDEPRESSANT COMPOUND WITH ANTIANXIETY ACTIVITY. 

003688 04-02 
DICHOTIC 

LATERAUZED DEFICITS AND DRUG INFLUENCES ON THE DICHOTIC 
LISTENING OF SCHIZOPHRENIC-PATIENTS. 

003443 03-14 
DICHROISM 

COMPARISON OF HIGHLY-ACTIVE AND ACTIVITY DEPLETED HEPARIN BY 
CIRCULAR DICHROISM SPECTROSCOPY. (UNPUBLISHED PAPER). 

001057 02-01 
DIET 

EFFECT OF LITHIUM-CHLORIDE IN COYOTE PUP DIET. 

001835 02-05 
SUBCUTANEOUS SILASTIC IMPLANTS: MAINTENANCE OF HIGH BLOOD 
ETHANOL LEVELS IN RATS DRINKING A UQUID DIET. 

001865 02-06 
DIETARY 

FUNCTIONAL AND STRUCTURAL CONSEQUENCES OF LONG-TERM DIETARY 
L-DOPA TREATMENT IN MICE. 

000257 01-03 
EFFECTS OF CHRONIC DIETARY UTHIUM ON ACTIVITY AND REGULATION 
OF NA-K-ADENOSINE-TRIPHOSPHATASE IN RAT-BRAIN. 

000297 01-03 
DIETARY PROTEIN INTAKE INFLUENCES THE ANTIHYPERTENSIVE POTENCY 
OF METHYLDOPA IN SPONTANEOUSLY HYPERTENSIVE-RATS. 

004025 04-03 
SUSTAINED DECREASE IN FAT CONSUMPTION PRODUCED BY 
AMPHETAMINE IN RATS MAINTAINED ON A DIETARY SELF-SELEQION 
REGIME. 

004150 04-04 
DIETETIC 

DRUG AND DIETETIC THERAPIES FOR HYPERKINETIC-CHILDREN. (PH.D. 
DISSERTATION). 

003576 03-17 
DIETHYLAMINOETHYLDIPHENYLPROPYLACETATE 

BETA DIETHYLAMINOETHYLDIPHENYLPROPYLACETATE (SKF-525-A) AND 
2,4 DICHLORO-6-PHENYLPHENOXYETHYLAMINE-HBR (DPEA) INHIBITION 
OF FAHY-ACID CONJUGATION TO 1 1 HYDR0XY-DELTA9- 
TETRAHYDROCANNABINOL BY THE RAT LIVER MICROSOMAL SYSTEM. 

000179 01-03 
DIETHYLDITHIOCARBAMATE 

COMPARISONS OF THE EFFEQS OF GUANETHIDINE, 6 
HYDROXYDOPAMINE AND DIETHYLDITHIOCARBAMATE ON RETENTION 
OF PASSIVE-AVOIDANCE. 

001742 02-04 
DIETHYLSTILBESTROL 

COMPARATIVE-STUDY OF PROPHYLACTIC LITHIUM AND 
DIETHYLSTILBESTROL IN SEXUAL-DEVIANTS. 

000663 01-11 
DIFENAMIZOLE 

NEUROCHEMICAL-STUDIES OF AN ANALGESIC, 1,3 DIPHENYL-5-2- 
DIMETHYLAMINOPROPIONAMIDE-PYRAZOLE (DIFENAMIZOLE) . 

002771 03-03 
DIFFERENTIAL 

DIFFERENTIAL REGULATION OF MUSCARINIC AGONIST BINDING-SITES 
FOLLOWING CHRONIC CHOUNESTERASE INHIBITION. 

000279 01-03 
DIFFERENTIAL SENSITIVITY OF HYPOTHALAMIC DOPAMINERGIC AND 
NORADRENERGIC NEURONES TO PHARMACOLOGICAL MANIPULATION. 

001310 02-03 
DIFFERENTIAL DOPAMINERGIC FUNCTION IN YOUNG AND OLD FEMALE 
RATS AS MEASURED BY THREE BEHAVIORS. 

001683 02-04 



I 



3 

ISk 



'5 
4te. 






>» 



S-139 



Subject Index 



Psychopharmacology Abstracts 



THE ROLE OF DIFFERENTIAL BLOCKADE OF ALPHA-ADRENERGIC AGONISTS 
IN CHLORPROMAZINE-INDUCED HYPOTENSION. 

001851 02-05 
THE DIFFERENTIAL DOSE-EFFECTS OF METHYLPHENIDATE ON 
HYPERACTIVE-CHILDREN AND THEIR MOTHERS. (PH.D. 
DISSERTATION). 

002143 02-11 
MIDBRAIN DOPAMINE NEURONS: DIFFERENTIAL RESPONSES TO 
AMPHETAMINE ISOMERS. 

002680 03-03 
DIFFERENTIAL REGULATION BY GUANINE-NUCLEOTIDES OF OPIATE 
AGONIST AND ANTAGONIST RECEPTOR INTERACTIONS. 

002688 03-03 
DIFFERENTIAL LOSS OF BIOLOGICAL-AQIVITY OF THE ENKEPHALINS 
INDUCED BY CURRENT. 

002783 03-03 
(3H)MIANSERIN: DIFFERENTIAL LABELING OF SEROTONIN AND 
HISTAMINE-RECEPTORS IN RAT-BRAIN 

002860 03-03 
DIFFERENTIAL REVERSAL BY SCOPOLAMINE AND THIP OF THE 
ANTISTEREOTYPIC AND CATALEPTIC-EFFECTS OF NEUROLEPTICS. 

002948 03-04 
THE DIFFERENTIAL NEUROCHEMICAL-BASES OF THE BEHAVIOURS ELICITED 
BY SEROTONERGIC-AGENTS AND BY THE COMBINATION OF A 
MONOAMINE-OXIDASE-INHIBITOR AND L-DOPA. 

002976 03-04 
DIFFERENTIAL ACTIONS OF CLASSICAL AND ATYPICAL ANTIPSYCHOTIC- 
DRUGS ON SPONTANEOUS NEURONAL ACTIVITY IN THE AMYGDALOID 
COMPLEX. 

003131 03-05 
DIFFERENTIAL DIAGNOSIS OF CIMETIDINE-INDUCED DELIRIUM. 

003488 03-15 
DIFFERENTIAL BINDING OF CHLORPROMAZINE TO HUMAN BLOOD CELLS: 
APPLICATION OF THE HYGROSCOPIC DESORPTION METHOD 

003556 03-16 
PRESYNAPTIC AND POSTSYNAPTIC STRIATAL DOPAMINE-RECEPTORS: 
DIFFERENTIAL SENSITIVITY TO APOMORPHINE INHIBITION OF 
(3H)D0PAMINE AND (14C)GABA RELEASE IN VITRO 

003741 04-03 
DIFFERENTIAL TOLERANCE TO THE EFFECTS OF MORPHINE ON EVOKED 
ACTIVITY IN THE HIPPOCAMPAL SLICE. 

003760 04-03 
ACTION OF ENKEPHALIN ANALOGUES AND MORPHINE ON BRAIN 
ACETYLCHOLINE RELEASE: DIFFERENTIAL REVERSAL BY NALOXONE AND 
AN OPIATE-PENTAPEPTIDE. 

003863 04-03 
DIFFERENTIAL INHIBITION OF ALPHA 1 -ADRENOCEPTOR AND ALPHA2- 
ADRENOCEPTOR MEDIATED PRESSOR RESPONSES IN PITHED RATS 

004057 04-03 
DIFFERENTIAL DIAGNOSIS AND TREATMENT OF PANIC AHACKS AND 
PHOBIC-STATES. 

004424 04-10 
DIFFERENTIAL-EFFECT 

KAINIC-ACID INDUCED LESION OF RAT RETINA: DIFFERENTIAL-EFFEQ ON 
CYCLIC-GMP AND BENZODIAZEPINE-RECEPTORS AND GABA- 
RECEPTORS. 

002743 03-03 
DIFFERENTIAL-EFFECT OF CHRONIC DESIPRAMINE AND AMITRIPTYLINE 
TREATMENT ON RAT-BRAIN ADRENERGIC AND SEROTONERGIC- 
RECEPTORS. 

002914 03-03 
POTENTIATION OF BARBITURATE HYPNOSIS BY PROBENECID: 
DIFFERENTIAL-EFFECT IN TOLERANT ANIMALS. 

003038 03-04 
DIFFERENTIAL-EFFECTS 

DIFFERENTIAL-EFFECTS OF N DIPROPYLACETATE AND AMINOOXYACETIC- 
ACID ON GAMMA AMINOBUTYRIC-ACID LEVELS IN DISCRETE AREAS 
OF RAT-BRAIN. 

000140 01-03 
A FURTHER CHARACTERIZATION OF THE DIFFERENTIAL-EFFEaS OF 
LEUCINE-ENKEPHALIN, METHIONINE-ENKEPHALIN AND THEIR ANALOGS 
ON MORPHINE-INDUCED ANALGESIA. 

000311 01-03 
DIFFERENTIAL-EFFECTS OF METHYLPHENIDATE ON SIGNALLED AND 
NONSIGNALLED REINFORCEMENT. 

000380 01-04 
DIFFERENTIAL-EFFECTS OF NALOXONE AGAINST THE DIAZEPAM-INDUCED 
RELEASE OF BEHAVIOR IN RATS IN THREE AVERSIVE-SITUATIONS. 

000480 01-04 
PRINCIPAL AND DIFFERENTIAL-EFFECTS OF HALOPERIDOL AND PLACEBO 
TREATMENTS UPON SPEECH DISFLUENCIES IN STUHERERS. 

000713 01-11 
DIFFERENTIAL-EFFECTS ON BENZODIAZEPINE DISPOSITION BY DISULFIRAM 
AND ETHANOL. 

000789 01-13 
THE DIFFERENTIAL-EFFECTS OF SHORT-ACTING AND LONG-AQING 
BENZODIAZEPINES UPON NOCTURNAL SLEEP AND DAYTIME 
PERFORMANCE. 

000822 01-14 
DIFFERENTIAL-EFFECTS OF COCAINE ON LIMBIC EXCITABILITY. 

001339 02-03 



DIFFERENTIAL-EFFECTS OF VARIOUS STIMULI ON AVP LEVELS IN BLOOD 
AND CEREBROSPINAL-FLUID. 

001370 02-03 
DIFFERENTIAL-EFFECTS OF SYSTEMIC VERSUS INTRACRANIAL INJEQION 
OF OPIATES ON CENTRAL, OROFACIAL AND LOWER BODY 
NOCICEPTION: SOMATOTYPY IN BULBAR ANALGESIA SYSTEMS. 

001446 02-03 
DIFFERENTIAL-EFFECTS OF IMIPRAMINE IN RATS AS A FUNQION OF DRL 
SCHEDULE VALUE. 

001714 02-04 
DIFFERENTIAL-EFFEaS OF MORPHINE ON FOOD AND WATER INTAKE IN 
FOOD DEPRIVED AND FREELY-FEEDING RATS. 

001765 02-04 
DIFFERENTIAL-EFFEaS OF AMPHETAMINE AND NEUROLEPTICS ON 
NEGATIVE VS POSITIVE SYMPTOMS IN SCHIZOPHRENIA 

001906 02-08 
ANTIPSYCHOTIC-DRUGS: DIFFERENTIAL-EFFECTS ON DOPAMINE NEURONS 
IN BASAL GANGLIA AND MESOCORTEX FOLLOWING CHRONIC 
ADMINISTRATION IN HUMAN AND NONHUMAN PRIMATES. 

002285 02-13 
DIFFERENTIAL-EFFECTS OF KAINIC-ACID ON BENZODIAZEPINE-RECEPTORS, 
GABA-RECEPTORS, AND GABA-MODULIN IN THE CEREBELLAR-CORTEX 

002477 02-16 
DIFFERENTIAL-EFFECTS OF PHARMACOLOGICAL-AGENTS AQING ON 
MONOAMINERGIC SYSTEMS ON DRUG-INDUCED ANOREXIA. 

002533 02-17 
DIFFERENTIAL-EFFECTS OF CANNABINOID EXPOSURE AND STRESS ON 
PLASMA PROLACTIN, GROWTH-HORMONE AND CORTICOSTERONE 
LEVELS IN MALE MICE 

002695 03-03 
DIFFERENTIAL-EFFEaS OF CLOMIPRAMINE AND CLORGYLINE ON THE 
SENSITIVITY OF CORTICAL NEURONS TO SEROTONIN: EFFEQ OF 
CHRONIC-TREATMENT. 

002847 03-03 
DIFFERENTIAL-EFFECTS OF SHORT-TERM AND LONG-TERM LITHIUM ON 
TRYPTOPHAN UPTAKE AND SEROTONERGIC FUNCTION IN CAT BRAIN. 

002911 03-03 
DIFFERENTIAL-EFFECTS OF POTASSIUM ON THE POTENCY OF DIFFERENT 
OPIOIDS IN THE MOUSE VAS-DEFERENS. 

002935 03-03 
DIFFERENTIAL-EFFEaS OF ELECTROCONVULSIVE-SHOCK AND 
ANTIDEPRESSANT-DRUGS ON SER0T0NIN2-RECEPT0RS IN RAT-BRAIN. 

003878 04-03 
DIFFERENTIAL-EFFECTS OF PENTOBARBITAL AND ETHER ON THE SYNAPTIC 
TRANSMISSION OF THE HIPPOCAMPAL-CAl -REGION IN THE RAT 

003903 04-03 
DIFFERENTIAL-EFFEQS OF ALPHA METHYLDOPAMINE, CLONIDINE AND 
HYDRALAZINE ON NOREPINEPHRINE AND EPINEPHRINE SYNTHESIZING 
ENZYMES IN THE BRAINSTEM NUCLEI OF SPONTANEOUSLY 
HYPERTENSIVE-RATS. 

003947 04-03 
DIFFERENTIAL-EFFEaS OF SEVERAL DOPAMINE UPTAKE INHIBITORS AND 
RELEASING-AGENTS ON LOCOMOTOR-AQIVITY IN NORMAL AND IN 
RESERPINIZED MICE. 

004130 04-04 
DIFFERENTIAL-REINFORCEMENT-OF-LOW-RATES 

THE EFFEQS OF TRICYCLIC-ANTIDEPRESSANTS ON PERFORMANCE UNDER 
A DIFFERENTIAL-REINFORCEMENT-OF-LOW-RATES SCHEDULE IN RATS. 

004175 04-04 
DIFFERENTIATE 

MINI-SYMPOSIUM: III. SIMPLE IN VIVO TESTS THAT DIFFERENTIATE 
PROTOTYPE AGONISTS AT OPIATE-RECEPTORS. 

004289 04-06 
DIFFERENTIATED 

N TETRAHYDROFURYIALKYL AND N ALKOXYALKYL DERIVATIVES OF (-) 
NORMETAZOCINE, COMPOUNDS WITH DIFFERENTIATED OPIOID AQION 
PROFILES. 

000013 01-02 
QUESTIONS OF DIFFERENTIATED TREATMENT FOR EPILEPTIC-PATIENTS. 

003605 03-17 
SOME PRINCIPLES OF DIFFERENTIATED METABOLIC DRUG-TREATMENT IN 
COMPREHENSIVE THERAPY OF MENTAL-DISORDERS. 

004433 04-1 1 
DIFFERENTIATES 

CATION REGULATION DIFFERENTIATES SPECIFIC BINDING OF 
(3H)SULPIRIDE AND (3H)SPIPER0NE TO RAT STRIATAL PREPARATIONS. 

004032 04-03 
DIFFERENTIATION 

BETA-ADRENOCEPTOR ANTAGONISTS: STUDIES ON BEHAVIOUR (DELAYED 
DIFFERENTIATION) IN THE MONKEY (MACACA-MULAHA). 

00044001-04 
DIFFERENTIATION OF KAINATE AND QUISQUALATE-RECEPTORS IN THE 
CAT SPINAL-CORD BY SELECTIVE ANTAGONISMS WITH GAMMA 
D(AND L) GLUTAMYLGLYCINE. 

002696 03-03 
DIFFERENTIATION OF OPIATE-RECEPTORS IN THE BRAIN BY THE SELEQIVE 
DEVELOPMENT OF TOLERANCE. 

003088 03-04 



S-140 



VOLUME 19, SUBJECT INDEX 



Subject Index 



PHARMACOLOGICAL DIFFERENTIATION OF PRESYNAPTIC INHIBITORY 
ALPHA-ADRENOCEPTORS AND OPIATE-RECEPTORS IN THE CAT 
NICTITATING MEMBRANE. 

003777 04-03 
MINI-SYMPOSIUM. I. THE IN VIVO DIFFERENTIATION OF OPIATE- 
RECEPTORS: INTRODUCTION 

004697 04-17 
DIFFUSE 

BEHAVIORAL CONFIRMATION Of DIFFUSE NOXIOUS INHIBITORY 
CONTROLS (DNIC) AND EVIDENCE FOR A ROLE OF ENDOGENOUS 
OPIATES. 

002791 03-03 
DIFLUORO 

FLUORINATED ANALOGUES OF THE TRICYCLIC NEUROLEPTICS: 2,3 
DIFLUORO DERIVATIVE OF CLOROTEPIN. 

000001 01-01 
DIFLUOROMETHYL-DOPA 

IRREVERSIBLE INHIBITION OF AROMATIC-L-AMINO-ACID-DECARBOXYLASE 
BY ALPHA DIFLUOROMETHYL-DOPA AND METABOLISM OF THE 
INHIBITOR. 

000248 01-03 
DIFLUOROPHENYLSALiCYLIC-ACID 

ANALGESIC ACTIVITY OF DIFLUNISAL (MK-647; 5 2,4 

OIFLUOROPHENYLSALICYLIC-ACID) IN RATS WITH HYPERALGESIA 
INDUCED BY FREUNDS-ADJUVANT. 

000502 01-04 
DIGITOXIN 

NONINTERACTION OF DIGITOXIN AND QUINIDINE. 

000968 01-17 
DI60XIN 

SUBJECTIVE ASSESSMENT OF SEXUAL-DYSFUNCTION OF PATIENTS ON 
LONG.TERM ADMINISTRATION OF DIGOXIN. 

002443 02-15 
EFFECT OF DOSE ON BIOAVAILABILITY OF ORAL DIGOXIN. 

003161 03-07 
DIHYDRO-6-PHENYL-1 H-S-TRIAZOLOBENZODIAZEPIN-1 -ONES 

2,4 DIHYDRO-6-PHENYL-lH-S-TRIAZOLOBENZODIAZEPIN-l-ONES WITH 
ANTIANXIETY AND ANTIDEPRESSANT ACTIVITY. 

001075 02-02 
DIHYDROALPRENOLOL 

DOWN REGULATION OF DIHYDROALPRENOLOL AND IMIPRAMINE 
BINDING-SITES IN BRAIN OF RATS REPEATEDLY TREATED WITH 
IMIPRAMINE. 

001317 02-03 
DIHYDROCAPSAICIN 

EXCITATORY EFFECTS OF DIHYDROCAPSAICIN ON NOCICEPTIVE NEURONS 
IN THE MEDIAL THALAMUS. 

003714 04-03 
DIHYDROERGOCRISTINE 

INHIBITION OF SULPIRIDE-INDUCED PROLACTIN SECRETION BY 
DIHYDROERGOCRISTINE IN MAN. 

002277 02-13 
DIHYDROERGOCRYPTINE 

CHARACTERIZATION BY (3H)DIHYDR0ERG0CRYPTINE BINDING OF 
ALPHA-ADRENERGIC-RECEPTORS IN NEUROBLASTOMA X GLIOMA 
HYBRID CELLS. 

003823 04-03 
DIHYDROERGOTAMINE 

DRUG-INDUCED ARTERIAL HYPOTENSION IN PSYCHIATRIC-PATIENTS 
TREATED WITH DIHYDROERGOTAMINE. 

001950 02-08 
DIHYDROERGOTOXINE 

NEUROPHARMACOLOGY OF BROMOCRIPTINE AND DIHYDROERGOTOXINE 
(HYDERGINE). 

001346 02-03 
EFFECTS OF REPEATED ADMINISTRATIONS OF DIHYDROERGOTOXINE 
(REDERGINE) ON THE SLEEP-WAKEFULNESS CYCLE IN THE CAT. 

003703 04-02 
CATECHOLAMINE TURNOVER IN RAT-CEREBRAL-CORTEX AND CAUDATE 
FOLLOWING REPEATED TREATMENT WITH DIHYDROERGOTOXINE. 

003765 04-03 
DIHYDROMORPHINE 

LOCALIZATION OF NALOXONE SENSITIVE (3H)DIHYDR0M0RPHINE 
BINDING-SITES WITHIN THE HIPPOCAMPUS OF THE RAT. 

001368 02-03 
ALTERATIONS IN DIHYDROMORPHINE BINDING IN CEREBRAL 
HEMISPHERES OF AGED MALE RATS. 

003936 04-03 
DIHYDROPICROTOXININ 

SOLUBILIZATION OF THE DIHYDROPICROTOXININ BINDING-SITES. 

001192 02-03 
INTERACTION OF STEREOISOMERS OF BARBITURATES WITH (3H)ALPHA 
DIHYDROPICROTOXININ BINDING-SITES. 

004036 04-03 
DIHYDROXY 

DIHYDROXY AND TRIHYDROXY ANALOGS OF CHLORPROMAZINE 
INFLUENCE THE CENTRAL-ACTIVITY OF ADENYLATE-CYCLASE AND 
CYCLIC-AMP-PHOSPHODIESTERASE . 

001405 02-03 



DIHYDROXYNOMIFENSINE 

EFFECTS OF 3', 4' DIHYDROXYNOMIFENSINE ON THE DOPAMINE 
VASCULAR RECEPTOR. 

003890 04-03 
DIHYDROXYPHENYLACETIC-ACID 

DOPAMINE, NORADRENALINE AND 3,4 DIHYDROXYPHENYLACETIC-ACID 
(DOPAC) LEVELS Of INDIVIDUAL BRAIN NUCLEI, EFFECTS OF 
HALOPERIDOL AND PARGYLINE. 

003792 04-03 
DETERMINATION OF PICOMOLE AMOUNTS OF DOPAMINE, 
NORADRENALINE, 3,4 DIHYDROXYPHENYLALANINE, 3,4 
DIHYDROXYPHENYLACETIC-ACID, HOMOVANILLIC-ACID, AND 5 
HYDROXYINDOLEACETIC-ACID IN NERVOUS-TISSUE AFTER ONE-STEP 
PURIFICATION ON SEPHADEX-G-IO, USING HIGH. 

004305 04-06 
DIHYDROXYPHENYLALANINE 

AUTORADIOGRAPHIC STUDIES ON DISTRIBUTION OF L-3,4 
DIHYDROXYPHENYLALANINE (L-DOPA) 14C AND L 5 
HYDROXYTRYPTOPHAN (L 5 HTP) 14C IN THE CAT BRAIN. 

003941 04-03 
DETERMINATION OF PICOMOLE AMOUNTS OF DOPAMINE, 
NORADRENALINE, 3,4 DIHYDROXYPHENYLALANINE, 3,4 
DIHYDROXYPHENYLACETIC-ACID, HOMOVANILLIC-ACID, AND 5 
HYDROXYINDOLEACETIC-ACID IN NERVOUS-TISSUE AFTER ONE-STEP 
PURIFICATION ON SEPHADEX-G-10, USING HIGH. 

004305 04-06 
DIHYDROXYPHENYLETHYLENE-GLYCOL-SULFATE 

EFFECTS OF MORPHINE AND OTHER CENTRALLY-ACTING DRUGS ON 3,4 
DIHYDROXYPHENYLETHYLENE-GLYCOL-SULFATE (D0PEG-S04) IN RAT- 
BRAIN. 

000136 01-03 
DIHYDROXYPHENYLETHYLENEGLYCOL 

POSTMORTEM STABILITY OF BRAIN 3 METHOXY-4- 
HYDROXYPHENYLETHYLENEGLYCOL AND 3,4 
DIHYDROXYPHENYLETHYLENEGLYCOL IN THE RAT AND MOUSE. 

004048 04-03 
DIHYDROXYTRYPTAMINE 

UNILATERAL 5,7 DIHYDROXYTRYPTAMINE LESIONS OF THE DORSAL 
RAPHE NUCLEUS (DRN) AND RAT ROTATIONAL-BEHAVIOUR. 

001578 02-04 
5,7 DIHYDROXYTRYPTAMINE LESIONS OF THE AMYGDALA REDUCE 
AMPHETAMINE-INDUCED AND APOMORPHINE-INDUCED STEREOTYPED- 
BEHAVIOUR IN THE RAT. 

001589 02-04 
THE EFFECTS OF INTRAVENTRICULAR 6 HYDROXYDOPAMINE AND 5,6 
DIHYDROXYTRYPTAMINE ON MORPHINE-INDUCED LOCOMOTOR- 
STIMULATION. 

001784 02-04 
DENERVATION SUPERSENSITIVITY TO 5 HYDROXYTRYPTOPHAN IN RATS 
FOLLOWING SPINAL TRANSECTION AND 5,7 DIHYDROXYTRYPTAMINE 
INJECTION. 

003722 04-03 
DIHYDROXYTRYPTAMINE-INDUCED 

5,7 DIHYDROXYTRYPTAMINE-INDUCED MOUSE-KILLING AND 
BEHAVIORAL-REVERSAL WITH VENTRICULAR ADMINISTRATION OF 
SEROTONIN IN RATS. 

001562 02-04 
DIISOPROPYLTRYPT AMINE 

N,N DIISOPROPYLTRYPTAMINE (DIPT) AND 5 
METHOXYDIISOPROPYLTRYPT AMINE (5 MEO-DIPT). TWO ORALLY 
ACTIVE TRYPTAMINE ANALOGS WITH CNS ACTIVITY. 

004310 04-07 
DIKETOPIPERAZINE 

HISTIDYL-PROLINE DIKETOPIPERAZINE DECREASES FOOD INTAKE IN RATS. 

004181 04-04 
DILATION 

CONSISTENT UNMASKING OF DOPAMINE-INDUCED DILATION OF THE 
CANINE FEMORAL VASCUUR BED. 

003911 04-03 
DILATOR 

DIRECT EVIDENCE AGAINST ACETYLCHOLINE AS THE DILATOR 
TRANSMITTER IN THE CAT CEREBRAL-ARTERY. 

001336 02-03 
DILTIAZEM 

TREATMENT OF UNSTABLE ANGINA BY DILTIAZEM. 

004307 04-07 
DILUTION 

A METHOD FOR THE DETERMINATION OF AMITRIPTYLINE AND ITS 
METABOLITES NORTRIPTYLINE, 10 HYDROXYAMITRIPTYLINE, AND 10 
HYDROXYNORTRIPTYLINE IN HUMAN PLASMA USING STABLE ISOTOPE 
DILUTION AND GAS-CHROMATOGRAPHY CHEMICAL-IONIZATION 
MASS-SPECTROMETRY. 

002486 02-16 
DIMENSIONS 

SOME OBSERVATIONS ON THE PSYCHOLOGICAL DIMENSIONS OF 
PLACEBO-EFFECTS. 

003573 03-17 



I 



^5? 

lai. 



'lit 
etc 

fi5 



tu. 



* 



If* 



'C 



S-141 



Subject Index 

DIMETHOXY-4-ALKYLPHENYLISOPROPYI.AMINES 

DOM AND RELATED 2,5 DIMETHOXY-4-ALKYLPHENYLISOPROPYLAMINES: 
BEHAVIORAL AND SEROTONIN-RECEPTOR PROPERTIES. 

003690 04-02 
DIMETHOXY-4-METHYI.AMPHET AMINE 

ENHANCEMENT OF THE BEHAVIORAL-EFFECTS OF 2,5 DIMETHOXY-4- 
METHYLAMPHET AMINE (DOM) BY PRETREATMENT WITH P 
CHLOROPHENYLALANINE. 

000364 01-04 

THE EFFECTS OF D LYSERGIC-ACID-DIETHYLAMIDE (LSD), 2,5 

DIMETHOXY-4-METHYLAMPHET AMINE (DOM) AND D-AMPHETAMINE 
ON OPERANT-RESPONDING IN CONTROL AND 6 HYDROXYDOPAMINE 

TREATED RATS. „„,.„. „o„. 

001595 02-04 
THE EFFECTS OF 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM) ON 
OPERANT-BEHAVIOR: INTERACTIONS WITH OTHER NEUROACTIVE- 

*^'''^- 004089 04-04 

DIMETHOXYMETHYL-PHENOBARBITAL 

METABOLISM OF DIMETHOXYMETHYL-PHENOBARBITAL (ETEROBARB) IN 
PATIENTS WITH EPILEPSY. ^^ „^ ,^ 

002235 02-13 
DIMETHYL-M-TYRAMINE 

THE ROLE OF DOPAMINE IN THE HYPERMOTILITY INDUCED BY H-77-77 
(4 ALPHA DIMETHYL-M-TYRAMINE) IN MICE. 

001762 02-04 
DIMETHYLAMINO-TETRAHYDROAZEPINOPHENOTHIAZINE 

CONFORMATIONALLY RESTRICTED PHENOTHIAZINE NEUROLEPTICS. 1. 3 
DIMETHYLftMINO-TETRAHYDROAZEPINOPHENOTHIAZINE. 

001359 02-03 
DIMETHYLAMINOBUTYNYICYCIOHEXYLHYDROXY 

THE CRYSTAL AND MOLECULAR STRUCTURE OF THE ACETYLCHOLINE 
ANTAGONIST OIMETHYL^MINOBUTYNYLCYCLOHEXYLHYDROXY 2 
PHENYLACETATE HCL. „ „ 

000003 01-01 
DIMETHYLAMINOPROPYI-5-METHYI-3-PHENYL-1H-INDAZOIE 
PHARMACOLOGICAL- STUDIES ON A NEW THYMOLEPTIC 
ANTIDEPRESSANT. DIMETHYLAMINOPROPYL-5-METHYL-3-PHENYL-1 H- 
INDAZOLE (FS-32). 

001659 02-04 
INFLUENCE OF A CHRONIC NEW POTENTIAL ANTIDEPRESSANT, 
DIMETHYLAMINOPROPYL-5-METHYL-3-PHENYL- 1 H-INOAZOLE (FS-32) 
AND ITS N DESMETHYLATED-COMPOUND (FS-97): TREATMENT ON 
MONOAMINERGIC-RECEPTOR SENSITIVITY IN THE RAT-BRAIN. 

002787 03-03 
DIMETHYLTRYPT AMINE 

BEHAVIOURAL-CHANGES INDUCED BY N.N DIMETHYLTRYPTAMINE IN 

RODENTS 

000413 01-04 

DIMETHYLTRYPT AMINES 

STUDIES ON SEVERAL 7 SUBSTITUTED N,N DIMETHYLTRYPTAMINES. 

001020 02-01 
DIMINISHES 

PIRACETAM DIMINISHES HIPPOCAMPAL ACETYLCHOLINE LEVELS IN RATS. 

002934 03-03 
DIMINUTION 

3H IMIPRAMINE BINDING IN HUMAN PLATELETS: DIMINUTION OF 
BINDING-SITES IN DEPRESSED-PATIENTS. 

003427 03-13 
DINORLAAM 

PHARMACODYNAMIC PROFILES OF L ALPHA ACETYLMETHADOL (LAAM) 
AND ITS N DEMETHYLATED METABOLITES, NORLAAM AND 
DINORLAAM, DURING SELF-ADMINISTRATION IN THE DEPENDENT RAT. 

000505 01-04 
DIPHENYL-5-2-DIMETHYLAMINOPROPIONAMIDE-PYRAZOLE 

NEUROCHEMICAL-STUDIES OF AN ANALGESIC, 1,3 DIPHENYL-5-2- 
DIMETH YLAMINOPROPIONAMIDE-PYRAZOLE (DIFENAMIZOLE) . 

002771 03-03 
DIPHENYLHYDANTOIN 

PLASMA LEVELS OF DIPHENYLHYDANTOIN AND THE CONTROL OF ADULT 
EPILEPTIC-SEIZURES: A CHILEAN EXPERIENCE. 

000102 01-03 
EFFECT OF DOPAMINERGIC AND GABAERGIC DRUGS GIVEN ALONE OR IN 
COMBINATION ON THE ANTICONVULSANT ACTION OF PHENOBARBITAL 
AND DIPHENYLHYDANTOIN IN THE ELEQROSHOCK-TEST IN MICE. 

000163 01-03 
EFFECTS OF DIPHENYLHYDANTOIN ON SPONTANEOUS MOTOR-AQIVITY. 

000284 01-03 
BEHAVIORAL-ANALYSIS OF AMYGDALOID KINDLING IN BEAGLE-DOGS 
AND THE EFFECTS OF CLONAZEPAM, DIAZEPAM, PHENOBARBITAL, 
DIPHENYLHYDANTOIN, AND FLUNARIZINE ON SEIZURE 
MANIFESTATION. 

000496 01-04 

SERUM CONCENTRATIONS OF PHENOBARBITAL AND 
DIPHENYLHYDANTOIN IN SEVERE MENTALLY-HANDICAPPED AND 
PHYSICALLY-HANDICAPPED-PATIENTS. 

000856 01-15 
PHOSPHORYLATION OF THE MEMBRANE-BOUND ACETYLCHOLINE- 
RECEPTOR: INHIBITION BY DIPHENYLHYDANTOIN. 

001257 02-03 



Psychopharmacology Abstracts 



CRITICAL PERIODS FOR DIPHENYLHYDANTOIN AND PHENOBARBITAL 
ADMINISTRATION DURING GESTATION. 

001630 02-04 
PERINATAL EFFECTS OF PSYCHOTROPIC-DRUGS: THE ANTICONVULSANT- 
DRUG DIPHENYLHYDANTOIN. (UNPUBLISHED PAPER). 

001842 02-05 
INTERRELATION AT PLASMATIC LEVEL BETWEEN ANTIEPILEPTIC-DRUGS 
AND LIPIDS. ITS IMPLICATIONS IN THE EFFICIENCY OF TREATMENT IN 
EPILEPSY. I. CHANGES INDUCED BY PHENOBARBITAL OR/AND 
DIPHENYLHYDANTOIN IN SERUM LIPIDS. 

002281 02-13 
PAROXYSTIC-DYSKINESIAS DURING TREATMENT WITH 
DIPHENYLHYDANTOIN. 

002319 02-14 
A COMPARISON OF THE EFFECTS OF PENTOBARBITAL AND 

DIPHENYLHYDANTOIN ON THE GABA SENSITIVITY AND EXCITABILITY 
OF ADULT SENSORY GANGLION CELLS. 

002692 03-03 
DIPHENYLHYDANTOIN REDUCES THE OUTWARD-CURRENT OF THE AQION 
POTENTIAL IN APLYSIA. 

002805 03-03 
CHANGES IN REGIONAL BRAIN LEVELS OF AMINO-ACID PUTATIVE 
NEUROTRANSMinERS AFTER PROLONGED TREATMENT WITH THE 
ANTICONVULSANT-DRUGS DIPHENYLHYDANTOIN, PHENOBARBITONE, 
SODIUM- VALPROATE, ETHOSUXIMIDE, AND SULTHIAME IN THE RAT. 

003961 04-03 
EFFECTS OF WITHDRAWAL FROM LONG-TERM DIPHENYLHYDANTOIN 
TREATMENT ON AUDIOGENIC-SEIZURES AND MAXIMAL 
ELECTROSHOCK-INDUCED SEIZURES IN RATS. 

004101 04-04 
MEASUREMENTS OF NERVE CONDUQION VELOCITY DURING DECREASING 
TOXIC DIPHENYLHYDANTOIN LEVELS AND THE BEGINNING OF 
CARBAMAZEPINE MEDICATION: A CLINICAL NEUROPHYSIOLOGICAL 
REPORT 

004441 04-11 
THE EFFECT OF DIPHENYLHYDANTOIN ON EEG CURVES IN EPILEPTICS 

004494 04-11 
TRANSIENT HYPERKINESIA AFTER A SINGLE INTRAVENOUS PERFUSION OF 
DIPHENYLHYDANTOIN: REPORT OF A CASE ASSOCIATED WITH 
NONTOXIC PLASMA LEVELS OF DIPHENYLHYDANTOIN. 

004638 04-15 
A COMPARISON OF RADIOIMMUNOASSAY WITH SPEQROPHOTOMETRY 
FOR THE DETERMINATION OF PLASMA DIPHENYLHYDANTOIN 
CONCENTRATIONS. 

004684 04-16 
DIPHENYLHYDANTOIN-INDUCED 

OIPHENYLHYDANTOIN-INDUCED BLOCK OF THE RAT PHRENIC-NERVE 
DIAPHRAGM PREPARATION PRETREATED WITH P 
HYDROXYMERCURIBENZOATE 

002749 03-03 
DIPIPERIDINOETHANE 

SYSTEMIC DIPIPERIDINOETHANE MIMICS THE CONVULSANT AND 
NEUROTOXIC-ACTIONS OF KAINIC-ACIO. 

000222 01-03 
LESIONS OF AMYGDALA, PYRIFORM CORTEX AND OTHER BRAIN 
STRUaURES DUE TO DIPIPERIDINOETHANE INTOXICATION. 

004273 04-05 

DIPOLAR 

NMR SPECTRAL STUDY OF PROTON TRANSFER IN AMITRIPTYLINE- 
HYDROCHLORIDE CHLORDIAZEPOXIDE-HYOROCHLORIDE COMBINATIONS 
IN DIPOLAR APROTIC SOLVENTS. 

003654 04-01 

DIPOTASSIUM-CHLORAZEPATE 

PHARMACOPSYCHOLOGICAL INVESTIGATION OF CHANGES IN MOOD 
INDUCED BY DIPOTASSIUM-CHLORAZEPATE WITH AND WITHOUT 
SIMULTANEOUS ALCOHOL ADMINISTRATION. 

000825 01-14 
PHARMACOKINETICS OF DIPOTASSIUM-CHLORAZEPATE IN PATIENTS 
AFTER REPEATED 50MG ORAL DOSES. 

002211 02-13 

DIPOTASSIUM-CLORAZEPATE 

PHARMACOPSYCHOLOGICAL INVESTIGATIONS CONCERNING THE 
COMBINED EFFECTS OF DIPOTASSIUM-CLORAZEPATE AND ETHANOL. 

003456 03-14 

DIPROPYL-ADTN 

AQIVATION OF PRESYNAPTIC ALPHA NORADRENALINE-RECEPTORS IN 
RAT-BRAIN BY THE POTENT DOPAMINE-MIMETIC N,N DIPROPYL-ADTN. 

001390 02-03 
DIPROPYLACET AMIDE 

EEG AND ANTICONVULSANT EFFEQS OF DIPROPYLACETIC-ACID AND 
DIPROPYLACET AMIDE IN THE BABOON PAPIO-PAPIO. 

001210 02-03 

DIPROPYLACETATE ^„,^ 

DIFFERENTIAL-EFFEaS OF N DIPROPYLACETATE AND AMINOOXY ACETIC- 
ACID ON GAMMA AMINOBUTYRIC-ACID LEVELS IN DISCRETE AREAS 
OF RAT-BRAIN. „ „, „, 

000140 01-03 



S-142 



VOLUME 19, SUBJECT INDEX 



Subject Index 



DIPROPYLACETATE-INDUCED 

DIPROPYLACETATE-INDUCED ABSTINENCE-BEHAVIOUR AS A POSSIBLE 
CORRELATE OF INCREASED GABAERGIC ACTIVITY IN THE RAT. 

001606 02-04 
DIPROPYLACETIC-ACID 

EEC AND ANTICONVULSANT EFFECTS OF DIPROPYLACETIC-ACID AND 
DIPROPYLACETAMIDE IN THE BABOON PAPIO-PAPIO. 

001210 02-03 
INFLUENCE OF DIPROPYLACETIC-ACID ON THALAMOCORTICAL RESPONSES 
IN RATS. 

001419 02-03 
DIPSOGENIC-EFFECT 

DIPSOGENIC-EFFECT OF L 5 HYDROXYTRYPTOPHAN IN RATS 

001623 02-04 
DIRECTIONALITY 

POSTURAL ASYMMETRY AND DIRECTIONALITY OF ROTATION IN RATS. 

001729 02-04 
DOES POSTURAL ASYMMETRY INDICATE DIRECTIONALITY OF ROTATION 
IN RATS: ROLE OF SEX AND HANDLING. 

003061 03-04 
DIRECTIONS 

DEPRESSION IN THE ELDERLY; RESEARCH DIRECTIONS IN 
PSYCHOPATHOLOGY, EPIDEMIOLOGY, AND TREATMENT. 

000998 01-17 
DISADVANTAGES 

ADVANTAGES AND DISADVANTAGES OF PROLONGED USE OF 
NEUROLEPTICS. 

003470 03-15 
DISAGGREGATION 

AMPHETAMINE STEREOTYPIES AND POLYRIBOSOMAL DISAGGREGATION 
IN RATS: EFFECTS OF ADRENERGIC AND SEROTONERGIC BLOCKING- 
AGENTS. 

001531 02-03 
DISCHARGE 

CORRECTION BY PROPRANOLOL OF THE ABNORMAL ADRENALINE 
DISCHARGE INDUCED BY EMOTIONAL-STRESS IN CEREBRAL 
HEMORRHAGE PATIENTS 

002295 02-13 
COMPARISON OF DRUG PRESCRIPTIONS FOR PSYCHIATRIC-PATIENTS 
AFER HOSPITAL DISCHARGE IN THE DISTRICTS TEPLICE AND UHERSKE- 
HRADISTE. 

002518 02-17 
EFFEQS OF PROLONGED TREATMENT WITH LITHIUM AND TRICYCLIC- 
ANTIDEPRESSANTS ON DISCHARGE FREQUENCY, NOREPINEPHRINE 
RESPONSES AND BETA-RECEPTOR BINDING IN RAT-CEREBELLUM: 
ELECTROPHYSIOLOGICAL AND BIOCHEMICAL COMPARISON. 

002884 03-03 
EFFECTS OF ACUTE AND CHRONIC AMPHETAMINE TREATMENT ON 
PURKINJE NEURON DISCHARGE IN RAT CEREBELLUM. 

003793 04-03 
EFFECT OF MEDIAN RAPHE STIMULATION ON HIPPOCAMPAL SEIZURE 
DISCHARGE INDUCED BY CARBACHOL IN THE RABBIT. 

003951 04-03 
DISCHARGED 

FOLLOWUP TREATMENT AND AFTERCARE OF DISCHARGED 
SCHIZOPHRENIC-PATIENTS. 

000944 01-17 
DISCHARGES 

INHIBITORY AQIONS OF TAUROCYAMINE, HYPOTAURINE, 
HOMOTAURINE, TAURINE AND GABA ON SPIKE DISCHARGES OF 
PURKINJE-CELLS, AND LOCALIZATION OF SENSITIVE SITES, IN GUINEA- 
PIG CEREBELLAR SLICES. 

002846 03-03 
ANTIPEROXIDANT PRETREATMENT AND IRON-INDUCED EPILEPTIFORM 
DISCHARGES IN THE RAT: EEG AND HISTOPATHOLOGIC STUDIES. 

002930 03-03 
DISCONTINUATION 

DISCONTINUATION OF ORAL AND DEPOT FLUPHENAZINE IN 
SCHIZOPHRENIC-PATIENTS AFTER ONE YEAR OF CONTINUOUS 
MEDICATION: A CONTROLLED- STUDY. 

001931 02-08 
PANIC-ANXIETY AFTER ABRUPT DISCONTINUATION OF AMITRIPTYLINE. 

003223 03-09 
EFFEQS OF GRADUAL DECREASE AND DISCONTINUATION OF 
NEUROLEPTICS ON CLINICAL CONDITION AND TARDIVE-DYSKINESIA. 

003469 03-15 
DISCONTINUATION OF ANTIPSYCHOTIC-DRUG THERAPY. 

003514 03-15 
CLINICAL AND BIOCHEMICAL-CORRELATIONS IN ABRUPT 
DISCONTINUATION OF PSYCHOPHARMACOTHERAPY 

004330 04-08 
A MODIFIED VERSION OF THE SIMULTANEOUS DISCONTINUATION OF 
PSYCHOTROPIC-DRUGS (COMBINED WITH THE ADMINISTRATION OF 
DIURETICS) AS A METHOD OF HALTING PROLONGED AHACKS OF 
SCHIZOPHRENIA. 

004584 04-14 
DISCONTINUING 

AN INVESTIGATION OF SOME SIDE-EFFECTS IN 47 PSYCHOTIC-PATIENTS 
DURING TREATMENT WITH CLOZAPINE AND DISCONTINUING OF THE 
TREATMENT. 

002424 02-15 



DISCRETE 

DIFFERENTIAL-EFFECTS OF N DIPROPYLACETATE AND AMINOOXYACETIC- 
ACID ON GAMMA AMINOBUTYRIC-ACID LEVELS IN DISCRETE AREAS 
OF RAT-BRAIN, 

000140 01-03 
THE EFFECTS OF OPIATES ON THE LEVELS OF CYCLIC-GUANOSINE- 
MONOPHOSPHATE IN DISCRETE AREAS OF THE RAT CENTRAL- 
NERVOUS-SYSTEM. 

000220 01-03 
BIOCHEMICAL-LOCALIZATION AND CHARACTERIZATION OF BOMBESIN- 
LIKE-PEPTIDES IN DISCRETE REGIONS OF RAT-BRAIN. (UNPUBLISHED 
PAPER). 

001046 02-01 
TOLERANCE TO BARBITURATE-INDUCED CENTRAL-NERVOUS-SYSTEM 
DEPRESSION: INVOLVEMENT OF STIMULUS SECRETION COUPLING IN 
DISCRETE BRAIN AREAS. (PHD DISSERTATION). 

001213 02-03 
CHOLECYSTOKININ-PEPTIDES PRODUCE MARKED REDUCTION OF 
DOPAMINE TURNOVER IN DISCRETE AREAS IN THE RAT-BRAIN 
FOLLOWING INTERAVENTRICULAR INJECTION. 

001239 02-03 
AGE DEPENDENT CHANGES IN THE BETA ENDORPHIN CONTENT OF 
DISCRETE RAT-BRAIN NUCLEI, 

002635 03-01 
MONOAMINE-OXIDASE-B ACTIVITIES TOWARD BETA PHENYLETHYLAMINE 
IN DISCRETE HYPOTHALAMIC AND CIRCUMVENTRICULAR NUCLEI OF 
THE RAT. 

002781 03-03 
INFLUENCE OF ESTROGEN AND PROGESTERONE ON GLUTAMIC-ACID- 
DECARBOXYLASE ACTIVITY IN DISCRETE REGIONS OF RAT-BRAIN. 

002927 03-03 
DISCRIMINABILITY 

THE EFFECT OF SEROTONIN DEPLETION ON THE DISCRIMINABILITY OF LSD. 

000499 01-04 
FACTORS REGULATING DRUG CUE SENSITIVITY: LIMITS OF 
DISCRIMINABILITY AND THE ROLE OF A PROGRESSIVELY DECREASING 
TRAINING DOSE IN FENTANYL SALINE DISCRIMINATION. 

004088 04-04 
DISCRIMINANT 

DRUG-VARIABLES IN THE ETIOLOGY OF TARDIVE-DYSKINESIA: 
APPLICATION OF DISCRIMINANT FUNCTION ANALYSIS. 

000844 01-15 
RESPONDERS AND NONRESPONDERS TO CHLORDIAZEPOXIDE AND 
PLACEBO: A DISCRIMINANT FUNCTION ANALYSIS. 

002482 02-16 
RESPONDERS AND NONRESPONDERS TO CHLORDIAZEPOXIDE AND 
PLACEBO. A DISCRIMINANT FUNCTION ANALYSIS. (UNPUBLISHED 
PAPER). 

004420 04-10 
DISCRIMINATE 

USING PROFILES OF SACCHARIN AND WATER DRINKING TO DETECT AND 
DISCRIMINATE ACTIONS OF DRUGS AND TOXICANTS. 

000503 01-04 
DISCRIMINATED 

MORPHINE EFFECTS UPON DISCRIMINATED APPROACH AND 

DISCRIMINATED AVOIDANCE IN RATS: ANTAGONISM BY NALOXONE. 

000338 01-04 
DISCRIMINATION 

A COMPARISON OF HUMAN TACTILE STIMULUS VELOCITY 

DISCRIMINATION WITH THE ABILITY OF S-l CORTICAL NEURONS IN 
AWAKE RHESUS-MONKEYS TO SIGNAL THE SAME VELOCITY 
DIFFERENCES BEFORE AND AFTER NONANESTHETIC DOSES OF 
PENTOBARBITAL. 

000055 01-03 
INVESTIGATION OF NARCOTICS AND ANTITUSSIVES USING DRUG 
DISCRIMINATION TECHNIQUES. 

000447 01-04 
DRUGS AND THE DISCRIMINATION OF DURATION. 

001561 02-04 
EFFECTS OF MORPHINE, D-AMPHET AMINE, AND PENTOBARBITAL ON 
SHOCK AND LIGHT DISCRIMINATION PERFORMANCE IN RATS. 

001639 02-04 
THE EFFECT OF MORPHINE, PIMOZIDE AND NALOXONE ON 
DISCRIMINATION BY RATS IN A SHOCK-ESCAPE-TEST. 

001700 02-04 
GO-HERE-GO-THERE PERFORMANCE AFTER AMPHETAMINE: THE 
IMPORTANCE OF THE RESPONSE REQUIREMENT IN SUCCESSIVE 
DISCRIMINATION. 

001759 02-04 
LACK OF EFFECT OF CHOLINE AND NARCOTIC ANTAGONISTS UPON 
APOMORPHINE DISCRIMINATION. 

001770 02-04 
EFFECTS OF PIMOZIDE ON ACCURACY OF PERFORMANCE AND 
DISTRIBUTION OF CORRECT RESPONDING ON A SIMULTANEOUS 
DISCRIMINATION TASK IN THE RAT. 

001806 02-04 



a. 

m 

•«it 
■'it 

He 






IS' 



I 



S-143 






Subject Index 

DISCRIMINATION OF FUNCTIONALLY HETEROGENEOUS RECEPTOR 
SUBPOPULATIONS: ANTIPSYCHOTIC AND ANTIDOPAMINERGIC 
PROPERTIES OF METOCLOPRAMIDE. 

002877 03-03 
THE EFFECTS OF PIMOZIDE DURING PAIRING ON THE TRANSFER OF 
CLASSICAL CONDITIONING TO AN OPERANT DISCRIMINATION. 

002956 03-04 
EXTENDED SCHEDULE TRANSFER OF ETHANOL DISCRIMINATION. 

003087 03-04 
FACTORS REGULATING DRUG CUE SENSITIVITY: LIMITS OF 

DISCRIMINABILITY AND THE ROLE OF A PROGRESSIVELY DECREASING 
TRAINING DOSE IN FENTANYL SALINE DISCRIMINATION. 

004088 04-04 
METHADONE-INDUCED ATTENUATION OF THE EFFECTS OF DELTA9 
TETRAHYDROCANNABINOL ON TEMPORAL DISCRIMINATION IN 

PIGEONS. 

004095 04-04 
DISCRIMINATION OF ELECTRIC-SHOCK: EFFECTS OF SOME OPIOID AND 
NONOPIOID DRUGS. 

004106 04-04 
A SIGNAL-DETECTION-ANALYSIS OF MORPHINE EFFECTS ON THE 
RESPONSE BIAS OF RATS IN A TWO-SHOCK DISCRIMINATION TASK 

004124 04-04 

NARCOTIC DISCRIMINATION IN PIGEONS. 

004132 04-04 
RAPID ACQUISITION OF A TWO-DRUG DISCRIMINATION: TIME OF DAY 
EFFECT UPON SALINE STATE. 

004214 04-04 
METHYLMERCURY-INDUCED CHANGES IN OPERANT DISCRIMINATION BY 
THE PIGEON. 

004271 04-05 

DISCRIMINATIONS 

EFFECTS OF PHENCYCUDINE, PENTOBARBITAL, AND D-AMPHETAMINE ON 
THE ACQUISITION AND PERFORMANCE OF CONDITIONAL 
DISCRIMINATIONS IN MONKEYS. 

001723 02-04 

DISCRIMINATIVE 

REINFORCING, DISCRIMINATIVE AND ACTIVATING PROPERTIES OF 
AMPHETAMINE. 

000804 01-14 
THE EFFECTS OF OPIATE ANTAGONISTS ON THE DISCRIMINATIVE 
STIMULUS PROPERTIES OF ETHANOL. 

002947 03-04 
INTRAVENTRICULAR CORTICOSTERONE INJECTION FACILITATES MEMORY 
OF AN APPETITIVE DISCRIMINATIVE TASK IN MICE. 

003051 03-04 
DISCRIMINATIVE RESPONSE CONTROL BY NALOXONE IN MORPHINE 
PRETREATED RATS. 

003053 03-04 
PHENCYCLIDINE-LIKE DISCRIMINATIVE EFFEQS OF OPIOIDS IN THE RAT 

004136 04-04 
AVOIDANCE ENHANCEMENT AND DISCRIMINATIVE RESPONSE CONTROL 
BY ANXIOLYTICS WITH DRUGS ACTING ON THE GABA SYSTEM. 

004193 04-04 
DISCRIMINATIVE-STIMULUS 

DISCRIMINATIVE- STIMULUS EFFECTS OF NALTREXONE IN THE MORPHINE- 
DEPENDENT RAT. 

000391 01-04 
LSD-25 AS A DISCRIMINATIVE-STIMULUS FOR RESPONSE SELECTION BY 
PIGEONS. 

000412 01-04 
DISCRIMINATIVE-STIMULUS EFFECTS OF PENTOBARBITAL IN PIGEONS. 

001651 02-04 
DELTA9 THC AS A DISCRIMINATIVE-STIMULUS IN RATS AND PIGEONS: 
GENERALIZATION TO THC METABOLITES AND SP-1 1 1 . 

001666 02-04 
DISCRIMINATIVE-STIMULUS EFFECTS OF PROTOTYPE OPIATE-RECEPTOR 
AGONISTS IN MONKEYS. 

001803 02-04 
TOLERANCE TO THE DISCRIMINATIVE-STIMULUS PROPERTIES OF D- 
AMPHET AMINE. 

002953 03-04 
DISCRIMINATIVE-STIMULUS PROPERTIES OF COCAINE, NORCOCAINE, AND 

N ALLYLNORCOCAINE. 

002954 03-04 
DISCRIMINATIVE-STIMULUS PROPERTIES OF PHENCYCUDINE AND FIVE 

ANALOGUES IN THE SQUIRREL-MONKEY. 

002961 03-04 
INFLUENCE OF MORPHINE ON THE DISCRIMINATIVE-STIMULUS 

PROPERTIES OF REWARDING LATERAL HYPOTHALAMIC STIMULATION. 
(PH.D. DISSERTATION). 

003041 03-04 
DISCRIMINATIVE-STIMULUS EFFEQS OF ETORPHINE IN RHESUS- 
MONKEYS. 

004134 04-04 

DISCRIMINATIVE-STIMULUS PROPERTIES OF COCAINE RELATED TO AN 
ANXIOGENIC ACTION. 

004219 04-04 
DISCRIMINATIVE-STIMULUS EFFEaS OF CYCLAZOCINE IN THE RAT 

004236 04-04 



Psychopharmacology Abstracts 



DISCRIMINATIVE-STIMULUS PROPERTIES OF THE HALLUCINOGENIC-AGENT 
DOM. 

004260 04-04 
MINI-SYMPOSIUM. IV. DISCRIMINATIVE-STIMULUS EFFECTS OF 

NARCOTICS: EVIDENCE FOR MULTIPLE RECEPTOR-MEDIATED AQIONS. 

004719 04-17 
DISEASE-INDUCED 

DISEASE-INDUCED CHANGES IN THE PLASMA BINDING OF BASIC DRUGS. 

000975 01-17 
DISFLUENCIES 

PRINCIPAL AND DIFFERENTIAL-EFFECTS OF HALOPERIDOL AND PLACEBO 
TREATMENTS UPON SPEECH DISFLUENCIES IN STUHERERS. 

00071301-11 
DISINHIBITING-AGENT 

PERSPECTIVES ON PRAZINIL (CARPIPRAMINE): A DISINHIBITING-AGENT 
WITH NO NEUROLEPTIC ACTIVITY. A REVIEW OF 38 CASES 

003149 03-07 
DISINHIBITION 

DISINHIBITION OF BEHAVIOR BY ANTIANXIETY-DRUGS. 

002403 02-15 
AMMONIA AND DISINHIBITION IN CAT MOTOR-CORTEX BY AMMONIUM- 
ACETATE, MONOFLUOROACETATE AND INSULIN-INDUCED 
HYPOGLYCEMIA, 

004276 04-05 
DISINHIBITORS 

METHODOLOGICAL-CONSIDERATIONS CONCERNING THE PRESCRIPTION 
AND USE OF SO CALLED DISINHIBITORS 

002571 02-17 
DISINHIBITORY 

CARPIPRAMINE: A DISINHIBITORY DRUG COMPOUND IN CHRONIC 
SCHIZOPHRENIA 

003192 03-08 
DISORDERS 

THE USEFULNESS OF THE ERYTHROCYTE LITHIUM INDEX IN THE 
EVALUATION OF DISORDERS OF ION-TRANSFER IN PATIENTS WITH 
DEPRESSIVE-SYNDROMES 

000625 01-09 
BRAIN FUNQION IN OLD-AGE: EVALUATION OF CHANGES AND 
DISORDERS. 

000684 01-11 
DISORDERS OF SMOOTH-PURSUIT EYE-MOVEMENTS IN SCHIZOPHRENICS 
AND THE EFFECT OF NEUROLEPTICS IN THERAPEUTIC DOSES. 

001912 02-08 
DRUG-INDUCED DISORDERS OF THE URINARY TRAQ. 

002393 02-15 
DRUG-INDUCED DISORDERS OF THE EYE. 

002396 02-15 
DRUG-INDUCED DISORDERS OF THE LIVER. 

002397 02-15 
DRUG-INDUCED DISORDERS OF MUSCLE. 

002435 02-15 
THE BIOLOGICAL-EFFECTS AND CLINICAL-EFFEaS OF ORAL MAGNESIUM 
AND ASSOCIATED MAGNESIUM VITAMIN-B6 ADMINISTRATION ON 
CERTAIN DISORDERS OBSERVED IN INFANTILE AUTISM. 

003291 03-11 
DISORIENTATION 

AGITATION DISORIENTATION, AND HALLUCINATIONS IN PATIENTS ON 
CIMETIDINE A REPORT OF THREE CASES AND LITERATURE REVIEW. 

000896 01-15 
DISPENSER 

A DRUG DISPENSER TO MEASURE INDIVIDUAL DRINKING IN RAT 
COLONIES. 

000530 01-06 

DISPOSITION 

DISPOSITION OF VALPROIC-ACID IN THE RAT: DOSE-DEPENDENT 
METABOLISM DISTRIBUTION, ENTEROHEPATIC RECIRCULATION AND 
CHOLERETIC-EFFECT 

000073 01-03 

EFFEaS OF UREA ON HEXOBARBITAL AND ANTIPYRINE DISPOSITION IN 

RATS 

000307 01-03 

DIFFERENTIAL-EFFECTS ON BENZODIAZEPINE DISPOSITION BY DISULFIRAM 

AND ETHANOL. „ ,„ 

000789 01-13 

CHLORDIAZEPOXIDE AND OXAZEPAM DISPOSITION IN CIRRHOSIS 

000790 01-13 
THE COMPARATIVE DISPOSITION OF NOMIFENSINE (MERITAL) IN THE 

PREGNANT AND NONPREGNANT RAT 

000853 01-15 
DISPOSITION OF (3H) PHENCYCUDINE IN THE RAT AFTER SINGLE-DOSES 
AND MULTIPLE-DOSES. 

001375 02-03 
EFFECTS OF ANTICONVULSANTS AND METHOTREXATE ON CALCIUM 

DISPOSITION, „^ 

001840 02-05 

DISPOSITION AND AQIVITY OF BETA-ADRENOCEPTOR ANTAGONISTS IN 
THE RAT USING AN EX VIVO RECEPTOR BINDING ASSAY. 

001878 02-06 



S-144 



VOLUME 19, SUBJECT INDEX 



Subject Index 



INFLUENCE OF PHENYTOIN AND PHENOBARBITAL ON THE DISPOSITION OF 
A SINGLE-ORAL-DOSE OF CLONAZEPAM 

002248 02-13 
DISPOSITION AND PHARMACOLOGICAL-EFFECTS OF M 
CHLOROPHENYLPIPERAZINE IN RATS 

002995 03-04 
DISPOSITION OF METHADONE IN THE OVINE MATERNAL FETAL UNIT. 

004027 04-03 
DISRUPTION 

DISRUPTION OF SELECTIVE AHENTION BY APOMORPHINE, BUT NOT 
AMPHETAMINE, IN THE MONGOLIAN-GERBIL. 

000358 01-04 
DISRUPTION OF 5 HYDROXYTRYPTAMINERGIC NEURONAL FUNCTION 
BLOCKS THE ACTION OF MORPHINE ON TUBEROINFUNDIBULAR 
DOPAMINERGIC NEURONS 

002700 03-03 
DISRUPTION OF AUTOSHAPED RESPONDING TO A SIGNAL OF BRAIN- 
STIMULATION REWARD BY NEUROLEPTIC-DRUGS. 

004199 04-04 
DISRUPTIVE 

NALOXONE POTENTIATES THE DISRUPTIVE EFFECTS OF MESCALINE ON 
OPERANT-RESPONDING IN THE RAT. 

000365 01-04 
DISSIMILAR 

DISSIMILAR EFFECTS OF NICOTINAMIDE AND INOSINE, PUTATIVE 
ENDOGENOUS LIGANDS OF THE BENZODIAZEPINE-RECEPTORS, ON 
PENTYLENETETRAZOL SEIZURES IN FOUR STRAINS OF MICE. 

000173 01-03 
DISSIMILARITIES 

SIMILARITIES AND DISSIMILARITIES BETWEEN DOPAMINE AND 
NEUROLEPTIC-RECEPTORS: FURTHER EVIDENCE FOR TYPE-1 AND TYPE-2 
DOPAMINE-RECEPTORS IN THE CNS. 

001480 02-03 
DISSOCIATION 

DISSOCIATION OF THE STRYCHNINE EFFECT ON VISUAL-MEMORY AND 
VERBAL-MEMORY IN ORGANIC-PSYCHOSYNDROMES. 

000816 01-14 
BETA ENDORPHIN: DISSOCIATION OF RECEPTOR BINDING-ACTIVITY FROM 
ANALGESIC POTENCY. 

001081 02-02 
DISSOCIATION OF D-AMPHETAMINE-INDUCED LOCOMOTOR-ACTIVITY AND 
STEREOTYPED-BEHAVIOUR BY LESIONS OF THE SUPERIOR-COLLICULUS. 

001755 02-04 
DISSOCIATION OF THE STRYCHNINE EFFECT ON VISUAL-MEMORY AND 
VERBAL-MEMORY IN ORGANIC-PSYCHOSYNDROMES. 

002155 02-11 
CLONIDINE ANALGESIA AND SUPPRESSION OF OPERANT RESPONDING: 
DISSOCIATION OF MECHANISM. 

003046 03-04 
DISSOCIATION BETWEEN FREE AND BOUND PHENYTOIN LEVELS IN 
PRESENCE OF SODIUM-VALPROATE. 

003367 03-1 1 
MULTIPLE BENZODIAZEPINE-RECEPTORS: EVIDENCE OF A DISSOCIATION 
BETWEEN ANTICONFLICT AND ANTICONVULSANT PROPERTIES BY PK- 
8165 AND PK-9084 (TWO QUINOLINE DERIVATIVES) 

003898 04-03 
DISSOCIATIVE-EFFECTS 

REWARD AND DETECTION THRESHOLDS FOR BRAIN-STIMULATION: 
DISSOCIATIVE-EFFECTS OF COCAINE. 

004160 04-04 
DISSOCIATIVE-SYNDROMES 

THE USE OF A MORPHINE ANTAGONIST (NALOXONE) IN THE TREATMENT 
OF DISSOCIATIVE-SYNDROMES. 

003194 03-08 
DISTRESS 

ASCENDING ENDORPHIN INHIBITION OF DISTRESS VOCALIZATION. 

003011 03-04 
DISTRIBUTION 

(3H) 2 AMINODIHYDROXYTETRAHYDRONAPHTHALENE (ADTN): 
REGIONAL DISTRIBUTION AND IN VIVO BINDING AFTER ACUTE AND 
CHRONIC DRUG-TREATMENT. 

000052 01-03 
EFFECTS OF PSYCHOTROPIC-DRUGS ON THE DISTRIBUTION OF 3H 
DOPAMINE INTO COMPARTMENTS OF RAT STRIATAL SYNAPTOSOMES 
AND ON SUBSEQUENT DEPOLARIZATION-INDUCED 3H DOPAMINE 
RELEASE. 

000067 01-03 
THE EFFECT OF DIAZEPAM ON TENSION AND ELECTROLYTE DISTRIBUTION 
IN FROG MUSCLE. 

000069 01-03 
DISPOSITION OF VALPROIC-ACID IN THE RAT: DOSE-DEPENDENT 
METABOLISM, DISTRIBUTION, ENTEROHEPATIC RECIRCULATION AND 
CHOLERETIC-EFFECT. 

000073 01-03 
STUDIES ON THE DISTRIBUTION OF 14C SULPIRIDE AND ITS METABOLITES 
IN THE RAT AND GUINEA-PIG. 

000078 01-03 
DISTRIBUTION AND EXCRETION IN THE RAT AND MONKEY OF (82BR) 
BROMOCRIPTINE. 

000196 01-03 



REGIONAL DISTRIBUTION AND BIOCHEMICAL-PROPERTIES OF 125! TYR8- 
SUBSTANCE-P BINDING-SITES IN SYNAPTIC VESICLES. 

000259 01-03 
DISTRIBUTION OF 14C PHENYTOIN IN RAT PURKINJE-CELLS, CEREBELLAR 
AND CEREBRAL NEURONAL TISSUE AFTER A SINGLE INTRAPERITONEAL 
INJECTION. 

000261 01-03 
PREDICTION OF THE VOLUME OF DISTRIBUTION FROM IN VITRO DATA 
AND USE FOR ESTIMATING THE ABSOLUTE EXTENT OF ABSORPTION 

000907 01-16 
ON THE MECHANISM OF A DIFFERENT DRUG DISTRIBUTION DURING 
CONVULSIVE-SEIZURE IN COMPARISON TO ANESTHESIA. 

001151 02-03 
EFFECTS OF PIMOZIDE ON ACCURACY OF PERFORMANCE AND 
DISTRIBUTION OF CORRECT RESPONDING ON A SIMULTANEOUS 
DISCRIMINATION TASK IN THE RAT. 

001806 02-04 
NA-DEPENDENT LI COUNTERTRANSPORT AND THE LITHIUM DISTRIBUTION 
ACROSS THE HUMAN ERYTHROCYTE MEMBRANE: INTRODUCTION 

002227 02-13 
COMPARATIVE-STUDIES ON THE METABOLISM AND THE DISTRIBUTION OF 
SULPIRIDE AND SULTOPRIDE. 

002240 02-13 
QUANTITATIVE STUDY OF THE DISTRIBUTION OF LITHIUM IN THE MOUSE- 
BRAIN FOR VARIOUS DOSES OF LITHIUM GIVEN TO THE ANIMAL. 

002299 02-13 
THE DISTRIBUTION OF CHLORPROMAZINE BETWEEN PLASMA AND 
ERYTHROCYTES. 

002496 02-16 
DISTRIBUTION OF MEMBRANE GLYCOPROTEINS AMONG THE ORGANELLES 
OF A SINGLE IDENTIFIED NEURON OF APLYSIA. II. ISOLATION AND 
CHARACTERIZATION OF A GLYCOPROTEIN ASSOCIATED WITH 
VESICLES. 

002657 03-03 
BETA-ADRENERGIC-RECEPTOR SUBTYPES: PROPERTIES, DISTRIBUTION, 
AND REGULATION. 

002829 03-03 
LAMINAR DISTRIBUTION OF PUTATIVE NEUROTRANSMinER AMINO- 
ACIDS AND LIGAND BINDING-SITES IN THE DOG OLFACTORY-BULB. 

002836 03-03 
DOPAMINERGIC AGONIST AND ANTAGONIST EFFECTS ON STRIATAL 
TYROSINE-HYDROXYLASE DISTRIBUTION . 

002898 03-03 
DISTRIBUTION OF CESIUM IN THE ORGANISM AND ITS EFFECT ON THE 
NUCLEOTIDE METABOLISM ENZYMES. 

003696 04-02 
AUTORADIOGRAPHIC STUDIES ON DISTRIBUTION OF L-3,4 
DIHYDROXYPHENYLALANINE (L-DOPA) 14C AND L 5 
HYDROXYTRYPTOPHAN (L 5 HTP) 14C IN THE CAT BRAIN. 

003941 04-03 
REGIONAL DISTRIBUTION OF (3H)IMIPRAMINE BINDING IN RAT-BRAIN. 

003955 04-03 
THE EFFECT OF P CHLOROPHENYL^LANINE ON THE DISTRIBUTION OF 
BIOGENIC-AMINES IN THE BRAIN, AND ON MEMORY IN RATS. 

004068 04-04 
EFFECT OF DESMETHYLIMIPRAMINE ON TISSUE DISTRIBUTION AND 
ANORECTIC-ACTIVITY OF CHLORPHENTERMINE IN RATS. 

004179 04-04 
DISTRIBUTIONS 

SEROTONIN-SENSITIVE ADENYLATE-CYCLASE AND (3H)SER0T0NIN 
BINDING-SITES IN THE CNS OF THE RAT - II. RESPECTIVE REGIONAL 
AND SUBCELLULAR DISTRIBUTIONS AND ONTOGENETIC 
DEVELOPMENTS. 

000214 01-03 
EXTRAHYPOTHALAMIC DISTRIBUTIONS AND FUNCTIONS OF 
HYPOTHALAMIC PEPTIDE-HORMONES. (UNPUBLISHED PAPER). 

001211 02-03 
DISTRICTS 

COMPARISON OF DRUG PRESCRIPTIONS FOR PSYCHIATRIC-PATIENTS 
AFTER HOSPITAL DISCHARGE IN THE DISTRICTS TEPLICE AND UHERSKE- 
HRADISTE. 

002518 02-17 
DISTURBANCE 

NEUROENDOCRINE DISTURBANCE IN DEPRESSION. 

004405 04-09 
DISTURBANCES 

BIOLOGICAL-RHYTHM DISTURBANCES IN AFFECTIVE-ILLNESS. 

002628 02-17 
DISTURBED 

AMPHETAMINIL IN THE TREATMENT OF DISTURBED ERECTION POTENCY. 

002129 02-11 
DOES P CHLOROPHENYLALANINE PRODUCE DISTURBED WAKING, 
DISTURBED SLEEP OR ACTIVATION BY PONTO-GENICULO-OCCIPITAL 
WAVES IN CATS? 

003704 04-02 
DISTURBED-BEHAVIOUR 

DISTURBED-BEHAVIOUR INDUCED BY HIGH-DOSE ANTIPSYCHOTIC-DRUGS. 

002375 02-15 



I 



( 

'»ll£ 



«5r: 



m 



S-145 



Subject Index 



Psychopharmacology Abstracts 



DISULFIDE 

SYNTHESIS AND BIOLOGICAL-ACTIVITY OF HUMAN BETA ENDORPHIN 
ANALOGS WITH DISULFIDE BRIDGES. 

003655 04-01 
COMT-A AND COMT-B: CATALYTIC DIFFERENCES AND ROLE OF DISULFIDE 

BONDS. 

003927 04-03 

DISULFIRAM ^,, ^ 

INHIBITION OF ALCOHOL-DEHYDROGENASE BY DISULFIRAM, POSSIBLE 
RELATION TO THE DISULFIRAM ETHANOL REACTION 

000270 01-03 
DIFFERENTIAL-EFFECTS ON BENZODIAZEPINE DISPOSITION BY DISULFIRAM 

AND ETHANOL „„„,„„„, ,, 

000789 01-13 

METHADONE DISULFIRAM INTERACTION DURING METHADONE 
MAINTENANCE. ^^„,„, „, ,^ 

000796 01-13 
DISULFIRAM ENCEPHALOPATHY AS A CAUSE OF THE CATATONIA- 
SYNDROME. 

000894 01-15 
EXPERIMENTAL-STUDIES ON HEPATOTOXICITY OF DISULFIRAM. 

001844 02-05 
A COMPARATIVE REVIEW OF THE PHARMACOLOGICAL AND 
TOXICOLOGICAL PROPERTIES OF DISULFIRAM AND CALCIUM- 
CARBIMIDE. „„,, 

003522 03-15 
DISULFIRAM AND NOCTURNAL PENILE-TUMESCENCE IN THE CHRONIC 
ALCOHOLIC. „„^„, „^ ,, 

004556 04-13 

DITHIADEN 

CLONAZEPAM AND DITHIADEN IN HYPERKINETIC-CHILDREN. 

000729 01-11 
DIURETICS 

DIURETICS ARE DANGEROUS WITH LITHIUM. 

002420 02-15 

A MODIFIED VERSION OF THE SIMULTANEOUS DISCONTINUATION OF 
PSYCHOTROPIC-DRUGS (COMBINED WITH THE ADMINISTRATION OF 
DIURETICS) AS A METHOD OF HALTING PROLONGED AHACKS OF 

SCHIZOPHRENIA. „„.c„.„. ,. 

004584 04-14 

DIURNAL GROWTH-HORMONE RESPONSES TO DEXTROAMPHETAMINE IN 
NORMAL YOUNG MEN AND POSTMENOPAUSAL- WOMEN. 

003411 03-13 
EFFECT OF LITHIUM ON REACTION-TIME ~ A STUDY OF DIURNAL 
VARIATIONS 

004607 04-15 

DIVALENT-CATION 

ALPHA2-ADREN0CEPT0RS IN RAT-BRAIN: THE DIVALENT-CATION SITE. 

001246 02-03 
DIVALENT-CATIONS 

MULTIPLE ALPHA2-N0RADRENERGIC-RECEPT0R SITES IN RAT-BRAIN: 
SELECTIVE REGULATION OF HIGH-AFFINITY (3H)CL0NIDINE BINDING BY 
GUANINE-NUCLEOTIDES AND DIVALENT-CATIONS. 

003992 04-03 
DIVERGENCES 

CONVERGENCES AND DIVERGENCES BETWEEN BIOLOGICAL-PSYCHIATRY 
AND PSYCHOTHERAPY. 

002536 02-17 

DIVERGENT 

DIVERGENT RESERPINE EFFECTS ON AMFONELIC-ACID AND 
AMPHETAMINE STIMULATION OF SYNAPTOSOMAL DOPAMINE 
FORMATION FROM PHENYLALANINE. 

001113 02-03 
DIVIDED 

SINTAMIL IN THE TREATMENT OF DEPRESSION: A COMPARISON OF 
SINGLE VS. DIVIDED DOSE ADMINISTRATION. 

000629 01-09 
THERAPEUTIC-EFFICACY OF DOXEPIN IN DIVIDED AND SINGLE-DOSE 
REGIME. 

003259 03-09 



DNA 



DMI 



PLASMA LEVELS OF IMIPRAMINE (IMI) AND DESMETHYLIMIPRAMINE 
(DMI) AND CLINICAL-RESPONSE IN PREPUBERTAL MAJOR DEPRESSIVE- 
DISORDER: A PRELIMINARY REPORT. 

000619 01-09 
INFERENTIAL CHANGES AFTER CHRONIC-TREATMENTS WITH LI, DMI, OR 
ETHANOL DETECTED BY ELEaROPHYSIOLOGICAL-CORRELATES. 

001136 02-03 
AN INVERSE CORRELATION BETWEEN SERUM LEVELS OF 

DESMETHYLIMIPRAMINE AND MELATONIN-LIKE IMMUNOREACTIVITY 
IN DMI RESPONSIVE DEPRESSIVES. 

003228 03-09 
EFFECTS OF SUBCHRONIC DESMETHYLIMIPRAMINE (DMI) TREATMENT OF 
THE CLASSICALLY CONDITIONED EYEBLINK RESPONSE IN RABBITS. 

004180 04-04 
SUBCHRONIC-TREATMENT WITH THE TRICYCLIC-ANTIDEPRESSANT DMI 
INCREASES ISOLATION-INDUCED FIGHTING IN RATS. 

004252 04-04 



EFFECT OF AMPHETAMINE ON THE METABOLISM AND INCORPORATION 
OF (3H) THYMIDINE INTO DNA OF DEVELOPING RAT-BRAIN. 

003729 04-03 
DMA-DEPENDENT 

PURIFICATION AND SUBUNIT STRUCTURE OF DNA-DEPENDENT RNA- 
POLYMERASE-BII FROM RAT-BRAIN NUCLEI. 

003679 04-01 
DOCA-SALT 

CENTRAL DOPAMINERGIC NEURONS DURING DEVELOPMENT OF GENETIC 
AND DOCA-SALT HYPERTENSION IN THE RAT. 

003899 04-03 
DOCLOXYTHEPIN 

COMPARISON OF BLOOD AND BILE LEVELS OF OXYPROTHEPIN AND 
DOCLOXYTHEPIN IN RATS. 

000242 01-03 
DOCUMENTATION 

COORDINATING CLINICAL-TRIALS IN PSYCHOPHARMACOLOGY: 
PLANNING, DOCUMENTATION, AND ANALYSIS. 

002574 02-17 

DOG 

MORPHINE ACTS THROUGH ALPHA-ADRENERGIC AND SEROTONINERGIC 
NEURONS TO STIMULATE GROWTH-HORMONE SECRETION IN THE DOG. 

000088 01-03 
PHARMACOKINETICS OF CARBAMAZEPINE IN THE DOG. 

000096 01-03 
PHARMACOKINETICS OF PRIMIDONE AND ITS ACTIVE METABOLITES IN 

THE DOG. 

000097 01-03 
THE EFFECT OF MONOAMINE-OXIDASE-INHIBITORS ON FIRST-PASS 

METABOLISM OF TYRAMINE IN DOG INTESTINE 

000141 01-03 
PHARMACOKINETICS AND METABOLISM OF 
CHLORODIMETHYLAMINOETHOXYDIBENZOTHIEPINE (ZOTEPINE) IN RAT, 
MOUSE, DOG AND MAN 

000219 01-03 
PHARMACOLOGY OF PHENETHYLAMINE TRACE AMINES IN THE DOG - 
DISCUSSION 

000469 01-04 
TOXICOLOGIC AND PHARMACOLOGIC-EFFEaS OF PHENCYCLIDINE-HCL IN 
THE DOG. (PH.D. DISSERTATION). 

000519 01-05 
LEVORPHANOL: RADIOIMMUNOASSAY AND PLASMA CONCENTRATION 
PROFILES IN DOG AND MAN. 

000898 01-16 
CORRELATIONS BETWEEN HEMODYNAMIC PARAMETERS OF THE LIVER 
AND NOREPINEPHRINE RELEASE UPON HEPATIC-NERVE STIMULATION IN 
THE DOG 

001547 02-03 

FURTHER STUDIES ON OPIATE-RECEPTORS THAT MEDIATE 
ANTINOCICEPTION: TOOTH-PULP STIMULATION IN THE DOG. 

001782 02-04 , 
THE EFFECTS OF THIORIDAZINE ON ELECTRICAL AND ISCHEMIC 
VENTRICULAR FIBRILLATION IN THE DOG HEART IN SITU. .| 

002697 03-03 
LAMINAR DISTRIBUTION OF PUTATIVE NEUROTRANSMIHER AMINO- 
ACIDS AND LIGAND BINDING-SITES IN THE DOG OLFACTORY-BULB. 

002836 03-03 
PHARAAACOLOGIC EVIDENCE FOR A TONIC MUSCARINIC INHIBITORY 
INPUT TO THE EDINGER-WESTPHAL NUCLEUS IN THE DOG. 

002889 03-03 
INTERACTION OF THE TRiaCLIC-ANTIDEPRESSANT AMITRIPTYLINE WITH 
PREJUNCTIONAL ALPHA AND MUSCARINIC-RECEPTORS IN THE DOG j 
SAPHENOUS VEIN. „ „, 

003756 04-03 

DOGS 

BIOAVAILABILITY OF 14C SULPIRIDE IN DOGS. I 

000017 01-03] 

ENZYME INDUCING EFFEQS OF PHENOBARBITAL ON NITRAZEPAM 

METABOLISM IN DOGS. „ „^ 

000086 01-03 

EFFEQ OF ISOPROTERENOL ON CEREBRAL CIRCULATION IN DOGS. 

000199 01-031 

CHOLINERGIC MECHANISMS AND CATAPLEXY IN DOGS. • 

000374 01-04 

THE INTERAQION OF ANTICHOLINESTERASES AND DIAZEPAM IN THE 
TREATMENT OF ANTICHOLINERGIC-SYNDROME IN DOGS. 

000389 01-04 

BIPHASIC-EFFEaS OF PIMOZIDE ON SLEEP-WAKEFULNESS IN DOGS. 

000495 01-04' 

BIOAVAILABILITY OF SULPIRIDE TABLET AND CAPSULE IN DOGS. 

001101 02-03 
RESPONSIVENESS TO VASOACTIVE-AGENTS OF CEREBRAL-ARTERIES AND 
MESENTERIC-ARTERIES ISOLATED FROM CONTROL AND RESERPINE 

TREATED DOGS «„,„,o«-,«, 

001273 02-03 



S-146 



VOLUME 19, SUBJECT INDEX 



Subject Index 



ANTIARRHYTHMIC-ACTIVITY OF AMITRIPTYLINE ANALOGUES IN 
CONSCIOUS DOGS AFTER MYOCARDIAL-INFARCTION: 
CYPROHEPTADINIUM-METHIODIDE . 

001534 02-03 
INFLUENCE OF IMIPRAMINE AND PARGYLINE ON THE 
ARRHYTHMOGENICITY OF EPINEPHRINE DURING HALOTHANE, 
ENFLURANE OR METHOXYFLURANE ANESTHESIA IN DOGS. 

001539 02-03 
ELECTROMYOGRAPHIC-ASSESSMENT OF SPINAL REFLEXES IN 
EXPERIMENTALLY DEPRESSED DOGS TREATED WITH 
ANTIDEPRESSANTS 

001620 02-04 
GENETIC AND EXPERIMENTAL FACTORS AFFECTING THE PARADOXICAL- 
EFFECTS OF AMPHETAMINE IN DOGS. 

001704 02-04 
INTRAVENOUS SELF-ADMINISTRATION OF COCAINE AND NORCOCAINE BY 
DOGS. 

001760 02-04 
THE EFFECTS OF IMIPRAMINE TREATMENT ON THE UNCONDITIONED 
ALIMENTARY BEHAVIOR AND CLASSICAL CONDITIONED SALIVARY 
REACTIONS IN DOGS. 

003030 03-04 
CENTRAL HYPOTENSIVE-EFFECT OF GAMMA AMINOBUTYRIC-ACID IN 
ANESTHETIZED DOGS. 

003772 04-03 
BETA-ADRENERGIC INFLUENCE ON CARDIAC DYNAMICS DURING SHOCK- 
AVOIDANCE IN DOGS. 

003813 04-03 
EFFECT OF MORPHINE AND NALOXONE ON LEU-ENKEPHALIN-LIKE 
IMMUNOREACTIVITY IN DOGS. 

003894 04-03 
DOSAGE FORM DESIGN FOR IMPROVEMENT OF BIOAVAILABILITY OF 
LEVODOPA III: INFLUENCE OF DOSE ON PHARMACOKINETIC BEHAVIOR 
OF LEVODOPA IN DOGS AND PARKINSONIAN-PATIENTS. 

004551 04-13 
DOM 

ENHANCEMENT OF THE BEHAVIORAL-EFFECTS OF 2,5 DIMETHOXY-4- 
METHYLAMPHETAMINE (DOM) BY PRETREATMENT WITH P 
CHLOROPHENYLALANINE. 

000364 01-04 
THE EFFEQS OF D LYSERGIC-ACID-DIETHYLAMIDE (LSD), 2,5 

DIMETHOXY-4-METHYLAMPHETAMINE (DOM) AND D-AMPHETAMINE 
ON OPERANT-RESPONDING IN CONTROL AND 6 HYDROXYDOPAMINE 
TREATED RATS. 

001595 02-04 
DOM AND RELATED 2,5 DIMETHOXY-4-ALKYLPHENYLISOPROPYLAMINES: 
BEHAVIORAL AND SEROTONIN-RECEPTOR PROPERTIES. 

003690 04-02 
THE EFFEQS OF 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM) ON 
OPERANT-BEHAVIOR: INTERACTIONS WITH OTHER NEUROACTIVE- 
AGENTS. 

004P89 04-04 
DISCRIMINATIVE-STIMULUS PROPERTIES OF THE HALLUCINOGENIC-AGENT 
DOM. 

004260 04-04 
DOMESTIC 

TONIC IMMOBILITY IN DOMESTIC FOWL: POSSIBLE INTERACTION OF 
SEROTONERGIC AND DOPAMINERGIC MECHANISMS. 

004246 04-04 
DOMESTIC-FOWL 

THE BEHAVIOURAL-STATE DURING CLIMAX (HATCHING) IN THE 
DOMESTIC-FOWL (GALLUS-DOMESTICUS) . 

001564 02-04 
DOMPERIDONE 

THREE CLASSES OF DOPAMINE-RECEPTOR (D-2, D-3, D-4) IDENTIFIED BY 
BINDING STUDIES WITH 3H APOMORPHINE AND 3H DOMPERIDONE. 

002900 03-03 
CHLORPROMAZINE, HALOPERIDOL, METOCLOPRAMIDE AND 
DOMPERIDONE RELEASE PROLACTIN THROUGH DOPAMINE 
ANTAGONISM AT LOW CONCENTRATIONS BUT PARADOXICALLY 
INHIBIT PROLACTIN RELEASE AT HIGH-CONCENTRATIONS. 

003731 04-03 
THE DOPAMINE-RECEPTOR ANTAGONIST DOMPERIDONE IS ALSO A 
COMPETITIVE ANTAGONIST AT ALPH A 1 -ADRENOCEPTORS. 

003785 04-03 
DOPA 

DOPA AND DOPAMINE AGONISTS IN DEPRESSION. 

002310 02-13 
OPPOSITE EFFECTS OF NALOXONE ON SUBSTANCE-P-INDUCED IN BRAIN 
DOPA SYNTHESIS AND IN LOCOMOTOR-ACTIVITY IN RATS. 

003799 04-03 
DOPA-DECARBOXYLASE 

COMPARATIVE-STUDIES OF L-DOPA ALONE AND COMBINATION WITH A 
PERIPHERAL DOPA-DECARBOXYLASE INHIBITOR, BENSERAZIDE-HCL, ON 
PARKINSONS-DISEASE ~ PART II: PHARMACOKINETIC-STUDY. 

002309 02-13 
THE INTERAQION OF 2,3,4 TRIHYDROXYBENZYLHYDRAZINE WITH 
DOPA-DECARBOXYLASE FROM PIG KIDNEY. 

002925 03-03 



DOPAC 

STRIATAL DOPAC LEVELS AS A PREDICTOR OF ANTIPSYCHOTIC-EFFICACY 

001533 02-03 
DOPAMINE, NORADRENALINE AND 3,4 DIHYDROXYPHENYLACETIC-ACID 
(DOPAC) LEVELS OF INDIVIDUAL BRAIN NUCLEI, EFFECTS OF 
HALOPERIDOL AND PARGYLINE. 

003792 04-03 
DOPAMINE 

ARYLDIALKENYLPIPERAZINES AS SELECTIVE AND VERY POTENT 
INHIBITORS OF DOPAMINE UPTAKE. 

000005 01-01 
ANTIHISTAMINE EFFECT ON SYNAPTOSOMAL UPTAKE OF SEROTONIN, 
NOREPINEPHRINE AND DOPAMINE. 

000035 01-03 
DOPAMINE, ACETYLCHOLINE, AND GABA EFFECTS IN ACUTE DYSTONIA IN 
PRIMATES. 

000043 01-03 
REPEATED TRICYCLIC-ANTIDEPRESSANTS INDUCE A PROGRESSIVE SWITCH 
IN THE ELECTROPHYSIOLOGICAL RESPONSE OF DOPAMINE NEURONS TO 
AUTORECEPTOR STIMULATION. 

000046 01-03 
THE INFLUENCE OF BENZOCTAMINE ON DOPAMINE AND NOREPINEPHRINE 
CONTENTS OF THE SUBSTANTIA-NIGRA AND ON THE MUSCLE STRETCH 
REFLEX OF THE CAT. 

000054 01-03 
EFFECTS OF PSYCHOTROPIC-DRUGS ON THE DISTRIBUTION OF 3H 
DOPAMINE INTO COMPARTMENTS OF RAT STRIATAL SYNAPTOSOMES 
AND ON SUBSEQUENT DEPOLARIZATION-INDUCED 3H DOPAMINE 
RELEASE. 

000067 01-03 
COMPARISON OF THE EFFECTS OF THE ISOMERS OF AMPHETAMINE, 
METHYLPHENIDATE AND DEOXYPIPRADROL ON THE UPTAKE OF L 
(3H)N0REPINEPHRINE AND (3H)D0PAMINE BY SYNAPTIC VESICLES 
FROM RAT-WHOLE-BRAIN, STRIATUM AND HYPOTHALAMUS. 

000091 01-03 
THE EFFECTS OF TWO ANALOGS OF DOPAMINE ON GANGLIONIC 
TRANSMISSION IN THE SYMPATHETIC-NERVOUS- SYSTEM. 

000162 01-03 
THE MONOAMINE-OXIDASE-INHIBITORS CLORGYLINE AND L DEPRENYL 
ALSO AFFECT THE UPTAKE OF DOPAMINE, NORADRENALINE AND 
SEROTONIN BY RAT-BRAIN SYNAPTOSOMAL PREPARATIONS. 

000171 01-03 
EFFECTS OF PERINATAL THYROXINE AND/OR CORTICOSTERONE 
TREATMENT ON THE ONTOGENESIS OF HYPOTHALAMIC AND 
MESENCEPHALIC NOREPINEPHRINE AND DOPAMINE CONTENT. 

000180 01-03 
ROLE OF DOPAMINE STORAGE FUNCTION IN THE CONTROL OF RAT 
STRIATAL TYROSINE-HYDROXYLASE ACTIVITY. 

000201 01-03 
ACUTE AND CHRONIC EFFECTS OF NEUROLEPTICS AND ACUTE EFFECTS OF 
APOMORPHINE AND AMPHETAMINE ON DOPAMINE TURNOVER IN 
CORPUS- STRIATUM AND SUBSTANTIA-NIGRA OF THE RAT-BRAIN. 

000215 01-03 
EFFECTS OF DES-TYR-GAMMA-ENDORPHIN ON DOPAMINE RELEASE FROM 
VARIOUS RAT-BRAIN REGIONS IN VITRO. 

000264 01-03 
LONG-TERM EFFECTS OF CONTINUOUS EXPOSURE TO AMPHETAMINE ON 
BRAIN DOPAMINE CONCENTRATION AND SYNAPTOSOMAL UPTAKE IN 
MICE. 

000287 01-03 
THE EFFECT OF A NEW FLUORINATED TRICYCLIC NEUROLEPTIC-DRUG 
ISOFLOXYTHEPIN ON THE RAT STRIATAL DOPAMINE METABOLISM. 

000306 01-03 
ANALYSIS OF THE ACTIVATION OF DOPAMINE METABOLISM BY A 
SEROTONIN UPTAKE INHIBITOR. 

000315 01-03 
SELECTIVE STORAGE IN VIVO OF 5,6 ADTN IN DOPAMINE RICH AREAS OF 
THE RAT-BRAIN. 

000324 01-03 
MESOLIMBICOCORTICAL DOPAMINE TERMINAL-FIELDS ARE NECESSARY 
FOR NORMAL LOCOMOTOR AND INVESTIGATORY EXPLORATION IN 
RATS. 

000383 01-04 
RELATIONSHIPS BETWEEN SELECTIVE DENERVATION OF DOPAMINE 

TERMINAL-FIELDS IN THE ANTERIOR-FOREBRAIN AND BEHAVIORAL- 
RESPONSES TO AMPHETAMINE AND APOMORPHINE. 

000384 01-04 
ROTATIONAL-BEHAVIOR INDUCED BY COCAINE ANALOGS IN RATS WITH 

UNILATERAL 6 HYDROXYDOPAMINE LESIONS OF THE SUBSTANTIA- 
NIGRA: DEPENDENCE UPON DOPAMINE UPTAKE INHIBITION. 

000404 01-04 
INTRAVENTRICULAR 6 HYDROXYDOPAMINE IN THE NEWBORN RAT AND 
LOCOMOTOR RESPONSES TO DRUGS IN INFANCY: NO SUPPORT FOR 
THE DOPAMINE DEPLETION MODEL OF MINIMAL-BRAIN-DYSFUNCTION. 

000448 01-04 
SEX-DIFFERENCES IN AMPHETAMINE-ELICITED ROTATIONAL-BEHAVIOR 
AND THE LATERALIZATION OF STRIATAL DOPAMINE IN RATS. 

000459 01-04 



lai, 



I 

'O.X 

/;ii- 



u. 






S-147 



Subject Index 



Ptychopharmacology Abstracts 



PSYCHIATRIC MANIFESTATIONS INDUCED BY DOPAMINE PRECURSORS OR 

DOPAMINE AGONISTS. „„„„,. „, ,c 

000865 01-15 
TETRAHYDRO-BETA-CARBOLINES AND CORRESPONDING TRYPTAMINES: 
IN VITRO INHIBITION OF SEROTONIN AND DOPAMINE UPTAKE BY 

HUMAN BLOOD-PLATELETS „„,„,, „^ „o 

001067 02-02 
TETRAHYDRO-BETA-CARBOLINES AND CORRESPONDING TRYPTAMINES: 
IN VITRO INHIBITION OF SEROTONIN, DOPAMINE AND 
NORADRENALINE UPTAKE IN RAT-BRAIN SYNAPTOSOMES. 

001078 02-02 
EFFECTS OF CHRONIC-TREATMENT WITH L SULPIRIDE AND HALOPERIDOL 
ON CENTRAL DOPAMINE TURNOVER EVALUATED IN DOPAMINE CELL 
BODY AND NERVE TERMINAL-RICH AREAS. 

001096 02-03 
INCREASED METABOLISM OF DOPAMINE AND SEROTONIN INDUCED IN 
FOREBRAIN AREAS BY ETORPHINE MICROINJECTION IN 

PERIAQUEDUCTAL GRAY. ^ ^^ ^^ 

001103 02-03 
BIPHASIC RESPONSIVENESS OF RAT PIAL-ARTERIOLES TO DOPAMINE: 
DIRECT OBSERVATIONS ON THE MICROCIRCULATION. 

001105 02-03 
DIVERGENT RESERPINE EFFECTS ON AMFONELIC-ACID AND 
AMPHETAMINE STIMULATION OF SYNAPTOSOMAL DOPAMINE 
FORMATION FROM PHENYLALANINE. 

001113 02-03 
CHLOROETHYLNORAPOMORPHINE, A PROPOSED LONG-ACTING 

DOPAMINE ANTAGONIST: INTERACTIONS WITH DOPAMINE-RECEPTORS 
OF MAMMALIAN FOREBRAIN IN VITRO. 

DOPAMINE SYNTHESIS: TOLERANCE TO HALOPERIDOL AND 

SUPERSENSITIVITY TO APOMORPHINE DEPEND ON PRESYNAPTIC- 

RECEPTORS. „„,,^^„o«^ 

001129 02-03 

DOPAMINE HYPOACTIVITY MEASURED BY IN VIVO VOLTAMMETRY. 

001149 02-03 
HA-966 EFFECTS ON STRIATAL DOPAMINE METABOLISM: IMPLICATIONS 

FOR DOPAMINE COMPARTMENTALIZAION. 

001150 02-03 
ADAPTIVE CHANGES OF THE STRIATAL DOPAMINE SYSTEM INDUCED BY 

REPEATED ADMINISTRATION OF NEUROLEPTICS AND ERGOT 

DERIVATIVES. „„,,., „„ „o 

001156 02-03 

DOPAMINE BIOSYNTHESIS IS REGULATED BY THE AMINE NEWLY 
RECAPTURED BY DOPAMINERGIC NERVE-ENDINGS. 

001163 02-03 
ALTERATIONS IN BASAL FIRING-RATE AND AUTORECEPTOR SENSITIVITY 
OF DOPAMINE NEURONS IN THE SUBSTANTIA-NIGRA FOLLOWING 
ACUTE AND EXTENDED EXPOSURE TO ESTROGEN. 

001167 02-03 
DOPAMINERGIC-SUPERSENSITIVITY: INFLUENCE OF DOPAMINE AGONISTS 
AND DRUGS USED FOR THE TREATMENT OF TARDIVE-DYSKINESIA. 

001169 02-03 
A COMPARISON OF STRIATAL AND MESOLIMBIC DOPAMINE FUNCTION IN 
THE RAT DURING 6-MONTH TRIFLUOPERAZINE ADMINISTRATION. 

001174 02-03 
CHANGES IN CEREBRAL DOPAMINE FUNCTION INDUCED BY A YEARS 

ADMINISTRATION OF TRIFLUOPERAZINE OR THIORIDAZINE AND THEIR 
SUBSEQUENT WITHDRAWAL. 

001175 02-03 
A COMPARISON OF THE EFFECTS OF METHYLPHENIDATE AND 

AMPHETAMINE ON THE SIMULTANEOUS RELEASE OF RADIOLABELLED 
DOPAMINE AND P OR M TYRAMINE FROM RAT STRIATAL SLICES. 

001207 02-03 
EFFECT OF MOXESTROL ON HALOPERIDOL-INDUCED CHANGES IN 
STRIATAL ACETYLCHOLINE LEVELS AND DOPAMINE TURNOVER. 

001218 02-03 
CHOLECYSTOKININ-PEPTIDES PRODUCE MARKED REDUCTION OF 
DOPAMINE TURNOVER IN DISCRETE AREAS IN THE RAT-BRAIN 
FOLLOWING INTERAVENTRICULAR INJECTION. 

001239 02-03 
THE AFFINITIES OF ERGOT COMPOUNDS FOR DOPAMINE AGONIST AND 
DOPAMINE ANTAGONIST RECEPTOR SITES. 

001254 02-03 
ANTAGONISM OF THE RENAL VASODILATOR AQIVITY OF DOPAMINE BY 
METOCLOPRAMIDE. 

001265 02-03 
FURTHER EVIDENCE FOR THE EXISTENCE OF MULTIPLE RECEPTORS FOR 
DOPAMINE IN THE CENTRAL-NERVOUS-SYSTEM. 

001296 02-03 
INTERNEURONES ARE PROBABLY NOT INVOLVED IN THE PRESYNAPTIC 
DOPAMINERGIC CONTROL OF DOPAMINE RELEASE IN RABBIT 
CAUDATE-NUCLEUS. 

001298 02-03 
THE HYPERKINETIC-SYNDROME FOLLOWING LONG-TERM HALOPERIDOL 

TREATMENT: INVOLVEMENT OF DOPAMINE AND NORADRENALINE. 

001299 02-03 
STEREOSELECTIVE ACTIONS OF SUBSTITUTED BENZAMIDE DRUGS ON 

CEREBRAL DOPAMINE MECHANISMS. 

001301 02-03 



ENDOGENOUS GUANYL-NUCLEOTIDES: COMPONENTS OF THE STRIATUM 
WHICH CONFER DOPAMINE SENSITIVITY TO ADENYLATE-CYCLASE. 

001313 02-03 
DRUG-INDUCED RELEASE OF DOPAMINE FROM CORPUS- STRIATUM. 
(PH.D. DISSERTATION). 

001343 02-03 
THE EFFEa OF CARBIDINE ON DOPAMINE TURNOVER IN THE CORPUS- 
STRIATUM OF THE BRAINS OF RATS. 

001352 02-03 
DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND DOPAMINE/ 
NEUROLEPTIC-RECEPTOR BINDING: EFFECT OF NEUROLEPTIC-DRUGS. 

001358 02-03 
EVIDENCE FOR INVOLVEMENT OF DOPAMINE IN THE AQION OF 
DIAZEPAM POTENTIATION OF HALOPERIDOL AND CHLORPROMAZINE 
ACTION IN THE BRAIN. 

001428 02-03 
EFFECT OF REPEATED TREATMENT WITH NEUROLEPTICS ON DOPAMINE 
METABOLISM IN CELL BODIES AND TERMINALS OF DOPAMINERGIC- 
SYSTEMS IN THE RAT-BRAIN. 

001464 02-03 
EFFEa OF MELANOSTATIN AND THYROLIBERIN ON THE BIOSYNTHESIS 
AND RELEASE OF DOPAMINE BY RAT-BRAIN STRIATAL P2-FRAaiONS. 

001472 02-03 
SIMILARITIES AND DISSIMILARITIES BETWEEN DOPAMINE AND 
NEUROLEPTIC-RECEPTORS: FURTHER EVIDENCE FOR TYPE-1 AND TYPE-2 
DOPAMINE-RECEPTORS IN THE CNS 

001480 02-03 
DETEQION OF MULTIPLE RECEPTORS FOR DOPAMINE. 

001481 02-03 
LONG-TERM APPLICATION OF HALOPERIDOL: EFFEQ OF ANTICHOLINERGIC 

TREATMENT ON THE RATE OF DOPAMINE SYNTHESIS 

001490 02-03 
EVIDENCE THAT NORADRENALINE MODULATES THE INCREASE IN 
STRIATAL DOPAMINE METABOLISM INDUCED BY MUSCARINIC- 
RECEPTOR STIMULATION. 

001518 02-03 
EVALUATION OF THE EFFEQ OF DRUGS ON DOPAMINE METABOLISM IN 
THE RAT SUPERIOR-CERVICAL-GANGLION BY HPLC WITH 
ELECTROCHEMICAL-DETECTION . 

001530 02-03 
MOTOR-AQIVITY AND ROTATIONAL-BEHAVIOR AFTER ANALOGS OF 
COCAINE CORRELATION WITH DOPAMINE UPTAKE BLOCKADE. 

001650 02-04 
PHENCYCLIDINE AS AN INDIRECT DOPAMINE AGONIST. 

001719 02-04 
EFFECT OF APOMORPHINE ON MORPHINE-INDUCED DECREASE IN 
LOCOMOTOR-ACTIVITY AND INCREASE IN DOPAMINE TURNOVER IN 

RATS. 

001728 02-04 

STEREOTYPED-BEHAVIOUR AND ELECTROCORTICAL-CHANGES AFTER 

INTRACEREBRAL MICROINFUSION OF DOPAMINE AND APOMORPHINE , 

IN FOWLS. 

001734 02-04 
THE ROLE OF DOPAMINE IN THE HYPERMOTILITY INDUCED BY H-77-77 ■ 
(4 ALPHA DIMETHYL-M-TYRAMINE) IN MICE. 

001762 02-04 

CIRCLING PRODUCED BY SEROTONIN AND DOPAMINE AGONISTS IN 
RAPHE LESIONED RATS: A SEROTONIN MODEL. 

001783 02-04 
ON THE USE OF OPERANT-BEHAVIOR TO STUDY THE 

NEUROPSYCHOPHARMACOLOGY OF OPIATES WITH SPECIAL REFERENCE 
TO MORPHINE AND ITS RELATIONSHIP TO DOPAMINE IN THE CENTRAL- 
NERVOUS-SYSTEM. 

001790 02-04 

BEHAVIORAL-EFFECTS OF DOPAMINE AGONISTS ACROSS THE ESTROUS- 
CYCLEINRATS 

001792 02-04 

EFFECT OF NICKEL ON THE LEVELS OF DOPAMINE, NORADRENALINE AND 
SEROTONIN IN DIFFERENT REGIONS OF THE RAT-BRAIN. 

001831 02-05 
CEREBRAL VENTRICLES AND DOPAMINE IN SCHIZOPHRENIA. 

(UNPUBLISHED PAPER). „ 

001928 02-08 

PHENYLETHYLAMINE, DOPAMINE AND NOREPINEPHRINE IN 
SCHIZOPHRENIA. (UNPUBLISHED PAPER) 

001957 02-08 
ANTIPSYCHOTIC-PROPERTIES AND ANTIDYSKINETIC-PROPERTIES OF 
ERGOT DOPAMINE AGONISTS. 

002178 02-11 
SPECIES-DIFFERENCES IN THE DEAMINATION OF DOPAMINE AND OTHER 
SUBSTRATES FOR MONOAMINE-OXIDASE IN BRAIN 

002233 02-13 
LITHIUM ANTAGONISM OF ETHANOL-INDUCED DEPLETION OF CEREBELLAR 
GUANOSINE-CYCLIC-MONOPHOSPHATE AND STIMULATION OF 
STRIATAL DOPAMINE RELEASE. 

002242 02-13 



S-148 



VOLUME 19, SUBJECT INDEX 



Subject Index 



ANTIPSYCHOTIC-DRUGS: DIFFERENTIAL-EFFECTS ON DOPAMINE NEURONS 
IN BASAL GANGLIA AND MESOCORTEX FOLLOWING CHRONIC 
ADMINISTRATION IN HUMAN AND NONHUMAN PRIMATES. 

002285 02-13 
DOPA AND DOPAMINE AGONISTS IN DEPRESSION. 

0023)0 02-13 
SHORT-TERM AND LONG-TERM EFFECTS ON GABA AND DOPAMINE 
NEURONS DURING TREATMENT WITH SULPIRIDE. 

002311 02-13 
DOPAMINE ANTAGONIST AND AGONIST TREATMENT OF TARDIVE- 
DYSKINESIA. 

002377 02-15 
CHANGES IN CEREBRAL DOPAMINE METABOLISM AND RECEPTORS 
DURING ONE-YEAR NEUROLEPTIC ADMINISTRATION AND SUBSEQUENT 
WITHDRAWAL: RELEVANCE TO BRAIN-BIOCHEMISTRY IN 
SCHIZOPHRENIA 

002390 02-15 
AN OBSERVATIONAL METHOD FOR QUANTIFYING THE BEHAVIOURAL- 
EFFECTS OF DOPAMINE AGONISTS: CONTRASTING-EFFECTS OF D- 
AMPHET AMINE AND APOMORPHINE. 

002484 02-16 
PLASMA LEVODOPA, DOPAMINE AND THERAPEUTIC RESPONSE 
FOLLOWING LEVODOPA THERAPY OF PARKINSONIAN-PATIENTS. 

002504 02-16 
A TOPOGRAPHIC LOCALIZATION OF ENKEPHALIN ON THE DOPAMINE 
NEURONS OF THE RAT SUBSTANTIA-NIGRA AND VENTRAL TEGMENTAL 
AREA DEMONSTRATED BY COMBINED HISTOFLUORESCENCE 
IMMUNOCYTOCHEMISTRY. 

002639 03-01 
PHENYLETHYLAMINE EFFECTS ON DOPAMINE SYNTHESIS. STRUCTURE- 
ACTIVITY RELATIONSHIPS. 

002649 03-02 
MIDBRAIN DOPAMINE NEURONS: DIFFERENTIAL RESPONSES TO 
AMPHETAMINE ISOMERS. 

002680 03-03 
CROSS-TOLERANCE OF DOPAMINE METABOLISM TO BACLOFEN, GAMMA 

BUTYROLACTONE AND HA-966 IN THE STRIATUM AND OLFACTORY 
TUBERCLE OF THE RAT. 

002681 03-03 
DOPAMINE AS A POSSIBLE NEUROTRANSMIHER IN THE SPINAL-CORD. 

002705 03-03 
METHYLPHENIDATE-LIKE STIMULANTS IN VITRO RELEASE (3H)TYRAMINES 

BUT NOT (14C)D0PAMINE. 

002706 03-03 
DOPAMINE DEPLETION SLOWS RETINAL TRANSMISSION. 

002708 03-03 
EFFECT OF MAZINDOL ON BRAIN DOPAMINE TURNOVER IN SPIPERONE 
TREATED RATS. 

002726 03-03 
GABA-RECEPTORS AND BENZODIAZEPINE-RECEPTORS. STUDIES ON THEIR 

LOCALIZATION IN THE HIPPOCAMPUS AND THEIR INTERACTION WITH 
CENTRAL DOPAMINE NEURONS IN THE RAT-BRAIN. 

002727 03-03 
THE PRESYNAPTIC STIMULATING EFFECT OF ACETYLCHOLINE ON 

DOPAMINE RELEASE IS SUPPRESSED DURING ACTIVATION OF 
NIGROSTRIATAL DOPAMINERGIC NEURONS IN THE CAT. 

002733 03-03 
MODULATION BY ENDOGENOUS DOPAMINE OF THE RELEASE OF 
ACETYLCHOLINE IN THE CAUDATE-NUCLEUS OF THE RABBIT 

002751 03-03 
THE EFFECT OF PHENCYCLIDINE ON DOPAMINE METABOLISM IN THE 
MOUSE-BRAIN. 

002766 03-03 
GABA ANTAGONISTS ENHANCE DOPAMINE TURNOVER IN THE RAT 
RETINA IN VIVO. 

002772 03-03 
LEVONANTRADOL, A POTENT CANNABINOID RELATED ANALGESIC, 
ANTAGONIZES HALOPERIDOL-INDUCED ACTIVATION OF STRIATAL 
DOPAMINE SYNTHESIS. 

002786 03-03 
NEUROLEPTIC-INDUCED ACUTE DYSTONIC REACTIONS MAY BE DUE TO 
ENHANCED DOPAMINE RELEASE ON TO SUPERSENSITIVE 
POSTSYNAPTIC-RECEPTORS. 

002789 03-03 
FLUORESCENCE HISTOCHEMISTRY INDICATES DAMAGE OF STRIATAL 
DOPAMINE NERVE TERMINALS IN RATS AFTER MULTIPLE DOSES OF 
METHAMPHET AMINE. 

002812 03-03 
PROPERTIES OF DOPAMINE AGONIST AND ANTAGONIST BINDING-SITES IN 
MAMMALIAN RETINA. 

002814 03-03 
EFFECT OF DOPAMINE ON ACTIVATION OF RAT STRIATAL ADENYLATE- 
CYCLASE BY FREE MG2 AND GUANYL-NUCLEOTIDES. 

002825 03-03 
NOREPINEPHRINE AND DOPAMINE CEREBRAL LEVELS AFTER CHRONIC- 
TREATMENT WITH NOMIFENSINE. 

002872 03-03 
ACUTE ACTION OF NOMIFENSINE ON NOREPINEPHRINE AND DOPAMINE 

LEVELS IN THE RAT-BRAIN. 

002873 03-03 



BIPHASIC-EFFECTS AND OPPOSITE-EFFECTS OF DOPAMINE AND 
APOMORPHINE ON ENDOGENOUS GABA RELEASE IN THE RAT 
SUBSTANTIA-NIGRA 

002923 03-03 
SPINAL MODULATION OF THE ACOUSTIC STARTLE RESPONSE: THE ROLE 
OF NOREPINEPHRINE, SEROTONIN AND DOPAMINE. 

002950 03-04 
ESTROGEN POTENTIATES THE STEREOTYPY INDUCED BY DOPAMINE 
AGONISTS IN THE RAT. 

002968 03-04 
EFFECTS OF ACUTE OR CHRONIC ADMINISTRATION OF LOW-DOSES OF A 
DOPAMINE AGONIST ON DRINKING AND LOCOMOTOR-ACTIVITY IN THE 
RAT. 

002982 03-04 
THE ROLE OF CALCIUM AND DOPAMINE MEMBRANE CARRIER IN 
MEDIATING THE BEHAVIORAL-EFFECTS AND BIOCHEMICAL-EFFECTS OF 
AMPHETAMINE. (PH.D. DISSERTATION). 

002996 03-04 
EFFECTS OF CHOLECYSTOKININ-OCTAPEPTIDE ON STRIATAL DOPAMINE 
METABOLISM AND ON APOMORPHINE-INDUCED STEREOTYPED CAGE 
CLIMBING IN MICE. 

003031 03-04 
AN INVOLVEMENT OF DOPAMINE IN HIGHER-ORDER CHOICE 
MECHANISMS IN THE MONKEY. 

003072 03-04 
DOPAMINE AND DEMENTIA, AN ANIMAL-MODEL WITH DESTRUCTION OF 
THE MESOCORTICAL DOPAMINERGIC PATHWAY: A PRELIMINARY 
STUDY. 

003085 03-04 
DOPAMINE DEPLETION BY 6 HYDROXYDOPAMINE PREVENTS 
CONDITIONED TASTE-AVERSION INDUCED BY METHYLAMPHETAMINE 
BUT NOT LITHIUM-CHLORIDE. 

003110 03-04 
ABNORMAL TRANSMETHYLATION REACTION DURING THE METABOLISM 
OF DOPAMINE, TRYPTAMINE, AND SEROTONIN, AND SCHIZOPHRENIC- 
SYMPTOMS: A CRITICAL REVIEW. 

003404 03-13 
DOPAMINE CONJUGATE IN CEREBROSPINAL-FLUID. 

003432 03-13 
ALTERATIONS IN CEREBROSPINAL-FLUID DOPAMINE METABOLITES 
FOLLOWING PHYSOSTIGMINE INFUSION. 

003477 03-15 
CHLORPROMAZINE, HALOPERIDOL, METOCLOPRAMIDE AND 
DOMPERIDONE RELEASE PROLACTIN THROUGH DOPAMINE 
ANTAGONISM AT LOW CONCENTRATIONS BUT PARADOXICALLY 
INHIBIT PROLACTIN RELEASE AT HIGH-CONCENTRATIONS. 

003731 04-03 
DOPAMINE METABOLITES IN CAUDATE AND CORTEX AFTER LITHIUM AND 
HALOPERIDOL. (UNPUBLISHED PAPER). 

003738 04-03 
PRESYNAPTIC AND POSTSYNAPTIC STRIATAL DOPAMINE-RECEPTORS: 
DIFFERENTIAL SENSITIVITY TO APOMORPHINE INHIBITION OF 
(3H)D0PAMINE AND (14C)GABA RELEASE IN VITRO. 

003741 04-03 
GABA-ENHANCEMENT OF (3H)D0PAMINE RELEASE FROM SLICES OF RAT 
STRIATUM: DEPENDENCE ON SLICE SIZE. 

003786 04-03 
THE EFFECT OF LONG-TERM CONCURRENT ADMINISTRATION OF 
CHLORPROMAZINE AND LITHIUM ON THE STRIATAL AND FRONTAL 
CORTICAL DOPAMINE METABOLISM IN RATS. 

003788 04-03 
DOPAMINE, NORADRENALINE AND 3,4 DIHYDROXYPHENYLACETIC-ACID 
(DOPAC) LEVELS OF INDIVIDUAL BRAIN NUCLEI, EFFECTS OF 
HALOPERIDOL AND PARGYLINE. 

003792 04-03 
COMPARATIVE-EFFECTS OF AMANTADINE AND AMFONELIC-ACID ON 
DOPAMINE METABOLISM IN RAT-BRAIN. 

003796 04-03 
DOPAMINE INHIBITS BURST-FIRING OF NEUROSECRETORY CELL R-15 IN 
APLYSIA-CALIFORNICA: ESTABLISHMENT OF A DOSE-RESPONSE 
RELATIONSHIP. 

003806 04-03 
PRESYNAPTIC MODULATION OF SYNAPTIC TRANSMISSION IN HELIX- 
POMATIA: THE EFFECTS OF SEROTONIN AND DOPAMINE 
ANTAGONISTS. 

003869 04-03 
INCREASED MESOLIMBIC DOPAMINE BINDING FOLLOWING CHRONIC 
HALOPERIDOL TREATMENT 

003872 04-03 
SOME BARBITURATES ENHANCE THE EFFECT OF MUSCIMOL ON 

DOPAMINE TURNOVER IN THE RAT RETINA. 

003873 04-03 
INHIBITION OF DOPAMINE D-1 AND D-2 BINDING-SITES IN NEURONAL 

TISSUE BY ASCORBATE. 

003876 04-03 
EFFECTS OF 3',4' DIHYDROXYNOMIFENSINE ON THE DOPAMINE 
VASCULAR RECEPTOR 

003890 04-03 



lai, 

n'ffi 
«€ 

■•;i:: 

•Mlt 



fc: 



:i>i; 

■iBi, 

IE 



S-149 



Subject Index 



Psychopharmacology Abstracts 



4!;' 



PHENYLETHYLAMINE EFFECTS ON DOPAMINE SYNTHESIS: STRUQURE- 
ACTIVITY RELATIONSHIPS. (UNPUBLISHED PAPER). 

003959 04-03 
EFFECTS OF IN VIVO AMPHETAMINE ADMINISTRATION ON DOPAMINE 

SYNTHESIS REGULATION IN RAT-BRAIN STRIATAL SYNAPTOSOMES. 
(UNPUBLISHED PAPER). 

003960 04-03 
WHY DOES SULPIRIDE NOT BLOCK THE EFFEQ OF DOPAMINE ON THE 

DOPAMINE-SENSITIVE ADENYLATE-CYCLASE? 

004055 04-03 
EFFECTS OF A HIGH-DOSE TREATMENT OF METHAMPHETAMINE ON 
CAUDATE DOPAMINE AND ANOREXIA IN RATS 

004073 04-04 
EFFECTS OF DOPAMINE, APOMORPHINE, GAMMA HYDROXYBUTYRIC- 
ACID, HALOPERIDOL AND PIMOZIDE ON REFLEX BRADYCARDIA IN 
RATS. 

004085 04-04 
GENETIC VARIATIONS IN MIDBRAIN DOPAMINE CELL NUMBER: PARALLEL 
WITH DIFFERENCES IN RESPONSES TO DOPAMINERGIC AGONISTS AND 
IN NATURALISTIC BEHAVIORS MEDIATED BY CENTRAL DOPAMINERGIC- 
SYSTEMS. (UNPUBLISHED PAPER) 

004)12 04-04 
THE EFFECT OF DOPAMINE UPTAKE BLOCKING-AGENTS ON THE 
AMPHETAMINE-INDUCED CIRCLING-BEHAVIOR IN MICE WITH 
UNILATERAL NIGROSTRIATAL LESIONS 

004117 04-04 
IS DOPAMINE ANTAGONISM A REQUISITE OF NEUROLEPTIC ACTIVITY? 

004122 04-04 
THE RELATIONSHIP BETWEEN LOSS OF DOPAMINE NERVE TERMINALS, 
STRIATAL (3H)SPIR0PERID0L BINDING AND ROTATIONAL-BEHAVIOR IN 
UNILATERALLY 6 HYDROXYDOPAMINE LESIONED RATS. 

004129 04-04 
DIFFERENTIAL-EFFECTS OF SEVERAL DOPAMINE UPTAKE INHIBITORS AND 

RELEASING-AGENTS ON LOCOMOTOR-ACTIVITY IN NORMAL AND IN 
RESERPINIZED MICE. 

004130 04-04 
INVOLVEMENT OF DOPAMINE IN CIRCLING RESPONSES TO MUSCIMOL 

DEPENDS ON INTRANI6RAL SITE OF INJECTION. 

004158 04-04 
DESTRUCTION OF 5 HYDROXYTRYPTAMINERGIC NEURONS AND THE 
DYNAMICS OF DOPAMINE IN NUCLEUS-ACCUMBENS SEPTI AND OTHER 
FOREBRAIN REGIONS OF THE RAT. 

004171 04-04 
AVOIDANCE RESPONSE IN RATS AFTER INJECTION OF DOPAMINE INTO 
THE NEOSTRIATUM. 

004255 04-04 
ANTAGONISM OF DOPAMINE SUPERSENSITIVITY BY ESTROGEN: 
NEUROCHEMICAL- STUDIES IN AN ANIMAL-MODEL OF TARDIVE- 
DYSKINESIA. 

004268 04-05 
DETERMINATION OF PICOMOLE AMOUNTS OF DOPAMINE, 
NORADRENALINE, 3,4 DIHYDROXYPHENYLALANINE, 3,4 
DIHYDROXYPHENYLACETIC-ACID, HOMOVANILLIC-ACID, AND 5 
HYDROXYINDOLEACETIC-ACID IN NERVOUS-TISSUE AFTER ONE-STEP 
PURIFICATION ON SEPHADEX-G-10, USING HIGH. 

004305 04-06 
DOPAMINE AND 5 HT SUPERSENSITIVITY IN NONORGANIC CENTRAL PAIN 
AND IN MORPHINE ABSTINENCE: FORTUITOUS OR REAL ANALOGY? 

004553 04-13 
DOPAMINE-ACTIVATED 

DOPAMINE-ACTIVATED ADENYLATE-CYCLASE OF SPINAL-CORD: 
SUPERSENSITIVITY FOLLOWING TRANSECTION OF THE CORD. 

003800 04-03 
DOPAMINE-AUTORECEPTOR 

REPEATED TRICYCLICS INDUCE A PROGRESSIVE DOPAMINE- 
AUTORECEPTOR SUBSENSITIVITY INDEPENDENT OF DAILY DRUG- 
TREATMENT. 

000047 01-03 
REPEATED ANTIDEPRESSANT TREATMENTS INDUCE A LONG-LASTING 

DOPAMINE-AUTORECEPTOR SUBSENSITIVITY: IS DAILY TREATMENT 
NECESSARY FOR CLINICAL EFFICACY? 

002659 03-03 
DOPAMINE-AUTORECEPTORS 

TRICYCLIC-ANTIDEPRESSANTS INDUCE SUBSENSITIVITY OF PRESYNAPTIC 
DOPAMINE-AUTORECEPTORS . 

000048 01-03 
DOPAMINE-AUTORECEPTORS: PHARMACOLOGY, FUNCTION AND 

COMPARISON WITH POSTSYNAPTIC DOPAMINE-RECEPTORS 

001453 02-03 
PHYSIOLOGICAL SIGNIFICANCE OF DOPAMINE-AUTORECEPTORS AS 
STUDIED FOLLOWING THEIR SELECTIVE BLOCKADE BY MOLINDONE. 

004065 04-04 
DOPAMINE-BETA-HYDROXYLASE 

DOPAMINE-BETA-HYDROXYLASE: A MODULATOR OF BETA-ADRENERGIC- 
RECEPTOR ACTIVITY. 

000302 01-03 
DOPAMINE-BETA-HYDROXYLASE ACTIVITY AND NORADRENALINE 
CONTENT IN PIAL-ARTERIES OF CAT AND GOAT. 

001357 02-03 



METHODOLOGICAL-ISSUES IN SPINAL-FLUID STUDIES OF SCHIZOPHRENIA: 
THE CASE OF NOREPINEPHRINE AND DOPAMINE-BETA-HYDROXYLASE. 
(UNPUBLISHED PAPER). 

001952 02-08 
PURIFICATION AND CHARAaERIZATION OF RAT PHEOCHROMOCYTOMA 
DOPAMINE-BETA-HYDROXYLASE. 

003664 04-01 
REDUCTION IN THE LEVEL OF IMMUNOTITRATABLE DOPAMINE-BETA- 
HYDROXYLASE AFTER CHRONIC ADMINISTRATION OF L-DOPA OR 
ALPHA METHYLDOPA. 

003764 04-03 
RESERPINE EFFECT ON THE AXONAL TRANSPORT OF DOPAMINE-BETA- 
HYDROXYLASE AND TYROSINE-HYDROXYLASE IN RAT-BRAIN. 

003904 04^3 
PLASMA DOPAMINE-BETA-HYDROXYLASE ACTIVITY IN CHRONIC 
SCHIZOPHRENIC-PATIENTS TESTED WITH SINGLE-DOSE OF 2 BROMO- 
ALPHA-ERGOCRIPTINE (PARLODEL). 

004343 04-08 
NORMAL PLASMA DOPAMINE-BETA-HYDROXYLASE IN NONTREATED AND 
TREATED PARKINSON-PATIENTS 

004471 04-11 
THE ACTIVITY OF DOPAMINE-BETA-HYDROXYLASE IN THE PLASMA OF 
PATIENTS WITH ENDOGENOUS DEPRESSIVE-SYNDROMES. 

004548 04-13 
DOPAMINE-DEPENDENT 

THE ROLE OF 5 HYDROXYTRYPT AMINE IN DOPAMINE-DEPENDENT 
STEREOTYPED-BEHAVIOUR. 

002966 03-04 
DOPAMINE-DEPENDENT HYPERACTIVITY IN THE FOLLOWING 
MANIPULATION OF GABA MECHANISMS IN THE REGION OF THE 
NUCLEUS-ACCUMBENS. 

003976 04-03 
DOPAMINE-EVOKED 

ALPHA FLUPENTHIXOL: AN ANTAGONIST OF DOPAMINE-EVOKED FLUID 
SECRETION BY AN INSECT SALIVARY-GLAND PREPARATION. 

000031 01-03 
DOPAMINE-INDUCEO 

CONSISTENT UNMASKING OF DOPAMINE-INDUCED DILATION OF THE 
CANINE FEMORAL VASCULAR BED 

003911 04-03 
EVIDENCE TO SUGGEST THAT DOPAMINE-INDUCED INCREASE IN GABA 
CONCENTRATIONS IN CHICK BRAIN IS MEDIATED THROUGH CYCLIC- 
AMP 

003952 04-03 
DOPAMINE-MEDIATED 

ACTIONS OF TETRAHYDRONORHARMANE (TETRAHYDRO-BETA- 
CARBOLINE) ON 5 HYDROXYTRYPTAMINE AND DOPAMINE-MEDIATED 
MECHANISMS 

002854 03-03 
EFFECT OF ACUTE AND CHRONIC TRIIODOTHYRONINE (T3) 
ADMINISTRATION TO RATS ON CENTRAL 5 HT AND DOPAMINE- 
MEDIATED BEHAVIOURAL-RESPONSES AND RELATED BRAIN- 
BIOCHEMISTRY 

002951 03-04 
DOPAMINE-MIMETIC 

AQIVATION OF PRESYNAPTIC ALPHA NORADRENALINE-RECEPTORS IN 
RAT-BRAIN BY THE POTENT DOPAMINE-MIMETIC N,N Dl PROPYL- ADTN. 

001390 02-03 
DOPAMINE-RADIORECEPTOR 

THE DOPAMINE-RADIORECEPTOR ASSAY - A CLINICAL APPLICATION. 

000904 01-16 
DOPAMINE-RECEPTOR 

CHRONIC HIGH-DOSE PROPRANOLOL DOES NOT INCREASE DOPAMINE- 
RECEPTOR NUMBER 

000083 01-03 
HYPOPHYSECTOMY PREVENTS THE STRIATAL DOPAMINE-RECEPTOR 
SUPERSENSITIVITY PRODUCED BY CHRONIC HALOPERIDOL TREATMENT. 

000132 01-03 
EVIDENCE FOR, AND LOCALIZATION OF, A UNITARY DOPAMINE- 
RECEPTOR COMPOSED OF COOPERATIVELY LINKED SUBUNIT BIN-^ING- 
SITES IN RAT STRIATUM. 

000186 01-03 
IN VITRO ACETYLCHOLINE RELEASE FROM RAT CAUDATE-NUCLEUS AS A 
NEW MODEL FOR TESTING DRUGS WITH DOPAMINE-RECEPTOR 
ACTIVITY. 

000289 01-03 
REDUCTION OF FOOD INTAKE BY PIRIBEDIL IN THE RAT: RELATION TO 
DOPAMINE-RECEPTOR STIMULATION. 

000355 01-04 
POSTSWIM GROOMING IN MICE INHIBITED BY DOPAMINE-RECEPTOR 
ANTAGONISTS AND BY CANNABINOIDS. 

000359 01-04 
INCREASED DOPAMINE-RECEPTOR BINDING IN THE STRIATUM OF RATS 
AFTER LONG-TERM ISOLATION 

000398 01-04 
N ALKYLATED 2 AMINOTETRALINS: CENTRAL DOPAMINE-RECEPTOR 

STIMULATING AQIVITY. 

000399 01-04 



S-150 



VOLUME 19, SUBJECT INDEX 



Subject Index 



EXTINCTION AND DOPAMINE-RECEPTOR BLOCKADE AFTER INTERMITTENT 
REINFORCEMENT TRAINING: FAILURE TO OBSERVE FUNCTIONAL 
EQUIVALENCE 

000490 01-04 
TRANSIENT ABOLITION OF GENERALIZED PHOTOSENSITIVE EPILEPTIC- 
DISCHARGE IN HUMANS BY APOMORPHINE, A DOPAMINE-RECEPTOR 
AGONIST. 

000714 01-11 
DOPAMINE-RECEPTOR: ISOLATION, PURIFICATION, AND REGULATION. 

OOlOn 02-01 
NO EVIDENCE FOR INCREASED DOPAMINE-RECEPTOR BINDING IN 
SUPERRESPONSIVE MICE AFTER A SINGLE-DOSE OF NEUROLEPTICS. 

001292 02-03 
DOPAMINE-RECEPTOR BLOCKADE IN RAT-BRAIN AFTER ACUTE AND 
SUBCHRONIC-TREATMENT WITH TRICYCLIC-ANTIDEPRESSANTS. 

001314 02-03 
THE PITUITARY DOPAMINE-RECEPTOR, 

001324 02-03 
DOPAMINE-RECEPTOR: FROM SYNAPTIC MEMBRANES TO 
SOLUBILIZATION. 

001326 02-03 
EFFECTS OF HALOPERIDOL, A DOPAMINE-RECEPTOR ANTAGONIST, ON A 
DELAYED TYPE HYPERSENSITIVITY REACTION TO 1 
CHLORODINITROBENZENE IN MICE. 

001473 02-03 
INHIBITION OF NEUROLEPTIC-INDUCED DOPAMINE-RECEPTOR 
SUPERSENSITIVITY BY CYCLO-LEU-GLY. 

001576 02-04 
DOPAMINE-RECEPTOR BLOCKADE BY IMIDOLINE AND ITS PROPOSED 
ACTIVE CONFORMATION. 

001687 02-04 
CHRONIC NEUROLEPTIC TREATMENT AND DOPAMINE-RECEPTOR 
REGULATION. 

001837 02-05 
APOMORPHINE HYPOTHERMIA: AN INDEX OF CENTRAL DOPAMINE- 
RECEPTOR FUNCTION IN MAN. 

002221 02-13 
NEUROCHEMICAL EVIDENCE AND BEHAVIORAL-EVIDENCE FOR A 
SELECTIVE PRESYNAPTIC DOPAMINE-RECEPTOR AGONIST. 

002236 02-13 
PERGOLIDE, A POTENT LONG-ACTING DOPAMINE-RECEPTOR AGONIST. 

002257 02-13 
DURING ONE YEARS NEUROLEPTIC TREATMENT IN RATS STRIATAL 
DOPAMINE-RECEPTOR BLOCKADE DECREASES BUT SERUM PROLACTIN 
LEVELS REMAIN ELEVATED. 

002707 03-03 
DOPAMINE-RECEPTOR SUPERSENSITIVITY IN THE CORPUS-STRIATUM 
FOLLOWING CHRONIC ELEVATION OF BRAIN GAMMA AMINOBUTYRIC- 
ACID. 

002716 03-03 
KAINATE LESION DISSOCIATES STRIATAL DOPAMINE-RECEPTOR 
RADIOLIGAND BINDING-SITES. 

002803 03-03 
LOCALIZATION OF GABA-RECEPTOR AND DOPAMINE-RECEPTOR SITES IN 
RETINAL GLIAL CELLS USING DL ALPHA AMINOADIPIC-ACID. 

002828 03-03 
THREE CLASSES OF DOPAMINE-RECEPTOR (D-2, D-3, D-4) IDENTIFIED BY 
BINDING STUDIES WITH 3H APOMORPHINE AND 3H OOMPERIDONE. 

002900 03-03 
A COMPARISON OF DOPAMINE-RECEPTOR BLOCKING ASSAY WITH 
PLASMA DRUG LEVELS OF HALOPERIDOL IN SCHIZOPHRENIC-PATIENTS. 

003182 03-08 
NEUROLEPTIC MALIGNANT- SYNDROME: A PATHOGENETIC ROLE FOR 
DOPAMINE-RECEPTOR BLOCKADE? 

003492 03-15 
THE DOPAMINE-RECEPTOR: ISOLATION, PURIFICATION AND REGULATION. 

003660 04-01 
DOPAMINE-RECEPTOR PURIFICATION AND CHARACTERIZATION. 

(UNPUBLISHED PAPER). 

003661 04-01 
THE DOPAMINE-RECEPTOR ANTAGONIST DOMPERIDONE IS ALSO A 

COMPETITIVE ANTAGONIST AT ALPHAl -ADRENOCEPTORS. 

003785 04-03 
RESPONSE OF STRIATONIGRAL SUBSTANCE-P SYSTEMS TO A DOPAMINE- 
RECEPTOR AGONIST AND ANTAGONIST. 

003826 04-03 
THE DOPAMINE-RECEPTOR COMPLEX: BIOCHEMICAL-CONSEQUENCES OF 
SUPERSENSITIVITY INDUCED BY TREATMENT WITH 6 
HYDROXYDOPAMINE OR MORPHINE. 

003958 04-03 
DOPAMINE-RECEPTOR BINDING IN BOVINE INTERMEDIATE LOBE 
PITUITARY MEMBRANES. 

004003 04-03 
A COMPARISON OF THE RESPONSES TO SOME DOPAMINE-RECEPTOR 
AGONISTS AND ANTAGONISTS IN THE ISOLATED PERFUSED RAT 
KIDNEY. 

004054 04-03 
RELEVANCE OF DOPAMINE-RECEPTOR BINDING STUDIES FOR EVALUATION 
OF ANTIPARKINSONIAN-DRUGS. 

004120 04-04 



DOPAMINE-RECEPTOR CHANGES FOLLOWING DESTRUCTION OF THE 
NIGROSTRIATAL PATHWAY: LACK OF A REUTIONSHIP TO 
ROTATIONAL-BEHAVIOR 

004229 04-04 
LITHIUM EFFECTS ON HALOPERIDOL-INDUCEO PRESYNAPTIC AND 
POSTSYNAPTIC DOPAMINE-RECEPTOR SUPERSENSITIVITY 

004244 04-04 
THE EFFECT OF THE DOPAMINE-RECEPTOR BLOCKING-DRUG PIMOZIDE ON 
THE STIMULANT AND ANORECTIC-ACTIONS OF DEXTROAMPHETAMINE 
IN MAN. 

004580 04-14 
DOPAMINE-RECEPTORS 

EVIDENCE FOR AN IRREVERSIBLE INTERACTION OF BROMOCRYPTINE 
WITH CENTRAL DOPAMINE-RECEPTORS. 

000023 01-03 
REGULATION OF STRIATAL ACETYLCHOLINE CONCENTRATION BY D2 
DOPAMINE-RECEPTORS. 

000269 01-03 
SODIUM-DEPENDENT INTERACTION OF BENZAMIDES WITH DOPAMINE- 
RECEPTORS. 

000285 01-03 
DOPAMINE-RECEPTORS AND SCHIZOPHRENIA: DRUG-EFFECT OR ILLNESS? 

000564 01-08 
METOCLOPRAMIDE AND SULPIRIDE AS SELECTIVE BLOCKING-AGENTS 
PRESYNAPTIC AND POSTSYNAPTIC DOPAMINE-RECEPTORS. 

001102 02-03 
DOPAMINE-RECEPTORS IN RAT-FRONTAL-CORTEX: PHARMACOLOGICAL- 
PROPERTIES IN VIVO AND IN VITRO. 

001112 02-03 
CHLOROETHYLNORAPOMORPHINE, A PROPOSED LONG-ACTING 

DOPAMINE ANTAGONIST: INTERACTIONS WITH DOPAMINE-RECEPTORS 
OF MAMMALIAN FOREBRAIN IN VITRO. 

001114 02-03 
PRESYNAPTIC DOPAMINE-RECEPTORS: INSENSITIVITY TO KAINIC-ACID 
AND THE DEVELOPMENT OF SUPERSENSITIVITY FOLLOWING CHRONIC 
HALOPERIDOL. 

001117 02-03 
IN VIVO (3H)SPIPER0NE BINDING TO THE RAT HIPPOCAMPAL 
FORMATION: INVOLVEMENT OF DOPAMINE-RECEPTORS. 

001131 02-03 
CENTRAL-NERVOUS-SYSTEM DOPAMINE-RECEPTORS. 

001185 02-03 
RADIOLIGAND BINDING STUDIES: EVIDENCE FOR MULTIPLE DOPAMINE- 
RECEPTORS. 

001186 02-03 
PERIPHERAL PRESYNAPTIC AND POSTSYNAPTIC DOPAMINE-RECEPTORS: 

ARE THEY DIFFERENT FROM DOPAMINE-RECEPTORS IN THE CENTRAL- 
NERVOUS-SYSTEM. 

001252 02-03 
AHEMPTS TO DEVELOP SUPERSENSITIVITY OR SUBSENSITIVITY RETINAL 
DOPAMINE-RECEPTORS AFTER VARIOUS TREATMENTS WITH 
ANTAGONISTS OR AGONISTS. 

001350 02-03 
MODIFICATION OF DOPAMINE-RECEPTORS IN BRAIN BY CONTINUOUS 
AMPHETAMINE ADMINISTRATIONS TO RATS. 

001395 02-03 
PRESYNAPTIC DOPAMINE-RECEPTORS IN STRIATAL NERVE-ENDINGS: 
ABSENCE OF HALOPERIDOL-INDUCED SUPERSENSITIVITY 

001424 02-03 
THE EFFECT OF CYCLO-LEU-GLY ON CHEMICAL DENERVATION 
SUPERSENSITIVITY OF DOPAMINE-RECEPTORS INDUCED BY 
INTRACEREBROVENTRICULAR INJECTION OF 6 HYDROXYDOPAMINE IN 
MICE. 

001435 02-03 
DOPAMINE-AUTORECEPTORS: PHARMACOLOGY, FUNCTION AND 
COMPARISON WITH POSTSYNAPTIC DOPAMINE-RECEPTORS 

001453 02-03 
SIMILARITIES AND DISSIMILARITIES BETWEEN DOPAMINE AND 
NEUROLEPTIC-RECEPTORS: FURTHER EVIDENCE FOR TYPE-1 AND TYPE-2 
DOPAMINE-RECEPTORS IN THE CNS. 

001480 02-03 
HIGH-AFFINITY DOPAMINE-RECEPTORS (D3) IN RAT-BRAIN. 

001509 02-03 
RADIORECEPTOR LABELING OF PRESYNAPTIC AND POSTSYNAPTIC 
DOPAMINE-RECEPTORS. 

001511 02-03 
BINDING OF (3H)PERG0LIDE-MESYLATE TO DOPAMINE-RECEPTORS OF 
MAMMALIAN BRAINS. 

001538 02-03 
NEUROLEPTIC/DOPAMINE-RECEPTORS: ELEVATION AND REVERSAL. 

001847 02-05 
NEUROLEPTICS AND DOPAMINE-RECEPTORS, THERAPEUTIC 
IMPLICATIONS. 

001942 02-08 
CLINICAL EVIDENCE FOR MULTIPLE DOPAMINE-RECEPTORS IN MAN. 

002264 02-13 
DRUG-EFFECTS ON PRESYNAPTIC AND POSTSYNAPTIC DOPAMINE- 
RECEPTORS. 

002372 02-15 



1 
lllf 



I 
••til' 

ill" 



fc: 



i 



S-151 



Subject Index 

SIMILARITIES BETWEEN THE BINDING OF 3H PIFLUTIXOL AND 3H 
FLUPENTIXOL TO RAT STRIATAL DOPAMINE-RECEPTORS IN VITRO. 

002760 03-03 
REGULATION BY CATIONS OF (3H)SPIR0PERID0L BINDING ASSOCIATED 
WITH DOPAMINE-RECEPTORS OF RAT-BRAIN. 

002922 03-03 
DOPAMINE-RECEPTORS, NEUROLEPTICS, AND SCHIZOPHRENIA. 

003197 03-08 
PRESYNAPTIC AND POSTSYNAPTIC STRIATAL DOPAMINE-RECEPTORS: 
DIFFERENTIAL SENSITIVITY TO APOMORPHINE INHIBITION OF 
(3H)D0PAMINE AND (14C)GABA RELEASE IN VITRO. 

003741 04-03 
SOLUBILIZATION OF NEUROLEPTIC/DOPAMINE-RECEPTORS OF HUMAN 

BRAIN STRIATUM. „„..,.„.„„ 

003767 04-03 
DOPAMINE-RECEPTORS IN SUBCELLULAR FRACTIONS FROM BOVINE 
CAUDATE: ENRICHMENT OF (3H)SPIPER0NE BINDING IN A 
POSTSYNAPTIC MEMBRANE FRACTION. 

003948 04-03 
MODULATION OF DOPAMINE-RECEPTORS BY OPIATES. (UNPUBLISHED 

^'^^^^^ 003949 04-03 

CHRONIC NEUROLEPTIC TREATMENT SPECIFICALLY ALTERS THE NUMBER 
OF DOPAMINE-RECEPTORS IN RAT-BRAIN. 

004033 04-03 

BRAIN DOPAMINE-RECEPTORS. „„,,,„.,-, 

004741 04-17 

DOPAMINE-SENSITIVE „ ^ 

DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND RECEPTOR BINDING- 
ACTIVITIES FOLLOWING ACUTE AND CHRONIC NEUROLEPTIC-DRUG 
TREATMENT. (UNPUBLISHED PAPER). ^^ ^^^ ^^_^^ 

DOPAMINE-SENSITIVE ADENYLATE-CYCLASE AND DOPAMINE/ 
NEUROLEPTIC-RECEPTOR BINDING: EFFECT OF NEUROLEPTIC-DRUGS. 

001358 02-03 
STEREOSPECIFIC INHIBITION OF DOPAMINE-SENSITIVE ADENYLATE- 
CYCLASE IN CARP RETINA BY THE ENANTIOMERS OF (/-) 1 
CYCLOPROPYLMETHYL 
TRIFLUOROMETHYLTHIODIBENZOCYCLOHEPTENYLIDENEPIPERIDINE 

003706 04-02 
STIMULATORY ACTION OF LISURIDE ON DOPAMINE-SENSITIVE 
ADENYLATE-CYCLASE IN THE RAT STRIATAL HOMOGENATE 

003718 04-03 
DOPAMINERGIC MECHANISMS IN THE TELEOST RETINA I DOPAMINE- 
SENSITIVE ADENYLATE-CYCLASE IN HOMOGENATES OF CARP RETINA; 
EFFECTS OF AGONISTS, ANTAGONISTS AND ERGOTS 

004051 04-03 
WHY DOES SULPIRIDE NOT BLOCK THE EFFECT OF DOPAMINE ON THE 
DOPAMINE-SENSITIVE ADENYLATE-CYCLASE? 

004055 04-03 
DOPAMINERGIC 

PRODRUGS OF SOME DOPAMINERGIC 2 AMINOTETRALINS: A REVIEW OF 
THEIR SYNTHESES AND NEUROCHEMICAL PROFILES 

000004 01-01 
EFFECTS OF DOPAMINERGIC AGONISTS AND ANTAGONISTS ON 

(3H)AP0M0RPHINE BINDING TO STRIATAL MEMBRANES: SULPIRIDE 
LACK OF INTERACTIONS WITH POSITIVE COOPERATIVE 
(3H)AP0M0RPHINE BINDING. 

000099 01-03 
EFFECT OF DOPAMINERGIC AND GABAERGIC DRUGS GIVEN ALONE OR IN 
COMBINATION ON THE ANTICONVULSANT AQION OF PHENOBARBITAL 
AND DIPHENYLHYDANTOIN IN THE ELECTROSHOCK-TEST IN MICE. 

000163 01-03 
DECARBOXYLATION OF EXOGENOUS L-DOPA IN RAT STRIATUM AFTER 
LESIONS OF THE DOPAMINERGIC NIGROSTRIATAL NEURONS: THE ROLE 
OF STRIATAL CAPILLARIES 

000202 01-03 
STRIATAL DOPAMINERGIC ACTIVITY DURING WITHDRAWAL FROM 

CHRONIC NEUROLEPTIC TREATMENT IN RATS. 

000203 01-03 
EFFECTS OF ALPHA CHLORALOSE ON THE ACTIVITY OF THE 

NIGROSTRIATAL DOPAMINERGIC SYSTEM IN THE CAT. 

000217 01-03 
INTRAVENOUS GABA AGONIST ADMINISTRATION STIMULATES FIRING OF 
AlO DOPAMINERGIC NEURONS. 

000320 01-03 
EFFECT OF PICROTOXIN AND NIPECOTIC-ACID ON INHIBITORY RESPONSE 
OF DOPAMINERGIC NEURONS IN THE VENTRAL TEGMENTAL AREA TO 
STIMULATION OF THE NUCLEUS-ACCUMBENS. 

000331 01-03 
ROLE OF BRAIN DOPAMINERGIC MECHANISMS IN RODENT AGGRESSIVE- 
BEHAVIOR- INFLUENCE OF ( OR -)N N PROPYLNORAPOMORPHINE ON 
THREE EXPERIMENTAL MODELS. 

000340 01-04 
EFFECTS OF DOPAMINERGIC AND CHOLINERGIC-DRUGS, NALOXONE AND 
L PROLYL-LEUCYL-GLYCINAMIDE ON LSD-INDUCED CATALEPSY. 

000360 01-04 
DIFFERENT DOPAMINERGIC MECHANISMS FOR AMFONELIC-ACID, 
AMPHETAMINE AND APOMORPHINE. 

000465 01-04 



Psychopharmacology Abstracts 



NALOXONE OVERCOMES THE DOPAMINERGIC. EEG, AND BEHAVIORAL- 
EFFECTS OF GAMMA HYDROXYBUTYRATE. 

000478 01-04 
CONTRIBUTION TO THE CLINICAL- STUDY OF CEREBRAL DOPAMINERGIC 
MECHANISMS: THE ACTION OF PIRIBEDIL IN PSYCHIATRY. FIRST 
RESULTS. 

000616 01-09 
BROMOCRIPTINE AND DOPAMINERGIC FUNCTION IN HUNTINGTON- 
DISEASE. 

000700 01-11 
DOPAMINERGIC FACTORS IN HUMAN PROLACTIN REGULATION: A 

PITUITARY MODEL FOR THE STUDY OF A NEUROENDOCRINE SYSTEM IN 
MAN. 

000776 01-13 
CONTRIBUTION TO STUDY OF CEREBRAL DOPAMINERGIC MECHANISMS: 
REALITY OF THE PROBLEM. 

000782 01-13 
DOPAMINE BIOSYNTHESIS IS REGULATED BY THE AMINE NEWLY 
RECAPTURED BY DOPAMINERGIC NERVE-ENDINGS. 

001163 02-03 
GLYCINE ENHANCEMENT OF CAUDATE NEURONAL ACTIVITIES: 

RELATIONSHIP WITH THE DOPAMINERGIC NIGROSTRIATAL PATHWAY. 

001225 02-03 
EFFECTS OF CHRONIC NEUROLEPTIC TREATMENT ON TYROSINE- 
HYDROXYLASE IN DOPAMINERGIC TERMINALS: COMPARISONS 
BETWEEN DRUGS AND BRAIN REGIONS REVEALS DIFFERENT 
MECHANISMS OF TOLERANCE 

001243 02-03 
ROLE OF CALMODULIN IN DOPAMINERGIC TRANSMISSION. 
(UNPUBLISHED PAPER) 

001270 02-03 
INTERNEURONES ARE PROBABLY NOT INVOLVED IN THE PRESYNAPTIC 
DOPAMINERGIC CONTROL OF DOPAMINE RELEASE IN RABBIT 
CAUDATE-NUCLEUS 

001298 02-03 
DIFFERENTIAL SENSITIVITY OF HYPOTHALAMIC DOPAMINERGIC AND 
NORADRENERGIC NEURONES TO PHARMACOLOGICAL MANIPULATION. 

001310 02-03 
LONG-TERM EFFECTS OF HALOPERIDOL, CLOZAPINE, AND METHADONE 
ON RAT STRIATAL CHOLINERGIC AND DOPAMINERGIC DYNAMICS. 

001325 02-03 
SHORT-TERM AND LONG-TERM EFFEQS OF METHAMPHETAMINE ON 
BIOGENIC-AMINE METABOLISM IN EXTRASTRIATAL DOPAMINERGIC 
NUCLEI 

001384 02-03 
PRESYNAPTIC AND POSTSYNAPTIC MECHANISMS IN HALOPERIDOL- 
INDUCED SENSITIZATION TO DOPAMINERGIC AGONISTS. 

001392 02-03 
INTERACTION OF DOPAMINERGIC ERGOT DERIVATIVES WITH CYCUC- 

NUCLEOTIDE SYSTEM ^ 

001482 02-03 
DENERVATION IN THE DOPAMINERGIC MESOLIMBIC SYSTEM: 
FUNCTIONAL CHANGES FOLLOWED USING (-)N N 
PROPYLNORAPOMORPHINE DEPEND ON THE BASAL AQIVITY LEVELS 

°^'^"^^ 001603 02-04 

INTERACTION OF CHOLINERGIC AND DOPAMINERGIC INFLUENCES ON 

YAWNING-BEHAVIOR „„,,., „.«. 

001656 02-04 

DOPAMINERGIC INVOLVEMENT IN AHENTION A NOVEL ANIMAL-MODEL. 

001678 02-04 
DIFFERENTIAL DOPAMINERGIC FUNQION IN YOUNG AND OLD FEMALE 
RATS AS MEASURED BY THREE BEHAVIORS. 

001683 02-04 

THE EFFECT OF SOME STRUQURAL GABA ANALOGUES ON THE 
SEROTONIN AND DOPAMINERGIC MECHANISMS. 

001736 02-04 

DYSKINESIA INDUCED BY LONG-TERM-TREATMENT WITH 
ANTIPSYCHOTIC-DRUGS: INVOLVEMENT OF PRESYNAPTIC AND 
POSTSYNAPTIC DOPAMINERGIC MECHANISMS. 

001839 02-05 

THE USE OF BROMOCRIPTINE FOR TESTING CEf'TRAL DOPAMINERGIC 

'^^^^^'^'^ 002205 02-13 

THE HYPOTHALAMIC DOPAMINERGIC REGULATION OF PROLAQIN: A 

MODEL FOR THE STUDY OF NEUROHORMONAL MECHANISMS IN MAN 

002568 02-17 
DOPAMINERGIC ABNORMALITIES IN POSTMORTEM SCHIZOPHRENIC 

^•^^"^ 002575 02-17 

DISRUPTION OF 5 HYDROXYTRYPTAMINERGIC NEURONAL FUNCTION 
BLOCKS THE ACTION OF MORPHINE ON TUBEROINFUNDIBULAR 
DOPAMINERGIC NEURONS. 002700 03-03 

THE PRESYNAPTIC STIMULATING EFFECT OF ACETYLCHOLINE ON 
DOPAMINE RELEASE IS SUPPRESSED DURING ACTIVATION OF 
NIGROSTRIATAL DOPAMINERGIC NEURONS IN THE CAT. 



S-152 



i 



VOLUME 19, SUBJECT INDEX 



Subject Index 



DOPAMINERGIC INVOLVEMENT IN THE HYPERALGESIC EFFECT OF 
NOMIFENSINE. 

002736 03-03 
BASAL GANGLIA DOPAMINERGIC CONTROL OF SENSORIMOTOR 
FUNCTIONS RELATED TO MOTIVATED BEHAVIOR. 

002815 03-03 
IN VIVO VOLTAMMETRIC INVESTIGATIONS INTO THE ACTION OF HA-966 
ON CENTRAL DOPAMINERGIC NEURONS. 

002832 03-03 
GLUCOSE SUPPRESSES BASAL FIRING AND HALOPERIDOL-INDUCED 
INCREASES IN THE FIRING-RATE OF CENTRAL DOPAMINERGIC 
NEURONS. 

002880 03-03 
DOPAMINERGIC AGONIST AND ANTAGONIST EFFECTS ON STRIATAL 
TYROSINE-HYDROXYLASE DISTRIBUTION. 

002898 03-03 
CHOLINERGIC, DOPAMINERGIC. NORADRENERGIC, OR GLUTAMINERGIC 
STIMULATION VENTRAL TO THE ANTERIOR SEPTUM DOES NOT 
SPECIFICALLY SUPPRESS DEFENSIVE-BEHAVIOR. 

002945 03-04 
INJECTIONS OF DOPAMINERGIC, CHOLINERGIC, SEROTONINERGIC AND 
GABAERGIC DRUGS INTO THE NUCLEUS-ACCUMBENS: EFFECTS ON 
LOCOMOTOR-ACTIVITY IN THE RAT. 

003019 03-04 
DOPAMINE AND DEMENTIA. AN ANIMAL-MODEL WITH DESTRUCTION OF 
THE MESOCORTICAL DOPAMINERGIC PATHWAY: A PRELIMINARY 
STUDY. 

003085 03-04 
DOPAMINERGIC AND GABAERGIC ASPECTS OF TARDIVE-DYSKINESIA. 

003302 03-1 1 
DOPAMINERGIC MECHANISMS IN THE TELEOST RETINA. II. FACTORS 
AFFECTING THE ACCUMUL^^TION OF CYCLIC-AMP IN PIECES OF INTACT 
CARP RETINA. 

003776 04-03 
RELATIONSHIP BETWEEN THE PRESENCE OF DOPAMINERGIC NEURONS 
AND GABA-RECEPTORS IN SUBSTANTIA-NIGRA: EFFECTS OF LESIONS. 

003797 04-03 
INFLUENCE OF THE DOPAMINERGIC AGONISTS BROMOCRIPTINE, PIRIBEDIL 
AND NOMIFENSINE ON THE SYMPATHETIC NEURAL TRANSMISSION IN 
THE NICTITATING MEMBRANE OF THE CAT. 

003822 04-03 
STUDIES ON AXONAL TRANSPORT IN DOPAMINERGIC NEURONS: EFFECT 
OF NEUROPHARMACOLOGIC LESIONS. 

003858 04-03 
CHANGE IN CATECHOLAMINE SENSITIVE NA-K-ATPASE ACTIVITY IN THE 
RAT STRIATUM MICROSOMES FOLLOWING ELECTROLYTIC OR 6 
HYDROXYDOPAMINE-INDUCED LESIONS OF DOPAMINERGIC NEURONS. 

003871 04-03 
CENTRAL DOPAMINERGIC NEURONS DURING DEVELOPMENT OF GENETIC 
AND DOCA-SALT HYPERTENSION IN THE RAT. 

003899 04-03 
EFFECTS OF METHAMPHETAMINE ON BLOOD FLOW IN THE CAUDATE- 
PUTAMEN AFTER LESIONS OF THE NIGROSTRIATAL DOPAMINERGIC 
BUNDLE IN THE RAT. 

003910 04-03 
DOPAMINERGIC MECHANISMS IN THE TELEOST RETINA. I. DOPAMINE- 
SENSITIVE ADENYLATE-CYCLASE IN HOMOGENATES OF CARP RETINA; 
EFFECTS OF AGONISTS, ANTAGONISTS AND ERGOTS. 

004051 04-03 
ACTIONS OF MU, KAPPA, SIGMA, DELTA AND AGONIST/ANTAGONIST 
OPIATES ON STRIATAL DOPAMINERGIC FUNCTION. 

004053 04-03 
EFFECTS OF DOPAMINERGIC DRUGS ON PHENCYCLIDINE-INDUCEO 
BEHAVIOR IN THE RAT. 

004083 04-04 
GENETIC VARIATIONS IN MIDBRAIN DOPAMINE CELL NUMBER: PARALLEL 
WITH DIFFERENCES IN RESPONSES TO DOPAMINERGIC AGONISTS AND 
IN NATURALISTIC BEHAVIORS MEDIATED BY CENTRAL DOPAMINERGIC- 
SYSTEMS. (UNPUBLISHED PAPER). 

004112 04-04 
RELATION BETWEEN BRAIN CATECHOLAMINE-RECEPTORS AND 
DOPAMINERGIC STEREOTYPY IN RAT STRAINS. 

004131 04-04 
DOPAMINERGIC AGONISTS DIFFERENTIALLY AFFECT OPEN-FIELD ACTIVITY 
OF RATS WITH AlO LESIONS. 

004135 04-04 
DOPAMINERGIC NEURONS OF SPINAL-CORD: A POSSIBLE SITE FOR THE 
ACTION OF NEUROLEPTIC-DRUGS. 

004188 04-04 
GENOTYPIC INFLUENCES ON STRIATAL DOPAMINERGIC REGULATION IN 
MICE. 

004217 04-04 
CHANGES OF RESPONSE TO DOPAMINERGIC DRUGS IN RATS SUBMITTED 
TO REM SLEEP DEPRIVATION. 

004239 04-04 
TONIC IMMOBILITY IN DOMESTIC FOWL: POSSIBLE INTERACTION OF 
SEROTONERGIC AND DOPAMINERGIC MECHANISMS. 

004246 04-04 



IN NORMAL YOUNG MEN ACUTE DOPAMINERGIC BLOCKADE DOES NOT 
IMPAIR FREE WATER EXCRETION FOLLOWING A STANDARD WATER 
LOAD. 

004600 04-15 
DOPAMINERGIC-ACTIVITY 

ROLE OF THE NEOSTRIATAL DOPAMINERGIC-ACTIVITY IN SEQUENCING 
AND SELECTING BEHAVIOURAL-STRATEGIES: FACILITATION OF 
PROCESSES INVOLVED IN SELECTING THE BEST STRATEGY IN A 
STRESSFUL-SITUATION, 

000366 01-04 
MORPHINE-DEPENDENCE AND DOPAMINERGIC-ACTIVITY: TESTS OF 
CIRCLING RESPONSES IN RATS WITH UNILATERAL NIGRAL LESIONS. 

001641 02-04 
CLINICAL PROCESSES AND CENTRAL DOPAMINERGIC-ACTIVITY IN 

PSYCHOTIC-DISORDERS 

002098 02-11 
THE EFFECT OF ALTERED DOPAMINERGIC-ACTIVITY ON FOOD INTAKE IN 
THE RAT: EVIDENCE FOR AN OPTIMAL LEVEL OF DOPAMINERGIC- 
ACTIVITY FOR BEHAVIOR. 

002632 02-17 
DOPAMINERGIC-AGENT 

A NEW DOPAMINERGIC-AGENT IN CURRENT PSYCHIATRIC-PRACTICE. 

003156 03-07 
DOPAMINERGIC-AGENTS 

THE EFFECTS OF DOPAMINERGIC-AGENTS ON THE LOCOMOTOR-ACTIVITY 
OF RATS AFTER HIGH-DOSES OF METHYLAMPHETAMINE. 

000427 01-04 
DOPAMINERGIC-EFFECTS 

CENTRAL DOPAMINERGIC-EFFECTS OF ERGOLINE DERIVATIVES. 

002540 02-17 
DOPAMINERGIC-RECEPTOR 

MODIFICATION OF DOPAMINERGIC-RECEPTOR SENSITIVITY IN RAT-BRAIN 
AFTER AMYGDALOID KINDLING. 

000106 01-03 
EFFECTS OF LISURIDE ON BODY-TEMPERATURE OF RATS AND RABBITS: 
RELATION TO MICROSOMAL BIOTRANSFORMATION AND 
DOPAMINERGIC-RECEPTOR STIMULATION . 

001161 02-03 
UNITARY DOPAMINERGIC-RECEPTOR COMPOSED OF COOPERATIVELY 
LINKED AGONIST AND ANTAGONIST SUBUNIT BINDING-SITES. 

001342 02-03 
EFFECTS OF CHLORPROMAZINE ON DOPAMINERGIC-RECEPTOR FUNCTIONS 
IN RAT-BRAIN - DIFFERENCE OF THE RESPONSE OF SEVERAL 
DOPAMINERGIC-SYSTEMS AFTER CHRONIC ADMINISTRATION. 

002773 03-03 
AN ENHANCED SENSITIVITY OF MUSCARINIC CHOLINERGIC-RECEPTOR 
ASSOCIATED WITH DOPAMINERGIC-RECEPTOR SUBSENSITIVITY AFTER 
CHRONIC ANTIDEPRESSANT TREATMENT. 

002788 03-03 
A CONTROLLED-STUDY OF L-DOPA IN SCHIZOPHRENIA WITH REFERENCE 
TO THE THEORY OF DOPAMINERGIC-RECEPTOR HYPERSENSITIVITY. 

004312 04-08 
DOPAMINERGIC-RECEPTORS 

SELECTIVE INFLUENCE OF ERGOT ALKALOIDS ON CORTICAL AND STRIATAL 
DOPAMINERGIC-RECEPTORS AND SEROTONERGIC-RECEPTORS. 

001447 02-03 
EFFECT OF LONG-TERM-TREATMENT WITH HALOPERIDOL AND SULPIRIDE 
ON DIFFERENT TYPES OF DOPAMINERGIC-RECEPTORS. 

001512 02-03 
EVIDENCE FOR THERMOREGULATORY DOPAMINERGIC-RECEPTORS 
LOCATED IN THE PREOPTICUS-MEDIALIS-NUCLEUS OF THE RAT 
HYPOTHALAMUS. 

003754 04-03 
EFFECTS OF ACUTE AND CHRONIC ADMINISTRATION OF PHENCYCLIDINE 
ON DOPAMINERGIC-RECEPTORS IN RAT STRIATUM. 

003901 04-03 
DOPAMINERGIC-SUPERSENSITIVITY 

DOPAMINERGIC-SUPERSENSITIVITY: INFLUENCE OF DOPAMINE AGONISTS 
AND DRUGS USED FOR THE TREATMENT OF TARDIVE-DYSKINESIA. 

001169 02-03 
STUDIES ON THE SPECIFICITY AND REVERSAL OF NEUROLEPTIC-INDUCED 
DOPAMINERGIC-SUPERSENSITIVITY. (PH.D. DISSERTATION). 

001469 02-03 
REDUCTION OF DOPAMINERGIC-SUPERSENSITIVITY BY A SINGLE-DOSE OF 
AMPHETAMINE. 

001642 02-04 
EFFECTS OF AGE ON DOPAMINERGIC-SUPERSENSITIVITY INDUCED BY 

CHRONIC FLUPHENAZINE. 

003940 04-03 
DOPAMINERGIC-SYSTEM 

ACUTE AND CHRONIC HALOPERIDOL TREATMENT: EFFECTS ON 
NIGROSTRIATAL DOPAMINERGIC-SYSTEM ACTIVITY. 

001153 02-03 
CHRONOLOGY OF EXTRAPYRAMIDAL-EFFECTS OF NEUROLEPTIC-DRUGS 
AND THE NIGROSTRIATAL DOPAMINERGIC-SYSTEM. 

002449 02-15 
NEUROLEPTICS: ACTIVATION OR INHIBITION OF THE DOPAMINERGIC- 
SYSTEM? 

003424 03-13 



"ijf 

lai. 

M 






tU.. 



iiii'» 

inlT 

Hi!, 



S-153 



Subject Index 



Psychopharmacology Abstracts 



*iii 



DOPAMINER6IC-SYSTEMS 

DOPAMINERGIC-SYSTEMS AND SPEECH FLUENCY. 

000821 01-14 
INFLUENCE OF DOPAMINERGIC-SYSTEMS ON THE LATERAL HABENULAR 
NUCLEUS OF THE RA